-- phpMyAdmin SQL Dump
-- version 2.11.9.5
-- http://www.phpmyadmin.net
--
-- Host: localhost
-- Generation Time: Dec 31, 2009 at 09:52 PM
-- Server version: 5.1.39
-- PHP Version: 5.1.6

SET SQL_MODE="NO_AUTO_VALUE_ON_ZERO";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;

--
-- Database: `petkang`
--

-- --------------------------------------------------------

--
-- Table structure for table `home_image`
--

CREATE TABLE IF NOT EXISTS `home_image` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `image_src` varchar(255) NOT NULL,
  `add_time` datetime NOT NULL,
  `url` varchar(200) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 COMMENT='首页图片保存' AUTO_INCREMENT=19 ;

--
-- Dumping data for table `home_image`
--

INSERT INTO `home_image` (`id`, `image_src`, `add_time`, `url`) VALUES
(14, '/image_server_dir/77a2aeaa6738f1b7d9be35dff77e3de8.jpg', '2009-09-27 15:26:42', ''),
(11, '/image_server_dir/31c55e07fed44d4f01e2cfd7d3fe122e.jpg', '2009-09-25 16:49:42', ''),
(16, '/image_server_dir/13082a6a2d1ce6f04aba4303c1c756b9.jpg', '2009-09-28 11:46:41', ''),
(17, '/image_server_dir/7537c439910cc6030be78f6a4b996624.jpg', '2009-09-28 12:01:07', ''),
(18, '/image_server_dir/adb7ef0f4a5d585be4cf5f3308d5f662.jpg', '2009-09-28 12:07:45', '');

-- --------------------------------------------------------

--
-- Table structure for table `link`
--

CREATE TABLE IF NOT EXISTS `link` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(200) NOT NULL,
  `url` varchar(200) NOT NULL,
  `add_time` datetime NOT NULL,
  `orderby` int(11) NOT NULL COMMENT '排序位置',
  `logo` varchar(200) NOT NULL COMMENT '网站logo',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 COMMENT='友情链接' AUTO_INCREMENT=12 ;

--
-- Dumping data for table `link`
--

INSERT INTO `link` (`id`, `name`, `url`, `add_time`, `orderby`, `logo`) VALUES
(4, '中华核医学专业网', 'http://www.csnm.com.cn/', '0000-00-00 00:00:00', 0, ''),
(7, '正核生物', 'http://www.nfpetct.com/', '0000-00-00 00:00:00', 4, ''),
(10, '希望网', 'http://www.newxiwang.com/', '0000-00-00 00:00:00', 2, ''),
(11, '久久维康', 'http://www.99times.cn/', '0000-00-00 00:00:00', 0, '');

-- --------------------------------------------------------

--
-- Table structure for table `lipi_duihuan`
--

CREATE TABLE IF NOT EXISTS `lipi_duihuan` (
  `id` int(11) unsigned NOT NULL AUTO_INCREMENT,
  `j_id` int(11) NOT NULL COMMENT '礼品ID',
  `user_name` varchar(200) NOT NULL,
  `j_name` varchar(200) NOT NULL,
  `add_time` datetime NOT NULL COMMENT '下单时间',
  `user_realname` varchar(200) NOT NULL COMMENT '真实姓名',
  `user_tel` varchar(200) NOT NULL COMMENT '电话号码',
  `user_address` varchar(200) NOT NULL COMMENT '配送地址',
  `stat` varchar(50) NOT NULL DEFAULT '未处理' COMMENT '订单状态',
  PRIMARY KEY (`id`),
  KEY `j_id` (`j_id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 AUTO_INCREMENT=9 ;

--
-- Dumping data for table `lipi_duihuan`
--

INSERT INTO `lipi_duihuan` (`id`, `j_id`, `user_name`, `j_name`, `add_time`, `user_realname`, `user_tel`, `user_address`, `stat`) VALUES
(1, 5, 'xltxlm', 'AUSSINO 全棉华夫格蓝色浴衣', '2009-09-04 21:01:21', '111', '2222', '333', '未处理'),
(2, 5, 'xltxlm', 'AUSSINO 全棉华夫格蓝色浴衣', '2009-09-04 21:07:05', '夏先生', '023399', '上海乐山路', '失败'),
(3, 11, 'xltxlm', 'adidas 男士激情沐浴露+男士幻影极限香水套装', '2009-09-04 21:39:45', 'iii', 'uuu', '999', '未处理'),
(4, 11, 'xltxlm', 'adidas 男士激情沐浴露+男士幻影极限香水套装', '2009-09-05 15:05:22', '', '', '', '失败'),
(5, 11, 'xltxlm', 'adidas 男士激情沐浴露+男士幻影极限香水套装', '2009-09-05 15:08:57', '夏琳泰', '15921427453', '上海乐山路', '成功'),
(6, 12, 'lingzhi', 'VICHY 盈动塑身纤体啫喱', '2009-09-06 21:23:20', '刘凌志', '15821337701', '上海淮海西路338号', '失败'),
(7, 12, 'lingzhi', 'VICHY 盈动塑身纤体啫喱', '2009-09-07 22:24:17', '刘凌志', '15821337701', '淮海西路338', '失败'),
(8, 11, 'gaowuming2008', 'adidas 男士激情沐浴露+男士幻影极限香水套装', '2009-10-13 11:56:27', '高武明', '15900971743', '上海市黄浦区延安东路175号1110室', '失败');

-- --------------------------------------------------------

--
-- Table structure for table `lipi_jigou`
--

CREATE TABLE IF NOT EXISTS `lipi_jigou` (
  `j_id` int(11) NOT NULL AUTO_INCREMENT,
  `j_name` varchar(200) NOT NULL,
  `j_shenfen` varchar(100) NOT NULL,
  `j_jiage` varchar(20) NOT NULL COMMENT '积分',
  `j_jibie` varchar(30) NOT NULL COMMENT '医院级别',
  `j_time` datetime NOT NULL,
  `j_ip` varchar(20) NOT NULL,
  `j_content` text NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `j_image_count` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`j_id`),
  KEY `j_jiage` (`j_jiage`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=15 ;

--
-- Dumping data for table `lipi_jigou`
--

INSERT INTO `lipi_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`) VALUES
(13, '欧姆电子体温计', '健康保健', '100', '', '2009-10-13 14:26:06', '116.231.11.88', '【品牌】：欧姆龙电子体温计\r\n【规格】：MC-141W\r\n【生产企业】： 欧姆龙（大连）有限公司 \r\n【市场价】：￥100.00 \r\n', 'llz007', 0),
(11, '欧姆电子体温计', '商务办公', '100', '', '2009-08-11 16:08:42', '116.228.6.98', '【品牌】：欧姆电子体温计\r\n【规格】：MC-142L\r\n【生产企业】： 欧姆龙（大连）有限公司 \r\n【市场价】：￥100.00 \r\n', 'xltxlm', 0),
(14, '医学咨询卡', '商务办公', '100', '', '2009-10-13 14:54:44', '116.231.11.88', '【品牌】：医学咨询会员卡\r\n【介绍】：推介会员到上海最具有权威的医学咨询委员会进行疑难杂症咨询。', 'llz007', 0),
(12, '欧姆电子体温计', '温馨家居', '100', '', '2009-08-11 16:10:04', '116.228.6.98', '【品牌】：欧姆电子体温计\r\n【规格】：MC-140\r\n【生产企业】： 欧姆龙（大连）有限公司 \r\n【市场价】：￥100.00 \r\n', 'xltxlm', 0);

-- --------------------------------------------------------

--
-- Table structure for table `lipi_shenfen`
--

CREATE TABLE IF NOT EXISTS `lipi_shenfen` (
  `name` varchar(100) NOT NULL COMMENT '省份',
  `pinyin` varchar(200) NOT NULL,
  UNIQUE KEY `name` (`name`),
  KEY `pinyin` (`pinyin`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `lipi_shenfen`
--

INSERT INTO `lipi_shenfen` (`name`, `pinyin`) VALUES
('生活时尚', 'sheng huo shi shang '),
('温馨家居', 'wen xin jia ju '),
('商务办公', 'shang wu ban gong ');

-- --------------------------------------------------------

--
-- Table structure for table `m_resource`
--

CREATE TABLE IF NOT EXISTS `m_resource` (
  `r_id` int(11) unsigned NOT NULL AUTO_INCREMENT,
  `r_name` varchar(200) NOT NULL,
  `r_url` varchar(255) NOT NULL COMMENT '网站的唯一标志',
  `r_note` text NOT NULL COMMENT '介绍说明,描述',
  `r_time` datetime NOT NULL COMMENT '节点的添加时间',
  `r_ip` varchar(20) NOT NULL COMMENT 'IP地址',
  `r_user_name` varchar(200) NOT NULL,
  `r_deep` int(10) unsigned NOT NULL DEFAULT '0' COMMENT '节点的深度',
  `r_parent_id` int(10) unsigned NOT NULL DEFAULT '0' COMMENT '父级节点的ID',
  `r_menu` varchar(1) NOT NULL DEFAULT 'Y' COMMENT '作为导航菜单输出',
  `r_order` int(5) NOT NULL DEFAULT '0' COMMENT '排序根据',
  `r_fav` int(11) NOT NULL DEFAULT '0' COMMENT '被点击的次数,经常点击的次数',
  PRIMARY KEY (`r_id`),
  KEY `r_user_name` (`r_user_name`),
  KEY `r_time` (`r_time`),
  KEY `r_deep` (`r_deep`),
  KEY `r_paren_id` (`r_parent_id`),
  KEY `r_url` (`r_url`),
  KEY `r_menu` (`r_menu`),
  KEY `r_ip` (`r_ip`),
  KEY `r_order` (`r_order`),
  KEY `r_fav` (`r_fav`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk COMMENT='资源' AUTO_INCREMENT=64 ;

--
-- Dumping data for table `m_resource`
--

INSERT INTO `m_resource` (`r_id`, `r_name`, `r_url`, `r_note`, `r_time`, `r_ip`, `r_user_name`, `r_deep`, `r_parent_id`, `r_menu`, `r_order`, `r_fav`) VALUES
(1, '网站管理', '', 'm.php', '2009-08-11 21:48:22', '114.94.98.107', 'xltxlm', 0, 0, 'Y', 3, 0),
(2, 'PET/CT中心机构管理', '/my_admin.php?act=jigou_index', '', '2009-09-07 23:21:09', '116.232.231.236', 'xltxlm', 1, 1, 'Y', 5, 0),
(3, '资源管理', '/m.php?act=resource_index', '', '2009-08-04 21:48:27', '116.233.103.72', '', 0, 4, 'Y', 1, 0),
(4, '后台的资源/帐户/角色', '', '', '2009-09-08 13:53:01', '116.228.6.98', 'xltxlm', 0, 0, 'Y', 100, 0),
(5, '角色管理', '/m.php?act=role_index', '', '2009-08-04 21:48:30', '116.233.103.72', '', 0, 4, 'Y', 2, 0),
(56, '兑换订单', '/my_lipi.php?act=duihuan_list', '', '2009-09-05 15:10:20', '116.232.218.35', 'xltxlm', 0, 37, 'Y', 1, 0),
(55, '派康网新闻', '/my_news.php?act=jigou_index', '', '2009-09-01 20:20:25', '116.232.218.35', 'xltxlm', 0, 1, 'Y', 0, 0),
(15, 'PET/CT知识', '/my_article.php?act=jigou_index', '', '2009-09-07 23:21:02', '116.232.231.236', 'xltxlm', 0, 1, 'Y', 3, 0),
(16, '接口说明', 'm.php?act=user_jiekou', '', '2009-08-06 16:19:35', '116.228.6.98', '', 0, 17, 'Y', 50, 0),
(17, '管理员帐户', '/m.php?act=user_index', '', '2009-08-04 21:48:34', '116.233.103.72', '', 0, 4, 'Y', 3, 0),
(20, '机构点评审核', '/my_admin.php?act=admin_jogou_dianpin', '', '2009-08-27 21:35:43', '116.232.218.35', 'xltxlm', 0, 2, 'Y', 4, 0),
(21, '帐户管理', '', '', '2009-08-30 21:35:59', '116.232.218.35', 'xltxlm', 0, 0, 'Y', 4, 0),
(22, '会员管理', '/my_user.php?act=jigou_index', '', '2009-09-11 21:07:10', '116.232.231.236', 'xltxlm', 0, 21, 'Y', 1, 0),
(59, 'PET/CT动态', '/my_active.php?act=jigou_index', '', '2009-09-07 23:20:11', '116.232.231.236', 'xltxlm', 0, 1, 'Y', -3, 0),
(27, '网站流量第三方统计', '/my_admin.php?act=tongji', '', '2009-08-06 19:33:52', '116.232.231.188', 'xltxlm', 0, 44, 'Y', 27, 0),
(63, '首页客户预约广告', '/my_guangao.php?act=jigou_index', '', '2009-11-18 21:02:36', '116.232.123.35', 'xltxlm', 0, 1, 'Y', 0, 0),
(61, '友情连接', '/my_link.php?act=alist', '', '2009-09-10 15:30:58', '116.228.6.98', 'xltxlm', 0, 44, 'Y', -1, 0),
(37, '换购礼品管理', '/my_lipi.php?act=jigou_index', '', '2009-08-10 22:40:09', '114.94.98.107', 'xltxlm', 0, 44, 'Y', 3, 0),
(60, '首页图片管理', '/image_server.php?act=home_image', '', '2009-09-10 14:53:58', '116.228.6.98', 'xltxlm', 0, 1, 'Y', -90, 0),
(44, '其他管理', '', '', '2009-08-11 21:47:53', '114.94.98.107', 'xltxlm', 0, 0, 'Y', 2, 0),
(43, '全国省份管理', '/my_admin.php?act=shenfen', '', '2009-08-11 21:45:45', '114.94.98.107', 'xltxlm', 0, 2, 'Y', 43, 0),
(45, '分类管理', '/my_article.php?act=shenfen', '', '2009-08-10 21:35:45', '114.94.98.107', 'xltxlm', 0, 15, 'Y', 0, 0),
(47, '分类管理', '/my_lipi.php?act=shenfen', '', '2009-09-05 15:10:10', '116.232.218.35', 'xltxlm', 0, 37, 'Y', 2, 0),
(48, '前台首页', '/petkang.php'' target=''_blank', '', '2009-08-11 21:47:49', '114.94.98.107', 'xltxlm', 0, 0, 'Y', 1, 0),
(50, '会员分类', '/my_user.php?act=shenfen', '', '2009-09-11 21:07:16', '116.232.231.236', 'xltxlm', 0, 22, 'Y', 0, 0),
(57, '预约订单管理', '/my_admin.php?act=jigou_yuding_list', '', '2009-09-07 17:41:05', '116.228.6.98', 'xltxlm', 0, 2, 'Y', -1, 0),
(58, '积分记录', '/my_user.php?act=jifen_log', '', '2009-09-07 17:23:58', '116.228.6.98', 'xltxlm', 0, 22, 'Y', -1, 0);

-- --------------------------------------------------------

--
-- Table structure for table `m_role`
--

CREATE TABLE IF NOT EXISTS `m_role` (
  `role_id` int(11) unsigned NOT NULL AUTO_INCREMENT,
  `role_name` varchar(200) NOT NULL,
  `role_time` datetime NOT NULL,
  `role_note` text NOT NULL,
  `role_ip` varchar(20) NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `resource_count` int(11) unsigned NOT NULL,
  `user_count` int(11) unsigned NOT NULL,
  PRIMARY KEY (`role_id`),
  KEY `role_time` (`role_time`),
  KEY `user_name` (`user_name`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=6 ;

--
-- Dumping data for table `m_role`
--

INSERT INTO `m_role` (`role_id`, `role_name`, `role_time`, `role_note`, `role_ip`, `user_name`, `resource_count`, `user_count`) VALUES
(1, '网站管理员', '2009-08-04 22:07:33', '只是管理网站', '116.233.103.72', '', 20, 5),
(2, '权限管理员', '2009-08-04 22:23:54', '管理 "后台的资源/帐户/角色"', '116.233.103.72', '', 5, 3),
(5, 'ylz', '2009-09-11 21:13:44', '', '114.81.86.108', 'llz007', 3, 1);

-- --------------------------------------------------------

--
-- Table structure for table `m_role_resource`
--

CREATE TABLE IF NOT EXISTS `m_role_resource` (
  `r_id` int(11) NOT NULL,
  `role_id` int(11) NOT NULL,
  UNIQUE KEY `main_id` (`r_id`,`role_id`),
  KEY `r_id` (`r_id`),
  KEY `role_id` (`role_id`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `m_role_resource`
--

INSERT INTO `m_role_resource` (`r_id`, `role_id`) VALUES
(1, 1),
(1, 5),
(2, 1),
(2, 5),
(3, 2),
(4, 2),
(5, 2),
(15, 1),
(16, 2),
(17, 2),
(20, 1),
(21, 1),
(22, 1),
(27, 1),
(37, 1),
(43, 1),
(44, 1),
(45, 1),
(48, 1),
(55, 1),
(56, 1),
(57, 1),
(57, 5),
(58, 1),
(59, 1),
(60, 1),
(61, 1),
(63, 1);

-- --------------------------------------------------------

--
-- Table structure for table `m_role_user`
--

CREATE TABLE IF NOT EXISTS `m_role_user` (
  `user_id` int(11) NOT NULL,
  `role_id` int(11) NOT NULL,
  UNIQUE KEY `main_id` (`user_id`,`role_id`),
  KEY `user_id` (`user_id`),
  KEY `role_id` (`role_id`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `m_role_user`
--

INSERT INTO `m_role_user` (`user_id`, `role_id`) VALUES
(2, 2),
(3, 1),
(3, 2),
(4, 5),
(5, 1),
(6, 1),
(6, 2),
(7, 1),
(8, 1);

-- --------------------------------------------------------

--
-- Table structure for table `m_user`
--

CREATE TABLE IF NOT EXISTS `m_user` (
  `user_id` int(11) unsigned NOT NULL AUTO_INCREMENT,
  `user_name` varchar(200) NOT NULL,
  `user_last_time` datetime NOT NULL,
  `user_pass` varchar(40) NOT NULL,
  `user_last_ip` varchar(20) NOT NULL,
  `user_note` text NOT NULL,
  PRIMARY KEY (`user_id`),
  KEY `user_name` (`user_name`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=9 ;

--
-- Dumping data for table `m_user`
--

INSERT INTO `m_user` (`user_id`, `user_name`, `user_last_time`, `user_pass`, `user_last_ip`, `user_note`) VALUES
(6, 'llz007', '2009-09-11 21:11:31', '633987aeb82bcd9ffabd38f8b1a97ca5', '114.81.86.108', ''),
(3, 'xltxlm', '2009-08-05 22:07:45', 'c4ca4238a0b923820dcc509a6f75849b', '116.233.103.72', ''),
(4, 'xltxlm_test', '2009-08-11 21:46:43', 'c4ca4238a0b923820dcc509a6f75849b', '114.94.98.107', ''),
(5, 'lzg', '2009-09-11 21:08:17', '7b5a834d39ac40a67cfb829ed11c2e4e', '114.81.86.108', ''),
(7, 'ylj', '2009-09-22 17:07:19', '649728cda7afa77b85d9655b29dd37f6', '114.81.152.254', ''),
(8, 'gwm', '2009-09-24 14:32:42', '404cb1264d34b2f004e2d9e06da61dba', '114.81.197.107', '');

-- --------------------------------------------------------

--
-- Table structure for table `wenzhang_jigou`
--

CREATE TABLE IF NOT EXISTS `wenzhang_jigou` (
  `j_id` int(11) NOT NULL AUTO_INCREMENT,
  `j_name` varchar(200) NOT NULL,
  `j_shenfen` varchar(100) NOT NULL,
  `j_jiage` varchar(20) NOT NULL,
  `j_jibie` varchar(30) NOT NULL COMMENT '医院级别',
  `j_time` datetime NOT NULL,
  `j_ip` varchar(20) NOT NULL,
  `j_content` text NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `j_image_count` int(10) unsigned NOT NULL DEFAULT '0',
  `click` int(11) NOT NULL DEFAULT '0' COMMENT '点击',
  PRIMARY KEY (`j_id`),
  KEY `j_jiage` (`j_jiage`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=309 ;

--
-- Dumping data for table `wenzhang_jigou`
--

INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(23, 'PET/CT肺癌诊断图谱', '病例介绍', '', '', '2009-09-28 12:14:32', '116.228.141.77', '<p style="text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;">患者，女性，产后一月，走路时气急，</span><span style="font-size:12pt;font-family:宋体;">CT</span><span style="font-size:12pt;font-family:宋体;">：心包积液，右肺占位，</span><span style="font-size:12pt;font-family:宋体;">06</span><span style="font-size:12pt;font-family:宋体;">年</span><span style="font-size:12pt;font-family:宋体;">12</span><span style="font-size:12pt;font-family:宋体;">月</span><span style="font-size:12pt;font-family:宋体;">8</span><span style="font-size:12pt;font-family:宋体;">日</span><span style="font-size:12pt;font-family:宋体;">纤支镜：右肺下叶基底段赘生物，左主支气管狭窄，</span><span style="font-size:12pt;font-family:宋体;"></span></p>\r\n<p style="text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;"><img alt="" src="/image_server_dir/c30d84473a2f25b2a033887c0433933f.jpg" border="0" />\r\n </span></p>\r\n<p style="text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;">报告：</span><span style="font-size:12pt;font-family:宋体;">1.</span><span style="font-size:12pt;font-family:宋体;">右肺下叶近肺门处代谢异常增高的结节样高密度占位，符合肺癌表现</span><span style="font-size:12pt;font-family:宋体;">2.</span><span style="font-size:12pt;font-family:宋体;">右侧锁骨上、纵隔内及右侧肺门多发代谢异常增高的淋巴结，部分融合成团，提示淋巴结转移</span><span style="font-size:12pt;font-family:宋体;">3.</span><span style="font-size:12pt;font-family:宋体;">右侧胸腔及心包少量积液。</span></p>\r\n<p style="text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;">术后<span style="font-size:12pt;font-family:宋体;">病理：低分化磷癌。</span></span><span style="font-size:12pt;font-family:宋体;"></span></p>', 'llz007', 0, 29),
(25, 'EPT-CT的适用人群', '详细介绍', '', '', '2009-09-28 16:10:37', '116.228.141.77', 'PET-CT在肿瘤、心脏和脑部疾病的诊断和疗效评估中具有独特的优势，常用于多数肿瘤的诊断、分期和治疗评估并进行精确定位，特别适合确定有无转移和肿瘤复发，对肺癌、头颈部肿瘤、淋巴瘤、结肠癌、食道癌、胰腺癌、乳腺癌、卵巢癌和黑色素瘤等的诊断准确性大于90%。 \r\n<p>　　PET-CT也被用于心血管系统的诊断中，对冠心病的诊断、危险度分级、疗效评价和预后判断方面均有其独特优势，而且它是评价心肌存活的“金标准”。</p>\r\n<p>　　PET-CT脑显像在癫痫灶的定位、脑肿瘤的诊断、恶性程度的分级、术后或放疗后有无复发的判断、脑血管病的血流灌注、脑代谢功能的评估以及老年痴呆症的早期诊断和鉴别等都有很强的优势。</p>', 'gwm', 0, 26),
(5, 'PET/CT主要应用', '详细介绍', '', '', '2009-08-30 21:06:37', '114.81.151.142', '1．早期发现病灶。<br />\r\n2.肿瘤的分期、再分期，决定治疗方案的选择。<br />\r\n3.疗效评价。<br />\r\n4.鉴别肿瘤治疗后坏死、纤维化与残留或复发。<br />\r\n5.鉴别良恶性肿瘤或病变。<br />\r\n6.帮助制定肿瘤的放疗计划。<br />\r\n7．帮助确定穿刺部位。<br />\r\n8．判断肿瘤的恶性程度，估侧预后。<br />\r\n9.寻找肿瘤的原发灶。<br />\r\n', 'admin', 0, 29),
(6, 'PET/CT应用健康体检', '临床应用', '', '', '2009-08-30 21:09:02', '114.81.151.142', '据世界卫生组织的统计，恶性肿瘤---癌症及心脑血管疾病已成为威胁人类健康的三大主要病因。事实上当临床根据症状发现肿块时，大多数肿瘤患者已到中晚期，这时癌细胞就会象决堤的洪水，势不可挡地蔓延开来。同时到了中晚期才进行治疗，已经丧失了治疗的最佳时机。事实上，肿瘤的发展是一个漫长的过程，从基因突变开始，经过解读异常、代谢异常、功能异常、结构异常最后到临床出现症状，大多需几年甚至几十年。实践证明当肿瘤处于早期阶段及时发现基本可以治愈；PET-CT是一种灵敏度高、准确性好的高科技检查方法，对癌肿具有早期发现、早期诊断的价值，全身扫描可以发现体内小癌灶，早期诊断可以使受检者能真正得到早期治疗，尤其是对于身居要位、工作压力大的中年人，老年人或有肿瘤家族史的人，建议每隔1～2年做一次PET-CT检查。', 'admin', 0, 33),
(7, 'PET/CT的优点', '详细介绍', '', '', '2009-08-30 21:09:33', '114.81.151.142', '●分子水平的影像<br />\r\n随着人类基因图谱的成功描绘，人们已认识到许多过去难治的疾病其实就是分子病，如癌症、帕金森病等。当今世界已把疾病诊断着眼于分子标记，而这一目标的实现目前只有依靠PET才可实现。<br />\r\n●早期诊断<br />\r\n由于肿瘤细胞代谢活跃，摄取显像剂能力为正常细胞的2-10倍，形成PET图像上明显的“光点”，因此在肿瘤早期尚未产生解剖结构变化前，即能发现隐匿的微小病灶，发掘出隐藏的癌症病灶，PET/CT检查结果较单独的PET、CT或MR具有更高的准确性，特别是显著提高了对小病灶的诊断能力，使肿瘤的诊断和治疗迈上一个新台阶。诊断率高达92%~95%。<br />\r\n●全身显像<br />\r\nPET—CT一次全身25分钟连续成像就能分别获得PET、CT和两者融合的全身断层图像，并可从三个不同断层方向或立体上对图像进行分析。可直观地看到全身病变情况。这对寻找肿瘤的原发灶，转移范围、肿瘤分期及评估治疗效果有很大帮助。<br />\r\n●安全无创性<br />\r\n因为PET—CT检查所采用的核素大多数是构成人体生命的基本元素或极为相似的核素，且半衰期很短，所接受的剂量相当于一次胸部CT扫描的剂量，十分安全，短时间可以重复检查。<br />\r\n●准确定性<br />\r\n对病变的定性诊断是选择正确合理的治疗方法的关键。例如，正确地判断肺部病灶是肺癌抑或是肺炎，治疗方法是完全不同的。PET可以准确地作出鉴别诊断，诊断准确率可在90%以上。<br />\r\n●精细定位<br />\r\nPET—CT中的CT能够提供精确的解剖信息，PET和CT的融合图像如同路标，能帮助确定和查找肿瘤的精确位置，其检查结果比单独得PET或CT有更高的准确性，特别是显著提高了对小病灶的诊断能力。<br />\r\n', 'admin', 0, 91),
(8, 'PET/CT显像的原理', '详细介绍', '', '', '2009-08-30 21:11:33', '114.81.151.142', '癌症细胞分裂迅速，新陈代谢旺盛，较正常细胞消耗更大量的葡萄糖，作为分裂的能源，葡萄糖会聚集于代谢特别旺盛的癌细胞组织。<br />\r\n利用这个原理，PET扫描使用微量带有正电子的氟化脱氧葡萄糖（简称18F-FDG）注入体内，经由血液循环传送至体内组织脏器，利用正电子衰变时发射的伽玛射线，以PET扫描仪探测射线的位置及数量，经电子计算机运算重建全身各层影像，就能显示代谢特别旺盛的癌症细胞，用于诊断恶性肿瘤。<br />\r\n很方便地进行全身扫描；<br />\r\n安全、无创伤性检查；<br />\r\n高分辨率、高灵敏度，对微小癌症病灶具有最高检出率；<br />\r\n早期发现潜藏癌症。<br />\r\n<br />\r\n运用PET扫描仪的高分辨率与灵敏度作全身的扫描，由于癌细胞分裂迅速，代谢活跃，摄取氟化脱氧葡萄糖达正常细胞二至十倍的特性，造成扫描图像上出现明显的“光点”，易于发现隐匿的癌症病灶92%~95%。<br />\r\n', 'admin', 0, 35),
(18, 'PET/CT在心脏方面的应用', '临床应用', '', '', '2009-09-07 20:49:37', '114.81.27.154', '1.冠心病的PET诊断：临床上常用心肌灌注成像的方法来诊断冠心病，心肌灌注成像包括静息灌注成像＋负荷心肌灌注成像，心脏负荷药物为潘生丁和多巴酚丁胺。PET诊断冠心病的灵敏度和特异性可以达到94％和95％。<br />\r\n<br />\r\n　　2.心肌存活的测定：存活心肌是指那些因严重缺血而尚失了收缩、传导功能，但没有发生不可逆坏死性改变的心肌。PET血流－代谢显像是诊断存活心肌的“金标准”。<br />\r\n<br />\r\n　　3.PET对早期冠状动脉硬化治疗效果的评估：PET对早期冠状动脉粥样硬化低脂治疗评价出治疗前和治疗后冠状动脉的血管扩张能力，为药物作用的评价提供了可靠的依据。 <br />\r\n<br />\r\n', 'admin', 0, 29),
(17, 'PET/CT体检成时尚健康礼品', '详细介绍', '', '', '2009-09-06 07:51:36', '114.81.86.197', '　　现在PET/CT检查主要用于健康人群的肿瘤筛查，因为肿瘤的好发年龄是40～60岁，而且逐渐已经成为城市白领阶层的“第一杀手”，积极预防、早期发现、早期治疗是对付肿瘤最有效的办法，而在检测方面最权威的手段就是PET/CT检查', 'admin', 0, 32),
(22, 'PET/CT在原发性肝癌的诊断', '病例介绍', '', '', '2009-09-28 12:05:20', '116.228.141.77', '<p><span style="font-family:宋体;">患者，男性，感觉上腹部隐痛</span><span>3</span><span style="font-family:宋体;">月余，乏力，纳差，尿黄，乙肝：表面抗原（＋），</span><span>HbeAb</span><span style="font-family:宋体;">（＋），</span><span>HbeAb</span><span style="font-family:宋体;">（＋），</span><span>B</span><span style="font-family:宋体;">超：门静脉矢状部可见</span><span>42</span><span style="font-family:宋体;">×</span><span>19</span><span style="font-family:宋体;">等回声团块充填，肝内可见数个中等偏低回声团块，其中一个</span><span>97</span><span style="font-family:宋体;">×</span><span>98,</span><span style="font-family:宋体;">结论：肝硬化，肝弥漫性巨块形占位，脾大。胃镜：胃底静脉曲张，酒</span><span>2</span><span style="font-family:宋体;">斤</span><span>/ </span><span style="font-family:宋体;">天，烟</span><span>1</span><span style="font-family:宋体;">包</span><span>/</span><span style="font-family:宋体;">天。</span><span>AFP&gt;105000ng/ml</span><span style="font-family:宋体;">。</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/ee089e008ffcbcfb75ab6af6abdb8d03.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;">报告：</span></p>\r\n<p><span style="font-family:宋体;"></span><span>1.</span><span style="font-family:宋体;">肝内弥漫性团块状代谢增高灶，符合原发性肝癌表现</span></p>\r\n<p><span>2.</span><span style="font-family:宋体;">肝硬化，脾大，右侧胸腔少量积液，大量腹水</span></p>', 'llz007', 0, 15),
(19, 'PET/CT肿瘤显像评价肿瘤转移', '临床应用', '', '', '2009-09-07 20:50:22', '114.81.27.154', 'PET肿瘤显像评价肿瘤转移 <br />\r\n<br />\r\n', 'admin', 0, 30),
(21, 'PET/CT是什么  什么是PET CT ', '详细介绍', '', '', '2009-09-27 11:33:46', '116.228.141.77', '<p style="vertical-align:baseline;text-indent:21pt;text-align:justify;"><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET</span><span style="font-size:10.5pt;color:#333333;"><font face="宋体">是正电子发射计算机断层显像，英文<span>positron emission computed tomography</span>的缩写，是一种进行功能代谢显像的分子影像学设备。<span>PET</span>检查采用正电子核素作为示踪剂，通过病灶部位对示踪剂的摄取了解病灶功能代谢状态，从而对疾病正确诊断；但是<span>PET</span>对解剖结构的分辨不如<span>CT</span>。</font></span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';"> </span></p>\r\n<p style="vertical-align:baseline;text-indent:21pt;text-align:justify;"><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">CT</span><span style="font-size:10.5pt;color:#333333;"><font face="宋体">是计算机体层扫描，英文<span>computed tomography</span>的缩写。<span>CT</span>是利用<span>X</span>线对人体选定的断层层面进行照射，通过测定透过的<span>X</span>线量，获得断层图像的一种成像装置。它可以清晰地显示人体的断层影像，准确描述病变（如肿瘤）的大小、位置、形态等解剖学特征；但仅靠病变的解剖学特征诊断疾病有一定的局限性，有些病灶性质<span>CT</span>难以做出准确的判断。</font></span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';"> </span></p>\r\n<p style="vertical-align:baseline;text-indent:21pt;text-align:justify;"><span style="font-size:10.5pt;color:#333333;"><font face="宋体">所谓<span>PET-CT</span>，是将<span>PET</span>和<span>CT</span>设备有机地结合在一起，使用同一个检查床和同一个图像处理工作站。<span>PET-CT</span>同时具有<span>PET</span>和<span>CT</span>的功能，但它绝不是二者功能的简单叠加，由于<span>PET</span>与<span>CT</span>优势互补，<span>1+1&gt;2</span>。<span>PET</span>可以显示病灶病理生理特征，更容易发现病灶；<span>CT</span>可以精确定位病灶，显示病灶结构变化。<span>PET-CT</span>除了具备<span>PET</span>和<span>CT</span>各自的功能外，其独有的融合图像，将<span>PET</span>图像与<span>CT</span>图像融合，可以同时反映病灶的病理生理变化及形态结构，明显提高了诊断的准确性。</font></span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';"> </span></p><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET-CT</span><span style="font-size:10.5pt;color:#333333;font-family:宋体;">在疾病的早期阶段就能观察到功能代谢的异常。疾病的早期发现、早期治疗对提高临床治愈率至关重要。此外，一次检查就可以完成全身显像，而不只是观察某一个部位，从而避免了遗漏病灶。目前，临床常用的</span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET-CT</span><span style="font-size:10.5pt;color:#333333;font-family:宋体;">检查主要集中于肿瘤、脑和心脏三个领域。其中，</span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET-CT</span><span style="font-size:10.5pt;color:#333333;font-family:宋体;">观察到的肿瘤代谢异常明显早于其他影像学手段，探测灵敏度更高，尤其对于肺部孤立结节的良恶性鉴别有很大优势。由于</span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET-CT</span><span style="font-size:10.5pt;color:#333333;font-family:宋体;">具有很高的灵敏度，对放疗、化疗疗效的判断更加准确灵敏，从而指导医生及时调整治疗方案。在神经及精神系统方面，</span><span style="font-size:10.5pt;color:#333333;font-family:''times new roman'';">PET-CT</span><span style="font-size:10.5pt;color:#333333;font-family:宋体;">也具有独特的作用。它可以提供功能、代谢、血流灌注等多方面的信息，帮助定位癫痫灶，为脑外科手术切除癫痫病灶提供了参考。</span>', 'llz007', 0, 80),
(24, 'PET/CT实现了医学的“四定”目标', '详细介绍', '', '', '2009-09-28 16:03:28', '116.228.141.77', 'PET/CT是当今最完美、最高档次的医学影像设备，全面实现了医学影像学“四定”目标： \r\n<p>　　“定位” ：发现病变和明确病变部位</p>\r\n<p>　　“定性” ：明确显示形态和功能变化的病理和病理生理性质</p>\r\n<p>　　“定量” ：量化疾病或病变在形态学上及功能上的改变</p>\r\n<p>　　“定期” ：确定疾病的发展阶段</p>', 'gwm', 0, 27),
(26, '注意事项', '检查指南', '', '', '2009-09-28 16:11:20', '116.228.141.77', '1、检查前禁食6小时以上，做心肌显像检查例外。 \r\n<p>　　2、糖尿病患者请注意，在预约时向中心医务人员说明糖尿病病情。</p>\r\n<p>　　3、用于诊断注射用的微量放射性药物对您及周围人无健康影响，但正在妊娠或哺乳的女性受检者，请告诉医生。</p>\r\n<p>　　4、患者检查前均需提前预约，因故不能按时来检查，请提前24小时来电取消检查或重新预约时间，以免造成药物浪费。</p>\r\n<p>　　5、小儿或危重患者要有医护人员陪同。</p>\r\n<p>　　6、检查当日请将所有病情资料(包括病历、化验结果、超声、ECT、CT、MRI、病理、手术或治疗经过等)带至PET/CT中心。</p>', 'gwm', 0, 68),
(27, 'PET-CT主要检查项目', '详细介绍', '', '', '2009-09-28 16:12:10', '116.228.141.77', '　1. 全身肿瘤断层显像： \r\n<p>　　肿瘤筛查、肿瘤定性与鉴别诊断，肿瘤的分期，不明原发灶检测，疗效监测和预测，肿瘤复发灶检测与再分期，放疗生物靶区精确定位等。 </p>\r\n<p>　　2. 心肌代谢显像： </p>\r\n<p>　　冠心病的诊断，确定和鉴别坏死心肌与可逆性缺血心肌，是目前判断心肌细胞活性最准确的方法，被称为“金标准”。 </p>\r\n<p>　　3. 脑代谢显像： </p>\r\n<p>　　原发性脑肿瘤的诊断与分级，脑肿瘤精确定位，癫痫定位， 帕金森病、早老性痴呆早期诊断等。</p>\r\n<p>　　4. 全身断层显像(高端查体)： </p>\r\n<p>　　早期发现、早期诊断严重危害生命的肿瘤、心脏、脑等疾病。</p>', 'gwm', 0, 24),
(28, 'PET－CT与ECT的区别', '详细介绍', '', '', '2009-09-28 16:25:17', '116.228.141.77', '医学中把应用计算机辅助断层技术进行显像的设备统称为ECT，它是医学影像技术的重要组成部分。ECT的中文名称为发射型计算机断层显像，是其英文名称缩写而成（Emission Computed Tomography）。 \r\n<p>　　ECT实际上又包括两大类设备即SPECT和PECT，SPECT是以放射r 射线的放射性核素做为发射体的显像设备，称为单光子发射型计算机断层显像，英文为 single photon emission computed tomography。由于以前国内没有PET，因此人们习惯上把SPECT简称为ECT，因此上面我们所讨论的ECT实际应该称为SPECT。SPECT并不是一种很新的设备，其由Kuhl等人于1979年研制成功。经过多年不断的改进，SPECT技术已经有了很大的发展，产生了许多不同型号、不同档次的产品，但是其显像的基本原理没有变化，总体上仍属于比较低端的核医学设备。目前国内很多三级以上医院都已经配备SPECT，数量达300台以上，主要用于全身骨骼、心肌血流、脑血流、甲状腺等显像。</p>\r\n<p>　　ECT的另一类设备PECT是以发射正电子的放射性核素做为发射体，称为正电子发射型计算机断层显像，其英文名称为 positron emission computed tomography，即我们通常所说的PET。PET是核医学领域中最先进的显像设备，被视为核医学史上划时代的里程碑，是最高水平核医学的标志。PET所应用的显像剂如C-11、N-13，O-15等都是人体组织的基本元素，易于标记到各种生命必须的化合物、代谢产物或类似物上而不改变它们的生物活性，且可以参与人体的生理、生化代谢过程，因而能够深入分子水平反映人体的生理、生化过程，从功能、代谢等方面前面评价人体的功能状态，达到早期诊断疾病、指导治疗的目的。定性准确和一次性完成全身显像的特点极大地促进了其在肿瘤、脑神经系统疾病以及心脏病等方面的应用。我国于1995年由山东淄博万杰医院引进国内第一台PET，其后增长较为缓慢。</p>\r\n<p>　　PET的先进性显而易见，但其最大的缺点是解剖结构显示不够清晰。因此人们尝试把擅长功能显像的PET与擅长显示解剖结构的全身CT结合起来，于是在2000年世界上第一台同机一体化PET－CT在美国CTI公司研制成功，被美国《时代》杂志评选为年度最伟大的发明创造。由于PET－CT是目前最先进的PET与最好的多排螺旋CT的完美组合，达到了一加一大于二的效果，一举成为目前最豪华的医学影像诊断设备。PET与CT的同机组合极大地提高了临床医生对PET的认知度，所以一经问世便在世界范围内高速增长。2002年第一台PET－CT在国内安家落户，目前PET－CT在国内已经呈献快速发展的趋势。</p>\r\n<p>　　总体上讲，SPECT与PET相比二者可以说具有本质的区别，数据表明，SPECT的最高探测效率仅为PET的1%-3%左右，图像质量远不能与PET－CT相比，诊断效能上差距较大。二者一种是普及型的低端产品，价格较低；一种是世界上公认的最高档次的医学影像诊断设备，价格昂贵、投资巨大，很难普及和推广。</p>', 'gwm', 0, 24),
(29, 'PET-CT是如何诊断肿瘤的', '详细介绍', '', '', '2009-09-28 16:26:25', '116.228.141.77', '机体正常组织细胞的结构完整和生理功能维持主要通过糖、蛋白质、脂肪及核酸等物质的不断合成和分解过程即新陈代谢来进行。肿瘤细胞由于其无限增殖特性，DNA合成增多，氨基酸、葡萄糖等代谢物质消耗增加，从而与正常组织细胞代谢之间具有明显差异。肿瘤代谢显像主要通过某些放射性核素（如11C、18F）对这些代谢底物或类似物进行标记示踪，并以图像形式直观显示出来，能够精确、动态反映肿瘤组织与机体正常组织细胞代谢的差异，从而达到对肿瘤进行早期诊断、治疗方案选择、疗效监测的目的。<br />\r\n　　正电子发射断层扫描（positron emission tomography，PET）以正电子核素在湮灭时发射出的双光子为探测对象，具有探测效率高、分辨率好等优点；发射正电子核素如11C、13N、15O是组成人体元素的同位素，用于标记引入体内后并不改变或影响体内原有的代谢过程；所以PET显像被称为活体分子生化代谢图像，可无创、动态、定量地从分子水平观察代谢产物或放射性药物在人体内的生理生化过程。<br />\r\n　　然而PET仍存在显像时间长、无法对病灶进行精确定位等缺点，目前已经逐渐被全新的PET-CT产品所取代。PET-CT设备由于采用X线进行图像衰减校正缩短显像时间、利用CT图像进行精确的病灶定位、采用PET-CT同机融合信息排除生理性伪影等优势，从而为肿瘤分子影像的发展奠定了坚实的基础。 ', 'gwm', 0, 40),
(30, '什么是“SUV值”？', '详细介绍', '', '', '2009-09-28 16:27:32', '116.228.141.77', 'SUV<span style="font-family:宋体;">值（标化摄取值）是用以肿瘤组织摄取</span><sup><span>18</span></sup><span>F-FDG</span><span style="font-family:宋体;">示踪剂定量指标，临床通常取</span><span>SUV</span><span style="font-family:宋体;">值的大小来鉴别恶性肿瘤与良性病变，并提示肿瘤的恶性程度。例如肺部结节</span><sup><span style="font-size:12pt;">18</span></sup><span style="font-size:12pt;">F-FDG</span><span>&nbsp; </span><span style="font-size:12pt;font-family:金山简隶书;">PET</span><span> SUV</span><span style="font-family:symbol;">&gt;</span><span>2.5</span><span style="font-family:宋体;">，提示恶性肿瘤可能性较大。</span><span>Benard</span><span style="font-family:宋体;">分析</span><span>17</span><span style="font-family:宋体;">例恶性胸膜间皮瘤病人</span><sup><span>18</span></sup><span>F-FDG<span>&nbsp; </span>PET SUV</span><span style="font-family:宋体;">的中值为</span><span>4</span><span style="font-family:宋体;">．</span><span>03</span><span style="font-family:宋体;">，以该值作为两条生存曲线</span><span>(</span><span style="font-family:宋体;">低</span><span>SUV</span><span style="font-family:宋体;">和高</span><span>SUV</span><span style="font-family:宋体;">值</span><span>)</span><span style="font-family:宋体;">的分界标准，这两条曲线显示：高</span><span>SUV</span><span style="font-family:宋体;">组生存预期值迅速下降，</span><span>SUV</span><span style="font-family:宋体;">大于中值</span><span>(4</span><span style="font-family:宋体;">．</span><span>03)</span><span style="font-family:宋体;">者</span><span>12</span><span style="font-family:宋体;">个月预期累积生存值为</span><span>0</span><span style="font-family:宋体;">．</span><span>17</span><span style="font-family:宋体;">，而低</span><span>SUV</span><span style="font-family:宋体;">者为</span><span>0</span><span style="font-family:宋体;">．</span><span>86</span><span style="font-family:宋体;">，高</span><span>SUV</span><span style="font-family:宋体;">组存活时间明显短于低</span><span>SUV</span><span style="font-family:宋体;">组</span><i><span>(P</span></i><span style="font-family:宋体;">＝</span><span>0</span><span style="font-family:宋体;">．</span><span>00142)</span><span style="font-family:宋体;">。</span><span> \r\n<p>&nbsp;</p></span>\r\n<p><span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>SUV=FDG<sub>region</sub>/(FDG<sub>dose</sub>/WT) \r\n<p>&nbsp;</p></span>\r\n<p></p>\r\n<p><span><span>　　</span>FDG<sub>region</sub> </span><span style="font-family:宋体;">经过衰减校正后局部</span><sup><span>18</span></sup><span>F-FDG</span><span style="font-family:宋体;">放射性药物聚积，单位：贝可</span><span>/</span><span style="font-family:宋体;">毫升；</span><span>FDG<sub>dose </sub></span><span style="font-family:宋体;">静脉注射</span><sup><span>18</span></sup><span>F-FDG </span><span style="font-family:宋体;">剂量，单位：贝可；</span><span>WT</span><span style="font-family:宋体;">受检者体重，单位：公斤。</span><span> \r\n<p>&nbsp;</p></span><span>&nbsp; \r\n<p>&nbsp;</p></span>\r\n<p></p>\r\n<p style="text-indent:21pt;"><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-size:12pt;"><span>&nbsp;</span><sup>18</sup>F-FDG </span><span style="font-size:12pt;font-family:金山简隶书;">PET</span><span style="font-size:12pt;"> SUV</span><span style="font-size:12pt;font-family:symbol;">&gt;</span><span style="font-size:12pt;">2.5</span><span style="font-size:12pt;font-family:金山简隶书;">对恶性肿瘤诊断作用</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p>\r\n<table cellspacing="0" cellpadding="0" border="1">\r\n<tbody>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">肿瘤类型</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">诊断精确度</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">肺癌</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>94% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">结直肠癌</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>90% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">黑色素瘤</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>100% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">淋巴瘤</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>95% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">乳腺癌</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>90% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">头颈部癌</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>90% \r\n<p>&nbsp;</p></span>\r\n<p></p></td></tr>\r\n<tr>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span style="font-family:宋体;">卵巢癌</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p></td>\r\n<td width="228" height="29">\r\n<p style="text-align:center;" align="center"><span>90% \r\n<p>&nbsp;</p></span></td></tr></tbody></table>', 'gwm', 0, 25),
(31, 'PET在肺癌中的应用', '临床应用', '', '', '2009-09-28 16:28:47', '116.228.141.77', '肺癌是最常见的肺部原发性恶性肿瘤，半个世纪以来，世界各地肺癌的发病率和死亡率逐年上升，尤其在发达国家。我国肺癌的发病率也在上升，个别城市肺癌死亡率已跃居恶性肿瘤死亡的首位。虽然X线胸片、CT、MRI的发展已经相当成熟，发现肺部病变颇为容易，然而要鉴别病变的性质有时却并非容易，许多病例为了进一步明确诊断往往需要通过有创伤性的检查，如经皮细针穿刺肺活检，有时甚至是开胸探查。这些检查并发症多，且给患者带来不必要的花费和痛苦。18F-FDG肿瘤代谢显像由于能够无创性地探测生理性放射性核素在体内的分布，在肺部肿瘤的诊治特别是早期诊治中发挥了越来越重要的作用。<br />\r\n1 鉴别肺部结节的良恶性<br />\r\n孤立结节或局灶性病变是肺内病变的常见形式，临床上需要鉴别其良恶性。影像学判断病变良恶性的依据是病变的大小和形态的异常，如直径大于3cm、边缘不规则、呈分叶状、有短小毛刺、缺乏钙化等征象常被认为是恶性的。但应用这些形态学的信息判断肺内病变性质常是不够准确的，文献报道大约70%的结节CT表现不典型，而其中52%最终被证明是良性的。肺内病变定性的金标准是通过侵入性检查获取病理学依据。这些侵入性检查包括纤支镜活检、CT引导下肺穿刺吸取活检、胸腔镜和开胸切除术。纤支镜活检灵敏度只有79%，CT引导下肺穿刺吸取活检的灵敏度和特异度分别为98%和92%，但其阴性结果并不能作为良性的依据。18F-FDG PET显像在区别肺癌原发病灶方面具有重要临床价值。综合文献报道对孤立性肺结节的诊断敏感性可达到82%~100%，特异性可达75%~100%，准确性可达79%~94%。但传统的定性诊断，即通过肉眼观察发现病灶其结果容易受到报告医师主观思维的影响，目前更多的学者使用一个半定量参数来进行判断，即标准摄取比(standardized uptake ratio，SUR，即病变区域摄取FDG的平均强度与每Kg体重注射剂量比)。Duhaylongsod等总结了53例有肺部阴影患者的PET结果，研究发现恶性病灶的标准摄取比(SUR)为5.9±2.7，良性病灶为2.0±1.7，两者差异有显著性。如以SUR值≥2.5作为肺癌的诊断标准，则FDG-PET对肺癌的敏感性为100%，特异性为79%。Patz等对38例肺部孤立性结节（SPN）作了FDG-PET检查，25例FDG的SUR&gt;2.5，平均6.5±2.5；13例SUR&lt;2.5，平均1.6±0.5。经病理学检查，前25例全部为恶性病变，而后13例全部为良性病变。Patz认为以SUR小于2.5作为标准，肺部病变良性的可能性为100%。Knight等报道45例肺部病变（其中29例为恶性、16例为良性）作FDG-PET，结果恶性病变的SUR为8.9±4.9，L/B（lesion/background，病灶/本底）为16.6±12；良性病灶则分别为2.8±2.9和4.5±5。若以SUR&gt;2.5或L/B&gt;5作为鉴别良恶性的标准，整体精确率为88%。<br />\r\n18F-FDG PET显像假阴性可能发生于原发性肺类癌瘤和支气管肺泡细胞癌。类癌生长缓慢，有丝分裂不活跃；支气管肺泡癌的倍增时间较长，增殖活力相对较低，所以摄取18F-FDG较低。<br />\r\n一些感染或炎性病灶可以摄取18F-FDG异常增高，如结核性肺炎、隐球菌病、组织胞浆菌病和曲霉病等，SUV也可能增高，从而形成假阳性。但在一般情况下，慢性病程、无痛性炎症和急性感染，18F-FDG的摄取并不增高。<br />\r\n2 肺癌进行分期<br />\r\n肺癌的TNM分期是肺癌诊断中的一个重要步骤，是选择治疗方案和预后评估的可靠依据。实践发现，TNM分期与肺癌患者的预后有高度相关性，I期患者5年生存率为60％~80％，II期患者5年生存率为25％~50％，IIIa期为10％~40％，IIIb期和IV期小于5％。尸体解剖发现，肺癌可转移至全身各个系统或器官。非小细胞肺癌（NSCLC）最常发生转移的部位是骨、肝脏、肾上腺和脑。<br />\r\n目前的影像学技术（CT、MRI）对肺癌的分期有着严重的不足，其断定良恶性淋巴结的方法往往是通过测量大小，直径大的偏向于恶性，直径小的偏向于良性，然而通过与手术及病理对照证明这种粗陋的鉴别方法有着明显的缺陷。与CT、MRI相比，PET依靠病变部位的生化代谢来显示病灶，属于功能性显像，因而能准确判断肿大的淋巴结是否由癌肿转移。Patz等历经2年总结42例患者，共有62个结节病灶，其中40个位于肺门/肺叶，22个位于纵隔。均在化疗前行PET及CT检查，结果发现对肺门/肺叶淋巴结转移，PET敏感性、特异性分别为73%、76%，CT仅为27%、36%；对纵隔淋巴结转移，PET敏感性、特异性分别为92%、100%，CT仅为58%和80%。Steinert等对47例肺癌患者进行FDG-PET和增强CT扫描，其结果与手术病理作对比，发现对于N2和N3期淋巴结转移的患者，两者灵敏度分别为89%和57%，特异性分别为99%和94%，阳性预测率、阴性预测率、准确率分别为96%、97%、96%和76%、87%、85%。FDG-PET的结果优于增强CT扫描。Bury等对109例肺癌患者进行回顾性分析，FDG-PET对远处转移灶的敏感性为100%，特异性为94%，准确性为96%。根据PET结果，有34%（37/109）的患者分期进行了纠正，20%以上的患者改变了治疗方案。<br />\r\n3 肺癌疗效评价和复发病灶的诊断<br />\r\n肺癌经手术或放疗后是否存在残留病灶后复发，这一判断在临床上十分重要，但有相当难度。肺癌患者经治疗后，有两种可能：(1)治疗有效，病灶局部纤维化；(2)效果不佳，肿瘤持续存在或复发。两种情况在CT上均表现为异常影像，难以区别，有些病例还得进行有创活检，然而这不仅并发症高，而且有时由于采样时技术上的原因，并非总能找到理想的标本组织，病理诊断也不一定可靠。FDG-PET能反映肿瘤细胞的代谢特征，为肺癌疗效的早期诊断提供了有效手段。Patz等对43例怀疑肺癌复发的患者进行了FDG-PET扫描，43例患者中有35例复发，FDG的SUR明显增高者（&gt;2.5，平均SUR为7.6）34例，占97%，而仅有1例肺癌切除术后12个月活检证明复发，其SUR为1.9。而另8例平均SUR仅为1.6，均小于2.4，经16~124个月的随访，临床证明无复发。以SUR值&gt;2.5为诊断标准，则敏感性为97.1%，特异性为100%。一项研究表明了肺癌预后与FDG摄取之间的关系，156例初发的非小细胞肺癌患者接受了FDG-PET检查。118例患者SUR值&lt;10，平均生存期为24.6个月；37例SUR值≥10，平均生存期为11.4个月，明显缩短。肺癌的FDG摄取量反映了肿瘤的代谢特征，恶性程度越高，增殖越快，FDG的摄取量也越高。故临床上表现为SUR值高的肿瘤对治疗敏感，但复发率高，临床预后差。<br />\r\n综上所述，FDG-PET作为一种非创伤性、功能性的影像诊断技术能有效区别肺内良恶性病灶，还可以对肿瘤进行准确的分期，指导进一步的治疗。该技术是影像学与细胞生物特征的结合，与CT和MRI成像有着完全不同的显像基础。 ', 'gwm', 0, 19),
(32, 'PET-CT与恶性淋巴瘤', '临床应用', '', '', '2009-09-28 16:29:31', '116.228.141.77', '恶性淋巴瘤是原发于淋巴结或淋巴结外组织或器官的恶性肿瘤。根据临床和病理特点的不同，其可分为霍奇金淋巴瘤(Hodgkin''s lymphoma，HL)和非霍奇金淋巴瘤(non-Hodgkin''s lymphoma，NHL)两大类。恶性淋巴瘤治疗的关键是早期诊断、准确分期、正确判断病情以及治疗反应的监测。<br />\r\n1. 早期诊断<br />\r\n在使用18F-FDG PET评价淋巴瘤的研究中，大多数研究对象为HL和弥漫性大B细胞性NHL，对其他组织学类型的淋巴瘤研究资料有限。Elstrom R等对172例各种类型淋巴瘤患者的18F-FDG PET进行回顾性研究：18F-FDG PET准确地探测到了弥漫性大B细胞性NHL、T细胞淋巴瘤、滤泡性淋巴瘤和HL病灶。18F-FDG PET探测边缘区淋巴瘤可靠性低，尤其是结外的边缘区淋巴瘤。在对惰性B细胞性NHL的研究中发现，18F-FDG PET对滤泡性NHL的诊断、治疗有潜在优势，但对小淋巴细胞性淋巴瘤，只能探测到50％的病灶。还有一些使用标准化摄取值(standardizeduptakevalue，SUV)测定肿瘤18F-FDG摄取程度的研究认为，18F-FDG PET能够预测惰性淋巴瘤的组织学转变。但是，SUV与淋巴瘤病理亚型、有丝分裂率的关系仍有争议。<br />\r\n2．临床分期<br />\r\nHL和NHL虽然只占所有恶性肿瘤的8％，但却是少数几种可治愈的肿瘤。对恶性淋巴瘤的治疗不仅取决于其组织学亚型，而且要根据具体、准确的临床分期。18F-FDG肿瘤显像通过发现代谢异常病灶，特别是探测到其他检查未发现的隐性的腹部病灶或脾脏病灶，可显著提高了淋巴瘤最初分期的准确性。BangerterM等应用18F-FDG PET对44例已确诊为HL的患者进行治疗前评价：5例分期上调，1例分期下调。初步研究表明，在HL和NHL患者的分期方面，18F-FDG PET优于67Ga显像。<br />\r\n<br />\r\n淋巴瘤的骨髓浸润较常见，是淋巴瘤患者预后不良的征兆之一，且决定淋巴瘤的分期。研究表明，用18F-FDG PET可准确显示淋巴瘤骨髓浸润。Buchmann等比较了18F-FDG PET与CT、骨髓活检在NHL和HL分期中的作用，结果是18F-FDG PET优于CT；8％（4／52）患者经18F-FDG PET导致分期上调，改变了治疗计划。Moog FM等对78例淋巴瘤患者的18F-FDG PET、骨髓活检结果进行了比较，其中64例患者的双侧骨髓活检与18F-FDG PET结果一致；对10例骨髓18F-FDG摄取增高而骨髓活检阴性的患者进行MRI、聚合酶链反应(polymerasechainreaction，PCR)等检查，证实其中8例淋巴瘤累及骨髓；有4例患者PET没有探测到骨髓浸润。<br />\r\n3．疗效评价<br />\r\n对淋巴瘤治疗的最终目标是通过化疗、放疗等疗法的毒性作用，彻底清除肿瘤细胞。然而，各种淋巴瘤对治疗的反应相差甚大。造成这种反应差异的原因是肿瘤组织学类型、生物学差异、药物抵抗机制、放疗或化疗敏感性的不同等。在治疗中或治疗后及早判断治疗反应有利于及时更改治疗方案。<br />\r\n常规解剖显像对肿瘤反应或进展的判断基于肿瘤的大小，治疗有效时，由于治疗引起的肿瘤结构变化滞后于肿瘤细胞的死亡，解剖显像上的肿块可持续存在。而18F-FDG PET可显示肿瘤代谢活性明显减低，肿瘤对18F-FDG摄取减少或消失是在临床或亚临床水平上对肿瘤治疗有效的早期标志，及时评价治疗效果可修正临床恶性淋巴瘤的治疗方案应用。 ', 'gwm', 0, 16),
(33, '什么是“放射性药物”？安全吗？', '详细介绍', '', '', '2009-09-28 16:30:02', '116.228.141.77', '<font face="宋体">放射性药物（</font><span>radiopharmaceuticals</span><span style="font-family:宋体;">）是一类含有放射性核素的、用于人类疾病诊断和治疗的特殊药物。放射性药物与一般非放射性药物一样，引入体内后，由于其本身的特点，能够聚集在特定的组织器官或参与组织细胞的代谢，通过</span><span>PET</span><span style="font-family:宋体;">探头内特殊的装置和计算机图像处理显示这些微量的放射性药物在体内的分布，巧妙地构成活体组织细胞的三维立体或断层影像。放射性药物的特点：化学量甚微，不存在体内蓄积而引起化学危害；具有微量的放射性，对受检者不构成大的损害。例如，</span><sup><span>18</span></sup><span>F-FDG</span><span style="font-family:宋体;">（</span><span>18-</span><span style="font-family:宋体;">氟标记氟代脱氧葡萄糖）是在一个脱氧葡萄糖分子上标记一个发射正电子核素</span><span>18-</span><span style="font-family:宋体;">氟原子，不改变</span><span>FDG</span><span style="font-family:宋体;">分子体内生化代谢特性，能够被正常的脑组织，以及恶性肿瘤组织摄取。<font color="#ff0000">一次检查所接受的放射量仅为一次胸部</font></span><font color="#ff0000"><span>X</span><span style="font-family:宋体;">光照片的放射量，无过敏反应，所以，</span><span>PET－CT</span><span style="font-family:宋体;">检查是安全的、无创伤性的。</span></font>', 'gwm', 0, 38),
(34, 'PET-CT在肿瘤临床诊断中的应用', '临床应用', '', '', '2009-09-28 16:30:28', '116.228.141.77', 'PET-CT适用于人体大多数良恶性肿瘤的鉴别诊断、分期分级以及全身状况的评估；治疗前后疗效评估（包括：手术后肿瘤残留情况或复发与疤痕组织的鉴别、放疗和化疗前后肿瘤病灶的变化、放射性肺炎与肿瘤复发的鉴别等） 及肿瘤转移灶的全身监测。肿瘤原发灶的及时诊断对制订治疗方案十分关键。对病人的预后及生存时间也致关重要。而临床上相当数量的转移性肿瘤患者难以检出原发肿瘤的部位。对这些原发灶不明的患者，进行全身PET-CT检查则可同时了解肿瘤原发灶及全身转移情况，包 括骨骼及软组织的转移，为指导组织学定位诊断及选择正确的治疗方案提供可靠依据。PET-CT在如下常见肿瘤临床诊断中的应用为：<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.肺癌：孤立性肺结节（SPN）的良恶性鉴别诊断。如果FDG摄取阴性，96%提示为良性病变；不明原因的恶性胸腔积液或肿瘤标志物增高或发现转移性肿瘤等欲寻找其原发病灶；肺癌精确的临床分期（TNM）：PET全身显像一次可提供肺、纵隔淋巴结、肝、肾、 肾上腺、骨骼、脑等部位有无转移的信息；肺癌治疗后有无残余的肿瘤活性病灶；评价 肺癌放疗、化疗的疗效。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.结直肠癌：结直肠癌术前临床分期，以指导制订临床治疗方案；结直肠癌术后CEA水平升高而常规检查阴性的患者；直肠癌放疗后局部肿瘤复发与纤维化的鉴别诊断淋巴瘤； 淋巴瘤临床分期? 淋巴瘤骨髓浸润的评价；淋巴瘤化疗、放疗疗效评价和临床缓解评 价；对不明原因发热的病因进行协助诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.头颈部肿瘤：头颈部肿瘤隐慝性病灶及浸润范围的诊断；颈部转移性肿瘤寻找原发病 灶；头颈部肿瘤的临床分期；头颈部肿瘤放化疗疗效评价，头颈部肿瘤治疗后肿瘤复发的 早期诊断，与纤维化鉴别诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.脑肿瘤：胶质瘤的分级和预后评估；恶性脑肿瘤和其他炎症等良性病变的鉴别；脑肿 瘤放疗后改变与复发的鉴别。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.食道癌：食道癌术前的临床分期，指导制订临床治疗方案；食道癌放疗后局部肿瘤复发 与纤维化的鉴别诊断；食道癌治疗后再分期。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.乳腺癌：乳腺癌术前诊断和分期；乳腺癌术后，协助指导制订临床治疗方案；乳腺 癌放疗后局部肿瘤复发与纤维化的鉴别诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.其他肿瘤：如黑色素瘤、骨肉瘤、胰腺癌、甲状腺癌、宫颈癌、卵巢癌、精原细胞癌等多种肿瘤的临床诊断与分期。 ', 'gwm', 0, 19);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(35, 'PET-CT与头颈部肿瘤', '临床应用', '', '', '2009-09-28 16:31:06', '116.228.141.77', '头颈部肿瘤是比较常见的肿瘤，在我国以鼻咽癌占首位，喉癌和甲状腺癌次之。在美国则以喉癌占首位。头颈部肿瘤所处位置软组织较紧，同时淋巴供应丰富，极易出现淋巴结转移，同时常常是不明原发灶癌淋巴道转移的首发部位。<br />\r\n头颈部解剖结构复杂，但易于进行病理活检和外科治疗。CT、MRI和超声诊断等由于其在解剖结构的高分辨能力而在该领域发挥重要作用，但在肿瘤诊断治疗中，这些影像技术有一定局限性。正电子发射断层（PET）显像在头颈部肿瘤的诊断、治疗后的评价方面具有重要价值。<br />\r\n一、 临床诊断<br />\r\n1．PET显像在头颈部肿瘤的诊断具有重要作用<br />\r\nDi Martino等对50例头颈部肿瘤病例进行一个预期性评价。患有糖尿病和急性炎症的病例被排除在外。所有的病人都进行彩超、CT和PET检查。显像都经衰减校正，同时对可疑病灶进行标准摄取值（SUV）计算。在平均约为1年的随访病人中，大约2/3的病人都进行了颈部手术。显像研究结果与行病理检查和全上消化道内镜检查的病例进行比较。PET显像对原发肿瘤的灵敏度与特异性分别为95％、92％，相较而言，CT显像的灵敏性与特异性分别为68％、69％，超声为74％、75％。而对再发肿瘤，PET显像的准确性为100％。CT显像的灵敏性与特异性分别为67％和80％，超声的灵敏性与特异性分别为67％和100％。从统计学上来讲，PET显像明显优于CT显像。然而PET的解剖定位的有限性导致其使用具有逐渐下降趋势，而CT显像仍是目前解剖定位的显像手段。PET-CT显像在此方面具有较好的融合效果。<br />\r\n2．对转移灶和第二原发瘤的诊断<br />\r\n头颈部鳞状细胞癌易于转移到局部淋巴结，如果存在淋巴转移，治愈率将下降50%，CT和MRI对淋巴转移的误诊率约7.58%，第二原发瘤占初诊病人的3%，<br />\r\n<br />\r\n此诊断结果有助于在肿瘤评价中进行淋巴结转移分类，制定治疗方案，减低复发率，提高生存率。与其他常规方法比较，PET在对转移灶和第二原发瘤诊断中有明显的优势。<br />\r\n3．对原发灶不明颈部淋巴结转移癌的诊断<br />\r\n一般以PET或PET-CT作为原发灶不明颈部淋巴结转移癌的首选检查手段。有研究报道不明颈部淋巴结转移癌患者的18F-FDG PET显像原发灶检出率为44%，诊断价值明显优于CT和MRI。18F-FDG PET显像的另一优势是可在全身范围内探查可疑原发灶和转移灶，有助于临床分期并指导治疗。文献也报道，不明原发灶上、中颈部淋巴结转移癌有相当一部分来源于同侧的扁桃体组织。<br />\r\n二、疗效评价<br />\r\nPET在头颈部肿瘤治疗疗效评价及治疗后复发诊断中有独到的作用。由于肿瘤手术、放疗后导致的组织结构的扭曲和疤痕形成（尤其在喉、舌根及口咽部），使常规影像方法难以检测残余肿瘤或肿瘤的复发，特别是在治疗后1年内。利用18F-FDG PET代谢显像可监测放化疗的疗效，对晚期肿瘤患者的化疗进行旱期疗效评价。由于治疗中的肿瘤细胞浓聚18F-FDG的量和生长速率呈线形关系，病灶部位FDG摄取增加意味着治疗的失败，并且可用于区分无治疗反应的病例，避免不必要的治疗副作用，及早改用其他方法。据研究报道，对44例晚期（3期、4期）头颈部肿瘤患者治疗后1年内进行18F-FDG PET检查，并与其他显像方法（MRI和CT）比较：在第一年中只有PET检测到所有的复发灶，灵敏度为100%，特异性为93%，而常规方法的诊断灵敏度仅为38%，特异性为85%。<br />\r\n鼻咽癌（NPC）不同于其他头颈部的肿瘤。基于解剖变化的CT显像，对于探测再发和残余NPC有低的灵敏性和中等的特异性，但在放疗（RT）后具有明显变化。放疗后普遍存在不同程度的纤维化团块和不对称性，这样将导致假阳性。而且，NPC再生多发于粘膜下，因此CT可以很容易地探察到NPC的再发与残余肿瘤。在Kao等的研究中，36位接受4个月放疗的NPC病人在治疗前曾经行99mTc的SPECT、CT、FDG-PET头颈部显像检查以用来区别NPC再发和残余与良性病变。基于活组织检查，99mTc-TF SPECT的灵敏度与特异性是64％和96％，用于区别再发或从良性病变中分辨NPC。其中CT的灵敏性与特异性分别为73％和88％，FDG为100％和96％。由此作者得出FDG-PET显像是探测NPC再发与残余的最佳工具。<br />\r\n', 'gwm', 0, 15),
(36, 'PET和PET－CT在肺癌早期发现中的作用', '临床应用', '', '', '2009-09-28 16:33:41', '116.228.141.77', '<strong>主持人：</strong>两位专家说得非常好。看一下网友的问题。 \r\n<p>　　<strong>网友：</strong>我父亲2004年5月做CT加密片，发现肺部有1.2×1.2厘米的肿瘤，因为不方便取病理，无法确诊，打消炎吊瓶20多天，最近又做了CT加密片，是1.5×1.5厘米，这会不会是误差，如果是恶性的话，两年变化这么小，可不可能，有什么更精确检测可以查一下吗？下一步应该怎么办？</p>\r\n<p>　　<strong>韩宝惠：</strong>他做了增强的胸部CT的检测，在2004年发现胸部CT有1.2×1.2厘米的肿块，但是遗憾的是没有做进一步检查，作为肿瘤来讲，一般要求是拿到肿瘤细胞，就是做到细胞学和组织学的检测，如果有特殊情况，在穿刺和检察上无法做到组织学和细胞学的检测，可以做一个更加比较先进的无创的检查，也就是所谓的PET按检查，PET检查也是敏感性和特异性，到目前为止是比较好的检测方法。 \r\n<table cellspacing="0" cellpadding="0" align="left" border="0">\r\n<tbody>\r\n<tr>\r\n<td valign="top"></td></tr>\r\n<tr>\r\n<td>\r\n<table>\r\n<tbody>\r\n<tr>\r\n<td></td></tr></tbody></table></td></tr></tbody></table>我不妨建议，如果他无法做其他的有创性的检查，应该再做一下PET检查，来确定这个肿块到底代谢的活性是高还是低，然后再根据这个判断一下恶性的还是良性。</p>\r\n<p>　　<strong>支修益：</strong>PET在我们国家越来越普遍，每个省市，省会医院，包括大的地市级医院都走进百姓生活中来，它不同于CT，从影像学角度能够看到病变代谢值，结合CT，特别是新一代的PET，PET－CT，更能够帮助，能够诊断和鉴别诊断一些肺癌的早期病变。第二，像刚才韩教授所讲，目前更加重视我们的细胞学诊断，如果你的病变是周围型的，可以通过CT 引导下的经皮的肺穿刺，得到细胞学的诊断。目前像北京市有七八台PET-CT和PET，上海也有很多，我们也希望在我们医保部门合理的调整价格的同时，进入医保项目的同时，更多的病人能从PET和PET-CT里在早期诊断里得到益处。</p>\r\n<p>　　<strong>主持人：</strong>但听说PETCT费用特别高，一次将近一万多对吧？</p>\r\n<p>　　<strong>支修益：</strong>没有，PET对全身的肿瘤和所有的恶性肿瘤是一万元，针对肺癌的分期，肺癌的诊断，单纯做一次胸部的话，也就在四五千块钱，我们做一个PET如果从自费角度只花两三千块钱，随着PET的普及，医保部门，医疗部门都能在好的设备下面给病人让出更多的利益，让病人得到检查。</p>\r\n<p>　　<strong>主持人：</strong>PET－CT和PET的敏感度怎样，对多大的肿瘤能早期发现？</p>\r\n<p>　　<strong>支修益：</strong>我们比较一下，CT整个准确率、精确率，诊断负荷，阳性预定值，按照老百姓的话叫准确率，在60%、70%、80%左右，PET特别是PET－CT，在整个病灶部位的诊断负荷率，阳性预值方面能达到90%甚至能达到95%，我们说病灶本身。因为中国是结核病大国，PET也存在假阳性和假阴性的情况，在结核病方面可能存在假阳性。如果你是专科医生，像韩教授和我，我们俩都是搞肺癌的医生，根据你的情况能除掉假阳性，假阴性，正确判断PET给我们的数据值，从而判断肺的病灶因素。目前PET和PET－CT，不光在病灶诊断方面，在肺癌的淋巴结方面有更多的临床研究。一会我们再继续说。</p>', 'gwm', 0, 27),
(37, 'PET/CT在冠心病治疗中的应用及其发展前景', '临床应用', '', '', '2009-09-28 16:34:42', '116.228.141.77', '　编者按：9月6—8号，第十六届中国国际医用仪器设备展览会暨技术交流会在京召开。其中，心血管病影像诊断新技术研讨会于9月7号在北京展览馆举行。会上，姚稚明教授以“PET/CT在冠心病诊治中的应用”为主题发表演讲。会后，心血管网记者就相关问题对姚稚明教授进行了采访。 \r\n<p><br />\r\n</p>\r\n<p align="center"><img style="width:299px;height:213px;" height="213" src="http://file.pet-ct.cn/PET-CT/linchuangyingyong/2009-01-20/77e14fc946e3f2c308e084a93b225ea6.jpg" width="299" border="0" />\r\n <br />\r\n姚稚明教授在<font face="Verdana">心血管病影像诊断新技术研讨会上讲课</font></font/></p></font/>\r\n<p></font/><strong>心血管网：</strong>姚教授，您好！很高兴可以采访到您！您能不能谈一下，PET/CT它的发展前景怎么样？<br />\r\n<strong>姚稚明教授：</strong>好的！目前PET/CT主要应用是在肿瘤方面，第二个应用方向就是心脏和神经系统。<br />\r\n　　我们国内去年完成的十家三甲医院的PET/CT调查发现，大概不到10%是用于心脏和神经，90%以上是用于肿瘤学的。我觉得这和国情是有关系的，像在美国和欧洲一些国家做PET/CT是可以报销的，所以在国外一些外科大夫做心脏搭桥手术之前一定会让你做一个有没有心肌存活的检测。如果没有心肌存活，没有心肌灌注的情况下，外科医生是会拒绝做这个手术的，因为搭完桥之后病人不解决问题，术前没做相关检查，保险公司肯定会找他的，国外的情况就是这样子。但是在我们国家，因为心脏PET/CT检查是私费的性质，所以有难度，不可能实行。<br />\r\n　　另外PET/CT在神经方面主要是神经受体的显像，因为现在没有任何一个影像学可以做到神经受体的显像，只有核医学可以做到这一点。核医学实际上很多是分子影像学方面的检查， PET成像用的正电子核素，如碳、氢、氧等，很容易标价到神经、受体、基因表达物质上，制作成PET显像剂。PET显像对分子水平变化的敏感性还是挺高的，它能有效测量体内分子水平微量变化，从而在分子水平显示病理生理和生物化学变化。<br />\r\n　　所以说PET成像还是非常有前景的，现在用PET/CT，今年已经有PET/MRI了，各种影像学都会往分子影像学上靠。最近这几年肿瘤核医学在PET/CT方面的应用已经热过了，下一步应该是在神经方面，神经方面主要是神经受体的显像剂，未来几年PET/CT在神经方面应该很有发展前景。PET在心脏方面的应用目前主要还是在存活心肌方面，因为国内受费用限制不会成为常规，国外心肌梗塞病人，尤其是有较广泛的心肌梗塞伴心功能不良的病人还是常规要做。<br />\r\n<br />\r\n</p>\r\n<p align="center"><img style="width:293px;height:215px;" height="215" src="http://file.pet-ct.cn/PET-CT/linchuangyingyong/2009-01-20/ebc7063a744ac994c5b758e02beaa34d.jpg" width="293" border="0" />\r\n <br />\r\n心血管网采访姚稚明教授</p>\r\n<p><strong>心血管网：</strong>PET/CT 能够完成定位、定性、定量、定期“四定”诊断，您是否可以谈一下PET/CT在冠心病的诊断治疗方面有怎样的作用？<br />\r\n<strong>姚稚明教授：</strong>目前在冠心病的诊断治疗中，临床用PET/CT的有两种。一个是心肌梗塞的病人，用来诊断梗塞区域有没有存活性。因为冠心病病人心肌梗塞了，里面有存活心肌，通过搭桥或者球囊扩张，把血管扩开，血流通，血流灌注到这个区域了，就能挽救濒临死亡的心肌。但是对于已经形成瘢痕的心肌，已经坏死了，已经有纤维组织替代了的那块的心肌区域，搭完桥血流通过去了，它照样不行，因为心肌细胞已经死亡了。所以我们在手术以前要检测心肌代谢情况。<br />\r\n　　另外一个就是心肌灌注显像，主要应用是看心肌有没有缺血。因为冠脉狭窄一般来说可以导致心肌缺血，但是有侧支的话，心肌血流灌注减低的程度可能并不是那么严重。因为血管有储备能力，做治疗之前先看有没有心肌缺血，再看心肌缺血的范围有多大。范围的大小涉及到治疗采取什么样的抉择，比方说三支血管病变，要确认是搭桥还是PCI呢？治疗方案有很大的差距。不仅需要冠状动脉造影予以确定，心肌灌注显像对再血管化方案的确定也有帮助。<br />\r\n　　另外，已经有冠状动脉狭窄，已经心肌缺血了，说明冠心病病情发展已经到了晚期。实际上我们要把冠心病的早期，还没有缺血，冠状动脉血流储备能力下降了就要早期介入。该戒烟的戒烟，该降血脂的降血脂。及早介入，这样病情就不会继续发展或会减缓发展。这是PET/ET做到的，它能够早期测量冠脉储备，在心脏目前用的就是这样。<br />\r\n　　还有一些显像，如细心肌胞凋亡的显像，心肌梗塞了，心肌细胞正在凋亡的过程也可以成像，目前还主要处于研究阶段。另外还有一些神经受体的显像，如胆碱能受体、交感神经能受体、还有神经递质都可以作为显像剂，这些显像都跟诊断心律失常、心肌病有关系，都处于研究状态，没有真正在临床常规用。现在常规用的是心肌灌注和心肌代谢显像。虽然研究中的显像剂最终走到临床的过程比较遥远，但它还是会逐渐的应用到临床当中。<br />\r\n<br />\r\n</p>\r\n<p align="center"><img style="width:253px;height:176px;" height="176" src="http://file.pet-ct.cn/PET-CT/linchuangyingyong/2009-01-20/eed124c6ef1abe3fd25c2bee81a3e09b.jpg" width="253" border="0" />\r\n <br />\r\n姚教授讲课</p>\r\n<p><strong>心血管网：</strong>您从事临床多年，是否可以给其他医生一些建议？谈一下PET/CT在临床应用上需要注意哪些方面？<br />\r\n<strong>姚稚明教授：</strong>我觉得虽然PET/CT比较贵，但是我们也可以以具备PET功能的ECT进行存活心肌的检测。具备部分PET功能（具有符合线路设计）的ECT，其检查费用还是可以部分报销的。尤其是心肌梗塞范围比较大、心功能不好的病人，在术前尽量做个存活心肌检测，这是非常重要的。否则，心肌梗死伴瘢痕形成病人术后愈后不仅不会好，做完后还可能会加重。对于这种病人，检测心肌存活的检查很实用。<br />\r\n<strong>心血管网：</strong>好的。谢谢姚教授！</font/></p>', 'gwm', 0, 17),
(38, '为什么要使用PET-CT', '详细介绍', '', '', '2009-09-28 16:35:19', '116.228.141.77', '<table cellspacing="0" cellpadding="0" width="100%" border="0">\r\n<tbody>\r\n<tr>\r\n<td>为什么要使用PET-CT？ </td></tr>\r\n<tr>\r\n<td>&nbsp;</td></tr>\r\n<tr>\r\n<td>PET/CT是本世纪新开发商品化的一种仪器，应用于临床到目前为止仅有4年时间，国内也是在近两年内陆续引进。主要是通过将目前临床使用的PET和CT融合在一起，通过将PET和CT两种诊断信息整合，较单一PET或单一CT更具临床价值。而且由于其可以缩短检查和报告时间，可明显提高工作效率和病人舒适性；使某些生理性FDG摄取得以和肿瘤病灶相区别，提高了诊断特异性，帮助治疗方案的选择和解释疾病的原因。临床上除了PET及CT的所有应用之外，还可用于肿瘤放疗计划的制订，使肿瘤放射治疗剂量更为精确和个性化。<br />\r\n</td></tr></tbody></table>', 'gwm', 0, 30),
(40, '第二代PET-CT用于肿瘤诊断', '临床应用', '', '', '2009-09-28 16:36:38', '116.228.141.77', '&nbsp;PET（正电子发射断层显像）是近年发展起来的一种新型分子影像技术，最近第二代PET－CT也已引入我国。PET的基本原理是用不稳定核素对某些可以在肿瘤细胞内浓聚的分子进行标记，这些带正电子的核素与体内的负电子结合后可被PET的光敏晶体探测到，从而得到被标记分子在人体内分布的三维图像。目前标记物中应用最多的是18F标记的脱氧葡萄糖（18F－FDG）。由于机体的病理变化总是代谢改变在先，形态结构改变在后。同时恶性肿瘤及其转移灶具有细胞生长速度快、新陈代谢旺盛、增殖能力强等特点。PET逐渐成为对肿瘤提前“报警”的方法。 <br />\r\n尽管PET在肿瘤的诊断方面具有无可比拟的优势，但其却存在病灶定位准确性差的缺点。上海四五五医院引进的第二代PET－CT能有效弥补这一缺陷，其将PET扫描装置和CT扫描装置同机结合，使人体各个器官组织的形态与功能信息有机结合在一起，有效地弥补了单纯PET图像或单纯CT图像的不足。 \r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PET－CT可用于诊断很多类型的肿瘤，包括肺癌、乳腺癌、淋巴瘤、结直肠癌等。 </p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 肺癌居我国城市居民癌症死亡病因的第一位。目前，18F－FDGPET显像用于肺癌诊断及临床分期的效－价比已得到充分肯定，其不仅能早期检出肺癌病灶，确定病变性质，准确进行临床分期，而且还可以进行疗效评价，监测复发。最近一项包括13个研究的综合分析报道显示，尽管PET－CT诊断肺结节的敏感性和特异性与CT无显著性差异，但鉴别诊断特异性明显高于CT。而肺内孤立结节的良、恶性判断常是临床医生与影像医生最为棘手的问题。除常规的葡萄糖代谢显像外，18F－FLT（18F－脱氧胸腺嘧啶）显像能够测定肿瘤细胞的增殖状况，特异性更强。 </p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 恶性淋巴瘤为一种全身性疾病，病灶分布广泛，通过全身葡萄糖代谢显像可以很方便地观察病灶的部位和分布情况，准确分期，为临床制订合理的化疗方案提供依据；对治疗后的患者可准确判断残余病灶的有无，以便临床医生及时调整化疗方案，并为进一步行干细胞移植手术保驾护航。 </p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 乳腺癌的早期诊断对治疗方案的选择具有重要意义，PET－CT诊断乳腺癌的灵敏度和特异性均在95％以上，同时还可有效发现转移灶。由于大多数乳腺癌细胞表面保留了正常乳腺组织所含有的类固醇激素受体，新近应用于临床的18F－FES（18F－雌激素受体）显像剂能够和乳腺癌细胞表面受体结合，监测乳腺癌组织中雌激素受体的分布和浓度情况，指导临床采取有针对性的治疗方案。 </p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PET－CT的价值还不仅仅是用于癌症最初诊断，它也是癌症病人整个治疗计划和治疗监控阶段的杰出“助手”。恶性肿瘤往往没有完整的包膜，在传统影像学上表现为浸润性生长，与正常组织不易区分，而获得准确的病灶信息对于肿瘤放射确定极为重要。PET－CT通过一次检查可准确获得病灶及周围组织转移的情况，区分有活性与无活性的肿瘤组织或转移性淋巴结，为放射治疗师勾画更为合理的生物靶区，为现有的精确放疗设备提供帮助。肿瘤治疗后疗效的好坏是患者和家属最为关心的问题，PET－CT使这些问题也轻松解决。 </p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 此外，PET－CT对原发灶不明的转移性肿瘤查找原发灶也具有无可比拟的优越性。 </p>', 'gwm', 0, 19),
(41, 'PET-CT有什么用?', '详细介绍', '', '', '2009-09-28 16:37:29', '116.228.141.77', '首先，对健康人群的常规体检可以排查肿瘤。肿瘤防治基本原则是“三早”：早期发现、早期诊断、早期治疗。根据以往的理论，有1/3的癌症是可以早期发现的，1/3的癌症是可以治愈的，1/3的癌症通过治疗可以延长寿命。PET-CT早期发现肿瘤的功能无疑将大大提高肿瘤防治水平。 \r\n<p>　　其次，PET-CT还对制订癌症的治疗方案，发挥重要作用。最新资料表明，通过PET-CT检查，使30％的肿瘤患者避免了不必要的外科手术，使20％的患者改变了放疗方案，从根治放疗变为姑息放疗，为患者减轻了很大的痛苦。</p>\r\n<p>　　PET-CT常用于肿瘤的诊断、分期和治疗评估并可进行精确定位，特别适合确定有无转移和肿瘤复发，对肺癌、头颈部肿瘤、淋巴瘤、结肠癌、食道癌、胰腺癌、乳腺癌、卵巢癌和黑色素瘤等的诊断准确性大于90％。</p>\r\n<p>　　据了解，上海四五五医院PET-CT高端体检中心引进的PET-CT中的16层螺旋CT，可以通过三维立体成像及多平面重建，清晰地展示病灶及其同周围组织的关系，不仅能准确诊断各种血管性病变，而且在肿瘤的诊断与鉴别诊断中提供更多的信息。另外16层螺旋CT具有仿真内窥镜功能，能很好反映空腔脏器的结构。</p>\r\n<p>　　另外，PET-CT也被用于心血管系统的诊断中，对冠心病的诊断、危险度分级、疗效评价和预后判断方面均有其独特优势，而且它是评价心肌存活的“金标准”。</p>\r\n<p>　　PET-CT脑显像还可用于癫痫灶的定位、脑肿瘤的诊断、恶性程度的分级、术后或放疗后有无复发的判断、脑血管病的血流灌注、脑代谢功能的评估以及老年痴呆症的早期诊断和鉴别等。</p>', 'gwm', 0, 33),
(42, 'PET-CT对肺癌的诊断价值 ', '临床应用', '', '', '2009-09-28 16:38:10', '116.228.141.77', '1.PET-CT对肺癌分期的价值： \r\n<p>　　CT、MR对直径大于1.5cm的淋巴结才考虑可能为转移,但病理发现小于1cm的淋巴结已有转移,大于1.5cm的淋巴结可以为炎性淋巴结,PET-CT通过分子和解剖显像的结合,能够发现5mm左右的转移淋巴结,特别对颈部、锁骨上、纵隔淋巴结转移的显示,优于其它影像学检查.</p>\r\n<p>　　2.对肺癌治疗决策的影响：</p>\r\n<p>　　部分病人行PET-CT显像后因发现了隐匿性转移灶使临床分期上升，从而避免了不必要的手术创伤和手术费用;</p>\r\n<p>　　部分病人因PET-CT除外了一些对分期有重要意义的转移灶而使分期下降，使之获得了根治性手术治疗;</p>\r\n<p>　　在适形放射治疗方面，PET-CT的意外发现可减少部分病人因漏诊转移灶而使治疗不彻底，从而提高了治疗的质量。</p>\r\n<p>　　3.在肺癌疗效监测及残余、复发病灶诊断方面的价值：</p>\r\n<p>　　PET-CT常能在病灶形态改变前灵敏地检测出病灶的代谢改变，治疗前阳性病灶经治疗后消失，提示完全反应（肿瘤细胞被灭活或被明显抑制）；病灶代谢程度明显降低者，提示部分反应；持续阳性者提示疗效差,从而对治疗方案进行评价并有助于及时地调整治疗方案。</p>', 'gwm', 0, 22),
(43, 'PET-CT在神经系统中的应用', '临床应用', '', '', '2009-09-28 16:38:46', '116.228.141.77', '脑代谢显像能准确了解正常情况下和疾病状态下的神经细胞活动及代谢变化，以及不同生理条件刺激和思维活动状态大脑皮质的代谢情况。通过PET直观地了解到人大脑代谢活动情况及各种生理性或病理性代谢变化，并以图像的方式反映出来。 \r\n<div align="left">&nbsp;</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>具体应用：</font></div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>1.&nbsp;&nbsp;癫痫定位：</font> 对脑癫痫病灶准确定位，为外科手术或伽玛刀切除癫痫病灶提供依据；</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>2.&nbsp;&nbsp;脑肿瘤定性和复发判断：</font> 脑肿瘤的良恶性定性、恶性胶质瘤边界的确定、肿瘤治疗后放射性坏死与复发的鉴别、肿瘤活检部位的选择等。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>3.&nbsp;&nbsp;痴呆早期诊断：</font>早老性痴呆的早期诊断、分期并与其他类型痴呆如血管性痴呆进行鉴别。&nbsp;</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>4.&nbsp;&nbsp;脑受体研究：</font>帕金森病的脑受体分析，进行疾病的诊断和指导治疗。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>5.&nbsp;&nbsp;脑血管疾病：</font>PET可以敏感地捕捉到脑缺血发作引起的脑代谢变化，因此可以对一过性脑缺血发作（TIA）和脑梗死进行早期诊断和定位，并进行疗效评估和预后判断。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>6.&nbsp;&nbsp;药物研究：</font>进行神经精神药物的药理学评价和指导用药，观察强迫症等患者脑葡萄糖代谢的变化情况，为立体定向手术治疗提供术前的依据和术后疗效随访等。 </div>', 'gwm', 0, 22),
(44, 'PET-CT在肿瘤临床诊断中的应用', '临床应用', '', '', '2009-09-28 16:39:11', '116.228.141.77', 'PET-CT适用于人体大多数良恶性肿瘤的鉴别诊断、分期分级以及全身状况的评估；治疗前后疗效评估（包括：手术后肿瘤残留情况或复发与疤痕组织的鉴别、放疗和化疗前后肿瘤病灶的变化、放射性肺炎与肿瘤复发的鉴别等） 及肿瘤转移灶的全身监测。肿瘤原发灶的及时诊断对制订治疗方案十分关键。对病人的预后及生存时间也致关重要。而临床上相当数量的转移性肿瘤患者难以检出原发肿瘤的部位。对这些原发灶不明的患者，进行全身PET-CT检查则可同时了解肿瘤原发灶及全身转移情况，包 括骨骼及软组织的转移，为指导组织学定位诊断及选择正确的治疗方案提供可靠依据。PET-CT在如下常见肿瘤临床诊断中的应用为：<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.肺癌：孤立性肺结节（SPN）的良恶性鉴别诊断。如果FDG摄取阴性，96%提示为良性病变；不明原因的恶性胸腔积液或肿瘤标志物增高或发现转移性肿瘤等欲寻找其原发病灶；肺癌精确的临床分期（TNM）：PET全身显像一次可提供肺、纵隔淋巴结、肝、肾、 肾上腺、骨骼、脑等部位有无转移的信息；肺癌治疗后有无残余的肿瘤活性病灶；评价 肺癌放疗、化疗的疗效。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.结直肠癌：结直肠癌术前临床分期，以指导制订临床治疗方案；结直肠癌术后CEA水平升高而常规检查阴性的患者；直肠癌放疗后局部肿瘤复发与纤维化的鉴别诊断淋巴瘤； 淋巴瘤临床分期? 淋巴瘤骨髓浸润的评价；淋巴瘤化疗、放疗疗效评价和临床缓解评 价；对不明原因发热的病因进行协助诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.头颈部肿瘤：头颈部肿瘤隐慝性病灶及浸润范围的诊断；颈部转移性肿瘤寻找原发病 灶；头颈部肿瘤的临床分期；头颈部肿瘤放化疗疗效评价，头颈部肿瘤治疗后肿瘤复发的 早期诊断，与纤维化鉴别诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.脑肿瘤：胶质瘤的分级和预后评估；恶性脑肿瘤和其他炎症等良性病变的鉴别；脑肿 瘤放疗后改变与复发的鉴别。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.食道癌：食道癌术前的临床分期，指导制订临床治疗方案；食道癌放疗后局部肿瘤复发 与纤维化的鉴别诊断；食道癌治疗后再分期。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.乳腺癌：乳腺癌术前诊断和分期；乳腺癌术后，协助指导制订临床治疗方案；乳腺 癌放疗后局部肿瘤复发与纤维化的鉴别诊断。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.其他肿瘤：如黑色素瘤、骨肉瘤、胰腺癌、甲状腺癌、宫颈癌、卵巢癌、精原细胞癌等多种肿瘤的临床诊断与分期。 ', 'gwm', 0, 18),
(45, '18F-FDG PET 延迟显像鉴别诊断原发性肺癌', '临床应用', '', '', '2009-09-28 16:39:53', '116.228.141.77', '18 F－脱氧葡萄糖(FDG) PET 显像诊断原发性肺癌的特异性并不高(约为80%) ,延迟显像对原发性肺癌病灶的探查更有效而可靠。笔者对70 例受检者分别行早期头部～盆腔显像和注射后4h 胸部延迟显像,以期提高对肺部恶性肿瘤诊断的特异性,现报道如下。 \r\n<p>　　资料与方法</p>\r\n<p>　　1. 临床资料。原发性肺癌组25 例,男13 例,女12 例,年龄25～91 岁,平均(60.0 ±12.0) 岁。其中18F－FDG PET 早期显像阳性22 例,阴性3 例,共发现肺部放射性摄取增高病灶31 个。患者均经询问病史、体格检查、实验室及影像学检查诊断,并有手术病理检查结果。肺结核组16 例,男10 例,女6 例,年龄38～80 岁,平均(54.9 ±6.6) 岁。其中18 F－FDG PET 早期显像阳性2 例,阴性14 例,共发现肺部放射性摄取增高病灶19 个。患者经肺部X 线、CT 、支气管纤维镜及痰培养等诊断,其中6 例有手术病理检查结果。正常对照组29 例,男17 例,女12 例,年龄16～91 岁,平均(5519 ±1314) 岁,为正常体格检查者。18 F－FDG PET 早期显像均未发现阳性病灶,均排除活动性肺结核、糖尿病、过敏等病史。</p>\r\n<p>　　2.方法。PET 仪为Siemens ECAT EXTRA HR+ 型。18 F－FDG 由CTI RDS 11 型医用回旋加速器生产。放化纯&gt;95 %。患者禁食6h 以上。肘静脉注射18 F－FDG 296～444 MBq , 安静平卧45～50 min 行早期显像,注射后4h 行延迟显像。按发射、透射扫描交替进行方式行三维采集,10 min/ 床位,穿透30 %(68 Ge/ 68 Ga 棒源) 。早期显像范围为头部～盆腔;延迟显像范围为胸部。根据测得的长度确定床位数,2 次显像条件一致。经衰减校正后行迭代法重建,层厚412 mm, 获得横断、矢状、冠状面图像。发射与透射扫描过程中无明显身体移动造成的伪影。</p>\r\n<p>　　3. 图像分析及数据处理。目测法:由2 位以上有经验的核医学科医生凭视觉判断病灶性质。对照组双肺形态正常, 肺野及纵隔放射性分布均匀透亮,未见局部放射性增高灶。双肺内见局部放射性高摄取灶,若病灶有分叶、形态不规整、与周围组织对比明显判为阳性。感兴趣区( ROI) 半定量分析:在放射性浓聚灶显示最清楚的层面上勾画ROI , 镜像拷贝到对侧相同部位。早期显像以标准摄取值(SUV) &gt; 2.5 判为阳性,延迟显像以SUV &gt;2.5 并较早期增高10 % 判为阳性。计算早期与延迟显像每个病灶平均直径大小及病灶与对侧正常组织放射性比值( T/ B) 。对照组ROI 设定为1.0 cm ×1.0 cm 圆形区域。</p>\r\n<p>　　4. 统计学处理。采用SPSS 10.0 统计软件。T/ B 以x.±s 表示。3 组早期与延迟显像T/ B 比较行配对样本t 检验;原发性肺癌不同病理类型组间比较采用方差分析和Tamhane 法两两比较;原发性肺癌与对照组比较行独立样本t 检验。</p>\r\n<p>　　结　　果</p>\r\n<p>　　1. 25 例原发性肺癌18 F－FDG PET 早期显像阳性22 例,阴性3 例,灵敏度、特异性和阳性预测值分别为88.0 % (22/ 25 例) 、87.5 %(14/ 16 例) 和91.7 %(22/ 24 例);延迟显像阳性23 例,阴性2例,灵敏度、特异性和阳性预测值分别提高为92.0 % (23/ 25 例) 、93.8 %(15/ 16 例) 和95.8 %(23/ 24 例) 。肺结核组早期显像阳性2 例,阴性14 例,假阳性率为12. 5 %(2/ 16 例);延迟显像阳性1 例,阴性15 例,假阳性率6.3 %(1/ 16 例) 。</p>\r\n<p>　　2. 原发性肺癌组、肺结核组与对照组早期与延迟显像T/ B 结果比较见表1。原发性肺癌组与肺结核组比较,早期显像T/ B 差异无显著性( t =0.945 , P =0.347) ,延迟显像肺癌组T/ B 明显增高( t =4.173 , P = 0. 000) 。原发性肺癌组早期和延迟显像T/ B 均较对照组高,差异有显著性( t =7109 、7. 49 , P = 0.000 、0. 000) 。肺结核组早期和延迟显像T/ B 高于对照组, </p>\r\n<p>　　差异有显著性( t =4.13 、3.81 , P =0.002 、0. 005) 。可见,对于早期显像发现局部放射性高摄取灶者,延迟显像能对原发性肺癌与肺结核病灶进行鉴别。</p>\r\n<p>　　表1 　3 组早期和延迟显像T/ B 比较</p>\r\n<p>　　组　别&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 例数&nbsp;&nbsp;&nbsp; 早期显像&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 延迟显像&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; t 值&nbsp;&nbsp;&nbsp;&nbsp; P 值</p>\r\n<p>&nbsp;</p>\r\n<p>　　对照组　　　&nbsp;&nbsp; 29&nbsp;&nbsp;&nbsp;&nbsp; 1.05 ±0.13&nbsp;&nbsp; 1.15 ±0.31&nbsp;&nbsp;&nbsp;&nbsp; 1.564&nbsp;&nbsp;&nbsp;&nbsp; 0.199 </p>\r\n<p>　　原发性肺癌组&nbsp;&nbsp;&nbsp; 25&nbsp;&nbsp;&nbsp;&nbsp; 4.33 ±3.00&nbsp;&nbsp; 7.91 ±7.08&nbsp;&nbsp;&nbsp;&nbsp; 4.173&nbsp;&nbsp;&nbsp;&nbsp; 0.000 </p>\r\n<p>　　肺结核组　　&nbsp;&nbsp; 16&nbsp;&nbsp;&nbsp;&nbsp; 3.67 ±2.17&nbsp;&nbsp; 3.67 ±1.86&nbsp;&nbsp;&nbsp;&nbsp; 0.049&nbsp;&nbsp;&nbsp;&nbsp; 0.966 </p>\r\n<p>&nbsp;</p>\r\n<p>　　3. 原发性肺癌组25 例患者PET 发现病灶31 个,病灶平均直径为(3.13 ±1.25) cm 。3 种病理分型的肺癌病灶延迟显像T/ B 较早期显像增高3.49 ±2.66 ( t =4.173 , P = 0. 000) ,以小细胞肺癌最高(早期6.03 ±3.77 , 延迟12.75 ±10.77) ,其次为鳞癌(早期4.86 ±2.99 , 延迟8.02 ±5192) 和腺癌(早期3.32 ± 2.21 , 延迟5.27 ±3.30) ,提示T/ B 与肺癌组织学类型存在明显关系。经方差分析和Tamhane 法两两比较,提示同一时相不同类型的T/ B 差异均无显著性[ F组间= 48.68 ; P =0.570 (小细胞癌/ 鳞癌组) 、0.065 (小细胞癌/ 腺癌组) 、0.141 (鳞癌/ 腺癌组)] 。</p>\r\n<p>　　4. 肺结核组16 例患者PET 发现19 个病灶,6 例经手术病理检查,10 例治疗后复查CT 和(或)MR , 病灶消失或缩小。早期与延迟显像T/ B 高于对照组而低于原发性肺癌组( t = 4.173 , P = 0. 000) 。</p>\r\n<p>　　讨　　论</p>\r\n<p>　　18 F－FDG PET 显像可通过观察组织内FDG 摄取量而确定其性质,恶性肿瘤FDG 摄取量明显高于正常组织和良性病变,故其在原发性肺癌诊断中起重要作用。但临床上常出现肺部葡萄糖高代谢灶,常规PET 显像对原发性肺癌与肺部严重感染、结核难以鉴别。肿瘤细胞恶性程度与18 F－FDG 高摄取一致,并在细胞内持久增高,而炎症局部葡萄糖代谢较恶性肿瘤细胞低,对葡萄糖的利用随时间减少,延迟显像T/ B 较早期显像无明显降低,对鉴别肺部良恶性病灶有十分重要的价值。文献报道延迟显像能提高乳腺癌、胰腺癌的诊断率,国内有关延迟显像在肺部病灶的研究不多。本研究结果示,延迟显像提高了诊断原发性肺癌的灵敏度、特异性和阳性预测值,降低了肺结核假阳性率,表明延迟显像能更好地发现并鉴别肺部恶性肿瘤。18 F－FDG PET 对肺癌的诊断不是特异的,肺部很多病变能摄取18 F－FDG 而呈阳性显像,因此肺癌显像总的特异性较低。临床上较难鉴别的是以增殖性病变为主的结核结节及类似肉芽肿等病变,此类病变有大量类上皮细胞、郎罕巨细胞和淋巴细胞等,外缘包有网状纤维。大量代谢旺盛的炎性细胞摄取18 F－FDG 而呈阳性显像。存在问题: ①本研究所选病例未完全包含各种良性病变,如肺结节病、非特异性炎症、错构瘤、嗜酸性肉芽肿等,文献报道这些良性病变SUV 或与周围正常组织FDG 摄取比值均较低, 但良性病灶FDG 摄取高于肿瘤病灶也并不少见。本研究所选均为经证实的肺结核病变,其他良性病变有待观察。②本研究常规显像范围为头颅～盆腔,延迟显像范围为胸部,2 次显像所用时间不一致,就可能存在扫描长度不同而致耗时误差。测定病灶和正常组织的放射性需设置2 次ROI , 可能受所选正常组织部位影响。③延迟显像必须考虑由18 F 衰减所造成的噪声,而FDG 高摄取灶能补偿由小病灶引起的统计准确性减低。④有研究显示原发性肺癌FDG 摄取的峰值在给药后4～7 h[7] ,本研究中受检者只做1 次延迟显像,由于行FDG 定量动态测量耗时且软件未能达到要求,目前也未制定判断标准,所以动态定量显像对不同类型肺癌的关系有待探讨。⑤本研究仅选取29 例体格检查者作为对照组,对我国肺部恶性病灶SUV 正常参考范围的确定尚待多中心研究。<br />\r\n</p>', 'gwm', 0, 22),
(46, '恶性肿瘤摄取18F-FDG的机制', '详细介绍', '', '', '2009-09-28 16:40:48', '116.228.141.77', '<span style="font-family:宋体;">早在</span><span>30</span><span style="font-family:宋体;">年代</span><span>Warburg</span><span style="font-family:宋体;">就发现恶性肿瘤组织葡萄糖氧化分解和无氧酵解均明显高于正常组织，而且病理分化程度越低的恶性肿瘤细胞生长、繁殖速度越快，能量需求越大，其葡萄糖摄取率和利用率越明显增加，为正常组织</span><span>20</span><span style="font-family:宋体;">～</span><span>30</span><span style="font-family:宋体;">倍。研究表明葡萄糖进入肿瘤细胞是通过肿瘤细胞膜上的葡萄糖运载分子（</span><span>glucose<span>&nbsp; </span>transport<span>&nbsp; </span>molecules</span><span style="font-family:宋体;">〕来完成的，已知有</span><span>5</span><span style="font-family:宋体;">种葡萄糖转运载体分子</span><span>(GluT1-GluT5</span><span style="font-family:宋体;">）</span><span>. </span><span style="font-family:宋体;">它们将血中的葡萄糖转运至肿瘤细胞内，其中</span><span>GluT1</span><span style="font-family:宋体;">一</span><span>G1uT3</span><span style="font-family:宋体;">较为重要</span><span>, GluT4</span><span style="font-family:宋体;">的活性取决于血中胰岛素的活性和水平。</span><span> \r\n<p>&nbsp;</p></span><span>&nbsp; \r\n<p>&nbsp;</p></span>\r\n<p></p>\r\n<table cellspacing="0" cellpadding="0" width="90%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><img height="250" src="http://file.pet-ct.cn/PET-CT/linchuangyingyong/2008-12-23/d40f5f779530244b8ae913a0d65e120c.gif" width="200" />\r\n </td>\r\n<td align="middle"><img height="160" src="http://file.pet-ct.cn/PET-CT/linchuangyingyong/2008-12-23/472853ce01ba90c86bc815abfa35ce17.gif" width="187" />\r\n </td></tr></tbody></table>\r\n<p style="text-indent:21.75pt;" align="center"><span style="font-family:宋体;">图</span><span>1</span><span style="font-family:宋体;">正常细胞代谢</span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="font-family:宋体;">图</span><span>2</span><span style="font-family:宋体;">肿瘤细胞代谢</span><span> \r\n<p>&nbsp;</p></span>\r\n<p></p>\r\n<p style="text-indent:21.75pt;"><span>\r\n<p>&nbsp;</p></span><span style="font-size:10.5pt;font-family:宋体;">图</span><span style="font-size:10.5pt;font-family:times new roman;">1</span><span style="font-size:10.5pt;font-family:宋体;">和图</span><span style="font-size:10.5pt;font-family:times new roman;">2</span><span style="font-size:10.5pt;font-family:宋体;">示正常细胞和肿瘤细胞对葡萄糖和</span><sup><span style="font-size:10.5pt;font-family:times new roman;">18</span></sup><span style="font-size:10.5pt;font-family:times new roman;">FDG</span><span style="font-size:10.5pt;font-family:宋体;">的不同代谢途径。图</span><span style="font-size:10.5pt;font-family:times new roman;">2</span><span style="font-size:10.5pt;font-family:宋体;">在肿瘤细胞中，</span><sup><span style="font-size:10.5pt;font-family:times new roman;">18</span></sup><span style="font-size:10.5pt;font-family:times new roman;">FDG</span><span style="font-size:10.5pt;font-family:宋体;">第一步可在六已糖激酶的作用下分解为脱氧葡萄糖一</span><span style="font-size:10.5pt;font-family:times new roman;">6</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">pO<sub>4</sub></span><span style="font-size:10.5pt;font-family:宋体;">（</span><sup><span style="font-size:10.5pt;font-family:times new roman;">18</span></sup><span style="font-size:10.5pt;font-family:times new roman;">FDG</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">6</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">PO<sub>4</sub></span><span style="font-size:10.5pt;font-family:宋体;">），但由于其分子结构与天然葡萄糖有差异，它进入第二步则不能被继续分解、利用，即不参与三羧酸循环。如是</span><sup><span style="font-size:10.5pt;font-family:times new roman;">18</span></sup><span style="font-size:10.5pt;font-family:times new roman;">FDG</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">6</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">PO<sub>4</sub></span><span style="font-size:10.5pt;font-family:宋体;">则被陷入（</span><span style="font-size:10.5pt;font-family:times new roman;">trapped</span><span style="font-size:10.5pt;font-family:宋体;">）在肿瘤细胞内，</span><sup><span style="font-size:10.5pt;font-family:times new roman;">18</span></sup><span style="font-size:10.5pt;font-family:times new roman;">FDG</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">6</span><span style="font-size:10.5pt;font-family:宋体;">一</span><span style="font-size:10.5pt;font-family:times new roman;">PO<sub>4</sub></span><span style="font-size:10.5pt;font-family:宋体;">在肿瘤细胞中的浓聚增高，为</span><span style="font-size:10.5pt;font-family:times new roman;">PET</span><span style="font-size:10.5pt;font-family:宋体;">显像诊断肿瘤奠定了基础。</span><span style="font-size:10.5pt;font-family:times new roman;">PET</span><span style="font-size:10.5pt;font-family:宋体;">全身扫描所需时间较长是其最大的限制，而对于肿瘤病人的分期，全身扫描是重要的。</span> ', 'gwm', 0, 35),
(47, 'PET与放射治疗疗效评价', '临床应用', '', '', '2009-09-28 16:41:33', '116.228.141.77', 'PET一直用于评价放射的治疗反应。FDG可以鉴别出放射治疗后葡萄糖代谢的变化，并认为其是肿瘤具有反应性的一个最好指标之一。但在放射治疗过程中对疗效进行随访的资料目前报道相当少。主要认为放射治疗可能引起早期急性炎症，从而与肿瘤高代谢不能相鉴别；但也有资料认为早期快速的代谢抑制可能指示肿瘤具有较强的反应性。因此，目前仍需要进一步的资料对肿瘤放射治疗过程中代谢的变化进行更为详细的研究。<br />\r\n然而，在放射治疗结束后利用PET进行评价中，如何区别葡萄糖摄取减少和葡萄糖摄取缺乏在疗效评价过程中至为重要。一些研究者认为仅仅是FDG减少并不能提示预后；而且认为葡萄糖代谢减少可能反应由于治疗损伤敏感细胞后的部分反应，而耐受细胞仍然维持着细胞活性，认为葡萄糖代谢变化部分反应肿瘤放疗后疗效。<br />\r\nPET评价放射治疗的时机也是目前争论较多的问题。目前相当多的资料认为在辐射治疗结束后4~6个月时建议通过PET进行评价。正常组织也可以对放射治疗具有反应。一些组织可能在几天内即可发生，包括骨髓、淋巴结、腮腺等等。几周后发生反映的组织包括肾、脑等等。因此，经常可能看到照射野内软组织葡萄糖代谢的增加。资料认为放射治疗后引起葡萄糖的早期代谢变化可能与照射野内正常组织的损坏有关。以胸部放射治疗损伤为例，研究也认为正常组织的损伤反应可以大到6个月甚至1年。 ', 'gwm', 0, 20),
(48, 'PET-CT在胰腺癌的应用', '临床应用', '', '', '2009-09-28 16:42:06', '116.228.141.77', '胰腺癌的早期诊断较为困难，通常诊断明确时已为III-IV期且多伴有淋巴结转移或远处转移。超声及CT等无创检查能提示胰腺肿块或胰管扩张等异常表现，特别是CT有助于胰腺癌的分期和评估大血管及周围组织是否受到肿瘤组织的浸润。但由于临床症状不典型，肿瘤小于2cm就有可能发生转移，故胰腺癌明确诊断后一年生存率仅为20%。此外胰腺癌和胰腺炎的鉴别仍是问题，CT引导下的穿刺活检有局限性和损伤性，而淋巴结有否转移则是另一个难题，因为大多数淋巴结小于1cm，CT和超声容易漏诊，最终导致手术不彻底提高早期复发率。<br />\r\nFriess等对80例准备行胰腺择期手术的患者行FDG-PET检查，结果发现42例术后证实胰腺癌的患者中41例有FDG摄取增高而32例慢性胰腺炎患者中有28例无FDG浓集。FDG-PET检测的敏感度和特异度分别为94%和88%，而且胰腺癌患者的FDG摄取值明显高于慢性胰腺炎组。Bares等对40例疑为胰腺癌的患者进行FDG-PET，CT和超声检测，结果发现CT的阳性预测率为73%、阴性预测率为100%、淋巴结和肝转移发现为5/17。FDG-PET三个值分别为92.6%、84.6、13/17。超声最低仅为70.4%、33%、1/17。PET淋巴结转移检出率为76%，显示了PET在评估胰腺癌淋巴结转移中的价值。肝转移检出率为57%，主要因为正常肝组织的FDG摄取率也很高，以致病变与正常肝的对比变小，但可通过延时扫描来弥补。Stollfuss等的研究也提示FDG-PET检测胰腺肿瘤的敏感度和特异度均为93%，CT特异度为76%。因此FDG-PET检测可减少不必要的剖腹探察，对CT发现的小肿瘤PET可显示其它检查难以发现的淋巴结转移以便术中切除。<br />\r\n', 'gwm', 0, 24);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(49, 'PET-CT与胃、食管癌', '临床应用', '', '', '2009-09-28 16:42:23', '116.228.141.77', '手术后的阶段常规检查和探测食道癌复发的检查包括内镜和经食道内镜超声，以及胸腹部的计算机断层扫描。这些技术应用于诊断完全依赖病变的解剖改变；由于手术的治疗引起手术部位的解剖改变影响了其特异性。有人研究，对临床性和/或放射性诊断怀疑食管癌再发的41例患者行全身FDG-PET显像。所有病人都进行了检查，包括胸腹部螺旋CT检查（n=39），经食管超声（n=13），和或内镜检查（n=18）。其中常规检查方法在准确性（83％）上较PET显像（88％）稍低。对于远处转移的病例（19例），常规显像检查方法检出探测病灶有15例（灵敏性79％），FDG-PET显像探测检出病灶为18例（灵敏性95％）。<br />\r\n化疗反应的预测在食管癌中是十分重要的。预先检查并不能对术前化疗给出一个生存利益的评价；实际上，对化疗无反应的患者比哪些仅接受手术治疗的患者情况更差，假定手术损伤与化疗相关的损伤相同。在治疗过程中，一个快速监测筛选出对化疗有潜在反应性的测试需要尽早进行。FDG-PET显像在40例贲门腺癌患者中进行来评价术前化疗。FDG-PET显像在第一个化疗循环疗程的14天时重复检查。FDG的摄取减少在治疗中，临床有反应的患者比无反应者明显减少（反应者，54％±17％；无反应者，15％±21％，P&lt;0.01）。FDG摄取减少超过35％在临床有反应和无反应肿瘤之间的区分上提供了最高的准确性。15个化疗反应肿瘤中14例和22个化疗无反应中肿瘤21例均被得到证实，提供了灵敏性与特异性分别为93％和95％。PET显像的效应与病理组织学反应的相关性很大（P&lt;0.001）。在15例具有代谢反应肿瘤中有8例（阳性预测值，53％）观测到组织病理学上有消退。但在22例无代谢反应性的肿瘤中仅有1例（阴性预测值，95％）观测到病理组织学消退。病理组织学的预测的灵敏性与特异性分别为89％和75％。最近Fukunaga等对48例术前拟诊为食道癌的患者行FDG-PET检查证实47例，准确率达到98.3%。 ', 'gwm', 0, 23),
(50, 'PET-CT与头颈部肿瘤', '临床应用', '', '', '2009-09-28 16:42:46', '116.228.141.77', '头颈部肿瘤是比较常见的肿瘤，在我国以鼻咽癌占首位，喉癌和甲状腺癌次之。在美国则以喉癌占首位。头颈部肿瘤所处位置软组织较紧，同时淋巴供应丰富，极易出现淋巴结转移，同时常常是不明原发灶癌淋巴道转移的首发部位。<br />\r\n头颈部解剖结构复杂，但易于进行病理活检和外科治疗。CT、MRI和超声诊断等由于其在解剖结构的高分辨能力而在该领域发挥重要作用，但在肿瘤诊断治疗中，这些影像技术有一定局限性。正电子发射断层（PET）显像在头颈部肿瘤的诊断、治疗后的评价方面具有重要价值。<br />\r\n一、 临床诊断<br />\r\n1．PET显像在头颈部肿瘤的诊断具有重要作用<br />\r\nDi Martino等对50例头颈部肿瘤病例进行一个预期性评价。患有糖尿病和急性炎症的病例被排除在外。所有的病人都进行彩超、CT和PET检查。显像都经衰减校正，同时对可疑病灶进行标准摄取值（SUV）计算。在平均约为1年的随访病人中，大约2/3的病人都进行了颈部手术。显像研究结果与行病理检查和全上消化道内镜检查的病例进行比较。PET显像对原发肿瘤的灵敏度与特异性分别为95％、92％，相较而言，CT显像的灵敏性与特异性分别为68％、69％，超声为74％、75％。而对再发肿瘤，PET显像的准确性为100％。CT显像的灵敏性与特异性分别为67％和80％，超声的灵敏性与特异性分别为67％和100％。从统计学上来讲，PET显像明显优于CT显像。然而PET的解剖定位的有限性导致其使用具有逐渐下降趋势，而CT显像仍是目前解剖定位的显像手段。PET-CT显像在此方面具有较好的融合效果。<br />\r\n2．对转移灶和第二原发瘤的诊断<br />\r\n头颈部鳞状细胞癌易于转移到局部淋巴结，如果存在淋巴转移，治愈率将下降50%，CT和MRI对淋巴转移的误诊率约7.58%，第二原发瘤占初诊病人的3%，<br />\r\n<br />\r\n此诊断结果有助于在肿瘤评价中进行淋巴结转移分类，制定治疗方案，减低复发率，提高生存率。与其他常规方法比较，PET在对转移灶和第二原发瘤诊断中有明显的优势。<br />\r\n3．对原发灶不明颈部淋巴结转移癌的诊断<br />\r\n一般以PET或PET-CT作为原发灶不明颈部淋巴结转移癌的首选检查手段。有研究报道不明颈部淋巴结转移癌患者的18F-FDG PET显像原发灶检出率为44%，诊断价值明显优于CT和MRI。18F-FDG PET显像的另一优势是可在全身范围内探查可疑原发灶和转移灶，有助于临床分期并指导治疗。文献也报道，不明原发灶上、中颈部淋巴结转移癌有相当一部分来源于同侧的扁桃体组织。<br />\r\n二、疗效评价<br />\r\nPET在头颈部肿瘤治疗疗效评价及治疗后复发诊断中有独到的作用。由于肿瘤手术、放疗后导致的组织结构的扭曲和疤痕形成（尤其在喉、舌根及口咽部），使常规影像方法难以检测残余肿瘤或肿瘤的复发，特别是在治疗后1年内。利用18F-FDG PET代谢显像可监测放化疗的疗效，对晚期肿瘤患者的化疗进行旱期疗效评价。由于治疗中的肿瘤细胞浓聚18F-FDG的量和生长速率呈线形关系，病灶部位FDG摄取增加意味着治疗的失败，并且可用于区分无治疗反应的病例，避免不必要的治疗副作用，及早改用其他方法。据研究报道，对44例晚期（3期、4期）头颈部肿瘤患者治疗后1年内进行18F-FDG PET检查，并与其他显像方法（MRI和CT）比较：在第一年中只有PET检测到所有的复发灶，灵敏度为100%，特异性为93%，而常规方法的诊断灵敏度仅为38%，特异性为85%。<br />\r\n鼻咽癌（NPC）不同于其他头颈部的肿瘤。基于解剖变化的CT显像，对于探测再发和残余NPC有低的灵敏性和中等的特异性，但在放疗（RT）后具有明显变化。放疗后普遍存在不同程度的纤维化团块和不对称性，这样将导致假阳性。而且，NPC再生多发于粘膜下，因此CT可以很容易地探察到NPC的再发与残余肿瘤。在Kao等的研究中，36位接受4个月放疗的NPC病人在治疗前曾经行99mTc的SPECT、CT、FDG-PET头颈部显像检查以用来区别NPC再发和残余与良性病变。基于活组织检查，99mTc-TF SPECT的灵敏度与特异性是64％和96％，用于区别再发或从良性病变中分辨NPC。其中CT的灵敏性与特异性分别为73％和88％，FDG为100％和96％。由此作者得出FDG-PET显像是探测NPC再发与残余的最佳工具。<br />\r\n', 'gwm', 0, 21),
(51, 'PET-CT与乳腺癌', '临床应用', '', '', '2009-09-28 16:43:17', '116.228.141.77', '<p>乳腺癌是妇女中最常见的恶性肿瘤之一，早期发现是提高乳腺癌治愈率的重要手段。近二十年来，随着乳腺X摄片、超声诊断学、磁共振和功能性显像等非侵入性影像诊断技术的发展，乳腺癌的影像学检查的作用已经发生了明显改变。乳腺癌影像学评价的重要性不仅在于早期诊断方面，而且在乳腺癌的临床分期、预后因素评估和疗效评价等方面均具有重要的应用价值。虽然目前乳腺X摄片、超声诊断等常规检查在临床应用比较广泛，但由于其在灵敏性和特异性方面的限制，常给患者带来不必要的花费，造成不应有的痛苦。18F-FDG显像在乳腺癌中的临床应用主要包括两个方面，一个是通过提供定性和定量的信息，帮助诊断和鉴别诊断乳腺癌原发灶，探测腋窝和远处淋巴结转移，对乳腺癌进行分期；第二个方面就是提供乳腺癌的生物学行为信息，对乳腺癌患者进行预后分析和疗效评价。<br />\r\n1. 诊断和鉴别诊断乳腺肿块<br />\r\n判断乳腺肿块的性质是早期发现乳腺癌的关键步骤，是提高乳腺癌患者治愈率，增加乳腺癌患者生存率的关键措施。病理活检是诊断乳腺肿块性质的直接证据，是目前临床确诊乳腺癌的“金标准”，但也存在创伤性和假阴性率高等缺陷。随着18F-FDG显像在肿瘤学中的广泛应用，大量的临床研究证实，18F-FDG显像对乳腺肿块的探测也具有较高的灵敏度和特异性。<br />\r\n1993年，Adler LP等在使用18F-FDG-PET对28例患者共35个乳房肿块进行18F-FDG显像研究，发现FDG-PET可准确从良性乳腺肿块中区别出恶性肿块，对乳腺肿块探测的敏感性为96%，特异性为100%；而且，在恶性患者中，发现标化后的FDG摄取率与乳腺癌分级存在明显的相关关系；并发现在乳腺癌原发灶中FDG的摄取独立于年龄、更年期、种族、肿瘤大小，组织分化等影响因素，因此作者认为FDG-PET不仅可以准确区别乳腺肿块的良恶性质，而且还可以对乳腺癌患者进行术前分期，提供预后信息。Schirrmeister H等在最近也报道，使用环型PET对117例患者进行研究，并将其结果与胸部X线、乳腺和肝脏部位超声、乳房造影和骨扫描等常规检查进行比较，发现探测恶性乳腺肿块的敏感性和特异性分别为93%和75%，探测多灶性损伤的敏感性和特异性为63%和95%，而常规临床检查的敏感性和特异性仅分别为32%和93%。<br />\r\nFDG-PET 显像对乳腺肿块的探测敏感性和特异性也受着各种因素的影响，许多学者对这些影响因素进行了探讨。如通过FDG-PET显像结果和术后组化和免疫组化的结果进行对比分析，包括FDG SUV与术后组化状态、肿瘤类固醇激素受体状态、嘧啶标记指数和P53表达状态等等，目前认为组化和免疫组化的结果并不足够解释乳腺癌摄取FDG间的差异；FDG显像并不能完全评价乳腺癌的一些生物学行为如分化、组化分级、细胞增生等等。<br />\r\n目前，FDG-PET在探测已知或怀疑乳腺癌病灶的准确性仍在进一步的研究中。虽然PET有时可以探测出常规检查方法不能检测出的病灶，但也存在着对病灶探测分辨率的限制。如在比较致密的乳房中，FDG的本底吸收常常高于含脂肪多的乳腺，从而导致使用现代技术很难探测出小于1cm大小的乳腺肿块，此时，还是需要使用活检来区别肿块的良恶性质。由于FDG-PET的阳性估计值高达96%，具有FDG高摄取的患者具有很高的发生可能，应优先进行活检明确。<br />\r\n2. 对腋窝淋巴结转移的探测<br />\r\n在乳腺癌患者中，对涉及的腋窝淋巴结的探测是很关键的。乳腺癌病灶的大小与腋窝淋巴结转移的危险性相关，早期发现隐匿性转移，可影响临床预后和治疗策略。腋窝淋巴结被侵犯，一般认为是远距离微扩散的指示，可影响患者生存率，并可作为联合化疗的基础。常规淋巴结切除（ALND）代价比较昂贵，而且由于这些切除的淋巴结是大部分是阴性结果，可导致大约70%的早期乳腺癌患者不能从中获得效益，但目前这些患者仍维持潜在的患病率和ALND的经济花费。临床常规检测方法包括常规X线技术也不能可靠的探测腋窝淋巴结转移，18FDG-PET显像目前被认为是探测腋窝淋巴结转移最有效的手段。<br />\r\n18FDG-PET显像通过对腋窝淋巴结转移的探测，可有效的乳腺癌患者进行分期。</p>\r\n<p>1998年，Crippa F对72例确诊为乳腺癌的患者进行全身18F-FDG-PET显像，评价腋窝淋巴结转移。通过对具有衰减校正PET图像进行视觉分析和计算标准摄取率（SUV），与手术后病理结果比较；发现诊断腋窝淋巴结转移的敏感性、特异性和准确性分别为85%，91%和89%。参考临床淋巴结分期，发现在0期患者中，其敏感性、特异性和准确性分别为70%，92%和86%，N1a：85.5%，100%，95%；N1b-N2中，敏感性、特异性和准确性分别为100%，67%和87%；在具有转移的乳腺癌患者中，量化的SUV值明显高于无转移者，但在两组中存在明显的重叠。作者认为PET可以很准确的评价腋窝淋巴结转移，特别是对N1a的患者尤为重要。最近，Greco M等对167例乳腺肿块小于50mm（平均21mm）的乳腺癌患者术前进行了全身PET显像，并与手术切除后的病理结果相比较，探测腋窝淋巴结转移情况。结果发现，FDG-PET探测腋窝淋巴结转移的敏感性、特异性和准确性分别为94.4%、86.3%、和89.8%。阳性预测值和阴性预测值分别为84%和95.3%。认为18F-FDG PET显像是对乳腺癌患者分期的较高敏感性和特异性的方法，可以确定患者是否可以从腋窝淋巴结切除中获得收益，或允许使用放疗替代手术治疗。<br />\r\n目前，虽然大部分资料均证实了18F-FDG PET在探测腋窝淋巴结转移，对乳腺癌患者进行准确分期中的重要作用。但随着研究的深入，有学者也发现18F-FDG PET在探测腋窝淋巴结和乳腺内侧淋巴结转移时，18F-FDG PET探测的结果变异较大，小于或等于5mm的病灶一般不很容易探测。如果PET显像结果是阴性，通常并不能完全取代前哨淋巴结或腋窝淋巴结的清扫手术。<br />\r\n3. 乳腺癌术后残余和复发<br />\r\n乳腺癌术后残余病灶的存在或复发对患者的预后及生存时间有着重要的作用。目前临床对这一方面也进行了大量的研究。Kim TS在最近的一篇资料中报道，为了评价FDG-PET显像探测乳腺癌患者在术后复发和转移的准确性，作者使用全身FDG-PET显像对27例乳腺癌术后怀疑复发和转移的患者共61个病灶进行探测，以患者作为基础，FDG-PET准确发现了17例患者中16例具有复发和转移性病灶的患者，探测敏感性、特异性和精确性分别为94%，80%和89%，以探测病灶为基础，FDG-PET准确发现了48个病灶中46个确认为复发和转移的病灶，其敏感性、特异性和精确性分别为96%，85%和93%，作者认为全身FDG-PET显像在探测乳腺癌患者术后怀疑具有复发和转移性病灶时是很有效的。Eubank WB也对73例乳腺癌怀疑具有纵隔和乳腺内侧淋巴结复发和转移的患者进行常规CT和FDG-PET显像研究，并进行比较。结果发现FDG-PET显像发现了40%患者具有异常纵隔和乳腺内侧淋巴结转移病灶，而CT仅发现了23%患者具有转移。而在33例经随访和活检确诊的患者中，发现FDG-PET探测的敏感性、特异性和准确性分别为85%，90%和88%，而CT探测的敏感性、特异性和准确性分别为54%，85%和73%。研究认为FDG-PET可以克服常规方法通常不能检测出的一些区域淋巴结转移，改变乳腺癌患者的分期和临床决策。<br />\r\n4. 乳腺癌疗效预测和监控<br />\r\n随着18F-FDG代谢显像在临床应用的广泛和深入，使用18F-FDG代谢进行肿瘤疗效的评价也越来越成为研究的重点。在1993年，Wahl分析了11个最近诊断原发性乳腺癌的患者，直径大于3cm，经过激素化疗联合治疗，发现在治疗后63天，肿瘤直径并没有明显减少，8例患者在治疗第8天后出现FDG摄取率出现减少，3例患者没有变化，认为在有效治疗后，量化FDG PET可以在出现肿瘤大小发生改变前，明显发现肿瘤葡萄糖代谢减少，而治疗没有反应的患者，FDG摄取并没有明显减少，FDG PET可作为癌症治疗有效的早期非侵入性代谢标志。2000年，Schelling M等为了研究FDG-PET在疗效监控中的作用，对22例患者总共24个乳腺癌病灶进行研究，分别在化疗前和化疗的第一个疗程和第2个疗程进行FDG-PET显像研究，并在化疗结束后进行组化病理分析。结果发现在化疗的第一个疗程后，所有出现疗效的病灶均被准确的区别出来，SUV值与化疗前相比减少55%以上，敏感性和特异性分别为100%和85%，组化病理在第一个和第2疗程后估计的准确性分别为88%和91%。作者认为乳腺癌患者在化疗后，FDG-PET可在治疗过程的早期区别出具有明显反应的患者，有助于改变临床决策，避免无效的化学治疗，并支持对具有反应的患者继续进行术前化疗等临床措施。</p>', 'gwm', 0, 21),
(52, 'PET-CT与脑肿瘤', '临床应用', '', '', '2009-09-28 16:43:56', '116.228.141.77', '仁济PET-CT中心整理<br />\r\n脑肿瘤又称颅内肿瘤，是一种缓慢起病逐渐加重的脑部疾病。约占所有肿瘤的2%，每年发生率为5.8 / 10万，好发于50岁以上成年人，预后较差(5年存活率 = 20%)。原发于颅内者称原发性颅内肿瘤；由全身其他部位的恶性肿瘤转移至颅内者称转移性颅内肿瘤。常见的颅内肿瘤有胶质瘤、脑膜瘤及神经鞘瘤。对脑肿瘤的研究和临床应用是PET显像开展最早的领域之一，早期生产的许多PET在大小和形状等方面专门为进行脑显像所设计。大量研究证实了18F-FDG PET显像诊断脑肿瘤的价值，目前18F-FDG显像已经成为脑肿瘤诊断或随访的重要方法之一。FDG脑肿瘤显像在脑肿瘤良、恶性的鉴别及肿瘤的分级和分期，鉴别脑肿瘤的复发和坏死，探测残留肿瘤等方面优于CT、MRI显像。FDG PET显像可准确地用于脑肿瘤术前的分期和鉴别诊断，它可鉴别CT、MRI不能区分的肿瘤复发活放疗引起的坏死，根据肿瘤摄取FDG的程度可判断脑肿瘤的预后。当肿瘤破坏神经纤维时，常导致对应神经中枢的FDG代谢降低，在脑肿瘤PET显像中，92%可观察到病灶远端特别是对侧小脑半球有异常代谢减低区即对侧小脑失联络现象。<br />\r\n1 脑胶质瘤<br />\r\n18F-FDG PET显像对星形细胞瘤的良恶性鉴别诊断具有重要的临床应用价值。低级别肿瘤FDG摄取较低，高级别肿瘤摄取增加，定量分析有助于提高诊断效率。星形胶质细胞瘤Ⅰ级18F-FDG PET显像常表现为低代谢影像，病灶的放射性浓聚程度低于正常脑组织，但星形胶质细胞瘤Ⅱ～Ⅲ级可表现为高代谢病灶，尤其以病灶边缘明显。星形胶质细胞瘤Ⅲ、Ⅳ级在18F-FDG PET显像时表现为高代谢病灶，肿瘤病灶显示为放射性异常浓聚影。当肿瘤内部发生出血、坏死时，相应部位可表现为放射性缺损。星形细胞瘤具有很强的复发性，CT、MRI对于星形细胞瘤手术或放疗后是治疗后复发或是治疗后疤痕形成的鉴别有一定困难，而18F-FDG PET显像则具有很强的优势，因为治疗后形成疤痕的糖代谢水平远远低于复发的肿瘤组织，在18F-FDG PET显像图上治疗后形成疤痕组织表现为放射性减低影（即低代谢灶），复发的肿瘤组织表现为放射性浓聚影（即高代谢灶）。大量临床研究结果证明，18F-FDG PET显像是鉴别星形细胞瘤手术或放疗后复发或治疗后疤痕形成的有效手段。<br />\r\n11C-MET脑组织吸收本底低与脑肿瘤对比明显，比18F-FDG更具有优势。在11C-MET PET影像上，复发性脑肿瘤或肿瘤残余组织呈高11C-MET聚集灶，而肿瘤放射性坏死组织11C-MET摄取与正常脑皮质相似，且不受炎症反应的影响。因此，11C-MET对复发性脑肿瘤的诊断要优于18F-FDG。<br />\r\n2 脑转移瘤<br />\r\n脑转移瘤与其原发恶性肿瘤灶一样，具有较强的18F-FDG集聚能力，18F-FDG PET显像表现为高代谢病灶，可与良性病变鉴别：如脑内内出血、坏死、囊性变及液化，FDG显像表现为放射性缺损。对于CT、MRI等检查先发现颅内转移瘤者，而原发病灶未明的肿瘤患者，进行PET全身显像，有助于检出肿瘤原发灶。18F-FDG PET显像对脑转移瘤放、化疗效果的判断、检测手术后残余病灶等均有重要价值。 ', 'gwm', 0, 20),
(53, 'PET-CT与临床决策', '临床应用', '', '', '2009-09-28 16:44:21', '116.228.141.77', '80年代中期世界卫生组织曾提出肿瘤控制的目标，认为1/3肿瘤是可以预防的，1/3肿瘤是可以治愈的，1/3肿瘤可以延长生命提高生活质量。如实现这一目标，肿瘤的发生可以减少1/3，死亡可以减少2/3，患者的痛苦极大减轻，肿瘤对人类的健康危害的状况将明显改善。然而，要实现这一目标，首先就要求临床对肿瘤能够做到早期发现，早期治疗。因此，如何利用现代科技发展，尽快提高目前肿瘤的诊疗水平将是临床肿瘤学家面临的一个重要问题。<br />\r\n正电子发射断层扫描（PET）是一种功能性显像设备，由于其可以非创伤性的研究人体生理、生化、受体及基因改变,通过定量测定C-11、N-13、O-15、F-18等正电子核素标记的人体代谢底物及生物活性分子,达到活体断层生化分析及细胞分子水平。在肿瘤的应用研究中，PET不仅能鉴别良恶性肿瘤,而且能判定肿瘤的恶性程度和治疗疗效，尤其在肿瘤治疗方案的确定与及时修正中显示出独特价值，研究证实约50%肿瘤患者在PET检查后修改了已有的治疗方案。PET-CT的产生是随着CT和PET融合技术的商品化及临床应用，它将PET反映分子功能代谢信息的优势和CT精确的解剖定位优势结合起来，从根本上解决了PET定位不准缺陷，不仅能提供精确的脏器代谢变化，而且能准确地描述代谢异常的解剖部位及其与周围组织的关系，从而使PET-CT成为目前肿瘤诊断最有发展前景的新技术之一。<br />\r\n目前，肿瘤的治疗仍以手术、放疗及化疗为主，手术和化疗主要控制局部病变或局限性的转移，仅化疗可应用于控制广泛的转移。因此，治疗前如何准确的评价肿瘤分期是临床决策的重要根据。肿瘤分期实际上是对恶性肿瘤累及范围的缩写，其建立在肿瘤累及的范围不同，有不同的生存期的基础上。人体恶性肿瘤的TNM临床分期价值包括有助于临床医师制定治疗计划；了解病人的预后；帮助评价疗效。TNM分期的规则仅限于有组织学证据及组织学分型的恶性肿瘤。分期系统描述的解剖范畴有以下三个基本评价指标：T 指原发瘤的大小，N指有无区域淋巴结转移，M 指有无远处转移。而PET特别是PET-CT由于其对区域性转移淋巴结及远处转移探测的优势，在肿瘤临床分期中的价值愈来愈显得重要。<br />\r\n<br />\r\n如德国埃森大学医院Antoch等报告，前瞻性对比研究（2001年12月-2002年10月）共纳入98例肿瘤病人（年龄27~94岁），病人先后采用全身FDG-PET/CT和全身MRI进行肿瘤分期。结果显示，77％的病人FDG-PET/CT分期（TNM分期）正确，11例病人分期过高，12例病人分期过低。相比之下，54％的病人MRI分期正确，19例病人分期过高，26例病人分期过低，在有病理分期资料的46例病人中，FDG-PET/CT正确分期37例；MRI正确分期24例。FDG-PET/CT诊断区域淋巴结转移的正确率为93％，而MRI只有79％。二种方法诊断远处转移率的正确率相似，分别为94％和93％。<br />\r\n肺癌方面，PET研究大都集中在由传统模式诊断的I期和II期肺癌未发生转移的FDG探测显像的价值上。这些病人仍可避免不必要的手术治疗。Tuker等一份研究报道，相对常规显像，附件FDG-PET信息，取消了30％患者的手术，19％患者允许手术。12份统一的研究分析，大约70％的患者临床决策改变，17％的患者附件化疗或放疗，8％的化疗和放疗被取消。最近研究还显示根据不同显像分期后进行放疗，其预后也具不同，使用PET分期的中位生存率为31个月，而非PET的中位生存率为16个月，反映FDG-PET在发现那些具有远处转移患者，避免进行放疗的价值。而Hicks等发表的论文着重报道了肺癌3-4期阶段的病人将被免于接受过分的放疗。在167例中32例（占19％）通过PET证实有远处的转移。1999年Meta分析临床医师提供的146例直结肠癌患者也发现FDG-PET提供多于40％的结直肠癌病人在临床发病期与主要治疗期差别的证据，使预期需要手术治疗的41％的病人免于手术。<br />\r\n', 'gwm', 0, 16),
(54, 'PET-CT与结直肠癌', '临床应用', '', '', '2009-09-28 16:44:58', '116.228.141.77', '结直肠肿瘤在美国居常见肿瘤发生率的第二位。其手术治疗后的复发率高达30%-40%，且大多发生在术后二年内。因此结直肠癌的诊断和术后复发的早期诊断显得尤为重要。Abdel-Nabi等对44例活检证实和4例临床高度怀疑为结直肠癌的患者施行FDG-PET检查，结果发现FDG-PET对结直肠癌的敏感度为100%、特异度为43%、阳性预测率为90%、阴性预测率为100%、对淋巴结转移的敏感度为29%、对肝转移的敏感度为88%，显示了较高的临床诊断价值。<br />\r\nFDG-PET最重要的应用在于早期发现结直肠癌的复发。通常复发多表现为局部、局段的复发或转移（特别是肝转移），这其中仅1/4的患者有机会再行手术治疗，但及时的诊断可使这一机会提高到大约70%。因此早期发现和定位复发在此人群中的作用特别重要。Conti等回顾了89-96年报道的192例局部结直肠癌复发的病例发现FDG-ET检测对结直肠癌复发诊断的敏感度为95%，特异度为98%，精确度为96%。Schiepers等报道76例结直肠癌复发患者分别行CT和FDG-PET检查其敏感度分别为60%和93%，特异度为79%和97%，精确度为68%和95%。Hussein等研究认为CT，MRI等结构成像技术容易受到外科手术后结构改变的影响。FDG-PET是基于代谢成像的，因此有助于术后复发肿瘤的定性和定位。<br />\r\n结直肠癌术后CEA升高是肿瘤复发的重要提示性标志之一。因此目前临床常用CEA作为结直肠癌术后可靠而价廉的监测指标。但是CEA水平的升高常伴有阴性的传统影像检查结果，以致于最终不得不依靠第二次探腹手术。尽管第二次探腹发现肿瘤复发的概率接近90%，但由于时间原因这些患者中适合再行根治性手术的患者仅12%-60%。Flanagan等对22例结直肠癌术后CEA不正常，但传统肿瘤测定方法检测正常的患者行FDG-PET检查。结果发现22例中有17例PET结果不正常，其中7例再手术证实为复发，余下10例<br />\r\n<br />\r\n中的8例，最终通过影像随访或临床病理检查证实为复发。并且FDG-PET提示不正常的15例中有4例得到完整切除，11例FDG-PET提示不能切除与手术结果相符。其研究结果表明FDG-PET对CEA升高的结直肠癌患者复发的阳性预测率为89%，阴性预测率为100%。Conti等总结了46例结直肠癌术后CEA升高的患者行FDG-PET检测的结果，认为FDG-PET对肿瘤复发的敏感度可达94%。因此可以认为FDG-PET技术对诊断结直肠癌复发有重要意义并且有助于复发肿瘤的定位和确定再次手术能否完全切除。 ', 'gwm', 0, 33),
(55, 'PET-CT与恶性淋巴瘤', '临床应用', '', '', '2009-09-28 16:45:25', '116.228.141.77', '恶性淋巴瘤是原发于淋巴结或淋巴结外组织或器官的恶性肿瘤。根据临床和病理特点的不同，其可分为霍奇金淋巴瘤(Hodgkin''s lymphoma，HL)和非霍奇金淋巴瘤(non-Hodgkin''s lymphoma，NHL)两大类。恶性淋巴瘤治疗的关键是早期诊断、准确分期、正确判断病情以及治疗反应的监测。<br />\r\n1. 早期诊断<br />\r\n在使用18F-FDG PET评价淋巴瘤的研究中，大多数研究对象为HL和弥漫性大B细胞性NHL，对其他组织学类型的淋巴瘤研究资料有限。Elstrom R等对172例各种类型淋巴瘤患者的18F-FDG PET进行回顾性研究：18F-FDG PET准确地探测到了弥漫性大B细胞性NHL、T细胞淋巴瘤、滤泡性淋巴瘤和HL病灶。18F-FDG PET探测边缘区淋巴瘤可靠性低，尤其是结外的边缘区淋巴瘤。在对惰性B细胞性NHL的研究中发现，18F-FDG PET对滤泡性NHL的诊断、治疗有潜在优势，但对小淋巴细胞性淋巴瘤，只能探测到50％的病灶。还有一些使用标准化摄取值(standardizeduptakevalue，SUV)测定肿瘤18F-FDG摄取程度的研究认为，18F-FDG PET能够预测惰性淋巴瘤的组织学转变。但是，SUV与淋巴瘤病理亚型、有丝分裂率的关系仍有争议。<br />\r\n2．临床分期<br />\r\nHL和NHL虽然只占所有恶性肿瘤的8％，但却是少数几种可治愈的肿瘤。对恶性淋巴瘤的治疗不仅取决于其组织学亚型，而且要根据具体、准确的临床分期。18F-FDG肿瘤显像通过发现代谢异常病灶，特别是探测到其他检查未发现的隐性的腹部病灶或脾脏病灶，可显著提高了淋巴瘤最初分期的准确性。BangerterM等应用18F-FDG PET对44例已确诊为HL的患者进行治疗前评价：5例分期上调，1例分期下调。初步研究表明，在HL和NHL患者的分期方面，18F-FDG PET优于67Ga显像。<br />\r\n<br />\r\n淋巴瘤的骨髓浸润较常见，是淋巴瘤患者预后不良的征兆之一，且决定淋巴瘤的分期。研究表明，用18F-FDG PET可准确显示淋巴瘤骨髓浸润。Buchmann等比较了18F-FDG PET与CT、骨髓活检在NHL和HL分期中的作用，结果是18F-FDG PET优于CT；8％（4／52）患者经18F-FDG PET导致分期上调，改变了治疗计划。Moog FM等对78例淋巴瘤患者的18F-FDG PET、骨髓活检结果进行了比较，其中64例患者的双侧骨髓活检与18F-FDG PET结果一致；对10例骨髓18F-FDG摄取增高而骨髓活检阴性的患者进行MRI、聚合酶链反应(polymerasechainreaction，PCR)等检查，证实其中8例淋巴瘤累及骨髓；有4例患者PET没有探测到骨髓浸润。<br />\r\n3．疗效评价<br />\r\n对淋巴瘤治疗的最终目标是通过化疗、放疗等疗法的毒性作用，彻底清除肿瘤细胞。然而，各种淋巴瘤对治疗的反应相差甚大。造成这种反应差异的原因是肿瘤组织学类型、生物学差异、药物抵抗机制、放疗或化疗敏感性的不同等。在治疗中或治疗后及早判断治疗反应有利于及时更改治疗方案。<br />\r\n常规解剖显像对肿瘤反应或进展的判断基于肿瘤的大小，治疗有效时，由于治疗引起的肿瘤结构变化滞后于肿瘤细胞的死亡，解剖显像上的肿块可持续存在。而18F-FDG PET可显示肿瘤代谢活性明显减低，肿瘤对18F-FDG摄取减少或消失是在临床或亚临床水平上对肿瘤治疗有效的早期标志，及时评价治疗效果可修正临床恶性淋巴瘤的治疗方案应用。 ', 'gwm', 0, 26),
(56, 'PET-CT已成腹部及盆腔肿瘤检查的首选方法', '临床应用', '', '', '2009-09-28 16:45:50', '116.228.141.77', '约翰霍普金丝大学医学院回顾和总结了该院2001年6月到2003年9月在核医学科进行的2700余例腹部及盆腔PET/CT扫描，研究和制定其适应症及优缺点。2700余例PET/CT扫描中，90%以上用于已知或怀疑肿瘤的病人。同时该院还检索和总结了腹部及盆腔PET/CT扫描的相关文献。<br />\r\n　　他们发现：PET/CT能精确定位肿瘤部位的放射性摄取；并能鉴别生理性摄取。PET/CT对绝大多数腹部及盆腔肿瘤适应症均具有定位准确、快速且易于实现的优点，而且还具有定量分析的功能。另外，对于肿瘤的复发的监测、随访、和疗效的评价都有其特殊价值。<br />\r\n　　约翰霍普金丝大学医学院专家预见在不久的将来，PET/CT将代替独立的PET和CT成为临床腹部及盆腔肿瘤检查、随访和疗效评价的首选检查方法和常规手段。而目前在约翰霍普金丝大学医学院PET/CT已成为腹部及盆腔肿瘤检查的首选方法。 ', 'gwm', 0, 21),
(57, 'PET－CT的临床应用', '临床应用', '', '', '2009-09-28 16:46:34', '116.228.141.77', 'PET利用正电子发射体的核素标记一些生理需要的化合物或代谢底物如葡萄糖、脂肪酸、氨基酸、受体的配体及水等，引入体内后，应用正电子扫描机而获得的体内化学影像。它以其能显示脏器或组织的代谢活性及受体的功能与分布而受到临床广泛的重视，也称之为“活体生化显像”。可以说，PET的出现使得医学影像技术达到了一个崭新的水平，使无创伤性的、动态的、定量评价活体组织或器官在生理状态下及疾病过程中细胞代谢活动的生理、生化改变，获得分子水平的信息成为可能，这是目前其他任何方法所无法实现的。因此，在发达国家，PET广泛应用于临床，已成为肿瘤、冠心病和脑部疾病这三大威胁人类生命疾病诊断和指导治疗的最有效手段。目前最常用的PET显像剂为18F标记的FDG（18F-FDG 氟化脱氧葡萄糖），是一种葡萄糖的类似物。 \r\n<div>&nbsp;</div>\r\n<div><font color="#006365"><font size="5"><font color="#000000" size="3">　　</font><strong>PET－CT</strong>在肿瘤疾病中的应用</font></font></div>\r\n<div><font color="#006365"></font>&nbsp;</div>\r\n<div><font color="#006365"><font color="#000000">　　</font>1.肿瘤的早期诊断和良恶性鉴别<strong>:</strong></font></div>\r\n<div>　　肿瘤组织的重要特点之一就是生长迅速、代谢旺盛，特别是葡萄糖酵解速率增高。因此，代谢显像是早期诊断恶性肿瘤的最灵敏的方法之一。如发现肺部单发结节，PET显示代谢明显活跃，则提示为恶性病变。若无代谢增高表现，提示良性病变可能性大，手术的选择就要慎重。<br />\r\n<font color="#006365"><font color="#000000">　　</font>2.确定各类恶性肿瘤的分期和分级:</font> &nbsp;</div>\r\n<div>　　PET能一次进行全身断层显像，这也是其它显像设备所无法实现的。除了发现原发部位病变，还可以发现全身各部位软组织器官及骨骼有无转移病变，对肿瘤的分期非常有帮助，并提供准确的穿刺或组织活检的部位，协助临床医生制订最佳的治疗方案。<br />\r\n<font color="#006365"><font color="#000000">　　</font>3.治疗效果评估和预后判断：</font></div>\r\n<div>　　对肿瘤各种治疗的疗效进行评估并进行预后判断，指导进一步的治疗。&nbsp;&nbsp;&nbsp;<br />\r\n<font color="#006365"><font color="#000000">　　</font>4.早期鉴别肿瘤复发，对肿瘤进行再分期：</font></div>\r\n<div>　　PET可以对治疗后肿瘤残留或复发进行早期诊断，并与治疗后纤维化、坏死进行鉴别，同时根据治疗后病灶分布情况进行再分期，CT及MRI等结构信息为主的影像手段很难做到这一点。<br />\r\n<font color="#006365"><font color="#000000">　　</font>5.肿瘤原发病灶的寻找：</font></div>\r\n<div>　　通过快速的全身PET/CT扫描，为不明原因的转移性肿瘤寻找原发病灶。<br />\r\n　　<font color="#006365">6.放疗生物靶区定位：</font></div>\r\n<div>　　帮助放疗科医生勾画生物靶区。例如在肺癌合并肺不张等情况下，放疗师很难判断肿瘤的实际边界，PET将有助于确定代谢活跃的病灶范围，为放射治疗（尤其是精准放疗）提供更合理、准确的定位，降低治疗的副作用。<br />\r\n<font color="#006365"><br />\r\n<font size="5"><font color="#000000" size="3">　　</font><strong>PET/CT</strong></font><font size="5"><strong>在心脏系统中的应用</strong></font></font></div>\r\n<div>　　心肌存活的研究已成为近年来的热门话题，普遍认为，PET心肌代谢显像的方法，是目前判断心肌细胞活性最准确的方法，称为“金标准”。PET显像可以帮助确定和鉴别坏死心肌与可逆性缺血心肌，对介入治疗、冠状动脉搭桥手术有重要的指导作用，可明显提高搭桥手术的成功率，同时可对术后心功能恢复情况进行预测。<br />\r\n</div>\r\n<div align="left">\r\n<div><font color="#006365" size="5"><font color="#000000" size="3">　　</font>PET/CT在神经系统中的应用</font><br />\r\n　　脑代谢显像能准确了解正常情况下和疾病状态下的神经细胞活动及代谢变化，以及不同生理条件刺激和思维活动状态大脑皮质的代谢情况。通过PET直观地了解到人大脑代谢活动情况及各种生理性或病理性代谢变化，并以图像的方式反映出来。</div>\r\n<div align="left">&nbsp;</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>具体应用：</font></div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>1.&nbsp;&nbsp;癫痫定位：</font> 对脑癫痫病灶准确定位，为外科手术或伽玛刀切除癫痫病灶提供依据；</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>2.&nbsp;&nbsp;脑肿瘤定性和复发判断：</font> 脑肿瘤的良恶性定性、恶性胶质瘤边界的确定、肿瘤治疗后放射性坏死与复发的鉴别、肿瘤活检部位的选择等。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>3.&nbsp;&nbsp;痴呆早期诊断：</font>早老性痴呆的早期诊断、分期并与其他类型痴呆如血管性痴呆进行鉴别。&nbsp;</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>4.&nbsp;&nbsp;脑受体研究：</font>帕金森病的脑受体分析，进行疾病的诊断和指导治疗。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>5.&nbsp;&nbsp;脑血管疾病：</font>PET可以敏感地捕捉到脑缺血发作引起的脑代谢变化，因此可以对一过性脑缺血发作（TIA）和脑梗死进行早期诊断和定位，并进行疗效评估和预后判断。</div>\r\n<div align="left"><font color="#006365"><font color="#000000">　　</font>6.&nbsp;&nbsp;药物研究：</font>进行神经精神药物的药理学评价和指导用药，观察强迫症等患者脑葡萄糖代谢的变化情况，为立体定向手术治疗提供术前的依据和术后疗效随访等。&nbsp;<br />\r\n<br />\r\n<font color="#006365" size="5"><font color="#000000" size="3">　　</font><strong>PET－CT在健康体检方面的应用</strong></font>&nbsp; \r\n<div>　　PET/CT是一种灵敏度高、准确性好、无创伤的检查手段，对许多疾病（尤其是常见的恶性肿瘤等疾病）具有早期发现、早期诊断的价值。PET/CT检查可一次性全身成像，便于发现全身体内是否存在危险的微小病变，早期诊断可使受检者能真正得到早期治疗而争取达到治愈。同时PET/CT检查也特别适合于判断大脑或心脏是否存在早期缺血、缺氧等代谢功能方面的异常变化，有助于指导受检者及时采取针对性治疗或采取恰当地预防措施。</div></div></div>', 'gwm', 0, 27),
(58, '最贵体检PET-CT 价格大曝光', '详细介绍', '', '', '2009-09-28 16:48:25', '116.228.141.77', '什么是PET-CT？ \r\n<p>　　PET-CT是将PET（功能代谢显像）、CT（解剖结构显像）两个已经相当成熟的技术相融合，实现了PET、CT图像的同机融合。使PET的功能显像与螺旋CT的精细结构显像两种最高档显像技术的优点融于一体，形成优势互补，一次成像既可获得PET图像，又可获得相应部位的CT图像，既可准确地对病灶进行定性，又能准确定位，其诊断性能及临床实用价值更高。</p>\r\n<p>　　PET-CT检查有什么好处？</p>\r\n<p>　　PET-CT检查较目前其他手段灵敏度高、准确性好，可一次全身成像，当PET-CT进行全身性扫描时，能够及时发现体内是否存在危险的微小病灶（尤其是恶性病灶的存在），通常大于0.5公分的实体肿瘤都躲不过它的检查，扫描出的立体图形还能帮助医生判断肿瘤会从某个部位转移到哪里去。PET-CT除了具有常规的影像检查功能外，它能反映细胞组织代谢的整个过程，比如心肌缺血的过程都能完整地呈现出来，甚至能看到炎症发生的代谢过程，帮助医生发现病因，进行有益的诊治。</p>\r\n<p>　　PET-CT检查要做多久？</p>\r\n<p>　　PET-CT是一种无创性检查，一般只需30分钟左右就可一次性完成全身扫描。</p>\r\n<p>　　PET-CT检查多久做一次？</p>\r\n<p>　　在国外，PET-CT检查被视为健康体检的最佳手段，定期的PET-CT检查健康检查可发现一些无症状的早期患者。一般来说每年做一次PET-CT检查比较合适。</p>\r\n<p>　　PET-CT检查要多少钱？</p>\r\n<p>　　全身检查 9500元</p>\r\n<p>　　单部位检查 6800元</p>\r\n<p>　　相对常规体检，PET-CT检查确实很贵，而且不属于医保范围，但是如果你属于40岁以上、家族有肿瘤病人、患慢性肝炎等肿瘤高危人群，经济情况允许的，可以考虑增加PET-CT检测，达到早期预防与治疗的目的。</p>\r\n<p><font color="#ff0000" size="4"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 降价了：从2008年11月20日起，上海市PET－CT检查价格大调整，全身检查降至7500元，局部检查费用降至4500元。</strong></font></p>\r\n<p><strong><font color="#ff0000" size="4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 上海派康网您提供最为便捷的PET－CT检查预约服务。</font></strong></p>\r\n<p><strong><font color="#ff0000" size="4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 敬请提前一天以上预约，PET－CT专线：4006-125-007，或与我们的在线客服进行预约。</font></strong></p>', 'gwm', 0, 114),
(59, 'PET—CT检查前准备工作', '检查指南', '', '', '2009-09-28 16:51:15', '116.228.141.77', '<p>·检查前6小时禁食、禁酒及饮料、禁输葡萄糖、避免剧烈或长时间运动。 <br />\r\n·糖尿病患者请注意，在预约时向中心医务人员说明糖尿病病情。 <br />\r\n·用于诊断注射用的微量放射性药物对您及周围人无健康影响，但正在妊娠或哺乳的女性受检者，请告知医生。 <br />\r\n·由于放射性药物的特殊性，希望病人不要更改预约好的检查日期，如不能按时前来，请提前24小时来电重新预约时间。 <br />\r\n·PET-CT中心万一出现供药或仪器问题而导致不能按预约时间对病人进行检查，届时将电话通知新的检查时间，对此我们希望得到病人及家属的理解。 <br />\r\n·检查当日请将所有病情资料（包括病历、CT、MRI、病理和治疗经过等）带至PET-CT中心。 </p>', 'gwm', 0, 114),
(178, 'PET-CT检查项目价格', '检查指南', '', '', '2009-10-13 16:33:38', '116.228.141.77', 'PET-CT检查项目分为全身和局部，局部分为头颈部、胸部、腹部。价格各地都有差异。在预约检查时请说明要检查的项目。', 'gwm', 0, 178),
(179, 'PET-CT检查结束后多久可以拿报告', '检查指南', '', '', '2009-10-13 16:37:18', '116.228.141.77', '&nbsp; 一般PET-CT检查做完以后，可以在第二天取得报告，节假日顺延。', 'gwm', 0, 134),
(180, '哪些人尤其适合做PET-CT检查？', '检查指南', '', '', '2009-10-13 16:38:22', '116.228.141.77', '适合做PET－CT的人群：1，有肿瘤家族史 2、肿瘤标志物异常 3、接触致癌物质的人 4、存在癌前病变的人群 5、肿瘤患者需要了解肿瘤相关情况者 6,四十岁以上健康体检筛查肿瘤。', 'gwm', 0, 186),
(60, 'PET－CT检查为什么要预约？', '检查指南', '', '', '2009-09-28 16:53:02', '116.228.141.77', '<p>PET－CT检查为什么要预约？</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 一、因为PET-CT检查需要注射示踪剂18F-FDG,18F-FDG是一种容易衰变的药剂，半衰期只有几个小时，故需要根据检查的人数提前预订和配制药剂的数量。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 二、因为PET-CT对被检查者全身扫描的时间约30分钟，故一天内检查的人数有限，而要求做该项检查的人数众多，几乎每天都安排的很满，如果临时前来，一般都很难安排。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 故做PET-CT检查都要提前预约，一般提前2-3天；另外如果预约好了，临时又变动，请尽早通知我们，以便把时间安排给其他人！</p>', 'gwm', 0, 62),
(61, 'PET－CT检查后注意事项', '检查指南', '', '', '2009-09-28 16:54:12', '116.228.141.77', '<p>PET－CT检查后注意事项：</p>\r\n<p>一、尽量多喝水，以利于18F-DG的代谢而排除体外。</p>\r\n<p>二、检查后10小时内请勿接触孕妇及儿童。</p>', 'gwm', 0, 87),
(62, 'PET-CT检查流程', '检查指南', '', '', '2009-09-28 16:55:30', '116.228.141.77', '<img alt="" src="/image_server_dir/0707a76ce035c7fc57187b0fa5c158a1.jpg" border="0" />\r\n ', 'gwm', 0, 133),
(64, '肺癌根治术后化疗效果评价', '病例介绍', '', '', '2009-09-29 15:14:15', '116.228.141.77', '&#1048698;患者男67岁<br />\r\n&#1048698;2003年1月我院行左肺上叶癌根治术<br />\r\n&#1048698;术中见：肿块位于左上肺尖后段，直径6cm，斜裂发育不全<br />\r\n&#1048698;病理：鳞癌II～III伴坏死（中央型4×4×4cm）。支气管截端及气管旁淋巴结（0/2），主动脉弓下淋巴结（0/5）<br />\r\n&#1048698;术后健择化疗6个疗程<br />\r\n&#1048698;胸部CT（03.7及04.2）左上肺块影，纵隔小淋巴结影，左膈抬高\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/30c59fd6bbba97c686febfe1d8006d11.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/30c59fd6bbba97c686febfe1d8006d11.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e9375bcee57ab09e946bacbd60dfed87.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e9375bcee57ab09e946bacbd60dfed87.jpg" width="300" border="0" />\r\n</a></p>\r\n<p align="left">&#1048698;PET/CT检查后诊断：左上肺术后瘢痕组织</p></td></tr></tbody></table>', 'gwm', 0, 20),
(65, '淋巴瘤', '病例介绍', '', '', '2009-09-29 15:15:10', '116.228.141.77', '&#1048698;患者女46岁<br />\r\n&#1048698;2003年2月因双侧腋下、腹股沟，右侧颌下淋巴结肿大就诊<br />\r\n&#1048698;CT检查：双侧腋下淋巴结肿大，腹膜后多枚淋巴结肿大，脾脏肿大，盆腔内淋巴结肿大<br />\r\n&#1048698;腹股沟淋巴结活检：NHL 大B细胞型<br />\r\n&#1048698;CHOP方案化疗6个疗程\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/eb3b75486f0580d5f6a9f53d81d2f9a8.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/eb3b75486f0580d5f6a9f53d81d2f9a8.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6c71f2c7a47d50525362a5004b427bf8.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6c71f2c7a47d50525362a5004b427bf8.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/11d6b7f4f567e2db2c2af7b0e9379b18.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/11d6b7f4f567e2db2c2af7b0e9379b18.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/ef20a07a122fc7451d41b087d315c507.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/ef20a07a122fc7451d41b087d315c507.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3e0e573c268abb5dd4be26d69e2e90b0.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3e0e573c268abb5dd4be26d69e2e90b0.jpg" width="300" border="0" />\r\n</a></p>\r\n<p align="left">&#1048698;PET/CT检查后诊断：非霍杰金淋巴瘤<br />\r\nIVa期</p></td></tr></tbody></table>', 'gwm', 0, 19);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(66, '胃窦癌术后化疗效果评价', '病例介绍', '', '', '2009-09-29 15:15:37', '116.228.141.77', '<p>&#1048698;患者男46岁<br />\r\n&#1048698;诊断：胃窦癌术后<br />\r\n&#1048698;2003年5月发现胃窦部肿瘤伴腹腔淋巴结及肝脏转移，行胃癌姑息切除、胃周淋巴结摘除、肝脏部分切除。病理为神经内分泌肿瘤。<br />\r\n&#1048698;术后CT示：胰头后淋巴结肿大，考虑转移。<br />\r\n&#1048698;2004年2月，第1次PET/CT检查示：胰头后方淋巴结肿大，伴FDG代谢增高，SUV=5.3。<br />\r\n&#1048698;2004年2－3月行化疗2次，泰素帝＋草酸铂<br />\r\n&#1048698;2004年3月，第2次PET/CT检查示：胰头后方淋巴结肿大，局部FDG代谢增高，SUV=4.2。</p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e4dc383c61e22a78ecf934391d65fd0e.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e4dc383c61e22a78ecf934391d65fd0e.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>', 'gwm', 0, 19),
(67, '子宫内膜癌术后化疗效果评价', '病例介绍', '', '', '2009-09-29 15:16:18', '116.228.141.77', '&#1048698;患者女55岁<br />\r\n&#1048698;诊断：子宫内膜癌术后<br />\r\n&#1048698;2002年4月子宫内膜癌手术，病理为浸润性腺癌。<br />\r\n&#1048698;2003年因胆囊炎手术发现腹腔内转移。<br />\r\n&#1048698;2003年9月，第1次PET/CT检查示：CT见肝脏右叶低密度影处呈现FDG代谢增高(SUV=4.6),考虑肿瘤肝脏转移。<br />\r\n&#1048698;2003年9－12月，化疗3次。<br />\r\n&#1048698;2003年12月，第2次PET/CT检查示：CT见肝脏右叶低密度影处，PET未见明显FDG代谢增高，考虑肿瘤病灶化疗后坏死。\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/a7b398b98b650ab99044bdcf10e17dbb.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/a7b398b98b650ab99044bdcf10e17dbb.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>', 'gwm', 0, 24),
(68, '肺癌的分期2', '病例介绍', '', '', '2009-09-29 15:16:51', '116.228.141.77', '<p>&#1048698;患者女67岁<br />\r\n&#1048698;干咳2月伴少量泡沫痰，无痰中带血<br />\r\n&#1048698;X线胸片：右肺肿块影<br />\r\n&#1048698;胸部CT：右肺上叶前段3×4cm不规则肿块影，并有胸膜牵引征<br />\r\n&#1048698;为确定是否有其它部位转移，选择手术适应征来行FDG-PET检查</p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/91c06a7a768cf32841906b221338ca1a.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/91c06a7a768cf32841906b221338ca1a.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/ff69756ebcd81d2e5363c0f164ca22de.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/ff69756ebcd81d2e5363c0f164ca22de.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c67bb930c71088354ea96ebd2bef5af8.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c67bb930c71088354ea96ebd2bef5af8.jpg" width="300" border="0" />\r\n</a></p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/33d10e679f7a8a89461032bb64f52bf2.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/33d10e679f7a8a89461032bb64f52bf2.jpg" width="300" border="0" />\r\n</a></p>\r\n<p align="left">&#1048698;PET/CT检查后分期：T2N2M1IV期</p></td></tr></tbody></table></td></tr></tbody></table>', 'gwm', 0, 33),
(69, '腺癌', '病例介绍', '', '', '2009-09-29 15:17:38', '116.228.141.77', '<p>&#1048698;患者女68岁临床诊断：右肺占位<br />\r\n&#1048698;2004年4月体检X线胸片：右下肺野内侧见2×2cm类圆形高密度影<br />\r\n&#1048698;胸部CT：右肺中叶近右心膈角处见一尖端指向肺门的三角形致密影，其间见支气管征；右肺门见一块影，分界不清，右主支气管腔变窄；纵隔未见肿大淋巴结<br />\r\n&#1048698;支气管镜：右中间支气管段下端支气管粘膜肥厚，向腔内生长阻塞管腔，活检病理示：腺癌<br />\r\n&#1048698;PET/CT检查前分期：T1N1M0IIa期</p>\r\n<p align="center"></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b6ad397af1f6d81edb68f8fd991f4c60.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b6ad397af1f6d81edb68f8fd991f4c60.jpg" width="300" border="0" />\r\n </a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3a5cf95e1e7db91939c58bbd1d081883.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3a5cf95e1e7db91939c58bbd1d081883.jpg" width="300" border="0" />\r\n </a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/5087159af155f6b6085755a5ba9f5109.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/5087159af155f6b6085755a5ba9f5109.jpg" width="300" border="0" />\r\n </a></p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c0ea82a6c1f4b6a7425c352178c2f09c.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c0ea82a6c1f4b6a7425c352178c2f09c.jpg" width="300" border="0" />\r\n </a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/d0e2a9474aa1a32b8bd005338a4349ea.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/d0e2a9474aa1a32b8bd005338a4349ea.jpg" width="300" border="0" />\r\n </a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/07bccfdc9884ffbd4d486fdf564205da.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/07bccfdc9884ffbd4d486fdf564205da.jpg" width="300" border="0" />\r\n </a></td></tr></tbody></table>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/f8fa1dee507aac4aab558f4430ca14d7.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/f8fa1dee507aac4aab558f4430ca14d7.jpg" width="300" border="0" />\r\n </a></p>\r\n<p align="left">&#1048698;PET/CT检查后分期：T1N2M1IV期</p></td></tr></tbody></table></td></tr></tbody></table>', 'gwm', 0, 32),
(70, '肺癌的分期', '病例介绍', '', '', '2009-09-29 15:18:25', '116.228.141.77', '<p>&#1048698;患者男52岁<br />\r\n&#1048698;因痰中带血于外院行胸部CT,示：左肺上叶支气管开口类圆形块影，周围见阻塞性炎症<br />\r\n&#1048698;04年2月我院手术，术中见：左肺上叶后段6×5×5cm肿块，左上叶支气管旁及主动脉弓下均有肿大质硬的淋巴结<br />\r\n&#1048698;病理：鳞癌III级（中央型6×4×4cm),累及主支气管，浸润至脏层胸膜外。<br />\r\n&#1048698;支气管旁淋巴结（1/3）,肺下动脉旁淋巴结、主动脉弓下淋巴结各见1枚癌组织浸润。<br />\r\n&#1048698;临床诊断：左肺癌术后</p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/496e68a30547669a0afa0ae8af071f7b.jpg" target="_blank"></a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/ee6f23fb2d33d9c82f5a8fd5de96115b.jpg" target="_blank"></a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/0aeb4bf41c1e0ecc5d14279566b16aa9.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/0aeb4bf41c1e0ecc5d14279566b16aa9.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6fe3de764934b0fb5c666c3428feb5fa.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6fe3de764934b0fb5c666c3428feb5fa.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b768cd7f64724113cd899ed9094a9f77.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b768cd7f64724113cd899ed9094a9f77.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e3ec8833c1676a27ac772290e5ce232d.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/e3ec8833c1676a27ac772290e5ce232d.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/f41a419c910a5c914239716bcd448c97.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/f41a419c910a5c914239716bcd448c97.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>\r\n<p align="left">&#1048698;检查前分期：IIIA<br />\r\n&#1048698;检查后分期：IIIB</p></td></tr></tbody></table>', 'gwm', 0, 27),
(71, '右下肺基底段结节灶', '病例介绍', '', '', '2009-09-29 15:18:52', '116.228.141.77', '<p>&#1048698;患者女78岁<br />\r\n&#1048698;2003年12月反复咳嗽、咳痰，行胸部CT检查示：右下肺后基底段结节影<br />\r\n&#1048698;经抗感染治疗后症状消失但结节无明显缩小<br />\r\n&#1048698;胸部CT（04.1）：右下肺团块影，炎性改变？建议治疗后复查；纵隔淋巴结增多<br />\r\n&#1048698;胸部CT（04.2）：结果基本同上<br />\r\n&#1048698;临床诊断：右下肺占位</p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/8540c2b92b060e4897ae5867f0ab870e.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/8540c2b92b060e4897ae5867f0ab870e.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/7ee056f206d60bd33b03af773d417672.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/7ee056f206d60bd33b03af773d417672.jpg" width="300" border="0" />\r\n</a></p>\r\n<p align="left">&#1048698;PET/CT检查后诊断：右下肺基底段结节灶，考虑为炎症吸收后组织机化<br />\r\n&#1048698;随访：患者一般情况良好，多次CT检查未见明显异常变化。</p></td></tr></tbody></table>', 'gwm', 0, 42),
(72, '两肺陈旧性病灶', '病例介绍', '', '', '2009-09-29 15:20:01', '116.228.141.77', '<p>&#1048698;患者女62岁<br />\r\n&#1048698;04年2月因发热、咳痰于外院就诊<br />\r\n&#1048698;胸部CT示：两肺多发小结节样病变，考虑转移可能性大<br />\r\n&#1048698;患者88年因子宫肌瘤行子宫及右卵巢切除术<br />\r\n&#1048698;目前妇科B超，PPD，痰找肿瘤脱落细胞、抗酸杆菌皆阴性<br />\r\n&#1048698;临床诊断：两肺多发转移癌待排</p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/a558de23194e1cd40dd8ee68978e0ab4.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/a558de23194e1cd40dd8ee68978e0ab4.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6167b9b790e0abdec6722c832eee1099.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6167b9b790e0abdec6722c832eee1099.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/5406b51e4f2df3b687fd27e29a9a5c14.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/5406b51e4f2df3b687fd27e29a9a5c14.jpg" width="300" border="0" />\r\n</a></td></tr></tbody></table>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6354218311e9263d20baca0d5b2e9f6f.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/6354218311e9263d20baca0d5b2e9f6f.jpg" width="300" border="0" />\r\n</a></td></tr>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b78242721cee6c0c0b6a0e4bafba4345.jpg" target="_blank"><img height="300" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/b78242721cee6c0c0b6a0e4bafba4345.jpg" width="300" border="0" />\r\n</a></p>\r\n<p align="left">&#1048698;PET/CT检查后诊断：两肺陈旧性病灶<br />\r\n&#1048698;随访：患者一般情况良好</p></td></tr></tbody></table>', 'gwm', 0, 53),
(73, '胸壁良性肿物', '病例介绍', '', '', '2009-09-29 15:20:31', '116.228.141.77', '<p align="left">&#1048698;患者女76岁<br />\r\n&#1048698;因发热伴咳嗽、咳痰入院<br />\r\n&#1048698;胸部CT（04.3）右上肺占位，局部胸膜胸壁组织增厚，局部肋骨形态不规则伴可疑骨质吸收改变，纵隔小淋巴结影。<br />\r\n&#1048698;X线胸片（04.5）右上侧胸壁肿物影，向胸腔内生长，与04年3月CT相比，大小变化不明显。<br />\r\n&#1048698;患者有银屑病史，长期使用激素<br />\r\n&#1048698;临床诊断：右上肺占位</p>\r\n<p></p>\r\n<table cellspacing="1" cellpadding="3" width="100%" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<p><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c5b1d4c64d5fcbc8fea8952c8caf602c.jpg" target="_blank"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/c5b1d4c64d5fcbc8fea8952c8caf602c.jpg" border="0" />\r\n </a></p>\r\n<p align="left"><a href="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3dc59bdf963a5a5cd01ef11e3ff525c4.jpg" target="_blank"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-10-09/3dc59bdf963a5a5cd01ef11e3ff525c4.jpg" border="0" />\r\n </a></p>\r\n<p align="left">&#1048698;PET/CT检查后诊断：胸壁良性肿物<br />\r\n&#1048698;随访：患者一般情况良好</p></td></tr></tbody></table>', 'gwm', 0, 23),
(74, '利用PET－CT寻找感染病灶', '病例介绍', '', '', '2009-09-29 15:21:38', '116.228.141.77', '<div>病史：因发热、寒战入院，血培养为金葡菌，万古霉素治疗一度好转，近又发热39.1度。超声：弥漫性肝病、脾大，胆囊多发结石、胆囊息肉、胆囊炎；ESR111mm/h;&nbsp; WBC 3.6*10^9/L。</div>\r\n<div>临床诊断：败血症，慢丙肝</div>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/2c38e12a52f4a03a4747b80e2c6cea25.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/61f87fb95e3a1aa1b16a0b106136a7e3.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/e68030c52f8924d1a6a21671b8589989.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/67e3936343c5d72e9af5ea68d08a7f6a.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/52f313550ada571066270dcded679fae.jpg" border="0" />\r\n</p>\r\n<div>空腹6小时以上，静脉注射显像剂1小时后行全身PET-CT断层显像：&nbsp;&nbsp;&nbsp; </div>\r\n<p>全身显影清晰，对比良好。</p>\r\n<p>右颈部胸锁乳突肌后方、斜角肌外侧间隙见多个淋巴结代谢轻度增高，SUVmax值3.0; 双侧腋下可见多个大小不一的肿大淋巴结影（左侧为著）、最大者直径约为1.5cm，葡萄糖代谢增高，SUVmax4.5;右肾上内后方见自右肾上极水平到腰方肌上缘水平、上下走行的代谢增高病灶，大小约为1.7×2.2×4.0cm，SUVmax7.7, CT可见相应肿物影，CT值20～40，与右肾被膜分界欠清，与腰方肌上缘界限也欠清晰。</p>\r\n<p>甲状腺显影未见异常，心脏及胸部大血管正常显影，双肺野较清晰；肺门及纵膈区未见异常的结节影及代谢异常表现。食管结构及代谢显影均未见异常。&nbsp;&nbsp;&nbsp; </p>\r\n<div>腹部肝脏、脾脏影像增大，未见异常的显像剂摄取增高灶，胃、胰腺、双肾大小、形态及显像剂分布未见异常；前列腺约为4.0×4.9cm大小，未见异常的显像剂摄取增高灶；腹膜后区未见淋巴结肿大及代谢异常表现；双侧肾盂及膀胱内显像剂滞留。&nbsp;&nbsp; </div>\r\n<p>全身其它部位软组织及骨骼显影未见异常。</p>\r\n<div>诊断结论：</div>\r\n<div>&nbsp;</div>\r\n<div>1.右肾后内方葡萄糖代谢异常活跃肿物，右颈部、双侧腋下多发淋巴结肿大，葡萄糖代谢增高，结合临床考虑右肾后方脓肿，淋巴结肿大及代谢活跃均与炎症有关。</div>\r\n<p>2.肝大、脾大，前列腺轻度增大。</p>', 'gwm', 0, 25),
(75, '胰腺癌病例', '病例介绍', '', '', '2009-09-29 15:22:25', '116.228.141.77', '<p align="left">病史：腹痛3月余，CT诊断为胰腺癌</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/a4fcc774fe98b78d7cdcbb36fd056a04.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/6818e5dcb89a71196ebe1c8ab582a275.jpg" border="0" />\r\n</p>\r\n<p align="left"><img style="width:232px;height:328px;" height="328" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/f2a1da2bf01bbee614552abe659c4a6d.gif" width="232" border="0" />\r\n</p>\r\n<div>空腹6小时以上，静脉注射显像剂1小时后行全身（颅底至股骨上段）PET-CT断层显像：&nbsp;&nbsp;&nbsp; </div>\r\n<div>检查范围显影清晰，对比良好。</div>\r\n<div>甲状腺右叶密度欠均匀，并有斑片状钙化影，代谢未见异常，左侧咽部扁桃体及颈前肌肉可见对称性显像剂浓聚，SUVmax值为5.5。颈部未见肿大淋巴结影及代谢异常活跃灶。右肺中下叶有小类圆形及小条状高密度影，大部已钙化，左肺舌叶亦有类似改变，纵膈内主肺动脉窗有小淋巴结影，代谢不活跃。心脏及大血管未见代谢异常活跃灶。&nbsp;&nbsp;&nbsp; </div>\r\n<div>肝脏左叶内侧段可见一类圆形水样密度影，直径约1.8cm，边界清晰，代谢不活跃。胃窦部可见斑片状代谢轻度活跃区，相应CT图像上未见明确病变征象。胰腺体尾部增大，密度不均匀，轮廓不整并向胰腺后方延伸，与邻近部分血管分界欠清，病变代谢异常活跃，SUVmax值为5.6，相应区域后腹膜可见较小的淋巴结影，代谢较为活跃，脾大小、形态及代谢未见异常，其内可见小斑点状钙化灶灶；子宫及附件结构及代谢未见明显异常；</div>\r\n<div>双肾淡显影，肾盂内可见一定量显像剂滞留；膀胱内可见显像剂生理性充盈。&nbsp;&nbsp; </div>\r\n<div>视野内全身其它部位软组织及骨骼未见明显异常的显像剂浓聚灶。&nbsp; </div>\r\n<div>&nbsp;</div>\r\n<div>诊断意见：</div>\r\n<div>1.胰腺体尾部占位性病变，并后腹膜淋巴结增大，代谢异常活跃，符合胰腺癌合并后腹膜淋巴结转移。</div>\r\n<div>2.右肺中下叶及左肺舌叶陈旧性病变。</div>\r\n<div>3.肝左叶内侧段囊肿。</div>\r\n<div>4.甲状腺右叶密度欠均匀，并斑块状钙化，代谢不活跃，腺瘤并钙化可能性大，请结合有关临床资料。</div>\r\n<div>5.左侧咽部扁桃体增大，代谢较为活跃，考虑为炎性病变。</div>\r\n<div>6.胃窦部代谢轻度活跃，考虑为炎性病变，请结合临床。</div>\r\n<p align="left">全身余部位葡萄糖代谢及CT显像未见异常。</p>', 'gwm', 0, 24),
(76, '体检发现小肝癌病灶', '临床应用', '', '', '2009-09-29 15:22:57', '116.228.141.77', '<p align="center"><img style="width:500px;height:493px;" height="493" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/1fccd504808d16351237316bb9a2a73e.jpg" width="500" border="0" />\r\n </p>\r\n<p align="center">红色十字线处为肿瘤病灶，绿色箭头处为囊肿<br />\r\n&nbsp;&nbsp; 病理结果为高分化肝细胞癌<br />\r\n&nbsp;</p>\r\n<p><img style="width:232px;height:328px;" height="328" src="http://file.pet-ct.cn/PET-CT/linchuangbingli/2008-12-02/522b65a7d64de76cedc77dea9d83b31b.gif" width="232" border="0" />\r\n </p>\r\n<p align="center"><br />\r\n</p>', 'gwm', 0, 43),
(77, 'PET-CT的组成', '详细介绍', '', '', '2009-10-12 09:53:14', '116.228.141.77', '<div><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;">扫描仪的组成</span></div>\r\n<div>&nbsp;</div>\r\n<div><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;">扫描仪由</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;">扫描仪和</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;">扫描仪组成，</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;">扫描仪位于</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;">扫描仪的前方，两者组合在一个机架内，后配</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;">、</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;">融合对位工作站，如图</span><span style="font-size:12pt;">x-3</span><span style="font-size:12pt;">。</span><span style="font-size:12pt;">一次成像同时完成CT及PET扫描，PET-CT融合工作站通过识别图像的位置标识进行对位、融合。PET-CT也可单独进行PET或CT显像，其中CT图像不但可用于病灶定位，还可用于PET图像衰减校正，从而取代了透射扫描，使全身显像时间缩短约40%。</span></div><img height="245" alt="" src="http://www.nfpetct.com/up_files/o7.JPG" width="654" />\r\n', 'gwm', 0, 18),
(78, 'PET的优缺点', '详细介绍', '', '', '2009-10-12 09:54:14', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 18pt;">与单光子发射计算机断层（SPECT）比较</div>\r\n<div>PET是高级的核医学显像技术。PET与SPECT之间有相同之处，也有差异。相同之间在于两者都是利用放射性核素的示踪原理进行显像，皆属于功能显像的范畴，显像结果也都表现为阴性显像或阳性显像。但两者也存在明显的差异，这主要表现在所用的显像剂和扫描仪方面。（1）在显像剂方面，PET 所用显像剂较SPECT更具“生理性”。（2）在扫描仪方面，PET采用多环探测器、电子准直、BGO小晶体模块，而SPECT采用平面单探头或多探头、机械准直、碘化钠晶体，故PET的探测灵敏度和分辨率明显高于SPECT；（3）图像质量方面，PET明显高于SPECT；（4）PET可行准确的衰减校正，还可以进行准确的绝对定量，SPECT在衰减校正及定量准确方面均不如PET。（5）运行成本PET明显高于SPECT。</div>\r\n<div>然而，随着技术的发展及符合探测在SPECT方面的应用，PET和SPECT之间的一些差异正逐渐变得模糊。</div>\r\n<div style="margin:0cm 0cm 0pt 54pt;"><span>（一）<span><font size="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></span></span>与CT/MR比较</div>\r\n<div>PET与CT/MR相比较，两者各有优缺点，前者以功能显像见长，后者以精确反映形态、结构改变见长，具有互补性。PET主要是探测疾病发生、发展过程度的功能、代谢改变，从理论上讲它要较以反映形态改变的CT/MR能更早期地检出病变的存在，在功能方面，特别在受体显像方面，PET具有CT/MR无法比拟优势。</div>', 'gwm', 0, 57),
(79, 'PET肿瘤显像', '详细介绍', '', '', '2009-10-12 10:02:30', '116.228.141.77', 'PET在大多数恶性肿瘤的诊断、分期、疗效评价、复发或残余病灶的检出方面具有重要的临床应用价值。\r\n<div style="margin:0cm 0cm 0pt 170.25pt;"><strong><span>一、<span><font size="3">&nbsp;&nbsp; </font></span></span></strong><strong>原<span>&nbsp; </span></strong><strong>理</strong></div>\r\n<div>恶性肿瘤生长及增殖快，对葡萄糖、氨基酸、核酸等物质需求量明显高于正常组织或良性肿瘤；同时在一些肿瘤，如乳腺癌、前列腺癌、神经内分泌肿瘤等，肿瘤表面存在某些受体（如雌激素、雄性激素、生长抑素受体）或抗体高表达现象。PET利用恶性肿瘤这些病理生理改变，用正电子核素标记葡萄糖、氨基酸、核苷酸、配体拮抗剂或抗体，注射入机体在病灶明显聚集而对肿瘤进行显像，属于阳性显像范畴。目前最常用的显像剂为<sup>18</sup>F-FDG。其显像原理如下：</div>\r\n<p style="text-indent:27pt;">\r\n<table cellspacing="0" cellpadding="0" width="100%">\r\n<tbody>\r\n<tr></tr></tbody></table>多数恶性肿瘤细胞具有以下特性：肿瘤局部在有氧环境中存在异常旺盛的无氧葡萄糖酵解现象。静脉注射<sup>18</sup>F-FDG后，<sup>18</sup>F-FDG 随血液循环到达肿瘤所在，由于肿瘤细胞表面存在高表达的葡萄糖转运蛋白（Glut1和Glut3）,<img height="347" alt="" src="http://www.nfpetct.com/up_files/o6.png" width="471" />\r\n使<sup>18</sup>F-FDG大量进入肿瘤细胞内，并在细胞内的已糖激酶（大多数恶性肿瘤内已糖激酶含量明显高于良性病变和正常组织）作用下，转变为6-磷酸-<sup>18</sup>F-FDG,由于FDG与正常葡萄糖存在分子结构的差异，它不参与葡萄糖的进一步代谢而滞留在细胞内，如图1。通过PET动、静态扫描，能准确地测量肿瘤的葡萄糖代谢异常程度并对其进行显像。在某些肿瘤，如高分化原发性肝癌，细胞内存在较高水平的葡萄糖-6-磷酸酶，能将存在于细胞内的6-磷酸-<sup>18</sup>F-FDG水解成<sup>18</sup>F-FDG ，后者通过自由扩散游离出细胞，<sup>18</sup>F-FDG便不在肿瘤细胞内聚集而出现假阴性。</p>\r\n<div style="margin:0cm 0cm 0pt -1pt;"><span>&nbsp;&nbsp;&nbsp; </span><strong>二．临床适应证</strong></div>\r\n<div>主要适应证： ①肺内孤立性结节的良恶性鉴别；②肺癌治疗前分期、疗效评价和残余或复发病灶的诊断；③大肠癌的诊断及分期；④恶性淋巴瘤的分期、恶性程度判断及疗效评价；⑥黑色素瘤的分期；⑦食道癌的诊断及分期；⑧脑内胶质瘤的分级、术后复发灶和疤痕组织的鉴别；⑨头颈部肿瘤，特别是鼻咽癌的分期、残余或复发病灶的检测；⑩乳腺癌的诊断及分期等。</div>\r\n<div>一般适应证：①胰腺癌的诊断及分期；②甲状腺癌术后复发或转移的诊断；③子宫、宫颈或卵巢癌的诊断、术后复发和转移的监测；④其他肿瘤：如肝癌、肾癌、前列腺癌等。</div>', 'gwm', 0, 38),
(80, 'PET心脏显像', '详细介绍', '', '', '2009-10-12 10:06:17', '116.228.141.77', '<div><strong>一、原理</strong></div>\r\n<div>正电子显像剂，如<sup>82</sup>铷（<sup>82</sup>Ru，钾的类似物）和<sup>13</sup>N-氨（<sup>13</sup>N-ammonia,<sup> 13</sup>N-NH<sub>3</sub>）注入静脉后随血流循环进入心肌组织内，并被心肌细胞所摄取而滞留于细胞内，心肌细胞对以上显像剂的摄取量与心肌血流量成正比。用PET扫描仪对心脏进行扫描，可以显示显像剂在心肌细胞内的分布情况，用于了解局部心肌血流灌注情况。</div>\r\n<div>葡萄糖和脂肪酸是心肌细胞的能量来源，<sup>18</sup>F-FDG做为葡萄糖的类似物，可为心肌细胞所摄取，通过对心肌进行显像，可以显示<sup>18</sup>F-FDG在心肌细胞内的分布，用于了解心肌细胞的局部葡萄糖代谢情况。</div>\r\n<div>二、显像方法</div>\r\n<div>（一）心肌血流灌注显像（以<sup>13</sup>N-NH<sub>3</sub>显像为例）</div>\r\n<div style="margin:0cm 0cm 0pt 45pt;"><span style="color:black;">1.<span><font size="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></span></span><span style="color:black;">病人准备：不须空腹。根据病情，尽量停用心脏药物</span><span style="color:black;">24</span>hr<span style="color:black;">以上。</span></div>\r\n<div style="margin:0cm 0cm 0pt 45pt;"><span style="color:black;">2.<span><font size="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></span></span><span style="color:black;">摆位：受检者采用脚前位，摆好体位，探头视野覆盖心脏。</span></div>\r\n<div><span style="color:black;">3</span><span style="color:black;">．药物负荷</span></div>\r\n<div><span style="color:black;">负荷显像：一般采用潘生丁负荷试验。潘生丁剂量为</span><span style="color:black;">0.14</span> mg/kg/min<span style="color:black;">，</span><span style="color:black;">4</span> min<span style="color:black;">内静脉注射完毕。</span></div>\r\n<div style="margin:0cm 0cm 0pt 17.95pt;"><span style="color:black;">静息显像：不必行负荷试验。于静息状态下注射显像剂。</span></div>\r\n<div><span style="color:black;">4</span><span style="color:black;">．注射显像剂：</span><sup>13</sup>N-NH<sub>3</sub><span style="color:black;">，活度约</span><span style="color:black;">1110</span> MBq<span style="color:black;"> (30m<span style="color:black;">Ci)</span></span><span style="color:black;">，床边注射。</span><span style="color:black;">2</span><span style="color:black;">次显像显像剂注射时间间隔不应少于</span><span style="color:black;">40</span>min</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="color:black;">5</span><span style="color:black;">．图像采集：</span></div>\r\n<div style="margin:0cm 0cm 0pt -0.1pt;"><span style="color:black;">发射扫描：先进行</span><span style="color:black;">1</span> min预定位<span style="color:black;">发射扫描，并立即重建，以确认左室是否在视野内，必要时重新摆位；注射显像剂</span><span style="color:black;">7</span> min后行心肌发射扫描<span style="color:black;">，一般采用</span><span style="color:black;">2D</span><span style="color:black;">采集，</span><span style="color:black;">1</span><span style="color:black;">个床位，采集时间为</span><span style="color:black;">10</span> min<span style="color:black;">~15 min</span><span style="color:black;">。</span></div>\r\n<div><span style="color:black;">透射显像：采集</span><span style="color:black;">1</span><span style="color:black;">个床位，采集时间为</span><span style="color:black;">20</span> min<span style="color:black;">。</span></div>\r\n<div style="margin:0cm 0cm 0pt 49.5pt;"><span>6．<span><font size="3">&nbsp; </font></span></span>图像重建和图像显示</div>\r\n<div>图像重建采用滤波反投影法，前滤波用Hanning,后滤波用Ramp。图像重建后进行重新切层并按短轴、水平长轴和垂直长轴进行显示。</div>\r\n<div style="margin:0cm 0cm 0pt 27pt;">（二）心肌葡萄糖代谢显像</div>\r\n<div><span style="color:black;">1</span><span style="color:black;">．病人准备：空腹</span><span style="color:black;">6</span><span style="color:black;">小时以上</span><span style="color:black;">,</span><span style="color:black;">根据病情，尽量停用心脏药物</span><span style="color:black;">24</span>hr<span style="color:black;">以上；糖负荷：口服葡萄糖</span><span style="color:black;">50</span>g<span style="color:black;">~100g</span>。<span style="color:black;">糖尿病人在行糖负荷时根据病情给予胰岛素和</span><span style="color:black;">/</span><span style="color:black;">或乐脂平（</span><span style="color:black;">125</span>mg<span style="color:black;">~250mg</span><span style="color:black;">）</span><span style="color:black;">, </span><span style="color:black;">行糖负荷后休息</span><span style="color:black;">40</span> min<span style="color:black;"> ~60 min</span><span style="color:black;">。</span></div>\r\n<div style="margin:0cm 0cm 0pt 17.95pt;"><span style="color:black;">2.</span><span style="color:black;">注射</span><sup>18</sup>F-<span style="color:black;">FDG</span><span style="color:black;">：静脉注射</span><sup>18</sup>F-<span style="color:black;">FDG 6~8mCi</span><span style="color:black;">；</span></div>\r\n<div><span style="color:black;">3.</span><sup> 18</sup>F-<span style="color:black;">FDG</span><span style="color:black;">体内分布、代谢：在安静的暗室内，安静休息</span><span style="color:black;">50</span> min<span style="color:black;"> ~60 min</span><span style="color:black;">。检查前排尿。</span></div>\r\n<div><span style="color:black;">4.</span><span style="color:black;">摆位：受检者采用脚前位，摆好体位，探头视野覆盖心脏，并嘱病人保持体位不动。</span></div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="color:black;">5.</span><span style="color:black;">图像采集：</span></div>\r\n<div style="margin:0cm 0cm 0pt -0.1pt;"><span style="color:black;">发射显像：选用</span><span style="color:black;">2D</span><span style="color:black;">采集方式，进行</span><span style="color:black;">1</span> min<span style="color:black;">预定位发射扫描，并立即重建，以确认左室心肌是否在视野内，必要时重新摆位；随后进行心肌发射扫描，时间为</span><span style="color:black;">10</span> min<span style="color:black;"> ~15 min</span><span style="color:black;">。</span></div>\r\n<div style="margin:0cm 0cm 0pt -0.1pt;"><span style="color:black;">透射显像：采集</span><span style="color:black;">1</span><span style="color:black;">个床位，采集时间为</span><span style="color:black;">20</span> min<span style="color:black;">。</span></div>\r\n<div style="margin:0cm 0cm 0pt 27pt;"><span style="color:black;">6.</span><span style="color:black;">图像重建和图像显示</span></div>\r\n<div>图像重建采用滤波反投影法，前滤波采用Hanning,后滤波采用Ramp。图像重建后进行重新切层并按短轴、水平长轴和垂直长轴进行显示。</div>\r\n<div style="margin:0cm 0cm 0pt 0.05pt;">（三）图像分析</div>\r\n<div style="margin:0cm 0cm 0pt 44.95pt;"><span>1．<span><font size="3">&nbsp; </font></span></span>心肌血流灌注图像分析</div>\r\n<div>正常情况下，心腔大小正常，心肌放射性分布基本均匀；间壁膜部可为放射性缺损，使心肌影像呈反“C”形。心肌影像下可见放射性聚集较高的正常肝脏影。</div>\r\n<div>放射性稀疏：短轴，和/或水平长轴，和/或垂直长轴断层图像连续2帧以上出现心肌节段性放射性分布低于正常心肌而高于本底，为放射性稀疏；</div>\r\n<div>放射性缺损：短轴，和/或水平长轴，和/或垂直长轴断层图像连续2帧以上出现心肌节段性放射性分布与本底相近，为放射性缺损。</div>\r\n<div><sup>18</sup>F-<span style="color:black;">FDG</span><span style="color:black;">代谢图像异常判断标准</span>与心肌血流灌注显像基本一致，只不过图像的具体含义不同而已。</div>\r\n<div style="margin:0cm 0cm 0pt -0.1pt;">（四）适应征</div>\r\n<div style="margin:0cm 0cm 0pt 35.9pt;"><span>1．<span><font size="3">&nbsp; </font></span></span>诊断冠心病并评估其严重程度</div>\r\n<div style="margin:0cm 0cm 0pt 35.9pt;"><span>2．<span><font size="3">&nbsp; </font></span></span>严重心肌缺血、梗塞心肌的存活性评价</div>', 'gwm', 0, 23),
(82, 'PET显像原理', '详细介绍', '', '', '2009-10-12 11:44:49', '116.228.141.77', '<p style="text-indent:27.1pt;"><font size="3"><span style="font-family:宋体;">当正电子核素或正电子核素标记的化合物注入人体内后，它们随血液循环分布至全身。由于正电子核素为贫中子核素，它们在衰变的过程中，质子衰变为中子，同时发射出</span><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">个正电子</span><span><font face="Times New Roman">β<sup>+</sup></font></span><span style="font-family:宋体;">，正电子在组织中飞行极短的距离后便与周围组织内的电子相遇并发生湮没辐射，正、负电子消失，其物质转变为</span><span><font face="Times New Roman">2</font></span><span style="font-family:宋体;">个方向相反（互成</span><span><font face="Times New Roman">180°</font></span><span style="font-family:宋体;">）、能量皆为</span><span><font face="Times New Roman">511 keV</font></span><span style="font-family:宋体;">的</span><span><font face="Times New Roman">γ</font></span><span style="font-family:宋体;">光子，穿透人体并被环绕人体的</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">扫描仪探测到。</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">扫描仪利用</span><span><font face="Times New Roman">γ</font></span><span style="font-family:宋体;">光子对的直线性和同时性两个特性来进行符合探测，当成对</span><span><font face="Times New Roman">γ</font></span><span style="font-family:宋体;">光子被</span><span><font face="Times New Roman">2</font></span><span style="font-family:宋体;">个互成</span><span><font face="Times New Roman">180°</font></span><span style="font-family:宋体;">的探测器在符合时间窗宽（</span><span><font face="Times New Roman">10<span style="color:black;">~</span>20ns</font></span><span style="font-family:宋体;">）内同时被探测到，便得到</span><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">个符合电脉冲（计算机记录为</span><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">次湮没辐射事件），如图</span><span><font face="Times New Roman">5</font></span><span style="font-family:宋体;">所示，计算机对这些符合电脉冲进行甄别、分析，确定哪些是真符合事件，哪些是随机符合和散射光子，然后通过图像重建处理，得到的断层图像便为</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像。</span></font></p>\r\n<p><font size="3"><span style="font-family:宋体;">所以</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像是正电子显像剂在机体内的断层分布图，不同的正电子显像剂可得到不同的</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像，理解</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像时，应先了解所用的显像剂。<img height="536" alt="" src="http://www.nfpetct.com/up_files/o5.JPG" width="518" />\r\n</span></font></p>', 'gwm', 0, 60);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(83, 'PET脑显像', '详细介绍', '', '', '2009-10-12 11:46:00', '116.228.141.77', '<div><strong><span style="font-size:14pt;">原理</span></strong></div>\r\n<div>用于脑部显像的显像剂主要有<sup>18</sup>F-脱氧葡萄糖（<sup>18</sup>F-FDG）、<sup>13</sup>N-氨水（<sup>13</sup>N-NH<sub>3</sub>）、<sup>15</sup>O-氧水（<sup>15</sup>O-H<sub>2</sub>O）、<sup>18</sup>F-多巴（<sup>18</sup>F-Dopa）、3-N-<sup>11</sup>C-甲基螺旋哌啶酮（3-N-<sup>11</sup>C－methyl-spiperone）等。静脉注射这些显像剂，然后用PET扫描仪进行图像采集，可以准确地定量分析和显示脑葡萄糖代谢、血流灌注及受体分布的变化。目前临床最常用的显像剂为<sup>18</sup>F-FDG 。葡萄糖是脑的最主要能量来源，<sup>18</sup>F-FDG为葡萄糖的类似物，它注射入静脉后随血液循环进入脑内，便为脑细胞所摄取并滞留在细胞内。利用<sup>18</sup>F 所产生的湮没辐射进行显像，可显示<sup>18</sup>F-FDG在脑内的分布情况。脑细胞对<sup>18</sup>F-FDG的摄取情况与其功能及器质性改变有关，通过分析脑实质对<sup>18</sup>F-FDG的摄取差异可对疾病进行诊断和定位。</div>\r\n<div>许多脑内疾病与受体-配体异常有关，PET可用正电子核素标记受体的配体或其衍生物进行受体显像。正电子受体显像剂注射入静脉后，随血液循环进入脑内，与相应的受体紧密结合而聚集于受体密集处，用PET进行显像可以客观、真实地显示受体的分布情况用于诊断和研究脑内疾病。如用<sup>18</sup>F-多巴可用于进行脑多巴胺受体显像以诊断和研究帕金森氏病。</div>\r\n<div>&nbsp;</div>\r\n<div><span style="font-size:12pt;">适应证</span></div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>1、<span><font size="3">&nbsp; </font></span></span>短暂性脑缺血发作(TIA)与急性脑梗塞的早期定位诊断、疗效评价和预后判断。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>2、<span><font size="3">&nbsp; </font></span></span>老年性痴呆的早期诊断与病程评价。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>3、<span><font size="3">&nbsp; </font></span></span>癫痫病灶的定位与疗效判断。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>4、<span><font size="3">&nbsp; </font></span></span>脑肿瘤的良恶性鉴别、临床分级、疗效评价、预后判断和复发或残存病灶定位&nbsp;。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>5、<span><font size="3">&nbsp; Parkinson</font></span></span>Parkinson病的早期诊断与病因探讨。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>6、<span><font size="3">&nbsp; </font></span></span>精神病的病因研究和临床用药方案的确定。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span>7、<span><font size="3">&nbsp; </font></span></span>脑生理研究与认知科学的探索。</div>\r\n<div>&nbsp;</div>\r\n<div><span style="font-size:12pt;">临床应用</span></div>\r\n<div style="margin:0cm 0cm 0pt 30pt;"><span style="font-size:12pt;">(一)<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:12pt;">短暂性脑缺血发作和脑梗塞</span></div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="font-size:12pt;color:fuchsia;">1．</span><span style="font-size:12pt;color:fuchsia;">早期诊断</span></div>\r\n<div>PET能准确测定脑各局部血流量变化，研究表明：当局部脑血流量低于正常下限但高于每分钟23ml/100g，患者可无临床症状，此时CT和MRI无异常发现，但PET已明确显示出局部血流的异常减低；提示核素脑血流灌注显像在脑缺血的早期定位诊断中明显优于CT及MRI等形态学诊断。在急性脑梗塞发病24h内，虽然PET脑血流测定已见异常减低，但CT常显示阴性，因此，PET在脑梗塞的早期定性和病程估价中具有明显优势。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="font-size:12pt;color:fuchsia;">2．</span><span style="font-size:12pt;color:fuchsia;">急性脑缺血区存活脑组织的判断和病程分期</span></div>\r\n<div>当局部脑血流量低于每分钟23ml/100g，局部将出现明显缺血，并表现出临床症状；当局部脑血流量低于每分钟12ml/100g，氧代谢率小于每分钟0.065 mmol/100g，局部可出现不可逆性损害；在严重缺血区，若局部存在<sup>18</sup>FDG摄取和氧代谢，表现为梗塞病灶局部血流量减低，但氧代谢率， 保持相对正常或不平行性减低，提示有存活脑组织，此时一旦恢复局部血供，脑细胞的功能可能恢复正常。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="font-size:12pt;color:fuchsia;">3．</span><span style="font-size:12pt;color:fuchsia;">治疗时机的选择</span></div>\r\n<div>目前的研究证实，在缺血性脑梗塞患者中存在着两个时机窗，即再灌注窗及治疗窗，超过这两个时限脑组织将发生不可逆性损害。因此，合理而准确地把握治疗时机，对提高临床治疗效果改善患者预后十分关键。核索脑血流灌注显像在临床治疗窗的选择中具有明确的指导价值。当梗塞区局部血幢异常减低，但氧代谢率相对正常，提示此时可能处于治疗窗中，如果进行积极治疗，并恢复局部血供，脑组织的功能可逐渐恢复正常，患者预后良好；如果梗塞区局部血流瞄注与氧代谢均近于正常，则提示可能已出现自发性血管再通并出现局部血流再灌注，无需治疗也可有良好的预后；如果梗塞区局部血流与氧代谢呈一致性减低，提示局部脑阻织已坏死，治疗时机已丧失。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;"><span style="font-size:12pt;color:fuchsia;">4．</span><span style="font-size:12pt;color:fuchsia;">疗效评价与预后的评估</span></div>\r\n<div>在治疗前后测定脑血流量和<sup>18</sup>FDG利用率的变化，能客观评价临床治疗效果，及时制定有效治疗方案。PET同时测定急性脑缺血患者局部脑血流量和氧代谢率，可准确判断局部脑组织的存活性，有效估测预后。当局部血流减低但氧摄取分数减低不明显，即局部血流/氧代谢率不匹配时，提示良好的预后，而局部血流和氧摄取分数呈一致性减低，提示预后不良。</div>\r\n<div style="margin:0cm 0cm 0pt 30pt;"><span>(二)<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:12pt;">痴呆症</span></div>\r\n<div>PET在痴呆症的早期诊断和鉴别中有明确作用， 目前主要用于<span style="color:black;">Alzheimer</span><span style="color:black;">病</span><span style="color:black;">(AD)</span><span style="color:black;">、多发性梗塞性痴呆</span><span style="color:black;">(MID)</span><span style="color:black;">和额叶型痴呆</span><span style="color:black;">(FLD)</span>等。在临床，AD的早期诊断较困难，CT和MRI常表现为阴性，PET测定脑各局部<sup>18</sup>FDG利用率在AD早期诊断中显示出独特作用，颞—顶叶皮质葡萄糖代谢的异常减低为AD的典型表现，平均减低率为同龄正常人的30％-50％，诊断正确率达95％，早期AD在脑皮质葡萄糖代谢异常减低的表现顺序为：顶叶上部-顶叶前部和下部-颞叶-额叶。与AD不同，MID的PET影像表现为脑皮质的多处局灶性低血流和低代谢区，而CT和MRI定位诊断明确，是这类疾病诊断的首选方法。</div>\r\n<div style="margin:0cm 0cm 0pt 30pt;"><span>(三)<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:12pt;">癫痫</span></div>\r\n<div>PET在致痫灶的定位方面是一种具有高灵敏度和高准确性的无创性检查。常用显像剂有<sup>18</sup>F-FDG，其他还有脑血流显像剂<sup>13</sup>N-NH<sub>3</sub>和<sup>15</sup>O-H<sub>2</sub>O、苯二氮卓受体显像剂<sup>11</sup>C-Flumazenil和阿片受体<sup>11</sup>C-Carfentanil等。由于其他显像剂对生产条件要求高，临床应用少。</div>\r\n<div>癫痫患者<sup>18</sup>F-FDG PET显像，发作间期致痫灶常表现为低代谢灶，而发作期致痫灶可出现低代谢灶、高代谢灶和正常等多种表现。发作期高代谢灶的发生率低，常出现于注射显像剂前后多次发作或发作持续时间较长（10～20min）者。视觉分析异常标准为：横断断层和冠状断层同时出现连续2帧以上限局性或弥漫性放射性分布降低或明显增高，左、右侧明显不对称。放射性分布降低者，为低代谢灶；增高者，为高代谢灶。须注意摆位不正所致的两侧不对称。不对称性指数（asymmetry index,AI）做为一种半定量指标有一定帮助，AI大于15%，一般考虑为异常。</div>\r\n<p style="text-indent:23.65pt;" align="left"><span></span></p>\r\n<div style="margin:0cm 0cm 0pt 30pt;" align="left"><span>(四)<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:12pt;">脑肿瘤</span><span style="font-size:12pt;">&nbsp;</span></div>\r\n<div style="margin:0cm 0cm 0pt 18pt;" align="left"><span style="font-size:12pt;color:fuchsia;">1．</span><span style="font-size:12pt;color:fuchsia;">脑肿瘤的良恶性鉴别</span></div>\r\n<div align="left">根据脑肿瘤恶性程度与局部<sup>18</sup>FDG利用率并结合<sup>11</sup>C-MET的显像特点，能较好地鉴别其恶性程度。 I～Ⅱ级脑胶质瘤<sup>18</sup>FDG摄取率低于正常灰质；Ⅲ级脑胶质瘤<sup>18</sup>FDG摄取率与正常灰质相似或略高；Ⅳ级脑胶质瘤<sup>18</sup>FDG摄取率明显高于正常脑灰质的<sup>18</sup>FDG摄取率。由此可见PET在肿瘤良恶性程度的鉴别诊断中有重要意义。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;" align="left"><span style="font-size:12pt;color:fuchsia;">2．</span><span style="font-size:12pt;color:fuchsia;">预后判断及疗效评价</span></div>\r\n<div align="left">脑肿瘤局部<sup>18</sup>FDG摄取量与患者的预后有直接关系，当肿瘤局部摄取高于周围正常组织1.4倍，患者平均生存时间仅为5个月，而低于1.4倍者 平均生存时间大于19个月。肿瘤治疗前后局部<sup>18</sup>FDG的摄取变化，可用于疗效的及时判断和有效治疗方案的合理制定。</div>\r\n<div style="margin:0cm 0cm 0pt 30pt;" align="left"><span>(五)<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:12pt;">其它</span></div>\r\n<div style="margin:0cm 0cm 0pt 18pt;" align="left"><span style="font-size:12pt;color:fuchsia;">1．</span><span style="font-size:12pt;color:fuchsia;">帕金森氏病</span><span style="font-size:12pt;color:fuchsia;">(Parkinson</span><span style="font-size:12pt;color:fuchsia;">病</span><span style="font-size:12pt;color:fuchsia;"> PD)</span></div>\r\n<div align="left">在PET的多巴胺显像中表现为基底节敢射性摄取的异常减低，尤以壳核最明显，呈现尾状核头部与壳核放射性减低不一致的特征，可与Parkinson综合征等鉴别；局部血流和<sup>18</sup>FDG代谢显像，在基底节常表现为近于正常或轻度减低。</div>\r\n<div style="margin:0cm 0cm 0pt 18pt;" align="left"><span style="font-size:12pt;color:fuchsia;">2．</span><span style="font-size:12pt;color:fuchsia;">精神病</span></div>\r\n<div align="left">在PET脑血流和代谢显像中，精神病患者至今未发现明确的特征性表现；在老年或长期治疗的患者中，常见额叶<sup>18</sup>FDG代谢的减低，部分患者可见基底节代谢的增高；PET在精神病患者的应用，可为病因探讨、疗效评价和临床药理机制研究提供信息。</div>', 'gwm', 0, 24),
(84, 'PET的发展史', '详细介绍', '', '', '2009-10-12 11:48:22', '116.228.141.77', '<div>PET技术的发展包括了PET扫描仪、回旋加速器及显像剂近一个世纪的缓慢发展过程。</div>\r\n<p style="text-indent:23.65pt;">1927年， Dirac.PAM预言了正电子的存在。5年后Anderson. C观测到第一个正电子。在这些物理实验后不久，对正电子发射体在医学影像中的应用就已开始探索。1932年，Ernest Lawrence发明了能产生β<sup>+</sup>核素的回旋加速器，<img alt="" src="http://www.nfpetct.com/up_files/o4.JPG" />\r\n1957年，经过不断的改进，第一台用于生长短半衰期正电子核素的医用小型加速器在伦敦Hammersmith医院启用。但利用回旋加速器产生的正电子核素进行正电子显像却历经了半个多世纪的发展过程。从正电子扫描仪的机型上，经历了正电子平面扫描机、正电子照相机和正电子发射计算机断层3个阶断。1960s后半期，华盛顿大学的的Terpogossian、Phelps和加利福尼亚大学的Edward Hoffman等设计出一种带铅准直器的探测器用以探测正电子，此为初期的正电子平面扫描机，但显像结果不理想。1966年，Anger.HO等用两个闪烁照相机在不使用传统准确器的情况下探测正电子湮没辐射光子，从而设计出了正电子照相机的技术模型，同时也创立了符合探测方法；不久，David E.Kuhl等证实用滤波反投影重建技术可产生正确的横断层图像。1970s初期，Gordon Brownell等建立了第一台医用正电子照相机。这种正电子照相机由两个互成180°的NaI(Tl) 大晶体后接光电倍增管及符合探测线路组成。70年代初，James S.Robertson等设计出一种环状的、不连续的探测器来进行正电子断层显像，从而迈出了断层显像的第一步，但却不知用什么数学算法进行图像重建。1973年，Hounsfied GN发明了X线CT 。受其启发，Phelps、Hoffman和Terpogossian放弃了原有的设计，建立了一台最早的可行断层显像的PET扫描仪原型（PETT Ⅱ）, PETT Ⅱ整合了所有现代PET扫描仪的基本原理，如合适的图像重建算法、湮没符合探测、合适的直线和成角采样、衰减校正等，但分辨率差（25mm）。后来经过多次改进而设计出PETT Ⅱ1/2（主要用于动物实验）、PETT Ⅲ（用于人体显像）和PETT Ⅳ（最早的多环PET装置）。 1976年，第一台商业化PET扫描仪（ECAT）面市，如图1所见。 80年代始，PET生产厂家CTI和Scanditronix分别与西门子和GE公司合作，大公司的介入使PET扫描仪的发展进入了新的发展阶段。90年代后，多环探测器、模块化晶体、3D结构等多种新技术及新型的晶体材料锗酸铋（BGO）的应用，使PET的射线探测能力和分辨率都有了明显的提高，能更好地满足临床的需要，从而促使了PET的临床应用的推广。在扫描仪发展的同时，回旋加速器的研制和正电子显像剂的临床应用也同样取得进展。小型回旋加速器的自动控制、显像剂的自动合成系统的发展使正电子核素的产生及正电子显像剂的合成更加简单、方便，机器的操作更加人性化、合理化和程序化，工作人员的辐射剂量也明显降低。80年后，多种正电子显像剂的研究逐步拓展，<sup>18</sup>F-FDG在脑显像和心肌存活显像，尤其是在恶性肿瘤显像中的成功应用使PET逐步受到临床的接受和青睐。90年代始PET开始从学院性研究进入临床竞技场。1997年，美国食品卫生管理局（FDA）批准了<sup>18</sup>F-FDG临床应用；1998年，美国健康卫生财政管理局（Health Care Financing Administration,HCFA）同意将多种<sup>18</sup>F-FDG PET适应症纳入医保范围，PET从而获得了一张广泛临床应用的“绿卡”，促使其进一步应用发展。</p>\r\n<div>PET的图像是一种功能图像，对病变检测灵敏度高，病灶边界显示清楚，但是解剖结构远不如CT/MR，在诊断和治疗定位上存在较大的困难，无法很好地满足临床需要。为了解决此难题，通用电气（GE）公司和西门子公司都相继推出了将PET和CT整合在一起的新型扫描仪：PET/CT。PET/CT能很好地对病灶进行定位,能满足越来越多的精确放疗要求；同时两者的优缺点互补，也有助于进一步提高诊断的准确性。</div>', 'gwm', 0, 29),
(85, '什么是PET-CT（派特CT）', '详细介绍', '', '', '2009-10-12 11:51:59', '116.228.141.77', '<p style="text-indent:21.1pt;"><font size="3"><strong><span><font face="Times New Roman">PET-CT<span style="font-family:arial;font-weight:normal;font-size:13px;">（派特CT）<span style="font-family:simsun;font-size:medium;"><span style="font-family:宋体;">是将</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">（功能代谢显像）、</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">（解剖结构显像）两个已经相当成熟的技术相融合，实现了</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">、</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">图像的同机融合。使</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">的功能显像与螺旋</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">的精细结构显像两种最高档显像技术的优点融于一体，形成优势互补，一次成像既可获得</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像，又可获得相应部位的</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">图像，既可准确地对病灶进行定性，又能准确定位，其诊断性能及临床实用价值更高。是当今最完美、最高档次的医学影像技术，被称之为近</span><span><font face="Times New Roman">20</font></span><span style="font-family:宋体;">年来在肿瘤诊断领域最重要的发展。</span></span></span></font></span></strong></font></p><p style="text-indent:21.1pt;">&nbsp;</p>\r\n<p style="text-indent:21pt;"><font size="3"><span><span><font face="Times New Roman">&nbsp;</font></span></span><span style="font-family:宋体;">举个例子来说明，</span><span><font face="Times New Roman">PET-CT</font></span><span style="font-family:宋体;">所产生的影像就像是电视气象预报中所显示的卫星云图与地图相结合一样。</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">图像可清晰显示癌症病灶，就象气象云图显示不同的降雨量；而</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">所显示的精细解剖影像就像地图，告诉医师癌症病灶的准确位置及病灶与周围组织结构的比邻关系。</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">与</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">有机结合而成的</span><span><font face="Times New Roman">PET-CT</font></span><span style="font-family:宋体;">就如同电视气象预报中的卫星云图与地图相结合，准确获得不同区域的天气状况或降雨量；精确的将</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">显示的癌症病灶及</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">显示的病灶精确位置及病灶与周围组织结构的比邻关系融合在一张影像资料中。最大限度满足临床各种精确治疗的需要。<br />\r\n<br />\r\n</span></font>&nbsp;</p>\r\n<p><strong><span style="font-size:14pt;"><font face="Times New Roman">PET-CT</font></span></strong><strong><span style="font-size:14pt;font-family:宋体;">与鹰眼的比较</span></strong>&nbsp;</p>\r\n<p style="text-indent:21pt;"><font size="3"><span style="font-family:宋体;">由于引进</span><span><font face="Times New Roman">PET-CT</font></span><span style="font-family:宋体;">价格昂贵、投资巨大，难以普及推广。美国</span><span><font face="Times New Roman">GE</font></span><span style="font-family:宋体;">公司，德国</span><span><font face="Times New Roman">SIEMENS</font></span><span style="font-family:宋体;">公司及</span><span><font face="Times New Roman">Philip ADAC</font></span><span style="font-family:宋体;">公司等在双探头</span><span><font face="Times New Roman">ECT</font></span><span style="font-family:宋体;">基础上增加了符合探测，即所谓的“小</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">”或鹰眼（</span><span><font face="Times New Roman">GE</font></span><span style="font-family:宋体;">公司生产）等。其组成与双探头</span><span><font face="Times New Roman">ECT</font></span><span style="font-family:宋体;">一样，有</span><span><font face="Times New Roman">2</font></span><span style="font-family:宋体;">个探头，显像检查时，</span><span><font face="Times New Roman">2</font></span><span style="font-family:宋体;">个探头互成</span><span><font face="Times New Roman">180</font></span><span style="font-family:宋体;">度，绕扫描部位旋转。探测效率仅为</span><span><font face="Times New Roman">PET-CT</font></span><span style="font-family:宋体;">的</span><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">～</span><span><font face="Times New Roman">3</font></span><span style="font-family:宋体;">％，图像质量远不能与</span><span><font face="Times New Roman">PET-CT</font></span><span style="font-family:宋体;">相比拟，特别是对一些小病灶容易造成漏诊，达不到临床准确分期，了解全身累及范围的目的。美国</span><span><font face="Times New Roman">GE</font></span><span style="font-family:宋体;">公司生产的“鹰眼”系统是在双探头</span><span><font face="Times New Roman">ECT</font></span><span style="font-family:宋体;">加符合探测的基础上增加了最低档的定位</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">，该</span><span><font face="Times New Roman">CT</font></span><span style="font-family:宋体;">图像难以达到诊断质量。因此，临床应用价值有限。</span><span><font face="Times New Roman"> </font></span></font></p><font size="3"><font face="Times New Roman"></font></font>', 'gwm', 0, 167),
(92, 'PET显像剂的种类', '详细介绍', '', '', '2009-10-12 12:52:49', '116.228.141.77', '<div><strong><span style="font-size:14pt;">PET</span></strong><strong><span style="font-size:14pt;">显像剂</span></strong></div>\r\n<table cellspacing="0" cellpadding="0" border="1">\r\n<tbody>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div align="center">显像剂类型</div></td>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center">核素</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div align="center">显像剂</div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div align="center">用途</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" width="142" rowspan="6">\r\n<div align="center">血流灌注型</div></td>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>13</sup>N</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>13</sup>N-NH<sub>3</sub> · H<sub>2</sub>O</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>心、脑血流测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>15</sup>O</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>15</sup>O-H<sub>2</sub>O</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>脑血流测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>15</sup>O</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>15</sup>O-CO<sub>2</sub></strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>血流测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>15</sup>O</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>15</sup>O-</strong><strong>正丁醇<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>血流量测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>82</sup>Rb</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>82</sup>RbCl</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>心肌血流量测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>62</sup>Cu</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>62</sup>Cu-Cu(PTSM)</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>心、脑血流量测定</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" width="142" rowspan="16">\r\n<div align="center">代谢型</div></td>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FDG</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>葡萄糖代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FET</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>氨基酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FPT</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>氨基酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FEMET</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>氨基酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-MET</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>氨基酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>乙酸盐</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>脂肪酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>棕榈酸盐</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>脂肪酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>胆碱</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>胆碱代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>胸腺嘧啶</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>核酸代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-</strong><strong>氟代甲基胆碱</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>胆碱代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-</strong><strong>氟代乙基胆碱</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>胆碱代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FLT</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>细胞增殖</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FMISO</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>乏氧显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FETNIM</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>乏氧显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-NaF</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>骨血流与骨盐代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>15</sup>O</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>15</sup>O-O<sub>2</sub></strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>氧代谢</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" width="142" rowspan="31">\r\n<div align="center">结合型</div></td>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-β-CIT</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺转运蛋白显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-SCH2339</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺D1受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C -Raclopride</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺D2受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-MSP</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺D2受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-McN5652</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>5-羟色胺转运蛋白显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-WAY100635</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>5-羟色胺受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-Flumazenil</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>苯并二氮卓受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C- Deprenyl</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>单胺氧化酶B活性显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong>S-[<sup>11</sup>C] CGP12177</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>肾上腺素能受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>东莨菪碱</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>乙酰胆碱能受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-MQNB</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>乙酰胆碱能受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-</strong><strong>烟碱</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>乙酰胆碱能受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-Carfentanil</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>阿片受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>11</sup>C</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>11</sup>C-Diprenorphine</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>阿片受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-DOPA</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺能神经递质显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-β-FP-CIT</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺转运蛋白显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-β-FM-CIT</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺转运蛋白显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FMSP</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺D2受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FESP</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>多巴胺D2受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Setoperone</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>5-羟色胺受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F -Flumazenil</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>苯并二氮卓受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FES</strong><strong>★</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>雌激素受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Carazolol</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>肾上腺素能受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-RGD</strong><strong>多肽</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>血管生成显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Annexin V</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>肿瘤细胞凋亡显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Cyclofoxy</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>阿片受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Haloperidol</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>σ受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-Octreotide</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>生长抑素受体显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FHBG</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>基因表达显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-FHPG</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>基因表达显像</div></td></tr>\r\n<tr>\r\n<td style="background-color:transparent;" valign="top" width="81">\r\n<div align="center"><sup>18</sup>F</div></td>\r\n<td style="background-color:transparent;" valign="top" width="142">\r\n<div><strong><sup>18</sup>F-</strong><strong>寡核苷酸</strong></div></td>\r\n<td style="background-color:transparent;" valign="top" width="170">\r\n<div>反义显像</div></td></tr></tbody></table>', 'gwm', 0, 35),
(93, 'PET在原发性肝癌中应用', '临床应用', '', '', '2009-10-12 12:58:46', '116.228.141.77', '<p>目前，PET在原发性肝癌中诊断价值有限，主要原因是18F-FDG PET对原发性肝细胞癌的灵敏度不够理想，仅约70%。约30%高分化肝细胞癌存在一定水平的葡萄糖-6-磷酸酶（G-6-P酶），使18F-FDG不在肿瘤细胞内聚集而出现假阴性，如<a href="/my_article.php?act=jigou_intro&amp;j_id=145" target="_blank">病例38</a>。葡萄糖-6-磷酸酶在分化较差的肝细胞癌内表达较少或不表达，因此这部分肝癌一般出现明显18F-FDG浓聚。肝内出现结节状或块状高代谢灶者（如<a href="/my_article.php?act=jigou_intro&amp;j_id=144" target="_blank">病例37</a>），诊断为原发性肝癌具有非常高的特异性，虽然个别肝脓肿可出现18F-FDG摄取而导致假阳性，但绝大多数肝内良性病变（如血管瘤、肝腺瘤、肝炎、肝脂肪浸润、局灶性结节状增生及绝大多数肝炎性假瘤皆不会出现18F-FDG高摄取。所以18F-FDG显像阳性者，基本上可诊断为肝癌，而阴性者则无法除外高分化肝细胞肝癌的可能。PET在了解肝癌介入、适形放疗、射频消融术后肿瘤残余和复发方面有比较重要的应用价值，肝癌治疗后坏死区呈放射性缺损，残余和复发病灶为限局性浓聚灶，如病例39，肝癌治疗后AFP明显增高而其他影像阴性者，很适合行PET显像；对于治疗前显像阴性者，18F-FDG PET不可用于疗效观察。<br />\r\n11C-乙酸PET显像能弥补18F-FDG的不足。11C-乙酸主要聚集于高、中分化肝细胞癌内，而低分化肝细胞癌却聚集较少，与18F-FDG刚好相反。因此， 11C-乙酸和18F-FDG联合显像将有助于明显提高PET对肝细胞癌的检出灵敏度。<br />\r\n18F-FDG PET对肝胆管癌检出率高于肝细胞癌。<a href="/my_article.php?act=jigou_intro&amp;j_id=144" target="_blank">病例37</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=145" target="_blank">病例38&nbsp;</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=146" target="_blank">病例39</a></p>', 'gwm', 0, 23),
(94, 'PET在胰腺癌中的应用', '临床应用', '', '', '2009-10-12 12:59:47', '116.228.141.77', '胰腺癌是一种发展快、预后差的恶性肿瘤,发病率存在逐渐增长的趋势。胰腺癌的早期诊断存在一定的困难。须结合临床表现、B超、CT、ERCP和血CA199进行诊断。<br />\r\n1．在胰腺癌诊断和鉴别诊断中的应用<br />\r\nPET在胰腺病变良恶性诊断中有一定的应用价值，鉴别诊断主要根据病灶的浓聚程度<br />\r\n并结合形态分析。正常情况下，胰腺不显影，绝大多数良性肿瘤病灶也不显影或轻度浓聚，<br />\r\n如<a href="/my_article.php?act=jigou_intro&amp;j_id=148" target="_blank">病例41</a>；胰腺癌病灶常表现高度浓聚灶，如病例40；少数良性病变（如活动性结核和<br />\r\n胰腺炎）而出现假阳性，须密切结合ERCP、CT和临床，形态分析也很重要（如<a href="/my_article.php?act=jigou_intro&amp;j_id=149" target="_blank">病例42</a>，<br />\r\n肝左叶病灶为边缘模糊轻度浓聚影，提示炎性改变的可能，胰头周围浓聚灶病灶不大，但<br />\r\n出现放射性缺损，提示存在干酪样坏死的可能）。18F-FDG PET诊断胰腺癌的灵敏度、特<br />\r\n异性和准确性分别为85%～95%、78%～99%、85%～93%。一般用于临床高度怀疑胰腺<br />\r\n癌而CT显像阴性者或临床怀疑为胰腺良性病灶而CT定性较困难者。CT与PET相结合<br />\r\n有助于提高诊断的准确性。PET结合临床表现（如有无进行性黄疸、腹痛、体重下降等）<br />\r\n和血CA199很重要。对于无症状、血CA199正常者，PET显像结果阴性者绝大多数为良<br />\r\n性病变；无临床症状、血CA199正常者，而PET显像阳性者，须除外结核的可能。日本<br />\r\n学者Nakamoto报道18F-FDG PET常规显像和2小时延迟显像相结合有助于进一步提高<br />\r\nPET的鉴别诊断价值(准确性从83.0%提高到91.5%)。肿瘤较小、同时有糖尿病病史者PET<br />\r\n易出现假阴性。<a href="/my_article.php?act=jigou_intro&amp;j_id=147" target="_blank">病例40</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=148" target="_blank">病例41</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=149" target="_blank">病例42&nbsp;</a> <br />\r\n2．在胰腺癌分期中的应用<br />\r\nPET在检测胰腺癌转移灶方面灵敏、准确，如病例43所示。PET检测肝内转移灶较CT灵敏、特异，对于肝内小病灶，PET可用于明确是否为转移灶, 而避免不必要的活检；PET在鉴别治疗后疤痕形成和肿瘤复发方面也有较重要的应用价值，疤痕不摄取18F-FDG，而肿瘤复发灶表现为高度异常浓聚灶。<a href="/my_article.php?act=jigou_intro&amp;j_id=150" target="_blank">病例43</a>', 'gwm', 0, 22);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(95, 'PET在消化道肿瘤中应用', '临床应用', '', '', '2009-10-12 13:00:31', '116.228.141.77', '<p>1．&nbsp; PETPET在大肠癌中的应用<br />\r\n(1)在大肠癌诊断中的应用<br />\r\n对于大肠癌，一般通过体检、肠镜检查便可明确诊断，因此PET较少用于初次诊断和鉴别诊断。PET可用于肠镜取样失败、结果可疑或难以耐受肠镜检查者，对于有明确的转移灶者，用PET寻找结、直肠原发灶也是一种非常好的选择，<a href="/my_article.php?act=jigou_intro&amp;j_id=137" target="_blank">如病例30</a>。大肠癌病灶一般表现为限局性浓聚灶，如<a href="/my_article.php?act=jigou_intro&amp;j_id=136" target="_blank">病例29</a>所示。对于结、直肠癌原发灶，PET显像的灵敏度＞90%。肠道生理性浓聚、少数肠道炎症及腺瘤样息肉可出现18F-FDG 浓聚而导致假阳性。延迟显像有助于鉴别肠道生理性浓聚和大肠癌，前者延迟显像浓聚影常出现形态、位置及浓聚程度的改变，而后者延迟显像病灶的大小、形态及位置常比较固定，浓聚程度不变或增高。在结、直肠癌的术前淋巴结转移分级方面，PET和CT皆不够灵敏。PET在检测肝内转移灶方面较CT灵敏、特异。<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=136" target="_blank">病例29&nbsp;</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=137" target="_blank">病例30</a></p>\r\n<p>(2)在监测大肠癌复发及复发性肿瘤的术前分期中应用<br />\r\n结、直肠癌术后2年内约1/3患者出现肿瘤复发。PET对结、直肠癌术后复发病灶的检出灵敏度相当高。当怀疑结、直肠癌复发时，全身18F-FDG PET显像应作为道选的诊断手段，特别是以下2种情况：①CT/MR发现骶前肿块而定性困难者；②血清CEA升高，但CT/MR显像阴性者。<br />\r\nCT/MR发现骶前肿块，高度提示复发的可能，但在鉴别疤痕形成还是复发方面有时有一定困难。PET在鉴别术后或放疗后骶前肿物的性质方面准确性高，复发病灶表现为高代谢病灶，如病例31，而疤痕组织则不摄取或轻度摄取18F-FDG。综合多中心的192例患者，PET对鉴别诊断结直肠局部复发和疤痕的灵敏度、特异性和准确性分别为95%、98%和96%。<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=138" target="_blank">病例31&nbsp;</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=139" target="_blank">病例33</a></p>\r\n<p>18F-FDG PET显像在检测大肠癌术后肝内及肝外转移方面具有非常高的灵敏度和特异性。<br />\r\nDelbeke等对61例患者的研究结果显示，PET对肝内转移灶的灵敏度为91%，较肝门静脉造影CT稍低（97%），而明显高于常规肝脏显像,但PET的准确性明显高于肝门静脉造影CT（92%比80%）。在肝外转移灶检测方面，PET对腹部淋巴结、腹膜、肠系膜及盆腔内转移灶检出较CT灵敏，306例PET与CT的直接比较结果显示，PET与CT对盆腔、腹膜后及腹部其他部位（除外肝脏）转移灶的检出率分别为97％、100％、79％和68％、58％、46％。在肺内转移灶的检出，PET的灵敏度约94％，较CT略低。PET全身显像还有助于检出其他部位的远处转移灶而改变临床分期。对多中心的454例患者的显像结果进行分析，PET对转移灶检出的总体灵敏度、准确性分别为87%～100%、83%～100%，行PET显像，约1/3因多检出转移灶而改变临床治疗方案。</p>', 'gwm', 0, 24),
(96, 'PET在胃癌中应用', '临床应用', '', '', '2009-10-12 13:01:00', '116.228.141.77', '<p>胃癌是消化道最常见的恶性肿瘤，绝大多数患者行胃镜可获得明确诊断。对于个别胃镜取样不成功者，PET有助于协助诊断。正常情况下，部分患者胃内会出现18F-FDG较明显的生理性摄取，但大多数为均匀性浓聚，对于限局性浓聚可疑有胃癌者，进食后延迟显像有较大的帮助，进食后胃腔常表现为囊腔状放射性缺损，如进食后胃壁仍出现明显的异常浓聚灶，应考虑存在胃癌的可能，进一步行胃镜检查是非常必要的。胃粘液腺癌和印戒细胞癌，PET显像易出现假阴性。<br />\r\nPET在胃癌转移灶的检出方面与食道癌相近，但报道较少。在了解转移与否时应与CT相结合，部分转移灶在CT上显示较清楚而PET可为阴性。<a href="/my_article.php?act=jigou_intro&amp;j_id=143" target="_blank">病例35 病例36</a></p>', 'gwm', 0, 17),
(97, 'PET在头颈部肿瘤中的应用', '临床应用', '', '', '2009-10-12 13:01:31', '116.228.141.77', '头颈部肿瘤是比较常见的肿瘤，在我国以鼻咽癌占首位，喉癌和甲状腺癌次之。在美国则以喉癌占首位。头颈部肿瘤所处位置软组织较紧，同时淋巴供应丰富，极易出现淋巴结转移。头颈部肿瘤主要采用放疗和手术治疗，治疗前了解病变累及的范围及有无转移十分重要。<br />\r\n在头颈部肿瘤诊断中应用<br />\r\n头颈部肿瘤90%以上为鳞状上皮癌，这类肿瘤绝大多数对18F-FDG摄取相当高，病灶多表现为结节状或团块状高代谢灶，边界清楚,如上述3个病例，特别是鼻咽癌。PET对头颈部肿瘤的总体检出灵敏度约90%。由于正常情况下和炎症状态下，头颈部组织可出现18F-FDG 不同程度的摄取，所以PET一般较少用于初次定性诊断，而主要用于肿瘤分期及了解病变侵及范围。有报道认为11C-acetate（醋酸盐）PET用于鼻咽癌和头颈部其他肿瘤的诊断及鉴别诊断优于18F-FDG。PET作为一种阳性显像技术，恶性病灶的显示不受复杂的组织结构影响，易于检出，因而灵敏度高，而MR和CT具有非常好的组织结构分辨率，在了解病变与周围组织之间的相互关系具有PET无法比拟的优势，两者相融合，取长补短，临床价值更大，如病例21。腮腺癌PET探测灵敏度较低（&lt;70%），其价值不如其他检查；部分甲状腺良性病变（如甲状腺腺瘤）及腮腺腺瘤，也可出现18F-FDG高摄取，应引起注意。<br />\r\n鼻咽癌原发灶及颈部转移灶最有效、最常用的治疗手段为放疗，肿瘤内组织处于乏氧状态会使其对放疗的敏感度下降而使治疗效果不理想，因此治疗前了解肿瘤的乏氧状况对预测放疗效果有重要的实用价值，PET乏氧显像剂（如18F-FMISO）在这方面的应用有潜在的应用价值。<a href="/my_article.php?act=jigou_intro&amp;j_id=128" target="_blank">病例19 病例20&nbsp; 病例21</a><br />\r\n在头颈部肿瘤分期中的应用<br />\r\nPET在头颈部肿瘤的分期方面有重要的临床应用价值。在淋巴结转移灶的检测方面，PET的灵敏度、特异性和准确性都比较高（分别为88%、93%、92%）。PET能检出正常大小（&lt;1cm）的淋巴结内转移，灵敏度高于CT/MR。熟悉正常生理性摄取（如咽后壁、扁桃体、唾液腺、喉部肌肉及颈部小肌群）对正常理解和鉴别是生理性摄取还是转移灶十分重要，注射18F-FDG前后若患者过多说话或唱歌，喉部常有较高18F-FDG摄取，会增加图像判读的难度，所以注射18F-FDG前后应禁止过多说话或唱歌。PET全身显像有助于检出远处转移灶而提高分期准确性，如腹膜后淋巴结转移、肝转移和骨转移等,如<a href="/my_article.php?act=jigou_intro&amp;j_id=129" target="_blank">病例22</a>（该病灶为全身显像时无意中发现）；对于甲状腺未分化癌、髓样癌，术前行18F-FDG PET有助探测到隐匿性病灶而提高手术治疗效果，如<a href="/my_article.php?act=jigou_intro&amp;j_id=131" target="_blank">病例24</a>。<a href="/my_article.php?act=jigou_intro&amp;j_id=129" target="_blank">病例22 病例23&nbsp;</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=131" target="_blank">病例24<br />\r\n</a>在头颈部肿瘤残余、复发病灶诊断中应用<br />\r\nPET在诊断头颈部肿瘤残余或复发病灶方面有比较重要的应用价值,复发或残余病灶一般表现为边界清楚的、限局性异常浓聚灶，如病例25，而疤痕组织一般不出现放射性异常浓聚。PET诊断头颈部肿瘤复发的总体灵敏度、特异性和准确性分别为94%、82%、87%，阴性预告值约91%，在鼻咽癌复发灶检出方面，优于头颈部其他肿瘤，准确性大于90%，阴性预告值约97%。放疗后如存在明显炎症反应，可出现18F-FDG异常浓聚，但其形态多不规则，边界较模糊，鉴别时须注意形态分析。PET显像一般应于放疗后3个月后才进行。部分病人放疗后头颈部正常组织生理性摄取出现差异而导致左右侧不对称，理解时应慎重，特别是舌下腺和颌下腺。甲状腺癌术后患者，PET主要应用于甲状腺球蛋白（TG）升高（提示存在复发或转移的可能）、而131I全身显像阴性者，在这种情况下，PET对转移灶的探测灵敏度为94%。病例25', 'gwm', 0, 32),
(98, 'PET在食管癌中应用', '临床应用', '', '', '2009-10-12 13:02:06', '116.228.141.77', '在消化道肿瘤中，食管癌是仅次于胃癌的一种非常常见的恶性肿瘤。X线钡餐检查、食道脱落细胞检查及胃镜检查是诊断和鉴别食管癌最常用的手段。食管癌一般经胃镜检查可明确诊断。PET一般不用于进行定性诊断，主要用于术前或放疗前分期、了解有无复发和评价疗效。<a href="/my_article.php?act=jigou_intro&amp;j_id=141" target="_blank">病例33 病例34</a><br />\r\n食管癌绝大多数为鳞癌，而鳞癌对对18F-FDG的摄取一般比较高，因此食管癌行PET显像是很合适的。病灶一般显示很清楚,多表现为结节状、块状或长粗条状，如<a href="/my_article.php?act=jigou_intro&amp;j_id=140" target="_blank">病例33</a>，矢状位对全面显示病变的长度有较大的帮助，PET对食管癌原发灶检出灵敏度为90％～100％。对于食管邻近的淋巴结转移，PET的检出率较低，部分原因是病灶较小与原发灶很难区分，灵敏度约80％，特异性为95％；但在远位转移灶的检出，如锁骨上窝及腹膜后淋巴结转移、肝转移等，PET较CT灵敏，PET在探测远处转移的灵敏度、特异性和准确性分别为88%、93%、91%。在食管下段，部分食道炎患者可出现轻度浓聚，须与食道癌相鉴别，前者浓聚程度一般较低、形态规则，而后者一般浓聚程度高，呈结节状或粗条状。<br />\r\nPET在评价食管癌适形放疗疗效方面是十分灵敏和准确的方法，病灶的浓聚程度明显降低或不浓聚提示疗效好、局部肿瘤被杀灭或被明显抑制，如病例34。PET全身显像，在疗效评估时常意外发现一些转移灶，这对临床采取进一步治疗很有帮助。食道癌术后，吻合口组织形态及厚度改变，使CT在判断有无复发方面存在一定的困难，PET为阳性显像，不受组织形态及厚度改变的影响，能灵敏地、准确地检出复发病灶，但部分炎症会出现18F-FDG摄取，分析时应慎重。', 'gwm', 0, 21),
(99, 'PET在乳腺癌中的应用', '临床应用', '', '', '2009-10-12 13:02:40', '116.228.141.77', '乳腺癌是一种常见恶性肿瘤。早期主要通过淋巴结转移，以腋下最常见（发生率约60%）。有无腋下淋巴结转移对预后影响很大，无腋下淋巴结转移者5年生存率为75%，1～3个淋巴结转移者5年生存率为45%左右，但多于3个淋巴结转移者5年生存率只有20%。<br />\r\n1．在乳腺癌诊断中的应用<br />\r\n乳腺癌是PET显像的主要适应症之一。PET显像对乳腺癌的诊断灵敏度及准确性皆较高，301例显像结果显示其灵敏度、特异性和准确性分别为92%、97%和92%。结节状或团块状病灶出现18F-FDG高摄取，基本上可确定为恶性病变，虽然小部分乳腺腺瘤、结核和脓肿也可出现18F-FDG高摄取而导致假阳性结果。然而，PET并非是乳腺癌理想的显像手段，病灶小于1cm者、生长慢、分化好的小部分乳腺癌PET可出现假阴性，因此对于临床高度怀疑乳腺癌的可能而PET显像阴性者，进一步活检确定或定期行其他影像学随诊是非常必要的。鉴于以上不足，同时由于检查费用昂贵，PET一般不做为常规定性检查，而主要用于乳腺密度高者、乳腺成形术后和活检不成功者的诊断和鉴别诊断。<a href="/my_article.php?act=jigou_intro&amp;j_id=133" target="_blank">病例26 </a><br />\r\n2．在乳腺癌分期中应用<br />\r\nPET在乳腺癌的分期方面有重要的应用价值。<br />\r\n在淋巴结转移灶检出方面，PET的灵敏度、特异性及准确性分别约82%、95%和90%，淋巴结出现18F-FDG 高摄取者，基本上可确定为淋巴结转移。对于较小的淋巴结转移灶，PET可出现假阴性，在PET显像前已行化疗的病人，由于淋巴结内肿瘤细胞的活性受抑制，PET也存在假阴性可能。PET显像与前哨淋巴结SPECT显像及活检相结合，对淋巴结转移的分级会更全面。在远处转移灶检测方面，PET无论对软组织(如肺、肝脏)或骨骼转移灶都具有相当高的灵敏度及特异性(灵敏度大于90%，特异性约为88%)。虽然PET无法100%的检出转移灶，但PET常能发现一些远处的、隐匿性转移灶而改变临床分期。对于进展性乳腺癌（如Ⅲ、Ⅳ期），为了更全面、准确地了解病变累及的严重程度，行PET全身显像进行分期是非常必要。<a href="/my_article.php?act=jigou_intro&amp;j_id=134" target="_blank">病例27<br />\r\n</a>3．在疗效评价及复发中的应用<br />\r\n18F-FDG PET可灵敏地反映乳腺癌的疗效。治疗前阳性病灶治疗后消失，如<a href="/my_article.php?act=jigou_intro&amp;j_id=136" target="_blank">病例29</a>，提示完全反应。病灶浓聚程度降低，提示部分反应。在以上2种情况，PET所见的代谢改变常较CT或乳腺钼靶显像所见的病灶大小改变早。病灶浓聚程度不变或反而增高，提示治疗效果差。<br />\r\n18F标记的雌二醇行雌激素受体（ER）显像能很好地预测抗雌激素的疗效，肿瘤内18F-雌二醇摄取高者，说明肿瘤细胞表面ER高表达，适合行雌激素治疗，而阴性者说明肿瘤细胞表面ER表达程度不高或不表达，一般不适合行雌激素治疗。<br />\r\n乳腺癌治疗后复发的病灶往往恶性程度高，这些复发病灶对18F-FDG 摄取一般较高，因此18F-FDG PET显像在复发肿瘤中应用更为合适。PET有助于更全面、准确地了解乳腺癌复发及全身转移情况，使治疗方案的制定更具科学性。但是由于分辨率的限制，PET对于小于6mm的复发灶和转移灶仍是难以做出比较确定的诊断，因此对于乳腺癌术后肺内出现小结节影者，用PET来进一步明确性质价值有限。<a href="/my_article.php?act=jigou_intro&amp;j_id=135" target="_blank">病例28</a>', 'gwm', 0, 26),
(100, 'PET在其他肿瘤中的应用', '临床应用', '', '', '2009-10-12 13:03:27', '116.228.141.77', '<p>1．在泌尿系统肿瘤中的应用<br />\r\nPET在泌尿系统中的应用价值有限，一方面是由于18F-FDG主要由泌尿系排泄，泌尿系统，（特别是膀胱和双肾）聚集大量放射线而掩盖肿瘤的显示，另一方面还因为肾癌18F-FDG显像灵敏度不够。18F-FDG PET探测肾癌的灵敏度约70%（部分透明细胞癌易出现假阴性），18F-FDG对肾癌的探测灵敏度与肿瘤的恶性程度有关，恶性程度高者，多表现高代谢病灶（如病例47），灵敏度为94%；而恶性程度低者，灵敏度只有20%～30%，多表现为低代谢病灶或不显影（如病例48）。膀胱内的高放射性浓聚使膀胱癌检出十分困难，但在显示其淋巴结转移方面，18F-FDG PET显像比较灵敏，特别在检出盆脸及腹部淋巴结转移方面，PET优于其他检查。<br />\r\n2．在生殖系统肿瘤中的应用<br />\r\n（1）在男性生殖系统肿瘤中应用<br />\r\n在前列腺癌中应用，18F-FDG PET的价值比较有限，灵敏度约60%～70%，典型影像表现如<a href="/my_article.php?act=jigou_intro&amp;j_id=156" target="_blank">病例49</a>，在前列腺骨转移检出方面也较骨显像灵敏度低，但在检出盆腔和腹部淋巴结方面比较灵敏，如病例50。胆碱类显像剂，如18F-胆碱（18F-choline）、11C-胆碱（11C-choline）最近发现在前列腺显像方面明显优于18F-FDG。在睾丸癌显像方面，正常情况下因睾丸也会出现不同程度的生理性摄取而影响诊断和疗效观察，其应用较少，临床价值尚不明确。<br />\r\n（2）在女性生殖系统肿瘤中的应用<br />\r\n18F-FDG PET在妇科恶性肿瘤诊断方面有一定的应用价值，如<a href="/my_article.php?act=jigou_intro&amp;j_id=158" target="_blank">病例51</a>、<a href="/my_article.php?act=jigou_intro&amp;j_id=159" target="_blank">52</a>。阳性预告值为86%。在检测卵巢癌残余和复发方面，PET灵敏度、特异性和准确性为96%、44%和71%。Hubner等报道PET与CT相结合在诊断卵巢癌术后复发方面具有十分重要的价值，当CT和PET皆阳性者，阳性预告值为100%；当CT阴性、PET阳性者，阳性预告值为81%；当CT阳性、PET阴性者，阳性预告值为16%；当CT和PET皆阴性者，阴性预告值为87%。子宫、宫颈和阴道癌对18F-FDG 摄取一般都较高，但其临床应用较少，具体临床价值尚不明确。<br />\r\n3．在肌肉和骨骼肿瘤方面<br />\r\nPET在骨骼和肌肉肿瘤检出和鉴别方面有一定的应用价值。骨肉瘤对18F-FDG 的摄取与其分级有关，高度恶性肿瘤对18F-FDG 摄取明显高于良性肿瘤和低度恶性肿瘤，SUV大于1.6者多为高度恶性肿瘤,而小于1.6 者多为良性病变或低度恶性肿瘤。有学者对20 例骨骼肿瘤进行随访研究发现，以SUV大于2.0作为鉴别阈值，PET可准确诊断14/15例恶性肿瘤和4/5 良性病变。但有学者认为低度或中度恶性肿瘤与良性病变对18F-FDG 的摄取存在部分重叠而使特异性不够理想。在检测肌肉和骨骼肿瘤复发病灶方面，PET的灵敏度和特异性分别为84%～100%和78%～97%。<br />\r\n在骨骼转移灶检出方面，除前列腺骨转移外，FDG PET的灵敏度与全身骨显像相近或略低，但特异性高于骨显像。<br />\r\n4．PET在探测未明原发灶肿瘤中的应用<br />\r\n未明原发灶肿瘤指有明确的转移灶、但用传统显像未能找到原发灶者。这类病人的原发灶一般皆比较小，位置比较隐蔽。18F-FDG 做为一种广谱恶性肿瘤显像剂，同时又能行全身显像，在检出未明原发灶方面具有独特的优势。30%～50%未明原发灶者PET能检出原发灶所在，如病例54。常见的部位为肺尖、肺门、肺内侧野主动脉旁、食道下段、甲状腺、舌部、涎腺、鼻咽部、咽喉部等。对于较小的病灶，如小于0.7cm者和某些特殊类型肿瘤,如前列腺癌、膀胱癌、高分化肝癌等，PET可存在假阴性的可能，定期复查是必要的。也有部分病人经随访多年一直未找到原发灶。</p>', 'gwm', 0, 30),
(101, 'PET在颅内肿瘤中的应用', '临床应用', '', '', '2009-10-12 13:04:04', '116.228.141.77', '对于颅内肿瘤，CT/MR具有不可替代的重要价值，但仍存在一些不足，PET做为一种功能显像技术，与CT/MR具有互补性。PET在脑肿瘤，特别是在脑胶质瘤的恶性程度分级、预后评价、术后或放疗后残余病灶的检出、复发病灶与疤痕、坏死的鉴别方面有较重要的临床应用价值。<br />\r\n1．在胶质瘤恶性程度分级中的应用<br />\r\n大多数原发性颅内肿瘤起源于神经胶质细胞，最常见的神经胶质肿瘤是星形细胞瘤。脑胶质瘤按肿瘤的分化和间变程度分为四级：一般Ⅰ级～Ⅱ级为低度恶性肿瘤；Ⅲ～Ⅳ级为高度恶性肿瘤。18F-FDG PET能较好地区分低度恶性肿瘤和高度恶性肿瘤，18F-FDG PET对脑胶质瘤恶性程度分级主要根据病灶的浓聚程度。一般采用视觉分析，Ⅲ～Ⅳ级胶质瘤表现为高代谢病灶（病灶18F-FDG摄取高于白质），如病例11；Ⅰ～Ⅱ级胶质瘤表现为低代谢病灶（病灶内18F-FDG摄取低于白质），如<a href="/my_article.php?act=jigou_intro&amp;j_id=119" target="_blank">病例12 </a>，但约10%Ⅱ级胶质瘤可表现为高代谢病灶，提示恶变的可能。当肿瘤/白质比值&gt;1.5用于诊断高度恶性胶质瘤，其灵敏度和特异性分别为94%、77%，另外脑胶质瘤病灶内常有异质性，PET能识别肿瘤内高度恶性部分，因此PET所示的部分高代谢区小于MR所示的增强区。<br />\r\n肿瘤18F-FDG摄取程度对预测预后有一定帮助，当病灶的放射性与对侧相应正常脑实质相比大于1.4时，其平均存活时间约5 个月，而小于1.4时，其平均存活时间约19个月。<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=119" target="_blank">病例12</a><br />\r\n2．鉴别治疗后疤痕与肿瘤残余、复发<br />\r\n18F-FDG PET在恶性胶质瘤残余或复发病灶的检出方面具有一定的优势。疤痕或坏死组织18F-FDG PET显像表现为放射性缺损，而复发病灶表现为限局性浓聚。在检出术后或放疗后残余病灶方面PET较CT/MR灵敏，在术后1～16天，PET便可以准确检出残余病灶。对于Ⅰ～Ⅱ级胶质瘤，由于18F-FDG显像为低代谢病灶，不适宜用于疗效评估。<br />\r\n在胶质瘤的分级及复发病灶检测方面，11C-蛋氨酸显像可弥补18F-FDG显像的不足。11C-蛋氨酸PET显像，正常脑组织放射性分布低，肿瘤靶/非靶（T/NT）比值高，病灶的范围和边界显示更清楚，同时与18F-FDG显像不同，低度恶性胶质瘤和高度恶性胶质瘤都可出现11C-蛋氨酸高摄取。11C-蛋氨酸显像结合18F-FDG显像对胶质瘤的分级更有诊断价值，一般认为11C-蛋氨酸高摄取、18F-FDG低摄取者为Ⅰ～Ⅱ级胶质瘤； 两者皆为高摄取者为Ⅲ～Ⅳ级胶质瘤。对于胶质瘤治疗后，11C-蛋氨酸和18F-FDG皆为高摄取者为Ⅲ～Ⅳ级胶质瘤术后复发，如<a href="/my_article.php?act=jigou_intro&amp;j_id=123" target="_blank">病例16</a>；11C-蛋氨酸高摄取、18F-FDG低摄取者，则为Ⅰ～Ⅱ级胶质瘤术后复发,如<a href="/my_article.php?act=jigou_intro&amp;j_id=122" target="_blank">病例15</a>；两者皆不摄取者为坏死或疤痕组织。<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=120" target="_blank">病例13</a>&nbsp;&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=121" target="_blank">病例14&nbsp;</a>&nbsp;<a href="/my_article.php?act=jigou_intro&amp;j_id=122" target="_blank"> 病例15</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=123" target="_blank">病例16<br />\r\n</a>3．在脑内其他肿瘤中的应用<br />\r\n除原发性脑胶质瘤外，脑部其他恶性肿瘤，如恶性淋巴瘤、精原细胞瘤、恶性胚胎肿瘤、脉络膜丛癌等也可出现18F-FDG高摄取，另外神经节神经胶质瘤也可出现18F-FDG高摄取。颅内原发恶性淋巴瘤可出现18F-FDG明显高摄取，病灶显示清楚，如病例17。对于AIDS患者，18F-FDG PET可用于鉴别脑内淋巴瘤和非肿瘤性病变（如弓形体病），弓形体病一般不出现18F-FDG高摄取，而淋巴瘤则常出现18F-FDG明显高摄取。<br />\r\n18F-FDG和11C-蛋氨酸显像皆可用于诊断脑垂体瘤，分泌型和非分泌型垂体瘤皆可出现18F-FDG或11C-蛋氨酸限局性高摄取。在评价垂体瘤治疗疗效方面，11C-蛋氨酸较MR灵敏，对于治疗效果好者，11C-蛋氨酸显像可在形态改变之前见到疗效。<br />\r\nPET在脑膜瘤和其他肿瘤中价值较低，绝大多数脑膜瘤不会出现18F-FDG高摄取，少数高摄取者常提示恶变的可能或提示术后易复发。<br />\r\n在脑内转移灶的检出方面，由于脑部正常情况下摄取高，18F-FDG PET的价值比较有限，18F-FDG PET的检出率不如CT/MR，部分转移灶，可表现为限局性低代谢区。11C-蛋氨酸或11C－酪氨酸对脑转移灶的检出灵敏度可能较18F-FDG 高。<br />\r\n', 'gwm', 0, 22),
(102, 'PET在肺癌中的应用价值', '临床应用', '', '', '2009-10-12 13:06:24', '116.228.141.77', '<p>孤立性结节和肿块的良恶性鉴别<br />\r\n&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>肺孤立性结节(solitary pulmonary nodule)是一种孤立的、球形的、小于或等于3cm的肺内占位性病变；病灶直径大于3.0cm者多称为肿块。肺孤立性结节中有20%～40%为恶性肿瘤，手术切除这部分肺癌的5年生存率为50%，明显高于肺癌的总体5年生存率（14%）。CT/MR和X线胸片在肺部孤立性结节和肿块的检出及诊断方面具有重要的临床价值，一般根据病灶的倍增时间、钙化情况、有无脂肪及病灶的边缘等征象能较明确地进行定性鉴别诊断，但部分结节CT诊断较困难，即所谓的“不确定性”（indeterminate）结节,提示存在恶性的可能，需要进一步明确。18F-FDG PET在肺部孤立性结节或肿块的良恶性鉴别有重要的应用价值，作者等对102例肺部病灶进行鉴别诊断，PET诊断恶性病灶的灵敏度、特异性分别约90%、90.4%。<a href="/my_article.php?act=jigou_intro&amp;j_id=108" target="_blank">病例1</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=109" target="_blank">病例2&nbsp;</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=110" target="_blank">病例3&nbsp;</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=111" target="_blank">病例4</a><br />\r\n结节状或团块状病灶，放射性均匀性浓聚，SUV＞2.5，病灶周边清楚，为肺癌的典型表现。当病灶大于3.0cm者，常可见边缘呈分叶状，如病例1、2。少数肺癌病灶内可见放射性缺损影(局部组织坏死所致)，但缺损影的周边组织常壁厚且放射性高度浓聚（一般SUV＞2.5）。将肺内结节状或团块状高代谢病灶、SUV大于2.5者诊断为肺癌，PET的灵敏度和特异性皆约90%。对于较小的病灶（&lt;2.0cm）且SUV介于2.0-2.5之间者，如病灶内放射性均匀性浓聚，仍应考虑有恶性肿瘤的可能，须结合临床表现、CT／MR所见并建议定期临床密切随诊，作者等曾对15例SUV&lt;2.5的肺癌病灶进行分析发现，部分肺癌病灶SUV较低与病灶较小有一定的关系，15例中，11/15例病灶小于2.0cm，6/15例病灶小于1.0cm，除与病灶小有关外，SUV低与特殊的细胞类型也有关系，如肺泡癌、疤痕癌，SUV常较低或不显影。<br />\r\n少数管壁浸润型肺癌PET可表现为肺门支气管区粗条状高度浓聚影或车轨状浓聚影（一般SUV＞2.5），诊断时结合CT非常重要，CT常可见气管管壁增厚及伴有阻塞性肺炎或肺不张。个别肺癌可表现为双肺多发结节型或块状高代谢病灶，病灶大小不等、浓聚程度不一，以弥漫型肺泡癌较多见。极少数肺癌可表现为大片状高代谢病灶（SUV＞2.5），病灶常位于肺部的周边且边界较清楚。<br />\r\n肺癌病灶18F-FDG PET不显影的很少，由于PET分辨率的限制，小于7mm的肺癌可出现假阴性，类癌和结节型支气管肺泡癌，由于生长较慢、倍增时间长，也易出现假阴性。<br />\r\n部分中央型肺癌，在CT图像上由于受肺门周围动静脉影的影响而难以检出，PET做为一种阳性显像方式，不受解剖组织的影响，其检出率高于CT。<br />\r\n肺部良性病灶一般放射性浓聚低，分布不均匀，边界模糊，如病例3,以病灶的SUV＜2.0诊断良性病变，阴性预告值约为92%，。<br />\r\n大多数结核和急、慢性炎症浓聚程度都相当低，但少数活动性肺结核和急性炎症可出现放射性高度浓聚,如病例4 ，这主要与病灶内大量中性粒白细胞和巨噬细胞对18F-FDG摄取有关。鉴别时仅靠SUV的高低是不够的，结合病灶的形态及临床表现、胸片和CT进行综合分析尤其重要。薄片状、条状、楔形或不规则形高度浓聚灶，多数病灶为急性炎症或活动性结核。<br />\r\n其他良性病变，如隐球菌病、组织胞浆菌病、曲霉病、脓肿、结节病、炎性假瘤和其他良性改变，在病变活动期也可出现18F-FDG高度浓聚，须结合CT、MR及临床表现进行综合分析。<br />\r\nPET在肺癌治疗前分期中的应用<br />\r\n18F-FDG PET显像,特别是全身显像，对肺癌转移灶检出灵敏、准确、全面，能一目了然地反映病情的严重程度，在分期方面具有独特的价值。<br />\r\n（1）&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 纵膈淋巴结转移灶的检出&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n纵膈淋巴结转移是肺癌转移最常见的地方，转移灶的数量、位置对确定是否行根治性切除手术十分重要。FDG PET在诊断肺门、纵膈淋巴结转移方面灵敏度、特异性高。其诊断标准多采用视觉分析，对肺癌患者，肺门和纵膈内出现结节状或小块状18F-FDG高摄取病灶，浓聚程度明显高于纵膈血池者，一般考虑为淋巴结转移。部分淋巴结转移灶可相互融合在一起呈粗条状、串珠状或不规则型浓聚影。综合多个作者报道的257例对比研究结果，18F-FDG PET在诊断纵膈淋巴结转移的平均灵敏度、特异性分别为88%、91%，而CT的灵敏度、特异<br />\r\n性分别为63%和80%。PET对纵膈淋巴结转移灶检出灵敏度高于CT，主要是由于它能检出小于1.0cm以下的淋巴结转移灶，同时不受纵膈内组织的影响。虽然PET对肺门、纵膈淋巴结转移的检出灵敏度高，但仍不能发现显微镜下所见的微小转移灶，对于0.5cm以下的转移灶检出率很低。肺门和纵膈淋巴结大于1.0cm者，并不一定为淋巴结转移，可能为淋巴结核、淋巴结反应性增生或结节病等，对于较大的淋巴结增大，PET显像未见FDG浓聚或仅出现轻度浓聚者， 基本上可除外淋巴结转移（但肺泡癌除外）。肺门和纵膈出现FDG浓聚者，并非都是淋巴结转移灶，肺门炎症和炎症性反应性淋巴结也可出现FDG浓聚，部分病灶甚至SUV明显高于2.5，但肺门炎症多表现为短条状浓影，并与支气管走向基本一致，仔细分析多数可与淋巴结转移相鉴别，特别是双侧肺门皆出现短条状浓影同时伴有咳嗽、咳痰者。CT和PET相结合，两者取长补短，能进一步提高诊断准确性。当PET表现为轻度或中度摄取，与CT结果相矛盾时，必要时可行纵膈镜检查进一步明确。病例5<br />\r\n（2）&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 全身其他部位转移灶的检出 </p>\r\n<p>PET全身显像在肺癌准确分期方面具有独特的应用价值。一次PET全身显像即可对全身转移灶进行全面探测，方便易行。PET对肺内、胸膜、锁骨上窝淋巴结、肝脏、肾上腺、腹部淋巴结等转移灶皆具有高于90%的灵敏度和准确性，优于其他检查手段 。但在脑转移灶检出方面，PET较CT、MR差，在骨骼转移灶检测方面，PET与SPECT全身骨显像相近，但两者之间有互补性。<br />\r\nFDG PET在检测肺癌脑转移方面较CT/MR差（灵敏度约68%），主要是由于脑部生理性摄取高。当转移灶较小或代谢率不高时，PET表现为限局性低代谢灶而缺乏特异性。脑内转移的典型表现为结节状或块状浓聚灶，从浓聚程度上可有低于白质、稍高于白质、高于白质而近于灰度和明显高于灰质4种类型，相当多转移灶可表现为周边环状浓聚而中心缺损，转移灶位于白质较位于灰质容易检出。脑内肉芽肿、脓肿、结核等有时可出现限局性高摄取而导致假阳性。对于灰质内限局性低代谢区，特别当病灶呈圆形时，应高度警惕有脑转移的可能，建议行CT/MR进一步明确是很必要的。<br />\r\n&nbsp; SPECT全身骨显像是检测全身骨骼转移灶的常规检查，灵敏度高，但特异性稍差。PET在检测骨骼转移方面与SPECT全身骨显像的灵敏度相近，但特异性较高。Bury等对110例肺癌患者行PET和传统检查进行分期研究时发现，PET和SPECT骨显像在检出骨转移方面灵敏度相同（皆检出19/21），但PET的特异性明显高于骨显像（96%比66%）,但也有学者认为PET在检测骨转移方面灵敏度较SPECT骨显像略低，Kao等对SPECT骨显像和FDG显像发现的98个骨骼病灶进行研究，PET诊断骨转移特异性明显高于SPECT骨显像，但灵敏度稍低于骨显像，在39例PET/SPECT骨显像结果不一致的患者中，PET检出8个骨显像未检测出的骨转移灶，而SPECT骨显像检出11个PET未检测出的转移灶。PET定位骨转移灶（特别是肋骨转移灶）比较困难，常须结合SPECT骨显像。经造血生长因子治疗和一些化疗后，骨髓代谢普遍明显增高，PET见全身骨髓代谢呈弥漫性、对称性浓聚，以骨松质为主，这种浓聚并非转移所致，诊断分析时应注意到这一点。<br />\r\n&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;PET全身显像常能检出临床“未怀疑到的”（unsuspected）转移灶而改变临床分期和治疗方案。澳大利亚学者Mac Manus对167例肺癌在放疗前行PET显像进行分期，并与常规分期手段进行比较，PET在32例（19%）中发现“意外”转移灶，并发现在Ⅲ期病人中，PET意外发现的比率较Ⅱ期和Ⅰ期多（24%比18%和7.5%,P=0.016）。Mac Manus认为在治疗决策制定前行PET显像（特别是全身显像）是非常必要的。Bury(1996)、Lewis(1994)、Valk(1995)等3组研究结果也证实PET能较常规显像多检出转移灶（10%、29%、11%）。但也有作者报道，在10%-20%非小细胞癌患者中，PET过高估计了胸外转移病变的分期。<a href="/my_article.php?act=jigou_intro&amp;j_id=113" target="_blank">病例6&nbsp;&nbsp;</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=114" target="_blank">病例7<br />\r\n</a>（3）&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PETPET对肺癌疗效的评价及对残余、复发病灶的诊断<br />\r\nPET在评价肺癌治疗疗效方面较CT等灵敏，常能在形态发生改变前检测出病灶的代谢改变，如<a href="/my_article.php?act=jigou_intro&amp;j_id=116" target="_blank">病例9</a>。治疗前阳性病灶治疗后消失，提示完全反应，如<a href="/my_article.php?act=jigou_intro&amp;j_id=117" target="_blank">病例9</a>、<a href="/my_article.php?act=jigou_intro&amp;j_id=118" target="_blank">10</a>；病灶代谢程度降低者，提示部分反应；持续阳性者提示疗效差。PET能及时地对治疗方案进行评价并有助于及时地调整治疗方案。<br />\r\nPET在检出残余和复发病灶方面灵敏度和准确性都比较高，Patz、Hubner、Inoue等多个作者分析了78例患者研究结果显示，PET对复发病灶的检出灵敏度、特异性及准确性分别为97%、77%和91%。对于放疗后的患者，放射性肺炎有时也可出现18F-FDG高摄取，一般表现为边界模糊的、不均匀性的、片状浓聚影，并与治疗范围一致，仔细分析其形态，基本上能将其与残余或复发病灶鉴别开来。手术所致软组织、骨骼及胸膜损伤会出现不同程度的放射性浓聚，有时术后1年多仍可见，分析PET图像时应结合手术史，了解手术野范围，并注重形态分析。肺癌射频治疗后，肿瘤灭活区呈放射性缺损，有时在治疗近期，缺损灶周围可见环状不均匀性轻中度放射性浓聚，一般为炎症所致；如出现一侧弧状或半环状高度浓聚，浓聚程度与治疗前病灶相近，则须考虑有残余的可能。<a href="/my_article.php?act=jigou_intro&amp;j_id=115" target="_blank">病例8</a>&nbsp;&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=116" target="_blank">病例9&nbsp;</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=117" target="_blank">病例10</a></p>', 'gwm', 0, 24),
(103, 'PET在恶性淋巴瘤中的应用', '临床应用', '', '', '2009-10-12 13:07:13', '116.228.141.77', '恶性淋巴瘤是淋巴结和（或）结外部位淋巴组织的免疫细胞肿瘤，来源于淋巴细胞或组织细胞的恶变。可分为霍杰金氏淋巴瘤（HD）和非霍杰金氏淋巴瘤（NHL）。前者病变常较局限，常仅累及一组淋巴结，主要通过淋巴道向相邻的淋巴结扩散，进展速度慢，结外病变发生较少、较晚，放、化疗效果良好；而后者病变范围常较广，多通过淋巴道、血循环向邻近或远处扩散，进展较快，结外病变较多见，发生较早。非霍杰金氏淋巴瘤可分为低度恶性、中度恶性和高度恶性淋巴瘤，恶性度越高，病期发展越快，预后越差。了解恶性淋巴瘤的全身播散情况及其恶性程度对治疗和预后判断很有帮助。<br />\r\n1. PET在恶性淋巴瘤分期及恶性程度评估中的应用<br />\r\n恶性淋巴瘤的诊断须经组织病理学确诊。PET的作用在于检测全身病变的分布情况以进行准确分期，并对病变的恶性程度进行评估，如病例44、45。Paul、Okada等研究结果显示，绝大多数的恶性淋巴瘤出现18F-FDG高摄取，肿瘤靶/非靶比值（T/NT比值）高于核素67Ga显像，HD与NHL对18F-FDG摄取无明显差异；多中心研究结果显示，在183例患者中，PET对病灶的检出灵敏度为97%，高于CT所见；其他学者发现恶性淋巴瘤对18F-FDG摄取与细胞增殖率呈正相关，并与组织学分级相平行，这种研究结果显示PET有助于对恶性淋巴瘤的恶性程度进行分级，并可用于预测预后。应用结果也显示，个别低度恶性淋巴瘤18F-FDG显像可出现假阴性。18F-FDG显像阴性者，11C-蛋氨酸显像有助于提高检出率，但11C-蛋氨酸的摄取与恶性程度无明显相关。<br />\r\n2．在恶性淋巴瘤疗效评估中的应用<br />\r\nPET能用于准确评价恶性淋巴瘤的疗效。其灵敏高，最早在化疗后数天内则可见到18F-FDG 摄取降低。经化疗后，如果病灶对18F-FDG摄取明显降低或不摄取，预示反应良好或完全反应，如病例46。对于化疗反应良好的患者，如CT仍见有淋巴结肿大，无法鉴别是否有残余肿瘤细胞，行PET显像有助于进一步明确，18F-FDG阴性者一般提示淋巴结内已无肿瘤细胞存在。', 'gwm', 0, 29),
(104, 'PET在脑血管性疾病中的应用 PET在心血管中的应用', '临床应用', '', '', '2009-10-12 13:08:03', '116.228.141.77', 'PET在脑血管性疾病中的应用<br />\r\n脑血管疾病是各种血管源性病因引起的脑部疾病的总称。大致可分为短暂性脑缺血、脑梗塞、脑出血等三大类。除少数临床表现不典型者，脑血管疾病的诊断并不困难。CT、MR、DSA对脑血管疾病可以进行定性和定位诊断，能满足临床需要，近代CT、MR的组织灌注像、弥漫加权像、CTA和MRA等技术的应用，使CT、MR在脑血管病的诊断与治疗决策方面越来越重要。<br />\r\nPET在脑血管病的诊断及实用性不如CT、MR。但PET可行灌注显像、氧代谢显像、葡萄糖代谢显像及受体显像等来诊断和评价脑血管疾病，具有一定的独特的价值。PET在短暂性脑缺血发作（TIA）及在评估脑梗塞灶周围缺血但存活的脑组织（即所谓的半暗区）方面有一定的优势。<br />\r\nTIA：PET脑灌注显像最常用的显像剂为15O-水（15O-H2O），它不受代谢影响，摄取量相当高，在显示脑血流量方面比较理想，同时其半衰期短（2.05min）可在短期内行多次显像。为了提高检测灵敏度，常结合药物负荷试验，一般用乙酰唑胺。PET根据平静状态下和负荷状态下的2次灌注显像结果可诊断TIA。平静状态下出现低灌注区、负荷状态下低灌注区增大，或平静状态下未见异常而负荷状态下出现低灌注则可明确诊断为TIA，还可通过绝对灌注定量计算病灶区的绝对血流量以评估其严重程度。<br />\r\n半暗区组织评估：可用局部脑代谢显像、局部脑氧代谢率、脑氧提取率等进行评估，局部脑代谢、局部脑氧提取保留区代表存活脑组织，另外绝对定量局部脑血流量（rCBF）和局部脑氧代谢率(rCMRO2)也可用于预测溶栓治疗效果,rCBF&lt;12ml/(100g&#8226;min) 或rCMRO2&lt;65μmol/100g&#8226;min)一般为不可逆受损。&nbsp;&nbsp; <br />\r\n在脑梗塞显像方面，PET是一种相当灵敏、准确的显像方式，它能灵敏、真实地显示梗塞后脑部皮质和皮层下核团的受累程度，其应用价值与CT/MR相近，但由于PET价格昂贵，临床应用并不多。<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=172" target="_blank">病例65</a><br />\r\n', 'gwm', 0, 25),
(105, 'PET在癫痫灶定位方面的应用 PET在神经系统方面的应用', '临床应用', '', '', '2009-10-12 13:08:45', '116.228.141.77', 'PET在癫痫灶定位方面的应用<br />\r\n1．颞叶癫痫：<br />\r\n颞叶癫痫是最常见的类型。对于颞叶癫痫，18F-FDG PET的检出灵敏度高，约80～92%，定位准确性约90%。低代谢灶多位于颞叶前部，尤其是内侧皮质（海马-杏仁核区），而且常较病理所见的范围大（如病例57、58）。内侧皮质代谢降低明显时常伴有外侧皮质代谢降低。部分病人同时伴有颞叶外（如额叶、顶叶、枕叶或基底神经节、丘脑、小脑等处）单处或多处低代谢灶。少数病人可见双侧颞叶代谢明显降低。低代谢灶的出现可能与局部神经元脱失有关，Engel等报道，在20例患者的低代谢区，组织病理发现19例存在不同程度的神经元脱失。病程长、发作频率高者阳性率高，病程较短、发作频率低者阳性率较低。低代谢区局限、降低明显者，手术和X-刀治疗效果相当好；低代谢区大、双侧存在者手术和X-刀治疗效果差。南方医院在PET显像定位下行X-刀治疗难治性癫痫，1年后无癫痫发作者约70%。发作期显像，高代谢灶病灶局限，定位准确性较低代谢灶高（如病例55、56）；少数皮层高代谢者，可同时伴有同侧基底神经节、丘脑和对侧小脑代谢增高（可能与神经纤维联络性增强有关）；在个别情况下，PET可检出无临床发作症状时的高代谢灶。<br />\r\n苯二氮卓受体显像剂11C-Flumazenil（氟马西尼）显像在颞叶癫痫的检出率与18F-FDG相近，它所显示的致痫灶一般较18F-FDG局限，另外18F-FDG显像示双颞叶低代谢灶者，11C-Flumazenil显像多为单侧颞叶，在这些情况下11C- Flumazenil显像能更好地对致痫灶进行定位。99mTc-ECD和99mTc-HMPAO发作期显像定位准确性也很高（约90%），在有条件的单位，可将发作间期PET与发作期SPECT相结合，这对致痫灶的精确定位更有帮助。PET对致痫灶的检出灵敏度和准确性高于MR，但MR可以确诊或排除诸如肿瘤、血管病变和其他器质性病变，并可对海马硬化进行定量、定性测量，与PET有互补作用。PET较表皮脑电图定位价值高，发作间期表皮脑电图虽阳性率高，但常无明确定位价值，发作间期和发作期脑电图结合24 小时闭路电视监视脑电图对致痫灶也有较好的定位价值，可与PET互相印证以进一步提高准确性，PET所见与脑电相一致者，定位准确率&gt;90%。对于PET结果与发作期脑电图矛盾者，术前皮层脑电进一步明确是必要的。<br />\r\n&nbsp;<br />\r\n病例55&nbsp; 病例56&nbsp; 病例57&nbsp; 病例58<br />\r\n2．颞叶外癫痫<br />\r\n20%～30%癫痫病灶位于颞叶外。18F-FDG PET显像对额叶致痫灶的检出灵敏度较颞叶低，约60%。PET所见的低代谢区在MR相应部位常有器质性病变存在，低代谢最明显处一般与MR所示的病灶相吻合，PET所示的低代谢灶常较MR所示的病灶大，发作期显像结果显示致痫灶多位于形态改变的周围，这提示形态改变周围的轻度低代谢区与癫痫发作更为密切，癫痫病灶应在低代谢区域内寻找。如有多发低代谢灶，PET阳性而MR正常者为致痫灶的可能性更大。PET对于枕叶、顶叶和皮层下致痫灶的检出也较颞叶低，常可见双侧顶叶呈对称性、较大范围代谢降低。<br />\r\n11C-Flumazenil显像在检出颞叶外致痫灶较18F-FDG灵敏度高。18F-FDG PET与发作期SPECT相结合有助于进一步提高定位的灵敏度和准确性。<br />\r\n值得注意的是，脑内低代谢灶不等于致痫灶，多种原因会出现低代谢灶，对于18F-PET所示低代谢灶，应结合临床表现、其他影像学所见和脑电图进行综合分析。对伴有脑内恶性肿瘤者，注射显像剂后应尽量行EEG监测，并结合MR所见。注射显像剂前后视、听觉封闭相当重要，需严格控制，特别是视觉封闭，否则视觉中枢及眼肌对18F-FDG摄取相当高而使图像质量降低，使结果分析难度增大。（见病例59 病例60）<br />\r\n&nbsp;<br />\r\n病例59&nbsp;&nbsp; 病例6 <br />\r\n', 'gwm', 0, 31);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(106, 'PET在癫痫灶定位方面的应用 PET在神经系统方面的应用', '临床应用', '', '', '2009-10-12 13:09:53', '116.228.141.77', '1．颞叶癫痫：<br />\r\n颞叶癫痫是最常见的类型。对于颞叶癫痫，18F-FDG PET的检出灵敏度高，约80～92%，定位准确性约90%。低代谢灶多位于颞叶前部，尤其是内侧皮质（海马-杏仁核区），而且常较病理所见的范围大（<a href="/my_article.php?act=jigou_intro&amp;j_id=164" target="_blank">如病例57</a>、<a href="/my_article.php?act=jigou_intro&amp;j_id=165" target="_blank">58</a>）。内侧皮质代谢降低明显时常伴有外侧皮质代谢降低。部分病人同时伴有颞叶外（如额叶、顶叶、枕叶或基底神经节、丘脑、小脑等处）单处或多处低代谢灶。少数病人可见双侧颞叶代谢明显降低。低代谢灶的出现可能与局部神经元脱失有关，Engel等报道，在20例患者的低代谢区，组织病理发现19例存在不同程度的神经元脱失。病程长、发作频率高者阳性率高，病程较短、发作频率低者阳性率较低。低代谢区局限、降低明显者，手术和X-刀治疗效果相当好；低代谢区大、双侧存在者手术和X-刀治疗效果差。南方医院在PET显像定位下行X-刀治疗难治性癫痫，1年后无癫痫发作者约70%。发作期显像，高代谢灶病灶局限，定位准确性较低代谢灶高（<a href="/my_article.php?act=jigou_intro&amp;j_id=162" target="_blank">如病例55</a>、<a href="/my_article.php?act=jigou_intro&amp;j_id=163" target="_blank">56</a>）；少数皮层高代谢者，可同时伴有同侧基底神经节、丘脑和对侧小脑代谢增高（可能与神经纤维联络性增强有关）；在个别情况下，PET可检出无临床发作症状时的高代谢灶。<br />\r\n苯二氮卓受体显像剂11C-Flumazenil（氟马西尼）显像在颞叶癫痫的检出率与18F-FDG相近，它所显示的致痫灶一般较18F-FDG局限，另外18F-FDG显像示双颞叶低代谢灶者，11C-Flumazenil显像多为单侧颞叶，在这些情况下11C- Flumazenil显像能更好地对致痫灶进行定位。99mTc-ECD和99mTc-HMPAO发作期显像定位准确性也很高（约90%），在有条件的单位，可将发作间期PET与发作期SPECT相结合，这对致痫灶的精确定位更有帮助。PET对致痫灶的检出灵敏度和准确性高于MR，但MR可以确诊或排除诸如肿瘤、血管病变和其他器质性病变，并可对海马硬化进行定量、定性测量，与PET有互补作用。PET较表皮脑电图定位价值高，发作间期表皮脑电图虽阳性率高，但常无明确定位价值，发作间期和发作期脑电图结合24 小时闭路电视监视脑电图对致痫灶也有较好的定位价值，可与PET互相印证以进一步提高准确性，PET所见与脑电相一致者，定位准确率&gt;90%。对于PET结果与发作期脑电图矛盾者，术前皮层脑电进一步明确是必要的。<br />\r\n&nbsp;<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=162" target="_blank">病例55&nbsp;</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=163" target="_blank">病例56</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=164" target="_blank">病例57</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=165" target="_blank">病例58<br />\r\n</a>2．颞叶外癫痫<br />\r\n20%～30%癫痫病灶位于颞叶外。18F-FDG PET显像对额叶致痫灶的检出灵敏度较颞叶低，约60%。PET所见的低代谢区在MR相应部位常有器质性病变存在，低代谢最明显处一般与MR所示的病灶相吻合，PET所示的低代谢灶常较MR所示的病灶大，发作期显像结果显示致痫灶多位于形态改变的周围，这提示形态改变周围的轻度低代谢区与癫痫发作更为密切，癫痫病灶应在低代谢区域内寻找。如有多发低代谢灶，PET阳性而MR正常者为致痫灶的可能性更大。PET对于枕叶、顶叶和皮层下致痫灶的检出也较颞叶低，常可见双侧顶叶呈对称性、较大范围代谢降低。<br />\r\n11C-Flumazenil显像在检出颞叶外致痫灶较18F-FDG灵敏度高。18F-FDG PET与发作期SPECT相结合有助于进一步提高定位的灵敏度和准确性。<br />\r\n值得注意的是，脑内低代谢灶不等于致痫灶，多种原因会出现低代谢灶，对于18F-PET所示低代谢灶，应结合临床表现、其他影像学所见和脑电图进行综合分析。对伴有脑内恶性肿瘤者，注射显像剂后应尽量行EEG监测，并结合MR所见。注射显像剂前后视、听觉封闭相当重要，需严格控制，特别是视觉封闭，否则视觉中枢及眼肌对18F-FDG摄取相当高而使图像质量降低，使结果分析难度增大。（<a href="/my_article.php?act=jigou_intro&amp;j_id=166" target="_blank">见病例59</a> <a href="/my_article.php?act=jigou_intro&amp;j_id=167" target="_blank">病例60</a>）<br />\r\n&nbsp;<br />\r\n<a href="/my_article.php?act=jigou_intro&amp;j_id=166" target="_blank">病例59&nbsp;</a>&nbsp; <a href="/my_article.php?act=jigou_intro&amp;j_id=113" target="_blank">病例6 </a><br />\r\n', 'gwm', 0, 20),
(107, 'PET在痴呆鉴别诊断中的应用 PET在神经系统方面的应用', '临床应用', '', '', '2009-10-12 13:10:46', '116.228.141.77', '痴呆是一种以慢性、获得性、进行性智能损害为特点的神经变性疾病。患者丧失智力、注意力、判断力、记忆力和语言，并常伴随人格的改变和其他一些神经特征。在65岁以上老年人，痴呆的发病率为15%。引起痴呆的疾病有阿尔茨海默病、脑血管梗死、皮克病、亨廷顿病、帕金森氏病等，其中以阿尔茨海默病和脑血管梗死性痴呆最常见。<br />\r\n神经病理学检查证实，大部分痴呆的基础是神经元的丢失或神经纤维改变。18F-FDG PET对痴呆的异常改变相当敏感，神经元的丢失会导致相应部分对18F-FDG的摄取减少或缺如而出现放射性分布降低。18F-FDG PET可用于显示痴呆病人的脑内改变及程度，并有助于鉴别导致痴呆的病因。PET所见的改变比形态学改变所见提前约12个月。<br />\r\n1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 阿尔茨海默病（AD）<br />\r\n早期18F-FDG PET典型表现为顶、后颞区及扣带回代谢降低，多为双侧降低，如<a href="/my_article.php?act=jigou_intro&amp;j_id=169" target="_blank">病例62</a>所示；进展期表现为顶、颞区低代谢范围增大、降低更明显，并出现额叶代谢降低。以上皮质代谢降低严重程度与认知功能损害基本成正比。AD患者的皮层下核团、小脑、中央前回、中央后回、颞横回和距状裂等较初级神经中枢较少累及。临床或病理确诊的AD患者中，97%出现18F-FDG PET摄取异常，66%为上述典型表现。（<a href="/my_article.php?act=jigou_intro&amp;j_id=168" target="_blank">见病例61</a>）<br />\r\n2．多发性梗死性痴呆（MID）<br />\r\n为血管梗死性痴呆中常见的一种。临床上常有高血压、动脉梗化、反复发作的脑血管病。18F-FDG PET典型表现为多发性、散在性、局灶性放射性降低，既可见于皮层，也可见于皮层下或小脑，多为楔形变，与某一特定动脉分布区有关。PET所见多在MR上可见相对应改变，但范围较后者大。多发性梗塞性痴呆病人顶叶受累较少。有部分病人可合并有阿尔茨海默病。<br />\r\n3. 额颞叶痴呆<br />\r\n额颞叶痴呆，是以额叶、颞叶皮质萎缩为特征的痴呆。其中有Pick小体的叫皮克病（Pick’s disease）。早期18F-FDG PET可仅有额叶代谢降低（<a href="/my_article.php?act=jigou_intro&amp;j_id=169" target="_blank">如图62所示</a>），随着病情发展可表现为双侧额叶及颞叶前部对称性代谢降低，与AD比较容易鉴别。<br />\r\n4. 亨廷顿病（Hungtington disease HD）<br />\r\n亨廷顿病是以异常运动、痴呆和家族史为三联征的一类痴呆。其症状包括运动障碍、认知障碍和精神障碍，舞蹈症常为首发的突出的临床特点。病理特点为纹状体神经元丢失、神经胶质增生。18F-FDG PET显像一般表现为尾状核头代谢降低，有时伴壳核代谢降低（<a href="/my_article.php?act=jigou_intro&amp;j_id=170" target="_blank">如图63</a>），病变的后期可出现脑皮质代谢降低。<br />\r\n5．&nbsp;&nbsp;&nbsp; 帕金森病性痴呆<br />\r\n帕金森氏病，是发生于中老年的黑质纹状体通路的变性性疾病。临床特征为震颤、肌强直、运动迟缓及姿势反射障碍。约30%病人可最终发展为痴呆。18F-FDG PET显像见大脑皮质广泛代谢降低，顶叶降低更为明显。18F-Dopa显像可明确诊断，其影像表现为基底神经节对18F-Dopa摄取明显降低，尤其是壳核，如病例64。壳核的摄取减少与运动瘫痪的程度呈正相关。<br />\r\n6．其他原因引起的痴呆，如进行性核上麻痹、正常压力脑积水、洒精中毒性痴呆、克-雅病性痴呆、艾滋病痴呆综合征18F-FDG PET显像也各有独特的影像表现。<br />\r\n总的来说，18F-FDG PET能早期诊断痴呆，并能将导致痴呆的各种原因进行鉴别，与CT/MR相比，有一定的优点，早期诊断可使病人尽早得到治疗，延缓或阻止疾病发展。<br />\r\n&nbsp;<br />\r\n', 'gwm', 0, 34),
(108, '病例1-肺癌', '病例介绍', '', '', '2009-10-12 13:13:47', '116.228.141.77', '<div>病例1：</div>\r\n<div>【病史】女，72岁，干咳、胸闷月余，CT示右肺门占位性病变。</div>\r\n<div>【PET所见】右肺门处见1个放射性异常高度浓聚灶，呈块状，病灶内放射性分布均匀，边缘清楚，大小为2.5x2.0x2.3cm，SUV为4.2。</div>\r\n<div>【PET拟诊】右肺门高代谢病灶，考虑为肺癌</div>\r\n<p><span style="font-size:10.5pt;">【病理】鳞癌</span></p>\r\n<p><span style="font-size:10.5pt;"><img height="279" alt="" src="http://www.nfpetct.com/up_files/o20.JPG" width="283" />\r\n </span></p>', 'gwm', 0, 18),
(109, '病例2-肺癌', '病例介绍', '', '', '2009-10-12 13:14:45', '116.228.141.77', '<div>病例2:</div>\r\n<div>【病史】男，60岁，查体时CT发现右上肺孤立性结节，大小为2.0x2.0cm，考虑为肺癌可能性大；</div>\r\n<div>【PET所见】右上肺结节状放射性浓聚灶，病灶内放射性分布均匀，边界清楚，SUV为2.8。</div>\r\n<div>【PET拟诊】右上肺结节状高代谢灶，考虑为肺癌</div>\r\n<div>【病理】腺癌</div><br />\r\n<img height="279" alt="" src="http://www.nfpetct.com/up_files/o21.JPG" width="283" />\r\n ', 'gwm', 0, 13),
(110, '病例3-结核', '病例介绍', '', '', '2009-10-12 13:16:09', '116.228.141.77', '<p>病例3：</p>\r\n<p>【病史】体检发现右下肺占位性病变，大小为3.2x2.8cm。无特殊症状及体征。</p>\r\n<p>【PET所见】右下肺背侧块状轻度浓聚灶，边界模糊，浓聚程度低于纵隔血池影，SUV为1.3 。</p>\r\n<p>【PET诊断】良性病变</p>\r\n<p>【病理】结核。 </p>\r\n<p><img alt="" src="/image_server_dir/4e40c9164dc7bd3331ccad84cfc073c4.jpg" border="0" />\r\n </p>\r\n<p>&nbsp;</p>', 'gwm', 0, 12),
(111, '病例4-活动性肺结核', '病例介绍', '', '', '2009-10-12 13:19:53', '116.228.141.77', '<div>病例4</div>\r\n<div>【病史】男，43岁，咳嗽、咳痰半年余，无咯血及体重下降</div>\r\n<div>【PET所见】左上肺大片状中度浓聚灶，内见多个散在分布的放射性缺损灶，壁薄，并可见条状浓聚影。</div>\r\n<div>【PET诊断】多考虑为良性病变，以活动性结核或急性肺炎可能性大。</div>\r\n<div>【病理】活动性肺结核</div><br />\r\n<img height="217" alt="" src="http://www.nfpetct.com/up_files/o23.JPG" width="235" />\r\n ', 'gwm', 0, 13),
(112, '病例5-PET/CT诊断左肺中央型肺癌伴纵隔多发淋巴结转移灶', '病例介绍', '', '', '2009-10-12 13:20:40', '116.228.141.77', '<div>病例5. </div>\r\n<div>【病史】男，46岁，干咳3个月，偶伴左背部不适。</div>\r\n<div>【PET所见】左肺门块状高度浓聚影，大小约4.0x3.8x3.8cm,SUV为8.1；纵隔内见多个结节状浓聚灶，浓聚程度明显高于纵隔血池影。</div>\r\n<div>【PET拟诊】左肺中央型肺癌伴纵隔多发淋巴结转移灶；</div>\r\n<div>【病理】鳞癌</div><br />\r\n<img height="379" alt="" src="http://www.nfpetct.com/up_files/o24.JPG" width="378" />\r\n ', 'gwm', 0, 17),
(113, '病例6-PET/CT诊断左上肺癌术后多发转移 ', '病例介绍', '', '', '2009-10-12 13:21:07', '116.228.141.77', '<div>病例6</div>\r\n<div>【病史】男，60岁，左上肺癌术后1年，腰痛1月余。</div>\r\n<div>【PET所见】左锁骨上窝、肝内、胸骨、左侧肋骨、脊柱多个椎体、双侧髂骨、右侧耻骨等处见多个大小、形态不一，浓聚程度不等的放射性高度浓聚灶；</div>\r\n<div>【PET拟诊】左上肺癌术后，左锁骨上窝淋巴结转移，肝内多发转移，全身骨骼多发转移。</div><br />\r\n<img height="389" alt="" src="http://www.nfpetct.com/up_files/o25.JPG" width="395" />\r\n ', 'gwm', 0, 17),
(114, '病例7-PET/CT诊断右下肺癌伴全身多发转移', '病例介绍', '', '', '2009-10-12 13:21:36', '116.228.141.77', '<div>病例7</div>\r\n<div>【病史】 男，56岁。CT发现颅内多发转移灶并行γ-刀治疗后5天，胸部CT疑右下肺肿瘤。</div>\r\n<div>【PET所见】右颞叶、右侧小脑结节状浓聚灶；右下肺结节状浓聚灶；右肺门、纵隔、双侧锁骨上窝多个小结节状浓聚灶；肝右叶2个结节状浓聚灶；右侧肩峰、多个椎体、双侧骶髂关节、双侧髂骨多发浓聚灶；。</div>\r\n<div>【PET拟诊】右下肺癌伴右肺门、纵隔、双锁骨上窝、肝脏、骨骼及脑内多处、多发转移灶。</div>\r\n<div>【病理】腺癌（锁骨上窝淋巴结活检明确）</div><br />\r\n<img height="417" alt="" src="http://www.nfpetct.com/up_files/o26.JPG" width="500" />\r\n ', 'gwm', 0, 11),
(115, '病例8-PET/CT诊断左上肺肺癌', '病例介绍', '', '', '2009-10-12 13:22:09', '116.228.141.77', '<div>病例8</div>\r\n<div>【病史】男，54岁，左胸部不适3个月。临床确诊为左上肺腺癌，在治疗前、后行PET评价疗效。</div>\r\n<div>【PET所见】2000-7-13 PET显像示左上肺块状高度浓聚灶，大小为3.2x3.0x3.0cm，SUV为5.6；PET显像后行左上肺病灶光子刀治疗和健择化疗，半年后再次行PET显像示左上肺浓聚灶消失。</div>\r\n<div>【PET诊断】左上肺肺癌经治疗后病灶消失，提示完全反应。</div>\r\n<div>【临床随访】第2次PET显像后CT随访1年，左上肺未见肿瘤复发。</div><br />\r\n<img height="298" alt="" src="http://www.nfpetct.com/up_files/o27.JPG" width="498" />\r\n ', 'gwm', 0, 15),
(116, '病例9-PET/CT诊断周围型肺癌射频消融术后', '病例介绍', '', '', '2009-10-12 13:22:35', '116.228.141.77', '<div>病例9</div>\r\n<div>【病史】男，62岁，CT发现右中上肺野小占位性病变，考虑为肺癌</div>\r\n<div>【PET所见】治疗前PET显像示右中上肺野结节状浓聚灶，SUV为3.0；随后行射频消融术，术后3天，PET显像于右中上肺野见1个较大的放射性缺损影，治疗前所见的浓聚灶消失。</div>\r\n<div>【PET诊断】右中上肺野周围型肺癌射频消融术后，肿瘤灶完全灭活。</div>\r\n<p style="text-indent:21pt;"><span>\r\n<table cellspacing="0" cellpadding="0" width="100%">\r\n<tbody>\r\n<tr></tr></tbody></table></span>【确诊及临床随访】CT随访1年，右上肺病灶逐渐缩小最后消失。</p><br />\r\n<img height="322" alt="" src="http://www.nfpetct.com/up_files/o28.JPG" width="306" />\r\n ', 'gwm', 0, 14),
(117, '病例10-PET/CT诊断右肺中央型肺癌放疗后右肺门仍有1个较小的残余病灶', '病例介绍', '', '', '2009-10-12 13:23:01', '116.228.141.77', '<div>病例10</div>\r\n<div>【病史】男，50岁，支气管镜确诊断为右肺中央型肺癌（腺癌），放疗前、后行PET显像评价疗效。</div>\r\n<div>【PET所见】治疗前PET见右肺门块状高度浓聚灶，大小为3.0x2.8x3.0cm,SUV为5.4；放疗后3个月PET见右肺门仍有1个小结节状高度浓聚灶，大小约1.0x1.0x1.0cm，SUV为3.0。</div>\r\n<div>【PET拟诊】右肺中央型肺癌放疗后右肺门仍有1个较小的残余病灶。</div><br />\r\n<img height="169" alt="" src="http://www.nfpetct.com/up_files/o29.JPG" width="332" />\r\n ', 'gwm', 0, 13),
(118, '病例11-PET/CT诊断恶性胶质瘤', '病例介绍', '', '', '2009-10-12 13:23:21', '116.228.141.77', '<div>病例11</div>\r\n<div>【病史】男，53岁，头痛逐渐加重1月余伴左下肢无力10余天，MR示头部多发肿瘤，多考虑为转移瘤。</div>\r\n<div>【PET所见】右额叶和右顶叶放射性浓聚灶，其中右额叶病灶浓聚程度稍高于白质而明显低于皮质，边界模糊，大小约1.9x2.2cm；右顶叶病灶中心呈放射性缺损，周边呈环状浓聚，浓聚程度与邻近皮质相近，大小为2.7x5.5cm。中线向左移位，侧脑室受压变形。全身其他部位未见异常。</div>\r\n<div>【PET拟诊】右额叶及右顶叶高代谢病灶，考虑为恶性胶质瘤，其中右顶叶病灶恶性程度高于右额叶。</div>\r\n<div>【病理诊断】星形细胞瘤Ⅱ-Ⅲ级。</div><br />\r\n<img height="299" alt="" src="http://www.nfpetct.com/up_files/o30.JPG" width="308" />\r\n ', 'gwm', 0, 14),
(119, '病例12-PET/CT诊断胶质瘤', '病例介绍', '', '', '2009-10-12 13:23:38', '116.228.141.77', '<div>病例12</div>\r\n<div>【病史】男，28岁，头痛、性格改变约半年，MR示右额叶T2信号增高。</div>\r\n<div>【PET所见】右额叶（包括皮质和白质）放射性分布明显降低，其中部分皮质呈放射性缺损。</div>\r\n<div>【PET】右额叶低代谢病灶，考虑为低级胶质瘤</div><span style="font-size:10.5pt;">【病理诊断】星形细胞瘤</span><span style="font-size:10.5pt;">Ⅰ</span><span style="font-size:10.5pt;">级</span><br />\r\n<img height="163" alt="" src="http://www.nfpetct.com/up_files/o31.JPG" width="283" />\r\n ', 'gwm', 0, 30),
(120, '病例13-PET/CT诊断恶性胶质瘤术后复发', '病例介绍', '', '', '2009-10-12 13:24:00', '116.228.141.77', '<div>病例13</div>\r\n<div>【病史】女，51岁，左额叶多形胶母细胞瘤术后6个月，放疗后2个月。MR可疑左额叶复发。</div>\r\n<div>【PET所见】左额叶见1个圆形的放射性浓聚灶，中心呈放射性缺损，周边环状浓聚，浓聚程度明显高于白质，病灶大小为4.3x3.1x2.8cm。</div>\r\n<div>【PET拟诊】恶性胶质瘤术后复发</div><span style="font-size:10.5pt;">【病理诊断】立体定位活检证实复发<br />\r\n<img height="185" alt="" src="http://www.nfpetct.com/up_files/o32.JPG" width="287" />\r\n </span>', 'gwm', 0, 14),
(121, '病例14-PET/CT诊断胶质瘤放疗后', '病例介绍', '', '', '2009-10-12 13:24:27', '116.228.141.77', '<div>病例14</div>\r\n<div>【病史】男性，34岁。左额叶恶性胶质瘤放疗后半年。</div>\r\n<div>【PET所见】左侧额叶见1个边界清楚的放射性缺损灶，邻近组织未见放射性异常浓聚。</div>\r\n<div>【PET拟诊】左额叶胶质瘤放疗后，局部为疤痕组织，未见肿瘤残余与复发。</div><span style="font-size:10.5pt;">【随访结果】</span><span style="font-size:10.5pt;">MR</span><span style="font-size:10.5pt;">随访</span><span style="font-size:10.5pt;">2</span><span style="font-size:10.5pt;">年，病灶未见明显改变</span><br />\r\n<img height="185" alt="" src="http://www.nfpetct.com/up_files/o33.JPG" width="287" />\r\n ', 'gwm', 0, 15),
(122, '病例15-PET/CT诊断胶质瘤治疗后复发', '病例介绍', '', '', '2009-10-12 13:24:46', '116.228.141.77', '<div>病例15</div>\r\n<div>【病史】男，48岁，右颞叶Ⅱ级胶质瘤放疗后7年，出现频繁癫痫发作。</div>\r\n<div>【PET所见】<sup>11</sup>C-蛋氨酸PET显像示右颞叶限局性浓聚； <sup>18</sup>F-FDG PET显像示右颞叶放射性分布降低。</div>\r\n<div>【PET拟诊】低分级胶质瘤治疗后复发</div>\r\n<div>【病理】术后病理为Ⅱ级胶质瘤复发。<br />\r\n<img height="168" alt="" src="http://www.nfpetct.com/up_files/o34.JPG" width="355" />\r\n </div>', 'gwm', 0, 21),
(123, '病例16-PET/CT诊断高分级胶质瘤治疗后复发', '病例介绍', '', '', '2009-10-12 13:25:04', '116.228.141.77', '<div>病例16</div>\r\n<div>【病史】女，54岁，左顶叶恶性胶质瘤放疗后半年。</div>\r\n<div>【PET所见】<sup>11</sup>C-蛋氨酸及<sup>18</sup>F-FDG PET显像皆于左顶叶见1个限局性浓聚灶。</div>\r\n<div>【PET拟诊】高分级胶质瘤治疗后复发</div><br />\r\n<img height="175" alt="" src="http://www.nfpetct.com/up_files/o35.JPG" width="281" />\r\n ', 'gwm', 0, 13),
(124, '病例17-PET/CT诊断颅内恶性淋巴瘤术后残余或复发', '病例介绍', '', '', '2009-10-12 13:25:27', '116.228.141.77', '<div>病例17</div>\r\n<div>【病史】男，71岁，发现脑内多发肿瘤半月余，行开颅手术，病理为恶性淋巴瘤。术后复查CT示肿瘤残存。</div>\r\n<div>【PET所见】右额叶见1个术后放射性缺损灶（术后改变），在其后缘及内侧缘和胼胝体处见多个结节状或块状浓聚灶，浓聚程度明显高于皮质。全身其他部位未见异常（图片未展示）。</div>\r\n<div>【PET拟诊】颅内恶性淋巴瘤术后残余或复发。</div><br />\r\n<img height="186" alt="" src="http://www.nfpetct.com/up_files/o36.JPG" width="324" />\r\n ', 'gwm', 0, 16),
(125, '病例18-PET/CT诊断垂体瘤', '病例介绍', '', '', '2009-10-12 13:25:43', '116.228.141.77', '<div>病例18</div>\r\n<div>【病史】男，62岁，MR发现垂体瘤1年，血液激素水平正常。行PET全身显像查体。</div>\r\n<div>【PET所见】于垂体所在区见1个限局性浓聚灶，大小约2.1x1.9x2.2cm,浓聚程度高于皮质，SUV为7.5。</div>\r\n<div>【PET拟诊】垂体瘤。</div>\r\n<div>【临床诊断】无分泌型垂体瘤。</div><br />\r\n<img height="135" alt="" src="http://www.nfpetct.com/up_files/o37.JPG" width="260" />\r\n ', 'gwm', 0, 13),
(126, '病例19-PET-CT诊断鼻咽癌', '病例介绍', '', '', '2009-10-12 13:26:10', '116.228.141.77', '<div>病例19</div>\r\n<div>【病史】男，36岁，鼻衄、鼻塞3月余，CT诊断为鼻咽癌。</div>\r\n<div>【PET所见】鼻咽部右侧结节状浓聚灶，大小为1.5x2.2x1.8cm，SUV为3.1,病灶内放射性分布均匀。</div>\r\n<div>【PET诊断】鼻咽癌</div><span style="font-size:10.5pt;">【病理诊断】低分化鳞癌<br />\r\n<img height="170" alt="" src="http://www.nfpetct.com/up_files/o38.JPG" width="330" />\r\n </span>', 'gwm', 0, 14),
(127, '病例20-PET/CT诊断喉癌', '病例介绍', '', '', '2009-10-12 13:26:36', '116.228.141.77', '<div>病例20</div>\r\n<div>【病史】女，51岁。右颈部肿块1个月，手术病理为鳞癌，常规检查未找到原发灶，行PET全身显像寻找原发灶。</div>\r\n<div>【PET所见】于右侧喉部见1个结节状浓聚灶，大小为2.0x1.8x2.6cm,SUV为3.1；全身其他部位未见异常浓聚灶。</div>\r\n<div>【PET拟诊】右侧喉癌</div>\r\n<div>【病理诊断】喉部鳞癌。</div>', 'gwm', 0, 11),
(128, '病例21-PET/CT诊断腭部及右磨牙区恶性肿瘤伴颈部多发淋巴结转移', '病例介绍', '', '', '2009-10-12 13:26:50', '116.228.141.77', '<div>病例21</div>\r\n<div>【病史】男，48岁，发现腭区恶性肿瘤10天，行PET和MR进行术前分期。</div>\r\n<div>【PET所见】此图为PET和MR融合图像，彩色部分为PET阳性病灶。于右腭部及右磨牙区见2个浓聚灶相融合在一起，另于右颈部见2个结节状浓聚灶。PET/MR融合图像清楚地显示病灶的位置及其毗邻关系。</div>\r\n<div>【PET拟诊】腭部及右磨牙区恶性肿瘤伴颈部多发淋巴结转移。</div><br />\r\n<img height="177" alt="" src="http://www.nfpetct.com/up_files/o39.JPG" width="341" />\r\n ', 'gwm', 0, 14),
(129, '病例22-PET/CT诊断鼻咽癌治疗后转移', '病例介绍', '', '', '2009-10-12 13:27:09', '116.228.141.77', '<div>病例22</div>\r\n<div>【病史】男，43岁，鼻咽癌放疗后半年，CT于鼻咽部未见肿瘤复发。</div>\r\n<div>【PET所见】鼻咽部未见异常浓聚灶，但于肝脏尾状叶发现1个结节状浓聚灶，大小为3.0x2.8x3.2cm,SUV为3.8。</div>\r\n<div>【PET拟诊】鼻咽癌治疗后未见肿瘤复发；肝脏尾状叶转移灶。</div>\r\n<div>【临床随访】CT和MR证实肝尾状叶转移灶。<br />\r\n<img height="321" alt="" src="http://www.nfpetct.com/up_files/o40.JPG" width="428" />\r\n </div>', 'gwm', 0, 13),
(130, '病例23-PET/CT诊断鼻咽癌治疗后全身多发转移', '病例介绍', '', '', '2009-10-12 13:27:38', '116.228.141.77', '<div>病例23</div>\r\n<div>【病史】男，53岁，鼻咽癌放疗后1年余，腰部不适10余天。</div>\r\n<div>【PET所见】鼻咽部未见异常浓聚灶。于左下肺、右上肺、纵隔见多个小结节状浓聚灶；于双侧多个肋骨、脊柱多个椎体、双侧骶髂关节、双侧髂骨、右肱骨头、双股骨上段见形态不一、浓聚程度不等的异常浓聚灶。肝右叶见1个较大的放射性缺损灶。</div><span style="font-size:10.5pt;">【</span><span style="font-size:10.5pt;">PET</span><span style="font-size:10.5pt;">拟诊】鼻咽癌治疗后鼻咽部未见恶性肿瘤征象；双肺及纵隔多发转移灶；全身骨骼多发转移灶。肝囊肿<br />\r\n<img height="252" alt="" src="http://www.nfpetct.com/up_files/o41.JPG" width="564" />\r\n </span>', 'gwm', 0, 11),
(131, '病例24-PET/CT诊断甲状腺癌伴多发淋巴结转移', '病例介绍', '', '', '2009-10-12 13:27:56', '116.228.141.77', '<div>病例24</div>\r\n<div>【病史】男，45岁，左颈部肿大1月余。</div>\r\n<div>【PET所见】左侧甲状腺区异常浓聚灶；颈前区、胸骨上窝及左颈部见多个结节状浓聚灶，颈前区浓聚灶与甲状腺区浓聚灶部分融合。左上纵隔结节状浓聚灶，大小为1.0x1.0x1.0cm,SUV为2.3。</div>\r\n<div>【PET拟诊】左侧甲状腺癌伴颈前区、胸骨上窝、左颈部及左上纵隔多发淋巴结转移。</div>\r\n<div>【临床随访】PET显像后行上胸部CT，未发现左上纵隔淋巴结肿大，但手术中发现左上纵隔多个小淋巴结转移。病理为甲状腺髓样癌。<br />\r\n<img height="316" alt="" src="http://www.nfpetct.com/up_files/o42.JPG" width="466" />\r\n </div>', 'gwm', 0, 13),
(132, '病例25-PET/CT诊断鼻咽癌复发', '病例介绍', '', '', '2009-10-12 13:28:26', '116.228.141.77', '<div>病例25</div>\r\n<div>【病史】女，56岁，左侧鼻咽癌放疗后1年。</div>\r\n<div>【PET所见】左侧鼻咽部结节状浓聚灶，大小为2.3x2.0cm,SUV为2.8；右侧鼻咽部也见1个小结节状浓聚灶，大小为1.0x1.0cm,SUV为2.0。MR未见明显异常。PET显像后行鼻咽部放疗，3个月后复查，鼻咽部浓聚灶消失。</div>\r\n<div>【PET拟诊】鼻咽癌复发；治疗后病灶消失。</div>\r\n<div>【病理诊断】第1次PET显像后行左侧鼻咽部活检证实肿瘤复发（低分化鳞癌）。</div><br />\r\n<img height="287" alt="" src="http://www.nfpetct.com/up_files/o43.JPG" width="293" />\r\n ', 'gwm', 0, 13),
(133, '病例26-PET/CT诊断乳腺癌', '病例介绍', '', '', '2009-10-12 13:28:54', '116.228.141.77', '<div>病例26</div>\r\n<div>【病史】女，40岁，发现左乳腺包块半年余。X线钼靶摄影示左乳腺内占位性病变，边缘分叶明显。</div>\r\n<div>【PET所见】于左乳外上象限见1个块状浓聚灶，大小为4.0x3.6x3.6cm，SUV为5.4；在此病灶的稍下方还可见1个大小为1.0x1.0x1.0cm的浓聚灶，SUV为2.8。</div>\r\n<div>【PET拟诊】左乳腺癌伴乳腺内转移；</div>\r\n<div>【病理诊断】中分化浸润型导管癌。<br />\r\n<img height="267" alt="" src="http://www.nfpetct.com/up_files/o44.JPG" width="242" />\r\n </div>', 'gwm', 0, 16),
(134, '病例27-PET/CT诊断乳腺癌术后全身多发转移', '病例介绍', '', '', '2009-10-12 13:29:33', '116.228.141.77', '<div>病例27</div>\r\n<div>【病史】女，45岁，左侧乳腺癌术后2年，肝区不适、腰痛3月余。</div>\r\n<div>【PET所见】左乳腺术后缺如。左侧胸壁及左腋下多个结节状浓聚灶；肝内多发浓聚灶，其中1个浓聚灶呈巨块型并有中心坏死；脊柱多个椎体、左肩部骨骼、骶骨、双侧骶髂关节、双侧髂骨多处高度浓聚灶。</div>\r\n<div>【PET拟诊】乳腺癌术后，左侧胸壁、左腋下多发转移灶；肝内多发转移灶；全身骨骼多发转移灶。<br />\r\n<img height="294" alt="" src="http://www.nfpetct.com/up_files/o45.JPG" width="406" />\r\n </div>', 'gwm', 0, 14),
(135, '病例28-PET/CT诊断乳腺癌术后多发转移', '病例介绍', '', '', '2009-10-12 13:29:49', '116.228.141.77', '<div>病例28</div>\r\n<div>【病史】女，45岁。左乳腺癌（浸润性导管癌）根治术后3 年余。发现右腋下小肿物1周，B超提示为实质性结节，考虑为转移灶。</div>\r\n<div>【PET所见】（见上图）右腋下结节状浓聚灶，大小为1.5x1.5x1.5cm,SUV为2.9；另于左上纵隔及左锁骨上窝见多个小结节状浓聚灶，大小介于0.7x0.8cm-1.9x1.5cm之间，SUV介于2.0-3.9之间。</div>\r\n<div>【PET诊断】左乳癌术后左乳腺缺如；右腋下、左侧纵隔、左锁骨上窝多发、多处淋巴结转移。</div>\r\n<div>【临床随诊】PET显像后，行健择等化疗，3个月后复查，以上淋巴结转移灶消失（见下图），提示治疗反应好。</div><br />\r\n<img height="372" alt="" src="http://www.nfpetct.com/up_files/o46.JPG" width="488" />\r\n ', 'gwm', 0, 15),
(136, '病例29-PET-CT诊断结肠癌', '病例介绍', '', '', '2009-10-12 13:30:12', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例29</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【病史】男，63岁，便血月余</div>\r\n<div>【PET所见】于结肠肝曲区见1个块状浓聚灶，大小为3.0x2.8x4.2cm,SUV为6.5。</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【PET拟诊】结肠肝曲高代谢病灶，考虑为结肠癌。</div>\r\n<div>【临床随诊】结肠腺癌。<br />\r\n<img height="192" alt="" src="http://www.nfpetct.com/up_files/o47.JPG" width="355" />\r\n </div>', 'gwm', 0, 14),
(137, '病例30-PET/CT诊断结肠癌，肝内多发转移灶。', '病例介绍', '', '', '2009-10-12 13:30:50', '116.228.141.77', '<div>病例30</div>\r\n<div>【病史】男，52岁，体检中MR发现肝内多发转移灶，原发灶未明。</div>\r\n<div>【PET所见】于肝脏内见4个大小不等的结节状浓聚灶；于相当于乙状结肠区见1个小块状浓聚灶，大小为3.0x2.5x2.0cm,SUV为5.0。</div>\r\n<div>【PET拟诊】乙状结肠区高代谢病灶，考虑为结肠癌；肝内多发转移灶。</div>\r\n<div>【病理诊断及临床随访】手术病理为乙状结肠中分化腺癌。术后行肝区光子刀治疗。<br />\r\n<img height="273" alt="" src="http://www.nfpetct.com/up_files/o48.JPG" width="266" />\r\n </div>', 'gwm', 0, 24),
(138, '病例31-PET/CT诊断直肠区肿瘤复发', '病例介绍', '', '', '2009-10-12 13:31:15', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例31</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【病史】男，83岁，结肠癌术后7年，反复腹泻和便秘1月余。</div>\r\n<div>【PET所见】于直肠区见1个结节状浓聚灶，大小约1.8x2.0x2.2cm,SUV为3.0。</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【PET拟诊】直肠区肿瘤复发；</div>\r\n<div>【病理诊断】肠镜及活检组织病理证实为直肠基细胞样鳞状细胞癌。<br />\r\n<img height="384" alt="" src="http://www.nfpetct.com/up_files/o49.JPG" width="519" />\r\n </div>', 'gwm', 0, 21),
(139, '病例32-PET/CT诊断结肠癌术后多发转移', '病例介绍', '', '', '2009-10-12 13:31:34', '116.228.141.77', '<div>病例32</div>\r\n<div>【病史】女，68岁，升结肠癌术后1年余。CT发现肝内多发转移灶。</div>\r\n<div>【PET所见】肝右叶多发异常浓聚灶，部分融合呈巨块状。右肺门、右侧纵隔及上腹部腹膜后区见多处、多个异常浓聚灶。</div><span style="font-size:10.5pt;">【</span><span style="font-size:10.5pt;">PET</span><span style="font-size:10.5pt;">拟诊】升结肠癌术后；肝脏内多发转移灶；右肺门、右侧纵隔及上腹部腹膜后区多发淋巴结转移灶</span><br />\r\n<img height="431" alt="" src="http://www.nfpetct.com/up_files/o50.JPG" width="431" />\r\n ', 'gwm', 0, 15),
(140, '病例33-PET/CT诊断下段食管癌伴左锁骨上窝淋巴结转移', '病例介绍', '', '', '2009-10-12 13:31:55', '116.228.141.77', '<div>病例33</div>\r\n<div>【病史】女，64岁，进食困难2个月，胃镜检查诊断为下段食管癌。</div>\r\n<div>【PET所见】食管下段异常浓聚灶，大小为2.2x2.3x3.2cm,SUV为4.6；另于左锁骨上窝见1个结节状异常浓聚灶，大小为1.8x1.5x2.0cm,SUV为3.0。</div>\r\n<div>【PET拟诊】下段食管癌伴左锁骨上窝淋巴结转移。</div>\r\n<div>【病理诊断】术后证实左锁骨上窝淋巴结转移。</div><br />\r\n<img height="318" alt="" src="http://www.nfpetct.com/up_files/o51.JPG" width="322" />\r\n ', 'gwm', 0, 21),
(141, '病例34-PET/CT诊断食管癌术后', '病例介绍', '', '', '2009-10-12 13:32:21', '116.228.141.77', '<div>病例34</div>\r\n<div>【病史】男，60岁，吞咽困难1月余。胃镜明确诊断为中段食管癌，行PET进行光子刀疗效观察。</div>\r\n<div>【PET所见】治疗前于食管中段见1个粗条状异常高度浓聚灶，大小为2.5x2.3x4.5cm,SUV为6.2；光子刀治疗后1个月，PET显像示食管中段浓聚灶消失。其周围轻度浓聚影，为放疗后改变</div>\r\n<div>【PET拟诊】中段食管癌光子刀治疗后病灶消失，提示治疗效果好。</div><br />\r\n<img height="260" alt="" src="http://www.nfpetct.com/up_files/o52.JPG" width="535" />\r\n ', 'gwm', 0, 20),
(142, '病例35-PET/CT诊断胃窦癌', '病例介绍', '', '', '2009-10-12 13:32:44', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例35</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【病史】男，44岁。腹胀、剑突下压痛48天。</div>\r\n<div>&nbsp;【PET所见】于相当于胃窦区见1个块状浓聚灶，大小为3.1x4.1x2.9cm,SUV为5.7。</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【PET拟诊】胃窦癌</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【病理诊断】胃窦部腺癌，分化程度低。<br />\r\n<img height="258" alt="" src="http://www.nfpetct.com/up_files/o53.JPG" width="341" />\r\n </div>', 'gwm', 0, 16),
(143, '病例36-PET/CT诊断胃癌', '病例介绍', '', '', '2009-10-12 13:32:59', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例36</div>\r\n<div>【病史】男，45岁。不规则腹痛半年余，加重伴消瘦、贫血月余。胃镜检查确诊为胃癌。</div>\r\n<div>【PET所见】胃区见放射性异常浓聚影，形态不规则，SUV为3.3；于中上腹部腹主动脉两侧见放射性异常浓聚灶，呈串珠状排列，SUV为4.8。</div>\r\n<div style="margin:0cm 0cm 0pt 24pt;">【PET诊断】胃癌伴中上腹腹膜后多发淋巴结转移。<br />\r\n<img height="257" alt="" src="http://www.nfpetct.com/up_files/o54.JPG" width="362" />\r\n </div>', 'gwm', 0, 25),
(144, '病例37-PET/CT诊断原发性肝癌', '病例介绍', '', '', '2009-10-12 13:33:18', '116.228.141.77', '<div>病例37</div>\r\n<div>【病史】男，57岁。肝区不适，AFP增高，CT示肝内占位。</div>\r\n<div>【PET所见】肝左、右叶交界区见1个块状高度浓聚灶，呈分叶状，SUV为7.2,病灶中心呈放射性缺损。于肝门附近见多个大小不等的结节状浓聚灶，SUV皆接近7.0；全身其他部位未见明显异常。</div>\r\n<div>【PET诊断】原发性肝癌（中心性坏死），肝门周围多个淋巴结转移。</div>\r\n<div>【病理诊断】原发性肝癌。<br />\r\n<img height="355" alt="" src="http://www.nfpetct.com/up_files/o55.JPG" width="372" />\r\n </div>', 'gwm', 0, 17),
(145, '病例38-PET/CT诊断高分化肝细胞癌', '病例介绍', '', '', '2009-10-12 13:33:36', '116.228.141.77', '<div>病例38</div>\r\n<div>【病史】男，64岁。肝区不适月余。CT发现肝右叶占位性病变，大小为2.5x2.5cm,考虑为原发性肝癌。</div>\r\n<div>【PET所见】于CT所见的占位性病变处，PET放射性分布与正常肝组织相近，未见异常浓聚灶。</div>\r\n<div>【PET诊断】肝脏内未见高代谢病灶。</div>\r\n<div>【病理诊断】高分化肝细胞癌。<br />\r\n<img height="156" alt="" src="http://www.nfpetct.com/up_files/o56.JPG" width="349" />\r\n </div>', 'gwm', 0, 34),
(146, '病例39-PET-CT诊断肿瘤残余', '病例介绍', '', '', '2009-10-12 13:33:58', '116.228.141.77', '<div>病例39</div>\r\n<div>【病史】男，42岁。右上腹疼痛2月，CT示肝右叶占位性病变，大小为8x10cm,考虑为肝癌，AFP明显增高。肝动脉栓塞化疗术后1月，复查CT示肝膈顶区部分碘油沉积欠佳，AFP仍较高。</div>\r\n<div>【PET所见】肝右叶见1个边界清楚的放射性缺损灶，大小约7.0x5.0cm,缺损灶的右上缘见1半月形异常浓聚灶，大小为2.8x6.4x3.0cm,SUV为3.0。肝内其他部位放射性分布正常。</div>\r\n<div>【PET拟诊】肝右叶肝癌介入治疗后病灶内大部分组织坏死，但其外上缘仍有较大的肿瘤残余。</div>\r\n<div>【临床随访】PET显像后行肝动脉造影证实有肿瘤残余，介入治疗后AFP逐渐降至正常。</div>\r\n<p>&nbsp;</p>\r\n<p><img height="173" alt="" src="http://www.nfpetct.com/up_files/o57.JPG" width="352" />\r\n </p>', 'gwm', 0, 16),
(147, '病例40-PET/CT诊断胰腺癌', '病例介绍', '', '', '2009-10-12 13:34:42', '116.228.141.77', '<div>病例40：</div>\r\n<div>【病史】男，73岁。上腹部痛3月余伴体重下降低（约10Kg）。CA199明显升高（319.34U/ml）,1个月前腹部CT及B超皆未见异常。</div>\r\n<div>【PET所见】胰体尾部见1个结节状异常浓聚灶，大小为1.3x2.7x2.1cm,SUV为3.0；腹膜后区见轻度浓聚影，边界模糊，SUV为2.0。</div>\r\n<div>【PET拟诊】胰体、尾部癌；腹膜后区可疑淋巴结转移。</div>\r\n<div>【临床随访】PET显像后行CT薄层增强扫描发现胰体、尾部占位性病变。行光子刀治疗后CA199明显降低，疼痛减轻，临床诊断为胰腺癌。</div><br />\r\n<img height="175" alt="" src="http://www.nfpetct.com/up_files/o58.JPG" width="499" />\r\n ', 'gwm', 0, 17),
(148, '病例41-PET/CT诊断大囊性腺瘤', '病例介绍', '', '', '2009-10-12 13:35:08', '116.228.141.77', '<div>病例41</div>\r\n<div>【病史】女，58岁。CT查体发现胰体尾部占位性病变，大小约10cm 。无特殊临床症状。</div>\r\n<div>【PET所见】胰体、尾部大块状轻度浓聚灶，边界模糊，SUV为1.7。</div>\r\n<div>【PET拟诊】胰体、尾部良性病变或低度恶性肿瘤</div>\r\n<div>【病理诊断】术后病理为大囊性腺瘤。</div>\r\n<div><img height="240" alt="" src="http://www.nfpetct.com/up_files/o59.JPG" width="349" />\r\n </div>', 'gwm', 0, 25),
(149, '病例42-PET/CT诊断胰头周围淋巴结结核', '病例介绍', '', '', '2009-10-12 13:35:48', '116.228.141.77', '<div>病例42</div>\r\n<div>【病史】男，37岁。上腹痛隐痛1月。CT、MR、B超发现胰头部增大，怀疑占位性病变。患者无黄疸，ERCP示胆管、胰腺正常。</div>\r\n<div>【PET所见】胰头所在区异常浓聚灶，病灶内见部分放射性缺损，SUV为4.8；肝左叶见轻度浓聚影，边缘模糊。腹部内见多个小结节浓聚影。</div>\r\n<div>【PET拟诊】胰头癌伴肝左叶及腹部小淋巴结转移。</div>\r\n<div>【病理诊断】胰头周围淋巴结结核（活动性）。</div>\r\n<div><img height="219" alt="" src="http://www.nfpetct.com/up_files/o60.JPG" width="306" />\r\n </div>', 'gwm', 0, 25),
(150, '病例43-PET/CT诊断胰腺癌伴多发转移', '病例介绍', '', '', '2009-10-12 13:36:03', '116.228.141.77', '<div>病例43</div>\r\n<div>【病史】男，59岁。肝区不适半年伴体重下降。CT示胰腺癌伴肝内多发转移。</div>\r\n<div>【PET所见】于胰腺体部见1个块状异常浓聚灶（如箭头所指），大小为3.2x4.8x2.8cm,SUV 为4.8；肝内见多个异常浓聚灶，呈散在、弥漫性分布；上腹部腹膜后区见多个结节状浓聚灶。</div>\r\n<div>【PET诊断】胰腺癌伴肝内多发、弥漫性转移、上腹部腹膜后多发淋巴结转移。</div>\r\n<div><img height="302" alt="" src="http://www.nfpetct.com/up_files/o61.JPG" width="524" />\r\n </div>', 'gwm', 0, 17),
(151, '病例44-PET/CT诊断非霍杰金氏淋巴瘤', '病例介绍', '', '', '2009-10-12 13:36:25', '116.228.141.77', '<div>病例44</div>\r\n<div>【病史】男，33岁。发现右颈部及双侧腹股沟淋巴结肿大约半年，抗炎治疗无效。活检证实为霍何金氏淋巴瘤（T-母细胞型）。</div>\r\n<div>【PET所见】双侧耳旁、耳后、双颌下、双侧后颈部、腹膜后、双腹股沟多发、多处异常浓聚灶，右侧腹沟股浓聚灶SUV为4.2。</div>\r\n<div>【PET诊断】非霍杰金氏淋巴瘤，全身多处淋巴结累及。为高度恶性淋巴瘤。</div>\r\n<div><img height="452" alt="" src="http://www.nfpetct.com/up_files/o62.JPG" width="488" />\r\n </div>', 'gwm', 0, 26),
(152, '病例45-PET/CT诊断非霍杰金氏淋巴瘤', '病例介绍', '', '', '2009-10-12 13:37:10', '116.228.141.77', '<div>病例45</div>\r\n<div>【病史】男，86岁。左下肺痛而就诊，外院诊断为非霍杰金氏淋巴瘤。CT示左肺、左侧胸膜及脊柱累及。</div>\r\n<div>【PET所见】纵隔、左肺、左侧胸膜、脊柱多个椎体、骨盆、左侧腹部、盆腔等处多发放射性异常浓聚影，病灶分布散在。左侧胸膜呈弥漫性浓聚，最浓处SUV为5.5。</div>\r\n<div>【PET诊断】非霍杰金氏淋巴瘤，全身广泛累及。为高度恶性淋巴瘤。</div>\r\n<div><img height="235" alt="" src="http://www.nfpetct.com/up_files/o63.JPG" width="487" />\r\n </div>', 'gwm', 0, 18),
(153, '病例46-PET/CT诊断恶性淋巴瘤', '病例介绍', '', '', '2009-10-12 13:37:36', '116.228.141.77', '<div>病例46</div>\r\n<div>【病史】男，48岁。查体时CT发现腹膜后多发淋巴结肿大，性质待定。</div>\r\n<div>【PET所见】于腹主动脉旁两侧及右侧髂总血管旁见多个放射性异常浓聚灶，多相互融合在一起，呈纵向排列，浓聚程度高，SUV为4.8。全身其他部位未见明显异常。</div>\r\n<div>【PET诊断】恶性淋巴瘤。</div>\r\n<div>【临床随访】PET显像后行腹主动脉旁穿刺活检，证实为非霍杰金氏淋巴瘤，随后行放、化疗，3个月后复查PET腹膜后病灶皆消失，提示疗效佳。</div>\r\n<div><img height="302" alt="" src="http://www.nfpetct.com/up_files/o64.JPG" width="475" />\r\n </div>', 'gwm', 0, 18),
(154, '病例47-PET/CT诊断透明细胞癌', '病例介绍', '', '', '2009-10-12 13:37:59', '116.228.141.77', '<div>病例47</div>\r\n<div>【病史】男，89岁。查体时CT发现左肾占位，性质待定。</div>\r\n<div>【PET所见】于左肾的外侧缘见1个块状放射性浓聚灶，大小为3.5x4.6x4.0cm,SUV为4.3,病灶内见1个放射性缺损影。</div>\r\n<div>【PET诊断】左肾肾癌，中心部分坏死。</div>\r\n<div>【病理诊断】透明细胞癌</div>\r\n<div><img height="243" alt="" src="http://www.nfpetct.com/up_files/o65.JPG" width="369" />\r\n </div>', 'gwm', 0, 22),
(155, '病例48-PET/CT诊断透明细胞癌', '病例介绍', '', '', '2009-10-12 13:38:27', '116.228.141.77', '<div>病例48</div>\r\n<div>【病史】女，47岁。左乳腺癌术后2年，B超发现右肾上极占位，直径约4.0cm,性质待定，CT考虑为囊肿可能性大。</div>\r\n<div>【PET所见】左侧乳腺术后缺如；于右肾上极见1个放射性缺损灶，边界清楚，大小为4.0x3.8x3.7cm。</div>\r\n<div>【PET拟诊】右肾上极良性病变</div>\r\n<div>【病理诊断】透明细胞癌</div>\r\n<div><img height="335" alt="" src="http://www.nfpetct.com/up_files/o66.JPG" width="257" />\r\n </div>', 'gwm', 0, 22),
(156, '病例49-PET/CT诊断前列腺癌', '病例介绍', '', '', '2009-10-12 13:39:14', '116.228.141.77', '<div>病例49</div>\r\n<div>【病史】男，50岁。血尿、排尿困难2个月。MR发现左侧前列腺占位性病变。</div>\r\n<div>【PET所见】左侧前列腺区见1个结节状浓聚灶，大小为1.5x1.2x2.0cm,SUV为3.0。</div>\r\n<div>【PET拟诊】前列腺癌</div>\r\n<div>【病理诊断】前列腺癌</div>\r\n<p>&nbsp;</p>\r\n<p><img height="182" alt="" src="http://www.nfpetct.com/up_files/o67.JPG" width="341" />\r\n </p>', 'gwm', 0, 24),
(157, '病例50-PET/CT诊断前列腺癌术后多发转移', '病例介绍', '', '', '2009-10-12 13:39:56', '116.228.141.77', '<div>病例50</div>\r\n<div>【病史】男，51岁。前列腺癌肝转移半年余，曾行3次肝动脉介入化疗，肝内碘油沉积良好。</div>\r\n<div>【PET所见】肝内见多个放射性缺损灶。于盆腔、中腹部腹膜后、上腹部（肝脏稍下方）、左侧纵隔、右上肺见多个放射性异常浓聚灶。上腹部浓聚灶呈长块状，大小为3.8x3.2x8.6cm，SUV为7.2。前列腺区未见异常浓聚灶。（注：膀胱下方圆形浓聚影为导尿管影）。</div>\r\n<div>【PET诊断】前列腺癌术后，局部未见恶性肿瘤征象。盆腔、腹部、左侧纵隔、右上肺多处转移灶；肝内转移灶介入后，肝内未见明显恶性肿瘤征象。</div>\r\n<p>&nbsp;</p>\r\n<p><img height="266" alt="" src="http://www.nfpetct.com/up_files/o68.JPG" width="352" />\r\n </p>', 'gwm', 0, 18),
(158, '病例51-PET/CT诊断卵巢恶性肿瘤', '病例介绍', '', '', '2009-10-12 13:40:10', '116.228.141.77', '<div>病例51</div>\r\n<div>【病史】女，50岁，右下腹部不适4个月。CT发现右侧附件包块影，均匀性强化，考虑为新生物，性质待定。</div>\r\n<div>【PET所见】于右侧附件区见1个放射性异常浓聚灶，大小为2.4x3.6x4.2cm,SUV值为4.0，病灶内放射性分布均匀。</div>\r\n<div>【PET拟诊】右侧卵巢恶性肿瘤</div>\r\n<p><span style="font-size:10.5pt;">【病理诊断】卵巢腺癌</span></p>\r\n<p><img height="254" alt="" src="http://www.nfpetct.com/up_files/o69.JPG" width="188" />\r\n </p>', 'gwm', 0, 28),
(159, '病例52-PET/CT诊断子宫内膜癌术后，广泛转移', '病例介绍', '', '', '2009-10-12 13:40:31', '116.228.141.77', '<div>病例52</div>\r\n<div>【病史】女，53岁，子宫内膜癌术后5年。B超发现肝内和腹膜后转移。</div>\r\n<div>【PET所见】子宫所在区呈放射性缺损。于右下肺、后纵隔各见1个小结节状浓聚灶。于肝内见多发结节状浓聚灶，呈弥漫性分布。于左上腹见1个小块状浓聚灶；于腹膜后见多个结节状浓聚灶相互融合并呈串珠状排列；于胸、腰椎多个椎体、骶骨、左侧骶髂关节、左侧髂骨见多发浓聚灶。</div>\r\n<div>【PET拟诊】子宫内膜癌术后。右下肺、纵隔、左上腹、肝脏、腹膜后及骨骼多发、广泛转移。</div>\r\n<div><img height="256" alt="" src="http://www.nfpetct.com/up_files/o70.JPG" width="456" />\r\n </div>', 'gwm', 0, 19),
(160, '病例53-PET/CT诊断黑色素瘤术后，多发转移灶', '病例介绍', '', '', '2009-10-12 13:40:51', '116.228.141.77', '<div>病例53</div>\r\n<div>【病史】女，29岁。左腰背部黑色素瘤术后1年，左腋窝淋巴结转移3个月。近日于左乳腺触及多个小结节。</div>\r\n<div>【PET所见】于左锁骨上下窝、左侧乳腺区及左腋下见多个大小不等的结节状或块状浓聚灶，大小介于0.8x0.8x0.8cm-2.7x2.7x3.8cm之间，SUV介于1.7-5.2之间。</div>\r\n<div>【PET拟诊】黑色素瘤术后；左锁骨上下窝、左乳腺区及左腋下多发转移灶。</div>\r\n<div><img height="421" alt="" src="http://www.nfpetct.com/up_files/o71.JPG" width="341" />\r\n </div>', 'gwm', 0, 34),
(161, '病例54-PET/CT诊断左上肺癌伴左肺门及多处骨转移', '病例介绍', '', '', '2009-10-12 13:41:43', '116.228.141.77', '<div>病例54</div>\r\n<div>【病史】男，56岁。腰痛2月，CT、MR示腰4椎体骨质破坏，行手术部分切除，病理为转移性腺癌。胸、腹部及盆腔CT及前列腺B超皆未找到原发灶。</div>\r\n<div>【PET所见】于左上肺及左肺门各见1个大小分别为1.4x1.8cm、1.2x1.2cm的异常浓聚灶，SUV分别为2.8、2.0。于第12胸椎、第4腰椎及左髂骨见放射性异常浓聚灶；第3腰椎也见放射性轻度浓聚影。</div>\r\n<div>【PET诊断】左上肺癌伴左肺门及多处骨转移。</div>\r\n<div><img height="255" alt="" src="http://www.nfpetct.com/up_files/o72.JPG" width="442" />\r\n </div>', 'gwm', 0, 27);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(162, '病例55-PET/CT诊断致痫灶', '病例介绍', '', '', '2009-10-12 13:43:49', '116.228.141.77', '<div>病例55</div>\r\n<div>【病史】男，21岁。阵发性腹痛8年余，每日约40次以上，偶有肢体抽搐，意识障碍。服多种抗癫痫药，症状无明显改善。MR示右颞叶及侧裂区可疑有萎缩征象。</div>\r\n<div>【PET所见】注射显像剂时出现发作性腹痛。于左颞叶内侧皮质见1个局限性放射性浓聚灶，大小为2.6x1.1x2.2cm,AI值为96%。</div>\r\n<div>【PET诊断】发作期：左颞叶内侧皮质高代谢灶，考虑为致痫灶</div>\r\n<div>【临床随访】根据PET结果行γ-刀治疗，5天后阵发性腹痛则明显减少，1个月发作次数降至5次。行PET显像复查，发现左颞叶内侧皮质仍有1个较小的高代谢灶，再次行γ-刀治疗，随访半年未有癫痫发作。</div>\r\n<div><img height="241" alt="" src="http://www.nfpetct.com/up_files/o73.JPG" width="247" />\r\n </div>', 'gwm', 0, 17),
(163, '病例56-PET/CT诊断致痫灶', '病例介绍', '', '', '2009-10-12 13:44:18', '116.228.141.77', '<div>病例56</div>\r\n<div>【病史】男，12岁。右颞叶自发性动静脉畸形自发性出血术后3年，反复癫痫发作，最多时1天发作3-4次，服抗癫痫药效果差。</div>\r\n<div>【PET所见】注射显像剂时出现癫痫大发作，持续约20min。右颞叶见1个范围较大的放射性缺损灶，于缺损灶的内侧缘（右颞叶内侧皮质）见2个放射性异常浓聚灶，边界清楚，范围皆比较局限，AI值为85%。</div>\r\n<div>【PET诊断】发作期：右颞叶内侧皮质高代谢灶，考虑为致痫灶。</div>\r\n<div>【临床随访】根据PET结果行X-刀治疗后，随访一年未有癫痫发作。</div>\r\n<div><img height="249" alt="" src="http://www.nfpetct.com/up_files/o74.JPG" width="241" />\r\n </div>', 'gwm', 0, 17),
(164, '病例57-PET/CT诊断致痫灶', '病例介绍', '', '', '2009-10-12 13:44:35', '116.228.141.77', '<div>病例57</div>\r\n<div>【病史】女，15岁。阵发性四肢抽搐、意识障碍2年，EEG提示左颞叶致痫灶，服多种抗癫痫药后无明显好转。临床诊断为癫痫。</div>\r\n<div>【PET所见】于左颞叶底面见放射性分布明显降低，范围较局限，AI值为26%。</div>\r\n<div>【PET诊断】发作间期：左颞叶低代谢灶，考虑为致痫灶</div>\r\n<div>【临床随访】根据PET结果行X-刀治疗，随访1年半未有癫痫发作。</div>\r\n<div><img height="177" alt="" src="http://www.nfpetct.com/up_files/o75.JPG" width="331" />\r\n </div>', 'gwm', 0, 19),
(165, '病例58-PET/CT诊断致痫灶', '病例介绍', '', '', '2009-10-12 13:44:53', '116.228.141.77', '<div>病例58</div>\r\n<div>【病史】男，23岁。阵发性四肢抽搐伴意识障碍10年，左侧肢体常先抽动，随后出现全身抽动，平时有左侧肢体麻木感。每次发作约持续1-2min。每个月约发作5次。EEG示中度异常脑电图，但无定位提示。MR未见异常。服抗癫痫药治疗效果欠佳。</div>\r\n<div>【PET所见】于右颞叶外侧皮质的前部及右侧中央前后回处见放射性分布明显降低，范围较大，最明显处AI为36%。</div>\r\n<div>【PET诊断】发作间期：右颞叶外侧皮质的前部及右侧中央前后回处低代谢灶，考虑为致痫灶。</div>\r\n<div><img height="179" alt="" src="http://www.nfpetct.com/up_files/o76.JPG" width="309" />\r\n </div>', 'gwm', 0, 18),
(166, '病例59-PET/CT诊断致痫灶', '病例介绍', '', '', '2009-10-12 13:45:07', '116.228.141.77', '<div>病例59</div>\r\n<div>【病史】女，21岁。发作性抽搐伴意识障碍4年，每周约发作1-2次。抗癫痫治疗效果差。EEG未见异常。MR未见异常。无明确外伤史。</div>\r\n<div>【PET所见】于右额叶见1个范围比较局限的放射性减低影，AI值为42%。</div>\r\n<div>【PET诊断】发作间期：右额叶低代谢灶，考虑为致痫灶。</div>\r\n<div>【临床随访】根据PET定位行X-刀治疗，发作次数明显减少，约2-3个月发作1次。</div>\r\n<div><img height="171" alt="" src="http://www.nfpetct.com/up_files/o77.JPG" width="309" />\r\n </div>', 'gwm', 0, 15),
(167, '病例60-PET/CT诊断癫痫', '病例介绍', '', '', '2009-10-12 13:45:21', '116.228.141.77', '<div>病例60</div>\r\n<div>【病史】男，8岁。阵发性右上肢抽搐、眼部闪光感4年余，多在活动过多时发作。服多种抗癫痫灶效果差。每天发作1-2次。EEG示不正常脑电图，无定位描述。MR示枕大池扩大。SPECT示左基底神经节浓聚。</div>\r\n<div>【PET所见】左侧枕叶（包括部分视皮质）见放射性分布明显降低，范围较局限，AI值为74%。</div>\r\n<div>【PET诊断】发作间期：左侧枕叶低代谢灶，考虑为致痫灶。</div>\r\n<div>【临床随访】根据PET定位行X-刀治疗，随访1年多无癫痫发作。</div>\r\n<div><img height="173" alt="" src="http://www.nfpetct.com/up_files/o78.JPG" width="313" />\r\n </div>', 'gwm', 0, 19),
(168, '病例61-PET-CT诊断阿尔茨海默', '病例介绍', '', '', '2009-10-12 13:46:02', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例61</div>\r\n<div>【PET图像描述】左侧的2帧图像为正常人<sup>18</sup>F-FDG PET图像。右侧的2帧图像为阿尔茨海默病人早期<sup>18</sup>F-FDG PET图像。从右侧的图像可见双侧顶叶和后颞叶放射性分布呈对称性明显降低（如箭头所指），而视皮质、双额叶、双侧基底神经节及丘脑放射性分布正常。</div>\r\n<div><img height="296" alt="" src="http://www.nfpetct.com/up_files/o79.JPG" width="323" />\r\n </div>', 'gwm', 0, 22),
(169, '病例62-PET/CT诊断痴呆', '病例介绍', '', '', '2009-10-12 13:46:43', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例62</div>\r\n<div>【PET图像描述】双侧额叶放射性分布明显降低，呈对称性。为早期额、颞叶痴呆的典型影像表现。</div>\r\n<div><img height="225" alt="" src="http://www.nfpetct.com/up_files/o80.JPG" width="184" />\r\n </div>', 'gwm', 0, 25),
(170, '病例63', '病例介绍', '', '', '2009-10-12 13:47:00', '116.228.141.77', '<div>病例63</div>\r\n<div>【PET图像描述】大脑皮质放射性分布轻度降低，双侧尾状核头、双侧壳核放射性分布明显降低，尤其是双侧壳核。</div>\r\n<div><img height="191" alt="" src="http://www.nfpetct.com/up_files/o81.JPG" width="155" />\r\n </div>', 'gwm', 0, 25),
(171, '病例64-PET/CT诊断帕金森氏病伴有痴呆', '病例介绍', '', '', '2009-10-12 13:47:34', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 24pt;">病例64</div>\r\n<div>【PET图像描述】</div>\r\n<div>第一排3帧图像为正常人图像。第1-2帧为<sup>18</sup>F-FDG图像，可见大脑皮质左右分布对称、灰质浓聚程度明显高于白质，各叶皮质与皮质下核团浓聚程度相近；第3帧为<sup>18</sup>F-DOPA图像，可见双侧尾状核头及壳核放射性分布高，左右对称。</div>\r\n<div>第二、三排图像为同一病人的演变过程：</div>\r\n<div>第二排：出现帕金森氏病但未发展到痴呆。<sup>18</sup>F-FDG图像基本正常；<sup>18</sup>F-DOPA图像：双侧尾状核显影基本正常，但双侧壳核放射性分布呈对称性明显降低。</div>\r\n<div>第三排：帕金森氏病伴有痴呆。<sup>18</sup>F-FDG图像：双侧顶叶、后颞叶及双侧部分额叶放射性分布对称性明显降低；<sup>18</sup>F-DOPA图像：双侧尾状核显影基本正常，双侧壳核放射性分布呈对称性明显降低。</div>\r\n<div><img height="409" alt="" src="http://www.nfpetct.com/up_files/o82.JPG" width="425" />\r\n </div>', 'gwm', 0, 25),
(172, '病例65-PET/CT诊断脑梗塞', '病例介绍', '', '', '2009-10-12 13:47:54', '116.228.141.77', '<div>病例65</div>\r\n<div>【病史】女，56岁。左侧肢体运动障碍10天。CT示右侧额叶脑梗塞。</div>\r\n<div>【PET所见】右侧额叶白质区（靠近屏状核处）见放射性分布明显降低，近于缺损；右侧额叶皮质放射性分布也明显降低；右侧尾状核头、豆状核和丘脑放射性分布明显降低。PET所显的累及范围明显大于CT所示。</div>\r\n<div>【PET诊断】右额叶脑梗塞，累及右额叶皮质、白质及右侧皮层下核团。</div>\r\n<p><img height="265" alt="" src="http://www.nfpetct.com/up_files/o83.JPG" width="361" />\r\n </p>', 'gwm', 0, 47),
(173, '病例66-PET/CT诊断心肌缺血', '病例介绍', '', '', '2009-10-12 13:48:17', '116.228.141.77', '<div>病例66</div>\r\n<div>【病史】男，67岁。心前区闷痛3个月，SPECT心肌灌注可疑前间壁心肌缺血。</div>\r\n<div>【PET所见】负荷显像：垂直长轴断层图像及负荷靶心图示前间壁近心尖处呈节段性放射性稀疏；静息显像：垂直长轴断层图像及静息靶心图示前间壁近心尖处放射性分布正常，与负荷显像相比出现明显放射性填充现象。</div>\r\n<div>【PET诊断】冠心病，前间壁心肌缺血。</div>\r\n<div><img height="186" alt="" src="http://www.nfpetct.com/up_files/o84.JPG" width="612" />\r\n </div>', 'gwm', 0, 44),
(174, '病例67-PET/CT诊断冠心病', '病例介绍', '', '', '2009-10-12 13:48:32', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 17.9pt;">病例67</div>\r\n<div>【病史】男，46岁。前壁心肌梗塞行PTCA+支架置入术后1年，当时冠脉造影示左前降支100%阻塞。</div>\r\n<div>【PET所见】上排图像为静息状态下<sup>13</sup>N-NH<sub>3</sub>心肌血流灌注图像（垂直长轴），于前壁近心尖处、心尖和部分下壁见放射性缺损；下排为<sup>18</sup>F-<span style="color:black;">FDG</span><span style="color:black;">心肌代谢图像，于前壁近心尖处、心尖和部分下壁也见放射性缺损，血流和代谢完全匹配。</span></div>\r\n<div>【PET诊断】冠心病，<span style="color:black;">前壁近心尖处、心尖和部分下壁心肌梗塞，梗塞区内无心肌存活。</span></div>\r\n<div><span style="color:black;"><img height="172" alt="" src="http://www.nfpetct.com/up_files/o85.JPG" width="399" />\r\n </span></div>', 'gwm', 0, 41),
(175, '病例68-PET/CT诊断心肌梗塞', '病例介绍', '', '', '2009-10-12 13:48:53', '116.228.141.77', '<div><span style="color:black;">病例</span><span style="color:black;">68</span></div>\r\n<div>【病史】男，57岁。心前区疼痛13天，在外院诊断前间壁急性心肌梗塞，已行药物治疗，心前区疼痛症状消失，拟行PTCA。</div>\r\n<div>【PET所见】上排图像为静息状态下<sup>13</sup>N-NH<sub>3</sub>心肌血流灌注图像（垂直长轴），于前间壁、心尖及部分下壁见放射性缺损；下排为<sup>18</sup>F-<span style="color:black;">FDG</span><span style="color:black;">心肌代谢图像，于</span>心尖区见放射性缺损（血流-代谢匹配），前间壁及部分下壁见较明显的放射性填充现象（血流-代谢不匹配）。</div>\r\n<div>【PET诊断】冠心病，前间壁、心尖及部分下壁心肌梗塞；心尖区无存活心肌，前间壁及部分下壁心肌为存活心肌。</div>\r\n<div><img height="288" alt="" src="http://www.nfpetct.com/up_files/o86.JPG" width="384" />\r\n </div>', 'gwm', 0, 46),
(176, '病例69-PET/CT诊断非霍杰金氏淋巴瘤', '病例介绍', '', '', '2009-10-12 13:49:13', '116.228.141.77', '<div style="margin:0cm 0cm 0pt 17.9pt;">病例69</div>\r\n<div>【图像分析】此图为1位非霍杰金氏淋巴瘤患者的PET/CT图像。左边左右排列的3帧图像依次为CT冠状断层图、PET冠状断层图、PET/CT融合图。右边上下排列的3帧图像从上往下依次为CT横断层图像、PET横断层图像、PET/CT融合图像。“+”线交叉点为淋巴结恶性病灶。PET/CT既能对病灶进行定性，也能很好地进行定位。</div>\r\n<div><img height="382" alt="" src="http://www.nfpetct.com/up_files/o87.JPG" width="560" />\r\n </div>', 'gwm', 0, 87),
(177, 'PET-CT检查如何预约', '检查指南', '', '', '2009-10-13 16:02:09', '116.228.141.77', '<p>PET-CT检查预约方法：</p>\r\n<p>一、在线预约：和我们在线客服预约，登记您所要预约的医院以及大致时间，以及简单的病史，在线客服根据该医院PET-CT当天预约的情况和你确定好时间，按时间前去即可。</p>\r\n<p>二、网络自助预约：点击首页你所要预约的医院，点击检查预约按钮<img alt="" src="/image_server_dir/d0999f3dcec064579938c46f7ce88c3b.jpg" border="0" />\r\n进入预约界面，输入相关信息，稍后我们客服人员我联系你，跟您确定好检查时间，即可。</p>\r\n<p>三，电话预约：致电免费电话4006-125-007。</p>', 'gwm', 0, 75),
(183, 'PET－CT与ECT的区别', '详细介绍', '', '', '2009-10-20 16:04:10', '116.228.141.77', '医学中把应用计算机辅助断层技术进行显像的设备统称为ECT，它是医学影像技术的重要组成部分。ECT的中文名称为发射型计算机断层显像，是其英文名称缩写而成（Emission Computed Tomography）。\r\n<p>　　ECT实际上又包括两大类设备即SPECT和PECT，SPECT是以放射r 射线的放射性核素做为发射体的显像设备，称为单光子发射型计算机断层显像，英文为 single photon emission computed tomography。由于以前国内没有PET，因此人们习惯上把SPECT简称为ECT，因此上面我们所讨论的ECT实际应该称为SPECT。SPECT并不是一种很新的设备，其由Kuhl等人于1979年研制成功。经过多年不断的改进，SPECT技术已经有了很大的发展，产生了许多不同型号、不同档次的产品，但是其显像的基本原理没有变化，总体上仍属于比较低端的核医学设备。目前国内很多三级以上医院都已经配备SPECT，数量达300台以上，主要用于全身骨骼、心肌血流、脑血流、甲状腺等显像。</p>\r\n<p>　　ECT的另一类设备PECT是以发射正电子的放射性核素做为发射体，称为正电子发射型计算机断层显像，其英文名称为 positron emission computed tomography，即我们通常所说的PET。PET是核医学领域中最先进的显像设备，被视为核医学史上划时代的里程碑，是最高水平核医学的标志。PET所应用的显像剂如C-11、N-13，O-15等都是人体组织的基本元素，易于标记到各种生命必须的化合物、代谢产物或类似物上而不改变它们的生物活性，且可以参与人体的生理、生化代谢过程，因而能够深入分子水平反映人体的生理、生化过程，从功能、代谢等方面前面评价人体的功能状态，达到早期诊断疾病、指导治疗的目的。定性准确和一次性完成全身显像的特点极大地促进了其在肿瘤、脑神经系统疾病以及心脏病等方面的应用。我国于1995年由山东淄博万杰医院引进国内第一台PET，其后增长较为缓慢。</p>\r\n<p>　　PET的先进性显而易见，但其最大的缺点是解剖结构显示不够清晰。因此人们尝试把擅长功能显像的PET与擅长显示解剖结构的全身CT结合起来，于是在2000年世界上第一台同机一体化PET－CT在美国CTI公司研制成功，被美国《时代》杂志评选为年度最伟大的发明创造。由于PET－CT是目前最先进的PET与最好的多排螺旋CT的完美组合，达到了一加一大于二的效果，一举成为目前最豪华的医学影像诊断设备。PET与CT的同机组合极大地提高了临床医生对PET的认知度，所以一经问世便在世界范围内高速增长。2002年第一台PET－CT在国内安家落户，目前PET－CT在国内已经呈献快速发展的趋势。</p>\r\n<p>　　总体上讲，SPECT与PET相比二者可以说具有本质的区别，数据表明，SPECT的最高探测效率仅为PET的1%-3%左右，图像质量远不能与PET－CT相比，诊断效能上差距较大。二者一种是普及型的低端产品，价格较低；一种是世界上公认的最高档次的医学影像诊断设备，价格昂贵、投资巨大，很难普及和推广。</p>', 'gwm', 0, 140),
(184, 'PET肿瘤代谢显像的临床应用', '详细介绍', '', '', '2009-11-11 09:51:31', '116.228.141.77', '<p style="text-indent:157.5pt;"><font face="宋体">一、<span>PET</span>肿瘤代谢显像概述</font></p>\r\n<p style="text-indent:21pt;"><span>PET</span><span style="font-family:宋体;">，即正电子发射断层显像（</span><span>positron emission tomography</span><span style="font-family:宋体;">）是当代最先进的核医学显像技术。该技术是将用正电子核素（</span><sup><span>18</span></sup><span>F</span><span style="font-family:宋体;">、</span><sup><span>15</span></sup><span>O</span><span style="font-family:宋体;">、</span><sup><span>13</span></sup><span>N</span><span style="font-family:宋体;">、</span><sup><span>11</span></sup><span>C</span><span style="font-family:宋体;">等）标记的放射性示踪剂通过静脉注射引入体内，这些示踪剂能直接或间接参与体内特定生化过程，我们用</span><span>PET</span><span style="font-family:宋体;">仪在体外监测（显像）其在体内被细胞摄取、结合、合成、分布、代谢与转运等生命活动过程，动态、定量、灵敏和精确地显示重要生命物质在正常人或病人体内的空间分布、数量及随时间的变化，可以在疾病发生功能、代谢等早期改变阶段，从分子水平发现病变，故称之为生化显像或分子显像。除了灵敏度高，可以早期（比临床提前数月乃至数年）诊断癌症外，</span><span>PET</span><span style="font-family:宋体;">还可以进行全身断层显像，通过一次检查获得全身各个部位的三维图像。这种检查方式对于了解恶性肿瘤病人有无转移（即临床分期）及寻找原发病灶具有重要意义。</span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">目前临床上最常用的</span><span>PET</span><span style="font-family:宋体;">肿瘤、心肌和脑葡萄糖代谢显像示踪剂是</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">（氟代脱氧葡萄糖）。其他常用的</span><span>PET</span><span style="font-family:宋体;">肿瘤示踪剂还有</span><sup><span>11</span></sup><span>C</span><span>-</span><span style="font-family:宋体;">胆碱、</span><sup><span>11</span></sup><span>C</span><span>-</span><span style="font-family:宋体;">乙酸盐、</span><sup><span>11</span></sup><span>C</span><span>-</span><span style="font-family:宋体;">蛋氨酸，</span><sup><span>18</span></sup><span>F</span><span>-L-</span><span style="font-family:宋体;">酪氨酸和</span><sup><span>11</span></sup><span>C</span><span style="font-family:宋体;">标记的其他氨基酸。</span></p>\r\n<p style="text-indent:21.1pt;"><b><span>1</span></b><b><span style="font-family:宋体;">．</span><sup><span>18</span></sup><span>F</span><span>-FDG PET</span></b><b><span style="font-family:宋体;">肿瘤显像的原理</span><span></span></b></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><sup><span>18</span></sup><span>F</span><span>-</span><span style="font-family:宋体;">氟脱氧葡萄糖（</span><sup><span>18</span></sup><span>F</span><span>-2-fluro-D-deoxy-glucose</span><span style="font-family:宋体;">，</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">，）为葡萄糖代谢示踪剂。</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">在体内的生物学行为与葡萄糖相似。在注入体内后，</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">通过与葡萄糖相同的摄取转运过程进入细胞内。</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">进入细胞后与葡萄糖同样在已糖激酶（</span><span>hexokinase</span><span style="font-family:宋体;">）的作用下被磷酸化形成</span><span>6-</span><span style="font-family:宋体;">磷酸</span><span>-<sup>18</sup>F</span><span>-FDG</span><span style="font-family:宋体;">（</span><span>6-P-<sup>18</sup>F-FDG</span><span style="font-family:宋体;">），但不能被进一步代谢，而滞留堆积在细胞内。细胞对</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">的摄取量与其葡萄糖代谢率成正比，故体内葡萄糖代谢率越高的器官组织，摄取聚集</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">越多。恶性肿瘤细胞的代谢特点之一是高葡萄糖代谢，故能聚集</span><sup> </sup><span style="font-family:宋体;">。可能机制与下述有关：肿瘤细胞膜上葡萄糖转运蛋白（</span><span>glucose transporter, Glut</span><span style="font-family:宋体;">）表达增加，如</span><span>Glut-1,Glut-2,Glut-3</span><span style="font-family:宋体;">等；肿瘤细胞内已糖激酶活性增高；葡萄糖</span><span>-6-</span><span style="font-family:宋体;">磷酸酶活性低（该酶可使</span><span>6-P-<sup>18</sup>F-FDG</span><span style="font-family:宋体;">去磷酸化而释出细胞外）等。</span></p>\r\n<p style="text-indent:21.1pt;text-align:left;" align="left"><b><span>2</span></b><b><span style="font-family:宋体;">．</span></b><b><span style="font-family:宋体;">PET</span></b><b><span style="font-family:宋体;">肿瘤代谢显像的应用价值</span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">临床</span><span>PET</span><span style="font-family:宋体;">研究中，占大多数的是用</span><sup><span>18</span></sup><span>F</span><span>-2-</span><span style="font-family:宋体;">脱氧葡萄糖（</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">）探查肿瘤。绝大部分恶性肿瘤存在着对葡萄糖高代谢倾向，</span><span>FDG</span><span style="font-family:宋体;">作为与葡萄糖结构相似的放射性物质，静脉注射后会在恶性肿瘤中浓聚。由于这一特性，</span><span>PET</span><span style="font-family:宋体;">显像能够分辨恶性肿瘤与正常组织及良性病变。同时也可对复发的肿瘤与周围坏死及瘢痕组织加以区分。在肿瘤化疗、放疗的早期（第一周期结束或全疗程的中期），当形态学检查尚未出现明显变化时，</span><span>PET</span><span style="font-family:宋体;">检查即可发现肿瘤代谢是否已经受到抑制，从而为确定进一步治疗方案提供帮助。目前</span><span>PET</span><span style="font-family:宋体;">已广泛用于肺癌、乳腺癌、肝癌、胰腺癌、结直肠癌、卵巢癌、脑肿瘤、头颈部肿瘤、淋巴瘤等多种肿瘤的诊断、分期和疗效监测。在肿瘤的诊断、鉴别诊断、分级、分期、预后及疗效判断。</span></p>\r\n<p style="text-indent:31.45pt;"><span style="font-family:宋体;">癌症治疗最重要的是早发现，因为早期癌症大多可以治愈。大量研究结果表明，</span><span>1/3</span><span style="font-family:宋体;">癌症可以预防；</span><span>1/3</span><span style="font-family:宋体;">癌症如能及早诊断，则可能治愈；合理有效的治疗可使剩余</span><span>1/3</span><span style="font-family:宋体;">癌症病人的生存期延长、生存质量提高。</span><span>PET</span><span style="font-family:宋体;">为我们早期发现及合理治疗癌症提供了可靠手段。</span><span>PET</span><span style="font-family:宋体;">显像还可用于健康人员的体检，可以早期发现体内存在的微小病灶，尤其是恶性病灶。一旦早期发现、早期诊断，可以使受检者能真正得到早期治疗。</span><b><span></span></b></p>\r\n<p style="text-indent:21.1pt;"><b><span>3</span></b><b><span style="font-family:宋体;">．</span></b><b><span>PET</span></b><b><span style="font-family:宋体;">肿瘤</span></b><b><span style="font-family:宋体;">代谢显像的适应证<span></span></span></b></p>\r\n<p style="text-indent:0.05pt;"><span>1</span><span style="font-family:宋体;">．脏器肿块良恶性的鉴别诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>2</span><span style="font-family:宋体;">．恶性肿瘤分期与分级及肿瘤转移灶的定位诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>3</span><span style="font-family:宋体;">．临床治疗后肿瘤残余或复发的早期诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>4</span><span style="font-family:宋体;">．肿瘤放化疗后局部坏死与存活肿瘤组织的鉴别诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>5</span><span style="font-family:宋体;">．临床疗效的监测、肿瘤耐药性的评价和预后随访。</span></p>\r\n<p style="text-indent:21pt;"><span>6</span><span style="font-family:宋体;">．肿瘤生物学评价，包括肿瘤细胞增殖状态、受体及抗原表达和新药与新技术的客观评价。</span></p>\r\n<p style="text-indent:0.05pt;"><span>PET</span><span style="font-family:宋体;">肿瘤</span><span style="font-family:宋体;">代谢显像</span><span style="font-family:宋体;">无明确禁忌证。</span><b><span></span></b></p>\r\n<p style="text-indent:21pt;"><b><span>4</span></b><b><span style="font-family:宋体;">．标准摄取值（</span><span>SUV</span></b><b><span style="font-family:宋体;">）</span><span></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">标准摄取值（</span><span>the Standardized Uptake Value, SUV</span><span style="font-family:宋体;">）是目前广泛使用的</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">在组织中静态聚集的半定量的测定方法，以量化肿瘤的恶性程度，为病灶的良恶性鉴别、肿瘤治疗监测及不同患者和疾病之间的比较提供客观依据。临床上常将</span><span>SUV&gt;2.5</span><span style="font-family:宋体;">作为恶性病变的判定标准。</span></p>\r\n<p style="text-indent:157.5pt;"><span style="font-family:宋体;">二、</span><span>PET</span><span style="font-family:宋体;">肿瘤代谢显像的优势</span></p>\r\n<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">1</span></b><b><span style="font-family:宋体;">．<span>PET</span></span></b><b><span style="font-family:宋体;">进行恶性肿瘤分型和分期准确率明显高于传统方法</span></b><b><span style="font-family:宋体;"></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">肿瘤组织生长迅速</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">萄糖利用率明显</span><span style="font-family:宋体;">高于正常组织</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">一般说</span><span style="font-family:宋体;">来</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">肿瘤组织的恶性程</span><span style="font-family:宋体;">度越高</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">摄取葡萄糖的</span><span style="font-family:宋体;">能力就越强。因此</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">利</span><span style="font-family:宋体;">用一种和葡萄糖生物学活性极为相似的正电子示踪剂</span><sup><span>18</span></sup><span style="font-family:宋体;">F-FDG </span><span style="font-family:宋体;">可以</span><span style="font-family:宋体;">很好的反映出肿瘤的恶性程度</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">同时还可以准</span><span style="font-family:宋体;">确测定肿瘤有无淋巴结及远处转移。</span><span>PET </span><span style="font-family:宋体;">在判定肿瘤</span><span style="font-family:宋体;">的生物学特性</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">预测和</span><span style="font-family:宋体;">早期发现肿瘤复发等方</span><span style="font-family:宋体;">面具有独特的优势。有</span><span style="font-family:宋体;">资料证实</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">同为组织学</span><span style="font-family:宋体;">分类</span><span> </span><span style="font-family:宋体;">E </span><span style="font-family:宋体;">级的肿瘤</span><span style="font-family:宋体;">，</span><sup><span>18</span></sup><span style="font-family:宋体;">F</span><span style="font-family:宋体;">-</span><span style="font-family:宋体;">FDG</span><span> </span><span style="font-family:宋体;">摄取差别很大</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">其</span><span style="font-family:宋体;">中</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">摄取高者</span><span style="font-family:宋体;"> 2 </span><span style="font-family:宋体;">年成活</span><span style="font-family:宋体;">率已降至</span><span style="font-family:宋体;">0</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">而摄取低者</span><span> </span><span style="font-family:宋体;">5 </span><span style="font-family:宋体;">年生存率达</span><span style="font-family:宋体;"> 80% </span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">这涉及肿瘤生物学特</span><span style="font-family:宋体;">性</span><span style="font-family:宋体;">与临床表现之间的复杂关系</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">单纯依靠形态</span><span style="font-family:宋体;">学、甚至组织形态学检查</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">是难以真实地反映</span><span style="font-family:宋体;">出来的。</span><span></span></p>\r\n<p style="text-indent:21.1pt;"><b><span>2</span></b><b><span style="font-family:宋体;">．</span></b><b><span>PET </span></b><b><span style="font-family:宋体;">显像评价肿瘤的治疗效果和监测肿瘤复发有</span></b><b><span style="font-family:宋体;">独特</span></b><b><span style="font-family:宋体;">优势</span></b><b><span style="font-family:宋体;"></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">恶性肿瘤在放疗、化疗或内分泌治疗后</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">对治疗有反应的瘤组织</span><span style="font-family:宋体;">变性坏死</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">代谢率显著下降</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">在</span><span>PET </span><span style="font-family:宋体;">显像时表现为肿瘤的</span><sup><span>18</span></sup><span style="font-family:宋体;">F-</span><span>FDG </span><span style="font-family:宋体;">摄取较前明显减低。这种表现</span><span style="font-family:宋体;">可以在治疗开始后数日、甚至数小</span><span style="font-family:宋体;">时后表现出来</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">因此</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">可在治疗开始</span><span style="font-family:宋体;">后早期为临床医生提供治疗是否有效的客观依据</span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">协助医生制定下一</span><span style="font-family:宋体;">步的治疗计划</span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">而不必等待数周或数月</span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">通过肿瘤体积的变化来判断治疗结果。</span><span></span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">在肿瘤治疗后</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">在瘤组织局部</span><span style="font-family:宋体;">和周围会遗留一些纤维化的癫痕组</span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">这些组织在大体形态上与复发</span><span style="font-family:宋体;">的肿瘤组织很相似</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">用常规影像学</span><span style="font-family:宋体;">方法很难鉴别</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">PET </span><span style="font-family:宋体;">可以特异</span><span style="font-family:宋体;">地显示复发灶的高代谢和</span><span style="font-family:宋体;">癍</span><span style="font-family:宋体;">痕低代</span><span style="font-family:宋体;">谢灶</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">特</span><span style="font-family:宋体;">点</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">从而有助于鉴别诊断。</span><span></span></p>\r\n<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">3</span></b><b><span style="font-family:宋体;">．<span>PET</span></span></b><b><span style="font-family:宋体;">是一种安全、</span></b><b><span style="font-family:宋体;">无创伤的</span></b><b><span style="font-family:宋体;">技术</span></b><b><span style="font-family:宋体;"></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">在进行</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查过程中</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">受检者</span><span style="font-family:宋体;">只需要经静脉注射药物</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">不需要承受其他</span><span style="font-family:宋体;">痛苦。</span><span>PET</span><span style="font-family:宋体;">显像所用放射性核素的半衰期很短（</span><span>2</span><span style="font-family:宋体;">分钟</span><span>-110</span><span style="font-family:宋体;">分钟），</span><span style="font-family:宋体;">衰变</span><span style="font-family:宋体;">和排泄</span><span style="font-family:宋体;">很快</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">其在受检者体内存留时间不长，</span><span style="font-family:宋体;">对人体不产生任何损害，</span><span style="font-family:宋体;">安全可靠，可以多次重复检查。</span><span style="font-family:宋体;">经大规</span><span style="font-family:宋体;">模</span><span style="font-family:宋体;">临</span><span style="font-family:宋体;">床调查</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">做一次</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">患者</span><span style="font-family:宋体;">所接受的由放射性核素引起的辐射量</span><span style="font-family:宋体;">低于</span><span style="font-family:宋体;">一次</span><span style="font-family:宋体;">CT</span><span style="font-family:宋体;">检查的</span><span style="font-family:宋体;">剂量</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">所以说<span>PET</span>是一种安全无创的检查。</span><span></span></p>\r\n<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">4</span></b><b><span style="font-family:宋体;">．<span>PET </span></span></b><b><span style="font-family:宋体;">检查实际上为患者</span></b><b><span style="font-family:宋体;">节省了医疗费用</span></b><b><span style="font-family:宋体;"></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">PET-CT</span><span style="font-family:宋体;">检查费用</span><span style="font-family:宋体;">较贵，使不少人产生疑虑：作</span><span>PET-CT</span><span style="font-family:宋体;">检查值得吗？有这种疑虑并不奇怪。</span><span style="font-family:宋体;">美国是最早使用</span><span>PET</span><span style="font-family:宋体;">、</span><span>PET-CT</span><span style="font-family:宋体;">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保。随着</span><span>PET</span><span style="font-family:宋体;">、</span><span>PET-CT</span><span style="font-family:宋体;">应用的普及，美国保险公司开始关注并重视该项检查的意义，经过对</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查的费用和效益进</span><span style="font-family:宋体;">行全面</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">调查核算，发现</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查可以对病人进</span><span style="font-family:宋体;">行更加准确的诊断</span><span style="font-family:宋体;">和疗效评估</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">使病人得到及时有效</span><span style="font-family:宋体;">的治疗</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">约有</span><span>40%</span><span style="font-family:宋体;">的肿瘤患者经</span><span>PET</span><span style="font-family:宋体;">检查而改变了临床分期，从而改变了治疗方案，避免了一些不必要的手术和有创性检查，节省了一系列相应费用。</span><span style="font-family:宋体;">仅</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">在肿瘤检查</span><span style="font-family:宋体;">一项</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">每年就可为美国医疗保险节省至少</span><span>2 </span><span style="font-family:宋体;">亿美元。</span><span style="font-family:宋体;"></span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">更重要的是，</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查</span><span style="font-family:宋体;">为</span><span style="font-family:宋体;">我们提供了</span><span style="font-family:宋体;">一条早期发现恶性肿瘤的</span><span style="font-family:宋体;">有效的途经，许多癌症患者因此受益。恶性肿瘤的早期发现和早期治疗不仅可以大大地节省总的治疗费用，其在挽救生命、延长生存时间、提高生活质量方面的作用是无法用价格来衡量的</span><span style="font-family:宋体;">。</span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">（来源：宁波明州医院PET-CT中心，作者：<span style="font-size:10.5pt;font-family:宋体;">孙</span><span style="font-size:10.5pt;font-family:''times new roman'';"> </span><span style="font-size:10.5pt;font-family:宋体;">达）</span><span></span></span></p>', 'gwm', 0, 30),
(185, 'PET-CT的价格效益', '详细介绍', '', '', '2009-11-11 09:59:44', '116.228.141.77', '<p style="text-indent:24pt;"><span style="font-size:12pt;">PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查由于其整套设备（包括</span><span style="font-size:12pt;"> PET </span><span style="font-size:12pt;font-family:宋体;">、螺旋</span><span style="font-size:12pt;"> CT</span><span style="font-size:12pt;font-family:宋体;">、回旋加速器和正电子药物生产线）耗资巨大，</span><span style="font-size:12pt;"> </span><span style="font-size:12pt;font-family:宋体;">且设备维护与运行成本高昂，</span><span style="font-size:12pt;"> </span><span style="font-size:12pt;font-family:宋体;">所以做一次</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查费用较之常规的影像管检查也相对较高，因此</span><span style="font-size:12pt;font-family:宋体;">使不少人产生疑虑：作</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查值得吗？有这种疑虑并不奇怪。</span><span style="font-size:12pt;font-family:宋体;">美国是最早使用</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">、</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保，随着</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">、</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">应用的普及，美国保险公司开始关注并重视该项检查的意义，发现</span><span style="font-size:12pt;font-family:宋体;">PET</span><span style="font-size:12pt;font-family:宋体;">检查可以对病人进</span><span style="font-size:12pt;font-family:宋体;">行更加准确的诊断</span><span style="font-size:12pt;font-family:宋体;">和疗效评估</span><span style="font-size:12pt;font-family:宋体;">，</span><span style="font-size:12pt;font-family:宋体;">使病人得到及时有效</span><span style="font-size:12pt;font-family:宋体;">的治疗</span><span style="font-size:12pt;font-family:宋体;">。</span><span style="font-size:12pt;font-family:宋体;">约有</span><span style="font-size:12pt;">40%</span><span style="font-size:12pt;font-family:宋体;">的肿瘤患者经</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">检查而改变了临床分期，从而改变了治疗方案，避免了一些不必要的手术和有创性检查，节省了一系列相应费用。</span><span style="font-size:12pt;font-family:宋体;">仅</span><span style="font-size:12pt;font-family:宋体;">PET</span><span style="font-size:12pt;font-family:宋体;">在</span><span style="font-size:12pt;font-family:宋体;">肺部</span><span style="font-size:12pt;font-family:宋体;">肿瘤检查</span><span style="font-size:12pt;font-family:宋体;">一项</span><span style="font-size:12pt;font-family:宋体;">，</span><span style="font-size:12pt;font-family:宋体;">每年就可为美国医疗保险节省至少</span><span style="font-size:12pt;">2 </span><span style="font-size:12pt;font-family:宋体;">亿美元。</span><span style="font-size:12pt;font-family:宋体;">此外，</span><span style="font-size:12pt;font-family:宋体;">还有许多国家也有人对</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查的价格</span><span style="font-size:12pt;">-</span><span style="font-size:12pt;font-family:宋体;">效益做过分析，结果也表明</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查的明显优势是节约总的医疗费用。</span><span style="font-size:12pt;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p><span style="font-size:12pt;font-family:宋体;">　</span><span style="font-size:12pt;"><span>&nbsp; </span></span><span style="font-size:12pt;font-family:宋体;">在美国和西欧，许多医疗保险公司都愿意为病人支付</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">在肿瘤疾病和心脏疾病方面的检查费用，目前美国的健康保健经济管理局（</span><span style="font-size:12pt;"> HCFA </span><span style="font-size:12pt;font-family:宋体;">）已承诺对下述疾病的</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查支付费用，包括肺癌（</span><span style="font-size:12pt;"> NSCLC </span><span style="font-size:12pt;font-family:宋体;">）、淋巴瘤、黑色素瘤、结肠癌、乳腺癌、食管癌、头颈部肿瘤、甲状腺癌的诊断、分期及再分期等，肺单发结节（</span><span style="font-size:12pt;"> SPN </span><span style="font-size:12pt;font-family:宋体;">）评价、难治性癫痫患者的术前评价以及在心血管病中的应用。其他疾病如：脑肿瘤、宫颈癌、卵巢癌、胰腺癌、小细胞肺癌、睾丸肿瘤、痴呆、软组织肉瘤等疾病的</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查也将相继被纳入</span><span style="font-size:12pt;"> HCFA </span><span style="font-size:12pt;font-family:宋体;">支付的范围。</span><span style="font-size:12pt;"></span></p><span style="font-size:12pt;font-family:''times new roman'';"><span>&nbsp;&nbsp; </span></span><span style="font-size:12pt;font-family:宋体;">更重要的是<span>，受检者得到的益处往往远大于检查付出的费用。因为通过</span></span><span style="font-size:12pt;font-family:''times new roman'';"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查使病人获得更加准确的诊断和分期，及时合理而有效的治疗，可避免许多不恰当的检查、误诊和误治，结果在总体上除大大减少了病人的医疗费用外，还减少了病人由于不恰当的诊治所带来的痛苦，提高了生活质量</span><span style="font-size:12pt;font-family:''times new roman'';"> , </span><span style="font-size:12pt;font-family:宋体;">更可贵的是争取了极为珍贵的治疗时间。现在欧美国家提出每一百万人口至少要有一台</span><span style="font-size:12pt;font-family:''times new roman'';"> PET </span><span style="font-size:12pt;font-family:宋体;">或</span><span style="font-size:12pt;font-family:''times new roman'';"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">，不少发达国家已达到这一要求。</span>', 'gwm', 0, 61);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(186, 'PET-CT与健康体检', '病例介绍', '', '', '2009-11-11 10:06:34', '116.228.141.77', '<p style="text-indent:24pt;"><span style="font-size:12pt;">PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查由于其整套设备（包括</span><span style="font-size:12pt;"> PET </span><span style="font-size:12pt;font-family:宋体;">、螺旋</span><span style="font-size:12pt;"> CT</span><span style="font-size:12pt;font-family:宋体;">、回旋加速器和正电子药物生产线）耗资巨大，</span><span style="font-size:12pt;"> </span><span style="font-size:12pt;font-family:宋体;">且设备维护与运行成本高昂，</span><span style="font-size:12pt;"> </span><span style="font-size:12pt;font-family:宋体;">所以做一次</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查费用较之常规的影像管检查也相对较高，因此</span><span style="font-size:12pt;font-family:宋体;">使不少人产生疑虑：作</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查值得吗？有这种疑虑并不奇怪。</span><span style="font-size:12pt;font-family:宋体;">美国是最早使用</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">、</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保，随着</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">、</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">应用的普及，美国保险公司开始关注并重视该项检查的意义，发现</span><span style="font-size:12pt;font-family:宋体;">PET</span><span style="font-size:12pt;font-family:宋体;">检查可以对病人进</span><span style="font-size:12pt;font-family:宋体;">行更加准确的诊断</span><span style="font-size:12pt;font-family:宋体;">和疗效评估</span><span style="font-size:12pt;font-family:宋体;">，</span><span style="font-size:12pt;font-family:宋体;">使病人得到及时有效</span><span style="font-size:12pt;font-family:宋体;">的治疗</span><span style="font-size:12pt;font-family:宋体;">。</span><span style="font-size:12pt;font-family:宋体;">约有</span><span style="font-size:12pt;">40%</span><span style="font-size:12pt;font-family:宋体;">的肿瘤患者经</span><span style="font-size:12pt;">PET</span><span style="font-size:12pt;font-family:宋体;">检查而改变了临床分期，从而改变了治疗方案，避免了一些不必要的手术和有创性检查，节省了一系列相应费用。</span><span style="font-size:12pt;font-family:宋体;">仅</span><span style="font-size:12pt;font-family:宋体;">PET</span><span style="font-size:12pt;font-family:宋体;">在</span><span style="font-size:12pt;font-family:宋体;">肺部</span><span style="font-size:12pt;font-family:宋体;">肿瘤检查</span><span style="font-size:12pt;font-family:宋体;">一项</span><span style="font-size:12pt;font-family:宋体;">，</span><span style="font-size:12pt;font-family:宋体;">每年就可为美国医疗保险节省至少</span><span style="font-size:12pt;">2 </span><span style="font-size:12pt;font-family:宋体;">亿美元。</span><span style="font-size:12pt;font-family:宋体;">此外，</span><span style="font-size:12pt;font-family:宋体;">还有许多国家也有人对</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查的价格</span><span style="font-size:12pt;">-</span><span style="font-size:12pt;font-family:宋体;">效益做过分析，结果也表明</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查的明显优势是节约总的医疗费用。</span><span style="font-size:12pt;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p><span style="font-size:12pt;font-family:宋体;">　</span><span style="font-size:12pt;"><span>&nbsp; </span></span><span style="font-size:12pt;font-family:宋体;">在美国和西欧，许多医疗保险公司都愿意为病人支付</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">在肿瘤疾病和心脏疾病方面的检查费用，目前美国的健康保健经济管理局（</span><span style="font-size:12pt;"> HCFA </span><span style="font-size:12pt;font-family:宋体;">）已承诺对下述疾病的</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查支付费用，包括肺癌（</span><span style="font-size:12pt;"> NSCLC </span><span style="font-size:12pt;font-family:宋体;">）、淋巴瘤、黑色素瘤、结肠癌、乳腺癌、食管癌、头颈部肿瘤、甲状腺癌的诊断、分期及再分期等，肺单发结节（</span><span style="font-size:12pt;"> SPN </span><span style="font-size:12pt;font-family:宋体;">）评价、难治性癫痫患者的术前评价以及在心血管病中的应用。其他疾病如：脑肿瘤、宫颈癌、卵巢癌、胰腺癌、小细胞肺癌、睾丸肿瘤、痴呆、软组织肉瘤等疾病的</span><span style="font-size:12pt;"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查也将相继被纳入</span><span style="font-size:12pt;"> HCFA </span><span style="font-size:12pt;font-family:宋体;">支付的范围。</span><span style="font-size:12pt;"></span></p><span style="font-size:12pt;font-family:''times new roman'';"><span>&nbsp;&nbsp; </span></span><span style="font-size:12pt;font-family:宋体;">更重要的是<span>，受检者得到的益处往往远大于检查付出的费用。因为通过</span></span><span style="font-size:12pt;font-family:''times new roman'';"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">检查使病人获得更加准确的诊断和分期，及时合理而有效的治疗，可避免许多不恰当的检查、误诊和误治，结果在总体上除大大减少了病人的医疗费用外，还减少了病人由于不恰当的诊治所带来的痛苦，提高了生活质量</span><span style="font-size:12pt;font-family:''times new roman'';"> , </span><span style="font-size:12pt;font-family:宋体;">更可贵的是争取了极为珍贵的治疗时间。现在欧美国家提出每一百万人口至少要有一台</span><span style="font-size:12pt;font-family:''times new roman'';"> PET </span><span style="font-size:12pt;font-family:宋体;">或</span><span style="font-size:12pt;font-family:''times new roman'';"> PET-CT </span><span style="font-size:12pt;font-family:宋体;">，不少发达国家已达到这一要求。</span>', 'gwm', 0, 19),
(187, '为什么说 PET 检查实际上为患者节省了医疗费用 ?', '检查指南', '', '', '2009-11-11 11:17:12', '116.228.141.77', '<p style="text-indent:21pt;"><span style="font-family:宋体;">&nbsp;PET</span><span style="font-family:宋体;">和与之配套的</span><span style="font-family:宋体;">设备</span><span style="font-family:宋体;">价格昂贵</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">每年</span><span style="font-family:宋体;">的日常管理和维</span><span style="font-family:宋体;">修</span><span style="font-family:宋体;">保养</span><span style="font-family:宋体;">费用</span><span style="font-family:宋体;">亦很高，</span><span style="font-family:宋体;">致使<span>PET</span></span><span style="font-family:宋体;">检查费用</span><span style="font-family:宋体;">较贵</span><span style="font-family:宋体;">。但</span><span style="font-family:宋体;">是通过</span><span style="font-family:宋体;">国内外</span><span style="font-family:宋体;">对</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查的费用和效益进</span><span style="font-family:宋体;">行全面分析</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">结果表明</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">的正确应用</span><span style="font-family:宋体;">可以</span><span style="font-family:宋体;">使</span><span style="font-family:宋体;">病人</span><span style="font-family:宋体;">得到早期、</span><span style="font-family:宋体;">准确的诊断</span><span style="font-family:宋体;">和</span><span style="font-family:宋体;">及时</span><span style="font-family:宋体;">、</span><span style="font-family:宋体;">有效</span><span style="font-family:宋体;">的治疗</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">避免了许多不恰当的检查、误诊</span><span style="font-family:宋体;">和</span><span style="font-family:宋体;">无效</span><span style="font-family:宋体;">治疗</span><span style="font-family:宋体;">，因而</span><span style="font-family:宋体;">从总体上大大节约了医疗费</span><span style="font-family:宋体;">用。</span><span style="font-size:11pt;font-family:宋体;">美国是最早使用</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">、</span><span style="font-size:11pt;">PET-CT</span><span style="font-size:11pt;font-family:宋体;">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保。随着</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">、</span><span style="font-size:11pt;">PET-CT</span><span style="font-size:11pt;font-family:宋体;">应用的普及，美国保险公司开始关注并重视该项检查的意义，对肿瘤患者的医疗费用进行了全面的调查核算，发现经过</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">、</span><span style="font-size:11pt;">PET-CT</span><span style="font-size:11pt;font-family:宋体;">检查的肿瘤患者约有</span><span style="font-size:11pt;">40%</span><span style="font-size:11pt;font-family:宋体;">病人的临床分期发生了改变，从而改变了治疗方案，避免了一些不必要的手术和有创性检查，节省了一系列相应费用，</span><span style="font-family:宋体;">仅</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">在</span><span style="font-family:宋体;">肺部</span><span style="font-family:宋体;">肿瘤检查</span><span style="font-family:宋体;">一项</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">每年就可为美国医疗保险节省至少</span><span>2 </span><span style="font-family:宋体;">亿美元。</span><span style="font-family:宋体;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">另外，</span><span style="font-family:宋体;">恶性肿瘤治疗</span><span style="font-family:宋体;">的关键在于早期发现、早期治疗</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">但是由</span><span style="font-family:宋体;">于恶性肿瘤起病隐匿</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">在病变的早期一般</span><span style="font-family:宋体;">无明显不适症状</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">致使就诊时病变己发展</span><span style="font-family:宋体;">到中晚期</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">从而失去了</span><span style="font-family:宋体;">根治</span><span style="font-family:宋体;">的机会。</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">的问世</span><span style="font-family:宋体;">为</span><span style="font-family:宋体;">我们提供了</span><span style="font-family:宋体;">一条早期发现恶性肿瘤的</span><span style="font-family:宋体;">有效的途经，许多癌症患者因此受益。所以，恶性肿瘤的早期发现和早期治疗不仅可以大大地节省总的治疗费用，其在</span><span style="font-family:宋体;">减少痛苦</span><span style="font-family:宋体;">、</span><span style="font-family:宋体;">挽救生命、延长生存时间、提高生活质量方面的作用是无法用价格来衡量的</span><span style="font-family:宋体;">。<span></span></span></p>', 'gwm', 0, 46),
(188, 'PET/CT能为肿瘤学提供那些信息 ?', '详细介绍', '', '', '2009-11-11 11:39:10', '116.228.141.77', '<p style="text-indent:0.05pt;"><span>1</span><span style="font-family:宋体;">．脏器肿块良恶性的鉴别诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>2</span><span style="font-family:宋体;">．恶性肿瘤分期与分级及肿瘤转移灶的定位诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>3</span><span style="font-family:宋体;">．临床治疗后肿瘤残余或复发的早期诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>4</span><span style="font-family:宋体;">．肿瘤放化疗后局部坏死与存活肿瘤组织的鉴别诊断。</span></p>\r\n<p style="text-indent:0.05pt;"><span>5</span><span style="font-family:宋体;">．临床疗效的监测、肿瘤耐药性的评价和预后随访。</span></p>\r\n<p style="text-indent:0.05pt;"><span>6</span><span style="font-family:宋体;">．肿瘤生物学评价，包括肿瘤细胞增殖状态、受体及抗原表达和新药与新技术的客观评价。</span></p>\r\n<p style="text-indent:0.05pt;"><span style="font-family:宋体;"></span>&nbsp;</p>\r\n<p style="text-indent:0.05pt;"><span style="font-family:宋体;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; （<span style="font-family:宋体;">宁波明州医院</span><span><font face="Times New Roman">PET/CT</font></span><span style="font-family:宋体;">中心</span>）</span></p>', 'gwm', 0, 44),
(189, '中国肿瘤的发展情况与PET-CT', '', '', '', '2009-11-11 11:59:58', '116.228.141.77', '<p style="text-indent:31.45pt;"><span>1975</span><span style="font-family:宋体;">年以前，我国城市居民死亡原因中占第一位的一直是呼吸系统疾病，</span><span>1975</span><span style="font-family:宋体;">年占第一位的是脑血管病，</span><span>1985</span><span style="font-family:宋体;">年是心脏病，进入</span><span>90</span><span style="font-family:宋体;">年代，恶性肿瘤</span><span style="font-family:宋体;">已成为人类健康和生命的主要威</span><span style="font-family:宋体;">胁之一，</span><span style="font-family:宋体;">被列为</span><span style="font-family:宋体;">居民的第一号杀手。在大城市中，每</span><span>4</span><span style="font-family:宋体;">例死亡病人中就有</span><span>1</span><span style="font-family:宋体;">例死于癌症。浙江省恶性肿瘤发病率</span><span>197.3/10</span><span style="font-family:宋体;">万，死亡率</span><span>136/10</span><span style="font-family:宋体;">万，癌症死亡率要比全国平均值高出</span><span>20</span><span style="font-family:宋体;">个点。近几年来浙江省癌症的发病率和死亡率均呈上升趋势，每年新发现病例约</span><span>9</span><span style="font-family:宋体;">万。目前癌症发病的另一特点是呈越来越年青的趋势，且症状也越来越隐蔽，许多中青年发现患了癌症，已是晚期，失去了治疗的最佳时期，以至英年早逝，令人十分惋惜。</span><span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p style="text-indent:31.45pt;"><span style="font-family:宋体;">癌症治疗最重要的是早发现，因为早期癌症大多可以治愈。大量研究结果表明，</span><span>1/3</span><span style="font-family:宋体;">癌症可以预防；</span><span>1/3</span><span style="font-family:宋体;">癌症如能及早诊断，则可能治愈；合理有效的治疗可使剩余</span><span>1/3</span><span style="font-family:宋体;">癌症病人的生存期延长、生存质量提高。临床</span><span>PET</span><span style="font-family:宋体;">应用中，</span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">肿瘤代谢显像占</span><span>85%</span><span style="font-family:宋体;">左右，</span><span>PET</span><span style="font-family:宋体;">为我们早期发现及合理治疗癌症提供了可靠手段。</span></p>', 'gwm', 0, 12),
(190, '18F-FDG PET肿瘤显像的原理', '详细介绍', '', '', '2009-11-11 12:00:52', '116.228.141.77', '<p style="text-align:center;" align="center"><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><b><sup><span style="font-size:14pt;">18</span></sup></b><b><span style="font-size:14pt;">F</span></b><b><span style="font-size:14pt;">-FDG PET</span></b><b><span style="font-size:14pt;font-family:宋体;">肿瘤显像的原理</span></b><b><span style="font-size:14pt;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></b></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span>&nbsp;</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><sup><span>18</span></sup><span>F</span><span>-</span><span style="font-family:宋体;">氟代脱氧葡萄糖（</span><sup><span>18</span></sup><span>F</span><span>-2-fluro-D-deoxy-glucose<sup> </sup></span><span style="font-family:宋体;">，</span> <sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">，）为葡萄糖代谢示踪剂。</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">是葡萄糖的类似物，其在体内的生物学行为也与葡萄糖相似。经静脉注射引入体内后，</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">通过与葡萄糖相同的摄取转运过程进入细胞内，在已糖激酶（</span><span>hexokinase</span><span style="font-family:宋体;">）的作用下被磷酸化形成</span><span>6-</span><span style="font-family:宋体;">磷酸</span><span>-<sup>18</sup>FDG</span><span style="font-family:宋体;">（</span><span>6-P-<sup>18</sup>FDG</span><span style="font-family:宋体;">）。但与</span><span>6-</span><span style="font-family:宋体;">磷酸葡萄糖不同的是，</span><span>6-P-<sup>18</sup>FDG</span><span style="font-family:宋体;">不能被进一步代谢，而滞留堆积在细胞内（如图所示）。细胞对</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">的摄取量与其葡萄糖代谢率成正比，故体内葡萄糖代谢率越高的器官组织，摄取聚集</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">越多。恶性肿瘤细胞的代谢特点之一是对葡萄糖的摄取和利用（消耗）较正常组织明显增高，表现为肿瘤部位</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">聚集异常增加，在</span><span>PET</span><span style="font-family:宋体;">显像时就呈现为异常放射性浓聚影。</span></p><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-size:10.5pt;font-family:''times new roman'';"><br />\r\n</span>', 'gwm', 0, 52),
(191, 'PET为什么能早期发现肿瘤?', '', '', '', '2009-11-11 12:02:17', '116.228.141.77', '<p><b><span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">与正常组织相对比</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">肿瘤组织具</span><span style="font-family:宋体;">有突出的生物学特点</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">例如</span><span style="font-family:宋体;">：</span><span style="font-family:宋体;">肿瘤组</span><span style="font-family:宋体;">织生长迅速</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">对</span><span style="font-family:宋体;">DNA</span><span style="font-family:宋体;">合成的前体物</span><span style="font-family:宋体;">质消耗量多</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">肿瘤蛋白的合成速度明</span><span style="font-family:宋体;">显增加等</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">这些变化</span><span style="font-family:宋体;">的发生</span><span style="font-family:宋体;">都早于形态学</span><span style="font-family:宋体;">的改变。</span><span style="font-family:宋体;">PET </span><span style="font-family:宋体;">显像所利用的正电</span><span style="font-family:宋体;">子示踪剂可特异的参加恶性肿瘤的代谢活动</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">可以敏感显示癌组织</span><span style="font-family:宋体;">中特殊的</span><span style="font-family:宋体;">微量</span><span style="font-family:宋体;">代谢变化</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">达到早期诊断肿</span><span style="font-family:宋体;">瘤的目的</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">并能通过观察癌组织特殊</span><span style="font-family:宋体;">代谢在治疗前后的变化</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">对肿瘤治疗</span><span>(</span><span style="font-family:宋体;">手术、放</span><span style="font-family:宋体;">疗、</span><span style="font-family:宋体;">化疗</span><span style="font-family:宋体;">) </span><span style="font-family:宋体;">后的疗效进行监测。</span><span style="font-family:宋体;"></span></p>\r\n<p><span style="font-family:宋体;"><span style="font-size:10.5pt;font-family:''times new roman'';"><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" />&nbsp;<img alt="" src="/image_server_dir/2f64068604e6b4916e53cdda45873372.jpg" border="0" />\r\n<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></span></p>\r\n<p><span></span><span style="font-family:宋体;"></span></p>\r\n<p style="text-indent:22pt;text-align:left;" align="left"><span style="font-size:11pt;font-family:宋体;">患者，男，</span><span style="font-size:11pt;">55</span><span style="font-size:11pt;font-family:宋体;">岁。</span><span style="font-size:11pt;">PET/CT</span><span style="font-size:11pt;font-family:宋体;">健康体检示胃窦部</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">高代谢，提示胃癌可能，建议行胃镜检查明确诊断。胃镜检查提示胃癌。术后病理证实胃癌，局部淋巴结无转移。</span></p>\r\n<p style="text-indent:22pt;text-align:left;" align="left"><span style="font-size:11pt;font-family:宋体;">（来源：宁波明州医院PET-CT中心）</span></p>', 'gwm', 0, 4),
(192, 'PET为什么能早期发现肿瘤?', '详细介绍', '', '', '2009-11-11 12:04:05', '116.228.141.77', '<p><b><span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">与正常组织相对比</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">肿瘤组织具</span><span style="font-family:宋体;">有突出的生物学特点</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">例如</span><span style="font-family:宋体;">：</span><span style="font-family:宋体;">肿瘤组</span><span style="font-family:宋体;">织生长迅速</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">对</span><span style="font-family:宋体;">DNA</span><span style="font-family:宋体;">合成的前体物</span><span style="font-family:宋体;">质消耗量多</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">肿瘤蛋白的合成速度明</span><span style="font-family:宋体;">显增加等</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">这些变化</span><span style="font-family:宋体;">的发生</span><span style="font-family:宋体;">都早于形态学</span><span style="font-family:宋体;">的改变。</span><span style="font-family:宋体;">PET </span><span style="font-family:宋体;">显像所利用的正电</span><span style="font-family:宋体;">子示踪剂可特异的参加恶性肿瘤的代谢活动</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">可以敏感显示癌组织</span><span style="font-family:宋体;">中特殊的</span><span style="font-family:宋体;">微量</span><span style="font-family:宋体;">代谢变化</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">达到早期诊断肿</span><span style="font-family:宋体;">瘤的目的</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">并能通过观察癌组织特殊</span><span style="font-family:宋体;">代谢在治疗前后的变化</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">对肿瘤治疗</span><span>(</span><span style="font-family:宋体;">手术、放</span><span style="font-family:宋体;">疗、</span><span style="font-family:宋体;">化疗</span><span style="font-family:宋体;">) </span><span style="font-family:宋体;">后的疗效进行监测。</span><span style="font-family:宋体;"></span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/6bd8fc8cbd39b2c62ffb7f6508fe81c1.jpg" border="0" />\r\n</span></p>\r\n<p><span></span><span style="font-family:宋体;"></span></p>\r\n<p style="text-indent:22pt;text-align:left;" align="left"><span style="font-size:11pt;font-family:宋体;">患者，男，</span><span style="font-size:11pt;">55</span><span style="font-size:11pt;font-family:宋体;">岁。</span><span style="font-size:11pt;">PET/CT</span><span style="font-size:11pt;font-family:宋体;">健康体检示胃窦部</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">高代谢，提示胃癌可能，建议行胃镜检查明确诊断。胃镜检查提示胃癌。术后病理证实胃癌，局部淋巴结无转移。</span></p>\r\n<p><span style="font-family:宋体;"></span>&nbsp;</p>\r\n<p><span style="font-family:宋体;">（来源：宁波明州医院PET-CT中心）</span></p>', 'gwm', 0, 47),
(193, '为什么说用 PET进行恶性肿瘤分型和分期准确率明显高于传统方法 ?', '详细介绍', '', '', '2009-11-11 12:04:31', '116.228.141.77', '<p style="text-align:center;" align="center"><b><span style="font-size:16pt;font-family:宋体;"></span></b>&nbsp;</p>\r\n<p style="text-indent:22pt;"><span style="font-size:11pt;font-family:宋体;">肿瘤的良恶性鉴别及恶性程度分级甚为重要，不仅关系到治疗方案，也直接影响到患者的预后。如患者肺部有一单个结节良恶性的确定直接影响到是否手术及手术范围的决断。</span><span style="font-family:宋体;">肿瘤组织生长迅速</span><span style="font-family:宋体;">，对</span><span style="font-family:宋体;">萄</span><span style="font-family:宋体;">葡萄糖的</span><span style="font-family:宋体;">利用率明显</span><span style="font-family:宋体;">高于正常组织</span><span style="font-family:宋体;">。通常，其</span><span style="font-family:宋体;">恶性程</span><span style="font-family:宋体;">度越高</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">摄取葡萄糖的</span><span style="font-family:宋体;">能力就越强。因此</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">利</span><span style="font-family:宋体;">用</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">／</span><sup><span style="font-family:宋体;">18</span></sup><span style="font-family:宋体;">F</span><span style="font-family:宋体;">-FDG</span><span style="font-size:11pt;"> </span><span style="font-family:宋体;">葡萄糖</span><span style="font-size:11pt;font-family:宋体;">代谢显像不仅可以鉴别结节的良恶性，也</span><span style="font-family:宋体;">可以</span><span style="font-family:宋体;">很好的反映出肿瘤的恶性程度</span><span style="font-size:11pt;font-family:宋体;">，为临床决策提供可靠的依据。</span></p>\r\n<p><span><span>&nbsp;&nbsp;&nbsp; <img alt="" src="/image_server_dir/36c64dbb5b5e5637bfb083cd441dc601.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/c0f82f0148fd89afc85db17ca49290ae.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/d620e3835a44b5761b4283e432849e73.jpg" border="0" />\r\n</span></span></p>\r\n<p><span><span></span></span>&nbsp;</p>\r\n<p><span style="font-size:15pt;"><span>&nbsp;&nbsp; </span></span><span style="font-size:11pt;font-family:宋体;">男，</span><span style="font-size:11pt;">55</span><span style="font-size:11pt;font-family:宋体;">岁，右上腹胀伴进行性黄疸半月余，</span><span style="font-size:11pt;">MRI</span><span style="font-size:11pt;font-family:宋体;">示：胰头部占位。</span><span style="font-size:11pt;">FDG PET</span><span style="font-size:11pt;font-family:宋体;">－</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">检查胰头局部葡萄糖代谢异常浓聚，首先考虑胰头癌。术后病理证实为中低分化腺癌。</span><span style="font-size:11pt;"></span></p>\r\n<p><span style="font-size:11pt;font-family:宋体;">肿瘤分期是决定患者治疗方案的重要依据。</span><span style="font-family:宋体;">利</span><span style="font-family:宋体;">用</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">／</span><sup><span style="font-family:宋体;">18</span></sup><span style="font-family:宋体;">F</span><span style="font-family:宋体;">-FDG</span><span style="font-size:11pt;"> </span><span style="font-size:11pt;font-family:宋体;">全身</span><span style="font-family:宋体;">葡萄糖</span><span style="font-size:11pt;font-family:宋体;">代谢显像</span><span style="font-family:宋体;">可以准</span><span style="font-family:宋体;">确</span><span style="font-family:宋体;">提供</span><span style="font-family:宋体;">有无淋巴结及</span><span style="font-size:11pt;font-family:宋体;">脑、肺、肝、肾上腺和骨骼等器官</span><span style="font-family:宋体;">远处转移</span><span style="font-size:11pt;font-family:宋体;">的信息</span><span style="font-family:宋体;">。</span><span style="font-size:11pt;font-family:宋体;">有利于对肺癌、乳腺癌、结肠癌、卵巢癌和淋巴瘤等多种肿瘤进行精确的临床分期。以诊断淋巴结转移为例，</span><span style="font-size:11pt;">PET-CT</span><span style="font-size:11pt;font-family:宋体;">更准确，这是因为</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">或</span><span style="font-size:11pt;">MRI</span><span style="font-size:11pt;font-family:宋体;">是将增大的淋巴结（＞</span><span style="font-size:11pt;">1cm</span><span style="font-size:11pt;font-family:宋体;">）视为转移，其中不乏由于慢性炎症引起的淋巴结增大，或将已受到肿瘤组织侵及的正常大小的淋巴结误判为正常，而</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">根据淋巴结的代谢活性判断是否转移，比只考虑病变大小更为准确。</span></p>\r\n<p><span style="font-size:11pt;font-family:宋体;"></span><span style="font-size:11pt;"><img alt="" src="/image_server_dir/9707fda9b598865a8322cf053911d64d.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span></span></p>\r\n<p style="text-indent:22pt;"><span style="font-size:11pt;font-family:宋体;">女性，</span><span style="font-size:11pt;">65</span><span style="font-size:11pt;font-family:宋体;">岁，直肠中分化腺癌术后一年余，</span><span style="font-size:11pt;">CEA</span><span style="font-size:11pt;font-family:宋体;">升高（</span><span style="font-size:11pt;">16.29ug/L</span><span style="font-size:11pt;font-family:宋体;">）。</span><span style="font-size:11pt;">FDG PET-CT</span><span style="font-size:11pt;font-family:宋体;">检查骶前部术后吻合口处增厚肠壁</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">代谢异常浓聚，盆腔右侧</span><span style="font-size:11pt;">1cm</span><span style="font-size:11pt;font-family:宋体;">大小淋巴结</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">代谢异常增高，乙状结肠系膜上软组织结节</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">代谢异常增高，提示直肠癌术后复发伴淋巴结及肠系膜转移。</span><span style="font-size:11pt;"></span></p>\r\n<p style="text-indent:22pt;"><span style="font-size:11pt;"><img alt="" src="/image_server_dir/c6d43c0f056834ee0f881da5529528c0.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span></span></p>\r\n<p><span style="font-size:9pt;"><span>&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:11pt;font-family:宋体;">男性，</span><span style="font-size:11pt;">52</span><span style="font-size:11pt;font-family:宋体;">岁，体检</span><span style="font-size:11pt;">B</span><span style="font-size:11pt;font-family:宋体;">超发现肝脾占位性病变，</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">示后腹膜多发淋巴结肿大。</span><span style="font-size:11pt;">FDG PET-CT</span><span style="font-size:11pt;font-family:宋体;">检查示胰腺周围、腹主动脉旁、脾门、右后颈部、左颌下、右腹股沟及脾内等处多发异常高代谢淋巴结，提示恶性病灶，首先考虑为淋巴瘤。取颈部淋巴结活检证实为非霍杰金氏淋巴瘤（弥漫性</span><span style="font-size:11pt;">B</span><span style="font-size:11pt;font-family:宋体;">细胞型）。</span><span style="font-size:11pt;"></span></p>\r\n<p style="text-indent:22pt;"><span style="font-size:11pt;"></span>&nbsp;</p>\r\n<p style="text-indent:21pt;"><span>PET </span><span style="font-family:宋体;">在判定肿瘤</span><span style="font-family:宋体;">的生物学特性</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">预测和</span><span style="font-family:宋体;">早期发现肿瘤复发等方</span><span style="font-family:宋体;">面具有独特的优势。有</span><span style="font-family:宋体;">资料证实</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">同为组织学</span><span style="font-family:宋体;">分类</span><span> </span><span style="font-family:宋体;">E </span><span style="font-family:宋体;">级的肿瘤</span><span style="font-family:宋体;">，<sup><span>18</span></sup><span>F</span></span><span style="font-family:宋体;">-</span><span style="font-family:宋体;">FDG</span><span> </span><span style="font-family:宋体;">摄取差别很大</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">其</span><span style="font-family:宋体;">中</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">摄取高者</span><span style="font-family:宋体;"> 2 </span><span style="font-family:宋体;">年成活</span><span style="font-family:宋体;">率已降至</span><span style="font-family:宋体;">0</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">而摄取低者</span><span> </span><span style="font-family:宋体;">5 </span><span style="font-family:宋体;">年生存率达</span><span style="font-family:宋体;"> 80% </span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">这涉及肿瘤生物学特</span><span style="font-family:宋体;">性</span><span style="font-family:宋体;">与临床表现之间的复杂关系</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">单纯依靠形态</span><span style="font-family:宋体;">学、甚至组织形态学检查</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">是难以真实地反映</span><span style="font-family:宋体;">出来的。</span><span style="font-size:11pt;"></span></p>', 'gwm', 0, 60),
(194, 'PET 显像评价肿瘤的治疗效果和监测肿瘤复发有哪些优势 ? ', '详细介绍', '', '', '2009-11-11 12:06:07', '116.228.141.77', '<p style="text-align:center;" align="center"><span style="font-size:12pt;font-family:宋体;"></span>&nbsp;</p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;"><span>&nbsp; </span>PET</span><span style="font-size:11pt;font-family:宋体;">／</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">能非常敏感地反映肿瘤组织的代谢特征及其变化，对放疗、化疗疗效的判断更加准确灵敏，有利于指导临床医师及时调整治疗方案。</span><span style="font-family:宋体;">恶性肿瘤在放疗、化疗或内分泌治疗后</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">对治疗有反应的瘤组织</span><span style="font-family:宋体;">变性坏死</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">代谢率显著下降</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">在</span><span>PET </span><span style="font-family:宋体;">显像时表现为肿瘤的</span><span style="font-family:宋体;"> </span><sup><span style="font-family:宋体;">18</span></sup><span style="font-family:宋体;">F</span><span style="font-family:宋体;">-</span><span>FDG </span><span style="font-family:宋体;">摄取较前明显减低。这种表现</span><span style="font-family:宋体;">可以在治疗开始后数日、甚至数小</span><span style="font-family:宋体;">时后表现出来</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">因此</span><span style="font-family:宋体;"> , </span><span style="font-family:宋体;">可在治疗开始</span><span style="font-family:宋体;">后早期为临床医生提供治疗是否有效的客观依据</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">协助医生制定下一</span><span style="font-family:宋体;">步的治疗计划</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">而不必等待数周或数月</span><span> </span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">通过肿瘤体积的变化来判断治疗结果。</span><span style="font-size:12pt;font-family:宋体;"><img alt="" src="/image_server_dir/741f13d4d424ef2ca375a02e1f3994ee.jpg" border="0" />\r\n<span style="font-size:12pt;font-family:宋体;"><img alt="" src="/image_server_dir/da8cbdd41ce4f78b792f849213f27ddc.jpg" border="0" />\r\n</span></span></p>\r\n<p style="text-indent:73.5pt;text-align:left;" align="left"><br />\r\n</p>\r\n<p style="text-indent:18pt;text-align:left;" align="left"><span style="font-size:9pt;font-family:arial;">&nbsp;PET</span><span style="font-size:9pt;font-family:宋体;">：</span><span style="font-size:9pt;font-family:arial;"> </span><span style="font-size:9pt;font-family:宋体;">治疗前</span><span style="font-size:9pt;font-family:arial;"><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:9pt;font-family:宋体;">治疗后</span><span style="font-size:9pt;font-family:arial;">2.7h<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span><span style="font-size:9pt;font-family:宋体;">治疗后</span><span style="font-size:9pt;font-family:arial;">9</span><span style="font-size:9pt;font-family:宋体;">天</span><span style="font-size:9pt;font-family:arial;"><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:9pt;font-family:arial;">CT</span><span style="font-size:9pt;font-family:宋体;">：</span><span style="font-size:9pt;font-family:arial;"> </span><span style="font-size:9pt;font-family:宋体;">治疗前</span><span style="font-size:9pt;font-family:arial;"><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style="font-size:9pt;color:#ffffcc;font-family:宋体;"></span></p>\r\n<p style="text-indent:9pt;"><span style="font-size:9pt;font-family:宋体;">治疗后</span><span style="font-size:9pt;font-family:arial;">6</span><span style="font-size:9pt;font-family:宋体;">月</span><span style="font-size:9pt;"></span></p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;font-family:宋体;">一例垂体泌乳素瘤患者用溴隐停治疗前后的</span><span style="font-size:11pt;">PET</span><span style="font-size:11pt;font-family:宋体;">和</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">检查对比</span><span style="font-size:11pt;"></span></p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;"></span>&nbsp;</p>\r\n<p style="text-indent:10.5pt;"><br />\r\n<span><span>&nbsp; </span></span><span style="font-family:宋体;">在肿瘤治疗后</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">在瘤组织局部</span><span style="font-family:宋体;">和周围会遗留一些纤维化的癫痕组</span><span style="font-family:宋体;">,</span><span style="font-family:宋体;">这些组织在大体形态上与复发</span><span style="font-family:宋体;">的肿瘤组织很相似</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">用常规影像学</span><span style="font-family:宋体;">方法很难鉴别</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">PET </span><span style="font-family:宋体;">可以特异</span><span style="font-family:宋体;">地显示复发灶的高代谢和</span><span style="font-family:宋体;">癍</span><span style="font-family:宋体;">痕低代</span><span style="font-family:宋体;">谢灶</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">特</span><span style="font-family:宋体;">点</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">从而有助于鉴别诊断。</span></p>\r\n<p style="text-indent:10.5pt;"><span style="font-family:宋体;"></span><span><img alt="" src="/image_server_dir/a65960b9c20821a2c5cb087c9edfe3d0.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/21cd1736ce0494a301902eae4bcf4fdd.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/de5fa54a331f04f55b8e59c6d243319a.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;font-family:宋体;">患者</span><span style="font-size:11pt;"> </span><span style="font-size:11pt;font-family:宋体;">男</span><span style="font-size:11pt;"> 67</span><span style="font-size:11pt;font-family:宋体;">岁。左肺上叶癌根治术后</span><span style="font-size:11pt;">6</span><span style="font-size:11pt;font-family:宋体;">个月。病理示：鳞癌</span><span style="font-size:11pt;">II</span><span style="font-size:11pt;font-family:宋体;">～</span><span style="font-size:11pt;">III</span><span style="font-size:11pt;font-family:宋体;">伴坏死。术后健择化疗</span><span style="font-size:11pt;">6</span><span style="font-size:11pt;font-family:宋体;">个疗程。半年后胸部</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">示：左上肺块影，纵隔小淋巴结影。</span><span style="font-size:11pt;">PET/CT</span><span style="font-size:11pt;font-family:宋体;">检查发现左上肺结节无</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">代谢，提示术后疤痕组织。病人随访近一年，结节无明显变化</span> <br />\r\n<span style="font-size:11pt;"></span></p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;"></span>&nbsp;</p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span style="font-family:宋体;">利用</span><span>PET-CT</span><span style="font-family:宋体;">一次成像可以了解全身各部位病灶的特点，除了探查癌症患者有无转移灶外，对于许多先发现转移灶的病人来说，还可以帮助寻找原发灶。</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span style="font-family:宋体;"><img alt="" src="/image_server_dir/bbc13e48f350bc4170a9f6247c5b3caa.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:18pt;text-align:left;" align="left"><span style="font-size:9pt;font-family:arial;"><font size="3"></font></span></p>\r\n<p style="text-indent:11pt;"><span style="font-size:11pt;"><span>&nbsp;</span></span><span style="font-size:11pt;font-family:宋体;">男性，</span><span style="font-size:11pt;">69</span><span style="font-size:11pt;font-family:宋体;">岁，活动后肩胛骨骨折，</span><span style="font-size:11pt;">ECT</span><span style="font-size:11pt;font-family:宋体;">示左侧肩胛骨、</span><span style="font-size:11pt;">T11</span><span style="font-size:11pt;font-family:宋体;">放射性异常浓聚，考虑转移性肿瘤可能。</span><span style="font-size:11pt;">FDG PET-CT</span><span style="font-size:11pt;font-family:宋体;">检查发现左肾下极略高密度占位灶</span><span style="font-size:11pt;">FDG</span><span style="font-size:11pt;font-family:宋体;">代谢异常浓聚，提示骨转移癌原发病灶为肾脏。</span><span style="font-size:11pt;"></span></p>\r\n<p><span style="font-size:11pt;"></span>&nbsp;</p><span style="font-size:10.5pt;font-family:''times new roman'';">（来源：宁波明州医院PET-CT）<br />\r\n</span>', 'gwm', 0, 31);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(195, 'PET-CT对中枢神经系统疾病的诊断', '临床应用', '', '', '2009-11-12 11:34:15', '116.228.141.77', '<p style="text-indent:21pt;"><span style="font-family:宋体;">中枢神经系统</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">特别是</span><span style="font-family:宋体;">大脑</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">在人体中具有十分重</span><span style="font-family:宋体;">要的地位。它是构成许多高级神经活动的基础</span><span> </span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">是神经、</span><span style="font-family:宋体;">精神活动的中心。</span><span> </span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">在</span><span style="font-family:宋体;">局部脑血流、脑</span><span style="font-family:宋体;">代谢、脑</span><span style="font-family:宋体;">受体和脑认知</span><span style="font-family:宋体;">功能</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">研究中具有</span><span style="font-family:宋体;">十分</span><span style="font-family:宋体;">突</span><span style="font-family:宋体;">出的作用。</span><span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p><span>1</span><span style="font-family:宋体;">．癫痫病灶的定位诊断与术前评价。</span></p><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" />\r\n<p style="text-indent:20pt;"><span style="font-family:''times new roman'';">PET</span><span><font face="宋体">对癫痫灶定位有很高的价值。部分性癫痫患者在发作期病灶部位的代谢明显增加，呈放射性浓聚区，而发作间期病灶部位代谢减少，呈低代谢区。因而</font></span><span style="font-family:''times new roman'';">PET</span><span><font face="宋体">脑显像可为癫痫的外科治疗提供可靠的定位依据。采用介入方法，可提高癫痫致痫灶定位的阳性率。</font></span></p>\r\n<p style="text-indent:20pt;"><span><img alt="" src="/image_server_dir/505c926d11fbc7c83757798842e842e9.jpg" border="0" />\r\n</span></p><span></span><span style="font-family:''times new roman'';">\r\n<p style="text-indent:31.5pt;"><span><font face="宋体">癫痫发作间期</font></span><span style="font-family:''times new roman'';"><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><font face="宋体"><span>癫痫发作时</span><span style="font-family:''times new roman'';"></span></font></p>\r\n<p><span>2</span><span style="font-family:宋体;">．痴呆的诊断（包括早期诊断和痴呆严重程度评价）及鉴别诊断。</span></p>\r\n<p style="text-indent:20pt;"><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-family:''times new roman'';">Alzheimer </span><span><font face="宋体">病是最常见的痴呆类型</font></span><span style="font-family:''times new roman'';">PET </span><span><font face="宋体">显像有助于</font></span><span style="font-family:''times new roman'';"> Alzheimer</span><span><font face="宋体">病的早期诊断和鉴别，其典型的表现为双侧额叶、顶叶</font></span><span style="font-family:''times new roman'';">FDG</span><span><font face="宋体">代谢降低，这种表现对</font></span><span style="font-family:''times new roman'';">AD</span><span><font face="宋体">具有诊断价值（尤其双侧对称出现时），诊断准确性约</font></span><span style="font-family:''times new roman'';">80%</span><span><font face="宋体">。</font></span></p>\r\n<p style="text-indent:20pt;"><span></span><span style="font-family:''times new roman'';"><img alt="" src="/image_server_dir/7871b95d8ddcee2b498c25c87348ed1c.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:21pt;"><span>3</span><span style="font-family:宋体;">．脑肿瘤恶性程度的分级判断、术前脑功能及预后评价；治疗后肿瘤复发与放射性坏死或纤维化的鉴别诊断；转移性脑肿瘤的诊断（全身显像有助于寻找肿瘤原发灶和颅外转移灶）。</span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;"><img alt="" src="/image_server_dir/a8f1f72649a71e8f9df54fc133dabada.jpg" border="0" />\r\n</span></p><span style="font-family:宋体;">\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span style="font-family:宋体;">女，</span><span><font face="Times New Roman">65</font></span><span style="font-family:宋体;">岁，进行性言语不清</span><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">月余，右侧肢体活动不灵半月。头颅</span><span><font face="Times New Roman">MRI</font></span><span style="font-family:宋体;">示多发长</span><span><font face="Times New Roman">T1</font></span><span style="font-family:宋体;">长</span><span><font face="Times New Roman">T2</font></span><span style="font-family:宋体;">病灶，慢性病毒感染，占位变不除外。脑</span><span><font face="Times New Roman">PET</font></span><span style="font-family:宋体;">示多处异常浓聚影，符合恶性肿瘤脑转移（肺癌）。</span><span></span></p>\r\n<p><span style="font-family:''times new roman'';">&nbsp;</span></p>\r\n<p><span style="font-family:''times new roman'';">&nbsp;</span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">4</font></span><span style="font-family:宋体;">．脑外伤、脑血管性病变、精神疾病、脑感染性病变（</span><span><font face="Times New Roman">AIDS</font></span><span style="font-family:宋体;">、弓形体病等）、药物成瘾及滥用、酗酒等有关脑功能的评价。</span></p>\r\n<p><span><font face="Times New Roman">5</font></span><span style="font-family:宋体;">．椎体外系疾病如</span><span><font face="Times New Roman">Parkinson</font></span><span style="font-family:宋体;">病、</span><span><font face="Times New Roman">Huntington</font></span><span style="font-family:宋体;">病等诊断与病情评价。</span></p>\r\n<p><span><font face="Times New Roman">6</font></span><span style="font-family:宋体;">．脑认知功能的研究。</span></p>\r\n<p style="text-indent:147pt;"><span style="font-family:宋体;">心肌葡萄糖代谢显像</span><span></span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">1</font></span><span style="font-family:宋体;">．心病心肌缺血的诊断（应与负荷试验结合）。</span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">2</font></span><span style="font-family:宋体;">．肌缺血范围与程度的客观评价与预后判断及心肌梗死区存活心肌的准确判断。</span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">3</font></span><span style="font-family:宋体;">．状动脉再通术前适应证选择的必要指标。</span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">4</font></span><span style="font-family:宋体;">．肌病的鉴别诊断。</span></p>\r\n<p style="text-indent:21pt;"><span><font face="Times New Roman">5</font></span><span style="font-family:宋体;">．心病心力衰竭患者，如药物治疗效果不佳，须考虑血运重建术或心脏移植术，心肌</span><font face="Times New Roman"><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><sup><span>18</span></sup><span>F</span><span>-FDG</span></font><span style="font-family:宋体;">显像有重要参考价值。</span><span></span></p>\r\n<p style="text-indent:21pt;"><img alt="" src="/image_server_dir/763330e1743a6147ba19260615fadf67.jpg" border="0" />\r\n</p>\r\n<p><span><span><font face="Times New Roman">&nbsp;&nbsp;&nbsp; </font></span></span><span style="font-size:9pt;font-family:宋体;">一例左前降支狭窄</span><span style="font-size:9pt;"><font face="Times New Roman">90%</font></span><span style="font-size:9pt;font-family:宋体;">的病人</span><span style="font-size:9pt;"><font face="Times New Roman">PTCA</font></span><span style="font-size:9pt;font-family:宋体;">术前心肌血流灌注显像是心肌前壁灌注受损，但心肌葡萄糖代谢显像正常，表明该部位心肌细胞缺血但仍存活，适合于进行手术治疗。术后</span><span style="font-size:9pt;"><font face="Times New Roman">3</font></span><span style="font-size:9pt;font-family:宋体;">天和</span><span style="font-size:9pt;"><font face="Times New Roman">2</font></span><span style="font-size:9pt;font-family:宋体;">个月复查心肌血流灌注显像和心肌葡萄糖代谢显像均正常，提示手术获得满意效果。</span><span style="font-size:9pt;"></span></p></span></span>', 'gwm', 0, 13),
(196, 'PET-CT与健康人体检', '临床应用', '', '', '2009-11-12 11:36:15', '116.228.141.77', '<p style="text-indent:147pt;"><span style="font-family:宋体;"></span><span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span>&nbsp;</p>\r\n<p style="text-indent:31.5pt;"><span>&nbsp;</span></p>\r\n<p style="text-indent:31.5pt;"><span style="font-size:11pt;font-family:宋体;">疾病的发生发展通常是一个渐近的过程，恶性肿瘤也不例外。从基因突变开始，经过代谢变化、功能损伤、结构异常，最后到临床出现症状。在出现临床症状前的整个过程统称为亚临床期，此时包括</span><span style="font-size:11pt;">B</span><span style="font-size:11pt;font-family:宋体;">超、</span><span style="font-size:11pt;">CT</span><span style="font-size:11pt;font-family:宋体;">、</span><span style="font-size:11pt;">MRI</span><span style="font-size:11pt;font-family:宋体;">及血尿常规检查等在内的常规体检往往不能发现病灶。一旦病灶部位的组织结构出现明显异常，患者出现临床症状，表明疾病进入临床期，此时常规检查就能发现病灶。但遗憾的是，此时，</span><span style="font-size:11pt;">2/3</span><span style="font-size:11pt;font-family:宋体;">的肿瘤患者已处于中晚期，丧失了治疗的最佳时机。</span><span>PET-CT</span><span style="font-family:宋体;">是健康查体的高级手段，</span><span style="font-size:11pt;font-family:宋体;">其灵敏度高、准确性好，</span><span style="font-family:宋体;">能早期发现严重危害生命的癌症和心、脑系统疾病，达到有病早治、无病预防的目的。特别</span><span style="font-size:11pt;font-family:宋体;">对肿瘤，远在没有出现临床症状之前（亚临床期），就能捕捉到微小病灶的早期改变，使恶性肿瘤发现时间提前一年以上，为患者赢得了宝贵的治疗时间和获得治愈的机会。</span></p>\r\n<p style="text-indent:31.5pt;"><span style="font-family:宋体;">日本中湖</span><span>HIMEDIC</span><span style="font-family:宋体;">影像中心首创以</span><span>PET</span><span style="font-family:宋体;">为主，搭配</span><span>CT</span><span style="font-family:宋体;">、</span><span>MRI</span><span style="font-family:宋体;">的健康检查方式，提供休闲健康检查服务。台湾新光医院、日本滨松医院，以及北京、上海和广州多家医院的</span><span>PET</span><span style="font-family:宋体;">中心也提供以</span><span>PET</span><span style="font-family:宋体;">为主的健康检查服务。在有条件的情况下，</span><span>40</span><span style="font-family:宋体;">岁以上的成年人，有肿瘤家族史、致癌物质接触史的高危人群，血清肿瘤标志物不明原因升高者，宜定期将</span><span>PET</span><span style="font-family:宋体;">作为健康体检的主要方法之一。</span></p>\r\n<p style="text-indent:31.5pt;"><span style="font-family:宋体;"><img alt="" src="/image_server_dir/bf0f3316538c0ad76052bfdcd5ac75b1.jpg" border="0" />\r\n</span></p>', 'gwm', 0, 14),
(197, 'PET-CT腰椎TB', '病例介绍', '', '', '2009-11-12 11:44:06', '116.228.141.77', '<p><span style="font-family:宋体;">陈某，男，</span><span>60</span><span style="font-family:宋体;">岁</span></p>\r\n<p><span style="font-family:宋体;">腰背部疼痛</span><span>2</span><span style="font-family:宋体;">月，骨</span><span>ECT</span><span style="font-family:宋体;">显示多发性骨转移灶可能，未发现原发灶，肿瘤全套（－），胸部</span><span>CT</span><span style="font-family:宋体;">（－）。寻找原发灶行</span><span>PET</span><span style="font-family:宋体;">－</span><span>CT</span><span style="font-family:宋体;">检查。</span></p>\r\n<p><span style="font-family:宋体;">报告：</span><span>1.PET</span><span style="font-family:宋体;">显像第</span><span>1</span><span style="font-family:宋体;">、</span><span>2</span><span style="font-family:宋体;">腰椎及右侧腰大肌代谢异常增高，</span><span>CT</span><span style="font-family:宋体;">相应部位骨质破坏伴周围软组织肿胀，考虑结核可能，但恶性肿瘤尚不能完全除外，建议定期复查。</span></p>\r\n<p><span>2.</span><span style="font-family:宋体;">右侧第</span><span>5</span><span style="font-family:宋体;">前肋局部代谢轻度增高，同机</span><span>CT</span><span style="font-family:宋体;">相应部位骨质密度增高，考虑良性病变可能大。</span></p>\r\n<p><span>3.</span><span style="font-family:宋体;">肝囊肿，左肾囊肿，右侧肾盂小结石。</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/3961c3b6a135bf6aefe7d5f46ba4daf3.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/565051afa68a637958cb28551d000efe.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/db4cd8ddd36abcf1a9e1fde982f3e01e.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/d1391d963466fa34823738a3ce4ec36c.jpg" border="0" />\r\n </span></p>', 'gwm', 0, 12),
(198, 'PET-CT与原发性肝癌', '病例介绍', '', '', '2009-11-12 11:48:33', '116.228.141.77', '<p><span style="font-family:宋体;">蔡某，男，</span><span>63</span></p>\r\n<p><span style="font-family:宋体;">感觉上腹部隐痛</span><span>3</span><span style="font-family:宋体;">月余，乏力，纳差，尿黄，乙肝：表面抗原（＋），</span><span>HbeAb</span><span style="font-family:宋体;">（＋），</span><span>HbeAb</span><span style="font-family:宋体;">（＋），</span><span>B</span><span style="font-family:宋体;">超：门静脉矢状部可见</span><span>42</span><span style="font-family:宋体;">×</span><span>19</span><span style="font-family:宋体;">等回声团块充填，肝内可见数个中等偏低回声团块，其中一个</span><span>97</span><span style="font-family:宋体;">×</span><span>98,</span><span style="font-family:宋体;">结论：肝硬化，肝弥漫性巨块形占位，脾大。胃镜：胃底静脉曲张，酒</span><span>2</span><span style="font-family:宋体;">斤</span><span>/ </span><span style="font-family:宋体;">天，烟</span><span>1</span><span style="font-family:宋体;">包</span><span>/</span><span style="font-family:宋体;">天。</span><span>AFP&gt;105000ng/ml</span><span style="font-family:宋体;">。</span></p>\r\n<p><span style="font-family:宋体;">报告：</span><span>1.</span><span style="font-family:宋体;">肝内弥漫性团块状代谢增高灶，符合原发性肝癌表现</span></p>\r\n<p><span>2.</span><span style="font-family:宋体;">肝硬化，脾大，右侧胸腔少量积液，大量腹水</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/9d36351873cff88c1b7157ff27b8775a.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/e105103ec45db5b3c80f4188419640a2.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/e5763b697100e030dbe888ee5faa8a82.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/21428f9f80faaba8896795054990ec0d.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/5b00df21a0f5ea62a53068d82095c3d2.jpg" border="0" />\r\n </span></p>\r\n<p><span style="font-family:宋体;"></span>&nbsp;</p>', 'gwm', 0, 13),
(199, 'PET-CT与肌肉摄取', '临床应用', '', '', '2009-11-12 11:51:16', '116.228.141.77', '<p><span style="font-family:宋体;">俞琳，女，</span><span>37</span><span style="font-family:宋体;">岁</span></p>\r\n<p><span style="font-family:宋体;">健康体检，既往体健，胃炎</span><span>10</span><span style="font-family:宋体;">年</span></p>\r\n<p><span style="font-family:宋体;">报告：</span><span>1.PET</span><span style="font-family:宋体;">（－）</span></p>\r\n<p><span>2.</span><span style="font-family:宋体;">双侧胸椎横突旁肌肉和软组织对称性放射性摄取增高。</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/2a2ed691ce067527854e19150e33e300.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/ea96a8d672ebb500ddcf0e5bd45be756.jpg" border="0" />\r\n</span></p>', 'gwm', 0, 10),
(200, 'PET-CT肺癌', '病例介绍', '', '', '2009-11-12 11:53:40', '116.228.141.77', '<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/311a8bb58d372ebd7c3ae0b071acd715.jpg" border="0" />\r\n厉某，女，</span><span>24</span><span style="font-family:宋体;">岁</span></p>\r\n<p><span style="font-family:宋体;">产后一月，走路时气急，至市一医院检查，</span><span>CT</span><span style="font-family:宋体;">：心包积液，右肺占位</span></p>\r\n<p><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><span>06</span><span style="font-family:宋体;">年</span><span>12</span><span style="font-family:宋体;">月</span><span>8</span><span style="font-family:宋体;">日</span><span style="font-family:宋体;">纤支镜：右肺下叶基底段赘生物，左主支气管狭窄，病理：分化差的癌。</span></p>\r\n<p><span style="font-family:宋体;">报告：</span><span>1.</span><span style="font-family:宋体;">右肺下叶近肺门处代谢异常增高的结节样高密度占位，符合肺癌表现</span></p>\r\n<p><span>2.</span><span style="font-family:宋体;">右侧锁骨上、纵隔内及右侧肺门多发代谢异常增高的淋巴结，部分融合成团，提示淋巴结转移</span></p>\r\n<p><span>3.</span><span style="font-family:宋体;">右侧胸腔及心包少量积液。</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/c2b3ee1292f05a0aa5fe7ab89e62d9e5.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/7e27e66e088c27bd71c88d6b6bc5379d.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/db2418d14b43e91f60a8b95b74f1ff05.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/9ebfb786db4e985661a18a394fc1e5d0.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"><img alt="" src="/image_server_dir/ee087afef1fd172767ebe7ba4ce7fbf7.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-family:宋体;"></span>&nbsp;</p>', 'gwm', 0, 30),
(201, 'PET-CT：肺癌全身转移', '病例介绍', '', '', '2009-11-12 11:56:13', '116.228.141.77', '<p><span style="font-family:宋体;">林某，女，</span><span>68</span><span style="font-family:宋体;">岁</span></p>\r\n<p><span style="font-family:宋体;">反复咳嗽</span><span>2</span><span style="font-family:宋体;">个月，</span><span>CEA900</span><span style="font-family:宋体;">，，左肺支气管镜病理：低分化腺癌。</span></p>\r\n<p style="text-align:left;" align="left"><span style="font-family:宋体;">报告：</span><span style="color:navy;font-family:宋体;">1、左肺下叶FDG代谢增高的软组织肿块伴周围斑片状高密度影，符合肺癌伴周围炎症表现。纵隔内、右侧肺门、左侧锁骨上FDG代谢增高的淋巴结，考虑转移。<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p>\r\n<p style="text-align:left;" align="left"><span style="color:navy;font-family:宋体;">2、胸骨、双侧肋骨多处、颈胸腰骶椎多处、骨盆多处及双侧股骨上端FDG代谢增高，伴部分骨质破坏，考虑骨转移。</span></p>\r\n<p style="text-align:left;" align="left"><span style="color:navy;font-family:宋体;">3、左侧肾上腺增大，FDG代谢增高，考虑转移。</span></p>\r\n<p><span style="color:navy;font-family:宋体;">4、左侧胸腔少量积液。</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/6314453e42d35f9dd6374ba9af3b50db.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/f74d13b8f0f796f173c65f08c79b879a.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/07e202f02a4ef39bc0108f4de1f4818c.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/835c7a7e27cf24c9fa3faeb0e7f97db6.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/04abaa5dc0cf429b769e068a84eae4d7.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"><img alt="" src="/image_server_dir/d99cfee7374d56c3aa6724abdde9bc67.jpg" border="0" />\r\n</span></p>\r\n<p><span style="color:navy;font-family:宋体;"></span>&nbsp;</p>', 'gwm', 0, 20),
(202, 'PET-CT检查适应证', '详细介绍', '', '', '2009-11-12 13:12:57', '116.228.141.77', '<p style="text-indent:144.55pt;"><b><span style="font-size:16pt;font-family:方正舒体;">PET-CT</span></b><b><span style="font-size:16pt;font-family:方正舒体;">检查适应证<span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></span></b></p>\r\n<p style="text-indent:70.85pt;text-align:center;" align="center"><b><sup><span>&nbsp;</span></sup></b></p>\r\n<p style="text-indent:129pt;"><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><b><sup><span style="font-size:12pt;">18</span></sup></b><b><span style="font-size:12pt;">F</span></b><b><span style="font-size:12pt;">-FDG PET</span></b><b><span style="font-size:12pt;font-family:宋体;">肿瘤显像</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:36.15pt;"><b><span style="font-size:12pt;font-family:宋体;">适应证：</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">1</span><span style="font-size:12pt;font-family:宋体;">．脏器肿块良恶性的鉴别诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">2</span><span style="font-size:12pt;font-family:宋体;">．恶性肿瘤分期与分级及肿瘤转移灶的定位诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">3</span><span style="font-size:12pt;font-family:宋体;">．临床治疗后肿瘤残余或复发的早期诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">4</span><span style="font-size:12pt;font-family:宋体;">．肿瘤放化疗后局部坏死与存活肿瘤组织的鉴别诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">5</span><span style="font-size:12pt;font-family:宋体;">．临床疗效的监测、肿瘤耐药性的评价和预后随访。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:36pt;"><span style="font-size:12pt;">6</span><span style="font-size:12pt;font-family:宋体;">．肿瘤生物学评价，包括肿瘤细胞增殖状态、受体及抗原表达和新药与新技术的客观评价。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:12.05pt;"><b><span style="font-size:12pt;font-family:宋体;">禁忌证：</span></b><span style="font-size:12pt;font-family:宋体;">无明确禁忌证。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:80.65pt;"><span style="font-size:12pt;">&nbsp;</span></p>\r\n<p style="text-indent:140.6pt;"><b><sup><span style="font-size:12pt;">18</span></sup></b><b><span style="font-size:12pt;">F</span></b><b><span style="font-size:12pt;">-FDG PET </span></b><b><span style="font-size:12pt;font-family:宋体;">脑显像</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:12.05pt;"><b><span style="font-size:12pt;font-family:宋体;">适应证：</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">1</span><span style="font-size:12pt;font-family:宋体;">．癫痫病灶的定位诊断与术前评价。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">2</span><span style="font-size:12pt;font-family:宋体;">．痴呆的诊断（包括早期诊断和痴呆严重程度评价）及鉴别诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">3</span><span style="font-size:12pt;font-family:宋体;">．脑肿瘤恶性程度的分级判断、术前脑功能及预后评价；治疗后肿瘤复发与放射性坏死或纤维化的鉴别诊断；转移性脑肿瘤的诊断（全身显像有助于寻找肿瘤原发灶和颅外转移灶）。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">4</span><span style="font-size:12pt;font-family:宋体;">．脑外伤、脑血管性病变、精神疾病、脑感染性病变（</span><span style="font-size:12pt;">AIDS</span><span style="font-size:12pt;font-family:宋体;">、弓形体病等）、药物成瘾及滥用、酗酒等有关脑功能的评价。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">5</span><span style="font-size:12pt;font-family:宋体;">．椎体外系疾病如</span><span style="font-size:12pt;">Parkinson</span><span style="font-size:12pt;font-family:宋体;">病、</span><span style="font-size:12pt;">Huntington</span><span style="font-size:12pt;font-family:宋体;">病等诊断与病情评价。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">6</span><span style="font-size:12pt;font-family:宋体;">．脑认知功能的研究。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:12.05pt;"><b><span style="font-size:12pt;font-family:宋体;">禁忌证：</span></b><span style="font-size:12pt;font-family:宋体;">无明确禁忌证。</span><span style="font-size:12pt;"></span></p>\r\n<p><span style="font-size:12pt;">&nbsp;</span></p>\r\n<p style="text-align:center;" align="center"><b><sup><span style="font-size:12pt;">18</span></sup></b><b><span style="font-size:12pt;">F</span></b><b><span style="font-size:12pt;">-FDG </span></b><b><span style="font-size:12pt;font-family:宋体;">心肌葡萄糖代谢显像</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:0.05pt;"><b><span style="font-size:12pt;"><span>&nbsp;</span></span></b><b><span style="font-size:12pt;font-family:宋体;">适应证：</span></b><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">1</span><span style="font-size:12pt;font-family:宋体;">．心脏病心肌缺血的诊断（应与负荷试验结合）。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">2</span><span style="font-size:12pt;font-family:宋体;">．心肌缺血范围与程度的客观评价与预后判断及心肌梗死区存活心肌的准确判断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">3</span><span style="font-size:12pt;font-family:宋体;">．冠状动脉再通术前适应证选择的必要指标。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">4</span><span style="font-size:12pt;font-family:宋体;">．心肌病的鉴别诊断。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;">5</span><span style="font-size:12pt;font-family:宋体;">．心脏病心力衰竭患者，如药物治疗效果不佳，须考虑血运重建术或心脏移植术，心肌</span><sup><span style="font-size:12pt;">18</span></sup><span style="font-size:12pt;">F</span><span style="font-size:12pt;">-FDG</span><span style="font-size:12pt;font-family:宋体;">显像有重要参考价值。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:0.05pt;"><span style="font-size:12pt;"><span>&nbsp; </span></span><b><span style="font-size:12pt;font-family:宋体;">禁忌证</span></b><span style="font-size:12pt;font-family:宋体;">：无明确禁忌证。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:21pt;"><span>&nbsp;</span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">摘自中华医学会编著：《临床技术操作规范和医学分册》，人民军医出版社，</span><span>2004</span><span style="font-family:宋体;">年</span><span>3</span><span style="font-family:宋体;">月</span></p>', 'gwm', 0, 80),
(203, 'PET-CT检查典型病例', '病例介绍', '', '', '2009-11-12 13:26:35', '116.228.141.77', '<div class="Section1">\r\n<p style="text-indent:24.1pt;"><b><span style="font-size:12pt;">1</span></b><b><span style="font-size:12pt;font-family:宋体;">．早期诊断和分级：</span></b><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">显像能够早期发现恶性肿瘤，分辨恶性肿瘤与正常组织及良性病变。</span></p>\r\n<p><span><span>&nbsp;&nbsp;&nbsp; <img alt="" src="/image_server_dir/a87db9c3ca2adff74ffda60a21722898.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/0f7c9f9d3c61fd6f5cce541ff1bab969.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/fb19be8d37e8f8655a11edbaee9ffddc.jpg" border="0" />\r\n</span></span></p>\r\n<p><span><span>&nbsp;</span></span><span style="font-size:12pt;"><span>&nbsp;</span></span><span style="font-size:12pt;font-family:宋体;">男，</span><span style="font-size:12pt;">55</span><span style="font-size:12pt;font-family:宋体;">岁，右上腹胀伴进行性黄疸半月余，</span><span style="font-size:12pt;">MRI</span><span style="font-size:12pt;font-family:宋体;">示：胰头部占位。</span><span style="font-size:12pt;">FDG PET</span><span style="font-size:12pt;font-family:宋体;">－</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;font-family:宋体;">检查胰头局部葡萄糖代谢异常浓聚，考虑胰头癌。术后病理证实为中低分化腺癌。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;text-align:left;" align="left"><span style="font-size:12pt;"></span>&nbsp;</p>\r\n<p style="text-indent:24.1pt;"><b><span style="font-size:12pt;">2</span></b><b><span style="font-size:12pt;font-family:宋体;">．鉴别诊断：</span></b><span style="font-size:12pt;font-family:宋体;">可以对复发的肿瘤与周围坏死及瘢痕组织加以区分。</span><b><span style="font-size:12pt;"></span></b></p>\r\n<p style="text-indent:18pt;text-align:left;" align="left"><span style="font-size:9pt;"><span>&nbsp;</span></span><span> <img alt="" src="/image_server_dir/eae932fb9434d3c366f2497168841a16.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;font-family:宋体;">女性，</span><span style="font-size:12pt;">65</span><span style="font-size:12pt;font-family:宋体;">岁，直肠中分化腺癌术后一年余，</span><span style="font-size:12pt;">CEA</span><span style="font-size:12pt;font-family:宋体;">升高（</span><span style="font-size:12pt;">16.29ug/L</span><span style="font-size:12pt;font-family:宋体;">）。</span><span style="font-size:12pt;">FDG PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查<span>骶</span>前部术后吻合口处增厚肠壁</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常浓聚，盆腔右侧淋巴结</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常增高，乙状结肠系膜上软组织结节</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常增高，提示直肠癌术后复发伴淋巴结及肠系膜转移。</span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;font-family:宋体;"></span><span style="font-size:12pt;"><img alt="" src="/image_server_dir/e2631cdb1676c0f4e44766f93e6a9538.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/87f140a5e4b5f9bf335dd78425b4c06c.jpg" border="0" />\r\n</span></p>\r\n<p><span></span></p>\r\n<p><span style="font-size:12pt;font-family:宋体;">男性，</span><span style="font-size:12pt;">62</span><span style="font-size:12pt;font-family:宋体;">岁。体检</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;font-family:宋体;">发现右肺结节。</span><span style="font-size:12pt;">PET-CT</span><span style="font-size:12pt;font-family:宋体;">发现右肺结节影</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常增高，考虑肺癌。术后病理证实为腺癌。</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span></span>&nbsp;</p>\r\n<p style="text-indent:24.1pt;"><b><span style="font-size:12pt;">3</span></b><b><span style="font-size:12pt;font-family:宋体;">．分期：</span></b><span style="font-size:12pt;font-family:宋体;">肿大淋巴结定性、定位及分期，为确定治疗方案提供可靠依据。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24.1pt;"><span style="font-size:12pt;font-family:宋体;"><font face="Times New Roman"><img alt="" src="/image_server_dir/8ed2c4a56f8c2e9e6317fb5ee7734a7e.jpg" border="0" />\r\n</font></span></p>\r\n<p style="text-indent:24.1pt;"><span style="font-size:12pt;font-family:宋体;">男性，</span><span style="font-size:12pt;">52</span><span style="font-size:12pt;font-family:宋体;">岁，体检</span><span style="font-size:12pt;">B</span><span style="font-size:12pt;font-family:宋体;">超发现肝脾占位性病变，</span><span style="font-size:12pt;">CT</span><span style="font-size:12pt;font-family:宋体;">示后腹膜多发淋巴结肿大。</span><span style="font-size:12pt;">FDG PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查示胰腺周围、腹主动脉旁、脾门、右后颈部、左颌下、右腹股沟及脾内等处多发异常高代谢淋巴结，提示恶性病灶，首先考虑为淋巴瘤。取颈部淋巴结活检证实为非霍杰金氏淋巴瘤（弥漫性</span><span style="font-size:12pt;">B</span><span style="font-size:12pt;font-family:宋体;">细胞型）。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;"><span style="font-size:12pt;"></span>&nbsp;</p>\r\n<p style="text-indent:24.1pt;text-align:left;" align="left"><b><span style="font-size:12pt;">4</span></b><b><span style="font-size:12pt;font-family:宋体;">．寻找原发灶：</span></b><span style="font-size:12pt;font-family:宋体;">对已明确有肿瘤转移，但原发病灶不明的患者，可帮助寻找肿瘤的原发灶。</span></p>\r\n<p style="text-indent:24.1pt;text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;"></span><span style="font-size:12pt;"><img alt="" src="/image_server_dir/0fc732da40600b69e409cf64073d09d9.jpg" border="0" />\r\n</span></p>\r\n<p style="text-indent:18pt;text-align:left;" align="left"><span style="font-size:9pt;font-family:arial;"></span></p>\r\n<p style="text-indent:24pt;text-align:left;" align="left"><span style="font-size:12pt;font-family:宋体;">男性，</span><span style="font-size:12pt;">69</span><span style="font-size:12pt;font-family:宋体;">岁，活动后肩胛骨骨折，</span><span style="font-size:12pt;">ECT</span><span style="font-size:12pt;font-family:宋体;">示左侧肩胛骨、</span><span style="font-size:12pt;">T11</span><span style="font-size:12pt;font-family:宋体;">放射性异常浓聚，考虑转移性肿瘤可能。</span><span style="font-size:12pt;">FDG PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查发现左肾<span>下极略高密度占位灶</span></span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常浓聚，提示骨转移癌原发病灶为肾脏。</span><span style="font-size:12pt;"> </span></p>\r\n<p style="text-indent:24pt;text-align:left;" align="left"><span style="font-size:12pt;"><img alt="" src="/image_server_dir/5f405f3cbea29e3ab2219058e184fc33.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/e0cb24a284ad7ae5c99f9d870c51a86a.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/b3a20e19f7ae41c4ea4d1d1c97354924.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/ce4e0638ffbef9a6f7bb03cc4f978256.jpg" border="0" />\r\n</span></p>\r\n<p><span></span></p>\r\n<p><span></span></p>\r\n<p><span style="font-size:12pt;font-family:宋体;">女性，</span><span style="font-size:12pt;">54</span><span style="font-size:12pt;font-family:宋体;">岁。右股骨下段术后半年，术后病理提示：转移性中分化腺癌。</span><span style="font-size:12pt;">FDG PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查发现左肺上叶</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常增高的结节，提示骨转移癌原发病灶为左肺。并且发现右侧股骨下段及膝关节、左侧股骨上端、右侧腹股沟淋巴结转移。</span><span style="font-size:12pt;"></span></p>\r\n<p style="text-indent:24pt;text-align:left;" align="left"><span style="font-size:12pt;"></span>&nbsp;</p>\r\n<p style="text-indent:24.1pt;text-align:left;" align="left"><b><span style="font-size:12pt;">5</span></b><b><span style="font-size:12pt;font-family:宋体;">、更正诊断</span></b></p>\r\n<p style="text-indent:24.1pt;text-align:left;" align="left"><b><span style="font-size:12pt;font-family:宋体;"></span></b><b><span style="font-size:12pt;"><img alt="" src="/image_server_dir/27848570e67d062418007d3f68888efb.jpg" border="0" />\r\n</span></b></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span></span></p>\r\n<p><span style="font-size:14pt;"><span>&nbsp; </span></span><span style="font-size:12pt;font-family:宋体;">男性，</span><span style="font-size:12pt;">58</span><span style="font-size:12pt;font-family:宋体;">岁，双侧胸部进行性疼痛</span><span style="font-size:12pt;">3</span><span style="font-size:12pt;font-family:宋体;">个月，</span><span style="font-size:12pt;">CA125<span style="font-family:宋体;"><span>升</span></span><span style="font-family:宋体;">高（</span>77.85ug/L</span><span style="font-size:12pt;font-family:宋体;">），全身骨</span><span style="font-size:12pt;">ECT</span><span style="font-size:12pt;font-family:宋体;">显像示双侧前位肋骨串珠样对称性多发放射性异常浓聚，临床考虑转移性肿瘤。</span><span style="font-size:12pt;">FDG PET-CT</span><span style="font-size:12pt;font-family:宋体;">检查示双侧肋骨多处、胸骨、脊柱多个椎体、双侧髂骨及双侧股骨弥漫性</span><span style="font-size:12pt;">FDG</span><span style="font-size:12pt;font-family:宋体;">代谢异常增高伴部分骨质破坏，提示恶性病变，首先考虑多发性骨髓瘤。骨髓穿刺活检证实为骨髓瘤</span><span style="font-size:12pt;"></span></p></div>', 'gwm', 0, 17),
(204, '肿瘤的定性（良、恶性鉴别）诊断：胰头癌', '临床应用', '', '', '2009-11-12 14:47:23', '116.228.141.77', '<h1><span style="color:windowtext;font-family:宋体;"></span><span style="color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span>&nbsp;</h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">&nbsp;</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">男，</span><span style="font-size:14pt;color:windowtext;">55</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，右上腹胀痛伴进行性黄疸半月余。</span><span style="font-size:14pt;color:windowtext;">MRI</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">和</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示胰头部占位，</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超示胰头部低回声团块影，血清肿瘤标志物</span><span style="font-size:14pt;color:windowtext;">CA199&gt;1000U/ml</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">。</span><span style="font-size:14pt;color:windowtext;"></span></h1>\r\n<h2 style="text-indent:0cm;"><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-size:10.5pt;color:windowtext;"></span></h2>\r\n<h2 style="text-indent:0cm;"><span style="font-size:10.5pt;color:windowtext;">&nbsp;<img alt="" src="/image_server_dir/5c9ad0db151ac37c1016f16fdedeb07b.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/9f1201b47b05ec3b4054403c4dcc9c1f.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/8fd24999197578e36732f28f431c567a.jpg" border="0" />\r\n</span></h2>\r\n<h2 style="text-indent:0cm;"><br />\r\n<span style="font-size:10.5pt;color:windowtext;"></span></h2>\r\n<h1><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">－</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示胰头局部葡萄糖代谢异常增高，考虑胰头癌。术后病理证实为胰头中低分化腺癌。</span><span style="font-size:10.5pt;color:windowtext;"></span></h1>', 'gwm', 0, 12),
(205, 'PET-CT对肿瘤的定性（良、恶性鉴别）诊断', '临床应用', '', '', '2009-11-12 14:51:17', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">女，</span><span style="font-size:14pt;color:windowtext;">64</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，上腹部闷胀不适一月余。胸部</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示右肺中叶占位，穿刺活检未找到癌细胞，全身骨显像示第三和第九胸椎、骶骨、左右髂骨、左肱骨、右股骨放射性浓聚，提示多发骨转移。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/01b6c5a0a274a2b34bf9cfcc45513a80.jpg" border="0" />\r\n<img alt="" src="/image_server_dir/75571bba0d4872816f6b242ed5413b5f.jpg" border="0" />\r\n</span></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span><span style="font-size:14pt;color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />\r\n<h1><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示右肺中叶一个大小约</span><span style="font-size:14pt;color:windowtext;">3.3</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">×</span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><span style="font-size:14pt;color:windowtext;">2.7cm</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">的放射性异常浓聚灶，</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值</span><span style="font-size:14pt;color:windowtext;">5.7</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值</span><span style="font-size:14pt;color:windowtext;">5.0</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示相应部位软组织肿块，周围可见不张肺。</span><span style="font-size:14pt;color:windowtext;">PET/CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">另见右下气管旁、隆突下多个肿大淋巴结放射性异常浓聚灶，最大者直径约</span><span style="font-size:14pt;color:windowtext;">1.8</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">×</span><span style="font-size:14pt;color:windowtext;">1.1cm</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值</span><span style="font-size:14pt;color:windowtext;">4.0</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值</span><span style="font-size:14pt;color:windowtext;">3.3</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">；第</span><span style="font-size:14pt;color:windowtext;">9</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">胸椎、骶骨左侧、右侧</span><span style="font-size:14pt;color:windowtext;">5</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">前肋、左侧肱骨头、双侧髂骨翼、左侧耻骨、右侧坐骨、右股骨不同程度的放射性摄取增高，</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">1.2</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">～</span><span style="font-size:14pt;color:windowtext;">3.2</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">1.0</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">～</span><span style="font-size:14pt;color:windowtext;">3.1</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，并见骨质结构不同程度破坏。</span><span style="font-size:14pt;color:windowtext;"></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">结论：考虑右肺癌伴纵隔淋巴结及骨转移。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span></h1>', 'gwm', 0, 29);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(206, 'PET-CT对孤立性肺结节的定性（良、恶性鉴别）诊断', '病例介绍', '', '', '2009-11-12 14:53:23', '116.228.141.77', '<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" />\r\n<h1><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-size:14pt;color:windowtext;font-family:宋体;">男性，</span><span style="font-size:14pt;color:windowtext;">62</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，晨起咳泡沫痰，体检</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">发现右肺结节。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/cb6014523c1787ee09a992c6f4b3f87c.jpg" border="0" />\r\n</span></h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET-CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">：发现右肺结节影</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，考虑肺癌。</span><span style="font-size:14pt;color:windowtext;"></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">手术后病理证实为肺腺癌。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span>\r\n<p><span style="font-size:14pt;color:windowtext;"><strong></strong></span>&nbsp;</p>', 'gwm', 0, 15),
(207, 'PET-CT明确（更正）诊断', '病例介绍', '', '', '2009-11-12 14:57:21', '116.228.141.77', '<p><span style="font-size:14pt;font-family:宋体;">男性，</span><span style="font-size:14pt;font-family:''times new roman'';">58</span><span style="font-size:14pt;font-family:宋体;">岁，双侧胸部进行性疼痛</span><span style="font-size:14pt;font-family:''times new roman'';">3</span><span style="font-size:14pt;font-family:宋体;">个月，</span><span style="font-size:14pt;font-family:''times new roman'';">CA125</span><span style="font-size:14pt;font-family:宋体;">升高（</span><span style="font-size:14pt;font-family:''times new roman'';">77.85 U/ml</span><span style="font-size:14pt;font-family:宋体;">），胸部</span><span style="font-size:14pt;font-family:''times new roman'';">CT</span><span style="font-size:14pt;font-family:宋体;">示胸腔积液，胸腔穿刺抽取积液检测未找到癌细胞，上腹部</span><span style="font-size:14pt;font-family:''times new roman'';">CT</span><span style="font-size:14pt;font-family:宋体;">和腰椎</span><span style="font-size:14pt;font-family:''times new roman'';">MRI</span><span style="font-size:14pt;font-family:宋体;">（－），全身骨骨显像：示双侧前位肋骨串珠样对称性多发放射性异常浓聚灶，考虑转移性肿瘤。</span></p>\r\n<p><span style="font-size:14pt;font-family:宋体;"><img alt="" src="/image_server_dir/27006de4440cf6521a8c4d2622247960.jpg" border="0" />\r\n</span></p>\r\n<p><span style="font-size:14pt;font-family:宋体;"><img alt="" src="/image_server_dir/fef8c6b01cfe75b16d76c66ac19eec38.jpg" border="0" />\r\n</span></p><span style="font-size:14pt;font-family:宋体;">\r\n<h1><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">PET-CT</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示双侧多处肋骨、胸骨、脊柱多个椎体、双侧髂骨及双侧股骨弥漫性</span><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">FDG</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高伴部分骨质破坏，提示恶性病变，首先考虑多发性骨髓瘤。</span><span style="font-size:14pt;color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">骨髓穿刺活检证实为骨髓瘤。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span>', 'gwm', 0, 19),
(208, 'PET-CT应用：肿瘤治疗（手术、化疗）后复查及再分期', '临床应用', '', '', '2009-11-12 15:00:36', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">女性，</span><span style="font-size:14pt;color:windowtext;">65</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，</span><span style="font-size:14pt;color:windowtext;">2002</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">年乳腺癌手术，浸润性导管癌，术后化疗，</span><span style="font-size:14pt;color:windowtext;">2005</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">年直肠癌根治术，高中分化腺癌，术后化疗。腹部</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超和全身</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">（－），血清肿瘤标志物</span><span style="font-size:14pt;color:windowtext;">CEA</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">升高（</span><span style="font-size:14pt;color:windowtext;">16.29 ug/L</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">）。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/2cd5e75108946d99fc48aa08378143eb.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">\r\n<h1><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">PET-CT</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示骶前术后吻合口处肠壁增厚伴</span><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">FDG</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，盆腔右侧淋巴结</span><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">FDG</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，乙状结肠系膜软组织结节</span><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman">FDG</font></span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，提示直肠癌术后复发伴淋巴结及肠系膜转移。</span><span style="font-size:14pt;color:windowtext;"><font face="Times New Roman"> <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></font></span></h1></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span><span style="font-size:14pt;color:windowtext;"></span>&nbsp;</h1>', 'gwm', 0, 27),
(209, 'PET-CT应用：明确诊断', '临床应用', '', '', '2009-11-12 15:02:52', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">女，</span><span style="font-size:14pt;color:windowtext;">30</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，</span><span style="font-size:14pt;color:windowtext;">7</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">月份开始无诱因发热，高热</span><span style="font-size:14pt;color:windowtext;">40</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">度，感体酸，乏力，抗炎治疗无效。先后在宁波和上海多家三级医院做过各种检查，包括</span><span style="font-size:14pt;color:windowtext;">HIV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">、梅毒、类风湿、蛇毒因子、骨髓涂片等。其中骨髓细胞学检查示粒细胞系统增生活跃、红细胞系统增生活跃。血清肿瘤标志物</span><span style="font-size:14pt;color:windowtext;">CEA=24.9ug/L</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">、</span><span style="font-size:14pt;color:windowtext;">CA125=318 U/ ml</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">、</span><span style="font-size:14pt;color:windowtext;">CA153=121 U/L</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，腹部和盆腔</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">均（－），胸部</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示胸腔积液，</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超示脾肿大。曾疑为上呼吸道感染、沙门氏菌感染、风湿性疾病、未分化型结缔组织病、中度贫血等。前后化了三个月时间，上海专家最后会诊意见还是“发热待查，肿瘤待排”。</span></h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span>\r\n<h1><span style="font-size:14pt;color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><img alt="" src="/image_server_dir/5fc9babc03b07bf6fa043ced7a4fbac0.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;"><img alt="" src="/image_server_dir/1bbcbf986dba8a844997003037508844.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">－</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">检查示腹膜后及盆腔内多发大小不等的放射性浓聚灶，最大者</span><span style="font-size:14pt;color:windowtext;">5.5</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">×</span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><span style="font-size:14pt;color:windowtext;">3.3cm</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">值最高为</span><span style="font-size:14pt;color:windowtext;">13.9</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">12.5</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，延迟显像示</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">16.7</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">14.6</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，相应部位</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示多发肿大淋巴结，部分融合成团。提示腹膜后及盆腔多发肿大淋巴结伴</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，考虑为恶性病变。</span><span style="font-size:14pt;color:windowtext;"></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">穿刺病理检查结果示印戒细胞癌。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span></h1>', 'gwm', 0, 22),
(210, 'PET-CT应用：寻找原发肿瘤病灶', '临床应用', '', '', '2009-11-12 15:05:37', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">男性，</span><span style="font-size:14pt;color:windowtext;">69</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，打喷嚏时出现肩胛骨疼痛，</span><span style="font-size:14pt;color:windowtext;">X</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">线检查提示肩胛骨骨折。全身骨显像示左侧肩胛骨、第</span><span style="font-size:14pt;color:windowtext;">11</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">胸椎放射性异常浓聚，考虑转移性肿瘤可能，胸部</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示肩胛骨、第</span><span style="font-size:14pt;color:windowtext;">11</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">胸椎骨质破坏，腰椎</span><span style="font-size:14pt;color:windowtext;">MRI</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示第</span><span style="font-size:14pt;color:windowtext;">11</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">胸椎轻度楔形异常信号。</span></h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span>\r\n<h1><span style="font-size:14pt;color:windowtext;">&nbsp;<img alt="" src="/image_server_dir/8a14506985b6dda76c2f0b40926fa312.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET/CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">检查发现左肾下极略高密度占位灶伴</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，提示原发病灶为左肾癌。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span></h1>', 'gwm', 0, 36),
(211, 'PET-CT应用：寻找原发肿瘤病灶', '临床应用', '', '', '2009-11-12 15:43:49', '116.228.141.77', '<h1><br />\r\n<span style="font-size:14pt;color:windowtext;font-family:宋体;">女性，</span><span style="font-size:14pt;color:windowtext;">54</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，右股骨下段肿瘤术后半年，术后病理示转移性中分化腺癌。胸片和腹部</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超均（—）。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/672210cddfd8391087e148f2ab8b04dc.jpg" border="0" />\r\n </span></h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span>\r\n<h1><span style="font-size:14pt;color:windowtext;">&nbsp;<img alt="" src="/image_server_dir/84e581c9fc915bddb5b2d640d2392bfd.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET-CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">发现左肺上叶</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高结节，提示骨转移原发病灶为左肺癌。</span><span style="font-size:14pt;color:windowtext;">PET-CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">同时还发现右侧股骨下段及膝关节、左侧股骨上端、右侧腹股沟淋巴结转移。</span><span style="font-size:14pt;color:windowtext;"> </span></h1></span></h1>', 'gwm', 0, 31),
(218, 'PET-CT相比单纯PET或CT的优势', '病例介绍', '', '', '2009-11-16 15:16:16', '116.228.141.77', '<p>CT成像</p>\r\n<p>CT主要通过不同组织的物理密度差异来形成图像，故CT可获得高质量的解剖图像（组织密度），分辨率可达毫米范围。但它不能反映组织内部的代谢情况。由此决定了CT具有以下的缺点：</p>\r\n<p>1、 有时不能肯定发现的团块是良性还是恶性。</p>\r\n<p>2 、1cm或1.5cm以下的淋巴结确定是否有肿瘤转移较为困难。</p>\r\n<p>3 、病灶经手术或放疗失去正常结构后，判断肿瘤复发或疤痕有困难。</p>\r\n<p>4 、对治疗疗效的判断不敏感。</p>\r\n<p>&nbsp;</p>\r\n<p>PET显像</p>\r\n<p>PET是通过不同组织对18FDG的摄取不同来形成图像，故PET是一种定量的功能（代谢）成像检查。但其分辨率不及CT，反映解剖结构的能力较差。由此决定了FDG显像具有以下的不足</p>\r\n<p>1、 分辨率不及CT</p>\r\n<p>2、 FDG的摄取并不完全是肿瘤特异性的：</p>\r\n<p>3 、感染和炎症有时会造成FDG摄取增高</p>\r\n<p>4、某些肿瘤有时摄取FDG不增高</p>\r\n<p>&nbsp;</p>\r\n<p>PET/CT显影</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;<img alt="" src="/image_server_dir/5063bc4fe14cf8eebf40a0c8be3763b3.jpg" border="0" />\r\n<br />\r\nPET-CT是通过CT和PET得同机融合，将解剖影像与分子影像有机结合，故可以取PET与CT所长而补其不足，概括来说有如下的优势</p>\r\n<p>1、 能准确地对PET检测到的异常进行空间定位。</p>\r\n<p>2、 不仅具有对异常组织的定位能力，还具有对正常组织的定位能力。</p>\r\n<p>3、 同时进行PET和CT检查，提高检查效率。PET/CT&gt;CT+PET<br />\r\n</p>', 'gwm', 0, 20),
(212, 'PET-CT应用：肿瘤复发与治疗后改变的鉴别诊断', '临床应用', '', '', '2009-11-12 15:45:29', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">女，</span><span style="font-size:14pt;color:windowtext;">58</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，</span><span style="font-size:14pt;color:windowtext;">2004</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">年行升结肠癌手术。自</span><span style="font-size:14pt;color:windowtext;">2006</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">年</span><span style="font-size:14pt;color:windowtext;">3</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">月发现</span><span style="font-size:14pt;color:windowtext;">CEA</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">进行性升高，最高为</span><span style="font-size:14pt;color:windowtext;">93.3 ug/L</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">。</span><span style="font-size:14pt;color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">2006</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">年</span><span style="font-size:14pt;color:windowtext;">12</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">月行肠术后吻合口活检示粘膜慢性炎症，腹部</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超检查阴性，</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示升结肠部位术后改变。</span></h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span>\r\n<h1><span style="font-size:14pt;color:windowtext;"><img alt="" src="/image_server_dir/d089fc4d973d15ffe3e10b9c28f45474.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示右侧髂腰肌前方约第</span><span style="font-size:14pt;color:windowtext;">5</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">腰椎水平处，局部环状及类圆形葡萄糖代谢增高灶，</span><span style="font-size:14pt;color:windowtext;">SUV </span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最大值</span><span style="font-size:14pt;color:windowtext;">3.9</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值</span><span style="font-size:14pt;color:windowtext;">3.6</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">。</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示相应部位不规则软组织肿块，周围脂肪间隙较清。考虑结肠癌术后复发。</span><span style="font-size:12pt;font-family:宋体;"></span></h1></span></h1>', 'gwm', 0, 31),
(213, 'PET-CT：肿瘤复发与治疗后改变的鉴别诊断', '临床应用', '', '', '2009-11-12 15:47:41', '116.228.141.77', '<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" />\r\n<h1><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-size:14pt;color:windowtext;font-family:宋体;">男，</span><span style="font-size:14pt;color:windowtext;">61</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，直肠癌术后</span><span style="font-size:14pt;color:windowtext;">15</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">个月，中分化腺癌，部分粘液腺癌。血清肿瘤标志物</span><span style="font-size:14pt;color:windowtext;">CEA</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">、</span><span style="font-size:14pt;color:windowtext;">CA199</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">进行升高</span><span style="font-size:14pt;color:windowtext;">3</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">个月，下腹部</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示左侧肛提肌区软组织结节影，直肠指检阴性。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/9cb5cd7af8c20dd342f53775ddb0873a.jpg" border="0" />\r\n</span></h1>\r\n<p><span style="font-size:14pt;color:windowtext;"></span>&nbsp;</p>\r\n<p><span style="font-size:14pt;color:windowtext;"><img alt="" src="/image_server_dir/57208293520b9780dfffb005b74bdd29.jpg" border="0" />\r\n</span></p><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示膀胱后方手术区域处团状软组织影，</span><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示相应部位团块状放射性浓聚灶，早期相</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">10.4</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">9.2</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，延迟相</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">16.0</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">11.2</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">。其左后方盆腔壁局部粘膜增厚，</span><span style="font-size:14pt;color:windowtext;">PET</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示异常放射性摄取增高，早期相</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">6.0</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">5.4</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，延迟相</span><span style="font-size:14pt;color:windowtext;">SUV</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">最高值为</span><span style="font-size:14pt;color:windowtext;">7.3</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">，平均值为</span><span style="font-size:14pt;color:windowtext;">6.2</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">。</span><span style="font-size:14pt;color:windowtext;"><br />\r\n</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">提示直肠癌手术区局部异常葡萄糖代谢增高，考虑为肿瘤术后复发。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span>', 'gwm', 0, 25),
(214, 'PET-CT应用:肿瘤术后复查与再分期', '临床应用', '', '', '2009-11-12 15:49:46', '116.228.141.77', '<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;">女性，</span><span style="font-size:14pt;color:windowtext;">65</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，直肠中分化腺癌术后一年余，</span><span style="font-size:14pt;color:windowtext;">CEA</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">升高（</span><span style="font-size:14pt;color:windowtext;">16.29ug/L</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">）。</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"><img alt="" src="/image_server_dir/0d280d33480d69afcb7464ce5dbdac79.jpg" border="0" />\r\n</span></h1>\r\n<p><span style="font-size:10.5pt;color:windowtext;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span>&nbsp;</p><span style="font-size:10.5pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">FDG PET-CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">全身显像示骶前部术后吻合口处增厚肠壁</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常浓聚，盆腔右侧淋巴结</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，乙状结肠系膜上软组织结节</span><span style="font-size:14pt;color:windowtext;">FDG</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">代谢异常增高，提示直肠癌术后复发伴淋巴结及肠系膜转移。</span><span style="font-size:14pt;color:windowtext;"></span></h1>\r\n<p><span style="font-size:10.5pt;font-family:''times new roman'';"><br />\r\n</span></span>&nbsp;</p>', 'gwm', 0, 32),
(215, 'PET-CT：明确诊断', '临床应用', '', '', '2009-11-12 15:52:13', '116.228.141.77', '<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" />\r\n<h1><?xml:namespace prefix = w ns = "urn:schemas-microsoft-com:office:word" /><br />\r\n<span style="font-size:14pt;color:windowtext;font-family:宋体;">男性，</span><span style="font-size:14pt;color:windowtext;">52</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">岁，体检时</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">超检查发现肝、脾占位性病变，</span><span style="font-size:14pt;color:windowtext;">CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示后腹膜多发淋巴结肿大、肝脏及脾脏占位性病变。临床考虑淋巴结转移及肝脏、脾脏转移瘤，拟寻找原发灶。</span></h1><span style="font-size:14pt;color:windowtext;font-family:宋体;"></span>\r\n<h1><span style="font-size:14pt;color:windowtext;"><img alt="" src="/image_server_dir/29e8be25b3a44343645f2bd5c6a008f2.jpg" border="0" />\r\n</span></h1>\r\n<h1><span style="font-size:14pt;color:windowtext;">\r\n<h1><span style="font-size:14pt;color:windowtext;">PET-CT</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">示左颌下、右后颈部、胰腺周围、腹主动脉旁、脾门、右腹股沟及脾多发异常高代谢淋巴结，提示恶性病灶，首先考虑淋巴瘤。后取颈部淋巴结活检，病理结果证实为非霍杰金氏淋巴瘤（弥漫性</span><span style="font-size:14pt;color:windowtext;">B</span><span style="font-size:14pt;color:windowtext;font-family:宋体;">细胞型）。</span><span style="font-size:14pt;color:windowtext;"></span></h1></span></h1>', 'gwm', 0, 29),
(216, 'PET-CT的巨大优势', '临床应用', '', '', '2009-11-12 15:54:48', '116.228.141.77', '<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">有效<span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></span></b></p>\r\n<p style="text-indent:31.45pt;"><span style="font-family:宋体;">葡萄糖是人体最重要的能源物质。用正电子核素</span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><sup><span>18</span></sup><span>F</span><span> </span><span style="font-family:宋体;">标记在葡萄糖上形成</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">（氟代脱氧葡萄糖），是目前应用最广泛的</span><span>PET</span><span style="font-family:宋体;">显像剂。因其可直接参与生理反应，能动态、实时、定量反映活体内器官、组织、细胞和病灶的葡萄糖代谢过程而被誉为“世纪分子”。恶性肿瘤细胞代谢旺盛，对葡萄糖的摄取和利用（消耗）异常增高，因此通过</span><span>PET</span><span style="font-family:宋体;">显像可以早期发现肿瘤原发及其转移病灶，准确鉴别其良恶性，从而正确指导临床决策。</span><span>PET-CT</span><span style="font-family:宋体;">不仅灵敏度、特异性及准确度高，而且可以进行全身扫描，即一次成像了解全身各部位的病灶，为临床提供更为全面、准确的信息。</span></p>\r\n<p style="text-indent:21pt;"><span>&nbsp;</span></p>\r\n<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">安全</span><span></span></b></p>\r\n<p style="text-indent:21pt;"><span>PET</span><span style="font-family:宋体;">检查所用放射性示踪剂的半衰期很短，如最常用的</span><sup><span>18</span></sup><span>F</span><span style="font-family:宋体;">的半衰期仅</span><span>110</span><span style="font-family:宋体;">分钟</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">衰变</span><span style="font-family:宋体;">和排泄</span><span style="font-family:宋体;">很快</span><span style="font-family:宋体;">, </span><span style="font-family:宋体;">在几个小</span><span style="font-family:宋体;">时的时间内就</span><span style="font-family:宋体;">可以</span><span style="font-family:宋体;">完全从人体内消失</span><span style="font-family:宋体;">，对人体</span><span style="font-family:宋体;">的影响</span><span style="font-family:宋体;">极其微</span><span style="font-family:宋体;">小</span><span style="font-family:宋体;">，因而安全可靠</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">经大规</span><span style="font-family:宋体;">模</span><span style="font-family:宋体;">临</span><span style="font-family:宋体;">床调查</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">做一次</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">患者</span><span style="font-family:宋体;">所接受的由放射性核素引起的辐射量</span><span style="font-family:宋体;">低于</span><span style="font-family:宋体;">一次</span><span style="font-family:宋体;">CT</span><span style="font-family:宋体;">检查的</span><span style="font-family:宋体;">剂量</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">所以说<span>PET</span>是一种安全无创的检查。<span></span></span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">&nbsp;</span></p>\r\n<p style="text-indent:21.1pt;"><b><span style="font-family:宋体;">节省</span></b><b><span style="font-family:宋体;">总的</span></b><b><span style="font-family:宋体;">医疗费用</span></b><b><span> </span></b><b><span></span></b></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">PET-CT</span><span style="font-family:宋体;">检查费用</span><span style="font-family:宋体;">较贵，使不少人产生疑虑：作</span><span>PET-CT</span><span style="font-family:宋体;">检查值得吗？有这种疑虑并不奇怪。</span><span style="font-family:宋体;">美国是最早使用</span><span>PET</span><span style="font-family:宋体;">、</span><span>PET-CT</span><span style="font-family:宋体;">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保。随着</span><span>PET</span><span style="font-family:宋体;">、</span><span>PET-CT</span><span style="font-family:宋体;">应用的普及，美国保险公司开始关注并重视该项检查的意义，经过对</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查的费用和效益进</span><span style="font-family:宋体;">行全面</span><span style="font-family:宋体;">的</span><span style="font-family:宋体;">调查核算，发现</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查可以对病人进</span><span style="font-family:宋体;">行更加准确的诊断</span><span style="font-family:宋体;">和疗效评估</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">使病人得到及时有效</span><span style="font-family:宋体;">的治疗</span><span style="font-family:宋体;">。</span><span style="font-family:宋体;">约有</span><span>40%</span><span style="font-family:宋体;">的肿瘤患者经</span><span>PET</span><span style="font-family:宋体;">检查而改变了临床分期，从而改变了治疗方案，避免了一些不必要的手术和有创性检查，节省了一系列相应费用。</span><span style="font-family:宋体;">仅</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">在肿瘤检查</span><span style="font-family:宋体;">一项</span><span style="font-family:宋体;">，</span><span style="font-family:宋体;">每年就可为美国医疗保险节省至少</span><span>2 </span><span style="font-family:宋体;">亿美元。</span><span style="font-family:宋体;"></span></p>\r\n<p style="text-indent:21pt;"><span style="font-family:宋体;">更重要的是，</span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">检查</span><span style="font-family:宋体;">为</span><span style="font-family:宋体;">我们提供了</span><span style="font-family:宋体;">一条早期发现恶性肿瘤的</span><span style="font-family:宋体;">有效的途经，许多癌症患者因此受益。恶性肿瘤的早期发现和早期治疗不仅可以大大地节省总的治疗费用，其在挽救生命、延长生存时间、提高生活质量方面的作用是无法用价格来衡量的</span><span style="font-family:宋体;">。<span></span></span></p>', 'gwm', 0, 35),
(217, 'PET-CT在恶性肿瘤诊断和治疗中的应用', '病例介绍', '', '', '2009-11-12 15:55:33', '116.228.141.77', '<p style="text-indent:31.45pt;"><span style="font-family:宋体;">当前恶性肿瘤已成为人类健康和生命的主要威</span><span style="font-family:宋体;">胁之一</span><span style="font-family:宋体;">，在许多国家都已被列为居民的第一号杀手。</span><span>PET-CT</span><span style="font-family:宋体;">在临床应用中的主要优势就是恶性肿瘤的早期探查、良恶性病灶的鉴别、恶性肿瘤分期、疗效监测、肿瘤残存复发的早期诊断和鉴别、寻找原发灶等。</span></p>\r\n<p style="text-indent:21pt;text-align:left;" align="left"><span>PET</span><span style="font-family:宋体;">肿瘤代谢显像最常用的示踪剂</span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><sup><span>18</span></sup><span>F</span><span>-</span><span style="font-family:宋体;">氟代脱氧葡萄糖（</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">，）是葡萄糖的类似物，其在体内的生物学行为与葡萄糖相似。经静脉注射引入体内后，</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">通过与葡萄糖相同的摄取转运过程进入细胞内，在已糖激酶（</span><span>hexokinase</span><span style="font-family:宋体;">）的作用下被磷酸化形成</span><span>6-</span><span style="font-family:宋体;">磷酸</span><span>-<sup>18</sup>FDG</span><span style="font-family:宋体;">（</span><span>6-P-<sup>18</sup>FDG</span><span style="font-family:宋体;">）。但与</span><span>6-</span><span style="font-family:宋体;">磷酸葡萄糖不同的是，</span><span>6-P-<sup>18</sup>FDG</span><span style="font-family:宋体;">不能被进一步代谢，而滞留堆积在细胞内。细胞对</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">的摄取量与其葡萄糖代谢率成正比，故体内葡萄糖代谢率越高的器官组织，摄取聚集</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">越多。恶性肿瘤细胞的代谢特点之一是对葡萄糖的摄取和利用（消耗）较正常组织明显增高，表现为肿瘤部位</span><sup><span>18</span></sup><span>F</span><span>-FDG</span><span style="font-family:宋体;">聚集异常增加，在</span><span>PET</span><span style="font-family:宋体;">显像时就呈现为异常放射性浓聚影。</span></p>\r\n<p style="text-indent:21pt;"><span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />&nbsp;</span></p>\r\n<p style="text-indent:21pt;"><span>1</span><span style="font-family:宋体;">．<b>恶性肿瘤的早期诊断和良恶性鉴别：</b>癌细胞在恶性增殖期间新陈代谢特别活跃，对葡萄糖（</span><span>FDG</span><span style="font-family:宋体;">）的摄取是正常细胞的至十倍，在</span><span>PET</span><span style="font-family:宋体;">扫描图上呈现为明显的浓聚影（热点）。据此，</span><span>PET-CT</span><span style="font-family:宋体;">显像能够早期发现恶性肿瘤，分辨恶性肿瘤与正常组织及良性病变。</span><span></span></p>\r\n<p style="text-indent:21pt;"><span>2</span><span style="font-family:宋体;">．<b>恶性肿瘤分期及肿瘤转移灶的探查</b>：恶性肿瘤在快速增殖的同时，也会通过各种方式向身体其他部位扩散转移，这些扩散的癌细胞也会高度摄取葡萄糖示踪剂。而</span><span>PET-CT</span><span style="font-family:宋体;">具有一次成像显示全身病灶的优势，可以全面了解恶性肿瘤有无转移到周围淋巴结和全身其他组织器官，为确定治疗方案提供可靠依据。</span></p>\r\n<p style="text-indent:21pt;"><span>3</span><span style="font-family:宋体;">．<b>放化疗后肿瘤残存</b></span><b><span>/</span></b><b><span style="font-family:宋体;">复发与局部坏死</span><span>/</span></b><b><span style="font-family:宋体;">癍痕的鉴别诊断：</span></b><span style="font-family:宋体;">残存或复发的肿瘤仍具有高代谢的特征，因此可以对治疗后肿瘤残存或复发进行早期诊断，并与治疗后无代谢活性的局部组织坏死及瘢痕加以区分。</span></p>\r\n<p style="text-indent:21pt;"><span>4</span><span style="font-family:宋体;">．<b>疗效监测和预后随访</b>：恶性肿瘤在有效治疗后形态学上的变化通常要过半年左右才能表现出来。然而在肿瘤化疗、放疗的早期（第一周期结束或全疗程的中期），当形态学检查尚未出现明显变化时，</span><span>PET</span><span style="font-family:宋体;">检查即可发现肿瘤的代谢是否已经受到抑制，从而为确定进一步治疗方案提供帮助。</span></p>\r\n<p style="text-indent:21pt;"><span>5</span><span style="font-family:宋体;">．<b>适型放疗计划：</b></span><span style="font-family:宋体;">协助放</span><span style="font-family:宋体;">射治疗师</span><span style="font-family:宋体;">更精确地定位肿瘤内部的增殖活性区（</span><span style="font-family:宋体;">生物靶区），帮助制订最佳放疗计划。</span><span></span></p>\r\n<p style="text-indent:21pt;"><span>6</span><span style="font-family:宋体;">．</span><b><span style="font-family:宋体;">寻找</span></b><b><span style="font-family:宋体;">原发灶：</span></b><span style="font-family:宋体;">对</span><span style="font-family:宋体;">于先发现转移性肿瘤，但原发病灶不明的患者，可帮助寻找肿瘤的</span><span style="font-family:宋体;">原发灶。</span></p>\r\n<p style="text-indent:21pt;"><span>7</span><span style="font-family:宋体;">．<b>肿瘤生物学评价</b>：包括肿瘤细胞增殖状态、受体及抗原表达、肿瘤耐药性和新药与新技术的客观评价。</span></p>', 'gwm', 0, 29),
(220, 'PET-CT在肿瘤学的应用价值', '详细介绍', '', '', '2009-11-17 14:47:01', '116.228.141.77', '■早期探测肿块，鉴别良恶性<br />\r\n■早期发现转移灶，对肿瘤进行分期与再分期<br />\r\n■明确肿瘤侵袭范围，优化放射治疗计划<br />\r\n■探测肿瘤生物学行为，预测肿瘤治疗反应<br />\r\n■早期鉴别肿瘤放疗后坏死和复发<br />\r\n■指导临床正确决策，节省总体医疗费用支出', 'gwm', 0, 39),
(221, '同机PET/CT比单纯PET或CT的优势', '详细介绍', '', '', '2009-11-18 12:59:06', '116.228.141.77', '<div>&nbsp;&nbsp; &nbsp;PET-CT是PET和CT得同机融合，那么同机PET-CT比单纯PET或CT有什么优势，我们先来看一组数据：</div><div><div><img src="/image_server_dir/013079482b88f40b7ffa7e4d0858b216.jpg" alt="" border="0" /></div></div><div>从中发现同机PET-CT有如此的优势：</div><div>一、对于40-50% 的患者可提高诊断准确性:</div><div>&nbsp;&nbsp;1、鉴别转移性病灶和生理性摄取</div><div>&nbsp;&nbsp;2、提高PET和CT对于病灶探测的灵敏度</div><div>&nbsp;&nbsp;3、转移病灶的精确定位:</div><div>&nbsp;&nbsp; &nbsp;⑴区分骨骼与软组织</div><div>&nbsp;&nbsp; &nbsp;⑵区分肝脏与肠道的界限</div><div>&nbsp;&nbsp; &nbsp;⑶准确分辨颈部结构</div><div>二、改变了10-20%患者的治疗方案</div>', 'gwm', 0, 41),
(222, '全身MRI 与PET-CT比较', '详细介绍', '', '', '2009-11-18 15:54:23', '116.228.141.77', '<div>&nbsp;&nbsp;■<b>98名患者的前瞻性研究</b></div><div>●TNM 分期:</div><div>&nbsp;&nbsp;△ PET-CT 纠正了 75 例</div><div>&nbsp;&nbsp;△MRI 纠正了53 例</div><div>●治疗方案更改</div><div>&nbsp;&nbsp;△PET-CT : 直接影响 12 例</div><div>&nbsp;&nbsp;△MRI: 直接影响 2 例</div><div>★结论: FDG PET-CT 可作为肿瘤分期的首选方法</div>', 'gwm', 0, 74),
(223, 'PET-CT在肿瘤学上的应用价值', '详细介绍', '', '', '2009-11-18 16:09:00', '116.228.141.77', '<div><p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">早期探测肿块，鉴别良恶性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">早期发现转移灶，对肿瘤进行分期与再分期</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">明确肿瘤侵袭范围，优化放射治疗计划</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">探测肿瘤生物学行为，预测肿瘤治疗反应</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">早期鉴别肿瘤放疗后坏死和复发</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">指导临床正确决策，节省总体医疗费用支出</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:宋体;mso-bidi-font-family:\r\n宋体">&nbsp;</span></p></div>', 'gwm', 0, 64),
(219, 'PET-CT诊断胸部良性肿物', '病例介绍', '', '', '2009-11-16 15:38:00', '116.228.141.77', '<p>■患者女76岁<br />\r\n■因发热伴咳嗽、咳痰入院<br />\r\n■胸部CT（04.3）右上肺占位，局部胸膜<br />\r\n胸壁组织增厚，局部肋骨形态不规则伴<br />\r\n可疑骨质吸收改变，纵隔小淋巴结影。<br />\r\n■&nbsp;X线胸片（04.5）右上侧胸壁肿物影，向<br />\r\n胸腔内生长，与04年3月CT相比，大小变<br />\r\n化不明显。<br />\r\n■患者有银屑病史，长期使用激素<br />\r\n■临床诊断：右上肺占位</p>\r\n<p><img alt="" src="/image_server_dir/dfa1c8fc9612268481bbe6091f84be1a.jpg" border="0" />\r\n</p>\r\n<p>■PET/CT检查后诊断：胸壁良性肿物<br />\r\n■随访：患者一般情况良好</p>', 'gwm', 0, 18),
(224, 'PET-CT诊断结肠癌原位复发', '病例介绍', '', '', '2009-11-18 16:24:05', '116.228.141.77', '61岁女性结肠癌病史怀疑原位复发<div><img src="/image_server_dir/74c0175445729535a637cd7602190121.jpg" alt="" border="0" /></div><div><img src="/image_server_dir/1f4088485f9b44c3dd131bbbe85a63c5.jpg" alt="" border="0" /></div>', 'gwm', 0, 20);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(225, 'PET-CT诊断胸壁良性肿物', '病例介绍', '', '', '2009-11-19 10:54:00', '116.228.141.77', '<div><p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">患者女</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">76</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">岁</span><span lang="EN-US" style="font-size:\r\n13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:\r\n0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">因发热伴咳嗽、咳痰入院</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">胸部</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">CT</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">（</span><span lang="EN-US" style="font-size:\r\n13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:\r\n0pt">04.3</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">）右上肺占位，局部胸膜胸壁组织增厚，局部肋骨形态不规则伴可疑骨质吸收改变，纵隔小淋巴结影。</span></p><p align="left" style="text-align:left;"><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span lang="EN-US" style="font-size:13.5pt;\r\nfont-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">X</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">线胸片（</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">04.5</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">）右上侧胸壁肿物影，向<span style="font-family:simsun;font-size:medium;"><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">胸腔内生长，与</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">04</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">年</span><span lang="EN-US" style="font-size:\r\n13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:\r\n0pt">3</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">月</span><span lang="EN-US" style="font-size:13.5pt;\r\nfont-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">CT</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">相比，大小变化不明显。</span></span></span></p><p align="left" style="text-align:left;"><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">患者有银屑病史，长期使用激素</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"></span></p>\r\n\r\n<p align="left" style="text-align:left;"><span style="font-size:13.5pt;font-family:宋体;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">◆</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">临床诊断：右上肺占位</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"></span></p><p align="left" style="text-align:left;"><font face="宋体" size="5"><span style="font-size:18px;"><img src="/image_server_dir/1c228bc69d0a19287ff093d2a402561a.jpg" alt="" border="0" /></span></font></p><p align="left" style="text-align:left;"><font face="宋体" size="5"><span style="font-size:18px;"></span></font></p><font face="宋体" size="5"><p align="left" style="text-align:left;">◆PET/CT检查后诊断：胸壁良性肿物</p><p align="left" style="text-align:left;">◆随访：患者一般情况良好</p></font><p></p></div>', 'gwm', 0, 17),
(229, 'PET-CT：肺癌术后', '病例介绍', '', '', '2009-11-20 13:11:45', '116.228.141.77', '<p><span lang="EN-US" style="font-family:宋体;mso-bidi-font-family:\r\n宋体">&nbsp;</span></p>\r\n\r\n<p><span style="font-family:宋体;">◆</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">患者</span> <span style="font-family:宋体;mso-ascii-font-family:\r\n&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">男</span><span> 52</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">岁</span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:10.5pt;text-indent:-10.5pt;mso-char-indent-count:\r\n-1.0"><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">◆因痰中带血于外院行胸部</span><span>CT,</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">示：左肺上叶支气管开口类圆形块影，周围见阻塞性炎症，</span><span>04</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">年</span><span>2</span><span style="font-family:\r\n宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">月我院手术，术中见：左肺上叶后段</span><span>6</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">×</span><span>5</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">×</span><span>5cm</span><span style="font-family:宋体;mso-ascii-font-family:\r\n&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿块，左上叶支气管旁及主动脉弓下均有肿大质硬的淋巴结</span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:10.5pt;text-indent:-10.5pt;mso-char-indent-count:\r\n-1.0"><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">◆病理：鳞癌</span><span>III</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">级（中央型</span><span>6</span><span style="font-family:\r\n宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">×</span><span>4</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">×</span><span>4cm</span><span>),</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">累及主支气管，浸润至脏层胸膜外。支气管旁淋巴结（</span><span>1/3</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">）</span><span>,</span><span style="font-family:\r\n宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺下动脉旁淋巴结、主动脉弓下淋巴结各见</span><span>1</span><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">枚癌组织浸润。</span></p>\r\n\r\n<p><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">◆临床诊断：左肺癌术后</span></p><p><font face="宋体"><img src="/image_server_dir/83b010c040c85e025f0205c2d15bdbf1.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/6458da3d46a83cf389dc902e861bde0e.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/1b8e3b0b4ac7aafddab6721c0037f520.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/98084309a5c0701585d63774b15c4468.jpg" alt="" border="0" /></font></p><p><font face="宋体"><p>检查前分期：IIIA</p><p>检查后分期：IIIB</p></font></p>', 'gwm', 0, 19),
(226, 'PET-CT诊断两肺陈旧性病灶', '病例介绍', '', '', '2009-11-19 11:02:31', '116.228.141.77', '<p><span>&nbsp;</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆患者女</span><span>62</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">岁</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆</span><span>04</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">年</span><span>2</span><span style="font-family:宋体;">月因发热、咳痰于外院就诊</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆胸部</span><span>CT</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">示：两肺多发小结节样病变，考虑转移可能性大</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆患者</span><span>88</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">年因子宫肌瘤行子宫及右卵巢切除术</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆目前妇科</span><span>B</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">超，</span><span>PPD</span><span style="font-family:宋体;">，痰找肿瘤脱落细胞、抗酸杆菌皆阴性</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆临床诊断：两肺多发转移癌待排</span><span></span></p><p><font face="宋体"><img src="/image_server_dir/f3b81fec62a9f4b3fb5fb75855bd33b5.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/76051c44d31778ab8398cfe6e919fae5.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/db1c1dd13951dc87c76938ea094d9003.jpg" alt="" border="0" /></font></p><p><font face="宋体"></font></p><font face="宋体"><p>◆PET/CT检查后诊断：两肺陈旧性病灶</p><p>◆随访：患者一般情况良好</p></font><p></p>', 'gwm', 0, 11),
(227, 'PET-CT：炎症吸收后组织机化', '病例介绍', '', '', '2009-11-19 11:37:27', '116.228.141.77', '<p><span>&nbsp;</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆患者女</span><span>62</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">岁</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆</span><span>04</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">年</span><span>2</span><span style="font-family:宋体;">月因发热、咳痰于外院就诊</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆胸部</span><span>CT</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">示：两肺多发小结节样病变，考虑转移可能性大</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆患者</span><span>88</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">年因子宫肌瘤行子宫及右卵巢切除术</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆目前妇科</span><span>B</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">超，</span><span>PPD</span><span style="font-family:宋体;">，痰找肿瘤脱落细胞抗酸杆菌皆阴性</span></p><p><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">◆临床诊断：两肺多发转移癌待排</span><span></span></p>\r\n\r\n<p><span>&nbsp;<img src="/image_server_dir/0c36dc3a9bb129a996926336313a98f6.jpg" alt="" border="0" /></span></p><p><img src="/image_server_dir/d8592bd7dd9d05565e0ad5dc7312360d.jpg" alt="" border="0" /></p><p><img src="/image_server_dir/bc2ffbd830e3b5e5ebe3de384947cd27.jpg" alt="" border="0" /></p><p><img src="/image_server_dir/12a218cba5a94892f8ff38adc1888c02.jpg" alt="" border="0" /></p><p><img src="/image_server_dir/8a6c3d94f4c151e826224409312403d2.jpg" alt="" border="0" /></p><p><img src="/image_server_dir/0fe7a5456b7627792d4937cc59991c9e.jpg" alt="" border="0" /></p><p><img src="/image_server_dir/1c20e5965f696fb570b1f64884a4ace2.jpg" alt="" border="0" /></p><p></p><p><span style="font-family:宋体;">◆</span>PET/CT检查后诊断：两肺陈旧性病灶</p><p><span style="font-family:宋体;">◆</span>随访：患者一般情况良好</p><p></p>', 'gwm', 0, 22),
(228, '', '', '', '', '2009-11-19 11:47:32', '116.228.141.77', '<p><span>&nbsp;</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆患者女</span><span>78</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">岁</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆</span><span>2003</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">年</span><span>12</span><span style="mso-bidi-font-size:13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">月反复咳嗽、咳痰，行胸部</span><span>CT</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆检查示：右下肺后基底段结节影</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆经抗感染治疗后症状消失但结节无明显缩小</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆胸部</span><span>CT</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">（</span><span>04.1</span><span style="mso-bidi-font-size:13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">）：右下肺团块影，炎性改变？建议治疗后复查；纵隔淋巴结增多</span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆胸部</span><span>CT</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">（</span><span>04.2</span><span style="mso-bidi-font-size:13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">）：结果基本同上</span><span></span></p>\r\n\r\n<p><span style="mso-bidi-font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">◆临床诊断：右下肺占位</span><span></span></p><p><font face="宋体"><img src="/image_server_dir/bbc191f109a20fb21746af1f2850516a.jpg" alt="" border="0" /></font></p><p><font face="宋体"><p>◆PET/CT检查后诊断：右下肺基底段结节灶，考虑为炎症吸收后组织机化</p><p>◆随访：患者一般情况良好，多次CT检查未见明显异常变化。</p></font></p>', 'gwm', 0, 0),
(230, 'PET-CT：改变肺癌分期', '病例介绍', '', '', '2009-11-20 13:23:42', '116.228.141.77', '<p><span style="font-family:宋体;">◆ 患者 女<span> 68</span>岁 临床诊断：右肺占位<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">◆<span> 2004</span>年<span>4</span>月体检<span>X</span>线胸片：右下肺野内侧见<span>2</span>×<span>2cm</span>类圆形高密度影<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">◆ 胸部<span>CT</span>：右肺中叶近右心膈角处见一尖端指向肺门的三角形致密影，其间见支气管<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">征；右肺门见一块影，分界不清，右主支气管腔变窄；纵隔未见肿大淋巴结<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">◆ 支气管镜：右中间支气管段下端支气管粘膜肥厚，向腔内生长阻塞管腔，活检病理<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">示：腺癌<span></span></span></p>\r\n\r\n<p><span style="font-family:宋体;">◆<span> PET/CT</span>检查前分期：<span>T1N1M0 IIa</span>期<span></span></span></p><p><font face="宋体"><img src="/image_server_dir/f31c28fb9e53145530708ab2ef92ca94.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/f49c86dc42b90ff61b79087c77155b17.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/08ccb0e59ec359a0732c9568aa4eff5c.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/bfa2ee238f8a7c2fba7d660cfb35256a.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/acb427ab8ff3acd9a26d9bdc2dde1bdf.jpg" alt="" border="0" /></font></p><p><font face="宋体"><img src="/image_server_dir/793345e730ff46c852a3db2d0ff39953.jpg" alt="" border="0" /></font></p><p><font face="宋体">★PET/CT检查后分期：T1N2M1 IV期</font></p>', 'gwm', 0, 22),
(231, '什么是TOF技术？', '', '', '', '2009-11-25 14:55:01', '116.228.141.77', '<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">什么是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF?</span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">即</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">time of fly </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">飞行时间技术。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;;\r\ncolor:#0A1414">在飞行质谱的检测系统中，蛋白芯片根据色谱原理，表面经化学</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">阳离子、阴离子、疏水、亲水和金属离子整合等</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">或生物化学</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">抗体、受体、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">DNA</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">等</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">处理，芯片特异性地和血清中测定蛋白结合，再通过选择性清洗，获得高分辨率的保留蛋白谱</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">第一次分离</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">。当加入能量吸收分子</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(EAM)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">后，芯片上保留的蛋白形成晶体。在特异的激光照射后，晶体发生解离作用，带电分子在通过电场时加速，记录仪记录飞行时间的长短，质量越轻，相对所带的电荷越多</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">质荷比</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">M/Z</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">越小</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">，飞行时间越短。信号由高速的模拟数字转化器传化并记录，被测定的蛋白质以一系列峰的形式呈现，这些特异的峰可看成此类疾病的指纹。单个蛋白在谱图上的位置取决于飞行时间。</span></span><span style="color:#0a1414;"><br />\r\n<span>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">飞行质谱这一技术目前已广泛用于多种疾病，如癌症、老年病、感染性疾病、心血管病和神经系统疾病，认为可以提高多种疾病的诊断率，其中应用于癌症的最多。国外研究人员应用</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">SELDI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">检测了转移性黑色素瘤、肉瘤和肾癌，敏感性达</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">87%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">。他们认为，该方法根据独特的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">～</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">24</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">条蛋白指纹图可以用于多种癌症的诊断，如肝癌、前列腺癌、乳腺癌、膀胱癌、食道癌，其检测限为飞摩尔</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">/</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">升。据报道，美国华盛顿伊丽莎白医院利用该技术检测肺癌，敏感性达</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">98%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">，特异性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">97%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">；美国霍普金斯医学院检测了卵巢癌敏感性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">82%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">，特异性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">98%.</span></span><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;color:#0A1414"><br />\r\n</span><span><span style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;;color:#0A1414">美国科学顾问委员会的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">300</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">多位从事生命科学或医疗一线的研究者普遍认为飞行质谱是一个极有前途的应用技术，将给诊断学带来一场革命或革新，大大改变目前一些疾病如肿瘤、心血管病等诊断落后的情况，前景美好。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">应用于</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">，将</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;color:#0A1414">技术带来极大的进步，主要来说有如下的优势：</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">一、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">通过</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;color:black">个光子到达晶体的飞行时间差来缩小重建范围，实现局部重建，从而压制噪声，提高图像的信噪比，由于信噪比提高了，相当于有效计数的百分比提高了，从而可以缩短扫描时间、减少用药剂量。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">二、，信噪比的提高可以提高图像质量，对小病灶和高本地处的病灶应该都可以看出来。</span></span></p><p><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">三、由于实现了局部重建，所以重建患者的体积没有关系了，可以提高肥胖病人的图像质量。</span></span><span></span></p>', 'gwm', 0, 0);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(232, '诊断性CT在PET/CT中的价值', '详细介绍', '', '', '2009-11-26 09:50:56', '116.228.141.77', '<p><span><span style="font-family:helvetica;color:black;">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">在肿瘤的诊断、分期、再分期及疗效监测等方面具有重要价值，同时其在心血管疾病中的应用、引导肿瘤放疗计划的制订与实施、穿刺活检或介入性治疗等也需要引起我们的足够重视，在有条件的单位宜尽早付诸实施。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p style="text-indent:26.25pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">与常规</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">相比，具有以下优点：</span></span><span><span style="font-family:helvetica;color:black;"></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:44.25pt;text-indent:-18.0pt;mso-list:\r\nl1 level1 lfo1;tab-stops:list 44.25pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-bidi-font-family:宋体;color:black"><span>①<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">显著缩短图像采集时间，增加病人流通量。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:44.25pt;text-indent:-18.0pt;mso-list:\r\nl1 level1 lfo1;tab-stops:list 44.25pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-bidi-font-family:宋体;color:black"><span>②<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">提高病变定位的精确性，有利于对</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">图像作出更好的解释，减少</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的假阳性与假阴性。</span></span><span><span style="font-family:helvetica;color:black;"></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:44.25pt;text-indent:-18.0pt;mso-list:\r\nl1 level1 lfo1;tab-stops:list 44.25pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-bidi-font-family:宋体"><span>③<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">诊断的准确性优于单纯的</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">或单纯的</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">以及</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">与</span></span><span><span style="font-family:helvetica;color:black;">CT\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">的视觉融合。</span></span><span><span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:44.25pt;text-indent:-18.0pt;mso-list:\r\nl1 level1 lfo1;tab-stops:list 44.25pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-bidi-font-family:宋体"><span>④<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的应用可避免</span></span><span><span style="font-family:helvetica;color:black;">FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">摄取阴性肿瘤的漏检。</span></span><span><span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:44.25pt;text-indent:-18.0pt;mso-list:\r\nl1 level1 lfo1;tab-stops:list 44.25pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-bidi-font-family:宋体"><span>⑤<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">可进行肿瘤生物靶体积（</span></span><span><span style="font-family:helvetica;color:black;">BTV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">）的定位，指导放射治疗计划的精确制订。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">中的</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">价值其不仅在于衰减校正及对</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">放射性摄取异常病灶进行精确定位，更重要的是诊断性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">（</span></span><span><span style="font-family:helvetica;color:black;">Diagnostic\r\nCT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">）的价值。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">何谓诊断性</span></span><span><span style="font-family:helvetica;color:black;">CT?\r\n</span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">相对</span></span><span><span style="font-family:helvetica;color:black;">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">中衰减校正</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">技术参数而言，诊断性</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">必须提供足够清晰的解剖图像，</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">管电流提高至</span></span><span><span style="font-family:helvetica;color:black;">200</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">－</span></span><span><span style="font-family:helvetica;color:black;">300mA</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">，静脉注射（</span></span><span><span style="font-family:helvetica;color:black;">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">－</span></span><span><span style="font-family:helvetica;color:black;">3ml/s</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">）</span></span><span><span style="font-family:helvetica;color:black;"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">或口服造影剂。</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">造影剂的应用可以引起</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">图像的伪影及高估</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">发射图像放射性的测量结果，因此诊断性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">可以在完成常规</span></span><span><span style="font-family:helvetica;color:black;">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查后进行。</span></span><span><span style="font-family:helvetica;color:black;"></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:52.5pt;text-indent:-31.5pt;mso-list:l0 level1 lfo2;\r\ntab-stops:list 52.5pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-bidi-font-family:\r\n宋体;color:black"><span>①<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">静脉注射造影剂可以增加病变组织和正常组织间的密度差别，提高病变的检出率；显示病变组织的血供情况，有助于诊断和鉴别诊断；显示肿瘤与周围血管以及邻近器官的关系，有助于术前判断肿瘤的可切除性。随着多层螺旋</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">扫描速度的进一步提高（</span></span><span><span style="font-family:helvetica;color:black;">16</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">层、</span></span><span><span style="font-family:helvetica;color:black;">64</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">层），冠状动脉血管成像的质量将显著改善。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:52.5pt;text-indent:-31.5pt;mso-list:l0 level1 lfo2;\r\ntab-stops:list 52.5pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-bidi-font-family:\r\n宋体"><span>②<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">口服造影剂的应用：上腹部检查提前</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">30</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">分钟口服</span></span><span><span style="font-family:helvetica;color:black;">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">％左右造影剂</span></span><span><span style="font-family:helvetica;color:black;">300ml</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">，充盈中上腹部小肠，扫描前再口服</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">300ml</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">充盈胃及十二指肠；全腹部需在</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">小时内分次口服</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">1500</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">－</span></span><span><span style="font-family:helvetica;color:black;">2000ml</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">造影剂，充盈整个肠管。</span></span><span><span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:52.5pt;text-indent:-31.5pt;mso-list:l0 level1 lfo2;\r\ntab-stops:list 52.5pt"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-bidi-font-family:\r\n宋体"><span>③<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">多层螺旋</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的多期增强扫描有助于病变解剖结构的精确定位和定性，对</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">阴性肿瘤的诊断价值尤为明显，如原发性肝细胞肝癌、肾脏透明细胞癌等。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">造影剂与</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">示踪剂的联合应用无疑会提高对病变的诊断效能。</span></span><span><span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:52.5pt;text-indent:-31.5pt;mso-list:l0 level1 lfo2;\r\ntab-stops:list 52.5pt"><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-bidi-font-family:宋体"><span>④<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">重视利用</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">强大的后处理功能，采用多平面重建（</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">MPR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">）、最大密度投影（</span></span><span><span style="font-family:helvetica;color:black;">MIP</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">）、</span></span><span><span style="font-family:helvetica;color:black;">VRT(</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">容积显示</span></span><span><span style="font-family:helvetica;color:black;">)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">、表面遮盖显示（</span></span><span><span style="font-family:helvetica;color:black;">SSD</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">）及</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">仿真内镜</span></span><span><span style="font-family:helvetica;color:black;">(CTVE)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等可以对病变进行二维及三维多方位显示，将提高对病变的精确定位能力。当需要对病变进行精确定位如制订放疗或手术计划、穿刺活检等，以及肿瘤或其转移灶</span></span><span><span style="font-family:helvetica;color:black;">18F</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">呈假阴性时，诊断性</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的应用尤为重要。</span></span><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt"></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:52.5pt;text-indent:-31.5pt;mso-list:l0 level1 lfo2;\r\ntab-stops:list 52.5pt"><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-bidi-font-family:宋体"><span>⑤<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">作为</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">临床医生，诊断性</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的应用与新型正电子药物的研制开发宜给予同等程度的重视。只有这样，才能充分发挥</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的资源优势，更好地为临床及人类健康服务。</span></span><span></span></p>', 'gwm', 0, 18),
(233, '18F-FDG正电子显像在脑肿瘤的应用价值', '临床应用', '', '', '2009-11-26 10:37:44', '116.228.141.77', '<span style="font-family:helvetica, arial, sans-serif;font-size:14px;">PET肿瘤应用中FDG脑肿瘤诊断最为人们所认识，肿瘤对葡萄糖的利用与其恶性程度成正比，FDG PET显像可准确地用于脑肿瘤术前的分期和鉴别诊断，它可鉴别CT,MRI不能区分的肿瘤复发活放疗引起的坏死，根据肿瘤摄取FDG的程度可判断脑肿瘤的预后，脑局部糖代谢的增加是恶性肿瘤的重要表现形式，这些通过PET显像均可早期发现。当肿瘤破坏神经纤维时，常导致对应神经中枢的FDG代谢降低，在脑肿瘤PET显像中，92%可观察到病灶远端特别是对侧小脑半球有异常代谢减低区即对侧小脑失联络现象。FDG脑肿瘤显像在脑肿瘤良、恶性的鉴别及肿瘤的分级和分期，鉴别脑肿瘤的复发和坏死，探测残留肿瘤等方面优于CT、MRI显像。<br /><br /><font color="#ff0000"><strong>1 脑胶质瘤</strong></font>：18F-FDG PET显像对星形细胞瘤的良恶性鉴别诊断具有重要的临床应用价值。星形胶质细胞瘤Ⅰ级18F-FDG PET显像表现为低代谢影像 ，病灶的放射性浓聚程度低于正常脑组织，但星形胶质细胞瘤Ⅱ～Ⅲ级可表现为高代谢病灶，尤其以病灶边缘明显，病灶的中心部位可表现为低代谢灶。星形胶质细胞瘤Ⅲ、Ⅳ级在18F-FDG PET显像时表现为高代谢病灶，肿瘤病灶显示为放射性异常浓聚影。当肿瘤内部发生出血、坏死时，相应部位可表现为放射性缺损。星形细胞瘤具有很强的复发性，CT/MRI对于星形细胞瘤手术或放疗后是治疗后复发或是治疗后疤痕形成的鉴别有一定困难，而18F-FDG PET显像则具有很强的优势，因为治疗后形成疤痕的糖代谢水平远远低于复发的肿瘤组织，在18F-FDG PET显像图上治疗后形成疤痕组织表现为放射性减低影（即低代谢灶），复发的肿瘤组织表现为放射性浓聚影（即高代谢灶）。大量临床研究结果证明，18F-FDG PET显像是鉴别星形细胞瘤手术或放疗后复发或治疗后疤痕形成的有效手段。<br /><br /><font color="#ff0000"><strong>2 垂体腺瘤</strong></font>：垂体腺瘤是鞍内最常见的肿瘤，临床观察证明正常脑垂体及激素分泌性腺瘤18F-FDG PET显像无明显FDG摄取，而无功能性细胞腺瘤对18F-FDG 有很高的摄取功能，18F-FDG PET显像显示为高代谢灶，清晰显示垂体腺瘤病灶。18F-FDG PET显像也可以用于观察垂体腺瘤对治疗的反应及监测复发。<br /><br /><font color="#ff0000"><strong>3 脑转移瘤</strong></font>：脑转移瘤与其原发恶性肿瘤灶一样，具有较强的18F-FDG集聚能力，18F-FDG PET显像表现为高代谢病灶，可与良性病变鉴别：如脑内内出血、坏死、囊性变及液化，FDG显像表现为放射性缺损。对于CT、MRI等检查先发现颅内转移瘤者，而原发病灶未明的肿瘤患者，进行PET全身显像，有助于检出肿瘤原发灶。18F-FDG PET显像对脑转移瘤放、化疗效果的判断、检测手术后残余病灶等均有重要价值。</span>', 'gwm', 0, 15),
(235, 'PET-CT：肺癌分期', '病例介绍', '', '', '2009-11-26 15:32:07', '116.228.141.77', '<div>▲患者女67岁</div><div>▲干咳2月伴少量泡沫痰，无痰中带血</div><div>▲X线胸片：右肺肿块影</div><div>▲胸部CT：右肺上叶前段3×4cm不规则肿块影，并有胸膜牵引征</div><div>▲为确定是否有其它部位转移，选择手术适应征来行FDG-PET检查</div><div><img src="/image_server_dir/62499186503e6b06ba4796758162eef3.jpg" alt="" border="0" /></div><div><img src="/image_server_dir/b4bb5dfe390ca6b56c78f2c63edea234.jpg" alt="" border="0" /></div><div><img src="/image_server_dir/8779165b95ba641d5bbfa98cb05e9498.jpg" alt="" border="0" /></div><div>PET/CT检查后分期：T2N2M1 IV期</div>', 'gwm', 0, 12),
(236, 'PET-CT：化疗后治疗效果评价', '病例介绍', '', '', '2009-11-26 15:41:17', '116.228.141.77', '<div><div>▲患者 女 55岁</div><div>▲诊断：子宫内膜癌术后</div><div>▲2002年4月子宫内膜癌手术，病理为浸润性腺癌。</div><div>2003年因胆囊炎手术发现腹腔内转移。</div><div>2003年9月，第1次PET/CT检查示：CT见肝脏右叶低密度影处呈现FDG代谢增高(SUV=4.6),考虑肿瘤肝脏转移。</div><div>2003年9－12月，化疗3次。</div><div>2003年12月，第2次PET/CT检查示：CT见肝脏右叶低密度影处，PET未见明显FDG代谢增高，考虑肿瘤病灶化疗后坏死。</div><div><img src="/image_server_dir/ac499672b22801aefcd589d14872dc9b.jpg" alt="" border="0" /></div></div>', 'gwm', 0, 10),
(237, 'PET-CT:胃窦癌术后化疗效果评价', '病例介绍', '', '', '2009-11-26 15:47:21', '116.228.141.77', '<div>▲ 患者 男 46岁</div><div>▲诊断：胃窦癌术后</div><div>▲2003年5月发现胃窦部肿瘤伴腹腔淋巴结及肝脏转移，行胃癌姑息切除、胃周淋巴结摘除、肝脏部分切除。病理为神经内分泌肿瘤。</div><div>▲术后CT示：胰头后淋巴结肿大，考虑转移。</div><div>▲2004年2月，第1次PET/CT检查示：胰头后方淋巴结肿大，伴FDG代谢增高，SUV=5.3。</div><div>▲2004年2－3月行化疗2次，泰素帝＋草酸铂</div><div>▲2004年3月，第2次PET/CT检查示：胰头后方淋巴结肿大，局部FDG代谢增高，SUV=4.2。</div><div><img src="/image_server_dir/8ac930498a0ecfe6a5023748bdee5bcf.jpg" alt="" border="0" /></div>', 'gwm', 0, 10),
(238, '18F-FDG国家暂行标准', '详细介绍', '', '', '2009-11-27 10:32:27', '116.228.141.77', '<span style="font-family:verdana;font-size:12px;">&#8226;本品为无载体的氟［18F］脱氧氧葡萄糖的无菌、无热原、等渗水溶液。含18F的放射性浓度，按其标签上记载的时间，为标示量的90.0－110%。<br />　　&#8226;性状：本品为无色澄明测试液体<br />　　&#8226;鉴别：（1）取本品适量，用合适的仪器测量本品的半衰期（中国药典2000版二部附录XIII，半衰期测定法），其半衰期为105－115分钟之间。<br />　　&#8226;(2)取本品适量，照g谱仪法（中国药典2000牘二部附录XIII，g谱仪法）测量，其主要光子的能量应为0.511Kev和可能有的合成峰1.022KeV.<br />　　&#8226;(3)取本品适量，照放射化学纯度项下的方法测量，在Rf值约为0.45处有放射性主峰。<br />　　&#8226;检查：pH值：应为4.5－7.5（中国药典2000牘二部附录XIII，pH值测量法）<br />　　&#8226;含氨基聚醚2.2.2（K2.2.2）量&nbsp; 对照溶液的配制&nbsp; 精密称取氨基聚醚(2.2.2)0.025g于50ml 烧杯,加热的二次蒸馏水溶解,次却后定量转移到250ml量瓶里,加水至刻度,摇匀即得含氨基聚醚(2.2.2)量为100.0mg的对照溶液.<br />　　&#8226;工作曲线的绘制:精密量取对照溶液0.00, 0.05.0.10,0.20,0.40ml,分别置于5ml容量瓶中,依次加入pH值为6.4的柠檬酸一氢钠缓冲溶液1.0ml(称取5.25g柠檬酸和2.0氢氧化钠于烧杯,用50ml水溶解,以0.1mol/L的NaOH溶液和pH计调节pH值为6.4,再稀释到250ml,摇匀,即可),含Pb2+500mg/ml的硝酸铅溶液(称取79.93mgPb(NO3)2于烧杯中,加水溶解,转移到100ml容量瓶中,用水定容,摇匀,即可)1.0ml,加水到刻度,摇匀.照紫外分光光度法(中国药典2000年版二部附录IV A),在254nm波长处分别测定吸光度,绘制工作曲线,工作曲线相关系数不小于0.99.<br />　　&#8226;测量法:精密量取供试品溶液0.5ml于5ml量瓶中,以下操作步骤同工作曲线的绘制.测定供试品的吸光度,根据工作曲线求出氨基聚醚(2.22)量.本品每ml含氨基聚醚(2.2.2)量不超过25mg.<br />　　&#8226;细菌内毒素:取本品适量,至少稀释6倍后,依中国药典2000年版二部附录XIE检查,本品每1ml含细菌内毒素量应小于15EU.<br />　　&#8226;无菌:取本品适量,依中国药典2000年版二部附录XI H,无菌应符合规定.<br />　　&#8226;其它:应符合注射剂项下有关规定(中国药典2000年版二部附录 IB)<br />　　&#8226;放射化学纯度&nbsp; 取本品适量,以硅胶为固定相,以乙腈:水(85:5 V/V)为展开剂,按放射化学纯度测量第一法(中国药典2000年版二部附录藏XIII)测量,含氟［18F］脱氧氧葡萄糖放射化学纯度应不低于90%.<br />　　&#8226;放射性浓度&nbsp; 取本品适量,按中国药典2000年版二部附录XIII,放射性浓度测量法第一法,按标签上记载的时间,放射性浓度应不低370MBq/ml.<br />　　&#8226;类别&nbsp; 放射性诊断用药<br />　　&#8226;规格&nbsp; 0.37-7.4GBq&nbsp;&nbsp;&nbsp;<br />　　&#8226;贮藏&nbsp;&nbsp; 本品密封于30ml或10ml无菌瓶中,置于铅容器内.</span>', 'gwm', 0, 38);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(239, 'PET-CT 能节省医疗费用吗', '详细介绍', '', '', '2009-11-27 11:32:07', '116.228.141.77', '<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">美国是最早使用</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">、</span></span><span><span style="font-family:helvetica;color:black;">PET-CT\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">的国家，开始时由于检查费用较高，保险公司拒绝将其纳入医保。随着</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">、</span></span><span><span style="font-family:helvetica;color:black;">PET-CT\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">应用的普及，美国保险公司开始关注并重视该项检查的意义，对肿瘤患者的医疗费用进行了全面的调查核算，发现经过</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">、</span></span><span><span style="font-family:helvetica;color:black;">PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查的肿瘤患者约有</span></span><span><span style="font-family:helvetica;color:black;">40%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">病人的临床分期发生了改变，从而改变了治疗方案，</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">避免了一些不必要的手术和有创性检查，</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">节省了一系列相应费用，总体上节省了大量的费用，所以美国保险公司已经将</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">13 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">种肿瘤的</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查纳入医疗保险。</span></span><span><span style="font-family:helvetica;color:black;"></span></span></p>\r\n\r\n<p><span><span style="font-family:helvetica;color:black;"><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">因此，单从一项检查费用上讲可能贵了点，但是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 40%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">的病人避免了一些不必要的手术和有创性检查，从而节省了大量医疗费用。更重要的是避免了不必要手术和有创性检查的痛苦，大大提高了病人的生存质量，延长了病人的生存时间。</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> <span></span></span></span></p>\r\n\r\n<p><span><span style="font-family:helvetica;color:black;"><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">一、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">及</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET-CT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">在</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> SPN</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">方面进行了最早的成本效益分析</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">早在</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 1996 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">年，</span></span><span><span style="font-family:helvetica;color:black;">Valk\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">等人在美国做了病例追踪后得出结论，即因为避免开胸手术或活检术，每名患者节省将近</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 2200 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">美元。随后其它学者也均得到同样的结论。而</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">对</span></span><span><span style="font-family:helvetica;color:black;">\r\nNSCLC</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">的术前分期的成本效益分析国际上仍有分歧。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">Gambhir </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">在早期用模型法进行的分析中认为</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">相对于</span></span><span><span style="font-family:helvetica;color:black;">\r\nCT </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">来讲生存率每增加</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 2.96 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">天节省</span></span><span><span style="font-family:helvetica;color:black;">1154\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">美元。然而，随后的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> Scott </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等人通过模型法得出的结果却是只有对</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">无明显纵隔淋巴结肿大的肺癌患者进行</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查才显得更高效，而在所有的患者中行</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查反而不如</span></span><span><span style="font-family:helvetica;color:black;">\r\nCT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">，仅仅是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查后在预期生存率方面较</span></span><span><span style="font-family:helvetica;color:black;">\r\nCT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">延长。问题的关键可能在于</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">不能诊断晚期肿瘤而实际上已经是晚期肿瘤的可能性的大小，这里不仅存在</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">和</span></span><span><span style="font-family:helvetica;color:black;">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">诊断率的问题，还存在流行病学的问题。因为我们知道</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">对其分辨率以上的病灶都能显示，</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">而</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">对诊断淋巴结肿大的标准是有一定的大小限度的，</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">淋巴结大小在这个区间内的肿瘤患者的数量是很重要的影响因素，再加上其它影响因素如各国的成本因素和产生效益的差异性，导致了在这个问题上各国的学者产生了分歧。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">二、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">及</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET-CT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">在结直肠肿瘤的成本效益分析</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> <span>PET </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">及</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET-CT </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">可以早期发现较小的而其它检查手段不易发现的结直肠肿瘤，或者在明确原发肿瘤病灶的同时发现较小的转移灶或者多发的远处转移，多发远处转移是手术的禁忌症，</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">而孤立的转移灶切除在临床证实是有助于肿瘤预后的。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> Valk</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等人对一组肿瘤标志物增高的和准备切除孤立转移灶的患者进行病例追踪后发现其中</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 25</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">％的人不能进行手术，这样</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">平均为每名患者节省了</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 2618</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">美元。</span></span><span><span style="font-family:helvetica;color:black;">Miles\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">利用一组澳大利亚本国患者进行的研究得出的数据是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 1723 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">澳元。因此，多数学者认为</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">在结直肠癌方面有着较高的性价比，这主要是因为</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">诊断准确率较高，从而能较好的把握手术指征，迅速寻找出可切除的原发灶和孤立转移灶，另一方面避免不必要的手术。</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> <span></span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">三、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">及</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET-CT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">在头颈部肿瘤的成本效益分析</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">头颈部的解剖结构在许多影响学检查方法中较难区分，因此</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">在头颈部肿瘤方面的诊断分期的准确率较其它方法有明显的优势。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> Valk</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等人通过病例追踪的方法提示通过</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">检查，每名患者节省了</span></span><span><span style="font-family:helvetica;color:black;">\r\n500 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">美元。而</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> Hollenbeak </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等人通过模型分析法得出结论认为</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">对</span></span><span><span style="font-family:helvetica;color:black;">CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">诊断为</span></span><span><span style="font-family:helvetica;color:black;">\r\nN0 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">期的患者其效率更高，原因是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">ET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">能检出</span></span><span><span style="font-family:helvetica;color:black;">\r\nCT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">无法诊断的淋巴结转移，从而改变分期，影响后续的治疗方案以及预后。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p><span><span style="font-family:helvetica;color:black;"><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">四、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">及</span></span><span><span style="font-family:helvetica;color:black;">\r\nPET-CT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">在其它肿瘤方面的成本效益分析</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:Helvetica;\r\ncolor:black"> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">在其它肿瘤方面的成本效益分析也有报道。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> Valk</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">等人对黑色素瘤的病例追踪报道认为</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">通过避免不必要的手术（包括确定诊断为手术禁忌以及确定为良性病灶）以及较高的诊断效率，为每名患者节省了</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 2175 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">美元。而在乳腺癌腋窝淋巴结分期方面，美国和澳大利亚的研究人员分别得出</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">为每名患者节省了</span></span><span><span style="font-family:helvetica;color:black;">300\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;mso-hansi-font-family:\r\nHelvetica;mso-bidi-font-family:Helvetica;color:black">美元和</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"> 550 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;mso-bidi-font-family:\r\nHelvetica;color:black">澳元。</span></span><span><span style="font-family:helvetica;color:black;"></span></span></p>', 'gwm', 0, 34),
(240, 'PET-CT 是如何诊断肿瘤的', '详细介绍', '', '', '2009-11-27 11:35:38', '116.228.141.77', '<div><p><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">机体正常组织细胞的结构完整和生理功能维持主要通过糖、蛋白质、脂肪及核酸等物质的不断合成和分解过程即新陈代谢来进行。肿瘤细胞由于其无限增殖特性，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">DNA</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">合成增多，氨基酸、葡萄糖等代谢物质消耗增加，从而与正常组织细胞代谢之间具有明显差异。肿瘤代谢显像主要通过某些放射性核素（如</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">11C</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">、</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 18F</span><span style="font-size:13.5pt;font-family:\r\n宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">）对这些代谢底物或类似物进行标记示踪，并以图像形式直观显示出来，能够精确、动态反映肿瘤组织与机体正常组织细胞代谢的差异，从而达到对肿瘤进行早期诊断、治疗方案选择、疗效监测的目的。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">正电子发射断层扫描（</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">positron emission tomography</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">）以正电子核素在湮灭时发射出的双光子为探测对象，具有探测效率高、分辨率好等优点；发射正电子核素如</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">11C</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">、</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">13N</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">、</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">15O</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">是组成人体元素的同位素，用于标记引入体内后并不改变或影响体内原有的代谢过程；所以</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">显像被称为活体分子生化代谢图像，可无创、动态、定量地从分子水平观察代谢产物或放射性药物在人体内的生理生化过程。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">&nbsp;</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">然而</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">仍存在显像时间长、无法对病灶进行精确定位等缺点，目前已经逐渐被全新的</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET-CT </span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">产品所取代。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET-CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">设备由于采用</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> X </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">线进行图像衰减校正缩短显像时间、利用</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">图像进行精确的病灶定位、采用</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET-CT </span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">同机融合信息排除生理性伪影等优势，从而为肿瘤分子影像的发展奠定了坚实的基础。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">&nbsp;</span><span><span></span></span></p></div>', 'gwm', 0, 66),
(241, 'PET-CT 已成腹部及盆腔肿瘤检查的首选方法 ', '临床应用', '', '', '2009-11-27 11:37:56', '116.228.141.77', '<p><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">约翰霍普金丝大学医学院回顾和总结了该院</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">2001</span><span style="font-size:13.5pt;font-family:\r\n宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">年</span><span lang="EN-US" style="font-size:\r\n13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:\r\n0pt">6</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">月到</span><span lang="EN-US" style="font-size:13.5pt;\r\nfont-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">2003</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">年</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">9</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">月在核医学科进行的</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 2700 </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">余例腹部及盆腔</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET/CT </span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">扫描，研究和制定其适应症及优缺点。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">2700 </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">余例</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET/CT</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">扫描中，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">90%</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">以上用于已知或怀疑肿瘤的病人。同时该院还检索和总结了腹部及盆腔</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET/CT</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">扫描的相关文献。</span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> <span></span></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">他们发现：</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET/CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">能精确定位肿瘤部位的放射性摄取；并能鉴别生理性摄取。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET/CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">对绝大多数腹部及盆腔肿瘤适应症均具有定位准确、快速且易于实现的优点，而且还具有定量分析的功能。另外，对于肿瘤的复发的监测、随访、和疗效的评价都有其特殊价值。</span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> <span></span></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">约翰霍普金丝大学医学院专家预见在不久的将来，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET/CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">将代替独立的</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">和</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> CT </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">成为临床腹部及盆腔肿瘤检查、随访和疗效评价的首选检查方法和常规手段。而目前在约翰霍普金丝大学医学院</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> PET/CT</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">已成为腹部及盆腔肿瘤检查的首选方法。</span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"></span></span></p>', 'gwm', 0, 16);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(242, 'PET-CT 与恶性淋巴瘤 ', '详细介绍', '', '', '2009-11-27 11:48:17', '116.228.141.77', '<p><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">&nbsp;&nbsp; &nbsp;恶性淋巴瘤是原发于淋巴结或淋巴结外组织或器官的恶性肿瘤。根据临床和病理特点的不同，其可分为霍奇金淋巴瘤</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">(Hodgkin''s lymphoma</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL)</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">和非霍奇金淋巴瘤</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">(non-Hodgkin''s lymphoma</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL)</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">两大类。恶性淋巴瘤治疗的关键是早期诊断、准确分期、正确判断病情以及治疗反应的监测。</span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">&nbsp;</span></p><p><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"><b><span>&nbsp;&nbsp; &nbsp;1.<span>&nbsp; </span></span></b></span><b style="mso-bidi-font-weight:\r\nnormal"><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">早期诊断</span></b><b><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> </span></b><span lang="EN-US" style="font-size:13.5pt;\r\nfont-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">在使用</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">评价淋巴瘤的研究中，</span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> </span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">大多数研究对象为</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">HL</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">和弥漫性大</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">B</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">细胞性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">，对其他组织学类型的淋巴瘤研究资料有限。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">Elstrom R</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">等对</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 172 </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">例各种类型淋巴瘤患者的</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">进行回顾性研究：</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">准确地探测到了弥漫性大</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">B</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">细胞性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">、</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">T</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">细胞淋巴瘤、滤泡性淋巴瘤和</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">病灶。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">探测边缘区淋巴瘤可靠性低，尤其是结外的边缘区淋巴瘤。在对惰性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">B</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">细胞性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">的研究中发现，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">对滤泡性</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">的诊断、治疗有潜在优势，但对小淋巴细胞性淋巴瘤，只能探测到</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 50</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">％的病灶。还有一些使用标准化摄取值</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">(standardizeduptakevalue</span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">SUV)</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">测定肿瘤</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">摄取程度的研究认为，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">能够预测惰性淋巴瘤的组织学转变。但是，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">SUV</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">与淋巴瘤病理亚型、有丝分裂率的关系仍有争议。</span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> <span></span></span></p>\r\n\r\n<p style="text-indent:27.1pt;"><b><span lang="EN-US" style="font-size:13.5pt;\r\nfont-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">2</span></b><b><span style="font-size:13.5pt;font-family:\r\n宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">．临床分期</span></b><b style="mso-bidi-font-weight:\r\nnormal"><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> <span></span></span></b></p>\r\n\r\n<p style="text-indent:27.0pt;"><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">和</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">虽然只占所有恶性肿瘤的</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">8</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">％，但却是少数几种可治愈的肿瘤。对恶性淋巴瘤的治疗不仅取决于其组织学亚型，而且要根据具体、准确的临床分期。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">肿瘤显像通过发现代谢异常病灶，特别是探测到其他检查未发现的隐性的腹部病灶或脾脏病灶，可显著提高了淋巴瘤最初分期的准确性。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">BangerterM</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">等应用</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;\r\n mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">-FDG PET</span><span style="font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">对</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 44 </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">例已确诊为</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">的患者进行治疗前评价：</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">5 </span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">例分期上调，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">1</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">例分期下调。初步研究表明，在</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">和</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">患者的分期方面，</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 18F-FDG PET</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">优于</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">67Ga</span><span style="font-size:13.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">显像。</span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">淋巴瘤的骨髓浸润较常见，是淋巴瘤患者预后不良的征兆之一，且决定淋巴瘤的分期。研究表明，用</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\n mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">可准确显示淋巴瘤骨髓浸润。</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">Buchmann</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">等比较了</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">与</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">CT</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">、骨髓活检在</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">NHL</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">和</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">HL</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">分期中的作用，结果是</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">优于</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">CT</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">；</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">8</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">％（</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">4</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">／</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">52</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">）患者经</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">导致分期上调，改变了治疗计划。</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">Moog FM</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">等对</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 78 </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">例淋巴瘤患者的</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">、骨髓活检结果进行了比较，其中</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> 64 </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">例患者的双侧骨髓活检与</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">结果一致；对</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 10</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">例骨髓</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">摄取增高而骨髓活检阴性的患者进行</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> MRI </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">、聚合酶链反应</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">(polymerasechainreaction</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">，</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PCR)</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">等检查，证实其中</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 8 </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">例淋巴瘤累及骨髓；有</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"> 4 </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">例患者</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">没有探测到骨髓浸润。</span></span><span><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> <span></span></span></span></p>\r\n\r\n<p style="text-indent:27.1pt;"><span><b><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">3</span></b></span><span><b><span style="font-size:13.5pt;font-family:\r\n宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt">．疗效评价</span></b></span><span><b><span style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt"> </span></b></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:\r\n宋体;color:black;mso-font-kerning:0pt"></span></span></p>\r\n\r\n<p style="text-indent:27.0pt;"><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">对淋巴瘤治疗的最终目标是通过化疗、放疗等疗法的毒性作用，彻底清除肿瘤细胞。然而，各种淋巴瘤对治疗的反应相差甚大。造成这种反应差异的原因是肿瘤组织学类型、生物学差异、药物抵抗机制、放疗或化疗敏感性的不同等。在治疗中或治疗后及早判断治疗反应有利于及时更改治疗方案。</span></span><span><span style="font-size:13.5pt;font-family:Simsun;\r\nmso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"> </span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">常规解剖显像对肿瘤反应或进展的判断基于肿瘤的大小，治疗有效时，由于治疗引起的肿瘤结构变化滞后于肿瘤细胞的死亡，解剖显像上的肿块可持续存在。而</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\n mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG PET</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">可显示肿瘤代谢活性明显减低，肿瘤对</span></span><span><span lang="EN-US" style="font-size:13.5pt;\r\n font-family:Simsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">18F</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt">-FDG</span></span><span><span style="font-size:13.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;mso-bidi-font-family:宋体;color:black;\r\nmso-font-kerning:0pt">摄取减少或消失是在临床或亚临床水平上对肿瘤治疗有效的早期标志，及时评价治疗效果可修正临床恶性淋巴瘤的治疗方案应用。</span></span><span><span lang="EN-US" style="font-size:13.5pt;font-family:\r\nSimsun;mso-bidi-font-family:宋体;color:black;mso-font-kerning:0pt"></span></span></p>', 'gwm', 0, 25),
(243, '用18FDG来探测肿瘤的原理', '详细介绍', '', '', '2009-12-01 17:07:31', '116.228.141.77', '<div>　18FDG肿瘤显像的生物学基础在于18FDG能被肿瘤细胞摄取，肿瘤组织中的18FDG 分布水平明显高于肿瘤组织周围的正常组织内18FDG 的分布。18FDG与人体生理糖代谢的底物棗左旋葡萄糖分子(DG)在化学结构上的差别仅仅在于DG碳环上2位的C被18F所取代。18FDG即保留了葡萄糖的部分生物活性，但同时在体内的分解代谢过程与葡萄糖又有明显的差异。</div><div>　　和葡萄糖的胞运过程一样，18FDG也通过葡萄糖转运体（GLUT）进入肿瘤细胞。18FDG进入肿瘤细胞后，在已糖激酶（HK）同工酶的催化下变成18F-2-脱氧葡萄糖6-磷酸（18F-2-G-6-P）. 由于在18F-2-G-6-P的C-2位上没有氧原子，所以不易被葡萄糖6-磷酸酶降解，同时18F-2-G-6-P也不受葡萄糖-6-磷酸脱氢酶（G6PDH）作用，也不被糖异生途径上酶分解，因此18F-2-G-6-P被陷留（trapped）在肿瘤细胞内。肿瘤细胞不仅摄取18FDG增多，而且胞浆线粒体内HK同工酶含量丰富，所以肿瘤细胞内18F-2-G-6-P的水平相当高，持续的时间也相当长，构成了18FDG肿瘤显像的生物学基础。</div>', 'gwm', 0, 30),
(244, 'PET-CT与核医学', '详细介绍', '', '', '2009-12-02 10:48:23', '116.228.141.77', '<p><font face="PMingLiU"><p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">X</span><span>射线的临床应用已有近一百年的历史，放射学</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Radiology)</span><span>早已成为一门独立的学科，它包括放射诊断学</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Diagnostic Radiology)</span><span>和放射治疗学</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Therapeutic Radiology)</span><span>。近年来放射线</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>包括<span>γ</span>光子、<span>β</span>粒子和中子流等</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">)</span><span>的临床应用发展迅速，其中应用封闭型放射性同位素</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>如</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">60</span></sup><span>钴</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>发射的<span>γ</span>光子和加速器产生的中子流等对疾病进行辐射治疗，无论在治疗原理、治疗方法和治疗病种等方面都与</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">X</span><span>射线治疗类似，故这方面的内容已列入放射治疗学。应用开放型放射性同位素发射的放射线对疾病进行诊断和内照射治疗，在应用原理、方法、条件设备和防护管理等方面都有特点，已形成一门新学科，即核医学</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Nuclear Medicine)</span><span>。在医院内由核医学科专门实施这方面的工作。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>关于放射线对生物的辐射效应、放射损伤的诊断与治疗、辐射安全防护等则完全属于另一范畴，研究这一范畴的科学称为放射医学</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Radiation Medicine)</span><span>。当然对于实施和应用核医学的人们来讲，了解放射医学的基本知识也是十分必要的。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<span style="font-size:10.5pt;mso-bidi-font-size:12.0pt;font-family:宋体;\r\nmso-ascii-font-family:PMingLiU;mso-hansi-font-family:&quot;Times New Roman&quot;;\r\nmso-bidi-font-family:&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:\r\nEN-US;mso-fareast-language:ZH-CN;mso-bidi-language:AR-SA">核医学包括诊断和治疗两个部分，其中诊断的内容丰富多样，是核医学的主体。诊断方法按放射性同位素是否引入受检者体内分为体内检查法</span><span lang="EN-US" style="font-size:10.5pt;mso-bidi-font-size:12.0pt;font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:\r\n&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:\r\nZH-CN;mso-bidi-language:AR-SA">(In vivo Method)</span><span style="font-size:\r\n10.5pt;mso-bidi-font-size:12.0pt;font-family:宋体;mso-ascii-font-family:PMingLiU;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">和体外检查法</span><span lang="EN-US" style="font-size:10.5pt;\r\nmso-bidi-font-size:12.0pt;font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">(In vitro Method)</span><span style="font-size:10.5pt;\r\nmso-bidi-font-size:12.0pt;font-family:宋体;mso-ascii-font-family:PMingLiU;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">。体内检查法根据最后是否成像又分为显像和非显像两类方法。利用放射性同位素实现脏器和病变显像的方法称作放射性同位素显像</span><span lang="EN-US" style="font-size:10.5pt;mso-bidi-font-size:12.0pt;font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:\r\n&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:\r\nZH-CN;mso-bidi-language:AR-SA">(Radionuclide Imaging)</span><span style="font-size:10.5pt;mso-bidi-font-size:12.0pt;font-family:宋体;mso-ascii-font-family:\r\nPMingLiU;mso-hansi-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">，这种显像有别于单纯形态结构的显像，是一种独特的功能显像，为核医学的重要特色之一。核医学的上述内容可以简单归纳如下：</span></font></p><p><font face="''Times New Roman''" size="4"><span style="font-size:14px;"><img src="/image_server_dir/ebab53310c84aea70aba0a2b2f4e616e.jpg" alt="" border="0" /></span></font></p><p><font face="''Times New Roman''" size="4"><span style="font-size:14px;">&nbsp;&nbsp; &nbsp; &nbsp;由此我们不难看出，PET-CT属于和医学中核素诊断类体内检查法的核素显像类！</span></font></p>', 'gwm', 0, 21);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(245, ' 核医学的诊疗原理和特点', '详细介绍', '', '', '2009-12-02 10:53:32', '116.228.141.77', '<p><b><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"><span>&nbsp;</span></span></b><b><span>核医学的诊疗原理和特点</span></b><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>一、体内检查法的诊断原理和特点</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>放射性同位素或其标记物与一般天然元素或其化合物一样，在被引入体内之后，根据其化学及生物学特性有其一定的生物学行为：或是被某一脏器的某种细胞摄取和聚集、或是经由某一脏器的某种细胞清除和排出、或是参与某一代谢过程、或是简单地在某一生物区积存，等等。由于它发射能穿透组织的放射线，用放射性探测器可以很容易地在体表定量探测到它的所在，从而把上述种种过程定量地显示出来。经过大量试验，用统计学方法求出正常规律、正常值、变异范围和某些疾病的异常特点，乃可根据这些规律和特点对这些疾病进行诊断。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">1. </span><span>放射性同位素显像的原理、种类和特点</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>放射性同位素显像是一种以脏器内、外或脏器与病变之间的放射性浓度差别为基础的脏器或病变显像方法。其基本条件是：</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">a. </span><span>具有能够选择性聚集在特定脏器或病变的放射性同位素或放射性标记物，使该脏器或病变与邻近组织之间的放射性浓度差达到一定程度；</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">b. </span><span>利用核医学显像装置探测到这种放射性浓度差，并根据需要以一定的方式将它们显示成像，即是脏器或病变的影像。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">A. </span><span>显像剂在脏器或病变中选择性聚集的机转</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>用于脏器或病变显像的放射性同位素和放射性标记物称为显像剂</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (Imaging Agent)</span><span>，它们能够选择性聚集在特定脏器或病变中的机转主要有以下几种：</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(1)</span><span>细胞选择性摄取</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>a.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>特殊需要物质</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> </span><span>有些物质是某些细胞完成某种功能所特需的，因而能被选择性地摄取。例如放射性碘和放射性碘标记的胆固醇与天然碘和胆固醇一样，作为合成甲状腺激素和肾上腺皮质激素的必要的特殊原料，可以分别被甲状腺上皮细胞和肾上腺皮质细胞选择性摄取而使甲状腺肾和上腺皮质显影。放射性标记的葡萄糖与天然葡萄糖一样可以作为能源物质被脑细胞和心肌细胞摄取，聚集量明显高于其它组织，故可使脑灰质和心肌显影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-1)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>b.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>代谢产物和异物</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> </span><span>特定脏器的特定细胞具有选择性摄取代谢产物和异物的功能，以完成把它们从血液中清除出去的任务。例如放射性碘标记的邻碘马尿酸类似代谢产物马尿酸，由肾小管上皮细胞摄取，再随尿液排出，因而可以使肾脏和尿路显影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-2)</span><span>。放射性碘标剂的玫瑰红</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>一种染料</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>和放射剂鎝标记的乙醯苯胺亚氨酸衍生物由肝细胞摄取，再随胆汁排出，因而可使肝和胆道显影。血液中的放射性胶体微粒由网状内皮细胞吞噬，使肝、脾和骨髓显影。皮下的放射性胶体微粒则是被组织内的吞噬细胞吞噬后汇集到淋巴结，淋巴系得以显影。血液中的放射性标记的热变性红细胞被拦截在脾窦内，可使脾脏显影。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="mso-bidi-font-family:\r\n宋体"><span>c.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>特殊价态物质</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> </span><span>一些细胞可以选择性摄取特殊价态物质。例如心肌细胞可以比邻近组织更多地摄取与钾离子</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(K</span><span style="font-size:7.5pt;">＋</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>类似的正一价物质，如铊</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(T1</span><span style="font-size:7.5pt;">＋</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>和放射性鎝标记的异氰类化合物的正一价部分等而使心肌显影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-3)</span><span>。脂溶性零价小分子物质，如放射性鎝标记的六甲丙烯胺</span><span style="font-family:pmingliu;"><!--[if gte vml 1]><v:shapetype\r\n id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"\r\n path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">\r\n \r\n \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n \r\n \r\n \r\n<v:shape id="_x0000_i1025" type="#_x0000_t75" alt="?.gif (882 bytes)"\r\n style=''width:12pt;height:11.25pt''/><![endif]--><img width="16" height="15" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image001.gif" alt="?.gif (882 bytes)" /></span><span>可通过血脑屏障进入脑细胞而使脑灰质显影。</span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(2)</span><span>化学吸附作用</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>骨胳的基本结构</span><span style="font-family:pmingliu;"><!--[if gte vml 1]><v:shape\r\n id="_x0000_i1026" type="#_x0000_t75" alt="?.gif (130 bytes)" style=''width:12.75pt;\r\n height:12pt''/><![endif]--><img width="17" height="16" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image002.gif" alt="?.gif (130 bytes)" /></span><span>基磷灰石晶体具有高度吸附放射性鎝标记的磷酸化合物的功能，故可使全身骨胳清晰显影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-4)</span><span>，骨外钙化病灶和沉积</span><span style="font-family:pmingliu;"><!--[if gte vml 1]><v:shape\r\n id="_x0000_i1027" type="#_x0000_t75" alt="?.gif (130 bytes)" style=''width:13.5pt;\r\n height:12.75pt''/><![endif]--><img width="18" height="17" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image003.gif" alt="?.gif (130 bytes)" /></span><span>基磷灰石的心肌梗塞病灶等亦可显影。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(3)</span><span>微血管栓塞</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>静脉注射大于毛细血管直径</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>﹥</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">7</span><span>μ</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">m)</span><span>的放射性颗粒，当它们随血流灌注到肺微血管床时将暂时栓塞在那里而使肺显影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-5)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(4)</span><span>特异性结合</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>放射性标记的受体配体只与该受体结合，放射性标记的抗体只与相应的抗原结合，从而可使受体和含有特殊抗原的组织显影，这种影像具有高度的特异性。例如放射性碘标记的间位碘代</span><span style="font-family:pmingliu;"><!--[if gte vml 1]><v:shape\r\n id="_x0000_i1028" type="#_x0000_t75" alt="?.gif (122 bytes)" style=''width:12pt;\r\n height:13.5pt''/><![endif]--><img width="16" height="18" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image004.gif" alt="?.gif (122 bytes)" /></span><span>胍能与肾上腺素能受体结合，因此可以使富含肾上腺素受体的嗜铬细胞瘤及其转移灶等显影，有高度的特异性。后者称为放射免疫显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Radioimmunoimaging</span><span>；</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">RII)</span><span>。由于肿瘤组织常含有特异抗原，因此这种显像是特异性诊断肿瘤的理想方法</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-6)</span><span>。放射性标记的白细胞和纤维蛋白原亦因能分别特异性地聚集在炎症病灶和血栓部位而使它们显影。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(5)</span><span>信道、灌注和生物区分布</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>将适当的显像剂引入某一信道或当显像剂通过某一信道时，可以使这些信道显影。例如静脉注射可以通过肺微血管并且不被肺泡上皮细胞吸收的任何放射性同位素或放射性标记物，它们将依序通过腔静脉、右心房、右心室、肺血床、左心房、左心室、升主动脉、主动脉弓而达到降主动脉，可使这些血管的管腔和心脏房、室腔陆续显影，称为放射性同位素心血管造影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-7)</span><span>。显像剂随血流从二级动脉向相应脏器血管床灌注也可获得脏器的动脉灌注影像。如果静脉注入的显像剂能够存留在血循环中，则可获大血管、心房、心室和各脏器的血池影像，并且使一些含血量明显增高的病变和出血部位得以显示</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-8)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>放射性标记的二乙三胺五醋酸直接注入脊髓蛛网膜下腔后，将随脑脊液扩散至整个脊髓蛛网膜下腔，然后进入各脑池，最后由脑凸面蛛网膜颗粒吸收回血，这可使其通过的各个部位相继显影，若有脑脊液漏存在也将在相应部位出现异常影像。放射性气体和放射性气溶胶吸入呼吸道和相继呼出则可使呼吸道显影。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">B. </span><span>显像的方式和种类</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>显像按影像显示方式的不同分为以下几类：</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(1)</span><span>静态显像与动态显像</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l6 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>a.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>静态显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Static Imaging) </span><span>当显像剂在脏器内或病变处的浓度处于稳定状态时进行显像称为静态显像。这种显像允许采集</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Acquisition)</span><span>足够的放射性计数用以成像，故所得影像清晰而可靠，多用作观察脏器和病变的位置、形态、大小和放射性分布。根据脏器整体和局部放射性的高低可对脏器的整体功能</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Global Function)</span><span>和局部功能</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Regional Function)</span><span>作出判断，并可发现脏器内有无病损存在。根据一定的生理数学模型，从各个局部的放射性浓度还可计算出一些定量参数，如局部脑血流量、局部葡萄糖代谢率等。局部参数值的大小用不同的灰度或颜色成像，即为参数影像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Parameter Image)</span><span>或称功能影像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Functional Image)</span><span>，是定量研究脏器局部功能和局部代谢的极好方法。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l6 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>b.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>动态显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Dynamic Imaging) </span><span>显像剂随血流流经和灌注脏器、或被脏器不断摄取和排泄、或在脏器内反复充盈和射出等过程，造成脏器内的放射性在数量上或在位置上随时间而变化。用放射性显像装置以一定的速度</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>如每秒</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1</span><span>帧</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>连续采集该脏器的多帧影像，把它们系列化或以电影方式显示，便成为能够反映上述各种变化过程的动态影像。利用计算器<span>“</span>感兴趣区<span>”</span></span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Region of Interest</span><span>；</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> ROI)</span><span>技术可以提取每帧影像中同一个感兴趣区域内的放射性数据，生成时间<span>–</span>放射性曲线</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体"> (Time-Activity Curve)</span><span>，进而计算出动态过程的各种定量参数</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-9)</span><span>。必要时还可计算出脏器影像中每一个像素</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Pixel)</span><span>的定量参数而获得参数影像。这种参数影像不仅可用于观察脏器每个微小局部的功能变化和差别，并且避免了多帧分析和现场电影显示的麻烦，集动态变化于一帧影像之上，一目了然，易于判断</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-9, </span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> 1-10)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>动态显像与静态显像联合进行，称为多相显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Multiphase Imaging)</span><span>。如静脉注射骨胳显像剂后先进行动态显像获得局部骨胳动脉灌注和血池影像，延迟三小时再进行显像得到反映骨盐代谢的静态影像，称为骨胳三相显像。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(2)</span><span>局部显像与全身显像</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l2 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>a.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>局部显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Regional Imaging) </span><span>指只显示身体某一部位或某一脏器的影像，最为常用。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l2 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>b.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>全身显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Whole Body Imaging) </span><span>利用<span>γ</span>照相机的放射性探测器沿体表作匀速移动，从头至足依序采集全身各部位的放射性，将它们显示为全身影像。常用于全身骨胳显像、全身骨髓显像、探寻肿瘤或炎性病灶，有重要的临床价值。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(3)</span><span>平面显像与断层显像</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l4 level1 lfo4;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>a.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>平面显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Planar Imaging)</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-hansi-font-family:宋体"> </span></p>\r\n\r\n<p><span>将放射性显像装置的放射性探测器置于体表的一定位置采集某脏器的放射性影像，称为平面显像，所得影像称为平面影像。平面影像实由放射性探测器投射方向上脏器各处放射性从前到后叠加所构成，叠加的结果可能掩盖脏器内局部的放射性分布异常，因此对较小的，尤其是较深在的病变不易发现。常以多体位显像来克服这种不足，即分别从受检者的前方、后方、侧方或斜方显像，达到充分暴露脏器内放射性分布异常的目的。以上各种显像分别称为前位、后位、侧位和斜位显像。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l5 level1 lfo5;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>b.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>断层显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Section Imaging</span><span>或</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">Tomography)</span><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:\r\n宋体"></span></p>\r\n\r\n<p><span>用特殊的放射性显像装置可以像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">X</span><span>射线</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">CT(</span><span>以下称</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">XCT)</span><span>一样，在体表连续或间断采集多体位平面影像数据，再由计算机重建</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Reconstruction)</span><span>成为各种断层影像，如横断层影像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Transaxial Image)</span><span>、冠状断层影像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Coronal Image)</span><span>和矢状断层影像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Sagittal Image)</span><span>等</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-11)</span><span>。断层影像在一定程度上避免了放射性的重叠，能比较正确地显示脏器内放射性分布的真实情况，有助于发现深在结构的放射性分布轻微异常，检出较小的病变，并可进行较为精确的定量分析，是研究脏器局部血流量和代谢率必不可少的方法。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">(4)</span><span>阳性显像和阴性显像</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l3 level1 lfo6;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>b.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>阳性显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Positive Imaging) </span><span>又称热区显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Hot Spot Imaging)</span><span>指在静态影像上主要以放射性比正常增高为异常的显像，如脑</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>病灶</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>显像、心肌梗塞灶显像、肝血池显像、骨胳显像和特异性结合显像等。这种显像较易于发现异常病灶。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l3 level1 lfo6;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>c.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>阴性显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Negative Imaging) </span><span>又称冷区显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Cold Spot Imaging)</span><span>在静态影像上主要以放射性比正常减低为异常的显像，临床上的常规显像如心肌灌注显像、肝显像、肾显像等属此类型。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l1 level1 lfo7;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>c.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>放射性同位素显像的特点</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>从以上的介绍不难看出放射性同位素显像有以下几个显著特点：</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:0cm;mso-text-indent-alt:-18.0pt;\r\nmso-list:l7 level1 lfo8;tab-stops:list 36.0pt"><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:\r\nPMingLiU"><span>i.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>放射性同位素显像是以脏器和病变内、外放射性差别和脏器内局部放射性差别为基础的显像方法，而脏器和病变内放射性的高低直接与显像剂的聚集量有关，聚集量的多少又取决于血流量、细胞功能、细胞数量、代谢率和排泄引流等因素，因此，放射性影像不仅显示脏器和病变的位置、形态、大小等解剖结构，更重要的是同时提供有关脏器和病变的血流、功能、代谢和引流等方面的信息。众所周知，血流、功能和代谢异常，常是疾病的早期变化，出现在形态结构发生改变之前。因此放射性同位素显像有助于疾病的早期诊断，并广泛应用于脏器代谢和功能状态的研究。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:0cm;mso-text-indent-alt:-18.0pt;\r\nmso-list:l7 level1 lfo8;tab-stops:list 36.0pt"><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:\r\nPMingLiU"><span>ii.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>放射性同位素显像具有多种动态显像方式，使脏器和病变的血流和功能情况得以动态而定量地显示，给出很多功能参数，与静态显像相配合常能提供疾病更为早期的表现。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:0cm;mso-text-indent-alt:-18.0pt;\r\nmso-list:l7 level1 lfo8;tab-stops:list 36.0pt"><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:\r\nPMingLiU"><span>iii.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>放射性同位素显像多因脏器或病变特异性聚集某一种显像剂而显影，因此影像常具有较高的特异性，可显示诸如受体、肿瘤、炎症、异位甲状腺、肾上腺外嗜铬细胞瘤等的影像，而这些组织单靠形态学检查常常是难以确定，甚至是根本不可能显示。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>因此，放射性同位素显像可以概括为一种有较高特异性的功能性显像，除显示形态结构外，它主要是提供有关脏器和病变的功能信息。与以显示形态结构为主的</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">XCT</span><span>、磁共振显像</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(MRI)</span><span>和超音波检查相比较，这一特点十分突出，也十分重要，是本法的优点。但本法受引入放射性活度的限制，成像的信息量不是很充分，使影像的清晰度较差，影响对细微结构的精确显示，在这方面不如</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">XCT</span><span>、</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">MRI</span><span>和超声检查。因此，根据临床需要，适当联合功能性显像和形态学显像将可获得最为全面而必要的信息，以对疾病作出既早期又全面的诊断和定位，有助于进行及时而准确的治疗。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体">2. </span><span>非显像检查法的原理</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>非显像检查法是利用较为简便的放射性探测器在体表探测和记录放射性同位素或放射性标记物在脏器或组织中被摄取、聚集和排出的情况，以时间<span>–</span>放射性曲线等形式显示</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-12)</span><span>。由于探测器是在体表根据脏器和组织的正常解剖位置定位，这种定位与受检者脏器和组织的实际位置不一定吻合，有时差异很大。定位的不确定性，影响测量结果的可靠性，是非显像检查法的重要缺点。因此在有条件进行显像的单位，非显像检查法已逐渐很少运用。但由于它具有价廉和方便的优点，作为初筛检查也有一定临床价值，仍可作为显像方法的一种补充。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>二、体外检查方法的诊断原理</span></p>\r\n\r\n<p><span>体外检查方法主要是体外放射配体结合分析，是一种利用放射性标记的配体为示踪剂，以竞争结合反应为基础，在试管内完成的微量生物活性物质检测技术。最有代表性且应用最广泛的是放射免疫分析。它的原理是：利用放射性标记的被测物和血液或尿液内的被测物共同与限量的被测物抗体竞争结合，用放射性探测器测得标记被测物被结合的量，根据它与血、尿内被测物的量呈一定的反比关系，可以计算出被测物的量。本法有很高的灵敏度和特异性，已广泛用于临床诊断和医学研究，也是核医学有特色的重要内容之一，将在第二章详细介绍。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>三、放射性同位素治疗原理</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>放射性同位素治疗属于内照射治疗，其治疗原理是通过高度选择性聚集在病变部位的放射性同位素或放射性标记物所发射出的射程很短的<span>β<sup>–</sup></span>粒子，对病变进行集中照射，产生足够的游离辐射生物学效应，达到抑制或破坏病变组织的目的，</span>\r\n<span>而邻近的正常组织和全身辐射吸收剂量很低。放射性核素治疗的疾病不多，但疗效较好，有方法简便、副作用小等优点</span><span>,</span><span>有较高的实用价值。</span></p>', 'gwm', 0, 23);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(246, '放射性药物、放射性试剂和常用核医学仪器', '详细介绍', '', '', '2009-12-02 10:54:49', '116.228.141.77', '<p><b>&nbsp;</b><b><span>放射性药物、放射性试剂和常用核医学仪器</span></b></p>\r\n\r\n<p><span>核医学的必备物质条件是放射性药物，放射性试剂和核医学仪器。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>一、放射性药物类</span><span>(Radiopharmaceuticals)</span></p>\r\n\r\n<p><span>凡需引入体内的放射性同位素和放射性标记物称作放射性药物，按不同用途分为诊断用放射性药物和治疗用放射性药物两种。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l1 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>1.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>诊断用放射性药物</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>诊断用放射性药物用于显像者</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">,</span><span>称显像剂</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (Imaging Agent) , </span><span>用于非显像检查的称示踪剂</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (Tracer)</span><span>。这一类药物种类繁多，除各自应具有特殊的化学性质、生物学行为和符合无菌、无热源、化学毒性小等安全要求外，其发射的射线种类、能量和半衰期还必须适当。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>核射线中只有<span>γ</span>光子适用于体内检查法，因其穿透力较强，引入体内后能在体表探测到；同时它在体内的电离密度较低，引起的游离辐射损伤较小。<span>γ</span>光子的能量以</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">100 ~300keV</span><span>为宜，能量太低，组织吸收过多，影响体表测量；能量过高，在放射性探测器中的电离密度太低，影响测量效率，且防护亦较困难。<span>γ</span>光子的物理半衰期</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体"> (T<sub>1/2</sub>) </span><span>以能满足检查所需的时间为度，一般以</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">10</span><span>小时左右为宜。超短</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>的放射性同位素不便应用，只能用于少数瞬间即可完成检查，如</span><sup><span lang="EN-US" style="font-family:PMingLiU;\r\n mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">81m</span></sup><span>氪</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">13</span><span>秒</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">)</span><span>用于肺通气显像；或别无他择，如人体最重要的天然组成元素碳、氮、氧的可用放射性同位素只有</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>很短的</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">11</span></sup><span>碳、</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">13</span></sup><span>氮、</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">15</span></sup><span>氧</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>表</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-1)</span><span>。</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>太长使受检者接受不必要的辐射剂量，废物和污染也较难处理，故应尽量不用。但当别无选择时也只能用之，如有的放射性药物只能由放射性碘标记，理想的放射性碘是</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">123</span></sup><span>碘，但因价格和供应问题，现在多只能用</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">131</span></sup><span>碘，而它的</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">8.04</span><span>天</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">,</span><span>并不理想。自</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1964</span><span>年</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> <sup><span>99m</span></sup></span><span>鎝问世，用于它是纯<span>γ</span>光子发射体，能量为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">141keV</span><span>，</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">6.02</span><span>小时，且能标记多种化合物，几乎可用于所有脏器显像，因此成为目前最理想和最常用的放射性同位素。</span><sup><span lang="EN-US" style="font-family:PMingLiU;\r\n mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">99m</span></sup><span>鎝是由</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼衰变而来。</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼组装成便于使用的</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼</span><span style="font-size:7.5pt;">–</span><span lang="EN-US" style="font-size:7.5pt;font-family:PMingLiU;mso-fareast-font-family:\r\n宋体;mso-hansi-font-family:宋体"> </span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n 宋体">99m</span></sup><span>鎝发生器</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(<sup>99</sup>Mo</span><span lang="EN-US" style="font-size:7.5pt;mso-ascii-font-family:\r\nPMingLiU">–</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:\r\n宋体;mso-hansi-font-family:宋体">99m</span></sup><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">Tc Generator)</span><span>或称</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼</span><span style="font-size:7.5pt;">–</span><sup><span lang="EN-US" style="font-family:PMingLiU;\r\n mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">99m</span></sup><span>鎝母牛，只要用生理盐水淋洗既可得到</span><sup><span lang="EN-US" style="font-family:PMingLiU;\r\n mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">99m</span></sup><span>鎝</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-13)</span><span>。</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼的</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">2.76</span><span>天，只要购得含有足够量</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">99</span></sup><span>钼的</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> <sup><span>99</span></sup></span><span style="mso-ascii-font-family:\r\nPMingLiU">钼</span><span lang="EN-US" style="font-size:7.5pt;mso-ascii-font-family:\r\nPMingLiU">–</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n 宋体">99m</span></sup><span>鎝发生器，就可以在一周内每天淋洗出足够量的</span><sup><span lang="EN-US" style="font-family:PMingLiU;\r\n mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">99m</span></sup><span>鎝供临床使用，十分方便。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n 宋体">113m</span></sup><span>铟的</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">100</span><span>分钟，只发射<span>γ</span>光子</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">,</span><span>可标记多种化合物，亦由发生器获得，便于应用。但其<span>γ</span>光子能量为</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">393keV</span><span>，不适用于一般的<span>γ</span>照相机，可与扫瞄机配合进行脏器显像。由于短半衰期放射性同位素的应用，受检者一次接受的辐射吸收剂量一般皆远低于一次</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">X</span><span>线照相或造影，放射性废物的处理也大大简化，污染环境的可能性大为减小。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>2. </span><span>治疗用放射性药物</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>利用放射性药物治疗疾病主要依赖于其发射的射线在病变组织中产生的游离辐射生物学效应。以半衰期较长的<span>β<sup>–</sup></span>粒子为宜。<span>β<sup>–</sup></span>粒子在组织中电离密度大，在局部组织中所产生的生物学效应一般比相同物理当量的</span><span>X</span><span>线和<span>γ</span>光子大得多；同时由于它在组织内具有一定的射程</span><span>,</span><span>能保证有一定的作用范围，而对稍远的正常组织不造成明显损伤。现在用于治疗的较理想的放射性同位素是</span><sup><span>32</span></sup><span>磷，它是纯<span>β<sup>–</sup></span>粒子发射体，<span>β<sup>–</sup></span>粒子的能量为</span><span>1711 keV</span><span>，在组织中的平均射程为</span><span>4mm</span><span>，</span><span>T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">14.28</span><span>天。</span><sup><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">131</span></sup><span>碘发射两种<span>β<sup>–</sup></span>粒子，能量分别为</span><span>336</span><span>和</span><span>607 keV</span><span>，</span><span>T<sub>1/2</sub></span><span>为</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">8.04</span><span>天，也同时发射能量为</span><span>364 keV</span><span>的<span>γ</span>光子，此<span>γ</span>光子既无明显治疗作用，又增加防护上的困难，因此，</span><sup><span>131</span></sup><span>碘并不是内照射治疗的理想同位素，但目前它还是唯一能够有效治疗甲状腺有关疾病的放射性同位素，所以还十分常用。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>α</span><span>粒子和能量太弱的<span>β<sup>–</sup></span>粒子的有效照射范围太小，同时难以控制<span>α</span>粒子可能造成的局部过度损伤，故不宜采用。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>二、放射性试剂</span><span>(Radioactive\r\nReagent)</span></p>\r\n\r\n<p><span>放射性试剂指不需引入人体的放射性同位素和放射性标记物。为便于测量和防护，以发射能量较低的<span>γ</span>光子为宜，</span><span>T<sub>1/2</sub></span><span>较长便于一次购货供较长时间使用。目前最常用的是</span><sup><span>125</span></sup><span>碘，其<span>γ</span>光子的能量</span><span>35.5keV</span><span>，</span><span>T<sub>1/2</sub></span><span>为</span><span>60.2</span><span>天。偶尔也有用</span><sup><span>3</span></sup><span>氢的，由于其发射的<span>β<sup>–</sup></span>粒子能量极低，需特殊的放射性探测仪器测量。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>三、核医学仪器</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>核医学诊疗工作中需用的各种放射性探测仪器，称为核医学仪器。为了不同的目的，需用各种不同类型的核医学仪器，但其基本部件大多是<span>γ</span>闪烁探测器</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体"> (</span><span>γ</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">Scintillation Detector)</span><span>，由它对体内和样品中的放射性进行探测，形成脉冲信号，输送给电子测量装置和</span><span>/</span><span>或计算机进行计数和运算处理，最后作出符合需要的显示。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span style="font-size:10.0pt;">表</span><span style="font-size:10.0pt;">1-1 </span><span style="font-size:10.0pt;\r\nmso-ascii-font-family:PMingLiU">用于临床诊疗的放射性核素表</span></p>\r\n\r\n<table class="MsoNormalTable" border="1" cellspacing="1" cellpadding="0" width="557">\r\n <tbody><tr>\r\n  <td width="7%" colspan="2" valign="top" style="width:7.36%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">用途</span></p>\r\n  </td>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">元素名称</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">核素符号</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">半衰期</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">主要光<span>γ</span>子能量</span><span style="font-size:10.0pt;">(keV)</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:9.75pt">\r\n  <p><span style="font-size:10.0pt;">主要带电粒子及其能量</span><span style="font-size:10.0pt;">(keV)</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="7%" colspan="2" rowspan="14" valign="top" style="width:7.36%;padding:\r\n  .75pt .75pt .75pt .75pt;height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"> </span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">诊</span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">断</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">︵</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">体</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">内</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"> </span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">法</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">︶</span></p>\r\n  </td>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">碳</span><span style="font-size:10.0pt;">Carbon</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">11</span></sup><span lang="EN-US" style="font-size:\r\n   10.0pt">C</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">20.38min</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">湮没辐射</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">：</span><span lang="EN-US" style="font-size:\r\n  10.0pt">916</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">氮</span><span style="font-size:10.0pt;">Nitrogen</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">13</span></sup><span style="font-size:10.0pt;">N</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">9.96min</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">湮没辐射</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">：</span><span lang="EN-US" style="font-size:\r\n  10.0pt">1190</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">氧</span><span style="font-size:10.0pt;">Oxygen</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">15</span></sup><span style="font-size:10.0pt;">O</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">122s</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">湮没辐射</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">：</span><span lang="EN-US" style="font-size:\r\n  10.0pt">1723</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">氟</span><span style="font-size:10.0pt;">Fluorine</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">18</span></sup><span lang="EN-US" style="font-size:\r\n   10.0pt">F</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">109.8min</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">湮没辐射</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体">+</span></sup><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">：</span><span lang="EN-US" style="font-size:\r\n  10.0pt">635</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">铬</span><span style="font-size:10.0pt;">Chromium</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">51</span></sup><span style="font-size:10.0pt;">Cr</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">27.7d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">320</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">镓</span><span style="font-size:10.0pt;">Gallium</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">67</span></sup><span style="font-size:10.0pt;">Ga</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">78.3h</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">93,185,300</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">氪</span><span style="font-size:10.0pt;">Krypton</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">81m</span></sup><span style="font-size:10.0pt;">Kr</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">13s</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">190</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">鎝</span><span style="font-size:10.0pt;">Technetium</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">99m</span></sup><span style="font-size:10.0pt;">Tc</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">6.02</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">141</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">铟</span><span style="font-size:10.0pt;">Indium</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">111</span></sup><span lang="EN-US" style="font-size:\r\n   10.0pt">In</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">2.83d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">171,245</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">131m</span></sup><span style="font-size:10.0pt;">In</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">100min</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">393</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">碘</span><span style="font-size:10.0pt;">Iodine</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">123</span></sup><span style="font-size:10.0pt;">I</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">13.0h</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">159</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">131</span></sup><span style="font-size:10.0pt;">I</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">8.04</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">364,637</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span>–</span></sup><sup><span style="font-size:10.0pt;">：</span></sup><sup><span style="font-size:10.0pt;">336,607</span></sup></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span><!--[if gte vml 1]><v:shapetype id="_x0000_t75"\r\n   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"\r\n   filled="f" stroked="f">\r\n   \r\n   \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n    \r\n   \r\n   \r\n   \r\n  <v:shape id="_x0000_i1025" type="#_x0000_t75" alt="?.gif (131 bytes)"\r\n   style=''width:12.75pt;height:10.5pt''/><![endif]--><img width="17" height="14" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image001.gif" alt="?.gif (131 bytes)" /></span><span style="font-size:10.0pt;">Xenon</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">133</span></sup><span style="font-size:10.0pt;">Xe</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">5.25d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">81</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span>–</span></sup><sup><span style="font-size:10.0pt;">：</span></sup><sup><span style="font-size:10.0pt;">346</span></sup></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">铊</span><span style="font-size:10.0pt;">Thallium</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">201</span></sup><span style="font-size:10.0pt;">Tl</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">74h</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span style="font-size:10.0pt;">167</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:12.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="3%" rowspan="2" valign="top" style="width:3.12%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span style="font-size:10.0pt;">　</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">诊</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">　</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">断</span></p>\r\n  </td>\r\n  <td width="4%" rowspan="2" valign="top" style="width:4.06%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span style="font-size:7.5pt;">︵</span><span lang="EN-US" style="font-size:7.5pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">体</span></p>\r\n  <p><span style="font-size:10.0pt;">外</span></p>\r\n  <p><span style="font-size:10.0pt;">法</span><span lang="EN-US" style="font-size:7.5pt;font-family:PMingLiU;mso-hansi-font-family:\r\n  宋体"></span></p>\r\n  <p><span style="font-size:7.5pt;">︶</span></p>\r\n  </td>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span style="font-size:10.0pt;">氢</span><span style="font-size:10.0pt;">Hydrogen</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><sup><span style="font-size:10.0pt;">3</span></sup><span style="font-size:10.0pt;">H</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span style="font-size:10.0pt;">12.33y</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:22.5pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span>–</span></sup><sup><span style="font-size:10.0pt;">：</span></sup><sup><span style="font-size:10.0pt;">18.6</span></sup></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:48.75pt">\r\n  <p><span style="font-size:10.0pt;">碘</span><span style="font-size:10.0pt;">Iodine</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:48.75pt">\r\n  <p><sup><span style="font-size:10.0pt;">125</span></sup><span style="font-size:10.0pt;">I</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:48.75pt">\r\n  <p><span style="font-size:10.0pt;">60.2d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:48.75pt">\r\n  <p><span style="font-size:10.0pt;">35.5</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:48.75pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="7%" colspan="2" rowspan="2" valign="top" style="width:7.36%;padding:\r\n  .75pt .75pt .75pt .75pt;height:14.25pt">\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">治</span><span lang="EN-US" style="font-size:\r\n  10.0pt;font-family:PMingLiU;mso-hansi-font-family:宋体"></span></p>\r\n  <p><span style="font-size:10.0pt;">&nbsp;&nbsp;</span><span lang="EN-US" style="font-size:10.0pt;font-family:PMingLiU;mso-fareast-font-family:\r\n  宋体;mso-hansi-font-family:宋体"> </span><span style="font-size:10.0pt;\r\n  mso-ascii-font-family:PMingLiU">疗</span></p>\r\n  </td>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:14.25pt">\r\n  <p><span style="font-size:10.0pt;">磷</span><span style="font-size:10.0pt;">Phosphorus</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:14.25pt">\r\n  <p><sup><span style="font-size:10.0pt;">32</span></sup><span style="font-size:10.0pt;">P</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:14.25pt">\r\n  <p><span style="font-size:10.0pt;">14.28d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:14.25pt">\r\n  <p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\n  color:navy">&nbsp;</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:14.25pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span>–</span></sup><sup><span style="font-size:10.0pt;">：</span></sup><sup><span style="font-size:10.0pt;">1711</span></sup></p>\r\n  </td>\r\n </tr>\r\n <tr>\r\n  <td width="14%" valign="top" style="width:14.74%;padding:.75pt .75pt .75pt .75pt;\r\n  height:15.0pt">\r\n  <p><span style="font-size:10.0pt;">碘</span><span style="font-size:10.0pt;">Iodine</span></p>\r\n  </td>\r\n  <td width="10%" valign="top" style="width:10.8%;padding:.75pt .75pt .75pt .75pt;\r\n  height:15.0pt">\r\n  <p><sup><span style="font-size:10.0pt;">131</span></sup><span style="font-size:10.0pt;">I</span></p>\r\n  </td>\r\n  <td width="12%" valign="top" style="width:12.78%;padding:.75pt .75pt .75pt .75pt;\r\n  height:15.0pt">\r\n  <p><span style="font-size:10.0pt;">8.04d</span></p>\r\n  </td>\r\n  <td width="23%" valign="top" style="width:23.62%;padding:.75pt .75pt .75pt .75pt;\r\n  height:15.0pt">\r\n  <p><span style="font-size:10.0pt;">364,637</span></p>\r\n  </td>\r\n  <td width="29%" valign="top" style="width:29.52%;padding:.75pt .75pt .75pt .75pt;\r\n  height:15.0pt">\r\n  <p><span style="font-size:10.0pt;">β</span><sup><span>–</span></sup><sup><span style="font-size:10.0pt;">：</span></sup><sup><span style="font-size:10.0pt;">336,607</span></sup></p>\r\n  </td>\r\n </tr>\r\n</tbody></table>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l8 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>1.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span lang="EN-US" style="mso-ascii-font-family:\r\nPMingLiU">γ</span><span>闪烁探测器的工作原理</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>γ</span><span>闪烁探测器由碘化钠﹝</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">NaI(T1)</span><span>﹞晶体，光电倍增管和前置放大器组成</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-14)</span><span>。一个<span>γ</span>光子入射碘化钠晶体，能使一个晶体分子激发而产生闪烁萤光</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Scintillation) </span><span>，此萤光射到光电倍增管阴极，通过光电转换产生光电子，所产生的光电子数量与入射萤光光子的数量成正比。由于在光电倍增管中有一个由稳压定电源维持着的各联极间及最后一个联极与阳极间的电位差，光电子在电场作用下加速射达下一个联极时，产生</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">3~6</span><span>倍的次级电子，这种电子倍增过程依次在联极中发展下去，在到达阳极前要通过</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">8~14</span><span>个联极，到最后一个联极时，电子数可增加</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">10<sup>5</sup>~10<sup>8</sup></span><span style="mso-ascii-font-family:\r\nPMingLiU">倍，这样大量的电子流最后射到阳极立即产生一个电位降，随即阳极电压又恢复到原有水平，这就形成一个瞬间负电压脉冲，脉冲经前置放大器放大即可输送到电子测量仪器和</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">/</span><span>或计算器进行处理和显示。可见，一个<span>γ</span>光子入射晶体产生一个闪烁事件，一个闪烁事件发生一个脉冲，因此记录这些脉冲数就是记录入射探测仪器的<span>γ</span>光子数量。</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-hansi-font-family:宋体"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l6 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>2.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>活度计</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Radioactivity Calibrator)</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-hansi-font-family:宋体"></span></p>\r\n\r\n<p><span>将盛有放射性药物或试剂的小瓶或注射器直接放入活度计，可直接准确读出贝克</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Bq)</span><span>或居里</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Ci)</span><span>数。活度计是核医学工作中最基本的量器，关系到诊疗用药量的准确性。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l4 level1 lfo4;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>3.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span lang="EN-US" style="mso-ascii-font-family:\r\nPMingLiU">γ</span><span>照相机</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (</span><span>γ</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">Camera)</span><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:\r\n宋体"></span></p>\r\n\r\n<p><span>γ</span><span>照相机是核医学科最基本和很重要的显像仪器。由直径</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">300~600mm</span><span>的<span>γ</span>闪烁探测器、探测器支架、计算机操纵运算台和显示器等部件组成</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-15)</span><span>。体内放射性由<span>γ</span>闪烁探测器探测到，形成定位脉冲信号由计算器采集和处理，最后以不同的灰度或颜色和不同的方式显示出脏器和病变的影像。若附有特殊装置可以进行全身显像。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l7 level1 lfo5;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>4.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>单光子计算机断层摄影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Single Photon Emission Computed Tomography; SPECT)</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>有多种类型，最常用者为旋转型<span>γ</span>照相机</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-16)</span><span>，由<span>γ</span>闪烁探测器围绕躯体作</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-fareast-font-family:宋体;mso-hansi-font-family:宋体">180</span><span>°</span><span>或</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">360</span><span>°</span><span>自动旋转，对体内的<span>γ</span>光子进行多角度的探测，众多的讯息由计算机采集，利用特殊软件和快速数组处理机重建成各种断层影像。当探测器不旋转时，该机亦可作一般<span>γ</span>照相机使用，也可进行全身显像，因此是一机三体，是性能最为全面的核医学显像仪器，机名中的</span><span style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> </span><span>”</span><span>单光子</span><span>”</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:\r\n宋体;mso-hansi-font-family:宋体"> </span><span>即是<span>γ</span>光子，</span><span>”</span><span style="mso-ascii-font-family:\r\nPMingLiU">发射</span><span>”</span><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:宋体">(Emission)</span><span>指<span>γ</span>光子是由体内发射出来，以区别于</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">X</span><span>线是从体外穿透</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Transmission)</span><span>人体而达接受器，故</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">XCT</span><span>属穿透型</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">CT(TCT) </span><span>，核素</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">CT</span><span>属发射型</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">CT (ETC)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l3 level1 lfo6;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>5.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>正子计算机断层摄影</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (Photon Emission Computed Tomography ; PET)</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p><span>PET</span><span>是专为探测体内正发射体互毁辐射时同时产生的方向相反的两个<span>γ</span>光子而设计的显像仪器。数十个直至上百个小<span>γ</span>闪烁探测器环形排列，在躯体四周同时进行探测，其它部件基本同</span><span>SPECT</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:\r\n宋体;mso-hansi-font-family:宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-17)</span><span>。</span><span>PET</span><span>是进行心、脑代谢显像不可缺少的设备，但因价格昂贵，正发射体及其标记物价格也高，故较难推广应用。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l2 level1 lfo7;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>6.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>扫描机</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Scanner)</span><span lang="EN-US" style="font-family:PMingLiU;mso-hansi-font-family:\r\n宋体"></span></p>\r\n\r\n<p><span>是旧式的核医学显像仪器，由<span>γ</span>闪烁探测器，探测器移动架、电子线路和打印或其它显示装置组成</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-18)</span><span>。<span>γ</span>闪烁探测器在体表做逐行等速移动，探测体内各点的放射性，由电子线路采集并输送到打印装置作同步逐点显示，最后形成脏器的影像，称扫描图。这种显像方法叫扫描</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Scanning)</span><span>。扫描图由于信息量少</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">,</span><span>质量远不如<span>γ</span>照相机所获得的影像。扫描成像很慢，不能进行变化很快的动态显像。故用扫描机进行放射性同位素显像难以显示功能显像的特点，价值有限，已被<span>γ</span>照相机取代。</span><span lang="EN-US" style="font-family:PMingLiU;\r\nmso-hansi-font-family:宋体"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l9 level1 lfo8;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>7.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>非显像核医学仪器</span><span style="font-family:pmingliu;"> </span></p>\r\n\r\n<p><span>常用的有甲状腺功能测定仪、</span><span style="font-size:7.5pt;font-family:PMingLiU;mso-fareast-font-family:宋体;\r\nmso-hansi-font-family:宋体"> </span><span>肾图仪、<span>γ</span>心功能仪和局部脑血流测定仪。皆由一个或多个<span>γ</span>闪烁探测器、探测器支架、电子测量装置、计算机、记录显示装置组成</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-19)</span><span>。用探测器对准甲状腺、两侧肾脏、左、右心室和脑各部位探测它们的放射性、由电子测量装置或计算器采集，最后以计数率或时间</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">-</span><span>放射性曲线的方式显示，给出功能参数。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l5 level1 lfo9;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>8.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>样品测量仪器</span><span style="font-family:pmingliu;"> </span></p>\r\n\r\n<p><span>常用的是井型<span>γ</span>计数器</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(Well Type</span><span>γ</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">Counter) </span><span>和液体闪烁计数器</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体"> (Liquid Scintillation Counter)</span><span style="mso-ascii-font-family:\r\nPMingLiU">，由<span>γ</span>闪烁探测器</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">/</span><span>液体闪烁探测器，电子线路、计算器、样品传送装置和计数打印装置等部件组成，手动或自动逐个探测每个样品中的放射性，定量记录和打印显示计数和各种运算结果</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">(</span><span>图</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">1-20)</span><span>。</span><span style="font-family:pmingliu;"></span></p>\r\n\r\n<p style="margin-left:0cm;text-indent:-18.0pt;mso-list:l0 level1 lfo10;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-family:\r\nPMingLiU;mso-hansi-font-family:宋体;mso-bidi-font-family:PMingLiU"><span>9.<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span><span>防护用沾染监测仪和剂量仪</span><span style="font-family:pmingliu;"> </span></p>\r\n\r\n<p><span>沾染监测仪用于探测皮肤、衣物和环境有无放射性沾染。剂量仪用于测量工作场所的照射量，读数常以</span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">mR/h</span><span>和<span>μ</span></span><span lang="EN-US" style="font-family:PMingLiU;mso-fareast-font-family:宋体;mso-hansi-font-family:\r\n宋体">R/S</span><span>表示。</span><span style="font-family:pmingliu;"></span></p>', 'gwm', 0, 23);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(247, '什么是核医学 ', '详细介绍', '', '', '2009-12-02 11:08:24', '116.228.141.77', '<p><span><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　核医学，又称原子（核）医学，是研究同位素及核辐射的医学应用及理论基础的科学，是核技术和医学相结合的一门新兴学科，也是人类和平利用原子能的一个重要方面。</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">　　</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span></span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　核医学的任务是用核技术诊断、治疗和研究疾病。核医学诊断技术包括脏器显像、功能测定和体外放射免疫分析。在进行脏器显像和</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">/</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">或功能测定时，医生根据检查目的，给病人口服或静脉注射某种放射性示踪剂，使之进入人体后参与体内特定器官组织的循环和代谢，并不断地放出射线。这样我们就可在体外用各种专用探测仪器追踪探查，以数字、图像、曲线或照片的形式显示出病人体内脏器的形态和功能。核医学显像方法简单、灵敏、特异、无创伤性、安全（病人所受辐射剂量低于一次</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">摄片所受剂量）、易于重复、结果准确、可靠，并能反映脏器的功能和代谢，因此在临床和基础研究中的应用日益广泛。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span></p>', 'gwm', 0, 22),
(248, '核医学仪器', '详细介绍', '', '', '2009-12-02 11:11:42', '116.228.141.77', '<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">核医学显像所用的仪器主要是γ照相机和</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">ECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　γ相机是现代核医学的重要诊断设备，γ相机可同时记录脏器内各个部份的射线，以快速形成一帧器官的静态平面图像，同时因其成像速度快，亦可用于获取反映脏器内放射性分布变化的连续照片，经过数据处理后，可观察脏器的动态功能及其变化，因此γ相机既是显像仪又是功能仪。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">ECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">包括</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">SPECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">和</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　我们通常所说的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">ECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">指的是单光子发射型计算机断层显像仪，即</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">SPECT</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">。它实际上就是一个探头可以围绕病人某一脏器进行</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">360</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">°旋转的γ相机，在旋转时每隔一定角度（</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">3</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">°或</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">6</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">°）采集一帧图片，然后经电子计算机自动处理，将图像叠加，并重建为该脏器的横断面、冠状面、矢状面或任何需要的不同方位的断层，切面图像，从而极大地提高了诊断的灵敏度和正确性。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">SPECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">同时也具有一般γ相机的功能，可以进行脏器的平面和动态（功能）显像。</span><span style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"> </span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">，即正电子发射计算机断层显像</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">(Positron Emission Computed Tomography),</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">是目前国际上最尖端的医学影像诊断设备，也是目前在分子水平上进行人体功能显像的最先进的医学影像技术。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">的基本原理是利用加速器生产的超短半衰期同位素</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">如</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18F</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">、</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">13N</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">、</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">150</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">、</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">11C</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">等作为示踪剂注入人体</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">参与体内的生理生化代谢过程。这些超短半衰期同位素是组成人体的主要元素，利用它们发射的正电子与体内的负电子结合释放出一对伽玛光子</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">被探头的晶体所探测</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">,,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">得到高分辨率、高清晰度的活体断层图像，以显示人脑、心、全身其它器官及肿瘤组织的生理和病理的功能及代谢情况。作为一种无创伤检查手段</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">可以从体外对人体内的代谢物或药物的变化进行定量、动态检测</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">成为诊断和指导治疗各类肿瘤疾病、冠心病和脑部疾病的最佳方法。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">的发展及其成功的临床应用是当代高科技医疗诊断技术的主要标志之一。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">在临床医学的应用主要集中于神经系统、心血管系统、肿瘤三大领域。但</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">价格昂贵，需配置小型医用回旋加速器，日常管理费用高，难以普遍推广。</span></p>\r\n\r\n<span style="font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">　　在临床应用方面：</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;;mso-fareast-font-family:宋体;mso-bidi-font-family:\r\n&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:\r\nZH-CN;mso-bidi-language:AR-SA">PET</span><span style="font-size:10.5pt;\r\nfont-family:宋体;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;;\r\nmso-bidi-font-family:&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:\r\nEN-US;mso-fareast-language:ZH-CN;mso-bidi-language:AR-SA">是非常灵敏与特异的诊断心脏病的工具；</span><span lang="EN-US" style="font-size:10.5pt;font-family:&quot;\\000B&quot;;mso-fareast-font-family:\r\n宋体;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:\r\nEN-US;mso-fareast-language:ZH-CN;mso-bidi-language:AR-SA">PET</span><span style="font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">对恼肿瘤、癫痫、痴呆、帕金森病、抑郁症、脑血管疾病及神经退行性疾病等的诊断、疗效观察具有独特的作用；</span><span lang="EN-US" style="font-size:10.5pt;font-family:&quot;\\000B&quot;;mso-fareast-font-family:\r\n宋体;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-font-kerning:1.0pt;mso-ansi-language:\r\nEN-US;mso-fareast-language:ZH-CN;mso-bidi-language:AR-SA">PET</span><span style="font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;;\r\nmso-font-kerning:1.0pt;mso-ansi-language:EN-US;mso-fareast-language:ZH-CN;\r\nmso-bidi-language:AR-SA">在肿瘤的诊断和指导治疗发挥着独特的作用，具体应用有：良、恶性的鉴别；评定恶性程度；临床分期；寻找原发灶和转移灶、评价疗效和确定是否复发。</span>', 'gwm', 0, 16),
(249, '功能性与解剖性影像学比较', '详细介绍', '', '', '2009-12-02 11:13:04', '116.228.141.77', '<p><span><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">医学影像学检查包括放射学（</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">平片、</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">等）、磁共振显像（</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">）、超声显像和放射性核素显像等。其中放射学和</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">属于解剖性显像（最新的</span></span><span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span></span><span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">也具有功能性成像的优点），放射性核素显像是功能性显像，而超声显像是形态和动态（功能）的结合。</span></span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　　　　　　　　　　　　　　　　</span><strong><span lang="EN-US" style="font-size:10.5pt;font-family:&quot;\\000B&quot;;mso-bidi-font-family:\r\n&quot;Arial Unicode MS&quot;">XCT </span></strong><strong><span style="font-size:10.5pt;\r\nfont-family:&quot;Arial Unicode MS&quot;;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;;mso-bidi-font-family:&quot;Arial Unicode MS&quot;">　</span></strong><strong><span style="font-size:10.5pt;font-family:&quot;\\000BArial Unicode MS&quot;">\r\n</span></strong><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">　</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">像普通</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">照片一样</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">也是一种穿透型的放射线成像技术。</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">线成像的基本原理是</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">:</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">放射源</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线球管</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">被放置在体外一定距离处</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">在给球管加上一定的高压电流的瞬间产生一束高度准直的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">穿透人体的靶器官</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">使放置在另一侧的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">片感光。由于人体靶器官的各个组织的密度不同</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">对透过的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线的能量的吸收亦不相同</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">在</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">片上产生不同程度的感光效应而显示出靶器官的二维平面影像。而</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">是将高度准直的</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">线束围绕靶器官作断层扫描</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">记录下的大量信息经电子计算机处理</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">计算出靶器官内不同部位和深度的各个点的</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">线吸收系数值</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">用不同的灰阶表示</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">形成靶器官的横断层解剖结构图像。其分辨力和灵敏度比普通</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">片又有很大的提高。通过增强扫描还可提高某些病变组织的对比度。因此</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">XCT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">不仅能显示病变的部位、大小和性质</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">也能清楚地显示病灶与周围组织的关系</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">为诊断和治疗提供重要的信息。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">\r\n</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　由于</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">线</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">成像直接与组织的密度有关</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">因此它只能探查解剖结构的改变而不能得到组织器官内的功能性</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">代谢、血流和受体</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">变化的信息。而且只有当病变部位的组织结构变化达到一定程度时</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">在</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像上才能反映出来。因此对于某些尚未出现结构性损伤和</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">/</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">或只有功能性变化的疾病，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">XCT</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">常常是阴性的。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　　　　　　　　　　　　　　　　</span><strong><span lang="EN-US" style="font-size:10.5pt;font-family:&quot;\\000B&quot;;mso-bidi-font-family:\r\n&quot;Arial Unicode MS&quot;">MRI </span></strong><strong><span style="font-size:10.5pt;\r\nfont-family:&quot;Arial Unicode MS&quot;;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;;mso-bidi-font-family:&quot;Arial Unicode MS&quot;">　</span></strong><strong><span style="font-size:10.5pt;font-family:&quot;\\000BArial Unicode MS&quot;">\r\n</span></strong><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">　</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">技术与通常</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">线成像技术在某些方面有其相似之处</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">但两者所依据的物理过程、接收和分析信息的方法及所获得的信息的内容却完全不同。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">X</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">射线和放射性核素成像原理都是利用光子流作为射线源</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">射线穿透人体或从人体中发射出来形成影像</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">;</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">而磁共振成像则利用人体内原子核固有的自旋特性</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">在外界射频场的作用下产生磁共振。由于所用的射线源为射频场</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">所以又称为射频成像</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">这种成像对人体是无损伤、无放射性的。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">技术具有不少独特的优点</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">如可获得多成像参数和多方向切层成像</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">;</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">有比</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">更高的软组织分辨能力</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">;</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">不需用造影剂即可显示血管结构</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">;</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">无骨性伪影等。最新的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">技术还可获得少量的功能性信息。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　　　　　　　　　　　　　<strong><span style="font-family:&quot;Arial Unicode MS&quot;;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;;mso-bidi-font-family:&quot;Arial Unicode MS&quot;">　放射性核素显像</span></strong></span><strong><span style="font-size:10.5pt;font-family:&quot;\\000BArial Unicode MS&quot;">\r\n</span></strong><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">　　</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　功能性即放射性核素显像与</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">XCT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">都是利用射线成像的技术</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">但与</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">XCT</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">不同的是</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">功能性显像是把放射源</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">(</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">放射性核素示踪剂</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">)</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">引入体内</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">用探头在体外探查核素在靶器官内的动态和</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">/</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">或静态分布状况。这些示踪剂具有一定的生理生化特征，借以可了解人体器官的功能和生理生化方面的变化。绝大多数疾病在病程的早期仅有功能（包括血流、代谢和受体）上的改变，有的疾病经治疗后结构上的变化恢复正常，但功能上的损伤仍然存在，此时</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">和</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">MRI</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">常阴性</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">而功能性显像可以为疾病的诊断</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">特别是早期诊断提供重要的信息。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　功能性脑显像的最大缺点是不能定性。它所反映的是各种病理生理和解剖结构变化均可引起的局部血流和代谢的改变</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">必须结合临床加以分析。</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"> </span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　　　　　　　　　　　<strong><span style="font-family:&quot;Arial Unicode MS&quot;;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;;mso-bidi-font-family:&quot;Arial Unicode MS&quot;">功能性和解剖性显像的关系</span></strong>　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"> </span></p>\r\n\r\n<p><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　人体器官的功能和解剖结构是相互依存的。人体器官的功能活动是以其解剖结构为基础，而解剖结构的存在又必须依赖其正常的功能活动</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">血供和代谢</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">。解剖结构的变化必然伴有功能的改变</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">而持久的功能活动异常也终将导致解剖结构的损伤</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">这就决定了功能性和解剖性显像两者之间的关系只能是相辅相成、互为补充、互为一体。然而这些影像学检查费用相对来说都是比较高的，不可能每个病人都重复利用这些检查手段。这就要求临床医生及放射学和核医学工作者在全面了解上述医学成像技术的原理、方法和各自特点的基础上，严格掌握它们的临床适应征，结合病人的具体情况</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">选择不同的检查方法，以达到诊断和治疗的目的</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"> </span></p>', 'gwm', 0, 32);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(250, '18FDG PET显像', '详细介绍', '', '', '2009-12-02 11:34:10', '116.228.141.77', '<p><b><sup><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">18</span></sup></b><b><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">FDG PET</span></b><b><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">显像</span></b><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　正电子发射断层摄影</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(positron-emisson tomography</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">，是利用符合电路探测正电子发射的相反方向一对</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">511keV</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">光子在组织内分布的全身断层扫描装置，是最新一代的核显像仪，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">已由研究阶段进入临床应用，至今，国外建立了上百个临床</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">PET</span><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">中心，我国在</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">1990</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">年研制成功二环</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">用于动物实验，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">1994</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">年</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">4</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">环</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">仪用于临床，</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">1995</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">年国内自山东淄博引进第一台</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">和医用加速器以来，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">1996</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">年北京、上海和广州等地相继引进</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">11</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">台</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET,</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">成立</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">7</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">个</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">中心，符合电路</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">SPECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">有</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">8</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">台，标志着我国的核显像技术已从</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">SPECT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">的功能显像进入</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">的</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">"</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">化学</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">"</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">或代谢显像。</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">显像的临床应用主要有肿瘤、心、脑疾病等</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">3</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">个方面，其中肿瘤占</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">85</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;\r\nmso-hansi-font-family:&quot;\\000B&quot;">％左右，心肌活力检测和脑退行性疾病、癫痫等病占</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">15</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">％左右。</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">是应用</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">F</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">正电子标记的脱氧葡萄糖，在己糖激酶的作用下，形成的</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;">FDG-6</span><span style="font-size:10.5pt;\r\nmso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">磷酸，不参与正常葡萄糖代谢，而在高糖酵解的肿瘤部位有较多的放射性浓集的原理来进行的。通常，肿瘤的恶性程度越高，高代谢的糖酵解越多，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">的聚集越多，相反低代谢良性疾病则</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">FDG</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">的浓集少或不浓集，因此</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像不但用于肿瘤诊断，还可用于良恶性疾病的鉴别诊断。</span><span lang="EN-US" style="font-size:\r\n10.5pt;font-family:&quot;\\000B&quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像在肿瘤方面的应用范围很广，可用于肺孤立结节、淋巴瘤、消化道肿瘤</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">包括结直肠、胰腺、胃、肝和食管肿瘤</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">、头颈部肿瘤包括甲状腺癌、乳腺癌、卵巢癌、黑色素瘤和脑肿瘤等病的诊断。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像在以下情况有独特的优势。①恶性肿瘤的诊断，良恶性肿块的鉴别和全身转移灶的探查，如肺部孤立性结节的良恶性质的鉴别，纵隔淋巴结以及全身远处转移提供的肿瘤的代谢情况远比</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CT</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">等解剖学信息正确；②病程病期的分类为合理的治疗方案提出依据；③肿瘤术后复发还是瘢痕组织的鉴别；④肿瘤放疗后复发还是放疗后坏死；⑤肿瘤治疗如放疗和化疗前后疗效监测等都有十分重要的临床价值；⑥对于血肿瘤标志物如</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CEA</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">AFP</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">、</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">CAl9-9</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">等持续增高的病人进行原发和全身转移灶的寻找更有其独特的优势；⑦根据脑肿瘤特别是星状细胞和胶质母细胞瘤对</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">摄取程度来反映组织学的分化程度可补充病理形态学的不足；⑧全身健康检查可早期发现隐匿的微小病灶为早期治疗创造了有利条件。</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;"></span></p>\r\n\r\n<p><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">　　在方法学上，由于</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">在病变组织浓集多而血液清除快，有较高的靶</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">/</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">非靶比值，再加以采用全身衰减校正，图像的清晰度和分辨率有了进一步的提高，灵敏度可达到小于</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">0.5cm</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">的深部肿瘤也能分辨。此外，应用</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">T/NT,</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">标准摄取比值</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">(SUV)</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">和局部葡萄糖代谢率</span><span lang="EN-US" style="font-size:10.5pt;font-family:\r\n&quot;\\000B&quot;">(rLGluMR)</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">等定量指标，使方法的正确性得到保证，特别是对良恶性病变的鉴别有重要价值，虽然</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像有上述诸多的优点，并有广泛的应用前景，但是</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;">FDG</span><span style="font-size:10.5pt;mso-ascii-font-family:\r\n&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">的摄取并非肿瘤组织所特有，也可浓集于心、脑等正常组织，而且炎症、肉样瘤、结核病变以及泌尿道等也有较多的</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">浓集，因此也有一定的假阳性，但有较高的阴性预测值。总之，目前</span><sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">18</span></sup><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">FDG PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像是最具发展前途的一种阳性核医学显像技术，相信随着临床应用经验的不断积累，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:\r\n10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:&quot;\\000B&quot;">显像仪的进一步改进和正电子显像剂的不断发展，</span><span style="font-size:10.5pt;font-family:&quot;\\000B &quot;">PET</span><span style="font-size:10.5pt;mso-ascii-font-family:&quot;\\000B&quot;;mso-hansi-font-family:\r\n&quot;\\000B&quot;">显像对肿瘤的诊断治疗和研究是具有很大潜力的。</span><span lang="EN-US" style="font-size:10.5pt;\r\nfont-family:&quot;\\000B&quot;"></span></p>', 'gwm', 0, 24),
(251, 'PET-CT 与恶性淋巴瘤 ', '临床应用', '', '', '2009-12-04 15:01:03', '116.228.141.77', '<p><span><span>&nbsp;&nbsp; &nbsp;PET-CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">与恶性淋巴瘤恶性淋巴瘤是原发于淋巴结或淋巴结外组织或器官的恶性肿瘤。根据临床和病理特点的不同，其可分为霍奇金淋巴瘤</span></span><span><span>(Hodgkin''s\r\nlymphoma</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span>HL)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和非霍奇金淋巴瘤</span></span><span><span>(non-Hodgkin''s\r\nlymphoma</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span>NHL)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">两大类。恶性淋巴瘤治疗的关键是早期诊断、准确分期、正确判断病情以及治疗反应的监测。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span>1.<span>&nbsp; </span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">早期诊断</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:26.25pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在使用</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">评价淋巴瘤的研究中，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">大多数研究对象为</span></span><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和弥漫性大</span></span><span><span>B</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">细胞性</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，对其他组织学类型的淋巴瘤研究资料有限。</span></span><span><span>Elstrom\r\nR</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 172 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例各种类型淋巴瘤患者的</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">进行回顾性研究：</span></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">准确地探测到了弥漫性大</span></span><span><span>B</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">细胞性</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">细胞淋巴瘤、滤泡性淋巴瘤和</span></span><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">病灶。</span></span><span><span>18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">探测边缘区淋巴瘤可靠性低，尤其是结外的边缘区淋巴瘤。在对惰性</span></span><span><span>B</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">细胞性</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的研究中发现，</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">对滤泡性</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的诊断、治疗有潜在优势，但对小淋巴细胞性淋巴瘤，只能探测到</span></span><span><span> 50</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的病灶。还有一些使用标准化摄取值</span></span><span><span>(standardizeduptakevalue</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>SUV)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">测定肿瘤</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取程度的研究认为，</span></span><span><span>18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">能够预测惰性淋巴瘤的组织学转变。但是，</span></span><span><span>SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">与淋巴瘤病理亚型、有丝分裂率的关系仍有争议。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span>2</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">．临床分期</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">虽然只占所有恶性肿瘤的</span></span><span><span>8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，但却是少数几种可治愈的肿瘤。对恶性淋巴瘤的治疗不仅取决于其组织学亚型，而且要根据具体、准确的临床分期。</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤显像通过发现代谢异常病灶，特别是探测到其他检查未发现的隐性的腹部病灶或脾脏病灶，可显著提高了淋巴瘤最初分期的准确性。</span></span><span><span>BangerterM</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等应用</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">对</span></span><span><span> 44 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例已确诊为</span></span><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的患者进行治疗前评价：</span></span><span><span>5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例分期上调，</span></span><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例分期下调。初步研究表明，在</span></span><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">患者的分期方面，</span></span><span><span> 18F-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">优于</span></span><span><span>67Ga</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">淋巴瘤的骨髓浸润较常见，是淋巴瘤患者预后不良的征兆之一，且决定淋巴瘤的分期。研究表明，用</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">可准确显示淋巴瘤骨髓浸润。</span></span><span><span>Buchmann</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等比较了</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">与</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、骨髓活检在</span></span><span><span>NHL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>HL</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期中的作用，结果是</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">优于</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；</span></span><span><span>8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％（</span></span><span><span>4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">／</span></span><span><span>52</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）患者经</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">导致分期上调，改变了治疗计划。</span></span><span><span>Moog FM</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span> 78 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例淋巴瘤患者的</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">、骨髓活检结果进行了比较，其中</span></span><span><span> 64 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者的双侧骨髓活检与</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">结果一致；对</span></span><span><span> 10</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例骨髓</span></span><span><span>18F</span></span><span><span>-FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取增高而骨髓活检阴性的患者进行</span></span><span><span> MRI </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、聚合酶链反应</span></span><span><span>(polymerasechainreaction</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>PCR)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等检查，证实其中</span></span><span><span> 8 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例淋巴瘤累及骨髓；有</span></span><span><span> 4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">没有探测到骨髓浸润。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span>3</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">．疗效评价</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:26.25pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对淋巴瘤治疗的最终目标是通过化疗、放疗等疗法的毒性作用，彻底清除肿瘤细胞。然而，各种淋巴瘤对治疗的反应相差甚大。造成这种反应差异的原因是肿瘤组织学类型、生物学差异、药物抵抗机制、放疗或化疗敏感性的不同等。在治疗中或治疗后及早判断治疗反应有利于及时更改治疗方案。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:26.25pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">常规解剖显像对肿瘤反应或进展的判断基于肿瘤的大小，治疗有效时，由于治疗引起的肿瘤结构变化滞后于肿瘤细胞的死亡，解剖显像上的肿块可持续存在。而</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">可显示肿瘤代谢活性明显减低，肿瘤对</span></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取减少或消失是在临床或亚临床水平上对肿瘤治疗有效的早期标志，及时评价治疗效果可修正临床恶性淋巴瘤的治疗方案应用。</span></span><span><span></span></span></p>', 'gwm', 0, 8);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(252, 'PET-CT 与结直肠癌', '临床应用', '', '', '2009-12-04 15:07:24', '116.228.141.77', '<p><span><span>PET-CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">与结直肠癌</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结直肠肿瘤在美国居常见肿瘤发生率的第二位。其手术治疗后的复发率高达</span></span><span><span>\r\n30%-40%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，且大多发生在术后二年内。因此结直肠癌的诊断和术后复发的早期诊断显得尤为重要。</span></span><span><span>Abdel-Nabi\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 44 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例活检证实和</span></span><span><span> 4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例临床高度怀疑为结直肠癌的患者施行</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查，结果发现</span></span><span><span> FDG-PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对结直肠癌的敏感度为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、特异度为</span></span><span><span> 43%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、阳性预测率为</span></span><span><span> 90%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、阴性预测率为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、对淋巴结转移的敏感度为</span></span><span><span> 29%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、对肝转移的敏感度为</span></span><span><span> 88%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，显示了较高的临床诊断价值。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">最重要的应用在于早期发现结直肠癌的复发。通常复发多表现为局部、局段的复发或转移（特别是肝转移）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，这其中仅</span></span><span><span> 1/4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的患者有机会再行手术治疗，但及时的诊断可使这一机会提高到大约</span></span><span><span> 70%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。因此早期发现和定位复发在此人群中的作用特别重要。</span></span><span><span>Conti\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等回顾了</span></span><span><span> 89-96 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年报道的</span></span><span><span> 192 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例局部结直肠癌复发的病例发现</span></span><span><span>\r\nFDG-ET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检测对结直肠癌复发诊断的敏感度为</span></span><span><span>95%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异度为</span></span><span><span> 98%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，精确度为</span></span><span><span> 96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Schiepers\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等报道</span></span><span><span> 76 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例结直肠癌复发患者分别行</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查其敏感度分别为</span></span><span><span> 60%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 93%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异度为</span></span><span><span> 79%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>97%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，精确度为</span></span><span><span> 68%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 95%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Hussein\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等研究认为</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>MRI </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等结构成像技术容易受到外科手术后结构改变的影响。</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">是基于代谢成像的，因此有助于术后复发肿瘤的定性和定位。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结直肠癌术后</span></span><span><span> CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">升高是肿瘤复发的重要提示性标志之一。因此目前临床常用</span></span><span><span> CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为结直肠癌术后可靠而价廉的监测指标。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">但是</span></span><span><span> CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">水平的升高常伴有阴性的传统影像检查结果，以致于最终不得不依靠第二次探腹手术。尽管第二次探腹发现肿瘤复发的概率接近</span></span><span><span> 90%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，但由于时间原因这些患者中适合再行根治性手术的患者仅</span></span><span><span>\r\n12%-60%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">。</span></span><span><span>Flanagan </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span> 22 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例结直肠癌术后</span></span><span><span>CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不正常，但传统肿瘤测定方法检测正常的患者行</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查。结果发现</span></span><span><span> 22 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例中有</span></span><span><span> 17 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结果不正常，其中</span></span><span><span> 7 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例再手术证实为复发，余下</span></span><span><span> 10 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例中的</span></span><span><span> 8 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例，最终通过影像随访或临床病理检查证实为复发。并且</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">提示不正常的</span></span><span><span> 15 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例中有</span></span><span><span> 4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例得到完整切除，</span></span><span><span>11 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">提示不能切除与手术结果相符。其研究结果表明</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">对</span></span><span><span> CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">升高的结直肠癌患者复发的阳性预测率为</span></span><span><span> 89%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，阴性预测率为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Conti\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等总结了</span></span><span><span> 46 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例结直肠癌术后</span></span><span><span>CEA </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">升高的患者行</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检测的结果，认为</span></span><span><span> FDG-PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对肿瘤复发的敏感度可达</span></span><span><span> 94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。因此可以认为</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">技术对诊断结直肠癌复发有重要意义并且有助于复发肿瘤的定位和确定再次手术能否完全切除。</span></span><span><span></span></span></p>', 'gwm', 0, 12),
(253, 'PET-CT与临床决策', '详细介绍', '', '', '2009-12-04 15:15:07', '116.228.141.77', '<p style="text-indent:21.0pt;"><span><span>80</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年代中期世界卫生组织曾提出肿瘤控制的目标，认为</span></span><span><span>1/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤是可以预防的，</span></span><span><span>1/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤是可以治愈的，</span></span><span><span>1/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤可以延长生命提高生活质量。如实现这一目标，肿瘤的发生可以减少</span></span><span><span>1/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，死亡可以减少</span></span><span><span>2/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，患者的痛苦极大减轻，肿瘤对人类的健康危害的状况将明显改善。然而，要实现这一目标，首先就要求临床对肿瘤能够做到早期发现，早期治疗。因此，如何利用现代科技发展，尽快提高目前肿瘤的诊疗水平将是临床肿瘤学家面临的一个重要问题。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">正电子发射断层扫描（</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）是一种功能性显像设备，由于其可以非创伤性的研究人体生理、生化、受体及基因改变</span></span><span><span>,</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">通过定量测定</span></span><span><span>C-11</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>N-13</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>O-15</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>F-18</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等正电子核素标记的人体代谢底物及生物活性分子</span></span><span><span>,</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">达到活体断层生化分析及细胞分子水平。在肿瘤的应用研究中，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不仅能鉴别良恶性肿瘤</span></span><span><span>,</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而且能判定肿瘤的恶性程度和治疗疗效，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">尤其在肿瘤治疗方案的确定与及时修正中显示出独特价值，研究证实约</span></span><span><span>50%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤患者在</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查后修改了已有的治疗方案。</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的产生是随着</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">融合技术的商品化及临床应用，它将</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">反映分子功能代谢信息的优势和</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">精确的解剖定位优势结合起来，从根本上解决了</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">定位不准缺陷，不仅能提供精确的脏器代谢变化，而且能准确地描述代谢异常的解剖部位及其与周围组织的关系，从而使</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">成为目前肿瘤诊断最有发展前景的新技术之一。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前，肿瘤的治疗仍以手术、放疗及化疗为主，手术和化疗主要控制局部病变或局限性的转移，仅化疗可应用于控制广泛的转移。因此，治疗前如何准确的评价肿瘤分期是临床决策的重要根据。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤分期实际上是对恶性肿瘤累及范围的缩写，其建立在肿瘤累及的范围不同，有不同的生存期的基础上。人体恶性肿瘤的</span></span><span><span>TNM</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">临床分期价值包括有助于临床医师制定治疗计划；了解病人的预后；帮助评价疗效。</span></span><span><span>TNM</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期的规则仅限于有组织学证据及组织学分型的恶性肿瘤。分期系统描述的解剖范畴有以下三个基本评价指标：</span></span><span><span>T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">指原发瘤的大小，</span></span><span><span>N</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">指有无区域淋巴结转移，</span></span><span><span>M<span>&nbsp; </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">指有无远处转移。而</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">特别是</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">由于其对区域性转移淋巴结及远处转移探测的优势，在肿瘤临床分期中的价值愈来愈显得重要。如德国埃森大学医院</span></span><span><span>Antoch</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等报告，前瞻性对比研究（</span></span><span><span>2001 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年</span></span><span><span> 12 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">月</span></span><span><span>-2002\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">年</span></span><span><span> 10</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">月）共纳入</span></span><span><span> 98 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肿瘤病人（年龄</span></span><span><span>\r\n27~94 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">岁），病人先后采用全身</span></span><span><span>FDG-PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和全身</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">进行肿瘤分期。结果显示，</span></span><span><span>77</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的病人</span></span><span><span>FDG-PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期（</span></span><span><span>TNM</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期）正确，</span></span><span><span>11 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病人分期过高，</span></span><span><span>12 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病人分期过低。相比之下，</span></span><span><span>54</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的病人</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期正确，</span></span><span><span>19 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病人分期过高，</span></span><span><span>26 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病人分期过低，在有病理分期资料的</span></span><span><span>46 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病人中，</span></span><span><span>FDG-PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">正确分期</span></span><span><span> 37 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例；</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">正确分期</span></span><span><span> 24 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例。</span></span><span><span>FDG-PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">诊断区域淋巴结转移的正确率为</span></span><span><span> 93</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，而</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">只有</span></span><span><span> 79</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。二种方法诊断远处转移率的正确率相似，分别为</span></span><span><span> 94</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span> 93</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺癌方面，</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">研究大都集中在由传统模式诊断的</span></span><span><span> I </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期和</span></span><span><span> <span>II </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">期肺癌未发生转移的</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">探测显像的价值上。这些病人仍可避免不必要的手术治疗。</span></span><span><span>Tuker\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等一份研究报道，相对常规显像，附件</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">信息，取消了</span></span><span><span> 30</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％患者的手术，</span></span><span><span>19</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％患者允许手术。</span></span><span><span>12 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">份统一的研究分析，大约</span></span><span><span> 70</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的患者临床决策改变，</span></span><span><span>17</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的患者附件化疗或放疗，</span></span><span><span>8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的化疗和放疗被取消。最近研究还显示根据不同显像分期后进行放疗，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其预后也具不同，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">使用</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期的中位生存率为</span></span><span><span> 31 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月，而非</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的中位生存率为</span></span><span><span> 16 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月，反映</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">在发现那些具有远处转移患者，避免进行放疗的价值。而</span></span><span><span>\r\nHicks </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等发表的论文着重报道了肺癌</span></span><span><span> 3-4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期阶段的病人将被免于接受过分的放疗。在</span></span><span><span> 167 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例中</span></span><span><span> 32 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例（占</span></span><span><span> 19</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）通过</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">证实有远处的转移。</span></span><span><span>1999 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年</span></span><span><span> Meta\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">分析临床医师提供的</span></span><span><span> 146 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例直结肠癌患者也发现</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">提供多于</span></span><span><span> 40</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的结直肠癌病人在临床发病期与主要治疗期差别的证据，使预期需要手术治疗的</span></span><span><span>41</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％的病人免于手术。</span></span><span><span> </span></span></p>', 'gwm', 0, 75);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(254, 'PET-CT 与脑肿瘤', '临床应用', '', '', '2009-12-09 16:35:23', '116.228.141.77', '<p><br /></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">脑肿瘤又称颅内肿瘤，是一种缓慢起病逐渐加重的脑部疾病。约占所有肿瘤的</span></span><span><span> 2%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，每年发生率为</span></span><span><span> 5.8\r\n/ 10</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">万，好发于</span></span><span><span> 50 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">岁以上成年人，预后较差</span></span><span><span>(5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年存活率</span></span><span><span> =\r\n20%)</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">。原发于颅内者称原发性颅内肿瘤；由全身其他部位的恶性肿瘤转移至颅内者称转移性颅内肿瘤。常见的颅内肿瘤有胶质瘤、脑膜瘤及神经鞘瘤。对脑肿瘤的研究和临床应用是</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像开展最早的领域之一，早期生产的许多</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在大小和形状等方面专门为进行脑显像所设计。大量研究证实了</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像诊断脑肿瘤的价值，目前</span></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像已经成为脑肿瘤诊断或随访的重要方法之一。</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">脑肿瘤显像在脑肿瘤良、恶性的鉴别及肿瘤的分级和分期，鉴别脑肿瘤的复发和坏死，探测残留肿瘤等方面优于</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像。</span></span><span><span>FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像可准确地用于脑肿瘤术前的分期和鉴别诊断，它可鉴别</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不能区分的肿瘤复发活放疗引起的坏死，根据肿瘤摄取</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的程度可判断脑肿瘤的预后。当肿瘤破坏神经纤维时，常导致对应神经中枢的</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">代谢降低，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在脑肿瘤</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像中，</span></span><span><span> 92%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可观察到病灶远端特别是对侧小脑半球有异常代谢减低区即对侧小脑失联络现象。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span><b>1 </b></span></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">脑胶质瘤</span></b></span><span><b><span> </span></b></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像对星形细胞瘤的良恶性鉴别诊断具有重要的临床应用价值。低级别肿瘤</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取较低，高级别肿瘤摄取增加，定量分析有助于提高诊断效率。</span></span><span><span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">星形胶质细胞瘤Ⅰ级</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像常表现为低代谢影像，病灶的放射性浓聚程度低于正常脑组织，但星形胶质细胞瘤Ⅱ～Ⅲ级可表现为高代谢病灶，尤其以病灶边缘明显。星形胶质细胞瘤Ⅲ、Ⅳ级在</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像时表现为高代谢病灶，肿瘤病灶显示为放射性异常浓聚影。当肿瘤内部发生出血、坏死时，相应部位可表现为放射性缺损。星形细胞瘤具有很强的复发性，</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对于星形细胞瘤手术或放疗后是治疗后复发或是治疗后疤痕形成的鉴别有一定困难，而</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像则具有很强的优势，因为治疗后形成疤痕的糖代谢水平远远低于复发的肿瘤组织，在</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像图上治疗后形成疤痕组织表现为放射性减低影（即低代谢灶），复发的肿瘤组织表现为放射性浓聚影（即高代谢灶）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。大量临床研究结果证明，</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像是鉴别星形细胞瘤手术或放疗后复发或治疗后疤痕形成的有效手段。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>11C</span></span><span><span>-MET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">脑组织吸收本底低与脑肿瘤对比明显，比</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">更具有优势。在</span></span><span><span>11C</span></span><span><span>-MET\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">影像上，复发性脑肿瘤或肿瘤残余组织呈高</span></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">11C</span></span><span><span>-MET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">聚集灶，而肿瘤放射性坏死组织</span></span><span><span>11C</span></span><span><span>-MET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取与正常脑皮质相似，且不受炎症反应的影响。因此，</span></span><span><span>11C</span></span><span><span>-MET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对复发性脑肿瘤的诊断要优于</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>2<span>&nbsp; </span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">脑转移瘤</span></b></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">脑转移瘤与其原发恶性肿瘤灶一样，具有较强的</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">集聚能力，</span></span><span><span>18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像表现为高代谢病灶，可与良性病变鉴别：如脑内内出血、坏死、囊性变及液化，</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像表现为放射性缺损。对于</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等检查先发现颅内转移瘤者，而原发病灶未明的肿瘤患者，进行</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">全身显像，有助于检出肿瘤原发灶。</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像对脑转移瘤放、化疗效果的判断、检测手术后残余病灶等均有重要价值。</span></span><span><span></span></span></p>', 'gwm', 0, 8),
(255, 'PET-CT 与乳腺癌', '临床应用', '', '', '2009-12-09 17:00:32', '116.228.141.77', '<p align="center" style="text-align:center;"><b><br /></b></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">乳腺癌是妇女中最常见的恶性肿瘤之一，早期发现是提高乳腺癌治愈率的重要手段。近二十年来，随着乳腺</span></span><span><span>X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄片、超声诊断学、磁共振和功能性显像等非侵入性影像诊断技术的发展，乳腺癌的影像学检查的作用已经发生了明显改变。乳腺癌影像学评价的重要性不仅在于早期诊断方面，而且在乳腺癌的临床分期、预后因素评估和疗效评价等方面均具有重要的应用价值。虽然目前乳腺</span></span><span><span>X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄片、超声诊断等常规检查在临床应用比较广泛，但由于其在灵敏性和特异性方面的限制，常给患者带来不必要的花费，造成不应有的痛苦。</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像在乳腺癌中的临床应用主要包括两个方面，一个是通过提供定性和定量的信息，帮助诊断和鉴别诊断乳腺癌原发灶，探测腋窝和远处淋巴结转移，对乳腺癌进行分期；第二个方面就是提供乳腺癌的生物学行为信息，对乳腺癌患者进行预后分析和疗效评价。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span><span>&nbsp;</span>1.<span>&nbsp;&nbsp;&nbsp; </span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">诊断和鉴别诊断乳腺肿块</span></b></span><span><b><span> <span></span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">判断乳腺肿块的性质是早期发现乳腺癌的关键步骤，是提高乳腺癌患者治愈率，增加乳腺癌患者生存率的关键措施。病理活检是诊断乳腺肿块性质的直接证据，是目前临床确诊乳腺癌的“金标准”，但也存在创伤性和假阴性率高等缺陷。随着</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像在肿瘤学中的广泛应用，大量的临床研究证实，</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像对乳腺肿块的探测也具有较高的灵敏度和特异性。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>1993</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年，</span></span><span><span>Adler\r\nLP</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等在使用</span></span><span><span>18F</span></span><span><span>-FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对</span></span><span><span> 28 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者共</span></span><span><span> 35 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个乳房肿块进行</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像研究，发现</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可准确从良性乳腺肿块中区别出恶性肿块，对乳腺肿块探测的敏感性为</span></span><span><span> 96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；而且，在恶性患者中，发现标化后的</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取率与乳腺癌分级存在明显的相关关系；并发现在乳腺癌原发灶中</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的摄取独立于年龄、更年期、种族、肿瘤大小，组织分化等影响因素，因此作者认为</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不仅可以准确区别乳腺肿块的良恶性质，而且还可以对乳腺癌患者进行术前分期，提供预后信息。</span></span><span><span>Schirrmeister\r\nH</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等在最近也报道，使用环型</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对</span></span><span><span> 117 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者进行研究，并将其结果与胸部</span></span><span><span>X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">线、乳腺和肝脏部位超声、乳房造影和骨扫描等常规检查进行比较，发现探测恶性乳腺肿块的敏感性和特异性分别为</span></span><span><span> 93%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 75%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，探测多灶性损伤的敏感性和特异性为</span></span><span><span>63%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 95%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，而常规临床检查的敏感性和特异性仅分别为</span></span><span><span> 32%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 93%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>FDG-PET<span>&nbsp; </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">显像对乳腺肿块的探测敏感性和特异性也受着各种因素的影响，许多学者对这些影响因素进行了探讨。如通过</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像结果和术后组化和免疫组化的结果进行对比分析，包括</span></span><span><span> FDG\r\nSUV</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">与术后组化状态、肿瘤类固醇激素受体状态、嘧啶标记指数和</span></span><span><span>P53 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">表达状态等等，目前认为组化和免疫组化的结果并不足够解释乳腺癌摄取</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">间的差异；</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像并不能完全评价乳腺癌的一些生物学行为如分化、组化分级、细胞增生等等。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前，</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在探测已知或怀疑乳腺癌病灶的准确性仍在进一步的研究中。虽然</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">有时可以探测出常规检查方法不能检测出的病灶，但也存在着对病灶探测分辨率的限制。如在比较致密的乳房中，</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的本底吸收常常高于含脂肪多的乳腺，从而导致使用现代技术很难探测出小于</span></span><span><span>1cm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">大小的乳腺肿块，此时，还是需要使用活检来区别肿块的良恶性质。由于</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的阳性估计值高达</span></span><span><span> 96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，具有</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">高摄取的患者具有很高的发生可能，应优先进行活检明确。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span><span>&nbsp;</span>2.<span>&nbsp;&nbsp;&nbsp; </span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">对腋窝淋巴结转移的探测</span></b></span><span><b><span> <span></span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在乳腺癌患者中，对涉及的腋窝淋巴结的探测是很关键的。乳腺癌病灶的大小与腋窝淋巴结转移的危险性相关，早期发现隐匿性转移，可影响临床预后和治疗策略。腋窝淋巴结被侵犯，一般认为是远距离微扩散的指示，可影响患者生存率，并可作为联合化疗的基础。常规淋巴结切除（</span></span><span><span>ALND</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）代价比较昂贵，而且由于这些切除的淋巴结是大部分是阴性结果，可导致大约</span></span><span><span> 70%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的早期乳腺癌患者不能从中获得效益，但目前这些患者仍维持潜在的患病率和</span></span><span><span>ALND</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的经济花费。临床常规检测方法包括常规</span></span><span><span>X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">线技术也不能可靠的探测腋窝淋巴结转移，</span></span><span><span>18FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像目前被认为是探测腋窝淋巴结转移最有效的手段。</span></span><span><span> <span>18FDG-PET</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">显像通过对腋窝淋巴结转移的探测，可有效的乳腺癌患者进行分期。</span></span><span><span>1998 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年，</span></span><span><span>Crippa\r\nF</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">对</span></span><span><span> 72 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例确诊为乳腺癌的患者进行全身</span></span><span><span>18F</span></span><span><span>-FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像，评价腋窝淋巴结转移。通过对具有衰减校正</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像进行视觉分析和计算标准摄取率（</span></span><span><span>SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，与手术后病理结果比较；发现诊断腋窝淋巴结转移的敏感性、特异性和准确性分别为</span></span><span><span> 85%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>91%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 89%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。参考临床淋巴结分期，发现在</span></span><span><span>0 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期患者中，其敏感性、特异性和准确性分别为</span></span><span><span> 70%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>92%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 86%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>N1a</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">：</span></span><span><span>85.5%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>95%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；</span></span><span><span>N1b-N2\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">中，敏感性、特异性和准确性分别为</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>67%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>87%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；在具有转移的乳腺癌患者中，量化的</span></span><span><span>SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值明显高于无转移者，但在两组中存在明显的重叠。作者认为</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可以很准确的评价腋窝淋巴结转移，特别是对</span></span><span><span>N1a</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">的患者尤为重要。最近，</span></span><span><span>Greco\r\nM</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 167 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例乳腺肿块小于</span></span><span><span> 50mm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（平均</span></span><span><span> 21mm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）的乳腺癌患者术前进行了全身</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像，并与手术切除后的病理结果相比较，探测腋窝淋巴结转移情况。结果发现，</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">探测腋窝淋巴结转移的敏感性、特异性和准确性分别为</span></span><span><span>\r\n94.4%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">、</span></span><span><span> 86.3%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、和</span></span><span><span>\r\n89.8%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">。阳性预测值和阴性预测值分别为</span></span><span><span>84%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>95.3%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。认为</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像是对乳腺癌患者分期的较高敏感性和特异性的方法，可以确定患者是否可以从腋窝淋巴结切除中获得收益，或允许使用放疗替代手术治疗。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前，虽然大部分资料均证实了</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">在探测腋窝淋巴结转移，对乳腺癌患者进行准确分期中的重要作用。但随着研究的深入，有学者也发现</span></span><span><span>18F</span></span><span><span>-FDG PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在探测腋窝淋巴结和乳腺内侧淋巴结转移时，</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">探测的结果变异较大，小于或等于</span></span><span><span lang="EN-US" style="mso-bidi-font-size:\r\n 10.5pt">5mm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">的病灶一般不很容易探测。如果</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像结果是阴性，通常并不能完全取代前哨淋巴结或腋窝淋巴结的清扫手术。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>3.<span>&nbsp;&nbsp;&nbsp; </span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">乳腺癌术后残余和复发</span></b></span><span><b><span> <span></span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">乳腺癌术后残余病灶的存在或复发对患者的预后及生存时间有着重要的作用。目前临床对这一方面也进行了大量的研究。</span></span><span><span>Kim\r\nTS</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">在最近的一篇资料中报道，为了评价</span></span><span><span> FDG-PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像探测乳腺癌患者在术后复发和转移的准确性，作者使用全身</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像对</span></span><span><span>27 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例乳腺癌术后怀疑复发和转移的患者共</span></span><span><span> 61 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个病灶进行探测，以患者作为基础，</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">准确发现了</span></span><span><span> 17 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者中</span></span><span><span> 16</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例具有复发和转移性病灶的患者，探测敏感性、特异性和精确性分别为</span></span><span><span> 94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>80%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 89%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span></span></span></p>', 'gwm', 0, 14);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(256, 'PET-CT与头颈部肿瘤', '临床应用', '', '', '2009-12-09 17:05:56', '116.228.141.77', '<p align="center" style="text-align:center;"><span><b><span>PET-CT</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">与头颈部肿瘤</span></b></span><span><b><span></span></b></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">头颈部肿瘤是比较常见的肿瘤，在我国以鼻咽癌占首位，喉癌和甲状腺癌次之。在美国则以喉癌占首位。头颈部肿瘤所处位置软组织较紧，同时淋巴供应丰富，极易出现淋巴结转移，同时常常是不明原发灶癌淋巴道转移的首发部位。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">头颈部解剖结构复杂，但易于进行病理活检和外科治疗。</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和超声诊断等由于其在解剖结构的高分辨能力而在该领域发挥重要作用，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">但在肿瘤诊断治疗中，这些影像技术有一定局限性。正电子发射断层（</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）显像在头颈部肿瘤的诊断、治疗后的评价方面具有重要价值。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span><span>&nbsp;</span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">一、</span></b></span><span><b><span> </span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">临床诊断</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">．</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像在头颈部肿瘤的诊断具有重要作用</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>Di\r\nMartino </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 50 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例头颈部肿瘤病例进行一个预期性评价。患有糖尿病和急性炎症的病例被排除在外。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">所有的病人都进行彩超、</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查。显像都经衰减校正，同时对可疑病灶进行标准摄取值（</span></span><span><span>SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）计算。在平均约为</span></span><span><span> 1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年的随访病人中，大约</span></span><span><span> 2/3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的病人都进行了颈部手术。显像研究结果与行病理检查和全上消化道内镜检查的病例进行比较。</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像对原发肿瘤的灵敏度与特异性分别为</span></span><span><span> 95</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％、</span></span><span><span>92</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，相较而言，</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像的灵敏性与特异性分别为</span></span><span><span> 68</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％、</span></span><span><span>69</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，超声为</span></span><span><span> 74</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％、</span></span><span><span>75</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。而对再发肿瘤，</span></span><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像的准确性为</span></span><span><span> 100</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像的灵敏性与特异性分别为</span></span><span><span> 67</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span> 80</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，超声的灵敏性与特异性分别为</span></span><span><span> 67</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span> 100</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。从统计学上来讲，</span></span><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像明显优于</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像。然而</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的解剖定位的有限性导致其使用具有逐渐下降趋势，而</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像仍是目前解剖定位的显像手段。</span></span><span><span>PET-CT\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像在此方面具有较好的融合效果。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>2</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">．对转移灶和第二原发瘤的诊断</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">头颈部鳞状细胞癌易于转移到局部淋巴结，如果存在淋巴转移，治愈率将下降</span></span><span><span>50%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对淋巴转移的误诊率约</span></span><span><span>7.58%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">第二原发瘤占初诊病人的</span></span><span><span>3%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，此诊断结果有助于在肿瘤评价中进行淋巴结转移分类，制定治疗方案，减低复发率，提高生存率。与其他常规方法比较，</span></span><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在对转移灶和第二原发瘤诊断中有明显的优势。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>3</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">．对原发灶不明颈部淋巴结转移癌的诊断</span></b></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">一般以</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为原发灶不明颈部淋巴结转移癌的首选检查手段。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">有研究报道不明颈部淋巴结转移癌患者的</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像原发灶检出率为</span></span><span><span> 44%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，诊断价值明显优于</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像的另一优势是可在全身范围内探查可疑原发灶和转移灶，有助于临床分期并指导治疗。文献也报道，不明原发灶上、中颈部淋巴结转移癌有相当一部分来源于同侧的扁桃体组织。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">二、疗效评价</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在头颈部肿瘤治疗疗效评价及治疗后复发诊断中有独到的作用。由于肿瘤手术、放疗后导致的组织结构的扭曲和疤痕形成（尤其在喉、舌根及口咽部）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，使常规影像方法难以检测残余肿瘤或肿瘤的复发，特别是在治疗后</span></span><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年内。利用</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">代谢显像可监测放化疗的疗效，对晚期肿瘤患者的化疗进行旱期疗效评价。由于治疗中的肿瘤细胞浓聚</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的量和生长速率呈线形关系，病灶部位</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取增加意味着治疗的失败，并且可用于区分无治疗反应的病例，避免不必要的治疗副作用，及早改用其他方法。据研究报道，对</span></span><span><span>44</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例晚期（</span></span><span><span>3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期、</span></span><span><span>4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">头颈部肿瘤患者治疗后</span></span><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年内进行</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">并与其他显像方法</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）比较：在第一年中只有</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检测到所有的复发灶，灵敏度为</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性为</span></span><span><span>93%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，而常规方法的诊断灵敏度仅为</span></span><span><span>38%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性为</span></span><span><span>85%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">鼻咽癌（</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）不同于其他头颈部的肿瘤。基于解剖变化的</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像，对于探测再发和残余</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">有低的灵敏性和中等的特异性，但在放疗（</span></span><span><span>RT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）后具有明显变化。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">放疗后普遍存在不同程度的纤维化团块和不对称性，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">这样将导致假阳性。而且，</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">再生多发于粘膜下，因此</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可以很容易地探察到</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的再发与残余肿瘤。在</span></span><span><span>Kao</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等的研究中，</span></span><span><span>36</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">位接受</span></span><span><span>4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月放疗的</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">病人在治疗前曾经行</span></span><span><span>99mTc</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的</span></span><span><span>SPECT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">头颈部显像检查以用来区别</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">再发和残余与良性病变。基于活组织检查，</span></span><span><span>99mTc-TF\r\nSPECT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的灵敏度与特异性是</span></span><span><span>64</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span>96</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，用于区别再发或从良性病变中分辨</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。其中</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的灵敏性与特异性分别为</span></span><span><span>73</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span>88</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span>100</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span>96</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。由此作者得出</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像是探测</span></span><span><span>NPC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">再发与残余的最佳工具。</span></span><span><span></span></span></p>', 'gwm', 0, 17),
(257, '  PET-CT 与胃、食管癌 ', '临床应用', '', '', '2009-12-09 17:09:37', '116.228.141.77', '<p><b><br /></b></p>\r\n\r\n<p><span><span><span>&nbsp;&nbsp;&nbsp; </span>PET-CT\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">与胃、食管癌手术后的阶段常规检查和探测食道癌复发的检查包括内镜和经食道内镜超声，以及胸腹部的计算机断层扫描。这些技术应用于诊断完全依赖病变的解剖改变；由于手术的治疗引起手术部位的解剖改变影响了其特异性。有人研究，对临床性和</span></span><span><span>/</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或放射性诊断怀疑食管癌再发的</span></span><span><span> 41 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者行全身</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像。所有病人都进行了检查，包括胸腹部螺旋</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查（</span></span><span><span>n=39</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">），经食管超声（</span></span><span><span>n=13</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">），和或内镜检查（</span></span><span><span>n=18</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）。其中常规检查方法在准确性（</span></span><span><span>83</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）上较</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像（</span></span><span><span>88</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）稍低。对于远处转移的病例（</span></span><span><span>19 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例），常规显像检查方法检出探测病灶有</span></span><span><span>15</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例（灵敏性</span></span><span><span> 79</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％），</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像探测检出病灶为</span></span><span><span>18 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（灵敏性</span></span><span><span> 95</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><span><span>&nbsp;&nbsp;&nbsp; </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">化疗反应的预测在食管癌中是十分重要的。预先检查并不能对术前化疗给出一个生存利益的评价；实际上，对化疗无反应的患者比哪些仅接受手术治疗的患者情况更差，假定手术损伤与化疗相关的损伤相同。在治疗过程中，一个快速监测筛选出对化疗有潜在反应性的测试需要尽早进行。</span></span><span><span>\r\nFDG-PET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像在</span></span><span><span> 40 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例贲门腺癌患者中进行来评价术前化疗。</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像在第一个化疗循环疗程的</span></span><span><span> 14 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">天时重复检查。</span></span><span><span>FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的摄取减少在治疗中，临床有反应的患者比无反应者明显减少（反应者，</span></span><span><span>54</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％±</span></span><span><span>17</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％；无反应者，</span></span><span><span>15</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％±</span></span><span><span>21</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，</span></span><span><span>P&lt;0.01</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）。</span></span><span><span>FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取减少超过</span></span><span><span>35</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％在临床有反应和无反应肿瘤之间的区分上提供了最高的准确性。</span></span><span><span>15 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个化疗反应肿瘤中</span></span><span><span> 14 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例和</span></span><span><span> 22 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个化疗无反应中肿瘤</span></span><span><span> 21 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例均被得到证实，提供了灵敏性与特异性分别为</span></span><span><span> 93</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span> 95</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。</span></span><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像的效应与病理组织学反应的相关性很大（</span></span><span><span>P&lt;0.001</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）。在</span></span><span><span> 15 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例具有代谢反应肿瘤中有</span></span><span><span> 8 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例（阳性预测值，</span></span><span><span>53</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）观测到组织病理学上有消退。但在</span></span><span><span> 22</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例无代谢反应性的肿瘤中仅有</span></span><span><span>1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例（阴性预测值，</span></span><span><span>95</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％）观测到病理组织学消退。病理组织学的预测的灵敏性与特异性分别为</span></span><span><span> 89</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％和</span></span><span><span> 75</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。最近</span></span><span><span>\r\nFukunaga </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 48 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例术前拟诊为食道癌的患者行</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查证实</span></span><span><span> 47 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例，准确率达到</span></span><span><span>\r\n98.3%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">。</span></span><span><span> </span></span></p>', 'gwm', 0, 19);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(258, 'PET-CT 在胰腺癌的应用', '临床应用', '', '', '2009-12-11 13:56:01', '116.228.141.77', '<p align="center" style="text-align:center;"><b><br /></b></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">胰腺癌的早期诊断较为困难，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">通常诊断明确时已为</span></span><span><span>\r\nIII-IV </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">期且多伴有淋巴结转移或远处转移。超声及</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等无创检查能提示胰腺肿块或胰管扩张等异常表现，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">特别是</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">有助于胰腺癌的分期和评估大血管及周围组织是否受到肿瘤组织的浸润。但由于临床症状不典型，肿瘤小于</span></span><span><span> 2cm </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">就有可能发生转移，故胰腺癌明确诊断后一年生存率仅为</span></span><span><span> 20%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。此外胰腺癌和胰腺炎的鉴别仍是问题，</span></span><span><span>CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">引导下的穿刺活检有局限性和损伤性，而淋巴结有否转移则是另一个难题，因为大多数淋巴结小于</span></span><span><span> 1cm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和超声容易漏诊，最终导致手术不彻底提高早期复发率。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>Friess\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 80 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例准备行胰腺择期手术的患者行</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查，结果发现</span></span><span><span>42</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例术后证实胰腺癌的患者中</span></span><span><span> 41</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例有</span></span><span><span> FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取增高而</span></span><span><span> 32</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例慢性胰腺炎患者中有</span></span><span><span> 28 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例无</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">浓集。</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检测的敏感度和特异度分别为</span></span><span><span> 94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 88%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，而且胰腺癌患者的</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取值明显高于慢性胰腺炎组。</span></span><span><span>Bares\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等对</span></span><span><span> 40 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例疑为胰腺癌的患者进行</span></span><span><span>\r\nFDG-PET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span>CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和超声检测，结果发现</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的阳性预测率为</span></span><span><span>73%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、阴性预测率为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、淋巴结和肝转移发现为</span></span><span><span> 5/17</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">三个值分别为</span></span><span><span> 92.6%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>84.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>13/17</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。超声最低仅为</span></span><span><span>\r\n70.4%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">、</span></span><span><span>33%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>1/17</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">淋巴结转移检出率为</span></span><span><span> 76%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，显示了</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在评估胰腺癌淋巴结转移中的价值。肝转移检出率为</span></span><span><span> 57%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，主要因为正常肝组织的</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取率也很高，以致病变与正常肝的对比变小，但可通过延时扫描来弥补。</span></span><span><span>Stollfuss\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等的研究也提示</span></span><span><span> FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检测胰腺肿瘤的敏感度和特异度均为</span></span><span><span> 93%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">特异度为</span></span><span><span> 76%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。因此</span></span><span><span>\r\nFDG-PET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检测可减少不必要的剖腹探察，对</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">发现的小肿瘤</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可显示其它检查难以发现的淋巴结转移以便术中切除。</span></span><span><span></span></span></p>', 'gwm', 0, 11);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(259, 'P E T/ C T在肺癌中的应用价值', '临床应用', '', '', '2009-12-11 14:11:09', '116.228.141.77', '<p align="center" style="text-align:center;"><b><br /></b></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">肺癌在许多国家是首位的癌症致死原因，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">因此早期诊断并及时手术切除显得尤为重要。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">随着</span></span><span><span>C\r\nT<span>&nbsp; </span>( c o m p u t e d<span>&nbsp; </span>t o m o g r a p h y<span>&nbsp; </span>)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">技术的进步与发展，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描方法的改进，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">使得大部分肺癌都能得到及时准确的诊断。但对一部分表现为孤立性肺结节</span></span><span><span>( s o\r\nl i t a r yp u l m o n a r y<span>&nbsp; </span>n o d u l e\r\n, S P N ) </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的肺癌仅依据其形态学特征仍然难以确定</span></span><span><span>; </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对纵隔淋巴结的术前分期，</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">仅依据淋巴结的大小来判断，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其准确率亦较低。由于</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不能提供病变的代谢及病理生理</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">学</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">信</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">息，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">所</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">以诊</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">断</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">受</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">到</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">限</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">制。而</span></span><span><span> F D\r\nG<span>&nbsp; </span>P E T<span>&nbsp;\r\n</span>( F l u o -r o d e o x y g l u c o s e<span>&nbsp;\r\n</span>p o s i t r o n<span>&nbsp; </span>e m i s s i o n<span>&nbsp; </span>t o m o g r a p h y ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对肺癌的诊断价值已经得到了广泛证实，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">但由于不同病理类型的肿瘤之间显像差异较大，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而且部分恶性肿瘤与良性病变之间显像结果又很相近，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">这就给鉴别诊断带来一定的困难。</span></span><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的出现弥补了这两方面的缺憾，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">其核心是融合专用的</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描仪和</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描仪的结合提供了来自两台扫描仪数据的独特信息。</span></span><span><span> P E\r\nT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">扫描仪提供有价值的功能方面的生理数据，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描仪提供像地图一样的解剖信息。结合的影像能确定和发现肿瘤的精确位置。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">同时</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的有关参数值与</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的征象相结合可以大大提高肿瘤性质的诊断正确率。</span></span><span><span></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span>1<span>&nbsp;&nbsp; </span>P E T - C T</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">的原理</span></b></span><span><b><span><span>&nbsp;&nbsp;&nbsp; </span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的全称是正电子发射计算机断层显像</span></span><span><span>/ X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">线计算机体层成像，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">就是通过一个较长的检查床将</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和螺旋</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">两个相对独立的、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">共轴的设备单元相连接，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">两个设备保持一个合理的距离，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">以免电磁干扰，</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描检测是分别进行，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">数据也是先有各自的工作站处理重建。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">两套系统可各自独立使用或联合使用，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">提供高分辨率的</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">及</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像。它通过正电子追踪的方法，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">应用计算机断层显像技术显示人体的全身主要器官以及大脑、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">心脏的生理代谢功能，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">它兼具</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的优点，同时展示人体解剖和生理功能的信息。一般说来，</span></span><span><span> P E\r\nT / C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">系统存在着一定的电磁兼容问题，</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可能会有一定的相互干扰，</span></span><span><span> B u\r\nr g e r </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等〔</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">‘</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">」</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对</span></span><span><span>1 4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者进行检查后，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对图像进行分析认为</span></span><span><span>: </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">当</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的能量在</span></span><span><span>4 0\r\n-1 4 0 k e v , P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">的扫描能量在</span></span><span><span>5 1 1\r\nk e v</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">时，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">不会对图像质量产生影响，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而这个能量方位完全能满足一般检查的需要。</span></span><span><span><span>&nbsp;&nbsp;&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">恶性肿瘤的葡萄糖及氨基酸代谢较正常组织增高已被体外及活体试验所证实。</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">利用葡萄糖的类似物</span></span><span><span>F - 2\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">一</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">脱氧</span></span><span><span>- D -</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">葡萄糖作底物，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">氟’</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">“</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为示踪剂，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和葡萄糖共享细胞膜上的转运蛋白，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">进人细胞膜后己糖激酶磷酸化成</span></span><span><span>F D G\r\n- 6 - P O4 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">而无法进一步转运，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">受滞于细胞内而达到显像目的。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">这就使得</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">非常适合作为一种肿瘤示踪剂。加之</span></span><span><span> F D\r\nG</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的制备在医用回旋加速器中心已十分成熟且可自动化，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其半衰期较长</span></span><span><span>( 1 1\r\n0 m i n<span>&nbsp; </span>) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为临床应用创造了条件。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其基本过程是</span></span><span><span>: P E\r\nT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">发射出正电子光束，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">经准直线校正后，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对兴趣区进行环形扫描。正电子与注射到体内的</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">中的氟‘</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">“</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">发射出的负电子发生碰撞，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">产生“</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">湮没”</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">现象和一对光子，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">被周围的探测器接受后，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">重建出</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">即体内葡萄糖分布的图像，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">因此它通过检测葡萄糖的分布来反映体内组织功能代谢情况。</span></span><span><span><span>&nbsp;&nbsp;&nbsp; </span><span>&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的基本检查方法</span></span><span><span>: </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">患者一般须在开始检查前</span></span><span><span>4 5 mi n</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">静脉注射</span></span><span><span>1 0 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">毫居里</span></span><span><span>( m c\r\ni ) </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">当蚤</span></span><span><span>( 3 7 0 MB p ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的氟脱氧葡萄糖</span></span><span><span>( F l\r\nu o r o d e o x y g l u c o s e , F D G ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。因为</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在体内代谢和分布需要一定的时间才能达到相应的稳态，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等到</span></span><span><span>4 5 mi n</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">后才能开始检查。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为了减少检查时间，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">一般首先进行</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描参数一般为</span></span><span><span>1 4 0\r\nK V,<span>&nbsp; </span>4 0 MA</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">层厚</span></span><span><span>5 m</span></span><span><span> m, 0\r\n.<span>&nbsp; </span>5 s / r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的螺旋扫描，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">数分钟后，</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">数据采集完毕，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">重建出普通的螺旋</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像。</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描的目的是获取病变区域的精细的解剖学定位，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">得到更多的形态学信息，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">获得基础图像。随后检查床将患者自动移至</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描区域，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">按照</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的扫描位置、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">层面和范围采集图像。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>2<span>&nbsp;&nbsp; </span>P E\r\nT/ C T</span></b></span><span><b style="mso-bidi-font-weight:\r\nnormal"><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:\r\n&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在肺瘤诊断中的应用价值</span></b></span><span><b><span><span>&nbsp;&nbsp;&nbsp; </span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对于中央型肺癌，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">行</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或纤支镜活检多可明确诊断，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">较少进行昂贵的</span></span><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查。单独</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">诊断的难点在于那些表现为孤立性肺结节的周围性肺癌。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">影像学诊断的目的就是鉴别</span></span><span><span>S P N</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的良恶性，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">从而使恶性结节尽快手术切除。</span></span><span><span><span>&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:15.75pt;"><span><span><span>&nbsp;</span>'' 8 F\r\n- F D G<span>&nbsp; </span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在进行良恶性鉴别诊断一般采用目视定性和定量的方法，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其中标准摄取值</span></span><span><span>( S t\r\na n d a r d i z e d<span>&nbsp; </span>U p t a k e<span>&nbsp; </span>V a l -u e , S UV) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">是临床应用最为广泛的一种半定量方法。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在此基础上常进行双时相显像</span></span><span><span>( D u\r\na l<span>&nbsp; </span>t i m e<span>&nbsp; </span>p o i n t ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前普遍接受</span></span><span><span>S\r\nU<span>&nbsp; </span>V</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等于</span></span><span><span>2 . 5\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">作为良恶性的分界点。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">恶性病变</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取随时间延长而增加，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">相反，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">良性病变</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取下降或保持不变。</span></span><span><span>H i c\r\nk e s o n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等</span></span><span><span>E 2 1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对</span></span><span><span>1 4 1\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">例肺结节病人进行双时相检查，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">结果显示双时相显像明显改进</span></span><span><span>F D\r\nG<span>&nbsp; </span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">诊断肺结节的准确性，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">双时相与单时间诊断的灵敏度分别为</span></span><span><span> 9 5\r\n. 7 %, 8 8 . 3 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">肠，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">阳性预测值分别为</span></span><span><span> 9 2\r\n. 8 %,9 1 .<span>&nbsp; </span>2 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">我们对</span></span><span><span>3 2 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺癌患者和</span></span><span><span>1 5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺良性病变患者行双时相显像，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结果显示以</span></span><span><span>S\r\nU<span>&nbsp; </span>V</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">升高</span></span><span><span>&gt;3\r\n0 %</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">为闭值，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">良恶性鉴别诊断的灵敏度、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">特异性和准确性分别为</span></span><span><span>9 0\r\n%, 1 0 0 %</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">和</span></span><span><span>9 3 . 3 %</span></span></p>\r\n\r\n<p style="text-indent:36.75pt;"><span><span>Ma r\r\no m</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等</span></span><span><span>1 4 ] </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">报道</span></span><span><span> 1 8\r\n5 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">例病人</span></span><span><span>1 9 2 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个病理证实的肺癌病灶中，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">所有病灶直长均</span></span><span><span>&lt;3 c m</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其中</span></span><span><span>1 8 3\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">个</span></span><span><span>( 9 5 ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">直径</span></span><span><span>0\r\n.<span>&nbsp; </span>5 ~<span>&nbsp;&nbsp;&nbsp;\r\n</span>3 c m( </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">平均直径</span></span><span><span> l\r\n.<span>&nbsp; </span>3\r\n c m) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">的病灶表现为低</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">这些病灶多为较小的肿瘤或为类癌及支气管肺泡癌。</span></span><span><span> J a\r\nn g</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等</span></span><span><span>I s ] </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">报道</span></span><span><span>4 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">上呈局灶性毛玻璃密度的早期肺泡细胞癌，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其中有</span></span><span><span> 2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例行</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查结果均阴性。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">因此，</span></span><span><span> F D\r\nG</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像需要与</span></span><span><span>S P N</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的形态学特征即</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">征象相结合。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">我们认为支气管肺泡癌在</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">中表现的低代谢是由于它呈现弥漫性生长，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">组织密度相对较低，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而这一病理学特征在</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">上则表现为特征性的“</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">毛玻璃样改变”</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。而活动期炎症或感染过程，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">如结核、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">曲霉菌、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">炎性假瘤、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肉芽肿等都可摄取</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">从而导致</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的阳性预测值较低。国内外已有许多</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">影像学与病理的对照研究证实，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分叶、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">毛糙</span></span><span><span>( </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">毛刺、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">棘状突起与锯齿征</span></span><span><span>) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">密度不均</span></span><span><span>( </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">空泡、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">支气管充气、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">磨玻璃密度等</span></span><span><span>) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">胸膜凹陷、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">血管聚集等征象与恶性结节有关，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而边缘光滑、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">密度均匀、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">钙化灶与卫星灶等则与良性结节显著相关。</span></span><span><span>P E T\r\n/ C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">能够实现解剖结构与功能两者图像的同机融合，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其诊断价值大大提高。</span></span><span><span> G o\r\ne r r e s </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等仁</span></span><span><span> 6 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">〕</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在</span></span><span><span>7 5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例平均肿瘤大小</span></span><span><span>1 0\r\n-3 0 m m</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的非小细胞肺癌的患者中，</span></span><span><span> P E\r\nT / C T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">的诊断准确性明显高于单纯的</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或</span></span><span><span>PET.</span></span></p>\r\n\r\n<p style="text-indent:36.9pt;"><span><b><span>3 </span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">、</span></b></span><span><b><span>P E T</span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">在肺癌分期中的应用价值</span></b></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:36.75pt;"><span><span>3 . 1\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">淋巴结分期</span></span><span><span><span>&nbsp;&nbsp;\r\n</span></span></span></p>\r\n\r\n<p style="text-indent:36.75pt;"><span><span><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">肺癌淋巴结有无转移是确定肺癌分期、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">决定治疗方案和推测预后的重要因素。</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">判断</span></span><span><span>N: </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">阳性与否的主要依据是淋巴结肿大，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">即淋巴结短径</span></span><span><span>&gt;l\r\nc m</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">而良性淋巴结也可能由于反应性增生、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">阻塞性肺炎、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">原发肿瘤所致的肺不张而肿大，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">另一方面发生微转移的淋巴结大小可能是正常的，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">这可导致假阳性、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">假阴性，削弱了</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">判断</span></span><span><span>N: </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">敏感性及特异性。而</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对于阳性结果的判断标准不依赖于淋巴结的大小，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而取决于其代谢强度，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">从而弥补了</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的不足。</span></span><span><span> G u\r\np t a </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等</span></span><span><span>[ 7 1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">总结了</span></span><span><span>1 0 3\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">例患者，</span></span><span><span> P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">探测纵隔淋巴结转移的灵敏度和特异性分别为</span></span><span><span>9 3 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>9 4 0\r\n0 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">而</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span>6 3 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 6 0\r\n0 0 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">在</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">遗漏的</span></span><span><span> 1 8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个转移淋巴结中，</span></span><span><span> P E\r\nT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显示</span></span><span><span> 1 5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个为阳性，</span></span><span><span> C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">发现增大淋巴结而</span></span><span><span>P E T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">排除转移的</span></span><span><span>2 6 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个淋巴结经病理证实确为阴性，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">从而对纵隔淋巴结分期起到了重要的指导作用。</span></span><span><span>R o m\r\na m</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等</span></span><span><span>[ a l </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">报道</span></span><span><span>3 2 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例淋巴结分期病例中，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">组织学证实</span></span><span><span> 9 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;T', 'gwm', 0, 22);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(260, 'PET与放射治疗疗效评价', '临床应用', '', '', '2009-12-11 14:14:34', '116.228.141.77', '<p align="center" style="text-align:center;"><b><br /></b></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">一直用于评价放射的治疗反应。</span></span><span><span>FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">可以鉴别出放射治疗后葡萄糖代谢的变化，并认为其是肿瘤具有反应性的一个最好指标之一。但在放射治疗过程中对疗效进行随访的资料目前报道相当少。主要认为放射治疗可能引起早期急性炎症，从而与肿瘤高代谢不能相鉴别；但也有资料认为早期快速的代谢抑制可能指示肿瘤具有较强的反应性。因此，目前仍需要进一步的资料对肿瘤放射治疗过程中代谢的变化进行更为详细的研究。</span></span><span><span> </span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">然而，在放射治疗结束后利用</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">进行评价中，如何区别葡萄糖摄取减少和葡萄糖摄取缺乏在疗效评价过程中至为重要。一些研究者认为仅仅是</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">减少并不能提示预后；而且认为葡萄糖代谢减少可能反应由于治疗损伤敏感细胞后的部分反应，而耐受细胞仍然维持着细胞活性，认为葡萄糖代谢变化部分反应肿瘤放疗后疗效。</span></span><span><span> </span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">评价放射治疗的时机也是目前争论较多的问题。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前相当多的资料认为在辐射治疗结束后</span></span><span><span> 4~6 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月时建议通过</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">进行评价。正常组织也可以对放射治疗具有反应。一些组织可能在几天内即可发生，包括骨髓、淋巴结、腮腺等等。几周后发生反映的组织包括肾、脑等等。因此，经常可能看到照射野内软组织葡萄糖代谢的增加。资料认为放射治疗后引起葡萄糖的早期代谢变化可能与照射野内正常组织的损坏有关。以胸部放射治疗损伤为例，研究也认为正常组织的损伤反应可以大到</span></span><span><span> 6 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月甚至</span></span><span><span> 1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年。</span></span><span><span> </span></span></p>\r\n\r\n<p><span><span>&nbsp;</span></span></p>', 'gwm', 0, 10);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(261, 'PET 在肺癌中的应用', '临床应用', '', '', '2009-12-11 14:21:41', '116.228.141.77', '<p align="center" style="text-align:center;"><span><b><span>PET </span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">在肺癌中的应用</span></b></span><span><b><span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺癌是最常见的肺部原发性恶性肿瘤，半个世纪以来，世界各地肺癌的发病率和死亡率逐年上升，尤其在发达国家。我国肺癌的发病率也在上升，个别城市肺癌死亡率已跃居恶性肿瘤死亡的首位。虽然</span></span><span><span>X</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">线胸片、</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的发展已经相当成熟，发现肺部病变颇为容易，然而要鉴别病变的性质有时却并非容易，许多病例为了进一步明确诊断往往需要通过有创伤性的检查，如经皮细针穿刺肺活检，有时甚至是开胸探查。这些检查并发症多，且给患者带来不必要的花费和痛苦。</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤代谢显像由于能够无创性地探测生理性放射性核素在体内的分布，在肺部肿瘤的诊治特别是早期诊治中发挥了越来越重要的作用。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>1 </span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">鉴别肺部结节的良恶性</span></b></span><span><b><span> </span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">孤立结节或局灶性病变是肺内病变的常见形式，临床上需要鉴别其良恶性。影像学判断病变良恶性的依据是病变的大小和形态的异常，如直径大于</span></span><span><span>3cm</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、边缘不规则、呈分叶状、有短小毛刺、缺乏钙化等征象常被认为是恶性的。但应用这些形态学的信息判断肺内病变性质常是不够准确的，文献报道大约</span></span><span><span>70%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的结节</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">表现不典型，而其中</span></span><span><span>52%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">最终被证明是良性的。肺内病变定性的金标准是通过侵入性检查获取病理学依据。这些侵入性检查包括纤支镜活检、</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">引导下肺穿刺吸取活检、胸腔镜和开胸切除术。纤支镜活检灵敏度只有</span></span><span><span>79%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">引导下肺穿刺吸取活检的灵敏度和特异度分别为</span></span><span><span>98%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>92%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，但其阴性结果并不能作为良性的依据。</span></span><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像在区别肺癌原发病灶方面具有重要临床价值。综合文献报道对孤立性肺结节的诊断敏感性可达到</span></span><span><span>82%~100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性可达</span></span><span><span>75%~100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，准确性可达</span></span><span><span>79%~94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。但传统的定性诊断，即通过肉眼观察发现病灶其结果容易受到报告医师主观思维的影响，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">目前更多的学者使用一个半定量参数来进行判断，即标准摄取比</span></span><span><span>(standardized\r\nuptake ratio</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，即病变区域摄取</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的平均强度与每</span></span><span><span>Kg</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">体重注射剂量比</span></span><span><span>)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Duhaylongsod</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等总结了</span></span><span><span>53</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例有肺部阴影患者的</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结果，研究发现恶性病灶的标准摄取比</span></span><span><span>(SUR)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span>5.9</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>2.7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，良性病灶为</span></span><span><span>2.0</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>1.7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">两者差异有显著性。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">如以</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值≥</span></span><span><span>2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为肺癌的诊断标准，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">则</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对肺癌的敏感性为</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性为</span></span><span><span>79%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Patz</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span>38</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺部孤立性结节（</span></span><span><span>SPN</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）作了</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查，</span></span><span><span>25</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的</span></span><span><span>SUR&gt;2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，平均</span></span><span><span>6.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；</span></span><span><span>13</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span>SUR&lt;2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，平均</span></span><span><span>1.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>0.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">经病理学检查，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">前</span></span><span><span>25</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例全部为恶性病变，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">而后</span></span><span><span>13</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例全部为良性病变。</span></span><span><span> Patz</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">认为以</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">小于</span></span><span><span>2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为标准，肺部病变良性的可能性为</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Knight</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等报道</span></span><span><span>45</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺部病变（其中</span></span><span><span>29</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例为恶性、</span></span><span><span>16</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例为良性）作</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，结果恶性病变的</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span>8.9</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>4.9</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>L/B</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（</span></span><span><span>lesion/background</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，病灶</span></span><span><span>/</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">本底）为</span></span><span><span>16.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>12</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；良性病灶则分别为</span></span><span><span>2.8</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>2.9</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>4.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">±</span></span><span><span>5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。若以</span></span><span><span>SUR&gt;2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或</span></span><span><span>L/B&gt;5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">作为鉴别良恶性的标准，整体精确率为</span></span><span><span>88%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>18F</span></span><span><span>-FDG\r\nPET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像假阴性可能发生于原发性肺类癌瘤和支气管肺泡细胞癌。类癌生长缓慢，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">有丝分裂不活跃；</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">支气管肺泡癌的倍增时间较长，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">增殖活力相对较低，所以摄取</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">较低。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">一些感染或炎性病灶可以摄取</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">异常增高，如结核性肺炎、隐球菌病、组织胞浆菌病和曲霉病等，</span></span><span><span> SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">也可能增高，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">从而形成假阳性。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">但在一般情况下，慢性病程、无痛性炎症和急性感染，</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的摄取并不增高。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:39.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 39.0pt"><span><span style="Times New Roman&quot;"><span>2<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">肺癌进行分期</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺癌的</span></span><span><span>TNM </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期是肺癌诊断中的一个重要步骤，是选择治疗方案和预后评估的可靠依据。实践发现，</span></span><span><span>TNM </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分期与肺癌患者的预后有高度相关性，</span></span><span><span>I </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期患者</span></span><span><span>5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年生存率为</span></span><span><span>60</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％</span></span><span><span>~80</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，</span></span><span><span>II </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期患者</span></span><span><span>5 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年生存率为</span></span><span><span> 25</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％</span></span><span><span>~50</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，</span></span><span><span>IIIa</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期为</span></span><span><span>10</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％</span></span><span><span>~40</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％，</span></span><span><span> IIIb\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">期和</span></span><span><span>IV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期小于</span></span><span><span> 5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">％。</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">尸体解剖发现，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺癌可转移至全身各个系统或器官。非小细胞肺癌（</span></span><span><span>NSCLC</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）最常发生转移的部位是骨、肝脏、肾上腺和脑。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:15.75pt;"><span><span><span>&nbsp;</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">目前的影像学技术（</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）对肺癌的分期有着严重的不足，其断定良恶性淋巴结的方法往往是通过测量大小，直径大的偏向于恶性，直径小的偏向于良性，然而通过与手术及病理对照证明这种粗陋的鉴别方法有着明显的缺陷。与</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>MRI</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">相比，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">依靠病变部位的生化代谢来显示病灶，属于功能性显像，因而能准确判断肿大的淋巴结是否由癌肿转移。</span></span><span><span>Patz</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等历经</span></span><span><span> 2 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年总结</span></span><span><span> 42 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者，共有</span></span><span><span> 62 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个结节病灶，其中</span></span><span><span> 40 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个位于肺门</span></span><span><span>/</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺叶，</span></span><span><span>22 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个位于纵隔。均在化疗前行</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">及</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查，结果发现对肺门</span></span><span><span>/</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺叶淋巴结转移，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">敏感性、特异性分别为</span></span><span><span>73%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>76%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">仅为</span></span><span><span> 27%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>36%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">；对纵隔淋巴结转移，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">敏感性、特异性分别为</span></span><span><span> 92%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">仅为</span></span><span><span> 58%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 80%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>Steinert</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span> 47 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺癌患者进行</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和增强</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描，其结果与手术病理作对比，发现对于</span></span><span><span>N2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span>N3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">期淋巴结转移的患者，两者灵敏度分别为</span></span><span><span> 89%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 57%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性分别为</span></span><span><span> 99%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，阳性预测率、阴性预测率、准确率分别为</span></span><span><span>96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>97%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> 76%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>87%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、</span></span><span><span>85%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的结果优于增强</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">扫描。</span></span><span><span>Bury</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span> 109 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺癌患者进行回顾性分析，</span></span><span><span>FDG-PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">对远处转移灶的敏感性为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，特异性为</span></span><span><span> 94%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，准确性为</span></span><span><span> 96%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。根据</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">结果，有</span></span><span><span> 34%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（</span></span><span><span>37/109</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）的患者分期进行了纠正，</span></span><span><span>20%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">以上的患者改变了治疗方案。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:39.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 39.0pt"><span><b><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;mso-fareast-font-family:&quot;Times New Roman&quot;"><span>3<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span></span></span></b></span><span><b><span style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">肺癌疗效评价和复发病灶的诊断</span></b></span><span><b><span> <span></span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肺癌经手术或放疗后是否存在残留病灶后复发，这一判断在临床上十分重要，但有相当难度。肺癌患者经治疗后，有两种可能：</span></span><span><span>(1)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">治疗有效，病灶局部纤维化；</span></span><span><span>(2)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">效果不佳，肿瘤持续存在或复发。两种情况在</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">上均表现为异常影像，难以区别，有些病例还得进行有创活检，然而这不仅并发症高，而且有时由于采样时技术上的原因，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">并非总能找到理想的标本组织，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">病理诊断也不一定可靠。</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">能反映肿瘤细胞的代谢特征，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">为肺癌疗效的早期诊断提供了有效手段。</span></span><span><span>Patz</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等对</span></span><span><span> 43</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例怀疑肺癌复发的患者进行了</span></span><span><span>\r\nFDG-PET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">扫描，</span></span><span><span>43 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者中有</span></span><span><span> 35 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例复发，</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的</span></span><span><span> SUR </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">明显增高者（</span></span><span><span>&gt;2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，平均</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span> 7.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）</span></span><span><span>34 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例，占</span></span><span><span> 97%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，而仅有</span></span><span><span> 1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺癌切除术后</span></span><span><span> 12</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月活检证明复发，其</span></span><span><span> SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为</span></span><span><span> 1.9</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。而另</span></span><span><span> 8 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例平均</span></span><span><span> SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">仅为</span></span><span><span> 1.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，均小于</span></span><span><span>2.4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，经</span></span><span><span>16~124\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">个月的随访，临床证明无复发。以</span></span><span><span>SUR</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值</span></span><span><span>&gt;2.5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">为诊断标准，则敏感性为</span></span><span><span>\r\n97.1%</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，特异性为</span></span><span><span> 100%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。一项研究表明了肺癌预后与</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取之间的关系，</span></span><span><span>156 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例初发的非小细胞肺癌患者接受了</span></span><span><span>\r\nFDG-PET</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">检查。</span></span><span><span>118 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例患者</span></span><span><span> SUR </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值</span></span><span><span>&lt;10</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，平均生存期为</span></span><span><span> 24.6\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">个月；</span></span><span><span>37 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例</span></span><span><span> SUR </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值≥</span></span><span><span>10</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，平均生存期为</span></span><span><span> 11.4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">个月，明显缩短。肺癌的</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取量反映了肿瘤的代谢特征，恶性程度越高，增殖越快，</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的摄取量也越高。故临床上表现为</span></span><span><span> SUR </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">值高的肿瘤对治疗敏感，但复发率高，临床预后差。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">综上所述，</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">作为一种非创伤性、功能性的影像诊断技术能有效区别肺内良恶性病灶，还可以对肿瘤进行准确的分期，指导进一步的治疗。该技术是影像学与细胞生物特征的结合，与</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">和</span></span><span><span> MRI </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">成像有着完全不同的显像基础。对肺部肿瘤的良恶性鉴别较单纯的影像学检查更具有说服力，尤其是在</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等难以判断的肺门及纵隔淋巴结性质的情况下，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">鉴别效果尤佳，对肺癌的临床分期提供了比</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">更为可靠的评价方法。同时由于其高度的准确性可避免象细针穿刺肺活检、胸腔镜、纵隔镜、甚至是剖胸探查等有创检查的并发症。</span></span><span><span> </span></span></p>', 'gwm', 0, 13);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(262, '肝细胞癌的P E T -C T研究进展', '临床应用', '', '', '2009-12-11 14:29:36', '116.228.141.77', '<p align="center" style="text-align:center;"><font face="宋体"><b><br /></b></font></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">肝细胞癌</span></span><span><span>( H e p a t o c e l u l a r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">二</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">‘</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">二</span></span><span><span> ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">是一种常见的恶性肿瘤，</span></span><span><span>P E F\r\n-C F </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">作为一种新的影像技术。在肝细胞庙的诊断中发挥着越来越重要的作用。</span></span><span><span>P E\r\nF<span>&nbsp; </span>( P u e i t r n<span>&nbsp; </span>e n u . i n n<span>&nbsp;\r\n</span>t o i n o g r 2 p h y )</span></span><span><span style="font-family:宋体;">利用特异性的示踪剂进行定性和定量的显像</span></span><span><span>.C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">良好的空间和密度分辨力为肝瘤的定位诊断发挥粉重要的作用。利用</span></span><span><span>P E F\r\n- - - - a</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">联合显像对小肝店的诊断研究目前尚未见到报道，单纯利用</span></span><span><span>P E T\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">对肝庙的研究已经取得了一定的进展</span></span><span><span>f i - z l</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">燎旋</span></span><span><span>C F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的出现为小肝细胞盛</span></span><span><span>\r\n(<span>&nbsp; </span>S m a l l<span>&nbsp; </span>h e p e t o c e l l u l a r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">二</span></span><span><span> .S H\r\nC C )</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">的诊断开辟了广阔的前景。</span></span><span><span><span>&nbsp;&nbsp;\r\n</span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span><span>&nbsp;</span>( </span></b></span><span><b><span style="font-family:宋体;">一</span></b></span><span><b><span>)P E T<span>&nbsp;\r\n</span>( P o s i t r n<span>&nbsp; </span>e m i e n i o\r\nn<span>&nbsp; </span>t o o n g m p h y<span>&nbsp; </span>P E T )</span></b></span><span><b><span style="font-family:宋体;">在诊断肝痛中的作用</span></b></span><span><b><span>:<span>&nbsp;&nbsp; </span></span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span>1 .<span>&nbsp; </span>P E\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">】</span></span><span><span> </span></span><span><span style="font-family:宋体;">对原发肝细胞庙的诊断现状</span></span><span><span>:P E\r\nF </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">中最常用的显像剂为</span></span><span><span>1 8\r\n F -F D C( </span></span><span><span style="font-family:宋体;">氛化脱载葡萄粮</span></span><span><span>1 8 F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span> I u\r\no r d e o x y g l u o o e e ) </span></span><span><span style="font-family:宋体;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">它的原理就是利用</span></span><span><span>F D C</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">与荀萄枯的分子结构相似性进行代谢显像。一般情况下肿启组织的有萄锗代谢非常活跃。表现为组织摄取葡</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">萄</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">糖明</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">显增高</span></span><span><span> t\r\n&gt; t</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">所以</span></span><span><span>P E F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">属于</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">分子水平上的敏</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">像。</span></span><span><span>K h a\r\nn<span>&nbsp; </span>M A </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">等人</span></span><span><span>[ t </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">利用</span></span><span><span>P E F\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">和</span></span><span><span>C T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对肝细胞癌进行对比</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">研究，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">发现</span></span><span><span>1 8 F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span>F D\r\nG<span>&nbsp; </span>P E F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">检出病灶的阳性率为</span></span><span><span>5 5\r\n%,</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">阴性率为</span></span><span><span>4 5 %,C F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的阳性率为</span></span><span><span>9 0\r\n%,</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">阴性率为</span></span><span><span>l o %<span>&nbsp; </span>o</span></span><span><span style="font-family:宋体;">显然</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">在检出肝细胞庙方面明显优于</span></span><span><span>P E T\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">，作者在总结时指出</span></span><span><span>P E T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">在发现肝外转移方面优于</span></span><span><span>C T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">，并且</span></span><span><span>P E I\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">，</span></span><span><span> </span></span><span><span style="font-family:宋体;">可以用来评价肿瘤的分化程度。</span></span><span><span>H oC\r\nL </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">等人</span></span><span><span>[ 5 1 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">研究表明</span></span><span><span>1 8 F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span> F D\r\nG<span>&nbsp; </span>P E I ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">地肝细胞癌的敏感性只有</span></span><span><span>4 7 3\r\n% a </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">侧</span></span><span><span>a n </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">尸研究也证明</span></span><span><span>F D G\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">对肝细胞癌的</span></span><span><span> </span></span><span><span style="font-family:宋体;">价</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">值有限</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">。另</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">外</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">有</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">人</span></span><span><span> [ +\r\nI </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">研</span></span><span><span> </span></span><span><span style="font-family:宋体;">究了</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝内</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">病</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">变对</span></span><span><span>F D ;\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">的</span></span><span><span> </span></span><span><span style="font-family:宋体;">摄取</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">情况认为</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝内</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的占位性病变对</span></span><span><span>F I; </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的摄取可以分成四种形态表现，形态的多样性与肿瘤的分化程度有关，因此</span></span><span><span>F D G</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">在诊断肝癌方而受到限制。随着</span></span><span><span>P E T\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">的研究深人特异性药物的开发和研究也在深人进行，</span></span><span><span>1<span>&nbsp; </span>I C -A c e t a t e( </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">乙酸盐</span></span><span><span>)</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">是目</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">前最有希望的诊断肝细胞瘤的显像剂。</span></span><span><span>1<span>&nbsp; </span>I<span>&nbsp; </span>C -A\r\nct a t </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">。</span></span><span><span> </span></span><span><span style="font-family:宋体;">在组织内可以迅速转变为乙酸辅酶</span></span><span><span>A </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">，乙欧醉</span></span><span><span>A</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">是三梭酸循环的始动物质。</span></span><span><span>1 1<span>&nbsp; </span>C -A\r\nc e t a t e </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">通过血流分布于组织，参与三梭酸循环，最后以</span></span><span><span>C l h</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的形式被洁除</span></span><span><span>"\r\n'' ,<span>&nbsp; </span>I<span>&nbsp;\r\n</span>I<span>&nbsp; </span>C -A c e t a t e </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对肝细胞癌诊断较为敏感，</span></span><span><span> H\r\no<span>&nbsp; </span>C L </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">等人</span></span><span><span>r , 1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的刘比研究表明</span></span><span><span>\r\nI<span>&nbsp; </span>l<span>&nbsp;\r\n</span>C -A ct a t e</span></span><span><span style="font-family:宋体;">诊断肝细胞癌的敏感性为</span></span><span><span>8 7 .\r\n3 % ( </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">相对于</span></span><span><span>1 8\r\n F -F D C</span></span><span><span style="font-family:宋体;">的</span></span><span><span>4 7 .\r\n3 %) </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">有了明显的提高</span></span><span><span>.</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">同时研究还表明两种示踪荆的联合应用对肝细胞癌的敏感度可以达到</span></span><span><span>1 0 0\r\n%,</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">而且两种示踪剂的摄取与肿瘤的组织病理学有关，</span></span><span><span>I<span>&nbsp; </span>I C -A c e t a t e </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对分化良好的肝细胞癌效果较好。</span></span><span><span>1 8 F -F D C</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">刘分化较差的肿瘤效果较好，</span></span><span><span>1 1<span>&nbsp; </span>C -A\r\nc e t a t e </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">对肝细胞癌共有较高的特异性，对于肝内非肝细胞癌</span></span><span><span> 1 1<span>&nbsp; </span>C -A\r\ne e t a t </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">。</span></span><span><span> </span></span><span><span style="font-family:宋体;">代谢不表现出异常</span></span><span><span><span>&nbsp;&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span>2 ,<span>&nbsp; </span>P E\r\nI </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">对转移性肝脏肿瘤的诊断</span></span><span><span>:</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝脏是转移性肿瘤好发的部位，</span></span><span><span> S o\r\nn<span>&nbsp; </span>H B '' } </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">利用</span></span><span><span>1 8 F -<span>&nbsp;\r\n</span>F D C P E I </span></span><span><span style="font-family:宋体;">、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对肝脏占位性病变的研究表明肝脏转移性肿瘤的</span></span><span><span>S U\r\nV( </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">标准摄取值</span></span><span><span>S t a n d a r l<span>&nbsp; </span>u p t a k ev a l u e<span>&nbsp; </span>S U V )</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">最高均明显高于</span></span><span><span>2 . 0\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">，而原发性肝癌的</span></span><span><span>S U V</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">只有部分患者的</span></span><span><span>S U V</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">大于</span></span><span><span>2 . 0\r\n,</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">良性病变的</span></span><span><span>S U V</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">小于</span></span><span><span>2 . 0\r\n&#65533;<span>&nbsp; </span>K o y m n o01 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">研究表明延时扫描对于诊断对于诊断肝脏转移性肿瘤效果好，肿瘤本底计数明显高于早期时段显像。</span></span><span><span>H u s\r\nf t u<span>&nbsp; </span>R</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">等人</span></span><span><span>[ </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">经对比</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">研究表明」</span></span><span><span> '' E\r\nC </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">对转移性肿瘤的敏感性、</span></span><span><span> </span></span><span><span style="font-family:宋体;">特异性、准确性均远远大于超声，略高于</span></span><span><span>C r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">。利用</span></span><span><span>I<span>&nbsp; </span>1<span>&nbsp; </span>C -A c e t a t e </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对肝脏转移性肿瘤的诊断目前尚未见到报道。</span></span><span><span><span>&nbsp;&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span>3 . </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝脏肿瘤治疗后的监测</span></span><span><span>:</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝脏肿瘤经各种治疗后效果的评价问题一直是临床医生非常关心的，</span></span><span><span>P E </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">】</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">作为一种特异的敏感的方法正在发挥着重要的作用。</span></span><span><span>7 1 .\r\n.<span>&nbsp; </span>S " '' </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">动物试验研究表明对于肝脏的恶性肿瘤，服药</span></span><span><span>2 4 1\r\n1 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">后</span></span><span><span>3 0 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的肿瘤细胞玻杀死。</span></span><span><span> T o\r\nd u t k a </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">丫</span></span><span><span> </span></span><span><span style="font-family:宋体;">”</span></span><span><span> } </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">等人对肝细胞癌介入治疗后进行了评价发现。介人治疗后的肝脏撇像可以分成三种类型</span></span><span><span>A</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">型肿瘤摄取</span></span><span><span>F D C</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">增加</span></span><span><span> ( S\r\nU V<span>&nbsp; </span>r a t i o<span>&nbsp; </span>o f<span>&nbsp; </span>1\r\n. 0 7 </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">一</span></span><span><span>2 . 6 6 ) ,<span>&nbsp; </span>B</span></span><span><span style="font-family:宋体;">型与非肿瘤区摄取相同</span></span><span><span> ( S\r\nU V<span>&nbsp; </span>r a t i o <span>&nbsp;</span>o 1 0 . 7 7 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一】</span></span><span><span> . 0\r\n4 ) ,<span>&nbsp; </span>C</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">型摄取减少或缺损</span></span><span><span> ( S\r\nl 1 V<span>&nbsp; </span>r a t i o4 0 . 1 3 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span> 0 .\r\n5 8 ) ,<span>&nbsp; </span>A</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">型</span></span><span><span>B</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">型说明肿瘤细胞还有活性，而</span></span><span><span>C</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">型说明肿瘤细胞已经尚失了活性或己经坏死，</span></span><span><span>P E I\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">，</span></span><span><span> </span></span><span><span style="font-family:宋体;">在评价介人效果方面起到</span></span><span><span>C T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">不可替代的作用。</span></span><span><span>A n d\r\ne m m</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">心</span></span><span><span>i z l </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对</span></span><span><span>A\r\nT<span>&nbsp; </span>O f </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">胞癌进行射频消融治疗的效果研究表明，</span></span><span><span>P E 7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">显像对肿瘤治疗效果的评价明显优于</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">和</span></span><span><span>M </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">工</span></span><span><span> H\r\no<span>&nbsp;&nbsp;&nbsp; </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">、</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.1pt;"><span><b><span>(</span></b></span><span><b><span style="font-family:宋体;">二</span></b></span><span><b><span>)</span></b></span><span><b><span style="font-family:宋体;">多层螺旋</span></b></span><span><b><span> C T<span>&nbsp; </span>(\r\nM u l e</span></b></span><span><b style="mso-bidi-font-weight:\r\nnormal"><span style="font-family:宋体;">一，</span></b></span><span><b><span> l i c e s<span>&nbsp;\r\n</span>c o m p u t e d<span>&nbsp; </span>t o m o g m p h\r\nyM S C T )</span></b></span><span><b style="mso-bidi-font-weight:\r\nnormal"><span style="font-family:宋体;">对小肝癌的诊断</span></b></span><span><b><span>:</span></b></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">作为</span></span><span><span>P E r\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">一</span></span><span><span>C T</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的一部分</span></span><span><span> M S\r\nC T</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">正在发挥着越来越重要的作用，从最先的定位和为</span></span><span><span>P E T\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">作哀减较正目前已经参与病灶的定性诊断，</span></span><span><span>M S (\r\nT</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">快速和薄层的特点可以更多地检出病灶和避免呼吸伪影的干扰。小肝瘾的</span></span><span><span>c r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">诊断一直为影像学者所观注，国内外许多学者对此进行了研究，取得了很大的进步，目前的共识认为。</span></span><span><span>'' H\r\nA<span>&nbsp; </span>( C r<span>&nbsp;\r\n</span>h e p a t i c a r e -d o g a p h y<span>&nbsp;\r\n</span>C T I I A )</span></span><span><span style="font-family:宋体;">和</span></span><span><span>C C A\r\nI ''<span>&nbsp; </span>( C T<span>&nbsp; </span>a , t e d a l p o r o g r a p h y<span>&nbsp; </span>( T A P )</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">是诊断肝脏肿瘤的最佳方法但也</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">存在似阴性和假阳性的问题</span></span><span><span>f u l</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">螺旋</span></span><span><span>C r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对</span></span><span><span>S l i\r\nc e</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">的检出率在动脉期为</span></span><span><span>8 6 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span> 9 0\r\n%,</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">门朴脉期为</span></span><span><span>6 0 %</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">一</span></span><span><span> 6 7\r\n. 3 %</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">，双</span></span><span><span> </span></span><span><span style="font-family:宋体;">期为</span></span><span><span>9 2 %\r\n[ u , i s l </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">。在肝脏两期扫描的基础上，又</span></span><span><span> </span></span><span><span style="font-family:宋体;">提出</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">了</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">三</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">期</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">扫</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">描的</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">概念，</span></span><span><span> M i\r\nl s m a k i </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">和</span></span><span><span>H w a n g [ "l </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">认为</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">三</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">期</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">扫描</span></span><span><span> ( t\r\nr p l e - p h a s e<span>&nbsp; </span>h e l c a l<span>&nbsp; </span>T H C r )</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">对于肝内小肿瘤是必须的，肝脏和肿瘤间密度差的对比以动脉期最好，延迟期次之，门静脉期最差。</span></span><span><span>( i a\r\n, n d i </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">认为动脉期对发现多血供的肿瘤特别有效，门静脉期和延迟期在发现少血供的如分化好的肝癌或微小肝癌</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">方而</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">有</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">效。</span></span><span><span> J a\r\nn g </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">等</span></span><span><span> </span></span><span><span style="font-family:宋体;">‘</span></span><span><span> w ) </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">总</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">结和比</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">较了</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">肝</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">动</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">脉</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">造</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">影</span></span><span><span>c r </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">动脉</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">门</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">静脉造彭</span></span><span><span>C T </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">和</span></span><span><span>T H C\r\nT </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">在检查肝癌中的作用，认为</span></span><span><span>T H C F </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">己足够检出和诊断病灶</span></span><span><span>.</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">术前不必作</span></span><span><span>C T H\r\nA</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">和</span></span><span><span>C r A P </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">检查，毕竟这两种检查均为创伤性、高费用，同时似阳性率也很高，同时也认为延迟期可增加</span></span><span><span>S H C\r\nC</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">组织和正常肝脏组织之间的对比度，</span></span><span><span> </span></span><span><span style="font-family:宋体;">提高分化较好、</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">乏血供</span></span><span><span>S H C\r\nC </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">的检出率。</span></span><span><span>K i m " '' </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">指出双期扫找在动脉期和门静脉期上呈等密度或与肝脏密度差极小的</span></span><span><span>S H C\r\nC </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">极易漏诊，而三期</span></span><span><span>5 a</span></span><span><span> u n </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的薄层扫描，特别是延迟期可加大病灶和正常组织问的密度差，便于发现病变，为诊断和鉴别诊断提供详尽的依据。多数的</span></span><span><span>S H C\r\nC</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">在三期扫描</span></span><span><span>L</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">呈典型表现。</span></span><span><span>S H C\r\nC</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman""="">定性诊断主要依靠增强的动态变化特点，三期扫描的表现可提高诊断和鉴别诊断能力</span></span><span><span><span>&nbsp;&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span><span>&nbsp;</span></span></span><span><span style="font-family:宋体;">综上所述，虽然肝癌的诊断取得了一定的迸展，但目前仍存在着示踪剂的特异性不高，以及假阴性、假阳性的问题，随着放射性药物学的发展，特异性药物必将会出现，加之多层螺旋</span></span><span><span>c </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman""="">的超薄层扫描必将对小肝癌乃至微小肝癌的诊断提供更可靠的依据。</span></span><span><span></span></span></p>', 'gwm', 0, 12);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(263, '如何观察 FDG-PET/CT 图像', '临床应用', '', '', '2009-12-11 14:42:08', '116.228.141.77', '<p align="center" style="text-align:center;"><br /></p><p align="center" style="text-align:center;"><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">一、</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">中的</span></span><span><span> PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像<span style="font-family:simsun;"><span><span>PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像无特定的靶器官，其反映的是全身葡萄糖代谢的情况。通过使用</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">直接测定</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在器官中的浓聚程度作了有关</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">全身生物分布研究发现，给药后一小时器官</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">浓聚程度由高到低依次为脑、肝脏、心脏、红骨髓及肾脏。剂量水平从</span></span><span><span> 6.9%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（脑）至</span></span><span><span> 1.3%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（肾脏）不等。约</span></span><span><span>70%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分布于全身其他器官，</span></span><span><span>20%</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">通过泌尿系统排泄。另外，骨骼肌、消化道、脾脏也有不同程度的摄取。在这些生理性摄取之外出现的任何异常高度</span></span><span><span> FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取我们均认为异常。</span></span></span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">二、</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">中的</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像：阅片同常规</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">三、</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">融合图像</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">将</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像中发现异常的病灶与</span></span><span><span> CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像融合可准确找出病灶位置，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">明确病</span></span><span><span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">变的良恶性质。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p><span><span><span>&nbsp;</span><img src="/image_server_dir/af3fcb86e1d97e8fd780679978011010.jpg" alt="" border="0" /></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">解说：右肺癌伴纵隔淋巴结转移患者，</span></span><span><span>PET-CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查如上图所示。左侧</span></span><span><span> PET</span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">图像发现右肺及纵隔</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">高摄取，中间</span></span><span><span> CT </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像示右肺肿块但纵隔淋巴结未见</span></span><span><span></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">明显增大，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">右侧</span></span><span><span>PET-CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">融合图像清楚显示右肺上叶恶性肿块和纵隔淋巴结转移。</span></span><span><span></span></span></p>', 'gwm', 0, 14),
(264, '为什么可以使用18F-FDG探测肿瘤', '临床应用', '', '', '2009-12-11 14:45:57', '116.228.141.77', '<p align="center" style="text-align:center;"><font face="宋体"><b><br /></b></font></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span>18F</span></span><span><span>-2-</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">氟</span></span><span><span>-2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">脱氧</span></span><span><span>-D-</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">葡萄糖（</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）是目前临床广泛使用的葡萄糖代谢显像剂。</span></span><span><span>18F</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">是一种发射正电子核素，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">半衰期为</span></span><span><span>\r\n109.8min</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">适合进行</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">或</span></span><span><span>PET-SPECT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像。</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的结构类似于葡萄糖，其中一个羟基基团被一个</span></span><span><span>F</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">原子所替代，摄取的过程开始类似于葡萄糖的糖酵解过程，经细胞转运后，在己糖激酶作用下被磷酸化；但与天然葡萄糖不同，</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">经磷酸化后，生成</span></span><span><span>FDG-6-PO4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">，不再参与进一步的糖代谢过程，被滞留在细胞中作为示踪剂进行显像，反映机体内细胞的葡萄糖代谢过程。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤组织是机体内一种异常的新生物，其细胞的代谢增生异常活跃，加上肿瘤细胞中葡萄糖转运蛋白和细胞内酶水平及基因表达均较正常细胞明显增加，肿瘤细胞中无氧糖酵解过程明显增加。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">使用</span></span><span><span>FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">显像即可以区别良性和恶性细胞中的代谢差异，</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">发现代谢旺盛的恶性肿瘤组织。而随着对肿瘤细胞摄取葡萄糖分子机制研究的深入，目前已经发现，肿瘤细胞摄取</span></span><span><span>18F</span></span><span><span>-FDG</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的机制主要与肿瘤细胞膜表面钠依赖的葡萄糖转运体家族的表达增加相关，特别是其中</span></span><span><span>GLU1~5</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">的表达与肿瘤的转移及预后具有明显相关性。而己糖激酶的表达增高或活性增强和葡萄糖</span></span><span><span>-6-</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">磷酸酶的表达降低或活性降低也可见文献报道。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">虽然随着肿瘤类型的不同，肿瘤细胞对</span></span><span><span> FDG </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">摄取有所不同，但已有大量资料证实，</span></span><span><span>FDG-PET\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像在区别良恶性肿瘤、对恶性肿瘤进行分期、分级，探测恶性肿瘤复发和监控肿瘤疗效等方面均具有重要临床价值。</span></span><span><span></span></span></p>', 'gwm', 0, 11),
(265, '肿瘤是如何发生的', '临床应用', '', '', '2009-12-11 14:48:33', '116.228.141.77', '<p align="center" style="text-align:center;"><font face="宋体"><b><br /></b></font></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤是以细胞分裂、细胞死亡和细胞与细胞及细胞与基质相互作用严重失调为特征的一类疾病。随着现代科学特别是分子生物学研究的进展，目前认为，肿瘤的发生主要是由于调控细胞生长分化和凋亡的多种基因改变的结果，导致细胞生长失控和缺乏分化而异常增生，并可侵犯正常组织和器官，最终导致全身播散。</span></span><span><span><span>&nbsp; </span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">其发病机制可以是基因改变，生长因子的增加或生长因子受体活性增加，或细胞膜及胞质与核内信号传导分子的激活，或抗增殖蛋白的失活，因而产生细胞周期蛋白促进增殖反应，</span></span><span><span>DNA</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">合成增多，或</span></span><span><span> DNA</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">破坏的修复缺陷，以至细胞分裂无休止的进行，临床上恶性肿瘤不断增大，消耗机体乃至死亡。</span></span><span><span> <span></span></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">临床实践和基础实验也证实，恶性肿瘤并不是突然发生，而是一个多阶段逐步演变的过程。从接触致癌剂到癌症的临床症状出现，常有一个相当的潜伏期，对人的致癌过程中，可长达</span></span><span><span>4~30</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年之久，平均</span></span><span><span>15~20</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年。</span></span><span><span></span></span></p>', 'gwm', 0, 16),
(266, '肿瘤与炎症可以鉴别吗', '临床应用', '', '', '2009-12-11 14:49:58', '116.228.141.77', '<p align="center" style="text-align:center;"><span><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">肿瘤与炎症可以鉴别吗</span></b></span><span><b><span></span></b></span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在肿瘤患者的</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像中炎症病灶也会显影，这将导致肿瘤、炎症共存时的错误诊断。在胸部疾病中炎症是相当常见的。通常</span></span><span><span> PET </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">在诊断肺部单发肿块时会因炎性病灶而降低特异性，如结核、肺炎、肺脓肿、隐球菌、曲霉球菌、组织浆细胞增多症和其他感染。特别是炎症和肉芽肿，由于代谢的原因和巨噬细胞的吞噬作用，局部组织偶尔可以显示摄取增高，而表现为假阳性的结果。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span><span><span>&nbsp;</span>Knight </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">等报道</span></span><span><span> 45 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例肺部病变的</span></span><span><span>\r\nFDG-PET </span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">显像结果，其中假阳性的</span></span><span><span> 6 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例，包括结核</span></span><span><span>2 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例、肉芽肿、炎症、神经鞘瘤（</span></span><span><span>schwanoma</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">）</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">、纤维性间皮瘤各</span></span><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例。</span></span><span><span>Bakheet\r\n</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">等回顾了</span></span><span><span>650 </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">例病例，发现绝大多数胸部假阳性病例为炎症或感染所致。</span></span><span><span></span></span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span><span><span>&nbsp; </span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">因此在对于肺部单发肿物的性质判定时应注意</span></span><span><span>CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">图像中是否有炎症或感染病灶的存在，并采取定量</span></span><span><span>SUV</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">分析</span></span><span><span> </span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">（一般良性病灶</span></span><span><span>&lt;\r\n2.5</span></span><span><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">），以提高诊断的准确性。</span></span><span><span><span>&nbsp;&nbsp;</span></span></span></p>', 'gwm', 0, 26),
(267, '为何 PET/CT要用作健康体检，有何必要性？', '临床应用', '', '', '2009-12-11 14:56:50', '116.228.141.77', '<p align="center" style="text-align:center;"><font face="宋体"><b><br /></b></font></p>\r\n\r\n<p><span><span><span>&nbsp;</span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查是一种灵敏度高、准确性好的检查手段，对许多疾病（尤其是最为常见的心脏疾病及肿瘤）具有早期发现、早期诊断的价值；</span></span><span><span><br />\r\n<span>&nbsp;&nbsp;&nbsp; </span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查可一次全身成像，便于发现全身体内是否存在危险的微小病灶（尤其是恶性病灶的存在）。早期诊断可以使受检者能真正地得到早期治疗并达到治愈。</span></span><span><span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">不仅能够发现肿瘤的原发病灶，而且能够发现早期的转移灶。这对于肿瘤的治疗是非常重要的，因为不同的肿瘤分期，对于肿瘤的治疗方案是不一样的。在国外，</span></span><span><span>PET</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">被视为健康体检的最佳手段，定期的</span></span><span><span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">健康检查发现了多例的早期癌症患者。由于</span></span><span><span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">采用的是低放射剂量模式、高质量图像方法，对人体是安全无害的，所以适合作为健康体检的方法。</span></span><span><span> <span><br />\r\n<span>&nbsp;&nbsp;&nbsp; </span>PET/CT</span></span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查还特别适合于判断大脑或心脏是否存在早期的缺血、缺氧等代谢功能方面的异常变化，检查结果有助于指导受检者及时采取针对性治疗或采取恰当的预防措施。一般来说宜每隔</span></span><span><span>1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">～</span></span><span><span>2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">年做一次</span></span><span><span>PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:&quot;Times New Roman&quot;">检查。</span></span><span><span> <span><span>&nbsp;&nbsp;</span></span></span></span></p>', 'gwm', 0, 30),
(268, 'PET-C相关T知识问答？', '临床应用', '', '', '2009-12-14 16:38:10', '116.228.141.77', '<span style="font-family:verdana, arial, helvetica, sans-serif;color:#012b31;font-size:14px;">\r\n<p><strong>1. 什么是SPECT 技术？</strong><br />\r\n人们通常所说的ECT指的是单光子发射型计算机断层显像仪，即SPECT。它实际上就是一个或多个探头围绕病人某一脏器进行360°旋转的γ相机，在旋转时每隔一定角度采集一帧图片，然后将图像叠加，并重建为该脏器的横断面、冠状面、矢状面或任何需要的不同方位的断层，切面图像，从而极大地提高了诊断的灵敏度和正确性。SPECT同时可以进行脏器的平面和动态（功能）显像。<br />\r\n<strong>64. 什么是PET 技术？</strong><br />\r\nPET，即正电子发射计算机断层显像。是目前国际上最尖端的医学影像诊断设备之一，也是目前在细胞分子水平上进行人体功能代谢显像最先进的医学影像技术。PET可以从体外对人体内的代谢物质或药物的变化进行定量、动态检测，成为诊断和指导治疗各种恶性肿瘤、冠心病和脑部疾病的最佳方法。PET的临床应用是当今发达国家高科技医疗诊断技术的主要标志之一。PET在临床医学的应用主要集中于恶性肿瘤、神经系统、心血管系统三大领域。</p>\r\n<p><br />\r\n<strong>2. 什么是PET/CT 技术？</strong><br />\r\nPET/CT，即最先进的正电子发射计算机断层显像仪和先进的高分辨多排螺旋CT"两强结合一体化组合型"大型功能代谢与分子影像诊断设备，同时具有PET和CT的检查功能，达到真正意义上的优势互补（1+1&gt;2），一次检查同时提供病变（如恶性肿瘤）精确的解剖结构和功能、代谢改变的信息，明显提高了疾病诊断的准确性，PET/CT的诊断准确性明显优于单纯PET或单纯多排CT检查结果，PET/CT是医学影像诊断技术发展史上一个划时代的里程碑。同时，PET/CT也是国际上生命科学（脑功能、基因蛋白质功能影像诊断）研究及其临床应用的最重要高新技术之一。</p>\r\n<p>---</p>\r\n<p><strong>3. PET/CT技术有何优势？</strong><br />\r\n医学影像成像模式大体可以分为两类：解剖成像和功能成像，前者主要描述人体解剖与形态变化信息，以X线放射影像为代表；后者主要描述人体功能代谢与分子异常信息，以核医学影像为代表，两者具有不同的特点。X线影像是利用穿透人体的X线，以X线透射后的衰减系数作为成像参数，从而获得反映人体组织器官密度差异的图像；而核医学影像是检测注入人体内被称为疾病"探针"的显像药物所发出极其微弱的信号变化作为成像参数，所得图像着重反映体内脏器功能、代谢等生理生化过程。<br />\r\nPET/CT，即最先进的PET技术和高分辨多排螺旋CT"两强结合一体化组合型"大型功能代谢与分子影像诊断设备。PET/CT将最先进的人体功能代谢显像技术与放射影像诊断技术多排螺旋CT"一体化"组合在一起，使用同一个检查床和同一个图像处理工作站，具有PET和多排CT的双重检查功能，一次检查同时提供病变（如恶性肿瘤）精确的解剖结构和功能代谢改变的信息，明显提高疾病诊断的准确性。PET/CT的诊断准确性明显优于单纯PET或单纯多排CT检查结果，PET/CT是当今医学影像诊断技术发展史上一个划时代的里程碑。<br />\r\n<strong>67. PET、PET/CT技术为何能发现早期肿瘤？</strong><br />\r\n恶性肿瘤及其转移灶具有细胞生长速度快、新陈代谢旺盛、增殖能力强等特点。在癌症早期，癌细胞在人体内尚未形成明显肿瘤时，其代谢水平即可明显异于正常细胞。PET、PET/CT显像技术是将极其微量的"肿瘤探针"注射到人体内，在特殊的体外探测仪器下，多维立体的影像显示人体各器官犹如一个"透明人"，显示出全身的生理代谢和解剖结构，各种病灶让医生一目了然，可发现2厘米以下（小到3毫米）的早期肿瘤，形成扫描图像上明显的"亮点"，使肉眼能看到代谢特别旺盛的癌症细胞，早期发掘隐藏的癌症病灶，实现癌症的早期发现、早期诊断、早期治疗。这一高新技术从根本上改变了传统影像设备对肿瘤诊断、治疗的方法，使临床医师能够从细胞分子水平了解肿瘤发生、发展的动态过程。同时，对冠心病、癫痫等神经和精神系统疾病等都可早期诊断。</p>\r\n<p>---<br />\r\n<strong>4. 核医学影像技术与放射超声影像诊断技术的比较有何特长？</strong><br />\r\n医学影像学检查包括放射学（X线平片、CT等）、磁共振成像（MRI）、超声和核医学影像（PET、PET/CT、SPECT）等。核医学影像技术与其他影像诊断技术不同的是，核医学影像是把被称为疾病"探针"的微量显像药物引入体内，用高新技术在体外探查"探针"在人体内或靶器官内的动态和/或静态分布状况。这些"探针"具有与人体内天然的新陈代谢物质相同的生理生化特征，借以可了解人体器官的功能、生理生化、代谢与基因表达等方面的变化。绝大多数疾病在病程的早期仅有功能（包括血流、代谢、受体与基因表达）方面的改变，有的疾病经过临床治疗后，病变局部结构上的变化恢复正常，但体内组织器官的功能与代谢上的损伤仍然存在，此时X平片、超声、CT和MRI检查常为阴性结果，而核医学影像就可以为疾病的诊断，特别是疾病的早期定性诊断和及时的疗效判断提供重要的诊断信息。<br />\r\n与其他影像诊断技术比较，核医学影像技术检查的优势在于：能早期诊断疾病；检查结果更加准确；能进行快速全身检查；检查安全无创。<br />\r\n<b><br />\r\n</b></p>\r\n<p><strong>5. PET和PET/CT能解决肿瘤患者什么问题？</strong><br />\r\n1．鉴别良恶性肿瘤或病变：众所周知，鉴别肿瘤的良恶性甚为重要，不仅关系到治疗方案，也直接影响到患者的预后。如患者肺部有一单个结节，经PET／CT检查，若该结节代谢活性不高，提示良性病变可能性大，对手术的选择应当慎重；反之，若该结节代谢活性增高，提示恶性可能，要采取积极的治疗措施，包括手术。<br />\r\n2．肿瘤分期：肿瘤分期是决定患者治疗方案的重要依据。PET／CT对患者进行全身显像，一次PET／CT全身显像可提供脑、肺、淋巴结、肝、肾上腺和骨骼等全身各器官有无转移的信息，有利于对肺癌、乳腺癌、结肠癌、卵巢癌和淋巴瘤等多种肿瘤进行精确的临床分期。以诊断淋巴结转移为例，PET／CT更准确，这是因为CT或MRI是将增大的淋巴结（&gt;1cm）视为转移，其中不乏由于慢性炎症引起的淋巴结增大，或将已受到肿瘤组织侵及的正常大小的淋巴结误判为正常，而PET根据淋巴结的代谢活性判断是否转移，比只考虑病变大小更为准确。<br />\r\n3．疗效评估：由于PET／CT具有很高的灵敏度及其功能代谢显像的特点，对放疗、化疗疗效的判断更加准确灵敏，有利于指导临床医师及时调整治疗方案。<br />\r\n4．鉴别肿瘤治疗后坏死、纤维化与残留或复发：PET／CT可以鉴别化疗、放疗和手术治疗后的肿瘤坏死、纤维化与残留或复发，而其它影像手段难以做到。<br />\r\n5．帮助制订肿瘤放疗计划：PET／CT能够帮助放射治疗师勾画更为合理的生物靶区，帮助制订放疗计划。<br />\r\n6．肿瘤原发灶的寻找：已明确有肿瘤转移灶的患者，通过PET／CT检查，可以进一步寻找肿瘤的原发病灶。</p>\r\n<p>---<br />\r\n<strong>6. PET和PET/CT能解决脑部疾病患者什么问题？</strong><br />\r\n1．癫痫病灶的定位及评估手术疗效：帮助定位癫痫病灶，为脑外科手术提供参考。PET／CT与创伤性的开颅皮层脑电图定位癫痫病灶的吻合率在90％以上，为癫痫病灶的定位提供了一项无创性的新的选择。PET／CT定位指导下进行癫痫灶切除术，绝大多数患者术后病情可得到控制。<br />\r\n2.痴呆的早期诊断：痴呆缺乏有效的治疗方法，但部分病人如早期发现，可以通过适当治疗改善症状或延缓疾病的进展。因此，PET／CT早期诊断痴呆，对病人、家庭和社会均有重要意义。同时可鉴别早老性痴呆和血管性痴呆。<br />\r\n3.在脑血管疾病中的应用：短暂性脑缺血发作（TIA）与脑梗死的早期定位、疗效评价和预后判断。<br />\r\n<strong>7. PET和PET/CT能解决心血管疾病患者什么问题？</strong><br />\r\n是判断心肌梗死部位心肌是否存活的最可靠方法。梗死区心肌是否存活，直接关系到能否接受冠状动脉搭桥术（CABG）和冠状动脉腔内成形术（PTCA），并估测手术预后。如果心肌梗死部位有存活心肌，将是CABG或PTCA的适应症，手术可获得成功。</p>\r\n<p>---<br />\r\n<strong>8. PET和PET/CT健康体检能带什么好处？</strong><br />\r\nPET和PET／CT技术是全球最高端的医学影像诊断设备，堪称"现代医学高科技之冠"。它可以灵敏地反映各脏器，如脑、心肺、肝、脾胃等器官的功能和代谢状况，其检查结果被形象地称为医学影像上的"半透明人"，能发现超早期处于代谢异常状态的恶性肿瘤，使人类早期诊断恶性肿瘤的梦想得以实现，被称之为探测肿瘤的"雷达"或发现肿瘤"神探"。随着人们生活水平的提高，自我保健意识的增强，社会上对健康体检有了更多的需求，由于PET／CT对早期发现肿瘤、脑、心血管等方面的疾病是一种灵敏度高、准确性好的检查手段，在发达国家和我国的发达地区，有的已将PET／CT作为一种有效的筛查肿瘤、脑、心血管疾病的高科技手段。恶性肿瘤如能早期发现，完全可以治愈。<br />\r\n<strong>9. 为什么称PET和PET/CT是探测肿瘤的"雷达"或发现肿瘤"神探"？</strong><br />\r\n每种疾病都会经历从基因突变→代谢异常→形态改变的发展过程。传统的X线平片、超声、CT和MRI检查方法大多在疾病发生到"形态改变"这一阶段才能发现病变，因此不能达到"早期诊断"的目的。PET和PET/CT能更准确的反映人体正常或异常的生理代谢活动，在分子水平上反映人体是否存在肿瘤的病理生理变化，明显提高了诊断的准确性以及治疗方案的合理性。PET和PET/CT是当今最完美、最高档次的恶性肿瘤影像诊断方法，全面实现了肿瘤诊断的"四定"目标： "定位" ：发现病变和明确病变部位。 "定性" ：明确显示形态和功能变化的病理和病理生理性质 。"定量" ：量化疾病或病变在形态学上及功能上的改变 。"定期" ：确定疾病的发展阶段。</p>\r\n<p>---</p>\r\n<p><strong>10. PET和PET/CT在肿瘤疾病的诊断与治疗中有何临床价值？</strong><br />\r\n如果你是一位早期肿瘤患者然而却茫然不知？如果你是肿瘤患者却不知进展到何种程度？如果你正在接受化疗或放疗而想知是否有效？如果你是肿瘤手术后患者不知有无复发？那么 , PET和PET/CT 会告诉你许多 ......<br />\r\na．早期诊断及鉴别诊断恶性肿瘤或病变：PET 显像利用的正电子示 踪剂的可特异性参加恶性肿瘤的代谢活动 ，可以敏感、早期显示癌组织中特殊的代谢变化，达到早期诊断肿瘤的目的。<br />\r\nb．进行精确的肿瘤临床分期：肿瘤分期是决定患者治疗方案的重要依据。 PET ／ CT 对患者进行全身显像，一次 PET ／ CT 全身显像可提供脑、肺、淋巴结、肝、肾上腺和骨骼等全身各器官有无转移的信息，有利于对肺癌、乳腺癌、结肠癌、卵巢癌和淋巴瘤等多种肿瘤进行精确的临床分期。<br />\r\nc．有利于指导或调整临床治疗方案：PET／CT 可以鉴别化疗、放疗和手术治疗后的肿瘤坏死、纤维化与残留或复发，而其它影像手段难以做到。 并能通过观察癌组织特殊代谢在治疗前后的变化，对肿瘤治疗（手术、放化疗）后的疗效进行检测。 已明确有肿瘤转移灶的患者，通过 PET ／ CT 检查，可以进一步寻找肿瘤的原发病灶。<br />\r\nd．帮助制订肿瘤放疗计划：PET／CT 能够帮助放射治疗师勾画更为合理的生物靶区，帮助制订放疗计划。</p>\r\n<p>---<br />\r\n<strong>11. 为什么所核医学影像检查是非常安全的？</strong><br />\r\n在进行核医学影像检查过程中，受检者只需要经静脉注射少量药物，不需要承受其他痛苦。而所注射的药物是一种超短半衰期的同位素，这种同位素的放射性是极其低微的，而且衰变很快，在十几分钟到几个小时的时间内就完全从人体内消失。例如：经大规模临床调查，做一次PET/CT检查，患者所接受的由放射性核素引起的辐射量仅为一次X光检查的1/10左右。<br />\r\n<strong>12. 为什么说PET、PET/CT检查实际为患者节省了医疗费用？</strong><br />\r\n在医院里你是否遭遇了不一次又一次的CT\\核磁共振\\B超\\X-RAY\\生化检查等的折磨,耗费了宝贵的时间,大量的精力和昂贵的医疗费用,有些人甚至付出了生命的代价......国内外大量经济学研究结果表明：如果全面对 PET、PET/CT 检查的费用和效益进行分析， PET、PET/CT 检查可以明显的节约医疗费用。因为通过 PET/CT 检查可以对病人进行更加准确的诊断，使病人得到及时有效的治疗，避免了许多不恰当的检查、误诊和治疗，结果从总体上大大节约了医疗费用。同时减少了病人由于不恰当的诊疗带来的痛苦，提高了生活质量。 由于 PET/CT 在节约医疗费用方面的明显优势，在美国和西欧，许多医疗保险公司都愿意为病人支付 PET/CT 在肿瘤和心脏疾病方面的检查费用，据调查，仅 PET/CT 在肿瘤检查一项，每年就可为美国医疗保险节省至少 2 亿美元。</p>\r\n<p>---<br />\r\n<strong>13. PET、PET/CT主要适用于哪些人群？</strong><br />\r\n肿瘤是引起人类死亡的主要原因之一，其发生，发展有一个过程，从基因突变开始，经过解读异常、代谢异常、功能异常、结构异常最后到临床出现症状．当临床出现症状发现肿块时，大多数患者已是肿瘤中晚期，丧失了治疗的最佳时机。当肿瘤处于早期阶段及时发现基本可以治愈 ;到了肿瘤的中、晚期才发现进行治疗，就会硝烟四起，病情急剧恶化，癌细胞就会象决堤的洪水，势不可挡地蔓延开来。 高科技的PET、 PET/CT已经为我们早期发现肿瘤提供了现代化的手段，对于身居要位、工作压力大的中年人，老年人或有肿瘤家族史的人，定期进行PET、PET/CT 检查是身体健康的保证．除孕妇外PET、 PET/CT 适用于任何人群，如患有糖尿病患者或者不能自主保持稳定的患者（如儿童）则需先告知医生，为其采取相应的措施后，方可进行检查。<br />\r\n<strong>14. 健康体检从没病找病开始有何意义？</strong><br />\r\n两位病人，一位多年来坚持每年一次体检。查体时被发现肺部有一小点阴影，被确诊为肺癌，随即做了手术，身体状况一直不错。另一位近几年老是咳嗽，总以为是气管炎的老毛病。但最近其身体状况越来越差，到医院检查，结果被确诊为肺癌晚期，对此现代医学已经无能为力。两位病人，患了同样的病，结局却有天壤之别。其原因就是预后良好的病人通过定期体检，早期发现肿瘤并尽早治疗。 医药界有句古语"不治已病治未病"，就是查出没有自我感觉但已经发生的疾病，做到早期治疗。体检治的就是"未病"，健康与疾病之间并不存在明显的界限。一个人的机体可能潜伏着病理性缺陷或功能不全，而表面上却仍是很"健康"，当身体处于健康与非健康的"临界"状态时，及时体检就能够抓住最佳处置时机。如果早期发现、及时治疗，各种恶性肿瘤的治愈率均会明显提高。例如胃癌早期手术的5年生存率高达90%以上，而中晚期手术的5年生存率仅8%~17%；乳腺癌的早期治愈率为90%，而中晚期治愈率不到50%。其它慢性疾病等到出现症状时，不仅出现严重合并症和脏器损害，而且治疗起来也非常棘手。令人生畏的是，有些恶性肿瘤早期一般无明显症状，很容易被人们忽视，待出现明显症状和体征时，往往已到疾病晚期，错过治疗的最佳时机。据统计，目前在我国，能够做到定期健康体检的人不足2%。从预防医学角度讲，所有健康人群至少应每年参加一次健康体检，"亚健康"人群更应如此。<br />\r\n我国恶性肿瘤发病率为0.12％，也就是说，每分钟都有2－3人被诊断为癌症患者或死于癌症，它已经成为我国居民的第一杀手。世界卫生组织指出，恶性肿瘤有1／3可防，1／3可有效治疗，1／3可保守治疗。只要积极预防、早期发现、合理治疗，患癌风险可以降低，恶性肿瘤治愈是可能的。如今，随着现代科技的发展，人体全身立体透明影像让我们一目了然地识别出某脏器的病变这就是人们所期待的探测肿瘤"神眼"--PET、PET/CT。</p></span>          ', 'gwm', 0, 133);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(269, 'PET－CT常见良性或生理性放射性摄取部位', '病例介绍', '', '', '2009-12-16 11:28:42', '116.228.141.77', '<font color="#CC3300" face="幼圆, sans-serif" size="6"><span style="font-size:21px;"><b><span style="color:#000000;font-family:宋体;font-size:16px;font-weight:normal;"><p></p><p><span style="font-family:simsun;font-size:14px;">PET－CT常见良性或生理性放射性摄取部位：脑组织、眼肌、鼻咽部、扁桃体、涎腺（舌下腺、下颌下腺、腮腺等）、口咽部、喉部、甲状腺、颈部淋巴结炎性摄取、（女性）乳腺、心肌、肺门淋巴结炎性摄取、肝脏、脾脏、胃壁、肠道、（女性）宫腔、卵巢和（男性）前列腺、睾丸等常见生理性摄取或炎性摄取；肾脏、输尿管、膀胱由于放射性排泄放射性聚集见放射性浓聚。寒冷天气偶可见棕色脂肪生理性摄取（常为对称性），胸锁乳突肌、椎肋关节等肌肉偶尔可见肌肉紧张摄取。</span></p><p><img src="/image_server_dir/1dadbe30226993a56be06151dd5b3e98.jpg" alt="" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">正常 PET 全身3D图&nbsp;</span></p><p><img height="587" src="http://www.cn-petct.com/FileUpload/200909/20090930140947587.jpg" width="586" border="0" style="width:340px;height:350px;" /></p><p><span style="font-family:simsun;font-size:14px;">全身冠状面：CT&nbsp; &nbsp;PET&nbsp;&nbsp; 融合图&nbsp; &nbsp;PET 3D图</span></p><p><img height="575" src="http://www.cn-petct.com/FileUpload/200909/20090930141024188.jpg" width="572" border="0" style="width:320px;height:352px;" /></p><p><span style="font-family:simsun;font-size:14px;">&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;全身矢状面：CT PET 融合图 PET 3D图</span><br /></p><p><img height="717" src="http://www.cn-petct.com/FileUpload/200909/20090930091627510.jpg" width="702" border="0" style="width:655px;height:608px;" /></p><p><span style="font-family:simsun;font-size:14px;">正常脑对称性放射性摄取</span></p><p><img height="712" src="http://www.cn-petct.com/FileUpload/200909/20090930091940987.jpg" width="703" border="0" style="width:660px;height:621px;" /></p><p><span style="font-family:simsun;font-size:14px;">鼻咽部生理性摄取</span></p><p><img height="574" src="http://www.cn-petct.com/FileUpload/200909/20090930091951940.jpg" width="633" border="0" style="width:657px;height:594px;" /></p><p><span style="font-family:simsun;font-size:14px;">扁桃体生理性摄取</span></p><p><img height="574" src="http://www.cn-petct.com/FileUpload/200909/20090930092016242.jpg" width="646" border="0" style="width:656px;height:584px;" /></p><p><span style="font-family:simsun;font-size:14px;">口咽部生理性摄取</span></p><p><img height="574" src="http://www.cn-petct.com/FileUpload/200909/20090930092031576.jpg" width="621" border="0" style="width:656px;height:601px;" /></p><p><span style="font-family:simsun;font-size:14px;">舌下腺生理性摄取</span></p><p><img height="574" src="http://www.cn-petct.com/FileUpload/200909/20090930092040101.jpg" width="621" border="0" style="width:655px;height:603px;" /></p><p><span style="font-family:simsun;font-size:14px;">下颌下腺生理性摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092112950.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">颈部淋巴结炎性摄取</span></p><p><img height="1027" src="http://www.cn-petct.com/FileUpload/200909/20090930113400601.jpg" width="1025" border="0" style="width:639px;height:516px;" /></p><p><span style="font-family:simsun;font-size:14px;">双侧胸锁乳突肌肌肉紧张摄取</span></p><p><img height="919" src="http://www.cn-petct.com/FileUpload/200909/20090930113301878.jpg" width="956" border="0" style="width:636px;height:570px;" /></p><p><span style="font-family:simsun;font-size:14px;">双侧胸锁乳突肌肌肉紧张摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092139163.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">（女性）乳腺生理性摄取</span></p><p><img height="573" src="http://www.cn-petct.com/FileUpload/200909/20090930092147586.jpg" width="645" border="0" style="width:633px;height:572px;" /></p><p><span style="font-family:simsun;font-size:14px;">心肌生理性摄取</span></p><p><img height="562" src="http://www.cn-petct.com/FileUpload/200909/20090930092155557.jpg" width="630" border="0" style="width:635px;height:567px;" /></p><p><span style="font-family:simsun;font-size:14px;">肺门淋巴结生理性摄取</span></p><p><img height="778" src="http://www.cn-petct.com/FileUpload/200909/20090930112950532.jpg" width="808" border="0" style="width:629px;height:615px;" /></p><p><span style="font-family:simsun;font-size:14px;">食道生理性摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092203580.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">肝脏、脾脏、胃壁轻度生理性摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092218236.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">肠道生理性摄取</span></p><p><img height="630" src="http://www.cn-petct.com/FileUpload/200909/20090930092230587.jpg" width="609" border="0" style="width:633px;height:647px;" /></p><p><span style="font-family:simsun;font-size:14px;">肾脏尿液排泄放射性聚集</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092255632.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">膀胱尿液排泄放射性聚集</span></p><p><img height="575" src="http://www.cn-petct.com/FileUpload/200909/20090930092306128.jpg" width="630" border="0" style="width:633px;height:579px;" /></p><p><span style="font-family:simsun;font-size:14px;">（男性）前列腺轻度生理性摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092315570.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">（男性）睾丸轻度生理性摄取</span></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930092325114.jpg" border="0" /></p><p><span style="font-family:simsun;font-size:14px;">（女性）月经期宫腔子宫内膜生理性摄取</span></p><p><img height="568" src="http://www.cn-petct.com/FileUpload/200909/20090930092332131.jpg" width="661" border="0" style="width:634px;height:552px;" /></p><p><span style="font-family:simsun;font-size:14px;">（女性）卵巢卵泡生理性摄取</span></p><p><img height="1029" src="http://www.cn-petct.com/FileUpload/200909/20090930113050769.jpg" width="1024" border="0" style="width:640px;height:591px;" /></p><p><span style="font-family:simsun;font-size:14px;">颈部棕色脂肪摄取</span></p><p><img height="1029" src="http://www.cn-petct.com/FileUpload/200909/20090930113152936.jpg" width="1024" border="0" style="width:643px;height:544px;" /></p><p><span style="font-family:simsun;font-size:14px;">颈部棕色脂肪摄取</span></p><p></p></span></b></span></font>                              ', 'gwm', 0, 11),
(270, 'PET－CT 脑受体显像', '临床应用', '', '', '2009-12-16 11:37:40', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;Neurology 受体显像</p><p><img height="258" src="http://www.cn-petct.com/FileUpload/200909/20090930153540881.jpg" width="378" border="0" style="width:358px;height:240px;" /><img height="438" src="http://www.cn-petct.com/FileUpload/200909/20090930153441306.jpg" width="624" border="0" style="width:484px;height:322px;" /></p><p><br /><img height="706" src="http://www.cn-petct.com/FileUpload/200909/20090930153321295.jpg" width="984" border="0" style="width:863px;height:651px;" /></p></span>', 'gwm', 0, 8),
(271, '脑外伤后功能代谢显像', '临床应用', '', '', '2009-12-16 11:38:12', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;&nbsp; 脑外伤后脑组织功能监测，判断预后及恢复情况。</p><p>右侧枕顶叶脑外伤后脑组织无功能，考虑软化灶形成。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930152530367.jpg" border="0" /></p></span>', 'gwm', 0, 6),
(272, 'PET－CT在帕金森氏（PD）病诊断中的应用', '临床应用', '', '', '2009-12-16 11:38:32', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>帕金森氏病又称震颤麻痹（Parkinson’s Disease, PD），CT、MRI常无特征性改变，<sup>18</sup>F-FDG PET－CT可见大脑皮层广泛代谢降低，顶叶更明显。18F-多巴胺显像可见基底神经节摄取明显降低。</p><p>11C-Raclopride&nbsp;&nbsp; D2 Receptor 显像</p><p><img height="462" src="http://www.cn-petct.com/FileUpload/200909/20090930152159555.jpg" width="437" border="0" style="width:380px;height:369px;" />&nbsp;<img height="461" src="http://www.cn-petct.com/FileUpload/200909/20090930152223412.jpg" width="425" border="0" style="width:401px;height:370px;" /></p></span>          ', 'gwm', 0, 11),
(273, 'PET－CT在阿尔海默氏病(Alzheimer’s)诊断中的应用', '临床应用', '', '', '2009-12-16 11:39:08', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>阿尔海默氏病，<sup>18</sup>F-FDG的早期典型表现为顶、后颞区及扣带回代谢减低，多为双侧，进展期上述区域低代谢范围进一步扩大，降低更明显，且出现额叶代谢降低，而基底神经节、中央前后回、视状裂等较少累及。临床确诊或病理确诊的Alzheimer’s中，97% PET/CT有异常表现，66%为典型表现。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930151740733.jpg" border="0" /></p><p><img height="741" src="http://www.cn-petct.com/FileUpload/200909/20090930154158997.jpg" width="977" border="0" style="width:859px;height:612px;" /></p></span>', 'gwm', 0, 8),
(274, 'PET－CT在癫痫致痫灶定位中的应用', '临床应用', '', '', '2009-12-16 11:39:31', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>PET－CT能灵敏地探测到功能性癫痫病灶，致痫灶在癫痫发作期表现为高代谢灶，或与周围正常脑组织相近似；发作间期则为低代谢灶；可以为癫痫灶γ刀治疗提供准确定位。</p><p align="center" style="text-align:center;"><img src="http://www.cn-petct.com/FileUpload/200909/20090930150405349.jpg" border="0" /></p><p align="left" style="text-align:left;">左侧额叶（额中回）萎缩，代谢减低，考虑考虑为致痫灶。</p><p align="left" style="text-align:left;"><img height="526" src="http://www.cn-petct.com/FileUpload/200909/20090930150655758.jpg" width="588" border="0" style="width:722px;height:620px;" /></p><p align="left" style="text-align:left;"><img height="512" src="http://www.cn-petct.com/FileUpload/200909/20090930150817380.jpg" width="528" border="0" style="width:720px;height:616px;" /></p><p align="left" style="text-align:left;">左侧颞叶代谢减低，考虑为致痫灶。</p><p align="left" style="text-align:left;"><img src="http://www.cn-petct.com/FileUpload/200909/20090930151207969.jpg" border="0" /></p><p align="left" style="text-align:left;"><img src="http://www.cn-petct.com/FileUpload/200909/20090930151225369.jpg" border="0" /></p></span>          ', 'gwm', 0, 10),
(275, '脑转移瘤PET－CT表现', '临床应用', '', '', '2009-12-16 11:39:58', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; 肺Ca颅内转移：右额前上部大脑镰旁高代谢结节（见下图）</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930144825917.jpg" border="0" /></p><p>&nbsp;&nbsp;&nbsp; 肺Ca脑、颅骨转移（见下图）</p><p><img height="494" src="http://www.cn-petct.com/FileUpload/200909/20090930145447228.jpg" width="525" border="0" style="width:415px;height:378px;" /><img height="462" src="http://www.cn-petct.com/FileUpload/200909/20090930145516937.jpg" width="504" border="0" style="width:408px;height:378px;" /></p><p align="left" style="text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>贲门Ca脑转移（见下图）</p><p align="left" style="text-align:left;"><img height="650" src="http://www.cn-petct.com/FileUpload/200909/20090930145220599.jpg" width="787" border="0" style="width:722px;height:634px;" /></p><p align="left" style="text-align:left;">&nbsp; 脑转移瘤PET断层</p><p align="left" style="text-align:left;"><img src="http://www.cn-petct.com/FileUpload/200909/20090930145945690.jpg" border="0" /></p><p align="left" style="text-align:left;">&nbsp;</p></span>', 'gwm', 0, 8),
(276, '右额叶脑胶质瘤术后复发（FDG和MET图对比）', '临床应用', '', '', '2009-12-16 11:41:28', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>“右额叶胶质瘤术后”，<sup>18</sup>F-FDG PET显像右侧额顶部相当于手术灶处不均匀性轻度放射性摄取，SUV约2.7，<sup>11</sup>C-MET PET显像相应部位呈片状放射性异常浓聚，SUV约2.6－2.9，?<sup>11</sup>C-MET显像浓聚范围大于?<sup>18</sup>F-FDG显像，CT相应部位见片状软组织密度影，平面大小约1.2cm×1.6cm，CT值约25HU；CT病灶周围见大片低密度影，平面最大约4.9cm×8.1cm，CT值约19HU。</p><p>诊断：“右额叶胶质瘤术后”，右侧额顶部<sup>11</sup>C-MET PET显像示蛋氨酸代谢明显增高，<sup>18</sup>F-FDG代谢轻度增高，考虑复发（随访证实）。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930144157681.jpg" border="0" /></p></span>          ', 'gwm', 0, 9),
(277, 'PET-CT:颈部淋巴瘤', '', '', '', '2009-12-17 16:38:08', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>颈部淋巴瘤，双侧颈部多发高代谢淋巴结</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091013162141956.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091013162154478.jpg" width="400" border="0" /></p></span>', 'gwm', 0, 4),
(278, 'PET-CT：甲状腺癌', '临床应用', '', '', '2009-12-17 16:39:05', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）右侧甲状腺高代谢结节：甲状腺乳头状癌</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162221366.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162235850.jpg" border="0" /></p><p>该病例术后一年复查：肿瘤无复发、转移</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162433130.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162456147.jpg" border="0" /></p><p>（病例二）左侧甲状腺Ca伴第1-2骶椎左侧部、左侧坐骨骨转移瘤。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162708483.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930162728299.jpg" border="0" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;甲 状 腺 癌</strong></p><p><strong><br /></strong>甲状腺癌是头颈部比较常见的恶性肿瘤，占全身恶性肿瘤的1％一2％，女性多见。由于它的病理类型较多，生物学特性差异很大。低度恶性的甲状腺癌有时可自然生存10年以上，有的甚至有肺部转移还能带病生存5年左右。但高度恶性的甲状腺癌可以在短期内死亡。绝大多数的甲状腺癌都发生在青壮年。&nbsp;<br />一、 病因&nbsp;<br />甲状腺肿瘤的病因目前尚无定论，但与以下因素有关。&nbsp;<br />1． 放射线接触 是目前惟一肯定与分化性甲状腺癌的发生密切相关的重要因素，包括&nbsp;<br />医源性外放射接触、放射线泄露污染、医源性内放射或核爆炸后射线的暴露等。&nbsp;<br />2．碘的摄人 饮食中碘的含量过低或过高都可能导致甲状腺癌的发生，如在碘缺乏区多发生滤泡状癌；而在高碘摄人地区，如我国沿海地区、冰岛、挪威、夏威夷等则乳头状癌高发。&nbsp;<br />3．遗传因素 主要表现在部分家族性甲状腺髓样癌的发生，可能与ret基因的突变相关。&nbsp;<br />4．其他因素 如性激素等。&nbsp;<br />二、病理学&nbsp;<br />(一)病理学分型&nbsp;<br />甲状腺上皮性恶性肿瘤主要有4种组织学类型：乳头状癌，滤泡状癌，髓样癌，末分化癌。非上皮性肿瘤有恶性淋巴瘤、肉瘤及其他杂类肿瘤。&nbsp;<br />(二)分期&nbsp;<br />2002年国际抗癌联盟(UICC)的甲状腺癌分期(第6版)：&nbsp;<br />T一原发肿瘤：可以分为孤立性肿瘤和多发性肿瘤两种&nbsp;<br />Tx 原发肿瘤大小无法测量&nbsp;<br />T0 没有原发肿瘤证据&nbsp;<br />T1 原发肿瘤最大径≤2cm，局限于甲状腺内&nbsp;<br />T2 原发肿瘤最大直径＞2cm，但≤4cm，局限于甲状腺内&nbsp;<br />T3 原发肿瘤最大直径＞4cm，局限于甲状腺内，或有轻微甲状腺外侵犯(如侵入及胸骨甲状肌或甲状腺周围软组织)&nbsp;<br />T4 任何大小的原发肿瘤，侵及甲状腺包膜外&nbsp;<br />T4a 侵犯皮下软组织、喉、气管、食管或喉返神经&nbsp;<br />T4b 侵犯椎前筋膜、纵隔血管或包裹颈总动脉&nbsp;<br />N一淋巴结转移：区域淋巴结包括颈部及纵隔淋巴结&nbsp;<br />Nx 淋巴结转移情况无法判断&nbsp;<br />N0 无区域淋巴结转移&nbsp;<br />N1 区域淋巴结有转移&nbsp;<br />N1a 伴有贝区淋巴结(气管前和气管夯，包括喉前及Delphian淋巴结&nbsp;<br />N1b 伴有一侧颈侧区，双颈，对侧或纵隔淋巴结转移&nbsp;<br />M一远处转移&nbsp;<br />M x 无法评价有无远处转移&nbsp;<br />M0 无远处转移&nbsp;<br />M1 有远处转移&nbsp;<br /><br />TNM分期&nbsp;<br />分化性甲状腺癌(乳头状癌及滤泡状癌)的TNM分期如下：&nbsp;<br />患者年龄＜45岁 患者年龄≥45岁&nbsp;<br />I期 任何T，任何N，M0 Tl，No，M0&nbsp;<br />II期 任何T，任何N，M1 T2,N0,M0&nbsp;<br />III期 T1-3，N1a，M。&nbsp;<br />T3,N0,M0&nbsp;<br />IV期 IV1A T1-3，N1b，M0&nbsp;<br />IV1B T4b，任何N，M0&nbsp;<br />IV1C任何T，任何N，M1&nbsp;<br />I期 T1,N0,M0&nbsp;<br />II期 T2,N0,M0&nbsp;<br />III期 T3,N0,M0&nbsp;<br />T1-3,N1a，M0&nbsp;<br />IV期 IV1A：T1-3，N1b，M0&nbsp;<br />T4a，N0,M0&nbsp;<br />T4a，N1a，M0&nbsp;<br />T4a，N1b，M0&nbsp;<br />IV1B：T4b，任何N，M0&nbsp;<br />IV1C：任何T，任何N，M1&nbsp;<br />所有的未分化癌病例均为IV期，而不考虑它的T，N，M在什么期&nbsp;<br />T4a 甲状腺未分化癌局限在甲状腺内——手术可切除；&nbsp;<br />T4b 甲状腺末分化癌侵犯至网状腺外——手术不能切除。&nbsp;<br />IV期&nbsp;<br />IVA T4a，任何N，M0&nbsp;<br />IVB T4b，任何N，M0&nbsp;<br />IVC 任何T，任何N，M1&nbsp;<br />二、 诊断与鉴别诊断&nbsp;<br />（一） 甲状脉乳头状癌的诊断与鉴别诊断&nbsp;<br />1．症状和体征 甲状腺乳头状癌占总甲状腺癌的3／4，好发于女性，男女比例约为1：2.5。发病年龄女性多在30一40岁左右。典型的临床表现为进行性增大的甲状腺无痛肿块，多数患者无自觉症状。病变发展缓慢，病程长，部分患者可出现声音嘶哑、呼吸困难、吞咽困难等肿瘤侵及邻近组织引起的症状。少数患者可以颈部淋巴结肿大为首发症状。晚期患者可出现由于远处转移导致的胸痛、痰中带血、腹部或骨路疼痛等症状。&nbsp;<br />乳头状癌以单发病灶多见，少数为多发或双侧性。病灶大小不一，但多为实质性，质地较硬，不规则，边界欠清，与气管或舌骨下肌群粘连时活动度受限；较大的病灶可伴有部分囊性。50％有颈部淋巴结转移，淋巴结多质地中等或质硬、成串、活动、有包膜，部分囊性。&nbsp;<br />2． 检查方法&nbsp;<br />(1)超声检查 超声检查是诊断甲状腺乳头状癌最常用的辅助检查方法。典型表现为甲状腺内的单个或多个实质不均质低回声肿块，少数可呈部分囊性但同时伴有囊壁上乳头状实质结节。形态不规则，无明显包膜，可以伴有或不伴有细小的钙化。多普勒检查肿块内部或周围可见异常粗大不规则血流。部分患者同时能发现气管前、气管旁或颈内静脉旁有肿大的淋巴结，内部回声不均匀或有异常血流。&nbsp;<br />(2)实验室检查 部分甲状腺乳头状癌的患者可有血清甲状腺球蛋白(HTG)的升高。甲状腺功能的检测对于甲状腺乳头状癌患者的术后监测有一定的价值：甲状腺乳头状捆患者，经全甲状腺切除术后HTG的持续性升高，常提示肿瘤的复发或转移。&nbsp;<br />(3)CT检查 是甲状腺癌的常用诊断方法之一，有良好的灵敏度和推确性，并能清晰地显示肿瘤与周围组织的解剖位置关系。CT检查对甲状腺乳头状癌患者术后的随访排除甲状腺及颈部有无肿瘤复发或远处转移有重要的价值。&nbsp;<br />(4)MRI 主要用于了解甲状腺癌原发肿瘤是否有包膜外的侵犯及周围气管、食管等受累及的范围，并能较准确地了解有无颈部淋巴结转移及作为术后复发或远处转移的随访手段。&nbsp;<br />(5)放射性核素检查放射性核素检查，尤其是131I的扫描在甲状腺癌的诊断中已被广泛应用。利用其易被肿瘤细胞摄取的特点而通过常规和延迟扫描可以鉴别甲状腺肿瘤的良恶性；另外SPECT和PET技术的应用，可以为寻找甲状腺癌患者是否有远处转移及进行转移灶精确定位，为临床治疗提供帮助。&nbsp;<br />(6)细针穿刺吸取细胞学检查 是术前诊断甲状腺乳头状癌最直接、简便的方法，加上辅助超声引导穿刺的技术，对甲状腺乳头状癌诊断的准确率可达到90％以上，与术中冰冻切片检查结果相当。而且，当同时伴有颈部淋巴结肿大时，细针穿刺检查还能术前鉴别有无淋巴结转移，对临床治疗有重要的参考价值。&nbsp;<br />3．鉴别诊断&nbsp;<br />(1)甲状腺腺瘤 病史较长，无自觉症状，不伴有声音嘶哑及颈部淋巴结肿大。体检甲状腺腺瘤质地中等或囊性，表面光滑、规则有包膜，边界清楚，活动度良好。B超及CT均提示形态规则，包膜清楚的实质均质或囊性占位，无不规则血流。细针穿刺吸取细胞学检查可以通过细肥核的特征与甲状腺乳头状癌相鉴别。&nbsp;<br />(2)结节性甲状腺肿 多见于地方性缺碘地区，也可散发。病史较长，无自觉症状，双侧性多见。体检甲状腺弥漫性肿大，结节感，质地软或中等，表面光滑，边界清楚，随吞咽活动。B超检查提示甲状腺弥漫性增大，可见大小不等的囊性或实质不均质结节，边界清楚，但无明显包膜，无异常不规则血流。细针穿刺吸取细胞学检查可见正常的滤泡上皮细胞，配合超声引导下的穿刺，可以排除结节性甲状腺肿合并甲状腺癌的可能。&nbsp;<br />(3)甲状腺炎 甲状腺炎患者可有典型的病史，罕见声音嘶哑或颈部淋巴结肿大。体检甲状腺多为双侧或单侧肿大，前后径增大，结节感不明显，亚急性甲状腺炎患者可有触痛。甲状腺功能检查可有甲状腺免疫指标的异常，如TGA和MCA的升高。B超检查显示甲状腺肿大，内部回声降低或欠均匀，但无不规则不均质结节改变，无异常不规则血流。细针穿刺吸取细胞学检查多能根据甲状腺滤泡上皮的形态及见到数量不等的淋巴细胞与甲状腺癌相鉴别，配合超声引导下的穿刺可以排除合并甲状腺癌或恶性淋巴瘤可能。&nbsp;<br />(二)其他甲状腺恶性肿瘤&nbsp;<br />1．滤池状癌 相对少见，好发于地方性缺碘地区，发病年龄较大，部分可有结节性甲状腺肿病史，病情发展比较缓慢，血液转移较常见。实验室及影像学检查发现多与乳头状癌相似。细针穿刺细胞学检查与术中冰冻切片检查鉴别滤泡状腺瘤与滤泡状癌常较困难。因为滤泡状癌细胞分化较好，故临床上常需依靠常规组织病理学检查。&nbsp;<br />2．髓样癌 是一种来源于甲状腺滤泡旁C细胞的神经内分泌肿瘤，部分有家族遗传倾向，可以伴有其他多发性内分泌肿瘤。其临床特点与甲状腺乳头状癌相类似，但可同时伴有因其他内分泌肿瘤引起的症状，如腹泻、面部潮红、血压升高、消化道溃疡、黏膜多发结节等。早期可出现颈部淋巴结转移。血清降钙素(PLT)和癌胚抗原(CEA)的升高是较特征性的实验室检查证据。细针穿刺细胞学检查结合免疫组化的检测常能术前做出正确诊断。&nbsp;<br />3.未分化癌 临床上最少见的甲状腺癌，恶性程度最高，治疗效果最差，多数患者在1年内因局部肿瘤复发或远处转移导致死亡。临床体检甲状腺肿块多较大，常为双侧性，质地硬，就诊时多已有周围器官组织的侵犯而出现活动受限、呼吸吞咽困难、声带麻痹等。常可发现颈部淋巴结肿大。影像学检查，早期可发现肺等其他部位的远处转移病灶。细针穿刺吸取细脑学检查可见分化差的小细胞癌。&nbsp;<br />四、治疗&nbsp;<br />(一)治疗原则&nbsp;<br />1．甲状腺癌的治疗原则以外科手术切除为主。不论病理类型如何．只要有手术指征就应尽可能地手术切除。&nbsp;<br />2．对于手术后有残留或术后有广泛淋巴结转移者，应及时给予术后放射治疗。&nbsp;<br />3．对于分化好的乳头状癌和滤泡癌，即使术后复发者也可再次手术治疗。&nbsp;<br />(二)原发灶手术治疗&nbsp;<br />1．乳头状癌 甲状腺乳头状癌是一种分化较好的低度恶性的肿瘤，外科手术是首选的治疗方法。对局限于一侧(T1、T2)的甲状腺乳头状癌患者采用病侧甲状腺腺叶加峡部切除术。对于非高危型或无既往颈部放射线接触史者，一侧腺叶加峡部切除术是比较合理的手术方式。对局限于峡部的甲状腺乳头状癌患者可采用峡部加双侧腺叶部分切除木。&nbsp;<br />2．滤泡状癌 滤泡状癌微小浸润型的恶性程度较低，很少发生淋巴结和血液转移，故一般行病侧腺叶加峡部切除术已足够。对于滤泡状癌广泛浸润型，行全甲状腺切除术或病侧腺叶加对侧次全切除术。如甲状腺原发肿瘤侵犯周围器官其处理同乳头状癌；肿瘤较大侵犯上纵隔时可考虑行胸骨劈开术，力争完全根治。甲状腺全切除时至少保留一例甲状旁腺。&nbsp;<br />3．髓样癌 甲状腺髓样癌的恶性程度较乳头状和滤泡状癌高，原发肿瘤常发生甲状腺腺体外的侵犯(T4)，较容易发生淋巴结和血液转移，双侧多中心病灶较常见，手术切除范围要广泛。&nbsp;<br />4．未分化癌 甲状腺未分化癌的恶性程度最高，临床上甲状腺的原发肿瘤常较大，可有周围器官的累及而局部固定。病程进展快，常早期发生颈部淋巴结和远处转移。治疗首选手术、放疗和化疗的综合治疗方法。对于原发肿瘤发现较早、体积较小尚未出现周围组织侵犯时，可考虑手术切除。&nbsp;<br />（三）颈部转移淋巴结的手术治疗&nbsp;<br />临床颈部淋巴结阳性，无论分化性甲状腺癌或髓样癌，如临床证实有颈部淋巴结转移者均应行治疗性颈部淋巴结清扫术。&nbsp;<br />(四)放射治疗&nbsp;<br />1．外放射治疗适应证 ①甲状腺末分化癌和甲状腺恶性淋巴瘤首选放射治疗；②原发肿瘤切除不净或残留的III、IV有小区癌细胞残留者；③广泛淋巴结转移；④甲状腺癌骨转移，特别是椎骨、颅底周围或可能引起病理性骨折导致功能障碍。&nbsp;<br />2．内放射治疗 内放射治疗也就是放射性核素治疗。临床上常将放射性核素131I治疗用于两个方面：①分化性甲状腺癌全甲状腺切除术后残留甲状腺组织的灭活，可以消灭残留的微小的甲状腺癌细胞降低局部复发率。治疗适用患者包括：年龄45岁或以上、甲状腺原发肿瘤超过1.5cm、癌细胞有明显的腺外侵犯或区域淋巴结转移；②在甲状腺癌原发肿瘤手术无法彻底或已出现远处转移而无法手术切除时，一般在治疗前均应常规先行全身131I扫描，确定肿瘤组织有否吸碘功能才能进行。&nbsp;<br />(五)化学治疗&nbsp;<br />分化性甲状腺癌和甲状腺髓样癌对化疗药物均不敏感，故不应作为常规的术后辅助治疗。化学治疗被主要运用于甲状腺未分化癌和甲状腺恶性淋巴瘤的治疗，也有将其作为部分复发性分化较差的甲状腺分化性癌或髓样癌的术前辅助治疗。 常用于甲状腺未分化癌的化疗药物主要有多柔比星、博莱霉素、顺铂、依托伯苷和米托蒽醌等，其中以多柔比星最为常用。联合用药以多柔比星和顺铂为主的化疗方案，甲状腺恶性淋巴瘤的化疗同样以CHOP方案为主(环磷酰胺、多柔比星、长春新碱、泼尼松)。有时，可联用博莱霉索，其化疗敏感性很高，完全缓解串可达80％以上。&nbsp;<br />(六)内分泌治疗&nbsp;<br />内分泌治疗主要是指TSH抑制治疗，亦被称为甲状腺素替代治疗，是临床上最常用的甲状腺癌患者的辅助治疗手段之一。&nbsp;<br />其治疗的目的：①替代，在甲状腺切除术后补充甲状腺袁，防止出现术后甲状腺功能低下；②抑制和减低TSH水平，建立不利于残留甲状腺癌细胞复发或转移的环境。&nbsp;<br />治疗剂量原则上需根据患者的年龄、性别、临床症状、原发肿瘤的病理类型及有无转移、体内T4和TSH水平综合考虑。年龄较大，原发肿瘤为甲状腺髓样癌、未分化癌、淋巴瘤，肿瘤无残留或转移，有潜在诱发甲状腺素毒性作用因素的患者可适当降低甲状腺素的剂量。&nbsp;<br />(七)疗效&nbsp;<br />有关甲状腺癌预后相关因素的报道很多，大多数研究结果认为患者的年龄、性别、肿瘤的大小、肿瘤的分化程度、肿瘤局部侵犯、区域淋巴结转移和远处转移等均与甲状腺癌的预后有关。女性小于51岁、男性小于41岁，不伴有远处转移；甲状腺原发肿瘤直径小于5cm或甲状腺乳头状癌局限于甲状腺腺体内、滤泡状癌无包膜侵犯预后好。TNM分期越晚，预后越差。年龄越大、肿瘤细胞分级越高、伴有腺外侵犯或远处转移、肿瘤直径越大，分期则越晚，预后越差。&nbsp;<br />〔预防与调护〕&nbsp;<br />1、预防&nbsp;<br />(1)减少颈部对射线的接触。&nbsp;<br />(2)心情调畅，防止内分泌紊乱。&nbsp;<br />(3)碘摄入保持相对平衡。&nbsp;<br />(4)甲状腺良件疾忠如甲状腺瘸，腺肿、淋巴性甲状腺炎等，都有癌变的可能，故应定期复查，&nbsp;<br />2．凋护&nbsp;<br />(1)对全甲状腺切除患者，终身服用甲状腺素片，减少复发几率。&nbsp;<br />(2)对甲状腺病侵及喉、气管、食管广泛切除术后患者．注意吞咽功能及发声的训练。&nbsp;<br />(3)对放疗后口咽干燥，吞咽不利者，可常服滋阴生津、利咽解毒之品，如玄参、土地、沙参、板蓝根、射十、白茅根、威灵仙等。&nbsp;</p></span>', 'gwm', 0, 8),
(279, 'PET-CT:喉咽癌', '', '', '', '2009-12-17 16:39:38', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;&nbsp;（病例一）右侧喉咽部Ca伴颈部淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930161000219.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930160820328.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930160839202.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930160913900.jpg" border="0" /></p><p>（病例二）“喉咽癌术后”肿瘤残留、复发伴颈部淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930161445821.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930161500862.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930161520844.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930161537518.jpg" border="0" /></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 喉&nbsp;&nbsp; 癌</strong></p><p><strong><br /></strong>喉癌占全身恶性肿瘤的2％，占头颈部恶性肿瘤的8％，占耳鼻喉科恶性肿瘤的首位，绝大多数为鳞癌。喉癌的发病男性明显多于女性，男女之比约为8：1。多发生于50一70岁之间。近年来喉癌的发病率有增高趋势。&nbsp;<br />一、 病因&nbsp;<br />喉癌的致病因素目前尚未完全了解，一般认为与以下因素有关。&nbsp;<br />1．吸烟 吸烟与喉癌关系密切，喉癌患者中约95％有长期吸烟史，严重吸烟者死于喉癌是非吸烟者的20倍，而且吸烟量与发病率呈正相关系，长期吸烟台并饮烈性酒，可能对致癌起协同作用。&nbsp;<br />2．慢性喉炎 用声过度，其病变部位与声门癌相同，均在声带前中1／3交界处。&nbsp;<br />3．大气污染 工业化地区空气污染严重，喉癌发病率高，而且逐年上升。&nbsp;<br />4．其他 病毒感染(如喉乳头状瘤病毒)和某些癌前病变(如喉角化症、喉乳头状瘤、慢性增生性喉炎等)。也有入认为，放射损伤可产生喉癌，特别是小剂量放射有致癌的危险性。&nbsp;<br />二、病理学&nbsp;<br />(一)喉癌前病变&nbsp;<br />1．喉角化症 本病包括白斑症和喉厚皮病，以前者较多见，部分可发展成癌。喉角化症可发生于喉内各部位，但以发生在声带最多见。&nbsp;<br />2．乳头状瘤 乳头状瘤可分幼儿型和成人型。幼儿型通常认为与病毒感染有关，常多&nbsp;<br />发，切除后易复发。成人型较易癌变，癌变率为1.5％一28.1％。&nbsp;<br />3．慢性增生性喉炎 多表现为上皮的不规则增生，上皮下层常有广泛的慢性炎性细胞浸润。有长期吸烟史的老年人，如喉茹膜出现局部不规则改变，如隆起、黏膜粗糙或浅在溃疡等情况，则有必要进行活检。&nbsp;<br />(二)鳞状细胞癌&nbsp;<br />1.原位癌 原位癌较少见，可发生于任何部位，以声带前端最为多见，外观无特征。但必须注意，活检时深度不足往往会遗漏早期浸润癌。&nbsp;<br />2．浸润性癌 浸润性癌约占喉癌的90％以上，可发生于喉的所有区域。但多见于声门区和声门上区，声门区者仅占喉癌的o一8％。&nbsp;<br />3.疣状瘤 疣状瘤最常发生的部位是声带，但可发生于声门上区和声门下区。其外观多呈白色，伴有乳头状突起。疣状瘤可破坏附近组织，包括软骨和骨。其特点是侵袭性小，甚少有淋巴结转移或远处转移。&nbsp;<br />(三)其他恶性肿瘤&nbsp;<br />1．类癌 可发生于喉的任何部位，肉眼形态为息肉样所见，也可有蒂，类癌对放射线不敏感，外科手术是惟一有效的方法。&nbsp;<br />2．纤维肉瘤 较为罕见，约占喉癌的0.32％一0.86％。纤维肉瘤常发生于声带前段或前联合，但其他部位也可发生，如环状软骨、喉室等。肉瘤肉眼外观可呈结节状或息肉祥，灰白色，坚硬，边缘较整齐。很少出现颈淋巴结转移，但可有血行转移。&nbsp;<br />三、诊断与鉴别诊断&nbsp;<br />(一)临床表现&nbsp;<br />1．声门上型 早期症状不明显，可仅有咽部不适感及异物感。肿瘤发生溃烂后，有咽喉疼痛或干咳。部分患者可有痰中带dK。如肿瘤向下侵犯，可出现声音嘶哑。肿瘤增大阻塞喉腔可引起呼吸困难。由于声门上区淋巴组织丰富，因此可较早出现颈淋巴结肿大。&nbsp;<br />2．声门型 此型喉癌早期可出现声音嘶哑。如肿瘤继续长大，则可引起痰中带血和呼吸困难。晚期有咽喉疼痛、呼吸困难和颈淋巴结肿大。&nbsp;<br />3．声门下型 声门下区较为隐蔽，早期无症状。随着肿瘤增大侵及声带，可出现声嘶、咳嗽、痰血和呼吸困难。喉镜检查可发现声门下区新生物。&nbsp;<br />(二)辅助检查&nbsp;<br />1．间接喉镜检查 间接喉镜检查是诊断喉癌最常用的方法，可以观察病变的部位、表面状况、累及范围以及功能状态等。间接喉镜检查时应自上而下，系统观察喉腔及周围结构，观察舌根、会厌溪、会厌、喉面、两侧会邹襞、室带、声带、声门裂、声门下腔、两侧梨状窝、环后区以及咽后区等。&nbsp;<br />2．直接喉镜检查 由于纤维喉镜的普遍应用，直接喉镜已很少应用于诊断。&nbsp;<br />3．纤维喉镜检查 纤维喉镜已普遍应用于喉癌的放疗前以及术前检查。其优点是无视&nbsp;<br />死角，能窥视间接喉镜所不易看到的部位如会厌舌根部、喉室、声门下区；纤维喉镜有放大作用，能更清楚地看到喉黏膜病变细微变化；还可以拍照。但对有呼吸困难的病人，纤维喉镜检查可能加重呼吸困难，必要时在气管切开后行之。&nbsp;<br />4．动态喉镜 动态喉镜亦称闪光喉镜，可看清声带振动情况。对早期声带癌的诊断极有帮助，恶性病变声带振动减弱或消失。&nbsp;<br />5.喉部CT扫描 不仅可以发现喉部新生物的存在，还能显示肿瘤的位置、大小和范围，显示喉部间隙如声门旁间隙、会厌前间隙的受累情况；显示喉部软骨受侵犯的情况以及显示颈部淋巴结肿大的情况。&nbsp;<br />6．磁共振成像 其性能与CT扫描相似，但较优越。不仅可做水平成像，也可根据需要做各种平面成像；对软组织的分辨率高于CT扫描，而且无X线损伤。&nbsp;<br />7．活体组织检查 活体组织检查是喉癌诊断中最重要的方法之一，是确定喉癌诊断的决定性步骤，对可疑的病例应做活体组织检查以明确诊断。一般在间接喉镜指导下钳取进行病理检查，少数不能成功的病例需行纤维喉镜钳取。另外，不可在有坏死组织及感染的组织上取活检。有呼吸困难者，应在气管切开后再行活检。&nbsp;<br />(三)鉴别诊断&nbsp;<br />1．喉结核 喉结核多继发于肺结核、青中年患者居多。主要症状是喉痛和声音嘶哑。喉镜检查可见喉黏膜苍白水肿，有少数浅溃疡，如虫蚀状，好发于喉的后部。肺部X线片以及痰结核菌检查、活检均可帮助鉴别；少数病例两者同时存在。&nbsp;<br />2．喉乳头状瘤 喉乳头状瘤各年龄组均可发生，可单发或多发。通常不引起声带运动障碍，最终仍需依靠活检加以鉴别。&nbsp;<br />3．喉角化症 多发生于声带游离缘。有长期声音嘶哑，亦多见于中年以上的男性。&nbsp;<br />4．喉梅毒 病变多见于喉的前部，常为梅毒瘤。继而破溃，破坏组织较多，愈合后有瘢痕粘连。病人喉痛及声音嘶哑较轻，有性病史，血康华反应阳性以及活检可确诊。&nbsp;<br />5.喉淀粉样瘤 喉淀粉样瘤为良性病变，可呈弥漫性沉积，亦可呈局限性肿瘤样突起，以引起声带的运动障碍，外观不易与肿瘤鉴别，活检时质地较硬，不易钳取。镜下不难鉴别。&nbsp;<br />(四)临床分期&nbsp;<br />采用国际抗癌协会的TNM分类法&nbsp;<br />T 指原发灶&nbsp;<br />N 指淋巴结&nbsp;<br />M 指远处转移&nbsp;<br />1． 声门癌TNM&nbsp;<br />T1 肿瘤限于声带，可累及前或后联合，声带活动正常&nbsp;<br />T1a 肿瘤限于一侧声带&nbsp;<br />T1b 肿瘤累及两侧声带&nbsp;<br />T2 肿瘤累及声门上区和(或)声门下区，声带活动正常或受限&nbsp;<br />T3 肿瘤限于喉内，声带固定&nbsp;<br />T4 肿瘤超腔，已侵犯口咽、甲状软骨、颈部软组织及皮肤&nbsp;<br />N0 临床上未们及淋巴结&nbsp;<br />N1 扪及同侧淋巴结肿大，完全活动，淋巴结最大直径＜2cm&nbsp;<br />N1a 临床上不像转移&nbsp;<br />N1b 临床上像转移&nbsp;<br />N2 双侧或对侧淋巴结肿大，淋巴结未固定，淋巴结量大直径＜2cm&nbsp;<br />N3 单侧或双侧淋巴结肿大，固定&nbsp;<br />M0 无远处转移&nbsp;<br />M1 有远处转移&nbsp;<br />2．声门上区癌TNM&nbsp;<br />Tl 肿瘤局限于声门上一侧，声带活动正常&nbsp;<br />T2 肿瘤累及原发部位一侧以上或声带，声带活动正常&nbsp;<br />T3 肿瘤限于喉内，声带固定和(或)累及环后区、梨状窝内侧壁和会厌前间隙&nbsp;<br />T4 肿瘤超腔累及口咽、颈部软组织或破坏甲状软骨&nbsp;<br />N及M分类与声门癌相同&nbsp;<br />3．声门下区癌TNM&nbsp;<br />T1 肿瘤限于声门下区&nbsp;<br />T2 肿瘤累及声带，声带活动正常或受限&nbsp;<br />T3 肿瘤累及声带，声带固定&nbsp;<br />T4 肿瘤超腔，侵人口咽及颈部软组织，有环状或甲状软骨破坏&nbsp;<br />N及M分类与声门癌相同。&nbsp;<br />四、治疗&nbsp;<br />(一)治疗原则&nbsp;<br />I、II期手术或放疗是治愈性疗法，二者效果相似，但注重病人的生活质量；III、IV期需要多学科的综合治疗，目前应用较多的是放疗加手术。&nbsp;<br />(二)声门癌的治疗原则&nbsp;<br />声门癌主要采用放射治疗和手术治疗。&nbsp;<br />1．T1、T2的病例放射治疗和手术治疗均能取得良好效果。但放疗能使绝大多数病人获得治疗并保持语言功能。即便有一部分放疗失败的病人，仍可有效地做全喉切除手术。因此，对T1、T2的声门癌病人都应首选放射治疗。&nbsp;<br />2．对T3患者因原发肿瘤太大，单纯放疗效果较差，多采用放疗加手术治疗或手术后加放射治疗等综合治疗手段。&nbsp;<br />3．T4病人应以手术治疗为主，但术前放疗是非常有价值的。&nbsp;<br />(三)外科治疗&nbsp;<br />喉癌外科治疗的原则是在彻底切除肿瘤的前提下，尽可能地重建和恢复喉的三大功能即发音、呼吸和吞咽功能，达到既能根治癌肿，又能提高患者术后生活质量的目的。&nbsp;<br />1．喉部分切除术 是一组手术的总称，是切除一部分喉的组织，保存另一部分喉组织，以期在彻底切除肿瘤的基础上尽可能地保存喉的功能。部分切除术已成为外科治疗喉癌的主要方法之一，适宜于早期喉癌。&nbsp;<br />2．喉全切除术声门下癌、晚期声门癌以及声门上区癌已不适合行喉部分切除术者均适宜行喉全切除术。有些喉癌局部病变虽可行部分切除术，而全身状况较差，也应行喉全切除术。&nbsp;<br />喉全切除术的切除范围为整个喉的气管上段、胸骨甲状肌，甲状舌骨肌，胸骨舌骨肌。舌骨是否切除可视病情而定，如肿瘤未破坏甲状软骨，末发展到喉外时，常可保留；如肿瘤已发展到喉外，侵及邻近组织时，则行扩大切除，切除部分舌根或部分甲状腺或部分下咽黏膜等。&nbsp;<br />3．颈淋巴结转移癌的处理 由于喉癌主要经颈淋巴结转移，因此对有颈淋巴结转移的患者，应同时行颈淋巴结清扫术。一般认为声门上型喉癌淋巴结转移率高，因此对临床上未发现淋巴结肿大的声门上型喉癌，也应行选择性颈清扫术或分区性颈淋巴结清扫术。&nbsp;<br />4．喉全切除术后发音重建 重建喉全切除术后发音功能的方法很多，归纳起来有三大类：&nbsp;<br />(1)喉全切除术后发音重建术在气管和食管或下咽部之间形成一通道，使呼出的气流通&nbsp;<br />过此通道进入食管或下咽腔，振动下咽黏膜发出声音，恢复语言能力。&nbsp;<br />(2)人工发音装置应用机械或电子装置，使病人获得语言能力。&nbsp;<br />(3)食管发音经过特殊训练，使无喉者能将一定量的空气吸入食管内，然后像打嗝一样将空气从食管内呼出，振动下咽黏膜而发音。&nbsp;<br />（四）放射治疗&nbsp;<br />1．单纯放射治疗 声门区Tl、T2和T3N0期病人可行单纯放疗。放射野以声带病变为中心，根据病变大小采用5cm×6cm或5cm×7cm野。一般以喉结下0.5cm为中心，后缘为颈椎前缘，下缘为环状软骨前缘，前缘超过皮肤。&nbsp;<br />放射治疗的方式及总剂量应根据病灶大小选择：1、病灶的照射剂量一般不应低于70Gy／(7—8)周；T2病变应采用75Gy／(7—8)周左右的剂量为佳；T3和T4声门癌的剂量可提高至75—80Gy。多采用常规放疗，也可采取超分割放疗。&nbsp;<br />2．术前放疗 指有计划的放射治疗与手术的结合，其目的是减少术后复发，提高治愈率。主要适宜于T3和T4或有颈淋巴结转移的病例，以及单纯放疗效果不显著的病人；原发灶为浸润或溃疡型的病例也常采用术前放疗。&nbsp;<br />术前放疗一般照射40一50Gy，休息3—4周后手术。如有颈部淋巴转移，应包括在照射野内。&nbsp;<br />3..术后故疗 术后放疗多应用于晚期喉癌直接行根治性手术的病例。术中发现某一部位无法彻底切除或手术标本病理检验时，发现切缘有癌细胞残留者。术后放疗应尽早进行，一般不宜超过2周时间。一般剂量在50一60Gy左右，术后放疗的病人应使用塑料套管，以防止金属套管产生电子污染。&nbsp;</p></span>', 'gwm', 0, 8),
(280, 'PET－CT 口底癌中的应用', '临床应用', '', '', '2009-12-17 16:40:00', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;右侧舌部、口底部高代谢占位，考虑口底Ca；颏下、双侧颌下、双侧颈前及颈动脉鞘间隙多发淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930160342815.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930160355833.jpg" border="0" /></p></span>', 'gwm', 0, 9);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(281, '鼻咽癌PET－CT表现', '临床应用', '', '', '2009-12-17 16:40:22', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）鼻咽右侧壁高代谢占位，考虑鼻咽癌，病变侵犯枕骨基底部、斜坡、蝶骨及右蝶窦外侧壁。右侧咽旁、右侧颈部多发高代谢淋巴结影，考虑淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930154649142.jpg" border="0" /></p><p><img height="651" src="http://www.cn-petct.com/FileUpload/200909/20090930154714978.jpg" width="650" border="0" style="width:661px;height:671px;" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930154928652.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930154941674.jpg" border="0" /></p><p align="left" style="text-align:left;"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 鼻 咽&nbsp; 癌</strong></p><p align="left" style="text-align:left;"><br />鼻咽癌是发生在鼻咽部的一种恶性肿瘤。在世界范围内，鼻咽癌高发区分布在三个地区，①中国南方和亚洲东南部一些国家，是世界最高发地区；②北美洲的美国阿拉斯加洲和加拿大西部；③非洲北部和东北部一些国家。&nbsp;<br />一、病因&nbsp;<br />鼻咽癌的病因尚未完全明确，可能相关的因素如下。&nbsp;<br />1．血源因素 表现为种族易感性差异，10％有癌家族史，其中56％为鼻咽癌家族史，并发现鼻咽癌高发家族。&nbsp;<br />2．地理环境因素 表现为地区差异性，东南亚地区特别是我国华南地区，鼻咽癌发病率和死亡率明显高于欧美各国。&nbsp;<br />3．微量元素研究表明：某些微量元素摄人不平衡易产生鼻咽癌，镍的含量与鼻咽癌死亡率呈正相关。&nbsp;<br />4．EB病毒感染 从鼻咽癌组织中已分离出、并建立起带EB病毒的类淋巴母细胞株，这些细胞株都带EB病毒抗原，少数还可以用电镜找到EB病毒颗粒。鼻咽癌患者的血清中常可分离出高滴度的抗EB病毒抗原的抗体，其水平与病情的发展呈正相关。故认为鼻咽癌与EB病毒的感染有关。&nbsp;<br />5．化学因素 研究表明：芳香烃、亚硝胺与鼻咽癌的发病有明显关系。高发区鼻咽癌患者饮食中，这些致癌化学物质明显高于低发区。&nbsp;<br />二、病理学&nbsp;<br />鼻咽癌以鳞状上皮癌最为多见，约占95％以上，其他有腺癌、淋巴瘤等。&nbsp;<br /><br />（一） 淋巴引流&nbsp;<br />鼻咽淋巴引流是组成韦氏环的一部分，包括颈外侧深淋巴结、颈内静脉旁淋巴结、副神经周围淋巴结及锁骨上淋巴结。&nbsp;<br />1．颈深上组 从颅底到舌骨水平，包括咽后淋巴结(Rouviere淋巴结)及颅底淋巴结、乳突尖淋巴结(鼻咽癌常在此淋巴结首先出现转移，故疑鼻咽癌时应首先注意乳突尖处淋巴结是否肿大)和二腹肌处淋巴结(其解剖标志为胸锁乳突前缘与下颌角之间)。咽后淋巴结即Rou—viere淋巴结位于环椎侧块前方，距中线约2cm。&nbsp;<br />2．颈深中组 包括舌骨水平以下的颈内静脉周围淋巴结及副神经周围淋巴结。&nbsp;<br />3．锁骨上淋巴结。&nbsp;<br />（二）按肿瘤表面形态分型&nbsp;<br />1．结节肿块型 鼻咽部可见新生物隆起，表面高低不平或弥漫性，最多见。&nbsp;<br />2．菜花型 肿块较大，表面不平，像花菜一样，血管丰富，易出血。&nbsp;<br />3．溃疡型 肿瘤边缘隆起，中间凹陷坏死，临床比较少见。&nbsp;<br />4．黏膜下型 肿瘤向腔内突起，左右不对称，肿块表面覆盖正常黏膜组织，临床往往咬不到肿瘤组织，采用细针穿刺可以明确诊断。&nbsp;<br />(三)按生长特点分型&nbsp;<br />（1）上行型 肿瘤主要向上发展，侵犯颅底、脑神经，甚至颅内。&nbsp;<br />（2）下行型 肿瘤主要向下侵犯，如口咽、颈淋巴结等。&nbsp;<br />（3）混合型 既向上又向下侵犯。&nbsp;<br />(四)病理分型&nbsp;<br />1．原位癌。&nbsp;<br />2．浸润癌&nbsp;<br />(1)分化好的癌：①分化好的鳞癌；⑧分化好的腺癌。&nbsp;<br />(2)分化差的癌：①分化差的鳞癌；⑧分化差的腺癌；③泡状核细胞癌；④末分化癌；⑤黏液表皮样癌。&nbsp;<br />3．其他恶性肿瘤 恶性淋巴瘤、恶性肉芽肿、黑色素瘤、胚胎性横纹肌肉瘤、脊索瘤等。&nbsp;<br />4．世界卫生组织(WHO)则将鼻咽癌的病理形态学描述如下：①WHOI型：分化好和中&nbsp;<br />等分化的角化性鳞状细胞癌，此型在高发区少见；②WHOII型：分化差的癌；②WHOIII型：未分化癌或淋巴上皮癌。&nbsp;<br />(五)临床分期&nbsp;<br />国内主要有1992福州分期与1997UICC分期。&nbsp;<br />1．1992福州分期&nbsp;<br />T—原发肿瘤&nbsp;<br />T1 局限于鼻咽腔内&nbsp;<br />T2 局部浸润，鼻腔、口咽、茎突前间隙、软腭、椎前软组织，颈动脉鞘区部分侵犯&nbsp;<br />T3 颈动脉鞘区肿瘤占据，颅底、翼突区、翼胯窝、单一前组或后组脑神经侵犯&nbsp;<br />T4 前后组脑神经同时受侵，鼻旁窦、眼眶、颞下窝、海绵窦，直接浸润第一、二颈椎&nbsp;<br />N一颈淋巴结&nbsp;<br />No 未扣及肿大淋巴结&nbsp;<br />N1 上颈淋巴结直径＜4cm，活动&nbsp;<br />N2 下颈淋巴结，或直径4—7cm&nbsp;<br />N3 锁骨上区淋巴结，或直径＞7cm&nbsp;<br />M一远处转移&nbsp;<br />M0 无远处转&nbsp;<br />M1 有远处转移&nbsp;<br />2．1997 UICC分期&nbsp;<br />Tis 原位癌&nbsp;<br />T1 肿瘤局限于鼻咽腔内&nbsp;<br />T2 肿瘤侵犯鼻腔和(或)口咽、茎突前间隙、软腭、椎前软组织，颈动脉鞘区部分侵犯&nbsp;<br />T3 颈动脉鞘区肿瘤占据，颅底、翼突区、翼胯窝、单一前组或后组脑神经侵犯&nbsp;<br />T4 前后组脑神经同时受侵，鼻旁窦、眼眶、颞下窝、海绵窦，直接浸润第一、二颈椎&nbsp;<br />N一颈淋巴结&nbsp;<br />N0 未扣及肿大淋巴结&nbsp;<br />N1 上颈淋巴结直径＜4cm，活动&nbsp;<br />N2 下颈淋巴结，或直径4—7cm&nbsp;<br />N3 锁骨上区淋巴结，或直径＞7cm&nbsp;<br />M一远处转移&nbsp;<br />M0 无远处转移&nbsp;<br />M1 有远处转移．&nbsp;<br /><br />1997 UICC分期&nbsp;<br />Tis 原位癌&nbsp;<br />T1 肿瘤局限于鼻咽腔内&nbsp;<br />T2 肿瘤侵犯鼻腔和(或)口咽&nbsp;<br />T2a 无咽旁间隙侵犯&nbsp;<br />T2b 有咽旁间隙侵犯&nbsp;<br />T3 肿瘤侵犯颅底骨质和(或)鼻旁窦&nbsp;<br />T4 肿瘤侵犯颅内、脑神经、下咽、颞下窝、眼眶&nbsp;<br />N0 无颈淋巴结转移&nbsp;<br />N1 单侧颈淋巴结转移，或直径≤6cm，位于锁骨上窝以上部位&nbsp;<br />N2 双侧颈淋巴结转移，或直径≤6cm，位于锁骨上窝以上部位&nbsp;<br />N3 颈淋巴结转移：(a)直径＞6cm；(b)锁骨上窝转移&nbsp;<br />Mx 远处转移不能评价&nbsp;<br />M0 无远处转移&nbsp;<br />M1 有远处转移&nbsp;<br />（六）鼻咽癌的扩展途径&nbsp;<br />1．鼻咽癌有浸润性生长的特点 容易沿黏膜下蔓延，以及通过颈淋巴结转移和远处转移。直接蔓延；①向下沿咽后壁或咽侧壁到口咽，包括软腭、扁桃体和舌根；②向前：可至鼻腔后部、筛窦、通过筛板到达颅前窝、上颌窦；③向上：到颅底，侵犯蝶骨体及枕骨底，沿蝶窦到蝶鞍浸润垂体。又常通过破裂孔，侵犯到海绵窦附近的硬脑膜下，损害第II到第Vl对脑神经，亦可沿颈静脉孔侵入颅内；④向外：侵犯咽旁间隙、颞下窝、茎突前后区、后组脑神经；⑤向后：穿过鼻咽后壁，侵犯上段颈椎，少部分患者可以侵犯颈段脊髓；⑥向两侧：可以侵犯咽鼓管至内耳、中耳。&nbsp;<br />2．淋巴结转移 鼻咽黏膜含有丰富的淋巴管网，故鼻咽癌很早就从淋巴道转移。先到咽后淋巴结，然后转移至颈深上淋巴结、副神经链淋巴结及锁骨上淋巴结。70％一80％的患者治疗时有颈淋巴结也肿大。晚期颈淋巴结可到达腋下、纵隔、腹膜后，甚至腹股沟淋巴结也肿大。有时鼻咽癌的原发灶很小，而颈淋巴结已经很大。&nbsp;<br />3．远处转移 最常见的转移部位为肝、骨和肺，其他还有肾、胰、腹膜后等。&nbsp;<br />三、诊断与鉴别诊断&nbsp;<br />(一)症状和体征&nbsp;<br />1．鼻咽癌的常见症状和体征&nbsp;<br />(1)颈淋巴结肿大 这是最常见的一个症状。肿大淋巴结常在耳垂的后下方。颈淋巴结肿大是30％一40％患者最早的症状，而治疗时70％一80％的患者有颈部淋巴结转移。肿块常较硬，触之无疼痛，活动常较差。晚期时其淋巴结可达锁骨上，甚至腋下、纵隔。&nbsp;<br />(2)回缩性血涕 回吸鼻腔后，从口腔吐出带血丝鼻涕，尤以早晨起床后为甚。可以持续一段时间，为肿瘤血管破裂出血所致。这是鼻咽癌的一个早期症状。&nbsp;<br />(3)耳鸣或听力减退 因为鼻咽部肿瘤生长在侧壁上，堵塞咽鼓管开口，引起中耳炎，是鼻咽癌的一个早期症状。&nbsp;<br />(4)头痛 常表现为枕部或颞部的疼痛，为钝痛。早期为血管反射性头痛，晚期为肿瘤破坏颅底骨或脑神经、肿瘤感染、颈淋巴结转移压迫血管神经等。&nbsp;<br />(5)鼻塞 为肿瘤阻塞后鼻孔或侵犯鼻腔，导致鼻腔通气不畅，有些患者可以鼻腔完全堵塞，并且有较多的脓血性分泌物。&nbsp;<br />(6)张口困难 为鼻咽癌的晚期症状，系肿瘤侵犯颞下窝、冀内肌、翼外肌、翼腭窝等。&nbsp;<br />(7)突眼眼球突出 可能为肿瘤侵犯眼球后所致。&nbsp;<br />(8)颅神经症状 鼻咽癌在向周围浸润的过程中可以使十二对颅神经以及交感神经受压或破坏而呈现不同的症状和体征，受累的颅神经可以是单条也可以是多条同时受累。其中三叉神经、外展神经、舌下神经、舌咽神经、动眼神经及滑车神经受累较多，而嗅神经、面神经、听神经受累者甚少。现将鼻咽癌在扩展过程中可能侵犯的颅神经分为如下四组：①鼻咽癌一咽隐窝—破裂孔一中颅窝(海绵窦区)一前颅窝一眶上裂一眼眶内一突眼。在此行程中可能侵犯第V、V、IV、III、II、I对颅神经，并产生相应的临床症状；⑦鼻咽癌，颅中窝一卵圆孔、圆孔、岩尖、斜坡等；鼻咽癌一茎突前间隙一颅底外面(蝶骨大翼)，在上述行程中可能侵犯的颅神经为V2 、V3、VII和VIII，出现相应的临床症状；②鼻咽癌一茎突前间隙一茎突后间隙。肿瘤直接侵犯或淋巴结转移均可使茎突后间隙处的第IX、X、XI、XII对颅神经受累，上述四对颅神经临床常称之为后组颅神经，受侵时产生相应的临床症状；④鼻咽癌一蝶窦一颅内一侵犯第II、III、IV、VI对颅神经，产生相应的临床症状。除上述的十二对颅神经外，当鼻咽癌侵犯至茎突后间隙除累及舌咽、迷走、舌下及副神经时，还可累及颈交感神经，引起Horner综合征。&nbsp;<br />（二）检查方法&nbsp;<br />1．临床检查 鼻咽癌的临床检查主要包括鼻咽部、颈淋巴结和脑神经的检查。&nbsp;<br />(1)鼻咽部检查 采用间接鼻咽镜和直接经口腔检查鼻咽部。可以清楚地观察到鼻咽部肿瘤的大小、表面形状、部位、侵犯范围等。也可以通过纤维鼻咽镜或电子鼻咽镜来检查。&nbsp;<br />(2)颈淋巴结检查 检查淋巴结的大小、部位、活动度、皮肤是否有侵犯等。鼻咽癌的颈淋巴结一般先转移到上颈部，而后到下颈部，再往下到锁骨上。淋巴结越大或位置愈低，则病期愈晚，预后愈差。&nbsp;<br />(3)脑神经检查 主要是检查12对脑神经的情况(详见症状部分)。&nbsp;<br />2．常规X线检查 X线检查包括鼻咽侧位片、颅底片、鼻咽钡胶浆造影等，对鼻咽癌的诊断和了解颅底骨质的破坏有一定的帮助，但不能反映出肿瘤咽旁侵犯蔓延的情况和规律。&nbsp;<br />3．CT检查 鼻咽癌CT检查可以查出黏膜下组织的早期病变，可以清楚地显示肿瘤向鼻咽腔外邻近组织的侵犯范围，并能清楚地显示颅底骨质的破坏情况，是目前进行临床分期和放射治疗计划设计的必要手段。&nbsp;<br />4．MRI检查 了解鼻咽部肿瘤以及向周围浸润情况。同时，它对放射治疗后有无复发或与放射治疗后纤维化的鉴别以及对放射治疗后脑、脊髓的放射性损伤的诊断可以提供重要依据。&nbsp;<br />5．鼻咽部活组织检查 鼻咽痛的诊断一定要有病理学依据，从鼻咽部取得组织的方法有&nbsp;<br />以下3种。&nbsp;<br />(1)间接鼻咽镜活组织检查 将活检钳从口腔向上到鼻咽部，钳下—小块肿瘤组织进行检查。并可从肿瘤组织上取下一小块组织做涂片送细胞学检查。&nbsp;<br />(2)直接鼻咽镜活组织检查 直接鼻咽镜检查并取活组织检查。这一检查方法通过鼻腔&nbsp;<br />来进行。&nbsp;<br />(3)鼻咽细针穿刺部分患者的肿瘤生长在黏膜下，黏膜表面完整，在这种情况下，可以通过鼻咽部细针穿刺来取得诊断。&nbsp;<br />6．化验室检查VCA—IgA检测鼻咽痛患者90％以上、VCA－IgA阳性，并且其滴度比较高，大多在1：40以上。假如患者仅有颈部淋巴结肿大，而原发灶不明显时，可行VCA—IgA检测，若其滴度很高，则需要认真检查鼻咽部，对可疑的部位进行活组织检查，以确定诊断。同时，对VCA－IgA滴度很高的患者，即使找不到原发灶，亦需要定期随访，有些患者可以在颈部治疗几年后出现原发灶。&nbsp;<br />(三)鉴别诊断&nbsp;<br />1．鼻咽结核 较少见，可发生在男性中青年，以颈部淋巴结肿大为主要临床表现，鼻咽顶壁以结节或增生多见，表面常有坏死，肉眼难与鼻咽癌区别。只有病理活组织检查才能确诊。&nbsp;<br />2．鼻咽增生性结节 本病在鼻咽镜下可见孤立的单个结节或多个结节，表面黏膜呈淡红色，与周围正常黏膜相同。病变常发生在鼻咽顶前或侧壁。囊性结节病变用活检钳头部轻压结节时可呈现脐形凹陷，活检咬破囊壁有液体流出。&nbsp;<br />3．鼻咽增殖体 本病常位于鼻咽顶前中央形成纵形峙状隆起，表面熟膜光滑，色泽与正常黏膜相同。增生严重者影响鼻腔呼吸，咽鼓管阻塞而致听力下降。病理表现为问质中淋巴组织增生，常见淋巴滤泡数目增加，体积增大，生发中心活跃，吞噬现象明显。毛细血管增生，内皮细胞增殖，管壁与周围有炎症细胞浸润。&nbsp;<br />4．鼻咽纤维血管瘤 肿瘤来自鼻咽颅底蝶骨和枕骨骨膜或颅底腹膜，10一25岁男性最多见。临床表现为反复大量鼻出血，伴鼻塞、听力下降、头痛等。临床检查鼻咽肿瘤呈红色或淡红色，表面光滑，可见血管。此瘤活组织检迎时可引起大出血，甚至危及生命。本瘤在CT和MRI诊断主要根据其血管丰富，造影后明显强化为特征。&nbsp;<br />5．蝶鞍区肿瘤 以垂体瘤和颅咽管瘤最常见。临床根据肿瘤类型、大小和生长情况，主要为内分泌和神经受压症状。垂体瘤和颅咽管瘤与鼻咽癌在CT和MRI可以区别。&nbsp;<br />6．原发肿瘤不明的颈部淋巴结转移性癌 指颈淋巴结病理学证实为转移性癌，原发肿痛经检查、喉镜检查、CT检查、X线摄片检查，一时尚难找到原发灶。&nbsp;<br />7．慢性颈淋巴结炎 由附近器官炎疾病变引起颈淋巴结炎症、肿大，这种肿大淋巴结难消退，表面较光滑，活动，一般不大于2cm，常有头颈部慢性炎症的病史，长期随访颈淋巴结不再增大。&nbsp;<br />四、治疗&nbsp;<br />(一)治疗原则&nbsp;<br />鼻咽癌的治疗是以放射治疗为首选，结合化疗的综合治疗，只有对放疗后未控或复发的病变，可以试行手术治疗。&nbsp;<br />(二)放射治疗&nbsp;<br />1．放射治疗原则&nbsp;<br />肿瘤局限于头颈部时可以单纯体外放射治疗。早期病例可以体外照射辅以鼻咽腔内高剂量宰近距离后装推量照射；晚期病例可同步化、放疗，以提高局部、区域控制率，降低远处转移率。近年来用立体定向放射治疗，主要适用于外照射后残存病灶或已接受故疗后复发病人的补量照射。强调放射治疗鼻咽癌是较理想的放疗方法，极大地减少了正常组织损伤。&nbsp;<br />2．照射技术&nbsp;<br />(1)照射范围及射线 常规照射的范围包括鼻咽、颅底骨和颈部3个区域。&nbsp;<br />(2)常用的照射野 ①双耳前野十鼻前野；②双耳前野十耳后野照射；③双耳前野十鼻前野及颅底野；④面颈联合野十耳前野十鼻前野；⑤颈淋巴结的放射治疗60Co颈前切线野照射加X线侧野垂直照射。&nbsp;<br />3．照射剂量 常规分割放射1.8-2.0Gy／次，5次／周，临床肿瘤剂量70Gy。颈部的照射剂量：无淋巴结转移作预防性照射为50一55Gy，有颈淋巴结转移则为50一65Gy，局部有残留时则可小野加量照射。&nbsp;<br />4．放疗的新技术&nbsp;<br />(1)近距离放射治疗 由于后装放射治疗是将放射源直接放在病灶表面，故肿瘤表面的剂量很高，而它的剂量下降很快，对深部的肿瘤不能起作用，而对正常组织有保护作用。目前用于足量(70Gy)外照射后鼻咽腔内残留的病变，及鼻咽癌放射治疗后鼻咽腔内复发的患者。一般每次8—10Gy，每周可治疗1次，剂量的计算参考位置为鼻咽顶黏膜下0.3cm或肿瘤基底下。&nbsp;<br />(2)非常规放射治疗 常规放射治疗即为每天1次，每周5天，总疗程为6—7周，总剂量为60一70Gy的治疗方法，如超分割放射、加速超分割放射。&nbsp;<br />(3)适形及调强放射治疗 由于鼻咽癌常向周围不规则浸润生长，常规的放射治疗设野方法不能完全避开；同时，常规放射设野腮腺的受量很高，超过腮腺的耐受剂量，放射治疗后都有口干。适形放射治疗的应用改善靶区的剂量分布，降低正常组织的剂量。采用调强放射治疗的方法，可以调节靶区不同部位的剂量强度，给肿瘤很高的剂量，而周围的正常组织剂量在可以耐受的范围。立体定向放射治疗目前在国内外仅用作鼻咽癌治疗后残留或复发病灶的辅助治疗。&nbsp;<br />(三)化学治疗&nbsp;<br />分为放疗前的诱导化疗、同期放化疗和放射治疗后的辅助化疗。&nbsp;<br />1．诱导化疗 又称新辅助化疗，主要用于病情较晚期、颅骨破坏、鼻咽部肿块大、颈淋巴结在4cm以上、颈部淋巴结位置低的患者。诱导化疗的疗程一般不宜超过3个疗程。化疗应采用联合用药，常用顺铂(DDP)十氟尿嘧啶(5—Fu)。&nbsp;<br />2．同期放化疗 是指在鼻咽癌放射治疗的同时使用化疗。与放射同时使用的药物有&nbsp;<br />DDP、环磷酰胺（CTX）、甲氨蝶吟(MTX)、博莱霉素(BLM)、羟基脲(HU)等，或者联合使用如DDP十5－Fu，或加用多柔比星(ADM)等。与放射同时使用的方法有每天使用、每周使用1次、或每3周使用1疗程。&nbsp;<br />3．辅助化疗 辅助化疗的用药方案基本同诱导化疗，应该用联合化疗者，应以5—6个疗程为佳。同时，辅助化疗的开始时间一般应等患者的急性放射反应基本消退，营养状况恢复后进行。大多在放疗结束后1个月左右进行。&nbsp;<br />4、姑息化疗 对于已发生远处转移的思者，单纯化疗难以治愈，但可以减轻患者的痛苦，提高生存质量。&nbsp;<br />(四)手术治疗&nbsp;<br />手术治疗主要适用于放疗后鼻咽部和(或)颈部残留与复发的病例，是一种有效的补救措 施。&nbsp;<br />(五)疗效和预后因素&nbsp;<br />鼻咽癌放疗5年生存率大多在50％一60％。影响鼻咽癌放射治疗疗效的主要因素如下：①年龄：一般认为30岁以下疗效较好；②临床分期：病期愈早，疗效愈好；②原发灶大小：与局部控制率明显相关。鼻咽原发肿瘤愈大，特别是侵犯脑神经和颅底骨质破坏的患者，局部控制率愈低，5年生存率愈低；④颈部淋巴结：颈部淋巴结与远处转移密切相关。淋巴结愈大，位置愈低，远处转移率愈多，预后愈差。&nbsp;<br />[预防与调护]&nbsp;<br />1．本病预防应注意不食霉变腌制食物，锻炼身体，提高免疫力，防止病毒感架；节制吸烟，消除环境污染；对于不明原出的鼻塞、头痛、听力减退、颈部肿物等症状，要引起重视，做到早发现，早诊断，早治疗。&nbsp;<br />2．鼻咽癌患者加强心理和饮食凋护，保证营养供给充分．适当进行体育锻炼。放疗患者要持别注意调护．放疗前宜清洗鼻腔．积极处理放疗中的局部反应和全身反应、如以薄荷油、鱼肝油滴鼻，盐水或多贝尔液漱口。尤应注意充分摄入水分及维生素B族。进食宜软，戒烟酒。故疗期间切勿拔牙。&nbsp;</p></span>', 'gwm', 0, 8),
(282, 'PET－CT在食道癌中的应用', '', '', '', '2009-12-18 16:04:11', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）食道胸下段癌（病理：鳞癌） 。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142013295.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142023405.jpg" border="0" /></p><p>（病例二）食道多发癌：食道中下段多发高代谢占位；考虑食道Ca伴食道下段后方淋巴结、 左侧肾上腺及骨骼多发转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142351415.jpg" border="0" />食道中下段多发癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142400115.jpg" border="0" />多断面重建图</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142410564.jpg" border="0" />食道后方淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142420108.jpg" border="0" />左侧肾上腺转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142429876.jpg" border="0" />右侧肩胛骨溶骨性转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006142437506.jpg" border="0" />左髋臼溶骨性转移</p></span>', 'gwm', 0, 4),
(283, '肺癌（高分化腺癌）18F-FDG及11C-MET表现（附一例图） ', '病例介绍', '', '', '2009-12-18 16:04:40', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例）：左肺下叶前基底段片状高密度病灶，<sup>18</sup>F-FDG及<sup>11</sup>C-MET PET显像相应部位均放射性异常浓聚，考虑周围型肺癌（病理：高分化腺癌）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006141059272.jpg" border="0" /><sup>18</sup>F-FDG显像</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006141130206.jpg" border="0" /><sup>18</sup>F-FDG显像</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006141208102.jpg" border="0" />隔日<sup>11</sup>C-MET 显像</p><p align="left"><img src="http://www.cn-petct.com/FileUpload/200910/20091006141249475.jpg" border="0" />隔日<sup>11</sup>C-MET 显像</p><p align="left"><img src="http://www.cn-petct.com/FileUpload/200910/20091006141348212.jpg" border="0" />上列<sup>18</sup>F-FDG显像；下列<sup>11</sup>C-MET 显像</p><p align="left"><img src="http://www.cn-petct.com/FileUpload/200910/20091006141528595.jpg" border="0" />上列<sup>18</sup>F-FDG显像；下列<sup>11</sup>C-MET&nbsp;</p></span>', 'gwm', 0, 8),
(284, '各种肺癌PET－CT表现', '', '', '', '2009-12-18 16:05:01', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;&nbsp;（病例一）：肺泡细胞癌：右肺中叶片状密度增浓影，轻度放射性增浓。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006134937463.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006134949314.jpg" border="0" /></p><p>（病例二）右肺下叶后基底段高代谢占位性病变，考虑周围型肺癌（纵隔镜淋巴结活检示：腺Ca）。</p><p>&nbsp;&nbsp; 纵隔内、右肺门多发肿大淋巴结，代谢增高，考虑淋巴结转移；心包腔积液。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135324228.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135341414.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135409645.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135426550.jpg" border="0" />纵隔淋巴结转移</p><p>&nbsp;&nbsp; （病例三）左肺上叶肺癌伴纵隔内淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135815724.jpg" border="0" />左肺高代谢肿块伴纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006135828971.jpg" border="0" />纵隔淋巴结转移</p><p>&nbsp;&nbsp; （病例四）左肺未分化腺癌伴纵隔淋巴结转移、右侧肾上腺及骨骼多发转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006140113419.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006140126115.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006140135546.jpg" border="0" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006140144243.jpg" border="0" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006140154578.jpg" border="0" />右侧肾上腺转移</p><p><img height="650" src="http://www.cn-petct.com/FileUpload/200910/20091006140205189.jpg" width="638" border="0" style="width:661px;height:677px;" />腰椎骨转移</p></span>', 'gwm', 0, 6);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(285, '乳腺癌', '病例介绍', '', '', '2009-12-18 16:05:30', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）左侧乳腺外下象限乳腺Ca伴左侧锁骨上、锁骨下窝、左侧腋窝多发淋巴结转移、C6、S1椎体多发骨转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163531698.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163557188.jpg" border="0" /></p><p>（病例二）右侧乳腺内下象限乳腺癌 （病理：浸润性小叶癌）伴右侧腋窝多发淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163704614.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163728242.jpg" border="0" /></p><p>（病例三）“左乳腺Ca术后、局部复发切除术后”肝转移：肝右叶近膈面高代谢结节影。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163822365.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163846240.jpg" border="0" /></p><p>（病例四）“左乳腺Ca术后”改变，未见明显复发征象；左侧肩胛骨、肋骨、胸腰椎、骨盆及右侧股骨颈等多发骨转移瘤。</p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163935590.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200909/20090930163957991.jpg" border="0" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; 乳 腺 癌</strong></p><p><strong>&nbsp;&nbsp;&nbsp;</strong>腺癌(breast cancer)是女性中最常见的恶性肿瘤。在全世界范围内，北美、北欧和西欧 属于乳腺癌的高发国家，而我国属低发国家。但是近年来我国乳腺癌的发病率也有逐步上升 的趋势，尤其在一些沿海大城市。城市和农村女性乳腺癌有差别，城市愈大，乳腺癌发病率愈高。乳腺癌的发病在20岁以下者极其罕见，30岁以后逐步增加，在45—50岁时达到最高峰，至绝经期前后略有下降，但在60岁以后又出现第二个高峰。男性乳腺癌甚为少见，大约占所有乳腺癌的1％。&nbsp;<br />近10年来，西方一些国家由于对高危人群乳腺癌普查，以及对乳腺癌术后患者采取全身辅助治疗措施和新药物的发明，使得乳腺癌的病死率正以每年1．7％的比例下降。同时，对早期乳腺癌采取保乳术，从而也大大提高了生活质量。因此，目前乳腺癌的诊断模式已从单纯的临床体检转变为多种诊断措施的联合应用。而治疗也已从单一的外科治疗模式转变成为多学科综合治疗模式，并且主张个体化的治疗方案。&nbsp;<br />一、病因&nbsp;<br />乳腺癌的病因尚未完全明了。但许多流行病学研究，支持乳腺癌的发病与生活方式有关。某些因素的存在，会导致乳腺癌发病危险性增加。&nbsp;<br />1．地区分布 北美、北欧最高，南美、东欧次之，亚非拉地区最低。&nbsp;<br />2．月经初潮年龄和绝经年龄 初潮年龄早于13岁者发病的危险性为初潮年龄大于17&nbsp;<br />岁者的2．2倍，绝经年龄大于55岁者比小于45岁的危险性增加l倍，行经40年以上的妇女比行经30年以下的妇女，发生乳腺癌的危险性增加1倍。&nbsp;<br />3．生育因素 初次足月产的年龄在20岁以前，其乳腺癌的发病率仅为第l胎足月生产&nbsp;<br />在30岁以后者1／3，危险性随着初产年龄推迟而逐渐增高。哺乳可降低乳腺癌发病的危&nbsp;<br />险性。&nbsp;<br />4．饮食习惯 高脂肪、高蛋白质，绝经后体重增加者发病率增高。&nbsp;<br />5．遗传因素 妇女有第一级直亲家族的乳腺癌史者，其乳腺癌的危险性是正常人群2-&nbsp;<br />3倍。危险性又与家属的乳腺癌发生年龄及单侧或双侧有关。&nbsp;<br />6．乳腺癌的发病危险性与电离辐射的剂量呈正相关系。&nbsp;<br />二、病理学&nbsp;<br />（一）乳腺癌的组织学分型(中国肿瘤病理学分类，2000年)&nbsp;<br />(1)非浸润性癌 包括导管内癌、小叶原位癌和乳头佩吉特(Paget)病。&nbsp;<br />(2)早期浸润性癌 包括导管癌早期浸润、小叶癌早期浸润。&nbsp;<br />(3)浸润性特殊型癌 包括乳头状癌、髓样癌伴大量淋巴细胞浸润、小管癌(高分化腺癌)、腺样囊性癌、黏液腺癌、鳞状细胞癌。&nbsp;<br />(4)浸润性非特殊型癌 包括浸润性导管癌、浸润性小叶癌、硬癌、髓样癌、单纯癌、腺癌、大汗腺癌。&nbsp;<br />(5)罕见癌 包括内分泌型癌、宫脂质癌(分泌脂质癌)、印戒细胞癌、纤维腺瘤癌变、乳头状瘤癌变、伴化生的癌等。&nbsp;<br />(二)乳腺癌的组织学分级&nbsp;<br />乳腺癌的组织学分级与患者的预后相关。它主要根据乳腺管形成的程度，细胞核的异型性以及核分裂计数分为I级(分化好)、Ⅱ级(中分化)、Ⅲ级(分化差)。&nbsp;<br />(三)临床分期&nbsp;<br />国际抗癌联盟(UICC)(1997)制定的TNM国际分期：&nbsp;<br />T一原发病灶&nbsp;<br />Tx 原发病灶情况不详(已被切除)&nbsp;<br />T0 原发病灶未们及&nbsp;<br />Tis 原位癌(导管内癌，小叶原位癌，无肿块的乳头Paget病)&nbsp;<br />(注：Paget病如们及肿块者，依照肿块大小分类)&nbsp;<br />T1 原发病灶最大直径≤2cm&nbsp;<br />T1mic 微小浸润性癌，最大径≤0.1cm&nbsp;<br />Tla 肿瘤最大径＞0.1cm，≤0.5cm&nbsp;<br />T1b 肿瘤最大径＞0.5cm，≤1.0cm&nbsp;<br />T1c 肿瘤最大径＞1.0cm，≤2.0cm&nbsp;<br />T2 肿瘤最大径＞2．0cm，但≤5.0cm&nbsp;<br />T3 肿瘤最大径＞5.0cm&nbsp;<br />T4 肿瘤任何大小，但直接侵犯胸壁或皮肤&nbsp;<br />T4a 肿瘤直接侵犯胸壁(包括肋骨、肋问肌、前锯肌，但不包括胸肌)&nbsp;<br />T4b 肿瘤表面皮肤水肿(包括橘皮征)，乳房皮肤溃疡或卫星结节，限于同侧乳房&nbsp;<br />T4c 包括T4a及T4b&nbsp;<br />T4d 炎性乳腺癌&nbsp;<br />N一区域淋巴结&nbsp;<br />Nx 区域淋巴结情况不定(已被切除)&nbsp;<br />No 无区域淋巴结肿大&nbsp;<br />Nl 同侧腋淋巴结肿大、转移，但能活动&nbsp;<br />N2 同例腋淋巴结肿大、转移、互相融合，或与其他组织相粘连&nbsp;<br />N3 转移到同侧内乳淋巴结&nbsp;<br />M一远处转移&nbsp;<br />Mx 有无远处转移不详&nbsp;<br />M0 无远处转移&nbsp;<br />Ml 远处转移&nbsp;<br />根据以上不同的TNM，可以组成临床不同的分期&nbsp;<br />0期 TisN0M0&nbsp;<br />I期 T1N0M0&nbsp;<br />Ⅱa期 T0N1M0,T1N1M0,T2N0M0&nbsp;<br />Ⅱb期 T2N1M0，T2N0M0&nbsp;<br />Ⅲa期 T0N2M0,T1-2N2M0,任何T，N2,M0&nbsp;<br />Ⅲb期 T4任何N，任何M0，任何T，N2,M0&nbsp;<br />Ⅳ期 任何T，任何N，M1&nbsp;<br />三、诊断与鉴别诊断&nbsp;<br />(一）症状和体征&nbsp;<br />1．乳房肿块 90％以上的患者是无意中发现乳房内肿块。典型的乳腺癌多表现为无痛性乳房肿块、进行性长大，质地硬，表面不光滑，与周围分界不清。&nbsp;<br />2．皮肤改变 特征性的表现：①累及乳腺悬韧带((cooper韧带)，在肿块表面皮肤形成所谓的“酒窝征”；②肿瘤侵犯皮下淋巴管可导致淋巴回流障碍，出现真皮水肿，皮扶呈“橘皮样”改变；③晚期患侧乳房表现为活动受限、固定、皮肤表面出现卫星结节和皮肤溃疡；④“炎性乳腺癌”，表现为乳腺皮肤的红、肿，皮肤增厚，皮温升高等类似炎症的改变。&nbsp;<br />3.乳头改变&nbsp;<br />(1)乳头溢液 乳腺癌的乳头溢液多为血性溢液，也可出现浆液性或水样的乳头溢液。乳头溢液常是起源于大导管的乳腺癌的一种早期的临床征象。&nbsp;<br />(2)乳头糜烂 是乳头Paget病(又称湿疹样癌)的典型症状，常伴乳头痛痒。早期时可见乳头增厚、变红、粗糙，或者仪表现为结痴、脱屑，伴有少量分泌物，揭去痂皮可见鲜红的糜烂面，经久不愈，易被误诊为乳头皮肤的湿疹。约2／3患者可伴有乳晕或乳房其他部位的肿块。&nbsp;<br />(3)肿瘤累及乳头或乳晕下区时 乳腺的纤维组织和导管系统可因此而缩短，牵拉乳头，使其凹陷，偏向，变平，回缩。&nbsp;<br />4．乳房疼痛 乳腺癌不常引起疼痛。但少数患者可以出现乳房牵拉感或轻微的疼痛。晚期病例肿瘤直接侵犯胸壁神经可引起明显的疼痛。&nbsp;<br />5．区域淋巴结肿大 最常见的淋巴转移部位是同侧腋窝淋巴结。淋巴结常由小逐步增大，淋巴结数目由少逐步增多。肿大的淋巴结如果侵犯、压迫腋静脉常可使同侧上肢水肿；如侵及臂丛神经时引起肩都酸痛。&nbsp;<br />6．远处转移 乳腺癌的远处转移包括远处淋巴结转移和血道转移。前者主要表现为锁骨上淋巴结、对侧腋窝及纵隔淋巴结的肿大。乳腺癌沿血道播散以骨、肺、肝、胸膜、肾上腺等较多见。转移到不同的器官或组织，引起不同的症状和体征。&nbsp;<br />1．乳腺X线检查 是常用的乳腺辅助检查手段之一，乳腺X线检查的适宜人群为35岁以上、非妊娠期的妇女，且两次检查的间隔时间不宜短于6个月。&nbsp;<br />(1)直接征象 主要包括肿块结节影和微小钙化：恶性肿块影常不规则，边缘有毛刺，密度较周围腺体高。微小钙化灶在乳腺癌早期诊断中具有十分重要的临床意义。若在每平方厘米中有15个以上的细小钙化点时常需考虑为乳腺癌。&nbsp;<br />(2)间接征象 主要有非对称性导管影、非对称性或弥漫性密度增加影、结构扭曲等。&nbsp;<br />2．B超 是临床诊断乳腺疾病的常用方法。在采用高分辨率的高频探头以及彩色多普勒技术后，乳腺超声鉴别良、恶性肿瘤的准确率一般在85％一90％之间。超声诊断尤其适用于鉴别囊性或实质性肿瘤，而鉴别1cm以下的实质性肿块效果不理想。&nbsp;<br />3.乳管内镜 乳管内镜可以更直观地观察乳腺导管内深达第五或第六级分支的病变情况，明确乳头溢液的原因，并可对临床不可们及的病变部位进行定位，以便手术活检。乳管内镜检查往往与乳头溢液细胞学涂片检查一起用于乳头溢液患者的筛检。&nbsp;<br />4.乳腺MRI 它是利用乳腺癌的血供较周围正常组织丰富为基本原理来对乳腺病灶的良恶性作出判断，具有很高的敏感性和特异性。能准确显示病灶范围以及发现亚临床乳腺癌，可用于乳腺癌保乳手术前的常规检查及乳腺癌高危人群的普查。&nbsp;<br />(三)病理学检查&nbsp;<br />乳腺的病理学检查包括细胞学检查和活组织检查两种。&nbsp;<br />1．细胞学诊断 ①脱落细胞学检查：对有乳头溢液的病例，可作溢液涂片细胞学检查，阳性率可达50％。对于乳头糜烂、怀疑为乳头Paget病时可作糜烂部位的刮片或印片检查、阳性率约70％一80％；②细针吸取细胞学检查：具有简便、快速、经济、准确等优点，对乳腺肿块的诊断敏感性一般在90％左右。另外，细针吸取细胞学检查还广泛用于腋窝、锁骨上淋巴结以及复发转移灶的诊断。&nbsp;<br />2．活组织检查 ①切除活检：切除活检是获得乳腺疾病组织学诊断最常用的方法。术中快速冰冻切片检查是乳腺癌是乳腺癌最常用的病理诊断方法；②空心针活检：空心针活检不仅可以获得组织学诊断，而且还具有经济、安全、微创等特点，是一种理想的术前获得明确诊断的方法。&nbsp;<br />(四)鉴别诊断&nbsp;<br />1.乳腺增生症 主要症状为乳房胀痛，疼痛与月经周期有关,月经前明显，来潮后减轻或消失。体检发现一侧或双侧乳房有弥漫性增厚，呈颗粒状、结节状或片状，与周围组织分界不清。B超可见腺体内有弥漫性均匀型较大回声，有时在增大、增厚的腺体内可见多个大小不等的低回声结节，在囊性增生病时腺体内可伴有大小不等的暗区。&nbsp;<br />2．乳腺纤维腺瘤 常见于年轻妇女，以20一25岁之间较多见。多为单发，表现为乳房内无痛性肿块，边界清，质实如橡皮样，光滑活动，有包膜感。月经周期对肿块并无影响。B超下纤维腺瘤表现为边缘清楚光滑的肿块，少数可呈分叶状、不规则，肿块内部有均匀的弱回声区。病理可明确诊断。&nbsp;<br />3.乳腺单纯囊肿 由乳腺导管扩张或乳汁在乳管内积聚而成。体检时可们及球形肿块，边界清楚有包膜感，与皮肤无粘连，亦无腋淋巴结肿大。如超声检查证实为囊性可以作穿刺抽液检查以明确诊断。&nbsp;<br />4．乳腺导管内乳头状瘤 多见于中年妇女，75％的病灶位于乳腺大导管的壶腹部，25％发生于中小导管内。临床常无自觉症状，常因乳头溢液污染内衣而引起注意，溢液性质常为血性或浆液性。X线及B超大多无特殊征象。乳头溢液涂片细胞学检查可见大量成堆的导管上皮细胞。&nbsp;<br />5．急性乳腺炎 大多发生在产后哺乳期的最初3—4周，以初产妇为多见。起病时有高热、寒战等全身中毒症状、患乳迅速增大，局部变硬，皮肤红肿，有压痛及搏动性疼痛，患侧腋淋巴结常肿大，白细胞计数常增高。抗生素进行治疗有效。&nbsp;<br />6．浆细胞性乳腺炎 临床上病情初起时表现为局部红肿热病等急性炎症症状，皮肤可呈水肿样。由于乳腺导管阻塞导致乳管内脂性物质溢出，进入管周组织而引起的无菌性炎症，其中主要有浆细胞的浸润。B超下常为边界模糊不清，局限性增厚，内部回声不均，形成囊肿时可见有液性暗区，因此具有一定的鉴别诊断价值。&nbsp;<br />四、治疗&nbsp;<br />1．乳腺原位癌 ①导管内癌局部切除+全乳放疗，辅助他莫昔芬治疗是最常用的治疗方案；⑧小叶原位癌采取局部切除，同时对患者进行严密的随访。&nbsp;<br />2．Ⅰ、Ⅱ期乳腺癌 手术治疗是首选治疗方法，手术治疗采用乳腺癌改良根治术或保乳术；同时应当根据具体情况采用辅助性的全身治疗和／或放疗。&nbsp;<br />3．Ⅲ期乳腺癌 先采取标难剂量的新辅助化疗；之后采取先手术后放疗或先放疗再手术或单纯根治性放疗；术后给予足疗程的辅助化疗；化疗之后再根据激素受体状况或者肿瘤的其他生物学指标给予辅助性内分泌治疗和／或生物治疗，同时给予局部放疗。&nbsp;<br />4．Ⅳ期乳腺癌 该类乳腺癌的治疗手段是姑息性治疗，治疗的目的是减缓疾病进展和延长生命，减轻患者痛苦，提高病人生活质量。治疗原则应首选化疗／或内分泌治疗；并结合对症处理。&nbsp;<br />5．炎性乳腺癌 应以全身化疗为主，之后给予根治性放疗；再辅助局部手术治疗。&nbsp;<br />6．特殊类型的乳腺癌&nbsp;<br />(1)Paget病 治疗可根据乳腺内有无肿块及腋淋巴结情况而定。乳腺内有肿块者的治疗方案与一般乳腺癌相似。乳腺内未发现肿块者如病变仅限乳头者只需行单纯乳房切除；如果乳晕亦有累及时可考虑同时清扫腋下群淋巴结。&nbsp;<br />(2)男性乳腺癌 可手术病例的治疗原则与女性乳腺癌相似。晚期或复发病例中对年龄较大或者激索受体阳性的患者应首选双侧睾丸切除或其他内分泌治疗，而激素受体阴性者以化疗为宜。&nbsp;<br />(3)妊娠、哺乳期乳腺癌 治疗方法应根据肿瘤的病期及妊娠的时期而定。一般除非在妊娠后期，均应考虑终止妊娠，之后按乳腺癌的治疗原则给予积极治疗。而在妊娠后期时，可考虑先处理肿瘤再等待自然分娩。哺乳期乳腺癌应立即终止哺乳，然后再治疗乳腺癌。妊娠、哺乳期乳腺癌的局部治疗与一般乳腺癌相似，手术前后辅以必要的综合治疗。&nbsp;<br />（二）手术治疗&nbsp;<br />手术治疗的基本原则是尽可能彻底地清除乳腺原发病灶和相应引流区域的淋巴结。同时，注重采用保留正常乳腺组织的保乳术，以提高生活质量。&nbsp;<br />1．手术适应证 乳腺癌手术治疗的适应证包括临床0，Ⅰ，Ⅱ，Ⅲa期的病例。通常这部分病例又被称作可手术乳腺癌。&nbsp;<br />2．手术方式&nbsp;<br />(1)乳腺癌根治术 乳腺癌根治术为乳腺癌手术的基本术式。其手术操作原则为：原发灶及区域淋巴结应做整块切除，切除全部乳腺及胸大、小肌，腋窝淋巴结做彻底的切除。&nbsp;<br />(2)乳腺癌改良根治术 乳腺癌改良根治术是目前最常用的手术治疗方式之一，主要应用于临床I及Ⅱ期的早期乳腺癌思者。有两种手术方式；①改良根治I式(Patey手术)：保留胸大肌，切除胸小肌，腋窝淋巴结做彻底的切除；②改良根治Ⅱ式(Auchincloss手术)：保留胸大、小肌，清扫中、下群腋淋巴结。&nbsp;<br />(3)乳腺癌扩大根治术 即在乳腺癌根治术(或改良根治术)的同时进行1—4肋间内乳区淋巴结的清扫。主要适用于Ⅱ及Ⅲ期，尤其病灶位于内侧及中央的患者。&nbsp;<br />(4)单纯乳房切除术 该手术方式适用于乳腺原位癌、原位癌有微小浸润以及Paget病仅限于乳头者；年老体弱不适合作根治术的患者也一可选用单纯乳房切除术加术后辅助治疗；也可作为乳腺癌保留乳房手术后局部复发的补救性术式。&nbsp;<br />(5)保留乳房手术 手术的方式自局部切除直到l／4乳房，术中行腋窝哨兵淋巴结活检，术后应用放射治疗。其适应证大致如下：⑥临床Tl及T2的病灶，具体应根据临床肿瘤与乳房大小的比例而定；②位于乳房周围的肿瘤；③单个病灶。&nbsp;<br />（三）化疗&nbsp;<br />根据治疗目的和时间的不同，通常将乳腺癌的化疗分为辅助化疗、新辅助化疗和晚期乳腺癌的化疗3种方式。最常用的化疗方案有以下几种。&nbsp;<br />①CMF方案：CTX 600mg／m2十MTX 30一40mg／m2十5—Fu 500 mg／m2，第l，第8天，静脉注射，每21—28天为1个疗程，共用6个疗程。&nbsp;<br />⑦CAF方案：ADM 50mg／m2或表柔比星60—90mg／m2，静脉注射，第1天，5—Fu 500mg／m2，第1，第8天静脉注射，每2l一28天为1个疗程，共用6个疗程。&nbsp;<br />③TE方案：多西紫杉醉80mg／m2静脉滴注第1天，表柔比星60mg／m2静脉注射，每21天为1疗程。&nbsp;<br />④NE方案：长春瑞滨30mg／m2．第1，第8天静脉注射，表柔比星60mg／m2静脉滴注第1天，每21天为1疗程。&nbsp;<br />（四）内分泌治疗&nbsp;<br />乳腺癌是一种激素依赖性的肿瘤，内分泌治疗通过改变乳腺癌生长所依赖的内分泌环境，便肿瘤生长受到抑制，从而达到临床缓解，因此是一种重要的全身治疗手段。&nbsp;<br />临床上常用的内分泌治疗方法全要有以下3种：①卵巢去势，包括手术切除卵巢、用放射线照射卵巢、药物(戈舍瑞林)抑制卵巢功能，主要适用于绝经前和因绝经期乳腺癌患者；⑦抗雌激素类：包括他莫昔芬、法乐通、Fasoladex等，适用于各年龄层患者。他莫昔芬是目前应用最多、疗效肯定的抗雌激素药物；③芳香化酶抑制剂：包括瑞宁得、依西美坦、来曲唑等。它们均为第三代芳香化酶抑制剂，高效、低毒、高选择性，主要适用于绝经后的忠者和绝经前双侧卵巢去势的患者。目前第三代芳香化酶抑制剂可取代他莫昔芬作为绝经后复发和转移性乳腺癌一线内分泌治疗药物。&nbsp;<br />内分泌治疗的指征：①对手术后的乳腺癌患者，肿瘤组织免疫组织化学检测发现ER和(或)PR阳性，应服用他莫昔芬(20mg／天)，治疗时间为5年。对于部分绝经前、高危复发的乳腺癌患者还可考虑卵巢去势；⑦复发和转移性乳腺癌的内分泌治疗 原发肿瘤组织免疫组织化学检测ER和(或)PR阳性，如果是绝经前的患者，可选择卵巢去势加他莫昔芬；如果是绝经后的患者，应首芳香化酶抑制剂。&nbsp;<br />（五）放疗&nbsp;<br />乳腺癌的放疗亦属于一种局部治疗措施，随着保留乳房手术的兴起，放疗在乳腺癌综合治疗中的地位被提高，并在加强局部控制减少局部复发中发挥着不可替代的作用。&nbsp;<br />1．保乳术后的放疗 保乳手术后加用全乳房放射治疗可以显著降低局部复发率。因&nbsp;<br />此，放疗是保乳治疗中不可缺少的部分。&nbsp;<br />2．乳腺癌行乳腺切除术后放疗的指征&nbsp;<br />(1)单纯乳房切除后应作全胸壁及淋巴引流区照射。&nbsp;<br />(2)根治术后病理检查腋淋巴结转移超过1／3以上，或有4个以上淋巴结转移，或腋中、上群淋巴结有转移者主张锁骨上区及内乳区照射。&nbsp;<br />(3)扩大根治术或内乳淋巴结探查后病理证实内乳淋巴结有转移者，应行锁骨上淋巴结和(或)内乳淋巴结区照射。&nbsp;<br />(4)术前病灶位于中央或内侧者经根治术后，尤其腋淋巴结有转移的病例，可考虑补充锁骨上淋巴结及内乳淋巴结区照射。&nbsp;<br />3．术前放疗 局部晚期或炎性乳腺癌，可先采用新辅助化疗后，再应用术前放疗使病灶进一步缓解。之后，再根据病情考虑是否需作局部姑息性手术切除。&nbsp;<br />(六)生物治疗&nbsp;<br />乳腺癌的生物治疗最成功的药物就是赫赛汀(Herceptin)。它是一类被称作Her-2/Neu的人类表皮生长因子受体的单克隆抗体，它可显著抑制有这种蛋白高度表达的人类乳腺癌细胞的生长。它与化疗联合应用治疗转移性乳腺癌时，可以明显延长患者的生存时间。&nbsp;<br />(七)疗效预测指标&nbsp;<br />肿瘤的大小、组织病理学性质(类型和分级)及淋巴结转移情况，是乳腺癌的3个最重要的预后指标。DNA倍体和细胞增殖分数，异倍体比例和增殖分数等生物学指标高者预后不良。激素受体水平是预测乳腺癌患者对内分泌治疗反应性的惟一指标。ER和PR阳性预后佳；阴性预后不良。年龄小于35岁患者的预后差。表皮生长因子受体Her-2蛋白的高表达者预后不良；同时，也提示对蒽环类药物敏感，而对CMF方案和他莫昔芬耐药。&nbsp;</p></span>', 'gwm', 0, 13),
(286, 'PET－CT心肌灌注、代谢显像同冠状动脉CTA检查在冠心病中的联合应用（推荐）', '病例介绍', '', '', '2009-12-18 16:06:15', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）：1、左室下间壁、侧壁（后侧壁为著）、心尖部心肌血流灌注减低，灌注－代谢不匹配，提示相应部位心肌缺血而存活。 2.左室室壁运动不协调，下间壁、心尖部、左室侧壁运动减低。 3、冠脉CTA多支病变：左前降支近段管腔中－重度狭窄；左回旋支近段管腔重度狭窄；冠脉主干及右冠状动脉近段、远段管腔轻度狭窄。4、建议积极行血运重建术（支架植入或冠脉搭桥术）。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007160508445.jpg" border="0" /></p><p>心肌PET灌注显像（上列）、代谢显像对比（下列）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007160631813.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007160750575.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007160808763.jpg" width="400" border="0" /></p><p>&nbsp; 冠脉CTA三维重建（左图）右冠状动脉&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; （右图）显示左前降支及左回旋支</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007160953987.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007161011780.jpg" width="400" border="0" /></p><p>冠脉CTA曲面重建：左前降支近段管腔中－重度狭窄</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007161112809.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007161128416.jpg" width="400" border="0" /></p><p>冠脉CTA曲面重建：左回旋支近段管腔重度狭窄</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007161235893.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007161251294.jpg" width="400" border="0" /></p><p>冠脉CTA曲面重建：冠脉主干及右冠状动脉近段、远段管腔轻度狭窄。</p><p>（病例二）：1、左室中上部局限性膨隆，与左室呈矛盾运动，考虑为室壁瘤（假性？）。 2、心尖部、前壁近心尖、前间壁及前侧壁心肌变薄、密度减低，相应部位血流灌注缺损，代谢－灌注相匹配，考虑为心肌梗死（心肌无活力）。 3、左室下侧壁小片状血流灌注减低，心肌存活。 4、左前降支中段重度狭窄（基本闭塞）。 5、右冠状动脉中段软斑块形成，相应部位管腔中度狭窄。6、建议保守治疗，不推荐行血运重建术</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007162239890.jpg" width="400" border="0" /><img height="377" src="http://www.cn-petct.com/FileUpload/200910/20091007162255946.jpg" width="400" border="0" style="width:400px;height:369px;" /></p><p>&nbsp;三维重建（左）右冠状动脉中段软斑块形成，相应部位管腔中度狭窄。（右）左前降支中段重度狭窄（基本闭塞）。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007162522136.jpg" width="400" border="0" /><img height="379" src="http://www.cn-petct.com/FileUpload/200910/20091007162540226.jpg" width="400" border="0" style="width:400px;height:359px;" /></p><p>冠脉三维重建（左图）左前降支中段重度狭窄（基本闭塞）。（右图）右冠状动脉中段软斑块形成，相应部位管腔中度狭窄。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007162925861.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007162940906.jpg" width="400" border="0" /></p><p>冠脉CTA曲面重建：&nbsp;&nbsp;左前降支中段重度狭窄（基本闭塞），右图为左前降支拉直图</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007163159693.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007163338107.jpg" width="400" border="0" /></p><p>曲面重建：左回旋支未见明显狭窄</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007163410296.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091007163444313.jpg" width="400" border="0" /></p><p>曲面重建：右冠状动脉中段软斑块形成，相应部位管腔中度狭窄。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007163538996.jpg" border="0" /></p><p>上列为心肌灌注显像，下列为心肌代谢显像：心尖部、前壁近心尖、前间壁及前侧壁心肌变薄、密度减低，相应部位血流灌注缺损，代谢－灌注相匹配，考虑为心肌梗死（心肌无活力）；左室下侧壁小片状血流灌注减低，心肌存活。不推荐行血运重建术。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007163557749.jpg" border="0" /></p><p>心肌3D模拟图动态观察室壁瘤运动情况及心功能评价EF＝28％</p><p>（病例三）：1、PET左室下壁、下侧壁血流灌注及代谢均减低，CT相应部位紧贴心腔见多发片条状低密度影，考虑陈旧性心梗（心内膜下为主），下壁、下侧壁部分心肌存活。 2、心尖部肥厚，请结合临床。 3、左前降支中段壁冠状动脉；左前降支近端管壁小点状钙化，相应部位管腔未见明显狭窄。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091008093555121.jpg" border="0" />PET左室下壁、下侧壁血流灌注及代谢均减低</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091008093633362.jpg" border="0" />PET左室下壁、下侧壁血流灌注及代谢均减低<img src="http://www.cn-petct.com/FileUpload/200910/20091008093741630.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091008093758136.jpg" width="400" border="0" /></p><p>冠脉CTA三维重建：左前降支中段壁冠状动脉；左前降支近端管壁小点状钙化，相应部位管腔未见明显狭窄。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091008093916681.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091008093952155.jpg" width="400" border="0" />&nbsp;&nbsp;</p><p>&nbsp; （左图）横断面示左前降支中段壁冠状动脉&nbsp;&nbsp;&nbsp; （右图）曲面重建：左前降支中段壁冠状动脉；左前降支近端管壁小点状钙化，相应部位管腔未见明显狭窄。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091008094155229.jpg" width="400" border="0" /><img src="http://www.cn-petct.com/FileUpload/200910/20091008094228915.jpg" width="400" border="0" /></p><p>冠状动脉CTA（左图）横断面（右图）矢状位示：左室下壁、下侧壁紧贴心腔见多发片条状低密度影，考虑陈旧性心梗（心内膜下为主）。</p></span>', 'gwm', 0, 8),
(287, 'PET－CT心肌代谢显像在评价心肌活力中的应用', '病例介绍', '', '', '2009-12-18 16:06:43', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）1.左心室下后壁、后外侧壁心肌血流灌注缺损。 2.左心室下后壁、后外侧壁灌注代谢完全不匹配，心肌全部存活。建议尽快行血管重建术。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;3. 左室下后壁、后外侧壁室壁运动减弱。平均LVEF=61%</p><p><img height="451" src="http://www.cn-petct.com/FileUpload/200910/20091007153959981.jpg" width="661" border="0" style="width:584px;height:424px;" /></p><p>心肌血流灌注显像（SPECT图）：左心室下后壁、后外侧壁心肌血流灌注缺损。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007154034108.jpg" border="0" /></p><p>心肌代谢显像：左心室下后壁、后外侧壁灌注代谢完全不匹配，心肌全部存活。建议尽快行血管重建术。</p><p><img height="552" src="http://www.cn-petct.com/FileUpload/200910/20091007154212359.jpg" width="624" border="0" style="width:574px;height:552px;" /></p><p>心肌代谢各轴面图，LVEF＝61％</p><p>（病例二）：1、左心室心尖、广泛前壁、间隔及外侧壁心肌梗死。心尖部室壁瘤形成。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;2.左心室心尖、前壁近心尖部及前壁中段、间隔灌注代谢完全匹配，无存活心肌。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.建议保守治疗，不推荐行血运重建术</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007154619279.jpg" border="0" /></p><p>心肌血流灌注显像：左心室心尖、广泛前壁、间隔及外侧壁血流灌注缺损。</p><p><img height="462" src="http://www.cn-petct.com/FileUpload/200910/20091007154633372.jpg" width="454" border="0" style="width:522px;height:500px;" /></p><p>心肌代谢显像：心肌血流灌注示左心室心尖、广泛前壁、间隔及外侧壁血流灌注缺损区未见放射性充填，提示心肌无活力，不推荐行心肌血运重建术。<img src="http://www.cn-petct.com/FileUpload/200910/20091007154717110.jpg" width="800" border="0" /></p><p>心尖部室壁瘤形成，LVEF＝52％</p><p>（病例三）：1、左室前壁、心尖部、侧壁近心尖及间壁放射性分布明显稀疏－缺损，其中间壁近基底部小部分灌注与代谢不匹配，提示心肌存活，其余部分心肌梗死。其它心肌节段静息血流灌注大致正常，心肌存活。 2、左室功能减低。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007155632600.jpg" width="850" border="0" /></p></span>', 'gwm', 0, 11),
(288, 'PET－CT心肌显像在心肌桥（壁冠状动脉）中的应用', '病例介绍', '', '', '2009-12-18 16:07:05', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>PET心肌代谢显像是判断心肌是否存活的金标准，指导冠心病治疗方案的选择，避免不必要的冒险治疗及无效治疗，多种联合检查可准确诊断冠心病、判断病情程度。 （病例一）：对角支肌桥：心肌显像的左室后外侧壁心肌缺血区，冠状动脉肌桥形成。<br />准备：13N-NH3腺苷负荷＋静息心肌灌注显像：静脉注射腺苷0.14mg/min/kg3分钟时注射显像剂13N-NH3，6分钟 后腺苷注射完毕，即刻行心脏PET-CT门控断层显像，当天下午行13N-NH3静息门控断层心肌灌注显像。隔日控制心率60次/分左右行冠状动脉CTA检查。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007152651552.jpg" border="0" />&nbsp;</p><p>&nbsp;&nbsp; 上列心肌血流灌注显像，下列心肌代谢显像：提示左室后外侧壁心肌缺血区处心肌存活。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007152812570.jpg" border="0" />靶心土图EF＝56％</p><p><img height="607" src="http://www.cn-petct.com/FileUpload/200910/20091007152922293.jpg" width="904" border="0" style="width:864px;height:529px;" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007153121271.jpg" width="800" border="0" />三维重建</p></span>', 'gwm', 0, 8),
(289, 'PET－CT在肾癌中的应用', '', '', '', '2009-12-21 10:10:17', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>肾透明细胞癌放射性摄取较低可致假阴性，部分肾癌因放射性排泄影响可致假阴性，可行速尿促排后延迟显像及行增强扫描协助诊断。</p><p>（病例一）右肾中下部癌。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112510992.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112536709.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112650308.jpg" border="0" />上行为促排后延迟显像</p><p>（病例二）左肾透明细胞癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006164026275.jpg" border="0" /></p><p><img height="501" src="http://www.cn-petct.com/FileUpload/200910/20091006164332900.jpg" width="513" border="0" style="width:394px;height:309px;" /><img height="501" src="http://www.cn-petct.com/FileUpload/200910/20091006164354408.jpg" width="512" border="0" style="width:378px;height:309px;" /></p><p>肾脏平扫&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后动脉期扫描</p><p><img height="512" src="http://www.cn-petct.com/FileUpload/200910/20091006164435107.jpg" width="513" border="0" style="width:395px;height:303px;" /><img height="512" src="http://www.cn-petct.com/FileUpload/200910/20091006164458461.jpg" width="512" border="0" style="width:384px;height:303px;" /></p><p>&nbsp;增强后静脉期扫描&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后延迟3分钟扫描</p></span>', 'gwm', 0, 0),
(290, 'PET－CT在胰腺癌中的应用', '', '', '', '2009-12-21 10:10:35', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）胰头癌伴肝内转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112005128.jpg" border="0" />胰头癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112030786.jpg" border="0" />胰头癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112046957.jpg" border="0" />肝转移瘤</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007112106208.jpg" border="0" />肝转移瘤</p><p>（病例二）胰腺体尾部癌伴肝内多发转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007111407378.jpg" border="0" />胰腺体尾部癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007111427604.jpg" border="0" />胰腺体尾部癌</p><p><img height="639" src="http://www.cn-petct.com/FileUpload/200910/20091007111456456.jpg" width="626" border="0" style="width:656px;height:656px;" />肝转移瘤</p><p><img height="638" src="http://www.cn-petct.com/FileUpload/200910/20091007111520768.jpg" width="626" border="0" style="width:654px;height:661px;" /></p></span>', 'gwm', 0, 0),
(291, 'PET－CT在胆囊癌中的应用', '病例介绍', '', '', '2009-12-21 10:10:58', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p align="left">（病例一）：胆囊Ca伴腹膜后、肠系膜间隙及纵隔内、肺门多发淋巴结转移；右侧腹壁、右侧肾上腺、全身骨骼多发转移灶。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100409202.jpg" border="0" />胆囊癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100421891.jpg" border="0" />胆囊癌病灶</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100432550.jpg" border="0" />腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100444118.jpg" border="0" />胸椎骨转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100456301.jpg" border="0" />右侧腹壁转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007100509774.jpg" border="0" /></p><p>（病例二）“胆囊癌切除术后” 肝门区、胆总管走行区、肝右叶多发转移；蝶鞍右侧骨转移瘤。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007101015656.jpg" border="0" /><br /><br /><img src="http://www.cn-petct.com/FileUpload/200910/20091007101050288.jpg" border="0" />肝门区淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007101142170.jpg" border="0" />肝右叶转移灶</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007101201478.jpg" border="0" />右侧蝶骨转移</p></span>', 'gwm', 0, 4),
(292, 'PET－CT在胆管细胞癌中的应用', '病例介绍', '', '', '2009-12-21 10:11:21', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）左肝胆管细胞癌伴肝胃间隙淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170003787.jpg" border="0" />左肝胆管细胞癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170015851.jpg" border="0" />肝门取淋巴结转移</p><p>（病例二）肝左叶胆管细胞癌伴小网膜囊、腹膜后淋巴结及左侧髂骨多发转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170400938.jpg" border="0" />左肝胆管细胞癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170424173.jpg" border="0" />肝门区淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170437421.jpg" border="0" />肝门区淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170450728.jpg" border="0" />腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170502748.jpg" border="0" />左髂骨转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006170518460.jpg" border="0" /></p></span>', 'gwm', 0, 4),
(293, '肝癌合并肾癌PET－CT及增强CT表现', '病例介绍', '', '', '2009-12-21 10:11:47', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>肝右叶近膈面肝细胞癌合并左肾透明细胞癌：对原发性肝细胞癌及肾脏透明细胞癌PET具有较高的假阴性，故行增强扫描是必不可少的，且能相互补充；必要时肾脏可行促排后延迟显像有时有助于诊断。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006164011238.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006164026275.jpg" border="0" /></p><p><img height="502" src="http://www.cn-petct.com/FileUpload/200910/20091006164046937.jpg" width="513" border="0" style="width:394px;height:348px;" /><img height="487" src="http://www.cn-petct.com/FileUpload/200910/20091006164110740.jpg" width="513" border="0" style="width:378px;height:348px;" /></p><p>&nbsp; 肝脏平扫&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后动脉期扫描</p><p><img height="475" src="http://www.cn-petct.com/FileUpload/200910/20091006164205141.jpg" width="512" border="0" style="width:397px;height:318px;" /><img height="488" src="http://www.cn-petct.com/FileUpload/200910/20091006164236241.jpg" width="512" border="0" style="width:379px;height:319px;" /></p><p>&nbsp; 增强后静脉期扫描&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后延迟3分钟扫描</p><p><img height="501" src="http://www.cn-petct.com/FileUpload/200910/20091006164332900.jpg" width="513" border="0" style="width:394px;height:309px;" /><img height="501" src="http://www.cn-petct.com/FileUpload/200910/20091006164354408.jpg" width="512" border="0" style="width:378px;height:309px;" /></p><p>肾脏平扫&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后动脉期扫描</p><p><img height="512" src="http://www.cn-petct.com/FileUpload/200910/20091006164435107.jpg" width="513" border="0" style="width:395px;height:303px;" /><img height="512" src="http://www.cn-petct.com/FileUpload/200910/20091006164458461.jpg" width="512" border="0" style="width:384px;height:303px;" /></p><p>&nbsp;增强后静脉期扫描&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后延迟3分钟扫描</p></span>', 'gwm', 0, 6),
(294, 'PET－CT在肝癌中的应用', '病例介绍', '', '', '2009-12-21 10:12:29', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）肝右叶原发性肝细胞癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006161025817.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006161037321.jpg" border="0" /></p><p>（病例二）部分原发性高分化肝细胞癌PET显像可为假阴性，但结合肝脏增强扫描（肝三期扫描）基本可以明确诊断。</p><p>&nbsp; 肝右叶前段占位，代谢部分增高，考虑原发性肝Ca（中央部分坏死）；肝右叶及左叶内侧段多发占位，考虑肝内转移，次日行肝脏增强扫描协助诊断。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006161741214.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006161820739.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006161904471.jpg" border="0" /></p><p><img height="511" src="http://www.cn-petct.com/FileUpload/200910/20091006161946577.jpg" width="512" border="0" style="width:390px;height:361px;" /><img height="512" src="http://www.cn-petct.com/FileUpload/200910/20091006162211485.jpg" width="513" border="0" style="width:367px;height:362px;" /></p><p>&nbsp;&nbsp;&nbsp; 肝平扫&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后动脉期扫描</p><p><img height="513" src="http://www.cn-petct.com/FileUpload/200910/20091006162323459.jpg" width="513" border="0" style="width:392px;height:354px;" /><img height="511" src="http://www.cn-petct.com/FileUpload/200910/20091006162333344.jpg" width="513" border="0" style="width:353px;height:354px;" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp; 增强后静脉期扫描&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 增强后延迟3分钟扫描</p><p>（病例三）肝左叶原发性肝Ca伴双肺转移及右侧锁骨上窝、 前胸壁、纵隔内、肝门区、腹膜后多发淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006163116304.jpg" border="0" />肝左叶肝癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006163249997.jpg" border="0" />右侧锁骨上窝淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006163129328.jpg" border="0" />双肺多发转移瘤</p><p><img height="646" src="http://www.cn-petct.com/FileUpload/200910/20091006163142860.jpg" width="711" border="0" style="width:668px;height:612px;" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006163209690.jpg" border="0" />髂动脉旁淋巴结转移</p></span>', 'gwm', 0, 5),
(295, 'PET－CT在结肠癌中的应用', '病例介绍', '', '', '2009-12-21 10:12:50', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）升结肠、乙状结肠多发结肠Ca （病理：乳头状腺癌）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154514101.jpg" border="0" />乙状结肠癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154542787.jpg" border="0" />升结肠癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154559295.jpg" border="0" />乙状结肠癌（多平面重建）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154613945.jpg" border="0" />升结肠癌（多平面重建）</p><p>&nbsp;&nbsp;&nbsp; 该病例术后一年多复查发现右肺转移结节</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154641678.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006154657568.jpg" border="0" /></p><p>（病例二）升结肠癌术后肝转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006155028776.jpg" border="0" /></p><p><img height="613" src="http://www.cn-petct.com/FileUpload/200910/20091006155047299.jpg" width="625" border="0" style="width:672px;height:646px;" /></p></span>', 'gwm', 0, 5);
INSERT INTO `wenzhang_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(296, 'PET－CT在十二指肠及空场癌中的应用', '病例介绍', '', '', '2009-12-21 10:13:11', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）十二指肠Ca伴肝门周围多发淋巴结转移：十二指肠球后部、 降段肿块，同胰头部及胰腺钩突分界不清。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153635276.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153652628.jpg" border="0" />十二指肠癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153705203.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153719855.jpg" border="0" />肝门区淋巴结转移</p><p>（病例二）左上腹部空肠Ca（多中心性）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153805155.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153816663.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153828399.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006153838504.jpg" border="0" /></p></span>', 'gwm', 0, 5),
(297, '18F-FDG PET/CT在胃部疾病诊断中的应用（附75例报告）', '临床应用', '', '', '2009-12-21 10:13:55', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;">&nbsp;福建省立医院核医学科（350001） 陈彩龙 陈文新 林美福 周庆伟 陈国宝 （福建医药杂志）<br />【摘 要】目的 探讨18F-FDG PET/CT在胃部疾病诊断的临床价值。方法 回顾性分析75例胃部病变患者PET-CT表现，部分患者胃部充盈下延迟2 h扫描或加行CT增强扫描表现。结果 （1）48例胃癌确诊35例，其中腺癌34例，印戒细胞癌1例，其中1例胃镜示黏膜下早期胃癌，PET/CT未发现明显病灶。（2）对胃间质瘤4例，良性平滑肌瘤2例，恶性间质瘤2例能准确定性、定位及显示毗邻关系。（3）对胃淋巴瘤3例均能准确定性、分期及显示累及范围等。（4）胃炎性摄取或生理性摄取20例，其中8例胃镜示慢性胃炎。结论 18F-FDG PET/CT检查对大部分胃部肿瘤及转移灶可准确定性，但早期黏膜下病灶有可能漏诊；对部分正常胃部或炎性病变结合放射性分布特点、胃壁形态，必要时胃部充盈下或低张状态下行CT扫描、延迟扫描或增强扫描等有助于良恶性鉴别。&nbsp;<br />【关键词】 18F-FDG PET-CT； 胃部疾病； 临床应用&nbsp;<br />【中图分类号】R735.2； R817.4 【文献标识码】A 【文章编号】1002-2600（2009）05&nbsp;<br />目前，将 18F-氟脱氧葡萄糖（18F-FDG）PET/CT用于胃癌诊断分析的报道相对其他肿瘤见少，结果也不尽理想，其主要原因为胃壁富含腺体和平滑肌组织，因此存在FDG的生理性摄取，干扰了胃癌的诊断[1]。为此，我科对疑为胃部病变的75例患者行18F-FDG PET/CT，并对资料进行回顾性分析，以探讨18F-FDG PET/CT在诊断胃部疾病中的应用价值。&nbsp;<br />1资料与方法&nbsp;<br />1.1 一般资料：收集2005年9月至2009年2月就诊为胃部病变的75例患者PET/CT资料，其中男59例，女16例，年龄（59.56±13.45）岁。所有病例最后经胃镜、术后病理检查及随访复查证实，其中胃癌48例，胃间质瘤4例，胃淋巴瘤3例，胃炎性摄取或生理性摄取20例。临床症状表现为上腹部不适、疼痛、呕吐、便血、消瘦等，部分病例为无症状体检见血CEA升高待查。&nbsp;<br />1.2 方法： 本组病例采用美国GE Discovery LS16 PET/CT仪器检查，注射显像剂18F-FDG（0.10～0.13 mci/kg），静卧休息50～60 min，起床后喝500 ml牛奶并饮水至自觉饱胀感，排空尿液后上检查床。扫描范围为颅顶至大腿根部（约6～7个床位）。扫描参数：管电压 120kV，管电流80～160mA，层厚5mm，PET采用迭代法重建，图像送至xeleris工作站进行图像融合。部分患者2 h胃部充盈后延迟扫描（必要时饮水前15～20 min肌注654-Ⅱ 10～20 mg，使胃肠处于低张状态），5例患者隔日行胃部CT增强扫描。&nbsp;<br />2 结果&nbsp;<br />本组胃癌48例确诊的有35例，其中腺癌34例，印戒细胞癌1例，13例晚期患者拒绝病理检查但经随访证实。其中，5例SUV＜2.5，9例SUV 2.5～4.0，34例SUV＞4.0；8例胃壁增厚＜1 cm，其中1例胃镜示黏膜下早期胃癌，PET/CT未发现明显病灶；19例患者胃壁增厚1.0～2.0 cm，其中1例寻找原发灶，由于病灶局限于胃底贲门后方，2次胃镜未发现，第3次在PET/CT提示下取得病理证实；21例患者胃壁增厚＞2cm，5例患者胃部病灶为肿块型，最大径3.4～5.6 cm。其中6例患者为胃部单发病灶；42例患者合并淋巴结及远处转移，淋巴结转移或远处病灶放射性摄取可高于胃原发灶。胃癌患者增厚的胃壁充盈后病灶扩张度差，厚度未见明显变薄，约95％增厚的胃壁放射性摄取高于其他部位，3例增强扫描示胃壁不规则增厚，胃腔变窄，强化不均，胃黏膜紊乱、中断，扩张后胃壁厚度未见明显改变。&nbsp;<br />胃间质瘤4例，良性平滑肌瘤2例，CT表现为类圆形肿块，边界清楚，最大径分别约2.0cm 、3.4 cm，1例未见放射性摄取，1例轻度放射性摄取，SUV约1.6；2例恶性间质瘤表现为不规则软组织肿块，最大径约5.4～8.0 cm，边缘不整，但均未见远处转移，SUV 4.2～11.5。&nbsp;<br />胃淋巴瘤3例，胃内病灶及淋巴瘤侵犯部位均放射性明显摄取，SUV高达3.1～11.5，胃壁厚达1.8～2.6 cm。&nbsp;<br />胃炎性摄取或生理性摄取20例（8例胃镜示慢性胃炎），其中，11例SUV＜2.5例，9例SUV＞2.5，最高约6.0；17例胃壁未见明显增厚（＜1cm），9例表现为胃壁轻度弥漫性放射性摄取，8例胃壁不均匀性摄取，SUV 2.3～4.9； 3例胃壁轻度局限性增厚，厚达1.0～1.6 cm，但增厚的胃壁放射性摄取未见明显增高，延迟2 h扫描胃腔扩张良好，胃壁柔软，增厚的胃壁伸展变薄，其中2例增强后扫描示胃黏膜完整、走行规则。&nbsp;<br />3 讨论&nbsp;<br />3.1胃癌影像学表现：胃癌多发生于胃窦部，较少发生于胃底及胃体。典型表现为：局部肿块、局限性胃壁增厚、腔内溃疡、邻近胃黏膜走行紊乱，增强扫描胃壁不均匀性强化，密度不均；发生于胃窦部者常导致梗阻性胃腔扩张，沿胃壁弥漫性生长的浸润性胃癌则使胃腔狭窄，胃癌直接侵犯周围组织的可能性较胃淋巴瘤大。PET胃部低分化腺癌及印戒细胞癌病灶放射性摄取较低，部分同正常胃壁摄取相仿，但局部胃壁大部分有局限性增厚，且低张充盈后扩张度差，形态未见明显改变，肝胃间隙及网膜囊常可见肿大淋巴结影可辅助诊断，肾门下淋巴结肿大较胃淋巴瘤少见；若合并淋巴结转移或远处转移，转移灶放射性摄取可较胃原发灶高，对极早期黏膜下胃癌PET-CT可能漏诊，应结合胃镜检查。&nbsp;<br />3.2胃肠道间质瘤影像学表现：胃肠道间质瘤（GIST）发病率很低，仅占胃肠道肿瘤的3％，它属于消化道的间叶源性肿瘤。该瘤好发于胃和小肠，免疫组化分析见c-kit蛋白（CD117）表达。目前大多数学者认为，只要是间质瘤就为潜在恶性，PET/CT根据18F-FDG摄取程度（良性大多轻微放射性摄取，SUV＜2.5；恶性则明显放射性异常浓聚，SUV一般远＞2.5）可鉴别间质瘤的良恶性，同时可清楚显示肿块大小、形态、范围及其边缘轮廓，并能显示肿块的内部情况，是否有坏死、囊变、出血等，以及向腔外突出的肿块同胃肠道的关系，显示肿块的生长方式及转移情况。增强CT扫描肿瘤实性部分动脉期中度或明显强化，部分病灶内或瘤旁可见增粗的供血动脉，静脉期强化较动脉期明显，低密度坏死或囊变灶无明显强化。对病人手术方案确定及病人的预后评估有明确指导意义。&nbsp;<br />3.3胃淋巴瘤影像学表现：胃淋巴瘤起自胃黏膜固有层和黏膜下层的淋巴组织。绝大多数为非霍奇金氏淋巴瘤（NHL），而霍奇金氏淋巴瘤罕见。胃淋巴瘤常累及胃窦、胃体、胃底，通常以胃体、胃窦多见。多数侵犯2个以上部位，但幽门很少累及[2]。表现为弥漫性增厚、节段性增厚、局限性增厚等，胃壁僵硬，大多数表现为弥漫性增厚，累及范围超过胃壁全周的50％，黏膜皱襞明显肥大呈梳齿状，胃淋巴瘤往往密度均匀，坏死、囊变少见。CT增强扫描见：胃淋巴瘤大部分强化均匀，强化不高，与肌肉强化程度相仿，黏膜表面溃疡少见，胃周组织侵犯少见，易合并腹部淋巴结肿大，尤其是腹膜后肾门水平下的腹膜后淋巴结肿大，绝大多数病例合并脾肿大。由于淋巴瘤在黏膜下生长，上消化道钡餐检查只能观察黏膜皱襞厚度，胃镜检查胃黏膜活检亦往往不能明确诊断，即使为阳性，也不能对分期、确定浸润范围、疗效检测提供依据。CT可以直接显示胃壁厚度、侵犯范围，是胃淋巴瘤有价值的检查方法，而PET-CT在肿瘤活性、疗效评价等更具有不可替代的优势。&nbsp;<br />3.4 胃壁良性摄取影像学表现：包括生理性摄取或炎性摄取。18F-FDG代谢显像中，正常胃壁常有FDG摄取，摄取程度不均，SUV可达1.0～6.0。丁勇等[3]认为，提高SUV阈值（＞3.0）可减少胃肠道生理或/和炎性摄取对结果的影响。这可能与胃平滑肌持续蠕动所致生理性摄取有关，也可能是代谢活跃的胃黏膜或吞咽的分泌物。在一般情况下，胃部生理性摄取程度较低，并且正常胃部摄取普遍较均匀，形态多为环行，无明显的局灶性浓聚灶，大部分生理性摄取多位于贲门区、胃窦部，一般弥漫性胃炎可致胃部弥漫性环状摄取，延迟2h采集大部分病灶放射性摄取减低，充盈后胃壁柔软，扩张良好，胃壁厚度＜0.5cm，胃窦部可呈环行增厚，但厚度均匀，密度均匀，形态可变。若病灶呈局限性增厚，且相应部位局限性放射性摄取，应高度怀疑恶性病变，应积极建议胃镜检查。&nbsp;<br />总之，18F-FDG PET/CT检查对大部分胃部肿瘤及转移灶可准确定性，但早期黏膜下病灶有可能漏诊；部分正常胃部或炎性病变亦可见放射性摄取增高，结合放射性分布特点、胃壁形态，必要时胃部充盈下（必要时低张状态下）CT扫描、延迟扫描或增强扫描等综合分析有助于良恶性疾病鉴别，具有较高的临床应用价值。&nbsp;<br />参考文献&nbsp;<br />1 田嘉禾. PET、PET/CT诊断学[M].北京：化学工业出版社，2007：325-330.&nbsp;<br />2 李琛.原发性胃恶性淋巴瘤的研究进展[J].国外医学外科学分册，2003，30(2〕：93-95.&nbsp;<br />3 丁勇，张文书，田嘉禾. 18FDG PET诊断胃癌及影响因素[J].中国医学影像学杂志， 2003，11（5）：335-337.</span>', 'gwm', 0, 8),
(298, 'PET－CT在胃癌中的应用', '病例介绍', '', '', '2009-12-21 10:14:26', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）胃底、体低分化腺癌伴脾门区、腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151141743.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151153644.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151204598.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151212567.jpg" border="0" /></p><p>（病例二）胃窦癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151408345.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151418226.jpg" border="0" /></p><p>（病例三）“胃大部切除术后”改变，残胃胃壁增厚，PET代谢增高，考虑残胃癌；肝右叶前段占位性病变，PET放射性异常浓聚，考虑转移瘤。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151608987.jpg" border="0" />残胃癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006151621904.jpg" border="0" />肝转移灶</p></span>', 'gwm', 0, 4),
(299, 'PET－CT在贲门癌中的应用', '病例介绍', '', '', '2009-12-21 10:14:45', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）：胃底贲门腺癌伴右肺、左锁骨上淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006144758458.jpg" border="0" />上列为延迟2小时后显像</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006144839891.jpg" border="0" />左锁骨上窝淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006144916721.jpg" border="0" />右肺上叶结节，考虑转移瘤</p><p>（病例二）：贲门、胃底、胃体部胃壁不均匀增厚，代谢增高，考虑胃体贲门癌； 肝胃间隙、肝门区、脾门区、腹膜后、前腹壁下淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145247546.jpg" border="0" />贲门区高代谢占位</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145259272.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145342165.jpg" border="0" />脾门区淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145315221.jpg" border="0" />腹壁下淋巴结转移</p><p>（病例三）：“贲门Ca根治性全胃切除术后”改变，吻合口周围、食道下段肿瘤复发 伴肝脏及纵隔、肝门区多发淋巴结转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145859377.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145912231.jpg" border="0" />吻合口复发</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145924299.jpg" border="0" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091006145939181.jpg" border="0" />肝右叶及肝门区淋巴结转移</p></span>', 'gwm', 0, 19),
(300, '前列腺癌的PET－CT表现（18F-FDG显像和18F-胆碱显像）', '病例介绍', '', '', '2009-12-21 10:15:27', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>前列腺癌伴全身多发骨转移。</p><p><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18</sup>F-FDG PET－CT显像</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123809170.jpg" border="0" />前列腺癌病灶</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123855377.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123908681.jpg" border="0" />前列腺癌骨转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123923275.jpg" border="0" />前列腺癌骨转移</p><p>&nbsp;&nbsp;&nbsp;&nbsp;<sup>18</sup>F－胆碱显像</p><p><img height="575" src="http://www.cn-petct.com/FileUpload/200910/20091007124124215.jpg" width="574" border="0" style="width:563px;height:517px;" /></p><p><img height="574" src="http://www.cn-petct.com/FileUpload/200910/20091007124109279.jpg" width="562" border="0" style="width:562px;height:523px;" /></p></span>', 'gwm', 0, 18),
(301, 'PET－CT在子宫内膜癌中的应用', '病例介绍', '', '', '2009-12-21 10:15:46', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）子宫内膜腺癌伴腹水</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123106808.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123117371.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123128823.jpg" border="0" />腹膜转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123138423.jpg" border="0" />腹膜转移</p><p>（病例二）“子宫内膜Ca术后”4年复查：盆腔、腹膜后、肝门区、右侧膈脊脚、左侧胸廓入口多发淋巴结转移及腹膜转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123203345.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007123214463.jpg" border="0" />多发淋巴结转移</p></span>', 'gwm', 0, 15),
(302, '外阴黑色素瘤PET－CT表现', '病例介绍', '', '', '2009-12-21 10:16:08', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>外阴恶性黑色素瘤</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122214276.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122244155.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122300942.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122316886.jpg" border="0" /></p><p>“外阴恶性黑色素瘤”术后6个月，会阴左侧壁高代谢结节，考虑术后复发或淋巴结转移；右侧腹股沟淋巴结转移，肝脏、肺部转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122531795.jpg" border="0" />会阴左侧壁转移结节</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122603122.jpg" border="0" />右侧腹股沟淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122637925.jpg" border="0" />肝转移瘤</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007122705566.jpg" border="0" />右肺转移结节</p></span>', 'gwm', 0, 17),
(303, 'PET－CT在宫体癌中的应用', '病例介绍', '', '', '2009-12-21 10:16:30', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>宫体癌伴全身多发淋巴结及双肺多发转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121538588.jpg" border="0" />宫体癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121604245.jpg" border="0" />宫体癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121620690.jpg" border="0" />左锁骨上窝淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121658811.jpg" border="0" />肺部转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121716155.jpg" border="0" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121737772.jpg" border="0" />腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121758827.jpg" border="0" />腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007121829554.jpg" border="0" />盆腔淋巴结转移</p></span>', 'gwm', 0, 14),
(304, 'PET－CT在宫颈癌中的应用 ', '', '', '', '2009-12-21 10:16:47', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）宫颈Ca伴胸骨、L4棘突、骶椎、左侧耻骨多发骨转移。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007120854852.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007120912429.jpg" border="0" />宫颈癌</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007120925507.jpg" border="0" />左侧骶椎转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007120944220.jpg" border="0" />左耻骨转移</p></span>', 'gwm', 0, 13),
(305, 'PET－CT在卵巢癌中的应用', '病例介绍', '', '', '2009-12-21 10:17:07', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）双侧卵巢Ca伴盆腔、腹腔多发转移（卵巢浆液性乳头状囊腺癌）</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007114705260.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007114727596.jpg" border="0" />双侧卵巢癌</p><p><img height="559" src="http://www.cn-petct.com/FileUpload/200910/20091007114813525.jpg" width="601" border="0" style="width:658px;height:568px;" />腹膜后淋巴结转移</p><p><img height="560" src="http://www.cn-petct.com/FileUpload/200910/20091007114843573.jpg" width="629" border="0" style="width:658px;height:587px;" />腹股沟淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007114937184.jpg" border="0" />腹腔转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007114955707.jpg" border="0" /></p><p>（病例二）“卵巢Ca术后”： 盆腔、双侧腹股沟区、 腹膜后、左锁骨上窝多发淋巴结转移</p><p><img height="567" src="http://www.cn-petct.com/FileUpload/200910/20091007115735476.jpg" width="626" border="0" style="width:661px;height:577px;" />左锁骨上窝淋巴结转移</p><p><img height="566" src="http://www.cn-petct.com/FileUpload/200910/20091007115820724.jpg" width="625" border="0" style="width:660px;height:573px;" />腹膜后淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007115846602.jpg" border="0" />盆腔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007115911753.jpg" border="0" />右侧腹股沟淋巴结转移</p></span>', 'gwm', 0, 17),
(306, 'PET－CT在外周T细胞淋巴瘤中的应用（附1例治疗4次前后对比图）', '病例介绍', '', '', '2009-12-21 10:18:58', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>1.外周T细胞淋巴瘤：全身多发高代谢肿大淋巴结；脾脏肿大，代谢普遍性增高；第5、6、11、12胸椎、右侧髂骨及右侧骶椎多发淋巴瘤骨骼侵犯。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144010784.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144025551.jpg" border="0" /></p><p>2.“外周T细胞淋巴瘤化疗后”4个月复查：1、双侧颈部多发高代谢结节，病灶明显减小、变小，代谢明显减 低。 胸椎、腰椎多个及右侧髂骨病灶代谢明显减低。&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp; 胃底、胃体部高代谢占位，食道下段近贲门处片状放射性异常浓聚，考虑淋巴瘤浸润。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144206439.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144219403.jpg" border="0" /></p><p>3.a、“外周T细胞淋巴瘤化疗后”8个月复查，胃部病灶同4个月前旧片对比，范围变小，代谢减低， 提示化疗后肿瘤细胞受抑制或（和）部分灭活。 b、双侧颈部、纵隔内、双肺门区及腋窝、腹膜后多发小结节影，同4个月前检查结果对比，部分 病灶变小、代谢减低，提示化疗受肿瘤细胞受抑制或（和）部分灭活。 c、双肺野多发高代谢病灶，考虑淋巴瘤浸润。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144440275.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144455208.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144507892.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144520639.jpg" border="0" /></p><p>4.a、“外周T细胞淋巴瘤化疗后”16个月复查：胃部病灶同8个月前旧片对比，代谢稍增高。 b、腹膜后腹主动脉旁、腹腔内小肠系膜间隙、双侧腹股沟及双侧颈部、双侧腋窝、纵隔内、双侧 肺门多发小结节影，同8个月前检查结果对比，病灶稍增多、变大，代谢增高。c、脾脏轻度肿大，放射性分布增浓，建议定期复查。 d、8个月前旧片所见双肺野高代谢病灶基本消失。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144906277.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144926265.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144938275.jpg" border="0" />胃部病灶代谢增高，提示复发</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007144951919.jpg" border="0" />腹股沟淋巴结变大、代谢增高</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007145004948.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007145017638.jpg" border="0" /></p></span>', 'gwm', 0, 11),
(307, 'PET－CT在淋巴瘤中的应用（附2例治疗前后对比）', '', '', '', '2009-12-21 10:19:16', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>（病例一）大B细胞淋巴瘤：纵隔内、颈部双侧、双侧腋窝、肝胃间隙、腹膜后、双侧髂窝、右侧腹股沟等处多发高代谢肿大淋巴结影；右心耳、左后胸膜及邻近的胸壁软组织、右侧髋骨及邻近肌肉、左股骨上端骨髓腔及脾脏淋巴瘤侵犯。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142203576.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142219848.jpg" border="0" />全身PET冠状面图</p><p>“大B细胞性淋巴瘤化疗后”3个月复查：原颈部、纵隔内、第4-5胸椎左旁、双侧腋窝、肝胃间隙、腹膜后、脊柱左旁、双侧髂窝、右心耳、右侧髋骨、左股骨上端骨髓腔内病灶基本消失，提示治疗后肿瘤细胞基本灭活、消失。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142303186.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142317905.jpg" border="0" />全身PET冠状面图</p><p>（病例二）B细胞淋巴瘤：纵隔内、胸骨旁、前胸壁、肋间肌、胸膜、胸椎旁、贲门周围、肝胃间隙、腹膜后、腹壁、大网膜、右侧髂窝等多发高代谢病灶，考虑恶性淋巴瘤（肝胃间隙、腹膜后病灶呈巨块状）。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142901601.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142916537.jpg" border="0" /></p><p>“恶性淋巴瘤化疗后及腹部肿块切除术后”3个月复查：同2006-8-15旧片对比，纵隔内、贲门周围、肝胃间隙、腹膜后、腹主动脉旁、髂窝等多处原高代谢病灶变小，代谢减低，部分消失。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143006224.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007142953760.jpg" border="0" /></p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143028414.jpg" border="0" />肝胃间隙淋巴瘤明显变小</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143055473.jpg" border="0" />盆腔淋巴结变小</p><p>“恶性淋巴瘤化疗后及腹部肿块切除术后”6个月复查：同2006-11-10旧片对比，病灶明显减少、变小，代谢减低。</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143143871.jpg" border="0" />肝胃间隙淋巴瘤变小、代谢减低</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143157510.jpg" border="0" />肝胃间隙淋巴瘤变小、代谢减低</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143209524.jpg" border="0" />纵隔淋巴结基本消失</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007143220129.jpg" border="0" />腹膜后淋巴结变小、代谢减低</p></span>', 'gwm', 0, 22),
(308, '胸膜间皮肉瘤PET－CT表现', '病例介绍', '', '', '2009-12-21 10:19:35', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>胸膜间皮肉瘤伴纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007124816535.jpg" border="0" />纵隔淋巴结转移</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007124834956.jpg" border="0" />纵隔胸膜侵犯</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007124848761.jpg" border="0" />胸壁肿瘤侵犯</p><p><img src="http://www.cn-petct.com/FileUpload/200910/20091007124902184.jpg" border="0" />心包肿瘤侵犯</p></span>', 'gwm', 0, 21);

-- --------------------------------------------------------

--
-- Table structure for table `wenzhang_news`
--

CREATE TABLE IF NOT EXISTS `wenzhang_news` (
  `j_id` int(11) NOT NULL AUTO_INCREMENT,
  `j_name` varchar(200) NOT NULL,
  `j_shenfen` varchar(100) NOT NULL,
  `j_jiage` varchar(20) NOT NULL,
  `j_jibie` varchar(30) NOT NULL COMMENT '医院级别',
  `j_time` datetime NOT NULL,
  `j_ip` varchar(20) NOT NULL,
  `j_content` text NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `j_image_count` int(10) unsigned NOT NULL DEFAULT '0',
  `click` int(11) NOT NULL DEFAULT '0' COMMENT '点击',
  PRIMARY KEY (`j_id`),
  KEY `j_jiage` (`j_jiage`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=198 ;

--
-- Dumping data for table `wenzhang_news`
--

INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(12, 'PET/CT的16层螺旋CT的优势', '', '', '', '2009-09-06 07:52:37', '114.81.86.197', '16层CT及64层CT，只要高于16层，图像将更加细腻，检查速度也大大提高。<br />\r\n<br />\r\n　　16层螺旋CT的主要检查优势如下：<br />\r\n<br />\r\n　　1、 成像速度快，移动伪影少，血管结构清晰；<br />\r\n<br />\r\n　　2、 可获得血管结构三维信息，原始数据可重叠方法重建，不遗漏解剖结构，保证整个扫描范围的血管图像的连续性；<br />\r\n<br />\r\n　　3、 可进行三维重建，指导手术；造影剂可用转高流速，提高信噪化，提高图像质量；<br />\r\n<br />\r\n　　4、 检查时间短，适合老年、小儿及外伤危重患者；<br />\r\n<br />\r\n　　5、 操作简便，安全系数高，噪音小。<br />\r\n&nbsp;<img border="0" alt="" src="/image_server_dir/e4ff7bab069590da5c6f4443ae091985.jpg" />\r\n', 'admin', 0, 67),
(17, '2009年PET读片会成功召开 ', '', '', '', '2009-09-28 12:28:51', '116.228.141.77', '<p>由中华医学会核医学分会主办、PET及分子显像学组承办的第四届中日韩核医学大会暨2009年全国PET(/CT)读片会及学术研讨会于2009年9月在海滨之城山东省青岛市成功举行。这次大会，是继2009年5月中华医学会核医学分会第八届全国核医学学术交流会之后的又一次成功的学术活动之典范，是中日韩核医学界的交流平台，是对国内PET(/CT)及分子显像技术、学术工作的回顾、肯定、总结，也是对国内PET(/CT)，乃至全体核医学工作者的相互交流、共同进步、展望未来的良机。</p>\r\n<p><img alt="" src="/image_server_dir/e2a3e3851bed729a0b4cbe7487315225.jpg" border="0" />\r\n </p>', 'llz007', 0, 33),
(18, '内蒙古医学院附属医院引进PET-CT等重要影像设备', '', '', '', '2009-09-29 11:19:42', '116.228.141.77', '<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924141310367.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp; 8月28日上午，具有国际先进水平的PET-CT、3.0TMRL和64排CT在内蒙古医学院附属医院正式开机，这对于提高内蒙古医疗设备水平，更好的服务内蒙古人民提供了可靠的技术支持。<br />\r\n　　PET-CT是目前世界上灵敏度最高、采集速度最快、注射计量最低的分子影像诊断设备，也是临床应用中最佳的分子影像设备。PET-CT的引进也填补了内蒙古缺少高端检查设备方面的空白。GE公司的64排CT、3.0TMRL同样以无创、高效、精确、立体的医学影像技术，为临床提供了更好、更多、更准确的图像，解决了以往一些医学难题，取代了一些有创的检查手段。 <br />\r\n　　据了解，内蒙古医学院附属医院是我国在少数民族自治区建立的第一所医院院校的附属医院，目前是内蒙古一所著名的大型综合性三甲医院。<br />\r\n</font></font></p>', 'gwm', 0, 25),
(19, '全国PET-CT（PET）配置、使用情况调查报告', '', '', '', '2009-09-29 11:24:10', '116.228.141.77', '<font face="Verdana" size="2">2009年6月，中华医学会核医学分会受国家卫生部规划财务司的委托，对全国（不包括港澳台）的PET-CT（含PET和医用回旋加速器）的配置使用情况进行了一次调查。现将情况汇报如下。</font>\r\n<p><font face="Verdana" size="2">一、调查的一般情况<br />\r\n1. 调查的工作安排<br />\r\n　　获知卫生部规财司的委托意向后，中华医学会核医学分会（以下简称学会）立即通知了全体常委和各省市自治区核医学分会（以下简称分会）主任委员，并在主要设备厂家的配合下，整理出各厂家在各地的装机名单，先期通过电子邮件发给各分会进行核实。<br />\r\n2. 数据的收集与核实<br />\r\n　　6月10日收到规划司的正式函件，调查工作自6月12日启动。学会建议填表人原则上由非本单位人员负责。考虑到部分省区不同使用单位在不同城市，可以由各省市自行决定填表人，学会负责差旅费。要求所填调查表需经各省区主委核实、签名后统一集中；调查期间，学会对各省区报来的数据及时核对，凡缺项或有疑问处，均经电话核实。对个别因种种原因没有按时上报调查结果的省区均及时提醒、督促。在全国各相关省区分会、各使用单位的大力配合下，至6月25日晨，本次调查发出的114份调查表全部收回。<br />\r\n3. 调查工作总体情况<br />\r\n　　(1)本次调查中，各地分会和各使用单位均给予了高度支持和配合。除2家单位不愿提供数据，另一单位原PET-CT引进计划改变外，目前学会掌握的其他所有使用单位的数据均较完整地收集到位。<br />\r\n　　(2)从统计结果结合学会掌握的信息判断，个别数据，特别是涉及使用范围、管理模式等方面的数据，个别单位可能没有完全据实报送。因此，这些数据的统计和引用应有所保留。<br />\r\n二、调查结果<br />\r\n1. 全国PET-CT配置情况<br />\r\n　　(1)此次调查，共涉及到115个单位的PET/CT数据调查表。其中，2007年12月底前安装使用的PET/CT共87个单位89台，分布于24个省市自治区；2008年装机单位8台；2009年即将装机20台；1台情况不明。<br />\r\n　　本次调查未包括港澳台地区；未包括使用二手设备的个别单位；国产设备（亿仁公司PET）因没有正式供货信息，学会不掌握其供应、使用单位情况，没有包括在统计之内。<br />\r\n　　2009年卫生部大型设备集中采购共21台PET-CT和10台加速器，部分单位无具体采购信息，部分内容未纳入本次调查统计。<br />\r\n　　(2)按目前安装（或即将安装）PET/CT台数排序：北京23台，广东14台，上海10台；详细配置情况请见附件1。<br />\r\n　　(3)PET-CT厂家配置台数排序：通用电器（GE）：58台（包括64排VCT 5台，16排STE 10台，16排ST 18台，8排ST 6台，4排ST 4台，16排LS 2台，8排LS 3台，4排LS 10台）。西门子：43台(包括64层HD 3台，64层52环 3台，64层39环 5台，40层39环 2台，16层39环 21台，2排 3台，单纯PET 6台)。飞利浦：16台（包括64排TOF 1台，16排TOF 1台，16排8台，2排 1台，C-PET 5台）。<br />\r\n　　(4)加速器配置：GE：35台；西门子：17台；住友：9台；IBA：2台；EBCO：2台。<br />\r\n2. 全国PET-CT使用情况<br />\r\n　　(1)管理运行模式：PET-CT由医院管理占76.6％，医院和投资方合作管理占22.5％，合作方管理占0.9%；隶属核医学科占55.0％，隶属放射科占10.8％，独立PET-CT中心占34.2％。<br />\r\n　　(2)2008年全国PET-CT检查总数：11.59万例；平均单台设备检查：1348.4例。年检查例数1000以上46家（53.9％），年检查量低于400例的单位10家（12%）。<br />\r\n　　(3)2009年PET/CT平均开机：4.31天/周；其中每周开机5天以上的占51.0％，开机4天的占20.4％，开机3天以下的占28.6％。较高的单一月份PET-CT检查量平均为163.3例（4～5月份）；较低的单一月检查量平均为82例（1月份，春节长假）。<br />\r\n　　(4)PET-CT工作内容：肿瘤学检查73.9％，心血管检查1.3％，神经系统检查3.7％，查体18.5％，其他2.6％。其中查体比例最高者：100％。受检者来源分布：门诊患者占41.2％，住院患者37.8%，外单位介绍21.0％。<br />\r\n　　(5)在2007年前装机单位中，近年PET-CT检查工作量上升的单位76个（88.37％），工作量下降单位4个（4.65％），持平单位6个（6.98％）。<br />\r\n　　(6)PET-CT检查收费：全身检查平均收费：8826元，局部检查平均收费：6020元；最高收费：全身13000元，局部11640元；最低收费：全身6370元，局部3500元。除4家医院外，PET-CT的同机CT检查，均未另加收费用。<br />\r\n　　(7)医疗保险复盖：目前国内有6家PET-CT全部费用进入医保，主要分布于深圳、黑龙江和湖南省；6家单位检查显像剂（药费）部分进入医保，主要分布于北京、辽宁和山东。<br />\r\n　　(8)临床医生与患者对PET-CT的认可情况：认可或非常认可者占绝大多数，没有负面反应。目前社会和临床上对PET-CT使用反映最多的问题包括：检查价格贵，不能报销；存在部分假阳性或假阴性结果；部分临床医生对PET-CT的期望值不客观等。<br />\r\n三、调查结果的初步解读<br />\r\n1. 国内PET-CT技术的需求在不断增加。<br />\r\n　　北京医院曾对2006年6~8月国内10家三甲医院工作进行抽样调查，与相比，本次调查显示：月平均检查量从120.72例（110.66~130.78）上升为163.3例（考虑到前次抽查均为大医院且选择工作量较高的月份，这一增长幅度还是很有意义的）；年均检查量超过1000例的单位比例由不足1/3增加到53.9％；月检查例数超过100例的单位从20.0％增加到59.8％。同时，体检所占工作量比重由32.9％下降到18.5％。<br />\r\n2. 国内PET-CT使用情况的发展极不平衡。2008年全国PET-CT单机最高检查量与最低检查量间相差75倍。即使是同类医疗单位、同种机型、相似工作条件，工作量的差别也达3倍以上<br />\r\n3. 国内PET-CT技术发展的几个特点<br />\r\n　　(1)地区：目前PET-CT工作状态好的地区，除北京、上海、广东、江苏等传统经济发达地区外，黑龙江、辽宁、浙江、湖北、湖南、安徽及新疆的使用情况也相对较好。但同一地区不同单位的使用情况差距较大。同时，需要进一步研究的是，5家年工作量最低的单位中，3家来自相对发达地区（深圳、上海）。<br />\r\n　　(2)单位：大型综合性医院与肿瘤专科医院的工作量差别不明显。总体上看，医院的学术地位与PET-CT使用量之间有联系，越有影响的单位，PET-CT使用情况越好。但也有例外。<br />\r\n　　(3)医保：无论医院大小、性质，凡有医保支持的单位，PET-CT的使用情况均较好。<br />\r\n　　(4)市场行为：由于市场运作多不公开，本次调查未能得到市场运作对PET-CT工作量的情况的真实数据。据了解，至少部分单位有不同程度的市场运作行为，一些单位的工作量增长与市场行为的参预直接相关。然而，即使在有市场行为的PET-CT中心，至少部分患者的PET-CT检查是正当和必要的，而且得益于市场运作中的学术方面的宣传。当然，肯定有部分检查不是PET-CT适应证，如何规范市场行为应该引起高度重视。<br />\r\n　　(5)加速器和PET-CT配置比例：根据国外资料和对加速器功能的分析，PET-CT与加速器配置的合理比例应该在4:1 ~ 6:1左右。而目前国内此比例约为1.82:1。这种失当的配置比例无疑会造成资源的巨大浪费。而同时，由于政策限制和资源共享困难等因素，没有加速器的PET-CT单位，常因药品供应问题而影响正常使用和技术发展，进而刺激了加速器的购置需求。<br />\r\n4. 使用单位对卫生行政主管部门的建议<br />\r\n　　PET-CT使用单位对管理部门的建议，按提出的频度依次为：尽快解决有条件、有控制的医保复盖；明确适应证、合理定价，限制不正当竞争和滥用；在合理增加配置额度基础上加强宏观配置管理；加强对加速器的配置管理、合理使用与医疗单位间药物配送的政策引导；加强质量控制与规范化使用方面的引导；强化技术准入、培训与规范化方面的管理等。 <br />\r\n（中华医学会核医学分会）</font></p>', 'gwm', 0, 30),
(16, '上海部分医院国庆就医指南', '', '', '', '2009-09-28 10:36:53', '116.228.141.77', '&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;●<strong><a href="http://yyk.39.net/sh/zonghe/4d8ef.html"><font color="#0066cc">上海第十人民医院</font></a></strong>：10月1日—8日门急诊均照常开放，所有专科、专家门诊照常门诊;择期手术如期进行，急诊手术照收不误，并且，上午所有体检服务也全部开放（开放时间：8：00—11：30）；同时，医院将根据节日期间患者需求的变化情况，合理安排医护力量，保证来院患者能得到及时、有效、高质量的医疗服务。 \r\n<p>　　咨询电话：021-66300588</p>\r\n<p>　　联系地址：延长中路301号</p>\r\n<p>　　●<strong><a href="http://yyk.39.net/sh/zonghe/4ea30.html"><font color="#0066cc">第九人民医院</font></a></strong>：10月1～8日整形外科专家门诊和激光美容门诊照常开放，其余门诊均停诊（其中10月8日按原周六门诊开放）。10月8日按原周六部分门诊开放（部分口腔门诊会因门诊超量予以限号）；10月9日门诊正常开放(按周五门诊安排);10月10日(周六)门诊正常开放（按周四门诊安排）；注：节日期间医院急诊各科24小时开放。</p>\r\n<p>　　咨询电话：021-23271699,63138341</p>\r\n<p>　　联系地址：上海市制造局路639号</p>\r\n<p>　　●<strong><a href="http://yyk.39.net/sh/zonghe/4ea31.html"><font color="#0066cc"> 上海仁济医院</font></a></strong></p>\r\n<p>　　门诊安排：各临床科室10月1日至10月4日，全天休息;10月5日按照周一门诊安排，10月6日至10月8日，全天休息。</p>\r\n<p>　　出入院结帐安排：10月1日至10月2日全天休息；10月3日全天办理出入院结账；10月4日全天休息；10月5日全天办理出入院结账；10月6日全天休息；10月7日全天办理出入院结账；10月8日全天休息。</p>\r\n<p>　　注意：门诊时间要注意，十一8天中只有5日才有门诊，5日的门诊是按照星期一的门诊时间正常门诊的。所以，要去仁济医院的市民可要掐准时间咯。</p>\r\n<p>　　咨询电话：021-58752345</p>\r\n<p>　　联系地址：上海市东方路1630号(东)</p>\r\n<p>　　● <strong><a href="http://yyk.39.net/sh/zonghe/54a6a.html"><font color="#0066cc">上海曙光医院</font></a></strong></p>\r\n<p>　　10月1日-8日：国庆节中秋节休假，门诊停诊，急诊照常开放；10月9日(周五)：按周五门诊开诊；10月10日(周六)：按周六门诊开诊。</p>\r\n<p>　　咨询电话：021-53821650</p>\r\n<p>　　联系地址：上海市普安路185号</p>\r\n<p>　　●<strong><a href="http://yyk.39.net/sh/zonghe/4cc80.html"><font color="#0066cc">上海海军411医院</font></a></strong>：根据节日就诊人群较多，妇科、泌尿外科门诊节假日期间不休，正常上班，门诊时间：8：00—21：00;</p>\r\n<p>　　其他科室找此安排：9月28日(周一)门诊全天开诊；9月29日(周二)门诊全天开诊；9月30日(周三)门诊全天开诊；10月1日(周四)休息；10月2日(周五)休息；10月3日(周六)门诊上午开诊，下午不开放；10月4日—8日均休息；10月9日(周五)门诊全天开诊；10月10日(周六)门诊全天开诊；10月11日(周日)休息。</p>\r\n<p>　　咨询电话：021-81824114,56969799,65876866</p>\r\n<p>　　联系地址：上海市虹口区东江湾路15号</p>\r\n<p>　　●<strong><a href="http://yyk.39.net/sh/zonghe/1ee22.html"><font color="#0066cc">上海中山医院</font></a></strong>：10月1日—8日门急诊均不开放；10月9日(周五)，门诊照常开放。</p>\r\n<p>　　咨询电话：021-64041990</p>\r\n<p>　　联系地址：上海市徐汇区枫林路180号</p>\r\n<p>　　●<strong><a href="http://yyk.39.net/sh/zhuanke/4e591.html"><font color="#0066cc">上海肿瘤医院</font></a></strong>：10月1日—6日门诊不开放，急诊照常(一般只接收危重病人)；10月7日(周三)—9日(周五)正常上班；10月10日(周六)—11日(周日)正常周末假，周六上午半天有普通门诊。</p>\r\n<p>　　注意：从10月1日起，放疗科吴开良副教授原周二上午专家门诊，改为周一上午。大肠外科蔡三军教授原周三下午特需门诊，改为周三上午。</p>\r\n<p>　　咨询电话：021-64175590</p>\r\n<p>　　联系地址：上海市徐汇区东安路270号</p>', 'llz007', 0, 33),
(14, '热烈祝贺派康网进入测试期！', '', '', '', '2009-09-09 21:35:20', '114.81.2.77', '', '', 0, 52),
(15, '职工医保有望长三角内互转', '', '', '', '2009-09-23 09:12:48', '114.81.149.130', '昨日，省人力资源和社会保障厅在其官方网站上公布了《关于长三角地区职工基本医疗保险关系转移接续的意见》、《关于对泛长三角地区异地居住企业退休人员养老保险待遇资格协助认证合作协议（征求意见稿）》等。根据意见稿，今后，江苏、上海、浙江和安徽有望在全国率先实现职工医保、失业保险关系转移，协助进行异地居住企业退休人员养老保险待遇的资格认证，还可以对异地就医医疗费用代办报销。\r\n<p><br />\r\n　　近年来，长三角各城市之间人员流动日益频繁，医保关系异地转移接续、养老金领取资格的异地认证、异地就医费用即时报销的愿望也越来越迫切。为此，江苏、上海、浙江和安徽三省一市的人力资源和社会保障厅（局）牵头成立了泛长三角地区社会保障合作专题组，在长三角地区建立医保定点机构的互认制度、异地就医医保费用代报销合作机制等方面进行了探索，并于近日出台了相关文件的征求意见稿。</p>\r\n<p><br />\r\n　　<strong>职工医保可在长三角内互转</strong></p>\r\n<p><br />\r\n　　在长三角职工医保关系转移接续的征求意见稿中，对医保关系转移的对象作出界定：应是在转出地已经参加城镇职工基本医疗保险，后因跨地区流动，医疗保险关系需随同转移，未达到国家法定退休年龄的人员，包括各类企业、机关、事业、灵活就业人员和农民工。转移时，应首先在转出地中止医保关系，办理注销手续，并出具其在当地的参保证明。转入地有接收单位的，由单位按照《社会保险登记管理暂行办法》的规定办理登记手续；其他流动人员应在30日内由个人到转入地办理登记参保手续。</p>\r\n<p><br />\r\n　　意见稿规定，在长三角不同统筹地区参保的年限和实际缴费年限，各地应予以承认，合并计算。</p>\r\n<p><br />\r\n　　<strong>异地就医费用代办报销</strong></p>\r\n<p><br />\r\n　　人员流动日益频繁的长三角地区，参保人员出于工作、学习需要，长期居住在异地或者退休由于无人照顾、随子女在异地定居或回原籍居住时，面临异地就医和报销的种种不便。记者了解到，目前泰州、扬州、南通等市已相继与江苏省异地就医平台联网，试运行比较平稳，到年底，其他各市也要跟省平台联网，明年13市之间互联，以便实现省内异地就医费用的即时结算。另外，镇江、常州、南通三市已实现跟上海的异地就医联网结算，当前长三角地区实现医保互通的城市已达9个。</p>\r\n<p><br />\r\n　　本次公布的《泛长三角地区医疗保险经办管理服务（征求意见稿）》规定，合作方应确保参保职工就地就医，就地结算。若能实现异地就医医保费用双向代报销，在长三角地区工作、生活的参保人就再也不用为报销医疗费用往返奔波，可实现当地看病、当地进行医保费用结算报销。</p>\r\n<p><br />\r\n<strong>　　养老金资格异地认证</strong></p>\r\n<p><br />\r\n　　对于居住在外地的企业退休人员来说，为能继续领取养老金，每年都要回参保地证明自己还活着，既麻烦又有点“触霉头”。而根据《关于对泛长三角地区异地居住企业退休人员养老保险待遇资格协助认证合作协议（征求意见稿）》，今后，在长三角地区异地居住的离退休人员，可在现居住地的社保经办机构或街道（乡镇）劳动保障工作机构进行资格认证，建议在每年第二季度（4-6月份）集中开展异地认证网上操作，统一认证时间、数据信息格式和认证工作流程。</p>', 'llz007', 0, 39),
(23, '我国高端医疗装备研制取得重大突破—16层CT、1.5T超导磁共振在东软问世', '', '', '', '2009-09-29 11:37:40', '116.228.141.77', '<p><font face="Verdana" size="2">16层CT、1.5T超导磁共振在东软问世，<br />\r\n向全球领先的医疗设备、医疗IT解决方案及健康服务提供商迈进</font></p>\r\n<p><font face="Verdana" size="2">　　8月28日，东软医疗系统有限公司（以下简称“东软医疗”）举行了主题为“创新·挑战·超越”的公司战略及新产品发布会，正式向全球发布其三款旗舰新品NeuViz 16多层螺旋CT、Sparkler 1.5T超导磁共振成像系统、Neulife直线加速器治疗系统，这标志着东软在CT、MRI以及治疗系统等高端医疗设备的研制与生产方面取得了新的重大突破。其中，NeuViz 16多层螺旋CT和Sparkler 1.5T超导磁共振成像系统的成功研制再次填补中国在该领域的空白，打破跨国公司多年来对中国和全球市场的垄断，中国也因此跻身到全球高端医疗设备生产国的行列。<br />\r\n　　东软医疗在发布3款旗舰新品的同时，还首次发布公司新的定位、愿景与使命。2009年伊始，东软集团着手对东软医疗业务进行重组和整合，先后将医疗软件事业部和健康服务业务并入东软医疗公司。如今，东软医疗公司业务定位为三个部分：大型或高附加值医疗设备产品与服务、医疗IT解决方案以及健康服务；东软医疗公司的愿景与使命是致力于成为全球领先的医疗设备，医疗IT解决方案及健康服务提供商，并通过医疗设备与IT技术的创新，服务于人类的健康。</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924135912894.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">　　沈阳市副市长邹大挺，沈阳浑南新区管委会主任黄凯等省市政府和有关部门领导，行业知名专家，国内外客户以及新闻媒体记者约700余人出席了东软医疗战略及新产品发布会，共同见证了东软医疗三款新品的闪亮登场和公司战略愿景的发布。<br />\r\n　　东软集团副总裁、东软医疗系统有限公司总裁江根苗在致辞中表示，从医院临床应用的发展趋势来看，16层CT和1.5T磁共振成像系统将成为今后高端医疗器械领域的主导机型，而我国的这一领域却长期被国际厂商所垄断。作为国内唯一的CT厂商，东软医疗16层CT的研制成功不仅打破了国际垄断、填补了中国在多层螺旋CT市场的空白，而且其首台产品已经出口美国，这标志着东软16层CT产品已经成功进入全球高端医疗市场。<br />\r\n　　据了解，东软医疗NeuViz 16多层螺旋CT以博采众长的技术特征、至臻的诊断效率、至善的患者关爱和高性价比的维护成本，实现了CT常规从形态学检查到功能性成像的飞跃，大幅缩短了中国CT技术与国际先进CT技术的差距。东软医疗Sparkler 1.5T超导磁共振成像系统的问世也同样打破了我国高场磁共振技术领域被外资企业垄断的局面。Sparkler1.5T超导磁共振基于临床实用性超导磁共振的定位，具有技术成熟、性能稳定和性价比高等特点，并以其高效快速的SENSE技术，强大的临床应用广受好评。有专家表示Sparkler 1.5T超导磁共振成像系统的推出将为医院磁共振的临床应用开展、医院医学影像的发展带来更加广阔的前景。<br />\r\n　　此外，Neulife直线加速器治疗系统是东软医疗面向广大医疗机构对肿瘤治疗的需求而研发的临床实用型数字化医用直线加速器，它的问世也标志着东软医疗正式进入放射治疗领域。随着该款直线加速器的推出，东软第一个面向基层的放疗解决方案应运而生——由CT模拟定位系统、治疗计划系统和加速器治疗系统组成的临床实用型流程方案既满足精确放疗的要求又便于放疗的普及推广。在此基础上，东软医疗还将提供EPID影像验证，动态楔形治疗以及行业放疗信息管理系统和肿瘤科管理系统，东软医疗的放疗解决方案将引领中国放疗行业尤其是基层放疗的技术应用达到新的高度。<br />\r\n　　东软集团董事长兼CEO刘积仁博士在讲话中表示，在国家、省、市各级领导的亲切关怀和大力支持下，12年来，东软医疗以“科技创造健康生活”的理念，不断创新、不断跨越，获得了快速发展。面向未来，随着信息技术、网络技术、医学影像学、医药学和数字化医疗设备之间的不断融合、优势互补，将使临床治疗达到新的水平，一方面现代大型医疗器械越来越向智能化方向发展，另一方面整个医疗模式将由过去单纯的医院内诊治为主的模式逐步发展为院前急救、临床诊治和康复保健结合的社区医疗、家庭护理的多元化的现代医疗保障体系，医疗IT和健康服务将成为医疗行业新的增长点。为了迎接这样一个全新时代的到来，东软已经整合全集团所有医疗行业的业务资源，确定了东软医疗新的业务定位与发展目标。我们希望通过3-5年的持续创新与不断努力，将东软医疗打造成为全球领先的医疗设备、医疗IT解决方案与健康服务的供应商。<br />\r\n　　刘积仁表示，东软在大力发展行业解决方案与服务外包产业的同时，将加大对发展医疗业务的投入，使医疗业务很快成为东软集团核心业务支柱并保持高速成长。与此同时，公司还将通过不断构建与加强市场能力、研发能力、运营能力；持续开发人力资源；深入理解与挖掘客户需求，以创新思维设计和开发具独特优势的解决方案与服务；不断提高运营速度和效率, 持续构建成本优势；不断提升技术核心能力与创新速度；坚持全方位的持续的质量改进，从而打造东软医疗的产品与服务品牌。<br />\r\n　　沈阳市副市长邹大挺在讲话中表示：在PET研制成功之后短短3个月的时间里，东软又推出了“16排CT、超导磁共振、直线加速器”三款高端新品，这是中国企业在高端医疗产品领域取得的重大突破，体现了东软医疗不断创新和开拓进取的精神。在当前全球金融危机的背景下，东软这种逆势而上的发展势头，已成为推进东北老工业基地振兴的重要力量，为中国的医疗健康产业做出了突出贡献，这是沈阳人的骄傲！他希望东软能够继续坚持科技创新和国际化发展的理念，不断研制和推出更多、更先进并且更加适用的高端医疗产品与服务，惠及民生，让百姓受益于中国的高科技产品与服务。<br />\r\n　　中国是一个拥有13.5亿人口的大国，医疗设备需求庞大，是世界上最大的普及型医疗器械市场，而长期以来我国高端医疗设备主要依赖进口。专家认为，东软医疗在CT、MRI、PET高端医疗设备方面获得的突破，将打破我国高端设备长期被国外厂商垄断的市场格局，并推动高端医疗设备更广泛地应用于临床诊断，使得高端医疗设备服务百姓，惠及民生成为现实。<br />\r\n（科讯网）</font></p>', 'gwm', 0, 31),
(24, '2009年青岛PET（/CT）读片会和学术研讨会评奖结果', '', '', '', '2009-09-29 11:42:46', '116.228.141.77', '<p><font face="Verdana" size="2">大会发言</font></p>\r\n<p><font face="Verdana" size="2">1 优秀病例<br />\r\n一等奖：李立伟 　空军总医院<br />\r\n二等奖：尹雅芙 　中国医科大学附属第一医院<br />\r\n　　　　陈　雯 　卫生部北京医院<br />\r\n三等奖：靳晓娜 　北京协和医院<br />\r\n　　　　邵　丹　 广东省人民医院<br />\r\n　　　　陈虞梅　上海交通大学医学院附属仁济医院</font></p>\r\n<p><font face="Verdana" size="2">2 思辨奖<br />\r\n吴湖炳&nbsp;&nbsp; 南方医院<br />\r\n周&nbsp; 硕&nbsp;&nbsp; 福建省立医院<br />\r\n梁英魁&nbsp;&nbsp; 海军总医院<br />\r\n宋秀宇&nbsp;&nbsp; 天津医科大学附属肿瘤医院<br />\r\n杨&nbsp; 鹏&nbsp;&nbsp; 深圳市PET/CT中心<br />\r\n张敬勉&nbsp;&nbsp; 河北医科大学第四医院</font></p>\r\n<p><font face="Verdana" size="2">壁报</font></p>\r\n<p><font face="Verdana" size="2">1 优秀壁报<br />\r\n赵　葵&nbsp;&nbsp; 浙江大学医学院附属第一医院<br />\r\n田　野&nbsp;&nbsp; 四川大学华西医院<br />\r\n钟尉端&nbsp;&nbsp; 卫生部北京医院</font></p><font face="Verdana">\r\n<p><br />\r\n<font size="2">2 壁报病例PET/CT诊断竞赛优胜奖<br />\r\n王　欣&nbsp;&nbsp;&nbsp; 哈尔滨肿瘤医院<br />\r\n李文婵&nbsp;&nbsp;&nbsp; 卫生部北京医院<br />\r\n曲莉莉&nbsp;&nbsp;&nbsp; 齐鲁医院<br />\r\n王建方&nbsp;&nbsp;&nbsp; 河北医科大学第四医院<br />\r\n董孟杰&nbsp;&nbsp;&nbsp; 浙江大学医学院附属第一医院<br />\r\n梁英魁&nbsp;&nbsp;&nbsp; 海军总医院<br />\r\n赵新明&nbsp;&nbsp;&nbsp; 河北医科大学第四医院<br />\r\n赵晋华&nbsp;&nbsp;&nbsp; 上海市第一人民医院<br />\r\n张雯杰&nbsp;&nbsp;&nbsp; 中国医学科学院肿瘤医院<br />\r\n宋建华&nbsp;&nbsp;&nbsp; 上海市第一人民医院<br />\r\n&nbsp;<br />\r\n青年读片竞赛参赛：</font></p>\r\n<p><font size="2">一等奖：上海队&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n市一医院 宋建华<br />\r\n肿瘤医院 杨忠毅<br />\r\n瑞金医院 徐昊平<br />\r\n仁济医院 陈虞梅<br />\r\n二等奖：北京队<br />\r\n海军总医院 梁英魁<br />\r\n宣武医院 苏玉盛<br />\r\n北京医院 陈&nbsp; 雯<br />\r\n医科院肿瘤医院 张雯杰<br />\r\n解放军总医院 关志伟<br />\r\n三等奖：东北队<br />\r\n哈尔滨肿瘤医院 王&nbsp; 欣<br />\r\n吉林大学第一医院 赵红光<br />\r\n黑龙江农垦医院 张嘉文<br />\r\n中国医大一附院 李雪娜</font></p>\r\n<p><font size="2">优秀奖：<br />\r\n中部西部队&nbsp; <br />\r\n四军医大西京医院 王胜军<br />\r\n华西医院 苏鸣岗<br />\r\n内蒙古医学院 张国建<br />\r\n武汉协和医院 魏&nbsp; 昊</font></p>\r\n<p><font size="2">华东华北队<br />\r\n南京军区总医院 吴&nbsp; 江<br />\r\n福建省立医院 周&nbsp; 硕<br />\r\n烟台毓璜顶医院 徐志英<br />\r\n天津医大肿瘤医院 宋秀宇<br />\r\n河北医大四院 张敬勉</font></p>\r\n<p><font size="2">广州队<br />\r\n中山大学第一医院 王晓燕<br />\r\n广州医学院附一院 陈仰纯<br />\r\n广东省人民医院 王思云<br />\r\n中山大学肿瘤医院 张&nbsp; 旭<br />\r\n（中华核医学专业网）<br />\r\n</font></p></font>', 'gwm', 0, 34),
(25, '厦门市第一医院举行双源CT等大型影像设备开机典礼', '', '', '', '2009-09-29 11:43:41', '116.228.141.77', '<font face="Verdana" size="2">8月29日，双源CT等大型影像设备开机典礼暨福建省影像学新进展研讨会在厦门市第一医院隆重举行。厦门市人大常委会副主任曾国玲出席了典礼。<br />\r\n&nbsp;&nbsp; 　专程来厦祝贺的中华医学会放射学分会主委郭启勇评价说，厦门市第一医院此次启用的双源CT、3T磁共振、双板DSA均是目前国内最先进的医疗设备，可以在更短的时间内提供更精确详细的检查，使病变的显示率和诊断精确度明显提高，为介入治疗开拓了许多新的应用领域。以双源CT为例，它的辐射量只有常规CT的50%，最大限度地保护了患者的健康和安全；它还可用于早期无创筛查冠心病，其成像成功率是传统CT无可比拟的。而3T磁共振是目前场强最高的磁共振，以前磁共振扫描脑部需20多分钟，3T磁共振则只需5分钟。<br />\r\n&nbsp;&nbsp; 　据悉，厦门市第一医院筹资引进的双源CT、3T磁共振、双板DSA这3个医疗设备均是闽南惟一的。院长杨叔禹表示，该院引进这些设备是为了进一步加快学科建设、提高医疗水平，随着这些设备的启用，该院的综合实力将大大增强，可以更好地满足厦门及周边地区百姓疑难病症检查治疗的需求。<br />\r\n（科讯网）</font><br />\r\n', 'gwm', 0, 28),
(26, '太原市旅游局：长假出游做好甲型H1N1流感预防', '', '', '', '2009-09-29 13:16:00', '116.228.141.77', '28日，太原市旅游局发布“十一”黄金周出游提示：要做好甲型H1N1流感预防，尽量避开人员密集、通风不良的场所，同时注意保持个人卫生和饮食安全。出境旅游返回后一周内，最好避免前往人员密集的公共场所。行程中和返回后，一旦发生流感样症状要及时就医。 \r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;市旅游局提醒游客，出行前，要做好身体、装备和资讯等方面的准备，关注旅游、气象和外交等有关部门发布的出行提示，行前购买个人旅游保险。旅游消费尽量使用信用卡、借记卡等，不要携带大量现金。行程中一旦发生意外事件及时报警，必要时向事发地人民政府有关部门或我国驻当地使领馆、政府派出机构求助。 （任晓明）</p>', 'gwm', 0, 27),
(27, '火锅底料国家标准有望出台 麻辣度将分等级', '', '', '', '2009-09-29 13:44:27', '116.228.141.77', '<p align="center"><img alt="火锅底料国家标准有望出台 麻辣度将分等级" src="http://img1.gtimg.com/cd/pics/21878/21878254.jpg" />\r\n</p>\r\n<p align="center"><span style="font-size:12px;">调制火锅底料 新华社</span></p>\r\n<p>　　本报讯 记者昨日获悉，由国家农副加工产品及调味品质量监督检验中心(以下简称“调味品中心”)负责起草的《火锅底料国家标准》有望年内出台。该《标准》由重庆主导，目前已通过国内40余位专家审查，报批稿现已报国家标准化委员会审批。</p>\r\n<div>\r\n<table class="rline" cellspacing="0" cellpadding="0" width="300" border="0">\r\n<tbody>\r\n<tr>\r\n<td width="298">\r\n<table cellspacing="0" cellpadding="0" width="280" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td></td></tr></tbody></table></td></tr></tbody></table></div>\r\n<p>　　<strong>未涉及火锅老油</strong></p>\r\n<p>　　据记者了解，起草《标准》的“调味品中心”是重庆市技术监督局的下设机构，其所采样的火锅底料也大多来自重庆。</p>\r\n<p>　　据领衔起草《标准》的“调味品中心”副主任李沿飞介绍，《标准》报批稿对麻辣火锅底料的定义是以动植物油脂、食盐、豆瓣、辣椒、花椒等香辛料等为主要原料，经炒制加工或部分熬制，配装或不配装其他辅料包装而成，并未涉及长期处于争议的火锅老油。</p>\r\n<p>　　重庆火锅协会称，我市对火锅老油标准的起草已开展了多年，今年还将扩大样本的采集，一旦具有传统工艺的老油通过检验，今后火锅企业在底料上，都将注明是一次性火锅底料或者传统工艺老油火锅底料，由消费者自行选择消费。</p>\r\n<p>　　李沿飞还说，原来这部标准全称叫《麻辣火锅底料国家标准》，后报国家标准委时，因考虑到全国各地风味、口感不一，才没有把“麻辣”的技术要求写进国标，于是去掉了“麻辣”二字。</p>\r\n<p>　　<strong>老油也不能多用</strong></p>\r\n<p>　　尽管老油未被写入国标，但在国标中有一个重要指标“酸价”对此作了考虑。</p>\r\n<p>　　屠大伟称，酸价是油脂精炼程度和品质好坏的重要标志。油脂的酸价超标通常有两个原因：一是加工中脱酸工艺不达标，二是储藏中发生氧化或水解反应产生羧酸。反复多次使用的食用油或已酸涩的“哈喇味”油，其酸价会升高许多。</p>\r\n<p>　　2003年重庆出台的“火锅底料地方标准”中，酸价指标要求是不高于4，而国标则将标准提升至不高于3.5。周君记、胖子天娇等参与国标起草的底料生产企业负责人介绍，酸价超标意味着油开始腐败变质；老油如果过多地用在底料中，也会被检测出来；那底料也就不达标。</p>\r\n<p>　　<strong>麻辣味要分等级</strong></p>\r\n<p>　　有人怕辣，有人不怕辣，有人怕不辣。“调味品中心”博士屠大伟介绍，今后重庆生产的火锅底料，完全能标明相应的辣度。</p>\r\n<p>　　屠大伟说，国际上辣度分15级，评定辣度的方法、基本过程是：把辣椒制备成一定量的辣椒素提取物，然后稀释，由5名训练有素的品尝师品尝。若仍感到辣味，则继续稀释，直到5名品尝师都感觉不到辣味为止。这时稀释倍数就是这种辣椒的辣度数值。辣度数值越高，辣椒也就越辣。</p>\r\n<p>　　屠大伟介绍，目前国际标准化组织已确认并制定了辣度单位的测定标准，且在全球辣椒贸易中使用该标准衡量辣椒及其制品的质量。</p>\r\n<p>　　接下来，对麻的程度，究竟是微麻、中麻、老麻，各火锅底料企业生产时，完全凭调料师口感掌握，一直缺乏标准。屠大伟介绍，“调味品中心”目前正与西南大学联合攻关，研究麻度与感官间的关系。一旦这个课题攻关成功，将率先补充进入重庆地方标准。</p>\r\n<p>　　<strong>禁用石蜡苏丹红</strong></p>\r\n<p>　　即将出台的《标准》征求意见稿中，明确将石蜡和苏丹红列入“不得检出”范围，同时还明确了石蜡的定性检测方法。</p>\r\n<p>　　不过，在报批稿中，“禁用石蜡和苏丹红”则未被纳入国标。屠大伟解释称，这是因为卫生部已经明确将苏丹红、吊白块等列入非法食品添加剂的范畴，制定国标就不必再重复。另外，尽管石蜡目前尚未进入“黑名单”，但这是迟早的事。</p>\r\n<p>　　另外，与2003年重庆出台的地方标准相比，国标征求意见稿考虑增加对辣椒、花椒的要求和农药残留量检测，但后考虑到各企业承受能力，也取消了这一要求。李沿飞表示，随着科技发达和人们生活水平的提升，这一点也会迟早写入国标。</p>', 'gwm', 0, 13),
(28, '狂犬病高发期 专家：被动物咬伤后首当冲洗伤口', '', '', '', '2009-09-29 13:45:39', '116.228.141.77', '<p>【龙虎网报道】昨天是狂犬病防治日。在省、市疾控部门举行的大型狂犬病防治咨询活动上，记者获悉，去年全省有83人死于狂犬病，南京地区也有近十例。目前正是狂犬病高发期，专家提醒市民被动物咬伤后，要立即以流动水冲洗伤口，然后再去打疫苗。</p>\r\n<p>　　省疾控中心透露，从我省发病人群的年龄分布上看，5—15岁人群发病数和发病率均出现高峰，这可能与儿童或青少年喜欢嬉逗动物且自我防护意识和能力较低有关；15—30岁发病率为各年龄段最低；30岁后随着年龄增加，男女的发病率均逐渐上升，至70—75岁达到高峰。另外，发病最多的人群为农民，占60%左右；其次为学生和散居儿童。</p>\r\n<p>　　市疾控中心专家胡洪宝介绍，一旦被动物咬伤后，要立即用流动的水冲洗伤口，伤口深的地方最好用器具灌注冲洗，其后再用20％浓度的肥皂水或弱碱性清洁剂对伤口再次清洗，清洗时间至少在15分钟以上，有条件的最好再用酒精消毒。然后立即接种狂犬病疫苗，伤势较重的人，最好再联合注射狂犬病免疫球蛋白或抗狂犬病毒血清。</p>', 'gwm', 0, 31),
(29, '蔬菜择优食用便可疗疾养生', '', '', '', '2009-09-29 13:47:15', '116.228.141.77', '<p>家常蔬菜营养不俗： </p>\r\n<p>　　常见蔬菜是人们生活必不可少的，也是老百姓经常常食用的，那么它们有什么营养和药用价值也是大家所关心的问题。下面向大家介绍几种常见蔬菜的营养作用与食疗功效。 </p>\r\n<p>　　萝卜： </p>\r\n<p>　　除含有蛋白质外，还含有各种糖类、丰富的维生素，特别富含胡萝卜素，它还含有许多人体必需的矿物质和微量元素，以及各种酶类。 </p>\r\n<p>　　萝卜所含的核黄素及钙、铁、磷等，比梨、橘子、苹果还要高，尤其维生素C含量比梨和苹果高6-10倍，被称为“不是水果，胜似水果”。 </p>\r\n<p>　　萝卜具有特殊的解腥能力。萝卜也有较好的药用价值，有“十月萝卜小人参”之说法。它有通气行气、健胃消食、解毒散瘀等功能，可除食积胀满、头痛、糖尿病等症。还有防癌和减肥作用。 </p>\r\n<p>　　白菜： </p>\r\n<p>　　被誉为“百菜之王”。所含的矿物质和维生素的量大致和萝卜相似，钙和维生素C含量均比苹果高5倍以上，核黄素含量高于苹果和梨3-4倍。所含微量元素锌高于肉类和蛋类。 </p>\r\n<p>　　白菜有养胃消食之功，可治胃阴不足、消化不良、十二指肠溃疡等症。还有清热解渴、止咳、抗癌等作用。 </p>\r\n<p>　　马铃薯： </p>\r\n<p>　　有地下苹果之称。富含糖类，含有较多的蛋白质和少量脂肪，也含有粗纤维、钙、铁、磷，还含有维生素C、维生素B1、维生素B2以及分解产生维生素A的胡萝卜素。 </p>\r\n<p>　　每100克鲜马铃薯所产生的热量达318千焦。比一般谷物食品高1倍多，比萝卜、甘蓝则高2倍。同等重量的马铃薯的营养价值是苹果的3.5倍。 </p>\r\n<p>　　马铃薯有和胃调中、健脾益气、强身益肾等作用，可治神疲乏力、筋骨损伤、心脏病、关节肿痛等。马铃薯还是断奶婴儿的好食品。 </p>\r\n<p>　　黄瓜： </p>\r\n<p>　　蛋白质含量虽少，但其中有精氨酸等人体必需氨基酸，对肝脏病人很有帮助。另外，脂肪含量甚低，糖的种类则较多，如葡萄糖、甘露糖、果糖等，并含有多种维生素、胡萝卜素、钙、磷、铁等，所含抗坏血酸高出西瓜4倍多。 </p>\r\n<p>　　黄瓜还有泽肌悦面、降低胆固醇、减肥等作用。 </p>\r\n<p>　　西红柿： </p>\r\n<p>　　含有多种营养成分，所含维生素C是苹果的2倍，蛋白质相当于苹果的3倍，硫胺素相当于苹果的5倍，钙、磷含量则高于苹果2-3倍，维生素A含量是莴笋的15倍。碳水化合物只有苹果的1/6，是理想的低热量营养果品。烟酸的含量位果品之冠。 </p>\r\n<p>　　西红柿有生津止渴、健胃消食、清热消暑、补肾利尿等功能，可治热病伤津口渴、食欲不振、暑热内盛等病症。它有显著止血、降压、降低胆固醇作用，对治疗血友病和癞皮病有特殊功效。 </p>\r\n<p>　　茄子： </p>\r\n<p>　　含有丰富的营养物质，其含量可与西红柿媲美，除维生素A、维生素C含量低于西红柿外，其余各类维生素、脂肪、磷、铁和糖类都非常接近，而所含的蛋白质和钙量高于西红柿3倍，热量高1倍。 </p>\r\n<p>　　此外，还含有胡萝卜素、硫胺素、核黄素以及人体所必需的8种氨基酸，所含的维生素E为茄果类中之魁，常食它具有提高人体对各种疾病的抵抗力和抗衰老功能。 </p>\r\n<p>　　茄子具有活血散瘀、清热解毒、祛风通络等功能，可治疗肠风下血、热毒疮疡、皮肤溃烂等症。茄子对降低胆固醇有独特之功，还可预防冠心病。</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 30),
(30, '我国心脏猝死发生率北方人多过南方人', '', '', '', '2009-09-29 13:48:57', '116.228.141.77', '<p>　信息时报讯 （记者 成小珍 通讯员 王海芳） 昨日，记者从中山大学心肺脑复苏研究所了解到，据最新心脏性猝死流行病学调查，我国心脏性猝死（SCD）发生率为41.84例/10万人。其中，北方心脏性猝死的发生率高过南方。</p>\r\n<p>　　调查采用人群监测的方法，在北京市、广州市和新疆分别选取20.6万、14.9万、16.0万城市居民，在山西省选取16.2万农村居民进行发病情况监测。北京市、广州市、盂县和克拉玛依市，心脏性猝死分别占总死亡的13.4%、8.5%、7.7%和8.3%。</p>\r\n<p>　　中山大学心肺脑复苏研究所所长、中山二院急诊科主任黄子通教授表示，这个调查也说明，就地域上来说，北方心脏性猝死的发生率高过南方，其中的原因，和气候、居住环境、饮食习惯都有关系，如北方人喜欢大鱼大肉，好喝酒等等。</p>', 'gwm', 0, 29),
(31, '夏末初秋这些疾病最该留神', '', '', '', '2009-09-29 13:50:45', '116.228.141.77', '<p>夏末初秋的天气既热又透出一丝的微凉，清晨感觉到阵阵的凉意，而到中午的时候太阳又让人感到热得难适应。稍不留神，一些疾病就可能悄然而至，而最容易在夏秋之交伺机而动的疾病有以下几种，因此提醒不同年龄的人都应该注意保护自己的身体防止这些疾病的伤害。</p>\r\n<p>　　肺结核：秋季户外活动多，容易在不知情的情况下与传染性结核病人有近距离接触引起感染。因此，当出现脸红、低烧、乏力、盗汗、咳嗽、吐痰等情况时，应提高警惕。要树立不随地吐痰传播疾病的意识，尽量减少在人员密集的公共场所久留，工作和生活区要保持通风，减少居住拥挤。有传染性结核病人的家庭或群体也不要恐慌，只要采取正确的预防方法就能避免感染。患者的用品和卧具，在阳光下直射5分钟即可杀死病菌，患者的痰可用纸巾包起而后烧掉。</p>\r\n<p>　&nbsp; 感冒：秋天气候变化异常，是感冒等上呼吸道感染病的高发季节。此时感冒的预防，要注意随温度变化选择衣物，增加户外活动，保持工作环境的良好通风至关重要;要适当多饮水，多吃水果;经常使用冷水洗脸洗鼻，也有助于感冒的预防。</p>\r\n<p>　　另外，尽量避免接触感冒患者，接触到感冒患者或他们碰触过的东西后要洗手，手指还要远离眼睛和鼻子。在感冒流行时可用陈醋熏蒸居室。</p>\r\n<p>　　气管炎：秋季是慢性气管炎的高发期，它对气候的变化较敏感，且适应性差，易因上呼吸道感染而发病，因此要针对气管炎反复发作、迁延不愈的特点，积极配合治疗。秋季草枯叶落，空气中过敏物较多，这也是诱发气管炎的病因之一，故应避免与过敏源接触。要注意保持良好的情绪，以增强身体的免疫力和抵抗力，并要改善居室环境，保持室内空气流通。</p>\r\n<p>　　肺炎秋燥症：入秋时节，因湿度降低而出现秋燥，而秋燥对人体危害最大的部分是肺部，因此，应积极锻炼，增强肺功能，预防肺炎的发生。要注意饮食方面的调养，少吃辛辣食物，多吃养阴润肺的食物，如梨、萝卜等，以增强肺部的水分。</p>\r\n<p>&nbsp;&nbsp;&nbsp; 肠胃炎症：秋季病菌繁殖快，食物易腐败，是细菌性食物中毒、细菌性痢疾、大肠杆菌肠炎、冰箱性肠炎等肠道疾病的多发季节，同时秋季也是胃病的多发与复发季节。如果防护不当，不注意饮食和生活规律，就会引发胃肠道疾病而出现反酸、腹胀、腹泻、腹痛等症，或使原来的胃病加重。</p>\r\n<p>　　防止腹部受凉是预防胃肠炎的重要措施。还要加强锻炼，注意饮食调养，胃病患者的饮食应以温、软、淡、素、鲜为宜，做到少吃多餐，同时还应注意进食时细嚼慢咽，以利于消化吸收，减轻胃肠负担，并要保持精神愉快和情绪稳定，同时，注意劳逸结合，防止劳累过度。</p>\r\n<p>　　关节炎：入秋之际，一方面暑湿蒸腾，另一方面又寒意袭人，极易发生外寒内湿的关节痛症。有关节炎病史者，可选食猪蹄炖海风藤、木瓜鸡蛋酒，以祛风通络、化湿止痛。还可用当归、鸡血藤、桂枝、杜仲等煎汤药浴，对防止关节炎发作有积极作用。患者应注意防寒保暖，尤其是大汗后不宜立即接触冷水或用冷水洗澡。</p>\r\n<p>　　皮肤感染：秋季，皮肤易被病原寄生虫和蚊虫叮咬出现红肿且奇痒，搔抓后可继发细菌感染，出现脓疱疮(疹)。被蚊虫叮咬之后切记不可抓搔，可涂抹风油精、清凉油消肿止痒。<br />\r\n</p>', 'gwm', 0, 22);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(32, '药监局恢复万荣三九药业鱼金注射液肌肉注射', '', '', '', '2009-09-29 14:11:19', '116.228.141.77', '<p>中新网9月29日电 日前，国家食品药品监督管理局发出通知，决定恢复万荣三九药业有限公司生产的鱼金注射液(2ml)肌肉注射使用。</p>\r\n<p>　　《通知》说，根据《关于鱼腥草注射液等7个注射剂有关处理决定的通知》和《关于肌注用鱼腥草注射液等注射剂恢复使用申报资料和程序的通知》的有关要求，国家局组织对万荣三九药业有限公司申请恢复鱼金注射液(2ml)肌内注射使用的申请资料进行了审查，对生产情况和条件进行了现场核查，并进行了抽样检验，结果符合恢复鱼金注射液肌内注射使用的相关要求。国家局同意恢复万荣三九药业有限公司鱼金注射液(2ml)肌内注射使用。</p>\r\n<p>　　《通知》要求各省(区、市)药监部门通知辖区内药品使用单位，由山西省食品药品监督管理局通知万荣三九药业有限公司，并加强监管工作。</p>', 'gwm', 0, 25),
(33, '防乳腺癌专家推荐海带白萝卜汤', '', '', '', '2009-09-29 14:13:46', '116.228.141.77', '<img alt="防乳腺癌专家推荐海带白萝卜汤" src="http://fashion.ef360.com/EditManager/UploadFashion_45/20099299859715.jpg" />\r\n\r\n&nbsp;\r\n<p>　　经常食用海带、紫菜等海产品，可以帮助防治乳腺癌。日前在健康时报与北京同仁医院联合举办的金钥匙健康大讲堂上，北京同仁医院普外科主任医师肖晖建议大家：海带、紫菜富含天然碘元素，女性朋友可以多吃一点。</p>\r\n<p>　　世界卫生组织人体营养专家委员会将人体必需的微量元素列出，其中碘为重要元素，其次为锌、硒、铁等。</p>\r\n<p>　　有医学研究表明，常吃含碘的海带、紫菜等海藻类食物可防止乳腺癌的发生。</p>\r\n<p>　　日本妇女比美国妇女的乳腺癌发病率低得多，可能与日本人喜欢吃海藻类食物的传统饮食习惯有关。</p>\r\n<p>　　研究发现，肿瘤患者的血液多呈酸性，而海藻类食物，能调节和平衡血液的酸碱度，从而起到一定的防癌作用。此外，海藻类食物还有清热解毒、软坚散结的作用，这与中医理论中防治乳腺癌的观点相一致。</p>\r\n<p>　　卫生部中日友好医院中医肿瘤科主任李佩文证实，不仅乳腺癌，卵巢癌、子宫内膜癌也都与缺碘有关。</p>\r\n<p>　　在我国南方，居民生活每餐必有汤，所以进食紫菜的机会也多，北方女性在用餐时如果重视紫菜的重要性同样可以经常食用紫菜。</p>\r\n<p>　　而海带的食用方法就更多了，南方多用于煲汤，北方以炖和凉菜为主。</p>\r\n<p>　　专家推荐海带白萝卜汤是最佳搭配。因为萝卜能顺气宽中，消积滞、化痰热，是药食同源的食物。</p>\r\n<p>　　而且科学研究发现，萝卜所含的吲哚类物质可抑制动物肿瘤的生长，萝卜中的纤维木质素可提高巨噬细胞吞噬细菌、异物和坏死细胞的功能，从而加强人体的抗癌能力。</p>\r\n<p>　　专家还告诫：少女月经初潮过早，会促进乳癌发生，女孩一定少吃油炸快餐。高纤维食物可减少食物中胆固醇吸收，使以胆固醇为原料的女性激素合成减少，使女性月经初期推迟。所以说高纤维的饮食可减少乳癌的发生率。<br />\r\n</p>', 'gwm', 0, 48),
(34, '血液测试可以检测出直肠癌', '', '', '', '2009-09-29 14:15:26', '116.228.141.77', '<p>　本报讯 英国《泰晤士报》21日报道，研究人员21日表示，新的血液测试能够帮助医生更简单、更便宜、更早地探测出病人是否身患结肠癌症和胃癌，让病人免受手术之苦。</p>\r\n<p>　　比利时生物医药公司OncoMethylome的约斯特·罗瓦吉团队分析了193名结肠癌症患者以及688名使用结肠镜检测的病人的血液样本；德国查特里医学院的乌尔里克·斯坦团队分析了158名结肠癌患者、190名直肠癌、91名胃癌患者以及51名没有肿瘤的志愿者的血液样本。</p>\r\n<p>　　分析结果显示，在这些癌症病人体内，S100A4基因的浓度明显偏高，在癌症已经扩散的病人身上，S100A4基因的浓度更高。S100A4基因在多种恶性肿瘤细胞中高表达，它可能在恶性肿瘤细胞的侵袭和转移等过程中发挥重要作用。</p>\r\n<p>　　斯坦同罗瓦吉一起在柏林举行的第15届欧洲癌症大会暨欧洲肿瘤内科学会上宣读了相关研究结果。罗瓦吉的团队也发现了两个甲基化基因SYNE1和 FOXE1，这两个基因同肿瘤的形成有关，结肠癌患者体内，这两个基因的浓度明显偏高。</p>\r\n<p>　　尽管在目前，结肠镜检查或者粪便样本的分析等方法效果不错，但是，它们都是侵入式的，昂贵而且让人不舒服。而血液测试很简单，护士或者保健医生就可以取出血液样本，无需特殊设备或者经过特殊训练。</p>\r\n<p>　　荷兰鹿特丹伊拉兹马斯摩纳哥大学医学中心胃肠肝病室主任恩斯特·奎帕斯表示，新测试表明，科学家可以研发出更高效的扫描技术。</p>\r\n<p>　　斯坦称，如果医生能够在病人的血液中探测到S100A4基因，就可以监控癌症的恶化情况，医生也能够在几年的治疗过程中进行监控。</p>\r\n<p>　　在美国和欧洲，直肠癌是第二大致人死亡的癌症“杀手”，每17个人中，就有一人患直肠癌，每年，大约有56万人罹患该癌症，25万人因此而亡。如果癌症能够早点被诊断出来，死亡率可能会大大降低。</p>', 'gwm', 0, 44),
(35, '生活家健康指南：透过手指疼痛有病可先知', '', '', '', '2009-09-29 14:17:30', '116.228.141.77', '健康的身体是我们每一个人更好地生活、工作和学习的基础，是做任何事情的首要前提。健康需要有乐观开朗的生活态度，同时健康也来自我们每一天良好的生活习惯。生活家小编为您精选了一些保健养生知识、健康小窍门，助您更好、更科学地调理好自己的身体，健康快乐地度过每一天！ \r\n<p><font>&nbsp;&nbsp;&nbsp; 健康的身体是我们每一个人更好地生活、工作和学习的基础，是做任何事情的首要前提。健康需要有乐观开朗的生活态度，同时健康也来自我们每一天良好的生活习惯。生活家小编为您精选了一些保健养生知识、健康小窍门，助您更好、更科学地调理好自己的身体，健康快乐地度过每一天！</font></p>\r\n<p><font>　　五根手指，各司其职，相互配合，才完成了各种复杂的工作；而同样的五根手指，从中医角度讲，又各主不同的脏器，相互补充，才保障了全身气血的顺畅。</font></p>\r\n<p><font>　　一般来说，拇指对应肺部经络，主心脏和肺；食指对应肺、大肠经络，能反映出肝脏、肺、胃和大肠的健康；中指有心包经通过，对应心、肝脏和血液循环系统；无名指为三焦、心包经络，对应脏腑是肺；小指对应心和小肠经络，主肾脏、循环系统。 </font></p>\r\n<p><font>　　一、拇指 </font></p>\r\n<p><font>　　突然出现拇指疼痛，可能提示心血管、肺部疾病。 </font></p>\r\n<p><font>　　但老人由于肢体末梢神经感觉较差，对这类疼痛不敏感，需同时观察其他症状。如伴有咳嗽、气喘、胸部胀满、心慌、心烦等，可经常按压双手拇指，刺激心肺经络，缓解症状。 </font></p>\r\n<p><font>　　二、食指 </font></p>\r\n<p><font>　　食指疼痛可能提示肺、大肠疾病，同时伴有咽喉肿痛、咳嗽、发热、出汗、呼吸急促、口干、牙痛、腹泻或便秘症状的人，应经常按压双手食指，刺激肺、大肠经络。 </font></p>\r\n<p><font>　　三、中指 </font></p>\r\n<p><font>　　中指疼痛可能提示肝脏、心脏疾病，如同时伴有胸闷、心悸、心烦、烦躁易怒等症状，建议经常按压双手中指，有缓解之效。 </font></p>\r\n<p><font>　　四、无名指 </font></p>\r\n<p><font>　　无名指疼痛，并伴有咳嗽、气喘、心烦口渴、痰多等症状的，可能提示肺脏疾病，要经常按压双手无名指。 </font></p>\r\n<p><font>　　五、小指 </font></p>\r\n<p><font>　　小指疼痛，提示肾脏和小肠疾病，可能同时伴有尿频、尿急、腰酸、腹泻等症状，这类患者可经常按压双手小指。 </font></p>\r\n<p><font>　　按压手指时，由掌心向指端方向，力度适中，频率一致，每次5分钟左右，每天2-3次即可。按压后轻甩双手放松。但必须提醒的是，按压手指仅作保健参考，如出现比较严重的症状，应立即到医院就诊。</font></p>', 'gwm', 0, 33),
(36, '女性服用抗抑郁症药物五朵金花有禁忌', '', '', '', '2009-09-29 14:21:30', '116.228.141.77', '<p>&nbsp;抑郁症患者都知道，服用抗抑郁症药物是控制抑郁症病情最快速的方法。然而心理学家经过多年临床治疗实践发现，女性抑郁症患者在服用抗抑郁症药物时，特别需要注意有些药品不能与之合用。</p>\r\n<p>&nbsp;&nbsp;&nbsp; 抗抑郁症药物中的五朵金花</p>\r\n<p>&nbsp;&nbsp;&nbsp; 目前临床上治疗抑郁症最常用的药物是选择性五羟色胺再摄取抑制剂，简称SSRI。抑郁症是由于大脑五羟色胺功能降低所致，这类药物如同高精度制导导弹，特异性地增加大脑五羟色胺的功能。SSRI包括氟伏沙明、氟西汀、西酞普兰、舍曲林和帕罗西汀，在精神科被称为抗抑郁症药物的“五朵金花”。</p>\r\n<p>点击浏览下一页</p>\r\n<p>&nbsp;&nbsp;&nbsp; 女性患者服药有禁忌</p>\r\n<p>&nbsp;&nbsp;&nbsp; 女性一生要跟各种各样的药物打交道。青春期女孩会使用复合维生素、减肥药，一些青年女性还不可避免地使用避孕药，妊娠期间会用各种营养品、保胎药，更年期使用各种激素替代疗法，老年女性合并使用治疗高血压、糖尿病、冠心病等药物。这些药物与抗抑郁药一旦发生相互作用，严重者可危及生命。</p>\r\n<p>&nbsp;&nbsp;&nbsp; 例如，维生素C和某些抗抑郁药物使用会增加胃肠道出血危险；常用避孕药是禁止和抗抑郁药物合并使用的；某些减肥药和抗抑郁药物在药理作用方面是一样的，因此合用时很容易发生药物相互作用；氟伏沙明与特非那丁合用会导致尖端扭转性心律失常。</p>\r\n<p>&nbsp;&nbsp;&nbsp; 此外，氟西汀与抗惊厥药物、β受体阻断剂、抗凝剂、苯二氮卓类、抗组胺药等有相互作用。帕罗西汀与肾上腺素、β受体阻断剂、抗心律失常药类及其他一些抗精神类药物有相互作用，等等。</p>\r\n<p>&nbsp;&nbsp;&nbsp; 心理专家表示，由于个人体质、服药史、抑郁病情存在不同差异，因此在选用抗抑郁症药物进行抑郁症治疗时，应由心理医生根据患者的具体情况作出综合判断，进而确定患者应服用哪种抗抑郁症药物，并谨遵医嘱服药。如果您还想了解更多抗抑郁药的信息，或者对抑郁症等心理问题感兴趣，欢迎随时连线我们的在线心理医生进行免费咨询。 </p>', 'gwm', 0, 49),
(37, '派康网成功启动在线预约服务', '', '', '', '2009-09-29 14:38:56', '116.228.141.77', '&nbsp;&nbsp;&nbsp; 在国庆前夕，派康网成功启动在线客服系统，在周一至周五工作时间，在线客服随时在线，访客将可以和在线客服进行无畅通的交流，欢迎新老客户体验前来咨询、预约，体验在线交流的通畅自由。', 'gwm', 0, 56),
(38, '卫生机构10月实施绩效工资', '', '', '', '2009-10-08 11:09:38', '116.228.54.246', '从2009年10月1日起，配合医药卫生体制改革，特别是实行基本药物制度，在疾病预防控制、健康教育、妇幼保健、精神卫生、应急救治、采供血、卫生监督等专业公共卫生机构和乡镇卫生院、城市社区卫生服务机构等基层医疗卫生事业单位实施 \r\n<p><br />\r\n　　从2010年1月1日起，在其他事业单位实施。事业单位实施绩效工资的同时，对离退休人员发放生活补贴</p>\r\n<p><br />\r\n　　根据9月2日国务院常务会议的研究决定，从本月起，公共卫生与基层医疗卫生事业单位实施绩效工资，其他所有事业单位明年1月1日起实施。而此前，义务教育学校已从今年1月1日起先行实施，</p>\r\n<p><br />\r\n　　目前，我国有事业单位120多万个，在职人员3000多万人，离退休人员900多万人，由于教育、科技、文化、卫生等领域皆与民生问题息息相关，所以改革消息一经发布，立即引起社会广泛关注。而关注的焦点也主要集中在以下五点，人力资源和社会保障部劳动工资研究所所长苏海南进行了一一解答。</p>', 'llz007', 0, 23),
(39, '2009年诺贝尔医学/生理学奖揭晓', '', '', '', '2009-10-09 10:55:34', '116.228.141.77', '<p align="center"><font color="#003399"><img src="http://cn.yimg.com/sp/sarticle/news/20091006084525_0.jpg" border="0" />\r\n</font></p>\r\n<p align="left">10月5日,在瑞典首都斯德哥尔摩举行的新闻发布会上,卡罗林斯卡医学院诺贝尔生理学或医学奖评选委员会展示2009年诺贝尔生理学或医学奖3位得主(从左至右)伊丽莎白·布莱克本、卡萝尔·格雷德和杰克·绍斯塔克的照片。</p>\r\n<p align="left">三名美国科学家以染色体端粒和端粒酶研究拿下2009年度诺贝尔生理学或医学奖。</p>\r\n<p align="left">这是诺贝尔生理学或医学奖第100次确定获奖者,也是首次由两名女性同时摘得这一奖项。</p>\r\n<p><strong>美国“三剑客”</strong></p>\r\n<p>位于瑞典首都斯德哥尔摩的卡罗林斯卡医学院诺贝尔生理学或医学奖评审委员会5日于欧洲中部时间11时30分(北京时间17时30分)公布评选结果。</p>\r\n<p>美国人伊丽莎白·布莱克本、卡萝尔·格雷德和杰克·绍斯塔克以始于上世纪70年代涉及如何完整复制染色体以及如何避免染色体老化的研究而获奖。他们在研究中发现,关键在于位于染色体末端的端粒和生成端粒的酶、即所谓“端粒酶”。</p>\r\n<p>评审委员会说,3名获奖者所做研究“解决了生物学一个长期存在的重大问题”。</p>\r\n<p>卡罗林斯卡医学院教授约兰·汉松负责通知身处大洋彼岸的获奖者。“他们都在家,我幸运地找到他们所有人。接电话时,他们略带睡意,但挺开心,”汉松告诉路透社记者。</p>\r\n<p>布莱克本凌晨2时左右在电话铃声中醒来。“获奖总是件好事,”她告诉美联社记者,“与卡萝尔·格雷德和杰克·绍斯塔克分享这一奖项挺不错。”</p>\r\n<p>格雷德清晨将近5时得知自己获奖。她说:“这真令人激动。这种事情事先没法预知。”</p>\r\n<p>帮几名子女做好上学前准备后,格雷德发表声明:“令像我这样的基础科学研究人员感兴趣的是,每当我们完成一系列实验、以为解答了一个问题时,又会冒出3个或4个新问题。”</p>\r\n<p>接到汉松来电后,绍斯塔克告诉美联社记者:“总有发生这类事情的细微可能。所以,当电话铃响起时,我想,也许就是它了。”</p>\r\n<p>每年诺贝尔奖揭晓前总有不少获奖热门人选的猜测,这次3名获奖者皆为预测者们重点关注的人选。</p>\r\n<p>布莱克本、格雷德和绍斯塔克2006年共同摘取艾伯特·拉斯克基础医学研究奖,即美国医学界最高奖项。不少艾伯特·拉斯克奖获得者日后成为诺贝尔奖得主。</p>\r\n<p>因战争等原因,诺贝尔生理学或医学奖曾9次空缺。今年是这一奖项自1901年以来第100次确定获奖人选。按照惯例,一项诺贝尔奖最多由3人共享。3名获奖者将分享1000万瑞典克朗(约合142.7万美元)奖金。</p>\r\n<p align="center"><img style="width:300px;height:409px;" src="http://cn.yimg.com/sp/sarticle/news/20091006084650_0.jpg" border="0" />\r\n</p>\r\n<p align="center">这是卡萝尔·格雷德的资料照片。</p>\r\n<p align="center"><img style="width:300px;height:207px;" src="http://cn.yimg.com/sp/sarticle/news/20091006084706_0.jpg" border="0" />\r\n</p>\r\n<p align="center">这是伊丽莎白·布莱克本的资料照片。</p>\r\n<p><strong>璀璨“姐妹花”</strong></p>\r\n<p>两名女性科学家布莱克本和格雷德同时获奖引起广泛关注。当发布会现场记者询问这是否是诺贝尔生理学或医学奖历史上首次由两名女性分享这一奖项,评审委员会回答:“是的。”</p>\r\n<p>这以前,已有192人获诺贝尔医学奖,其中8人为女性。</p>\r\n<p>布莱克本1948年生于澳大利亚塔斯马尼亚州首府霍巴特,在墨尔本大学获学士和硕士学位,1975年在英国剑桥大学获博士学位,随后前往美国耶鲁大学从事分子和细胞生物学研究,现执教于加利福尼亚大学旧金山分校。</p>\r\n<p>布莱克本从小对生物感兴趣,甚至唱歌给动物听。</p>\r\n<p>美国《时代周刊》2007年把布莱克本列入“世界上100名最具影响力人物”,但错把她的年龄写为44岁。谈及这件事,时年58岁的布莱克本告诉美国《纽约时报》记者:“我可不会要求纠正。如果他们想把时钟往回拨,挺好。”</p>\r\n<p>格雷德1961年生于美国加州,后随布莱克本攻读博士,现为马里兰州约翰斯·霍普金斯大学分子生物学教授。上世纪七八十年代以来,她与导师布莱克本共同研究染色体端粒和端粒酶,获得不少重要发现。</p>\r\n<p>绍斯塔克1952年生于英国首都伦敦,本科就读于加拿大麦基尔大学,在美国康奈尔大学获生物化学博士学位,1979年前往哈佛大学医学院创立自己的实验室,现为马萨诸塞综合医院遗传学教授。他首次成功制成酵母人造染色体,为后人绘制哺乳动物基因图和操纵基因创造了条件。</p>\r\n<p><strong>突破“三道门”</strong></p>\r\n<p>诺贝尔生理学或医学奖一般颁给在相关领域实现特定突破的研究人员。卡罗林斯卡医学院教授鲁内·托夫特戈德说,端粒和端粒酶研究有助于攻克医学领域3方面难题,即“癌症、特定遗传病和衰老”。</p>\r\n<p>端粒位于染色体末端,能阻碍细胞老化。如果端粒变小,细胞会加剧老化。布莱克本和格雷德在研究中发现一种能够促成端粒生成的酶、即端粒酶,而癌细胞利用端粒酶实现扩散。绍斯塔克所做研究则加深了人们对端粒作用的了解。</p>\r\n<p>评审委员会说,3名获奖者的研究成果“为世人理解细胞(运行机制)提供新视角,有助于摸清疾病原理,促进开发潜在新疗法”。</p>\r\n<p>汉松说,研究人员可依据布莱克本等人所获突破进一步开发血液病、皮肤病和肺病的治疗手段。</p>\r\n<p>谈及研究成果对攻克癌症所作贡献,格雷德说,“刚开始这项研究时,我们丝毫不知端粒酶与癌症存在关联,只是对染色体如何保持完整无损感到好奇……我们所用方法表明,既可以针对特定疑问展开研究,也可以凭本能做事”。</p>\r\n<p>绍斯塔克说,自己出于对脱氧核糖核酸(DNA)如何实现复制感兴趣而展开研究,“当时并不知道后来会发现那许多关联”。(杨舒怡)</p>\r\n<p align="center"></p>', 'gwm', 0, 39),
(40, '台湾女艺人文英因肺癌不幸病逝 享年73岁', '', '', '', '2009-10-09 10:56:26', '116.228.141.77', '<img alt="台湾女艺人文英因肺癌不幸病逝 享年73岁" src="http://file.pet-ct.cn/Health/News/2009-08-07/7eee1402467dae0488d6c65ae5cf87b8.jpg" />\r\n<br />\r\n<span style="color:blue;"></span><br />\r\n<br />\r\n\r\n<p>　　<span style="color:blue;"><font color="#000000">台湾</font></span>资深艺人文英<span style="color:blue;"><font color="#000000">阿姨</font></span>8月5日早上因<span style="color:blue;"><a href="http://www.pet-ct.cn/"><font color="#07519a">肺癌</font></a></span><span style="color:blue;"><font color="#000000">病逝</font></span>台大医院，享年73岁。　</p>\r\n<p>　　文英阿姨今天上午11点因肺癌病逝台大医院，享年73岁，消息传开至<span style="color:blue;"><font color="#000000">演艺</font></span>圈大家都不敢相信文英阿姨病情如此不佳，许多人闻讯大哭。　</p>\r\n<p>　　文英有抽烟习惯，今年初去日本北海道玩，回来发现胸闷不舒服，左肩也出现硬块，她随后赴台大医院切除，经检查出患肺癌第3期，她积极抗癌，母亲节她在5位子女和孙子们陪同下，开心办派对，许多演艺圈好友，如利菁、许杰辉等人都出席。今年5月还开心过母亲节，公开露面向大家报平安。当时文英行动自如，气色不错，也没掉头发，还自称胖了3公斤。但2周前，她再度住院，昨传出她的情况并不乐观，动了脑部手术，时而昏迷、时而清醒，头发掉光，有时甚至认不出家人和好友。　</p>\r\n<p>　　今天原本有媒体报道白冰冰乐观地说，阿姨病情反覆还在抢救，希望神佛可以保佑，没想到言犹在耳，上午就传出文英阿姨病逝的消息，稍晚白冰冰也会出面说明。　</p>\r\n<p>　　文英阿姨今早病逝，演艺圈朋友难以置信，许多人闻讯大哭。　</p>\r\n<p>　　白冰冰早前受访时表示，某次文英上白冰冰节目，两人先是开玩笑，后来商讨谁先走最后一程，另一人就要负责帮忙处理身后事，白冰冰说：“我对阿姨有承诺，人生总会走到这条路，不管如何，她有需要我时，身边绝对有我在。”　</p>\r\n<p>　　文英的生平　</p>\r\n<p>　　台湾资深艺人文英阿姨生于台北，原名黄锦凉，在日治时代名英子。　</p>\r\n<p>　　她在出生40多天后就被送当养女，另有九名兄弟姐妹。为担负家计，她17岁就加入黑猫歌舞团，正式展开演艺生涯。　</p>\r\n<p>　　也因为该歌舞团为当时台湾一流的歌舞团，奠定她的演艺界地位。19岁那年，她与时为演员的方龙结婚，并由他取艺名“文英”，两人育有5名子女。　</p>\r\n<p>　　她曾参演的第一部电视作品是《星星知我心》，最后一部则是去年和台湾偶像杨丞琳和潘玮柏合作的《不良笑花》。敢讲敢玩，个性直爽乐观的她也担任过主持。　</p>\r\n<p>　　除了电视综艺，她还出过个人专辑，也投身电影圈。她先后3次入围金马奖，并于1995年凭陈玉勋执导的《热带鱼》中的角色荣获金马奖的最佳女配角。　</p>', 'gwm', 0, 28),
(41, '烂姜会产生毒素能致癌 ', '', '', '', '2009-10-10 09:13:43', '116.228.141.77', '冬吃萝卜夏吃姜，不用医生开药方”、“家备小姜，小病不慌”、“夏季常吃姜，益寿保安康”、“四季吃生姜，百病一扫光”、“早吃三片姜，胜过人参汤”……诸多民谚都反映了生姜的保健功效，而自古以来中医也有“生姜治百病”的说法。中医讲究冬吃萝卜夏吃姜，姜在炎热时节有兴奋、排汗降温、提神等作用，可缓解疲劳 \r\n<table align="left">\r\n<tbody>\r\n<tr>\r\n<td><span></span></td></tr></tbody></table>、乏力、厌食、失眠、腹胀、腹痛等症状，生姜还有健胃增进食欲的作用，但姜并不适合所有的人群，比如阴虚体质的人是不能吃姜的。 \r\n<p>　<strong><font color="#0000ff">　增加食欲防胃病 </font></strong>\r\n<p>　　无论是蒸鱼做菜，还是调味作料，生姜绝对是桌上一味，其辛辣滋味可去鱼腥、除膻味，菜汤加姜还可以祛寒和中，味道清香。赵主任介绍，有民谚“饭不香，吃生姜”，就是说，当吃饭不香或饭量减少时吃上几片姜或者在菜里放上一点姜，能够改善食欲，增加饭量。胃溃疡、虚寒性胃炎、肠炎以及风寒感冒也可服生姜以散寒发汗、温胃止吐、杀菌镇痛。 \r\n<p>　　生姜还是传统治疗恶心、呕吐的中药，有“呕家圣药”之誉。在夏季，尤其是伏天内，细菌生长繁殖异常活跃，容易污染食物而引起急性肠胃炎，但是适当吃些生姜能起到防治作用，生姜还有杀灭口腔致病菌和肠道致病菌的作用。夏季人们好贪凉，喜爱电扇空调对着吹，很容易受风寒，引起伤风感冒。这时及时喝点姜糖水，将有助于驱逐体内风寒。中医认为生姜能“通神明”，即提神醒脑，所以此时经常出现头昏、心悸及胸闷恶心的人，适当喝点生姜汤大有裨益。另外，生姜辛温，具有促进血液循环的作用，女性吃姜还能抗衰老、减少胆结石的发生。 \r\n<p>　　<font color="#0000ff"><strong>腐烂生姜产生毒素可致癌 </strong></font>\r\n<p>　　姜的吃法很多，比如姜汤、姜粥，做菜时可加姜片，做水饺馅时加点姜，既能使味道鲜美，又有助醒胃开脾、提神、促进食欲、帮助消化和有助胃肠对营养成分的吸收。 \r\n<p>　　但有些人吃姜喜欢削皮，这样做不能发挥姜的整体功效，只要将姜洗干净就可以了。还有的人认为“烂姜不烂味”，这种想法是没有科学依据的，也很危险，因为腐烂的生姜会产生毒素，严重时会导致肝癌和食道癌的发生。 \r\n<p>　　虽然夏吃姜对人体有益，但也应适度，因为天气炎热，人们容易口干、烦渴、咽痛、汗多，而生姜性辛温，属热性食物，根据“热者寒之”的原则，不宜多吃，只在做菜或做汤的时候放几片生姜即可。 \r\n<p>　<font color="#0000ff"><strong>　产后女性可用姜水洗浴 </strong></font>\r\n<p>　　中医认为，姜是助阳之品，于是自古以来中医素有“男子不可百日无姜”之语。姜具有加快人体新陈代谢、通经络等作用，因此，姜常被用于男性保健，可以起到助阳的作用，对肾虚阳痿也有一定的治疗作用。 \r\n<p>　　如果男性常感胃寒、食欲不振，可以经常含服鲜姜片，刺激胃液分泌，促进消化。干姜温中散寒，健胃活血，枸杞子滋补肝肾，益精明目，配合食用可以治疗由于肾阳虚引起的阳痿、畏寒肢冷、腰疼、腰膝酸软、倦怠等。 \r\n<p>　　产后的女性坐月子时，餐餐以姜醋佐膳，有利体质复原及喂养婴儿。另外，姜水洗浴还可以防风湿头痛。尤其是产妇坐月子不洗头洗澡的做法，是很不科学的，炎炎夏日一个月不洗头，不但不卫生，还可能造成皮肤发炎、长痱子。产妇可以试用姜片煲水洗头洗澡，甚至洗脸洗手，因为姜片可以驱寒，用姜煲水进行洗浴，可以防风湿和偏头痛。 \r\n<p>　<font color="#0000ff"><strong>　阴虚体质人群禁食姜 </strong></font>\r\n<p>　　“姜素以药食俱佳见称，经常食用能保健强身，养生益寿，但阴虚体质的人群是绝对不能吃。”赵主任特别提醒，万物进食需有时，古代医书中也有“一年之内，秋不食姜；一日之内，夜不食姜”的警示，随着夏天结束，天气将慢慢变凉，然而秋天气候干燥，燥气伤肺，再吃辛辣的生姜，容易伤害肺部，加剧人体失水、干燥，所以秋季不宜吃姜。此时吃姜也不宜过多，以免吸收姜辣素，在经肾脏排泄过程中会刺激肾脏，并产生口干、咽痛、便秘等症状。 \r\n<p>　　还有阴虚火旺、目赤内热者，或患有痈肿疮疖、肺炎、肺脓肿、肺结核、胃溃疡、胆囊炎、肾盂肾炎、糖尿病、痔疮者，都不宜长期食用生姜，尤其是阴虚体质的人，绝对不能吃姜。阴虚就是燥热体质，表现为手脚心发热，手心有汗爱喝水，经常口干、眼干、鼻干、皮肤干、心烦易怒、睡眠不好，而姜性辛温，阴虚的人吃姜会加重阴虚的症状。(长春中医药大学附属医院治未病中心主任 赵为民<br />\r\n</p>', 'gwm', 0, 37),
(42, '为解决挂号难卫生部将推行实名预约挂号', '', '', '', '2009-10-14 09:42:15', '116.228.141.77', '<p align="center"><img title="alt=" src="http://www.ycen.com.cn/images/site2/20091014/51255478011543_change_p26_b.jpg" border="0" />\r\n</p>\r\n<p style="text-align:left;" align="left">&nbsp;&nbsp;&nbsp; 在浙江，病历经常是排队的依据。这样的场面，似乎离我们很远。资料图片</p>&nbsp;&nbsp;&nbsp;&nbsp;日前，卫生部《关于在公立医院施行预约诊疗服务工作的意见》（下称“意见”）最终稿下发，要求从今年11月起，所有公立三级医院都要开展实名预约挂号服务。针对患者反映突出的“挂号难”现象，卫生部建议各医院逐步运用信息技术，为病人提供优质预约服务。 \r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;在北京、广州等地公立医院纷纷开展预约诊疗服务，甚至一些城市出现了“挂号中介”之时，银川的情况如何呢？10月12日，记者相继走访了我区数家医院。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;宁夏医科大学附属医院是我区接待患者数量最大的三级甲等医院。该院门诊挂号办公室张主任答复记者，医院接待患者以银川市周边地区患者较多，他们一般都会选择来门诊排队挂号。根据目前的情况来看，“医院门诊号基本是随到随挂，预约的必要性不大”。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;北京、广州等城市公立医院已开始了网络平台预约服务。宁夏医科大学附属医院目前正在建设网络预约平台。其负责人表示，网络预约主要针对慢性病或需要反复就诊的患者，一般不建议初诊患者预约挂号，因为这样会因患者挂错号而浪费医疗资源，建议他们直接排队挂号。“实名预约是肯定的，届时患者必须凭借本人有效身份证件才能拿上号。但是很多农村患者不会上网，致使预约挂号受众面较小。”</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;银川市妇幼保健院尽管是一家综合专科医院，但其日常门诊挂号量也不小。该院院办相关人员介绍，目前医院尚未接到上级主管部门的任何文件或通知。对于该院来说，门诊量随着季节变化较为明显，如天凉了，感冒儿童增多，此时排队挂号的患者也大幅增多。而平时，医院的号并不紧张。限号的科室如儿童康复科，则一直沿用患者排队挂号的形式。“银川城市小，患者一般会根据当天限号的数量自己权衡的。”一位医护人员认为，预约挂号的真正作用是节省患者候诊时间，降低人群聚集密度，而这些情况在大城市较为普遍，银川真正需要预约挂号的医院不多。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;相对于一些外市医院猖獗的“号贩子”来说，银川各医院门诊号、专家号也没有出现倒号、串号现象。部分公立医院对抢手的知名专家号进行了限定，根据病情诊断所需时间的长短分别放号，如宁医附院心理咨询科一般每天上午只放5~10个号，皮肤科则可能限制到50个号之内。</p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;记者了解到，银川地区拥有各级各类医疗卫生机构694所（截至2008年初），其中，区直属医疗机构中三级综合医院2所，市直属医疗机构三级综合医院1所。多数患者认为，加上社区卫生服务力量，银川市医疗资源较丰富，除了部分“抢手科室”以外，并未感到在公立医院门诊挂号有多难。</p>\r\n<p>&nbsp;</p><!--/enpcontent--><!--/enpcontent-->', 'gwm', 0, 23),
(43, '研究发现：孕妇患癌可通过胎盘传染给腹中胎儿', '', '', '', '2009-10-14 09:46:42', '116.228.141.77', '中新网10月14日电 据香港《文汇报》14日援引外电报道，美国国家科学院院刊中一项研究发现，由于癌细胞的一个基因突变，怀孕期间患癌的妇女在罕见情况下，可以透过胎盘将癌症“传染”给胎儿，研究解开困扰科学家百年的谜团。 \r\n<p>　　为了研究癌细胞如何穿过胎盘屏障，科学家通过胎儿，找出一些对外来细胞能够免疫的证据。他们研究了婴儿的癌细胞基因，并发现了一个缺失突变──区分癌细胞身分的DNA消失，癌细胞俨如“隐形”，所以成功避开胎儿免疫系统的耳目。 </p>\r\n<p>　　数据显示，母亲怀孕患癌机会只有千分之一，母亲和孩子患有相同癌症的情况更为罕见，迄今只有大约30例。生物学理论一直认为，即使一个癌细胞能穿过胎盘屏障，也会被婴儿的免疫系统排斥并毁灭，但这种理论现在被打破。 </p>\r\n<p>　　<strong>推翻胎盘保胎说法</strong></p>\r\n<p>　　伦敦大学癌症研究中心的格里夫斯与日本的医生发现，一名28岁日本母亲怀孕期间并不知道自己患癌，在顺产诞女后一个月，母亲确诊患上末期血癌，终在产后几周去世。 </p>\r\n<p>　　女婴其后亦证实患上淋巴瘤，虽然两人患不同癌症，但两人的癌细胞上都有相同的突变癌基因“BCR-ABL1”。这表明，这名11个月大女婴不可能自己患上这类白血病，癌细胞是源自母亲。 </p>\r\n<p>　　格里夫斯教授称，科研人员和医学专家一直确信胎盘能保护胎儿，所以都假定癌细胞不可能扩散到胎儿。但这项研究推翻了这种说法。 </p>\r\n<p>　　<strong>血癌皮肤癌为主</strong></p>\r\n<p>　　不过格里夫斯强调，怀孕妇女将癌细胞传到胎儿的机会相当小。有本港肿瘤科专家表示，癌细胞基因变异，经母体传给胎儿的情况，香港未发生过，外国已知个案，主要是血癌和皮肤癌，因为这些癌细胞容易变异。 </p>\r\n<p>　　癌病研究中心教授约翰逊在报章撰文指出：“癌细胞出现的情况比我们想象的多，很可能我们时时刻刻都会产生一些癌细胞，但最终都被免疫系统消灭。现时我们要做的，就是要研究如何令免疫系统认出所有癌细胞。” </p>', 'gwm', 0, 30),
(44, '癌症预防指南：女性 抵御癌症从预防开始', '', '', '', '2009-10-14 09:49:43', '116.228.141.77', '癌症是我国居民死亡的主要原因之一，2000年我国居民每死亡5人中，即有1人死于癌症。但是癌症并不是没有治愈的机会的，如果能够充分重视，及早预防和发现，就会使癌症的发病率大大降低。\r\n<p>　　<strong>你是癌症易患人群吗</strong></p>\r\n<p>　　1、从理论上讲人人都可能患上癌症，但医学调查证实，有些人患癌症的可能性更大，应及早防范：</p>\r\n<p>　　2、经常饮用高温(70摄氏度以上)的浓茶水，茶中的鞣质可沉积在损伤部位，刺激受伤的食道上皮细胞，导致癌变；</p>\r\n<p>　　3、癌细胞夜间分裂最旺盛，如果夜晚睡眠不足、经常熬夜的人，人体的免疫力就会降低；</p>\r\n<p>　　4、憋大小便，也会导致癌症；</p>\r\n<p>　　5、凡是有哮喘和对某些药物或化学试剂过敏的人，比无过敏者更易发生癌症，有过敏史的女性，罹患乳腺癌的几率比正常人要高30%；</p>\r\n<p>　　6、血清胆固醇过低的，其结肠癌发生率较高；</p>\r\n<p>　　7、每天以猪、牛、羊等畜肉为主食的人，患肠癌的比例比那些每月只吃几次少量肉食者高2.5倍；</p>\r\n<p>　　8、癌症病人的后代，患癌的风险显著高出一般人群；</p>\r\n<p>　　9、夫妻双方同时或先后患癌的现象，有逐渐增多的趋势；</p>\r\n<p>　　10、高血压虽不能直接导致癌症，但相同的不良嗜好，比如嗜酒、吸烟、食盐过多等，也可能导致癌症；</p>\r\n<p>　　11、体内保护性维生素少的人易受癌症侵犯。</p>\r\n<p>　　<strong>识别癌症的信号</strong></p>\r\n<p>　　<strong>如果出现以下症状，就要及早到正规医院进行检查治疗：</strong></p>\r\n<p>　　1、有持续性头痛，伴有恶心呕吐或视物障碍，或鼻出血、头晕、耳鸣耳聋等症状；</p>\r\n<p>　　2、身体任何部位出现肿块，哪怕只有黄豆大的肿块，特别在颈部、乳房、心窝部、右肋下、锁骨上等处出现，且肿块不断增大；</p>\r\n<p>　　3、乳房左右不对称，大小有变化，乳头流出血性或乳样分泌物，或者发生糜烂；</p>\r\n<p>　　4、经久不愈的干咳，无痰或少量痰液，伴有声音嘶哑，痰中夹血丝或小血块；</p>\r\n<p>　　5、吞咽时有哽噎的感觉，胸骨后有异物附着感或烧灼感或有隐痛；</p>\r\n<p>　　6、长期食欲不振，消化不良，上腹部饱胀，没有吐酸水，或大便黑色如柏油；月经紊乱的潜在危险(图)</p>\r\n<p>　　7、中年以后，性交时阴道出血，或阴道不规则流血，或白带多且有恶臭；</p>\r\n<p>　　8、大便习惯改变，或不明原因的大便次数增多，或便血不止；</p>\r\n<p>　　9、身体任何部位长出的疣或色素痣迅速增大，颜色变深，局部毛发脱落或发生破溃；</p>\r\n<p>　　10、身上较长的骨骼(如四肢骨)某处不明原因的疼痛且进行性加重。</p>\r\n<p>　　<strong>女性常患癌症的种类</strong></p>\r\n<p>　　女性一般常患的癌症种类是乳腺癌和宫颈癌。月经初潮早，闭经晚的女士，没有对孩子进行母乳喂养的产妇，工作压力比较大的职业女性，以及经常吃激素类食物，比如油炸食物和碳酸饮料的女性，容易患乳腺癌；而患有久治不愈的妇科炎症或是性经历过早、性伴侣过多的女性得宫颈癌的几率比较大。</p>\r\n<p>　　<strong>重视妇科肿瘤检查</strong></p>\r\n<p>　　一定要定期到正规医院进行查体，一般35岁以上的女性，每两年就应该做一次钼钯，每年都要进行阴道脱落血检查，因为宫颈癌早期一般不容易查出。</p>\r\n<p>　　一般可以进行自查的是乳腺癌，应该每个月自查一次，但需要注意的是，要避开月经期，因为月经期激素水平改变，乳腺导管扩张，常常会被误认为是肿块。具体自查的方法是：脱下上衣站在镜子前，看乳房是否对称，外观上有没有产生变化，有没有乳头内陷或肿块，有没有橘皮产生；然后以食指、中指、无名指三指的指腹，从乳房外侧慢慢触摸，不能有遗漏的地方，这样从外侧上方到下方，再到内侧的上下方；最后是乳晕区，进行全方面的检查，接着再把手伸到腋窝下面，上下左右进行触摸，检查淋巴结是否有肿块。</p>\r\n<p>　　<strong>早期发现至关重要</strong></p>\r\n<p>　　早期发现的癌症患者十年生存率为90%以上，可到晚期发现，五年生存率就很低。比如，前不久一位老师，在单位查体时发现有肿块，当时医生只是在病例上写了一句，并没有特殊交代，可该老师自己特别重视，很快到医院进行全面检查，发现是癌症，所幸的是癌细胞没有扩散，手术后做了一次放疗没有发现病变。还有一位在药房工作的女士，十年前得了乳腺癌，因为自己是医务人员，一直比较注意自己的身体状况，发现得比较早，切除乳房后从来没发过病，一直上班工作。</p>\r\n<p>　　可相反的例子也不少，比如一位女士，家在农村，很早就发现自己乳房上有肿块，但是她自己却认为不疼不痒的肯定没事，拖到后来腋窝里也有了肿块。一次碰巧到医院看望病人，就顺便查查，结果一查得的是乳腺癌，而且是晚期，已经很难再进行治疗了。</p>', 'gwm', 0, 22),
(45, '中青年女性乳腺癌高发母乳喂养少是一大因素', '', '', '', '2009-10-15 10:00:31', '116.228.141.77', '10月是世界乳腺癌防治月。记者从“第十届全国乳腺癌会议暨上海国际乳腺癌论坛”上公布的癌情监测数据了解到，乳腺癌是目前上海女性发病最高的恶性肿瘤，而中青年女性成为乳腺癌最高发人群。其中主要原因就是患者运动少，母乳喂养少导致体内雌激素水平上升。 \r\n<p>　　上海是目前全国各省市肿瘤登记点中女性乳腺癌发病和死亡水平最高的城市，在本市肿瘤登记的30多年中，女性乳腺癌发病呈明显上升趋势，各年龄段女性的乳腺癌发病水平均有增高。 </p>\r\n<p>　　昨天公布的一份对300名白领产妇调查显示，近6成不愿母乳喂养。其中，工作压力大，担心影响身材，成了白领不愿让宝宝获得“最佳营养”的理由。复旦大学附属肿瘤医院乳腺外科副主任柳光宇提醒孕产妇，母乳喂养时间越长，患乳腺癌的几率越低。同时改变不健康的生活方式，提高对自身健康的关注程度是对抗乳腺癌的关键。 </p>', 'gwm', 0, 20),
(46, '沪15日起免费接种疫苗 先临床医护人员后教师学生', '', '', '', '2009-10-15 10:18:36', '116.228.141.77', '东方网实习生周媛10月15日报道：甲型H1N1流感疫苗临床接种工作将从今天起在上海市全面展开。临床医护人员将首批接种疫苗。\r\n<p>　　据悉，今天将接种甲流疫苗的都是临床一线的医护、医技人员。上海市甲流疫苗的接种工作将按照先医护人员后公共服务人员，再教师、学生等的顺序逐步展开，到年底前全部完成疫苗的接种工作。</p>\r\n<p>　　据卫生专家介绍，在通常情况下，接种疫苗两周后人体内抗体水平达到保护效果，起到保护作用；同时，接种疫苗后可能会出现一些诸如头晕、发热等不适反应。这些副反应以轻度为主，主要表现为局部的红肿、疼痛，另外有些还表现为发热、呕吐、乏力等症状，大多发生在接种后24小时内。</p>\r\n<p>　　卫生专家提醒，国家调拨的疫苗是安全可靠的，但不排除少数人接种后可能出现发热等不适反应，这些是轻型的反应，属于正常情况。而对于那些有“禁忌症”的人群，如：对鸡蛋过敏、对疫苗反应过敏的人群，专家将劝其不接种。</p>', 'gwm', 0, 18),
(47, '癌症护理指南：癌痛用药五原则！', '', '', '', '2009-10-15 11:06:21', '116.228.141.77', '关于癌症疼痛产生的机制，目前认为有三个途径，即癌症发展所致的疼痛，诊断和治疗癌症引起的疼痛以及癌症病人并发感染、慢性疼痛性疾病和癌症疼痛综合征所发生的疼痛。在这三个途径中，75％～80％的病人是由于肿瘤侵入软组织、骨髓以及神经系统所引起，15％～20％是在癌症的诊断和治疗过程中产生的，5％～10％则是由于合并了疼痛性疾病。\r\n<p>　　控制癌痛最主要的方法是世界卫生组织（WHO）推荐的三阶梯止痛法，这是一种根据患者的疼痛程度不同而分别使用不同等级止痛药物的止痛方法。将患者的癌痛分为轻、中、重三级，再按照WHO提出的癌痛治疗的5个主要原则给药。</p>\r\n<p>　　原则一：口服给药。</p>\r\n<p>　　原则二：按时给药。</p>\r\n<p>　　原则三：三阶梯给药。按患者疼痛的轻、中、重不同程度，给予不同阶梯的药物。另外，一些辅助药物的使用可增加止痛的效果，减少了止痛药的剂量。这些药物包括皮质类固醇激素地塞米松和强的松，可减轻周围神经水肿和压迫引起的疼痛；抗抑郁药阿米替林、多虑平、美舒郁、百忧解，用来镇痛、镇静、改善心情；抗惊厥药卡马西平、苯妥英钠，可治疗撕裂性及烧灼样痛和放化疗后疼痛；羟嗪类抗组胺药，用于镇痛、镇静、镇吐。</p>\r\n<p>　　原则四：用药个体化。</p>\r\n<p>　　原则五：严密观察患者用药后的变化，及时处理各类药物的副作用，观察评定药物疗效，及时调整药物剂量。</p>\r\n<p>　　此外，还要注意药物之间的相互作用，以及药物止痛与其他方法相结合的综合治疗等问题。目前，国家食品药品监督管理局取消了癌症病人使用吗啡的极量限制，这体现了对癌痛控制与姑息治疗工作的支持。 </p>', 'gwm', 0, 21),
(48, '河南济源千名儿童血铅超标 32家污染企业停产(图) ', '', '', '', '2009-10-16 10:29:32', '116.228.141.77', '<p align="center"><img src="http://news.youth.cn/gn/200910/W020091016350915719572.jpeg" />\r\n</p>\r\n<p>　　在济源市第二人民医院，接受驱铅治疗的患儿卢重羽在妈妈陪同下玩耍。 记者 曹树林摄</p>\r\n<p>　　截至10月14日，河南省济源市已完成对3个重点镇中10个重点村的儿童血铅检测工作：3108名14岁以下儿童中，血铅值在250ug/L以上需立即接受驱铅治疗的有1008人，占32.4%。</p>\r\n<p>　　目前，济源市政府正分批为这些儿童提供免费的驱铅治疗。</p>\r\n<p>　<strong>提供免费血铅检测和驱铅治疗</strong></p>\r\n<p>　　济源，是我国重要的铅冶炼生产基地。</p>\r\n<p>　　济源市环保局环境科学研究所所长李真理说，陕西凤翔等地发现血铅超标事件后，济源市环保局立即对该市可能存在的铅超标问题进行调查研究。</p>\r\n<p>　　按照国家有关标准，济源将豫光金铅、万洋、金利3家大型铅冶炼企业周边1000米范围内的10个村列为防护区，对区内14岁以下少年儿童进行免费血铅检测。</p>\r\n<p>　　济源市卫生局局长卫宗长告诉记者，济源市专门配备了最先进的检测仪器，并已指定济源市人民医院、市第二人民医院和妇幼保健医院为定点医院，为患儿提供免费<strong>治理整顿涉铅企业与脱离铅环境同步推进</strong></p>\r\n<p>　　济源市有关负责人告诉记者，治理铅超标最有效的办法，是脱离铅环境，并配合药物驱铅和营养干预。</p>\r\n<p>　　本着“保安全健康、保社会稳定、保产业发展”的原则，济源市制订了一套完整的医疗救护和环境治理方案，包括关停污染企业、整村搬迁和积极实施驱铅治疗等。</p>\r\n<p>　　首先实施的，是治理整顿涉铅企业。济源市振兴金铅、太行金铅等32家小型企业被停产整顿，豫光金铅、万洋、金利3家企业的烧结机工艺生产线也被关停。</p>\r\n<p>　　豫光金铅总经理李继红表示，虽然该集团自主研发的富氧底吹熔炼技术符合国家标准，并不意味着对环境完全没有危害。豫光将积极配合市政府做好铅防治工作。</p>\r\n<p>　　在接受检测的1000米安全范围以外的191名儿童中，仅有12人血铅值超过250ug/L。</p>\r\n<p>　　由此可见，大量儿童血铅超标，与未严格划定安全防护距离有直接联系。</p>\r\n<p>　　济源市有关负责人说，这是一个历史问题。铅厂初建时，企业和村庄规模都比较小；但随着两者不断扩展，加之此前缺乏防范意识，部分民居就进入1000米防护区之内了。</p>\r\n<p>　　目前，济源市正对防护区内10个村的居民按一村一策的原则实行整体搬迁；各村正按照“四议两公开”的工作方法，确定具体搬迁方案。</p>\r\n<p>　<strong>排铅产生费用由政府统一协调解决</strong></p>\r\n<p>　　记者了解到，济源市对所有6岁以下儿童，按照每个儿童每月725元的标准给予补贴，使他们能脱离铅环境，搬到市区或其他安全区域居住。</p>\r\n<p>　　该补助一直发放到整村搬迁完成或小孩入学；6到14岁已入学的儿童，由教育主管部门协调在防护区以外寄宿学校就读，并免费提供营养干预食品。</p>\r\n<p>　　济源市教体局李伯勇主任介绍，防护范围内两所学校的343名小学生和119名初中生，现已全部转到市区上学。目前，10个村的14岁以下儿童均已脱离铅环境。</p>\r\n<p>　　同时，济源市积极采取排铅医疗措施，所有费用由市政府统一协调解决，确保铅超标儿童得到及时有效的治疗。</p>\r\n<p>　　血液中铅含量在100ug/L至249ug/L的，在卫生专家指导下给予营养干预和行为指导。生活在防护范围之外，但经市级以上检测机构认定血铅含量在250ug/L以上的儿童，市政府也将给予免费治疗。</p>', 'gwm', 0, 28);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(49, '女子吞虫卵减肥致十几条蛔虫寄生腹中', '', '', '', '2009-10-16 10:35:48', '116.228.141.77', '<div align="center"><img alt="女子吞虫卵减肥致十几条蛔虫寄生腹中" src="http://i1.sinaimg.cn/dy/s/2009-10-16/1255630422_ipX0ra.jpg" border="1" />\r\n</div>\r\n<div class="f12" align="center">网上销售的虫卵减肥药及服用方法(资料图片)</div><br />\r\n<!-- publish_helper name=''原始正文'' p_id=''1'' t_id=''1'' d_id=''18838795'' f_id=''3'' -->\r\n<p>　　<strong>美女减肥很猛很恐怖</strong></p>\r\n<p>　　减肥，你能想到的招数有多狠？家住九龙坡区天兴路佳庆园B栋，年仅23岁的黄霞，为了变成魔鬼身材，按网络上传授的恐怖减肥法，吃寄生虫减肥。半个月之后，非但魔鬼身材未修炼成功，反倒把自己送进了医院。</p>\r\n<p>　　<strong>她不胖</strong></p>\r\n<p><strong>　　要减肥</strong></p>\r\n<p><strong>　　身高1.65米 体重53公斤</strong></p>\r\n<p>　　“恐怖！”昨上午，看着在西南医院门诊输液的女儿，张明英满脑子装的只有这个词。若非女儿肚子疼得太厉害，一天要拉稀八次，她和丈夫仍不知道，23岁的女儿居然吃寄生虫减肥。</p>\r\n<p>　　“体重其实很正常。”张明英说，女儿从小就偏瘦，从未胖过。前不久，和她逛街时，女儿到药店的体重秤上称，只有53公斤。“她身高1.65米，配这样的体重，完全是标准身材。”</p>\r\n<p>　　怎料，黄霞偏要减肥。针灸、按摩和有氧运动，全都试过，还是不满意。“这下可好，把身体给减出毛病来了。”张明英感慨，前天，女儿一天拉稀了八次，人都快虚脱了。昨天一早，赶紧送医院，在医生的逼问下，女儿才交代吃寄生虫减肥的荒唐事。</p>\r\n<p>　　<strong>要减肥</strong></p>\r\n<p><strong>　　网上买虫卵 每天吃三粒</strong></p>\r\n<p>　　“我就是太想拥有明星般的身材。”坐在输液椅上的黄霞，气色很差，说话有气无力。她抱怨，全是被网络害了。由于以前的减肥方法没见效，上个月，她在网上搜索，发现了几种恐怖减肥法，排在首位的就是吃寄生虫。据说，这种办法，在日本等国家非常流行。她在淘宝网上搜索，居然发现有卖寄生虫卵减肥产品的商家。</p>\r\n<p>　　黄霞二话没说，花几百元买回两盒寄生虫卵减肥产品。她描述，该产品是类似胶囊的颗粒，黄色，据说里面装的是经过培育的蛔虫卵。只要吃下肚，虫卵会在肠道里孵化成蛔虫，蛔虫会吃寄主摄取的食物，从而达到瘦身目的。</p>\r\n<p>　　“虽然觉得有点恶心，但网上说很多明星都是如此减肥，就一口气吞下肚，水都没喝。”黄霞说，她每天要吃三四粒虫卵，吃了半个月，身材也没啥变化。但最近几天，她的肚子开始“乱叫”，上厕所的气味很臭，最终腹泻不止，吃止泻药也不管用。</p>\r\n<p>　　<strong>很受伤</strong></p>\r\n<p><strong>　　蛔虫十多条 全在肚子里</strong></p>\r\n<p>　　医生诊断，黄霞患上肠炎。大便化验结果出来，差点没把在场的人吓晕——黄霞肚里的蛔虫多达10多条。医生说，必须赶快吃打虫药，杀掉这些蛔虫。</p>\r\n<p>　　西南医院消化科主任汪荣泉称，蛔虫有钻孔习惯，易造成肠穿孔、肠道蛔虫病及其它危险病症，若钻入肌肉、血液，进入脑部，就麻烦了。汪荣泉说，使用偏激的减肥办法，不仅达不到减肥目的，还会使健康出现问题，比如造成肝肾功能混乱，甚至卵巢早衰等。如果体重正常，完全没必要减肥。</p>\r\n<p>　　虫卵减肥药无生产批文</p>\r\n<p>　　昨日，记者登录淘宝等网站发现，确有寄生虫卵减肥药销售，每盒200元左右，既有颗粒状的，也有胶囊状的，还有液体状的。有媒体曾报道，国家药监局政策法规司表示，药监部门从未批准生产类似药品。</p>\r\n<p>　　本报新闻律师团成员、志同律师事务所律师陈昊称，不管网上还是药店，销售的产品必须具备国家相关部门的生产和销售批文，才能在市面上流通。如果没有，销售则是违法行为。</p>\r\n<p>　　恐怖减肥法</p>\r\n<p>　　1</p>\r\n<p>　　服用利尿素</p>\r\n<p>　　注射细菌针割胃或小肠拒绝喝水</p>\r\n<p>　　利尿素是一种对尿素形成有重要作用的氨基酸，属医用药物。喝了利尿素，能让人脱水、利尿，达到减肥目的，但容易损伤肾脏。</p>\r\n<p>　　2</p>\r\n<p>　　注射细菌针</p>\r\n<p>　　肉毒杆菌是一种生长在缺氧环境下的细菌，应用在美容领域，这种细菌被注射入脸或身体其他肉多的部位，可使肌肉变小，从而达到瘦脸或瘦身的效果。但如果剂量掌握不好，可能造成注射部位变形。</p>\r\n<p>　　3</p>\r\n<p>　　割胃或小肠</p>\r\n<p>　　割掉部分胃，减少胃容量，术后用网兜罩上，防止胃再次变大，以控制食量，稍微吃一点就有了饱胀感。割小肠，则是减少食物的吸收，一些极端人士甚至为快速减肥，将小肠全部切掉，全靠药物维持身体的营养。</p>\r\n<p>　　4</p>\r\n<p>　　拒绝喝水</p>\r\n<p>　　日本的美容技术在世界上数一数二，而它的减肥方法也是层出不穷，掐脂肪等都是来自日本。1989年，日本的拳击手轮岛功一发表了自己对减肥的“高见”：十天断水可以减掉10斤，只有到受不了的时候才喝一些葡萄汁和柠檬汁。</p>', 'gwm', 0, 18),
(50, '门急诊交押金先诊疗后结算引争议 医患都有顾虑', '', '', '', '2009-10-16 10:38:04', '116.228.141.77', '<p>日前，卫生部在北大人民医院开展 “门急诊交押金先诊疗后结算”试点模式。消息传开，在我省医疗界引发了不少质疑。昨日，记者走访了省会部分医院，医患双方都有疑虑。</p>\r\n<p>　　【门诊】</p>\r\n<p>　　交过押金看病不排队</p>\r\n<p>　　“先诊疗后结算”，医院可对每位病人收取押金，并设置独立的信息识别码。 <br />\r\n&nbsp;<br />\r\n病人每接受一次诊疗，信息系统就会自动从押金中扣除相关费用。因为病人来看门诊时都会带着钱，所以交押金一般是不成问题的，而且交过押金后，病人不用再排队等候，所以对来看门诊的病人来说这是比较大的变化。</p>\r\n<p>　　这和我省部分医院实行的“一卡通”类似。已实行“一卡通”的省人民医院的门诊部负责人介绍，实行数字化管理系统后，患者的就诊时间大大缩短，平均每人减少三分之一。</p>\r\n<p>　　【急诊】</p>\r\n<p>　　“先诊疗”会不会增加“无主病人”</p>\r\n<p>　　“很多是车祸患者，或者路上突然发病的，身上一般很少带大量现金，有的甚至身无分文”。郑州市一家三级综合医院急诊部一刘姓负责人认为，急诊病人一般都属突发疾病，让这样的患者，预交押金有点不现实，比较难操作。</p>\r\n<p>　　这一刘姓负责人认为，“先诊疗后结算”这一新流程对“先诊疗”的强调会导致更多“无主病人”出现。该刘姓负责人说，对于医院来说，对急诊病人一直都是采取挂号和救治同时进行的原则，而对于急危重病人，都是先抢救，“医院还会开辟绿色通道直接推病人进手术室抢救，不会因为患者不交钱就不救治”。</p>\r\n<p>　　对“先诊疗”的强调，会不会让一些钻空子的人冒急诊之名故意不交钱，而导致“伪无主病人”的出现，引发更多的医疗欠费？这成为诸多医院的担忧。</p>\r\n<p>　　“要知道现在每年医院为各种跑账的病人，都要垫付五六十万元。”省会一家医院医务科负责人说。</p>\r\n<p>　　【观点】</p>\r\n<p>　　政府设基金，为急诊病人先垫费</p>\r\n<p>　　对于医院遇到的欠费问题，也有患者表示理解，“提供医疗服务收取费用，这也是天经地义的”。37岁的市民孙玮认为，最好的办法就是政府能设立救济基金，急诊病人的费用，这个基金先垫付着，病人抢救过来再支付，让医院免去后顾之忧，全力诊治。“最好以社会福利的方式，建立一个长效机制”。</p>\r\n<p>　　而郑州市中心医院急诊科主任陈保卫也提到，虽然有一些急诊病人是“恶意欠费”，但还有一部分确实是被迫的。因为身上没有证明身份的物品，患者又因疾病无法沟通而导致“无主”。对此，他也提到，对于这些病人，身份识别非常重要。</p>\r\n<p>　　因此，他建议能否对现在的医保卡进行升级改造，在其中储存个人的医疗信息和健康档案。这个卡可随身携带，如果患者入院，卡上信息有助于医生迅速判断病情和制订抢救方案，也有利于尽快找到家人，而卡上的费用也可以用来支付医药费。</p>\r\n<p>　　【探访“一卡通”先行者】</p>\r\n<p>　　病人别担心押金被乱扣</p>\r\n<p>　　预交押金，是不是强制性的？会不会导致过度医疗增加患者负担？交的押金会不会被挪用，会不会有乱七八糟的费用要扣？钱一押到医院，会不会检查项目就多了……记者走访省会多家医院，病人多是担心费用不够透明。</p>\r\n<p>　　对此，记者采访了已经实行“一卡通”的省人民医院和郑州市妇幼保健院。两家医院的相关负责人都提到，这种方式完全是自愿，并不强制。省人民医院的相关负责人说，这种方式主要是为了让患者减少排队次数，简化就诊流程，提高就医效率。</p>\r\n<p>　　同样，患者的押金完全用于诊疗，不会被挪用或者乱扣。“医生开具的检查单、化验单，只有在检查、化验完成后，才扣除费用”。此外，这位负责人还表示，看病过程中，患者可以随时取出押金，当日交钱当日结算，如果当日不取出，押金可在下次就诊时继续使用。此外，患者也能像查询银行卡一样，随时查询卡上的余额和就诊明细。</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 23),
(51, '饮食保健：详解病在不同脏器的饮食要点', '', '', '', '2009-10-19 11:02:48', '116.228.141.77', '当人们患病就医时，自然会想到根据身体的不同部位出现的不适去相应科室就医;各科室会根据患者的不同疾病给出不同的治疗方案。\r\n<p>　　但不是每位患者都能认识到，病在不同的脏器，不仅治疗方案不同，饮食也会不同。</p>\r\n<p align="left"><strong>&nbsp;&nbsp;&nbsp; 心脏疾病</strong></p>\r\n<p>　　当心脏有疾患时，比如患冠心病、心力衰竭，必须进食适宜数量的食物，一般情况推荐每日摄入1600~2000千卡的能量。最好选择优质、易消化的蛋白质，如瘦肉、鸡蛋、鱼肉，以及蛋白粉，并补充足量的维生素和微量元素。</p>\r\n<p>　　同时，必须限制钠离子的摄入。</p>\r\n<p>　　饮食要点</p>\r\n<p>　　应避免过多食入产气的食物而增加心脏负担。</p>\r\n<p>　　易产气的食物包括粗粮、土豆、红薯、韭菜、菠菜、芹菜、洋葱、萝卜、豆类、奶类等。</p>\r\n<p><!--分页--></p>\r\n<p align="center"><img src="http://img.022net.com/ImgFile/200910/19/44/11416879047258162256.jpg" />\r\n</p>\r\n<p align="left">&nbsp;&nbsp;&nbsp; 必要时还要从食物中补充足够的钾离子，以增强心脏的收缩能力。</p>\r\n<p>　　对于心脏病患者来说，最佳的胃肠道补钾的方法是将绿叶蔬菜切碎后制作蔬菜汤汁，直接饮用或者用其来制作其他食物。</p>\r\n<p>　　<strong>肾脏疾病</strong></p>\r\n<p>　　当肾脏有疾患时，饮食营养会有很大的不同。</p>\r\n<p>　　首先要控制蛋白质的食入量，就是说从荤食和素食中食入的总蛋白质数量不能超标，过多的蛋白质会导致肾功能进一步恶化。</p>\r\n<p>　　临床营养师会根据病情程度制定出一个合适的蛋白质食入量。</p>\r\n<p>　　为了让有限的蛋白质在体内发挥最大作用，还要适当提高糖类的食入量。</p>\r\n<p>　　应将素食中节省出的蛋白质数量让给荤食，尽可能多吃一些荤食。</p>\r\n<p>　　当尿量减少时，需要限制钾离子的食入量，选择含钾低的食物。</p>\r\n<p>　　这与心脏疾患正好相反。</p>\r\n<p>　　饮食要点</p>\r\n<p>　　由于钾离子普遍存在于各种食物中，所以在食物制作过程中有效减少钾离子才是最重要的。</p>\r\n<p>　　例如，可以将蔬菜切碎后先用热水烫过再炒，并且勿食汤汁以防止摄钾过多。</p>\r\n<p>　　同时，慢性肾衰病人不要吃含磷高的食物，过多的磷可加速肾功能衰竭。</p>\r\n<p>　　内脏类、豆类、全谷类(如糙米、全麦面、薏仁、麦片等)、坚果、奶类均是含磷高的食物。</p>\r\n<p>　　此外，给食欲不好的肾功能衰竭患者喝麦片粥和普通牛奶的做法也是错误的。</p>\r\n<p><!--分页--></p>\r\n<p align="center"><img src="http://img.022net.com/ImgFile/200910/19/12/2695915157728711068.jpg" />\r\n</p>\r\n<p align="left"><strong>&nbsp;&nbsp;&nbsp; 肺部疾病</strong></p>\r\n<p>　　当肺部有疾患时，尤其是慢性阻塞性肺病的患者，由于本身食欲下降，家属往往只给患者吃一些小米粥和面条，恰恰这类患者不能食入大量的主食(碳水化合物)。</p>\r\n<p>　　因为在三大供能营养素(蛋白质、脂肪、碳水化合物)中，体内碳水化合物代谢需要消耗的氧分子是最多的。这些呼吸困难的患者，血液中氧含量本身就已减少，这样的饮食只能是雪上加霜。</p>\r\n<p>　　饮食要点</p>\r\n<p>　　减少碳水化合物的比例，增加脂肪的摄入(消耗氧分子最少)，适当增加蛋白质。</p>\r\n<p>　　<strong>肝脏疾病</strong></p>\r\n<p>　　当肝脏有疾患时，每天吃多少食物也不是随性而定的。</p>\r\n<p>　　吃得太少不利于肝细胞的再生和愈合，吃得太多会形成脂肪堆积于肝脏。</p>\r\n<p>　　饮食要点</p>\r\n<p>　　肝病患者如果想要进食含蛋白质高的荤食，则需要视病情轻重来定;</p>\r\n<p>　　有严重感染、消化道出血、严重腹水的肝病病人，蛋白质的摄入可以多一些(每公斤体重可达1.5克);</p>\r\n<p>　　对于肝性脑病的肝病病人，蛋白质的摄入要有严格限制(每公斤体重0.6~0.8克)。</p>\r\n<p>　　许多疾病对饮食都有一定的限制。患者和家属一定要多请教临床营养师，请他们帮助配备病人的一日三餐，这样会对疾病的康复大有益处。</p>', 'gwm', 0, 26),
(52, '预约挂号方便市民看病 患者爽约医院遭遇尴尬', '', '', '', '2009-10-19 11:06:13', '116.228.141.77', '从１０月开始，我市所有三级医院均按卫生部要求开展预约诊疗服务，并在预约挂号时推广采取实名制方式。预约挂号现在开展得怎么样？昨（18）日，记者走访城区各大医院发现，电话预约挂号在为患者提供方便的同时，医院也遇到市民爽约的烦恼。<br />\r\n<br />\r\n　　<b>记者体验<br />\r\n<br />\r\n　　挂号不用再排队</b><br />\r\n<br />\r\n　　“我想预约明天的消化内科。”昨日下午，家住阳光新城的陈女士打进市中心医院电话进行挂号预约。工作人员根据医生的时间，安排陈女士第二天上午10点30分来医院看病。记者在现场看到，从市民打进电话预约挂号到放下电话，整个时间不足一分钟。<br />\r\n<br />\r\n　　昨日下午3点，记者打进市中心医院的预约挂号电话，表示想预约一个心内科的专家号。工作人员询问记者的就诊卡及什么时候可以来医院就诊，记者表示第二天下午有时间，工作人员又详细询问了记者的姓名等，逐一登记后告诉记者，第二天下午3点30分来医院取号便可就诊。整个时间不足一分钟。随后，记者拨打了市三医院的预约专线，流程跟中心医院差不多。此外，工作人员还叮嘱记者，现在虽然挂号不用再排队，但一定要按照约定时间前来医院取号就诊。<br />\r\n<br />\r\n　　<b>方便患者<br />\r\n<br />\r\n　　每天百余人预约</b><br />\r\n<br />\r\n　　据市中心医院相关工作人员介绍，为了方便患者就医，医院从今年7月1日起就已经实行实名制预约了。来医院的患者需要办理就诊卡，患者在办卡时需要出示身份证，看病时输入卡号就会在电脑上显示名字。同时，就诊卡上还有专家的预约电话，让患者提前预约，节省时间。实行预约挂号以来，已经有5300余人预约，平均每天有大约100人。<br />\r\n<br />\r\n　　针对外地患者挂号不方便的问题，市三医院也已经推出了电话预约服务。工作人员表示，患者只需要打入医院挂号室的电话，就可以拿到号，目前已经有近百名患者受益。主要在心理咨询科、外科等科室预约，由于部分患者的病情涉及隐私，所以医院对实名制并不强制要求。<br />\r\n<br />\r\n　　<b>医院尴尬<br />\r\n<br />\r\n　　无故爽约忽悠医生</b><br />\r\n<br />\r\n　　“电话预约挂号的患者只来了四个，还有两人没有来。”记者在市三医院采访时，工作人员无奈地说，可能患者突然间感觉不舒服，就打电话预约挂号，但第二天有其他事情就不来了。但据了解，这种爽约的情况还较少。<br />\r\n<br />\r\n　　中心医院一位工作人员说：“在中心医院心理门诊科，有时候会遇到预约的6个人只有一人来看病。这种爽约的情况和天气有关，有时候头天预约，第二天遇到下雨，患者就不会来看病。”<br />\r\n<br />\r\n　　据介绍，目前，城区几大预约挂号的医院遭遇爽约的情况还不少，共有上百起。这不仅忽悠了医院和医生，也损害了其他患者的利益。“如果这种爽约的情况出现三次，我们就不会再为其办理预约服务。”<br />\r\n<br />\r\n　　<b>市民建议<br />\r\n<br />\r\n　　加大宣传广泛推广</b><br />\r\n<br />\r\n　　记者采访中还了解到，不少市民难改传统的就医观念，仍然习惯到医院排队挂号。在三医院，前来看病的孙女士觉得，打电话预约挂号不如到医院排队挂号“踏实”，“预约挂号听说过，但看了这么多年的病，都是得了病到医院来挂号，然后做检查和看医生，最后拿药，还是不适应打电话挂号。” <br />\r\n<br />\r\n　　在医院看病的李先生告诉记者，自己是从朋友那听说这种挂号方法，头一天打电话预约挂号后，自己还不是很放心，直到第二天真的在预约时段内看上病了，才放下心来。他表示，这种方便快捷的看病途径是老百姓真正需要的，但是他目前还不太习惯。<br />\r\n<br />\r\n　　还有一些市民表示，预约挂号有利于患者就医咨询，提前安排就医计划，减少候诊时间，也有利于医院提升管理水平，提高工作效率和医疗质量。因此，医院方面也应加大宣传，让更多的市民知晓。<br />\r\n', 'gwm', 0, 27),
(53, '“艾滋卖淫女”初检无艾滋 警方称已锁定嫌疑人', '', '', '', '2009-10-19 11:21:34', '116.228.141.77', '<img src="http://img.scol.com.cn/200910/19/47/4977544954772471467.gif" />\r\n<br />\r\n　　前日，闫德利的父亲在河北容城家中接到女儿的电话（左）。闫德利家人在村里搜集到的传单（右）。记者 张涛 摄 <br />\r\n<br />\r\n　　河北容城警方称已基本锁定嫌疑人，呼吁北京警方介入 <br />\r\n<br />\r\n　　昨日，博文中自称患艾滋卖淫，当事人闫德利返回老家保定容城县，接受艾滋病检测。昨晚，闫亲属告诉媒体，初步检测显示其并没有患艾滋病。同时，正在调查此事的当地警方表示，期望能与北京警方联手侦查。<br />\r\n<br />\r\n　　<b>当地领导认为损害容城形象</b><br />\r\n<br />\r\n　　两天来，容城县疾控中心也一直在寻找闫德利。为此，该中心多次与闫家联系，并于前晚还派人赶到闫家，要求闫德利务必接受艾滋病检测。疾控中心负责人称，他们接到领导指示，全天等候闫德利。<br />\r\n<br />\r\n　　昨晚，闫德利的堂哥闫国清透露，闫德利于昨天下午两点，在疾控中心接受检测。5个小时后，家属得到消息，闫德利的艾滋病毒检测呈阴性，“她并没有患艾滋病。”<br />\r\n<br />\r\n　　但闫国清表示，家属为了彻底消除公众疑问，还将在当地卫生部门的陪同下，到更高级别的机构检测。届时结果再出来，家属不排除召开新闻发布会，以正视听。<br />\r\n<br />\r\n　　此前，众多法律专家评论说，倘若“艾滋卖淫”情节属实，闫德利将面临刑事追究。<br />\r\n<br />\r\n　　据悉，此事在网上闹得沸沸扬扬，容城当地也几乎家喻户晓，让当地领导认为“损害了容城的形象”，故要求各部门尽快查清真相。<br />\r\n<br />\r\n　　<b>呼吁北京警方介入调查</b><br />\r\n<br />\r\n　　昨日上午，容城县公安局一位负责人说，目前掌握的线索显示，网上自发艳照、自曝艾滋的“闫德利”应为他人冒名，其前男友有重大嫌疑。“他不但有途径拥有性爱视频和怀孕诊断单，也有动机搞臭闫德利的名声。”<br />\r\n<br />\r\n　　据查，此人家住北京市朝阳区，在某拆迁办工作，已有妻儿。今年夏天，此人曾赶到闫德利老家，向闫家索要分手赔偿，双方发生殴斗。<br />\r\n<br />\r\n　　之后，有人趁夜在贾光村散发彩色传单，称闫德利在北京做小姐，还以怀孕为由敲诈嫖客，传单附有闫的全家福和裸体照，以及闫家人的电话号码。农历七月七深夜，还有人往闫家院子里扔燃烧瓶。闫家坚信这些都是闫德利前男友所为。<br />\r\n<br />\r\n　　据当地警方初步了解， “艾滋卖淫女”最早的博客和照片，都发表于北京的IP，“容城即使想破这个案，也没有权限。”<br />\r\n<br />\r\n　　一位警方负责人透露，他们曾与北京市公安局治安总队联系，请求联手破案。“请媒体也帮助呼吁一下。”<br />\r\n<br />\r\n　　<b>闫德利回避记者</b><br />\r\n<br />\r\n　　但通过闫家，记者无法得知闫德利前男友的电话。“他经常换号，我们也不知道。”<br />\r\n<br />\r\n　　昨日中午，闫德利在容城县贾光乡派出所做了一份报案笔录。据知情警察解释，鉴于此事尚未立案，警方只能根据闫所述内容，再研究处理意见。<br />\r\n<br />\r\n　　“其实她一开始并不配合。”这位警察说，在警方的说服教育下，闫德利才回到了老家。<br />\r\n<br />\r\n　　此前，闫德利及其亲属都答应将与媒体见面，“说出真相。”到昨日，闫的母亲却表示，有公安局管，不用媒体费心了。<br />\r\n<br />\r\n　　在当地开车接送闫德利的堂兄闫国清，任容城县科协主席。昨日，他留给记者的电话，也一直无法接通。<br />\r\n<br />\r\n　　昨晚，闫德利再次赶到贾光乡派出所接受调查。9时50分左右，她离开派出所，随从的闫国清拒绝记者采访其堂妹。<br />\r\n<br />\r\n　　<b>- 讲述</b><br />\r\n<br />\r\n　　<b>容城公安副局长“被嫖妓”</b><br />\r\n<br />\r\n　　警务通手机号上嫖客名单，称将起诉诽谤者<br />\r\n<br />\r\n　　“艾滋女卖淫”事件爆出后，不少网民对279个所谓“嫖客手机号”很感兴趣，甚至拨打核实，结果都遭到了否认。这些“嫖客”中，有16岁的少年，还有女性。<br />\r\n<br />\r\n　　让容城县公安局副局长孟贺安气愤的是，他的警务通手机号也在其列。连日来，不断有陌生人给他打电话、发短信。“哈哈，你出名了，一夜风流换来艾滋，等死吧！”有人如此嘲笑。<br />\r\n<br />\r\n　　“我根本不认识闫德利。”孟贺安说，“但我能想起这个名字。”<br />\r\n<br />\r\n　　8月的一天，孟贺安值班时，接待了两名上访者，一男一女。男子叫杨某某，自称在北京发生一起交通事故，容城县女子闫德利欠他5000元赔偿金不还，他去闫家要账被打，“派出所处理不公，他要求派出所全体回避”。<br />\r\n<br />\r\n　　孟向派出所了解，获知殴斗的原因是分手赔偿纠纷，加之杨的要求于法无据，就拒绝了他。交涉无果，孟贺安应杨的要求，给了他自己的警务通号码。<br />\r\n<br />\r\n　　进入10月中旬，孟贺安连续接到几条彩信，称“我是闫德利，你进入我的QQ空间，会有惊喜”，并附有浏览地址。“我手机看不了彩信，没在意。”孟说。<br />\r\n<br />\r\n　　直到279个“嫖客”号码公开后，孟接到下属报告，称“你的号码上网了，不太好……”他打开那些QQ空间，看到了大量艳照，和自己的号码。<br />\r\n<br />\r\n　　同时接到彩信的，还有贾光乡派出所所长张景战。<br />\r\n<br />\r\n　　“我一定要起诉这个诽谤我的人。”孟贺安现在每接到一个不明电话和短信，都随手记下，希望这些“不明真相的网友”，能成为其诉讼的人证。<br />\r\n<br />\r\n　　<b>- 疑问</b><br />\r\n<br />\r\n　　<b>早有艳照 为何不立案？</b><br />\r\n<br />\r\n　　警方称传播淫秽物品超过一定数目才构成犯罪<br />\r\n<br />\r\n　　早在几个月前，闫德利所在的贾光村，就有人散发淫秽传单，其所述内容，与其后博客上的大同小异，容城警方当时为何不立案侦破呢？<br />\r\n<br />\r\n　　同时也是受害者的容城县公安局副局长孟贺安说，按照法律规定，传播淫秽物品超过一定数目，才构成犯罪。闫家当时向派出所报案时，并没有证明达到了这个标准。<br />\r\n<br />\r\n　　在前天，闫德利父母向记者展示了半编织袋传单，“还有不少被邻居们看了后，点着引火了。”农历七月七晚，院子被扔进燃烧瓶后，闫家也报了案，警方赶到现场进行了勘查，但至今仍无破案头绪。<br />\r\n<br />\r\n　　“艾滋女卖淫”爆出后，容城警方又发现，因发帖的IP地址在北京，所以只能等北京侦破此案后，容城警方再将之前案件归并处理。', 'gwm', 0, 21),
(54, '“不孕潮”中国涌动 18年无婴儿出生不是噩梦！', '', '', '', '2009-10-20 09:56:56', '116.228.141.77', '\r\n<img alt="“不孕潮”中国涌动 18年无婴儿出生不是噩梦！" src="http://image.39.net/0910/19/510434_.jpg" />\r\n<br />\r\n\r\n<p><br />\r\n<strong>“不孕潮”在中国涌动</strong></p>\r\n<p><strong>　　生个孩子有多难？</strong></p>\r\n<p>　　中国人不孕不育率已接近发达国家水平，精神和环境的双重压力让我们的身体付出沉重的“生命代价”</p>\r\n<p>　　 2027年，英国。一个女人坐在轮椅上，随着她略显呆滞的<a class="blue" href="http://hzpk.39.net/hz/hufu/yanbu/6633f.html%3C!return_edit%3E" target="_blank"><font color="#000000">眼神</font></a>，镜头缓缓摇向对面墙上的一幅幅触目惊心的新闻图片———“不孕率达90％！”“18年来地球上没有一个婴儿出生！”</p>\r\n<p>　　这一美国科幻片《人类之子》中场景，或许真的会成为现实。 </p>\r\n<p>　　根据一项名为《国家家庭计划》的国外研究机构调查显示：如今，全球有10％家庭有不孕问题。有国外专家甚至将这一现象称为“不孕潮”。</p>\r\n<p>　　如今，这股“不孕潮”在中国也开始涌动，据称，“近年来，中国国民的生育能力不断下降，不孕不育的比例已与西方接近。”</p>\r\n<p><strong>　　工作压力让怀孕搁浅</strong></p>\r\n<p>　　一组数字触目惊心：20年前，我国育龄人群中的不孕不育率仅为3%，处于全世界较低水平。而如今，全国平均每8对育龄夫妇中就有1对面临生育方面的困难，不孕不育率攀升到12.5%～15%，接近发达国家15%～20％的比率。据今年8月底召开的2009中国不孕不育高峰论坛公布的《中国不孕不育现状调研报告》显示，我国不孕不育者以25岁至30岁人数最多，呈年轻化趋势。</p>\r\n<p>　　数字背后是一张张无助和焦虑的面孔。当35岁的林女士走进北京一所生殖中心的候诊大厅时，里面的情景让她非常惊愕：大厅里人头攒动，拥挤不堪。坐在她对面的一对年轻夫妇满脸焦虑，不时伸头望向诊室的门。“我没想到现在有这么多人受不孕不育症的困扰！”林女士感慨万分。</p>\r\n<p>　　林女士是北京某外资企业工作的白领，高节奏的工作让她疲于应<a class="blue" href="http://hzpk.39.net/hz/xs/nanshi/a10f4.html%3C!return_edit%3E" target="_blank"><font color="#000000">战</font></a>，每天下班后坐夜班车回家的路程变成了最美的时光。林女士坦言，正是因为工作的原因，怀孕计划搁浅直至错过了最佳生育时期。</p>\r\n<p>　　在生殖健康专家王一飞看来，事业对女性的压力是造成不孕不育的重要原因，“大城市的女性不孕的同比增长率已经高于全球平均水平。其中不孕女性不少都是高学历、高收入的知识女性。”<a class="blue" href="http://yyk.39.net/bj/zonghe/4fa63.html%3C!return_edit%3E" target="_blank"><font color="#000000">北京大学第一医院</font></a>生殖中心主任左文莉的一项临床研究也显示，随着现代生活方式的改变，普遍的晚婚晚育现象、不良的现代生活方式（如过度节食减肥、吸烟饮酒、熬夜）、巨大的工作精神压力，是造成不孕不育率迅速上升的主因。</p>\r\n<p>　<strong>　环境污染扼杀生命</strong></p>\r\n<p>　　另外，导致中国不孕不育夫妇迅速增加的一个重要原因是在工业化和城市化过程中，环境污染的加剧，使男性<a class="blue" href="http://jbk.39.net/keshi/nanke/6eff4.html%3C!return_edit%3E" target="_blank"><font color="#000000">无精症</font></a>、少精症、弱精症病人明显增加，生精细胞严重损害，精子质量下降。</p>\r\n<p>　　据相关统计表明，与三四十年前相比，中国男性每毫升精液所含<a class="blue" href="http://jck.39.net/jiancha/huaxue/jyhqlxy/9c2cf.html%3C!return_edit%3E" target="_blank"><font color="#000000">精子数</font></a>量从1亿个左右降至目前的2000万到4000万个。现代化程度越高的地区，精子质量下降速度越快。<a class="blue" href="http://yyk.39.net/bj/zonghe/4cef5.html%3C!return_edit%3E" target="_blank"><font color="#000000">北京大学第三医院</font></a>泌尿外科和男科门诊的洪锴博士告诉《国际先驱导报》：“来看病的患者越来越多，他们不育的原因都是一个：精子数量少，质量下降。”</p>\r\n<p>　　不孕不育的发病率不断上升，想要孩子的夫妇就只能仰赖精子银行或是人工受孕。几乎每天，从凌晨5时开始，北京大学第三医院生殖医学中心门前就排起了数十米的长龙。很多夫妇来此等待接受人工受孕，有时一排队就是一两年，很多等不到精子的夫妻无奈以离婚收场。</p>\r\n<p><strong>　　一切从健康生活开始</strong></p>\r\n<p>　　从3％到1/8，从自然受孕到人工受孕，随着我国不孕不育的比率向西方国家靠拢，不孕不育的发展图谱也十分相似。4年前，英国生殖专家就预测，10年后，1/3的欧美国家的孕期夫妇将无法怀孕，生育难已成为欧美“通病”。而如今在美国，人工受孕成为不孕夫妻的救命稻草，每年创造着数千个新家庭。不过随之而来的副作用是，越来越多的婴儿是双胞胎甚至八胞胎，<a class="blue" href="http://jbk.39.net/keshi/fuchan/chanke/4e33f.html%3C!return_edit%3E" target="_blank"><font color="#000000">早产</font></a>成为常见现象，同时婴儿死亡和患疾病的风险增加。</p>\r\n<p>　　两个月前，接受人工受孕的马什特拉早9周生下一对双胞胎，但因为两个婴儿无法自主呼吸，在医院护理51天后才恢复健康，期间的医药费高达120万美元。在美国、英国、德国，这样的事情正在频频发生。</p>\r\n<p>　　西方国家的前车之鉴早就应当让我们警醒。其实，一部分不孕不育完全可以预防，甚至避免。除了避免过度晚婚晚育外，辅助手段是调整生活方式。首先，男女都应该避免体重不足或超重，因为肥胖会影响男性精子的数量和活力，也可能导致女性月经异常。要做爸爸妈妈的人，还要戒烟戒酒。有研究表明，一个星期喝5次酒，会影响妇女的生育能力；吸烟会降低女性40%的怀孕几率。为了避免“被丁克”，“戒掉”肥胖、抽烟、咖啡、不规律的生活，恢复健康的生活习惯是年轻夫妇马上要做的事情。</p>', 'gwm', 0, 27),
(55, '我们的眼泪为何而流？', '', '', '', '2009-10-20 09:59:07', '116.228.141.77', '<img alt="我们的眼泪为何而流？" src="http://image.39.net/0910/18/509518_s_0000.jpg" />\r\n\r\n<p><br />\r\n　　我们哭泣是因为哭泣会让我们感觉好些吗？或者哭泣能清除掉体内那些让我们感觉压抑的化学物质吗？抑或是如Oren Hasson在他的新理论里面说的那样，一次正确的哭泣能让你受到关注、获得认同？ </p>\r\n<p>　　我们会在疼痛的时候流眼泪，但流泪的目的是什么呢？ </p>\r\n<p>　　一位名叫Oren Hasson科学家最近提出了一条新理论来解释为什么哭泣在进化：眼泪可以让外界知道你已经降低了防范。 </p>\r\n<p>　　“哭泣是一项已经高度进化的行为，”以色列特拉维夫大学（Tel Aviv University）的进化生物学家Oren Hasson说，“我通过分析研究认为，泪水可以使视线模糊，因而可以降低防范，还可以有效地传递出让对方顺从你的信号，或是来寻求帮助，甚至让两个人或者一群人凝聚起来。” </p>\r\n<p>　　在自然界中，人类的感情是独一无二的，因而我们会流眼泪。在过去，研究者认为哭泣可以让那些让我们感觉压抑的化学物质排出体外，或者仅仅是让我们感觉好些，婴儿哭则是因为他们又健康问题。 </p>\r\n<p>　　如今，Hasson指出，当泪水模糊我们视线的时候，它们可以轻易地防止我们进行攻击性行为。眼泪原本就显示了我们的脆弱性，从战略上说，它可以让其他人在感情上与你联系在一起。 </p>\r\n<p>　　Hasson认为，泪水可以建立并加强人与人之间的关系。比如，“你可以通过哭泣显示你已经顺从于一个对你发起攻击的人，这就有可能引来敌人对你的怜悯，或是获取其他人对你的同情心，甚至有可能获得他们在重要的支持”。 　　</p>\r\n<p>　　此外，Hasson说，与他人分享眼泪，“就代表着我们已经联系在一起，我们可以成为朋友，因为我们分享的是同一种感情，这就是严格意义上的人类”。 </p>\r\n<p>　　Hasson补充说道：“当然，这种进化的行为的效力总是取决于你哭诉的对象以及你哭的伤心程度。而如果你在不适合表达感情的地方哭，比如办公室，将不会有任何帮助。” </p>\r\n<p>　　Hasson的新理论“提出了最有可能的一种有关眼泪和哭泣功能进化的一种假说”，美国得克萨斯大学的进化心理学家David Buss这样评价，他并没有参与Hasson的研究。他说：“其他人都在研究眼泪可能具备的功能，而Hasson思考这个问题的角度却是高度原创性。</p>', 'gwm', 0, 23),
(56, '疯狂锻炼胸肌四部曲', '', '', '', '2009-10-20 10:01:37', '116.228.141.77', '想要练出完美胸肌，就要系统的进行锻炼和练习。那么，在健身房中，该如何自己训练呢！？下面，跟着健身专家，一起来看看，完美胸肌如何训练成型！<strong>\r\n<img alt="疯狂锻炼胸肌四部曲" src="http://image.39.net/0910/11/502294_s_1170.jpg" />\r\n\r\n<p><br />\r\n　　（一）、平卧推举</strong></p>\r\n<p>　　作用：发展胸大肌外侧翼，中间沟、下缘沟的力量。</p>\r\n<p>　　要领：仰卧凳上，必须使躯干从肩部到臀部成“桥形”，只有肩背部和臀部接触凳面，手握杠铃放在第3根肋骨上（即在胸部乳头以上一厘米左右）向正上方推起至两臂伸直。</p>\r\n<p>　　注意事项：卧推举要两臂伸直，并保持胸肌紧张。</p>\r\n<p>　　呼吸方法：上推时用鼻子吸气，还原时用口呼气。</p>\r\n<p><strong>　　（二）、上斜卧推举</strong></p>\r\n<p>　　作用：锻炼胸大肌的上部及外侧翼上端。</p>\r\n<p>　　要领：仰卧在斜板角度为25-35上，双手正握杠铃，用胸大肌的收缩力争向上推起至两臂伸直，然后缓慢地复位。</p>\r\n<p>　　呼吸方法：上推时用鼻子吸气，还原时用口呼气。</p>\r\n<p>　　注意事项：斜板角度的变化对胸部的练习效果也有所改变。</p>\r\n<p>　　另如横杠贴近乳头部位上推，对胸大肌内侧及外侧训练效果为佳。</p>\r\n<p>　　如横杠贴近颈部，对胸大肌上半部和里面半部训练效果最佳。</p>\r\n<p><strong>　　（三）、下斜卧推</strong></p>\r\n<p>　　作用：锻炼胸大肌外侧翼下部及下缘沟。</p>\r\n<p>　　要领：倒仰卧在斜板角度为20-30上，用胸大肌的收缩力争向上推起至两臂伸直，然后缓慢地复位。</p>\r\n<p>　　呼吸方法：上推时用鼻子吸气，还原时用口呼气。</p>\r\n<p>　　注意事项：勾脚和斜板要安全、牢固，上推时肱三头肌不要主动用力。</p>\r\n<p>　　以上三种卧推方法都可以用壶铃或哑铃顶替，其效果相同。</p>\r\n<p><strong>　　（四）、哑铃卧推</strong></p>\r\n<p>　　作用：锻炼胸大肌外侧翼下部及下缘沟。</p>\r\n<p>　　要领：平卧在凳上，双手掌心相对直臂相靠持哑铃，下放时，掌心逐渐向前至肩两侧，用胸大肌的收缩力争向上推起至两臂伸直，然后缓慢地复位。</p>\r\n<p>　　呼吸方法：上推时用鼻子吸气，还原时用口呼气。</p>\r\n<p>　　注意事项：下放时，掌心逐渐向前至肩两侧，这时，要两臂自然下垂，成手、肘面与地面垂直，上推时肱三头肌不要主动用力。</p>', 'gwm', 0, 32),
(57, '基本药物零售指导价明执行 虚高销售高罚款', '', '', '', '2009-10-22 09:40:11', '116.228.141.77', '<p align="center"><img alt="基本药物零售指导价明执行 虚高销售高罚款" src="http://img1.gtimg.com/news/pics/22571/22571831.jpg" />\r\n</p>\r\n<p>　　中广网北京10月21日消息 按国家发改委要求，市面上流通量和使用量很大的基本药品制定了零售指导价（简称基本价）。基本价明日起强制执行，一经发现虚高销售，最高可处以千元以上罚款，屡犯者甚至可能吊销营业执照。</p>\r\n<p>　　基本价适用范围主要为市民常用药、基本药品，如三黄片、藿香正气液、十滴水、青霉素胶囊等，全国共计2787种剂型，涉及上百个种类和药品生产企业。</p>\r\n<p>　　记者从市物价局获悉，参照具体情况，我市基本价确定的药物比国家发改委公布的2349个具体剂型规格品价格足足多了338种。如阿莫西林，在我市就增加了250mg×10片等六种规格。</p>\r\n<p>　　与以前的药价相比，调整后的价格有45％的药品降价，49％的药品价格未做调整；仅有6％的短缺药品价格有所提高。这次基本药物指导价是按药品通用名称制定，不因生产厂家的不同而出现价格差异。重庆晚报 </p>', '', 0, 26),
(58, '上海中小学接种甲流疫苗遇冷 家长质疑安全性', '', '', '', '2009-10-22 10:51:30', '116.228.141.77', '<p>新民网10月22日报道 “学校要为孩子统一接种甲流疫苗，你的态度是?”近日，在上海的育儿论坛上很多家长都发帖询问是否要为孩子接种甲流疫苗一事。新民网记者看到，不少家长持怀疑态度，表示不愿接种。</p>\r\n<p>据悉，上海将在10月中旬至年底前后，基本完成“重点人群”甲型H1N1流感疫苗的接种。“重点人群”包括：医疗卫生机构一线工作人员，口岸、公安、民航、交通等部门的关键岗位公共服务人员，托幼机构教职员工、中小学校学生及教职员工。</p>\r\n<p>家长犹豫不决论坛发帖寻意见</p>\r\n<p>从本学期开学起，便有家长在论坛里发布《上海市学校流感信息汇总专贴》，吸引了不少家长跟帖。很多家长都及时汇报了孩子所在学校有关发热、流感的状况。</p>\r\n<p>近日，又有很多家长在论坛发帖询问是否给孩子接种甲流疫苗。新民网记者在一个投票帖中看到，共有73位家长参加对孩子接种甲流疫苗态度的投票，其中，65位家长表示不同意接种，占总数的89.04%，3位家长表示非常担心，但还是同意接种，仅3位家长称不担心，同意接种。</p>\r\n<p>跟帖中，大多数家长对这种新型疫苗持不信任态度。网名为“乖猪猪妈妈”的网友说：“昨天犹豫了很久，写了同意。刚看完(育儿论坛)小学圈子里‘关于甲流疫苗接种’话题，决定不打。专家都觉得疫苗论证还不够成熟，接种要谨慎。”</p>\r\n<p>区县卫生局组织甲流疫苗接种遇冷</p>\r\n<p>“我们在组织中小学接种甲流疫苗时，确实有很多家长不愿意孩子接种，我们的原则就是自愿。”某区卫生局有关人士向新民网记者表示。</p>\r\n<p>10月21日，徐小姐告诉记者，她的孩子所在的班级里仅有三分之一的孩子准备接种疫苗。她一开始也并不同意孩子去接种，怕疫苗有副作用，其丈夫则认为注射疫苗总归有个保护，万一真的感染了甲流，对身体伤害更大。</p>\r\n<p>“这种疫苗刚刚生产出来，我实在不愿意自己的孩子去做‘小白鼠’，但是，老师总归希望孩子去接种的，他们也不希望出什么事情。”陈小姐的孩子已经接种了疫苗，但她至今还比较担心。</p>\r\n<p>专家建议接种甲流疫苗</p>\r\n<p>新民网记者了解到，上海产甲流疫苗由上海生物制品研究所生产，重点人群接种所需的甲流疫苗由上海市政府采购，符合条件的市民可免费自愿接种。</p>\r\n<p>上海公共卫生中心临床中心副主任卢洪洲教授在接受新民网采访时表示，中小学生是比较活跃的、爆发疾病可能性较大的群体，综合考虑，政府将他们列为优先接种的行列里。“从目前甲流疫苗接种的效果来看，发生副作用的概率是非常低的，而且副作用的程度较轻，1-2天副作用的症状便可缓解;从保护性来看，还是有一定保护作用的。因此，我建议接种比较好。”卢洪洲说。</p>\r\n<p><br />\r\n此前，有媒体报道，中国工程院院士钟南山在提及甲流疫苗时曾表示，大规模接种一定要慎重，“现在完成的安全性的观察，对象还是比较少。做大规模、大面积、广泛的接种之前，要看两个情况。第一个，它的安全性是不是已经有绝对的保证;第二个就是要看风险评估的机制，目前比较适合的是有针对性的接种和自愿接种。”</p>\r\n<p>对于钟南山的话，卢洪洲表示，目前我国的疫苗生产已经非常成熟，虽然每年都有副作用的案例发生，但从总体来看，利大于弊，尽管少数人有副作用，但接种疫苗仍然可以避免感染流感。 (本文来源：新民网 )&nbsp; <br />\r\n</p>', '', 0, 35),
(59, '女性进化趋势：身体更棒更加丰满', '', '', '', '2009-10-22 10:54:01', '116.228.141.77', '<p>北京时间10月22日消息，据英国《新科学家》杂志报道，美国耶鲁大学的研究人员发现，随着人类的进化，未来女性的身材可能更加矮小和丰满，同时拥有更为健康的心脏以及更长的生育期限。</p>\r\n<p>　　未来女性的这些变化是根据迄今为止发现的最强有力的证据预测的，它们的出现说明人类一直处于不断进化状态。</p>\r\n<p>　　医学进步意味着人类寿命不断增长，这种增长促使人们产生这样一种想法，人类已经不再受自然选择影响，也就是说，我们已停止进化脚步。美国耶鲁大学进化生物学家史蒂芬·斯特恩斯表示：“这种观点显然是错误的。”他指出，虽然生存状态的变化可能不再选择“更适合”的人类以及他们的基因，但生育方面的变化仍会产生这种影响。问题是拥有更多孩子的女性是否能够区分将遗传给下一代的特征。</p>\r\n<p>　　为了寻找这个问题的答案，斯特恩斯及其同事将目光投向弗拉明汉姆心脏研究计划获取的数据。这项研究计划开始于1948年，共对马萨诸塞州弗拉明汉姆的超过1.4万名居民的病史进行了跟踪调查，对一些家庭的跟踪对象涉及到3代人。</p>\r\n<p>　　研究过程中，斯特恩斯等人对2238名已经过了更年期和生育期的女性进行了研究。对于女性身高、体重、血压、胆固醇水平以及其它特征是否与所生孩子数量存在关系，他们进行了测试。与此同时，他们将源于社会和文化因素的变化进行约束，以计算自然选择影响这些特征的程度。</p>\r\n<p>　　根据他们的研究发现，通常情况下，与身材较高并且体重较轻的女性相比，身材更加矮小同时体重更高的女性往往能够孕育更多孩子。血压较低以及胆固醇水平较低的女性也能生下更多孩子。毫不令人感到惊讶的是，在相对更早的年龄产下第一个孩子的女性或者进入更年期时间相对较晚的女性也同样是“多产者”。值得关注的是，这些特征也会遗传给她们的女儿，女儿长大后成为与母亲一样的“多产者”。</p>\r\n<p>　　根据斯特恩斯进行的计算，如果这种趋势延续10代，与当前女性相比，截至2409年女性的平均身高将降低2厘米，平均体重则将增加1公斤。此外，生第一胎的时间也要比当前女性提前大约5个月，进入更年期的时间则比当前女性晚10个月。</p>\r\n<p>　　我们很难确定选择这些特征究竟为了什么，同时也很难辨别它们是否通过女性的基因遗传给下一代。但由于斯特恩斯将很多社会和文化因素加以控制，他的研究发现可能证明真正起作用的是遗传因素，而不是一种文化进化过程。</p>\r\n<p>　　在确定自然选择是否仍影响当前人类方面，斯特恩斯等人的研究并不具有开创性。所不同的是，此前的很多研究根据基因频率中的地理差异得出结论，而不是根据对生育成功进行的直接计算。从这个角度上说，斯特恩斯的研究可能是有史以来对现代人进化进行的最为详细的一次计算。他说：“令人感到好奇的是，我们仍可以在文化因素下方探测到生物学构架。对其它长期医学数据的分析能够加深我们对遗传与文化间相互影响的了解。”</p>\r\n<p>&nbsp;</p>', '', 0, 29);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(60, '如何进行防癌体检', '', '', '', '2009-10-22 17:01:09', '116.228.141.77', '<p>&nbsp;&nbsp; 如果您是40岁以上的人群，特别注重防癌体检，那么你应该做到一下几点：</p>\r\n<p>一、建议你在做常规体检的时候，一定注意选取防癌体检的项&nbsp;目。</p>\r\n<p>如查血的项目需要加上肿瘤标志物，实性脏器的肿瘤检查，需要影像学的检查如X线，空腔脏器需要内镜检查，如胃肠镜，体表肿瘤需要触诊或超声检查等。 </p>\r\n<p>二、要配合医生的检查。</p>\r\n<p>有些妇女只接受B超检查，不接受妇科检查，这样就漏了对子宫颈及阴道癌症的筛查时机。还有些人拒绝肛门指检。而70%——80%的直肠癌可以通过肛门指检发现。 </p>\r\n<p>三、根据自己的情况选择对应的检查项目。</p>\r\n<p>例如乙肝病毒携带者、常年吸烟者筛查应每半年一次，乳腺癌筛查每年一次。</p>\r\n<p>四、经济条件较好的人士，建议每年做一次PET-CT全身扫描。</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 37),
(61, '国内首例体检隐私侵权案体检者获胜 获补偿5000元', '', '', '', '2009-10-23 10:13:13', '116.228.141.77', '<p>　　昨天，浙江汉鼎律师事务所律师张立恒向记者透露，他代理的一起体检隐私侵权案，体检者获胜。将乙肝检测结果告知求职者所应聘的用人单位的杭州下沙街道社区卫生服务中心，将向原告支付5000元的补偿金。</p>\r\n<p>　　国内知名反乙肝歧视机构北京益仁平中心称，这是我国第一起体检者获胜的隐私侵权案。专家称其意义重大，将警示医疗体检机构增强对体检者隐私权的保护，并警示体检机构规范乙肝检测行为，促进从源头上消除乙肝歧视现象。</p>\r\n<p>　　□首席记者 刘忠/文图</p>\r\n<p>　　<strong>求职应聘</strong></p>\r\n<p>　　<strong>体检之后被拒录</strong></p>\r\n<p>　　今年25岁的郭林是中国近1亿乙肝病毒携带者(俗称乙肝携带者)中的一员。大学毕业后，郭林到杭州发展，于2007年5月17日到富士康集团统合电子(杭州)有限公司应聘“资讯专员”一职。笔试和面试都顺利通过后，公司通知他去医院体检。2007年6月1日，郭林到公司指定的下沙医院进行了自费体检。当天下午5时左右，公司以郭林是乙肝病毒携带者为由拒绝录用他。郭林称，他得知这一消息后，陷入震惊和恐惧。为了解自己的身体状况，他与“统合电子”多次交涉后，终于拿到了体检表。体检表显示他只是“乙肝携带者”，而不是“乙肝病人”，但虽多次交涉，公司的拒录决定依然无法更改。</p>\r\n<p>　　<strong>明文规定</strong></p>\r\n<p>　　<strong>体检者隐私权受保护</strong></p>\r\n<p>　　郭林称，被拒录后的他陷入了茫然，于是在网上搜寻相关的信息，希望能了解自己的身体状况，了解自己到底是否可以正常工作。</p>\r\n<p>　　在全国最大的乙肝携带者公益网站“肝胆相照论坛”上，他惊喜地发现，就在2007年5月18日，国家劳动和社会保障部、卫生部联合发布了《关于维护乙肝表面抗原携带者就业权利的意见(劳社部发［2007］16号)》，其中规定，用人单位在招工时不得进行乙肝检测，并规定，“各级各类医疗机构在对劳动者开展体检过程中，要注意保护乙肝表面抗原携带者的隐私权”。郭林发现，他的遭遇就发生在这一新规生效之后，应该受到新规的保护。</p>\r\n<p>　　郭林还发现，《中华人民共和国传染病防治法》第十二条也规定：“疾病预防控制机构、医疗机构不得泄露涉及个人隐私的有关信息、资料。”通过“肝胆相照”网站，郭林联系到了公益律师，经咨询他了解到，体检医院未经他同意便将体检结果告知医院的行为，构成了对他隐私权的侵犯，不仅违反了政府的新规，也违反了国家的法律。这时，从不服输的他，又燃起了依法维权的念头。</p>\r\n<p>　　<strong>不屈不挠</strong></p>\r\n<p>　　<strong>三次起诉医院终获胜</strong></p>\r\n<p>　　为了督促行政部门纠正体检医院非法泄露隐私的行为，2007年11月，郭林首先向杭州市江干区卫生局投诉下沙医院违规体检。在投诉未得到满意回复的情况下，2008年3月，郭林又委托公益律师将体检单位下沙医院告上了江干区法院；5月13日，法院驳回了郭林的起诉，理由是被告杭州经济技术开发区下沙医院不在江干区法院管辖范围之内；2009年5月，郭林再次起诉，将被告医院名称按照法院的提示改为“杭州江干区下沙医院”，一个月后，他的起诉再次被驳回，理由是该医院已更名为“杭州经济技术开发区下沙街道社区卫生服务中心”。</p>\r\n<p>　　2009年8月份，郭林在律师的帮助下第三次向法院递交了起诉书。8月20日，杭州市江干区法院终于立案受理了郭林的起诉，并于9月16日适用简易程序进行了开庭审理。</p>\r\n<p>　　10月9日，杭州市江干区人民法院在对原、被告双方进行调解后，下达了《民事调解书(2009)杭江民初字第1981号》。记者在调解书上看到，法院依照适用简易程序公开进行了审理。</p>\r\n<p>　　审理过程中，经法院主持调解，双方当事人自愿达成协议并签字：杭州经济技术开发区下沙街道社区卫生服务中心补偿郭林人民币5000元。法院对这一协议进行了确认。</p>\r\n<p>　　据悉，被告方已经将5000元款项缴纳给了法院，郭林很快就能拿到这笔补偿款了。</p>\r\n<p>　　<strong>专家观点</strong></p>\r\n<p>　　<strong>侵犯体检隐私权需杜绝</strong></p>\r\n<p>　　“医院最终能认识到自己的错误，这是最让我高兴的。”郭林说。郭林表示，自己之所以最后能获胜，主要是因为最近两年法律和政策环境的改善。“现在法律对乙肝携带者的保护程度比两年前进步了许多，政府对乙肝歧视问题的重视程度也提高了许多，整个社会环境越来越有利于我们”，郭林说，“我很庆幸，自己能在公益律师、公益机构和乙肝携带者朋友们的支持下把维权坚持了下来，我也想告诉所有的乙肝携带者朋友，坚持下去，就能看到胜利。”</p>\r\n<p>　　郭林的代理人、浙江汉鼎律师事务所张立恒律师介绍：本案中，被告下沙街道社区卫生服务中心不仅违规为企业入职体检检查了乙肝指标，还将劳动者的个人隐私直接告知企业，导致劳动者被歧视而失去了工作的机会，违反了中央政府的文件和国家的法律，构成对劳动者隐私权的侵犯。</p>\r\n<p>　　国内知名反歧视公益人士、北京益仁平中心负责人陆军认为，医疗机构为企业入职体检进行乙肝检测的现象非常普遍，这成为就业领域乙肝歧视的源头。“卫生部近日宣布将取消入学、就业体检中的乙肝检测，这一举措非常正确，也非常有必要，这是杜绝乙肝歧视的根本途径。”陆军认为。</p>\r\n<p>　　陆军同时呼吁，主管部门应重视对体检机构隐私保护工作的监督和管理，杜绝体检单被随意翻看、随意转交的现象，保护体检者个人隐私信息。</p>\r\n<p>　　<strong>相关调查</strong></p>\r\n<p>　　<strong>有人助用人单位钻空子</strong></p>\r\n<p>　　10月19日，北京益仁平中心发布了《北京市区体检中心入职体检服务中的乙肝检测状况调查报告》。该机构调查发现，体检机构向用人单位提供的入职体检套餐普遍包含乙肝检测项目，一些体检机构甚至为用人单位出谋划策，帮助用人单位规避“乙肝歧视”的法律风险。</p>\r\n<p>　　全国最大的乙肝携带者公益网站“肝胆相照论坛”法律版版主杨占青认为，杭州一案获胜意义非常重大。“自去年以来，在北京、山东、浙江等省市都发生了乙肝携带者起诉体检医院侵犯隐私权的诉讼，乙肝携带者依法维权意识已经越来越强，如果医疗体检机构不提高自己的隐私保护意识，将会越来越多地被推到被告席上。”</p>', 'gwm', 0, 22),
(62, '中国开始甲流第二波疫情 中西部或成主战场', '', '', '', '2009-10-23 10:19:04', '116.228.141.77', '日前，中国疾控中心首席流行病学专家认为，我国内地甲型H1N1流感疫情第二波已经开始，由于缺乏防控经验，中小城市和中西部地区将成为防范甲流疫情的薄弱地带，或成为与之决战的主战场。 \r\n<p>　　“目前，中国内地甲型H1N1流感(简称甲流)病毒传播速度加快，疫情波及范围越来越广，发病数出现快速增长趋势，因此，可以说甲流疫情第二波已经开始”。这是中国疾病预防控制中心首席流行病学专家曾光教授做出的最新判断。</p>\r\n<p>　　随着秋冬季节的到来，沉寂了一段时间的甲流疫情再次吸引了人们的目光。不久前，国务院办公厅已发出关于应对甲型H1N1流感疫情防控工作通知。而世界卫生组织在每周一次的最新通报中称，目前不论是在南半球还是在北半球，甲流病毒仍是最为流行的流感病毒。</p>\r\n<p>　　<strong>目前全球流感病例近76%为甲流</strong></p>\r\n<p>　　世界卫生组织最新发布的一份通报显示，目前全球各地报告的流感病例中，有近76%是甲流病例。其余为普通季节性流感以及其他流感病例。</p>\r\n<p>　　从地域划分来看，目前北半球温带地区的流感传播情况复杂多变。在北美地区，美国近来报告出现流感样症状的人数呈上升趋势，目前的流感活动强度超过了以往普通季节性流感的强度。而加拿大和欧洲、中亚地区的流感活动强度总体上保持在较低水平。在日本，由于近来南部冲绳县甲流病例显著增多，整个国家的流感活动强度稳步上升，已超过往年普通季节性流感的强度。南亚和东南亚的大部分国家以及中南美洲国家，有的报告出现流感局部传播，有的则广泛传播。</p>\r\n<p>　　<strong>中小城市和中西部地区是薄弱地区</strong></p>\r\n<p>　　在中华医学会首届全国公共卫生学术会议上，曾光强调，随着季节变化，甲流南半球流行高峰趋于平缓，北半球的疫情开始迅速升高。中国与北半球趋势一致，近来1天发生的病例数相当于1月前的10天，特别是9月以来，不同地区的多所学校同期出现暴发流行，预示甲流进入了快速传播期，即俗称的第二波传播开始。</p>\r\n<p>　　“甲流向中小城市和中西部地区快速传播之势已成，这些地区是防范甲流的薄弱地区，很可能成为与之决战的‘主战场’。”他认为：当前疫情发展凶猛，且不同于过去境外输入的渐进模式，而是由数量庞大的国内流动人口，通过火车、汽车、飞机、轮船等交通工具广泛传播，往往发生严重的社区暴发流行后才被发现，而且各城际间没有任何防线。由于这些地区缺乏防控经验，可能导致病例迅速增加，出现成批危重病例。</p>\r\n<p>　　<strong>我国的防治策略应及时调整</strong></p>\r\n<p>　　鉴于目前我国的实际情况，曾光认为，我国的防治策略应及时调整，要认真研究中小城市和中西部地区的问题和对策，此前的成功经验未必都适合这些地区。如，在这些地区“外堵输入”的概念已经完全不同了，要堵已经非常困难，不宜勉强为之。</p>\r\n<p>　　“‘内防播散’的内容则要具体化。”曾光说，首先要强调“严阵以待”，各级政府应有效启动“联防机制”，做好“监测”“预测”“队伍训练”“后勤准备”和“层层督导”等项工作；其次要提倡“早发现、早报告、早隔离、早治疗、早抢救、早动员群众”，特别要强调“早期发现、隔离本地第一例病例”“早期发现和控制本地第一起社区暴发流行”“早期发现和救治本地第一例重症病例”。</p>\r\n<p>　　同时，曾光还指出，医院对危重病人的抢救能力不足，是我国突出的“软肋”。他最担心的是很多城市和农村同时出现较多的危重病例，超出了各地医院的救治能力，又不能及时组织外来援助。“因此，预防这种情况的发生是上策，坚持综合防治措施，延缓传播速度。”他还提出中国流感大流行严重程度的分级标准的建议。　</p>\r\n<p>　　<strong>老人、小孩等高危人群是防范重点</strong></p>\r\n<p>　　据上海市疾病预防控制中心应急办主任孙晓冬介绍，此前第一波甲流侵害对象以青壮年为主。但是对于今秋可能来袭的第二波甲流，像老年人、小孩、慢性呼吸系统和心血管系统疾病患者、糖尿病患者等都属于高危险人群，因此要谨防甲流。防止继发性肺炎，需及早采取措施进行预防。</p>\r\n<p>　　中国疾病预防控制中心副主任杨维中也指出，根据前期收集的临床病例统计发现，我国不到5%的甲流病例出现了以轻症为主的、程度不同的肺炎，他建议甲流高危病例一定要及时就诊，避免变成重症甚至是死亡。</p>\r\n<p>　　此外，由曾光主持的一项甲流流行病学调查发现：流感暴发传播的元凶是飞沫。在美国疾控中心最新一期《新发传染性疾病》发表的该调查报告称：患者讲话或咳嗽时，通过飞沫将病毒传播给他人是暴发的主要传播途径，而未发现经空气传播病毒的证据。</p>\r\n<p>　　曾光说，这增强了对抗甲流的信心，人们不必戴防护级别较高的口罩，也不必对空气进行消毒，可通过改变行为、养成良好的个人卫生习惯来保护自己。</p>\r\n<p>　　“无论什么时候，大家都应真正建立起良好的卫生习惯。”曾光指出，人与人之间谈话不要直面，尽量保持在2米外的防飞沫“安全距离”；勤洗手、换洗衣服；打喷嚏时用手纸遮掩口鼻。为减少飞沫传播，只需要在咳嗽或打喷嚏时用纸巾、毛巾、衣袖等遮住口、鼻，勤洗手，避免与病人近距离接触，就可以收到良好的效果。</p>\r\n<p>　　另外，曾光再三强调，患者要第一时间主动报告，戴口罩，自觉休息、隔离；学校、工厂、公司、军营、看守所等要切实落实防控措施，坚持晨检，早报告、早控制，该停课、停工的要果断坚决，千万不要心存侥幸。</p>', 'gwm', 0, 18),
(63, '广西累计报告甲型H1N1流感确诊病例745例', '', '', '', '2009-10-26 10:32:22', '116.228.141.77', '据自治区卫生厅通报，截至10月25日15时，全区累计报告甲型H1N1流感确诊病例745例，全部为轻症病例。其中538例已治愈出院，207例正在住院治疗。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;自治区卫生厅相关负责人介绍，国庆长假结束以后，学校出现甲型流感病例的情况有所上升。这主要是因为长假期间人员流动大，接触频繁，增加了学生感染甲型流感的机会。由于返校复课后，学生生活、学习环境集中，比较容易造成疫情的扩散。因此，卫生部门要求各类学校严格执行每日的晨检和午检，教室、宿舍保持开窗通风，做好疫情处理和报告以及与家长沟通等工作', 'gwm', 0, 25),
(64, '中药注射剂遭遇安全危机备受质疑', '', '', '', '2009-10-26 10:35:26', '116.228.141.77', '<span style="font-family:kaiti_gb2312;">“在北京，有些大型综合性医院已将中药注射剂清出药房”</span>\r\n<p><span style="font-family:kaiti_gb2312;">　　中药注射剂遭遇危机 再评价将洗牌市场</span></p>\r\n<p>　　本报记者 李松涛</p>\r\n<p>　　<strong>中药注射剂安全吗</strong></p>\r\n<p>　　从第一支中药注射剂柴胡算起，已有60多年历史的中药注射剂家族，从来没有像今天这样遭遇安全质疑。</p>\r\n<p>　　仅2008年至今，刺五加注射液、茵栀黄注射液、双黄连注射液相继出现使用致死事件。加上几年前的鱼腥草注射液、舒血宁注射液等中药注射剂事件，中药注射液已备受质疑。</p>\r\n<p>　　目前，中药注射剂产业年销售额超过200亿元，每年有4亿人次使用中药注射剂。在心脑血管疾病、抗肿瘤、抗病毒以及一些急症的治疗领域，中药注射剂正在发挥着重要甚至是不可替代的作用。</p>\r\n<p>　　但是，“在北京，有些大型综合性医院已将中药注射剂清除出药房。”在北京中医药大学东直门医院提供的一份资料中，记者看到了这样的内容。</p>\r\n<p>　　<strong>问题集中在使用环节</strong></p>\r\n<p>　　根据北京市药品不良反应发生情况的统计，2007年，在上报的所有药品不良反应中，化学药品占86.7%，中成药占11.9%，生物制药占1.4%。2008年，在药品不良反应统计中，化学药品占86.1%，中成药占13.2%，生物制药占0.74%。</p>\r\n<p>　　从数据上看，中成药发生不良反应的比例远低于化学药品；作为中成药一部分的中药注射剂的不良反应的比例，更是低于化学药品。</p>\r\n<p>　　在北京中医药大学东直门医院的临床使用中，中药注射剂的使用已有多年历史，品种和数量也在逐年上升。</p>\r\n<p>　　据院长王耀献介绍，目前该院共有26个中药注射剂品种，中药注射剂在该院住院患者中的使用率占51%，在呼吸科等个别科室甚至达到了90%，但全院每年与中药注射剂有关的不良反应，只有40例左右，而且多是轻微的过敏反应。</p>\r\n<p>　　王耀献向记者提供了一份东直门医院常用中药注射剂与不良反应发生情况的对照表。该统计显示，2007年，该院为1300名患者使用清开灵注射液27200支，不良反应1例；2008年使用清开灵注射液29440支，不良反应3例。2007年、2008年，东直门医院使用参麦注射液分别为7800支、10799支，没有一例不良反应发生。</p>\r\n<p>　　北京中医药大学东直门医院副院长刘清泉参加过多次中药注射剂不良事件的调查。在他看来，中药注射液不良事件的出现，与药物本身没有太大关系。除了部分与患者的特异体质有关，最重要的原因，在于临床的不合理使用。</p>\r\n<p>　　“比如今年在青海出现的双黄连注射液致死事件，患者只是得了感冒，医院先是对其使用了头孢、林可霉素等多种抗生素，最后使用双黄连注射液，导致病人死亡。”刘清泉说，其实并不是双黄连注射液的问题，而是将西药与中药注射剂不合理联合使用的问题。</p>\r\n<p>　　今年上半年，河北省食品药品监督管理局接到报告，河南一名患者在使用了神威药业有限公司生产的清开灵注射液后死亡。该局安监处在对神威药业有限公司进行检查后，并没有发现生产环节出现问题。</p>\r\n<p>　　“看了患者的用药情况才发现问题。”处长李讯说，患者就是感冒发烧，但在两个半小时之内，通过打点滴，医生对其使用了包括清开灵、头孢、病毒灵、胰岛素等十几种药物，是联合用药不当导致死亡。</p>\r\n<p>　　富有戏剧性的是，这位患者居然是所在医院的副院长，是他为自己开的药。</p>\r\n<p>　　在近几年发生的中药注射剂不良事件中，政府的一般做法是，立即要求药厂停产。但让很多药厂不能理解的是，对事件的责任认定迟迟不公布，企业恢复生产的日期也遥遥无期。</p>\r\n<p>　　“我反对一出问题就把药厂停掉。”神威药业有限公司总裁李振江说，是企业的责任要依法处理，不是企业的责任不能总是关药厂。</p>\r\n<p>　　<strong>基层医生需要更多培训</strong></p>\r\n<p>　　从近几年中药注射剂不良事件来看，大多发生在基层、乡镇医疗机构。由于基层医疗机构医疗水平问题，出现严重不良反应后，往往没有更好的抢救办法。</p>\r\n<p>　　“我们对中药注射剂是持扶持态度，但在使用上，需要弄清楚病情病症，对症使用。”国家食品药品监督管理局稽查专员毛振宾说。</p>\r\n<p>　　正是由于大量产品在基层使用，神威药业有限公司自己制作了药品使用的宣传册，由销售人员带到基层医疗机构，向医护人员进行宣传。</p>\r\n<p>　　“在药品的使用上，能外用的就不要口服，能口服的就不要肌肉注射，能肌肉注射的就不要静脉注射，中药与西药都要遵循这样的原则。”刘清泉说，中药注射剂通常是用于急危重病人，一般不能随便使用；如果合理使用，其安全性是有保障的。但不知道是谁误导了患者，导致很多患者仅仅感冒就要求打点滴。</p>\r\n<p>　　在东直门医院提供的资料中，中药注射剂成分复杂，临床中要尽量避免与其他药品联合使用，也要避免超剂量长期使用。此外，配置时间、滴注速度、使用温度、储存条件、不同溶媒的使用上都要严格按照规定。</p>\r\n<p>　　辩证用药也是中药注射剂使用的一个原则，比如清开灵注射液用于热症发热，不能用于寒症发热。如果用错，将会大大增加不良反应发生的可能。</p>\r\n<p>　　然而，中医的这种辩证用药原则在临床中并不能得到完全的落实。据有关部门统计，在中药注射剂的临床使用中，西医的使用量要远大于中医，而西医往往缺少足够的中医知识。</p>\r\n<p>　　王耀献告诉记者，中医基本的辩证用药方法并非高深莫测，西医在经过相应的培训之后可以基本掌握，尤其对于中药注射剂的使用，本身并不难。</p>\r\n<p>　　“西医用中药、中医用西药都需要培训，不能再这么混乱下去。”王耀献说，中药注射剂的说明书也需要改进，有哪些副作用、禁忌都要详细列出来，给医生用药指导。</p>\r\n<p>　　<strong>再评价拉开洗牌大幕</strong></p>\r\n<p>　　对河北省食品药品监督管理局安监处处长李讯来说，中药注射剂是个让他时刻紧张的品种。因为相对于中药汤剂、片剂等品种来说，直接进入血液的中药注射剂本身风险很高。</p>\r\n<p>　　尽管相对化学药品，中成药的不良反应不高，但在中成药的不良反应中，中药注射剂占据了最大的比例。在北京市2007年药品不良反应统计中，中药注射剂的不良反应占到中成药不良反应的71.9%。</p>\r\n<p>　　李讯在对河北省的中药注射剂生产企业进行调查后发现，在河北，生产中药注射剂的药厂共有7家，涉及17个品种41个品规。2008年，这7家企业的中药注射剂销售额为8.2亿元，但其中8亿元都集中在神威药业有限公司一家企业，其余6家企业加起来的销售额只有2000万元。</p>\r\n<p>　　“按照我们的设想，河北省有一家中药注射剂的生产企业就够了，规模太小的企业没有必要涉足这个领域。”李讯说。</p>\r\n<p>　　李讯所说的大量小企业生产中药注射剂的情况在全国很普遍。比如鱼腥草注射液，全国有100多家企业生产，中药注射剂中成分最复杂的清开灵注射液全国也有十几家企业在生产。这些企业工艺水平相差很大，药品质量也有明显差异。</p>\r\n<p>　　今年上半年，国家食品药品监督管理局启动中药注射剂再评价，要求企业全面开展生产及质量控制环节的风险排查，控制中药注射剂安全隐患。国家食品药品监督管理局对重点品种，分批、分阶段对中药注射剂的质量控制和风险效益展开综合评价。这项工作在业内被称为是中药注射剂的大洗牌。</p>\r\n<p>　　据李讯介绍，河北省食品药品监督管理局要求除神威药业有限公司之外的6家企业暂停生产中药注射剂，在自行检查、提高水平之后恢复生产。</p>\r\n<p>　　由于中药注射剂再评价需要企业将原材料、生产工艺、药品标准、指纹图谱等每个细节都提高标准，产品合格才可以生产，企业需要的投入非常大。</p>\r\n<p>　　李讯为河北省内那6家生产中药注射剂的企业进行了再评价的估算，一个品规的中药注射剂就需要大概500万元的投入。这个数字让这几家企业犹豫不决，其中有两家企业因投入巨大已经放弃再评价，“他们放弃之后，我们就撤销了其药品批准文号。”</p>\r\n<p>　　对目前水平最高、仍在生产的神威药业有限公司，李讯也不敢掉以轻心，每周都会到企业看看情况，告诫企业重视安全。</p>\r\n<p>　　“我国对中药的化学成分研究还不够，中药注射剂更是如此。”国家食品药品监督管理局稽查专员毛振宾告诉记者，去年国家食品药品监督管理局就提高了生产中药注射剂的门槛，严把审批关，这两年一个都没有批过。</p>\r\n<p>　　对中药注射剂的成分问题，国家药监局要求在成分不能完全明确的情况下，至少要知道其60%的成分。在这60%成分中，要知道80%的有效成分；在有效成分中，90%要可控。</p>\r\n<p>　　这个标准被称之为689原则，但据业内人士介绍，这样的标准太高，目前绝大多数企业都做不到。</p>\r\n<p>　　“我们赞成中药注射剂的再评价，这个领域需要提高门槛，只有提高了门槛才能提高质量。”神威药业有限公司总裁李振江说，中国产品的竞争往往是价格竞争，导致不少企业以牺牲质量为代价。</p>\r\n<p>　　根据李振江的介绍，神威药业有限公司目前已经占据国内中药注射剂30%以上的市场份额，做到这个程度，对质量、安全的关注更是严格。</p>\r\n<p>　　以清开灵注射液为例，神威药业有限公司所作的指纹图谱已经能够明确其85.79%的成分。这样就能够保证每个批次的药品在质量上的均一性。</p>\r\n<p>　　“我们对原料供应商采取飞行检查，事先不通知进行突击检查。”李振江说，药品质量关系到患者生命，也关系着企业的生命。</p>', 'gwm', 0, 21),
(65, '秋季饮食保健：吃鸡蛋勿只吃蛋白不吃蛋黄', '', '', '', '2009-10-26 10:35:57', '116.228.141.77', '营养学界日益认识到，健康来自于整体的膳食结构，提倡健康的饮食模式，而不是“禁忌”某种食品。中国营养学会推荐成人每日蛋类摄入量为25-50g。健康人一日一个全蛋，对健康是有益的。建议高胆固醇血症患者一周吃3-5只鸡蛋，并注意定期监测血清胆固醇水平。 \r\n<p style="text-indent:2em;">显然，吃蛋弃蛋黄没有必要。 \r\n<p style="text-indent:2em;">众所周知，鸡蛋是一种营养价值很高的食品，富含蛋白质、不饱和脂肪酸、维生素和矿物质，是人体的营养来源。蛋黄中含有较高的胆固醇，每100g达1510mg，是其他肉类食品的数倍甚至数十倍。因此，有些人认为食用鸡蛋可使血脂升高，是导致冠心病的祸根，因而对蛋的食用价值产生了疑惑甚至恐惧。 \r\n<table cellspacing="0" cellpadding="0" align="left" border="0">\r\n<tbody>\r\n<tr>\r\n<td valign="top">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td>\r\n\r\n\r\n            \r\n<!--\r\n             document.write(''<'' + ''/script>'');\r\n            \r\n//-->\r\n\r\n          \r\n\r\n\r\n\r\n</td></tr></tbody></table></td>\r\n<td width="10"></td></tr></tbody></table>\r\n<p style="text-indent:2em;">吃鸡蛋是否会升高血脂水平，这主要取决于吃的量。过量吃鸡蛋可能是冠心病的一个危险因素。但是适量摄入，不仅不会促进动脉硬化和冠心病，相反对人体健康有益。国外许多研究资料显示，给60岁-80岁的老人，其中包括患动脉硬化、冠心病、高血压者，每天吃两个鸡蛋，连续3个月，未见血清胆固醇和血脂水平增高。两个鸡蛋的胆固醇含量约700mg，远远超出了专家提出的每日胆固醇摄入量不超过300mg的建议，但为什么能保持血脂正常呢？这与鸡蛋中含有丰富的卵磷脂和胆固醇存在的形式有关。 \r\n<p style="text-indent:2em;">卵磷脂是一种很强的乳化剂，能使胆固醇和脂肪颗粒变小，并保持悬浮状态，有利于脂类透过血管壁为组织所利用，使血液中的胆固醇减少。鸡蛋黄丰富的卵磷脂在肠内被酶消化后，能释放出胆碱，再由血液输送到大脑，与脑组织中的醋酸结合转化为乙酰胆碱，从而提高大脑乙酰胆碱浓度，乙酰胆碱是神经细胞中传递信息的化学物质，对增进和改善人类记忆力大有裨益。 \r\n<p style="text-indent:2em;">如果要降低胆固醇水平，更重要的是减少饮食中的饱和脂肪含量，如肥肉、全脂奶制品和蛋糕、饼干、点心等。(孙建琴复旦大学附属华东医院营养科主任) </p>', 'gwm', 0, 23),
(66, '首期投入355.79亿3年内缓解看病难看病贵', '', '', '', '2009-10-26 10:37:26', '116.228.141.77', '首期投入355.79亿\r\n<p>　　3年内缓解看病难看病贵</p>\r\n<p>　　我省公布新医改方案，本报今起推出系列报道进行详细解读</p>\r\n<p>　　□本报记者 黄淼君 何丽娜 翁浩浩</p>\r\n<p>　　未来3年，我省财政将投入355.79亿，让老百姓的人均寿命达到77岁，出门20分钟就能找到医生……日前，我省公布《关于深化医疗卫生体制改革的实施意见》（以下简称《意见》），这是《意见》中透露出来的医改近期目标。除了已经出台的《意见》，今年年底前，我省还将陆续出台一系列配套政策，让全省人民都能感受到新医改带来的实惠。</p>\r\n<p>　　从今天起，本报推出“聚焦浙江医改”系列报道，详细解读我省医改方案。</p>\r\n<p>　　无论你是医药界人士、专家学者，还是普通市民，如果你对医改有任何建议、看法，都欢迎拨打早报热线85055555，让我们共同关注浙江医药卫生体制改革。</p>\r\n<p>　　［医改方案］</p>\r\n<p>　　十易其稿的台前幕后</p>\r\n<p>　　“今年4月中旬，在国家颁布新医改政策后，我省马上成立了深化医药卫生体制改革领导小组，由省发改委牵头，会同省卫生厅、人力社保厅、财政厅起草了《意见》。”昨天，省发改委副主任、省医改领导小组办公室主任姚作汀，简单介绍了医改方案出台的过程。</p>\r\n<p>　　在接下来的近半年时间里，省医改办的工作人员采用调查研究、广泛征求社会意见等形式，十易其稿，最终于8月下旬递交省政府常务会议、省委常委会审议通过。</p>\r\n<p>　　《意见》共分为六大部分，提出到2020年前，率先建立覆盖城乡居民的基本医疗卫生制度的远期目标；同时还提出用3年时间，切实缓解群众“看病难、看病贵”的近期目标。</p>\r\n<p>　　值得一提的是，为了让新医改方案能够在我省迅速实施，省卫生厅特意组织了全省248名乡镇卫生院院长及社区卫生中心的主任，分两期进行医改政策培训，重点学习国家和省医改政策，以及基本公共卫生服务、绩效管理、医疗事故防范等。</p>\r\n<p>　　人均期望寿命</p>\r\n<p>　　要达77岁以上</p>\r\n<p>　　《意见》主要从医改的总体目标、完善四大体系、2009—2011年重点改革任务等方面进行了阐述。</p>\r\n<p>　　我省新医改的总体目标，是要在2020年前，率先建立健全覆盖城乡居民的基本医疗卫生制度，为群众提供安全、有效、方便、价廉的医疗卫生服务。</p>\r\n<p>　　而近期目标，则要在3年内，促进全民健康——通过强化公共卫生服务，使人均期望寿命达到77岁以上，5岁以下儿童死亡率控制在9％。以下，孕产妇死亡率控制在12/10万以下；减轻群众负担——增加政府投入，降低药品价格，个人医疗费用占卫生总费用的比例从47%下降到40%左右；提高服务效率——改善医院服务流程，缩短挂号、取药和候诊时间，平均住院日进一步缩短；保障卫生公平——基本医疗保险覆盖全省90%以上城乡居民，构建20分钟医疗服务圈。</p>\r\n<p>　　完善医药卫生的四大体系内容包括，全面加强公共卫生服务体系建设、进一步完善医疗服务体系、加快完善医疗保障体系、建立健全药品供应保障体系。</p>\r\n<p>　　［专家解读］</p>\r\n<p>　　平常少生病</p>\r\n<p>　　强化公共卫生服务体系，通俗地讲，即为平常少生病。</p>\r\n<p>　　改革的重点任务包括，调整基本公共卫生服务范围，确定3大类12个服务项目；完善健康体检制度，继续做好城乡居民健康体检工作，逐步提高健康体检经费标准；实施重大公共卫生服务项目，继续实施结核病、艾滋病等重大疾病预防和国家免疫规划。</p>\r\n<p>　　胡崇高（省卫生厅妇幼保健和社区卫生处处长）：</p>\r\n<p>　　这次医改，很大的一个亮点，就是促进公共卫生服务均等化，意在让城乡居民都享受到改革成果。</p>\r\n<p>　　均等化不是平均化。所谓均等化，就是大家享受公共卫生服务的起步是均等的，享受到的项目是均等的。这次我省出台的《意见》，明确了三大类12项重大公共卫生服务项目以及相关保障措施，同时还在积极制定相关配套文件。</p>\r\n<p>　　这些项目都是针对我省省情，使重大公共卫生服务项目均等化，切实解决制约浙江人民健康的瓶颈，提高全省人民的生命质量。正像世界卫生组织给公共卫生服务下的定义那样，我省就是要通过新医改“让人人享有健康”。</p>\r\n<p>　　得病有保障</p>\r\n<p>　　加快完善医疗保障体系的目的，是为了使老百姓得病后有保障。</p>\r\n<p>　　改革的任务包括，扩大基本医疗保障覆盖面，3年内，城镇职工、城镇居民和新农合，参保率均达到90%以上；提高基本医疗保障水平，2010年，各级财政对城镇居民和新农合的补助标准，提高到每人每年120元以上等。</p>\r\n<p>　　傅鸿翔（省劳动和社会保障厅医疗保险处副处长）：</p>\r\n<p>　　我省公布的医改方案中，有关得病有保障方面的内容，我总结起来主要是6个字：扩面、提待和服务。</p>\r\n<p>　　“扩面”就是要让更多的人，或者说最终目标是人人享有基本医保。</p>\r\n<p>　　“提待”，意为提高待遇。到2010年，城镇职工、城镇居民基本医保的基金支付“封顶线”要从职工平均工资、城镇居民可支配收入的4倍提高到6倍。</p>\r\n<p>　　第三块就是“服务”，也就是通过加强医疗保障经办服务点的建设，让老百姓享受到更加优质的医保服务。大家比较关心的是医保卡的“一卡通”。这方面，我省现阶段主要从三方面入手，一是委托管理，比方说，从去年开始安置在上海的杭州退休人员可以直接在上海报销医药费。接下去，杭州和宁波之间也将实现医疗费异地报销。二是异地经办，可以让参保人员在异地住院时省掉很多麻烦。三是联网结算，我省准备首先实现医保的市一级统筹，年底前要在杭州、嘉兴、绍兴和衢州试点。</p>\r\n<p>　　治病少花钱</p>\r\n<p>　　建立健全药品供应保障体系，目的是为了让老百姓在治病时，少花钱。内容包括，实施基本药物制度、加强药品生产供应保障。</p>\r\n<p>　　孙哲勇（省发改委社会体改处处长）：</p>\r\n<p>　　在这个体系中，最难的是要实施基本药物制度。基本药物制度是一个全新的制度，这在我省乃至全国都是在摸索中建设的。目前国家颁布的基本药物目录有307种，我省是否要增补药物目录以及增补哪些药物，都还在研究中，适当的时候将会有一个具体的方案出来。</p>\r\n<p>　　基本药物目录就是基本治疗中都会用到的药物，按照《意见》的规定，在今年年底前，在全省30%的政府办城市社区卫生服务机构和县(基层医疗卫生机构)实施基本药物制度，也就是说让到社区看病的患者，都能享受到按零差率销售的基本药物。</p>\r\n<p>　　根据我省群众的用药习惯，将适当增补基本药物品种，扩大受惠面，真正减轻老百姓的负担。同时，目前我省有关部门正在积极组织实施全省药品网上集中统一招标采购，降低药价是目标，但首要前提就是保证药品质量。</p>\r\n<p>　　看病更方便</p>\r\n<p>　　进一步完善医疗服务体系，目的是为了使老百姓看病时更方便。</p>\r\n<p>　　这一块的内容包括：大力发展农村医疗卫生服务体系、完善以社区卫生服务为基础的新型城市医疗卫生服务体系，扶持和促进中医药事业发展等。</p>\r\n<p>　　陈卫强（杭州市卫生局局长）：</p>\r\n<p>　　进一步完善医疗服务体系，就是为了使群众能够就近看病，在基层首诊；而在有需要的时候，又能享受到优质医疗资源。要实现这一目标，浙江省与国家的方案保持一致，主要分城市与农村两只手来抓。</p>\r\n<p>　　一手抓城市，完善以社区卫生服务为基础的新型城市医疗卫生服务体系。关于“社区卫生服务”的概念，我省从1999年起步，在全国算是比较早的。近10年来，浙江省社区卫生服务中心达到1254个，覆盖率达到90%，社区卫生服务站6558个，覆盖率达到76.8%，都已经走在全国前列。</p>\r\n<p>　　另一只手抓农村，大力发展农村医疗卫生服务体系。我省正在通过基层医疗卫生机构标准化建设，来改善基层卫生基础条件，从而加快健全以县级医院为龙头，乡镇卫生院和村卫生室为基础的农村三级医疗卫生服务网络，使居民就近获得医疗卫生服务。</p>\r\n<p>　　此外，除了以上所述硬件上的建设外，要建立一个相对完善的医疗服务体系，还必须同时进行服务质量与水平等软件上的提升。</p>\r\n<p>　　就目前来看，群众对基层医生的服务态度满意度很高，但提到“信任度”时，大家还有许多期盼。所以，在接下来的改革中，一是要加强基层医疗卫生人才队伍建设，特别是全科医生的培训；二是大医院携手社区医院，大医院定期下基层坐诊的同时，安排基层医生到大医院轮岗学习等。</p><!-- publish_helper_end --><!-- google_ad_section_end --><!-- 正文内容 end -->', 'gwm', 0, 24),
(67, '赵本山住院疗养半月花销至少过百万(组图)', '', '', '', '2009-10-26 16:36:49', '116.228.141.77', '<p align="center">&nbsp;&nbsp;&nbsp;&nbsp;<img alt="赵本山住院疗养半月花销至少过百万(组图)" src="http://i1.ce.cn/ce/xwzx/gnsz/gdxw/200910/26/W020091026229673148448.jpg" />\r\n <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<img alt="赵本山住院疗养半月花销至少过百万(组图)" src="http://i2.ce.cn/ce/xwzx/gnsz/gdxw/200910/26/W020091026229674592528.jpg" />\r\n </p>\r\n<p><br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;据《南方都市报》报道，本月初，赵本山紧急入院的消息牵动亿万群众的心。赵本山的住院和疗养生活，其中有不少颇有趣味的细节，让我们重新梳理这一个月来本山大叔的诊疗故事。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<strong>1400元/天高级病房包三间</strong> <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;赵本山10月3日晚离开重症监护病房后，住进华山医院6号楼12层高级病房。该病房有两个床位，都被赵本山包下，一间病房每天的费用为1400元，病房内设施齐全，医院还特地搬来大尺寸的液晶电视让赵本山解闷。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;前来探望的亲友太多，加上送来的礼物如水果、补品等东西塞满整个病房，甚至连走廊上都塞满花篮。赵本山只有专门包下另外两间病房给亲友休息及放礼品。据悉，待他出院后，工作人员花了一小时才整理完礼物，装入一辆10人座的面包车运走。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<strong>大闸蟹、河豚汤、饺子，想吃就吃</strong> <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;术后的赵本山，心情好，胃口也好，多次喝河豚汤补身体，还点名要吃大闸蟹，中秋那天则声明要吃饺子，身边亲友自然样样给他准备好。据悉，每日有朋友专程从院外带来极为滋补的河豚汤，一锅价值大约在250元左右。集团工作人员还买了豆浆机、榨汁机和电饭煲，以便在病房中开小灶，以满足赵本山。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;赵本山生日当天，医院营养师特意为赵本山准备了东北菜。出院前一天，心情大好的他亲自下厨做拿手好菜：刀鱼炖豆腐，和身边的人一起品尝。此外，工作人员还买来泡脚桶，让赵本山在院中也能洗脚按摩，放松一把。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<strong>住院半个月，至少花了30万元</strong> <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;赵本山此次入院，手术费用逾8万元，病房费用超过5万元，加上后期治疗费用、营养费用、复健费用等，至少花了30万元。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<strong>60多万换来半个月贵宾级待遇</strong> <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<strong>花园别墅半月房费就达64.4万元</strong> <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;赵本山大病初愈，虽已出院，但得遵从医嘱：不能马上离开上海，需要复查及进一步观察，3个月内不能坐飞机，不能过度用力、忌食烟酒、情绪保持平稳。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;疗养期间，赵本山入住贵宾级酒店——上海西郊宾馆。该宾馆是上海重要接待项目及高端商务活动的首选之地，广受名流青睐，接待过包括英国女皇、日本天皇等在内的百余位国内外名人政要。 <br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;该宾馆是上海最大的花园别墅宾馆，赵本山入住的是一套花园别墅，每天包房价格是40250元，包含3.5万元房费和每天15%的服务费5250元。据说赵本山可能包住16天，仅房费方面就达64.4万元，若按疗养一个月计算，仅房费就要支付120多万元。</p>', 'gwm', 0, 31),
(68, '卫生部拟取消乙肝检测 消除乙肝歧视尚待时日', '', '', '', '2009-10-27 14:56:19', '116.228.141.77', '<p>　　近日，卫生部表示正在制订取消入职、升学体检中乙肝两对半检测的指导性意见，以保护乙肝病毒携带者的权益。但取消乙肝检测是否能消除乙肝歧视？指导意见在现实中会不会变成一纸空文？</p>\r\n<p>　　10月21日上午，由搜狐公益频道组织的新一期“益论坛”在搜狐大厦举行，北京市疾控中心副主任、流行病学专家贺雄，地坛医院肝病专家杨玉英，以及反歧视民间组织等多位嘉宾到场参与讨论。</p>\r\n<p>　　<strong>一亿乙肝病毒携带者</strong></p>\r\n<p>　　<strong>期待公平</strong></p>\r\n<p>　　论坛上，北京地坛医院肝病科副主任医师杨玉英女士表示，目前公认的乙肝传播途径就是血液传播，母婴传播，性传播，以及通过共用剃须刀，共用牙刷所产生的密切接触传播。</p>\r\n<p>　　由于80年代初期美国才率先研制乙肝疫苗，中国是从80年代中期才开始陆续逐步开展免疫预防工作，所以在此之前的漫长岁月，中国许多传统家庭通过共用牙刷、剃须刀等方式，导致被传染乙肝病毒的人越来越多，致使一个国家达到了近一亿的病毒携带者。</p>\r\n<p>　　但北京市疾控中心副主任、流行病学专家贺雄表示，经过这二十年新生儿疫苗接种，现在青少年人群里乙肝病毒携带率由过去的6%、7%降到1%以下，北京80年代后新生儿疫苗接种比例更是几乎达到100%，所以将来这个问题会逐步的越来越不成为重大的公共卫生问题。</p>\r\n<p>　　但是，由于目前庞大的成年乙肝病毒携带者群体，在入职、升学等体检后遭遇歧视、拒录取、拒招，而产生了严重的社会问题。</p>\r\n<p>　　民间反歧视组织、北京益仁平中心负责人陆军先生表示，卫生部10月10日明确以官方的形式表态，取消入学、就业体检中的乙肝“两对半”不会影响他人健康，不会造成乙肝的传播，卫生部正依据以上共识制订相关指导性意见。这对于反歧视来说有着非常重大的历史意义。</p>\r\n<p>　　<strong>乙肝病毒携带者的“隐私权”PK非感染者的“知情权”</strong></p>\r\n<p>　　搜狐网的调查显示，对于取消乙肝升学、入职体检，赞成的人占大多数，90%的人同意，但是还是有10%的人坚决反对。一些反对者认为，如果本人是一个没携带乙肝病毒的健康人，我可能认为取消这个检测对本人来说是不公平了，增加了我患病的几率。到底是非感染者的“知情权”重要还是乙肝携带者的“隐私权”重要？</p>\r\n<p>　　北京市浩盛律师事务所的李静林律师表示，乙肝病毒携带者不是乙肝病人，他没有发病，由于这种病毒传播途径有限，所以一般来说不会对公众身体健康构成危害，所以他的隐私应该保护。</p>\r\n<p>　　而公共知情权应该涉及到公共利益的知情权，这个问题不涉及到公共利益。所以不存在一般公众的知情权，最多是密切接触者的知情权问题。</p>\r\n<p>　　<strong>真正消除乙肝歧视</strong></p>\r\n<p>　　<strong>尚待时日</strong></p>\r\n<p>　　虽然卫生部的指导意见即将出台，但会不会出台之后，并不能消融社会的乙肝歧视，变成一纸空文，落实不到企业招聘和学校招生的实际工作当中去？</p>\r\n<p>　　“任何一项政策的调整和改变，在刚开始的时候肯定有一个逐步适应的过程，经过磨合，慢慢就走顺了，”贺雄主任表示。</p>\r\n<p>　　但李静林律师表示，如果今后的就业、升学不检测乙肝两对半，这当然是一个防止乙肝歧视的一个有效手段，但是在就业升学入职之后每年要年检怎么办，所以制订相关条例时可以考虑对于坚持要检的单位，有一个处罚措施。</p>\r\n<p>　　而且从指导性意见的说法来看，法律层级很低，没有多大的法律效应，建议相关部门在制定指导意见的时候，应该要考虑把它至少上升到规章，对医院卫生系统有约束力，在发生纠纷的时候，那么引用那个条款的效力就要保持。</p>\r\n<p>　　地坛医院的杨玉英也表示，对于乙肝病毒携带者，从临床上看病毒发展成肝炎、肝癌的几率非常低，所以携带者不用过于恐惧，而应养成良好的生活习惯，定期检查。</p>\r\n<p>　　最后贺雄主任乐观地表示，“我借用刚跑完国际马拉松赛的乙肝病毒携带者行者说的一句话，‘半程马拉松都跑完了，曙光会在前面。’”</p>', 'gwm', 0, 30);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(69, '我国拟立法明确医疗机构免责情形 ', '', '', '', '2009-10-28 11:11:36', '116.228.141.77', '新华网北京１０月２７日电（记者 隋笑飞、黄小希）２７日全国人大常委会开始第三次审议的侵权责任法草案，拟对医疗机构不承担责任的情形作出明确规定。 \r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;此前，草案规定了医疗损害责任一章。有的部门提出，草案对医疗机构在哪些情况下应当承担医疗损害责任作了规定，同时还应对医疗机构不承担责任的情形作出规定。 \r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;全国人大法律委员会经研究，建议在这一章中增加规定：“因下列情形之一，患者有损害的，医疗机构不承担赔偿责任：（一）患者或者其近亲属不配合医疗机构进行必要的诊疗的；（二）医务人员在抢救危急患者等紧急情况下已经尽到合理注意义务的；（三）限于当时的医疗水平难以诊疗的。”</p>', 'gwm', 0, 33),
(70, '我国入学就业体检取消乙肝检测获国际赞赏', '', '', '', '2009-10-29 10:03:07', '116.228.141.77', '中新社北京十月二十八日电(记者 曾利明)世界肝炎联盟主席查尔斯。高瑞(Charles Gore)今天对中国卫生部制订取消体检乙肝两对半检测指导意见表示高度赞赏，称“这是中国政府在消除乙肝病毒携带者的入学、就业歧视方面所做出的又一重要举措。”\r\n<p>　　本月十日，中国卫生部新闻办公室主任邓海华宣布，入学就业体检中的乙肝血清学检测将被取消；目前卫生部有关部门正制订指导性意见，他认为，当前社会上对乙肝病毒携带者的误解主要是由于对乙肝知识缺乏了解。</p>\r\n<p>　　他称，乙肝是血源性传播性疾病，不会通过呼吸道和消化道传染，日常生活和工作接触不会传播乙肝病毒；乙肝病毒携带者不是乙肝病人，身体没有临床症状，肝功能正常，不会因一般的生活接触、共同学习、工作等对周围人群构成威胁。</p>\r\n<p>　　有关专家提出，取消入学、就业体检中的乙肝血清学检测项目(乙肝五项检测，俗称“两对半”)不会影响他人健康，也不会造成乙肝的传播；从及早发现乙肝病人、及早治疗、对患者健康负责的角度出发，在入学、就业体检中保留丙氨酸氨基转移酶检查项目以及评价肝脏功能，比检测乙肝五项对诊断乙肝更具有临床参考意义。</p>\r\n<p>　　查尔斯。高瑞指出，“目前全球大约有三点五亿人感染慢性乙肝病毒，社会歧视非常普遍。由于担心遭受歧视，人们不得不选择沉默。而这正是虽然乙肝病毒每年导致全球六十万人死亡，但是迄今仍未上升为全球卫生工作的重要议程的原因之一”。他强调，应通过立法形式消除歧视，以提高社会对防治乙肝工作的关注，降低乙肝死亡率。”</p>\r\n<p>　　世界肝炎联盟是非政府组织，代表全球逾二百个乙肝和丙肝患者团体。其宗旨是遏制慢性病毒性乙型和丙型肝炎的死亡人数，改善这两种疾病患者的生活；通过认知、预防、护理、支持和获得治疗，最终在地球上根绝这些疾病。(完)</p><!-- publish_helper_end --><!-- google_ad_section_end --><!-- 正文内容 end --><!-- $ {新版相关媒体新闻显示} -->', 'gwm', 0, 25),
(71, '20名大学生鉴定生育力 一半人"精力"不达标或不育', '', '', '', '2009-10-29 10:07:23', '116.228.141.77', '青壮年肯定“精力”十足吗？不一定！近日，我市某大学20名男生相约去市计生研究院男性生育力监测中心，结果一半人的精液不合格。昨日是第十个男性健康日，研究表明不健康的生活和饮食习惯正在损害着男性的生育力，专家提醒青年男性应该提前保存“精力”。 \r\n<p>　　<strong>20男生半数精液不合格</strong> </p>\r\n<p>　　“不可能哟，我会不育？”近日，21岁大学男生赵然（化名）拿到鉴定单后，无法相信鉴定结果。和他同样惊讶的还有另外9名同学，他们都被市计生研究院男性生育力监测中心鉴定为精液不合格，也就是说他们都可能是不育患者。 </p>\r\n<p>　　正值生命力旺盛时期，刚20出头的男大学生怎么想到监测生育力？赵然说，一个多月前在网上偶尔看到现在男性的生育力正在逐渐下降，许多青年男性也正在成为不育患者。当时正值市计生研究院男性生育力监测中心还有少量免费监测的名额，赵然等20名大学生为了鉴定自己到底“行不行”，便相约来到计生研究院进行监测。检查结果让人难以置信：20名大学生竟有半数精液不合格，主要问题是精液密度低、活力差、畸形率高。 </p>\r\n<p>　　市计生研究院生殖技术研究所副所长蔡敏说，这些精液不合格的大学生本身没有器质方面的疾病，主要是和自身行为有很大关系。 </p>\r\n<p>　　<strong>精液密度50年降8成</strong> </p>\r\n<p>　　“男性的生育力正在下降，这是个不争的事实！”蔡敏告诉记者，精液质量是衡量一个男性生育力最重要的指标，它包括精子的形态、活力、数量和密度等等。其中，WHO（世界卫生组织）在50年前对合格精液密度的标准为1亿/毫升，但这个标准在不断调低，现在的标准则降低至2千万/毫升，蔡敏毫不客气地说，这个标准拿到50年前根本就不合格。而且她认为，现代男科学太注重男性不育的治疗，而对男性生育力的提前保护却不太在意，其实这是错误的。特别是20~25岁的青壮年，往往以为自己还年轻有的是“本钱”而不注意保存“精力”，将来很可能发展成为不育患者。 </p>\r\n<p>　　据了解，该男性生育力监测中心目前每个月平均有近50名男性来进行监测，这些男性几乎都是婚后不育才来检查的，年龄多在30岁以上。“有的精子畸形得厉害，治疗起来也有难度！”蔡敏说，很多男性自述在青年时期就有熬夜、酗酒、抽烟的坏习惯，如果他们早点注意改变不良生活方式，或者早点来了解自己的生殖能力，可能情况就不会这样了。然而，由于传统观念影响，大部分男性都不愿意去做精液检查，而把不孕的责任全部推给女性。 </p>\r\n<p>　　<strong>影响精液质量的不良习惯</strong> </p>\r\n<p>　　■抽烟、喝酒、熬夜 </p>\r\n<p>　　■长时间上网 </p>\r\n<p>　　■性生活无节制 </p>\r\n<p>　　■喜欢吃洋快餐 </p>\r\n<p>　　<strong>专家教你六招保持“精力”</strong> </p>\r\n<p>　　蔡敏说，精子是很“小气”的东西，它很容易因外部环境发生变化，实验证明一个男性酗酒、熬夜之后的精液和之前的精液质量绝对有很大差别。同时，青壮年男性自身的不良生活习惯也是导致精液质量变差、生育力下降的主要原因。为此，蔡敏提出几点建议，让男性保持“精力”。 </p>\r\n<p>　　■改变不良生活习惯。不抽烟、不喝酒、不熬夜。据资料报道，每天吸烟30支以上的男性，其畸形精子的比例超过20%，精子的存活率只有49%；酗酒会造成睾丸萎缩。而熬夜则会加剧疲劳，影响精液质量，蔡敏建议青壮年最好晚上12点前睡觉。 </p>\r\n<p>　　■尽量减少上网时间，特别是不要在网吧久呆。蔡敏说，电脑对身体会产生局部辐射影响精液产生，特别忌讳把笔记本电脑放在身体上，上网2小时就应该休息一下。 </p>\r\n<p>　　■有节制和卫生的性生活。青壮年因为性欲旺盛，很容易不加节制地进行性行为，这会过度刺激生殖细胞使生精功能疲劳，建议一周不超过3次为好。另外，性生活中尽量使用安全套，避免受到炎症侵害。 </p>\r\n<p>　　■少吃快餐。研究证明，洋快餐中的雌激素是精子最怕的“杀手”，男性应该多吃蔬菜、水果等有营养的食物。 </p>\r\n<p>　　■注意性器官卫生，少穿牛仔裤。每天睡前清洗外阴有利健康。 </p>\r\n<p>　　■加强体育锻炼。男性应该从青年时就加强锻炼，慢跑、游泳等既有助于身体健康，也对强壮精子的产生起很大作用。 </p>\r\n<p>　　<strong>相关新闻 </strong></p>\r\n<p>　　<strong>男性三年龄段 心理问题突出</strong> </p>\r\n<p>　　昨日，记者从重医附一院心理卫生中心了解到，男性三个年龄段存在着不同的心理健康问题，专家指出，要正确面对自己的问题，学会倾诉。 </p>\r\n<p>　　“每个阶段的心理健康问题都不同。”重医附一院心理卫生中心副主任况利介绍，青少年最大的心理问题是强迫症，中年人则由工作压力大、性心理方面的问题引起不同程度的心理健康问题，老年人则由于年龄的增加，害怕孤独。 </p>\r\n<p>　　况利告诉记者，青少年、中年人、老年人很喜欢把话憋在心里，这样造成了男性心理健康问题突出。男性应该积极的通过倾诉来释放压力，正视存在的问题，不能压抑自己的情感。　本组稿件由记者 陈瑜 实习生 刘洲海 采写</p>', 'gwm', 0, 24),
(72, '世卫预测甲型流感将感染全球80%人口', '', '', '', '2009-10-30 09:22:28', '116.228.141.77', '<p>病例数快速攀升，重症病例和死亡病例不断增加。聚集性疫情96.4%发生在学校。</p>\r\n<p>现在流感监测结果表明，在流感病毒中，甲型H1N1病毒占近80%。</p>\r\n<p>85%以上的人群接种甲流疫苗之后具有保护作用。</p>\r\n<p>“中国目前报告的甲流重症病人，多数都有慢性基础病，随着疫情发展人数的增长，将来出现重症死亡还会增加。”</p>\r\n<p>“疫苗接种是保护易感人群，让易感者免于发病或者发病以后症状不会太重的一个特别有效的手段。”</p>\r\n<p>截至10月28日，中国31个省(区、市)累计报告甲流确诊病例4.2万余例，已治愈3.1万余例。19个省(区、市)累计报告重症病例66例，已治愈11例，目前尚有39例在院进行救治。</p>\r\n<p>截至10月28日，31个省份累计报告聚集性疫情1502起，其中96.4%是发生在学校相关的聚集性疫情。</p>\r\n<p>截至目前，全球累计报告甲流确诊病例39万多，死亡病例5000多例。但世界卫生组织认为，全球实际发病数和死亡数远远超过目前这个报告数。（文/中新）</p>\r\n<p>预测每天会出现10万患者</p>\r\n<p>本报讯 随着甲型H1N1流感在全球范围内的新一轮大暴发，韩国等国学校停课，感染人数纷纷刷新纪录。而韩国《中央日报》10月28日说，流感疫情已经进入一个月中最紧要的关头，世卫组织相关人士预测，直到全球人口的80%都感染后疫情才会结束。</p>\r\n<p>韩国《中央日报》报道称，目前韩国每天确诊病例“都超过了4000人”，和夏天相比幅度大幅提升。报道称，世界卫生组织西太平洋本部相关人士预测道：“随着第二次过冬，每天会出现10万名患者，直到全球人口的80%都感染后疫情才会结束。”</p>\r\n<p>住院和死亡可能性加大</p>\r\n<p>经记者核实，这一惊人的消息来源于世界卫生组织西太平洋区相关人士的说法。</p>\r\n<p>“随着北半球各国甲型H1N1流感第二波大流行的传播，住院和死亡的可能性将加大。”该官员表示。据早期研究显示，某些人群中，包括少数民族和土著人群，住院和死亡的可能性更高。</p>\r\n<p>韩国200所学校停课</p>\r\n<p>据报道，韩国因甲流而停课的学校28日超过了200所。比前一天增加了一倍以上，达到了8月份开始正式统计甲流停课学校数据以来的最高值。(《法制晚报》)</p>\r\n<p>抗体保护力可维持半年左右</p>\r\n<p>中国疾控中心疾病控制与应急反应办公室副主任余宏杰昨日在回答网友的提问时透露，从目前的临床实验来看，至少有85%以上的人群接种甲流疫苗之后具有保护作用，疫苗保护的持久性仍在观察中。</p>\r\n<p>余宏杰说，疾控中心已经做了13000多例的临床实验，有效性和安全性都非常好，而从接种情况来看，疫苗的安全性也非常好，虽然极少数出现了一些反应，但都是在正常范围之内的。至于疫苗的持久性观察，目前有关部门也正在进行中，最早的临床实验是7月份接种的，到现在才短短的两三个月，但抗体至少可以维持到冬、春季。</p>\r\n<p>重症病人多数本来有慢性病</p>\r\n<p>“中国目前报告的甲流重症病人，多数都有慢性基础病，随着疫情发展人数的增长，将来出现重症死亡还会增加。”昨天，中国疾控中心疾病控制与应急反应办公室副主任余宏杰在接受采访时表示，对慢性病人等高危人数的救治将成为一个难点。</p>\r\n<p>余宏杰说，监测数据表明，疫情现在处于上升的阶段。但流感具有季节性的特点，每年的冬春季节是一个发病高峰。甲流也是这样，所以目前北半球多数国家都呈现发病上升的趋势，中国也是这样的。相对发病的人数来说，甲流的致死率是极少的。</p>\r\n<p>北京出现首例甲流死亡病例 一名新生死亡(图)</p>\r\n<p>北京市卫生局28日通报：北京航空航天大学2009级军训团暴发甲型H1N1流感聚集性疫情，其中一名大一新生染甲流后，病情恶化后送医，但最终抢救无效，于10月27日死亡。</p>\r\n<p>这是自今年5月北京出现甲流疫情后，北京市首次报告因感染甲流直接导致死亡的病例。10月23日，北京市报告一位七旬老人，在甲流治愈后因慢阻肺加重导致呼吸衰竭死亡。详细》》》</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 31),
(73, '网上预约挂号道德先行', '', '', '', '2009-10-30 09:53:10', '116.228.141.77', '<p>虽然预约挂号服务将在后天正式展开，但其执行问题依然让各方存疑，如记不住各个医院的预约电话；电话没人接、老占线；电话网上预约要办预约卡；爽约或被纳入“黑名单”，终身不能预约，等问题。<br />\r\n　　然而，记者近日从广州市一些大型专科医院了解到，预约挂号服务早已实现了“24小时全天候”，如广州女子医院推出一套全天候24小时预约服务系统，通过免费电话预约、网络预约、QQ在线预约、网络免费电话预约、商务通、专家咨询电话预约、专家夜诊等形式，很好解决了患者看病挂号难、长时间排队等待、病情咨询难等问题。&nbsp; <br />\r\n&nbsp;</p>\r\n<p>　　体验</p>\r\n<p>　　几分钟就看到医生</p>\r\n<p>　　前段时间，家住深圳的何小姐得了妇科疾病，走访了当地和广州多间医院，“医生简单看了一下，就说没办法根治，只能通过药物控制病情的恶化，我问多几句，他们就很不耐烦了。”何小姐说，自己希望能认真了解病情再进行治疗，所以继续寻找，并通过网络搜索到广州女子医院，“先是在网上问他们的咨询医生，包括发帖、QQ通迅，没想到晚上也会有人回答，而且对于自己的问题都详细地回答了，有什么表现、原因、治疗方法啊，也不会说你要交钱了或者预约了才回答问题。”</p>\r\n<p>　　通过一段时间的接触，何小姐利用网上咨询得到比较详细的了解，于是决定亲自到医院求诊，当时她就采用了网上预约挂号，“预约了医生和时间，到医院后就有导医接待，办手续，过了几分钟，就直接见到医生了，如果是公立医院的专家，可能要排几个小时吧。”何小姐说以前在其他医院求诊，早上9点挂号，等到下午3点才看诊。“这里能给我一个比较清晰的治疗方案，我觉得比较可信，才决定在这里治疗。”</p>\r\n<p>　　美国华侨刘女士同样有通过网上预约方式到医院求诊的经历，“在国外刚怀孕就搜索到我们医院了，然后成了这段时间电话咨询最多的产妇，”广州女子医院客服部牛朝萍介绍说，刘女士回广州后还没有确定到哪间医院待产，但对于孕期的任何问题，她都习惯通过网上以及电话咨询广州女子医院的医生。“有时候晚上一点多发现宝宝胎心不稳，她就马上打电话来咨询，后来通过预约挂号，亲自过来求诊并了解一下医院的环境，我们当时就把妇产科杨医生的电话留给她，让她有问题可以直接咨询专家，直到差不多到预产期了，她才确定在这里生小孩，因为我们一直给她产前帮助，她特别满意。”</p>\r\n<p>　　对比</p>\r\n<p>　　80%的门诊是预约挂号</p>\r\n<p>　　“目前通过预约挂号方式来看诊的病人约占门诊总量的80%，平均每天有100多人。”据广州女子医院客服部牛朝萍介绍，该院自2007年就开始实施预约挂号方式，主要包括QQ在线、商务通、免费电话、网上问答等形式，而目前通过预约挂号的人越来越多，规模也在不断扩大。“目前，医院预约挂号采用24小时全天候形式，在电话预约方面，我们设置了10个号码，每个号码10条线，可容纳100个病人同时打电话进来；在网络预约方面，我们有30个医生同时在线，细分到妇产科每一类别，保证网上提问、QQ在线能第一时间回答病人的问题，并详细解答。”</p>\r\n<p>　　对于专科医院预约挂号的最大特色，牛朝萍表示，是对该学科的各种病症都进行了细分化。“例如预约挂号的科室就细分为炎症科、肌瘤科、不孕不育科、无痛人流、产科、内分泌科等十几个，病人进行电话或者网络咨询，咨询医生会根据病人情况，直接在后台转到相应医生回答。”此外，该院对电话、网络做全程记录，保证医生能够正确详细解答病人问题，而通过预约挂号到医院后，整个过程都有导医陪同，数分钟左右就可以见到医生。对于“爽约”的病人，广州女子医院客服部也会有跟踪服务，打电话给病人问询，并询问是否需要另约时间。</p>\r\n<p>　　观察</p>\r\n<p>　　有效分流杜绝医生“赶工”</p>\r\n<p>　　对于不少患者反映的专家挂号多，导致每个病人看诊时间短等问题，广州女子医院客服部牛朝萍表示，医院实施的全天候预约服务系统，一方面能使得患者真正预约到需要的专家，另一方面是为了有效实施分流控制，避免医生“赶工”的情况，“医院已经明文规定，每个初诊病人的问诊时间不能低于15分钟，如果当天病人比较多，医院会进行分流，如增设专家门诊、限制医生门诊量等，避免医生‘赶工’情况，令病人能更详细地介绍自己的情况，让医生更准确地确认病情，治疗、用药更有针对性，保证治疗质量。”<br />\r\n</p>', 'gwm', 0, 29),
(74, '免费预约挂号新规下月全面展开 ', '', '', '', '2009-10-30 10:06:36', '116.228.141.77', '<p>　　“花几十至上百元办一张‘预约挂号卡’，就可以享受预约挂号服务，一年内通过上网预约的方式，可以由提供服务的机构代劳在医院挂专家号……”这种被部分消费者称为“绿色通道”的收费网络挂号业务，从下月起将被取消；取而代之的是，广州所有的公立三级医院都要开展实名预约挂号服务，与社会中介机构合作预约挂号服务的，也一律不得收取额外的费用。</p>\r\n<p>　　预约挂号不收费，本来是一件好事，但是已经花钱购买了这些有偿“预约挂号卡”的市民却忧心忡忡：还能不能继续使用手里的预约卡挂号？已经缴纳的费用能否退回？</p>\r\n<p><strong>　　调查： 卡内余额将如何处理</strong></p>\r\n<p>　　家住广州市荔湾区的曹小姐今年6月在某医院花了50元办理了一张“1m1m健康网”的预约挂号卡，“还不到几个月，就改成不收费了，我的卡到现在一次都没用，钱不是白给了吗？”曹小姐向信息时报记者反映。</p>\r\n<p>　　为此，信息时报记者调查发现，存在“挂号卡”困扰的不单止曹小姐一人，患有糖尿病的袁阿姨是中山一院的忠实“粉丝”，每隔一段时间就到中山一院复诊，但日前袁阿姨发现她的预约卡已经不能挂任何中山一院的号，焦急中，她咨询得知中山一院已取消了与网站的合作，转向与114合作，开展免费预约挂号服务。对此，袁阿姨十分愤怒：“办卡是因为感觉用卡预约复诊比较方便省事，现在都不能预约我要的医生，我的卡是不是就等于作废了？”</p>\r\n<p>　　据悉，医院方面也接到不少反映“预约挂号卡”的投诉，除了咨询预约卡能不能继续使用外，更多人关心的是没到期的预约卡能否退费。对此，广东省中医院负责人表示，“现在卫生部有了新的要求，我们已经按要求取消了一切有偿挂号的服务，至于预约卡内的余额怎么处理，患者要和售卡的公司具体协商。”</p>\r\n<p><strong>　　网站： 不退钱，但提升业务质量</strong></p>\r\n<p>　　信息时报记者调查发现，广州与三级医院有合作的挂号中介机构主要有三家，包括1m1m健康网、爱康网、阳光医疗网。1m1m健康网是这三个中介网当中最庞大的一个，挂号卡50元一张，时间为一年；爱康网与广州近20家医院合作开展预约挂号，一张价值50元的预约挂号卡成为会员，会员一年内可在广州地区合作医院中享受年内17次预约挂号的服务。阳光医疗网在广州市场所占份额较少，注册成为其会员后便可免费获得可预约挂号的康众卡，充值后使用，每次挂号费在卡内扣。</p>\r\n<p>　　对于消费者投诉的问题，1m1m健康网在其网站上发表公告，表示已经购买了他们推出的预约挂号卡的市民，卡内的余额不退还，但原有持卡用户可免费升级，除了使用期限延长至无限期外还可享受健康管理咨询服务。</p>\r\n<p><strong>　　政府： 禁止第三方收取额外费用</strong></p>\r\n<p>　　卡内费用和办卡费用是否能收回呢？信息时报记者就详细阅读了卫生部下发“预约诊疗最终稿”。记者注意到，终稿中明确表示：“已经与社会中介机构合作开展有偿预约挂号服务收取额外费用的，要立即进行清理整改”。</p>\r\n<p>　　就此问题，广东省卫生统计信息中心主任李奕明表示：“将来公立医院的预约服务不能有额外的收费。为此，有关部门将对相关预约额外收费行为进行清理、整顿，防止企业行为及人为设置障碍。”</p>\r\n<p>　　但关于医院与中介合作的问题，目前卫生部的正式规定、要求还没有下来，但对于三甲医院搞免费、实名制预约，也不会说是一刀切，即也可能还是允许合作，允许有合理的成本收费，但不允许有额外的收费。因此，省卫生厅目前还在等卫生部的通知，等接到正式通知后，会根据广东的具体情况制订相应的意见。</p><!--jrj_final_context_end-->', 'gwm', 0, 40),
(75, '侯耀华代言10则违法广告 明星代言需法律约束', '', '', '', '2009-11-02 10:52:08', '116.228.141.77', '<p style="text-indent:2em;">本报讯 (记者窦红梅) 知名演员侯耀华代言的亚克口服液、澳鲨宝胶囊、渭肠益生元等10则广告均未经批准且含有违法违规内容。昨天，中国广告协会有关负责人在“品牌代言人行为规范与社会责任”论坛中，点名曝光了侯耀华的行为。并呼吁各界明星、广告代言人，承担义不容辞的社会责任。</p>\r\n<p style="text-indent:2em;">“广告中的代言人应当对自己的言行举止负责。”中国广告协会法律服务中心主任李方午说，侯耀华所代言的10个电视或者平面广告包括天元牌亚克口服液、澳鲨宝胶囊、渭肠益生元、加拿大V6胶囊、角燕G蛋白胶囊、黄金九号、伯爵胶囊、康大夫茶愈胶囊、方舟凯达降压仪、杜仲降压片(贵阳德昌祥药业有限公司)。</p>\r\n<p style="text-indent:2em;">上述保健食品、药品、医疗器械广告均未经行政主管部门批准，使用演员作主持人，或使用专家、患者、消费者名义和形象作证明，且均含有其它违法内容，如处方药违规在大众媒介发布广告，保健食品却宣传比药物更好的治疗作用等。这些广告多次被投诉，消费者反响较强烈，认为广告代言人不负责任、见利忘义。目前，10个广告已分别被浙江、辽宁、山西等地工商局或食品药品监督管理局通报、查处。</p>\r\n<p style="text-indent:2em;">业内人士呼吁，对明星的代言行为进行法律约束，如规定明星必须是其代言的商品或服务的实际使用者等。如果明星代言了虚假广告，在不明知或不应知的情况下，明星虽不应当承担民事上的连带赔偿责任，但并不能免除其应当承担的行政责任，如罚款、没收违法所得等。</p>\r\n<p style="text-indent:2em;">我国今年6月1日施行的《食品安全法》，第一次以法律的名义规定了代言人在虚假广告中承担连带责任，但在《广告法》中还未有相应条款，对代言食品以外的产品也未作相应规定。中国广告协会副秘书长杨洪丰透露，《广告法》的修订已经列入十一届全国人大常委会立法规划，国家工商总局经广泛调研，已将修订稿提交国务院法制办进行审议。在修订送审稿中已明确将代言人纳入广告活动主体的范畴，并将对其代言虚假违法广告的法律责任作出规定。</p>\r\n<p style="text-indent:2em;">中消协秘书长杨红灿表示，名人代言广告要对消费者负责。消费者受到名人代言虚假广告侵害有5种维权途径：与经营者协商解决，请求消费者协会调解，向有关行政部门申诉，根据与经营者达成的仲裁协议提请仲裁机构仲裁，向人民法院提起诉讼。</p>', 'gwm', 0, 26),
(76, '要宅就宅得更健康 宅男将出现的七退化猜想 ', '', '', '', '2009-11-02 12:53:30', '116.228.141.77', '<p style="text-indent:30px;">在各种各样环境问题日益严重的今天，宅在家中似乎已经转变成一种顺势而生的生活方式。要宅就宅得更健康吧！</p>\r\n<p style="text-indent:30px;"><strong>宅男健康7大退化猜想</strong></p>\r\n<p style="text-indent:30px;">心理学家和健康学家对这种过于脱离社会的生活方式颇有微辞，“宅”是不利于身心健康和未来生活的。美国芝加哥大学心理学教授约翰·卡西奥波研究发现，孤独可以削弱人体免疫系统，使血压上升，压力增大，还有造成抑郁症的危险，孤独者和社交活跃者的健康水平存在一定差距，基本类似于吸烟者和非吸烟者、肥胖症患者和非肥胖症者的差距。宅男因为过分依赖网络所形成的虚拟世界，会逐渐脱离现实世界，甚至出现新型“自闭”。“宅人族”可能退化基本社交技能，甚至会患上“电脑自闭”，导致心理障碍。</p>\r\n<p style="text-indent:30px;">看看《WALL.E》中700年后人类的生活：整天呆在太空船中，肥胖如球，四肢短小，连走路都要依靠飞椅。人类学专家推断，1000年后人类进化抵达至生理构造“黄金时期”：为了更适合宅居，人类的身高降至1.7米以下；肥胖、秃头；上肢长、下肢短。由于过分依靠科技，将失去自我防卫和与家人、朋友社交的能力，人类基本的情感都将损失。看看你是不是也有下面这些问题，会不会慢慢退化（还是进化？）成ET！</p>\r\n<p style="text-indent:30px;">1、退化症状：突眼大耳原因：视力听力下降两耳不闻身边事，一心只听耳中音。大多数宅男每天开起播放器塞起耳机，放着听不完的流行音乐。这样下去，耳膜受损，听力下降。另外，长时间用电脑，眼睛还会干涩，出现干眼症或角膜炎，高度近视者视网膜易脱离。</p>\r\n<p style="text-indent:30px;">退化结果：未来的宅男们必然有一双突出的眼睛和招风大耳。</p>\r\n<p style="text-indent:30px;">2、退化症状：腿短腰软原因：久坐肌肉萎缩长时间坐在电脑前，肌肉活动减少，造成血液流量减少，进一步引发肌肉供氧量不足，肌肉酸痛、松弛、衰弱甚至萎缩。久坐不动者的关节滑液显著减少而变得干燥，继而容易引发骨与关节疾病，如关节退化、融合。</p>\r\n<p style="text-indent:30px;">退化结果：未来的宅男们身体柔软，腿因为久坐已经退化成婴孩般的短肢，上肢却长而有力。</p>\r\n<p style="text-indent:30px;">3、退化症状：绿色血液原因：心率血压改变对心脏来说，久坐不动的姿势使血液循环减缓，身体对心脏工作量的需求也就减少了，时间长了甚至会使心脏机能衰退，引起心肌萎缩，血管弹性变差，更容易进展为动脉硬化、高血压、冠心病等。长此以往，心脏机能衰退，大脑供血不足，伤神损脑，身体各主要器官都会出现病变。血黏度升高，血流缓慢，很容易形成血栓。</p>\r\n<p style="text-indent:30px;">退化结果：未来宅男的血液呈绿色，是因为血液里含有大量叶绿素。每天只要定时用光照射就会恢复血液动力，更多地制造氧气。&nbsp;</p>\r\n<p style="text-indent:30px;">4、退化症状：肛门退化消失原因：痔疮久坐不动的人，身体缺乏运动，肠道蠕动功能就减弱，比较容易便秘，长期便秘会引起痔疮。而久坐不动也使血液循环减慢，身体内静脉回流受阻，直肠静脉容易扩张。血液淤积后，局部静脉曲张，更容易患痔疮。</p>\r\n<p style="text-indent:30px;">退化结果：未来的宅男们根本不需要肛门，他们会在身体上安装自动排泄装置，定时自动开启，排泄物就直接落入下水管道。</p>\r\n<p style="text-indent:30px;">5、退化症状：声带消失原因：孤僻暴躁脾气坐电脑前什么都忘了。因为太专注，一被别人打扰就会发脾气。与家人的感情交流几乎全被电脑占据了。习惯于在屏幕上和人交流，打字速度飞快，而开口说话很难，直接与人接触时反应慢，甚至词不达意。</p>\r\n<p style="text-indent:30px;">退化结果：未来的宅男由于越来越少讲话，声带也因为越来越少被应用而退化。那时大家的交流已经完全通过手指、键盘和网络。</p>\r\n<p style="text-indent:30px;">6、退化症状：大头原因：头晕失眠多梦因为休息没有规律，全身及大脑长时间处于一种紧张的状态中，促使神经系统紊乱。继而出现头晕、失眠等现象。</p>\r\n<p style="text-indent:30px;">退化结果：未来宅男的头会越来越大，而且头发也退化光了。头容量增加能存储更多的梦。</p>\r\n<p style="text-indent:30px;">7、退化症状：肚子大，肠变粗原因：消化系统紊乱不按时饮食，而且多吃一没营养，二不利于肠胃吸收的快餐方便面等。为了节省时间经常会狼吞虎咽或忍饥挨饿，这样会造成消化系统紊乱，常会大便无规律，而且引发便秘、肚子疼或拉肚子。</p>\r\n<p style="text-indent:30px;">退化结果：未来的宅男们的小肠已经全部退化成大肠，可以长时间消化食物而且数天不去大便。</p><!--/enpcontent--><!--/enpcontent-->', 'gwm', 0, 24),
(77, '内地共报告甲流4.75万例 部分地区进入高发期', '', '', '', '2009-11-03 09:19:02', '116.228.141.77', '<p>本报北京11月2日电（记者白剑峰）“目前我国甲型H1N1流感防控已经进入关键时期。各地卫生部门对疫情防控工作的艰巨性和复杂性要有一个清醒的认识，要把甲型H1N1流感防控工作作为今冬明春卫生工作的重中之重。”卫生部部长陈竺今天在全国卫生系统甲型H1N1流感防控工作视频会议上表示。</p>\r\n<p>截至11月1日，我国内地31个省份累计报告甲型H1N1流感确诊病例4.75万余例，其中重症病例104例，死亡病例6例(编者注：11月2日又出现1例，目前已累计7例)。当前我国疫情主要呈现以下特点：一是以学校暴发疫情为主。二是疫情从城市向农村地区持续蔓延。三是甲型H1N1流感流行强度持续增加，部分地区已进入高发期。</p>\r\n<p>陈竺对下一步的防控工作提出了明确要求：大力推进疫苗接种工作。各地要做好疫苗接种的组织动员工作，加快疫苗分发和接种工作进度，各省在接到疫苗后2周内要争取完成接种工作。着力加强重症病例救治工作。各地要继续坚持“集中患者、集中专家、集中资源、集中救治”的“四集中”原则，将重症与危重病例集中收治到医疗救治力量雄厚的定点医院；要组建由重症医学、感染、呼吸等多学科人员组成的重症病例医疗救治团队，对重症与危重病例采取综合治疗措施；要及时组织会诊和抢救，提高重症与危重病例抢救成功率，降低病死率；要充分发挥中医药在甲感医疗救治工作中的作用，对轻症病人要积极应用中医药治疗方案。认真抓好学校等重点场所疫情防控工作等。</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 22),
(78, '秋冬季儿童肺炎将高发 肺炎成为我国幼儿死亡首因', '', '', '', '2009-11-03 09:51:11', '116.228.141.77', '昨天是第一个世界肺炎日。据估计，肺炎球菌病每年导致高达100万儿童死亡，在死亡率最高的前10个国家和地区中，一半为亚洲肺炎球菌病发病率最高的国家和地区。昨天，沪上儿童呼吸科专家纷纷指出，秋冬季节孩子最容易得肺炎，严重的流感患者也会发展为重症肺炎。 \r\n<p>　　为什么孩子总是在秋冬易发肺炎？甲型H1N1流感会转为肺炎吗？家长应如何保护孩子免患肺炎？这一系列的问题在昨日浦东新区卫生局、上海交通大学医学院附属上海儿童医学中心、世界健康基金会共同主办的“让孩子远离蓝色病菌，迎世博共创美好生活”首个世界肺炎日的活动现场得到解答。 </p>\r\n<p>　　上海儿童医学中心内科专家王莹主任医师提醒，由于甲型H1N1流感的蔓延和传播，社会、学校和家庭更应关注儿童肺炎的预防，帮助家长提高对肺炎的了解和认识，以便早发现、早治疗，最大限度保护孩子不受疾病困扰。 </p>\r\n<p>　　据世界卫生组织统计，全球每年约有70万-100万5岁以下儿童死于肺炎球菌引发的疾病。在我国，肺炎更是5岁以下儿童死亡的首位原因。秋冬季一直是儿童肺炎高发的时期，通常进入10月下旬后，患有流感及肺炎等呼吸道疾病的患儿明显增加。 </p>\r\n<p>　　王莹介绍，病毒感染、细菌感染及支原体感染都可引发肺炎，大多数患儿可能通过社会交往受到肺炎球菌的感染而患上肺炎。由于病原菌在秋冬季较易滋生，加上这一时期婴幼儿免疫力和抵御力较弱，人们常处于封闭的环境中，空气流通性差，婴幼儿更易患上肺炎。 </p>\r\n<p>　　另外，秋冬季由于温差较大，也是流感等疾病的高发期，先期患有流感或一般感冒的婴幼儿处理不及时也会发展成为肺炎。针对家长较关心甲型H1N1流感是否会发展为肺炎的问题，王莹表示，严重的流感患者可能发展为重症肺炎，引起呼吸困难、缺氧导致各脏器多种并发症，因此家长要特别关注孩子的病情发展，及时在正规医院就诊，确定病因后对症治疗。通常对细菌性感染的肺炎使用抗菌素治疗，医院对抗菌素的使用应执行严格的资格等级审查制度，以避免抗菌素的滥用。 </p>\r\n<p>　　<strong>[预防肺炎小贴士]</strong></p>\r\n<p>　　●早晚凉意重，注意为孩子保暖； </p>\r\n<p>　　●避免人多拥挤的公共场所，戴口罩可以阻挡病菌； </p>\r\n<p>　　●保持家居清洁、空气清新，每天两次通风，每次30分钟； </p>\r\n<p>　　●合理配置饮食，多吃富含维C的水果，以增加免疫力； </p>\r\n<p>　　●天气情况许可的情况下，进行体育锻炼，增强体质； </p>\r\n<p>　　●高危人群可通过接种疫苗有效预防。</p>', 'gwm', 0, 25),
(79, '3袋脐带血运到京津储存库后神秘消失 理由荒唐(图)', '', '', '', '2009-11-04 10:59:35', '116.228.141.77', '<p align="center"><img src="http://image.xinmin.cn/2009/11/04/20091104074510866544.jpg" />\r\n</p>\r\n<p align="center"><img src="http://image.xinmin.cn/2009/11/04/20091104074511319794.jpg" />\r\n</p>\r\n<p>　　10月26日，一市民出示脐带血检验报告和脐带干细胞保存广告。 本报记者 杨新宇 摄</p>\r\n<p>　　业务员都称储存成功率超过90%；初检都合格，但都在合同即将生效时被告知“不合格” </p>\r\n<p>　　重庆三个相互之间很熟悉的同学，她们都把自己的婴儿脐带血储存在北京、天津的脐带血库。脐带血最初的检测都是合格的，然而一两个月后，三人的脐带血全部因为“检测不合格”而神秘消失。储存前，业务员曾告诉孕妇，脐带血储存成功率为90%-95%。“我们三人的脐带血都不合格，太让人不能接受了。我们的脐带血究竟在哪里？会不会用在了别处？或卖了好价钱？” </p>\r\n<p>　　婴儿脐带血，可以治疗多种难治性疾病，如白血病、肝癌等，有不可估量的临床应用价值。一份脐带血如果出售，价格约5万元。 </p>\r\n<p>　　<strong>第一袋 </strong></p>\r\n<p>　　<strong>被梅菌感染？ </strong></p>\r\n<p>　　<strong>想要回销毁却被拒</strong> </p>\r\n<p>　　陆静是去年8月下旬生下女儿的。临产前，陆静在江北区一家大医院做产检。医生向她讲述了储存婴儿脐带血的诸多好处，还可以得到一份30万元的保险。随后，医生写下一个电话，叫陆静和对方联系。对方姓李，是北京脐带血库的重庆业务员。 </p>\r\n<p>　　李女士称，存脐带血需要交检测费（1000多元）、保管费（每年600元、交10年以上）和运输费，公司与你还要签一份合同。一般来说，合同是临产前5天签字。说完，业务员李女士给陆静一个袋子，“生娃儿时，你把这个袋子给医生，医生知道如何为你保存脐带血。” </p>\r\n<p>　　李女士称，“我们会在采血后的24-48小时内，将血空运到北京。按合同规定，2-3个月后，合同生效，公司送的30万元保险也随之生效。今后，孩子生病住院，均可按规定比例报销。” </p>\r\n<p>　　陆静临产前几天，向李女士交了6500元的脐带血储存费。8月27日剖腹产，顺利生下了女儿。医生告诉她，当时采了50毫升脐带血后，立即送到北京，一切正常。 </p>\r\n<p>　　一个月后，李女士给陆静回话称“你的脐带血正常”。 </p>\r\n<p>　　两个月后，北京脐带血库给陆静打来电话称，“你的脐带血被梅菌感染，不能用了。除了扣除检测费1000多元后，其余的钱将全部退还给你。” </p>\r\n<p>　　陆静很气愤，对业务员和公司说，“你们是不是把我的脐带血卖了？一份脐带血可以卖好几万元。” </p>\r\n<p>　　对方回答，“没有卖。你的脐带血感染了梅菌，按规定必须销毁。” </p>\r\n<p>　　陆静要求拿回脐带血或当其面销毁。对方称，“按国家规定，公民私人不能擅自处理血液，公司也不可能再把已被污染的血空运回重庆。” </p>\r\n<p>　　陆静近日告诉记者，眼下，双方僵持着，公司没有还她的脐带血，也没有退她的钱。 </p>\r\n<p>　　<strong>第二袋 </strong></p>\r\n<p>　　<strong>细胞数不合格？ </strong></p>\r\n<p>　　<strong>500定金没有退还</strong> </p>\r\n<p>　　何莎的婴儿脐带血，只交了500元保证金。何莎是去年10月21日在沙区一家大医院剖腹产生下儿子的。在医院的产检中心，一名赵女士自称是天津脐带血造血干细胞库重庆分公司的人。赵女士在说明脐带血储存对孩子的重要意义的同时，还特别强调，储存脐带血的成功率高达95%。何莎接受了，交了500元的定金。 </p>\r\n<p>　　一个多月后，何莎询问赵女士，“血合格吗？” </p>\r\n<p>　　天津方面回答，“不合格。你的细胞数不合格。我们已给你出具了脐带血基本情况报告。” </p>\r\n<p>　　何莎告诉记者，她的500元定金没有退。 </p>\r\n<p>　　<strong>第三袋 </strong></p>\r\n<p>　　<strong>签废弃协议 </strong></p>\r\n<p>　　<strong>退了5880元</strong> </p>\r\n<p>　　刘燕是陆静、何莎的高中同学，她生女儿时也选择了脐带血储存。 </p>\r\n<p>　　今年4月13日，刘燕交了6380元的检测费、保管费，也是存在天津市脐带血造血干细胞库的。刘燕说，当时，业务员说成功率在90%以上。产后两天，业务员来了，并告诉她“脐带血正常”。 </p>\r\n<p>　　40天后，刘燕又打电话问脐带血情况。业务员回答，“你的脐带血细胞数不合格，血太少了。” </p>\r\n<p>　　刘燕说，“你们说脐带血不合格，有何权威证据？我要要回脐带血，请重庆的权威专家鉴定。”　　 </p>\r\n<p>　　业务员回答，“可以，中途出了事自己负责。” </p>\r\n<p>　　刘燕同意。 </p>\r\n<p>　　几天后，对方没有动静，刘燕又追问原因。业务员回答，“国家规定，私人不能处理血液及血液制品。”天津方面给她出具了一个没有公章的传真件，上面写着“细胞数不合格”。刘燕对此结论并不接受。 </p>\r\n<p>　　7月，刘燕急需用钱，被迫与天津市脐带血造血干细胞库重庆分公司签定了脐带血废弃协议，协议签字后，对方退了5880元。 </p>\r\n<p>　　<strong>名词解释》》 </strong></p>\r\n<p>　　<strong>脐带血</strong>　</p>\r\n<p>　　脐带血是胎儿娩出、脐带结扎并离断后残留在胎盘和脐带中的血液，通常是废弃不用的。近十几年的研究发现，脐带血中含有可以重建人体造血和免疫系统的造血干细胞，可用于造血干细胞移植，治疗多种疾病，如白血病、骨髓瘤、肝癌等，有不可估量的临床应用价值。脐带血已成为造血干细胞的重要来源，特别是无血缘关系造血干细胞的来源。</p>\r\n<p>　　<strong>法规链接》》　</strong></p>\r\n<p>　　1999年5月26日卫生部颁发了《脐带血造血干细胞库管理办法》（试行），现摘录如下： </p>\r\n<p>　　任何单位和个人不得以营利为目的进行脐带血采供活动； </p>\r\n<p>　　未取得脐带血造血干细胞库执业许可证的单位和个人，一律不得开展采供脐带血造血干细胞业务； </p>\r\n<p>　　未经批准擅自设置和开办脐带血造血干细胞库，非法采集、提供脐带血的，由省级人民政府卫生行政部门予以取缔，没收擅自开办脐带血造血干细胞库的违法所得和设备、器材以及采集的脐带血，并处以3万元以下的罚款；构成犯罪的，依法追究刑事责任。</p>\r\n<p>　　<strong>数据》》　</strong></p>\r\n<p>　　每月20多袋运外地保存 </p>\r\n<p>　　存一袋血总共花16000元 </p>\r\n<p>　　■重庆每月约有20多例脐带血经过空运保存于外地脐带血库。 </p>\r\n<p>　　■存脐带血的家长需交6380元，其中5800元是分期检测费，580元是一年的保管费。一般存22年，检测费和保管费加起来要花16008元。 </p>\r\n<p>　　■如果只存脐带还要贵些，分期检测费是8500元，保管费一年是600元。22年脐带检测费和保管费总共19068元。</p>\r\n<p>　　<strong>暗访》》</strong></p>\r\n<p>　　<strong>医院都有业务员收脐带血 </strong></p>\r\n<p>　　<strong>自称一份血可卖几万元</strong>　</p>\r\n<p>　　记者以何莎表姐的身份，来到渝中区上清寺太平洋广场A座2303天津市脐带血造血干细胞库重庆分公司，想取回何莎脐带血检测报告，在“脐带血病原菌培养检测”一栏下面写着：“需氧菌培养阳性；厌氧菌培养阳性”。重庆分公司的人说，何莎脐带血两项指标检测均为阳性，血液不合格。 </p>\r\n<p>　　业务员说，天津市脐带血造血干细胞库是国家卫生部批准成立的合法的脐带血库，说完，对方让记者看了挂在墙上的卫生部相关批文。重庆分公司的人还说，一份脐带血如果出售，价格约5万元。 </p>\r\n<p>　　昨天，记者走访了几家大医院，在产检中心都能看到脐带血储存推销员的身影。在渝中区一家大医院产检中心，业务员傅林介绍，现在存脐带血的人越来越多。天津市脐带血造血干细胞库重庆分公司在许多地方，如渝中、沙坪坝、江北、南岸区的大医院产检中心，设有业务员。医生和她们配合，为产妇收集脐带血。如果运气好，一个月就可以收集5-6个脐带血，一年下来少说也有几十个脐带血。现在，天津脐带血库已存了23万份脐带血，重庆有3000份。 </p>\r\n<p>　　傅林说，脐带血的储存成功率高达90%-95%，“我们收集婴儿脐带血都有合法手续。你看，这是卫生部批准我们执业的通知。” </p>\r\n<p>　　傅林拿出几份复印文件，这是卫生部卫医发（2002）262号文，这是她们的许可证号，卫脐血干细胞库字[2002]第002号。记者要求保留傅林所说的复印文件。她不同意，“只能看，不能印。” </p>\r\n<p>　　“如果脐带血不合格，我们也不能保存。除了500元的保证金不退外，其余都会退，但不合格的情况很少。”傅林说。 </p>\r\n<p>　　脐带血的用处很大，如果卖给需要者，是什么价钱呢？傅林闪烁其词，“是的，一份血可以卖好几万呢。”</p>\r\n<p>　　<strong>相关新闻》》</strong></p>\r\n<p>　　<strong>市政府已同意 </strong></p>\r\n<p>　　<strong>重庆将建脐血库</strong>　</p>\r\n<p>　　华龙网讯 （记者 陈军）市红十字会负责人冉茂民说，卫生部曾在2002年3月批复同意重庆在市血液中心设置脐血库，后因非典和几次大的灾情延迟建设。今年4月28日，市红十字会在给市政府的请示中称，重庆每年近2000人患白血病，其中儿童患病率较高，对脐血造血干细胞需求量大。　</p>\r\n<p>　　目前市政府已同意建立重庆脐带血造血干细胞库（简称“脐血库”），作为骨髓库的重要补充，市红十字会目前正在牵头实施，力争尽快建成开放。　</p>\r\n<p>　　据了解，脐血库分公共库和自体库，公共库是骨髓库的重要补充，接受无偿捐献，捐者不需付费，检验入库及保管费用由脐血库承担，捐者同样享有配型成功后的使用权。自体库则接受个人交费入库，只供捐者本人及直系亲属使用。重庆拟建脐血库公共部分首期库容约为5000份。 </p>\r\n<p>　　又讯 记者日前拨通卫生部血液处的电话，一位姓沈的工作人员说，卫生部的确批准了天津市成立脐带血造血干细胞库。但2006年以后，卫生部将血液管理的权限下放给了各地卫生行政部门。</p>', 'gwm', 0, 24);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(80, '治个感冒花2500元 医院涉嫌借甲流发财', '', '', '', '2009-11-04 11:01:58', '116.228.141.77', '<p>星辰在线11月4日讯 11月3日，网友伍元香女士向记者诉苦，女儿日前感冒，住进了慈利县人民医院，出院时，医院给了一份长长的费用核查清单，收费项目竟达64项，医疗费用达2572.42元。仔细核查后，伍女士更郁闷：有20多项收费项目不知是什么意思。</p>\r\n<p><strong>女儿“甲流”住院</strong></p>\r\n<p>伍女士回忆，10月23日，女儿出现了发烧症状，于是到慈利县人民医院进行检查，“医生说近段时间甲流严重，为了孩子健康，建议住院观察、治疗”。伍女士随即交了200元钱入院。</p>\r\n<p>“当天晚上，女儿打了针，输了液，第二天5点就退烧了”。随即，院方告知伍女士已欠费，“刚进来怎么会欠费呢？”伍女士查询后吓了一跳，仅一晚上竟花了1022元钱。之后的几天，医生主要针对炎症等病状为女儿治疗。</p>\r\n<p><strong>无菌手套竟用了70双</strong></p>\r\n<p>10月30日，女儿出院，拿到费用清单后，伍女士着实吓住了：总计收费2572.42元！回家仔细核对，发现收费项目竟多达64项，其中，20多项收费项目实在不明白是什么意思；清单上有两项为“一次性枕芯”、“一次性枕套”，后面备注为“病人自愿购买”，“医院根本就没有征求过我的意见。”第40项收费项目为“无菌手套7.5#”，更是令伍女士疑惑不已，住院7天，医生竟然用了70双手套，每天达10双之多。</p>\r\n<p>伍女士问医生女儿究竟是什么病，医生的回答更让她大跌眼镜，“您女儿就是个普通感冒。”</p>\r\n<p><strong>特殊时期，特殊照顾？</strong></p>\r\n<p>慈利县人民医院传染科邢主任称，并没给出“普通感冒”的结论。“患者送来时，高烧伴随头痛，第二天体温降后，仍有扁桃体发炎和咳嗽症状，按特殊时期的规定，需留观一周。”邢主任称，正因为这样，费用才会高一些。</p>\r\n<p>邢主任还称，近期该院的发热病人都被作为甲流疑似病例对待，一般一个病例治疗费用在2000元左右。对伍女士女儿的诊断结论就是甲流疑似病例。</p>\r\n<p><strong>网友质疑</strong></p>\r\n<p>借“甲流”发财？</p>\r\n<p>网友“muzimei”：病了花钱理所应当，但你要让我花得明明白白，更不能强迫我自愿！</p>\r\n<p>网友“木左”：如果人民医院也借“甲流”发昧心财，未免有自毁形象之嫌。</p>\r\n<p>网友“大草”：是甲流就是甲流，该怎么治就怎么治；怕就怕不是甲流，硬说疑似甲流，太不厚道啦。</p>', 'gwm', 0, 31),
(81, '卫生部调查北大医院 非法行医之说无法律根据', '', '', '', '2009-11-05 11:02:41', '116.228.141.77', '中广网北京11月5日消息 据中国之声《央广新闻》8时15分报道，近日，没有职业医师资格证书的医学生在北大医院涉嫌非法行医的报道引起了社会各界的广泛关注。 \r\n<p>　　卫生部表示，医学临床学习和实践活动是医学教育教学的重要组成部分。按照《执业医师法》和《高等教育法》的有关规定，严格意义上说，医学生和试用期医学毕业生在医疗机构的临床实践活动是医学教育中的临床实践活动，而不是正式的行医。对这种活动的管理，是有法可依，有章可循的。</p>\r\n<p>　　我国刑法对于“非法行医”的具体界定，是不包括医学生和试用期医学毕业生从事临床实践活动。所以有关媒体报道的许多没有执业医师执业证书的医学生在北大医院“非法行医”，这一说法应该是没有法律依据的。</p>\r\n<p>　　卫生部已经责成北京市卫生局对媒体报道的北大医院医学生从事临床诊疗问题进行认真调查，查清事实，提出处理意见，并及时向社会公布。</p>', 'gwm', 0, 24),
(82, '寒潮来袭要防四种病 ', '', '', '', '2009-11-05 11:03:36', '116.228.141.77', '<p align="center"><img src="http://www.gmw.cn/images/2009-11/05/xin_06110605084840600872.jpg" />\r\n</p>\r\n<p>　　北风呼啸而至，广州昨日顿时进入秋季。今明两天，气温将进一步下降。由于气温的突降，人们的免疫力也随之下降，与此同时，会有很多疾病乘虚而入。 </p>\r\n<p>　　<font color="#0000ff"><strong>呼吸系统疾病 </strong></font>\r\n<table align="left">\r\n<tbody>\r\n<tr>\r\n<td><span></span></td></tr></tbody></table>\r\n<p><font color="#0000ff"><strong>　　易发度：★★★★★ </strong></font>\r\n<p>　　呼吸系统疾病受天气影响最大。寒潮是呼吸系统疾病的一道坎。低温使得呼吸的局部温度很低，毛细血管收缩，黏膜上皮的纤毛活动减慢，气管排出细菌的功能减弱，同时由于干燥，呼吸道黏膜干燥弹性减少，免疫力下降，排泄异物的功能减退，导致细菌及病毒在呼吸道生长。 \r\n<p>　　<font color="#0000ff"><strong>心脑血管疾病 </strong></font>\r\n<p><font color="#0000ff"><strong>　　易发度：★★★★★ </strong></font>\r\n<p>　　在低温状态下，人体外围的血管会收缩，造成血管阻力及血压的上升，使心脏负荷增加，增加脑溢血和心肌梗塞发作的机会;由于寒冷，身体消耗能量以产生热量，心脏必须发挥更大的功能，增加心肌梗塞发作的机会。 \r\n<p>　　<font color="#0000ff"><strong>青光眼 </strong></font>\r\n<p><font color="#0000ff"><strong>　　易发度：★★★★</strong></font> \r\n<p>　　近年研究发现，气温的突然变化与青光眼发作有密切关系。原因是气温降幅过大影响了体温的调节中枢，再通过植物神经干扰了血压，造成眼压波动，进而诱发青光眼。 \r\n<p>　　<font color="#0000ff"><strong>胃肠病 </strong></font>\r\n<p><font color="#0000ff"><strong>　　易发度：★★★ </strong></font>\r\n<p>　　在寒冷的气候下，胃肠道的活动增加，腺体分泌旺盛，胃和十二指肠溃疡患者往往频发上腹痛、返酸、上消化道出血也多数发生在寒冷的季节。 \r\n<p>　　<font color="#0000ff"><strong>寒潮来了吃什么养生？ </strong></font>\r\n<p><font color="#0000ff"><strong>　　牛肉、羊肉 </strong></font>\r\n<p>　　牛肉富含肉毒碱，肉毒碱主要用于脂肪的新陈代谢。中医认为羊肉补中益气，味甘性热，具有利尿效果。所以多吃牛肉和羊肉有助于加快新陈代谢，抵御寒冷。 \r\n<p>　　<font color="#0000ff"><strong>含碘食物 </strong></font>\r\n<p>　　海带、紫菜、海蜇、蛤蜊、菠菜、玉米等含碘食物可以促进人体甲状腺激素分泌。甲状腺激素具有生热效应，它能加速体内绝大多数组织细胞的氧化过程，增加产热，使基础代谢率增高，皮肤血液循环加强，抗冷御寒。 \r\n<p>　　<font color="#0000ff"><strong>根茎类蔬菜 </strong></font>\r\n<p>　　菠菜含铁高，血液中有了铁元素，人的耐寒能力增强。藕、胡萝卜、百合、山芋、大白菜等含有丰富的无机盐，不妨与其他食品掺杂食用。</p><!--/enpcontent-->\r\n', 'gwm', 0, 24),
(83, '卫生部下发关于做好输入性疟疾防治工作通知', '', '', '', '2009-11-05 11:04:35', '116.228.141.77', '中广网北京11月5日消息（记者刘天思）2009年1月—9月，我国疟疾疫情总体呈下降趋势，全国报告疟疾病例数11735例，其中恶性疟832例，较2008年同期分别下降41%和2%，但是，输入性疟疾疫情依然给我国疟疾防治工作带来严重威胁。近期，安徽、甘肃和辽宁3省卫生部门陆续报告7名自非洲返乡人员感染恶性疟，其中死亡1人。为进一步做好疟疾防治工作，卫生部就有关工作通知如下： \r\n<p>　　<strong>高度重视输入性疟疾防治工作</strong></p>\r\n<p>　　各级卫生行政部门要充分认识输入性疟疾对人民身体健康的严重危害和对我国疟疾防治工作的不利影响。现有疟疾流行的省（区、市），要保持和加强疟疾防治工作力度，充分利用现有的工作基础和条件做好输入性疟疾防治工作，不能有丝毫松懈。非疟疾流行区的省（区、市），要加强疟疾防治意识，加强对自东南亚、非洲等疟疾高流行区返乡人员疫情的动态监测，结合实际情况采取相应措施，做好输入性疟疾防治工作。</p>\r\n<p>　　<strong>不断提高各级医务人员诊治水平</strong></p>\r\n<p>　　各级卫生行政部门要对相关医务人员，尤其是农村和社区基层卫生服务机构人员，开展疟疾诊疗知识培训，使其熟悉掌握疟疾的症状、诊断、治疗等内容。各级各类医疗机构要利用各种方式，不断提高本单位医务人员疟疾病例的发现意识和诊疗水平，要主动询问就诊的发热病人是否有赴疟疾高流行区旅游、务工史，并根据结果及时开展疟原虫血检项目，要全程、规范治疗疟疾病例。非恶性疟流行省份和向疟疾高流行区输出劳务的大省，特别要做好恶性疟诊断治疗方面的培训，建立本地区的诊断治疗专家库，保证恶性疟病例早诊断、早治疗，最大限度地保护患者身体健康。</p>\r\n<p>　　<strong>切实保障信息沟通顺畅运转</strong></p>\r\n<p>　　各级卫生行政部门要保障医疗机构之间、医疗和疾病预防控制机构之间通畅的信息沟通渠道。要及时将本省或其他省发生的输入性疟疾病例的诊断治疗情况向省内各级医疗和疾病预防控制机构通报，汲取经验教训，不断提高诊治水平。各级卫生行政部门要主动和有关部门联系，及时获得自疟疾高流行区返乡的人员信息，并向医疗和疾病预防控制机构通报，增强防范意识。各级医疗机构要严格按照有关要求报告疟疾病例，疾病预防控制机构要及时开展流行病学调查、病例追踪等工作。</p>\r\n<p>　　请各级卫生行政部门将此文转发给各医疗机构，共同做好疟疾防治工作。</p>', 'gwm', 0, 29),
(84, '北大医院是否非法行医 当事双方法庭激辩(图)', '', '', '', '2009-11-06 09:40:38', '116.228.141.77', '<p align="center"><img src="http://image.xinmin.cn/2009/11/06/20091106065533864251.jpg" />\r\n</p>\r\n<p align="center">王建国怀抱妻子遗像，与北大医院第二次对簿公堂■摄影/郝羿</p>\r\n<p>　　■受非法行医指责的于峥嵘成被告代理人</p>\r\n<p>　　■于峥嵘论文成为原告方提供的新证据</p>\r\n<p>　　■法官宣布休庭后表示择日继续审理</p>\r\n<p>　　昨天（5日）下午2点10分，“北大教授死于北大医院案”在北京市高院二审。处于“非法行医”指责之巅的于峥嵘作为北大医院的代理人之一出现在法庭上。</p>\r\n<p>　　由于双方发言都涉及诸多医学的专业知识，表述相对复杂，尽管法官多次提醒双方尽量控制时间，但一直到下午4点30分左右才完成全部流程，此后法官宣布择日开庭继续审理。</p>\r\n<p>　　<strong>■双方诉求</strong></p>\r\n<p>　　<strong>■原告王建国方</strong></p>\r\n<p>　　1.重新认定熊卓为病情</p>\r\n<p>　　2.认定北大第一医院“非法行医”</p>\r\n<p>　　3.提高北大第一医院的赔偿金额</p>\r\n<p>　　■<strong>被告北大第一医院</strong></p>\r\n<p>　　一审法院在审理此案时程序不合法，对熊卓为的死亡不应进行司法鉴定，应由具有临床医学鉴定资质的机构进行医疗事故技术鉴定</p>\r\n<p>　　<strong>庭审现场怀抱妻子遗像上公堂</strong></p>\r\n<p>　　为妻子熊卓为之死奔走两年一直默默无闻的王建国，昨天在北京市高院二审出庭前获得了前所未有的“礼遇”，数十家媒体早在他到场前一个小时就守候在高院门口，希望在第一时间采访到他本人，也为了“争夺”仅有20余席的旁听机会。</p>\r\n<p>　　再次与北京大学第一医院对簿公堂，王建国捧着妻子的遗像走进法庭，要求死亡赔偿、精神抚慰金等共计约500万元。双方就是否存在非法行医，是否进行医疗鉴定，患者死亡原因以及病历真假等问题仍存在针锋相对的观点。</p>\r\n<p>　　同时在场的还有王建国夫妇的亲属、朋友和学生以及闻讯从外地赶来、同样因医疗纠纷打了多年官司的普通百姓。也许是没有预料到这场官司的旁听机会如此抢手，法院在当事人双方和媒体之间分配有限的旁听名额，让开庭时间比预定推迟了半个多小时。</p>\r\n<p>　　两年前的2007年10月，王建国将北大医院诉至法院，认为该院“非法行医”，并由于医院医疗过失造成熊卓为死亡，索赔500万元。今年7月，北京市一中院一审宣判认定，北大第一医院存在医疗过失，造成熊卓为死亡的损害后果。该院承担全部民事损害赔偿责任，赔偿王建国及其岳母共计70多万元。但一审法院并未认定“非法行医”。一审判决后，双方均表示不服，此后相继提出上诉。</p>\r\n<p>　　<strong>三大交锋　三大焦点引激烈交锋</strong></p>\r\n<p>　　■<strong>交锋一：是否存在非法行医</strong></p>\r\n<p>　　昨天，本案涉及的医生于峥嵘以北大医院代理人的身份出庭，但除了和身旁律师私语几句，整个庭审一言不发。对于被指“暴力抢救”，于峥嵘表示，他在抢救过程中，“院内外共十几二十名专家、主任级别的医生在场”，而对于死者病历中没有上级医师的审查签字问题，他认为“我们在医学操作的层面上是完全合法的，只是在记录上没做到周全”。</p>\r\n<p>　　于峥嵘等人是否非法行医成为交锋的核心。王建国方代理律师卓小勤认为，北大医院为熊卓为实施诊疗服务的“医师”包括于峥嵘、段鸿洲、肖建涛，这三名“医师”中于峥嵘仅取得了执业医师资格，但没有经过医师执业注册，未取得《医师执业证书》，段鸿洲和肖建涛则既未取得执业资格，又没有经医师执业注册，也未取得《医师执业证书》。上述事实已被市卫生监督所认定为非法行医，但未在一审判决中予以认定。</p>\r\n<p>　　记者看到，在王建国出具的复函中，认定于峥嵘、段鸿洲和肖建涛为熊卓为实施诊疗行为属非法行医，并写明“市卫生监督所就北京大学第一医院的违法行为下达了《卫生监督意见书》”。对此，北大医院代理律师表示，“并不清楚医院是否收到意见书。”并且强调于峥嵘并不存在非法行医，“他为熊卓为治疗时任医院骨科总住院医师，于2005年6、7月间参加并通过医师资格证考试，2005年12月获发证书，2006年5月获得《执业医师证》。”</p>\r\n<p>　　■<strong>交锋二：是否进行医疗鉴定</strong></p>\r\n<p>　　北大医院一审庭审中提出过进行医疗事故技术鉴定的申请，昨天律师又一次向法院提出了同样申请，认为一审未进行医疗事故技术鉴定存在程序违法。</p>\r\n<p>　　王建国方则认为，于峥嵘和段鸿洲的行为已构成非法行医，据相关规定，非法行医造成患者人身损害不属于医疗事故，触犯刑律的当依法追责。并且根据《医疗事故技术鉴定暂行办法》，非法行医造成患者身体健康损害的，医学会不予受理医疗事故技术鉴定。</p>\r\n<p>　　■<strong>交锋三：是否死于不及时溶栓</strong></p>\r\n<p>　　于峥嵘作为第一作者发表在《中国脊柱脊髓杂志》上一篇论文，成为王建国方提交的新证据。卓小勤认为这篇名为《脊柱手术后静脉血栓栓塞的风险与预防》的文章提到：“2005年8月-2006年7月我科由同一组术者施行脊柱手术的患者共156例，根据术后抗凝剂应用与否分组，说明被答辩人医院的医师对脊柱手术发生深静脉血栓和肺栓塞的风险是‘知道或者应当知道’的，而且也知道并掌握相应的检查和诊断技术。”</p>\r\n<p>　　卓小勤认为，于峥嵘等医师在长达10个多小时里，未对熊卓为进行血栓检查和诊断，错过了早期溶栓和防止严重肺栓塞发生的时机。他还提出，“熊卓为治疗及死亡时间，正好处于该论文中被选取病例的时间段，有理由怀疑熊卓为是被放在不进行溶栓治疗的一组内的实验品，未及时溶栓也是熊卓为死亡的重要因素。”</p>\r\n<p>　　北大医院代理律师则认为，一篇论文并不等于一个科研题目，所谓“实验”一说更是对于峥嵘等人的攻击。</p>\r\n<p>　　<strong>官方表态</strong></p>\r\n<p>　　<strong>西城区卫生局副局长刘文秀――</strong></p>\r\n<p>　　<strong>是否非法行医待查 可能存在管理不严</strong></p>\r\n<p>　　昨天下午，记者就“北大教授死于北大医院”一案，采访了出席西城法院“医患纠纷专题研讨会”的西城区卫生局副局长刘文秀。</p>\r\n<p>　　记者：北大医院属西城区卫生局管辖，贵局是否参与了对北大医院的调查？进展如何？</p>\r\n<p>　　刘局长：目前是北京市卫生局调查此事，西城区卫生局虽没有参加调查，但我们非常关注。</p>\r\n<p>　　记者：从目前情况看，北大医院是否存在“非法行医”？</p>\r\n<p>　　刘局长：现在还不能下结论说存在。一般医院如果出现没有取得国家执业医师资格的医生给患者看病，可以断定是“非法行医”。但北大医院是“教学医院”，承担实习医生临床实践基地的任务，这样的“教学医院”出现实习医生参与治疗，除去“非法行医”还有可能是管理不严的问题。</p>\r\n<p>　　<strong>双方声音</strong></p>\r\n<p>　　<strong>于峥嵘落泪：非法的帽子压力太大</strong></p>\r\n<p>　　昨天下午，北大医院召开了一场小规模发布会。参与熊卓为抢救的该院原骨科主任朱天岳、心内科主任丁文惠、麻醉科主任王东信及受到“非法行医”指责的于峥嵘等人均到场。院方表示，在熊卓为的抢救中不存在“非法行医”。</p>\r\n<p>　　参与抢救的医生称，2006年1月30日夜，正在住院术后康复的熊卓为摔倒，“我是科室第一个到达现场的大夫，当时熊精神还清醒，之后突然失去心跳。”该院原骨科主任、心内科主任等先后抵至ICU病房抢救，“北医院长及家属请来的阜外医院正副院长均到场，参与抢救的主任医师就在10位以上”。院方称，报道所指的“3名非法行医的学生”均有上级医师指导。但抢救记录等病历处无3人上级医师签名，这令医院很“被动”。据称，对熊卓为长达7小时的心脏复苏中，几位医师不间断为其进行人工按压。“长时间大力度按压并采用全身抗凝，出现心肺出血情况很常见。此外，如果按压没导致肋骨折断，却反证明按压不到位，起不到复苏效果。”</p>\r\n<p>　　昨天下午5时许，刚出庭归来的于峥嵘显得紧张疲惫。“我当时是在上级医师指导下参与抢救，主要实施人工按压。‘非法行医’扣给我，压力太大了。”言语不多的他当场落泪。</p>\r\n<p>　　<strong>王建国疾呼：愿生命唤醒医生良知</strong></p>\r\n<p>　　王建国在搜狐的博客从11月4日注册起，截至上庭前的一天多时间，已经发表了包括判决书、声明、证据等文章十余篇。</p>\r\n<p>　　“在妻子去世之后我没有耽误过一节课，有时候一边上课一边哭，持续了一两年时间。”王建国说，妻子的死不该仅仅是一场惨死和一次牺牲，自己要争取的赔偿金额也绝对不是一个数字。庭审结束后，他对记者再一次讲出了博客开篇的《怀念爱妻卓为》中的最后一句，“但愿你的宝贵的生命能警醒医院对管理制度的改善，能唤醒医生对病人生命珍视的良心和责任感，由此而挽救更多无辜的生命。但愿你光辉的一生能激励更多的人献身科学和社会。”</p>', 'gwm', 0, 26),
(85, '“开胸验肺”农民工张海超成功“洗肺”', '', '', '', '2009-11-06 09:53:38', '116.228.141.77', '人民网秦皇岛11月5日电&nbsp;&nbsp;（王明浩、朱润胜）“我的呼吸比手术前顺畅多了，感觉精神爽快、头脑清醒、肢体有力。”11月5日下午，“开胸验肺”农民工张海超从容地介绍着自己“洗肺”后的身体状况。当日，在中国煤矿工人北戴河疗养院举行的医疗报告会上，李玉环院长宣布：对张海超实施的大容量全肺灌洗手术取得圆满成功，患者已达到出院标准。<br />\r\n<br />\r\n　　张海超是河南新密市刘寨镇老寨村村民，2004—2007年间，他到地处新密市曲梁乡的郑州振东耐磨材料有限公司上班，先后从事杂工、破碎、开压力机等有害工种，不幸患上尘肺病。面对职业病鉴定难题，今年6月22日，张海超毅然在郑州大学第一附属医院“开胸验肺”，以一种近乎自残的方式证明了自己的病情——尘肺三期，被媒体称为“开胸验肺”事件，一下轰动全国，舆论为之哗然。<br />\r\n<br />\r\n　　在中国尘肺医疗基金会的帮助下，9月22日，张海超来到中国煤矿工人北戴河疗养院准备接受肺灌洗手术。刚入院时，他身体非常虚弱，咳嗽、多痰、胸闷等症状明显，走上十几步就会气喘吁吁。针对这种情况，医疗专家为其制定了先康复疗养再洗肺治疗的方案。<br />\r\n<br />\r\n　　在医护人员的精心照料下，张海超的体质逐渐好转，于10月先后接受了2次左右分期肺灌洗手术。从双侧肺脏中清洗出大量生产性粉尘、27.12亿个吞噬了粉尘而中毒的巨噬细胞，以及这些细胞所释放出的各种导致肺脏纤维化的有害因子。<br />\r\n<br />\r\n　　目前，张海超术后恢复良好，比入院前体重净增了6公斤，各项重要生理指标也明显改善，尤其是肺脏的弥散功能和最大通气量较手术前分别提高了22%和6%。张海超的主治医师马国轩表示，完全可以预期，张海超接受此次洗肺治疗后的远期生命和生活质量会更加美好。<br />\r\n<br />\r\n　　会上，张海超被中国煤矿工人北戴河疗养院聘为“职业卫生安全联络员”。张海超表示，他要通过自己的亲身经历，唤起全社会对职业病防治的重视和对农民工群体的关注，并积极宣传职业病的危害和防治知识，让农民工兄弟姐妹们不再有他的“开胸之痛”。', 'gwm', 0, 32),
(86, '孕妇和3岁内儿童能否接种甲流疫苗', '', '', '', '2009-11-06 10:01:11', '116.228.141.77', '新华社北京11月4日电&nbsp;(记者周婷玉)因为缺少临床试验数据，3岁内儿童和孕妇此前一直被列为接种甲型H1N1流感疫苗的禁忌人群。但中国疾病预防控制中心免疫规划中心主任梁晓峰表示，我国正在对两类人群进行研究，他们能否接种疫苗在不久的将来就会有结论。“一般的临床试验，如果成人和儿童这两个年龄组比较安全，就会扩大到幼儿，这是做临床试验的惯例，我们也在遵循这个惯例。”梁晓峰说。&nbsp;', 'gwm', 0, 26),
(87, '可抑制甲流病毒口罩研发成功 抑制率达到92%', '', '', '', '2009-11-09 13:02:22', '116.228.141.77', '据新华社北京11月8日电一种可有效抑制流感病毒的抗病毒口罩日前研发成功并面世，经过国家流感中心检测，这种专用口罩对甲型H1N1流感病毒抑制率达92%。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;这种抗病毒防流感的新型口罩，由天津市明大科技开发有限公司科技人员运用分子链接抗微生物技术和远红外技术研制而成。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;中国科学院理化技术研究所抗菌材料检测中心对这种口罩针织材料所做的检测报告说，该材料可杀死大量对人体有害的细菌，尤其是对大肠杆菌、金黄色葡萄球菌、白色念珠菌的杀灭率高达99%以上。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;据介绍，这种口罩具有长效抗病毒、杀病菌作用，水洗也不失效。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;据新华社济南11月8日电记者注意到，甲型H1N1流感进入流行高峰以来，消毒液的销售呈现上升态势。疾控专家介绍，甲流不同于 SARS，不提倡大面积的环境消毒，只要保持清洁即可。<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;济南市疾控中心消毒监测所副所长刘慧媛介绍，甲型H1N1流感属呼吸道疾病，病毒主要通过飞沫传播，因此防控甲流，不提倡大面积的环境消毒。疾控专家介绍，如果一定要消毒，可采取擦拭消毒的办法。消毒液的配比不需要浓度过大，家庭消毒可以用500毫升的矿泉水瓶量出两瓶水，用矿泉水瓶盖量出一盖 84消毒液加入，用抹布擦拭即可，浓度过大易对环境造成危害。', 'gwm', 0, 30),
(88, '新版医保目录将于11月底公布', '', '', '', '2009-11-09 13:35:21', '116.228.141.77', '<p>2009版《国家基本医疗保险、工伤保险和生育保险药品目录》（以下简称《医保目录》）将于11月底公布，将增加药品使用指南与基本原则，以强化医疗保险经办机构对药品使用合理性的监督管理。</p>', 'llz007', 0, 33);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(89, '央视：坊间流传接种甲流疫苗会得一种怪病(图)', '', '', '', '2009-11-10 10:05:44', '116.228.141.77', '<p><!--function: topic() parse end  3ms cost! --></p>\r\n<div class="zi14 hanggao24"><!--function content() parse begin-->\r\n<table cellspacing="20" cellpadding="0" align="center">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://pic.enorth.com.cn/0/06/35/61/6356167_798428.jpg" border="0" />\r\n </td></tr>\r\n<tr>\r\n<td>　　在当前这种严峻的情行下，接种甲流疫苗是一种行之有效的办法，但这些天街头坊间却流传出接种甲流疫苗会得一种怪病，而记者调查后了解，接种疫苗出现的副作用比例非常低，随着疫情升级，甲流病毒可能变异，因此接种疫苗刻不容缓。</td></tr></tbody></table>\r\n<p>　　据卫生部通报，11月6日15时至11月9日15时，中国内地报告甲型H1N1流感确诊病例4551例。截止到11月9日，中国内地31个省市自治区报告59478例甲型H1N1流感确诊病例，已治愈44662例。累计报告重症病例242例，已治愈53例，死亡30例。</p><!--advertisement code begin--><!--none--><!--advertisement code end-->\r\n<p>　　通报称，截至11月9日12时，国家食品药品监管局累计完成批签发235批次3960.0万人。全国31个省(区、市)和新疆生产建设兵团累计签收甲型H1N1流感疫苗仍为2631万人份。全国31个省份和新疆生产建设兵团均已开展对重点人群的接种工作，累计完成接种874.5万人。</p>\r\n<p><strong>　　再问甲流疫苗安全性</strong></p>\r\n<p>　　今天北京下雪了，北方不少城市大幅降温，这种天气，将助长甲流病毒的传播；温度骤降，人们抵抗力下降，遭甲流侵袭风险提高；疾控专家呼吁市民积极接种疫苗，建立公众免疫屏障。</p>\r\n<p>　　没错，随着秋冬季的到来，我国目前已经提前进入了甲流疫情的流行高发期，目前甲流疫情呈现三大特点:一是以学校暴发疫情为主，二是疫情从城市向农村地区持续蔓延，三是甲型H1N1流感流行强度持续增加，部分地区已进入高发期。</p>\r\n<p>　　按理说在当前这种严峻的情行下，接种甲流疫苗是一种行之有效的办法，但是，这些天街头坊间却流传出一些说法，说接种甲流疫苗会得一种怪病。</p>\r\n<p>　　情况真的是这样吗？让我们一起去看一看。</p>\r\n<p><strong>　　怪病儿童是甲流疫苗引起的吗？</strong></p>\r\n<p>　　近日社会上流传，儿童医院接受了一个得怪病的孩子，怪病的原因是接种了甲流疫苗。那么事实究竟是怎么样的呢？对此记者专程来到了传说中患有怪病的孩子董帅的家。从董帅母亲我们那里得知，董帅确实得了一种罕见的病，叫EB病毒感染并发噬血细胞综合症，小董帅所患的这种病症在全世界的发病率仅为万分之二，他目前正在儿童医院接受一期化疗。</p>\r\n<p>　　“他刚开始就是发烧，一直高烧不退，40度，肚子已经很大了，鼓起来了，我们现在已经进行了30次的疗程，30次化疗，他现在稳定多了，起码来说不发烧了，生命体征比较平稳。”</p>\r\n<p>　　不过，对于得这个病的原因，董帅的母亲李女士告诉记者，具体原因他们也不知道，不过跟打流感疫苗没什么关系。</p>\r\n<p>　　“不是，跟这个甲流疫苗没有关系，当时我们3月份打针的时候，甲流还没出来。”</p>\r\n<p>　　东帅没有打过流感疫苗，那么为什么社会上会传闻他是打了疫苗才引发的怪病呢。李女士告诉记者，发现孩子得病后，迟迟不能确诊，她和丈夫怀疑是孩子在3月份的时候接种麻疹疫苗造成的，在网上的求诊说明里没有说清楚，可能引起了误解。</p>\r\n<p>　　“那是什么疫苗呢？”</p>\r\n<p>　　“麻疹，到3月8日打完预防针，到3月13日他就一直发烧。”</p>\r\n<p>　　看来，注射甲流疫苗得怪病是一个误会，这个孩子接种的疫苗是麻疹疫苗，跟接种甲流疫苗没有一丁点关系。</p>\r\n<p>　　此前疾控中心的专家多次强调，接种任何疫苗都可能出现不良反应，甲流疫苗也不例外。一些人接种甲流疫苗后，可能出现注射部位疼痛、红肿、硬结，或发烧、寒战、疲劳、头痛等，这些都属于正常现象。这些不良反应通常1至2天内消失，无需治疗。</p>\r\n<p>　　但是除了这些症状，甲流疫苗会不会造成更严重的不良反应，对此，疾空部门也在密切监控当中，所以大家还是有不少的担忧和猜测，你看董帅只是接种过麻疹疫苗，得病原因也跟接种甲流疫苗毫无关系，但是传闻还是把两件不相干的事情联系在了一起，认为是甲流疫苗引起了“怪病”。</p>\r\n<p>　　针对大家广泛关心的疫苗接种安全性问题，有关专家近日指出，接种甲流疫苗安全有效，不良反应出现率低，疫苗保护率达85%以上。那么、目前接种甲流疫苗的市民，到底都有些什么症状，有没有出现所谓比较怪的怪病？记者到北京市多家医院进行更大范围的调查。</p>\r\n<p>　　到底是否有孩子因接种甲流疫苗得了怪病，记者特地拨通了儿童医院和儿研所的电话。</p>\r\n<p>　　北京儿童医院:“我们没有，因为我们都跟他们说了好几遍了。”</p>\r\n<p>　　记者:“打完甲流疫苗以后，有没有一种得了不适或者怪病的儿童上您这来就诊？”</p>\r\n<p>　　首都儿科研究所:“从没发现有，不适的也没有，打什么疫苗都会有人有一些小小的不舒服，有些些感冒症状，但是不会很严重，基本上没有太多不适，反正最近没有到，我们医院来看这个病的。”</p>\r\n<p>　　看来，儿童医院和儿研所都没有因为接种甲流疫苗得怪病的情况，随后，记者又在北京市几家三甲医院进行了调查。</p>\r\n<p>　　记者:“有没有收到一个打完甲流疫苗以后得了一种怪病的儿童。”</p>\r\n<p>　　北京协和医院:“没听说，因为本身我们单位就不是负责给孩子打疫苗的单位。”</p>\r\n<p>　　记者:“那有没有收到过打完疫苗以后身体出现不适的其他病人？”</p>\r\n<p>　　中国人民解放军总医院(301医院):“没有，都挺好的。”</p>\r\n<p>　　中日友好医院:“这个我不太清楚，应该不会有得怪病的吧，因为如果有肯定医院会知道，他们会报道，但是我们这边没有任何这方面的消息。”</p>\r\n<p>　　医院的答复是明确的，目前注射甲流疫苗的人群，出现的不良反应都是正常的，确实没有所谓怪病的说法。怪病之说，是大家对疫苗安全性的担忧造成的。</p>\r\n<p>　　我觉得，相关部门特别是卫生部门应该在解疑释惑方面，进一步采取措施，加大专家咨询、社区宣传和媒体报道的力度，使公众充分了解疫苗的性能、接种疫苗引起各种反应的原理以及最终结果，以便让人们用得放心、安心。</p>\r\n<p>　　目前，全国各地接种甲流疫苗的工作正在全面铺开，疫苗接种情况到底怎么样，接种人群的反应如何，有没有出现严重不良反应的情况呢？</p>\r\n<p><strong>　　石家庄:突发不良反应忙坏医护人员</strong></p>\r\n<p>　　河北省毗邻京津，目前这里的甲流疫苗注射情况如何？有没有出现严重不良反应的情况呢，前去采访的记者刘莹告诉我，采访的时候还是遇到一些状况，一位市民在接种甲流疫苗之后反应强烈，让所有的医护人员紧张不已，好一通忙活，到底是出了什么状况呢？我们随着记者的摄像机一起去看一看。</p>\r\n<p>　　记者:“你接种甲流疫苗了吗？”</p>\r\n<p>　　市民:“没有。”</p>\r\n<p>　　记者:“你会去打吗？”</p>\r\n<p>　　市民:“应该不会。”</p>\r\n<p>　　记者:“有点担心？”</p>\r\n<p>　　市民:“心里边有点顾虑，挺有顾虑的。”</p>\r\n<p>　　市民:“我想接种，没有啊，我上哪儿种去。”</p>\r\n<p>　　记者:“你不知道去哪儿接种？”</p>\r\n<p>　　市民:“不知道。”</p>\r\n<p>　　记者:“你是已经退休在家？”</p>\r\n<p>　　市民:“退休了。”</p>\r\n<p>　　记者:“没有人来组织你去接？”</p>\r\n<p>　　市民:“对，有的话我是接种去，可是我不知道上哪儿，我上那儿人家给我种不，我不知道。”</p>\r\n<p>　　市民:“还没搞。”</p>\r\n<p>　　记者:“如果搞的话，你会去打吗？”</p>\r\n<p>　　市民:“打啊，国家有这么好方法为什么不用。”</p>\r\n<p>　　市民:“国家都统一，因为我们还没接到通知。”</p>\r\n<p>　　记者:“还没组织你去接种？”</p>\r\n<p>　　市民:“没有。”</p>\r\n<p>　　记者:“如果组织你接种你会愿意去接种吗？”</p>\r\n<p>　　市民:“还跟着形式走，因为俺们这儿，这个还没有走到咱们这儿。”</p>\r\n<p>　　市民:“应该不是很放心，因为我感觉如果疫苗长时间的接种的话，抵抗力会比较不是那么好，可能到这个月中旬，我们组织去一次接种这个疫苗。”</p>\r\n<p>　　记者:“那你会去吗？”</p>\r\n<p>　　市民:“肯定会去。”</p>\r\n<p>　　记者:“你不担心会有一些不良的反应吗？有没有这样的担心？”</p>\r\n<p>　　市民:“可能会有点顾虑，但是为以后和自己的可能说健康着想，咱还是去接种一些。”</p>\r\n<p>　　在记者随机采访的30多位市民中，没有接种的占97%，其中，有17位表示愿意接种，但没有接到统一的安排；另有13位对接种稍有顾虑。从10月28日开始，河北省开始了首批甲流疫苗的接种工作，首批接种人群为:公安、司法干警、口岸检疫、海关、边检、民航等关键岗位公共服务人员，一线医疗卫生人员，部分托幼机构教职工和中小学校学生及教职工。那么这些优先接种甲流疫苗的人群，接种后的反应如何呢？当记者赶到石家庄市妇幼保健医院的时候，该院的医护人员正在进行甲流疫苗的接种，这位刚刚接种完的医生叫林鹏，接种后她忽然面色煞白，呼吸紧张，医院的另外两名医生急忙提着急诊箱赶了过来。</p>\r\n<p>　　“主任打电话所以我们就赶紧跑过来了，以为有休克或者有什么这些，因为它上面不良反应里边不是也有，最严重的的那个，主任就赶紧叫我们俩就上来了，说打针那有点事。”</p>\r\n<p>　　这样的突发状况，让在场所有人吃了一惊，在吸上氧气放松下来之后，林鹏的血压、心率才恢复了正常。</p>\r\n<p>　　林鹏:“刚才有点头晕，然后喘不上起来，现在好多了，能正常呼吸了。”</p>\r\n<p>　　记者:“刚才的症状是不良反应吗？”</p>\r\n<p>　　医生:“不太像，没有问题，呼吸、心率、血压都没有问题。”</p>\r\n<p>　　记者:“像这个的情况多吗？”</p>\r\n<p>　　医生:“不多，第一个，有时候，打针的时候，采血的时候，有的病人也会出现这种现象，有的人精神过度紧张，是比较敏感的人。”</p>\r\n<p>　　这样的情况在石家庄妇幼保健院接种点虽然只此一例，但是石家庄市妇幼保健院感染管理科主任祖桂花告诉记者，全院共有500名医护人员接种了甲流疫苗，其中也有4、5位出现过轻微的不良反应。</p>\r\n<p>　　医院主管:“也个别有轻度的头晕，轻度的头晕乏力有这种情况，休息一下一会也就过去了，最多的不超过一天，有的是几个小时就过来了。”</p>\r\n<p>　　除了在医院进行接种，在部分学校还设立了临时接种点，学生们的接种情况如何呢？</p>\r\n<p>　　石家庄市桥东区疾控中心主任副主任:“在我们学校安排的临时接种点的，我们一般都会张贴我们制作的统一的宣传画，通过的宣传形式让孩子们了解到这个疫苗是做什么的，这样能够达到我们自愿接种的目的。”</p>\r\n<p>　　这些正在测量体温的学生，是石家庄市第十七中学初三毕业班的学生，作为石家庄市首批接种人群，他们正在做接种前的体检和登记。</p>\r\n<p>　　记者:“需要登记什么样的信息？”</p>\r\n<p>　　医生:“他本人的身份证、姓名还有他的出生年月，父母亲的姓名还有联系电话、家庭住址这些，主要问一下他对鸡蛋有没有过敏的，还有平时有没有慢性病急性发作的。”</p>\r\n<p>　　这些学生的监护人都已经在《甲型H1N1流感疫苗接种知情同意书》签过字，完成登记后他们就可以马上接种了。</p>\r\n<p>　　记者:“有没有点害怕？”</p>\r\n<p>　　学生:“有点，但不是很特别担心。”</p>\r\n<p>　　学生:“我妈妈说她打过，最后觉得挺疼了，害怕我打的时候哭了。”</p>\r\n<p>　　学生:“会有一点，就很害怕，打之前。”</p>\r\n<p>　　记者:“你有没有怕疼或者怕红肿、头晕？”</p>\r\n<p>　　学生:“我们班就是有个同学家长说，可能这个打了以后胳膊会发硬。”</p>\r\n<p>　　虽然有些担心，这些学生陆续完成了接种，那么在接种过程中，会不会发生严重的不良反应呢？</p>\r\n<p>　　接种工作人员:“个别的有轻度的发烧，轻度的发烧，这个没关系，这个跟其他疫苗一般都一样。”</p>\r\n<p>　　记者:“这样的情况你遇到过吗？”</p>\r\n<p>　　李彩辉:“遇到过，遇到过，一般就是低烧的话，我们就可以多喝点水自己处理就可以，如果发烧到超过38.5度的话，临床上吃点退烧药这些基本处理就可以了。”</p>\r\n<p>　　这个观察室里的同学刚刚完成接种，正在接受不良反应观察，他们的感觉如何呢？</p>\r\n<p>　　学生:“我就是在打针前会有一些不良反应。”</p>\r\n<p>　　记者:“担心什么样的不良反应，你都听到些？”</p>\r\n<p>　　学生:“可能会休克什么的。”</p>\r\n<p>　　记者:“那你打完之后有没有什么感觉？”</p>\r\n<p>　　学生:“没有，就是有时候有一点刺痛感。”</p>\r\n<p>　　学生:“打针之前我担心会不会有什么副作用。”</p>\r\n<p>　　记者:“你们都听到担心有些什么副作用？”</p>\r\n<p>　　学生:“就头晕、呕吐什么的，然后打完针观察半个小时之后然后感觉很好，打针之前比较紧张，打针之后感觉没有什么事。”</p>\r\n<p>　　记者:“你打完什么感觉。”</p>\r\n<p>　　学生:“有点冷，没事。”</p>\r\n<p>　　在甲流疫苗接种知情同意书上，明确的注明的接种反应为:局部反应:常见疼痛；偶见红、肿、骚痒；全身反应:常见发热、疲劳乏力、头痛、头晕、恶心；偶见咽喉疼痛、肌肉疼痛、咳嗽、腹痛、关节疼痛、活动异常(活动减少/增多)、口干、食欲不振、腹泻、过敏、胸闷。记者从河北省疾控中心了解到，从10月28日全省开始接种甲流疫苗起，每天每个接种点都会将疫苗的接种情况输入到不良反应监测系统，截止11月6日，全省的不良反应监测系统，共监测到了147例异常反应的记录。</p>\r\n<p>　　疾控中心工作人员:“系统现在是大概是报了147，我们叫做AEFI，就是疑似异常反应，里边含这么几类，包括一般反应、异常反应、心因性反应。”</p>\r\n<p>　　免疫规划所所长:“现在我们总体来说，河北省来说还没有严重的异常反应报告，那么一般反应是有的，一般情况下都是比较轻型的这种一过性的反应。”</p>\r\n<p>　　记者:“你怎么界定这个不是非常严重的？”</p>\r\n<p>　　免疫规划所所长:“是这样，咱们国家有一个，出台就是咱们甲型H1N1流感疫苗接种的时候，他后面有一个关于异常反应调查诊断处理的一个预案，那么根据这个预案我们可以判断一下就说什么是一般反应，什么是异常反应，哪些是比较严重的，上边都有一个，就是说以后会不会出现这样的情况我们现在还不好说，我们希望就是不出现严重异常反应。”</p>\r\n<p><strong>　　南京:不良反应都在监控之中</strong></p>\r\n<p>　　前不久，吸疾病专家、中国工程院院士钟南山说，接种疫苗出现的副作用比例非常低，而随着疫情升级，甲流病毒可能变异，因此接种疫苗刻不容缓。</p>\r\n<p>　　人类发展史证明，每一种新出现的疫病都会给人类生命健康造成威胁，给人们心理带来恐惧，但只要科学认识、重视防范，人类就有能力战胜疫病。</p>\r\n<p>　　其实公众的担心，不只是针对甲流疫苗的安全性，但家担心的还有一点，接种疫苗一旦发生了不良反应，能不能被尽快确诊，得到治疗。</p>\r\n<p>　　为了了解这方面的情况，我的同事周翊祥特地到江苏省进行了一次体验，一起来看看他的发现。</p>\r\n<p>　　记者:“这里是南京市市级机关医院，江苏省第一批甲流疫苗的接种已经从11月4号正式开始，而这所医院也是南京十所集中接种甲流疫苗的医院之一，那经过了三天接种之后，甲流疫苗是否安全，接种的情况又是怎么样，我们进去做一个调查。”</p>\r\n<p>　　记者在甲流疫苗注射室，正好碰见了前来接种疫苗的南京市教育局干部叶勇。他并不是直接就去接种疫苗，而是首先来到门口的预诊台，在一张甲型H1N1流感疫苗接种知情同意单上签上了自己的名字，并接受预诊医生的询问。</p>\r\n<p>　　南京市市级机关医院预诊医生:“小时候有没有得过癫痫？”</p>\r\n<p>　　“没有。”</p>\r\n<p>　　“心脏血压的情况还好啊？”</p>\r\n<p>　　“还行。”</p>\r\n<p>　　“有没有其他严重的慢性病？”</p>\r\n<p>　　“没有。”</p>\r\n<p>　　“近期有没有接种过其他疫苗？”</p>\r\n<p>　　“没有。”</p>\r\n<p>　　在全部的询问完之后，预诊医生认为符合疫苗接种条件，便在知情同意单上签上了自己的名字。叶勇就可以到接种台接种疫苗。很快医生在他的左臂注入了疫苗之后，叶勇就到旁边的多功能厅，休息观察30分钟。</p>\r\n<p>　　记者:“刚才看你接种了甲流疫苗，你现在身体感觉怎样？”</p>\r\n<p>　　南京市教育局干部叶勇:“感觉还好，没什么其他的症状。”</p>\r\n<p>　　记者:“你有没有听说过出现不良反应？”</p>\r\n<p>　　南京市教育局干部叶勇:“我听说过，我们好像有个别不良反应，但都比较轻的。”</p>\r\n<p>　　南京市市级机关医院副院长印小荣告诉记者，如何防范甲流疫苗不良反应的发生是他们接种工作的重点。因此他们在预诊环节就把好关，并不是每一个前来接种点接种疫苗的人都能接种，他们已经劝回了不少人。</p>\r\n<p>　　预诊医生:“单子上只是写的是庆大霉素过敏不能接种，但是我们要求扩大范围，只要有药物过敏我们都列入不可以打的范围，近期正在有上呼吸道感染的病人，都劝他们等到后面再接种，这次就算了。”</p>\r\n<p>　　记者:“多吗，这种情况？”</p>\r\n<p>　　预诊医生:“有一部分，大概10个里面有2个，有的人愿意离开有的人还要进一步劝说。”</p>\r\n<p>　　同时，为了保证每一个接种者如果接种后出现不良反应有据可查，他们还建立了非常详细的登记系统。记者就找到了刚才接种疫苗的叶勇的信息。</p>\r\n<p>　　记者:“我们刚才看到的叶勇是不是已经登记下来了？”</p>\r\n<p>　　南京市市级机关医院护士:“是的，从疫苗的类型开始，到接种的日期，到生产的厂家到生产批号，接种的部位和接种的医生都要登记下来。”</p>\r\n<p>　　记者:“任何一个人出现不良反应都能马上查到。”</p>\r\n<p>　　南京市市级机关医院护士:“对，这个表今天接种结束之后都要上报，上报到网上面，每一个他的资料都很全。”</p>\r\n<p>　　记者:“那你们这几天接种了多少个甲流疫苗？”</p>\r\n<p>　　南京市市级机关医院副院长印小荣:“甲流疫苗我们三天快了400多个。”</p>\r\n<p>　　记者:“有没有不良反应的发生？”</p>\r\n<p>　　南京市市级机关医院副院长印小荣:“目前只发现了有一例，感觉到有一点头晕和恶心，吸了半个小时的氧就好了，血压啊心脏体征都没有问题，还没有出现过敏的症状。”</p>\r\n<p>　　尽管只有一例轻微不良反应，但根据规定每天都得向当地的疾控中心进行汇报。即使当天没有发生不良反应。</p>\r\n<p>　　“从4号开始的第一天，是无，第二天也是无，今天是第三天，第三天还没有登记，因为第三天这一例我们也要上报的，即使有点不舒服我们都要上报的。”</p>\r\n<p>　　记者:“这里是南京市鼓楼区疾控中心的应急处置组，每一天甲流疫苗接种不良反应者的详细的记录，都将会在这里录入到电脑，并向上级进行汇报。”</p>\r\n<p>　　在应急处置组工作人员的办公桌上，记者见到了接种点刚刚送来的三份个案报告卡。</p>\r\n<p>　　南京市鼓楼区疾控中心疾控科科员张丽:“很详细，报告卡，留样表，怎样调查的，怎样处置的，都有。”</p>\r\n<p>　　记者:“这个调查表上不良反应的主要情况怎样的？”</p>\r\n<p>　　张丽:“主要就是一些过敏性的皮疹，都比较轻，他们治愈情况怎样，两例已经治愈，一例好转。”</p>\r\n<p>　　随后，工作人员将个案报表的内容，包括个人信息，接种疫苗信息，不良反应情况和处理情况都详细地输入到信息管理系统中。输入完提交之后，位于南京市疾控中心免疫规划科的工作人员就可以看到，并进行审核后，通过网络实时上报给江苏省疾控中心。</p>\r\n<p>　　南京市疾控中心免疫规划科主管医师陈敏:“我们最主要要看他反应发生日期和发现日期，我们一定要在发现他48小时之内，必须报告，我在48小时之内必须调查结束。”</p>\r\n<p>　　记者:“那你们现在有没有发现比较重的不良反应？”</p>\r\n<p>　　陈敏:“到现在还没有发现，最重的也是过敏性皮疹。”</p>\r\n<p>　　那么疾控中心是否进行如是上报呢。记者联系到了个案报表上的三个病人。</p>\r\n<p>　　记者:“你上次你种甲流疫苗出现不良反应，现在情况怎么样了？”</p>\r\n<p>　　不良反应者:“现在还可以，没什么。”</p>\r\n<p>　　记者:“已经治愈了吗？”</p>\r\n<p>　　不良反应者:“没治他就已经愈了。”</p>\r\n<p>　　记者:“什么时候好的？”</p>\r\n<p>　　不良反应者:“今天早上就好了。”</p>\r\n<p>　　记者:“上次甲流出现不良反应我们进行回访，现在你的情况怎样？”</p>\r\n<p>　　不良反应者:“没有没有，一切正常，一切正常。”</p>\r\n<p>　　记者:“你现在情况怎样了？”</p>\r\n<p>　　不良反应者:“还是痒啊，应该算有好转吧。”</p>\r\n<p>　　据了解，南京市目前已经接种甲流疫苗5万人次，不良反应人数不超过10人。南京市疾病预防控制中心副主任陆小军告诉记者，他们已经建立了接种叫停机制。</p>\r\n<p>　　南京市疾病预防控制中心副主任陆小军:“或者我们接种后副反应发生率明显高于一般的副反应，或者出现一系列社会事件的时候，我们将报给省级疾控中心，由省级部门来决定是否暂停这项工作。”</p>\r\n<p><strong>　　半小时观察:</strong></p>\r\n<p>　　按照《传染病防治法》规定，传染病暴发、流行时，国务院卫生行政部门负责向社会公布传染病疫情信息，并可以授权省、自治区、直辖市人民政府卫生行政部门向社会公布本行政区域的传染病疫情信息。从记者的报道里，我们感到，公布传染病疫情信息应该更及时、更准确，及时和透明是消除谣言最好的方法。另外，在这里我要忠告大家的是:当季节性流感流行时，不要恐慌，应时刻保持乐观心态；同时注意做好自我防护；另外注意搜集来自国家正规渠道的信息，不要传谣信谣。最后，我想说的是接种甲流疫苗对自己是机会，对别人是责任。</p><!--function: content() parse end  2ms cost! --></div><!--function eap(news_zhengwennei) parse begin-->\r\n\r\n<!--function: eap(news_zhengwennei) parse end  0ms cost! -->', 'gwm', 0, 25),
(90, '控制癌症有哪些手段？', '', '', '', '2009-11-10 10:32:31', '116.228.141.77', '<p>昔日被认为是“绝症”的恶性肿瘤，现在已经被认为是可以控制的慢性病了。控制癌症的方法有手术、放疗、化疗、生物靶向治疗等等。</p>\r\n<p>手术：是一种局部治疗手段。对于早期肿瘤，手术可以完全切除肿瘤。对于中晚期肿瘤，手术可以去除部分肿瘤，减轻肿瘤带来的不良症状。对非常晚期的肿瘤病人，手术也可能会起到缓解症状的作用。</p>\r\n<p><br />\r\n放疗：也是一种局部治疗，包括根治性放疗、姑息性放疗、术前放疗、术后放疗等。特别是有些肿瘤不能手术，对放射线敏感，可以采用根治性放疗。</p>\r\n<p>化疗：使用抗肿瘤药物来治疗全身或区域性肿瘤。静脉化疗，是一种全身性的治疗；介入化疗，是使介入的局部器官或组织化疗药物浓度升高，经过血液循环，使药物到达全身。分子靶向治疗：是一种新的很有前景的治疗方法。目前国内已上市的分子靶向药物主要有两大类：一类是抗血管内皮生长因子的药物，目前建议与化疗联合使用；一类是抗表皮生长因子受体药物，目前主要用于化疗失败后的二线治疗。文/吴琦</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 26),
(91, '网友网上显摆用血浆做花肥 声称捡的破口血浆袋', '', '', '', '2009-11-11 09:43:11', '116.228.141.77', '<p>\r\n<table cellspacing="0" cellpadding="0" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://photocdn.sohu.com/20091110/Img268084079.jpg" />\r\n</td></tr></tbody></table></td></tr>\r\n<tr>\r\n<td style="font-size:12px;" align="middle"></td></tr></tbody></table><br />\r\n\r\n<table cellspacing="0" cellpadding="0" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://photocdn.sohu.com/20091110/Img268084080.jpg" />\r\n</td></tr></tbody></table></td></tr>\r\n<tr>\r\n<td style="font-size:12px;" align="middle">\r\n<p>　成都网友显摆用血浆做花肥</p>\r\n<p>　　发帖者:我道歉 成都血液中心:我们是无辜的</p>\r\n<p>　　日前，一位名为“来来回回”的网友将献血者捐献的、仍在使用期内的血浆兑入清水浇灌兰花，作兰花“肥料”，同时拍下照片上传至论坛，显摆自己给兰花的肥料是“高蛋白的营养品”。这种做法立刻引来千夫所指。</p>\r\n<p>　　发帖:血浆成浇花肥料</p>\r\n<p>　　7日晚，在某兰花交易论坛，网友“来来回回”发帖:《看看我的肥料哈高蛋白的营养品哦》。帖子中，“来来回回”上传了自己拍摄的用血浆做肥料的全过程。</p>\r\n<p>　　此人高调的姿态和触目的血浆图片很快引起网友关注，网友将此帖再次制作后取名《成都自愿献血者的血浆竟成浇花肥料》，上传至各大论坛，“血浆肥料”自此流传开来。</p>\r\n<p>　　在图片上，记者看到，血浆袋上标注着:成都血液中心、普通冰冻血浆、血量150“1、献血者的编号等基本信息。令网友最为气愤的是，血浆袋上标明的采血日期为:2009年10月3日13时44分，失效日期为2014年10月3日13时44分。“这表明，血浆并未失效，仍可使用。”</p>\r\n<p>　　网友:这是在践踏爱心</p>\r\n<p>　　针对此事，网友愤怒至极，认为这种做法是在践踏献血者的爱心。</p>\r\n<p>　　网友“h°y°”: 献血的那位人士看到了真是……心寒!楼主丢人现眼!</p>\r\n<p>　　网友“匿名人士200209”:我们的爱心都被浪费了。</p>\r\n<p>　　网友“三W点坑你点COM”:要献血，直接去医院，找血库;要捐款，直接去灾区找需要帮助的人，爱心都被利用成赚黑心钱的工具了。</p>\r\n<p>　　网友“木左”:血浆的管理和使用应该是有严格规定和程序的，这袋血浆是怎么流出来的呢?</p>\r\n<p>&nbsp;</p></td></tr></tbody></table>\r\n<table cellspacing="0" cellpadding="0" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://photocdn.sohu.com/20091110/Img268084082.jpg" />\r\n</td></tr></tbody></table></td></tr>\r\n<tr>\r\n<td style="font-size:12px;" align="middle"></td></tr></tbody></table><br />\r\n\r\n<table cellspacing="0" cellpadding="0" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://photocdn.sohu.com/20091110/Img268084083.jpg" />\r\n</td></tr></tbody></table></td></tr>\r\n<tr>\r\n<td style="font-size:12px;" align="middle"></td></tr></tbody></table><br />\r\n\r\n<table cellspacing="0" cellpadding="0" align="center" border="0">\r\n<tbody>\r\n<tr>\r\n<td align="middle">\r\n<table cellspacing="0" cellpadding="0" border="0">\r\n<tbody>\r\n<tr>\r\n<td><img alt="" src="http://photocdn.sohu.com/20091110/Img268084084.jpg" />\r\n</td></tr></tbody></table></td></tr>\r\n<tr>\r\n<td style="font-size:12px;" align="middle"></td></tr></tbody></table><strong>道歉:捡了破了口的血浆袋</strong></p>\r\n<p>　　8日晚，“来来回回”在该兰花交易论坛发帖道歉:“我昨天在坛子上发了篇自己用报废血浆浇花的帖子，没有意识到反响会这么大。在这里对各位道歉。希望大家原谅!”</p>\r\n<p>　　“血浆上的失效日期为2014年，还报废血浆?你当我们是小孩子吗?”回帖再次遭唾沫淹没。</p>\r\n<p>　　经多方努力，湖南在线记者联系到了“来来回回”。据他介绍，前几天，他去医院看望朋友，在垃圾桶旁看到一个破了口子的血浆袋，考虑到血浆的高蛋白含量，便捡了回来把它作为兰花的肥料，并拍下照片上传至网上。</p>\r\n<p>　　“我不会透露具体是在哪家医院捡到的，我现在压力很大，我已发帖澄清、道歉，我很后悔。”</p>\r\n<p>　<strong>　血液中心:卫生局已在调查</strong></p>\r\n<p>　　成都血液中心宣传科负责人邓敏向湖南在线记者表示，网上流传的血浆图片确实来自该中心，但血液中心绝对是按正常、规范的程序将血浆发到用血的医院。</p>\r\n<p>　　邓敏称，成都市卫生局已就血浆是如何流出的等问题进行调查，预计近期会得出相关结论。<br />\r\n</p>', 'gwm', 0, 25),
(92, '成都“血浆种花”事件相关责任人被处理', '', '', '', '2009-11-11 09:44:03', '116.228.141.77', '<p>　新华网成都11月10日电（记者陈健）成都市卫生局10日下午公布了近日在社会上引起轩然大波的“血浆种花”事件调查结果，该血浆系本地一工矿医院输血科值班人员进行血浆报废时没有按规定处理所致，成都市卫生局现已对有关责任人进行了严肃、顶格处理。</p>\r\n<p>　　“看看我的肥料哈！高蛋白的营养品哦！”11月7日，在某网络论坛中，名为“来来回回”的网友图文并茂地描述了他用血浆兑水浇灌兰花的过程。网帖照片中，在血浆袋上可以清楚地看到“成都市血液中心”字样，以及血浆编号、献血者编号、采血日期（2009．10．03）和失效日期（2014．10．03）等信息。论坛资料显示，该网友来自四川成都。</p>\r\n<p>　　该网帖迅速在国内一些知名网络论坛和网站传开。一些网友认为，用血浆浇花让广大无偿鲜血者心寒，是对生命的不尊重；还有网友对血浆来源表示关注。</p>\r\n<p>　　成都市卫生局主管宣传的甄英处长10日下午向新华社记者表示，现已查明该血浆是由成都市血液中心发到某县级储存血库，随后再转至本地一家工矿医院。“问题出在该工矿医院血液报废管理程序上，输血科值班人员发现血液有絮状物后，进行报废处理时没有按规定处理，而是交给科室另一人员传递给了其朋友。”甄英说。<br />\r\n甄英说，成都市卫生局知悉网帖情况后，迅速责成血液中心、执法大队及相关处室，对事件进行联合调查。目前，成都市卫生局已对有关责任人进行处理，对输血科值班人员解除劳动合同，并对科主任予以解职，传递者给予了留用察看处分。<br />\r\n<br />\r\n　　刚刚在2周前无偿献血的四川大学2006级工业设计专业学生戴恒男说：“我们去献血是为了帮助别人挽救生命，知道"血浆浇花"事件后我感到非常难受，但我今后还是会继续去无偿献血，因为我相信这样的事情只是个别事件。” </p>', 'gwm', 0, 25),
(93, '医生被指玩游戏致婴儿死亡续:引入第三方调查组', '', '', '', '2009-11-12 09:27:15', '116.228.141.77', '本报南京11月11日电（记者申琳）继昨日江苏省、南京市卫生部门发布初步调查结果后，南京市卫生局、南京市纠风办等部门今日组织引入第三方的联合调查组，对南京市儿童医院5个月婴儿死亡事件进行再次调查。\r\n<p><br />\r\n　　南京市卫生部门解释，由于一些社会公众，特别是网民，对卫生部门单独调查的公正性提出质疑，所以江苏省、南京市卫生部门决定，成立一个由第三方参与的联合调查组。</p>\r\n<p><br />\r\n　　该联合调查组由南京市卫生主管部门、市纠风办以及媒体代表、网民代表、人民调解机构代表以及计算机专家等多方面人士组成，同时吸纳了没有隶属关系的江苏省属医疗机构的有关专家参与。</p>\r\n<p><br />\r\n　　联合调查组除了对医护人员的治疗过程做详细调查外，值班医生有无上网玩游戏、有无发牢骚等社会舆论普遍关注的内容也是调查重点。</p>\r\n<p><br />\r\n　　联合调查组负责人表示，调查组将通过深入、细致、全面的调查，还事实以本来面目，给医患双方和社会公众一个客观、真实、公正的调查结果。</p>\r\n<p><br />\r\n　　<strong>延伸阅读：</strong></p>\r\n<p><br />\r\n<strong>　　副院长几度哽咽 求网友放过医生家人</strong></p>\r\n<p><br />\r\n<strong>　　婴儿死亡事件成立第三方调查组</strong></p>\r\n<p><br />\r\n　　扬子晚报记者应邀参加，南京儿童医院恳求网友不要干扰当事医生家人</p>\r\n<p><br />\r\n　　<strong>儿童医院婴儿死亡</strong></p>\r\n<p><br />\r\n　　10日，南京市卫生行政主管部门公布南京市儿童医院患儿死亡事件调查结果后，本报11日的报道中提出“希望第三方调查介入”，报道很快有了回音：昨天下午，南京市卫生局第二次召开新闻通气会，宣布成立一个第三方联合调查组，组成人员包括卫生主管部门、媒体代表、网民代表和相关部门代表等。本报记者刘大颖作为媒体代表参加了这个调查组。</p>\r\n<p><strong>一查到底不姑息</strong> </p>\r\n<p></p>\r\n<p><br />\r\n<strong>　　结果将第一时间通报</strong></p>\r\n<p><br />\r\n　　南京市卫生局纪委丁海洋书记表示， 为了进一步深入调查，彻底查清此次事件中群众反映强烈的如儿童医院对患儿的治疗、抢救是否及时、合理，医生在值班时有无失职等问题，市卫生局与相关部门决定成立联合调查组，一查到底，决不姑息。联合调查组由14人组成，当中有4名是南京市卫生局主管部门工作人员，5名包括本报记者在内的中央省市媒体记者，1名网民代表（由南京市纠正不良之风领导小组办公室推荐），1名计算机专家，2名省级综合性医院医疗专家，1名人民调解委员会成员。</p>\r\n<p><br />\r\n　　联合调查组昨天下午已经开始工作，力争用较短的时间开展调查，包括医患双方相关当事人的谈话、调阅相关录像资料、检查值班医生使用的计算机等，形成完整的证据，以严格的程序，公开、公正地向社会公布进一步调查结果，相关部门将根据调查结果采取进一步措施。同时感谢社会各界、新闻媒体以及广大网民对市儿童医院的批评和关心，调查结果卫生局将在第一时间向大家通报。丁海洋书记表示，他们已经和患儿的家长见面了，这个联合调查组的成立是患儿家属认可的。</p>\r\n<p><br />\r\n　　<strong>副院长几度哽咽</strong></p>\r\n<p><br />\r\n<strong>　　求网友放过医生家人</strong></p>\r\n<p><br />\r\n　　昨日，南京市儿童医院表示，欢迎第三方调查团进驻医院调查，医院将积极配合调查人员，也希望调查组能尽快地将调查结果向社会公布。</p>\r\n<p><br />\r\n　　而记者昨日在儿童医院院办采访时看见，几乎每隔5分钟，就有人打电话来询问这个事件。院办的工作人员告诉记者，大多是市民和网友，一些人情绪激动，一打来就直接要求医院要“讲实话”，有的市民对院方昨日的解释表示不满，甚至有人要求医院调查组组长黄松明副院长“当心点”。对此，昨日在接受南京一些媒体采访的过程中，南京市儿童医院副院长黄松明一度哽咽。他说，每一个医务工作者出现这样的事情都是承担巨大的压力。他说，目前已经停职的当事人毛晓君医生，被网上疯狂“人肉搜索”。在医院调查组核对材料的时候，黄副院长曾与毛晓君医生有过接触，了解到毛医生和家人也受到了一些威胁。黄松明副院长说，当事医生犯的错误由医生本人来承担，希望网友不要干扰他们的家人。</p>\r\n<p><br />\r\n　<strong>　已经与调查组</strong></p>\r\n<p><br />\r\n<strong>　　接触了一个多小时</strong></p>\r\n<p><br />\r\n　　记者昨日联系上了患儿的父亲徐先生，徐先生告诉记者，昨天下午三点左右，他被卫生局请到南京一家宾馆，此时他才知道成立了第三方联合调查组。之后调查组对他进行了一个多小时的询问，让他复述了事件的经过，并作了详细的记录。徐先生回忆说，进行调查的有南京市卫生局纪委丁书记、人民日报记者和南京纠风办的工作人员等四人，而卫生局也已经让他们准备进行第二次询问，但具体时间地点不清楚。</p>\r\n<p><br />\r\n　　“我相信政府能给我一个信服的答案。”徐先生说。</p>\r\n<p><strong>相关阅读：南京通报“患儿突死”事件 医生对患儿病情凶险程度估计不够</strong></p>\r\n<p><br />\r\n　　据新华网南京１１月１１日电（记者 朱旭东）一个５月大的患儿，因患眼睛蜂窝组织炎在南京市儿童医院救治一天后死亡，引起社会及网络的关注。南京市卫生局１０日通报了对该事件的初步调查结果，并对当事医生作暂时停职处理。调查认为，医院整个救治过程及时，抢救方案合理，不足之处是医生对患儿病情凶险程度估计不够。</p>\r\n<p><br />\r\n　　１１月１日，患儿徐某因发热、眼眶红肿到江宁区医院就诊，３日上午转到南京市儿童医院治疗。儿童医院医生诊断患儿为“蜂窝组织炎”收治入院，次日凌晨５点多患儿不治身亡。事件发生后，一时众说纷纭，网上流传最广的是“当事医生上班期间在网上玩‘种菜’，责任心不强，导致患儿死亡”。还有的说家属夜里几次敲门，医生以耽误睡觉为由没有积极抢救，给孩子病情恶化埋下祸根。据南京市卫生局介绍，事件发生后，医院立即成立调查组对１１位相关医护人员进行调查，发现网上传闻与事实不符。医生上班期间不可能上网玩游戏，因为值班房不具备有线上网条件，家属前去敲门时，医生正在电脑上写论文而不是网上“种菜”。</p>\r\n<p><br />\r\n　　据南京市儿童医院副院长黄松明介绍，因为这种病是一种不常见的疾病，不及时抢救死亡率较高。医院遇到上一例如此严重的“蜂窝组织炎”还是在１０年前，值班医生是工作不到１０年的主治医师，主观上无过错，只是水平还不够高，平时欠学习、提高。患儿的死亡原因初步考虑为重度感染，海绵窦血栓，但最终以尸检结果为准。</p>\r\n<p><br />\r\n　　卫生局表示，目前事件还在继续调查，如果发现当事医生有主观过错将严肃处理。</p>', 'gwm', 0, 22),
(94, '广西成功用甲流康复者血液救治重症患者', '', '', '', '2009-11-13 10:09:47', '116.228.141.77', '<p>中新社南宁十一月十二日电 (庞娟妮)广西壮族自治区卫生厅医政处副处长王建政十二日在接受记者采访时说，广西成功实践了以甲流康复者血液救治甲流重症患者的治疗方法。</p>\r\n<p>　　他说，十月三十日，南宁市报告了广西首例甲流重症病例。医疗部门采集了两份甲流康复者血液。甲流康复者血液送到医院后，立即用于该甲流重症患者的治疗，并取得了很好的效果。目前，这名重症患者已经解除了重症警报，病情正在逐渐好转。</p>\r\n<p>　　王建政指出，甲型H1N1流感痊愈者血浆是治疗甲型H1N1流感重症患者的有效方式，广西下一步将根据甲型H1N1流感重症者的病情，适量使用，同时不放弃其他治疗方式，综合全面医治甲型H1N1流感患者。王建政鼓励甲型H1N1流感痊愈者出院半个月后和接种甲型H1N1流感疫苗满一个月的爱心人士到当地的血站献血浆。</p>\r\n<p>　　广西卫生厅十二日宣布，截止十一月十一日，广西累计报告甲型H1N1流感确诊病例一千六百四十八例，已治愈一千一百七十九例。重症病例八例，已治愈出院二例，死亡一例，其他五例病情稳定。</p>\r\n<p>　　十二日，广西卫生厅紧急出台了十项措施，防御甲型H1N1流感大面积爆发。</p>\r\n<p>　　这十条措施包括：实行分级分类救治甲型H1N1流感病人、加强医疗救治的物资准备、组织开展甲型H1N1流感疫苗的接种工作、组织开展对甲型H1N1流感痊愈者和甲型H1N1流感疫苗的接种人员病毒抗体血浆采集工作等。</p>\r\n<p>&nbsp;</p>', 'gwm', 0, 17);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(95, '南京眼疾婴儿入院死亡事件调查：医生玩游戏', '', '', '', '2009-11-13 10:18:29', '116.228.141.77', '<p align="center"><img alt="眼疾婴儿入院死亡事件查清 院方12人受处分" src="http://img1.gtimg.com/news/pics/23755/23755090.jpg" />\r\n</p>\r\n<p align="center"><span style="font-size:12px;">发布会现场，媒体云集。 张 筠 摄</span></p>\r\n<p>　　<strong>“婴儿死亡”联合调查结果公布</strong></p>\r\n<p>　　昨天下午，南京市卫生局召开新闻发布会，公布由专家、网民、记者等组成的联合调查组对于南京儿童医院患儿死亡事件的最终调查结果，发布会现场内容读者可登录扬子晚报网观看。</p>\r\n<p>　　调查组连夜分别向医患双方当事人共33人次调查核实，并调阅了相关录像资料，检查了值班医生使用的计算机等，形成了最终调查结果：患儿家属的投诉情况基本属实。在此次事件前期调查中，值班医生隐瞒事实真相，市儿童医院调查手段简单、调查深度不够、调查结果与事实不符。</p>\r\n<p>　　第一次调查的结论与事实不符，上网玩游戏的当事医生被吊照开除，南京儿童医院诊治措施有失职行为，院长书记分别受处分。</p>\r\n<p>　　<strong>朱善璐批示：</strong></p>\r\n<p>　　<strong>人民生命问题上不允许半点马虎</strong></p>\r\n<p>　　江苏省委常委、南京市委书记朱善璐做出批示：这一事件必须引起高度重视，从调查情况看，确有部分医护人员工作不负责任，医院的管理和服务也确实存在问题和漏洞，对这一事件必须一查到底，严肃处理，绝不允许任何对人民生命不负责任、并导致严重后果的现象逍遥于法纪监管和道德谴责之外。</p>\r\n<p>　　朱善璐指出，这一事件及后果已经引起极大的社会关注，造成了恶劣影响。除了迅速客观地依据事实和法规给予严肃处理、绝不姑息、公之于众，给社会、患者以公道之外，更要重视从这一事件中吸取足够教训，举一反三，在整个卫生系统内对医护人员和管理者开展教育和警示。要通过这一事件开展行风自查，凡是存在类似问题，必须严肃批评和处理。在这种事关人民生命的问题上，不允许有半点马虎，更不允许玩忽职守。</p>\r\n<p>　　<strong>记者会实录</strong></p>\r\n<p>　　<strong>够彻底：连医生亲戚关系都公开了</strong></p>\r\n<p>　　在昨天的新闻发布会上，南京市卫生局局长陈天明，南京市卫生局纪委书记丁海洋和南京市卫生局医政处许民生处长答记者问。</p>\r\n<p>　　问：为什么两次调查有大出入？</p>\r\n<p>　　丁海洋：值班医生隐瞒事实真相，市儿童医院调查手段简单、调查深度不够、调查结果不实，轻信当事人的证言，南京市卫生局审核不够严格。</p>\r\n<p>　　问：是不是说明儿童医院在调查时有集体包庇和作假呢？卫生行政部门会不会因此道歉？</p>\r\n<p>　　陈天明：第一次新闻通气会通报的是一个初步调查的情况。儿童医院在第一次调查过程中，调查方法简单，调查手段粗糙。所以在第二次调查时，分了若干组，用10多个小时，把事情的真实情况全面查实了，并对相关责任人追究责任，决不姑息。</p>\r\n<p>　　问：毛晓珺医生是否和医院领导有裙带关系？</p>\r\n<p>　　陈天明：据调查，毛晓珺与儿童医院一名院长助理有亲戚关系，但这层关系对调查结果和调查过程等都没有影响，在调查时与之有亲戚关系的领导都已经回避。毛晓珺还有一名亲戚也是卫生系统的，但是在其他医院。</p>\r\n<p>　　问： 根据患儿家长反映，患儿同病区的家属都被转移走了？</p>\r\n<p>　　许民生：这是第一次听说，我们将在下一步调查核实。</p>\r\n<p>　　问：患儿家属向李旭医生下跪，为什么对李旭仅是警告？</p>\r\n<p>　　丁海洋：考虑到李旭医生不是眼科医生，而是耳鼻喉科病区的医生。患儿家属在心情急迫的情况下，无法区分谁是耳鼻喉科医生，谁是眼科医生。而此时李旭医生自然会说，我是耳鼻喉科医生，你找眼科医生。但是作为医生，应该有良好的职业道德，应该主动协助患儿家属，所以给予处分。同时考虑到后来李旭也协助护士给ICU打电话抢救患儿，所以处理有区别。</p>\r\n<p>　　问：为什么独立的联合调查组中没有徐宝宝家长提供的人员？</p>\r\n<p>　　丁海洋：昨晚家长提出，调查组中能不能由他们提供两名记者，我们明确地表示可以。但是上午10：00他才提供了两个记者的名单，但此时我们调查已经基本结束了。</p>\r\n<p>　　问：网民代表为何不“海选”？</p>\r\n<p>　　丁海洋：因为调查的时间很紧迫，所以来不及在网上海选，所以就请纠风办推荐了人选。</p>\r\n<p>　　问：医院赔偿有多少？</p>\r\n<p>　　许民生：卫生局已经督促儿童医院积极妥善地做好善后工作，患儿的家属可以选择医患双方协商、行政部门调解、法院民事诉讼、医患纠纷人民调解委员会调解这四种解决方法中的任何一种。</p>\r\n<p>　　问：此次事件会不会对儿童医院医护人员的心理上造成影响？</p>\r\n<p>　　陈天明：对儿童医院这样的处理在南京还是第一次，医院行政部门已经采取了善后工作，由2名局领导和5名相关处室负责人，协助儿童医院的工作重新恢复正常轨道，同时对儿童医院医护人员的工作进行监督，确保儿童医院和全市卫生系统的稳定和秩序的正常。</p>\r\n<p>　　问：会不会追究医生刑事责任？</p>\r\n<p>　　许民生：已经依法吊销毛晓珺医生的医师执业资格证，家属有权进一步追究医生的刑事责任。</p>\r\n<p>　　问：网上有很多关于南京各级医院的投诉，卫生行政怎么看待？</p>\r\n<p>　　陈天明：网络上发布的信息很多，卫生局也是高度重视。上周五我在北京开会时，就收到短信，说儿童医院事件在网上引起了很大的影响。我们欢迎网络媒体对卫生系统的工作进行监督。</p>\r\n<p>　　问：通过这次事件，今后医院和卫生行政部门在医患纠纷的处理上有没有更加快捷有效的方法？</p>\r\n<p>　　许民生：医患纠纷的解决的主体永远是医患双方，但是一般来说医疗纠纷时，由于双方信息的不对称，还是很难在短时间内达成一致的。</p>\r\n<p>　　问：以后在处理医患纠纷的时候，会不会延用“第三方”调查的方式？</p>\r\n<p>　　市政府新闻发言人：新闻媒体提前介入到行政机构调查的过程中，这种方式可以采用。</p>\r\n<p>　　本版撰稿 本报记者 于丹丹</p>\r\n<p>　　<strong>联合调查结论</strong></p>\r\n<p>　　患儿家属的投诉情况基本属实。值班医生毛晓珺值班期间曾在网上下过两盘围棋，违反了相关工作制度；患儿家属多次到护士站和医生值班室请求医生观察病情，但毛晓珺仅3次观察患儿病情，没有发现应该发现的问题，当事医生对病患家属的多次请求，没有引起应有的重视，没有施行相关救助措施阻止病情发展，没有组织相关科室的会诊存在失职行为；在患儿抢救期间，患儿母亲在耳鼻喉科医生值班室门口向耳鼻喉科医生李旭下跪请求帮助。</p>\r\n<p>　　<strong>南京儿童医院 12人受处分</strong></p>\r\n<p>　　南京市儿童医院院长方如平因对此事件负有处置不力、初步调查结果不实等领导责任,给予其行政记大过、党内严重警告处分,对儿童医院党委书记金福年给予党内严重警告处分,对毛晓珺给予吊销医师执业证书并行政开除的处分。</p>\r\n<p>　　管床医师冯晓津、陈娟因没有对患儿血象异常表现及时请会诊,没有重点向夜班医生交班,受到行政记大过处分;眼科护士周颖、毛婷、徐源媛、夏矜因输液不及时或护理巡视不够,受到行政记过处分;眼科主任陈志钧、眼科护士长彭明琪因负有科室管理责任而受到行政记过处分;耳鼻喉科值班医生李旭受到行政警告处分。</p>\r\n<p>　　<strong>两次调查对比医院调查结论</strong></p>\r\n<p>　　医生上班期间不可能上网玩游戏，因为医院不允许上班进行炒股、玩游戏等行为，而且患儿家属是站在医生对面的，不可能看到医生那台华硕电脑上的内容的；此外，家属前去敲门时，医生正在电脑上写论文而不是网上“偷菜”。至于跪求医生，则是转移了时间、地点，在早晨7点，医生和父亲谈放弃治疗时，母亲跪下要求抢救，于是又抢救了半小时。医院对患儿的抢救措施都是合理的。</p>\r\n<p>　　医院的责任主要是对患儿病情判断上的失误，对病情的凶险性估计不足。而这根本原因是医生水平不过关，说得轻是疏忽大意，说得重就是责任心不强，技术不过硬。　</p>', 'gwm', 0, 29),
(96, '长沙49.3万名大学生今起陆续获医疗保障', '', '', '', '2009-11-17 10:52:13', '116.228.141.77', '本报讯（首席记者 张怀中）普通大学生每年只需缴纳40元，就可获城镇居民基本医疗保障！昨日，记者从长沙市大学生参加城镇居民基本医疗保险工作会议上获悉：从现在开始，省会49.3万名大学生将陆续参保。市政府要求，各部门和各高校要积极引导大学生在第一时间参保，到今年年底，各高校大一学生参保率要达到100%，其他年级学生参保率要达到80%以上。副市长文树勋以及省市有关单位、各高校负责人参加会议。<br />\r\n　　<br />\r\n　　近年来，长沙城乡医疗保险体系不断完善，唯有在校大学生的社会医疗保险制度是一项空白，大学生一旦患上大病，家庭难以承受。为此国务院决定将大学生纳入城镇居民基本医疗保险范围，省政府把驻长的中央部属和省属高校全部放在长沙参保。根据长沙新颁布的大学生参保政策，长沙市辖区内国家批准设立并实施高等学历教育的各类院校都可以参加城镇居民医保。<br />\r\n　　<br />\r\n　　普通大学生参保每年只需出40元。根据长沙参保政策：大学生参加城镇居民基本医疗保险按照每人每年120元筹资，其中政府补助80元，个人缴费40元。大学生参保后，驻长高校的大学生，不论所在高校的隶属关系、办学性质如何，都可以享受同等的基本医疗保险待遇。<br />\r\n　　<br />\r\n　　在校参保大学生的就医管理和基本医疗保险待遇按长沙城镇居民医保政策执行。大学生住院统筹基金起付标准为：社区卫生服务机构100元、一级医院200元、二级医院400元、三级医院700元。大学生住院统筹基金支付比例：一级医院（含社区卫生服务机构）70%、二级医院60%、三级医院50%。<br />\r\n　　<br />\r\n　　一个结算年度内，统筹基金最高支付限额为10万元（包括特殊病种门诊和意外伤害门诊医疗费用）。对大学生享受医疗补助后，个人住院医疗费用负担仍过重的，按照城市医疗救助制度的有关规定给予救助。<br />\r\n　　<br />\r\n　　大学生的基本医疗保险当年9月1日至次年8月31日为一个结算年度。大学生自缴纳参保费用之日起在结算年度内享受基本医疗保险待遇。大学生门诊医疗办法暂按每人每年30元的标准实行“总额包干、定点门诊”管理。<br />\r\n　　<br />\r\n　　为确保大学生尤其是大四学生的利益，长沙医保政策规定，大学生在校期间参保的实际缴费年限，可视同城镇职工医保的实际缴费年限累计计算。在与其他保险衔接方面，长沙规定：原已参加新型农村合作医疗或已缴纳2009年度城镇居民基本医保的学生，可从2010年1月开始计算个人缴费，个人缴费标准为25元。', 'gwm', 0, 15),
(97, '上海科学家找到“聪明基因”有助提高记忆功能', '', '', '', '2009-11-17 11:07:36', '116.228.141.77', '华东师大昨天传出消息，该校脑功能基因组学研究所成功构建转基因“聪明大鼠”,找到了决定动物智商的因素和让人变得更聪明的秘诀。华东师大科学家发现，NR2B基因对大鼠的学习记忆功能起到了重要作用。这项成果还发表在最新一期的《公共科学图书馆·综合》杂志上，科学家们认为，这将对脑科学的进一步发展起到重要作用，也对改善人脑的学习记忆功能提供了理论依据。\r\n<p>　　20世纪90年代，华东师大钱卓教授利用特异性的基因剔除技术，证明了NMDA受体在学习记忆中的作用。随后，他领导的研究小组又利用区域特异性的转基因技术，创建了“聪明小鼠”，进一步证明了NMDA受体的NR2B是小鼠学习记忆的关键分子开关。而与小鼠相比，大鼠是生物医学研究比较理想的动物模型。因为有关大鼠生理、药理和行为学方面已积累了大量的研究历史资料；而且大鼠的身体大、脑体积也大，更适于进行高密度群体神经元在体记录，有利于从神经元网络水平研究脑功能的机制。与此同时，人类的NR2B基因与大鼠、小鼠的NR2B基因非常相似。因此，该项工作也为改善人脑的学习记忆功能提供了理论指导依据。</p>', 'gwm', 0, 17),
(98, '华龙网11月17日21：45分讯 （数字记者王森） 11月5日，阳光重庆栏目记者报道了渝华医院剖腹产半月内死亡两人的消息，报道发出后引起社会强烈反响。渝北区卫生局也先后向该医院下达了行政处罚通知和具体的整顿工作实施方案。  　　今日下午，记者从渝北区卫生局获悉，渝华医院已将整顿的相关情况上报了渝北区卫生局，自己承认在两起剖腹产死亡事件中存在3方面的责任。下一步，渝北区卫生局将按照具体的法律法规，同', '', '', '', '2009-11-18 12:05:00', '116.228.141.77', '<span style="font-family:arial;font-size:14px;"><p>华龙网11月17日21：45分讯 （数字记者王森） 11月5日，阳光重庆栏目记者报道了渝华医院剖腹产半月内死亡两人的消息，报道发出后引起社会强烈反响。渝北区卫生局也先后向该医院下达了行政处罚通知和具体的整顿工作实施方案。</p><p>　　今日下午，记者从渝北区卫生局获悉，渝华医院已将整顿的相关情况上报了渝北区卫生局，自己承认在两起剖腹产死亡事件中存在3方面的责任。下一步，渝北区卫生局将按照具体的法律法规，同时邀请相关方面的专家，对渝华医院的整顿情况进行验收。验收合格后，渝华医院才能重新开始诊疗活动。</p><p>　　渝北区卫生局副局长王继书，今日下午在接受阳光重庆栏目记者采访时说，渝北区卫生局在11月1日就向医院下达了停业整顿的通知。11月4日，该区卫生局还向渝华医院发出了停业整顿的具体实施方案。王继书告诉记者，对渝华医院的整改，将从医院自查、查找问题、对问题进行整改以及检查验收4个阶段进行，“目前，医院已将自查整改的情况上报了区卫生局，他们自己也查找了医院存在的问题。”</p><p>　　随后，记者在重庆渝华医院11月11日上报给渝北区卫生局的停业整顿工作报告中看到，医院对自身的设施、设备、技术、医师资格证等进行了全面的清查，对两名产妇的手术过程也作了详细的回顾，并从中查找了存在的一些问题。</p><p>　　渝华医院在该报告中说，在两起剖腹产孕妇死亡的事件中，医院主要存在对孕妇产后严重并发症的后果预计不足，应急抢救措施不够细致，医院管理不到位；同时医务人员对急性肺栓塞等严重并发症的抢救能力不够强，组织针对性的学习和急救训练开展不够，存在业务素质上的不足；还有医院在高危孕产妇管理上存在薄弱环节，防范医疗风险上及时采取有力措施不够，存在安全意识上的不足3个方面的问题。</p><p>　　不仅如此，医院还提出了针对性的整改方案，包括医院将以抓高危孕产妇管理为切入点，加大医疗风险防范力度；加强与市级妇产科专家的联系；抓好医院的医疗质量和医疗安全的管理等。渝华医院表示，经过近20天的整顿工作，医院已经取得了阶段性成果，基本达到了整改的目的。</p><p>　　王继书表示，下一步，卫生局将组织专家和工作人员，对渝华医院的整改工作进行验收。阳光重庆栏目也将对验收工作继续追踪报道。</p></span>', 'gwm', 0, 27),
(99, '服中药抗流感 4女工中毒进医院', '', '', '', '2009-11-18 12:06:36', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;">&nbsp;药房负责人及患者所在的物业公司负责人均表示将对中毒原因进行调查<br /><br />　　喝完公司熬好的预防流感的中药，10多分钟的时间内，4位女员工就出现了不同程度的呕吐、心胸发闷、颤抖等症状。经过及时送医救治，医生初步诊断为轻度中毒，目前暂无生命危险，但需输液做进一步观察。目前，开药方的杏林大药房的负责人以及4位当事女工所在的绿都物业负责人均表示，他们会将药材带回去进行检测，看是否是药材引起的中毒……<br /><br />　　<b>喝抗感药 她们出现不良反应</b><br /><br />　　昨日上午11点左右，在成都一所高校做保洁工作的马蓉等4人，喝下了公司熬好的抗流感中药，没想到的是，喝了药不到20分钟的时间，她们4人就出现了不同程度的药物中毒现象，周围的工作人员见状，急忙拨打120将4人送往了成都市第六人民医院进行救治。<br /><br />　　马蓉称，喝了药后她就去吃午饭了，刚吃了没几口，就觉得胸口发闷，头晕，而另一位也喝了药的郑菊华不适反应更加强烈，吐了六七遍，剩下两位喝了药的女员工也出现了头重脚轻、不断打嗝等症状。马蓉当时和另外两位同事一起喝了一个大碗中的药，“可能每个人只喝了300ml左右。”而出现中毒现象较重的郑菊华则是一个人喝了一杯，近700ml。<br /><br />　　经过医生的初步检查，诊断马蓉等4人为轻度中毒，表现为乏力恶心、腹痛、腹胀等胃肠道反应，要求4人立即洗胃输液做进一步观察。据马蓉等4人所属的绿都物业的工作人员周亮表示，公司是考虑到这段时间气温骤降，为了防止公司员工感冒，他们前日下午特地到四川杏林医药连锁有限公司建设路店，找到了当日看诊的医师李有才，开了一服预防流感的中药，30人的剂量，一服药分成了3袋来包，共花费99.05元钱。周亮指着李有才开的药方表示，李有才共开了9种药材，分别是板蓝根300g、大青叶300g、黄芩300g、山豆根300g、射干300g、防风300g、山楂300g、甘草300g、丁香100g。周亮称，他们在拿到药的当晚就让煮饭的阿姨熬了一包，熬好后有10多位男护卫人员服用了该药，当时并无不适反应，但昨日，有3位护卫人员出现了腹泻、头昏等现象，目前已在医院做了血液检查。而第二天中午马蓉等4人服药后，出现了前述不良反应，不得不送进医院救治。周亮表示，他们会将余下的药材送到四川省食品药品监督管理局进行检测。<br /><br />　　<b>超量服用 体质太弱引起的？</b><br /><br />　　昨日，马蓉等人入院后，杏林大药房建设路店立即派了一名工作人员来到医院跟进此事。大约3个小时后，该店的营销主管胡沂嘉也赶到了医院。对于此事，胡沂嘉称开药的医生李有才是星期一才到他们药房上班的，今年79岁的李有才退休前是一家医院的医生，有多年的从医经验，并有国家颁发的执业医师执照。胡沂嘉表示，他个人认为中毒的4人应该是超量服用了药物以及自身体质较弱所致。“他开的这服药本身就是大寒药，脾胃虚寒的人吃了很容易引起不适。但他们的用量并不大，怎么会引起中毒呢？”胡沂嘉表示，这段时间因为天气的原因，有很多人都会到他们药房看病开药，所开的药方与李有才开的药方大同小异，还没有任何人因此出现药物中毒现象。<br /><br />　　周亮并不同意胡沂嘉关于脾胃虚寒者慎用该药的说法，他认为，既然该药有如此大的副作用，李有才当时为何不提前告知呢？胡沂嘉称，一般只有市民单独来看病时，他们才会在药方上注明医嘱，而像周亮他们公司来开这种多人服用的预防性汤料用药，只是常规叮嘱，是不会注明医嘱的。<br /><br />　　目前，杏林大药房建设路店会先支付马蓉等人住院所产生的所有费用，但若经过四川省食品药品监督管理局检测得出，马蓉等人药物中毒并非他们药店的原因，他们则不会支付之后的治疗费用。“我们也会将他们剩下的中药拿回去检测，看究竟是不是药材问题。”<br /><br />　　<b>山豆根 不适合大众使用</b><br /><br />　　中医名医馆的兰学良看了此药方后表示，山豆根这种药材具有毒性，若剂量过大容易引起中毒，需要谨慎使用，脾胃虚寒者更要忌服。而药方中的板蓝根和大青叶都是伤胃的药材，用了其中一种就不应再用另一种，丁香也需谨慎使用，会伤人脾胃。<br /><br />　　兰学良称，他们一般在给病人开预防流感的药时会因人而异，多数情况下不会使用山豆根这种药材，即使要用也一定要把握好剂量，这种药材并不适合大众使用。对于这服药方，成都市第六人民医院的中医师也称，山豆根这种药材的确有毒性，需要慎用，他们医院目前已无这种药材;而开的这服预防由风热引起的流感药，他认为不应开丁香，因为没什么用处。<br /><br />　　而开这服药的医生李有才称，开药后他特地问了绿都物业来开药的两位小伙子公司有没有女员工，当得知有4位女员工时，他叮嘱了对方要这4位女员工谨慎用药，并且所有喝了这服药的人在一个小时之内不要服用任何生冷之物，否则会引起不良反应，但由于这服药是常规的预防性汤料用药，他并未在药方上写下医嘱注明。李有才认为，山豆根用在这服药中没有任何问题，马蓉等人应该不是药物中毒，只是服药后出现了一些不良反应而已。</span>', 'gwm', 0, 14),
(100, '乌克兰超级流感致328死 波兰白俄现死亡病例', '', '', '', '2009-11-18 15:23:42', '116.228.141.77', '<div>乌克兰爆发的“超级流感”至少已经造成328人死亡，死亡人数还在不断增加。“超级流感”的爆发已经在乌克兰民众中引发恐慌，人们不仅买不到疫苗，甚至就连普通抗病毒药物都销售一空。目前波兰已经出现死亡病例，白俄罗斯情况要严重一些，死亡率要高很多。报道称，乌克兰对病情的通报延迟很多。</div><div><br /></div><div>乌克兰卫生部今天公布的数据显示，乌克兰27个行政区中，已经有16个出现大规模感染现象，现在只剩下卢甘斯克一个区没有报告感染病例。基辅最新感染人数已经从4964人增长到104154人，医院就医人数已经增加到78326人，但是感染者死亡率依然在以每天16人到26人的速度增加。</div><div><br /></div><div>乌克兰总统尤先科已经在9个地区发布紧急隔离命令，并且命令大量部署可移动的军事医院。他宣布，乌克兰同时遭到包括甲流在内的三种流感病毒的袭击，并暗示着三种病毒正在融合成为新型的“超级流感”病毒。</div><div><br /></div><div>尤先科说：“与其他国家当前爆发的流感疫情不同，两种季节性流感和加州流感病毒引发的感染正在乌克兰融合。病毒学家们得出结论认为，这些病毒融合可能发生变异，从而创造出更具攻击性的新病毒。”一些观察家怀疑，这种新型“超级流感”可能引发病毒性出血肺炎，这种病症可以损伤肺部组织，直到肺部大出血致人死亡。但这种怀疑目前没有得到官方证实。</div><div><br /></div><div>科学家目前还没有公布任何有关乌克兰“超级流感”的基因序列，世界卫生组织也在保持沉默。乌克兰所有公共活动都被禁止，学校封校，与捷克和俄罗斯的边境也被关闭。</div><div><br /></div><div>现在，乌克兰面临的最严峻问题是缺少疫苗。随着疫情的不断发展，乌克兰政府没有对流感疫情保持足够的警惕。现在，疫苗几乎无处购买，抗病毒药物储量也十分有限，公众信息十分闭塞。普通乌克兰人几乎不可能享受到健全的医疗服务，国内的药品要么买不起，或者已经被销售一空。</div><div><br /></div><div>英国科学家现在正对新型病毒进行化验，希望能够找出它们为何如此致命的原因。而乌克兰主流媒体也谴责乌克兰脆弱的卫生医疗系统，是造成如此高的死亡率的主因。但是他们没有涉及到其他因素，包括生活在高海拔地区缺乏维他命D以及阳光等。</div><div><br /></div><div>乌克兰切尔诺夫策地区法医部首长、布克维纳国立医科大学教授巴钦斯基接受采访谈这种新型病毒。</div><div><br /></div><div>1，新型病毒如何治疗</div><div><br /></div><div>如果人们的免疫系统足够强就能攻克病毒。病人不应该服用抗生素，这会降低人体免疫体系的抗病毒能力。在乌克兰人们随便服用抗生素也是大面积人群受害的原因。</div><div><br /></div><div>2，病人并非死于肺炎</div><div><br /></div><div>人们并非死于肺炎，这种病毒毒性很大，能摧毁人的肺。如果免疫系统弱，病毒会使肺部流血，持续数小时。血纤维凝固，抱住了肺泡，病人虽然呼吸氧气，但氧已经无法转移到肺组织内。病人只是喘气，进而心肺细胞衰竭，心源性休克，然后死亡</div><div><br /></div><div>3，人民应采取哪些措施</div><div><br /></div><div>目前首要的防护措施是戴口罩，这可以增加30%的防护。如果带眼罩、防风镜之类可以增加40%，为病毒可以穿过黏膜。提高人体免疫力是必要的，不仅仅是现在，而是长期的。在乌克兰，很多人喜欢去露天大市场买东西。如果避免去这种人群密集的地方，感染的人数还可以再少些。</div><div><br /></div><div>4，已经将建议送到卫生部长手中</div><div><br /></div><div>我们已经将数据、应对草案、治疗标准和诊断方法等送往卫生部官员手中。</div>', 'gwm', 0, 19),
(101, '南京首批近9万人接种甲流疫苗 不良反应仅20多例', '', '', '', '2009-11-19 10:13:57', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>&nbsp;&nbsp; &nbsp;记者昨天从南京市疾控中心获悉，南京主城区首批重点人群甲流疫苗接种工作已经完毕，近9万人接种疫苗，仅20多人发现轻度副反应，其安全性不容怀疑。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;据中心副主任陆小军介绍，湖南、广东的两例猝死事件，根据卫生部的通报，主要是心源性猝死，基本排除甲流疫苗导致的猝死，属于极个别的、严重的异常反应和偶合事件。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;陆小军说，本着“知情、同意、自愿、免费”原则，南京目前已为近9万人接种了甲流疫苗，只有20多例出现轻度的不良反应低热、皮疹、疼痛等症状。随着接种人数的继续增多，也许会发生极个别偶合现象，但不会影响既定的接种计划。同时希望以后接种疫苗的居民，一定要向医生讲清楚自己的过敏史、疾病史、有无心脏病史等，以供医生判断是否适合接种。</p></span>', 'gwm', 0, 13),
(102, '95%英国人不愿种甲流疫苗 担心副作用不信政府', '', '', '', '2009-11-19 10:15:21', '116.228.141.77', '<span style="font-size:15px;"><p>中新网11月17日电 据法新社报道，一项调查显示，英国人接受甲型H1N1流感疫苗注射的热情并非像想象的那么高：据估计，仅有5%的英国人乐意接种甲流疫苗。</p><p>　　据报道，英国一份医学报纸搜集了107名全科医师的报告，报告指出，甲流疫苗接种面临着重重困难。许多英国人出于对疫苗副作用的担心，以及“甲流不是严重疾病”这一普遍概念的影响，并不愿注射甲流疫苗。医生们表示，虽然孕妇是可能感染甲流的高危人群，但要说服她们接受疫苗接种是很难的。一名医生估计，在20人中只有1人乐意接受甲流疫苗的接种，比例仅为5%。</p><p>　　据统计，到目前为止，英国患甲流死亡的人数已破百，英国大多数人也面临着潜在的健康问题。为此，英国政府已制定了一个目标，即为全国50.7%年龄跨度从出生6个月到65岁的临床高危人群注射疫苗。但医生对此表示担心，认为该目标难以实现，接受疫苗接种的人数将低于预期。</p><p>　　报道指出，到目前为止，出于对为患者注射疫苗的实际经验和物资运送问题的综合考虑，只有37%的受访医生相信英国政府的这一目标切合实际。一名医生表示，部分甲流患者对待注射疫苗一事的态度“非常消极”，政府目标“将异常难以达到”。而且，另一名医生补充称，他们预计明日将在当地展开甲流疫苗的接种工作，但只收到了500株可用疫苗，因此“绝无可能”为所有目标人群注射疫苗。</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td></td></tr></tbody></table><p></p><p>　　进行调查的这家医学报纸的主编认为，英国政府没有为接种甲流疫苗的好处做出充分的、令人信服的说明。无论是患者还是医生，大多无法相信政府关于甲流疫苗的安全性和必要性的解释，认为政府的说法“缺乏足够证据”。该主编认为，政府需要为迄今所收集的关于疫苗安全性的数据做出更为清晰明了的解释。</p><p>　　据世界卫生组织统计，甲流自今年4月爆发以来，已造成全球逾5700人死亡，死亡人数美洲居多。</p></span>', 'gwm', 0, 18),
(103, '中国看病为什么这么难？', '', '', '', '2009-11-20 11:00:49', '116.228.141.77', '<p><font face="宋体"><b><br /></b></font></p>\r\n\r\n<p><b><span>&nbsp;<span style="font-family:宋体;">中国目前的就医现状</span></span></b></p>\r\n\r\n<p style="text-indent:21.75pt;"><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">在中国经常可以看到，一些大医院的挂号处排着长长的队伍，很多外地的病号，甚至凌晨</span><span>3</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">、</span><span>4</span><span style="mso-bidi-font-size:13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">点钟起床起来排队，而知名专家的号更是一号难求，不得不求助于号贩子，同事也在中国催生了一种新的职业</span><span>—</span><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">黄牛，就是挂上了号，也是要派上的队伍，有时候为了看病，都得全家人出动，就是挂上了号，等等的时间也是很漫长，上个厕所也要找人来代替自己排队；这样的情况不用多说，很多看过病的人都有切身的体会！</span><span></span></p>\r\n\r\n<p><b><span style="mso-bidi-font-size:13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;\r\nmso-hansi-font-family:&quot;Times New Roman&quot;">物以稀为贵，难道中国的医疗资源真的就这么紧张吗？</span></b><b><span lang="EN-US" style="mso-bidi-font-size:\r\n13.5pt"></span></b></p>\r\n\r\n<p style="text-indent:21.75pt;"><span style="mso-bidi-font-size:\r\n13.5pt;font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">让我们来看一组数据：</span><span><span style="font-family:simsun;color:black;">2005</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;color:black">年中国每千人有</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">．</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">51</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">个医生，在世界</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">192</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">个国家和地区中，排在第</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">70</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">位，比人均</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">GDP</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">排名高出</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">40</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">位。美国的人均医生数是每千人</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">．</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">59</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">个，法国</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">3</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">．</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">37</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">，英国</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">．</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">，韩国</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">．</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">，新加坡</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">1.4</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">，印度</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">0.6</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">。另外在中国</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">70</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">％医护人员分布在城市，因此在北京这样的大城市，医生的数量是一定可以和发达国家媲美。那么如果用医生不足来解释</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">“</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">看病难</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">”</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">这个问题，在小城市或广大农村，这是可以理解的。但在大城市为什么大家同样抱怨</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">“</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">看病难</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">”</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">呢？再进一步看，发现城市也不是所有的医院都是这样排着长龙，在同一个城市难看到的医院和医生总是那几家那几个。那么原因究竟在哪儿？</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;color:black">我们再来看看发达国家的情况</span></b></span><span><b><span style="font-family:simsun;color:black;"></span></b></span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">我曾经和以下这些国家或地区的医生讨论过他们的医生培训制度：美国、香港、法国、德国、意大利、澳大利亚。我并不意外的发现，尽管在细节上存在差异，但在一个原则性问题上每个国家或地区的做法都大致相同。那就是，医生的就业选择并不从医科大学毕业的那个时候开始。</span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span style="font-family:宋体;mso-ascii-font-family:&quot;Times New Roman&quot;;mso-hansi-font-family:\r\n&quot;Times New Roman&quot;">详细的说，就是这个时候他们可以合法的行医，但不能自由的选择进入公立医院、私人医院或私人诊所行医，通常他们只能进入非常有限的一些有医生培训资格的医院。这些医院全部是被严格筛选的大医院，它们必须具有最高的医疗、教学和科研水平，有这个国家中最高水平的医生在此工作。甚至在一些国家（比如法国、澳大利亚），住院医生还必须在这些医院间流动。</span></p>\r\n\r\n<p style="text-indent:20.6pt;"><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">所有这些其实都是为了保证培训水平的一致和均衡。通常这个阶段会持续</span><span style="font-family:simsun;color:black;">3</span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">－</span><span style="font-family:simsun;color:black;">5</span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">年</span><span style="font-family:simsun;color:black;">,</span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">然后在经过考试或其他形式的认定后，医生才可以自由选择医院执业。这保证了多数医生可以变成一个我们所指的</span><span style="font-family:simsun;color:black;">“</span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">好医生</span><span style="font-family:simsun;color:black;">”</span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">。</span><span style="font-family:simsun;color:black;"></span></p>\r\n\r\n<p><b><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">那么中国的医生水平为什么这样参差不齐呢？</span></b><b><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;font-family:Simsun;color:black"></span></b></p>\r\n\r\n<p style="text-indent:21.75pt;"><span style="mso-bidi-font-size:\r\n10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\ncolor:black">问问我们的医学院校的毕业生就业情况我们或许很有所感悟：<span>在中国，一个医生的三六九等，很大程度上是在出校门的那个时候决定的。大学毕业后进入高水平的大医院的学生，有机会见识各种病人，跟随对专业有深刻认识和丰富经验的高年资医生培养各种技能。而进入低水平医院的学生便从此丧失了同等水平的训练。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">临床培训过程不仅仅是一个授人以鱼的过程，更是一个授人以渔的过程。既要见，要积累经验，更要想，在了解的基础上寻找规律，还要讨论，在与已有认识的前辈医生的交流中获得提高。更别说那日复一日熟能生巧的操作练习。而所有这些条件，其差异在不同水平医院间一望而知。所以从毕业的那一刻起，一个班同学的诊疗水平便在各自进入的医院间划开鸿沟，渐行渐远。而</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">“</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">好医生</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">”</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">便在不断拉大的差距中，越变越少。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p><span><b style="mso-bidi-font-weight:\r\nnormal"><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:\r\nSimsun;mso-hansi-font-family:Simsun;color:black">原因我们终于发现：<span style="color:#fe2419;">中国僵硬的医疗制度没有充分发挥医生的人力资源，而是把医生划分了三六九等，我们不仅对天悲叹：中国延续了几千年的封建等级制度仍然在紧扼着中国医疗制度的咽喉！</span></span></b></span><b><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;font-family:Simsun;color:black"></span></b></p>\r\n\r\n<p><b><span>&nbsp;</span></b></p>', 'gwm', 0, 19);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(104, '甲流病毒已经变异    ', '', '', '', '2009-11-24 11:45:39', '116.228.141.77', '<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;color:black">众所周知，所有流感病毒均会出现轻微基因转变，上周挪威变种病毒导致两人死亡。目前香港</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">岁男童被验出感染变种甲型流感病毒（与挪威病毒相同），曾在</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">月底入住沙田韦尔斯医院。根据世界卫生组织数据显示，其它地区包括巴西、内地、日本、墨西哥、乌克兰和美国均曾发现病毒变种，但没有出现与挪威相同的变种病毒。发言人指目前并无证据显示，病毒变种后会导致甲型流感感染个案不寻常地增加，甚至出现更多严重或死亡个案。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">目前在香港的病例，更应该引起我们注意，上周导致挪威两人死亡的变种病毒，可能早于</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">月已在香港出现。香港卫生署</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">23</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">日公布，从一名</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">1</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">岁男童的呼吸道样本发现与挪威病例相同的变种病毒，更令人震惊的是，该男童早在今年</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black">7</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">月染病，虽然早已完全康复，但较挪威的病例更早出现。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><b><span style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-ascii-font-family:Simsun;mso-hansi-font-family:Simsun;\r\ncolor:black">目前的问题是：之前的流感疫苗是否会失效</span></b></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">？</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">因为有微生物学专家指，虽然所有流感病毒均会出现轻微基因转变，但倘若病毒基因出现大幅度变异，有可能令特区政府早前订购的疫苗失效，令流感第二波疫情更严峻，促请有关单位详细排列变种甲型流感的基因变异幅度，并在有需要时调整抗疫策略。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">香港大学微生物学助理教授黄世贤表示，所有流感病毒均会出现轻微基因转变，但期望特区政府尽快公布变种病毒的详细报告，以了解病毒有否变恶、致命性有否增强，倘病毒基因出现大变异，则有可能令疫苗失效。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Simsun;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.75pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Simsun;\r\nmso-hansi-font-family:Simsun;color:black">香港个案的男童已经痊愈，加上病毒没有出现抗药性，显示变种病毒杀伤力不算惊人。世卫早前公布，挪威变种病毒的抗原没有改变，相信特区政府早前订购的甲型流感疫苗仍具有效防御力，呼吁市民要做好个人卫生，高危人士也应接种甲型流感疫苗作预防。</span></span></p>', 'gwm', 0, 10),
(105, 'PET-CT检查呈爆发式增长！', '', '', '', '2009-11-24 12:03:09', '116.228.141.77', '&nbsp;&nbsp; &nbsp;日前，从全国各PET-CT中心获悉，各中心的PET-CT检查都成大幅度的增长，以前只能每天做10个病人左右的PET-CT中心，现在都增加了一倍；而有些一周只开机3-4天的，现在一周都开满，少数医院的PET-CT中心，更是难以预约，只有增加周六加班。<div>&nbsp;&nbsp; &nbsp;对于这样PET-CT检查人数的爆发式增长，派康网PET-CT预约中心刘医生解释到：对了目前PET-CT检查人数的大幅度增长，主要有以下几个原因，一、是了解PET-CT的人数越来越多，之前很少有人听说PET-CT，基于网络技术的发展，更多的人了解到了PET-CT检查的意义作用。二、将PET-CT作为健康体检的人数越来越多，之前PET-CT只是作为肿瘤病人的检查手段，随着人们检查意识的增强，越来越多的人使用PET-CT做为检查体检的手段，一般来说此时是健康体检的高峰期，很多人在体检时发现结果异常，如肿瘤标志物异常等等，进一步选择PET-CT检查。第三，随着环境污染，人工作压力的增加，肿瘤患者越来越多，直接促使了人们对健康管理的认识，认识到了体检及早期预防的意义。</div><div>&nbsp;&nbsp; &nbsp;总之，PET-CT检查人数的增加是一个好事，这会是这样高端的检查设备发挥更多的经济社会效益，使更多的人享受这样的服务，同时也会促使PET-CT检查价格的下降，就如同普通的CT一样进入寻常百姓医院，我们期望:全国的PET-CT都能进入医保！</div>', 'gwm', 0, 23),
(106, '安徽省立医院PET/CT检查降价通知', '', '', '', '2009-11-24 18:31:39', '220.178.118.18', '<p><span style="font-family:宋体;">我院为了响应国家卫生部医改指示精神，参照安徽省物价局规定，经医院研究决定调整</span><span>PET-CT</span><span style="font-family:宋体;">检查收费标准，让广大的检查人群可以得到更安全、准确、省时、优质的检查。收费：全身检查收费:</span><span>8200</span><span style="font-family:宋体;">元，局部检查收费:</span><span>6500</span><span style="font-family:宋体;">元，头颅检查收费:</span><span>5000</span><span style="font-family:宋体;">元。同时我们将保持原来服务品质，遵循医院及科室各项服务承诺，真诚及时的为您提供服务。特此通知！ </span></p>\r\n<p align="right"><span style="font-size:10.5pt;font-family:''times new roman'';"><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span></span><span style="font-size:10.5pt;font-family:宋体;">派康网编辑</span><span style="font-size:10.5pt;font-family:''times new roman'';">&nbsp;<span>&nbsp;</span><span>&nbsp;</span></span></p>', 'llz007', 0, 24),
(107, '安徽医科大学第一附属医院PET/CT开业了！', '', '', '', '2009-11-24 19:32:55', '220.178.118.18', '<span style="color:black;font-family:仿宋_gb2312;">\r\n<p style="text-indent:21pt;"><span style="color:#333333;"><font face="宋体">国内第四台</font></span><span style="color:#333333;font-family:''times new roman'';">52</span><span style="color:#333333;"><font face="宋体">环</font></span><span style="color:#333333;font-family:''times new roman'';">64</span><span style="color:#333333;"><font face="宋体">层</font></span><span style="color:#333333;font-family:''times new roman'';">PET-CT</span><span style="color:#333333;"><font face="宋体">在安徽医科大学第一附属医院</font></span><span style="color:#333333;font-family:''times new roman'';">PET/CT</span><span style="color:#333333;"><font face="宋体">中心成功落地开张了，</font></span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><span style="color:#333333;font-family:''times new roman'';">11</span><span style="color:#333333;"><font face="宋体">月</font></span><span style="color:#333333;font-family:''times new roman'';">3</span><span style="color:#333333;"><font face="宋体">日</font></span><span style="color:#333333;"><font face="宋体">，安医大一附院全球最高端的</font></span><span style="color:#333333;font-family:''times new roman'';">52</span><span style="color:#333333;"><font face="宋体">环</font></span><span style="color:#333333;font-family:''times new roman'';">64</span><span style="color:#333333;"><font face="宋体">层</font></span><span style="color:#333333;font-family:''times new roman'';">PET-CT</span><span style="color:#333333;"><font face="宋体">正式投入使用。该设备的投入使用，标志着安徽省医疗诊断水平迈入国内先进水平。据悉，该设备是当今世界核医学最高水平的标志，它可以发现</font></span><span style="color:#333333;font-family:''times new roman'';">2mm</span><span style="color:#333333;"><font face="宋体">的肿瘤，对肿瘤的早期诊断、分级、分期、疗效监测和协助指导治疗及肿瘤在全身累及状况方面具有突出功能。传统需要</font></span><span style="color:#333333;font-family:''times new roman'';">30</span><span style="color:#333333;"><font face="宋体">分钟的</font></span><span style="color:#333333;font-family:''times new roman'';">PET-CT</span><span style="color:#333333;"><font face="宋体">检查，该设备只需要</font></span><span style="color:#333333;font-family:''times new roman'';">7</span><span style="color:#333333;"><font face="宋体">分钟即可完成，并且可以得到更好的图像质量，能更早发现早期微小的</font></span><span style="color:#333333;font-family:''times new roman'';">2mm</span><span style="color:#333333;"><font face="宋体">肿瘤转移灶。另一个突出的优势是独有的肿瘤随访引擎，能对肿瘤进行容积分析，</font></span><span style="color:#333333;font-family:''times new roman'';">PET</span><span style="color:#333333;"><font face="宋体">、</font></span><span style="color:#333333;font-family:''times new roman'';">CT</span><span style="color:#333333;"><font face="宋体">融合图像分析，使医生能够比较病人两个扫描时间点的图像，帮助其作出更加精确的诊断和制定后续治疗方案，对肿瘤早期治疗、个性化治疗提供有力保障。</font></span><span style="color:#333333;font-family:''times new roman'';"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></p><span>\r\n<p style="text-indent:21pt;text-align:right;" align="right"><span style="color:#333333;"><font face="宋体">派康网编辑</font></span><span style="color:#333333;font-family:''times new roman'';"></span></p></span></span>', 'llz007', 0, 33),
(108, '浅谈改革医药服务价格形成机制的意见', '', '', '', '2009-11-24 22:21:00', '220.178.118.18', '<span style="font-size:7.5pt;color:#333333;font-family:宋体;">\r\n<p><span style="font-size:12pt;color:#333333;font-family:宋体;">&nbsp;&nbsp;&nbsp; 国家发展与改革委员会、卫生部和人力资源社会保障部刚联合发布《改革药品和医疗服务价格形成机制的意见》</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">, </font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">这意见的发布明确了未来国家对药品和医疗服务价格的定价机制</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">对于引导医药企业和医院进行相应的调整，以适应国家医疗体制改革政策对医疗产业的需求有积极的意义。从具体措施来看</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">鼓励医药商业兼并重组</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">压缩渠道费用</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">高价药给与较低的加价率</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">低价药给与较高的加价率是控制目前高价药品的主要手段</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">对于创新药和首仿药则给与较高的利润率水平</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">逐步取消医院对药品的加成率。</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">&nbsp;</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">医药企业将会进一步分化</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">鼓励医药商业企业的兼并重组</span><span style="font-size:12pt;color:#333333;"><font face="Times New Roman">,</font></span><span style="font-size:12pt;color:#333333;font-family:宋体;">大型医药企业的发展前景更为看好，研发能力较强的医药企业也能享受到政策的利好。</span></p><span style="font-size:12pt;color:#333333;font-family:宋体;"></span><span style="font-size:12pt;color:#333333;">\r\n<p align="right"><span style="font-size:12pt;color:#333333;font-family:宋体;">派康网编辑</span><span style="font-size:12pt;color:#333333;"></span></p></span></span>', 'llz007', 0, 9),
(109, '物价上涨已成定局是真的吗？', '', '', '', '2009-11-24 23:51:45', '220.178.118.18', '<span style="font-size:9pt;color:black;font-family:宋体;">\r\n<p><span style="font-size:12pt;color:black;font-family:宋体;">目前，随着水、电、气、菜、肉、钢材等的涨价，新一轮价格上涨似乎已经山雨欲来。各地调高水、电、气等公共产品价格必然转移到终极产品和服务价格之中，天气逐渐转冷，致使农产品供应出现暂时性紧张也引发涨价，蔬菜和鲜果价格的温和上涨之势还将继续，我们准备好了吗？我们将如何来面对？</span></p>\r\n<p align="right"><span style="font-size:12pt;color:black;font-family:宋体;">&nbsp;派康网编辑</span></p></span><span style="font-size:9pt;color:black;font-family:verdana;"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span>', 'llz007', 0, 11),
(110, '世卫官员证实中国内地曾出现甲流病毒变种病例', '', '', '', '2009-11-25 10:59:47', '116.228.141.77', '<div>据法制晚报报道 昨天上午，世界卫生组织驻华代表处新闻官陈蔚云向记者证实，中国内地确实出现过甲流病毒变种的病例。</div><div><br /></div><div>据香港媒体报道，根据世界卫生组织资料，巴西、中国、日本、墨西哥、乌克兰和美国都曾发现病毒变种。</div><div><br /></div><div>陈蔚云告诉记者，今年6、7月份，中国内地曾经出现过两三个甲型H1N1流感变种病毒的病例，这种病毒和近日在挪威出现的病毒相同，但她没有透露更多的细节。</div><div><br /></div><div>陈蔚云表示，专家还在做进一步研究和分析，但目前为止该病毒没有对甲流疫苗产生抗药性，因此世界卫生组织暂时不打算发布新的建议或改变此前的建议。</div><div><br /></div><div>据新京报报道 从10月24日卫生部通报北京首个甲流致死病例至今，已有26人在感染甲流后，相继在京医治无效死亡。</div><div><br /></div><div>北京市卫生局昨日称，26名死亡患者中，16人因感染甲流导致慢阻肺等基础病急性发作，最终死于基础病；其他10人，直接因甲流病毒严重侵害身体而死亡。死亡患者中11人来自外省市或国外，他们或在京居留期间染疫、或在染疫出现严重症状后抵京求治。“目前从北京来看，甲流疫情的致死率不高于普通流感或其他疾病，普通的季节性流感每年都会致人死亡。”</div><div><br /></div><div>北京市卫生局昨日下午2时发布的监测报告显示，截至11月23日24时，北京累计报告甲流确诊病例9007例，其中危重病人80人。</div><div><br /></div><div>北京市卫生部门估计，目前北京地区约有40万人感染了甲流，绝大多数为轻症患者，甚至有很大一部分是无症状的潜在感染者。</div><div><br /></div><div>据法制晚报报道 据深圳卫视最新报道，广东省卫生厅最新评估，未来流感最高峰期，全省会有15%至20%人口、即高达1800万人感染流感。</div><div><br /></div><div>广东省卫生厅表示，当前仍是第一波流感高峰期，明年2、3月或迎来流感第二波，而最高峰时间广东省会有1800万人感染流感，当中包括季节性流感以及甲流。</div><div><br /></div><div>专家解读</div><div><br /></div><div>全军甲型H1N1流感联防联控督导检查专家组成员、空军总医院感染控制科主任曹晋桂说：“病毒变异，意味着深入到肺部，‘深入’一词代表两个方向，其一是向下呼吸道发展，其二是向肺内的肺泡发展。”</div><div><br /></div><div>曹晋桂主任说：“如果患上甲流病毒性肺炎，其影响最大的就是呼吸系统，呼吸功能下降，使得人体的氧分压、血液中的氧分压都会下降，也就是说人在呼吸过程中，吸进去的有效氧分压就下降了。”</div><div><br /></div><div>当吸入的有效氧分压下降的时候，直接影响到身体中的各个大器官，尤其当内脏功能下降的时候，甚至可引起各功能的衰竭。</div><div><br /></div>', 'gwm', 0, 19),
(111, '石家庄市中院对三鹿奶粉案2名主犯执行死刑', '', '', '', '2009-11-25 11:08:41', '116.228.141.77', '<div><br /></div><div>张玉军(左一)、张彦章(右二)在法庭上受审。丁力辛 摄</div><div><br /></div><div><br /></div><div><br /></div><div>被告人耿金平（前左）和耿金珠（前右）在法庭上受审。新华社发 丁立新 摄</div><div><br /></div><div>根据最高人民法院执行死刑的命令，石家庄市中级人民法院于11月24日对“三鹿”刑事犯罪案犯张玉军、耿金平执行死刑。</div><div><br /></div><div>河北省石家市中级人民法院于2009年1月21日作出刑事判决，认定被告人张玉军犯以危险方法危害公共安全罪，判处死刑，剥夺政治权利终身；认定被告人耿金平犯生产、销售有毒食品罪，判处死刑，剥夺政治权利终身，并处没收个人全部财产。宣判后，张玉军、耿金平提出上诉。河北省高级人民法院经依法开庭审理，于2009年3月26日裁定驳回张玉军、耿金平上诉，维持原判，并依法报请最高人民法院核准。</div><div><br /></div><div>最高人民法院经复核确认：2007年7月，被告人张玉军明知三聚氰胺是化工产品、不能供人食用，人一旦食用会对身体健康、生命安全造成严重损害的情况下，以三聚氰胺和麦芽糊精为原料，在河北省曲周县河南瞳镇第二瞳村，配制出专供在原奶中添加、以提高原奶蛋白检测含量的含有三聚氰胺的混合物(俗称“蛋白粉”)。后张玉军将生产场所转移至山东省济南市市中区党家庄村，购买了搅拌机、封口机等生产工具，购买了编织袋，定制了不干胶胶条，陆续购进三聚氰胺192.6吨、麦芽糊精583吨，雇佣工人大批量生产“蛋白粉”。至2008年8月，张玉军累计生产“蛋白粉”770余吨，并以每吨8000元至12000余元不等的价格销售给张彦章(同案被告人，已判刑)及黄瑞康、张树河、刘继安、周全彬(均另案处理)等人，累计销售600余吨，销售金额6 832 120元。</div><div><br /></div><div>在此期间，张玉军生产、销售，张彦章销售的“蛋白粉”又经赵怀玉、黄瑞康等人分销到石家庄、唐山、邢台、张家口等地的奶厅(站)，被某些奶厅(站)经营者添加到原奶中，销售给石家庄三鹿集团股份有限公司(以下简称三鹿集团)等奶制品生产企业。三鹿集团等奶制品生产企业使用含有三聚氰胺的原奶生产的婴幼儿奶粉等奶制品流入全国市场后，对广大消费者特别是婴幼儿的身体健康、生命安全造成了严重损害，导致全国众多婴幼儿因食用含三聚氰胺的婴幼儿奶粉引发泌尿系统疾患，多名婴幼儿死亡。国家投入巨额资金用于患病婴幼儿的检查和治疗，众多奶制品企业和奶农的正常生产、经营受到重大影响，经济损失巨大。</div><div><br /></div><div>最高人民法院认为，被告人张玉军为谋求非法利益，置广大人民群众的身体健康、生命和财产安全于不顾，大量生产、销售专供往原奶中添加的含三聚氰胺的混合物即“蛋白粉”，经逐级分销后被添加到原奶中，奶制品生产企业使用被添加含有三聚氰胺混合物的原奶生产的婴幼儿奶粉等奶制品流入市场后，对广大消费者特别是婴幼儿的身体健康造成严重损害，导致众多婴幼儿因食用遭受三聚氰胺严重污染的婴幼儿配方奶粉引发泌尿系统疾患，造成多名婴幼儿致病死亡，并致使公私财产遭受了重大损失，其行为构成以危险方法危害公共安全罪。张玉军犯罪情节极为严重，犯罪手段极其恶劣，社会危害性极大，应依法惩处。第一审判决、第二审裁定认定的事实清楚，证据确实、充分，定罪准确，量刑适当。审判程序合法。依照《中华人民共和国刑事诉讼法》第一百九十九条和《最高人民法院关于复核死刑案件若干问题的规定》第二条第一款的规定，最高人民法院裁定核准河北省高级人民法院维持第一审以以危险方法危害公共安全罪判处被告人张玉军死刑，剥夺政治权利终身的刑事裁定。</div><div><br /></div><div>最高人民法院经复核确认：被告人耿金平在河北省正定县南楼乡东宿村经营正定县金河奶源基地，从事鲜奶收购和销售。为牟取非法利益，耿金平伙同其弟耿金珠(同案被告人，已判刑)自2007年10月开始从正定县赵志超(另案处理)处和行唐县赵军花(另案处理)的化工试剂门市部，多次购买含有三聚氰胺的混合物(俗称“蛋白粉”)18袋，每袋20公斤.共计560公斤。2007年10月至2008年8月，耿金平在明知该混合物为非食品原料、不能供人食用的情况下，多次按每1000公斤原奶添加0.5公斤该混合物的比例，将含有三聚氰胺的该混合物约434公斤添加到其收购的90余万公斤原奶中，销售到石家庄三鹿集团股份有限公司等处，销售金额280余万元。耿金平将含有三聚氰胺混合物的原奶销售给石家庄三鹿集团股份有限公司，该公司生产的含有三聚氰胺的婴幼儿奶粉等奶制品流入市场后，给婴幼儿的身体健康及生命安全造成严重损害。全国已有多名婴幼儿因食用含有三聚氰胺的三鹿牌婴幼儿配方奶粉死亡、众多婴幼儿住院进行手术或治疗。</div><div><br /></div><div>最高人民法院认为，被告人耿金平明知含有三聚氰胺的混合物是非食品原料，而多次、大量进行购买，并添加到其所收购的原奶中，销售给石家庄三鹿集团股份有限公司等处，其行为已构成生产、销售有毒食品罪。三鹿集团股份有限公司以耿金平交售的原奶为原料生产的含有三聚氰胺的婴幼儿奶粉等奶制品流入市场后，给婴幼儿的身体健康及生命安全造成严重损害，全国已有多名婴幼儿因食用含有三聚氰胺的三鹿牌婴幼儿配方奶粉死亡、众多婴幼儿住院进行手术或治疗，危害后果特别严重。耿金平在共同犯罪中系主犯，犯罪情节、后果均特别严重，亦无法定、酌定从轻的情节。第一审判决、第二审裁定认定的事实清楚，证据确实、充分，定罪准确，量刑适当。审判程序合法。依照《中华人民共和国刑事诉讼法》第一百九十九条和《最高人民法院关于复核死刑案件若干问题的规定》第二条第一款的规定，最高人民法院裁定核准河北省高级人民法院维持第一审以生产、销售有毒食品罪判处被告人耿金平死刑，剥夺政治权利终身，并处没收个人财产的刑事裁定。(来源：燕赵都市报)</div>', 'gwm', 0, 11),
(112, '中国城市公职人群健康状况差 超四成人超重', '', '', '', '2009-11-25 11:09:36', '116.228.141.77', '<span style="font-size:14px;"><p style="text-indent:2em;">中新社北京十一月二十四日电 中国城市公职人员总体健康状况不佳：约百分之三十四患有颈椎疾病，百分之二十八有咽喉炎，四分之一患有痔疮，五分之一有慢性肠炎和脂肪肝。这是24日下午发布的《中国城市健康状况调查》之公职人员健康报告提供的最新数据。</p><p style="text-indent:2em;">由中国医师协会、中国医院协会、北京市健康保障协会、人民网等单位联合进行的该项调查，涉及全国三十一个省、区的五百八十九个城市，共收回问卷九万二千三百二十份。专家结合北京、广州、上海、南京、武汉等地体检抽样报告数据，进行综合分析，结果显示：</p><p style="text-indent:2em;">公职人群患痔疮、脂肪肝、高血压、血脂异常、高血糖的比例高于普通脑力劳动者，大城市公职人员发病率比小城市高，居领导岗位的公职人员身体状况更差；超过四成超重或肥胖，一成心电图异常，百分之六以上有胆囊疾病，百分之二十三有前列腺疾患。</p><p style="text-indent:2em;">在心理方面，有近一半有疲倦感，四成六有平淡感，三成八感到烦躁。这些负面情绪要远高于满足、充实及快乐感等正面情绪。被调查的公职人员普遍认为工作“一年比一年累”，必须放弃双休和法定长假，“工作压力大”，北京、广州、上海、深圳，南京等地尤其突出。调查问卷数据还表明：公职人员级别越高则健康状况越差，男性体检的异常率高于女性。</p><p style="text-indent:2em;">中国医师协会HMO委员韩小红博士指出，公职人员脂肪肝和血压、血脂、血糖三高以及痔疮发病率高的主要原因，一是百分之五十八的公职人员“每日在坐位办公五至八小时”，有四分之一甚至超过“八到十二小时”，长期伏案、缺少体育锻炼。而职务级别越高健康状况越差，与该群体年龄构成比普通公职人员高、领导岗位责任压力、心理负荷和饮食睡眠不规律等因素有关。</p></span>', 'gwm', 0, 16),
(113, '我国首台飞利浦带TOF的PET-CT安装', '', '', '', '2009-11-25 14:54:02', '116.228.141.77', '<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">据悉，唐山工人医院核医学科最新引进了一台</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">philips</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">公司生产的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">（</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">64</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">排），这台机器具有先进的的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">技术，分辨率可以达到</span></span><span><span style="font-family:helvetica;color:black;">2mm</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">.</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;color:black">这是国内引进的第一台由</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PHILIPS</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">公司生产的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">PET/CT</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">（</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">64</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">排）。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">什么是</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF?</span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">即</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">time of fly </span></span><span><span style="font-family:宋体;">飞行时间技术。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:"times="" roman";="" color:#0a1414"="">在飞行质谱的检测系统中，蛋白芯片根据色谱原理，表面经化学</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="font-family:宋体;">阳离子、阴离子、疏水、亲水和金属离子整合等</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="font-family:宋体;">或生物化学</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="font-family:宋体;">抗体、受体、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">DNA</span></span><span><span style="font-family:宋体;">等</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="font-family:宋体;">处理，芯片特异性地和血清中测定蛋白结合，再通过选择性清洗，获得高分辨率的保留蛋白谱</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="font-family:宋体;">第一次分离</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="font-family:宋体;">。当加入能量吸收分子</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(EAM)</span></span><span><span style="font-family:宋体;">后，芯片上保留的蛋白形成晶体。在特异的激光照射后，晶体发生解离作用，带电分子在通过电场时加速，记录仪记录飞行时间的长短，质量越轻，相对所带的电荷越多</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">(</span></span><span><span style="font-family:宋体;">质荷比</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">M/Z</span></span><span><span style="font-family:宋体;">越小</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">)</span></span><span><span style="font-family:宋体;">，飞行时间越短。信号由高速的模拟数字转化器传化并记录，被测定的蛋白质以一系列峰的形式呈现，这些特异的峰可看成此类疾病的指纹。单个蛋白在谱图上的位置取决于飞行时间。</span></span><span style="color:#0a1414;"><br />\r\n<span>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span><span style="font-family:宋体;">飞行质谱这一技术目前已广泛用于多种疾病，如癌症、老年病、感染性疾病、心血管病和神经系统疾病，认为可以提高多种疾病的诊断率，其中应用于癌症的最多。国外研究人员应用</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">SELDI</span></span><span><span style="font-family:宋体;">检测了转移性黑色素瘤、肉瘤和肾癌，敏感性达</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">87%</span></span><span><span style="font-family:宋体;">。他们认为，该方法根据独特的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">8</span></span><span><span style="font-family:宋体;">～</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">24</span></span><span><span style="font-family:宋体;">条蛋白指纹图可以用于多种癌症的诊断，如肝癌、前列腺癌、乳腺癌、膀胱癌、食道癌，其检测限为飞摩尔</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">/</span></span><span><span style="font-family:宋体;">升。据报道，美国华盛顿伊丽莎白医院利用该技术检测肺癌，敏感性达</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">98%</span></span><span><span style="font-family:宋体;">，特异性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">97%</span></span><span><span style="font-family:宋体;">；美国霍普金斯医学院检测了卵巢癌敏感性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">82%</span></span><span><span style="font-family:宋体;">，特异性</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">98%.</span></span><span lang="EN-US" style="mso-bidi-font-size:\r\n10.5pt;color:#0A1414"><br />\r\n</span><span><span style="mso-bidi-font-size:10.5pt;\r\nfont-family:宋体;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" roman";color:#0a1414"="">美国科学顾问委员会的</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">300</span></span><span><span style="font-family:宋体;">多位从事生命科学或医疗一线的研究者普遍认为飞行质谱是一个极有前途的应用技术，将给诊断学带来一场革命或革新，大大改变目前一些疾病如肿瘤、心血管病等诊断落后的情况，前景美好。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">TOF</span></span><span><span style="font-family:宋体;">应用于</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">PET-CT</span></span><span><span style="font-family:宋体;">，将</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414">PET-CT</span></span><span><span style="font-family:宋体;">技术带来极大的进步，主要来说有如下的优势：</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\ncolor:#0A1414"></span></span></p>\r\n\r\n<p style="text-indent:21.0pt;"><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">一、</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">TOF</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">通过</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black">2</span></span><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;mso-ascii-font-family:Helvetica;\r\nmso-hansi-font-family:Helvetica;color:black">个光子到达晶体的飞行时间差来缩小重建范围，实现局部重建，从而压制噪声，提高图像的信噪比，由于信噪比提高了，相当于有效计数的百分比提高了，从而可以缩短扫描时间、减少用药剂量。</span></span><span><span lang="EN-US" style="mso-bidi-font-size:10.5pt;\r\nfont-family:Helvetica;color:black"></span></span></p>\r\n\r\n<p><span><span style="mso-bidi-font-size:10.5pt;font-family:宋体;\r\nmso-ascii-font-family:Helvetica;mso-hansi-font-family:Helvetica;color:black">二、，信噪比的提高可以提高图像质量，对小病灶和高本地处的病灶应该都可以看出来。三、由于实现了局部重建，所以重建患者的体积没有关系了，可以提高肥胖病人的图像质量。</span></span><span></span></p>', 'gwm', 0, 29),
(114, '东软和Positron 合资生产的PET获得美国FDA认证！', '', '', '', '2009-11-25 16:09:04', '116.228.141.77', '<span style="font-family:helvetica, arial, sans-serif;font-size:14px;">新华网沈阳５月２６日专电（记者徐扬、田晓航）东软集团股份有限公司２６日对外宣布，由其全资子公司东软医疗系统有限公司成功自主研发ＰＥＴ（正电子发射断层扫描装置），并获得了美国ＦＤＡ（美国食品药物管理局）认证，使我国成为全球少数几个能够独立研制和生产ＰＥＴ的国家之一。<br /><br />&nbsp; &nbsp; 据东软集团副总裁、<br />东软医疗系统有限公司总裁刘健介绍，ＰＥＴ作为分子影像学设备，涉及核物理学、软件学、快电子学、机械学、医学、药学、分子生物学、分子影像学等诸多领域，由１３００余种物资、数万个零件（包括阻容件）组成，技术门槛高，全球只有几家跨国公司能够独立研制和生产，并垄断全球市场，我国则全部依靠进口。此次成功研发并生产的东软系列ＰＥＴ包括ＮＳＰ－Ｐ８和ＮＳＰ－Ｐ６Ｃ两个型号的产品，已经达到国际同类产品的先进水平，能够满足肿瘤、神经系统的临床应用，且在心脏疾病诊断方面具有技术优势。<br /><br />&nbsp; &nbsp; 据业内专家介绍，ＰＥＴ（正电子发射断层扫描装置）在全身肿瘤和心脏等疾病的早期诊断与治疗方面有巨大的临床价值。比起传统的检测方法如Ｘ线、ＣＴ、ＭＲＩ等，ＰＥＴ对各种身体病变的早期诊断更胜一筹，不仅能够保证足够的治疗时间，而且能够大大降低相关的治疗费用。<br /><br />&nbsp; &nbsp; 据刘健介绍，目前东软ＰＥＴ整机部件国产化率已达９０％以上，预计东软第一台ＰＥＴ将在今年７月正式销往美国。</span>', 'gwm', 0, 25),
(115, '中国核学会2009年学术年会在京隆重召开', '', '', '', '2009-11-26 08:38:06', '221.229.120.18', '<p><span style="font-size:10.5pt;font-family:宋体;">中国核学会</span><span style="font-size:10.5pt;font-family:''times new roman'';">2009 </span><span style="font-size:10.5pt;font-family:宋体;">年学术年会于</span><span style="font-size:10.5pt;font-family:''times new roman'';"> 2009</span><span style="font-size:10.5pt;font-family:宋体;">年</span><span style="font-size:10.5pt;font-family:''times new roman'';">11</span><span style="font-size:10.5pt;font-family:宋体;">月</span><span style="font-size:10.5pt;font-family:''times new roman'';">18-20</span><span style="font-size:10.5pt;font-family:宋体;">日在北京国家会议中心召开。会议安排了一天的全体会议，来自相关领域的</span><span style="font-size:10.5pt;font-family:''times new roman'';">40</span><span style="font-size:10.5pt;font-family:宋体;">多位院士和</span><span style="font-size:10.5pt;font-family:''times new roman'';">1400</span><span style="font-size:10.5pt;font-family:宋体;">多名代表参加了会议，黄钢教授应邀做了核医学的大会报告。中国核学会核医学分会组织了一个分会场，来自全国及北京市的核医学工作者代表共</span><span style="font-size:10.5pt;font-family:''times new roman'';">100</span><span style="font-size:10.5pt;font-family:宋体;">余人参加了分会场的学术交流，核医学老前辈王世真院士、夏宗勤教授及中国原子能科学研究院张锦荣副院长出席了会议。</span><span style="font-size:10.5pt;font-family:''times new roman'';"><br />\r\n<br />\r\n</span><span style="font-size:10.5pt;font-family:宋体;">　　核医学分会用一整天的时间进行学术交流，包括多个精彩的大会专题学术报告及大会口头发言。会议邀请了我国多名知名核医学专家做专题学术报告，有夏宗勤教授、张永学教授、李亚明教授、李思进教授、李方教授、王茜教授、姚稚明教授、王自正教授、何作祥教授、郑容教授和兰晓莉副教授等。</span><span style="font-size:10.5pt;font-family:''times new roman'';"><br />\r\n<br />\r\n</span><span style="font-size:10.5pt;font-family:宋体;">　　王世真院士在会上作了精彩点评。大家一致认为，这是一次极富学术内涵的盛会，既有最前沿的核医学进展，又有许多与临床紧密相关的报告，大家受益匪浅。</span></p>\r\n<p align="right"><span style="font-size:10.5pt;font-family:宋体;"><span style="font-size:10.5pt;font-family:宋体;">派康网编辑报道</span></span></p>\r\n<p><span style="font-size:10.5pt;font-family:宋体;"></span>&nbsp;</p>', 'llz007', 0, 23),
(116, '医药行业：改革药品和医疗服务价格形成机制点评', '', '', '', '2009-11-26 12:43:30', '116.228.141.77', '<span style="font-family:宋体, arial, helvetica, clean, sans-serif;font-size:12px;"><h1 style="font-size:20px;font-family:黑体;font-weight:normal;text-align:center;"><span style="font-family:宋体, arial, helvetica, clean, sans-serif;font-size:14px;">2009年11月23日，国家发展与改革委员会、卫生部和人力资源社会保障部日前联合发布《改革药品和医疗服务价格形成机制的意见》，作为医疗体制改革的配套文件，这意见的发布明确了未来10年国家对药品和医疗服务价格的定价机制，对于引导医药企业和医院进行相应的调整以适应国家医疗体制改革政策对医疗产业的需求有积极的意义。</span></h1><div style="font-size:14px;text-align:left;"><p style="text-indent:28px;font-size:14px;">从基本原则上看，药品和医疗服务价格继续受到国家的管理，在考虑创新和产品质量的情况下，制定出符合我国目前国情和人民群众承受能力的价格。</p><p style="text-indent:28px;font-size:14px;">在三年任务上，还是要降低一些虚高的药品、医疗器械以及医疗服务的价格，合理提高一些临床必须的低价药品的价格，用提高医疗服务的价格来置换药品在医院的加成率。</p><p style="text-indent:28px;font-size:14px;">从具体措施来看，鼓励医药商业兼并重组，压缩渠道费用，高价药给与较低的加价率，低价药给与较高的加价率是控制目前高价药品的主要手段，对于创新药和首仿药则给与较高的利润率水平，逐步取消医院对药品的加成率。</p><p style="text-indent:28px;font-size:14px;">这次意见的出台对医药行业整体来说是中性偏空的，意味着2010年新一轮的价格调整即将来临，而医院药品加价率的取消也会减少医生开处方的积极性，影响药品在医院渠道的销售。</p></div></span>', 'gwm', 0, 16);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(117, '“我是治疗肺病 为何医院查梅毒”', '', '', '', '2009-11-26 12:47:59', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;"><p><img src="http://www.cqwb.com.cn/cqwb/res/1/20091126/30651259172435619.jpg" /></p><p>“明明是肺上得了毛病，可医院却要检查我是否有梅毒、乙肝，真弄不明白。”昨天，面对医院的费用汇总清单，市民黄女士表示“完全无法理解”。</p><p>　　黄女士今年56岁。黄女士介绍，最近一个多月，她咳嗽不止，当地社区卫生服务中心初步诊断是肺炎，建议她到专科医院治疗。本月20日，她来到市公共卫生医疗救治中心住院。入院第一天，就预交了2000元治疗费用，随后做了抽血、尿检等几项检查。</p><p>　　第三天，她接到了医院的欠费通知。“才住了两天医院，2000元钱就花完了？”她调出费用清单查看，竟发现检查项目多达66项！</p><p>　　更让黄女士无法理解的是，药费单上还有三项“莫名其妙”的检查：梅毒螺旋体特异抗体测定40元、丙型肝炎抗体测定20元、乙型肝炎表面抗原测定4元。</p><p>　　“明明是检查的是肺上的毛病，为什么还要查梅毒、肝病呢？况且现在都这把年纪了，还查这个（梅毒），真是羞死个人。”黄女士说，她参加了城市合作医疗保险，“现在清单上居然有梅毒检查，让别人看了会怎么想。”&nbsp;</p><p>　　黄女士的丈夫陈先生表示，院方没有告知他的妻子做什么检查项目，他们也没有要求做梅毒、乙肝检查，为此要求医院给个说法。</p><p>　　市公共卫生医疗救治中心医务科刘科长解释，医生拍片发现，黄女士的肺上不但有炎症，还有空洞出现，有手术、输血的可能，按照相关规定，须做输血前检查，其中就包括梅毒、乙肝病毒等项目。刘科长说，“可能是医务人员沟通未到位，才造成了患者的误会。”</p><p>　　市卫生局医政处工作人员表示，医生可以根据具体病症情况决定需要检查的项目，但应该事先告之患者。重庆经博律师事务所律师连毅认为，医院在未征得患者同意的情况下进行梅毒等项目的检查，明显侵犯了消费者的知情权。</p><p>　　记者&nbsp;程洪川</p><p>　　我们身边的“过度医疗”</p><p>　　一般认为，超出需求的医疗服务，可以视为“过度医疗”。“过度医疗”主要发生在检查、治疗、开药三个环节。</p><p>　　1过度检查</p><p>　　哈尔滨一女童到杭州某医院做“阑尾割除”手术。而医院出具的药价清单让孩子父母吓了一大跳：女童所做的化验包括甲肝、乙肝、丙肝、丁肝、戊肝系列检查，还有lg全套检查，尿常规、粪便常规、凝血谱分析全套检查、生化全套检查等，总计104项。更加不可思议的是，术后还做了艾滋病检测。</p><p>　　2过度治疗</p><p>　　2005年6月，安徽阜阳的打工妹叶雨林与丈夫到号称“送子医院”的上海长江医院检查治疗，医院诊断是输精管堵塞。夫妻俩四处借钱接受治疗，前后花去3.7万元治疗费。7月，离开长江医院近30天的叶雨林因呕吐不止，到上海崇明庙镇人民医院检查，却发现自己已经怀孕66天了。这意味着，去长江医院之前叶雨林就怀孕了！</p><p>　　3过度用药　　</p><p>　　2005年6月，74岁的翁文辉因恶性淋巴瘤并发症被送进哈尔滨医科大学第二附属医院的心外科重症监护室。在67天住院时间里，他的家人向医院缴纳了139.7万多元医药费，加上医生建议的自购药，总支出超过500万元。尽管如此，老人还是撒手人寰。</p></span>', 'gwm', 0, 20),
(118, '1顿木炭火锅吃倒7人　一患者不治身亡（图）', '', '', '', '2009-11-27 10:57:39', '116.228.141.77', '<span style="color:#262626;font-family:宋体, arial, helvetica, sans-serif;font-size:14px;"><div>入冬后，热热闹闹吃火锅成为不少人聚会用餐的首选。25日，石市7人吃炭火锅时不慎一氧化碳中毒，其中一人不治身亡。根据医院的统计，进入11月份，一氧化碳中毒患者猛增，石家庄进入了一氧化碳中毒病情的高发期。</div><p align="center"><img alt="" src="http://www.yzdsb.com.cn/pic/0/10/10/97/10109740_829285.jpg" /></p><p align="center">煤气中毒患者骤增，治疗室忙了</p><div><strong>　　一顿涮锅吃倒7个人</strong></div><div><strong></strong>&nbsp;</div><div><strong></strong></div><div><strong>　　</strong>&nbsp;25日19时左右，7位患者被送到石家庄市中心医院急诊室。经血液诊断证明，患者均一氧化碳中毒。患者家属对于事发过程缄默不言。据了解，一家木炭火锅店新开张，中毒者中午13时左右开始用餐，持续时间较长。</div><p>　　其中，一位60多岁的女性中毒最重，经120现场急救和医院1小时的抢救后，终因中毒过深抢救无效死亡。另有一位重度患者一直处于昏迷状态，一患者较轻。其余几人则出现不同程度的头晕、恶心、呕吐、抽搐等症状。</p><p>　　昨日下午，除一人中毒症状较轻出院外，其他5人仍在医院接受治疗。</p><p>　　昨日14时左右，在医院脑卒中科、神经内科，建通派出所民警分别向患者问话。之后，几位患者被送到高压氧舱治疗。</p><div><strong>　　11月起进入煤气中毒高发期</strong></div><div>&nbsp;</div><div><strong>　　</strong>据医生介绍，半个月来，这已是该院接诊的第二个一氧化碳中毒死亡病例了。</div><p>　　不久前，一个儿童也因一氧化碳中毒不治身亡。据该院急救科接诊记录显示，自11月1日至11月26日，已经接诊39位一氧化碳中毒患者，而10月份接到的患者不超过10例。</p><p>　　“这个时间正是一氧化碳中毒的高发期。”医生说，该院是石家庄市少数具备高压氧舱的医院，进入11月份，因接诊一氧化碳中毒患者增加，医院高压氧舱的利用率颇高。</p><p>　　“往年也有吃炭火锅导致一氧化碳中毒的病例，但像这样7人同时中毒的事件还是比较少。”该院急救科医生介绍说，据粗略统计，烧蜂窝煤取暖成为一氧化碳中毒的主要原因，其次是用燃气热水器洗澡，之后就是吃炭火锅。-摄／本报记者刘刚</p><div><strong>　　防一氧化碳中毒切记通风</strong></div><p>　　据医生介绍，此次7人食用炭火锅一氧化碳中毒的原因，可能是因为炭锅长时间燃烧耗氧，加之室内通风不畅，造成室内缺氧。</p><p>　　在密闭居室中使用煤炉取暖、做饭，由于通风不良，供氧不充分，可产生大量一氧化碳，这是引发一氧化碳中毒的重要原因。</p><p>　　&nbsp;因此，石市中心医院急诊科医生提醒大家：</p><p>　　1、燃蜂窝煤取暖时，一定要保证炉灶排气通畅，并最好使用向下的烟囱，防止烟气倒灌。2、洗浴时最好能够在门窗处留出适当通风的空间，而直排式热水器存在严重安全隐患，不符合国家有关规定，应尽快更换。</p><p>　　3、使用燃气具洗浴或食用炭火锅时，尽量不要时间过长。</p><p>　　&nbsp;一旦发现有人煤气中毒，应尽快让伤者离开中毒环境，并立即打开门窗，流通空气，并让患者安静休息，避免活动后加重心、肺负担及增加氧的消耗量，充分给以氧气吸入，同时注意保暖。如遇呼吸心跳停止，立即进行人工呼吸和心脏按压，并呼叫120急救服务，待病情稳定后，将病人护送到医院进一步进行高压氧舱等检查治疗。（记者刘刚 陈雪）</p></span>', 'gwm', 0, 19),
(119, '世卫组织说美英近日报告的甲型流感耐药性病例有免疫系统缺陷', '', '', '', '2009-11-27 11:00:09', '116.228.141.77', '<div>新华网日内瓦１１月２６日电（记者 刘国远）世界卫生组织助理总干事福田敬二２６日说，美国和英国近日出现的甲型Ｈ１Ｎ１流感耐药性病例均为免疫系统严重受损者，这表明甲型流感病毒在这部分人群体内易产生抗药性，因此医生在治疗这类病人时需特别注意。</div><div><br /></div><div>&nbsp;&nbsp; &nbsp;福田敬二是世卫组织大流行性流感特别顾问。他在当</div><div><br /></div><div>天举行的电话记者会上说，上周英国相关部门在５位住院患者身上发现了对“达菲”具有耐药性的甲型Ｈ１Ｎ１流感病毒，而美国也在４名住院患者身上发现了耐药性甲型流感病毒，这两批病例均为免疫系统严重受损者。</div><div><br /></div><div>&nbsp;&nbsp; &nbsp;福田说，此前发现的大部分耐药性病例都与患者在发病前先服用“达菲”进行预防有关，而新近发现的这两批病例却是在治疗过程中形成耐药性的，因此不同寻常。不过这也突出地表明，甲型流感病毒在免疫系统严重受损的患者体内容易产生耐药性，因此今后在对这部分人群进行治疗时需特别注意用药方式及其对药物的反应情况。</div><div><br /></div><div>&nbsp;&nbsp; &nbsp;至于上述两批病例的出现是否意味着甲型Ｈ１Ｎ１流感病毒的流行病学特征发生了变化，福田说，目前世卫组织尚不能给出确定答案。不过，就现有的调查情况来看，病毒本身应该没有发生重要变化。他同时强调了对新发现的病毒耐药性情况进行进一步调查和研究的必要性。</div><div><br /></div><div>&nbsp;&nbsp; &nbsp;福田同时重申，上述耐药性病例的出现并不能说明“达菲”等抗病毒药物对甲型Ｈ１Ｎ１流感的疗效下降。只要及时、正确地用药，这些药物仍可有效防止重症病例的出现。</div>', 'gwm', 0, 18),
(120, '甲流病毒引起脑部感染 多名患儿神经系统病变', '', '', '', '2009-11-30 09:55:59', '116.228.141.77', '<div>甲流病毒会引起脑部感染</div><div><br /></div><div>　　深圳已出现8例脑白质病变病例</div><div><br /></div><div>　　提醒家长，要高度注意孩子“头痛伴随呕吐或抽搐”</div><div><br /></div><div>　　11岁的小袁、9岁的小唐和7岁的小杨，深圳市最危重的3例甲流重症病例，昨日上午，被诊断为脑死亡的小袁已经不幸离世了，小唐被基本诊断脑死亡，小杨接近脑死亡状态，他们都是因为感染甲流病毒导致神经系统出现病变。</div><div><br /></div><div>　　市儿童医院院长李成荣介绍，来就诊的甲流患儿中已有8例出现了属于神经系统病变的脑白质病变。甲流病毒会引起脑部感染或者病变，目前这个情况仅在深圳、东莞、广州三地发生，是否为本地区的特性，目前仍然有待专家的进一步论证。“一开始，我们认为这是重症病毒性脑炎，但后来经研究发现这是甲流病毒引起脑白质病变，引起中枢神经细胞的髓鞘损害。”李成荣说。</div><div><br /></div><div>　　甲流病毒频繁袭脑的原因，专家组仍在研究。不过专家都有一个统一的意见：越早发现这一倾向，治疗效果越好。</div><div><br /></div><div>　　病例实录</div><div><br /></div><div>　　小袁病例</div><div><br /></div><div>　　但小袁、小唐和小杨的病例都恰好是没有发现早期症状，延误了最佳治疗时机，造成了严重的后果。记者在采访中了解到，11岁的小袁平时身体健康，1.53米的他已经有50多公斤重。11月15日傍晚6时多，小袁告诉父亲袁国强，自己下午开始咳嗽、喉咙痛、浑身没劲。后家人带他去社康中心就诊，医生给小袁打了肌注退烧针，开了点药。16日上午，小袁高烧未退，袁国强再次带儿子到社康中心输液。中午时分，小袁突然喊饿，当袁国强买完包子回来时，小袁竟然突然大笑起来，袁国强说，从没见过儿子这样的表情。在转院的救护车上，小袁一直嘟嘟囔囔地说胡话。袁国强现在回想起来，认为这就是病毒入侵了脑部的表现。他一直责怪自己没有留意到孩子的这个变化。</div><div><br /></div><div>　　小唐病例</div><div><br /></div><div>　　家住平湖的小唐，11月19日发高烧达38.5摄氏度，父亲带孩子到附近一家小诊所打针后，还将儿子送回学校上学。父亲认为，儿子从小就爱生病，易感冒，平时都是在这个诊所开药、打针，很快就好了，也就没有在意。小唐连续上了两天学，甚至还上了体育课。11月20日放学回家，母亲发现小唐还在发烧，又带他到小诊所打针。打针当中，孩子开始喊、发生抽搐，于是医生拔掉了针管。</div><div><br /></div><div>　　小唐又说想睡觉，父母带其回家休息。直到21日2时，孩子喝了一碗水后说要上厕所，结果却没拉出来。半个小时后，他又说要拉，父母发现他已经拉了一点在床上。凌晨4时，小唐还没退烧，这时父母才发现他已经昏迷了。小唐随后入院被确诊为甲流。</div><div><br /></div><div>　　小杨病例</div><div><br /></div><div>　　而小杨的病情和前两位小哥哥相似，都是已经发生了抽搐、昏迷才被送入医院，情况非常危急。主治医生表示，目前小杨处于深度昏迷中，自主呼吸很弱，基本处于命悬一线的状态。</div><div><div>专家提醒</div><div><br /></div><div>　　家长要高度注意孩子“头痛伴随呕吐或抽搐 ”</div><div><br /></div><div>　　深圳市儿童医院院长李成荣提醒家长，如果孩子出现了惊厥、昏迷才送往医院，此时脑部病变已经非常严重了，延误了最佳治疗时机。家长要高度重视“头痛伴随呕吐或抽搐 ”的青少年患者。</div><div><br /></div><div>　　李成荣说，第一，要留意孩子的精神症状，如果孩子出现反应迟钝、说话不连贯，还有性格大变，就要引起重视。他说，“曾经有个活泼的孩子突然变得不爱说话，父母问了他一遍又一遍，他竟然大哭了起来，后来这个孩子也被确诊为甲流引起的脑白质病变。”还有就是一些神经症状，例如小孩突然烦躁、莫名其妙大笑、胡闹或嗜睡等，都是属于神经系统病变的脑白质病变的早期表现。</div><div><br /></div></div>', 'gwm', 0, 13),
(121, '甘肃省累计治疗157名艾滋病病人 疫情仍呈上升趋势', '', '', '', '2009-12-01 09:17:53', '116.228.141.77', '<span style="color:#006699;font-family:宋体;font-size:13px;"><p><span style="color:#000000;">新华网甘肃频道消息 11月30日下午，在省政府新闻办召开的新闻发布会上记者获悉，目前，我省已累计为157名艾滋病病人开展了国家免费抗病毒药物治疗，治疗后，绝大多数病人临床症状得以改善，能准确反映人体免疫力状况的CD4T淋巴细胞数均有回升。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;据介绍，CD4T淋巴细胞是人类主要的免疫调节细胞，也是艾滋病病毒攻击的主要对象。人体感染了艾滋病病毒后，主要症状就是免疫系统遭到破坏，CD4T淋巴细胞大量丢失。从2005年1月开始，我省全面启动了对艾滋病病人的抗病毒治疗。通过监测艾滋病病人的CD4T淋巴细胞数量，科学合理地给予抗病毒药物治疗，取得了很好的疗效，大大提高了艾滋病病人的生活质量，减少了有可能发生的多种并发症。截至今年10月底，全省共有205名艾滋病感染者和病人得到随访、免费咨询和检测，有157人获得免费的抗艾滋病治疗药物，有75名艾滋病病人获得家庭病床治疗。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;与此同时，我省各级政府和相关部门积极落实国家“四免一关怀”政策，各级领导多次看望慰问艾滋病感染者和患者，积极参加全省防治艾滋病的宣传活动，各级相关部门积极落实对感染者和病人的关怀救助政策，部分病人还被纳入低保和救助范围，并开展了生产自救活动。（记者 宜秀萍）</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;本报兰州11月30日讯(记者 宜秀萍)省政府新闻办今天下午召开的新闻发布会上，省卫生厅有关负责人通报了我省艾滋病流行现状及防治工作情况。通报称，我省艾滋病疫情在全国处于低流行地区，但疫情仍呈上升趋势，正从高危人群向一般人群传播，防治工作处于关键时期。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;通报称，全省艾滋病监测数据显示，截至2009年10月31日，累计报告HIV感染者904例，其中艾滋病病人287例，死亡144例。今年前10个月新发现HIV感染者222例，其中艾滋病病人87例，死亡31例，与去年同期相比增加了39.38%。目前，性传播已成为我省艾滋病主要传播途径。在今年新发现的HIV感染者中，血液传播占28.83%，其中静注毒品占18.47%，既往受(供)血占8.56%，其他占1.80%；性途径传播占41.89%，其中异性性传播占25.23%，同性传播占16.67%；传播途径不详占29.28%，专家估计主要以性传播为主；无母婴传播。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;从地区分布来看，全省14个市州、79个县市区均有感染者报告，其中兰州、天水和临夏3市州感染者人数占全省总数的66.26%。具体分布为:兰州市352例，天水市150例，临夏州97例，平凉市44例，陇南市37例，酒泉市36例，庆阳市33例，白银市32例，武威市29例，定西市27例，金昌市21例，张掖市17例，嘉峪关市10例，甘南州9例。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;我省累计发现的及今年前10个月新发现的HIV感染者和艾滋病病人中，20岁-49岁的青壮年占到80%以上，在这些感染者中，一半以上为农民、农民工和无业人员，文化程度为文盲、小学和初中文化。</span></p><p><span style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;从性别构成来看，累计发现的HIV感染者男性685例，女性219例，男女性别比为3.13:1；艾滋病病人男性200例，女性87例，男女性别比为2.30:1。</span></p></span>', 'gwm', 0, 19),
(122, '天津艾滋病感染者告白：不要因一时放纵毁了自己', '', '', '', '2009-12-01 09:23:52', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;"><p>&nbsp;<strong>新华网11月30日</strong>：“遏制艾滋病，履行承诺——权益、责任、落实。”2009年12月1日，第22个世界艾滋病日的主题。</p><p>&nbsp;&nbsp;&nbsp; 每年的这个时候，我们都会从官方得到新一年艾滋病的发展趋势，今年的天津市艾滋病疫情介绍中指出，总体上仍呈低流行趋势，但近几年艾滋病病毒感染者和发病人数呈增长趋势。</p><p>&nbsp;&nbsp;&nbsp; “虽然数字在增长，但并不代表它越来越可怕。”天津市疾病预防控制中心性病艾滋病预防控制所程绍辉博士介绍，以前不知道不代表没有，只是没有发现，近几年，医疗、疾控部门在基于多部门合作的机制下，加强了艾滋病的筛查力度，鼓励更多人勇敢地检测，勇敢地面对艾滋病。</p><p>&nbsp;&nbsp;&nbsp; 发现了才能面对，普及艾滋病筛查的可及性、加强宣传艾滋病知识尤为重要。</p><p>&nbsp;&nbsp;&nbsp;<strong>&nbsp;感染数字在增长</strong></p><p>&nbsp;&nbsp;&nbsp; 几天前，第五届中国艾滋病防治国际合作项目经验交流会上，国家卫生部部长陈竺指出，特定人群和部分重点地区已经出现艾滋病高流行态势，疫情正在从高危人群向一般人群扩散。</p><p>&nbsp;&nbsp;&nbsp; 据陈竺部长介绍，截至2009年10月31日，全国累计报告艾滋病感染者和病人319877例，其中艾滋病病人102323 例；死亡49845例。卫生部与联合国艾滋病规划署和世界卫生组织对中国2009年艾滋病疫情的联合评估结果显示，截至2009年底，估计中国目前存活艾滋病感染者和病人约74万人，其中，艾滋病病人为10.5万人；估计2009年当年新发艾滋病感染者4.8万人。</p><p>&nbsp;&nbsp;&nbsp; “今年艾滋病疫情总体上仍呈低流行趋势，但近几年艾滋病病毒感染者和发病人数呈增长趋势。”天津市疾病预防控制中心性病艾滋病预防控制所程绍辉博士介绍，今年病例较去年同期增长50例，增长26%。从发病年龄来看，以青壮年为主，20—50岁的感染者所占比例接近感染者总数的90%。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;<strong>同性传播比例高</strong></p><p>&nbsp;&nbsp;&nbsp; “从感染途径上来看，性传播感染病例构成比持续增大，其中性传播中同性传播占有较高的比例。”程博士介绍，这也与本市近两年加大在该类人群中的检测力度有关，相关调查显示这些人很多有合法的配偶，提示本市艾滋病的传播有可能从特殊人群向一般人群扩散。</p><p>&nbsp;&nbsp;&nbsp; 程博士介绍，今年和明年艾滋病的防控方向更将向“同志”人群的宣传和干预工作倾斜。“了解到同性传播的增长趋势，今后将在同性恋人群的筛查项目和干预投入更多资金和精力，并加强宣传力度。”程博士介绍，对同性传播的防控是今后艾滋病防控工作的重点之一。&nbsp;<br />&nbsp;防控艾滋新模式</p><p>&nbsp;&nbsp;&nbsp; 在多部门合作的协调机制下，加强与非政府组织的合作，发展“同志”人群中艾滋病宣传志愿者，是</p><p>&nbsp;&nbsp;&nbsp; 目前在同性恋人群中开展宣传干预的主要手段。</p><p>&nbsp;&nbsp;&nbsp; “这些志愿者大部分来自同性恋人群自身，他们之间更有认知度，彼此更加信任，也很愿意成为宣传艾滋病知识、帮助其他感染者的‘艾心大使’。”</p><p>&nbsp;&nbsp;&nbsp; 程博士解释，天津市的几个艾滋病防治非政府组织与政府的合作非常好，卫生部门深入草根组织内部，发展草根组织的防控艾滋病宣传点。</p><p>&nbsp;&nbsp;&nbsp; 本市河北区、塘沽区、东丽区、津南区被确定为全国艾滋病综合防治示范区。示范区工作的开展为今后更好发挥其艾滋病防治工作的示范作用、推广工作经验、探索解决防治工作中的重点难点问题奠定了基础。</p><p>　　<strong>好好走剩下的路</strong></p><p>&nbsp;&nbsp;&nbsp; 刚被检测出感染了艾滋病，小罗的脑袋一片空白，整日待在租的小房子里，不吃不喝，几乎绝望了。</p><p>&nbsp;&nbsp;&nbsp; “天气冷了，多穿衣服，最近还好吗。”小罗打开手机，里面是彩虹互助组的成员们发给他的短信。</p><p>&nbsp;&nbsp;&nbsp; “看到这短信，我大哭了一场，一下子发泄了出来。”小罗说，就是这条短信把他拉了回来，他来到彩虹互助组，其他的艾滋病感染者给了他家人一样的温暖。“我们同病相怜，大家能互相安慰。”</p><p>&nbsp;&nbsp;&nbsp; 了解到艾滋病现在已被定义为慢性病，可以通过药物延缓发病的时间，小罗又有了信心。</p><p>&nbsp;&nbsp;&nbsp; 更重要的是，小罗开始审视自己的人生，认识到以前的种种错误。他把工作辞了，不再和社会上的朋友联系，怕传染给其他同学不敢回宿舍，也没有了任何收入，彩虹互助组收留了他。</p><p>&nbsp;&nbsp;&nbsp; “我要珍惜每一天了，不能荒废下去，做点有意义的事吧。”小罗白天上学，放了学就回到互助组，帮助大家做点力所能及的事，也学着开导其他感染者，他有新的计划，今年大专毕业后，他要继续接本科，好好走自己剩下的路。</p><p>&nbsp;&nbsp;&nbsp; 自愿直面媒体的大学生艾滋病感染者</p><p>&nbsp;&nbsp;&nbsp;&nbsp;<strong>叛逆让艾滋乘虚而入</strong></p><p><strong>&nbsp;&nbsp;&nbsp; 勇敢告白</strong></p><p>&nbsp;&nbsp;&nbsp; 中午吃饭的时间，彩虹互助组的成员围坐在一起，边吃边聊，他们大多都是艾滋病感染者。</p><p>&nbsp;&nbsp;&nbsp; 小罗端着饭静静地坐在一边，看见谁吃完了，小罗马上走过去，帮对方收拾碗筷。</p><p>&nbsp;&nbsp;&nbsp; “他很谨慎，有种寄人篱下的感觉。”鹏鹏在一旁观察着小罗的一举一动，话语间有丝疼惜。从鹏鹏的讲述中，记者了解到，小罗10月底刚刚被检测出感染了艾滋病。</p><p>&nbsp;&nbsp;&nbsp; 如今的小罗确实一无所有了，不敢回家，不敢回宿舍，没有了工作，无处可去。几天前，彩虹互助组收留了他，让他有了一个栖身之处。</p><p>&nbsp;&nbsp;&nbsp; 眼前的小罗很瘦，文文静静的，有如女孩般的羞涩，他似乎想用行动回报互助组的帮助，忙碌着为大家端茶倒水。</p><p>&nbsp;&nbsp;&nbsp; 事先没得到采访他的许可，也怕刺激他脆弱的心，记者并没有采访他的计划，但没想到，就在采访的间歇时间里，小罗竟然走上前来。</p><p>&nbsp;&nbsp;&nbsp; “姐姐，能不能通过报纸告诉和我同龄的年轻人，千万不要因一时的放纵毁了自己。”小罗的声音不大，但非常坚定。</p></span>', 'gwm', 0, 12),
(123, '新华时评：为两亿农民工筑起“艾滋病防线”', '', '', '', '2009-12-01 09:26:44', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>新华社重庆１１月３０日电（记者 梁宇广 茆琛）今年１２月１日是第２２个世界艾滋病日。来自广西、云南等地的统计数据显示，农民工正成为受艾滋病危害的群体。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;当前，我国农民工数量已超过２亿人。政府、社会应在农民工这一特殊群体中加快普及艾滋病预防知识，加大免费筛查等服务工作，加强农民工群体的道德自律意识，为农民工兄弟筑起“艾滋病防线”。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;在广西，农民工成为艾滋病感染者的特殊群体；在甘肃，今年１月至１０月发现的ＨＩＶ感染者中，农民、农民工和无业人群占总人数的５５．４１％。收入偏低，流动性强，防艾知识贫乏，体检、医疗保险等权利难以保障等，制约着农民工群体的艾滋病预防工作。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;指导、帮助农民工预防艾滋病，首先要在农民工群体中广泛、深入普及防艾知识，切勿“一阵风”、“走过场”。在以往的农民工防艾工作中，不乏“艾滋病日”、“农民工日”到工地发放避孕工具，宣传册的“送温暖”活动，但特定时间一过，即鲜见关心农民工健康的活动；还有不少地方尝试在民工学校开设“防艾”知识课，但稍遇经费不足、听众乏人的阻力，即止步不前。艾滋病的宣传教育是现有的最有效疫苗，是遏制艾滋病最有效的途径，向农民工普及预防艾滋病知识，需要注重宣传，更需要注重宣传效果，而宣传工作也应制度化、规范化。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;指导、帮助农民工预防艾滋病，应适当增加对农民工的防艾免费服务。农民工收入偏低，“小病能忍则忍，大病舍不得吃药”是他们的生活常态。在不清楚艾滋病感染者的初期症状等基本尝试情况下，农民工群体的体检和艾滋病自我筛查并不现实。因此，急需政府、社会加大投入，对农民工群体进行免费的筛查和体检。在条件具备的情况下，城市政府可考虑通过为农民工提供“廉租”或免费住房，使常年分居的农民工夫妻能够有相聚的机会。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;还应从关爱农民工的角度，加强对农民工的道德教育，引导他们了解防控的社会责任。道德面前人人平等，人人都负有社会责任。对于每一个公民而言，在预防艾滋病方面，最简单而又最有效的做法就是洁身自好，一是慎重处理好性行为，二是坚决远离毒品。</p></span>', 'gwm', 0, 14),
(124, '广电总局要求《蜗居》删除涉乙肝台词', '', '', '', '2009-12-02 09:00:28', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p align="center"><img alt="《蜗居》台词：不洗手" src="http://img1.gtimg.com/news/pics/24790/24790819.jpg" /></p><p align="center" style="font-size:10pt;font-family:宋体;">《蜗居》台词：不洗手</p><p align="center"><img alt="《蜗居》台词：回头得乙肝" src="http://img1.gtimg.com/news/pics/24790/24790821.jpg" /></p><p align="center" style="font-size:10pt;font-family:宋体;">《蜗居》台词：回头得乙肝</p><p align="center"><img alt="《蜗居》台词：找工作都没人要" src="http://img1.gtimg.com/news/pics/24790/24790823.jpg" /></p><p align="center" style="font-size:10pt;font-family:宋体;">《蜗居》台词：找工作都没人要(图片来源：正义网)</p><p style="text-indent:2em;">本报天津12月1日电（记者张国）书面投诉电视剧《蜗居》涉嫌歧视乙肝病毒携带者的年轻网民“静心才情”（中国青年报11月28日报道），得到了行业主管部门的答复。今天上午，国家广播电影电视总局工作人员致电告知他，广电总局已要求《蜗居》制作方删除涉及乙肝的台词。</p><p style="text-indent:2em;">被要求删除的台词出现在《蜗居》第一集，主角郭海萍称“不洗手，回头得乙肝，找工作都没人要”。“静心才情”认为此语违背科学常识，极易误导观众，含有歧视色彩，恶化了乙肝患者及乙肝病毒携带者的处境。11月25日，他援引多部法律规章，向官方寄出投诉信。</p><p style="text-indent:2em;">广电总局工作人员答复这位观众：经过认真研究，我们认为这句台词确实不妥。尽管制作方解释说，那仅仅是剧中角色的陈述，制作方主观上没有对乙肝的歧视，但这样的台词确实容易带来误解。特别是前些天有关部门已经宣布不应搞乙肝歧视，这样的台词就更不应该出现。所以我们已经要求制作方把这句台词删掉，以后这部电视剧里就不会再有这句台词了。</p><p style="text-indent:2em;">中国青年报记者从广电总局电视剧管理司证实了此事。据介绍，电视剧管理司今天收到投诉函，当天就给出了答复。</p><p style="text-indent:2em;">广电总局的答复之快，出乎投诉者的预料。“静心才情”告诉记者，自己对广电总局的办事效率及处理结果“非常满意”。</p><p style="text-indent:2em;">除删除争议台词之外，“静心才情”希望《蜗居》制作方能够公开道歉，尽管他并未与对方取得联系。投诉《蜗居》之后，他联合一些支持者成立了一个科普维权小组，宣传防控肝炎的科学知识。</p><p style="text-indent:2em;">今天，他还以“渴望早日消除乙肝歧视的中国公民”身份，向卫生部、人力资源和社会保障部寄出信件，希望卫生部向民众澄清，“不洗手，回头得乙肝”的说法是否正确。他也希望人力资源和社会保障部说明，乙肝病毒携带者“找工作没人要”是否合法。</p><p style="text-indent:2em;">乙肝病毒携带者针对《蜗居》的投诉引起了争议。11月29日，在中国政法大学宪政研究所主办的“反就业歧视媒体培训班”上，“静心才情”的做法成了专家与记者们热议的案例。中国政法大学副教授刘小楠认为，《蜗居》这句台词，前一半“不洗手，回头得乙肝”，传播了一种错误的观念，而后半句“找工作都没人要”则是对现实生活中乙肝歧视的辛酸描述。</p><p style="text-indent:2em;">北京外国语大学国际新闻与传播系教授展江一方面认为《蜗居》属于文艺作品，人们不应强求编剧具备所有方面的知识。另一方面又对“静心才情”的投诉之举表示理解，“通过文明的方式来做，哪怕是剑走偏锋，还是值得尊重”。</p><p style="text-indent:2em;">由于担心遭遇歧视，“静心才情”始终不敢以真实姓名示人。很多人支持他的“较真”，也有人指责他过于“敏感”。广电总局工作人员则对他说：“感谢你对我们的信任和对我们工作的支持。”(中青在线－中国青年报)</p></span>', 'gwm', 0, 14),
(125, '甲流疫苗生产原理和过程', '', '', '', '2009-12-03 11:08:20', '116.228.141.77', '<p style="text-indent:24.0pt;"><span><span style="font-size:10.5pt;color:black;">用通俗的比喻来说流感疫苗就像月饼，每年制作工艺相同，今年只是馅不同，用了新毒株，疫苗其实是用毒株残破的肢体制成的。<span></span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span><span style="font-size:10.5pt;color:black;">甲流疫苗原理：甲型<span>H1N1</span>病毒（病毒身上突出的那两种触角<span>H1</span>、<span>N1</span>，能引起人体免疫系统的攻击，这是疫苗原理基本前提。）→灭活和裂解（人们先让病毒失去活性，再将它分裂成许多碎片，这样病毒就无法攻击人类。）→制成疫苗（人们再将<span>H1</span>和<span>N1</span>以及其他蛋白质收集起来，构成疫苗，注入人体后，免疫系统便能识别该种病毒了。<span></span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span style="font-size:10.5pt;color:black;"><a href="http://news.qq.com/zt/2009/zlg/" target="_blank"><span lang="EN-US" style="color:black;text-decoration:none;\r\ntext-underline:none"><span>甲型H1N1</span></span><span style="color:black;text-decoration:none;"><span>流感</span></span></a></span><span style="font-size:10.5pt;color:black;">病毒就像是个球，球上布满触角，它们是血凝素蛋白质<span>(H1)</span>神经氨酸酶<span>(N1)</span>。而这些<span>H1</span>和<span>N1</span>蛋白质是会引起人体免疫系统攻击的，所以我们称它们为抗原。<span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span style="font-size:10.5pt;\r\ncolor:black">制作疫苗，就是先将病毒杀死，将它分裂，再收集起那些触角<span>H1</span>和<span>N1</span>，也包括一些其他无害的蛋白质，这就构成疫苗的主要组成部分。<span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span style="font-size:10.5pt;\r\ncolor:black">当这些无害的触角<span>H1</span>和<span>N1</span>注射到人们体内，免疫系统便会发起攻击，将它们吞噬。从此以后，人体开始认识这一新病毒。当真正的病毒侵入人体后，就会很快被人体消灭。<span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span><span style="font-size:10.5pt;color:black;">这种工艺已用了四五十年，用这种工艺制造的流感疫苗已经接种了几亿人。流感病毒年年变，所以流感疫苗每年都要重新做，有时用甲型<span>H2N2</span>，有时用甲型<span>H3N2</span>，而这次用的是新甲型<span>H1N1</span>。<span></span></span></span></p>\r\n\r\n<p style="text-indent:24.0pt;"><span><span style="font-size:10.5pt;color:black;">打个比喻，疫苗像月饼，制作工艺早就设计好，只不过今年做的月饼馅不同。所以，疫苗制作工艺应该没太大问题，不是个完全创新的东西。<span></span></span></span></p>', 'gwm', 0, 18),
(126, '部分地区干辣椒涨至42元/公斤 传可防甲流', '', '', '', '2009-12-03 11:11:15', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p align="center"><img alt="部分地区干辣椒涨至42元/公斤 传可防甲流" src="http://img1.gtimg.com/news/pics/24865/24865785.jpg" /></p><p align="center"><span style="font-size:12px;">11月份，江西婺源的农民在收辣椒。</span></p><p style="text-indent:2em;">继大蒜价格疯涨之后，昨日国内部分地区干辣椒每公斤价格与去年同期相比从7元涨到42元，在广州罗冲围批发市场，来自四川、湖南等地的干辣椒价格也上涨了2至3倍。商家反映辣椒今年产量不高，很难拿到货。不过有批发市场人士透露，近期辣椒价格上涨属于恢复性上涨，价格上涨如此之高与<a class="a-tips-Article-QQ" target="_blank" href="http://news.qq.com/zt/2009/zlg/">甲流</a>因素导致辣椒采购量加大以及人为炒作有关。</p><p style="text-indent:2em;">“去年7元/公斤的湖南干辣椒，昨日在广州市场上的批发价最贵能卖到42元/公斤，而且价格还要上涨。”昨日，来自湖北的张女士在罗冲围某副食品批发市场采购作料时，被湖南的干辣椒的价格吓了一跳。</p><p style="text-indent:2em;">记者昨日在东川新街市看到，指天椒价格已涨到20元/斤，而10天前价格为15元，涨幅超过30%。不过，其他辣椒价格稳定，如尖椒3元/斤，灯笼椒3.5元/斤，彩椒从4.5元/斤涨到5元/斤。</p><p style="text-indent:2em;">记者昨日来到罗冲围一带的新粮油、东旺等副食品批发市场。湖南某贸易公司的总经理许先生说，“以前各地农家催着我收货，现在是我要求他们给点货，广州冬天打边炉的店很旺，销量正出现井喷。”为了扩展货源，许先生以“广州辣王”的名义，在中国辣椒网发帖求购新青辣椒30吨。</p><p style="text-indent:2em;"><strong>影响：川湘菜馆暂不涨价</strong></p><p style="text-indent:2em;">在广州，辣椒价格大幅上涨，影响最大的是川菜馆和湘菜馆。在广州拥有十几家分店的湘菜馆洞庭土菜馆消费的主要是指天椒，“我们一个月十几家店采购指天椒的量为100多斤。一个月前，这种辣椒才4元/斤，但昨日已涨到7元/斤，这个价格是历史新高。”</p><p style="text-indent:2em;">知名川菜馆陶然居也表示：“最近干辣椒价格贵得离谱。”据介绍，川菜馆主要消费的是干辣椒，一个月一家店的采购量就达到3吨多，一个月前这种辣椒的价格为2.9元/斤，但是这几天已涨到9元/斤，涨幅高达2倍。</p><p style="text-indent:2em;">不过，这些酒楼均表示，菜价菜牌是定期更改的，不会因为某种原材料价格上涨而上调菜价。</p><p style="text-indent:2em;"><strong>原因分析</strong></p><p style="text-indent:2em;"><strong>种植面积缩小产量普跌30%有人囤货炒作</strong></p><p style="text-indent:2em;">湖南某贸易公司的总经理许先生说，2007年和2008年的辣椒种植面积持续增加，去年最便宜的才4元/公斤。今年农民大幅度缩小辣椒面积，河南、河北等辣椒主产区的产量普遍下跌30%，产地都没有货了。</p><p style="text-indent:2em;">他说，今年的辣椒产量没有去年多，而且不排除有人恶意囤积辣椒。“炒完了大蒜之后开始炒辣椒了。最近我听到有客户说，辣椒可以制成药用辣椒精、辣椒素，不仅可以抵御甲流，还能起到杀菌的作用。客户进货的数量比平时都大，大概在一百多吨左右。”</p><p style="text-indent:2em;">在江南果菜批发市场，有商户表示，“最近有人放风，一大批大蒜炒家涌进了辣椒市场。”一位做批发生意的大户直言，“不少商家正囤积货源，待合适时机再高价出售。”（刘幸 林晓丽）</p></span>', 'gwm', 0, 14),
(127, '2011支问题疫苗入渝 反应严重者可能致命', '', '', '', '2009-12-04 11:32:51', '116.228.141.77', '<span style="font-family:arial;font-size:14px;"><p>近期打了狂犬病疫苗的市民，如果有不适，请立即就医</p><p>　　华龙网讯 （记者 曹嘉智 罗小光）最近打过狂犬病疫苗的市民要注意了，国家食药监局昨天发布信息称，江苏延申生物科技股份有限公司和河北福尔生物制药有限公司生产的7个批次狂犬疫苗不合格，相关部门已立案调查。</p><p>　　市食药监局有关人士透露，目前流入我市的问题疫苗至少有2011支，打了狂犬病疫苗的市民，如果有不适症状，请立即向当地疾控部门反映。</p><p>　　<strong>7批次疫苗不合格</strong></p><p>　　据了解，问题疫苗分别是：延申公司生产批号为200810F01、20080732、20080834、20080837的疫苗，福尔公司生产批号为20080753、20080758、20080754010的疫苗。此外，延申公司生产批号为20080939―3的问题疫苗，尚未上市销售。</p><p>　　目前，国家食药监局已派出调查组开展调查，河北、江苏两地食药监局已分别对两企业立案，并组织专家对问题疫苗可能造成的风险进行评估。上述两家企业已被责令停产，面临严肃查处，如涉嫌犯罪将移交公安机关追究刑责。</p><p>　　<strong>重庆流入2000余支</strong></p><p>　　“问题疫苗流向已基本查清，共有4批次至少2011支流入了我市。”昨天，重庆市食药监局有关人士透露，疫苗主要流入了我市秀山、酉阳、九龙坡、合川、潼南、綦江、梁平、云阳、铜梁、丰都、江北、开县、垫江等地。其中，仅九龙坡区疾控中心就购进1200人份问题疫苗。目前，市食药监局及市疾控部门已展开调查，对问题疫苗去向进一步核实。</p><p>　　市食药监局有关人士提醒，近期接种了狂犬病疫苗的市民，一旦出现不适症状，请立即到疾控部门或医院进行检查，及时预防。</p><p>　　<strong>卫生部门正在调查</strong></p><p>　　记者就此事向市卫生局求证。市卫生局领导回复：“正在调查中。”</p><p>　　市疾控中心办公室主任陈星表示，经查，江苏延申公司与市疾控中心签订了送货协议，却一直没有向市疾控中心供货。河北福尔公司在疫苗招标中，没有中标。因此，市疾控中心并没有问题疫苗。</p><p>　　但是，各区市县有权自行购买疫苗，只要运输途中冷藏不好，疫苗质量就难以保证。</p><p>　　随后，记者拨通了九龙坡区疾控中心电话，区疾控中心叫找区卫生局。45分钟后，区卫生局预防科回复，此事正在调查中。记者又拨通了潼南等郊县疾控中心电话，对方均回答：“不知道此事。”</p><p>　　<strong>问题疫苗可能致命</strong></p><p>　　市食药监局透露，疫苗一直是国家严格控制、定点生产的。如果这些问题疫苗中间还有活毒，简直就等于人工散毒。这对人、对家禽产生的后果不可估量，严重者甚至可能致命。</p><p>　　据悉，狂犬病是严重危害人体健康的传染病，一旦感染发作，病死率几乎是100%。因此被狗咬伤后，24小时内应该注射狂犬病疫苗。一旦注射假疫苗，对人体的危害可想而知。</p><p>　　市食药监局呼吁，市民一旦发现问题疫苗，应及时向当地疾控部门反映，也可拨打电话68810509举报。</p></span>', 'gwm', 0, 12),
(128, '大蒜预防甲流无充足科学依据 胃病患者需慎食', '', '', '', '2009-12-04 11:40:24', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;">　红网长沙12月1日讯（潇湘晨报滚动新闻<font face="Verdana">记者 刘少龙 通讯员 陶艳</font>）大蒜，因甲流变得“疯狂”起来。最近有消息称大蒜能预防甲流，于是，市民跟风抢购，大蒜价格便一路飙升。<br />　　<br />　　大蒜真能预防甲流？30日，省中医院（省中医附二）中医药专家王竹鑫教授称：目前还没有足够的证据表明大蒜有预防甲流的功效，虽然大蒜具有一定的杀菌作用，但不适宜大量食用。<br />　　<br /><strong>　　胃病患者需慎食大蒜</strong><br />　　<br />　　“从中医理论来讲，大蒜的作用是防止人体受到外邪侵犯，即防止病毒从呼吸道（口、鼻）进入，具有固表除邪、滋养脾胃的作用，在民间被广泛用于预防多种疾病，但目前还没有足够的证据表明，大蒜有预防甲流的功效。”<br />　　<br />　　王竹鑫教授说，大蒜由于含有“大蒜辣素”，对胃肠道有明显的刺激作用，不宜多吃，更不要空腹大量食用。特别是患有慢性胃炎、胃溃疡的病人，空腹或过多食用大蒜，会令胃黏膜受到损害，产生烧心、泛酸等现象，此外还易引起肠道过敏，导致拉肚子等现象发生。<br />　　<br /><strong>　　调理膳食防甲流可靠得多</strong><br />　　<br />　　其实，日常生活中有许多方法防范甲流。王竹鑫建议通过调理膳食，如食用富含高蛋白、高纤维食物及谷蔬粗粮来均衡营养，来提高机体免疫力，构筑防治甲流的坚固身体。<br />　　<br />　　例如食用鸡汤、鱼、蘑菇、贝类等，能使脏腑功能旺盛，气血充实，使机体适应自然界的应变能力增强，能抵御和防止流感病邪侵袭，即中医所谓“正气存内，邪不可干”。王竹鑫说这样既没有副作用，还可以起到药物起不到的作用。<br />　　<br />　　目前，虽然甲流病毒仍然活跃，王竹鑫认为市民也不必过分恐慌，养成良好个人卫生习惯，保证充足睡眠，勤于锻炼，避风保暖，充足营养，多喝开水，科学洗手，保持环境清洁等，尽量避免和甲流患者近距离接触，尽量少去公共场所，避免触摸眼睛、鼻子、嘴巴等部位，认真做到这些，已经足矣。</span>', 'gwm', 0, 14);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(129, '农大副院长:我国每年几百万吨地沟油进入市场', '', '', '', '2009-12-04 11:45:27', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p align="center"><span style="font-size:12px;"><img alt="农大副院长:我国每年几百万吨地沟油进入市场" src="http://img1.gtimg.com/news/pics/24925/24925760.jpg" /></span></p><p align="center"><span style="font-size:12px;">节目现场</span></p><p align="center"><span style="font-size:12px;"><img alt="农大副院长:我国每年几百万吨地沟油进入市场" src="http://img1.gtimg.com/news/pics/24925/24925758.jpg" /></span></p><p align="center"><span style="font-size:12px;">节目录制现场</span></p><p align="center"><span style="font-size:12px;"><img alt="农大副院长:我国每年几百万吨地沟油进入市场" src="http://img1.gtimg.com/news/pics/24925/24925759.jpg" /></span></p><p align="center"><span style="font-size:12px;">中国农业大学食品科学与营养工程学院副院长胡小松</span></p><p style="text-indent:2em;">CCTV-12将播出：《胡小松：每年有几百万吨的地沟油进入市场》，以下为节目内容：</p><p style="text-indent:2em;">在12月4日即将播出的CCTV-12法律服务动车行收官节目《相聚到北京》中，当讨论到食品安全的话题时，参加节目录制的中国农业大学食品科学与营养工程学院副院长胡小松在现场提到，在农村市场和城乡接合部的市场中，每年将有几百万吨的地沟油进入市场。</p><p style="text-indent:2em;"><strong>知情人现场揭露食品交易黑幕</strong></p><p style="text-indent:2em;">在CCTV-12法律服务动车行收官节目《相聚到北京》的录制现场，一位来到现场但不愿透露真实姓名的知情人现场揭露了食品的交易黑幕，为了谋取暴利，很多商人直接将一些并不能食用或者是作为煎炸食物用途的油投放到市场，知情人说道，这也是现在食品交易过程中的一条浅规则。</p><p style="text-indent:2em;">知情人在现场拿出了自己所带的三种油的样品，一种是行业内称之为毛油的油，也就是我们俗称的地沟油，它是用过期的食用油质炼制的，其实也就是过期的油；还有一种叫大油，它是从正常猪皮上，各个肉联厂、加工厂，猪皮上采下来的油，这种油的酸价高达20，是标准食用油的近几十倍；最后一种油叫白油，是用前两种油精炼而成的一种油。知情人透露，按照规定这三种油是不能投放到市场上用作食用用途的，但有很多商人却将他们直接或者掺杂一些其他油之后投放到市场中去，给食品市场造成了非常大的伤害。</p><p style="text-indent:2em;"><strong>胡小松：科学无法分辨这些油</strong></p><p style="text-indent:2em;">在CCTV-12法律服务动车行收官节目《相聚到北京》的录制现场，中国农业大学食品科学与营养工程学院副院长胡小松提到，虽然我们知道食品行业有这样的潜规则，知道有不法商人贩卖不合标准的油来谋取暴利，但我们很难分辨。“油掺油，神仙愁，神仙都很难分开它，所以地沟油大概应该已经有20年以上的历史。即便到今天的话呢，我们依然能看到不同的地区还是比较普遍的，主要在农村市场和城乡接合部的市场，同时我们也感受到它进入了大食堂，大的集体食堂。如果按吨位算的话，每年消化掉的地沟油，统称吧，应该在几百万吨。我也很惭愧，我们到现在也找不到一个很有效的技术手段来鉴别，这种油是地沟油，这种油不是地沟油。”胡小松在CCTV-12法律服务动车行收官节目《相聚到北京》的现场指出，现在我们的检测手段还没有攻克这个技术，无法科学的分辨油的好坏，但在去年国家科技部已经针对这个事情专门立项，相信不久之后一定能够用科学的手段来分辨油的好坏。</p></span>', 'gwm', 0, 14),
(130, '老人右腿骨折左腿被手术 管床医生:我是笔误(图)', '', '', '', '2009-12-07 10:29:59', '116.228.141.77', '<span style="font-family:宋体, arial, helvetica, clean, sans-serif;font-size:14px;"><p align="center" style="text-indent:28px;font-size:14px;"><img src="http://img.ifeng.com/hres/200911/30/09/a84aecead919d895eb1b66b8ee4590e4.jpg" /></p><p align="center" style="text-indent:28px;font-size:14px;">右腿骨折，左腿动刀</p><p style="text-indent:28px;font-size:14px;">中广网北京11月30日消息 据中国之声《新闻纵横》7时28分报道，湖北咸宁市通城县84岁的赵荣斌老人，不久前摔断了右腿，竟然被医院荒唐地将钢板植入到了健康的左腿里。湖北省卫生厅日前向全省卫生系统发出通报，要求从这起医疗责任事故中吸取深刻教训，引以为戒，举一反三，认真开展自查自纠。</p><p style="text-indent:28px;font-size:14px;">目前，相关部门已经对当事人员和相关责任人进行了处理，通城县卫生局局长被行政记过，县中医院院长和分管副院长被行政撤职，负有直接责任的主刀医生和管床医生被分别处以开除留用和停止执业一年的处罚。</p><p style="text-indent:28px;font-size:14px;">84岁的老人赵荣斌被推进这间手术室的时候是右腿骨折，而推出这件手术室的时候，左腿被植入了钢板。事故的原因其实很简单，就是管床医生在手术通知单上错把“右腿”写成了“左腿”。</p><p style="text-indent:28px;font-size:14px;">管床医生谢润林:我是笔误。</p><p style="text-indent:28px;font-size:14px;">记者:你知道笔误，医生做手术的时候，你就没有提醒过主刀大夫吗？</p><p style="text-indent:28px;font-size:14px;">谢润林:主任记错了。摆体位的时候摆在左边，我当时以为主任知道哪个是患肢，就没有去想。</p><p style="text-indent:28px;font-size:14px;">通城县中医院骨科主任李盛望:我自己也觉得不可思议，从诊断到治疗到进手术室是正确的，治疗也是正确的。手术通知单下错以后，管床医生来落实。</p><p style="text-indent:28px;font-size:14px;">记者:就是管床医生当时落实的时候落实错了，他搞错了，您当时是按他的指令来进行的。</p><p style="text-indent:28px;font-size:14px;">通城县中医院骨科主任李盛望:还是我的指令，他按我的指令去做。根本没有想不到，这对我来说也是很大的打击，非常沉痛。</p><p style="text-indent:28px;font-size:14px;">赵荣彬老人好端端的左腿，被拧进一根85毫米的鹅头钉，植入了一块钛合金钢板。按照现在的情况，84岁高龄的他至少还要经历两场手术，也就是取出左腿钢板的手术和在右腿植入钢板的手术。</p><p style="text-indent:28px;font-size:14px;">目前，赵荣斌老人已经转院到武汉协和医院。老人说，自己本来不想做手术，上点药就可以了，结果一做手术就引来了这样的麻烦。湖北通城县政府已经表示，会积极处理相关善后事宜。</p><p style="text-indent:28px;font-size:14px;">通城县办公室副主任吴海舟表示，要承担以后因为这个责任事故造成的经济后果，并对全县卫生系统加强卫生行业管理。</p><p style="text-indent:28px;font-size:14px;">中国卫生法学会常务理事郑雪倩律师认为，赵荣斌老人和他的家属可以要求通城县中医院进行赔偿。骨折的腿没有得到及时的救治，医院应该承担相应的赔偿责任，还有精神上的损害，都可以得到相应的赔偿。</p><p style="text-indent:28px;font-size:14px;">管床医生的一个笔误，就让84岁的老人受了这么大罪。而参与赵荣彬骨折复位手术的包括主刀医生、助手、器械师、麻醉师等一共5人，竟然没有一个人对这起错误的手术提出异议。最近一段时间，相继发生了南京“婴儿死亡”事件、成都“血浆种花”事件等引起社会各界广泛关注，湖北这起离奇的“左右腿”医疗事故又再次给医疗服务行业敲响了警钟。</p><p style="text-indent:28px;font-size:14px;">中国卫生法学会常务理事郑雪倩认为，这不是医术的问题，而是医德的问题，折射出的是医院管理的混乱。</p><p style="text-indent:28px;font-size:14px;">郑学倩:这反映出两个问题，一个是医护人员要有责任心，做手术的时候不是拿上来就做，而是真正对一个人的生命负责。另外一个就是医院管理制度里是否有相关的保证患者安全的措施。在医院管理中，除了医生本人要有责任感责任心以外，医院还要有相关的、配套的管理措施，杜绝这样的事情发生。</p><p style="text-indent:28px;font-size:14px;">医务工作者一直被誉为“白衣天使”，他们是生命希望的寄托，是社会敬重的象征。然而，随着“就医难、看病贵”等现象久治难愈，加上离奇的医疗事故、低级错误，已经给医疗行业带来了“信任危机”。期望正在进行的“新医改”能够重建医患互信。</p></span>', 'gwm', 0, 9),
(131, '江苏镇江卫生局：产妇输尿管被缝属人为失误', '', '', '', '2009-12-07 10:30:43', '116.228.141.77', '<span style="font-family:宋体, arial, helvetica, clean, sans-serif;font-size:14px;"><p style="text-indent:28px;font-size:14px;"><strong>镇江产妇输尿管被缝</strong></p><p style="text-indent:28px;font-size:14px;"><strong>连续报道</strong></p><p style="text-indent:28px;font-size:14px;">“镇江剖腹生娃输尿管意外被缝”事件经本报报道之后，国家、省、市卫生行政部门领导高度重视。镇江市卫生局为此立即成立由市卫生局纪委书记金长安任组长的联合调查组，对这起医疗纠纷事件展开调查。经过一天的调查和讨论，调查组认为，这起事件乃人为操作失误所致，并非手术并发症。为此，镇江市卫生局责令京口区卫生局对相关人员进行处理，并对患者进行补偿。</p><p style="text-indent:28px;font-size:14px;"><strong>调查:患者输尿管留下数针缝扎线</strong></p><p style="text-indent:28px;font-size:14px;">调查组经过认真调查核实，也对患者张龙银及其家人进行了询问了解。得知患者于今年3月13日入住京口区人民医院。确认产妇曾在2002年顺产一女婴，2003年引产一次，2005年剖宫产一次。今年入院后，于3月14日凌晨剖腹产生下一女。术中子宫切口撕裂，长超过3厘米，于是进行了常规缝合、止血、抗炎等处理。但是到了3月15日，产妇阴道有较多水样液体流出，请外院会诊后，给予保留导尿等处理。3月18日产妇左肾部位出现疼痛，虽然3月20日在江苏大学附属医院行了造影检查，但是检查提示“左侧肾脏、输尿管未显影”。当日，产妇转入了江苏大学附属医院，手术探查中查明在输尿管可见数针缝扎线，予以拆除。4月18日出院后，患者又曾有两次因“尿路感染发热”入院。8月31日，患者在江苏大学附属医院经手术治疗后，现已基本恢复健康。</p><p style="text-indent:28px;font-size:14px;"><strong>结论:医生疏忽检查造成输尿管被缝</strong></p><p style="text-indent:28px;font-size:14px;">调查组认为，京口区人民医院对患者行剖宫产术术中误伤输尿管是客观事实，是有一定责任的，院方也予以认可。调查组确认这起事件与经治医生的疏忽大意有直接关系。尽管患者客观上也存在一些情况，但作为一名医生有无法推卸的责任。输尿管被缝应该属于人为操作失误。</p><p style="text-indent:28px;font-size:14px;">调查组中一位不愿透露姓名的妇产科专家在接受记者采访时说，患者曾经4次怀孕，之前曾做过一次引产，一次剖宫手术，腹腔内组织粘连严重，正因如此，在剖腹产的过程中很容易造成子宫切口裂伤。根据调查，当时，患者发生裂伤之后，医生已经引起了重视，手术中已经对邻近器官进行了检查，当时并未发生异常，但医生却疏忽了检查理顺输尿管。</p><p style="text-indent:28px;font-size:14px;"><strong>补偿:医院承担医疗费用并赔偿5万余元</strong></p><p style="text-indent:28px;font-size:14px;">这起医疗纠纷发生后，医患双方2个多月共协商达10余次。期间京口区人民医院主动承担了患者在江苏大学附属医院3次住院全部医疗费用近3万元，退还了患者在该院住院的治疗费用4100元，并满足了患者的要求，赔偿其50500元。</p><p style="text-indent:28px;font-size:14px;">院方在处理纠纷过程中曾多次建议患方采取司法诉讼、进行医疗事故技术鉴定、镇江市医患纠纷调解中心调解等途径，妥善合理解决医疗纠纷，维护自身的合法权益，京口区公安分局也多次积极参与此次纠纷的调处工作，但患方拒绝采纳上述各种途径。本报报道之后，镇江市卫生局和京口区卫生局高度重视，主动约请患者商谈。昨日下午，双方终于达成补偿协议。患者张龙银在接受记者采访时说，他们对结果还是比较满意的。</p><p style="text-indent:28px;font-size:14px;"><strong>警示:卫生部门将处理相关人员</strong></p><p style="text-indent:28px;font-size:14px;">昨日下午，镇江市卫生行政部门便着手研究对相关人员的处理问题。京口区卫生局赵局长在接受记者采访时说，他们将本着实事求是的态度，公平公正处理剖腹产中输尿管损伤一事。局党委决定对医院相关领导以及当事医务人员作出相应处理，并通过适当的方式向患者致歉。镇江市卫生局纪委书记金长安对记者说，镇江市卫生局也将要求全系统医务工作者认真吸取经验教训，严格执行医疗规章制度，加强业务学习，精益求精，强化行风建设。</p></span>', 'gwm', 0, 14),
(132, '药监局:4月以来发现并摧毁制毒贩毒大型犯罪集团', '', '', '', '2009-12-08 11:08:13', '116.228.141.77', '<span style="font-family:宋体, arial, helvetica, clean, sans-serif;font-size:14px;"><p align="center" style="text-indent:28px;font-size:14px;"><img src="http://img.ifeng.com/hres/200912/08/10/07633630694edcf38a995604ab00a728.jpg" /></p><p align="center" style="text-indent:28px;font-size:14px;">国家食品药品监督管理局新闻发言人颜江瑛 中国网 杨楠摄</p><p style="text-indent:28px;font-size:14px;">2009年12月8日国家食品药品监督管理局举行例行新闻发布会，请新闻发言人颜江瑛介绍餐饮服务食品安全整顿阶段性检查重点情况，并就大家关注的问题回答记者提问。中国网现场直播。</p><p style="text-indent:28px;font-size:14px;">在发布会上记者获悉，2009年4月以来，经过公安、食品药品监管等部门历时6个多月的侦破，发现并摧毁了一个涉嫌非法买卖含麻黄碱类复方制剂、制造贩卖毒品的庞大犯罪集团。现该案已结案并转入司法审判程序。在案件侦破过程中，宜宾市、吉林市两地食品药品监管部门在四川省、吉林省食品药品监管局的指导下，切实履行监管职责，认真开展针对含麻黄碱类复方制剂的监督检查，发现疑点主动跟踪调查，积极配合、协同办案，体现了高度的敏感性、责任心和大局意识，为避免大量含麻黄碱类复方制剂从药用渠道流失发挥了重要作用。?</p><p style="text-indent:28px;font-size:14px;">一、对可疑流向的不懈追查。?</p><p style="text-indent:28px;font-size:14px;">吉林省吉林市食品药品监管局在日常监管中采取“定期查与飞行查、普遍查与重点查、企业自查与药监检查”三结合的方式，对辖区内含麻黄碱类复方制剂的生产企业、药品批发企业和药品零售企业进行全方位、对批次的跟踪检查，并对发现的可疑之处及时发出协查通报。?</p><p style="text-indent:28px;font-size:14px;">今年3月底，四川省宜宾食品药品监管局接到吉林省吉林市食品药品监管局的协查函，请协助核查宜宾市南溪县医药有限责任公司是否委托他人向吉林维康制药有限公司购买197件复方茶碱麻黄碱片，药品是否到达南溪县医药有限责任公司。?</p><p style="text-indent:28px;font-size:14px;">宜宾食品药品监管局使用“药品物流追踪管理信息系统”认真核查药品流向。核查结果表明，南溪县医药有限责任公司并未有该批药品的进出购销台账记录。后经药监人员明察暗访发现，该公司库房也没有该批药品，产品极有可能流入了非法渠道。根据安监管辖规定，宜宾市局将案件移交宜宾市公安局，请求立案侦查，彻底查清该批药品的流向。?</p><p style="text-indent:28px;font-size:14px;">2009年4月8日，宜宾市公安局、宜宾食品药品监管局共同研究确定，由宜宾市公安局对“4 08”非法买卖制毒物品立案侦查，并上报四川省公安厅和公安部、国家食品药品监管局。?</p><p style="text-indent:28px;font-size:14px;">5月，公安部对“4 08”专案进行挂牌督办。四川省公安厅成立了专案指挥部，宜宾市组建了宜宾市公安局禁毒支队为主、宜宾食品药品监管局协助的“4 08”专案组。通过对违法盗用、套用宜宾市南溪县医药公司合法资质，骗购、套购含麻黄碱类复方制剂的线索不断深入追查，发现并彻底摧毁了涉及全国21个省（区、市）涉嫌制造、贩卖毒品，非法买卖制毒物品的庞大犯罪集团。?</p><p style="text-indent:28px;font-size:14px;">在此次“4 08”案件中，吉林、宜宾两地食品药品监管部门密切配合，积极行动，以高度的敏感性发现了重大案情。同时，各级各地食品药品监管部门密切配合公安部门开展调查和案件办理工作，形成了打击违法犯罪活动的重拳合力。</p><p style="text-indent:28px;font-size:14px;"><p style="text-indent:28px;font-size:14px;">二、对易制毒化学品的严格监管。</p><p style="text-indent:28px;font-size:14px;">麻黄碱是制造冰毒的重要原料，在我国，麻黄碱被列入药品类易制毒化学品管理，受到食品药品监管部门的严格监管。?</p><p style="text-indent:28px;font-size:14px;">自2005年《易制毒化学品管理条例》颁布实施以来，经过各级食品药品监管部门的共同努力，监管法规体系、管理制度日臻完善，药品类易制毒化学品的生产、经营、购用、安全管理等环节的监管得到加强。药品类易制毒化学品的生产、经营须由药品监管部门许可；药品类易制毒化学品单方制剂由麻醉药品定点经营企业经销，且不得零售；购买药品类易制毒化学品须经药品监管部门批准；进出口、运输药品类易制毒化学品须经相关部门批准。?</p><p style="text-indent:28px;font-size:14px;">同时，在日常监管中，各级食品药品监管部门建立了派驻监督员、重点监管以及日常巡查制度，日常监督检查与集中性专项检查相结合，监管责任得到落实，日常监督检查得到加强。?</p><p style="text-indent:28px;font-size:14px;">各级食品药品监管部门还加强了信息化建设和监管队伍建设，监管能力和监管效率得到明显提高；通过各类宣传培训活动，药品类易制毒化学品生产、经营企业的守法观念和自律意识普遍较强，以上这些因素都使得药品类易制毒化学品的生产、经营和使用秩序得到有效规范，药品类易制毒化学品管理工作取得了明显成效。?</p><p style="text-indent:28px;font-size:14px;">2007年底至2008年上半年，国家食品药品监管局和公安部在全国范围开展了麻黄碱专项检查，进一步规范麻黄碱的生产、经营、使用秩序，依法查处违法违规企业和个人，严厉打击走私和非法买卖麻黄碱的违法犯罪活动，全面提高麻黄碱的管理水平。?</p><p style="text-indent:28px;font-size:14px;">三、对含麻黄碱类复方制剂的严格监管。</p><p style="text-indent:28px;font-size:14px;">近年来，随着我国药品类易制毒化学品的生产经营日趋规范，不法分子难以从合法渠道获取药品类易制毒化学品，因而将目标转向含麻黄碱类复方制剂，从中提取麻黄碱后再制造毒品，严重危害公共卫生和社会稳定，在国内外造成了不良影响。?</p><p style="text-indent:28px;font-size:14px;">犯罪分子大量套购含麻黄碱类复方制剂提取麻黄碱后制毒，使该类药品在非法市场价格不断飙升，巨大的经济利益驱使不法分子不择手段、铤而走险。?</p><p style="text-indent:28px;font-size:14px;">自2007年以来，国家食品药品监管局与有关部门采取了一系列加强含麻黄碱类复方制剂管理的措施，严格控制麻黄碱原料药的购用审批，加强对含麻黄碱类复方制剂销售核查，切实规范含麻黄碱类复方制剂销售渠道，对发现的违法违规行为依法严厉打击。</p><p style="text-indent:28px;font-size:14px;">首先，为保障公众用药需求，合理控制生产总量，国家食品药品监管局与公安部联合制定了麻黄碱类原料药购用审批的指导意见。其次，针对含麻黄碱类复方制剂销售环节问题较多的情况，国家食品药品监管局制定了相关措施，加强对此类药品的销售管理。?</p><p style="text-indent:28px;font-size:14px;">根据要求，药品生产、批发企业经营含麻黄碱类复方制剂时，应当建立客户档案，核实并留存有关资质证明，按规定开具票据，禁止现金交易，确保药品送达购买方仓库。药品零售企业零售含麻黄碱类复方制剂时，处方药应当严格执行处方药与非处方药分类管理有关规定，非处方药一次销售不得超过5个最小包装。含麻黄碱类复方制剂的销售过程中如发现异常情况，企业应立即暂停销售，并向所在地设区的市级药品监管部门、公安机关报告。?</p><p style="text-indent:28px;font-size:14px;">国家食品药品监管局在全国范围内开展的含麻黄碱类复方制剂生产经营专项检查和宣传警示活动，严查违法违规行为，积极引导企业守法经营。?</p><p style="text-indent:28px;font-size:14px;">为保证合法贸易和公众用药需求，国家食品药品监管局与公安部又联合下发了麻黄碱类原料药购用审批指导意见，指导省级药品监管部门科学审批购用原料药，合理控制含麻黄碱类复方制剂生产总量。?</p><p style="text-indent:28px;font-size:14px;">为加强含麻黄碱类复方制剂销售环节的管理，国家食品药品监管局还下发了《关于切实加强部分含特殊药品复方制剂销售管理的通知》，要求企业销售含麻黄碱类复方制剂时严格核实购买方资质，按规定开具票据，严格执行出库复核制度，禁止现金交易，限制零售数量；要求药品监管部门加大监督检查力度，严肃查处违法违规行为，从而切实加强此类药品的销售管理。?</p><p style="text-indent:28px;font-size:14px;">面对当前药物滥用和禁毒的严峻形势，各级药品监管部门还将严肃查处各类违法违规行为。对检查发现的药品生产、经营企业违反有关规定销售含麻黄碱类复方制剂的，按照《药品管理法》第七十九条严肃查处，其中查实直接导致含麻黄碱类复方制剂流入非法渠道的，吊销《药品生产许可证》或《药品经营许可证》。对涉嫌触犯刑律的，将及时移送公安机关处理。</p></p></span>', 'gwm', 0, 7),
(133, '国务院办公厅发布关于2010年部分节假日安排通知', '', '', '', '2009-12-09 09:32:40', '116.228.141.77', '<span style="color:#333333;font-family:宋体;font-size:14px;">　国务院办公厅关于2010年<br /><br />　　部分节假日安排的通知<br /><br />　　国办发明电〔2009〕27号<br /><br />　　各省、自治区、直辖市人民政府，国务院各部委、各直属机构：<br /><br />　　根据《国务院关于修改&lt;全国年节及纪念日放假办法&gt;的决定》，为便于各地区、各部门及早合理安排节假日旅游、交通运输、生产经营等有关工作，经国务院批准，现将2010年元旦、春节、清明节、劳动节、端午节、中秋节和国庆节放假调休日期的具体安排通知如下。<br /><br />　　一、元旦：1月1日至3日放假公休，共3天。<br /><br />　　二、春节：2月13日至19日放假调休，共7天。2月20日（星期六）、21日（星期日）上班。<br /><br />　　三、清明节：4月3日至5日放假公休，共3天。<br /><br />　　四、劳动节：5月1日至3日放假公休，共3天。<br /><br />　　五、端午节：6月14日至16日放假调休，共3天。6月12日（星期六）、13日（星期日）上班。<br /><br />　　六、中秋节：9月22日至24日放假调休，共3天。9月19日（星期日）、25日（星期六）上班。<br /><br />　　七、国庆节：10月1日至7日放假调休，共7天。9月26日（星期日）、10月9日（星期六）上班。<br /><br />　　节假日期间，各地区、各部门要妥善安排好值班和安全、保卫等工作，遇有重大突发事件发生，要按规定及时报告并妥善处置，确保人民群众祥和平安度过节日假期。<br /><br />　　国务院办公厅<br /><br />　　二○○九年十二月七日</span>', 'gwm', 0, 11),
(134, '网友破解农夫山泉“砒霜门”：假如我是黑手', '', '', '', '2009-12-09 15:20:32', '116.228.141.77', '<span style="font-family:arial;font-size:14px;"><p><strong>核心提示：“砒霜门”结果离真相到底有多远?问题到底出在哪里?我们有知道真相的权利。“砒霜门”闹到现在，越来越扑朔迷离了，越来越像看一部悬疑剧了，或许真相会令人大吃一惊，难于意料，剧情一起三伏，跌荡千回。“演员们”演得精彩纷呈，但公众却看得云里雾里。网友“北归雁”建言，把真相破解的权利交给民间，交给极富智慧的广大网友们。12月7日，南海网网友“007cat”在南海网发出“假如我是黑手”的声音。</strong></p><p>　　南海网12月9日消息(南海网记者 杨振东)：“如果我是‘黑手’，我会在何处下手”?12月7日，南海网网友“007cat”在南海网阳光岛社区海南观察版发帖，针对农夫山泉公然声称农夫山泉“砒霜门”有“黑手”在幕后操纵的说法进行了剖析。“007cat”对检测过程中的各个环节用排除法进行分析后，将矛头直指检测部门。(详见http://nanhai.hinews.cn/thread-1837304-1-1.html)</p><p>　　<strong>缘起农夫山泉质疑“砒霜门”背后有黑手</strong></p><p>　　“007cat”分析，从技术角度看，检测结果出错只能在采样、送检、检测和出具检测报告这几个地方出错。而且农夫山泉也正是抓住了关键，首先质疑了一切麻烦的源头――采样，也就是抽样预备送检的过程是违反程序的，因此是非法的取证行为，因此非法的取证行为也必然导致证据的被排除。农夫山泉还提供了一些似是而非的证据，暗示工商部门的抽样检查行为背后有黑手。</p><p>　　<strong>“砒霜门”事件中海口工商应该是诚实的</strong></p><p>　　“007cat”认为，一般来讲，出具一份虚假的或伪造一份检测报告，风险实在是太大，而且很容易暴露，“黑手”不会去考虑。倒是抽样、送检、检测3个环节有机可乘。在这3个环节里，我们基本上可以排除掉送检环节，原因很简单，送检人相对来讲不会太多，而且检测方还要严格(假设会)检查送检的样本的完整，所以如果动手脚，很容易被当场揭穿，风险还是很大。在剩下的两个环节，“黑手”都是有机可趁的，但是根据海口市工商局主动送去复检的结果可以看出，同批留样搞出了不同的结果，恰恰可以排除掉取样环节，因为海口工商是最不愿意看到出现不同检测结果而且还是否定初检结果的情形，如果这一情形出现的话，最起码说明海口工商在抽样取样过程中是诚实的，没有做手脚。</p><p>　　<strong>我们有不接受采访的权利最令人玩味</strong></p><p>　　运用排除法，最后剩余的一个无法排除的环节――检测。莫非就是我们所希望的结果吗?作为“黑手”，从检测环节下手那是最有利的，方法不外乎三招：搞定人，搞定样本，搞定仪器。如果出什么意外，和“黑手”是没有关系的，最多不过几条理由就可以打发公众：未按检测流程、业务素质不够、技术水平有限、检测仪器故障……可惜检测部门自己堵上了这几条退路，面对媒体的追问，只是以“我们有不接受采访的权利”搪塞。检测部门倒成了被怀疑的重点。</p><p>　　<strong>把破解“砒霜门”真相的权利交给民间</strong></p><p>　　接下来，我们只有等上级的调查结果了。在结果没有出来之前，我们所谈的是非似乎也该适可而止了，因为我们都在等待真相被揭露，而在这个过程中，我们不想再因为我们的多嘴阻滞了揭露真相的脚步。但是，网友“北归雁”可不苟同这种等下去的观点，于是在南海网阳光岛振臂一呼：把真相破解的权利交给民间，交给极富智慧的广大网友们。</p></span>', 'gwm', 0, 12),
(137, '央视三批"侯药华" 专家痛斥侯耀华死不认错', '', '', '', '2009-12-14 15:58:05', '116.228.141.77', '<span style="font-size:15px;"><font color="#0000ff"><img alt="" src="http://www.qhnews.com/pic/0/00/20/46/204630_711557.jpg" /></font><p align="center"><font color="#0000ff"></font></p><p align="center"><font color="#0000ff">侯耀华在《今日说法》中表示，自己当时医学知识浅薄。</font>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;因代言虚假广告而被老百姓称为“侯药华”的侯耀华在11日又被央视《今日说法》“点名”批评，《今日说法》播出了“侯耀华代言门事件全记录”，节目中侯耀华以“这不是私人的问题”、“医学知识浅薄”来推卸自己的责任。这也是继央视《新闻30分》、《经济半小时》公开曝光后，第三次批评侯耀华。</p><p><strong>　　&nbsp;&nbsp;&nbsp;&nbsp;侯耀华 看着题字器说的</strong></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;侯耀华在《今日说法》中称，全世界的广告，全有夸张的成分在里面，因为不夸张就不叫广告，“广告就是告诉您有个新的东西出来，选择权在您自己。”侯耀华说，自己被广告协会披露出来的十条广告都是自己以主持人身份参加的，“我的劳务也就八千一万两万顶多三万。”对于广告中的虚假广告词，侯耀华为自己辩解到，“我没有吃过，因为我没这毛病我怎么可能吃这药，我是看着题字器说的。”侯耀华表示，由于录制节目时自己的医学知识浅薄，才会犯下这样的错误，并且认为自己其实是做了一件“好事”，“如果有一种家庭能承受得起，而且又有一定疗效的药，让老百姓看病不用去花钱挂号，坐车，领药，又能减轻一点疾苦，这是好事。”</p><p><strong>　　&nbsp;&nbsp;&nbsp;&nbsp;专家 涵盖所有违法形式</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;《今日说法》还采访了多位当事人及专家，其中中国广告协会法律服务中心主任李方午，对于侯耀华的表现表示了“不满”，认为侯耀华代言的十则广告几乎涵盖了所有名人代言广告的违法形式，“无论他拿到酬劳的高低，只要在节目中夸大疗效，给予承诺的做法，就是违法，而侯耀华广告中代言人已从本职工作转变成了推销员身份，应当对自己的言行举止负责</p></span>', 'gwm', 0, 9),
(138, '广东规定食用农产品必须亮出“身份证”', '', '', '', '2009-12-14 16:22:10', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p align="center"><img alt="广东规定食用农产品必须亮出“身份证”" border="1" src="http://img1.gtimg.com/news/pics/25522/25522253.jpg" /></p><p></p><p>　　担心买到来源不明的“污水菜”？担心吃到药物残留超标的私宰肉？担心家人的健康被损害，却无从查证？……这类的疑虑将可很快打消。笔者昨日从广东省农业厅了解到，《广东省食用农产品标识管理规定》已正式实施，相关标识管理工作现正全面展开。</p><p>　　这是一项雄心勃勃的工程：到明年11月前，全省主要食用农产品在面对消费者时，都要标注产地来源、生产者等信息，让消费者买得放心、吃得舒心；在此基础上，我省将构建农产品溯源管理体系，一旦出现食品安全问题，即可沿着农产品标识信息的路径追到源头，从而依法执罚。</p><p>　　这是一项艰巨繁重的工程：广东全省仅常住人口就近亿，每日消费的主要食用农产品种类繁多、数量巨大。贯彻落实标识管理，既需要生产、运输、批发、零售等各环节的配合，也需要农业、工商、卫生等多部门的通力协作；更重要的是，必须得到全省广大消费者的理解和支持，通过提高消费者的法律意识、自保意识来促进机制的运作。</p><p><strong>　　农产品标识要明确</strong></p><p>　　根据今年10月1日颁布的《广东省食用农产品标识管理规定》，食用农产品是指“来源于农业，未经加工或者仅经过挑拣、干燥、粉碎、分割、保鲜、包装等方法初级加工的可供人食用的植物、动物、微生物及其产品”，其涵盖面相当广，包括粮食、蔬菜、水果、干果、竹笋、畜禽、肉品、奶、蛋、蜂蜜、水产品及食用菌等等。</p><p>　　《规定》对农产品的标识要求标注产品名称、产地、生产日期、生产者或者销售者名称、地址、联系电话等相关信息；</p><p>　　法律、法规或者国家标准、行业标准及地方标准对食用农产品保质期有明确要求的，应标注保质期。保质期与贮藏条件有关的，应当予以标明……</p><p>　　实施了《规定》的地区，消费者到超市、肉菜市场购买食用农产品，应该可看到场内表明了青菜什么时候摘的、鱼虾什么时候捞的、生猪什么时候宰的；如果对产品不放心，可以记下生产者或销售者的联系方式，日后用作追查线索。</p><p><strong>　　建立食品追溯体系</strong></p><p>　　和流程严谨的工业生产不同，食用农产品长久以来一直有分散生产、经营的特点，其品质参差不齐、鱼龙混杂，出现安全事故后往往难以追溯到源头。</p><p>　　“进行标识管理后，我们就可以要求生产商、销售商建立台账，对每一批产品进行登记，确保可以追溯到源头。”省农业厅相关负责人说，未来广东省的食用农产品不论自产还是从外省进口，都将有“从田野到市场”的完整纪录链条。</p><p>　　有了追溯体系，将来相关管理部门在查处“污水菜”、“瘦肉精”等问题时，就可“一竿子插到底”，直接追究到具体责任人。</p><p>　　广东全省每天均有大量农产品交易，建立追溯体系需要巨大的人力物力投入。省农业部门目前主要抓龙头企业、规模化生产大户的标识管理；针对“千家万户”式的散户生产，则主要抓紧农产品市场经营者和销售者的管理，通过建立市场食用农产品入市流通信息登记制度和食用农产品标识的使用管理措施、经营记录等制度，由销售方保证销售的农产品附有标识。</p><p><strong>　　广东走在全国前列</strong></p><p>　　在《规定》出台前，省委、省政府就对食用农产品标识工作高度重视，省领导多次作出重要指示，要求抓紧研究、建立广东省农产品标识制度，确保农产品质量安全。上下齐心的推动，使广东在探索标识管理机制上走在了全国的前列。</p><p>　　在9月30日召开的全省电视电话会议上，副省长李容根要求各地、各有关部门认清形势，提高认识，进一步增强做好食用农产品标识管理的紧迫感和责任感。</p><p>　　广东省农业厅谢悦新厅长表示，推进农产品标识管理要和农业标准化生产、建立农产品生产档案制度、建立农产品监督抽查制度结合起来，健全农产品质量安全溯源管理的制度。2010年第16届亚运会和第26届大学生运动会将分别在广州和深圳举行，做好标识管理工作对保障两大体育盛会的农产品供应有重大意义。</p></span>', 'gwm', 0, 6),
(136, '陕西金桥乳业卖五吨三聚氰胺奶粉 总经理被逮', '', '', '', '2009-12-11 10:11:21', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;"><p>去年9月11日，三鹿问题奶粉事件被披露后，由此引发了席卷全国的“三聚氰胺”事件。一年之后的现在，陕西金桥乳业有限公司又被查出5.25吨问题奶粉，其中11袋275公斤奶粉三聚氰胺超标。令人吃惊的是，这些问题奶粉生产于“三聚氰胺”事件之前，但金桥乳业并没有销毁这些问题奶粉，一年过后，又重新包装，卖给广西一个厂家。所幸被及时发现，未流入市场造成危害。</p><p><strong>　　5部门调查金桥乳业</strong></p><p>　　昨日下午，省公安厅召开新闻通报会，联合农业厅、工商局、畜牧业局、质监局及全国视频安全整顿办公室披露：今年11月24日，接公安部通知，位于我省泾阳县的陕西金桥乳业有限公司，有一批销往广西的奶粉三聚氰胺严重超标，要求我省公安机关配合质检部门快速查清此案。</p><p>　　对此，省公安厅高度重视，立即向省政府领导汇报，并派人同省质检部门积极联系。11月26日，公安厅通知咸阳市公安局，要求抽调专人开展调查。11月29日，泾阳县公安局对省质检部门移送的金桥乳业总经理刘平等人涉嫌乳品质量违法犯罪案件进行立案。</p><p>　　12月2日，公安机关侦破了此案。对涉嫌生产销售有毒有害食品罪的犯罪嫌疑人刘平、苗文军、吕小强予以刑事拘留。</p><p><strong>　　检测时将样品偷梁换柱</strong></p><p>　　经查，2008年10月，位于泾阳县的陕西金桥乳业生产的“2008.5.16”批次4袋0.1吨和“2008.9.24”批次206袋5.15吨全脂淡奶粉(均为供乳品企业进行再加工或生产使用的工业用粉，每袋25公斤)，分别于同年9月27日、10月8日送省质检所质检，两次检验均因三聚氰胺严重超标，结论为“三聚氰胺含量为11mg/kg，为不合格产品”。泾阳县质监局遂将这5.25吨奶粉予以封存。</p><p>　　对上述两批号不合格的全脂淡奶粉，该公司总经理刘平于2008年11月提出复检。在抽样前，刘平调换被封存奶粉位置，将自认为合格的产品放置在易抽检部位。2008年11月17日，泾阳县质监局抽样后将样品送西安市质检所检验，11月18日检验结论为合格产品。刘平将上述检验结论告知了该县质监局，该局答复予以解封销售。但刘平自知此两批号奶粉有问题不敢轻易销售，一直存放在库房中。</p><p><p><strong>共275公斤严重超标</strong></p><p>　　今年9月初，广西南宁越前食品添加剂公司(以下简称“越前公司”)要求刘平提供5吨全脂淡奶粉和5吨全脂奶粉。刘平因时间紧，库存不足，遂于9月4日、5日召集库房管理员苗文军和工人吕小强将210袋问题奶粉利用工人下班后的晚上，从库房搬至包装车间逐袋剔除结块、变色的奶粉，再添加少部分新生产的乳粉，换成新的黄色包装袋，更换出厂日期进行封口，共将这批问题奶粉重新包装成200袋全脂淡奶粉。连同2009年9月生产未经检验的5吨全脂奶粉 (200袋，白色包装)一起套用2009年7月10日、7月15日、7月20日、7月25日四个生产批次打包，9月6日，由刘平负责联系车辆发往南宁越前公司。</p><p>　　今年11月初，广西越前公司电话告知刘平，10吨乳品中，5吨黄色包装的全脂淡奶粉被检出含有三聚氰胺，要求退货。11月7日，5吨问题奶粉被退回金桥公司。</p><p>　　在本次调查中再次经省质监局检测，刘平销往广西南宁越前食品添加剂公司的奶粉中有11袋275公斤三聚氰胺严重超标。由于查处及时，毒奶粉未流入社会。</p><p><p>据省公安厅副厅长许强介绍，根据《食品安全法》规定，食品生产经营者是食品安全第一责任人。刘平作为企业负责人，熟知乳制品加工配方，明知三聚氰胺为国家明令禁止添加的有毒有害物质，仍将含有三聚氰胺的奶粉通过倒换包装、套用批次的方法予以销售，其性质十分恶劣。刘平、苗文军、吕小强主观故意、客观行为均符合《刑法》第144条关于生产销售有毒有害食品罪的规定，涉嫌构成犯罪。12月8日，经泾阳县检察院批准，已对刘平、苗文军、吕小强实施逮捕。</p><p>　　金桥乳粉案件性质明确，案情基本清楚，属个别企业实施的刑事犯罪行为。由于其所售问题乳粉被及时查扣，因此未造成实际健康危害，也没有酿成涉及全局的重大食品安全事故。省公安厅等5部门希望通过媒体，将金桥乳粉案件公之于众，以示政府维护人民生命健康、打击食品安全违法犯罪的坚强决心。同时，警告那些违法犯罪分子，绝不要心存侥幸、执迷不悟，如果胆敢顶风作案，以身试法，必将受到法律的严惩。</p></p></p></span>', 'gwm', 0, 9),
(139, '医院副院长因患者猝死为躲避冲突摔下3楼', '', '', '', '2009-12-15 12:15:22', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p>“听说三院一名副院长跳楼自杀了，不过人没死，伤了几根肋骨！”昨日中午12点半左右，本报接到读者爆料，称常州市第三人民医院发生一件怪事，一位副院长突然不知为何从三楼跳了下来，“寻了短见”。接到爆料后，记者迅速赶往事发医院。</p><p><strong>　　避免正面冲突副院长“跳楼”</strong></p><p>　　记者赶到医院时，经过打听才得知，原来该院副院长并非“寻短”，而是遭遇了一群人的“围攻”，无奈之下跳的楼。记者看见，医院周围聚集了几十名民警在维持秩序。记者根据指点来到行政楼里，发现多处木质房门已被砸毁，医院职工情绪十分不稳定，神色间显得颇为紧张。</p><p>　　记者试图采访工作人员，欲对跳楼事件始末进行了解，但大伙对此都三缄其口。“我们不知道什么情况，也不知道对方是什么人！有什么问题你们去问院领导！”一位在场的医院工作人员如是告诉记者。随后，记者找到该院宣传科，一位工作人员告诉记者，医院行政楼被砸一事是一起医患纠纷所导致的，病人家属一行四五十个人已经在医院里闹了大半天，现在情绪才基本稳定。但她否认了“副院长跳楼”一说。关于医患纠纷的发展经过、细节等，该名工作人员不愿透露，仅表示目前此事公安部门已经介入。“有什么需要了解的，可以去问公安部门。”为此，记者联系了常州天宁公安局，一位警官表示，“由于案件正在调查中，还没有一个结果，所以警方不方便透露。”</p><p>　　随后，记者通过相关途径了解到，的确有该院吴姓副院长“跳楼”一事。据两位知情人士透露，死者是一名35岁的兴化人，日前因饮酒后摔伤住进了肝胆外科病房，上周五原本已经在办理出院手续的患者不知为何突然猝死，尸体还停放在医院等待检查。</p><p>　　昨日上午，死者家属情绪爆发，一大早便集中了“黑压压”的一帮人冲到医院行政楼“示威”。当时，“凡是看见锁着的门就砸，看见躲在办公室的人就打！”该院人事科科长、保卫处处长、副院长等都遭到了人身攻击。为了避免事态进一步恶化，副院长吴某跑进保卫室，打算从三楼爬至二楼的车棚上，再跳到一楼，避免与患者家属发生正面冲突，然而不幸失手，摔成重伤。“六七根肋骨断了，还出现了气胸病症。”</p><p><strong>　　公安部门介入调查处理</strong></p><p>　　昨晚8时许，常州市卫生局给本报记者发来了新闻通稿，介绍了事件的经过：</p><p>　　12月12日9时许，常州市第三人民医院七病区传出一阵阵吵闹、哭叫声，病区走廊上聚集了几十名患者家属，医院数名医生和保卫科干部被殴打。当日上午10时许，患者家属在医院门口拉横幅，堵大门，经公安干警劝说，患者家属同意下午到常州市医患纠纷调处中心进行调解。12月14日8:20，三十余名患者家属围堵医院办公楼，踢坏多个办公室门，殴打前来劝说的医院工作人员和保安人员，一位副院长在处理纠纷时也不慎摔伤。随后，患者家属封堵医院大门，部分人员还在兰陵北路拉横幅，堵塞交通。在公安干警的制止下，患者家属停止上述行为，并同意继续到常州市医患纠纷调处中心进行调解。</p><p>　　常州市第三人民医院七病区负责人介绍说，患者宦某，男，34岁，因“右上腹痛4小时”，于12月9日6时收住入院。患者父亲反映，入院前有饮酒及腰部外伤史。入院后各项检查显示，生命体征正常，右上腹有压痛，右腰背部轻压痛；B超、腹部X光摄片、心电图、血生化、肝功能等检查结果均正常。入院诊断为“腹痛待查”。经对症治疗，患者次日腹痛症状明显减轻，能进流质饮食，精神状态较好，患者父亲向科主任和床位医生提起出院要求，科主任考虑患者病情刚刚稳定，尚需继续观察。12月11日患者腹痛症状消失，精神、饮食均正常。19:06患者与同病室患者聊天时，突然四肢抽搐，神志不清，口唇紫绀，同室患者家属立即呼救，医生、护士立即赶到，发现患者呼吸、心跳停止，瞳孔扩大，立即实施心肺复苏等抢救措施，随后进行气管插管、人工辅助呼吸，终因抢救无效，患者于20:30死亡。</p><p>　　“患者腹痛入院，经诊治腹痛明显缓解，并未出现新的病情。患者病情突变并死亡，医学上属于‘猝死’。其死因需通过尸体解剖才能得出科学的结论。”常州市医患纠纷调处中心一位调解员如是说。常州市第三人民医院院长罗立波表示，我们一定本着实事求是的态度，在查清患者死亡原因的基础上，根据国家有关法律法规，客观公正地处理这起医患纠纷。目前，公安部门已介入这起事件的调查处理。</p></span>', 'gwm', 0, 6);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(140, '揭秘男人真正需要的九大补药', '', '', '', '2009-12-15 12:19:17', '116.228.141.77', '<span style="font-family:瀹嬩綋;font-size:16px;color:#000000;">当代中国的中年<font color="#0000FF"><span style="color:#000000;">男人</span></font>正处在一个“上有老，下有小，中间有老婆、事业，惟独没有自己”这样一个充满生存压力的人生阶段，为了争取到<font color="#0000FF"><span style="color:#000000;">男人</span></font>该有的地位和尊严，他就必须得拼命赚钱，虽然赚的钱多了，但身体也被透支得更多。因此各种奇思妙想的“补药”扑面而来，再加上厂家天花乱坠的宣传，仿佛中国男人真的到了不进补就无法生存的地步了。<img src="http://www.people.com.cn/mediafile/pic/20091215/36/9353770984580501064.jpg" /><span style="color:#000000;">男人真正需要的九大补药</span><br /><br />　　真是这样吗？答案是：NO。我们目前一提起补药往往都往“那”方面去想。其实，<font color="#0000FF"><span style="color:#000000;">男性</span></font>真正需要的是整个身体各方面的<font color="#0000FF"><span style="color:#000000;">健康</span></font>、年轻、活力。许多鲜活的例子表明，不适当的乱补所谓的“补药”不但与己无益，有时反而有害。<br /><br />　　其实你要是真正爱他的话，下面这些东西才是他真正需要的“补药”。<br /><br />　　<strong><span style="color:#000000;">补药一：硼——前列腺之宝&nbsp;</span></strong><br /><br />　　<font color="#0000FF"><span style="color:#000000;">男性</span></font>前列腺癌的发生率正有越来越高的趋势，前列腺癌一直是男人的最大杀手，国外研究发现，硼的摄入量大的男性，患前列腺癌的几率比摄入量小的男性低65%。这说明摄入适量的硼可以有效减轻前列腺癌的发生。多吃西红柿也会保护前列腺，就是因为西红柿里面有比较丰富的硼。<br /><br />　　量：硼是广泛存在于<font color="#0000FF"><span style="color:#000000;">水果</span></font>和果仁中。美国药物研究协会发现，每天服用3毫克的硼最为合适，这个剂量刚刚可以产生抗癌作用，而且在这个剂量的硼还可以改善记忆力和注意力。其他富含硼元素的<font color="#0000FF"><span style="color:#000000;">食物</span></font>包括葡萄、干果、鳄梨、红酒和葡萄汁。另外一个既能治病又能解馋的方法就是吃香草冰激凌。这是因为香草冰激凌里就含有硼。<br /><br />　　<strong><span style="color:#000000;">补药二：ω-3s脂肪酸——男性“护心”专家&nbsp;</span></strong><br /><br />　　ω-3s脂肪酸能阻止血液中的血小板聚集和黏附成团而形成板块，让血液流动性增加，可以降低血压和甘油三脂水平以及维持心脏规律的跳动。研究证明ω-3s脂肪酸的确能够降低心脏病的死亡率。研究者们还发现ω-3s能有效<font color="#0000FF"><span style="color:#000000;">治疗</span></font>自身免疫性疾病（如<font color="#0000FF"><span style="color:#000000;">风湿</span></font>性<font color="#0000FF"><span style="color:#000000;">关节</span></font>炎和系统性红斑狼疮），并能调节脑细胞的脂含量、延缓脑细胞衰老<br /><br />　　量：每天1克就够了。但对那些有心脏问题的男性每天的摄入量应在2至4克，这种脂肪酸有有一定的鱼腥气味。<font color="#0000FF"><span style="color:#000000;">食物</span></font>中如沙丁鱼、金枪鱼、鲱鱼等被认为是ω-3s脂肪酸的良好来源。食用ω-3s脂肪酸也不可过量，因为过量的ω-3s脂肪酸可以他增加患感冒的风险。<br /><br />　　<strong><span style="color:#000000;">补药三：叶酸让男性远离早老年痴呆</span></strong><br /><br />　　瑞典的研究者发现，男性早老年痴呆发生率高。半胱氨酸增高可以增加早老年痴呆病的发生，从而出现智力减退、记忆力丧失等早期症状，另外半胱氨酸还是一种促进血液凝固的氨基酸。进一步的研究发现，叶酸可以有效的降低半胱氨酸水平，从而能够提高进入到大脑中的血液量，因此叶酸可以帮助预防动脉栓子形成。这对饱受<font color="#0000FF"><span style="color:#000000;">工作</span></font>压力之苦而有可能患上早老年痴呆的他来说可谓好消息。<br /><br />　　量：每天服用500毫微克就可以使半胱氨酸水平降低18%甚至更多。叶酸的食物来源包括柑橘、豆类、谷类等。</span><div><font face="瀹嬩綋"><span style="color:#000000;">-------------------------------------------------------</span></font></div><div><font face="瀹嬩綋"><span><span style="font-size:16px;color:#000000;"><img src="http://www.people.com.cn/mediafile/pic/20091215/73/9940291578359271929.jpg" /><span style="color:#000000;">男人真正需要的九大补药</span><br /><br />　　<strong><span style="color:#000000;">补药四：钙让男性的骨骼硬起来&nbsp;</span></strong><br /><br />　　中国男人每天从食物中摄入的钙远远不能满足身体需要，而且中年男人的钙每天都在流失。研究发现摄入钙较多的男性骨骼较为强壮，而且比摄入量少的男性平均起来要苗条一些，也就是说，适当补充钙质还具有<font color="#0000FF"><span style="color:#000000;">减肥</span></font>疗效，这对于那些大腹便便&nbsp;的男人来说不啻为一个好消息。<br /><br />　　量：医学推荐男性每天推荐摄入钙的量为1克，但大部分男性都做不到这一点。柠檬酸钙比较适于吸收。可以这样来分配摄入量：早晨摄入一半的量即大概600毫克，晚上摄入另一半，因为这样服用可以达到最大吸收量。其实一杯牛奶里就含有300毫克的钙质！多喝点牛奶也能解决问题。另外注意补钙也不要超过2.5克，因为那会带来危险。<br /><br />　　<strong><span style="color:#000000;">补药五：激发男性能量的辅酶</span></strong><br /><br />　　辅酶Q10又名“泛醌”，是一种存在于多种生物体内的脂溶性天然维生素类物质。辅酶Q10可以帮助人体细胞设法获取能量，从而可以激发男性能量释放，是让他年轻并充满活力方法。它还是细胞自身产生的天然抗氧化剂，但是当男性年龄增大了以后，身体产生的Q10辅酶也会相应减少。近年来的研究还表明，辅酶Q10能增强人体免疫力功能和对抗癌症、<font color="#0000FF"><span style="color:#000000;">帕金森</span></font>氏病和亨廷顿病！并且可以让血液变稀，从而预防心脏疾病。<br /><br />　　量：近几年来美国国内形成了真正的天然保健品热，由于辅酶Q10效果确切，故很受西方消费者欢迎。研究者建议，每天100毫克最为合适。这种物质可以在保健品店购买。<br /><br />　　<strong><span style="color:#000000;">补药六：甲壳素—男性关节的润滑油&nbsp;</span></strong><br /><br />　　也许你已经注意到了，30多岁的他已经不再拥有19岁时那样柔韧的关节，这是因为他身体中的甲壳素减少所致。英国《柳叶刀》杂志发表了一篇对200个有关节疾病的人进行的连续3年的研究报告，该报告指出，甲壳素可以减轻关节疼痛，并使关节的强度增强25%，还可以预防进行性风湿性膝关节炎。因此甲壳素可以预防关节损伤，从而使他身手矫健。<br /><br />　　另外，日本研究证实，甲壳素具有免疫强化作用，有助于减少肿瘤细胞的伤害；在环境污染日益严重的今天，减少体内重金属的积蓄甲壳素有助于体内废物的排除，而确保人体生理机能的正常运作。<br /><br />　　量：让他每天服用1.5克的甲壳素，如果和软骨素一起服用效果会更好。饮食中添加虾蟹等食物可以增加甲壳素的摄入。</span></span></font></div><div><font face="瀹嬩綋"><span style="color:#000000;">-------------------------------------------------------</span></font></div><div><font face="瀹嬩綋"><span><span style="font-size:16px;color:#000000;"><img src="http://www.people.com.cn/mediafile/pic/20091215/88/2275397880670410876.jpg" /><span style="color:#000000;">男人真正需要的九大补药</span><br /><br />　　<strong><span style="color:#000000;">补药七：硒——有助于男性抗癌的物质&nbsp;</span></strong><br /><br />　　“没有任何一种单一的<font color="#0000FF"><span style="color:#000000;">营养</span></font>物质比硒的抗癌性更强，硒可以让癌症细胞自行灭亡。”美国药物协会人类营养研究中心的主任Gerald&nbsp;F&nbsp;Combs博士说。Combs博士研究的是提高硒摄入量与癌症发病风险降低之间的联系，这些癌症包括前列腺癌，克隆病，<font color="#0000FF"><span style="color:#000000;">肺癌</span></font>以及其他癌症。试验证明，饮食中硒的缺乏，会造成脂质过氧化物的增加。这种脂质过氧化物长在<font color="#0000FF"><span style="color:#000000;">皮肤</span></font>上就是老年斑，也会存积于心脏、血管、肝脏及脑细胞中，引起诸多系统病变。North&nbsp;Carolina大学动物实验证实：身体内硒含量较低可以让病毒更容易发生突变，从而加重感冒的症状。<br /><br />　　量：需要每天补充硒。按世界卫生组织要求：人体膳食中每日需含200微克硒，当然，如果他生病了，最好要多一些。巴西坚果中含有丰富的天然硒，每个坚果中含有100毫微克的硒！<br /><br />　　<strong><span style="color:#000000;">补药八：延缓他衰老的维生素&nbsp;</span></strong><br /><br />　　维生素E是目前最为有效的抗氧化物质之一。研究还发现维生素E还具有减少运动后肌肉损伤的作用。自由基氧化作用可造成细胞的损坏，促使人体衰老以及增加各种疾病的发病率。当男性还年轻的时候，正常的生理机能可生成抗氧化剂来抵制自由基的氧化反应。但当男性到30-40岁时，体内生成的自由基会越来越多，而生成的抗氧化剂却越来越少。因此对处于生存压力日重的男性来说，补充维生素E是预防衰老的有效办法。<br /><br />　　量：每天使用400国际单位，既然大部分人只能从日常的饮食中摄取一小部分维生素E（混合性食物含有45国际单位）。你可以让他通过吃些干果和油类来提高维生素E的摄入量。在自然界，维生素E广泛分布于动植物油脂、蛋黄、牛奶、水果、莴苣叶等食品中，在麦胚油、玉米油、花生油、棉子油中含量更丰富。最好购买天然的维生素E，而不是人工合成的，因为后者不易被人体利用。<br /><br />　　<strong><span style="color:#000000;">补药九：锌——“性福”的物质&nbsp;</span></strong><br /><br />　　有人统计，人体内200多种酶及大脑中的九化学信号传递系统——神经传递物质的产生都离不开锌。因为锌对维持细胞的完整性、细胞增殖、基因调控、核酸代谢及免疫功能均有重要作用。男性精液中含有高浓度的锌，因而性活动频繁的男性容易缺锌，更应经常补充锌，这对维持旺盛的性功能有很大帮助。锌还有协助维持大脑机能的作用。<br /><br />　　量：推荐的摄入量标准800mg/天，但最新的膳食调查表明，中国男性锌的摄入量达到要求的不到1/3。含锌丰富的食品有海产品（牡蛎、贝壳类、海鱼类）、瘦肉、粗粮及豆科植物等。<br /><br />　　<strong><span style="color:#000000;">中医专家提示&nbsp;</span></strong><br /><br />　　祖国医学强调气血调和、阴阳调和，更强调男人的调补。但是现在许多“补药”一味强调“补”，其实已经走入误区。许多所谓补药大多含刺激神经性药物成分，或许对某些人来说，可以在短时间达到立竿见影的效果。但这些药物沉积在体内，不仅有害人体健康，甚至带来难以弥补的副作用。因此中药“补药”要有明确的针对性，要从调整人体阴阳平衡去考虑，不要人为地破坏了机体的阴阳平衡。</span></span></font></div>', 'gwm', 0, 8),
(141, 'PET/CT在健康体检中的应用', '', '', '', '2009-12-15 13:31:22', '116.228.141.77', '<p><b><span style="font-size:14.0pt;font-family:宋体;color:blue;">为什么要选择<span>PET/CT</span>体检？<span></span></span></b></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;color:#000066;">&nbsp;</span></b></p>\r\n\r\n<p class="MsoNormal" align="left" style="text-align:left;text-indent:24.7pt;\r\nmso-char-indent-count:2.06"><span style="font-size:12.0pt;font-family:宋体;">“<b>身体是革命的本钱”，也是幸福生活的基础。现代人们对物质、文化追求的同时越来越重视身体健康的重要性，全球有关统计表明，近年来，在发达国家或地区对健康体检的需求明显逐年升高，并且有程序设计专业化、项目选择精简化、检查手段规范化、检查方法安全化和检查效果高效化的发展趋势，随着二十世纪末具有划时代意义的<span>PET/CT</span>设备进入临床应用以来，它就已迅速进入健康体检的选择之列。<span></span></b></span></p>\r\n\r\n<p class="MsoNormal" align="left" style="text-align:left;text-indent:24.8pt;\r\nmso-char-indent-count:2.06"><b><span style="font-size:12.0pt;font-family:宋体;">PET/CT</span></b><b><span style="font-size:12.0pt;font-family:\r\n宋体">以其无创性、全身大范围检查、同时反映人体功能与形态表现、图像清晰、早期发现恶性病变及诊断准确性高等独有的、其他检查方法无法替代的优势，必然成为健康体检的真正选择。<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" align="left" style="text-align:left;text-indent:24.8pt;\r\nmso-char-indent-count:2.06"><b><span style="font-size:12.0pt;font-family:宋体;">&nbsp;</span></b></p>\r\n\r\n<p><b><span style="font-size:14.0pt;font-family:宋体;color:blue;">我们为什么要做健康体检<span>?</span></span></b></p>\r\n\r\n<p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\ncolor:blue">&nbsp;</span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">现代人重视健康<span>,</span>希望得到科学、定期的健检，使健康状态最大限度得以保持。<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">现代人以积极的态度应对亚健康期的各种轻微的症状，通过科学、定期的健检<span>,</span>能够早期发现、早期治疗、早期预防，避免和消除疾病隐患。<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">每年一次定期键检，可以建立属于自己的健康<span>“</span>参考值<span>”</span>，作为自身健康状况的指标，针对性较好。<span></span></span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p><b><span style="font-size:14.0pt;font-family:宋体;color:blue;">为什么要选择<span>PET/CT</span>体检？<span></span></span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p style="text-indent:23.6pt;"><b><span style="font-size:12.0pt;font-family:宋体;">二十世纪末具有划时代意义的<span>PET-CT</span>设备进入临床应用并迅速进入健康体检的选择之列<span></span></span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p style="text-indent:17.7pt;"><b><span style="font-size:12.0pt;font-family:宋体;">PET-CT</span></b><b><span style="font-size:12.0pt;font-family:宋体;">－－健康体检的必然选择</span></b><span style="font-size:12.0pt;font-family:宋体;"></span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">全身大范围检查<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">同时反映人体功能与形态表现<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">图像清晰<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">早期发现恶性病变<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">无创伤<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l2 level1 lfo2;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">诊断正确性高<span></span></span></b></p>\r\n\r\n<p><span style="font-size:12.0pt;font-family:宋体;"><!--[if gte vml 1]><v:shapetype\r\n id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"\r\n path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">\r\n \r\n \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n  \r\n \r\n \r\n \r\n<v:shape id="_x0000_s1026" type="#_x0000_t75" style=''width:171.75pt;\r\n height:190.65pt;mso-position-horizontal-relative:char;\r\n mso-position-vertical-relative:line'' stroked="t" strokecolor="lime">\r\n <v:imagedata src="file:///C:\\DOCUME~1\\ADMINI~1\\LOCALS~1\\Temp\\msohtml1\\01\\clip_image001.png"\r\n  o:title="多平面全身"/>\r\n \r\n \r\n<![endif]--><img width="231" height="256" src="file:///C:/DOCUME~1/ADMINI~1/LOCALS~1/Temp/msohtml1/01/clip_image002.jpg" /></span></p>\r\n\r\n<p><span style="font-size:12.0pt;font-family:宋体;">&nbsp;</span></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;color:blue;">图像质量高<span></span></span></b></p>\r\n\r\n<p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\ncolor:blue"><span>&nbsp;</span></span></p>\r\n\r\n<p style="text-indent:23.6pt;"><b><span style="font-size:12.0pt;font-family:\r\n宋体">肿瘤医院<span>PET/CT</span>机为德国西门子公司近年推出的最新型超高档功能性影像设备<span>-</span><span>西门子<span>BIOGRAPH\r\n16HR PET/CT</span></span></span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;"><span>&nbsp;&nbsp;&nbsp;\r\n</span></span></b><b><span style="font-size:12.0pt;font-family:宋体;">专业技术居于世界领先地位，为国内同型机器首台，具有显像清晰、分辨率高、图像融合精准、后处理功能强大的优点，让你成为“透明人”。<span></span></span></b></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;">&nbsp;</span></b></p>\r\n\r\n<p><span style="font-size:12.0pt;font-family:宋体;">&nbsp;</span></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;color:blue;">准备简易、检查简便</span></b><span style="font-size:12.0pt;font-family:宋体;color:blue;"> <span></span></span></p>\r\n\r\n<p><span lang="EN-US" style="font-size:12.0pt;font-family:宋体;\r\ncolor:blue">&nbsp;</span></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">检查前只注射几毫升的显像剂稀释液，<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">检查过程中受检者只需保持静躺不动，<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">根据不同情况，合理调整检查方案，使受检者感受更人性化、更舒适的服务，<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">而且检查时间短，一般实际检查时间只需<span>20</span>分钟左右。<span></span></span></b></p>\r\n\r\n<p class="MsoNormal" style="margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo3;\r\ntab-stops:list 36.0pt"><span lang="EN-US" style="font-size:\r\n12.0pt;font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:\r\nWingdings;mso-bidi-font-weight:bold"><span>l<span style="Times New Roman&quot;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><b><span style="font-size:12.0pt;font-family:宋体;">受检者只需做好检查前空腹、非剧烈体力活动后等准备即可<span> </span></span></b></p>\r\n\r\n<p><b><span style="font-size:12.0pt;font-family:宋体;"><span>&nbsp;</span></span></b></p>\r\n\r\n<p><b><span style="font-size:14.0pt;font-family:宋体;color:blue;">复旦大学附属肿瘤医院<span> PET-CT</span>中心拥有一流的医疗专家队伍<span></span></span></b></p>\r\n\r\n<p><b><span lang="EN-US" style="font-size:12.0pt;font-family:\r\n宋体">&nbsp;</span></b></p>\r\n\r\n<p><span style="font-size:12.0pt;font-family:宋体;"><span>&nbsp;&nbsp;&nbsp; </span></span><b><span style="font-size:12.0pt;\r\nfont-family:宋体">在复旦大学附属肿瘤医院这一高层次医院的平台上，拥有国内一流的核医学<span>PET-CT</span>专家、教授及专业医学影像工程师，长期从事肿瘤核医学诊断及治疗临床工作，具有扎实的理论基础、丰富的临床实践经验及先进的诊疗思维，擅长全身各个系统的常见病、多发病、较疑难病变，尤其是肿瘤性病变的诊断及鉴别诊断，诊断全面、准确率高，保证了高质量诊断报告，为您的健康保驾护航，是您可以信赖的健康保健专家。<span></span></span></b></p>', 'gwm', 0, 11),
(142, '认识陌生的核医学', '', '', '', '2009-12-15 13:33:53', '116.228.141.77', '<p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">论及最先进的诊断仪器，很多人会想到<span style="background-color:#ffffff;">PET/CT(</span>正电子断层扫描<span style="background-color:#ffffff;">)</span>。但普通老百姓可能并不知道，<span style="background-color:#ffffff;">PET/CT</span>属于核医学类。现代医学发展日新月异，核医学堪称其中的典型代表，它的发展史与原子能的发现几乎同步。仅仅数十年，核医学已在疾病的诊断治疗中发挥巨大作用。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">&nbsp;&nbsp;&nbsp; </span><strong><span style="font-size:18pt;font-family:宋体;color:blue;background-color:#ffffff;">核医学：临床诊断的一把<span style="background-color:#ffffff;">“</span>利剑<span style="background-color:#ffffff;">”</span></span></strong><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><strong><span style="font-size:18pt;font-family:宋体;color:blue;background-color:#ffffff;">&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;<span style="color:#000000;font-family:simsun;font-size:medium;font-weight:normal;"><img src="/image_server_dir/7af5e27457e4b1422a479aac3aa80deb.jpg" alt="" border="0" /></span></span></strong></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">&nbsp;</span><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　<span style="background-color:#ffffff;">&nbsp;</span></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;"><span style="background-color:#ffffff;">&nbsp; </span></span><span style="font-size:14.0pt;color:black;"><span style="background-color:#ffffff;">&nbsp;&nbsp;&nbsp;</span></span><span style="font-size:14pt;color:black;background-color:#ffffff;">上图说明：右上角为正电子放射性药物氟<span style="background-color:#ffffff;">-18-</span>脱氧葡萄糖的分子结构，左上角为生产这种药物的设备之一回旋加速器，下图为显示药物在人体内分布的分子影像设备<span style="background-color:#ffffff;">PET/CT</span>。上述两种设备已安装在复旦大学附属肿瘤医院核医学科<span style="background-color:#ffffff;">PET</span>中心，可用于肿瘤诊断和健康体检。<span></span></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:14.0pt;color:black;"><span style="background-color:#ffffff;">&nbsp;</span></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;"><span style="background-color:#ffffff;">&nbsp;</span></span><strong><span style="font-size:13.5pt;font-family:宋体;color:black;background-color:#ffffff;">核医学不等于核辐射</span></strong><b><span style="font-size:13.5pt;color:black;background-color:#ffffff;"><br />\r\n</span></b><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　谈到核医学，先来说说核医学的主角<span style="background-color:#ffffff;">———</span>放射性核素。在元素周期表内，占据每个小格子的每个元素，大多有自己的孪生兄弟，互称同位素。它们<span style="background-color:#ffffff;">“</span>长相相似<span style="background-color:#ffffff;">”———</span>即化学性质一样，<span style="background-color:#ffffff;">“</span>性格各异<span style="background-color:#ffffff;">”———</span>即物理性质不一样。<span style="background-color:#ffffff;">“</span>沉稳<span style="background-color:#ffffff;">”</span>的被称为稳定同位素，<span style="background-color:#ffffff;">“</span>活泼<span style="background-color:#ffffff;">”</span>的则会发射出各种射线，如<span style="background-color:#ffffff;">γ</span>（伽玛）射线、<span style="background-color:#ffffff;">β</span>（贝塔）射线等，它们又被称为放射性同位素，或放射性核素。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　不少人会以为：核辐射对人体危害颇大，多接触核医学肯定弊大于利。这样的看法其实很片面。先来解释一下核辐射。原子核从一种结构或一种能量，转变为另一种结构或另一种能量过程中所释放出来的微观粒子流，被称为核辐射。核辐射必须达到足够的量与时间才会伤害到人体。在医学诊疗中，患者并不长期接触核物质，因此不必担心安全问题。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　我们从核医学诊断来看，每个放射性核素都有自己的寿命，医学术语称之为<span style="background-color:#ffffff;">“</span>半衰期<span style="background-color:#ffffff;">”</span>。拿<span style="background-color:#ffffff;">PET/CT</span></span><span style="font-size:13.5pt;background-color:#ffffff;">检查作比方，所用的正电子核素量非常少，半衰期也仅为<span style="background-color:#ffffff;">110</span>分钟，在体内释放一个正电子后，核素也已<span style="background-color:#ffffff;">“</span>奄奄一息<span style="background-color:#ffffff;">”</span>了；诊断上用的最多的单光子核素，其半衰期也只有<span style="background-color:#ffffff;">6.02</span>小时，射线能量非常低。以这种半衰期及能量来看，核素的威力对人体并没有危害。但在临床治疗中所用的核素，射线能量会很高或半衰期很长，正规医疗机构会严格控制适应症和使用场所，将放射性核素的副作用降低到最低程度，并消除一切可能的放射性污染。</span><span style="font-size:14.0pt;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　<strong><span style="font-family:宋体;background-color:#ffffff;">核医学与其他影像诊断有何不同</span></strong></span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　同样是诊断手段，核医学诊断与<span style="background-color:#ffffff;">CT</span>、<span style="background-color:#ffffff;">B</span>超等一般影像诊断有什么区别吗？简单地说来，器官、组织、细胞和生命物质发生生化或功能改变那一刻，</span><span style="font-size:13.5pt;background-color:#ffffff;">核医学诊断便可以在影像中体现出来<span style="color:black;background-color:#ffffff;">。做核医学影像之前，被检查者必须口服或注射放射性药物到体内，再利用伽玛相机、<span style="background-color:#ffffff;">SPECT</span>或<span style="background-color:#ffffff;">PET</span>，显示存在于体内特定器官、组织、细胞和生命物质上的射线的密度。通过射线密度，可以从分子医学的水平早期反映体内生化改变。诸如<span style="background-color:#ffffff;">CT</span>、<span style="background-color:#ffffff;">B</span>超等的医学影像无须引入造影剂，就可以产生一个解剖性图像，这类图像分辨率非常高，不过难以识别形态上尚未发生改变的病变组织。</span></span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　那么，两者孰优孰劣？其实各有各的好处。解剖性的医学诊断如同步入亮满灯的灯具店，放眼望去，映入眼帘的全是亮着的各式各样的灯，你很难找出暗的坏掉的灯。核医学诊断则如同黑暗里的一盏明灯，很容易被发现，表明代谢增高、存在恶性肿瘤，但“明灯”的周围还有什么结构就不能表现出来。因此，现代的核医学已经结合了放射诊断科的<span style="background-color:#ffffff;">CT</span>，引进了带有<span style="background-color:#ffffff;">CT</span>的<span style="background-color:#ffffff;">SPECT</span>、<span style="background-color:#ffffff;">PET,</span>即<span style="background-color:#ffffff;">SPECT/CT</span>、<span style="background-color:#ffffff;">PET/CT,</span>这些设备充分结合了核医学和其它影像诊断的优点，将生化的、功能的影像与解剖图像融合在一起，给临床医生提供更早期、更精确的影像诊断。迄今为止，核医学在肿瘤、心脑血管疾病诊断等领域已发挥出巨大作用。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\r\n</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　<strong><span style="font-family:宋体;background-color:#ffffff;">肿瘤标志物高了，并非一定生肿瘤</span></strong></span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　目前，肿瘤标志物已成为核医学科标记免疫学测量的主要内容。何谓肿瘤标志物？它是指在正常人体内仅微量存在，或仅在出生后的一段时间内存在，但发生肿瘤后浓度会增加的物质，它可以是蛋白质、激素等。具有较高敏感度及特异性的肿瘤标志物是临床上肿瘤辅助诊断、病情分期、疗效判断、诊断复发的重要指标。不过，肿瘤标志物只是一种参考，患者测出肿瘤标志物高，并非肯定患上肿瘤。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　由于肿瘤标志物会非特异性地增高，例如患者得了胃肠道炎症或长期抽烟等，就会出现一定水平的肿瘤标志物。因此，当测出肿瘤标志物水平偏高时，不应该马上就确定患了肿瘤。若连续观察，肿瘤标志物水平较上一次测量高出<span style="background-color:#ffffff;">30%</span>以上，则有可能生肿瘤；若低于<span style="background-color:#ffffff;">30%</span>，则不必太过恐慌。<span style="background-color:#ffffff;">&nbsp;&nbsp;</span></span><span lang="EN-US" style="font-size:14.0pt;\r\ncolor:black"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:14pt;color:black;background-color:#ffffff;"><br />\r\n</span><span style="font-size:13.5pt;color:black;background-color:#ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;<strong><span style="font-family:宋体;background-color:#ffffff;">&nbsp;</span></strong></span><strong><span style="font-size:13.5pt;font-family:宋体;color:black;background-color:#ffffff;">什么叫做核医学？</span></strong><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">&nbsp; </span><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　 很多老百姓知道，拍<span style="background-color:#ffffff;">X</span>线、做<span style="background-color:#ffffff;">CT</span>会对人体产生辐射，自然而然地，听到<span style="background-color:#ffffff;">“</span>核医学<span style="background-color:#ffffff;">”</span>这个新名词，有些人便<span style="background-color:#ffffff;">“</span>谈核色变<span style="background-color:#ffffff;">”</span>。其实，核医学并非全新的医学领域，作为现代医学的重要组成部分，核医学已有<span style="background-color:#ffffff;">60</span>多年的历史，我国核医学起步于上个世纪五十年代末。<span style="background-color:#ffffff;"><br />\r\n</span>　　那么，什么叫做核医学？核医学就是利用放射性核素发射出的射线，进行研究、诊断和治疗的一门医学分支，它的发展有赖于放射性药物和放射性探测设备。核医学涉及核药学、生物化学与分子生物学、免疫学、应用化学、核物理、核电子、计算机等多种基础与边缘学科。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:13.5pt;color:black;background-color:#ffffff;">　　临床核医学一般分为体内、体外两个部分。体内诊断，即用<span style="background-color:#ffffff;">ECT</span>、<span style="background-color:#ffffff;">PET/CT</span>探测诊断性放射性药物在人体内的分布，继而产生各种图像，为临床诊断作参考；体内治疗，即利用能浓聚在病变部位的治疗性放射性药物（包括粒子）发出来的射线，以此消灭病变细胞。要强调的是，体外诊疗时，放射性药物是不进入体内的。体外诊断，也就是标记免疫分析，它利用各种物质（包括放射性或稳定性的同位素等），测量人体内一些微量成分如激素、肿瘤标志物等，为临床诊断作参考。体外治疗，则是用放射性物质与皮肤、黏膜的近距离接触，对局部病变组织进行照射治疗。</span><span style="font-size:14.0pt;color:black;"></span></p><span style="background-color:#ffffff;">\r\n\r\n</span><p><span style="font-size:14pt;color:black;background-color:#ffffff;">&nbsp;</span></p><span style="background-color:#ffffff;">\r\n\r\n</span><span style="font-size:13.5pt;font-family:''times new roman'';color:black;background-color:#ffffff;">&nbsp;&nbsp; </span><strong><span style="font-size:13.5pt;font-family:宋体;color:black;background-color:#ffffff;">专家档案</span></strong><span style="font-size:13.5pt;font-family:''times new roman'';color:black;background-color:#ffffff;"><br />\r\n</span><span style="font-size:13.5pt;font-family:宋体;color:black;background-color:#ffffff;">　</span><span style="font-size:13.5pt;font-family:楷体_gb2312;color:black;background-color:#ffffff;"> 章英剑 复旦大学附属肿瘤医院核医学科主任，硕士生导师，主任医师。担任中华医学会核医学分会委员、<span style="background-color:#ffffff;">PET</span>与分子核医学专业委员会副主任委员，上海市医学会核医学分会副主任委员，上海市核学会理事、临床核医学专业副主任委员、标记免疫学专业委员会副主任委员，中华核医学杂志、中国癌症杂志编委。每周二下午开设专家门诊。</span>', 'gwm', 0, 10),
(143, '在美国瘦意味着高贵地位高的人不会肥胖', '', '', '', '2009-12-16 10:50:17', '116.228.141.77', '<p>林顿、布什的经济顾问，轰动全球的《财富第五波》作者北大开讲——</p><p>　　在美国，瘦意味着高贵</p><p>　　如今在美国，公司高管、政府要员等大都有着标准的身材，反而是雇员、生活不济者却是大腹便便。国际著名经济学家、美国前总统克林顿和布什的经济顾问保罗皮尔泽说，这个一个很有意思的现象，在美国，似乎胖和瘦也成为了旁人判断一个人成功与否的标签。</p><p>　　保罗胖瘦刚刚好，他说：“越是有身份有一定社会地位的人，越能认识到健康对于个人和社会的重要性，因此，绝不会让肥胖成为健康的隐形炸弹。而这些人也影响着所有的美国大众，他们已经成为美国人争相减肥的榜样。”</p><p>　　保罗在其著作中强调，继蒸汽机、电力生物技术、计算机和网络后，全球财富第五波明星产业将是健康保健。“拿美国为例，前两年在疾病治疗上的花费达两万五千亿美元，这个数字几乎相当于中国GDP的一半了。如此巨额的医疗费用，正是前些年没有很好地关注公众营养的恶果。因此，更多的人把治疗转向了预防。健康保健便必然会成为全民关注的、人人都要经营的产业。”</p><p>　　保罗如今也将眼光投向了健康产业，他说：健康已经成为美国人推动一切经济发展的根基。</p><p>　　当被问及他自己的保健方法时，保罗总结：运动+合理膳食+必要的膳食补充剂。</p>', 'gwm', 0, 11),
(144, '癌症康复者因体检不合格被卫生局拒绝录用', '', '', '', '2009-12-16 10:54:00', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p>时报讯 近日，温州某论坛上，一个叫“窦娥”的网友发的帖子引起了网友们的关注。</p><p>　　“窦娥”在帖子中称：今年8月，瓯海区卫生系统公开招聘工作人员，她报考了助产士专业，最后考了第一名。但是，因为曾得过癌症，录用体检时她被告之自己“不合格”。</p><p>　　“我得的病在7年前就治好了。”“窦娥”说，“为此我还特地跑了一趟上海，复查结果显示我的身体一切正常。这么多年来，我在自己的岗位上为6万多名孕妇做过检查，凭什么拒绝录用我？”</p><p>　　有网友称，歧视癌症康复者，和歧视“乙肝携带者”一样，是完全不合理的。</p><p>　　<strong>工作10年，一直是临时工</strong></p><p>　　“窦娥”姓沈，1976年出生。1999年，沈小姐从温州医学院毕业，被瓯海区第三人民医院聘为助产士，而后一直在该医院上班，工作性质为临时工。</p><p>　　2003年，在一次体检中，沈小姐被查出了左肾癌。同年7月份，沈小姐到上海复旦大学附属肿瘤医院进行了左肾根治性切除术。手术后3个月，沈小姐又回到单位上班。</p><p>　　今年8月份，瓯海区组织了医疗卫生单位公开招聘考试，沈小姐报考的是助产士。</p><p>　　“我理论基础69分，专业知识68分，是我这个岗位笔试的第一名。”沈小姐说，“当时得知自己的成绩，我兴奋极了。”</p><p>　　但是，随后的体检却给沈小姐浇了一盆冷水。10月20日，沈小姐按照招聘程序到瓯海区人民医院体检，体检的结果是“不合格”。之后，沈小姐提出了复检申请，复检的结论仍然为“不合格”。</p><p>　　虽然曾经患过癌症，但如今已经康复了，而且医院也有证明，为什么在体检时会被认定为不合格？</p><p>　　“手术后，我的身体一直都很健康，每次复查各项指标都正常，从没为此请过病假。”沈小姐愤怒地说，“他们这是在歧视癌症康复者。”</p><p>　　<strong>卫生局：</strong></p><p>　　<strong>根据的是体检情况及病史记录</strong></p><p>　　对此，瓯海区卫生局一名姓林的负责人表示，此次瓯海区卫生系统的录用体检，参照了《公务员录用体检通用标准》。他说：“体检不合格是根据沈小姐体检情况及病史材料，按照公务员录用体检标准第八条及条文解释，综合分析后作出的。”</p><p>　　《公务员录用体检通用标准》第八条规定，“各种恶性肿瘤和肝硬化，不合格。”但是，在该条文解释中则表示：“有恶性肿瘤病史者原则上应从严掌握，一般作不合格结论。对个别自述幼时曾患‘恶性肿瘤’，经治疗无复发迹象，经专家特别鉴定后按合格对待。”</p><p>　　对沈小姐做复检的瑞安市人民医院的主检医师黄佰曙说：“(沈小姐)体检各项目值都正常。”</p><p>　　当记者询问，如何把握公务员体检标准中所说的“一般作不合格结论”的尺度时，黄医生说，本次体检复检结论由两个医生做出，如果不服可以到其他医院再做检查。同时，黄佰曙医生表示，对恶性肿瘤康复的有关情况，目前医学界也有许多不同的说法，并不能认定沈小姐已经彻底康复。</p></span>', 'gwm', 0, 9);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(145, '网帖称病人呼吸机停止多时 值班医生在看电影', '', '', '', '2009-12-17 09:53:11', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p>儿子探病时候发现父亲的呼吸机已停止多时，而负责医生正忙于看当时的热片《功夫熊猫》……</p><p>　　文/记者陆建銮</p><p>　　此前网上疯炒的医生偷菜治死病人的新闻刚过去不久，近日，网上一个帖子《ICU医生看〈功夫熊猫〉 不知病人呼吸机停电》再度曝光类似的情况，医护人员的责任心问题再度被网友推到了风口浪尖。</p><p>　　帖子称，唐某在中南大学湘雅医院总ICU治病，唐某儿子探病时发现唐某的呼吸机已停止多时，而负责医生正忙于看当时的热片《功夫熊猫》，随后唐某陷入深度昏迷，并最后死亡。昨日，本报致电中南大学湘雅医院医务部门时，医务部工作人员称，确实有唐某呼吸机停止随后死亡一事，但医疗鉴定证实并非医疗事故。</p><p><strong>　　唐某儿子：</strong></p><p><strong>　　父亲呼吸机停止 医生忙看《功夫熊猫》</strong></p><p>　　该网帖最先发布在著名网友张洪峰的博客，记者通过联系人，找到了事件中唐某的儿子唐先生。身在湖南长沙的唐先生表示，事情发生在2008年6月25日，但是由于父亲曾任乡交通局局长，家里在当地也算有点名望，本不想把事情公开，“后来跟医院协商一直都没什么结果，我在录音取证后，就想公开这个事情，大家评评理。”据唐先生回忆，当时他与母亲一进房门，发现父亲用的呼吸机灯不亮了，“我赶紧大叫医生和护士过来，当我冲到医生办公室时，发现值班医生马新华正在看流行的电影《功夫熊猫》，我催促他，他还满脸不高兴，怪我打扰他。”唐先生一再表示，呼吸机停止的时间并不短，但医院没有及时发现并采取措施。</p><p><strong>　　提供录音</strong></p><p><strong>　　医院承认呼吸机停机先由家属发现</strong></p><p>　　唐先生向记者提供了医院给他们家属的疑问答复。这份盖有中南大学湘雅医院医务部公章的答复里称，“2008年6月25日晚，出现跳闸停电，不是重大事故，而是意外”，答复还称，患者在医院ICU治疗过程符合程序，医院一直采取积极治疗措施，医院对患者治疗过程中不存在任何的差错和事故。</p><p>　　唐先生称，正是出于对这份答复及医院态度的不满，他再次找上医院协商，并全程录音。记者在录音里听到，唐先生质疑呼吸机停止是由家属发现。医务部负责人称：“我们不否认这个事实。”另外一个医务部人员说：“我们承认这个事实就是了。”</p><p><strong>　　医院医务部：</strong></p><p><strong>　　确有唐某呼吸机停止一事，医院无过错</strong></p><p>　　昨日下午，记者致电中南大学湘雅医院医务部，一名工作人员接电话后表示，确实有唐某呼吸机停止并过几天后死亡一事，该事也是由医务部与家属协商：“对于这个事情，我们有医疗鉴定结果，可以证实我们医院没有过错，而且事情正与家属通过司法途径解决。”</p><p>　　记者想要医疗鉴定结果并试图核实当时是否值班医生在观看电影，医务部工作人员不作正面回应。</p></span>', 'gwm', 0, 8),
(146, '网帖称病人呼吸机停止多时 值班医生在看电影', '', '', '', '2009-12-17 10:00:39', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p>儿子探病时候发现父亲的呼吸机已停止多时，而负责医生正忙于看当时的热片《功夫熊猫》……</p><p>　　文/记者陆建銮</p><p>　　此前网上疯炒的医生偷菜治死病人的新闻刚过去不久，近日，网上一个帖子《ICU医生看〈功夫熊猫〉 不知病人呼吸机停电》再度曝光类似的情况，医护人员的责任心问题再度被网友推到了风口浪尖。</p><p>　　帖子称，唐某在中南大学湘雅医院总ICU治病，唐某儿子探病时发现唐某的呼吸机已停止多时，而负责医生正忙于看当时的热片《功夫熊猫》，随后唐某陷入深度昏迷，并最后死亡。昨日，本报致电中南大学湘雅医院医务部门时，医务部工作人员称，确实有唐某呼吸机停止随后死亡一事，但医疗鉴定证实并非医疗事故。</p><p><strong>　　唐某儿子：</strong></p><p><strong>　　父亲呼吸机停止 医生忙看《功夫熊猫》</strong></p><p>　　该网帖最先发布在著名网友张洪峰的博客，记者通过联系人，找到了事件中唐某的儿子唐先生。身在湖南长沙的唐先生表示，事情发生在2008年6月25日，但是由于父亲曾任乡交通局局长，家里在当地也算有点名望，本不想把事情公开，“后来跟医院协商一直都没什么结果，我在录音取证后，就想公开这个事情，大家评评理。”据唐先生回忆，当时他与母亲一进房门，发现父亲用的呼吸机灯不亮了，“我赶紧大叫医生和护士过来，当我冲到医生办公室时，发现值班医生马新华正在看流行的电影《功夫熊猫》，我催促他，他还满脸不高兴，怪我打扰他。”唐先生一再表示，呼吸机停止的时间并不短，但医院没有及时发现并采取措施。</p><p><strong>　　提供录音</strong></p><p><strong>　　医院承认呼吸机停机先由家属发现</strong></p><p>　　唐先生向记者提供了医院给他们家属的疑问答复。这份盖有中南大学湘雅医院医务部公章的答复里称，“2008年6月25日晚，出现跳闸停电，不是重大事故，而是意外”，答复还称，患者在医院ICU治疗过程符合程序，医院一直采取积极治疗措施，医院对患者治疗过程中不存在任何的差错和事故。</p><p>　　唐先生称，正是出于对这份答复及医院态度的不满，他再次找上医院协商，并全程录音。记者在录音里听到，唐先生质疑呼吸机停止是由家属发现。医务部负责人称：“我们不否认这个事实。”另外一个医务部人员说：“我们承认这个事实就是了。”</p><p><strong>　　医院医务部：</strong></p><p><strong>　　确有唐某呼吸机停止一事，医院无过错</strong></p><p>　　昨日下午，记者致电中南大学湘雅医院医务部，一名工作人员接电话后表示，确实有唐某呼吸机停止并过几天后死亡一事，该事也是由医务部与家属协商：“对于这个事情，我们有医疗鉴定结果，可以证实我们医院没有过错，而且事情正与家属通过司法途径解决。”</p><p>　　记者想要医疗鉴定结果并试图核实当时是否值班医生在观看电影，医务部工作人员不作正面回应。</p></span>', 'gwm', 0, 6),
(147, '研究称满月会诱发人性中“狼性” 令人暴躁', '', '', '', '2009-12-17 10:03:14', '116.228.141.77', '<div>满月诱使“狼人”“变身”</div><div><br /></div><div>　　研究表明一些人在满月期间具有暴力倾向</div><div><br /></div><div>　　月圆之夜，人变身成狼……这似乎只存在于魔幻故事中。澳大利亚研究人员观察发现，满月确实会诱发人性中的“狼性”，令人脾气暴躁，更具暴力倾向和攻击性。</div><div><br /></div><div>　　满月暴力</div><div><br /></div><div>　　澳大利亚纽卡斯尔卡尔瓦里梅特医院毒理学临床研究护士莱奥妮·卡尔弗和同事观察发现，医院急诊部在月圆之夜收到的暴力倾向病人较往常多。</div><div><br /></div><div>　　在2008年8月至2009年7月期间，共有91名具有暴力倾向和攻击性的病人被送往医院急诊部。</div><div><br /></div><div>　　“一些病人像动物一样攻击医务人员，又抓又咬，”卡尔弗说，“就像过去传说中的狼人，狼人也只在月圆之夜现身。”</div><div><br /></div><div>　　医务人员不得不给这些病人使用镇静剂或者束缚他们的身体，以防伤人。</div><div><br /></div><div>　　“变身”原理</div><div><br /></div><div>　　卡尔弗说，在狼人传说中，人通过涂抹“魔力药膏”或吸入这类药物的蒸汽，变身为野兽。“魔力药膏”的主要成分包括颠茄和龙葵。这两种物质都能导致人精神错乱，产生变身幻觉。</div><div><br /></div><div>　　她说，“现代狼人”通常喜欢酒精或者违禁药物。研究涉及的91个病例中，60名病人即66%受酒精或违禁药影响。我们的研究证实，满月期间，更多具有暴力倾向和攻击性行为的人被送往急诊部。</div><div><br /></div><div>　　多种解释</div><div><br /></div><div>　　卡尔弗说，先前关于满月影响人类情绪的解释有多种。</div><div><br /></div><div>　　一种说法是，水约占人体重量的70%。月球引力也能像引起海洋潮汐那样对人体中的液体发生作用，称之为生物潮。满月时，月亮对人的情绪影响比较大，易使人亢奋激动。另一种说法是，月圆之夜的月亮更加明亮，一些人因此难以入眠，由此产生狂躁情绪。</div><div><br /></div><div>　　她说，这些说法都没有解释满月与暴力之间的联系。一些人可能在月圆之夜更喜欢饮酒或服用违禁药物，从而导致暴力和精神错乱病例增加。</div>', 'gwm', 0, 8);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(148, '过度医疗成中国医患对立焦点 医学被指淡忘使命', '', '', '', '2009-12-17 10:14:40', '116.228.141.77', '<span style="font-family:verdana, arial, helvetica, sans-serif;font-size:14px;"><p>1936年4月17日，面对蒙特利尔内外科学会的诸位同道，白求恩医生慷慨宣称：“让我们把盈利、私人经济利益从医疗事业中清除出去，使我们的职业因清除了贪得无厌的个人主义而变得纯洁起来。让我们把建筑在同胞们苦难之上的致富之道，看作是一种耻辱。”</p><p>　　如今，73年过去了，我们不得不尴尬地承认：白求恩许下的，仍旧是一个未竟的宏愿。</p><p>　　有人认为，二十多年来，中国的情形是更糟糕了——医患之间的经济利益正逐步变得对立，甚至是敌对，过度医疗即为明证。</p><p>　　人们发现：能吃药不打针、能打针不输液的医疗常识似乎有些不好用了，询问病史、体格检查等常规程序也不很流行了；取而代之的是，“最好的”药物、“最高端的”检查、“最先进的”手术，当然，还有最昂贵的费用。</p><p>　　人们又发现：这些巨资换来的药物、检查、手术，有时候尚属物尽其用，有时候却只是“高射炮打蚊子”——获益未必很大，风险却着实不小。</p><p>　　于是人们惊讶了：这些看上去不那么理性的医疗行为，其实透着另一种“理性”——只要你采取的是医院、医生的立场。</p><p>　　正如有学者指出的，在现行体制机制下，“医院要赚钱，赚钱就要扩大规模，扩大规模要有资金，资金靠贷款，还贷款就逼迫医生进一步赚钱”，而医院、医生赚钱的办法就是卖药、卖检查。换言之，是体制、机制把医患推入冲突。</p><p>　　同样值得警惕的，是自20世纪以来对“科学”、“技术”近乎迷信的崇拜和几乎无条件的追随。</p><p>　　一百多年来，从普通X射线到核磁共振成像，从铁肺到人工脏器，医学技术日新月异，不断突破着生命的禁区，人类因而前所未有地健康长寿。</p><p>　　孰料，这些寄托着人们美好愿望的先进技术设备，却也为今日的医疗埋下了利益驱动、技术崇拜的伏笔。有人甚至断言：“目前某些备受推崇的‘高技术’其实既不高明也不高效，只是费用高昂而已。”</p><p>　　学者们亦开始反思：技术、设备是不是正在使医学背离自己的初衷？医学是不是正在淡忘自身的使命？</p><p>　　更大的挑战是，在医疗卫生资源总体有限的现实下，有多少人是站在社会公正的角度上，去评估医学技术的社会价值？在“审计”社会为医学技术的进步支付了何种代价？</p><p>　　在公众对医生动机的怀疑、对医疗技术的失望中，中国的新一轮医改启动了。</p><p>　　面对渐次展开的对公立医院的改革、对种种利益关系的调整，我们格外需要医务工作者们像白求恩那样，清洁自己的精神，守住医疗的“度”。</p><p>　　因为，健康所系，性命相托。(文/张冉燃)</p><p>　　<strong>阅读导航： 　</strong></p><p>　　医用设备的“生意”</p><p>　　“人文不是可有可无的”</p><p>　　<strong>被植入体内的“GDP”</strong></p><p>　　“一个医院能不能通过三甲医院评审，做了多少例介入手术是一个标志性指标，像GDP一样”</p><p>　　<strong>文/《瞭望》新闻周刊记者张冉燃</strong></p><p>　　如果你的心脏被置入一枚支架，你需要为这种直径2～4毫米、重量不足万分之一克的“金属丝网”支付大约1万～2万元钱。</p><p>　　“如果患者花这么多钱，买到的只是精神上的痛苦和身体上的损失，那是非常尴尬的。如何避免介入技术的过度使用，这让我非常焦虑。”中华医学会心血管分会主委、北京大学人民医院心脏中心主任胡大一告诉《瞭望》新闻周刊。</p><p>　　据统计，2008年，中国接受冠心病介入治疗的患者约18.8万人。</p><p>　　卫生部心血管疾病(冠心病介入)医疗质量控制中心负责人、北京大学第一医院心内科主任霍勇对这个数字喜忧参半：“这的确说明冠心病介入技术得到普及推广，但我们并不知道，这些病例中究竟有多少不合乎规范。”</p><p>　　霍勇坦言，中国需要在高起点上解决冠心病介入技术使用不足与过度同时存在的问题：既要抓技术的普及推广，又要强调规范和质量。</p><p>　　<strong>介入与搭桥</strong></p><p>　　在冠心病介入技术进入中国之初的上世纪80年代，它承载的是帮助患者“起死回生”的希望。</p><p>　　冠心病是冠状动脉性心脏病的简称，它是由于冠状动脉粥样硬化或痉挛，导致血管狭窄或阻塞，最终引发心肌缺血缺氧梗死的一种疾病。</p><p>　　这种最常见的心脏病，发病率高、死亡率高，多年来一直位列中国人口死因前列。</p><p>　　据霍勇介绍，冠心病的治疗大致包括药物疗法、外科搭桥疗法和内科介入疗法三种传统方法，以及尚处于研究初期的基因治疗等新型疗法。“世界上是先有搭桥疗法，后有介入疗法，但就进入中国的时间来说，二者几乎同时。”</p><p>　　搭桥手术是外科中较复杂、较昂贵的手术之一，且死亡率较高。与之相比，介入疗法无需打开胸腔，只需穿刺外周动脉插入一根导管，把支架送到狭窄的冠状动脉，即可解决问题。</p><p>　　霍勇评价说：“介入治疗是心血管病治疗史上的一场革命。”</p><p>　　30多年来，以单纯球囊扩张术、金属裸支架置入术和药物洗脱支架置入术为标志，冠心病的介入治疗已经跨越3个台阶。中国无不亦步亦趋，紧紧追随。</p><p>　　霍勇说，为了攻克单纯球囊扩张术后出现的急性血管闭塞、术后中远期再狭窄率高(30%～50%)等问题，发明了支架置入术；然而，早期的金属裸支架未能从根本上解决再狭窄问题，只是将血管再狭窄率降到20%～30%，药物洗脱支架的诞生，使血管再狭窄率得以低于10%。</p><p>　　胡大一向本刊记者回忆说，他上世纪80年代被派到美国学习时，想的就是应该学习这项先进技术，让中国的老百姓能够有权利、有勇气享受现代医学科学技术的进步。“所谓勇气，就在于当时对介入治疗方法，很多人谈虎色变，毕竟这种治疗会带来创伤。”</p><p>　　对于微创手术的看法尚且如此，术中需要开胸、全麻的搭桥技术在中国面临的压力可想而知。霍勇评论道：“搭桥和介入虽几乎同时被引入中国，但介入治疗的发展形势远远好于搭桥。”</p><p>　　霍勇行医近三十年，目睹并亲身经历了心脏病介入治疗，尤其是冠心病介入治疗的发展。“从1984年到1996年，中国总共只做了5000例介入手术，起初每年只能做几十例。从1996年至今，随着大批医生从国外培训回来，介入技术迅速发展，日臻成熟，2007年总共完成14万多例介入手术，2008年达到18.8万例，今年的统计数字肯定超过去年。”</p><p>　　<strong>是否滥用</strong></p><p>　　大发展中，介入技术开始遭遇质疑——人们对冠心病介入诊治的“度”存有争议，因而反思这种大发展是不是“大跃进”。</p><p>　　2004年，中国生物医学工程学会副理事长、工程院院士俞梦孙在接受媒体采访时，直率地以心脏支架手术为例，抨击过度医疗。他说，现在有很多心血管病人动辄就需要“插导管、放支架”，这本来是急救措施，但目前已经到了“使用泛滥”的地步，很多心脏科医生都最擅长这个技术难度很高的手术。</p><p>　　俞梦孙认为，在没有出现支架之前，很多心血管阻塞的病人通过改变生活方式和行为嗜好缓解病情，医疗效果非常显著，如无意外发生，根本不需要在心脏内安放用于扩张血管的支架。</p><p>　　霍勇表示，“对于某个病例究竟是药物治疗，还是选择搭桥、介入治疗，这是可以说得清的。”</p><p>　　据他介绍，根据《经皮冠状动脉介入治疗指南》，稳定性心绞痛症状不严重的患者一般只需药物治疗，而在发生较大面积较严重心肌缺血或出现急性心脏事件时，应考虑介入治疗，前提是接受药物治疗的患者必须严格控制危险因素，遵医嘱服药。“当然，指南不是强制性的，经治医生有权决定最终治疗方案。有些医生没有始终严格遵循指南，看到狭窄就首先考虑放支架，问题是一旦支架扩张导致血管发生撕裂或其他并发症，患者的情况反而会恶化。这种做法不提倡。”</p><p>　　如果确定药物保守治疗不奏效，那就要考虑是搭桥还是介入。这被视为冠心病治疗的第二道关口。</p><p>　　“假如介入医生告诉患者，冠心病可以搭桥，也可以介入，搭桥要开胸，介入不开胸，我认为这种引导是非常荒谬的。”胡大一说。</p><p>　　支架是否过热、介入技术是否滥用，是一道摆在全世界心脏医生面前的问题。据胡大一介绍，2001~2006年，全世界约600万人接受了支架介入手术。</p><p>　　“特别是在引进药物洗脱支架后，一时间，中国的医生对药物洗脱支架预防再狭窄的结果过于兴奋，甚至觉得可以取消搭桥手术了，外科搭桥大夫也可以失业了。”胡大一说。</p><p>　　胡大一疑惑的是：搭桥手术已有半个多世纪的发展史，技术非常成熟，这样一种在发达国家和印度广泛开展的技术为什么在我国至今未能充分推广？介入技术却得到大范围的普及？</p><p>　　霍勇认为，选搭桥还是选介入，“既有学术观点不同，同时也有患者及其家属的观念问题”。</p><p>　　以冠状动脉左主干病变导致的狭窄为例，胡大一拥护搭桥技术，认为介入技术不适宜。“这不是我个人的看法，这是美国心脏协会等六大相关学会召集心内科、心外科专家、公共卫生学、卫生经济学和政府代表等人士一起研究后达成的共识。”</p><p>　　胡大一说：“搭桥术后10年，90%以上的血管依然开通。如果置入药物洗脱支架，则存在中远期的血栓风险。一旦发生血栓，后果常常是猝死。为了预防血栓，患者需长期服用阿司匹林和氯吡格雷，但这又会使患者处于出血危险性增高的境地，老年患者尤其让人担心。还不讲一片药20多元钱。”</p><p>　　<strong>恶性循环</strong></p><p>　　霍勇表示，由于搭桥技术的出现和成熟早于介入技术，国际上左主干90%的传统治疗方法是搭桥。但是，药物洗脱支架和搭桥技术的中长期比较结果目前尚未出现，中国、韩国等亚洲国家使用左主干介入技术比较多，因此更有发言权。“只是国际上还没有广泛采用我们的数据，不过这个问题并不是铁板一块。美国7月份的最新说法是对经选择的左主干病变也推荐支架，但要更谨慎地掌握适应症，同时应该在有条件的大型医疗中心由有经验的术者施行”。</p><p>　　霍勇说，介入治疗由于疗效显著、创伤小、起效快、疗程短等优势，受到心血管医生和患者的青睐，国外的搭桥手术做得多，成功率也比较高，但在中国，“不客气地说，我们能找出很多称职的介入医生，但合格的搭桥医生很少”。</p><p>　　霍勇并不讳言这可能造成外科搭桥技术的恶性循环：病情不重不做搭桥，不得不考虑搭桥的往往是复杂病变，于是手术成功率低，越低越没人做。“当然，如果让一个明明介入治疗就能够有效的患者去做创伤和风险较大的搭桥，我也不忍心，同时搭桥术后的桥血管病变不论对外科大夫还是内科大夫都是一个很难处理的难题。”</p><p>　　胡大一认为，中国搭桥发展缓慢有多种原因，其中之一是心内科没有很好支持心外科发展，本应搭桥的患者也介入了。“在一些搭桥做得很精彩的医院，介入医生也不转诊左主干和复杂病变的患者，而在患者身上放入过多支架。”</p><p>　　谈及搭桥手术的恶性循环，胡大一表示，药物洗脱支架确实让再狭窄率维持在一个较低的水平，但这毕竟没有消除再狭窄，恰恰相反，支架内再狭窄的处理变得更为棘手。“药物洗脱支架置入后失败或并发症的处理正面临更为严峻的挑战。”</p><p>　　冠心病诊治的第三关在于：如果需要用介入疗法，是使用金属裸支架还是药物洗脱支架。当然，后者的价格高于前者。</p><p>　　2002年，强生公司研发的药物洗脱支架——“心扉”(CYPHER)率先在欧洲通过认证上市，随后获准进入中国，当时的市场定价是3.6万元。</p><p>　　据胡大一介绍，药物洗脱支架数的使用比例一度高达整个支架使用数的98%。“这在美国、巴西、古巴、印度等很多国家都是不可能出现的。”</p><p>　　2006年，中华医学会胸心血管外科分会主委、中国医学科学院阜外心血管病医院院长胡盛寿公开表示，冠心病介入治疗需进一步规范，药物洗脱支架热该降温了。</p><p>　　在本刊联系采访胡盛寿时，该院主管新闻宣传的工作人员表示，胡盛寿前往国外出差，“但他对药物洗脱支架等技术仍然关注，看法应该没有变化。”</p><p>　　胡大一认为，药物洗脱支架只是针对再狭窄，因此，对再狭窄危险不大而出血风险大的患者来说，对其使用药物洗脱支架是不合理也不安全的。</p><p>　　霍勇表示，药物洗脱支架的潜在问题的确需要进一步研究。“可以肯定的是，它适用于大部分病人，但不是适用于所有病人。”</p><p>　　胡大一忧虑地说：“直到今天，我们有两件事没有解决，一是药物洗脱支架的成本效益问题，即我们能否承受这种技术带来的经济代价；第二，我们尚未看到太多金属裸支架和药物洗脱支架的预后比较。”</p><p>　　此时，以药物洗脱支架为主的介入技术(霍勇估计约90%)正以每年数万例的增长不断刷新着中国冠心病的治疗记录。</p><p>　　<strong>趋利暗流</strong></p><p>　　胡大一曾遇到“回炉”患者，“他们有些并不符合介入治疗的适应症，却被置入一个甚至多个支架，由于再度多次血栓导致出现更为严重的心肌梗死。”</p><p>　　“我们还没有明确的数字，美国的结论是，过度医疗致残致死的后果，已经远远超出自然灾害、战争、空难和交通事故所导致的伤害后果。”</p><p>　　胡大一说到这里，声音陡然提高：“大量不需要介入治疗或不能从介入治疗中获益的患者正在被置入支架，如果不是诱导消费、过度医疗，怎么会在人体内置入13个支架？”</p><p>　　霍勇表示，所谓介入技术滥用，有人为故意因素，也有学术争鸣的因素，“明确的人为故意滥用是少数”。</p><p>　　“我这个心内科主任，每天都要面临同行之间比介入手术数量的压力。做了多少例介入，成为科室牛不牛、行不行的标志。”胡大一表示。</p><p>　　霍勇也感觉到：“我们至今未能脱离单纯攀比介入手术数量的阶段，仍然是一种粗放式的发展，甚至一个医院能不能通过三甲医院评审，做了多少例介入手术是一个标志性指标，像GDP一样。”</p><p>　　霍勇认为，1996年后，介入技术大发展局面的形成，得益于中国经济整体向好、医保报销比例增加、公众对介入技术认可度提高、更多医院、医生立志研究学习介入专业等多种原因。</p><p>　　亦有观点认为，介入技术过热的背后，是医院、医生趋利的暗流。</p><p>　　本刊记者尚未能获悉医生使用支架能否获得回扣，据霍勇说，根据北京物价规定，医院可在进价基础上加价5%。</p><p>　　据媒体报道，紧随心扉支架进入中国的另一进口药物洗脱支架——美国波士顿科学公司研制的紫杉醇支架(TAXUS)，选择直销方式，售价仅1.8万元，有别于心扉支架在中国市场的定价远高于其他市场的策略。然而，在世界有些国家市场占有率通常高达60%~70%的紫杉醇支架，面对中国市场却是水土不服，在长达半年的时间里，其销售几乎为零。</p><p>　　数年后，强生亦曾试点将心扉支架改为直销，但试点地区的销售下滑70%，大大高于30%的预估，强生的转型努力在2006年底宣告夭折。据悉，两家国产支架公司借猛烈的销售攻势撬走了市场——虽然其招标后的市场价(以北京招标价为准)不到1.5万元，但其给经销商的利润空间可高达50%。</p><p>　　胡大一说，医院管理者把介入当作经济增长点、摇钱树，医生重视支架带来的利益，致使不能认真把控介入的适应症，“这种情况是少数，但绝不是个别”。</p><p>　　<strong>人文之失</strong></p><p>　　“现在的情况是，大医院在比毛收入，医生在追求和炫耀自己做过多少例介入手术，究竟有多少管理者和医生在认真思考，这项技术的研发推广是不是坚持了公益性？对患者的手术到底该不该做？我们不要总是想我们能做什么，而要去想患者需要什么、什么对患者最好。”胡大一说。</p><p>　　在他看来，“如同没有完美的药物一样，也不存在主流的技术。再好的技术也不能过度使用甚至是滥用。不是好的设备、好的技术一定能够带来好的效果，技术可以让人获益，也能给人造成不可逆的伤害。如果是个心脏病患者就动员他做介入，说什么有备无患，那么病人可能会面临危险，对医学也是一种伤害。”</p><p>　　在胡大一的心目中，一份优化的诊疗方案，其实是在获益和风险、成本与效益这两个问题中寻找平衡。</p><p>　　霍勇认为，“能否设计出优化的诊疗方案，说难也难，说易也易，就是看医生的爱心和技术。”</p><p>　　胡大一坦陈，“现在医院的硬件往往很不错，引进高精尖设备不差钱，先进技术迅速引入，但如果有技术没人文素养，有数量没质量控制，就很难上档次，甚至可能陷入技术崇拜的误区。”</p><p>　　“自古至今，国内国外，医学史上能站得住的大医都是讲人文的，人文不分朝代不讲国别。然而现在，有些医生动辄提出做挑战性病变，却对这门技术的社会价值考虑不多。”</p><p>　　胡大一举例说，某中年女患者，两周来常常在夜间憋醒，检查没有发现高血压、糖尿病、血脂异常，其父母均健在且未得过心肌梗死，但她的心电图出现一些变化，接下来，肯定会有医生主张她去做冠脉造影。“就像马克吐温说的那样，‘手里拿锤子的人看到什么都像钉子’，医生可能会认为既然医院有这个设备，那就动员患者做，美其名曰用高科技给你‘摘帽子’。”</p><p>　　他说，女性在绝经期前，如无其他危险因素，不太可能得冠心病，很少需要做冠脉造影。临床医生主要应该做一些解释，如果发现她有焦虑心理则可加以疏导。“冠脉造影要花五千多块钱不说，还可能造成她一生的肿瘤风险。可以说，这笔钱买到的更多是焦虑和风险。”</p><p>　　胡大一曾在一个评审高级职称的会议上，听到某医生自豪地说自己最近十年都没有戴过听诊器。“我真不知道他是如何当的心脏科医生？由此可见，大家都在忽视最基本的东西，转而去关注高端技术，甚至用高端技术解决常见病。”</p><p>　　霍勇肯定地说：“介入技术属高端技术，需要适度发展；常规技术则需要优先发展。这是非常清楚的。问题恰恰出在我们对高端技术没有有效的刹车机制。”</p><p>　　他认为，介入技术考验着医生的技术能力，同样考验着医生的医德医风。“我们要强调医德医风的养成，也要狠抓技术规范的落实。技术规范是底线，即便医生医德不很高尚，但只要他遵循规范尚不至于离谱，最要命的就是不遵守规范。”</p><p>　　霍勇介绍，基于以上情况，卫生部自2007年启动介入手术准入制度后，又相继展开培训制度和质控制度，“特别是从今年7月1日启用的全国心血管介入治疗直报系统，将使每一例介入治疗处于可控范围内，便于进行有效的质量监控。”</p><p>　　霍勇告诉本刊记者，他不能同意介入领域是过度医疗的“重灾区”，但他承认，公众确实对“过度”的介入治疗有所质疑。“纠正偏差必须从医生自身修养、行业自律、法律规范、社会观念、患者期望值等多个层面着手，非一朝一夕之功。”</p><p>　　胡大一在开出让医学回归临床、回归基本功、回归人文，理顺卫生体制机制等药方后，亦陷入沉思：美国的医疗有各方利益互动后达成的标准，有第三方相对独立的监控，却仍然没能解开“过度医疗”这道世界性难题，中国将如何向“过度医疗”宣战？</p><p>　　<strong>医用设备的“生意”</strong></p><p>　　“设备越来越先进，医生学历越来越高，但是，似乎医生越来越不会看病了，医患关系也越来越差了”</p><p>　　<strong>文/《瞭望》新闻周刊记者张冉燃</strong></p><p>　　杜治政的老伴当年险些遭遇过度检查。</p><p>　　77岁的杜治政是《医学与哲学》杂志主编，在医学哲学、医学人文圈内素有声望。</p><p>　　他告诉《瞭望》新闻周刊：“当时我老伴的情况是晚上血压升高，医生的意见是一定让她做脑动脉造影。我知道这造影剂一旦打进去可能发生激烈反应，有一定风险，于是比较警惕，就想请熟人会诊。结果这位更为权威的专家认为，没有需要做造影的迹象。之后我老伴啥事也没有。”</p><p>　　杜治政说：“我是因为认识人，而且这个人又是权威，否则，当时医生态度那么明确，可能很多人都要去做造影了。”</p><p>　　脑动脉造影术依托较为先进的大型医用设备，对脑动脉瘤等疾病的检出较有价值。但是，“倘若医生滥施检查，这个设备也就背离了研制的初衷。”杜治政说。</p><p>　　医生利用医疗器械过度检查，反而给患者造成危害的问题，正在被越来越多的人所关注。</p><p>　　有关主管部门做出最新回应。11月23日，国家发改委网站全文公布《改革药品和医疗服务价格形成机制的意见》，规定要进一步理顺医疗服务比价关系，在规范医疗服务价格项目的基础上，适当提高临床诊疗、护理、手术以及其他体现医务人员技术劳务价值的医疗服务价格，同时降低大型医用设备检查和治疗价格。</p><p>　　<strong>大提速</strong></p><p>　　“改革开放以来，为不断满足公众的医疗需求，中国医学装备技术迅速发展，其背景就是上世纪60年代末以来医学技术的突飞猛进。”中国医学装备协会秘书长白知朋告诉《瞭望》新闻周刊。</p><p>　　比如诊断设备，X线电子计算机断层扫描装置(CT)、正电子发射型断层仪(PET)、X线-正电子发射计算机断层扫描仪(PET-CT)、医用磁共振成像设备(MRI)等，屡屡出新，使临床诊疗能力快速提高。</p><p>　　再如治疗设备，伽马射线立体定位治疗系统(γ刀)、医用电子回旋加速治疗系统(MM50)、质子治疗系统等，有效降低了人群死亡率。</p><p>　　据介绍，医学装备主要包括诊断设备和治疗设备，同时，按照卫生部的口径，又将诊断设备和治疗设备中“资金投入量大、运行成本高、使用技术复杂、对卫生费用增长影响大的”称为甲类大型医用设备，有关管理品目中甲类设备之外的为乙类大型医用设备。</p><p>　　据卫生部副部长陈啸宏在11月18日召开的“中国医学装备协会第五次全国会员代表大会”上透露的数据，2008年，中国医疗卫生机构万元以上设备224万台件，与2003年相比增长了62%，CT、B超、X光机等影像设备已成为医疗机构常规装备；截至2008年年底，中国装备PET-CT、头部伽马刀等甲类大型设备150台，CT、磁共振和直线加速器等乙类大型设备1.5万台。</p><p>　　“中国的医学装备技术不仅造福了公众日常的医疗需求，而且在SARS、禽流感、汶川大地震等重大突发事件中发挥着重要作用。”白知朋评价说。</p><p>　　<strong>“人歇机器不歇”</strong></p><p>　　大型医用设备进入中国以来，一直在经受多不多、贵不贵的追问，人们对大型设备引进“贪多求洋”的批评几乎不曾止歇。</p><p>　　以1993年开始引进的头部伽马刀为例，在此后约两年中，中国内地已经使用和正在装备的伽马刀即达13台，占当时世界伽马刀总数的20%，且集中在沿海开放地区和内地大城市，有关主管部门据此判断“γ刀装备已出现过热趋势”。</p><p>　　其他诸如，在1978年引进第一台CT后，中国内地CT总数在1987年增加到170台，2000年达到4258台；1985年开始使用的MRI，在1993年即达200多台，2000年则有约950台。</p><p>　　“我们在调研中还发现，有的医院买不起新设备，就想方设法从国外或国内一些发达地区购进淘汰设备，这些二手设备有些部件老化、备件缺乏，极大影响着诊断质量，但直到现在，有的省还有30%的CT是二手的。”白知朋说。</p><p>　　2006年8月，卫生部原副部长朱庆生在《中国医学装备》上发表《我国卫生技术装备配置管理及发展趋势》，文章认为，卫生技术装备配置与利用管理存在不可忽视的问题：装备不切实际，引进了一些并不成熟的新技术；配置分布不均，虽然总量不多，但相对集中于某些地区；配置不适宜，盲目追求高档次，导致设备相当一部分功能闲置，无法开发利用。</p><p>　　中华医学会放射肿瘤学分会候任主委、中国医学科学院肿瘤医院放疗科主任李晔雄告诉《瞭望》新闻周刊：“少数医院的确存在大型医用设备利用率不高的现象，有的是因为患者没有钱做，有的是因为医生想不到要做，但从宏观上看，放疗设备配置不足，是短缺的。有人说北京和上海的设备配置已经达到很高的比例，但是，至少从北京的实际情况看，相当多的患者是外地慕名赶来的，我们医院的外地患者比例超过50%。”</p><p>　　以直线加速器这一重要的放疗设备为例，据殷蔚伯等人2007年在《中华放射肿瘤学》杂志上刊发的调查报告，2006年全国直线加速器为918台，每百万人口为0.7台；而世界卫生组织推荐的百万人口拥有数为2～3台，英国是3.4台，法国是5台，美国达到8.2台。</p><p>　　殷蔚伯曾担任中华放射肿瘤学会主任委员、中国医学科学院肿瘤医院放疗科主任。他的这份调查报告还显示：2002年中国新发癌症220万人，其中65%～75%(不含老患者)应当进行放射治疗，但即便是2006年，实际接受放射治疗的人数只有40多万人，有很多的病人应该接受放疗，但因各种原因未接受放疗。</p><p>　　这份调查报告得出结论：过去5年放射肿瘤学在中国有了很大的发展，但还不能满足癌症患者的需要。</p><p>　　李晔雄告诉本刊记者，在当前的配置政策下，他所在的科室为了满足患者的就医需求，缓解就医难、看病难的矛盾，采取了“人歇机器不歇”的办法，人和机器都处在超负荷工作的状态。</p><p>　　据他介绍，国外的放疗科医务人员通常每天安排每台加速器治疗为一个班，8小时后下班；而他们科室目前每天排2个班，工作量非常大。国内有些科室，甚至要安排3个班。此外，国外一台加速器一般每天治疗30来个病人，而据他所在科室近几年的统计，他们的7台加速器总共每天要治疗400～500名患者，平均每台加速器要治疗六七十位。</p><p>　　<strong>“身份歧视”</strong></p><p>　　大型设备引进面对的第二大质疑，即国产设备遭遇“身份歧视”。</p><p>　　据上海第一财经研究院医药行业研究员黄丁毅2008年在媒体专栏中提供的数据，某权威数据公司2005年对中国医疗器械市场的专项调查显示，中国约80%的CT市场、90%的超声波仪器市场、85%的检验仪器市场、90%的磁共振设备、90%的心电图机市场、80%的中高档监视仪市场、90%的高档生理记录仪市场以及60%的睡眠图仪市场均被外国品牌所占据。</p><p>　　“中国大型医用设备很少拥有独立知识产权，而且国际知名品牌无论从科学技术上还是工艺水平上也都比我们好，但我还是主张在同等条件下首选国货。”白知朋说。</p><p>　　他曾接触到一些大医院的管理者，“他们仿佛已经形成了不成文的规定，国产货一律不用不买，理由是国产的质量不行等，但这个结论往往并不是数据对比后得出的，而是从印象出发形成的一种习惯，甚至有的大医院99%的设备都是进口货。”</p><p>　　他表示，中国的医用设备往往傻大黑粗，显得不那么人性化，甚至会给人粗糙的感觉，但是，“它的确具有非常重要的价格优势”。</p><p>　　白知朋以一套“全科检查设备”为例，进口的要1万多美元，国产的只需1万多人民币，二者差了六七倍。</p><p>　　白知朋说：“通过30多年的努力，国产中低档的医用装备，我敢说不管是质量还是工艺水平，都已经与国外相差无几，甚至功能更多，你有什么道理不支持性价比好的民族工业？”</p><p>　　<strong>卫生部两难</strong></p><p>　　资源浪费之外，其最让人诟病的，还在于一些医院因添置了设备而引发的诱导需求，俗称“大检查”。</p><p>　　《2009中国卫生统计年鉴》显示，综合医院门诊病人次均医药费用中，检查治疗费从1990年的2.1元，渐升到2004年的35.1元、2008年的45.3元；出院病人人均医药费用中，检查治疗费(含手术费)则从1990年的121.5元，攀升至2004年的1566.3元、2008年的1887元。</p><p>　　中国人民大学医药物流研究中心研究员李宪法2008年在媒体专栏中写道：“患者在医院接受检查治疗是一个被动消费的过程。大型医用设备配置过多，超出合理检查治疗的资源需求，医院可以通过过度检查治疗将配置成本转嫁给患者，自己无需承担不合理资源配置的成本代价。”</p><p>　　为避免医生动辄让患者做核磁、CT等大型检查，卫生部在《医院管理评价指南(2008年版)》中，明确将CT检查阳性率≥70%、MRI检查阳性率≥70%等指标列为三级综合医院评价指标参考值。换言之，接受CT、MRI检查后确有问题的患者要占到检查总人数的至少七成。</p><p>　　李晔雄认为，“在大型医用设备的配备上，卫生部是比较保守的，他们担心一旦放宽设备的配置许可，一些医院就会诱导需求，导致医疗费用支出迅速上涨。”</p><p>　　陈啸宏在“2008年全国卫生系统基本建设和装备管理工作会议”上提出，大型医用设备具有三个特点：一是资金投入量大、运行成本高、检查治疗收费价格较高；二是应用技术复杂，对医务人员素质要求高；三是大型医用设备的适宜配置可发挥火车头作用，对提高医疗机构临床诊疗能力效果明显。人民群众对大型医用设备诊疗服务的关注也主要集中在费用、质量和能力三个方面。</p><p>　　陈啸宏说：“管理松一些，设备配置多一些，人民群众对服务能力会满意，但会抱怨费用高和质量差；管理紧一些，设备配置少一些，人民群众对费用和质量会满意，但又会抱怨服务能力低。”</p><p>　　在国务院近年来大量削减行政审批项目的背景下，2004年，卫生部、财政部等部委联合颁布《大型医用设备配置与使用管理办法》，2005年卫生部又出台《全国乙类大型医用设备配置规划指导意见》，2008年，卫生部又制定出《卫生部甲类大型医用设备配置审批工作制度(暂行)》，将大型医用设备配置许可的审批制度逐步强化。</p><p>　　媒体评论旋即指出：“报批、论证与审批等诸多环节均在卫生系统内部进行，而以医疗机构在本系统内的‘人脉资源’及其与卫生行政管理部门之间的利益连带关系，大型医用设备购买报批制能在多大程度上发挥实质性作用需要打上一个问号”，此种报批制度未对大型设备的使用环节进行规范，对医疗机构利用大型医用设备对患者滥检滥查现象无遏制能力，故而“仅在大型医用设备购买上设限还不够”。</p><p>　　中华医学会放射肿瘤学分会常委兼秘书长、空军总医院放疗科主任夏廷毅告诉《瞭望》新闻周刊：“放疗学科乃至放疗学界发展的关键是获得设备配置许可和安装设备。因此，在设备配置上采用‘宽进严管’的监管政策，即设备配置相对宽松，而设备使用监管非常严格，可能更有利于缓解看病难、治病贵的矛盾。”</p><p>　　白知朋说：“政府从上世纪80年代就开始重视大型医用设备的管理，提出合理配置、有效利用这八字方针，但这短短8个字，我们到现在还没有太多心得。”</p><p>　　<strong>“天使”或“生意人”</strong></p><p>　　“医学装备本身不是坏的，关键在于你的出发点是什么，如果你拿它当摇钱树，当赚取利益、增加经费的方式，极端的甚至去搞开单提成，那它就容易走偏。”白知朋说。</p><p>　　据他介绍，大型医用设备早已成为医院吸引病人、赢得竞争的必要条件。“一家大型城市医院成功地引进一套大型医用设备，就如同在当地医疗市场占领了一块技术高地并由此形成竞争优势。”</p><p>　　他同时表示：“医院没有好设备就无法吸引患者从而陷入恶性循环的例子是非常现实的问题，有的医院一年获得的财政经费甚至连垃圾处理费都交不起。”</p><p>　　白知朋亦不否认医疗器械能带给个人的利益。“这方面的诱惑是有的，违法的贿赂、回扣且不论，目前来说，出国学习、参观考察都是可以的。”</p><p>　　2008年，时任卫生部党组书记的高强在《健康报》上发表署名文章《医患携手共建和谐》，文中披露：“现在，各级政府对医院的投入平均只有医院支出的7%左右，有些大医院只占2%～3%，有的甚至要求医院上缴部分收入。医生的工资福利待遇、医院的基本建设和设备购置基本上都靠医疗服务创收解决。”</p><p>　　高强认为，“这种体制实际上把医患双方推到经济利益对立的地位。医生增加收入，患者就会增加负担；而减轻患者负担，医生就会减少收入。”</p><p>　　中国社会科学院哲学研究所研究员邱仁宗告诉本刊记者：“医院要赚钱，赚钱就要扩大规模，扩大规模要有资金，资金靠贷款，还贷款就逼迫医生进一步赚钱。这是资本本性所致，不是任何人能救治的。”</p><p>　　他认为，政府保障医生获得高收入的办法是通过卖药、卖检查给病人，让医生收入与病人缴纳的费用挂起钩来。这样，医生在考虑救治病人时，就不得不同时考虑病人能缴纳多少费用，因为这关系到医生和医院的收入。于是医生就成为具有双重角色的人，一方面，他是救死扶伤的天使；另一方面，他是卖药、卖检查的生意人。</p><p>　　“这双重角色之间往往会发生利益冲突，结果是，少数医生的天使角色可能战胜了生意人的角色，但恐怕多数医生是生意人角色战胜了天使角色，患者的最佳利益让位于医院和医生自己的经济利益。”</p><p>　　面对这种体制机制性困境，卫生部部长陈竺在“2008年深化医院管理年活动暨全国医政工作会议”上强调，“我们一定要从坚持基本医疗卫生服务的公益性这样一个宗旨出发，来考虑医疗机构的发展，而不能把创收作为主要任务。”</p><p>　　陈竺提出，“希望将来大医院的领导们在一起交谈的时候，更多地谈我们在惠民服务方面做了多少工作，在使用基本药物方面采取了哪些措施，在降低人民群众最关切的重大疾病的死亡率、致残率，提高生存率、康复率方面取得了哪些成就。”</p><p>　　陈啸宏亦在“2008年全国卫生系统基本建设和装备管理工作会议”、“中国医学装备协会第五次全国会员代表大会”等多个场合申明，“医疗机构要利用适宜医学装备为群众提供适宜服务，不再单纯依靠增加大型设备、提供昂贵检查来吸引病人和发展医院”，“大型医用设备不应是医疗机构‘赚钱’的利器，医院发展不能走高投入、高收入的规模扩张之路”。</p><p>　　<strong>“越来越不会看病”</strong></p><p>　　白知朋说：“比利益更需要警惕的是，假如医生过于追求高精尖的技术和装备，忽视常规设备的使用和临床基本功，这种依赖很可能会导致医生临床实践水平下降。重设备、轻医疗的风气是要不得的。”</p><p>　　他表示，现代医学的发展，越来越依赖设备，人起到的作用越来越少，仪器设备也越来越傻瓜，“医生只要会按设备的按钮，按错了也不怕，返回重来就好，没什么深奥的，结果临床思维能力大大受限”。</p><p>　　白知朋回忆说，上世纪60年代我们衡量一个医生高不高明，很重要的就是看他到底开多少化验单能把病诊断出来，如果一个医生常常开一个化验单、检一两个项目就能给你确诊，那我们都会说这医生真厉害，因为他通过物理检查就能够诊断得八九不离十。现在的情况是，你到医院，一堆的化验待查单子，一个化验单又往往包括几十、上百个项目，你不做检查医生甚至会告诉你没法给你看病，因为他都是根据机器设备的结果来诊断，没他自己的什么东西。</p><p>　　说到这里，白知朋摊开双手，显得非常无奈：“于是你发现，设备越来越先进，医生学历越来越高，但是，似乎医生越来越不会看病了，医患关系也越来越差了。”</p><p>　　<strong>中国大型医用设备管理政策脉络</strong></p><p>　　1985年，针对技术引进中的不必要重复和多头管理等问题，原国家经委下发《关于控制重复引进、制止多头对外的报告》(即90号文件)，开始对大型医用设备实施管理。</p><p>　　1995年，卫生部以第43号部长令的形式发布《大型医用设备配置与应用管理暂行办法》，决定对大型医用设备实施“三证”管理，即《大型医用设备配置许可证》《大型医用设备应用质量合格证》和《大型医用设备上岗人员技术合格证》。</p><p>　　2004年，卫生部、国家发展和改革委员会、财政部颁布《大型医用设备配置与使用管理办法》，强调“配置大型医用设备必须适合我国国情、符合区域卫生规划原则，充分兼顾技术的先进性、适宜性和可及性，实现区域卫生资源共享，不断提高设备使用率”，明确对大型医用设备的管理实行配置规划和配置证制度。</p><p>　　2005年，卫生部颁布《全国乙类大型医用设备配置规划指导意见》，提出对由省级卫生行政部门编制的5种乙类大型医用设备配置规划的指导意见，要求贯彻“发展卫生事业要从国情出发，合理配置资源，注意提高质量和效率”的指导思想，实现优化配置大型医用设备，改善大型医用设备布局，提高大型医用设备使用效率和医疗服务水平，为人民健康提供技术保障。</p><p>　　2008年，卫生部发布《卫生部甲类大型医用设备配置审批工作制度(暂行)》，进一步规范甲类大型医用设备配置审批工作，明确审批程序和要求。(文/张冉燃)</p><p>　　<strong>“人文不是可有可无的”</strong></p><p>　　“现在治病越来越像修机器，甚至个别医生做完介入手术后都不知道患者多大年龄、什么性别，这些都反映出医学与人文越来越遥远”</p><p>　　<strong>文/《瞭望》新闻周刊记者张冉燃</strong></p><p>　　11月21日下午1:30。北京。</p><p>　　“医学人文的理念与实践”分论坛上蒸腾着一股热气。</p><p>　　50多个席位不仅满员，且有十数人站立听讲。门不断地被打开又被合上，夹杂传入一声抱怨：组织者真是失算，这里才是主战场，却安排了这么小的地方。</p><p>　　这是首届“医学发展高峰论坛——医学整合”开设的讨论会场之一。论坛的主办方——《医学与哲学》杂志，率先在中国开展生命伦理学等研究，被誉为中国医学人文的主阵地。</p><p>　　本刊记者在论坛前后穿插采访了《医学与哲学》杂志主编杜治政，中华医学会心血管分会主委、北京大学人民医院心脏中心主任胡大一，北京大学人民医院院长王杉，卫生部心血管疾病(冠心病介入)医疗质量控制中心负责人、北京大学第一医院心内科主任霍勇，解放军总医院基础教研室、人文教研室主任赵美娟，请他们就过度医疗的有关问题予以解答。</p><p>　　<strong>“正气很难树立”</strong></p><p>　　《瞭望》：诱导需求是任何市场都存在的问题，似乎大家对医疗领域的诱导需求更为关注？</p><p>　　杜治政：这是由医生的职业性质决定的，由于医患双方信息不对称，患者缺少辨别能力，医生对患者具有绝对权威，二者地位不对等。比如，当一个病人坐在医生面前，医生说，张开嘴，把衣服掀起来，你就得张开嘴，把衣服掀起来；医生说，你有病，需要吃药，需要开刀，你就得吃药，接受手术；医生说，你得锯腿保住生命，你就得锯腿。从普通百姓到国家元首，都得像小羊羔一样，乖乖听候医生的处置。在这种情况下，其他任何知识、权力都无济于事。</p><p>　　《瞭望》：医疗领域的诱导需求往往需要通过医生来实现，是不是中国的医生特别容易受到诱惑？</p><p>　　杜治政：美国医疗的市场化程度比较严重，我们比美国还严重，由此造成医疗机构的体制性、机制性弊病压着医生去关注诱惑；另外，医生心理混沌，对诱惑甚至习以为常。</p><p>　　我曾听说，北京大学某教授在医院演讲时说，给在座医生两个忠告——凡是可抢救可不抢救的一定不抢救，凡是可检查可不检查的一定要检查，在场医生热烈鼓掌，我对跟我讲这个事的人说，你怎么不提问质疑？他说，你不知道现场气氛多热烈，医生情绪多激动，我不敢站起来提问。</p><p>　　我是觉得，现在在医生队伍里，正气很难树立，如果一个医生拒绝行业内的潜规则，他可能被孤立。</p><p>　　《瞭望》：大型设备、高端技术，这一诊一治中发生了很多过度医疗的故事，你怎么看？</p><p>　　杜治政：我们现在对知识的理解往往是培根告诉我们的“知识就是力量”，而不是古希腊时期出于享受知识的出发点。慢慢的，技术也变成了力量。</p><p>　　从某种程度上讲，力量就是权力。换言之，谁掌握了知识、谁掌握了技术，他在社会上的地位就提高了，于是很多人就积极追求知识、追求技术，把知识和技术当作一种竞争手段，一种控制他人、让他人接受自己的办法。有了知识和技术，名呀、利呀都来了，于是就有医生拼命抓技术。</p><p>　　我们不是不发展技术，而是要在医德的支撑下，合理使用技术。</p><p>　　可惜的是，目前舆论也不太重视医生是不是对患者尊重，有没有耍态度，反而也在关心他是否掌握着技术。特别现实的是，大型设备和高端技术还能给医院和医生带来利益。据说医生安一个进口的骨关节可以得2万块，这个利益太大了。</p><p>　　当然老百姓也不会总那么傻，你可以看到，人们常常怀着急切的心情盼望新的医学技术治好他的病，但同时又害怕这种治疗给身体带来新的疾病。</p><p>　　<strong>医生的社会责任</strong></p><p>　　《瞭望》：你认为医生应该承担哪些社会责任？</p><p>　　胡大一：首先告诉患者真实的信息。</p><p>　　一位复旦大学的老校长曾告诉我，有人因胸痛前后看了3个专家，一个说你做介入吧，一个说你应该搭桥，第三个说你的情况很稳定，只要吃药就行，这个老校长说患者就糊涂了，为什么同一个级别的专家会有不同的标准？这就像“文革”时期打语录仗一样，不参加还好，一参加倒是糊涂了。医生不是推销商品，而是要把中远期的后果告诉患者。</p><p>　　其次是帮助大众改善生活方式，有效预防疾病，维护大众健康。</p><p>　　研究表明，从1984年到1999年，等患者有了心绞痛或心肌梗死到医院治疗只减少了642人死亡，其中搭桥和介入治疗稳定性心绞痛对死亡下降的贡献是2%，然而同期新增1822人的死亡，且发病致残致死年轻化。原因就在于没有很好地控制危险因素。你知道，这15年间，老百姓吃鸡蛋、吃肉多了，加上缺乏运动、生活不规律等原因，血胆固醇水平升高了，心肌梗死也增加了。这说明，仅仅做搭桥、做介入，而不去改善生活方式，不做预防和控制，你不可能打赢战争。</p><p>　　我现在的希望就是，我们大家通过10年的努力，10年不行就20年，让中国出现心血管病死亡率下降的拐点。</p><p>　　《瞭望》：你在医生和公众当中做了很多类似的宣讲，你觉得医生们意识到预防控制疾病的重要性了吗？他们行动了吗？</p><p>　　胡大一：我现在对医生这个职业的理解，不仅仅是看病，而且是要维护公众的健康。我也看到，很多手术很精湛的外科大夫，比如吴英恺教授，先后在阜外医院、安贞医院致力于流行病学调查和首钢居民高血压防控模式的探索，我相信2009年以后的医生面临着职业的转型、转身。</p><p>　　这个转型、转身，就是说医生不可以只是坐堂行医，坐等患者看病。你要知道，冠心病患者中有一半人，他们第一次有不舒服就是急性心肌梗死和猝死，毫无先兆，他们不知道自己的心脏处于危险之中，比如侯耀文等人的悲剧。因此，我提倡医生应该走出医院，宣讲健康教育。</p><p>　　你可以想象，如果中国每年的介入手术做的跟美国一样多，甚至更多，那中国老百姓的心血管一定糟透了，我想老百姓不会满意、不能允许，政府同样不能允许。</p><p>　　我认为，医生和大众没有症状不看病的现象非常荒谬，防控疾病的重点恰恰应该是那些没有症状有风险的人群，如果我看到一个人35岁得了急性心肌梗塞，我会觉得这非常冷酷，因为这本来是可以预防住的，那么我就会想我要为此承担什么责任。如果这种“等症状”的问题不解决，我相信将会给国家造成非常大的负担。</p><p>　　《瞭望》：你觉得让一个惯于治疗的医生去讲疾控，容易吗？</p><p>　　胡大一：现在治病越来越像修机器，甚至个别医生做完介入手术后都不知道患者多大年龄、什么性别，这些都反映出医学与人文越来越遥远。</p><p>　　我想我们还是要讲医生的同情心和责任感。当一名医生，如果你还担任着科室主任等职务，我想你会发现各种利益都出来找你，什么利益都想通过你实现，甚至一个临床试验不同厂家能做出大相径庭的解释。只有时时考虑患者利益、一切为了公众健康，我想你才能交出合格的答卷。</p><p>　　我常常说，医生也要有体面的生活，医生的孩子也要上好学校，但一个医生应该没有公众健康和患者利益以外的利益。我希望大家每天睡觉前、一觉醒来后，一把尺子一杆秤，量量道德称称良心。</p><p>　　我觉得，让更多的老百姓不得高血压，不得糖尿病，不得冠心病，这是一个医生最大价值的体现。这当然不容易做到，但往往越不容易做的事情越值得做。我想，大家把眼前利益看得淡一些，就会视野开阔、心胸开阔；把局部利益看得少一点，自然目光长远。</p><p>　　<strong>医院竞争之本</strong></p><p>　　《瞭望》：在你的视野里，大医院树立自己的品牌靠什么？或者说，大医院应该把竞争的着力点放在哪里？</p><p>　　王杉：谈品牌的竞争，我想通俗说就是争老百姓的口碑。口碑包括两个方面：一是医疗水平、医疗质量要高，二要看你的服务水平。</p><p>　　我想，对同级医院来说，医疗设备、医疗技术相差不会太大，在保证医疗质量和技术水平的前提下，今后医院竞争的关键点将是服务水平。</p><p>　　《瞭望》：这种认识的依据是什么？是国际知名医院的管理经验吗？</p><p>　　王杉：其实任何一个机构，不一定是医院，都是一样的，都要比服务。坦率说，老百姓对你医院的学科建设、技术水平等方面的提高，体悟不会很清晰，但他对医院服务水平的提升却非常直观。比如我们医院在白塔寺那里的老院区，已经有90年了，甚至可以说那里的就诊环境和设施并不好，但它照样赢得了很多患者，甚至有一家五代都选择在那里看病的情况。医患之间比较熟悉，也比较信任，我想这种患者资源就不容易被抢占，只要他得了该到人民医院看的病，他一定会到人民医院来。</p><p>　　《瞭望》：人民医院从中得益了吗？</p><p>　　王杉：那是当然，我体会很深。从医疗水平、医疗质量方面，我们医院近些年有十多位医生在中华医学会各种专业分会中担任主任委员、候任主任委员，这说明我们的技术水平、学科建设得到了业内公认。</p><p>　　从服务水平上看，我们医院这些年通过改善各种内部环节，优化了200多项流程程序，赢得了患者，我们现在还在不断改进中。</p><p>　　《瞭望》：能举个改善服务的例子吗？</p><p>　　王杉：比如我们对需要预约服务的检查科室制定的绩效考核指标，非常简单，只有两项，一个是当日解决率，一个是次日解决率。通俗说就是今天开的检查你今天完成了多少，第二天又完成多少。仅仅这一个预约时间的改进，病人一下都拥来了。你要知道，在别的地方预约检查，往往需要等一周、半个月，甚至是一个月。</p><p>　　我的结论是，在保障医疗水平、医疗质量的前提下，要想在竞争中立于不败之地，就必须在服务上下功夫。</p><p>　　《瞭望》：你对医疗机构大量引进高端设备诱导医疗需求的批评怎么看？</p><p>　　王杉：这种现象是有的，但医疗行业上上下下的监督、管理，其实都在力求避免这些情况出现。我还是要讲服务，你把他坑了，你等于永远失去了他和他周围人群这种宝贵的资源。应该讲，大家对这个都看得越来越清楚了。我相信，一个有追求的医疗机构，是不会在这种短期效果上动太多心思的。</p><p>　　胡大一：其实有些大医院对发展趋势、发展方向还是一头雾水。大医院的发展离不开经济的支持，我们今天如果不讲利益那就是空谈，但我认为，有远见的大医院院长不能够再去跟社区抢不该抢的利益了，眼睛不能总是盯着门诊量，去诊治大量普通感冒和高血压患者。发展的途径很多，比如高水平的研发创新，比如复杂、疑难、危重病症的治疗，还有做标准、搞培训，等等，这些都是既能提高医院知名度又能获得经济收入的好办法。</p><p>　　我认为，现在悟出来的院长，他看到的是未来10年、20年的情况，看到得早、实干得早，就能在未来获得更大的回报。</p><p>　　<strong>终极关怀</strong></p><p>　　《瞭望》：过度医疗往往源于医患信息不对称。作为临床医生，你有什么对策？</p><p>　　霍勇：让患者及患者家属参与治疗方案的决策。把各种方案的利弊陈述清楚，请他们选择最终的治疗方案，医生更多扮演一种提供不同方案的角色。</p><p>　　《瞭望》：让医疗方案的决策民主化？</p><p>　　霍勇：其实医学是很不完美的，医生也不是万能的，如果患者所有决定都由医生来抉择，医生承担的压力相当大，另一方面，医生仅仅从自己的立场出发，漠视了患者的真实需求，尽管他可能是无意的，也可能有充分的理由，最终的治疗结果常常都是不理想的。</p><p>　　我想，医生应该充分告知患者他所主张的治疗方案的利弊得失，在医患双方充分沟通之前，患者可能不容易作出治疗方案的选择，或者即使选择也是盲从的，但充分沟通后，患者和患者家属应该有权利也有能力作出自己的选择。往往这种选择不需要太多的专业知识。</p><p>　　《瞭望》：这会不会导致医生最终把责任都推给患者，反而加剧过度医疗？</p><p>　　霍勇：一般不会，充分沟通容易达成一致，但是也可能会有医生利用患者追求健康的迫切心态，诱导他尝试过度的医疗，甚至以患者自己强烈要求作借口，把自己的“过度”行为合理化。我想这个问题最终还是要靠自身修养、行业自律、法律规范三者并进加以改善。</p><p>　　《瞭望》：你特别强调医生的人文修养，你对医学人文有什么认识？</p><p>　　赵美娟：人文追求的是情感，也就是对生命的终极人文关怀。要认识到生命的有限性和过程性，但人是不满足于这种有限性和短暂过程性的，人还有超越性，人性是不放弃追求永恒和美好的。所以人都有理想或梦想。</p><p>　　人的这种超越性和永恒性在医学这里，就是需要医生认识和理解到：人文不是可有可无的，而是人的一种情感需要；人文是人的真实需要，而不是时髦口号。讲人文，只有从境界与修养入手，使我们的人文立足在生命哲学的层面，而不只是懂得一些“规矩”和“应该”，还要上升到生命的形而上的层面，使医学故事回归生命的完整性和真实性。</p><p>　　《瞭望》：人文在你看来有操作性吗？</p><p>　　赵美娟：“可操作性”是一个技术层面的词。我理解的人文直指人性与人生。我会觉得“医患沟通技巧”之类的说法不妥。因为，沟通的问题关涉人的情感与境界，从来就不是技巧的问题，不然，掌握技巧不就解决问题了？</p><p>　　我们讲人文，是要自立现实，同时又要提升到哲学层面，兼顾起来，否则，人文就流于表浅的形式主义和技巧操作之类。在生命的高度上，万变不离其宗。</p><p>　　从这个角度讲，医学的人文教育首先要确定一些可视、可听、可触的规矩，但在这个层面打住是不行的，还必须上升到理念，也就是说，我们要告诉大家，人文的使命是帮助大家回归人的真实状态，回应人的情感需要。□</p><p>　　<strong>西方病人权利运动</strong></p><p>　　18世纪90年代的法国大革命时期，病人争取健康权利的运动开始出现。</p><p>　　20世纪六七十年代，病人权利运动进入高潮。1973年，美国医院协会制定并发表《病人权利法案》。1975年，欧洲议会理事会将有关保证病人权利的建议草案提交给会员国。1980年，美国召开全国第一届病人权利大会。1981年，世界医学会在葡萄牙通过《病人权利宣言》。目前，不少国家都制定了有关病人权利的文件。□</p><div><br /></div></span>', 'gwm', 0, 9);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(149, '近九成肺癌患者被烟所害', '', '', '', '2009-12-17 10:33:32', '116.228.141.77', '<span style="font-size:14px;"><p align="center"><img alt="1103a3101.jpg" src="http://www.dahe.cn/xwzx/live/beauty/W020091103374632659873.jpg" border="0" /></p><p align="center">资料图片</p><p>　　每年的１１月是“国际肺癌关注月”。肺癌是全球第一癌症杀手，每年全球新增病例１２０万，每３０秒就有人因此死亡。我国肺癌的发病率和死亡率高居肿瘤第一位。医生说，５０岁以上、吸烟指数（吸烟指数＝每天吸烟支数×吸烟年数）４００以上的人是肺癌的高危人群。</p><p>　　□记者辛渐通讯员陈锦屏</p><p>　　省肿瘤医院内科副主任医师朱辉说，８７％的肺癌患者与吸烟或被动吸烟有关，其他还跟家族遗传因素、放射性暴露因素、环境或者职业因素等有关，如果家族中有肺癌病人，自己又长期大量吸烟者，应该提高警惕。</p><p>　　郑州市第三人民医院肿瘤内科主任张阳说，癌症治疗效果贵在早发现、早诊断、早治疗。癌症如能得到早期明确诊断，一半以上可以手术治疗，五年生存率一般可达９０％以上。所谓癌症早期，就是指人体组织细胞所发生的体积很小，不超过３厘米的原位癌和表浅浸润癌。癌细胞浸润局限于黏膜或黏膜下层，且无区域性淋巴结转移。</p><p>　　肺尖癌容易“漏网”</p><p>　　张阳说，有些肺癌症状不典型，容易“迷惑”人，比如“肺尖癌”。它出现的症状主要是肩部疼痛，而咳嗽、咯血等肺部的症状不典型。这是因为肺尖部的上方正好是胸腔出口部，邻近有许多神经根和神经。当肺尖周边部发现癌细胞后，不断发展的癌组织直接压迫或侵犯神经。如侵犯臂丛神经，就会出现类似颈椎病、肩周炎的颈肩部疼痛。</p><p>　　由于肺尖癌缺乏特异性症状，特别是在早期可以无症状，很易漏诊。如果出现肩部疼痛的症状，经过常规治疗不见好转，甚至出现加重的趋势，需查查肺部，排除肺尖癌的可能。</p><p>　　不同阶段个性化治疗</p><p>　　“特别需要强调的是首诊对于肺癌治疗的重要性，它直接关系到治疗方案的正确与否和治疗效果的好坏，首诊既需要主治大夫的丰富经验，又需要医院检测设备的精确，二者缺一不可。”河南省肿瘤医院内科主治医师王慧娟说，针对肺癌患者，主要做康复性预防，采取各种医疗手段，防止病情恶化、复发和转移，早中期尽量手术根治，提高治愈率；晚期病人需要综合治疗，制订化学治疗、靶向治疗、放射治疗、免疫治疗等个性化方案。</p><p>　　早期筛查注意四个问题</p><p>　　据介绍，成年人每年要常规参加健康体检，健康体检时一定要行胸片正侧位检查。在诊断时应注意以下几个问题：</p><p>　　一是男性，５０岁以上，吸烟指数４００以上的人应定期做胸部Ｘ线片或胸部ＣＴ检查，一旦发现可疑病变，应采取有效手段尽快确诊。</p><p>　　二是顽固性胸痛，或上肢疼痛，对症治疗疼痛不能缓解者。</p><p>　　三是原有的慢性咳嗽进行性加重或出现咯血、气急、声嘶等症状者。</p><p>　　四是对中青年人顽固的颈肩痛、关节痛，应仔细寻找原因。检查时一般可先做胸部Ｘ线正侧位片和胸部ＣＴ扫描，了解肿瘤的部位、大小，周围骨骼有没有受到影响。必要时做胸部核磁共振检查，以更好地显示肿瘤与血管及神经的关系，了解肿瘤对周围骨侵犯范围。肺癌诊断的金标准是病理学，可行纤维支气管镜检查、经皮穿刺肺活检等，获取病理组织明确诊断。ＰＥＴ－ＣＴ　检查能更好地进行肿瘤临床分期。</p><p>　　预防肺癌从三方面做起</p><p>　　几位医生说，针对健康人群，预防肺癌主要从三方面做起，即远离烟草和污染源、健康饮食和保持良好的心态。</p><p>　　所谓健康饮食就是饮食要多样化，增加食物中蔬菜、水果的摄入量，尤其多食富含胡萝卜素、维生素Ｃ、维生素Ｅ、叶酸、微量元素硒等食品，可以降低肺癌的发病率。高脂肪、高胆固醇膳食和饮酒会增加患肺癌的危险性。</p><p>　　什么是良好的心态？就是保持心情愉快，遇事想得开，不钻牛角尖。保持生活规律、劳逸结合，积极锻炼身体，提高免疫力，增加防病抗病的能力。</p><p>　　对于４０岁以上的长期吸烟者，经常接触煤烟、煤焦油和油烟者，接受过量放射线照射者，长期接触无机砷、石棉、铬、镍者，慢性肺病患者，慢性咳嗽、痰中带血者，有肺癌家族史者等高危人群，预防肺癌更要小心，仅靠普通的健康体检是不够的，需要定期进行癌症筛查。</p></span>', 'gwm', 0, 9),
(150, '流感病例中甲流比例降低', '', '', '', '2009-12-18 10:01:19', '116.228.141.77', '<span style="color:#222222;font-size:14px;"><p>&nbsp;河北省卫生厅昨天通报了上周（12月7日－12月13日）全省甲流疫情报告，全省11个市报告甲型H1N1流感确诊病例338例，住院治疗149例，死亡12例。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;流感哨点监测结果显示，上周省内流感病例占流感样病例的比例为37.0%，比前一周的49.0%有所下降；甲型H1N1流感病例占流感病例的比例为82.9%，比前一周的91.1%有所下降。 &nbsp; &nbsp;</p></span>', 'gwm', 0, 7),
(151, '婚姻登记处提示一个萝卜多个坑', '', '', '', '2009-12-18 10:02:13', '116.228.141.77', '<span style="font-family:宋体;font-size:12px;"><div class="ep_img_box" style="text-align:center;"><a href="http://epaper.jinghua.cn/res/1/20091218/90071261089981974.jpg"><img src="http://epaper.jinghua.cn/res/1/20091218/90071261089981974.jpg" /></a><h2 style="font-size:14px;"></h2></div><div class="con_news" style="font-size:14px;"><p style="text-indent:28px;">&nbsp;&nbsp;&nbsp;&nbsp;日前，有新人到沈阳市大东区婚姻登记处办结婚登记时发现，服务大厅东墙上的4块展板“温馨提示”的内容是“对于男人的偶尔出轨，有时候不必看得过重”，“优秀的人，不管男女，都会是一个萝卜好几个坑”，看完很不舒服。大东区婚姻登记处负责人表示，提示板上的话是从网站摘来的，已立在大厅约5年。初衷是对新人起到提示、安抚作用。昨天，4块提示板被撤下。《华商晨报》供图</p></div></span>', 'gwm', 0, 11),
(153, '45岁女子服用减肥产品后肝功能衰竭死亡(图)', '', '', '', '2009-12-21 09:51:50', '116.228.141.77', '<span style="font-family:宋体, arial, sans-serif;font-size:14px;"><p align="center"><img alt="45岁女子服用减肥产品后肝功能衰竭死亡(图)" src="http://img1.gtimg.com/news/pics/25910/25910445.jpg" /></p><p align="center"><span style="font-size:12px;">死者丈夫坐美容院要讨说法，一旁墙上还挂着“减肥冠军排行榜”。 记者 冉文 摄</span></p><p align="center"><img alt="45岁女子服用减肥产品后肝功能衰竭死亡(图)" src="http://img1.gtimg.com/news/pics/25910/25910446.jpg" /></p><p align="center"><span style="font-size:12px;">杨素兰吃的“五谷素”</span></p><p style="text-indent:2em;"><strong>家属称死者服用“五谷素”后致病，高新区相关部门已介入调查</strong></p><p style="text-indent:2em;">昨天，高新区人民医院，45岁女子杨素兰走完了她生命的最后时光：医生诊断，杨系药物性肝功能衰竭死亡。家属称，杨的死亡跟服用一种叫“五谷素”的减肥产品有关。目前，高新区社会发展局、公安局等相关部门已介入调查。</p><p style="text-indent:2em;"><strong>美容院老板被堵房中</strong></p><p style="text-indent:2em;">昨下午，高新区石桥铺华宇名都1号楼3—3房，10余死者家属情绪激动，将被怀疑“惹事”的重庆友好美容美体院老板周友好堵在房中讨说法。面对众多死者家属，周友好把自己关在房间里，一声不吭，表示沉默。直到有警察和卫生部门执法人员前来，他才走出房门。</p><p style="text-indent:2em;">挂在墙壁上的工商营业执照显示，该美容店仅具有一般美容、保健资质。进屋的右墙上，张贴有数张减肥海报，从黑板上罗列的减肥冠军排行榜上看到，至少有10名顾客在此参与减肥有关的活动。</p><p style="text-indent:2em;"><strong>5000元买两瓶减肥药</strong></p><p style="text-indent:2em;">家属质疑，杨素兰的死亡跟服用从该美容院购买的“五谷素”减肥产品有关。</p><p style="text-indent:2em;">杨素兰，45岁，生意人。其女范馨月介绍，去年4月11日，母亲成了重庆友好美容美体院的顾客。为保证减肥效果，该美容美体店与杨素兰签订了减肥合同，采用一种刮疗的方法进行减肥。</p><p style="text-indent:2em;">杨素兰每隔两三天前往刮疗一次，工作人员还向她推荐了一种叫“五谷素”的减肥产品，杨花5000元购买了两瓶“五谷素”。范馨月说，减肥前，母亲曾做过体检，各项指标健康。</p><p style="text-indent:2em;">范馨月说，母亲按说明书每天服用两片“五谷素”，当她服完半瓶（30粒）后，问题出现了——开始胸闷，拉肚子。询问工作人员，被告知属“正常反应”，需继续服用。去年12月中旬，杨素兰将第二瓶“五谷素”服用了大部分，家人发现其病情越来越严重，咳嗽不止，面部黄如蜡纸。</p><p style="text-indent:2em;">杨先后被送入大坪医院、西南医院和高新区人民医院救治。医生诊断：杨属药物性肝炎（重度）、亚急性肝功能衰竭。经长达1年时间的治疗，杨的病情愈发严重，昨日上午11时，杨素兰死亡，前后花去治疗费近30万元。</p><p style="text-indent:2em;">死者家属称，发现服用“五谷素”致药物性肝炎后，家人多次找过重庆友好美容美体院老板要说法，但对方一直回避该问题。家人透露，期间他们向九龙坡卫生监督所举报，执法人员检查发现，该美容美体院不具备销售减肥药资质，且工作人员还将“五谷素”藏匿，卫生监督对其做出了警告和整改处理。</p><p style="text-indent:2em;"><strong>相关部门已介入调查</strong></p><p style="text-indent:2em;">昨天，死者丈夫范正军向记者出示了一份5月2日签署的“医疗费用垫付协议书”。这份有美容院老板周友好签名的协议书显示：杨素兰所患药物性肝炎被疑服用“五谷素”减肥药所致，美容美体院暂一次性垫付5万元医药费。协议书中，美容美体院老板周友好和“五谷素”厂家代理人要求，此协议书签订之日起，杨素兰及家属不得在任何机构和媒体方面做出有损该美容美体院经营或名誉的行为。同时承诺，杨的病情鉴定结果确为“五谷素”所致，厂家愿承担相关责任。</p><p style="text-indent:2em;">昨天，记者发现，“五谷素”为蓝白色相间的胶囊，生产单位为吉林某保健品公司，生产批号为“卫食”字号，不属药品。包装盒说明书上称，其含有减脂素，可平衡营养，帮助脂肪代谢。</p><p style="text-indent:2em;">昨下午，高新区社会发展局、辖区街道和派出所前来联合展开调查。一工作人员称，从目前掌握的情况看，该美容美体院相关手续有问题，不排除有非法行医的可能。杨素兰死亡是否与服用“五谷素”有关，还需鉴定。 记者 徐其勇</p><p style="text-indent:2em;"><strong>链接</strong></p><p style="text-indent:2em;"><strong>如何选择减肥药</strong></p><p style="text-indent:2em;">专家介绍，选择减肥药品首先要根据自己的身体素质情况(如对哪种药物会不会产生不良反应、有没有其它疾病等)有个全面的了解，如果自己对情况不能确定的话，应请教专家或专业人士，不要自行妄下判断。</p><p style="text-indent:2em;">一般来说，选择减肥产品应注意以下几个问题：</p><p style="text-indent:2em;">1、包装：看其配方是否含有性激素，含激素的产品会引起内分泌的失调，导致其它并发症。</p><p style="text-indent:2em;">2、机理：看清说明书上有无药物的减肥机理，确定安全有效性。</p><p style="text-indent:2em;">3、看肥胖类型：减肥品一般对单纯性肥胖、饮食和运动无法控制的肥胖有效，对遗传性肥胖等疗效不佳，如果自己无法确定肥胖类型，可到当地的减肥中心咨询医生或请教医学专业人士帮助你，制定适合自己的减肥方案后，再选用适合的减肥产品。</p><p style="text-indent:2em;">4、批号：要注意产品的批准文号，是否是国药准字批号等国家权威主审机关审批。一般国家主审机关的审核要求比地方审批机关严格，能够通过国家主审机关审批的产品，品质和安全性都是可靠的。</p><p style="text-indent:2em;">5、品牌：尽可能选择一些大品牌，这些大厂家整体实力强大，产品发展目标明确，技术力量先进，质量当然也有很高的保障，且售后服务周到。</p></span>', 'gwm', 0, 5),
(154, '喉癌患者做切喉手术后改学用食道说话', '', '', '', '2009-12-21 09:53:09', '116.228.141.77', '<span style="font-family:宋体;font-size:14px;"><p>本报讯 昨天，是重医附一院无喉者语言康复中心宣布正式成立的日子，宣告结束了西部地区没有无喉者语言康复中心的历史。就在这一天，我市8名因喉癌切除咽喉的患者，也作为首批学员宣布“毕业”。</p><p>　　67岁的柴光栋就是这批学员中的一员，他也是中心的志愿者和老师。柴光栋是2006年3月因喉癌做了喉全切除手术。</p><p>　　2007年初，柴光栋前往湖南株洲，学习用食道发音。接受采访时，柴光栋不停打嗝。见记者纳闷，他解释，“学习食道说话，基本功就是打嗝。”</p><p>　　据了解，食道发声，就是将空气引入食道，借助胸内压力，如同打嗝一样，将空气从食道内逼出，冲击食道上端或者咽部黏膜而与舌、齿、鼻等器官共鸣发音。</p><p>　　重医附一院耳鼻喉科主任胡国华介绍，从2003年至2009年，医院每年接诊喉癌患者80余例，有两成因为害怕成为哑巴而放弃手术。这部分患者，大多可能因为癌细胞转移而失去生命。“食道发音能解决患者的后顾之忧，相信更多的患者会毫不犹豫选择手术。”</p></span>', 'gwm', 0, 6),
(155, '白领压力源:买房健康婚姻孩子教育', '', '', '', '2009-12-21 09:54:14', '116.228.141.77', '<span style="font-family:宋体, verdana, arial, ''times new roman'';font-size:15px;">买房、父母健康、婚姻和孩子教育，成为现代白领的四大“压力源”。昨天，由中国医师协会举办的“城市与健康论坛”上发布的2009中国城市健康白皮书之压力来源调查显示，目前买房成为现代白领的头号“压力源”，父母健康问题则是第二大压力来源，“移民白领”最担心“空巢父母”的健康，此外，“剩男、剩女”问题也是未婚白领不快乐的根源之一。&nbsp;<br /><br />　　白领亚健康比例高&nbsp;<br /><br />　　这项白皮书是中国历年规模最大的一次城市健康状况大调查，历时6个月，涉及31个省和直辖市、589座城市，共回收到51.3万份问卷。结果显示，买房为第一压力的受调查者比例达46%，父母健康问题成第二大压力来源的比例达38%，而留守老家的“空巢父母”无人照顾等问题，成为“移民白领”心里的痛。且城市越大，压力越大，“移民白领”更担心“空巢父母”健康。另外，“剩男、剩女”问题则成为未婚白领不快乐的根源之一。&nbsp;<br /><br />　　调查还发现，城市白领亚健康比例达76%，处于过劳状态的接近六成，真正意义上的“健康人”比例较低。近八成白领饮食睡眠不规律，每天感觉比较疲倦。由于生活方式不科学和健康意识不足，使人体器官衰老速度加快，抗病能力大大降低，白领患病几率逐年上升。&nbsp;<br /><br />　　公职人员压力较大&nbsp;<br /><br />　　据调查，现在公职人员压力较大，普遍反映工作“一年比一年累”。每当重大任务来临，公职人员必须放弃双休和法定长假，即使休年假，“一个电话通知，还得赶回单位”的情况很普遍。相关调查数据还显示，公职人员超重或肥胖比例较高，超重或肥胖（40.7%）、血脂异常（28.7%）、血压异常（14.2%）、心电图异常（10.4%）位居公职人员常见疾患前四种，脂肪肝和“三高”问题相对普通脑力劳动者分别高出4.4%和3.2%，肩颈酸胀（75%）和眼睛酸胀（60%）是最常见问题。&nbsp;<br /><br />　　据分析，不良生活习惯是主要原因。58%的公职人员“每日久坐办公5至8小时”，更有25%“每日久坐办公8至12小时”，这与他们长期伏案工作、缺少体育锻炼都有关，未引起自己对健康的重视也是另一方面原因。</span>', 'gwm', 0, 7),
(156, '中国50%白领或在未来两年中破产？', '', '', '', '2009-12-21 09:56:08', '116.228.141.77', '<span style="font-family:宋体, verdana, arial, ''times new roman'';font-size:15px;">过度负债而收入下降，是2009年中国城市居民白领家庭的基本趋势。近日，本人走访了上海、北京两大白领集中的城市10多户今年开始有房贷的家庭，七成家庭月供比例超过家庭收入的五成；生活成本本来只占三成，但最近水电油气全面调价增大了成本，提高了不少；所以，每月积蓄不到一成，旅游、购物等消费大为减少。<br /><br />　　按发达国家的白领收入月供比例，房贷月供占家庭总收入的30%比较合适。中国城市白领家庭超出合理月供比例的40%，风险系数正在加大。<br /><br />　　从今年的住房按揭贷款增加幅度来看，中国住房按揭贷款从2003年的3329亿元，至2009年9月末，加上行公积金贷款已经突破4万亿，贷款增加数以年均75%的速度增长。从总量来看，美国的住房按揭市场发展50多年，其住房贷款余额也不过在3万亿左右，但是中国房地产市场刚发展不到十年，其个人住房按揭贷款余额就达到3.3万多亿元，加以公积金住房贷款7000多亿元，已经超过了4万亿元。<br /><br />　　现在来看，假如CPI上涨3%，住房贷款月供比例超过50%的家庭，每月就开始发生入不敷出，不仅积蓄没有了，还将开始负债。对他们来讲，要么增加收入，要么降低生活质量，要么继续啃老。但是，在生活成本处于上升通道时，是没有办法降低的。如果银行再加息2%，那么，今年买房的年轻白领，断供将成为常态。这对中国社会来说，是首次发生的经济现象，其后果不亚于美国的次债危机。<br /><br />　　在调查中，我还发现一种十分有害的心理。有的认为，如果发生通货膨胀，至少收入会增加吧。抱有这种侥幸心理的大有人在。这种情况放在美国，那是没问题，美国有强大的工会组织，一发生通货膨胀足以让资本家加薪。但是，在中国不行。加薪这条路实际行不通。因为在这个时期，正是政府在加税的通道运行。中国的企业税赋很重，如果再给员工加薪，那很多企业会关门大吉。<br /><br />　　还有一种心理也是盲目乐观，那就是如果实在不行就把房子卖掉。可是，你的房子是在房价泡沫最严重的时候购买的，只要央行宣布加息，许多房子房价要跌去30%至50%，首付款都跌没了，你还怎么卖？当回收流动性的时候，大量的囤积在炒家手上的住宅会爆发性的投向市场，有价无市的局面很快形成。还怎么买房子呢？<br /><br />　　中国住宅市场是严重畸形的市场，已经埋下了足以颠覆中国经济三驾马车的巨大隐患，导致资源错配，资产价格猛涨，产业结构型矛盾加剧，社会购买力被高房价吞噬殆尽，再印钞票解决不了问题。所以，我认为应该考虑这个问题了。明年加薪无望的家庭，应该采取措施，将大房子换成小房子，小房子改为租房，手上留一点现金以备不时之需。</span>', 'gwm', 0, 8),
(157, '大蒜怎样吃才具备杀菌作用', '', '', '', '2009-12-21 10:07:32', '116.228.141.77', '<span style="font-family:宋体;font-size:12px;"><div align="center"><font size="2"><table cellspacing="0" cellpadding="3" align="center"><tbody><tr><td align="center" style="font-size:12px;color:#000000;"><img src="http://gs.people.com.cn/media/200912/17/NewsMedia_24304.jpg" /></td></tr><tr><td align="center" style="font-size:12px;color:#000000;"><br /><br /></td></tr></tbody></table></font></div><font size="3">&nbsp;&nbsp;&nbsp;&nbsp;大蒜是古老的药食两用珍品，在国外被称作“健康保护神”。中国自古也有“大蒜上市，药店关门”的说法。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;吃蒜的两大好处&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;首先，大蒜中所含的大蒜素是细菌的强力杀手，对葡萄球菌、大肠杆菌等都有抑制和杀灭作用。可以用来治疗和预防细菌性痢疾、百日咳等疾病。&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;大蒜也是高血脂患者的福音，香肠、腊肉等高脂食物，吃了之后血液中的脂肪成倍上升。如果同时吃蒜，脂肪上升趋势会到受到遏制。&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;第一步&nbsp;生吃才杀菌：“大蒜之所以有这么出色的功效，”北京医院营养室副主任营养师李长平解释说：“是因为它含有蒜氨酸和蒜酶这两种有效物质。一旦把大蒜碾碎，它们就会互相接触，从而形成大蒜素。大蒜素很强的杀菌作用，但大蒜素遇热时会很快失去作用，所以吃生蒜要比熟蒜杀菌效果好。”&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;第二步&nbsp;捣碎，不要切碎：因此，如果想达到最好的保健效果，食用大蒜最好捣碎成泥，而不是用刀切成蒜末。并且要先放10—15分钟，让蒜氨酸和蒜酶在空气中结合产生大蒜素后再食用。所以家庭里用蒜生拌凉菜，吃饺子时候用醋和少量芝麻油调的蒜泥都是很健康的吃法。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;腊八蒜：我国传统美食—北方人过腊八节用醋、糖腌制的腊八蒜，成品蒜呈淡绿色，味道酸甜辣俱全，可以缓解口干、增强食欲。蒜里面含有丰富的维生素，与醋酸结合有益健康。&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;烤蒜：&nbsp;对于体质虚弱和胃肠衰弱的人，可以适当吃些熟蒜比如烧蒜。夏季吃烧烤的人们爱把大蒜放在火炉上烤一下趁热吃。这种烧出来的蒜几乎没有臭味，吃起来像白果一样，味道很好，但是这种蒜的杀菌消毒作用要大打折扣。&nbsp;</font></span>', 'gwm', 0, 8),
(158, '甘肃武威胃癌死亡率全国居首', '', '', '', '2009-12-21 16:12:45', '116.228.141.77', '<span style="color:#333333;font-family:宋体;font-size:12px;"><p><font size="4" face="宋体">近期发布的调查报告显示，甘肃武威<strong>胃癌</strong>死亡率为十万分之九十点六一，是中国平均水平的五点六一倍。&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;</font><font size="4" face="宋体">兰州大学第二医院消化科主任医师黄晓俊今天告诉记者，武威是世界胃癌高发地区，居中国首位，占当地人群十万分之九十点六一，比广东省这些感染低发地区高出一倍。目前武威人群感染<a href="http://www.newxiwang.com/Article/List_196.html" target="_blank">胃癌</a>率为百分之七十至百分之八十。</font></p><p><font size="4" face="宋体">　业内专家介绍说，胃癌感染可能因素为幽门螺旋杆菌的感染率高，饮食、水污经口感染，其次，与武威人的生活习惯有关，腌制食品，高原饮食，嗜酒、吸烟以及有家庭性疾病、家庭性肿瘤病史等，都是胃癌高发的高危因素，一般四十五岁至六十岁为高发年龄。</font></p><p><font size="4" face="宋体">&nbsp; 据甘肃省一百六十余家拥有胃镜医院的临床检查统计，甘肃胃癌早期发现率不足百分之一，绝大多数患者确诊时已发展为晚期，丧失了最佳治疗时机。黄晓俊说，“早发现、早诊断、早治疗，可使病情遏制在萌芽状态，早期癌症几乎能达到治愈的效果，术后五年生存率在百分之九十五以上，如果是晚期能达到百分之十左右。”</font></p></span>', 'gwm', 0, 8),
(159, '宫颈癌的放疗治疗效果好', '', '', '', '2009-12-21 16:13:25', '116.228.141.77', '<font color="#333333" face="宋体"><span style="font-size:large;"><div>宫颈癌的治疗主要是手术治疗。对于2期B以前的，包括2期A的病人，还有一部分2期B经过先期化疗以后，都可以首先选择手术。宫颈癌放疗是宫颈癌的主要治疗方法之一，所有期别的病人都能进行宫颈癌放疗，但放射治疗它有一定的局限性。对于一些早期的病人和年轻的病人，如绝经期以前的妇女，做了放射治疗后，卵巢功能就受到破坏，而且这些病人在接受放射治疗以后会出现一定的并发症。近年来，对于局部晚期的病人，放疗加化疗，给病人带来了很好的希望。</div><div>　　</div><div>　宫颈癌是一个以局部侵犯和淋巴转移为主的一个疾病。其发展主要是以局部的一个蔓延和一个局部的淋巴结的转移为主，远处的转移几率比较少。因此，80%以上患者都在4期A以前，都是局部的病变。因此，如果局部的病变得到很好的控制，那么这些人就可以长期的生存下来。所以，对于一个局部病变的病人来说，宫颈癌放疗和手术一样，都能够发挥很好的作用。本文结合宫颈癌放射治疗发展的历史，谈谈宫颈癌放射治疗的进展。</div><div>　　</div><div>　宫颈癌放疗是建立在CT定位基础上的三维适形放疗计划，实现了对肿瘤高精度，高剂量、高疗效的照射，而肿瘤周围正常组织和器官受到了最佳的保护。由此三维适形放疗技术已逐渐成熟，而随之出现的调强放疗技术被认为是肿瘤放疗技术的重大突破。</div><div>　　</div><div>　据国外统计，1982～1993年期间，在世界范围内，在治疗中曾用过放疗的病例超过宫颈癌患者总数的80%。放疗的适应症广泛，各期宫颈浸润癌均可采用放疗。例如，不适于手术的原位癌患者，可采用放疗；不宜行根治性治疗的晚期患者，亦可采用放疗。</div></span></font>', 'gwm', 0, 11),
(160, '日本研究人员找到大脑厌恶不公平的部位', '', '', '', '2009-12-22 10:26:25', '116.228.141.77', '<span style="font-family:宋体;font-size:16px;"><p>新华网东京１２月２１日电　日本玉川大学脑科学研究所研究员春野雅彦等人在２１日的《自然·神经科学》网络版上发表文章称，他们发现当人们感到自己被不公平对待时，大脑的杏仁核会活跃起来。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;杏仁核位于大脑颞叶的前部、海马的末端，呈杏仁状。它与人的情绪，尤其是恐惧等情绪的处理和记忆有关。春野雅彦等人通过测定大脑活动，发现当一个人身处不公平的境地并对此感到厌恶时，杏仁核就会变得活跃，但其反应的强烈程度存在个体差异。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;研究人员以６４名大学生为研究对象，设定多种在大学生之间分配报酬的方法，比如，方案一，公平地分给他们１００日元；方案二，给一名大学生１１０日元，给另外一名大学生６０日元等。然后让这些大学生选择他们认为合理的分配方式。在研究过程中，研究人员利用功能磁共振成像仪测量研究对象大脑血流的变化，以确定他们大脑活动中活跃的部位。</p><p>&nbsp;&nbsp;&nbsp;&nbsp;结果显示，偏向公平分配报酬的研究对象在面对不公平的分配方案时，他们的杏仁核就会变得活跃，并且，越是强调公平的人，杏仁核越活跃。</p></span>', 'gwm', 0, 6),
(161, '警惕：几种电器千万不要放卧室', '', '', '', '2009-12-22 15:40:45', '116.228.141.77', '<span style="color:#115586;font-size:12px;"><font><p>健康的身体是我们每一个人更好地生活、工作和学习的基础，是做任何事情的首要前提。健康需要有乐观开朗的生活态度，同时健康也来自我们每一天良好的生活习惯。生活家小编为您精选了一些保健养生知识、健康小窍门，助您更好、更科学地调理好自己的身体，健康快乐地度过每一天！</p><div></div><p></p><p>　　研究证实：磁场会增加儿童得癌的风险，而且从2mG(毫高斯)起，风险开始加倍。事实上，长期处在磁场超过1mG的地方你就已经受到辐射污染了，而实际上在家中所测到的数据远远高于这个数字。</p><p>　　<strong>卧室：“床头音响”勿放床头</strong></p><p>　　床铺大概要算是测量家中电磁场的重头戏。如果长期睡在高磁场的地方，可以想见这影响有多大。由此也可以知道所谓的“床头音响”是不应该放置在床头的。原则上任何的电器用品都应该远离你的床铺。游人总抱怨睡眠质量不好，其实很可能就是宾馆的床铺附近放置了电暖器、电风扇、空气清新机、空调等电器作怪，要知道，一个小型电暖器的磁场就可以高达200mG以上。微波炉：微波对小男孩伤害大一些微波炉的磁场极高。与其他家电用品不同的是，即使仅是插着电没有使用它，有的机型前方按键板的磁场仍可高达30~60mG，使用时的磁场则超过200mG。另外，研究显示，这些泄漏的微波对男性生殖系统的伤害尤其大，因此小男孩更应避开。</p><p>　　<strong>冰箱：把散热管上灰尘吸掉</strong></p><p>　　电冰箱是厨房中一个高磁场的所在，特别是在冰箱正在运作、发出嗡嗡声时，冰箱后侧或下方的散热管线释放的磁场更是高出前方几十甚至几百倍(冰箱前后范围测得1~9mG，后方正中央可高达300mG)。如果冰箱的效率不高，嗡嗡声就特别久，也特别大，如果用吸尘器把散热管线上的灰尘吸掉，就会提高冰箱的效率，也减低家中的磁场。</p><p>　　非照明用的小型灭蚊灯，可别小看它，其磁场也可以超过500mG，应该把它放在墙角。</p><p>　　很多家长让孩童在电视前玩耍，或是靠得太近观看，要知道发育中的小孩受磁场的干扰比成人更大。</p><p>　　<strong>电脑：液晶显示器辐射较小</strong></p><p>　　如果你的电脑桌太小，迫使你与屏幕的距离太近，不妨将显示器尽可能向后退，当然，换成液晶显示器，辐射就相当小了。至于电脑主机，一般人也容易忽视而常常放置在腿边的位置，以方便插入磁盘。主机前方磁场可超过4mG，越靠后面磁场越高，所以能放远一点就尽量放远一点。电脑桌下方常常有一堆电线及变压器，要尽可能地远离你的脚。</p><p>　　<strong>手机充电器：与之保持距离</strong></p><p>　　带变压器的低压电源一般磁场都很高，在接线的地方可以测到300mG以上，不过距离仅30厘米远就马上掉到1mG以下了。手机充电器、便携式单放机在插座上的变压器磁场也较高，所以要保持距离，以策安全。</p><p>　　磁场的穿透性很强，千万不要忽视了相邻房间或楼上楼下的影响。特别是一般电器的管线都接在后方，所以常常测得最高的指数是在电器的正后方，那么与高磁场一墙之隔的位置就要注意了。如果你经常坐在沙发上，你头后面是墙，而隔壁邻居的电视的尾部刚好对着你的头，那你可就遭殃了。</p><p>　　曾有人在孩子床上枕头的位置测到1.6mG的磁场强度，最后发现是因为相邻的主卧房有电视开着，而这电视就在小孩床头的正后方；当一个书桌设在冰箱所靠的墙后方时，书桌的磁场在2~7mG之间。所以，沙发、座椅和枕头都最好不靠近与邻居相隔的墙，因为你不知道墙那边会有什么。</p><p>　<strong>　多吃胡萝卜加强抗辐射能力</strong></p><p>　　电磁辐射对人的影响虽普遍存在，却并不可怕。不同的人或同一人在不同年龄段对电磁辐射的承受能力是不一样的，即使在超标环境下，也不意味着所有人都会得病，但对老人、儿童、孕妇或装有心脏起搏器的病人，对电磁辐射敏感人群及长期在超剂量电磁辐射环境中工作的人来说，应采取防患措施。</p><p>　　不要把家用电器摆放得过于集中或经常一起使用，特别是电视、电脑、电冰箱不宜集中摆放在卧室里，以免使自己暴露在超剂量辐射的危险中。</p><p>　　各种家用电器、办公设备、移动电话等都应尽量避免长时间操作。</p><p>　　当电器暂停使用时，最好不让它们处于待机状态，因为此时可产生较微弱的电磁场。</p><p>　　<strong>对各种电器的使用，应保持一定的安全距离。</strong></p><p>　　佩带心脏起搏器的患者以及抵抗力较弱的孕妇、儿童、老人等，应配备阻挡电磁辐射的屏蔽防护服。</p><p>　　手机接通瞬间释放的电磁辐射最大，最好在手机响过一两秒或电话两次铃声间歇中接听电话。</p></font><p><font>　　多吃胡萝卜、西红柿、海带、瘦肉、动物肝脏等富含维生素A、C和蛋白质的食物，加强肌体抵抗电磁辐射的能力。(来源：凤凰网)</font></p></span>', 'gwm', 0, 6),
(162, '荷兰扑杀4万头怀胎母羊 防“羊流感”疫情扩散', '', '', '', '2009-12-22 15:41:44', '116.228.141.77', '<span style="font-size:14px;">荷兰21号开始在全国范围内出现Q热疫情的牧场扑杀怀胎母羊，以防止Q热疫情扩散。<br /><br />　　据报道，这次被扑杀的怀胎母羊有4万头之多。在被证实出现Q热疫情的牧场，只要是怀胎的母羊，无论是否已经感染Q热病毒，都在被扑杀之列，以防止它们在分娩或流产时扩散Q热病毒。扑杀方式是注射致命药剂，并在一天内将尸体销毁。<br /><br />　　Q热俗称“羊流感”，可通过动物传染给人类。2007年起，Q热开始在荷兰南部传播。据荷兰官方日前公布的数据，截至今年12月，荷兰全国已有2300人感染Q热病毒，其中有6人死亡。<br /><br />　　1935年，澳大利亚屠宰场的工作人员间曾流行一种原因不明的疾病，被称为Q热，意为“原因不明的热性疾病”，后被证实此病是由贝氏考克斯菌所造成的人畜共通感染症。被感染者的症状类似流感。Q热的动物宿主主要为山羊、绵羊等。(记者金力) (来源：国际在线)</span>', 'gwm', 0, 5),
(163, '生活家健康指南：乱拔手上的倒刺危险', '', '', '', '2009-12-22 15:49:32', '116.228.141.77', '<span style="font-family:新宋体;font-size:14px;"><p>健康的身体是我们每一个人更好地生活、工作和学习的基础，是做任何事情的首要前提。健康需要有乐观开朗的生活态度，同时健康也来自我们每一天良好的生活习惯。生活家小编为您精选了一些保健养生知识、健康小窍门，助您更好、更科学地调理好自己的身体，健康快乐地度过每一天！</p><p>　　冬后因天气开始变得干燥，很多人在手指靠近甲根的皮肤上开始出现皮肤裂开，形成翘起的三角形倒刺，如果刮到衣服或碰到这些刺儿会觉得疼痛，一歇下来看见它们总会不自觉想将它们拔掉，可要是真拔了，不仅疼，还常会弄得手指血迹斑斑，严重者还可能出现皮肤感染。</p><p align="center"><img src="http://img.022net.com/ImgFile/200912/22/66/777632405069597154.gif" /></p><p>　　这些“倒刺”在医学上称为“逆剥”，是指从甲皱襞的近端或侧缘开裂而翘起的小块长三角形表皮，时有疼痛。</p><p>　　长倒刺最主要的原因为皮肤干燥、出现裂隙及习惯性咬指甲引起。咬甲癖是很常见的一个原因，因此青少年更容易长倒刺，而成人也会长倒刺，更多的可能是与皮肤干燥有关。如果很久了仍不愈合，那就可能与缺乏维生素或微量元素导致的皮肤长期干燥有关。</p><p>　　这种“倒刺”只是皮肤浅表层的损伤，本不足为患，但常有人拔撕倒刺，由于甲上皮的结构是向下和向后连接，企图撕下会造成倒刺的进一步撕裂，其结果是倒刺越撕越大，越撕越深，造成皮肤深层的进一步损伤，并引起出血及感染。</p><p>　　指甲与周围皮肤交接处的沟称为甲沟，倒刺一旦感染，很快会波及甲沟而引起甲沟炎，使局部红肿疼痛甚至化脓;如不及时治疗，可进一步发展为甲下脓肿和脓性指尖炎，前者要拔甲，后者要切开指尖引流排脓，才能得到治愈。可见小小倒刺，由于处理不当，会带来多大的痛苦。</p><p align="center"><img src="http://img.022net.com/ImgFile/200912/22/91/9851690134675069071.jpg" /></p><p>　　因此，如果发现手指上有倒刺切不可撕扯，正确的做法是先用温水浸泡有倒刺的手约5分钟，等指甲周围的皮肤变得柔软后，再用指甲钳或小剪刀在倒刺的根部将其剪掉即可。</p><p>　　因为干燥的倒刺在剪除时可能形成皮肤微小的撕裂，导致出现更多的倒刺。由于在剪除倒刺时有较少的机会会发生感染，因此在剪之前，指甲钳或小剪刀需先用酒精消毒，倒刺在剪掉前与剪掉后也需涂上碘酒。如果倒刺周围发红或出现了化脓，则很可能是出现了感染，最好到医院就诊。</p><p>　　对于倒刺的预防一方面是家长不要让孩子不自觉的的撕咬指甲，如果皮肤干燥需时常涂保湿霜或维生素E霜。在外部滋润手指的同时，还可考虑补充维生素A、E、C以及微量元素锌、硒等，比如多食用胡萝卜、哈密瓜、蛋、牛奶、杏仁、海带、紫菜、海鱼、绿色蔬菜等。</p></span>', 'gwm', 0, 7),
(164, '美国研制出大脑思维翻译器 欲将思想变语言(图)', '', '', '', '2009-12-23 10:17:08', '116.228.141.77', '<div><br /></div><div><span style="font-family:arial;font-size:14px;"><p align="center"><img src="http://image.xinmin.cn/2009/12/23/20091223073113363700.jpg" /></p><p align="center">“大脑机器界面”模型及语言合成流程</p><p>　　据美国媒体报道，近日，美国科学家发明了一种可以实时翻译大脑信号的技术，置入大脑内部的装置以无线的方式向外传送大脑信号，外部的语言合成器可以实时接收大脑信号并将其翻译成人类语言。目前，基于这项技术的“大脑机器界面”已经在一位闭锁综合症患者身上取得实验成功。</p><p>　　据科学家介绍，利用这项技术，“思想变语言”的过程仅仅需要50毫秒，这个时间量恰好与神经正常的人用语言表达自己的思想时反应时间相同。这一研究成果首次成功地证明，可以在人类大脑中置入无线装置，通过大脑意识对外部的语音设备进行实时控制。对于那些因为神经受损而失去控制能力的人来说，这项成果将是他们的福音。</p><p>　　该项研究由美国波士顿大学科学家弗兰克-古恩特尔领导实施，波士顿大学感知与神经系统系、健康与复原科学学院、哈佛-麻省理工学院卫生科学与技术部的科学家们共同参与了这项研究。这项研究成果将发表于美国《公共科学图书馆&#12539;综合》杂志上。</p><p>　　古恩特尔介绍说，“我们的研究成果表明，‘大脑机器界面’的用户可以直接控制语言输出，比使用相对较慢的打字过程要好得多。”</p><p>　　科学家们将这项技术应用于一位26岁的闭锁综合症患者身上进行实验。该患者在16岁时曾经有过一次脑干中风，这次脑干中风造成患者的运动神经元受到损伤。运动神经元主要是用于执行人体的行为和动作。运动神经元受损意味着患者可能会出现肢体麻痹、肌肉萎缩，甚至瘫痪等严重问题。除了眼睛可以上下运动外，这位患者已经出现了全身麻痹症状。不过，他的意识是清醒的，这种情况就是所谓的“闭锁综合症”，即意识清醒，但不能说话、不能活动。</p><p>　　五年前，科学家将一个电极置入患者的大脑内部，大约位于与语言相关的运动前区皮层和运动皮层之间。此后，神经突开始生长至电极上。三四个月后，神经突在电极上产生了信号。三年后，研究人员开始测试“大脑机器界面”，准备合成语音产品。由于该系统是基于遥感技术的，因此不需要电线或传感器连接到患者皮肤之内，这也排除了感染的风险。</p><p>　　电极将神经信号扩大并转化为无线电信号。在患者的头部贴有两片薄片，这两片薄片起到信号接收天线的作用。当大脑内的无线电信号向外发送时，头皮上的接收天线就可实现及时接收并将这些信号传送到电生理学记录系统中。记录系统将信号进行数字化转换并分类。分类后的数据被输入一个神经信号解码器中进行解码。然后，解码后的结果再输入到语言合成器中。最后，由语言合成器生成人类的语言。目前，科学家们仅仅是实验了元音字母。整个过程平均花费时间仅为50毫秒。</p><p>　　尽管目前的研究成果只是合成了一小部分元音，但是研究人员认为随着该系统的逐步完善，不久的将来可能会实现连贯的语音产品。古恩特尔表示，“我们当前的计划就是尽快研制一种新的语言合成器，合成更多的连贯语音。”</p></span></div>', 'gwm', 0, 6);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(165, '医生从医25年平均单张处方不超80元 小钱治大病', '', '', '', '2009-12-23 10:59:04', '116.228.141.77', '<span style="color:#333333;font-family:宋体;font-size:14px;"><table align="center" style="font-size:12px;"><tbody><tr><td style="font-size:12px;"><table cellspacing="0" cellpadding="0" border="0" style="font-size:12px;"><tbody><tr><td style="font-size:12px;"><img height="573" src="http://photocdn.sohu.com/20091223/Img269136494.jpg" width="400" border="1" /></td></tr></tbody></table></td></tr></tbody></table><br />　　好医生王争艳，从医25年，平均单张处方不超过80元——<br /><br />　　昨日，武汉市汉口医院医生王争艳在社区医生岗位上正式退休。<br /><br />　　9月25日，经过36000多市民无记名投票，她从20000多名医生中当选“武汉市人民满意的好医生”。<br /><br />　　2009年12月22日清晨。王争艳起床，简单的早餐后，骑着自行车出门。<br /><br />　　天蒙蒙亮，已有病人在汉口金桥社区卫生中心外等候，王争艳裹着一身寒气到达。55岁的王争艳，头发花白，脚上是一双已不多见的翻毛皮鞋。她在那件旧旧的黑色棉衣上罩上白大褂，习惯性摸了一下装备：左上口袋里的小电筒，左下口袋里的棉签，右下口袋里的听诊器。一天开始。<br /><br />　　王争艳说话语速快，音量大，常伴手势，这是长期在嘈杂诊室里工作养成的。不过，她有个习惯——从不打断病人讲述，始终微笑着注视对方。接下来，她用双手为病人做检查。这是一双关节粗大、皮肤粗糙的手，多年来，这双手已像一台精密仪器，可以在病人就诊的几分钟里，基本锁定病源。<br /><br />　　不敢喝水，以免如厕。一直到中午12点半，病人稀少，她才敢在微波炉里热一下中饭——那是家里头天晚上吃剩的饭菜。没有午休，王争艳始终呆在诊室，重复着上午的繁杂。没有下班时间，最后一个病人离开，王争艳才能善后：收好一天的病历资料，脱下白大褂，检查一下小灵通是否通畅——她的小灵通号码就贴在诊室里。<br /><br />　　冬日的太阳已落下，很冷，王争艳走出大门，深呼吸。这是医生王争艳重复了25年的普通一天。这是医生王争艳的最后一天。从这一天起，她正式退休，25年的医生生涯，在岁月的流逝中划上句号。<br /><br />　　9月25日，她成为30名“江城好医生”中的一名。这是她医生生涯中最后一个荣誉，也是她最看重的一个荣誉——她视之为老百姓为她送别的歌声。<br /><br />　　1984年，30岁的王争艳从同济医科大学本科毕业。前30年，她随南下军医的父亲和在医院做护士的母亲在洪湖市长大。少年时最清晰的记忆来自母亲。这位在手术室工作的护士是O型血，常常一边工作，一边挽袖子为手术台上的病人献血。23岁考上大学，途中因严重的肺结核休学。这段病人生涯，为王争艳的人生规划完成最后一笔：不为良相，即为良医。<br /><br />　　30岁的王争艳在武汉市汉口医院（原汉口铁路医院）开始了医生生涯。做了11年的内科住院医师后，在医院下设的四个门诊站点担任全科医生，最后成为一名社区医生。<br /><br />　　一代名医裘法祖，曾给王争艳上过大课。裘老仙逝时，王争艳自觉没资格以弟子名义送行。但是，25年后，王争艳依然能背出裘老师在大课上说的一段话：“先看病人，再看片子，最后看检查报告，是为上医；同时看片子和报告，是为中医，只看报告，提笔开药，是为下医。”<br /><br />　　王争艳自认是个合格的学生。她对每个病人都严格的执行教科书所教“视、触、叩、听”原则。因此，她自信的说，病人走进诊室10分钟，她心里就有谱了。黄陂农民刘耀东深有体会。他因持续消瘦四处求医，做过上千元的检查仍无果。王争艳用双手为他“摸”了10分钟，问“您是不是得过血吸虫病？”刘耀东惊讶：“几十年前的事，您怎么晓得？”——谜底揭晓。<br /><br />　　患者王荣华患有世界罕见的“亚急性脊髓联合变性”，理论上应长期住院。但王荣华穷得连医保中自己支付的部分都拿不出来，王妻说，丈夫将不死于病，就死于钱。王争艳的方案是，抢救一缓过劲就回家，她来根据病情调整药物，王妻拿处方去药店买药。这一方案，已维持一个罕见疾病患者的生命十余年。王妻说，没有王大夫，就没有我丈夫的命，我这个家就完了。<br /><br />　　王争艳曾不好意思的说，做医生，对治病是有瘾的。不久前，有个甲流病人就诊，久治不愈。王争艳观察后说，可能合并支原体感染，要抽血。久病之人怒气一触即发：久治不愈，又不能出门，不来医院。王争艳说，你不来，我亲自到家里替你抽，你不愿付费，我出钱替你付，血一定要抽。检查结果出来——支原体阳性，需要疗程治疗。<br /><br />　　<strong>大爱无疆<br /></strong><br />　　能治好病，是合格的医生，能花最少的钱治好病，才是好医生。25年来，王争艳只有这么一个心得。<br /><br />　　50岁的王爹爹是高血压病人，在顶级大医院领到了每月800元的处方单——超过他每月退休金的一半。王争艳为他调整处方，每月只需80元药费。王争艳说，没有诀窍，任何一种病，都有可开可不开的药，都有高中低价位的药物，就看医生一支笔。<br /><br />　　王争艳从医25年，平均单张处方不超过80元，至今还常开两毛钱的处方。她解释，阿托品，调节心率，就只两毛钱。<br /><br />　　有病友如此推荐王争艳参评“好医生”：她时刻为病人着想，是个干干净净的医生。<br /><br />　　王争艳笑道，我不是为病人着想，我本来就是他们中的一分子。王争艳所在的医院，服务辖区内多是经济能力不高的居民。王争艳本人，现在每月收入两千元左右，丈夫是车工，每月扣除三金的净收入约六百元。一家三口18年来住的房子不足50平方米，读大学的儿子，至今还睡在阁楼上。洪湖市老家的老人到汉，一家三口要挤儿子的阁楼，把床让给老人。<br /><br />　　王争艳说，我是怎么过日子，我的病人就是怎么过日子；高一点贵一点的药，我下不了手。25年来，最初的不忍逐渐成为习惯，她的处方，就像海绵里的水，越挤越干。她的生活，也形成了习惯，一分钱一角钱都会攒起来放在小盒子里留着买菜用。一家人很少上餐馆，家里的电视还是17吋的老古董。<br /><br />　　然而，今年3月，几个同事突然上门，逼着借钱给她，要她到隔壁新区买房，房子都替她看好了——此时金融危机，房价便宜。王争艳最后招架不住，借款36万元，买下一套46万的一楼住房。“逼着借钱”的同事只有一句解释，这么好的医生，不该住这样的房子。<br /><br />　　王争艳不觉得苦。她先后呆过4个门诊站点，每到一处，既有老病人辗转追随，又有新病人聚少成多。她说，医生怎么样，其实同行和老百姓心里明镜似的，只看人家说不说，怎么说。<br /><br />　　因为病人经济条件普遍较差，王争艳有替人垫钱的习惯。几块钱的挂号费，十几块钱的药费，她常垫，但是多年来，却保持着一个纪录：垫出去的钱，从来没有不回来的。一个农民工在工地摔伤，连缝合带药费30元，病人只有20元，王争艳垫了10元钱，木讷的民工连个谢字也没有。第二天，一瘸一拐的病人却捏着10元钱回来了。<br /><br />　　王争艳常说，她只是尽医生的职责，病人回报的却是更加的良善和信任，他们的爱更大。此次评选“江城好医生”，可以上网和电话投票，但很多人，搭着公汽，辗转半个江城，来投她一票。<br /><br />　　<strong>一件制服</strong><br /><br />　　王争艳的母校同济医科大学，是全国有名的医科学府。她的79级同学们，大都比她小十岁，如今正是各大医院顶梁柱。与她一同分到汉口医院的3名同学，一名高飞，一名南下，一名已是科主任；只有她，越做越“沉”，起初是本院住院医师，后来到门诊站点，最后做了一名社区医生。<br /><br />　　汉口医院的负责人说，没有办法，王争艳就是一剂药，放她到哪里，哪里的门诊就能“活”。她到金桥社区3个月，这个门诊就扭亏为盈。“处方廉价，何能盈利？”局外人不解。内行解释，说俗一点，就是薄利多销。<br /><br />　　2009年，王争艳第一次参加了同学聚会，这是79级同学入学30年纪念。10年、20年纪念时，她没去。她的同学大都住着高档小区，开着名牌小车，而她，连件像样的衣服都没有，她不好意思。30年聚会时，有同学出妙招，每人发一件制服，大家穿着同样的衣服去参加，她答应了。<br /><br />　　回来时，她带回一本30年纪念相册和一件制服。相册上，当初的青涩少年，而今神态各异，但制服却是一统的。儿子笑，不如都穿白大褂去好了。她正色道，白大褂是对病人穿的，制服是对同学穿的，要是年年碰头，都穿同一件制服，她还是愿意经常去与同学、同行、同道们相会。<br /><br /><strong>　　鲁珊</strong><br /><br />　　事实上，王争艳就是一剂药。<br /><br />　　这剂药采自三种原料。她那O型血的护士母亲，常在手术室边工作边挽起袖子为病人献血，她是王争艳的前传和同道。一代名医裘法祖，并不认识自己的学生王争艳，但阶梯教室里一段关于医者仁心的论述，完成了师生的师道传承、医者的精神呼应。数量庞大的病人们，是王争艳的第三种养分，这些人以信任和良善反哺了王争艳，他们是这剂药的受益者，也为其注入驱动力和幸福感。<br /><br />　　一剂良药，应当准确的指向病根，并且是守在普通柜台，而非贴着VIP的标签，站在橱窗里。<br /><br />　　良药讲究对症。药物和疾病相生相克的原理，揭示着一些最基本的逻辑：比如医生是治病的，不是医药代表，医生是站着的人，不是检查仪器的利润；比如最好的医生不一定需要最好的医院，最响的名头；比如小处方同样能使医疗机构获得良好生存；比如医生天平的另一端是病人，不是钱、权、地位和上级；再比如温总理所说的，医疗体制改革的成败，关键在人。<br /><br />　　需要指出，药不是万能的，所以王争艳清贫。但是，王争艳不差钱。很多人得到的，是她失去的；而她得到的，也正是许多人失去的。<br /><br />　　一剂良药的最大价值，在于它值得依赖，值得托付以性命——天使的境界，也莫过若此。</span>', 'gwm', 0, 9),
(166, '科学家欲研制棕色脂肪药丸 加速新陈代谢助减肥 ', '', '', '', '2009-12-23 11:00:08', '116.228.141.77', '<span style="font-family:arial;font-size:14px;"><p align="center"><img src="http://image.xinmin.cn/2009/12/23/20091223095326202850.jpg" /></p><p>　　或许将来一种棕色脂肪药丸可以让人燃烧更多的白色脂肪，从而让胖子可以顺利减肥。</p><p>　　<strong>网易探索12月23日报道</strong>&nbsp;据《科学美国人》报道，近期科学家们发现了一种加速人体新陈代谢的新方法，即激活人体的“棕色脂肪”细胞。这种方法可以通过分子手段促进棕色脂肪活力。棕色脂肪“药丸”将成为接下来的十年来减肥的历史性突破。</p><p>　　2004年2月，亚伦&#12539;塞比斯获得了对脂肪的新领悟。作为波士顿的贝斯-以色列医疗中心内分泌学研究员，塞比斯碰巧参加了一次讲座。讲座上，一名博士向大家展示人类正电子发射层析扫描图。事后，塞比斯回想起当时博士指着脖子一块区域，非常不屑地说：瞧，这是棕色脂肪。塞比斯听后一惊。讲座后，他找到博士，对博士说，你一定弄错了，每个人都知道成人身体上不存在棕色脂肪。博士笑着说道：“当然有，我们随时可以看见它。”</p><p>　　长久以来人们都认为棕色脂肪只存在于婴儿或者类似老鼠这样的动物中。但是直到最近，科学家们才认为它们在人体转入成人期时便消失了，留下的只是白色脂肪――与人体重增加有着密切联系。与储存能量的白色脂肪不同的是，栗子色的棕色脂肪燃烧热量。棕色脂肪细胞内含大量的细胞器供给，这些细胞器被称作线粒体。除此之外，棕色脂肪细胞中还有一种能够帮助线粒体从食物热量中释放能量的酶。</p><p>　　2009年春天，《新英格兰医学期刊》（New England Journal of Medicine）上出现了各种各样的相关研究，其中包括与塞比斯合作的一份研究。现在乔瑟林糖尿病中心的一名研究人员提出：棕色脂肪不仅仅在成人体上很常见，它对新陈代谢也起着至关重要的作用：与较老，圆胖的人相比，越年轻，越瘦的人体内可检测出的棕色脂肪就越多。正因为如此，医生们仍在研究脂肪如何工作。现在脂肪在人们看来已不是肥肥的毫无活力的一团东西，而是高级的和合乎科学的复杂生物器官，其对人体的重要性足以与肝肾相匹敌。科学家们相信脂肪分泌性激素和能够调整人们行为和健康的发信号分子。白色脂肪对人体免疫系统发挥着极重要的作用。一份今年8月发布在免疫学杂志上的研究报告显示，脂肪分泌物能够帮助人体抵抗免疫系统入侵者。另一份2008年发布在《细胞新陈代谢》（Cell Metabolism）的研究报告发现那些积攒在臀部和大腿的脂肪（皮下脂肪）实际上能够降低患糖尿病的可能性。塞比斯说：“我们之前学的只是白色脂肪能够有效地储存能量，仅此而已。现在脂肪经历了一次复兴。”</p><p>　　尽管对脂肪的新观点出现，但是医生仍然认为大部分人身上储存的白色脂肪超过他们需要的量。20岁以上的美国人中，34%都是过度肥胖的，而这些过度肥胖的人身上的脂肪大部分积聚在内脏。这些脂肪包裹着人们重要的器官，增加了他们患糖尿病、癌症和中风的可能性。对于这些人，集中在颈部和胸部的棕色脂肪的发现无疑给他们带来了一丝希望。科学家们已经开始考虑将脂肪作为一种潜在的治疗肥胖等情况的方法，而不是将肥胖归咎于脂肪。</p><p>　　<strong>轻弹“肥胖按钮”，肥胖不再有</strong></p><p>　　塞比斯的研究还发现，除了年轻纤瘦的人外，女人体内拥有的活跃棕色脂肪数量大约为男人的两倍，可能因为女人缺少肌肉群，她们需要棕色脂肪来保暖。事实上，温度好像是棕色脂肪活跃度的一个重要控制器。斯文&#12539;埃纳柏克（Sven Enerbck）是瑞典哥德堡大学（University of Gothenburg）的一名医学遗传学者。他带领的研究队伍发现，当被试者穿着薄衣在一间冷冻间待两个小时，期间间歇性地有冰水浸湿他们的脚，那么他们体内的棕色脂肪燃烧能量的数量为在室温下燃烧的能量的15倍以上。一位被试者拥有足以供每年消耗8到9磅体重的棕色脂肪。荷兰研究人员了解到24个被试者中有23个在寒冷的时候体内会出现活性棕色脂肪，而温暖的时候就没有。英国诺丁汉大学(University of Nottingham)的研究报告显示棕色脂肪活跃度还与季节性阳光减少有着密切联系。</p><p>　　除人体研究外，对动物的研究同样提出棕色脂肪有助于减轻体重的结论。去年，斯德哥尔摩大学的科学家们发现体内不会产生棕色脂肪的老鼠，与那些会产生棕色脂肪的老鼠相比，体重增加了50%。一份2008年研究报告中，老鼠被喂以高脂肪食物并且生活在室温下，那它们死的时候要比那些被喂以同样的食物然而生活在摄氏温度3.9度的老鼠死的时候重将近4倍。研究人员估计约62.2克的活性棕色脂肪每天能够消耗300到500卡路里。对此，塞比斯表示：“一点的棕色脂肪就对你身体的新陈代谢产生很好的效果。”</p><p>　　然而要怎样不用把脚浸湿在冰水中也能够转化出棕色脂肪呢?波士顿Dana-Farber癌症研究所的一位博士后研究员帕特里克&#12539;史奥鉴定出一种称作“PRDM-16”的蛋白质，这种蛋白质在每一个棕色脂肪细胞中都能发现，但是在白色脂肪细胞中却没有。当他人工停止年轻棕色脂肪细胞中PRDM-16的活跃性时，棕色脂肪细胞变成了肌肉细胞。现在史奥致力于研究出能使PRDM-16恢复活性的基因。</p><p>　　史奥在Dana-Farber癌症研究所的导师布鲁斯&#12539;施皮格尔曼正在测试一种新疗法，这种疗法将动物体内的白色脂肪前体细胞取出，注入活跃的PRDM-16，然后再将这种细胞植入动物体内。通过这样的实验，他想要看看重新植入细胞的这些动物是否会减轻体重。然而对此，宾夕法尼亚大学医学院研究糖尿病、肥胖和新陈代谢等领域的研究所所长米切尔&#12539;拉扎尔认为，这种方法相当牵强。“另一方面，我又不能解释这种方法行不通的理由。”</p><p>　　<strong>制作魔力药丸，解除肥胖困扰</strong></p><p>　　塞比斯和他的同事们正集中精力研究不同的蛋白质，其中也包括了BMP-7（帮助骨骼生长，骨骼往往与脂肪相通）。最近一位科研人员发现老鼠体内的BMP-7能够促进产生棕色脂肪，并且使其避免肥胖。美国食品和药物管理局(FDA)已同意一种BMP-7药物用于外科手术中的脊椎麻醉，所以塞比斯正在测试这种药物对外科手术病人的作用，同时也看这种药物是否会增加棕色脂肪。塞比斯表示：“如果它有作用，那么这将是我们过去几年研究的一次大飞跃。”</p><p>　　最后，史奥和塞比斯一致预想的药物就是一种“棕色脂肪药丸”。这种药物可以通过分子方法增强棕色脂肪的活性。塞比斯非常期待：“我有一些重达400磅的病人，我要找出帮助他们的办法。”当然，他们也知道这样的药物并不会对肥胖产生立竿见影的快速功效。但是棕色脂肪可以帮助人们达到每天燃烧额外500卡路里热量的减肥目标。</p><p>　　在这样的药丸可用前，人们有很多种方法增强棕色脂肪的活性。埃纳柏克说：“我不认为我们可以使很多人忍受冷疗法。”但是，人们可以做到关小家里的空调，并在秋季和冬季的时候多到户外活动。研究发现，那些在户外工作的人们体内的棕色脂肪活跃度要比人体平均水平高，所以“在凛冽寒风中走路去上班会加速新陈代谢”这样的讲法并不荒唐。</p><p>　　现在科学家们正以一个新角度（脂肪是人体内分泌系统的重要器官）研究脂肪，他们一定会研究出更多的成果。例如，7月发布的一份研究报告对运动和减肥建立了一个新视野：身体活动能够增加大脑对食欲的敏感度，抑制诸如瘦蛋白和胰岛素这样的性激素，从而达到减肥目的，而不是以往人们认为的燃烧卡路里。</p><p>　　或许我们也可以设想一下“锻炼药丸”。当然，这听起来很荒谬。但是富于想象力也不伤大雅。用埃纳柏克的话说，我们当然需要新奇的方法来思考如何与日益“流行”的肥胖作战。</p></span>', 'gwm', 0, 7),
(167, '慢生活，让你更健康(图)', '', '', '', '2009-12-23 11:02:14', '116.228.141.77', '<span style="font-family:arial;font-size:14px;"><p align="center"><img src="http://image.xinmin.cn/2009/12/23/20091223100455616088.jpg" /></p><p align="center">文/芹芹</p><p>　　在忙碌的消费时代，人们不光消费了劳动所得，也牺牲了宝贵的健康。如何寻求一种更加健康的生活方式，一直是困扰着许多人的问题。“慢生活”的倡导，使快节奏中的人们开始重新思索自己的生活，唤起了人们对健康的追求。</p><p>　　名词解释“慢生活”</p><p>　　“慢生活”是相对于当前社会匆匆忙忙、纷纷扰扰的快节奏生活而言的另一种生活方式。这里的“慢”，并非速度上的绝对慢，而是一种意境，一种回归自然、轻松和谐的意境。</p><p>　　从健康角度讲，古代医学之父已有箴言：“阳光、空气、水和运动，这是生命和健康的源泉。”健康的核心就是亲近自然，顺应自然。怎样才是顺应自然呢？简单地说，就是顺应日月运行、生命运动、四季变化的规律。一天的时间中，工作、生活、睡眠三者各占约8小时，不能偏颇。只要偏离这个生命最基本的规律，就必然要用健康来偿还，人人都不例外。在心态上，“正气存内，邪不可干”，淡泊宁静，和谐有序。慢生活并非散漫和慵懒，而是自然与从容。</p><p>　　八种慢生活方式</p><p>　　慢餐饮</p><p>　　城市的快节奏正以生产力的名义扭曲我们的生命和环境，我们要以慢慢吃为开始，放慢快节奏的生活。慢生活的第一要义就是慢餐饮，换言之，美妙慢之旅，由唇齿间开始。慢慢吃，这是慢一族最显著的行为主义。</p><p>　　所谓的慢餐运动是为了唤醒人们遭快餐催眠的味觉，提倡回归对食物及用餐环境品质的要求，主调不过是“来，慢慢吃吧，没有太特别的事情要赶的”。既然美妙的生活开始于缓慢的吃法，习惯了快速度的我们该怎样在平日里培养慢餐态度？比如适当调整一下生活习惯，提早20分钟起床准备早餐，至少为自己煎一个鸡蛋、调制一杯新鲜果汁。与自己约定12点准时去吃午餐，因为上午没做完的工作下午还可以继续做。</p><p>　　慢睡眠</p><p>　　睡眠好的人不是没有烦恼，只是他们懂得放弃，最起码要放弃一晚，等到明天再想。所以，在我们决定睡觉的那一刻，没有人可以打扰我们的美梦。慢生活的推崇者总能慢条斯理地入睡，一夜安眠，第二天醒来，容光焕发、精力充沛地投入工作中，睡出了情趣，睡出了健康。</p><p>　　慢工作</p><p>　　这代表了一种更为自由、开放、弹性的工作方式。尽管还要为工作和业务拼搏，但可以把努力工作当作一件很愉快的事。很多自以为看起来很苦的事情慢下来欣赏，也是很美的。</p><p>　　也许有人会迷惑不解，工作怎么可以慢呢？现代化的工作节奏的确是“慢”的大敌，但是你可以用更自由、更开放、更弹性的工作方式来对待，让工作更有计划性，避免很多重复性的工作，让自己工作着，快乐着。</p><p>　　慢读书</p><p>　　对于好书的兴趣，一如对于各色美味。善待自己的生命，也用心守候着自己灵魂的家园。</p><p>　　这个世界上很多事都可以追求快，但阅读却是一件需要慢慢做的事情，而且越慢越好。对于追求优雅和舒适生活的慢一族，阅读指的是“触动心灵”的“读”，不是泛泛地看。</p><p>　　慢运动</p><p>　　运动对于一般人而言，享受的是过程，而不是目的或者结果，我们运动的标准不是速度快了多少，也不是肌肉又增强了几分，我们的目的是使自己更健康、更快乐。对于平时疏于运动的都市人来说，高强度的运动可能反而对自己的身体有害，而慢运动才能真正提高生活品质，带来健康。那种形式上的慢速度、慢动作，所带来的是内心本质加速度的放缓。柔韧、平衡、放松才是现代都市生活中最佳也是最快乐的运动方式。</p><p>　　慢休闲</p><p>　　无论跑到哪一个城市，就如回到自己的家：黄昏走到街市买菜，在住处周遭闲逛，不带任何东西两手空空、潇洒走过。这样的旅游绝对比“到达、拍照、话题”这样的模式要痛快。休闲是什么？就是身体和灵魂放轻松，让平时劳碌的身体停歇，让紧张的神经彻底放松，让浮躁的心态沉淀下来。只要能达到这个目的就够了，至于形式可以随心所欲。</p><p>　　慢音乐</p><p>　　拒绝噪声，我要健康，我要我的慢音乐。喜欢慢生活的人通常喜欢听轻柔的音乐，慢音乐不仅能陶冶人的气质修养还能促进人的身心健康。每每聆听那些高山流水一样的曲调，我们就能明显感觉到心灵在舒缓，所谓天籁之音，就包含着一种不可思议的神秘慢力量。</p><p>　　慢社交</p><p>　　职场如江湖，算计别人不如修炼自己。做最好的自己，反而可以轻松打通人脉，以四两拨千斤。即使在职场上，主张慢社交的人也总是不温不火，不慌不忙。在他们眼里，职场中的人际关系说复杂也复杂，说简单也简单。主张快社交的人往往主动出击，为自己假想了很多危机，时时处于“备战”状态准备扑火，而主张慢社交的人却总是坚信，练好内功是根本，因此他们不做小动作，只是本分地做最好的自己，与人为善。</p></span>', 'gwm', 0, 9),
(168, '完全取消两对半检测有难度 消除歧视需要缓冲期', '', '', '', '2009-12-24 11:11:23', '116.228.141.77', '<span style="font-family:瀹嬩綋;font-size:16px;"><img src="http://www.people.com.cn/mediafile/pic/20091224/72/2299589298712709248.jpg" />吴伟洪摄<br /><br />　　“就业、入学时的<a href="http://health.people.com.cn/GB/119042/135705/index.html" target="_blank"><font color="#0000FF">乙肝</font></a>检测取消”真要实施起来,感觉还是有一定的难度,毕竟社会上存在的对<a href="http://health.people.com.cn/GB/119042/135705/index.html" target="_blank"><font color="#0000FF">乙肝</font></a>的歧视不是一两天、一两年才形成,这种上十年来就有的观念需要给一个过渡期来逐渐消除。<br /><br />　　卫生部近日表态,将取消就业、入学时的乙肝两对半检测。从几个月前传出的疾控中心专家建议,到现在的卫生部官方发声表态,取消相关的乙肝检测似乎已板上钉钉,社会上传来叫好声一片。但欢呼之后,冷静下来,各类担忧开始出现,记者在采访医生、患者、体检机构时就听到了不少类似本文第一段的观点和看法。<br /><br /><b>　　消除歧视需要缓冲期</b><br /><br />　　广州市第八人民医院门诊部主任罗洁介绍,实际上,无论乙肝患者还是乙肝病毒携带者,在日常生活中,传染性都很有限。加上政府一直不断加强乙肝防治<a href="http://health.people.com.cn/GB/14741/21489/index.html" target="_blank"><font color="#0000FF">工作</font></a>,特别是1992年将乙肝疫苗接种纳入计划免疫管理,乙肝疫苗普及率越来越高。取消就业、入学时的乙肝两对半检测,是很好的举措。<br /><br />　　但罗洁同时也表示,该举措具体实施起来,感觉还有一定难度,毕竟社会上存在的对乙肝的歧视不是一两天、一两年才形成,这种上十年来就有的观念需要给一个过渡期来逐渐消除。“我们在门诊中就遇到患者这样诉苦”:政府规定不得歧视“乙肝”,不得以是乙肝病毒携带者、乙肝患者为借口,而拒绝对其录用,但就有用人单位在知道检查结果后,用其他诸如不适合该岗位等其他借口,拒绝录用。<br /><br />　　对此,有企业主向记者解释说,不是说血液也是乙肝病毒的一个传播途径吗?如果有<a href="http://health.people.com.cn/GB/119042/134697/index.html" target="_blank"><font color="#0000FF">牙</font></a>齿出血的问题,那在一起吃饭不就有传染可能,各种风险都很难预见的,与其整天小心翼翼,还不如一开始就弄个明白,防范于未然。<br /><br /><b>　　“福利体检”令结果难保密</b><br /><br />　　卫生部新闻办主任邓海华在接受媒体采访时曾表示,员工进入单位后会有“福利”体检,乙肝携带者依然可能被歧视。他说,单位不能强行让职工进行体检,对职工体检的隐私,要进行保护。国家卫生部也将对医疗机构进行规范,在体检中对两对半尽量不查,就算是查了,结果也只应对应体检当事人,而不是对单位,不能让体检结果成为人尽皆知的“公开秘密”。医院方不应在体检中“泄密”。<br /><br />　　一位体检机构负责人向记者表示,现如今员工的维权意识越来越强,“我们常会遇到,有员工要求乙肝检查结果只能本人知道,但他们所做的体检又是所在单位付的钱,单位是我们的客户,不能得罪,而客户又要求看员工的体检结果。这弄得我们很为难,经常出现纠纷。”该负责人坦言,所以说,如果真要取消就业的乙肝检查,很难,企业很可能“上有政策,下有对策”,到头来,还是乙肝患者、病毒携带者吃亏。<br /><br /><b>　　■专家建议<br /><br />　　加强正确<a href="http://health.people.com.cn/GB/index.html" target="_blank"><font color="#0000FF">健康</font></a>知识宣传</b><br /><br />　　广州市第八人民医院门诊部主任罗洁建议说,消除歧视,还有赖于不断加强正确<a href="http://health.people.com.cn/GB/index.html" target="_blank"><font color="#0000FF">健康</font></a>知识的宣传。当前社会上对乙肝病毒携带者的误解主要是由于人们对乙肝知识缺乏了解。乙肝是血源性传播性疾病,不会通过呼吸道和消化道传染。取消入学、就业体检中的乙肝血清学检测项目(乙肝五项检测,俗称“两对半”)不会影响他人健康,也不会造成乙肝的传播。<br /><br /><b>　　可通过检测肝功能、乙肝表面抗体来替代</b><br /><br />　　罗洁同时说,身体没有临床症状,肝功能正常,不会因一般的生活接触、共同学习、<a href="http://health.people.com.cn/GB/14741/21489/index.html" target="_blank"><font color="#0000FF">工作</font></a>等对周围人群构成威胁。这样的话,可以建议入学、就业体检将肝功能检测来替代“乙肝两对半”检测。还有乙肝表面抗体,也是一个不错的替代检测项目。<br /><br />　　在此前的卫生部例行新闻发布会上,卫生部新闻办主任邓海华也表示,在入学、就业体检中保留丙氨酸氨基转移酶(ALT,简称转氨酶)检查项目以及评价肝脏功能,比检测乙肝五项对诊断乙肝更具有临床参考意义。<br /><br /><b>　　不同用人单位区别实施</b><br /><br />　　还有公司负责人建议,可以针对不同类型的单位,来实施“乙肝检测取消”。例如对于餐饮行业等服务业来说,最好还是保留乙肝检测,而对于电子类企业招聘员工不存在什么影响。具体实施应有所变通,否则不大现实。<br /><br />　　罗洁补充说,幼师、从事食品行业的工种,以及容易出现身体破损的工作,最好还是对乙肝检查方面有所注意。乙型肝炎病毒存在于乙肝病人的血液、汗液、唾液、月经、乳汁及泪液等分泌物中。与乙肝急性期和慢性肝炎急性发作期时病人的上述体液及分泌物接触后,乙型肝炎病毒进入血液中即可传染上乙型肝炎。</span>', 'gwm', 0, 6),
(169, '年关焦虑绑住你了吗', '', '', '', '2009-12-24 11:14:43', '116.228.141.77', '<table width="99%" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td align="center"><img src="http://xmwb.news365.com.cn/kjy/200912/W020091223510587180781.JPG" width="165" /><br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</td></tr><tr><td height="19" valign="middle"><p>　<br />　<span style="font-size:12px;text-decoration:none;"><font size="2">&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;◎采访：朱砂<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;◎专家支持：连淑芳&nbsp;&nbsp;上海政法学院心理学教授&nbsp;&nbsp;孙嘉仪&nbsp;&nbsp;知音心理咨询中心&nbsp;&nbsp;咨询师<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;岁末将至，商场门口搭起了人工景观，街道两旁的行道树上挂起了彩灯。节日气氛渐渐浓郁的日子里，有人却因为来自各方面的压力陷入焦虑中。假如你发觉最近自己常常失眠、情绪低落沮丧，一点小事也可能让你发脾气，那可要当心了，也许你已经被年关焦虑缠上了。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />【事件回放一】<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;500强企业做销售的Tony最近有点烦，为了在年终前“闯关”，如果完不成工作量，就意味着年终奖可能泡汤。“每周的例会，老板会挨个质问为何没完成工作量。年底又到了员工考核阶段，如果业绩不好，最惨的结果就是被解除劳动合同。”<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />【事件回放二】<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;为了赶在春节前将外地的客户跑完，Jack告诉记者，他一周有4天都在出差。对此妻子很不满，常向他抱怨。每次老婆一开始嘀咕，Jack立刻就不耐烦，常常会爆发争吵。吵完了又后悔。Jack称，可能是近期压力太大了，自己最近总是莫名其妙地向家人发脾气。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />A职场压力&nbsp;&nbsp;从业绩冲刺到续签合同如同过关<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;连淑芳教授指出，岁末时节是各种事务纠缠的时间节点，也是很多人心情纠结的关口。人们总在这时总结过去展望将来，在年度的工作总结中梳理这一年的工作业绩，让不少职场人陷入深深的失落和沮丧——时间过得那么快，可是自己似乎并没有多少成就；展望将来，心中亦有几许不安全感。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;年底也是工作压力最大的时刻，业务员进行最后的业绩冲刺，这些业绩也许决定着自己的年终奖金和来年的职位，做得好也许可以得到升迁，完不成任务，也许续签合同的名单里就没有了自己的名字。而不那么景气的大环境也让很多人对于未来充满焦虑。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;不少人在为自己能不能保住职位焦虑的同时，另有一部分人则会在年底为是否跳槽而烦恼。没有发展空间，人际关系复杂，年底考评感到遭遇不公待遇……也许换个工作未必就没有这些问题，但年关将近，种种的负面情绪大爆发，让人觉得不换个环境，简直不知道该怎么继续把日子过下去了。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />B生活压力&nbsp;&nbsp;和最亲爱的人一不小心就吵架<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;翻翻日历，岁末总有很多喜气洋洋的节日。与此同时“红色罚单”也来得格外频繁。很多白领刚领了工资，几个红包一送，工资就所剩无几。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;岁末了，回家过年也是件让很多离家在外的游子们焦虑的大事。为了回家的车票，很多人挖空心思找门路托关系。还有些单身族，过年回家最怕的就是长辈催婚，花钱雇人假扮情侣，算是这类焦虑的典型表现。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;在咨询工作中，孙嘉仪咨询师还发现，有些年轻人组成的小家庭，为了岁末过节回哪个家，会发生矛盾争执。“在我接到的咨询案例中还遇到过婆婆来过年而导致家庭纷争的。所以，中国人说年关，的确很有道理。这是一年中人际关系大碰撞的时间，由此引发的焦虑绝非无病呻吟。”<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />C原因解读&nbsp;&nbsp;年关是个特殊的矛盾引爆点<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;“其实很多压力平时都存在，只是岁末是个比较特殊的时间点，很多问题集中爆发出来了。”连淑芳教授提醒说，有些心理问题会引发躯体症状，如心跳加速、血压升高、容易疲劳、难以入睡等。去医院检查可能查不出器质性病变，但症状却依然存在。同时，也有诸如内分泌失调等生理疾病可能引发心理问题。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;此外，连淑芳教授表示，并不是人人都会在岁末焦虑。个性自卑、敏感、内向、情绪不稳定、不善于沟通的人，更容易遭遇年关焦虑的困扰。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;孙嘉仪咨询师则从另一个角度解读了年关焦虑。“人类有多种多样的需要，较低层次的需要获得满足以后，自然会有较高层次的需要有待满足。欲望是很容易升级和膨胀的，而现实生活中我们的愿望通常是实现的少，受挫的多。”通常，人们都会习惯性地放大不良情绪，在年关到来之际，有很多人会因一个小挫折而否定掉自己一年来很多其他的成就，陷入焦虑中。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />专家支招&nbsp;&nbsp;认知角度&nbsp;&nbsp;试着换个角度看问题<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;首先要明白，适度的紧张和压力能够起到保持生命活动积极活跃的作用。生活如果持续松弛懈怠，也会削弱人体抗病能力和适应环境的能力，促使机体衰老。面对岁末的压力，与其抱怨回避，不如鼓励自己积极应对。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;其次就是我们的评价系统，我们应该对应激事件作出恰当的评价。相关的研究显示，应激的产生及其强度与外部事件往往没有直接关系，而主要取决于人们对应激事件如何感知、评价以及采取什么样的应对方式。所谓恰当评价就是对应激源的意义及其可能存在的威胁性作出客观全面的评价，避免从主观上过分夸大，以至于造成过分的焦虑、恐惧等情绪反应。年底虽然是个比较敏感的时期，可是也不必对自己遇到的不顺、挫折看得过分严重。有时候，把情况预先想得过分复杂和困难，会导致丧失正确的判断和决策能力。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />行为策略&nbsp;&nbsp;问问自己到底在担心什么？<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■可以列一张清单，把必须要处理的事情做个排序，分成三类，一类是需要“立即行动”的；第二类是“等待时机将来行动”的；第三类是“可以忽略和适应”的。处理时的轻重缓急一目了然。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■做必要的身体检查，确定没有器质性病变。然后问问自己，到底是什么事情让我陷入焦虑？弄清楚原因的过程也许你就会发现自己不像先前那么焦虑了。而是把注意力更多集中到解决具体问题上。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■说出或者写出自己的担忧。可以找自己信任的好友或心理咨询师倾诉自己的心情，这可以让你感觉不那么孤单无助。不喜欢跟别人说的，不妨把心情写下来，就像写日记那样。这是一个自我对话的过程，可以帮助你梳理和分析自己遇到的问题。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■寻找适合自己的放松方式。不要把每天的工作排得太满，身体的疲劳会导致不良的情绪体验。至于选择什么方法，根据自己的喜好就行。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■受挫情绪比较强烈的时候，不妨多多回顾一年来自己取得的成就。人们常常会因一个挫折就否定自己所有的努力。提醒自己，这一年虽然有不顺利的，但也有不少收获呢。<br />&nbsp;&nbsp;&nbsp;&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;■试着每天记住至少一件令自己愉快的事情，并把它拿来和周围人分享。</font></span></p></td></tr></tbody></table>', 'gwm', 0, 5),
(170, '接种怕影响胎儿 甲流疫苗接种孕妇陷入两难', '', '', '', '2009-12-24 14:09:24', '116.228.141.77', '<span style="font-family:宋体, arial, helvetica, sans-serif;font-size:14px;"><table class=" FCK__ShowTableBorders" cellspacing="5" cellpadding="0" width="100%" border="0" style="font-size:14px;"><tbody><tr><td align="middle" style="font-size:14px;"><img src="http://dzauto.dzwww.com/shandong/shandonggedi/qingdao/200912/W020091224334380787504.jpg" border="0" /></td></tr><tr><td align="middle" height="5" style="font-size:14px;"><div align="center" style="font-size:14px;">?医务人员准备为市民注射甲流疫苗。 本报记者盛文静 摄</div></td></tr></tbody></table><div style="font-size:14px;">&nbsp;&nbsp;&nbsp;&nbsp;日前，卫生部将孕妇纳入到甲流疫苗的重点接种人群。而在即将运抵青岛的第二批甲流疫苗中，也为岛城的孕妇预留了部分疫苗。但是22日记者采访了解到，对于接种甲流疫苗，多数孕妇犹豫不决——<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;本报记者&nbsp;&nbsp;崇真<br /><br />种还是不种？<br /><br />胎儿为重<br /><br />&nbsp;&nbsp; 22日上午记者走访了几家医院，在青岛市妇幼保健院产科门诊走廊上的长椅上，坐满了前来排队做孕期检查的“准妈妈”。记者随机采访了十几人，她们大都表示目前没有接种疫苗的计划，最终决定是不是接种，要看对胎儿有没有影响。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;“前段时间报纸和网络上还说孕妇不能接种甲流疫苗，现在又说可以接种了，真不知道听哪种意见好。”怀孕6个多月的郭女士感到很矛盾，她说，现在看来，甲流疫苗刚研制出来没多久，还是个新生事物，不知道是不是稳定，怕接种了对胎儿不好，毕竟现在一家只有一个孩子。在一家事业单位工作的赵女士怀孕快3个月了，她说怀孕时正赶上甲流，所以一直很关注关于甲流疫情、甲流疫苗的报道。“到现在也没有孕妇接种疫苗后平安生下孩子的例子，而且即使平安生下来了也不知道对孩子有没有后期影响，所以我现在不打算接种甲流疫苗。”<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;前来做四维彩超的市民马女士告诉记者，自从怀孕后，怕感染上甲流，她上下班一直都打车，和以前坐公交车相比，每天要多花三四十块钱。“听说孕妇可以接种甲流疫苗后我考虑了很久，但是想到即使接种了甲流疫苗也不一定就百分之百能预防甲流，最重要的是我很担心对孩子有影响，因为现在我毕竟不是一个人，如果孩子万一有什么事，后悔都来不及。”<br /><br />种还是不种？<br /><br />是个问题<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;虽然担心对胎儿不利而不愿意接种疫苗，但这些“准妈妈”同时也非常担心被感染患上甲流。“甲流传染性这么强，如果不接种甲流疫苗，万一被传染了怎么办？”即担心接种疫苗会影响胎儿的发育，又担心自己感染甲流不仅保不住胎儿，还会影响自己的生命，种还是不种，成了搁在“准妈妈”们面前的一道难题。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;青岛市甲流指挥部有关专家说，孕妇在妊娠期间，身体免疫水平会出现很大改变，代谢负担也随之加重。孕妇因怀着胎儿，心肺负荷较大，随着胎儿的发育，其心肺功能的负担日益增加，孕产妇本身机体免疫力下降，容易感染甲流，而且一旦感染甲硫，发病速度要比普通人快，发病后的死亡率也比普通人群高。因此，早期发现和早期治疗很重要，预防也很关键。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;记者在几家医院采访时注意到，进来检查的孕妇大多都戴着口罩，有的进门后就摘下来，有的则一直戴着。孕妇于女士说：“戴着口罩觉得憋得慌，还不知道有没有用，但是不管怎么样，至少是个心理安慰吧。”潘女士告诉记者，她现在上下班都打车，尽量不到公共场所，早睡早起，勤洗手，家里办公室都勤通风，通过保持良好的生活习惯来提高自免疫力，对抗甲流。“除了好的生活习惯，还要保持好心情。”市民马女士补充说。<br /><br />种还是不种？<br /><br />因人而定<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;带着准妈妈们的疑问，记者采访了青岛市疾控中心专家以及妇产科专家，专家表示，按照国家的规定，甲流疫苗接种要遵循“知情、自愿、免费”原则，要不要接种最终得看孕妇自己的选择。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;专家说，根据目前世界卫生组织和其他国家的经验来看，接种甲流疫苗对孕妇和胎儿都不会产生不良影响。国家卫生部已经于12月11日发出通知，把孕产妇纳入到甲流重点接种人群，而且妊娠各期均可进行接种。记者了解到，卫生部的专家此前也表示，在防控甲流这种疾病的时候，原则是“两害相权取其轻”，孕妇被感染以后出现重症的概率大，这个“害”要远远大于疫苗接种以后会出现一些一般的不良反应。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;“甲流疫苗是灭活疫苗，其中的病毒已经被杀死，根据国内外专家的说法，不会对胎儿造成不良影响。”青岛市妇幼保健院院长张占红说，但是，并不是所有孕妇都能接种甲流疫苗。患有妊娠并发症及习惯性流产的孕妇，接种前应该咨询妇产科医生。此外，患有妊娠噶血压、糖尿病等疾病或者慢性疾病急性发作的孕妇也是要在咨询医生后，才可接种。<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;此外，记者从青岛市疾控中心获悉，孕妇何时接种疫苗还没有具体的时间表，疾控中心传染病防治科主任姜法春告诉记者，目前他们正在制订计划，一旦确定何时接种、如何接种，将及时告知孕妇。</div></span>', 'gwm', 0, 5);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(171, '美国总统经济顾问：中国人需要“健康产业”', '', '', '', '2009-12-24 14:30:51', '116.228.141.77', '<div>“在美国，治疗病人所花的费用，几乎相当于中国GDP的一半，公众医疗体系的改革已成为美国一个非常重要的议题。”在冷风瑟瑟的北京，美国两任总统的经济顾问、著名经济学家保罗·皮尔泽首次来到了中国。不过，他并不是来传教美国在公众医疗发面的成就，相反，他是来“取经”的，“研究一下中国正在蓬勃发展的健康产业。”</div><div>　　在保罗看来，美国巨额的医疗费用，是此前没有很好关注公众营养的“恶果”，但几个世纪以来，中医药理念根深蒂固。随着东方医学风靡全球，中国，或许将成为世界健康产业经济下一波的主角。</div><div>　　事实上，对中国经济部门来说，保罗的这番理论算得上“正中下怀”。</div><div>　　从健康产业到“质量经济”</div><div>　　2004年，保罗·皮尔泽出版了一本书《The wellness revolution》（《健康革命》 ），在中国翻译成《财富第五波》。这本关乎世界产业经济走向预测的作品，被当作致富畅销书，再版四次。</div><div>　　当年保罗认为，继个人计算机和网络产业之后，随着生物和细胞生化科技的突破，引发全球财富第五波的将是健康产业。</div><div>　　这样的预测不仅建立于现代人对健康的需求，更是国家经济的需要。</div><div>　　“在中国城市人口中，大概有15%属于超重，7%临床认为达到肥胖症的指标，加之中国人口基数较大，整体数字已超过了美国。而这将可能给中国政府带来极大的医疗保障负担。”在与中国多方的交流中，保罗表达了这样的观点。</div><div>　　事实上，中国早已意识到了这点。2001年，发改委成立了“公众营养与发展中心”，这个看似本应归属于卫生部门的机构，专门从事营养经济学及相关宏观政策研究。据介绍，中国每年因营养素摄取不足和结构失衡造成的损失高达2460亿-4100亿元。</div><div>　　“不仅如此，在刚刚结束的中国经济会议上，中央国务院都在考虑，正处在关键节点上的中国经济该怎么办。”公众营养与发展中心主任于小冬说，投资和出口方面招数已尽，消费刺激的拉动实际上也是回天乏术，于是，此次中央经济工作会上提出一些“小的方法”—做产业。</div><div>　　“在中国提出推动健康经济产业，实际上关系到中国经济今后怎么走的大方向。”于小冬如是说。</div><div>　　在于小冬看来，保罗的这次来华正当其时：“他提出来的健康产业发展，涉及到国民经济的各个部门，意味着中国要发展‘质量经济’。”</div><div>　　所谓“质量经济”，于小冬将其归总为三个层面。首先提高个体的健康质量；其次将原来的食品工业、农业全面的升级，提高产业的质量；最终提高整个国家经济的质量。</div><div>　　保罗也给中国算了一笔账：“如果中国出口一个iPhone手机，可能这个手机价钱是150美元，而其中很多零件都是来自于别的国家，真正中国得到的钱只有20美元。如果中国出口一个中医药产品，我们可以确定里面的成分，100%来源于中国，是中国制造的。”他说，要是能把中医药产品向世界很好地推广，将会对中国经济带来非常深远的影响。</div><div>　　不过，于小冬心目中，中国能从健康产业中获得的好处不仅如此：“计算机技术和网络，核心技术不在我们手里，但因为掌握中医药，我们可以卖整个营养产业。”</div><div>　　中医药理广受欢迎</div><div>　　保罗·皮尔泽坦率地说，自己对中国经济还不算熟悉，但是他却看好健康产业在中国的发展。其中一个依据，是中国人已经“进口”了西方不健康的生活方式。</div><div>　　据于小冬介绍，2002年，我国第五次全国营养与健康调查的结果显示，全国城乡人口能量日摄入量已从20年前的2491.3千卡，下滑到当年的2253.5千卡；蛋白质日摄入量没有增加；脂肪日摄入量与10年前相比平均提高了30.7%；微量营养素Va、B1、B2的日摄入量覆盖面和缺乏程度相当严重；常量元素钙和磷的日摄入量也与需求相差悬殊。</div><div>　　“这是一种‘隐性饥饿’，从而导致慢性疾病的高发。”于小冬如是说。</div><div>　　在保罗看来，现在的中国人也需要“健康产业”。不过，保罗强调，对于中国而言，健康产业并不是从外国引进的。中医药的积淀和发展，是让保罗看好中国健康产业更为重要的原因。</div><div>　　“在世界各地，中国传统中医药理论已得到越来越多的欢迎。”虽然并非生物专家也不是商人，但短暂的中国之行，保罗专门找到中医药专家进行探讨。让他感兴趣的是，在西医理论中，只有生病才会找医生，完全不存在中医中要求治病与防病相结合的理念。这种区别进一步印证了他五年前的那本著作：“防病”对于美国人，意味着一场认知上的“革命”。</div><div>　　“美国人需要中医，而中国也需要把中医推广到世界。”保罗说。</div><div>　　不过，准确地看，保罗口中美国人所需要的“中医”，是一种理念，比如 “治未病”和 “药食同源”。他分析，在美国，因为吃得不健康，65%的人口已经超重，而医疗费用方面，95%是可以通过“预防”节省出来的。</div><div>　　保罗坦承，他希望进入美国的中医不仅是理念，最好包括产品。但是，通过与中医专家的座谈，他也发现，目前中医药产品进入美国最大的障碍在法律方面，而美国各个州的法律不同，产品进入美国市场，必须和50个州的法律打交道，这将是一个非常困难的过程。</div><div>　　事实上，另一种解决方案已经显现。当世界维生素业诞生的那一刻，中医理念早已为西方健康产业作出了贡献，世界上第一粒维生素补充剂、当今安利旗下的纽崔莱，灵感就来源于中医。</div><div>　　75年前，这种药片的发明者在上海对中医产生了迷恋，发现中药的来源都是自然界中的植物、动物和矿物，他所发明的第一款维生素竟然提炼于“草头”，一种江浙紫花苜蓿嫩芽，农民们把它揉入米粉中，做成煎饼，预防疾病。</div><div>　　“中医通过号脉进行健康判断，‘脾虚’或是‘肝旺’，西方人没办法理解和接受。”安利中国技术总监许洪民说，能够将中医药发展的方法，就是利用中医理论和西方技术相结合，形成产业化。</div><div>　　被妖魔化的保健品业</div><div>　　在安利中国技术总监许洪民看来，中国健康产业的发展还需要政策法规的建立和企业标准的提高：“在人们概念中，保健食品几乎和假冒伪劣、夸大宣传等同，实际上对健康产业的发展非常不利。”</div><div>　　事实上，类似的情况在美国也有发生，以至于该国每年700亿美元的膳食补给品产业的声誉，被蒙上一层阴影。</div><div>　　保罗·皮尔泽认为，消费者的指控并非“无的放矢”，只不过罪魁祸首并非补给品本身。他说，美国销售的膳食补给品（维生素、矿物质和草药）有四分之一到三分之一含有以下问题：产品成分标志不实；并未警告所含的危险物质。所以，三分之一使用过膳食补给品的人会认为无效或者危险。</div><div>　　在中国，狭义健康产业中的保健品依然处于法律的真空地带。2008年7月，保健食品的卫生监督管理职责由卫生部划入药监局。今年5月底，由药监局起草的《保健食品监督管理条例》公开征求意见。但是这项原本预定六月前出台的条例，至今未见眉目。</div><div>　　“政府部门明确意识到保健品行业需要管理，但是如何地管理，如何保证审批、实验，还是较难解决。” 许洪民说，如果法律监管和行业标准顺利完成，中国健康产业的发展会比保罗预测的还要快。</div><div>　　为此犯愁的，不是许洪民一个人。公众营养与发展中心主任于小冬现在的工作，一边是推动产业发展，另一边就是“宣传教育、法律法规”。</div><div>　　“现实中，中国的保健品生产销售涉及多个部门，药监、工商、质监等等，对于某类产品发展可能采取不同的态度，一个堵一个放，做健康产业的人个个感到困难。”由此，时不时地，于小冬还要在高层中讲讲健康经济和营养理念。</div><div>　　评判中国健康产业的现状和未来，于小冬说，目前产业的发展还是很快，只是产业基数太低。“中国人营养消费仅为美国的1/108。下一个五年规划，至少要使30%的人接受健康营养产业的观念，并且形成习惯。”而许洪民相信，中国经济的发展也将成为促进健康产业的动力。</div>', 'gwm', 0, 5),
(172, '专家详解转基因水稻玉米安全性及应用前景', '', '', '', '2009-12-25 09:55:50', '116.228.141.77', '<span style="font-size:14px;"><p>就转基因抗虫水稻及转植酸酶基因玉米的安全性及应用前景等问题，农业转基因生物安全委员会部分委员、专家及农业部转基因生物安全管理办公室负责人进行了详细解答。</p><p><br />　<strong>　转基因技术能改善农业生态环境，增加农民收入</strong></p><p><br />　　中国科学院遗传与发育生物学研究所研究员朱祯：转基因技术与传统育种技术有两点不同：第一，传统技术一般只能在生物种内个体上实现基因转移，而转基因技术所转移的基因则不受生物体间亲缘关系的限制；第二，传统的杂交和选择技术一般是在生物个体水平上进行，操作对象是整个基因组，所转移的大量基因，不可能准确地对某个基因进行操作和选择，对后代的表现预见性较差。而转基因技术所操作和转移的一般是经过明确定义的基因，功能清楚，后代表现可准确预期。因此，将转基因技术与常规育种技术紧密结合，可相得益彰，大大提高品种改良效率。<br />　　转基因技术被称为“人类历史上应用最为迅速的重大技术之一”，已成为世界各国增强农业核心竞争力的焦点。转基因技术作为现代农业生物技术的核心，在缓解资源约束、保障食物安全、保护生态环境、拓展农业功能等方面已显现出巨大潜力。一是减轻病虫害危害，改善农业生态环境。全球转基因技术的研发与应用表明，抗虫和抗除草剂等转基因作物的种植不仅在提高农作物产量方面成效显著，而且在改善农业生态环境方面也显示出巨大的优势。1996～2006年，转基因作物的应用累计减少农药使用量（有效成分）28.9万吨，相当于将农药对作物与环境的影响降低了15.5%。培育抗病虫、抗除草剂、抗旱、耐盐碱、养分高效利用等的转基因新品种，将显著减少农药、化肥和水的使用，缓解养殖污染，改善生态环境。二是降低生产成本，增加农民收入。由于转基因新品种在增产、优质优价、低耗等方面的优势，已使全球转基因作物种植农户累计获得纯经济效益340亿美元，农民增收25%左右。抗除草剂转基因大豆的应用，实现了密植和免耕，有利于水土保持。我国棉农也因种植转基因棉花，每亩减支增收130元，累计实现农民增收200多亿元。三是拓展产业形态，提高产品附加值。目前，功能性和治疗性转基因食品、转基因生物能源和环保产品相继研制成功，部分转基因药物上市销售，使转基因品种正在由简单性状改良向复杂性状改良、由农业领域向医药、加工、能源、环保领域拓展等方向发展。</p><p><br />　　<strong>我国农业转基因生物安全管理科学规范</strong></p><p><br />　　农业转基因生物安全委员会主任委员、中国农业科学院植保所所长吴孔明：为了加强农业转基因生物安全管理，保障人体健康和动植物、微生物安全，保护生态环境，2001年国务院颁布了《农业转基因生物安全管理条例》（以下简称《条例》），农业部和国家质检总局相继发布了有关配套规章，管理范围涵盖了转基因动物、植物、微生物及其产品的研究、试验、生产、加工、经营和进出口各个环节。<br />　　根据《条例》及配套规章规定，国家建立农业转基因生物安全评价制度，对农业转基因生物实行分级、分阶段安全评价和管理。国家设立农业转基因生物安全委员会，按照《条例》、配套规章、评价指南的要求，遵循科学、个案、熟悉、逐步的原则，参考国际食品法典委员会、联合国粮农组织、世界卫生组织、经济合作组织等制定的转基因生物安全评价指南，开展农业转基因生物安全评价工作。<br />　　根据《条例》规定，安全评价分为实验研究、中间试验、环境释放、生产性试验和申请领取安全证书五个阶段。经安委会安全评价和农业部批准，申请单位就转基因水稻分别于1999～2000年开展了中间试验、2001～2002年开展了环境释放，2003～2004年开展了生产性试验。2004年申请转基因水稻生产应用安全证书。除申请单位提供的技术资料外，根据安委会的评价意见，2004～2008年，农业部转基因生物安全检测机构对转基因水稻的分子特征、环境安全和食用安全的部分指标进行了复核检测。经安委会综合评价，并履行完所有相关法律规定程序后，农业部于2009年8月发放了“华恢1号”和“Bt汕优63”在湖北省的生产应用安全证书。<br />　　据农业部转基因生物安全管理办公室负责人介绍，根据《农业转基因生物安全管理条例》、《中华人民共和国种子法》及《主要农作物品种审定办法》等法律法规的规定，该转基因抗虫水稻和转植酸酶基因玉米获得安全证书后，还要通过品种审定，获得种子生产许可证和种子经营许可证后，方可进入商业化生产。<br />　　我国对转基因生物安全管理包括研究、试验、生产、加工、经营和进出口等各个环节，实行全程管理。农业部一向高度重视农业转基因生物安全管理工作，将其与转基因生物技术研究同等重视、同步发展，本着“加快研究、推进应用、规范管理、科学发展”的指导方针，严之又严、慎之又慎地全面加强这项工作，确保安全监管法制化，产品生产可控制，市场产品有标识，产业应用能溯源，切实保障广大人民群众的知情权和选择权。下一步，我们将进一步完善农业转基因生物安全法规规章，加强监管能力建设，加大执法监管力度，加强对品种审定、生产、加工、经营等环节的监管，以及转基因作物商业化应用后生态环境监测，保障转基因生物产业健康可持续发展。</p><p><br />　　<strong>转基因抗虫水稻可有效防治水稻鳞翅目虫害</strong></p><p><br />　　吴孔明：目前，螟虫和稻纵卷叶螟等鳞翅目害虫是水稻生产上的主要害虫，是导致水稻减产的主要原因之一。大量使用化学杀虫剂，严重影响生态环境和生物多样性，增加了生产成本和劳动强度，加大人体中毒几率。大规模的水稻种质资源筛选尚未发现有效的抗水稻鳞翅目害虫的基因资源。转基因抗虫水稻可高效专一控制水稻鳞翅目害虫，是防治水稻鳞翅目虫害的新途径。<br />　　转基因抗虫水稻“华恢1号”和“Bt汕优63”是由华中农业大学培育的高抗鳞翅目害虫转基因水稻品系。“华恢1号”的受体品种是水稻三系恢复系“明恢63”，外源基因是由我国科学家人工改造合成的苏云金芽胞杆菌（简称Bt）杀虫蛋白融合基因，其表达产物可以专一、高效地控制水稻二化螟、三化螟和稻纵卷叶螟等水稻鳞翅目害虫。通过基因枪介导共转化法导入外源抗虫基因，经多代选择获得抗虫基因可以稳定遗传表达的“华恢1号”。“华恢1号”与“珍汕97A”所配制的杂交水稻组合被命名为“Bt汕优63”。</p><p><br />　　<strong>消费者可放心食用转基因水稻</strong></p><p><br />　　农业转基因生物安全委员会副主任委员、中国疾病预防控制中心研究员杨晓光：食用安全性分析表明，转基因水稻与非转基因对照水稻同样安全，消费者可放心食用。<br />　　在营养学评价方面，转基因水稻与非转基因对照水稻在主要成分、微量营养成分以及抗营养因子等方面，没有生物学意义上的差异。<br />　　在毒理学评价方面，转基因水稻的大鼠90天喂养试验、短期喂养试验、遗传毒性试验、三代繁殖试验、慢性毒性试验以及Bt蛋白的急性毒性试验结果表明，对试验动物未见不良影响。<br />　　在致敏性评价方面，Bt蛋白与已知致敏原蛋白的氨基酸序列同源性比较结果显示，Bt蛋白与已知致敏原蛋白无序列相似性。cry1Ab/cry1Ac蛋白体外模拟胃肠道消化试验结果表明，该蛋白易被分解，不具消化稳定性。人类发现Bt蛋白的来源生物苏云金芽胞杆菌已有百年，Bt制剂作为生物杀虫剂的安全使用记录已有70多年，大规模种植和应用Bt玉米、棉花等转基因作物已超过10年。其间没有苏云金芽胞杆菌及其蛋白引起过敏反应的报告，也没有与生产含有苏云金芽胞杆菌的产品有关的职业性过敏反应的记录。<br />　　转基因水稻中的Bt蛋白是一种高度专一的杀虫蛋白，可与鳞翅目害虫肠道上皮细胞的特异性受体结合，引起害虫肠麻痹，造成害虫死亡。只有鳞翅目害虫的肠道上含有这种蛋白的结合位点，而人类肠道上皮细胞没有该蛋白的结合位点，因此不会对人体造成伤害。</p><p><br />　　<strong>转基因水稻在国内生产种植对生态环境是安全的</strong></p><p><br />　　农业转基因生物安全委员会委员、中国农业科学院植保所研究员彭于发：试验分析表明，转基因水稻在国内生产种植对生态环境是安全的。<br />　　室内外多点、多代遗传分析结果显示，转基因水稻植株中的Bt蛋白基因可以稳定遗传和表达，对稻纵卷叶螟、二化螟、三化螟和大螟等鳞翅目主要害虫的抗虫效果稳定在80%以上，对稻苞虫等鳞翅目次要害虫也有明显的抗虫效果。<br />　　在生存竞争能力方面，转基因水稻与非转基因对照水稻相比，在有性生殖特性和生殖率、花粉传播方式和传播能力、有性可交配种类和异交结实率、花粉离体生存与传播能力、落粒性和落粒率、休眠性和越冬能力、生态适应性和生物量等性状和评价指标上，均未发现明显的差异，在杂草性和入侵性方面也未发现变化。<br />　　在基因漂移对生态环境的影响方面，根据国内外文献和对转基因水稻的试验观察，转基因水稻基因漂移的可能性及其基本规律与非转基因水稻常规品种是一致的，没有发现Bt蛋白基因漂移对农田生态和自然环境安全有不良影响。<br />　　在对非靶标生物和生物多样性影响方面，根据室内和田间试验分析结果，没有发现转基因水稻对非靶标害虫、稻田天敌、益虫、经济昆虫有影响，也没有发现对主要昆虫种群结构和功能以及节肢动物的多样性产生不良影响。</p><p><br />　<strong>　转基因水稻对野生稻资源的影响与常规品种一致</strong></p><p><br />　　彭于发：我国是世界上公认的农作物八大起源中心之一，也是亚洲栽培稻起源地之一。野生稻属国家二级保护植物，蕴藏丰富的优异基因，是提高水稻生产能力的战略资源。<br />　　水稻属内种间以及种内亚种和品种间的基因漂流是自然界的一个普遍现象。基因漂流是当前野生稻资源保护的主要问题之一，但这种现象不单来自于转基因作物，普通栽培稻与野生稻具有较近的亲缘关系和较高的杂交亲合力，同样可能通过基因漂流影响野生稻资源。<br />　　根据国内外文献和对“华恢1号”转基因水稻的试验研究，该转基因水稻的基因漂移基本规律与非转基因对照“明恢63”等栽培稻常规品种一致，没有发现Bt蛋白基因漂移对农田生态和自然环境安全有不良影响。<br />　　此外，我国野生稻零星分布于广东、广西、海南、云南等南方数省。对野生资源的保护我国已于1996年发布实施了《野生植物保护条例》，建立了专门的保护体系，通过原生境保护和异地保护等方式对包括野生稻在内的野生资源进行保护。</p><p><br />　　<strong>转植酸酶基因玉米可提高饲料利用效率，减少动物粪便造成的环境污染</strong></p><p><br />　　吴孔明：外源基因表达产物植酸酶可以降解玉米、大豆等饲料加工原料中含有的植酸磷，提高饲料利用效率，减少饲料中磷酸氢钙的添加量，降低饲养成本。同时，可减少动物粪、尿中植酸磷的排泄，减轻环境污染，有利于环境保护。利用农业种植方式替代原有工业发酵生产方式生产植酸酶，可减少厂房、设备、能源消耗等投入，具有节能、环保、低成本的优势。<br />　　转植酸酶基因玉米自交系BVLA430101由中国农业科学院生物技术研究所培育。该玉米以“Hi-Ⅱ”玉米自交系为受体，通过基因枪共转化方法导入我国科学家自行克隆的植酸酶基因，并经多代筛选获得植酸酶基因可以稳定遗传表达的自交系。<br />　　经安委会安全评价和农业部批准，申请单位就转基因玉米分别于2004～2005年开展了中间试验，2006年开展了环境释放，2007～2008年开展了生产性试验。2008年11月申请转基因玉米生产应用的安全证书。经安委会综合评价，并履行完所有相关法律规定程序后，农业部于2009年8月发放了BVLA430101在山东省的生产应用安全证书。</p><p><br />　　<strong>转基因玉米主要用于动物饲料，但按照食用标准进行了安全评价</strong></p><p><br />　　杨晓光：植酸酶在玉米、小麦、水稻、大豆等许多植物中广泛存在，人类或动物有长期安全食用或饲用的历史。尽管转基因玉米主要用于动物饲料，但安委会按照食用标准进行了安全评价。食用安全性分析表明，转基因玉米与非转基因对照玉米同样安全。<br />　　在营养学评价方面，转基因玉米与非转基因对照玉米在主要成分、微量营养成分等方面，没有生物学意义上的差异。<br />　　在毒理学评价方面，转基因玉米的大鼠90天喂养试验以及植酸酶急性毒性试验、遗传毒性试验和慢性毒性试验结果表明，对试验动物未见不良影响。<br />　　在致敏性评价方面，植酸酶与已知致敏原蛋白的氨基酸序列同源性比较结果显示，植酸酶与已知致敏原蛋白无序列相似性。与过敏人群血清无交叉反应。植酸酶基因的来源黑曲霉是重要的发酵工业菌种，在食品工业中广泛应用。用微生物和转基因微生物发酵生产的植酸酶作为饲料添加剂也已有多年安全应用的记录。</p><p><br />　<strong>　转基因玉米在国内种植对生态环境无不良影响</strong></p><p><br />　　彭于发：试验分析表明，转基因玉米在国内种植对生态环境是安全的。<br />　　室内外多点、多代遗传分析结果显示，转基因玉米籽粒中植酸酶基因能够稳定遗传表达，根、茎、叶中检测不到植酸酶蛋白。<br />　　在生存竞争能力方面，该转基因玉米与非转基因对照玉米相比，在有性生殖特性和生殖率、花粉传播方式和传播能力、有性可交配种类和异交结实率、花粉离体生存与传播能力、落粒性和落粒率、休眠性和越冬能力、生态适应性和生物量等评价指标上，均未发现明显的差异，在杂草性和入侵性方面也未发现变化。<br />　　在基因漂移对生态环境的影响方面，根据国内外文献和对该转基因玉米的试验观察，转基因玉米能够向其他栽培玉米发生基因漂移，其基因漂移的可能性和基本规律与非转基因对照玉米是一致的，没有发现植酸酶基因漂移对农田生态和自然环境有不良影响。中国没有玉米野生近缘种，因此不存在转基因向野生种漂移的风险。<br />　　在对植物病虫害和生物多样性影响方面，根据室内和田间试验分析结果，没有发现该转基因玉米对玉米田害虫的生长发育以及玉米病害的发生有影响，也没有发现对玉米田天敌、益虫和节肢动物多样性有不良影响。</p><p><br />&nbsp;&nbsp; 【<strong>背景资料</strong>】</p><p><br />　<font face="楷体_GB2312">　转基因技术：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，从而引起生物体的性状的可遗传的修饰，这一技术称为转基因技术。利用转基因技术可实现跨物种间基因的定向改造和重组转移，对品种的抗病虫、抗逆、高产、优质等性状协调改良，培育新品种。<br />　　全球转基因玉米商业化应用情况：第一例转基因玉米于1996年商业化种植，截止到2008年，全球有17个国家（地区）种植转基因玉米，转基因玉米种植面积为3730万公顷，占全球转基因作物种植面积的30%。23个国家（地区）批准进口转基因玉米。已商业化应用的转基因玉米转化体有52个，涉及抗除草剂、抗虫性状、品质改良（增加赖氨酸含量）和用于生物燃料生产的转a-淀粉酶等性状。Bt基因：即编码δ－内毒素或杀虫晶体蛋白的基因。Bt基因普遍存在于Bt菌的质粒上。随着人们对Bt基因及其所产生的杀虫晶体蛋白研究的逐步深入，人们已从不同的Bt菌的亚种中分离出对不同昆虫（如鳞翅目、鞘翅目、双翅目等）和无脊椎动物（如寄生线虫、原生动物等）有特异毒杀作用的杀虫晶体蛋白的Bt基因。<br />　　植酸酶：植酸酶是一种磷酸酯酶，可以作用于植酸，将其分解为肌醇和可以被动物利用的磷，并且打破其对钙、铁、锌、镁或与氨基酸的束缚，转变为可被利用的状态。也就是说植酸酶可以减轻植酸的抗营养作用，从而提高动物对磷和钙、镁、锰、铁或与氨基酸等营养物质的利用效率，减少高磷粪便的排放，有利于环境保护。<br />　　这种特异性分解植酸的植酸酶，广泛存在于多种微生物和植物体内，如黑小麦、小麦、玉米、大麦、稻、菜豆、绿豆、豌豆、番茄、麸皮以及白芥菜、马铃薯、萝卜、莴苣、菠菜、百合花粉等。</font></p></span>', 'gwm', 0, 5),
(173, '专家详解转基因水稻玉米安全性及应用前景', '', '', '', '2009-12-25 10:20:32', '116.228.141.77', '<span style="font-size:14px;"><p>就转基因抗虫水稻及转植酸酶基因玉米的安全性及应用前景等问题，农业转基因生物安全委员会部分委员、专家及农业部转基因生物安全管理办公室负责人进行了详细解答。</p><p><br />　<strong>　转基因技术能改善农业生态环境，增加农民收入</strong></p><p><br />　　中国科学院遗传与发育生物学研究所研究员朱祯：转基因技术与传统育种技术有两点不同：第一，传统技术一般只能在生物种内个体上实现基因转移，而转基因技术所转移的基因则不受生物体间亲缘关系的限制；第二，传统的杂交和选择技术一般是在生物个体水平上进行，操作对象是整个基因组，所转移的大量基因，不可能准确地对某个基因进行操作和选择，对后代的表现预见性较差。而转基因技术所操作和转移的一般是经过明确定义的基因，功能清楚，后代表现可准确预期。因此，将转基因技术与常规育种技术紧密结合，可相得益彰，大大提高品种改良效率。<br />　　转基因技术被称为“人类历史上应用最为迅速的重大技术之一”，已成为世界各国增强农业核心竞争力的焦点。转基因技术作为现代农业生物技术的核心，在缓解资源约束、保障食物安全、保护生态环境、拓展农业功能等方面已显现出巨大潜力。一是减轻病虫害危害，改善农业生态环境。全球转基因技术的研发与应用表明，抗虫和抗除草剂等转基因作物的种植不仅在提高农作物产量方面成效显著，而且在改善农业生态环境方面也显示出巨大的优势。1996～2006年，转基因作物的应用累计减少农药使用量（有效成分）28.9万吨，相当于将农药对作物与环境的影响降低了15.5%。培育抗病虫、抗除草剂、抗旱、耐盐碱、养分高效利用等的转基因新品种，将显著减少农药、化肥和水的使用，缓解养殖污染，改善生态环境。二是降低生产成本，增加农民收入。由于转基因新品种在增产、优质优价、低耗等方面的优势，已使全球转基因作物种植农户累计获得纯经济效益340亿美元，农民增收25%左右。抗除草剂转基因大豆的应用，实现了密植和免耕，有利于水土保持。我国棉农也因种植转基因棉花，每亩减支增收130元，累计实现农民增收200多亿元。三是拓展产业形态，提高产品附加值。目前，功能性和治疗性转基因食品、转基因生物能源和环保产品相继研制成功，部分转基因药物上市销售，使转基因品种正在由简单性状改良向复杂性状改良、由农业领域向医药、加工、能源、环保领域拓展等方向发展。</p><p><br />　　<strong>我国农业转基因生物安全管理科学规范</strong></p><p><br />　　农业转基因生物安全委员会主任委员、中国农业科学院植保所所长吴孔明：为了加强农业转基因生物安全管理，保障人体健康和动植物、微生物安全，保护生态环境，2001年国务院颁布了《农业转基因生物安全管理条例》（以下简称《条例》），农业部和国家质检总局相继发布了有关配套规章，管理范围涵盖了转基因动物、植物、微生物及其产品的研究、试验、生产、加工、经营和进出口各个环节。<br />　　根据《条例》及配套规章规定，国家建立农业转基因生物安全评价制度，对农业转基因生物实行分级、分阶段安全评价和管理。国家设立农业转基因生物安全委员会，按照《条例》、配套规章、评价指南的要求，遵循科学、个案、熟悉、逐步的原则，参考国际食品法典委员会、联合国粮农组织、世界卫生组织、经济合作组织等制定的转基因生物安全评价指南，开展农业转基因生物安全评价工作。<br />　　根据《条例》规定，安全评价分为实验研究、中间试验、环境释放、生产性试验和申请领取安全证书五个阶段。经安委会安全评价和农业部批准，申请单位就转基因水稻分别于1999～2000年开展了中间试验、2001～2002年开展了环境释放，2003～2004年开展了生产性试验。2004年申请转基因水稻生产应用安全证书。除申请单位提供的技术资料外，根据安委会的评价意见，2004～2008年，农业部转基因生物安全检测机构对转基因水稻的分子特征、环境安全和食用安全的部分指标进行了复核检测。经安委会综合评价，并履行完所有相关法律规定程序后，农业部于2009年8月发放了“华恢1号”和“Bt汕优63”在湖北省的生产应用安全证书。<br />　　据农业部转基因生物安全管理办公室负责人介绍，根据《农业转基因生物安全管理条例》、《中华人民共和国种子法》及《主要农作物品种审定办法》等法律法规的规定，该转基因抗虫水稻和转植酸酶基因玉米获得安全证书后，还要通过品种审定，获得种子生产许可证和种子经营许可证后，方可进入商业化生产。<br />　　我国对转基因生物安全管理包括研究、试验、生产、加工、经营和进出口等各个环节，实行全程管理。农业部一向高度重视农业转基因生物安全管理工作，将其与转基因生物技术研究同等重视、同步发展，本着“加快研究、推进应用、规范管理、科学发展”的指导方针，严之又严、慎之又慎地全面加强这项工作，确保安全监管法制化，产品生产可控制，市场产品有标识，产业应用能溯源，切实保障广大人民群众的知情权和选择权。下一步，我们将进一步完善农业转基因生物安全法规规章，加强监管能力建设，加大执法监管力度，加强对品种审定、生产、加工、经营等环节的监管，以及转基因作物商业化应用后生态环境监测，保障转基因生物产业健康可持续发展。</p><p><br />　　<strong>转基因抗虫水稻可有效防治水稻鳞翅目虫害</strong></p><p><br />　　吴孔明：目前，螟虫和稻纵卷叶螟等鳞翅目害虫是水稻生产上的主要害虫，是导致水稻减产的主要原因之一。大量使用化学杀虫剂，严重影响生态环境和生物多样性，增加了生产成本和劳动强度，加大人体中毒几率。大规模的水稻种质资源筛选尚未发现有效的抗水稻鳞翅目害虫的基因资源。转基因抗虫水稻可高效专一控制水稻鳞翅目害虫，是防治水稻鳞翅目虫害的新途径。<br />　　转基因抗虫水稻“华恢1号”和“Bt汕优63”是由华中农业大学培育的高抗鳞翅目害虫转基因水稻品系。“华恢1号”的受体品种是水稻三系恢复系“明恢63”，外源基因是由我国科学家人工改造合成的苏云金芽胞杆菌（简称Bt）杀虫蛋白融合基因，其表达产物可以专一、高效地控制水稻二化螟、三化螟和稻纵卷叶螟等水稻鳞翅目害虫。通过基因枪介导共转化法导入外源抗虫基因，经多代选择获得抗虫基因可以稳定遗传表达的“华恢1号”。“华恢1号”与“珍汕97A”所配制的杂交水稻组合被命名为“Bt汕优63”。</p><p><br />　　<strong>消费者可放心食用转基因水稻</strong></p><p><br />　　农业转基因生物安全委员会副主任委员、中国疾病预防控制中心研究员杨晓光：食用安全性分析表明，转基因水稻与非转基因对照水稻同样安全，消费者可放心食用。<br />　　在营养学评价方面，转基因水稻与非转基因对照水稻在主要成分、微量营养成分以及抗营养因子等方面，没有生物学意义上的差异。<br />　　在毒理学评价方面，转基因水稻的大鼠90天喂养试验、短期喂养试验、遗传毒性试验、三代繁殖试验、慢性毒性试验以及Bt蛋白的急性毒性试验结果表明，对试验动物未见不良影响。<br />　　在致敏性评价方面，Bt蛋白与已知致敏原蛋白的氨基酸序列同源性比较结果显示，Bt蛋白与已知致敏原蛋白无序列相似性。cry1Ab/cry1Ac蛋白体外模拟胃肠道消化试验结果表明，该蛋白易被分解，不具消化稳定性。人类发现Bt蛋白的来源生物苏云金芽胞杆菌已有百年，Bt制剂作为生物杀虫剂的安全使用记录已有70多年，大规模种植和应用Bt玉米、棉花等转基因作物已超过10年。其间没有苏云金芽胞杆菌及其蛋白引起过敏反应的报告，也没有与生产含有苏云金芽胞杆菌的产品有关的职业性过敏反应的记录。<br />　　转基因水稻中的Bt蛋白是一种高度专一的杀虫蛋白，可与鳞翅目害虫肠道上皮细胞的特异性受体结合，引起害虫肠麻痹，造成害虫死亡。只有鳞翅目害虫的肠道上含有这种蛋白的结合位点，而人类肠道上皮细胞没有该蛋白的结合位点，因此不会对人体造成伤害。</p><p><br />　　<strong>转基因水稻在国内生产种植对生态环境是安全的</strong></p><p><br />　　农业转基因生物安全委员会委员、中国农业科学院植保所研究员彭于发：试验分析表明，转基因水稻在国内生产种植对生态环境是安全的。<br />　　室内外多点、多代遗传分析结果显示，转基因水稻植株中的Bt蛋白基因可以稳定遗传和表达，对稻纵卷叶螟、二化螟、三化螟和大螟等鳞翅目主要害虫的抗虫效果稳定在80%以上，对稻苞虫等鳞翅目次要害虫也有明显的抗虫效果。<br />　　在生存竞争能力方面，转基因水稻与非转基因对照水稻相比，在有性生殖特性和生殖率、花粉传播方式和传播能力、有性可交配种类和异交结实率、花粉离体生存与传播能力、落粒性和落粒率、休眠性和越冬能力、生态适应性和生物量等性状和评价指标上，均未发现明显的差异，在杂草性和入侵性方面也未发现变化。<br />　　在基因漂移对生态环境的影响方面，根据国内外文献和对转基因水稻的试验观察，转基因水稻基因漂移的可能性及其基本规律与非转基因水稻常规品种是一致的，没有发现Bt蛋白基因漂移对农田生态和自然环境安全有不良影响。<br />　　在对非靶标生物和生物多样性影响方面，根据室内和田间试验分析结果，没有发现转基因水稻对非靶标害虫、稻田天敌、益虫、经济昆虫有影响，也没有发现对主要昆虫种群结构和功能以及节肢动物的多样性产生不良影响。</p><p><br />　<strong>　转基因水稻对野生稻资源的影响与常规品种一致</strong></p><p><br />　　彭于发：我国是世界上公认的农作物八大起源中心之一，也是亚洲栽培稻起源地之一。野生稻属国家二级保护植物，蕴藏丰富的优异基因，是提高水稻生产能力的战略资源。<br />　　水稻属内种间以及种内亚种和品种间的基因漂流是自然界的一个普遍现象。基因漂流是当前野生稻资源保护的主要问题之一，但这种现象不单来自于转基因作物，普通栽培稻与野生稻具有较近的亲缘关系和较高的杂交亲合力，同样可能通过基因漂流影响野生稻资源。<br />　　根据国内外文献和对“华恢1号”转基因水稻的试验研究，该转基因水稻的基因漂移基本规律与非转基因对照“明恢63”等栽培稻常规品种一致，没有发现Bt蛋白基因漂移对农田生态和自然环境安全有不良影响。<br />　　此外，我国野生稻零星分布于广东、广西、海南、云南等南方数省。对野生资源的保护我国已于1996年发布实施了《野生植物保护条例》，建立了专门的保护体系，通过原生境保护和异地保护等方式对包括野生稻在内的野生资源进行保护。</p><p><br />　　<strong>转植酸酶基因玉米可提高饲料利用效率，减少动物粪便造成的环境污染</strong></p><p><br />　　吴孔明：外源基因表达产物植酸酶可以降解玉米、大豆等饲料加工原料中含有的植酸磷，提高饲料利用效率，减少饲料中磷酸氢钙的添加量，降低饲养成本。同时，可减少动物粪、尿中植酸磷的排泄，减轻环境污染，有利于环境保护。利用农业种植方式替代原有工业发酵生产方式生产植酸酶，可减少厂房、设备、能源消耗等投入，具有节能、环保、低成本的优势。<br />　　转植酸酶基因玉米自交系BVLA430101由中国农业科学院生物技术研究所培育。该玉米以“Hi-Ⅱ”玉米自交系为受体，通过基因枪共转化方法导入我国科学家自行克隆的植酸酶基因，并经多代筛选获得植酸酶基因可以稳定遗传表达的自交系。<br />　　经安委会安全评价和农业部批准，申请单位就转基因玉米分别于2004～2005年开展了中间试验，2006年开展了环境释放，2007～2008年开展了生产性试验。2008年11月申请转基因玉米生产应用的安全证书。经安委会综合评价，并履行完所有相关法律规定程序后，农业部于2009年8月发放了BVLA430101在山东省的生产应用安全证书。</p><p><br />　　<strong>转基因玉米主要用于动物饲料，但按照食用标准进行了安全评价</strong></p><p><br />　　杨晓光：植酸酶在玉米、小麦、水稻、大豆等许多植物中广泛存在，人类或动物有长期安全食用或饲用的历史。尽管转基因玉米主要用于动物饲料，但安委会按照食用标准进行了安全评价。食用安全性分析表明，转基因玉米与非转基因对照玉米同样安全。<br />　　在营养学评价方面，转基因玉米与非转基因对照玉米在主要成分、微量营养成分等方面，没有生物学意义上的差异。<br />　　在毒理学评价方面，转基因玉米的大鼠90天喂养试验以及植酸酶急性毒性试验、遗传毒性试验和慢性毒性试验结果表明，对试验动物未见不良影响。<br />　　在致敏性评价方面，植酸酶与已知致敏原蛋白的氨基酸序列同源性比较结果显示，植酸酶与已知致敏原蛋白无序列相似性。与过敏人群血清无交叉反应。植酸酶基因的来源黑曲霉是重要的发酵工业菌种，在食品工业中广泛应用。用微生物和转基因微生物发酵生产的植酸酶作为饲料添加剂也已有多年安全应用的记录。</p><p><br />　<strong>　转基因玉米在国内种植对生态环境无不良影响</strong></p><p><br />　　彭于发：试验分析表明，转基因玉米在国内种植对生态环境是安全的。<br />　　室内外多点、多代遗传分析结果显示，转基因玉米籽粒中植酸酶基因能够稳定遗传表达，根、茎、叶中检测不到植酸酶蛋白。<br />　　在生存竞争能力方面，该转基因玉米与非转基因对照玉米相比，在有性生殖特性和生殖率、花粉传播方式和传播能力、有性可交配种类和异交结实率、花粉离体生存与传播能力、落粒性和落粒率、休眠性和越冬能力、生态适应性和生物量等评价指标上，均未发现明显的差异，在杂草性和入侵性方面也未发现变化。<br />　　在基因漂移对生态环境的影响方面，根据国内外文献和对该转基因玉米的试验观察，转基因玉米能够向其他栽培玉米发生基因漂移，其基因漂移的可能性和基本规律与非转基因对照玉米是一致的，没有发现植酸酶基因漂移对农田生态和自然环境有不良影响。中国没有玉米野生近缘种，因此不存在转基因向野生种漂移的风险。<br />　　在对植物病虫害和生物多样性影响方面，根据室内和田间试验分析结果，没有发现该转基因玉米对玉米田害虫的生长发育以及玉米病害的发生有影响，也没有发现对玉米田天敌、益虫和节肢动物多样性有不良影响。</p><p><br />&nbsp;&nbsp; 【<strong>背景资料</strong>】</p><p><br />　<font face="楷体_GB2312">　转基因技术：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，从而引起生物体的性状的可遗传的修饰，这一技术称为转基因技术。利用转基因技术可实现跨物种间基因的定向改造和重组转移，对品种的抗病虫、抗逆、高产、优质等性状协调改良，培育新品种。<br />　　全球转基因玉米商业化应用情况：第一例转基因玉米于1996年商业化种植，截止到2008年，全球有17个国家（地区）种植转基因玉米，转基因玉米种植面积为3730万公顷，占全球转基因作物种植面积的30%。23个国家（地区）批准进口转基因玉米。已商业化应用的转基因玉米转化体有52个，涉及抗除草剂、抗虫性状、品质改良（增加赖氨酸含量）和用于生物燃料生产的转a-淀粉酶等性状。Bt基因：即编码δ－内毒素或杀虫晶体蛋白的基因。Bt基因普遍存在于Bt菌的质粒上。随着人们对Bt基因及其所产生的杀虫晶体蛋白研究的逐步深入，人们已从不同的Bt菌的亚种中分离出对不同昆虫（如鳞翅目、鞘翅目、双翅目等）和无脊椎动物（如寄生线虫、原生动物等）有特异毒杀作用的杀虫晶体蛋白的Bt基因。<br />　　植酸酶：植酸酶是一种磷酸酯酶，可以作用于植酸，将其分解为肌醇和可以被动物利用的磷，并且打破其对钙、铁、锌、镁或与氨基酸的束缚，转变为可被利用的状态。也就是说植酸酶可以减轻植酸的抗营养作用，从而提高动物对磷和钙、镁、锰、铁或与氨基酸等营养物质的利用效率，减少高磷粪便的排放，有利于环境保护。<br />　　这种特异性分解植酸的植酸酶，广泛存在于多种微生物和植物体内，如黑小麦、小麦、玉米、大麦、稻、菜豆、绿豆、豌豆、番茄、麸皮以及白芥菜、马铃薯、萝卜、莴苣、菠菜、百合花粉等。</font></p></span>', 'gwm', 0, 3);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(174, '肥胖不仅关乎美丽 更重要是已成为众多疾病的源头', '', '', '', '2009-12-25 10:31:14', '116.228.141.77', '<span style="font-family:瀹嬩綋;font-size:16px;">北京协和医院内分泌科金自孟教授介绍，体重指数（BMI，体重&nbsp;(公斤)&nbsp;/身高&nbsp;2&nbsp;(米2)）是国际上通用的判定肥胖的标准。中国人的正常体重应该在18.5—23.9之间，≧24为超重，≧28则为肥胖。“按此来计算，中国肥胖症患者已超过7000万，是全世界肥胖增长速度最快的国家。而北京等大城市则更是‘重灾区’。2005年流行病学调查表明，北京18岁以上成人的超重和肥胖率已高达49.6%，居全国首位。并且，这一状况还有日渐严重之势。”金自孟教授说。<br /><br />　　但很多国人意识不到上述问题，主要是很少看到外国人那种犹如“大山”般的体型。殊不知，由于人种的差别，东西方人肥胖的类型也不同，西方人属于整体肥胖，而中国人则是典型的“中心型肥胖”，即腰围过大。近年，腰围已经成为判定肥胖的另一个重要指标：<a href="http://health.people.com.cn/GB/14744/index.html" target="_blank"><font color="#0000FF">男性</font></a>腰围超过两尺六，<a href="http://health.people.com.cn/GB/119042/126654/index.html" target="_blank"><font color="#0000FF">女性</font></a>腰围超过两尺四，就等于肥胖。美国科学家研究认为：“中国人的腰围已比世界上任何地方的人增长都快”。<br /><br />　　腰围大，不单单是形象的问题，它反映出的是内脏脂肪超标，这才是伤害<a href="http://health.people.com.cn/GB/index.html" target="_blank"><font color="#0000FF">健康</font></a>的根源。目前研究表明，肥胖是多种疾病的“源头”，包括心脑血管病、呼吸功能障碍、<a href="http://health.people.com.cn/GB/119042/163585/index.html" target="_blank"><font color="#0000FF">胃</font></a>食管反流、<a href="http://health.people.com.cn/GB/119042/120597/index.html" target="_blank"><font color="#0000FF">糖尿病</font></a>、高血脂、脂肪肝、胆囊结石、<a href="http://health.people.com.cn/GB/26466/122279/138460/8483878.html" target="_blank"><font color="#0000FF">关节</font></a>炎、多囊卵巢综合征、癌症等。因此，“减腰围，增寿命”应该成为一句口号。<br /><br />　　想要远离肥胖，最简单的就是“少吃多动”。其次，可以选择药物<a href="http://health.people.com.cn/GB/14746/index.html" target="_blank"><font color="#0000FF">治疗</font></a>。“目前上市的<a href="http://health.people.com.cn/GB/40246/48920/index.html" target="_blank"><font color="#0000FF">减肥</font></a>药物只有两种，分别是抑制中枢食欲的西布曲明和促进脂肪排泄的奥利司他。”金自孟说。<br /><br />　　对于BMI超过37的病态肥胖者以及有多种合并症的患者，可以进行外科手术。北京协和医院外科于健春教授介绍，目前有一种微创手术，就是给胃系个能调节的带子，让大胃变小胃，以减少食量。当体重减到一定程度，患者养成良好的饮食习惯后，可以将这根带子取出，非常安全和方便。</span>', 'gwm', 0, 6),
(175, '是否健康你身上有十条蛛丝马迹', '', '', '', '2009-12-28 11:05:18', '116.228.141.77', '<span style="color:#333333;font-family:verdana, arial, 宋体, simsun;font-size:14px;">　■编辑说话<br /><br />　　你戴多大尺码的胸罩？你的嗅觉怎么样？大学时的牛仔裤现在还能穿吗？所有这些问题的答案以及其它怪异的身体线索可能是一个令人吃惊的预报器，预示着未来面临的潜在健康问题。你可以进行一次“快速自检”寻找这些线索，以了解未来的健康状况。<br /><br />　　在对人类生命健康的研究过程中，科学家发现了越来越多奇怪的身体特征和线索，它们可能就是阿尔茨海默氏病、糖尿病、癌症等疾病的早期征兆。现在，就请拿出一面镜子和一个卷尺，利用以下的10个DIY检测，预知未来的健康状况。与此同时，你也可以了解能够帮助改变自身命运的最理想策略。<br /><br />　　1.指长，食指与无名指的长短比关乎女性膝骨关节炎<br /><br />　　2008年进行的刊登在《关节炎与风湿病》杂志上的一项研究发现指出，食指比无名指短的女性患膝骨关节炎的几率可能是其他女性的两倍。研究人员表示，拥有这一主要在男性身上出现的特征女性趋向于分泌更少的雌激素，雌激素可能在骨关节炎形成中扮演角色。<br /><br />　　如何预防：强化膝盖周围的肌肉。坐下时，伸直腿并与地板平行，一共做10次，每次坚持5到10秒。<br /><br />　　2.身高，1.57米是可能影响人类寿命的一个参照<br /><br />　　根据《美国国家科学院院刊》刊登的一项研究发现，身高超过5英尺2英寸（约合1.57米）的女性可能缺少一个能够帮助她们活到100岁的基因突变。<br /><br />　　如何预防：养成加利福尼亚州第七日耶稣复临论者那样的生活习惯，他们是世界上百岁老人最为集中的人群之一。他们的生活习惯包括不吸烟、少喝酒以及少吃肉。<br /><br />　　3.腿长，短而粗的人要格外注意肝脏<br /><br />　　如果双腿短而粗，你可能需要更注意自己的肝脏。根据《流行病学与社区健康期刊》刊登的2008年进行的一项研究，研究人员发现腿长在20至29英寸（约合50至73厘米）之间的女性体内4种预示肝病的酶水平高于其他女性。研究人员表示，童年营养不良等因素不但会影响生长模式，同时也会影响肝脏的发育并且一直到进入成年期。<br /><br />　　如何预防：避免让你的肝脏遭到毒素侵害，这样才能让它更健康。使用有毒化学物质进行清理工作时，需要戴口罩和手套。限制饮酒，每天葡萄酒摄入量不超过5盎司（约合141克），啤酒摄入量不超过12盎司（约合340克）。<br /><br />　　4.嗅觉，功能受损的老人警惕帕金森症<br /><br />　　根据《神经学年鉴》刊登的2008年进行的一项研究，无法辨别香蕉、柠檬、桂皮或其它东西气味的老年人4年内患帕金森氏症的几率是其他老人的5倍。研究人员认为，大脑中负责嗅觉功能的区域可能是最先受到患帕金森氏症侵袭的目标之一。值得关注的是，嗅觉损伤在帕金森氏病确诊前2到7年就已出现。<br /><br />　　如何预防：服用鱼油补充剂。欧米伽-3脂肪酸能够提高大脑对帕金森氏症致病因素MPTP的抵抗力。MPTP是一种有毒化合物。<br /><br />　　5.臂长，较短的人可能预示晚年老年痴呆风险大<br /><br />　　你是否因为手臂不长很难接触到碗柜的顶部？根据《神经学》杂志刊登的2008年进行的一项研究，臂展最小的女性患阿尔茨海默氏病的几率是拥有更长臂女性的1.5倍。伸开手臂与地板平行，从左手指尖到右手指尖的长度就是臂展，不到60英寸（约合1.52米）被视为最短臂展人群。塔夫斯大学的研究人员表示，在重要发育期出现的营养不良以及其它亏损可能与臂长较小有关，较短的手臂可能预示着一个人在晚年时认知能力下降。<br /><br />　　如何预防：培养绘画或陶艺等需要灵活使用手臂的业余爱好。拉什大学医学中心阿尔茨海默氏病中心进行的一项为期5年的研究发现，花较少时间挑战大脑的成年人患阿尔茨海默氏病的风险是积极参加休闲活动的成年人的2.5倍。<br /><br />　　6.耳垂折痕，可能与即将遭遇心血管事件有关<br /><br />　　多项研究显示，一个或两个耳垂上出现线状皱纹可能预示着未来将遭遇“心血管事件”，例如心脏病发作、心脏搭桥手术或者心脏死亡。根据《美国医学杂志》刊登的一项研究，一个耳垂上出现折痕，患心血管疾病风险提高33%，两个都有将提高77%，即使将其它已知因素考虑在内也是如此。虽然并不十分确定，但专家们怀疑缺少弹力纤维可能导致折痕出现以及动脉硬化。<br /><br />　　如何预防：利用其它方式保持心脏健康，例如减肥以及降低胆固醇和血压。<br /><br />　　7.牛仔裤尺寸，越大越容易患老年痴呆<br /><br />　　根据《神经学》杂志刊登的2008年进行的一项研究，在40多岁时腹部较大的成年人70多岁时患痴呆症的几率将是腹部较小的人的3.6倍，即使他们并不是超重人群也是如此。造成这种联系的一个可能原因是，与皮下脂肪（位于皮肤下方并且较为明显的脂肪）相比，内脏脂肪（器官周围的危险脂肪）隐藏着更多与认知能力下降有关的激素。<br /><br />　　如何预防：养成地中海风格的饮食习惯，对摄入量进行控制。研究显示，橄榄、坚果、种子类、鳄梨以及黑巧克力等食物中所含的单不饱和脂肪酸能够预防脂肪堆积。<br /><br />　　8.胸罩，越大越面临糖尿病的挑战<br /><br />　　胸部越大，患糖尿病风险越高。根据《加拿大医学协会期刊》刊登的一项为期10年的研究，D罩杯以上女性在20岁患2型糖尿病的风险是A罩杯以下女性的1.5倍，即使在研究人员将肥胖、饮食习惯、吸烟、家族史等因素考虑在内也是如此。研究人员表示，女性胸部中的脂肪组织可能对激素较为敏感，同时影响胰岛素的抵抗力。<br /><br />　　如何预防：进行高强度间歇式锻炼。在一项研究中，经过6次锻炼，每次骑固定式健身脚踏车进行6次冲刺，每次坚持30秒，中间休息4分钟的成年女性血糖代谢能力提高了近25%，足以降低糖尿病风险。<br /><br />　　9.小腿，越细越容易出现颈动脉斑块<br /><br />　　虽然听起来违反直觉，但法国2009年进行的一项研究显示，小腿围较小（33厘米以下）的女性往往出现更多颈动脉斑块，这种斑块是中风的一个已知危险因素。研究发现刊登在《中风》杂志上。研究人员表示，较粗小腿的皮下脂肪可能从血液中抽取脂肪酸，并将它们储存在其危险性较小的区域。<br /><br />　　如何预防：并不需要为小腿“增肥”，而是多喝绿茶以保持心脏健康。在一项由40500名日本男性和女性参与的研究中，每天喝5杯以上绿茶的人死于心脏病和中风的风险最低。<br /><br />　　10.血型，A型、B型和AB型的人可能更容易患胰腺癌<br /><br />　　根据波士顿达纳-法伯癌症研究所和哈佛医学院最近进行的一项由107503名成年人参与的研究，A型、B型或AB型血的人患胰腺癌的几率比O型血人高出44%。这可能意味着，决定血型的基因导致人在遗传上具有胰腺癌患病风险。<br /><br />　　如何预防：服用维生素D补充剂。根据2006年进行的一项研究，与维生素D每天摄入量低于150 IU （国际单位）的成年人相比，每天摄入量在300 IU以上的成年人患胰腺癌风险可降低44%。多吃低脂乳制品和鲑鱼等鱼类是从食物中获取维生素D的最理想方式。</span>', 'gwm', 0, 3),
(176, '我国专家质疑癌症早期筛查无用说法', '', '', '', '2009-12-28 11:06:33', '116.228.141.77', '<span style="font-size:14px;"><p style="font-size:14px;">健康时报记者 王志胜 郑帆影</p><p style="font-size:14px;">　　<span style="font-family:kaiti_gb2312;">内容提要：艾滋病有疫苗啦，肥胖的密码找到了……近日美国《时代》周刊评选出了<a href="http://news.sina.com.cn/h/2009-12-16/094919271605.shtml" target="_blank">2009年世界十大医学突破</a>，各个媒体竞相报道，但是，其中有两个“突破”引起了中国和部分美国医学专家的共同反对：</span></p><p style="font-size:14px;">　　一个“突破”说：乳腺癌筛查没必要从40岁开始，应该延迟到50岁；另一个“突破”说：前列腺癌的筛查和早期检测根本没用。</p><p style="font-size:14px;">　　我国医学家明确指出，这俩“突破”不能信，就连美国的医学研究机构也呼吁“不要理会”，否则会大大增加乳癌和前列腺癌的死亡率！</p><p style="font-size:14px;">　　<strong>医学突破还是政治丑闻？</strong></p><p style="font-size:14px;">　　“不要理会他们，因为那样做将使死于乳腺癌的妇女增加。”曾任美国国家卫生研究院院长的伯纳丁·希利博士大声疾呼。他所指的“他们”，是美国预防服务工作组。</p><p style="font-size:14px;">　　2009年11月16日，美国预防服务工作组发布了减少妇女乳腺癌X光筛查的最新指南，建议美国女性没必要在40岁～49岁就开始接受X光乳腺癌筛查，建议延迟到50岁以后，并且每两年接受一次即可。也不建议美国女性进行乳腺自检——需要说明的是，美国预防服务工作组是一个由政府资助的、很有影响力的机构。</p><p style="font-size:14px;">　　面对新“指南”，美国医学界一开始就表现出很强的质疑声。不少医生怀疑这是一桩政府和医疗保险公司相勾结的政治丑闻。美国癌症基金会的苏珊医生说：“如果指南被认可的话，那么医疗保险公司可能就不会再给年轻女性的乳腺癌筛查费用买单。”</p><p style="font-size:14px;">　　美国妇产科学院、美国癌症学会和美国放射学院采取了折衷建议，女性应继续接受X光乳腺癌筛查，但建议40岁～49岁女性每1～2年一次，50岁或50岁以上女性每年一次更为合理。</p><p style="font-size:14px;">　　<strong>乳癌筛查“赶早不赶晚”</strong></p><p style="font-size:14px;">　　解放军305医院乳腺外科秦洪真说，现代女性生活工作压力加大，乳腺疾病的发病年龄提前，因此对乳腺癌的筛查更要“赶早不赶晚”，50岁以后有些晚了。</p><p style="font-size:14px;">　　在乳房自检方面，她也认为不能取消，一旦摸到肿块，马上就医是非常重要的。</p><p style="font-size:14px;">　　在今年乳腺癌防治月中，卫生部疾控局慢病处处长雷正龙说，对55万中国妇女的调查显示，中国的乳腺癌发病率呈现出双高峰的态势：一是45岁～55岁年龄段，二是60岁～65岁的年龄段。</p><p style="font-size:14px;">　　如此看来，如果推迟到50岁，很显然本来是早期的乳腺癌就可能已经是晚期甚至命都丢了。</p><p style="font-size:14px;">　　秦洪真认为，除了X光机以外，用B超和钼靶检查来筛查乳腺癌会效果更好。</p><p style="font-size:14px;">　　<strong>前列腺癌筛查不能废</strong></p><p style="font-size:14px;">　　如果说上面这个“突破”，只是建议筛查乳腺癌推迟，那么另一个“突破”更为惊人：建议叫停前列腺癌的一切筛查和早期检测。</p><p style="font-size:14px;">　　2009年3月，美国国家癌症研究所公布了一项研究成果：一半志愿者被分配到筛查组，或手动检查，或前列腺抗原检查(PSA)。另一半志愿者不接受筛查，自行决定是否接受年度体检。结果证明，筛查组有50名男子死于前列腺癌，而另一组中则有44人死亡——这说明筛查和早期检测并不能降低前列腺癌死亡率。</p><p style="font-size:14px;">　　在美国，PSA筛查前列腺癌一直受到质疑。其原因是PSA检测的敏感性和特异性不高。</p><p style="font-size:14px;">　　“这不能否定前列腺筛查的意义。”北京协和医院泌尿外科严维刚副教授说，检查肿瘤有很多标志物，比起其他癌症，PSA筛查前列腺癌的敏感性是最高的了。</p><p style="font-size:14px;">　　严维刚建议：只要超过50岁，就应该每年定期做前列腺癌的相关筛查，如PSA，很方便，抽点血就行了，现在不少大单位在体检中，已经为达到年龄标准的人选择了这项检查。如果体检没选，自己去检查，医保也是能报销的。</p><p style="font-size:14px;">　　前列腺癌临床治愈率较高，因此早期筛查非常必要。严维刚指出：70岁以下的早期前列腺癌患者可以采用根治手术或化疗。75岁以上身体不能耐受手术的，可以选择内分泌治疗。</p><p style="font-size:14px;">　　一位不愿透露姓名的专家说：这两个“突破”也许可以给国人一个提示，那就是不要外国人说什么我们就信什么，特别是在健康问题上，“癌症筛查，有比无好，早比晚好——这是铁律。”</p><p style="font-size:14px;">　　<strong>链接：</strong></p><p style="font-size:14px;">　　预防艾滋病有疫苗了：美国和泰国的研究人员对一种新艾滋病疫苗进行了测试。结果表明，新疫苗可使接种者感染艾滋病风险降低31%。</p><p style="font-size:14px;">　　甲型H1N1流感疫苗：面对来势凶猛的甲型H1N1流感，美国、中国在内的一些国家都已成功研制出甲型H1N1流感疫苗，并投入使用。</p><p style="font-size:14px;">　　发现孤独症“嫌犯”：研究人员“抓捕”到了引起儿童孤独症的最大“嫌疑犯”——5号染色体的变异。5号染色体变异可能是15%的孤独症患者的主要病因。</p><p style="font-size:14px;">　　骨质疏松症有新药：当前，治疗骨质疏松症的药物主要是通过抑制破骨细胞的功能来发挥作用。目前，一种正接受美国食品和药品管理局审查的新药却找到新路子——直接抑制破骨细胞的生成。</p><p style="font-size:14px;">　　早老性痴呆新基因被发现：2009年9月，科学家又找到了三个可能引发早老性痴呆的新基因。</p><p style="font-size:14px;">　　解除干细胞研究限制：2009年3月，美国总统奥巴马推翻布什政府在2001年做出的对联邦经费资助人类胚胎干细胞研究进行限制的规定。</p><p style="font-size:14px;">　　用皮肤细胞育出老鼠：2009年7月，中国科学家首次采用诱导多能干细胞，引入四种基因将其重组为胚胎状态，最终育出老鼠。</p><p style="font-size:14px;">　　褐色脂肪是肥胖关键：瑞典研究者发现：瘦人的褐色脂肪远多于胖人，褐色脂肪细胞在低温环境下更活跃。</p></span>', 'gwm', 0, 4),
(177, '研究揭秘快乐家庭秘诀：夫妻一起做家务', '', '', '', '2009-12-28 11:07:29', '116.228.141.77', '<span style="font-family:arial, helvetica, sans-serif, &#65533;&#65533;&#65533;&#65533;;font-size:14px;"><p>中国日报网消息：这也许是妻子们抱怨多年的话题：为什么总是我来做饭洗碗做家务？加拿大学者们一项最新研究结果可能为妻子们提供一把打开婚姻幸福秘密的钥匙，但也是不少“懒”丈夫不愿意听到的：幸福婚姻的秘诀是夫妻一起做家务。</p><p>据英国《每日邮报》12月26日报道，加拿大西安大略大学的研究人员对全国近5万名成人的生活状态进行问卷调查，结果发现，那些共同分担家务的夫妻比仅由妻子或丈夫做家务的夫妻更快乐。而且据研究人员们估计，夫妻间快乐生活的最理想状态是，两人中任何一个人都不要承担超过60%的家务活。</p><p>按照这样的结论看，传统家庭中，由丈夫外出工作，妻子在家做家务以及照看孩子，这种状态的婚姻幸福度就比较低。这种婚姻里，丈夫会感到更多压力，而妻子则因不能给家里带来经济收入而缺乏成就感。没有收入的妻子还会感到更脆弱。</p><p>在另一种婚姻里，妻子外出赚钱，丈夫照看家庭，也会产生问题。因为丈夫会不开心而且不健康，妻子则会感到压力太大。</p><p>不过，听起来容易做起来难。分摊家务也不是每个家庭都能做到的。根据这项研究结果，平均分担家务劳动的家庭最快乐，而这些夫妻要么就是双方都工作，要么就是还没有孩子，或者孩子已经足够大而不需要家长持续的照顾。</p><p>主导这项研究的学者罗德·博若指出，这些研究结果表明了在职场中以及家庭中为男性和女性提供平等机会的价值，也体现出男性在家务活中采取积极主动态度的益处。</p><p>英国肯特大学社会学教授弗兰克·菲雷迪认为，这项研究表明，对于夫妻双方来说，在生活中有一些能够使他们获得独立感和成就感的事情是非常重要的。此外，如果他们能够共同做一些事情，比如家务事或照顾孩子，就会创造一种亲密、交流、温情以及互信的纽带。</p></span>', 'gwm', 0, 3),
(178, '美国调查发现婚前同居者离婚率高', '', '', '', '2009-12-28 11:09:53', '116.228.141.77', '<span style="font-size:14px;"><p style="font-size:14px;">人类身上饱含着无数奥秘，让一代代科学家探索不止，因此，每年我们在了解自身上都会有所斩获。12月23日，美国MSNBC网站报道称，2009年度，又有9项人体奥秘被解开。</p><p style="font-size:14px;">　<strong>　成人也有“婴儿肥”。</strong>长期以来，科学家认为褐色脂肪是婴儿和儿童的专利，一旦他们长大成人后，这种脂肪就消失了。但《新英格兰医学》杂志的一项最新研究却发现，成人仍然保留了褐色脂肪。研究者称，褐色脂肪可以燃烧热量，有助于减肥。研究者预测，适当增加褐色脂肪能助人减肥。</p><p style="font-size:14px;">　<strong>　皮肤是“细菌天堂”。</strong>美国科学家发现，人体上隐藏的细菌比我们以前知道的还要多，最新发现大约有1000多种细菌寄居在人体表面，而且不同地方的细菌分布不一样，以潮湿而多毛的部位最多。另外，研究者还发现，前臂的细菌就多达44种。</p><p style="font-size:14px;"><strong>　　早醒比晚睡更值得警惕。</strong>比利时研究人员发现，与晚睡的人相比，早醒的人更容易疲劳，注意力和反应能力也都不好。另外，意大利研究者也发现，晚上10点04分左右，人的创造性思维最为活跃，因此晚睡也是有好处的。</p><p style="font-size:14px;">　<strong>　右耳朵听到的话更容易让人高兴。</strong>意大利研究者发现，进入右耳朵的音节会被左脑半球优先处理，而左脑是人类的语言中枢，更善于理解话语的意思，而且更容易从中发现快乐的因子。</p><p style="font-size:14px;">　<strong>　同时处理多种信息让你更慢。</strong>人们通常认为，同时处理几个事情是一种能力，能提高工作效率。但美国研究者最新发现，这样会导致事倍功半，因为它会加快应激激素和肾上腺素的分泌，产生负面的生理作用。因此，同时处理多种信息会让你的效率降低，而且“一心多用”的时间越长，你集中注意力的能力就越差。</p><p style="font-size:14px;">　<strong>　婴儿哭声有“口音”。</strong>德国研究者发现，婴儿哭声的口音不仅存在国家差异，在同一国家也存在地区差异。这是因为胎儿在子宫内就会受到父母谈话口音的影响。法国婴儿的哭声是“先低后高”，而德国婴儿的哭声则“先高后低”。</p><p style="font-size:14px;">　<strong>　人为啥生下来不会走路。</strong>一些动物落地几小时就能走路了，但作为高级动物的人类却要经历一年左右的时间，这是为什么呢？科学家称，哺乳动物大脑中主管走路的神经机制是相似的，大脑需要发育到一定程度来激活这些机制。只不过人脑发育的时间较长而已。</p><p style="font-size:14px;">　<strong>　七成孩子缺乏维生素D。</strong>孩子缺乏维生素D的情况比我们想象得要严重。美国今年的最新报告称，大约70%的孩子体内维生素D的含量偏低，这增加了他们将来患心脏病、高血压等风险。</p><p style="font-size:14px;">　<strong>　婚前同居者易离婚。</strong>美国丹佛大学的调查发现，43%婚前同居的人，结婚后容易对婚姻不满，甚至出现较多的沟通问题，离婚概率也较高。▲&nbsp;</p></span>', 'gwm', 0, 3),
(179, '科学家计算出美女脸部黄金比例公式(图)', '', '', '', '2009-12-28 11:12:41', '116.228.141.77', '<span style="font-size:14px;"><div align="center" style="font-size:12px;"><img src="http://i2.sinaimg.cn/dy/h/2009-12-23/U2108P1T1D19321259F21DT20091223111736.jpg" border="1" alt="科学家计算出美女脸部黄金比例公式(图)" /></div><div class="f12" align="center" style="font-size:12px;">根据新的公式，杰西卡·阿尔芭拥有最美的脸部</div><br /><p style="font-size:14px;">　　黄金比例表</p><p style="font-size:14px;">　　西方女性：</p><p style="font-size:14px;">　　眼睛到嘴巴占脸长36%、双眼距离占脸宽46%</p><p style="font-size:14px;">　　东方女性：</p><p style="font-size:14px;">　　眼睛到嘴巴占脸长33%、双眼距离占脸宽42%</p><p style="font-size:14px;">　　据《中国经济网》报道，怎么样的女性脸型才算是漂亮呢？美国和加拿大研究团队计算出最新的黄金比例公式，发现眼睛到嘴巴占脸长36%、双眼距离占脸宽度46%的新黄金比例，是大家公认最迷人的脸蛋，而最符合的就是美国女星杰西卡·阿尔芭。</p><p style="font-size:14px;">　　不过令人意外的是，一向都是性感代表的安吉丽娜·朱莉和杰西卡·辛普森竟然都不符合黄金比例。</p><p style="font-size:14px;">　　另外，专家也表示，东方女性由于五官略为宽大，因此黄金比例应是眼睛到嘴巴长度比例占脸长的33%、双眼距离则占脸宽的42%。</p><p style="font-size:14px;">　　研究人员还建议，如果发现不符合黄金比例也不用太伤心，也许可换个新发型，就能轻松改变脸孔比例。</p></span>', 'gwm', 0, 3),
(180, '血铅儿童为什么 总是自查才发现？', '', '', '', '2009-12-28 11:14:38', '116.228.141.77', '<span style="color:#333333;font-family:verdana, arial, 宋体, simsun;font-size:14px;">　来　论<br /><br />　　大半年时间内，多名生活在清远市经济开发区龙塘镇银源工业区广进员工公寓的儿童，先后检测出血铅超标，一名出生仅10个月的婴儿，血铅含量竟高达550微克/升。记者经两天调查走访，已证实44名孩子血铅超标。家长表示，如果政府展开细致排查，“将绝不止这个数字”。（12月25日《南方日报》）<br /><br />　　为什么这些儿童会血铅超标？企业称，铅尘排放是达标的，有当地环境监测站的监测报告为证。当地环保部门也确认这种说法。然而，也正是在这种看似正常的生产环境下，出现了这批血铅儿童，这如何解释？<br /><br />　　一个很大的漏洞在于，这些血铅儿童的发现，都是家长在医疗机构“一不小心”检测出来的。换句话说，如果家长们不自查，儿童们的健康问题将有可能还是一个谜。近年来，在各地频频发生的血铅儿童事件，问题的苗头也普遍地源起于这种自查。<br /><br />　　这其实也意味着在制度上缺少一种足够的卫生防御系统，当家长们发现血铅儿童时，问题有可能已经积累、蔓延到令人吃惊的地步。以今年发生的三起典型事件来看：陕西凤翔血铅超标事件中，当地政府部门组织检测的1016名儿童中，共查出851名儿童血铅超标；湖南武冈儿童血铅超标事件，1958名儿童中超标人数为1354人；福建上杭儿童血铅超标事件：287名儿童，有121人血铅含量超标。总结起来，当地超过50%以上的儿童都受到铅污染，健康受到了威胁，这是一个已经很迟到的发现。<br /><br />　　所以，要保护污染工业区儿童的健康安全，如果仅仅只是制定一些标准来约束企业，是远远不够的。这些数字提醒我们，一个很急迫的问题在于，政府应该承担起呵护当地民众的公共责任，有必要定期组织这些工厂生活区儿童进行包括血铅在内的微量元素检测，在根源上早日发现问题，以防范污染问题进一步蔓延与严重化。<br /><br />　　从某种程度而言，管好企业与防范健康问题同样重要。如果只是关心企业生产有没有符合标准，而漠视了人的健康问题，那么，这种“标准合格了、民众却很受伤”的怪现象还有可能会继续出现。政府部门要以人的健康为准，而不应该仅仅只机械地关注那些冰冷的数字合不合格。康真金（广东　职员）</span>', 'gwm', 0, 3),
(181, '男人多喝牛奶 女人多喝豆浆', '', '', '', '2009-12-28 11:48:26', '116.228.141.77', '<span style="font-family:verdana;font-size:14px;">牛奶和豆浆都富含很多营养物质，对人体有益，但是经调查牛奶适合于男人喝，豆浆更适合女性。特别是对于黄皮肤的中国人，豆浆更适合。对于处于30~45岁的女性而言，妇科疾病频发，乳腺肿瘤、子宫肌瘤、卵巢囊肿，这些疾病都与雌激素水平变化密切相关。这个阶段要多喝豆浆。为什么呢?<br />　　&nbsp;<br />　　鲜豆浆被我国营养学家推荐为防治高血脂症、高血压、动脉硬化等疾病的理想食品。饮用鲜豆浆可防治缺铁性贫血。豆浆对于贫血病人的调养，比牛奶作用要强。以喝熟豆浆的方式补充植物蛋白，可以使人的抗病能力增强，从而达到抗癌和保健作用。长期坚持饮用豆浆能防治气喘病。<br />　　&nbsp;<br />　　豆浆———心脑血管保健液。作为日常饮品，豆浆中含有大豆皂甙、异黄酮、大豆低聚糖等具有显着保健功能的特殊保健因子。多喝鲜豆浆可预防老年痴呆症的发生。常饮豆浆可维持正常的营养平衡，全面调节内分泌系统，降低血压、血脂，减轻心血管负担，增加心脏活力，优化血液循环，保护心血管，并有平补肝肾、抗癌、增强免疫等功效，所以有科学家称豆浆为“心血管保健液”。<br />　　&nbsp;<br />　　豆浆与糖尿病人。糖尿病大多是由于不科学的饮食长期积累造成的，不当的饮食往往会影响镁、磷、铜、锌、铬、钴、锗等元素的吸收，最终导致糖尿病的发生。最近国外有学者研究证实，豆品饮料具有降血糖作用，豆浆是糖尿病患者极其宝贵的食物，因为糖尿病患者摄取大豆富含水溶性纤维的食物，均有助于控制血糖。<br />　　&nbsp;<br />　　鲜豆浆更适于女性养颜。科学研究认为，女性青春的流逝与雌激素的减少密切相关。现代营养研究认为，鲜豆浆除了含有植物雌激素以外，还有大豆蛋白、异黄酮、卵磷脂等物质，对某些癌症如乳腺癌、子宫癌还有一定的预防作用，是一味天然的雌激素补充剂。同时，豆浆还含有一种牛奶所没有的植物雌激素“黄豆苷原”，该物质可调节女性内分泌系统的功能。每天喝上300~500毫升的鲜豆浆，可明显改善女性心态和身体素质，延缓皮肤衰老，达到养颜美容之目的。<br />　　&nbsp;<br />　　豆浆不仅便宜，对许多中老年人，特别是高血压、高血脂及脑血管病患者来说，喝豆浆更有利健康，豆浆中脂肪所含脂肪酸和豆油酸，可降低血胆固醇，防止动脉化，牛奶中脂肪都可促使动脉硬化，豆浆中较多的铁质，又易吸收利用，也宜于儿童及缺铁性贫血患者饮用。此外，大豆血糖指数为15%，而牛奶为30%，这对肥胖者和血糖高的人来说，选择豆浆更安全。<br />　　&nbsp;<br />　　联合国国际会议上说，牛奶里含的是乳糖，而全世界有三分之二的人不吸收乳糖，在亚洲黄种人中有70%不吸收乳糖，我们是黄种人。有人牛奶是喝了，但并没有吸收多少。对牛奶吸收量最大的是白种人。<br />　　&nbsp;<br />　　北京市调查的结果是40%的人不吸收乳糖。全国普查的结果，吸收最好的是广东。豆浆有什么优点?豆浆里含的是寡糖，它100%吸收。<br />　　&nbsp;<br />　　牛奶里没有抗癌物质，而豆浆里有5种抗癌物质。其中特别是异黄酮专门预防、治疗乳腺癌、直肠癌、结肠癌，所以对我们黄种人来说最合适的是豆浆。我不反对大家喝牛奶，但为了防癌一定要喝点豆浆。有人停牛奶改喝豆浆了。这方法也不一定好。牛奶可以接着喝，又适当加点豆浆。<br />　　&nbsp;<br />　　因此人们常说：牛奶益男，豆浆益女。<br />　　&nbsp;<br />　　医学家对3000余名中老年男子进行了长达22年的研究，发现坚持喝牛奶的男子，血栓栓塞脑卒的发生者明显低于不喝牛奶者。研究者认为，牛奶中的一些物质对中老年男子有保护作用，喝牛奶的男子身材往往比较苗条，体力充沛，高血压的患病率也较低。从而得出结论：男子在中年以后喝牛奶有益于身体健康，能减少脑血管病的发生。医学家认为，中老年女子喝豆浆对身体健康有好处，豆浆除富含抗氧化剂、矿物质和维生素以外，还含有牛奶中没有的植物雌激素——黄豆苷原，能调节女性内分泌系统的功能，抑制雌激素依赖性癌细胞和其它女性生殖系统癌细胞的生长繁殖，对防止对脉硬化有重要意义。医学实验已经证实，中老年女性每天喝500毫升豆浆，可以明显改善心理状态。<br />　　&nbsp;<br />　　最好是中年男子每天以喝牛奶为主，辅以少量豆浆，而中老年女子则以喝豆浆为主，辅以少量牛奶。</span>', 'gwm', 0, 5),
(182, '女性肺癌的病因', '', '', '', '2009-12-28 16:39:27', '116.228.141.77', '<span style="color:#333333;font-family:宋体;font-size:12px;"><p><font face="宋体" size="4">&nbsp;&nbsp; &nbsp;&nbsp;<a href="http://www.newxiwang.com/Article/List_189.html" target="_blank"><u><b></b></u></a>&nbsp;<img height="250" src="http://www.newxiwang.com/Article/UploadFiles/200803/20080307211547874.jpg" width="368" border="0" style="width:332px;height:202px;" /></font></p><p><font face="宋体" size="4">&nbsp;&nbsp;&nbsp; 100多年前，肺癌非常少见，在所有尸检证实为癌症的病人中肺癌只占到了1％。到1918年这个百分比增长了10倍，在20世纪20年代增长了14倍。 在第一次世界大战之后更加明显。绝大多数肺癌发生在男性，但是女性中肺癌的发生也在稳步增长。</font></p><p><font face="宋体" size="4">&nbsp;&nbsp;&nbsp;&nbsp;来自我国的数据显示，自2000年至2005年，男性肺癌从26万增至33万，增幅为26.9%，女性则从12万增至17万，增加38.4%。增幅明显高于男性。现在已知：肺癌主要和吸烟以及暴露于职业和周围环境致癌物质有关。其他诸如家庭聚集倾向，基因变异也被指出和肺癌的发展有关。那么到底哪些是女性<strong>肺癌的病因</strong>呢？</font></p><p><font face="宋体" size="4">&nbsp;&nbsp;&nbsp;&nbsp;<strong>“</strong>二手烟<strong>”</strong>让女性被动受害</font></p><p><font face="宋体" size="4">　　有资料显示，如今在肺癌患者中，不吸烟的女性患者人数逐渐增多。这是怎么回事？</font></p><p><font face="宋体" size="4">　　最新的调查结果发现二手烟是不吸烟女性肺癌的病因之一。调查表明，被动吸烟吸入的烟雾所受危害甚至比吸烟还高，一些与吸烟者共同生活的女性，患肺癌的几率能比正常人多出6倍。因此女性预防肺癌，除了自身不抽烟，还应远离被动吸烟的毒害。</font></p><p><font face="宋体" size="4">　　由于人呼吸系统直接与外界相通，故女性肺癌的发病率与周围环境质量的好坏密切相关。据中国癌症研究基金会副主席孙燕院士介绍，现在公认了的三大女性肺癌的病因分别为：一是大气污染，二是烟草的泛滥(吸烟与被动吸烟)，三是小环境的污染(如粉尘、油烟等)。</font></p><p><font face="宋体" size="4"><strong>　　</strong>戒烟仍是预防之本</font></p><p><font face="宋体" size="4">　　研究表明“多达90%的男性肺癌患者和79%的女性肺癌患者和吸烟有关，无论是被动吸烟还是主动吸烟”。因此女性戒烟是预防肺癌的最根本的措施也是最可控制的良法。有研究发现，抽烟的女性患肺癌的风险是未抽烟者的5倍。女性戒烟越早越好，只有戒烟五年以上的人的肺癌发病率才下降到与无吸烟嗜好的正常人接近。</font></p><p><font face="宋体" size="4"><strong>　　</strong>厨房油烟“熏”出肺癌</font></p><p><font face="宋体" size="4">　　来自上海的一项长达5年的肺癌流行病学调查显示，女性长期在厨房做饭时接触高温油烟，会使其患肺癌的危险性增加2-3倍。究其原因与厨房做饭时产生的有毒烟雾长期刺激眼和咽喉，损伤呼吸系统细胞组织有关。</font></p><p><font face="宋体" size="4">　　鉴于此我们应改变烹饪习惯，炒菜时不要把油锅烧得太热；厨房里必须安装抽油烟机，在烹饪过程中，要始终打开；如果厨房内没有抽油烟机也一定要开窗通风，使油烟尽快散尽。</font></p></span>', 'gwm', 0, 5),
(183, '09年国人舍得为健康花钱了 6成家庭健康消费超3000', '', '', '', '2009-12-29 09:59:53', '116.228.141.77', '<p>岁末年初，许多人都习惯对即将过去的2009年来个总结盘点，其中，一年的收入和支出是重头戏，而在每家账本上，“健康投入”是一项必不可少的内容。</p>\r\n<p>　　健康养生书籍的热销，让过年送健康成了新时尚；“一年之计在于春，一生健康在体检”的理念，又把许多人带进了体检中心；奥运一周年，全民健身的热潮依然未减；一场突如其来的甲流，则让人们备足了感冒药和口罩……2009年，人们有太多的理由为健康掏钱，也有太多的感慨与保健投入有关。岁末，《生命时报》联合39健康网进行了“国人健康投入”大型调查，结果显示———中国人越来越舍得“花钱买健康”了。</p>\r\n<p>　　六成家庭花在健康上的钱超过3000元</p>\r\n<p>　　本次调查共有5142名网友参与。结果显示，在过去一年中，人们在健康方面的花费主要是“看病吃药”（27.60%）、“购买医疗保险”（23.40%）、“用于保健器械、保健品”（19.50%）以及“购买健康书籍”（4.63%）。与10年前相比，现在的健康支出增长点主要在“医疗保险”、“保健器械、保健品购买”以及体检三个方面。</p>\r\n<p>　　“从调查结果中可以看出，老百姓在健康投入方面正在多元化。”北京大学公共卫生学院社会医学与健康教育系副主任钮文异对调查给予肯定，他说，“越来越多的人意识到获取健康不仅是去医院看医生，而应该通过保险、保健预防、锻炼身体等多种方式为健康保驾护航，这是社会健康意识提高的重要表现，很令人欣慰。”</p>\r\n<p>　　不过，在问及“09年为健康花的最大一笔钱”时，多数人表示是“为自己看病”（36.37%）和“为父母看病”（30.82%）。钮文异表示，这并不出乎意料，因为现在“看病贵、看病难”是一个普遍存在的问题，在社会医疗保障体系不够完善的情况下，个人势必要为医疗花费而埋单。“健康投入包含国家投入和个人投入两部分，由于我国的医保还刚刚起步，新型农村合作医疗和城镇居民医疗保险都尚在健全当中，加上人口多、医疗投入有限，因此医疗费用不能完全由政府负担，个人要承担一部分。还有些人根本没有社会医疗保险，因此看病吃药的花销还是很大的。今年国家开始将8500亿投入到医疗卫生上，希望这对缓解看病贵有所帮助。”但全国政协委员、安徽省政协副主席俞祖彭则认为，看病吃药费用高，与医疗费用的飞快增长有关，“现在中国个人年均医疗费用的支出已由1980年的14.51元上涨到512.5元，26年增加了30多倍！这是全世界都在面临的问题，不是一个人的事情。”</p>\r\n<p>　　调查还显示，60.78%的家庭每年为健康花费3000元以上，其中9000元以上的高达11.24%。“健康花费在家庭总支出的比例”中，80.38%的人表示“超过5%”，其中58.28%人在5%—10%，19.12%的人达到40%。与过去10年相比，这一数字在成倍增长。对此，中华预防医学会健康风险评估和控制专业委员会副秘书长、首届健康管理师国家职业专家委员会委员李明表示：“在美国，家庭的平均健康保健支出在1990年是1480美元，到2007年上升到2853美元，这在家庭总支出中占到5%—6%。从这个角度来看，超过80%的国人健康花费都超过5%，说明中国人更舍得为健康花钱了，对健康也比过去重视了。”</p>\r\n<p>　　老人孩子花钱多，中青年男性较“吝啬”</p>\r\n<p>　　调查中，健康花销最大的两大人群是老人和孩子，分别占到总支出的45.49%和22.50%，接下来是中青年女性，占22.08%，而中青年男性仅占9.94%。</p>\r\n<p>　　“老人在健康方面的花费多，这是由他们的自身特点所决定的。”中国老龄科学研究中心老龄社会保障与产业研究室主任陶立群表示，人进入老年期后，人体组织结构进一步老化，各器官功能逐步减退，身体抵抗力逐步衰弱，活动能力降低，很容易患上多种疾病，“尤其是现在的老年人，年轻时保健意识跟不上，有很多不良生活习惯，因此是疾病的高发人群。”对于儿童，复旦大学社会学系副教授于海表示：“一方面孩子处于生长阶段，抵抗力差，需要加强保健，例如吃钙片、补充微量元素等；另一方面现在的家庭都是一个孩子，家长更加重视孩子健康，投入自然也会有所侧重。”</p>\r\n<p>　　据李明介绍，在美国，65岁以上的人口占12%，但花去了整个医疗支出的30%，比例也是很高的。“为老人和孩子多花些钱是合理的，因为这两个人群都是健康上的弱势人群，在这方面国人做得很好。”</p>\r\n<p>　　但中青年对健康花销的“吝啬”却颇令人担心。本报以前曾针对职场中青年进行过相关调查，结果显示，六成职场中青年人每年花在体检、购药、就医、购买健康物品或书刊的费用总计不超过500元。</p>\r\n<p>　　中青年人，尤其是男性在健康方面花费低，一方面说明大多数年轻人身体健康状况较好，但另一方面，也反映了职场人对于健康问题的严重忽视。于海分析，中青年人是社会的中坚力量，上有老下有小，工作和生活压力都很大，很容易出现健康问题。调查中，近八成中青年人曾出现或经常出现浑身酸痛、神经衰弱、失眠、脱发、烦躁、忧郁等问题，其中超过四成人选择“顺其自然”来应对，仅有17.5%的中青年人用体检保证健康，坚持锻炼身体的中青年人则少之又少。“这部分人要对健康给予足够重视，尤其是男性，一定要避免‘过劳’，不能指望吃老本来保持健康。”于海说。健康支出呈现三大增长点</p>\r\n<p>　　对未来在健康上的投入打算，人们也是各有己见。例如，有人打算加强体育锻炼，有人为防大病专门存下一笔钱，也有人打算学会放松，定期去做保健按摩……在这其中，三大新的增长点值得关注。</p>\r\n<p>　　一是购买健康保险，这在诸多选项中占到了24.95%。“人们购买健康保险，说明已经开始为健康做更加长远的计划和投入。”华中科技大学医保研究中心教授赵金辉表示，保险的主要功能是分担风险，从这个意义上来讲，一旦出现健康问题，就不用为过多的医疗费用担心。据统计，多种癌症的发病年龄已经从六七十岁下降到三四十岁，而高血压、脂肪肝、糖尿病等疾病发病率也在不断上升，所以疾病随时可能发生，买保险是未雨绸缪，专家估计这一支出比例会不断增加。</p>\r\n<p>　　二是养老，比例占到18.26%。老百姓之所以打算在养老方面多投入，与“老年人容易出现健康问题，健康花销大”的调查结果相互呼应。陶立群说：“养老就像找板凳，要稳就必须准备多条腿的。首先，要靠稳一条腿，就是基本的社会养老保险，虽然这一项收入只能维持基本生活，但至关重要。现在一些小公司违规不给工人上保险，这时员工一定要争取自己的权利，要知道，这是为将来做打算。另外，还要做多方面的准备，例如，可以给自己选择一些合适的商业养老保险，也可以做一些基金、股票投资，增加积蓄，准备好经济基础。同时，还要保持健康的生活方式，健康地老去。”</p>\r\n<p>　　三是买保健品和健康杂志书籍，占13.2%。对于很多人把“健康保险”压在了保健品上的做法，钮文异认为，目前保健品市场的火热与之密切相关，但人们不能对保健品给予太多希望，现在国内保健品市场普遍存在宣传夸大的现象，在消费时一定要保持理性。对于健康杂志书籍，钮文异指出，获取健康知识至关重要，“卫生部最近公布的一项调查显示，我国公民健康素养不足7%，主要缺少的就是健康常识，因此人们有必要多读健康杂志书籍，但现在有些书不太客观，读者要学会甄别。”</p>\r\n<p>　　“预防上多投入1元，治疗上就少花8.5元”</p>\r\n<p>　　中国医学科学院院长助理、北京协和医学院公共卫生学院院长黄建始指出，最合理的健康投入方式，就是把钱花在预防上。调查中，尽管有97.29%的人都表示，“更愿意把钱花在预防上”，但卫生部新闻发言人、卫生部办公厅副主任毛群安却指出，“中国人一生中在健康方面的投入，60%—80%花在临死前一个月的治疗上！”可见，国人对健康的预防还是行动晚于意识。</p>\r\n<p>　　黄建始表示，世界卫生组织调查显示，达到同样健康标准所需的预防投入与治疗费、抢救费比例为1∶8.5∶100，即预防上多投入1元钱，治疗就可减支8.5元，并节约100元抢救费。美国经过20年研究，发现90%的人通过健康管理和教育，能把医药费降10%。“如果你愿意把钱花到早期的健康管理上，就可以把很少的钱花到后期治疗上，这是很划算的。”因此，中国人预存健康，需要在行动上努力，不要等到生病了才开始关注健康。</p>\r\n<p>　　“实际上，花钱多少不是衡量健康的标准。”李明表示，健康投资是一个长期的，周而复始的工作，它包含两个方面，一个是建立科学的生活方式，如坚持运动和合理饮食，这是我们保持健康的基础，而且不需要花费很多钱，就能带来长远的好处。另外一方面，要将健康作为个人的财产来进行管理，合理地投入一些资金，比如购买健康保险以及人身保障服务。</p>', 'gwm', 0, 3);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(184, '英国女子被误诊为癌症17年后产下男婴(图)', '', '', '', '2009-12-29 10:02:06', '116.228.141.77', '<span style="color:#000000;"><span style="font-size:14px;">\r\n<div style="font-size:12px;margin:0px;" align="center"><img alt="英国女子被误诊为癌症17年后产下男婴(图)" src="http://i2.sinaimg.cn/dy/h/2009-12-29/U2468P1T1D19358843F21DT20091229082254.jpg" border="1" />\r\n</div>\r\n<div class="f12" style="font-size:12px;margin:5px 0px 0px;" align="center">英国最严重误诊丑闻受害者产下男婴，曾被医生断定无法生育。</div><br />\r\n\r\n<div style="font-size:12px;margin:0px;" align="center"><img alt="英国女子被误诊为癌症17年后产下男婴(图)" src="http://i0.sinaimg.cn/dy/h/2009-12-29/U2468P1T1D19358843F23DT20091229082254.jpg" border="1" />\r\n</div>\r\n<div class="f12" style="font-size:12px;margin:5px 0px 0px;" align="center">1993年，8岁的妮卡因化疗头发全掉光，《每日邮报》当时曾在头版报道她的遭遇。</div><br />\r\n\r\n<p style="font-size:14px;">　　据《每日邮报》12月28日报道，英国儿科护士妮卡-奇特温(NiekaChetwyn)8岁的时候因医生误诊接受癌症治疗，结果被断定永远失去生育能力。然而，两周前，妮卡却在医院产下一个健康的宝宝，一家人在狂喜中见证了“奇迹”的诞生。</p>\r\n<p style="font-size:14px;">　　妮卡今年25岁，是英国最严重的一起癌症误诊丑闻的受害者，当时她被告知，漫长的治疗可能已令其永远不能实现母亲梦。但是，经过不懈努力，妮卡终于在12月17日产下一名男婴，重7磅14盎司(约合3.57公斤)，取名乔斯卡(Joscar)。妮卡27日在接受采访时说：“我一直期待着拥有自己的孩子，可我想实现这一愿望只能靠收养了，所以说，这真的是个奇迹。”</p>\r\n<p style="font-size:14px;">　　1993年，8岁的妮卡因化疗头发全掉光，《每日邮报》当时曾在头版报道了她的遭遇。由于误诊，她接受了积极的癌症治疗，结果身体遭受了严重伤害，医生当时称小妮卡几乎肯定失去生育能力。英国卫生当局还对数千患者的检查结果重新核对，发现很多患者可能因不必要的癌症治疗而遭遇创伤，这些人因此获得了补偿。</p>\r\n<p style="font-size:14px;">　　然而，妮卡的父母并未得到一分钱的补偿，因为她的确患有癌症，但这却是一种不同于被诊断类型的癌症。家人一直想搞清小妮卡是否会永远活在这起意外事故的阴影下，这种积极的治疗是否真的有必要。在多位癌症专家的帮助下，妮卡最终被确定不会有生命危险，但没人敢保证她将来有一天可以自然受孕。</p>\r\n<p style="font-size:14px;">　　妮卡7岁那年，父母在她的腿肚子上发现了一个可疑肿块。医生随后进行了活组织检查，并将检查结果送到伯明翰塞利-奥克医院供卡罗尔-斯塔基(Carol Starkie)博士分析，后者断定妮卡患上了尤文氏肉瘤。妮卡随后进行了手术，并在曼彻斯特皇家儿童医院接受了18个疗程的漫长化疗。</p>\r\n<p style="font-size:14px;">　　与此同时，有人对斯塔基的医术提出了质疑，英国卫生当局于是对2000多个斯塔基接手的病例进行了复检。复检结果表明，妮卡的确患有癌症，但不是尤文氏肉瘤，而是横纹肌肉瘤。尽管如此，由于贻误了治疗的最佳时机，主治医生不得不坚持原来的方案。妮卡的父亲菲利普说：“糟糕的是，我们恐怕永远不清楚更为稳妥的治疗是否可以治愈妮卡所患的疾病。”</p></span></span>', 'gwm', 0, 3),
(185, '研究发现女性生育1次可增加10年免疫力', '', '', '', '2009-12-29 10:05:25', '116.228.141.77', '<span style="color:#000000;"><span style="font-size:14px;">\r\n<p style="font-size:14px;">　时下不少女性拒绝生育，有关医学专家为此深感忧虑，因为这会给女性生理和心理健康埋下隐患。</p>\r\n<p style="font-size:14px;">　　研究表明，女性的一生中如果有一次完整的生育过程，就能增加10年的免疫力，这种免疫力主要是针对乳腺癌、卵巢癌等妇科肿瘤的。此外，由于不生育的女性得不到孕激素及时有效的保护，还容易发生激素依赖性疾病，如子宫肌瘤、子宫内膜异位症等。</p>\r\n<p style="font-size:14px;">　　调查还发现，相对于未生育的妇女，有生育史的妇女除了有更强的免疫力抵抗妇科肿瘤和疾病外，还可推迟更年期的到来。由于在妊娠期和哺乳期，卵巢推迟了一二十个孵子的排出，因此有生育史妇女的更年期往往比未生育的妇女来得晚。</p>\r\n<p style="font-size:14px;">　　此外，孕育儿女不仅可以使女性的生理更趋成熟，其心理也将更加健康。&nbsp;&nbsp;</p></span></span>', 'gwm', 0, 5),
(186, '2009年44.8%的人比去年更烦恼 健康成为最大烦心事', '', '', '', '2009-12-29 10:08:45', '116.228.141.77', '<p><span style="color:#000000;"><span style="font-size:16px;font-family:瀹嬩綋;">　2009年，步伐匆匆的我们，有时满腔烦闷无从诉说，有时心底欢唱却没人共鸣。在这一年走到尾声时，《生命时报》联合新浪网健康频道进行了一项“09年你经历了哪些快乐和烦恼”的网络调查，邀请了多位权威心理学专家，与参与调查的2996名网友一起，探讨我们一年的心路历程。<br />\r\n<br />\r\n　　本次被调查者的年龄集中在20—50岁，其中，20—30岁的占31.5%；30—35岁的14.3%；35—40岁的占18.1%；40—45岁的占14.7%；其他的共占21.4%。在悉心盘点自己的2009年后，有44.8%的人认为自己和去年相比烦恼更多了，28.2%的人觉得自己比以前更快乐了，还有27.0%的人觉得今年和往年一样，没有更快乐，但也没有更烦恼。在记者的随机调查中，对于2009年，人们也有不同的感慨。<br />\r\n<br />\r\n　　“2009年是我最幸运的年份，这一年，我和老公一起拥有了第一套属于自己的房子，我们的宝宝也在上个月降生了，一切美好的事物都来得这么快。”张小姐这样对记者说。而对于赵先生来说，2009则是失落的一年：升职机会被有背景的同事抢走了；工作不如意，回家和妻子总是吵架，现在已经走到了离婚的边缘。“我想，我最大的烦恼就是，这些不如意已经无法让我伤心或是愤怒了，可以用一个词来形容，就是麻木。高兴不高兴的事，对我来说都没有影响。”<br />\r\n<br />\r\n　　“其实，这样的结果一点也不意外。”上海心理咨询协会会长王裕如这样对《生命时报》记者说，即将告别的2009年，充满了动荡和不确定性，房价高涨、物价上涨、就业困难……来自方方面面的苦闷和压力在人们心里积聚而无处释放，逐渐形成慢性的、恶性的循环，导致人们的幸福感降低，即便有小小的幸福，在巨大的压力前也显得微不足道了。情商管理专家、美国乔治亚理工学院心理学博士张怡筠也表示，许多的社会事件，比如金融危机、甲型H1N1流感，也奠定了2009年充满压力和变数的基调。<br />\r\n<br />\r\n　　中国科学院心理学研究所研究员、中国社会心理学会副会长时勘教授表示，这项研究的结果是与近年我国民众健康问题的新趋势相符合的。由于我国经济目前正处于人均GDP在1000美元至3000美元的发展阶段，是“经济容易失调、社会容易失序、心理容易失衡”的“三失”时期。处于这种瓶颈约束最为严重的时期，人们感受到自己和家人的健康、特别是心理健康方面的压力，是情理之中的事情。<br />\r\n<br />\r\n　　华南师范大学社会心理学教授郑希付说，宣泄不快的动力比分享快乐的强得多，快乐的人看到这个调查，可能会一笑而过，而不快乐的人，往往借机发泄，产生共鸣。就像网上负面新闻的帖子，总会有最多的跟帖一样。“也有一种可能，每年做这个调查，结果都会是人们的烦恼比快乐多。归根结底，所有烦恼都来自于现实与期望值之间落差。人们最难看见的，就是自己已经拥有的快乐和幸福。”<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<br />\r\n<b>&nbsp;&nbsp;&nbsp;&nbsp;5大烦心事</b><br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;那么，到底是哪些事让我们烦心呢？我们看看排前5位的烦心事：<br />\r\n<br />\r\n　　自己和家人的健康，占15.3%。张怡筠解读说，人们最担忧健康，是因为在这个问题上个人的掌控力最差，一般来说，失去掌控的事物，最容易让人感受到压力。2009年的经济氛围虽然不好，但是钱、房子，毕竟还是可以通过努力获得的，而健康则不然。万一某天癌症来袭，人们只能听天由命。<br />\r\n<br />\r\n　　婚姻和家庭问题，占13.5%。张怡筠指出，“家庭和婚姻”受关注与此次被调查群体集中在20—40岁有关。这个年龄段的人上有老下有小，结了婚的要学习和伴侣相处，没结婚的担心成为“剩男剩女”，这些担忧都会给个人幸福感带来很大的影响。<br />\r\n<br />\r\n　　工作压力，占13.3%。时堪说，现代工作不仅需要付出艰辛的体力和脑力，最重要的是还要求人们扮演一个“情绪劳动者”———需要在工作中表现出与工作相符的情绪情感，不仅教师、客服人员、销售人员等，连做个技术人员，也逃不开这个角色。而长期的情绪劳动也可能让人体验到更多的负性情绪，从而容易产生工作倦怠、难于应付压力。<br />\r\n<br />\r\n　　薪水和升职，占12.5%。时堪认为，社会的快速发展，带来更多的机会，让人们能够在满足温饱等基本需要后，去获得自身价值的实现。同时，生存更具难度，单一寻找“铁饭碗”、满足于“一个萝卜一个坑”，相当于是逆水行舟，这时只有不停地调试自己的职业定位，才能有自己的竞争优势。因此，追求加薪和升职已经成为许多人实现高级心理需求的体现。<br />\r\n<br />\r\n　　子女教育，占10.9%。时堪还认为，“三失”让工作与家庭的平衡也遭到破坏，“男主外女主内”变成了双职工，孩子的教育就成为谁也不能全力以赴、但谁又不能推脱责任的问题。再加上社会转折时期出生的70后、80后都开始生儿育女，育儿经受到了传统和现代的双重冲击，众多变数让他们感觉压力重重。<br />\r\n<br />\r\n　　那么，这些烦心事的排名说明什么问题呢？“当人们想到切身的烦恼时，首先都会选择离自己‘最近’的点，比如健康、家人。因为这方面的烦恼会时刻与人共处。比如说得了病，那么你时时刻刻都能感受到这种病痛，再比如和伴侣的关系不好，每天回到家，这种不好的想法都会在脑海中反复强化。”郑希付解释说，而工作、薪水、升职这些问题，则离人本身更“远”，容易逃离也容易找到替代品。<br />\r\n<br />\r\n　　另外，在被问及2010年最想避免的烦心事时，网友们选择的前5项竟与2009年的一样，只是排名先后略有不同。王裕如对此评论道：“从另一个角度看，这也是社会进步的一种表现。说明人们已经走过了物欲横流的时代，转而关注自己的身体和心灵，这也一定程度形成了稳定的生活观和价值观。”<br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;<b>5大找乐法</b><br />\r\n<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;同样的烦恼，对不同人的影响也各异。有些人笑笑而过，有些则会在心里积压数月乃至数年。56.2%的被调查者表示，在烦恼时会及时调整心情，39.2%偶尔会调整，从来不会调整心情的人只占4.6%。这数据足以说明大部分人还是能给自己“找乐”的。人们最常用的找乐法是以下5种：<br />\r\n<br />\r\n　　找亲朋好友聊天或聚会，13.50%。郑希付认为，中国人自古以来就十分注重人际关系，因此从中也能取得最大的幸福感。尤其是快节奏生活成为常态时，面对面地陪伴、交流，能很好地应对孤独感。<br />\r\n<br />\r\n　　听音乐，12.3%。心理学家认为，音乐不仅愉悦人心，对人的身心也具有一定的疗伤作用，而现在mp3、KTV等的普及，让音乐成为人们，特别是年轻人便捷的放松手段。<br />\r\n<br />\r\n　　购物、看电影，9.6%。购物能使大脑产生“快乐激素”，让人流连忘返；而看电影，则可以让人们日常无法满足的愿望（如成为英雄、超人）得到替代性实现。<br />\r\n<br />\r\n　　回忆以往美好快乐的时光，7.7%。不仅老年人爱说当年勇，现在还有些“80后”都开始怀旧起来。因为回忆中的积极体验能提高自身效能感、获得自尊和自信。<br />\r\n<br />\r\n　　大吃一顿，7.2%。吃美食相当于一种自我抚摸方式，能给人慰藉并转移注意力。<br />\r\n<br />\r\n　　对这一系列“找乐”现状，张怡筠首先表示肯定，“压力、烦恼就像心理上的一道伤口，在它还小的时候，贴上创可贴就可以好；万一伤口炎溃烂了，康复的时间和难度就会大大增加。而5天之内是正常的焦虑周期，很高兴看到大部分人能在这个时间内把自己的问题消化掉。”郑希付说，如果负面情绪长期得不到宣泄，就会导致负面心态累积，影响活力、创造力、理性思维能力，还会带来诸如头疼、胃疼、失眠等生理症状。<br />\r\n<br />\r\n　　但时勘也指出。这5种找乐方法虽然对排解烦恼、增进幸福感有参考价值，但总体来说，这些方法都在应对压力方面采用了宣泄情绪、回避问题的方式。在心理学上，处理压力的方式有“以情绪为中心”和“以问题为中心”两种，前者注重宣泄、缓和情绪，方法有哭泣、倾诉或采取抽烟喝酒、逛街、暴食等转移注意力的方式，后者注重解决问题本身，方法有理性分析问题、想办法取得别人支持、请教有经验的人等。<br />\r\n<br />\r\n　　这两种方式没有好坏之分，但是提倡综合运用，而不是像这5种方法一样，都采取防御性或逃避性的方法。时勘建议，在感觉到对事情还有所控制时，应该积极解决问题，而感觉无力回天时，以情绪为中心的应对策略会更为合适。<br />\r\n<br />\r\n　　最后，时勘建议寻求一些专业、先进的方法来减压和找乐，“目前，国内已经有专门的《心理健康服务体系》，针对个人或组织的需要，利用3G技术，通过手机、114信息台和互联网为大众和企业提供EAP(员工辅助计划）心理健康服务。</span></span></p>', 'gwm', 0, 5),
(187, '教育部:未接通知 高考体检绕不开乙肝五项 ', '', '', '', '2009-12-30 12:21:57', '116.228.141.77', '目前，教育部门尚未接到相关文件，至于会否影响明年高考体检规定，他表示，还要以明年四五月份出台的四川2010年高考体检实施规定为准。\r\n<br />\r\n<br />　　据记者了解，目前成都市内中小学“早就不检查乙肝五项了”。根据省卫生厅、省教育厅今年10月印发的《四川省中小学生健康体检管理办法》，所有体检项目中也未包括“乙肝五项”。而肝功能相关的项目是“寄宿制学生在必要时到符合规定的医疗机构进行的体检项目”。\r\n<br />\r\n<br />　　但在高考环节，“乙肝五项”仍然是绕不开的。记者从省教育厅了解到的情况是，目前高校录取依据的体检标准是卫生部、教育部于2003年发布的\r\n《普通高等学校招生体检工作指导意见》。按照意见，乙型肝炎表面抗原携带者，不能就读学前教育、航海技术、飞行技术、面点工艺、西餐工艺、烹饪与营养、烹\r\n饪工艺、食品科学与工程等专业。\r\n<br />\r\n<br />　　而在高考体检中，乙型肝类表面抗原（HBSAg）检查是不可逃避的一项。 如果考生转氨酶正常，乙肝表面抗原阴性，则为合格，而转氨酶正常，乙肝表面抗原阳性则以上特殊专业可不录取该考生。\r\n', 'gwm', 0, 2),
(188, '故意侵害病人身体 台湾3名医师被废止医师证书', '', '', '', '2009-12-30 12:22:38', '116.228.141.77', '岛内医界爆发大丑闻，有集团勾结医师，掉包检体并为未罹癌民众切除乳房、直肠，诈领保险金恐逾10亿元（新台币，下同），涉案医院达10几家。台当局“卫生署”罕见在法院判决前，大动作宣布废止3名涉案医师的医师证书。\r\n<p>　　据台湾《联合报》报道，这是台“卫生署”首度祭出最严厉的废止医师证书处分，“卫生署”医事处坦言，过去最重处分是停业，近4年来连医师执业执\r\n照都未废止过，医师遭废止证书后，永不得再任医师。台湾医院协会理事长吴德朗说，医界重视纪律及医学伦理，应严惩医界害群之马、败类。</p>\r\n<p>　　根据台“刑事局”侦四队发现，傅建森集团从2003年起，勾结医师、人头病患，掉包检体，假罹癌真手术，给没罹癌病人施行直肠、乳房、子宫、卵\r\n巢切除手术。基隆医院医师杨超然、桃园县怡仁综合医院医师赖德兴以及云林县天主教若瑟医院医师吴国精已坦承犯案、证据确凿，“卫生署”遂决定废止3人医师\r\n证书。</p>\r\n<p>　　台“卫生署长”杨志良昨天与台湾医师公会全联会理事长李明滨、医院协会理事长吴德朗共同说明，除上述3名涉案医师，还有7名病人涉案，其中4人接受乳房次全切除、乳房切片或化疗，2人做了化疗，傅建森本人也接受直肠手术及化疗。</p>\r\n<p>　　预估案情还会扩大，仍有4位医师被侦查，涉案医院包括公、私立医院，层级从医学中心到区域医院，规模之大前所未见。杨志良表示“非常沈痛”，虽仍有案件尚在侦办，法院尚未判刑，为维持医界尊严，先废止被起诉医师的证书。</p>\r\n<p>　　台“卫生署”医事处长石崇良说，以往医师不法行为，充其量就是出具不实诊断证明，从未见医师故意侵害病人身体。这次涉案医师掉包检体，还把其他癌患检体以福马林浸泡，掺入涉案民众正常检体里，施行手术、安排化疗。</p>', 'gwm', 0, 2),
(189, '肿块不痛不痒被“遗忘” 5年后肿瘤已有鸡蛋大', '', '', '', '2009-12-30 12:25:48', '116.228.141.77', '<span>6年前因为惧怕开刀，现在增大的肿瘤已经将气管牢牢压迫住，话说不出，连呼吸都困难了。对于当时的讳疾忌医造成现在的后果，躺在病床上的肖先生真是懊悔万分。\r\n<p>　　肖先生家住余杭，今年60岁。昨天，我们在杭州市中医院外科病区见到了肖先生。躺在病床上他，显得相当虚弱，表情也很痛苦。</p>\r\n\r\n<!--advertisement code begin--><table align="left" border="0" cellpadding="0" cellspacing="0" width="260">\r\n    <tbody><tr>\r\n      <td height="255" valign="bottom">\r\n        \r\n        \r\n        \r\n        \r\n        <embed src="http://www.hsw.cn/adv/2009/01/ty.swf" quality="high" type="application/x-shockwave-flash" height="250" width="250" />\r\n      </td>\r\n    </tr>\r\n</tbody></table> \r\n <!----><!--advertisement code end--><p>　　“5年前，我发现脖子上有一个肿块，核桃大小。”肖先生连着比划手势，告诉我们，但是说不到一句话，他就累得气喘吁吁，上气不接下气，最后只能有一旁的医生来介绍情况。</p>\r\n\r\n<p>　　因为当时不痛不痒，他不急着去医院看病。后来一次无意中和家里人说起，家人催促他去医院看看，他这才去当地医院检查。“当地医院让他立即住院开\r\n刀。”他一想慌兮兮的，而且那个时候手头上还有一大堆事情，就把这个要紧事情搁牢了。后来干脆就将这个颈部肿块“选择”性地忘记了。</p>\r\n\r\n<p>　　就在上周，肖先生出现了呼吸急促，稍微一动就上气不接下气。这时他再摸颈部那个已经被他遗忘的块块，他不禁吓了一跳，竟然有鸡蛋大小。</p>\r\n\r\n<p>　　“询问病史后，吓了一跳。现在竟然还有如此讳疾忌医的病人！”外科的专家们在为病人感到心痛惋惜的同时，也非常惊讶。病人的甲状腺肿块从头颈部\r\n上方一直延伸到胸骨后方，估计有15厘米长。肿块也相当大，就像一只大大的手，将脖颈牢牢掐住，气管被压迫得只一线窄缝。接着又在局麻下做了活检，提示有\r\n恶性甲状腺癌的可能，同时双肺都已出现转移灶。</p>\r\n\r\n<p>　　由于肖先生的肿块实在太大了，现在连做手术也失去了时机，气管压迫狭窄，手术麻醉无法插管，难以实现麻醉。气管内侵润的肿块如果插管后，将被挤破出血，有可能引起术中窒息。面对这一情况，医生只能为他选择保守疗法，来尽力减轻他的痛苦。</p>\r\n\r\n<p>　　据悉，香港明星汪明荃在几十年前也得了甲状腺癌，后来经过手术治愈了，现在还一直活跃在舞台之上。胸外科的董礼文副主任医生告诉我们，“太可惜了，甲状腺癌其实可以说是比较温和的一种癌，和乳腺癌一样，只要早期治愈，后期的存活率非常高的。”</p></span>', 'gwm', 0, 2),
(190, '男性癌症易忽略15种症状', '', '', '', '2009-12-30 12:26:15', '116.228.141.77', '<div class="left_con">       \r\n            \r\n      <p><strong>现将和男性癌症有关的15种症状列举如下：</strong></p>\r\n<p><strong>乳房肿块</strong> 绝大多数男性不会想到患乳癌，往往认为这是女性的“专列”。其实它虽很少见，却是有可能的。当男性发现乳房有肿块时，尤其是局部皮肤凹陷有皱纹，乳头内缩或有分泌物，乳房发红或脱屑，一定要去就诊。</p>\r\n<p><strong>疼痛</strong> 虽然绝大多数疼痛不是癌症，但局部持续疼痛，应该就诊。即使医生诊断不是癌症，其他疾患也都得到治疗，是值得的。</p>\r\n<p><strong>睾丸改变</strong> 当睾丸有任何症状时都应请医生检查。例如睾丸增大或萎缩，或者有块，或者阴囊有沉重感等。有时睾丸肿瘤生长极快，所以早期发现是关键。</p>\r\n<p><strong>淋巴结改变</strong> 如果腋下、颈部或其他部位发现肿块或淋巴结肿大，就应就诊。尤其是淋巴结持续增大一个月以后，就一定要请医生检查。</p>\r\n<p><strong>发热</strong> 如果有发热而原因不明，就有可能是肿瘤。当然多数发热是因感染或肺炎等也应请医生诊治。有些癌症在某一时期会引起发热，如癌症扩散、转移，或因血癌，如淋巴瘤或白血病。所以不能解释的发热一定要找医生。</p>\r\n<p><strong>体重减轻</strong> 你并没有节食及运动想减肥，但体重却明显下降。如在短期内(如几周)减轻10%以上，就应就医。</p>\r\n<p><strong>腹部不断的绞痛并有抑郁</strong> 如果腹痛并有抑郁症，就应好好检查，因胰腺癌与抑郁症有关。其他症状还可能有黄疸或大便颜色改变，如灰色便。</p>\r\n<p><strong>疲乏</strong> 疲乏也是极常见的症状。每个人工作或活动久了都会乏力。如果常感极度疲乏而休息后并不消除，就应请医生检查，因为可能与癌症有关。例如白血病、某些结肠癌、胃癌等。</p>\r\n<p><strong>持续咳嗽</strong> 感冒、流感、过敏等都会咳嗽，某些药的副作用也有咳嗽。但久咳(指咳三四周以上)，则不应忽略，尤其是吸烟者，应就医。它可能是肺癌的症状，也可能是慢性支管炎或酸反流。</p>\r\n<p><strong>吞咽困难</strong> 有些人感到吞咽困难，但不以为意，自己认为多吃些流质，多喝汤，就解决了问题。其实吞咽困难可能因消化道肿瘤，如食管癌，要请医生检查。</p>\r\n<p><strong>皮肤改变</strong> 皮肤上色素痣增大，大家都知道要警惕癌。但在皮肤上其他改变也应注意。如皮肤上突然出血或过度脱屑都应就医。皮肤改变多久才可能有问题很难说，一般认为超过几周就应注意。</p>\r\n<p><strong>不应出血的地方出血</strong> 例如咯血、吐血痰、胃肠出血、尿血等都应该看医生。不要以为大便有血就因痔疮，结直肠癌的表现也是大便出血。</p>\r\n<p><strong>口腔改变</strong> 如果你吸烟，应特别注意口腔内有无白斑或舌上白点，这些改变表示有血斑病。这是癌前病变，可能进展为口腔癌。应请医生或牙医诊治。</p>\r\n<p><strong>排尿问题</strong> 男人年老多有排尿问题，如尿频、尿急、排尿不尽等。但这些症状严重时应看泌尿外科医生，以排除前列腺癌或者前列腺增生。</p>\r\n<p><strong>消化不良</strong> 许多人尤其是老年人，认为明显的消化不良是心脏病发作的影响。但持续的消化不良可能是因食管癌、胃癌所致，应就医。</p>\r\n<p>总之，一些看似最常见的症状，如疲乏、发热、疼痛等，如果持续较久，千万不要以为我自己是“最好的医生”而忽略不顾，还是应请正规医院的医生检查为宜。</p>             </div>', 'gwm', 0, 2),
(191, '一氧化碳中毒事件频发 需提高防范意识', '', '', '', '2009-12-30 12:27:45', '116.228.141.77', '<br />河南台记者邱菊报道：<br />&nbsp;&nbsp;&nbsp; 入冬以来，随着气温不断下降，人们在日常生活用火、取暖和洗澡时缺乏安全防范意识，导致一氧化碳中毒事件的不断发生。对此120提醒，要选择正确采暖的方式，用炉子取暖时，要及早开窗通风，不断提高安全 。<br />&nbsp;&nbsp;&nbsp; 据郑州市紧急医疗救援中心统计，自2009年11月1号至12月29号，郑州市区共接诊一氧化碳中毒患者324例，比去年同期239例增加了85例，患者从儿童到老年人分布在各个年龄段，主要发生原因包括使用煤火炉取暖不当、使用天然气热水器洗澡时通风不良等，特别是外来务工人员，在出租屋内使用煤火取暖方式不当，已经导致了部分患者严重中毒死亡。<br />&nbsp;&nbsp;&nbsp; 一氧化碳中毒，主要表现为开始患者自觉头晕、头痛、耳鸣、眼花，四肢无力和全身不适，症状逐渐加重时，出现恶心、呕吐、胸部紧迫感，皮肤粘膜出现樱桃红色等症状，继之昏睡、昏迷、呼吸急促，甚至死亡。<br />　　专家提醒，当发现患者发生一氧化碳中毒时，立即开窗通风，并迅速将患者转移到通风的地方，注意保暖；对意识不清的患者，平卧，解开衣领及腰带以利其呼吸，并将患者头部轻轻地偏向一侧，避免呕吐物窒息，如果口中有呕吐物，想办法将口腔内的呕吐物清理出来。同时迅速拨打“120”求救，让患者尽快得到专业救治。', 'gwm', 0, 2),
(192, '2009中国医事：开胸验肺悲壮 “偷菜”伤身要命', '', '', '', '2009-12-30 12:28:41', '116.228.141.77', '<img src="http://i1.ce.cn/ce/xwzx/gnsz/gdxw/200912/30/W020091230406647589836.jpg" border="1" height="282" width="450" /><br />　　中新网12月30日电 （朱博）2009年的中国医事热闹异常，从千呼万唤始出来的新一轮医药卫生体制改革，到席卷全球的甲型H1N1流感疫情，从为了争取活的权利开胸验肺的张海超，再到医生被爆“偷菜”造成的婴儿死亡事件……<br /><br />　　这一年中的每一件事，都看似偶发却又足够吸引眼球，不但为公众提供了丰富的谈资，还引出一场场针锋相对的口水仗。当热闹归于理性，我们重新再对各事梳理分析的时候，不禁感叹，曾经不起眼的它们，必将在未来成为一个个里程碑式的记忆。<br />　　 \r\n<table align="center">\r\n<tbody>\r\n<tr>\r\n<td><img src="http://i2.ce.cn/ce/xwzx/gnsz/gdxw/200912/30/W020091230406647647548.jpg" border="1" height="380" width="336" /></td></tr></tbody></table>\r\n最委屈<br /><br />　　　　<strong>猪：仓促蒙冤</strong><br /><br />　　“猪”的委屈，\r\n全拜年初由墨西哥爆发的“人感染猪流感”疫情所赐。由于发病突然并且迅速在全球蔓延开来，使得世界人民在慌乱中只记住了“猪”，并且果断地把猪当成了罪魁\r\n祸首。随着疫情的传播，人们对“猪”的误会越来越深，从最初的不吃猪肉及猪肉制品，发展到了谈“猪”色变的地步。直到有一天，这个新流感被命名为“甲型\r\nH1N1流感”，才终于为无辜的猪们洗脱了恶名。<br /><br />　　事实上，时至今日，全球范围内甲流的活跃程度都尚未达到巅峰，国内外专家仍难排除第\r\n三波疫情爆发的可能，世卫组织甚至还在为病毒的变异而担忧。然而，经历了前两波疫情的考验，目睹了感染病例爆发和死亡病例激增等诸多的疫情变化，接受了流\r\n感病例中甲流所占比例加大这一客观存在，人类的应对态度却早已不似刚开始的那样恐慌不安，而愈发地理性从容了。<br /><br />　　伴随着人类对这一新兴疾病的认识加深，世界各国都根据自身情况开展着各项防控措施，特别是当疫苗成功研发并顺利接种之后，人类似乎也更有信心战胜“甲型H1N1”了，毕竟，对于任何一项新的事物都需要经历一个了解的过程。<br /><br />　　或许不久的将来，人们再说起“甲流”会像现在说起“流感”一样轻松、平常，只是可怜了那些“待宰圈中”的猪，恐怕至今都不知道自己的身价和声誉曾经历过这样一番严峻的考验。<br /><br />　　<strong>碘盐：“顶替”蒙冤</strong><br /><br />　　2009年年中，在全民补碘15年之后，一场关于“中国人是否还需要补碘”的讨论轰轰烈烈地展开了。8月13日，中国卫生部公开回应了“食盐加碘过量导致甲状腺疾病”的质疑，并表示，将于明年适当下调现行食盐加碘量，体现“因地制宜、分类指导”的科学原则。<br /><br />　　近年来，中国沿海和内陆部分高碘地区的居民高发甲状腺疾病，让公众一致将矛头指向了已推行15年之久的“碘盐”，一系列数据和事实，使原本“不相干”地区的人们，也开始对本地区“碘盐”存在的必要产生了怀疑。<br /><br />　　质疑和声讨之势，使得卫生部不得不出面，重新向公众分析“全民食盐加碘”这一政策实施15年来的利弊。<br /><br />　\r\n　首先“碘盐致病说”缺乏科学依据，因为国际控制碘缺乏病理事会已经明示，人群中甲状腺癌的发病率并不受碘摄入量的影响；其次“全民食盐加碘”利远大于\r\n弊，因为中国是受碘缺乏威胁最严重国家之一，缺碘地区学龄儿童的智商比非缺碘地区低约10—11个百分点，弱智(智商在69以下)儿童的比率为\r\n5-15%，这对人口素质和社会经济发展所带来的损失难以弥补，因此，食盐加碘防病措施所产生的社会经济效益是难以估量的，同时，中国在消除碘缺乏病方面\r\n所取得的成绩，已成为国际组织号召学习的榜样。<br /><br />　　最后，在卫生做出将对现行的食盐碘含量进行小幅下调的表态后，“碘盐”的不白之冤才终于在这个双赢的结果中昭雪，并将继续在中国人的厨房里扮演不可或缺的角色。<br /><br />　　<strong>中药：牵连蒙冤</strong><br /><br />　　今年2月，青海发生的双黄连注射液致死事件引起人们对中药注射剂安全性的广泛关注，据不完全统计，清开灵注射液、双黄连注射液、葛根素注射液、穿琥宁注射液、参麦注射液、鱼腥草注射液、莲必治注射液等都曾因不良反应而遭通报，也让公众对“中药”的不信任达到了巅峰。<br /><br />　\r\n　有业内人士分析表示，中药注射液所引发的不良反应，约占到整个中药不良反应的70%，而频发的不良事件，最终导致一部分中药注射剂被封杀，一部分被限制\r\n使用，而一些大城市的大型综合性医院更是直接把中药注射剂清除出药房。一些患者因为“双黄连注射液”，否定了“双黄连口服液”、“双黄连颗粒”，从而将所\r\n有的中药产品都列入了“黑名单”，使本就艰难前行的中医药产业再陷困境。<br /><br />　　面对公众对“中药注射剂”严重的信任危机，中国官方启动了中\r\n药注射剂再评价工作，要求中药注射剂生产企业对照《基本技术要求》主动开展研究工作，以期全面提高中药注射剂的安全性、有效性和质量可控性，从而消除公众\r\n的顾虑，重塑中药注射剂和中医药在国人心中的形象和地位。事实上，专家调查分析后发现，近几年发生的中药注射剂不良事件大多与药物本身没有太大的关系，其\r\n风险来自于中药注射剂在原料、生产工艺、质量控制等方面存在的固有缺陷，而临床上的不合理使用更是不良事件频发的重要原因之一。<br /><br />　　可见，“中药”本无错，错在谁来用、怎么用，就比如砒霜，在医生的眼里是治疗血液疾病的良药，但更多的人却只知道它的“狠毒”一面。<br />　　 \r\n<table align="center">\r\n<tbody>\r\n<tr>\r\n<td><img src="http://i3.ce.cn/ce/xwzx/gnsz/gdxw/200912/30/W020091230406647744711.jpg" border="1" height="299" width="450" /></td></tr></tbody></table>\r\n最悲壮<br /><br />　　　　<strong>开胸验肺：悲壮求生</strong><br /><br />　　2009年6月，河南籍农民工张海超“开胸验肺”之举，震惊了所有人。这个被多家医院诊断出患有“尘肺”，却不能依法享受职业病待遇的人，拿出破釜沉舟的勇气，用命为自己争取了“活下去”的权利。<br /><br />　\r\n　说起“职业病”，人们很多时候想起的都是诸如“键盘手”、“鼠标肘”之类“无关痛痒”的小毛病，所以，张海超这般惊世骇俗地证明自己确实患有“职业病”\r\n的行为，才显得那么刺眼。让人们警醒，原来“职业病”并不是平时所说的那样轻松、简单，享受“职业病待遇”更不是想象中的那么顺理成章。<br /><br />　\r\n　就像“空姐”与“美女”对应，“商人”和“精明”搭配一样，每个行业的从业者都有区别于其他行业的印记，而这些，其实都可以算成是“职业病”。只不过，\r\n隔行如隔山，坐在办公室里的人，恐怕很难体会到在尘土飞扬的车间、矿井下工作是什么滋味，也就更无从知晓其中的辛酸和无助。所以，张海超绝不是被职业病逼\r\n上“绝路”的第一人，但却是敢于抗争并且维权成功的第一人。<br /><br />　　只盼“开胸验肺”能推动中国的职业病防治进程，让职业病的危害越来越少、监管和维权能有章可循，至少，别再出现这种“置之死地而后生”的事件，来刺痛每个人的心。<br /><br />　　<strong>暴走妈妈：悲壮舐犊</strong><br /><br />　　“暴走”是一种高强度又简单易行的户外运动方式，但当它与一个在短短七个月时间里，每天暴走10公里减掉重度脂肪肝，以便能够“捐肝救子”的母亲联系在一起的时候，却显得那么深沉感人。<br /><br />　\r\n　“减肥”本就是一件极其考验意志和耐心的事情，“割肝”恐怕就更加恐怖和危险了，而当这一切都与儿子的生命联系在一起的时候，辛苦和危险就会化作无穷的\r\n希望和动力，支撑着一个母亲“走”破了四双鞋。这个平凡的母亲之所以如此牵动国人的心，是因为她用自认为再平常不过的行为，让每一个忘我打拼而忽略了太多\r\n的人，猛然想起了自己远在家中、守着电话的父母，想到了他们因为操劳而斑白的两鬓，以及同样“掏心挖肺”的爱子情深，或许还有人会暗自庆幸，自己不是这场\r\n故事的主人公，并发自内心地为这对母子祝福。<br /><br />　　其实，这就是父母，是每个人最常忽视却又坚强无比的后盾，是绝对可以托付一切却又最不求回报的人。所以，当我们被别人的“暴走妈妈”感动的时候，请为自己家中的“暴走妈妈”做些什么，哪怕仅仅拨一通电话，对他们来说，足矣。<br /><br />　　<strong>明星代言：悲壮逐利</strong><br /><br />　　2009年11月初，中国广告协会对侯耀华代言的十则违法广告进行公开点评，再次点燃了长久以来公众对明星虚假代言的不满，一时间，众明星的公众形象一落千丈，并激起了社会上对明星“不管不顾”追逐金钱利益的道德谴责，更有人强烈呼吁，应当立法惩治那些说谎明星。<br /><br />　\r\n　翻看近几年所谓的“代言门”，国内众多一线明星均有“案底”。从重庆老太状告邓婕代言三鹿奶粉，到推销榨菜的张铁林搬出“爷爷的爷爷”，再到唐国强为不\r\n孕不育医院殷勤揽客，有关明星代言的讨论早就不是什么新鲜话题。只不过，一个人代言10个虚假广告同时曝光，还是让早已见怪不怪的消费者多少有些“吃不消\r\n”。当网上的人为明星虚假代言吵得不可开交的时候，众明星或许正满足地坐在自己的豪宅里，数着靠“合法劳动”换来的钞票，面对并不友善的批评和指责，没准\r\n还会为自己的曝光度再次提升而窃喜。<br /><br />　　可见，仅靠唤醒明星的责任感和羞耻心，用“道德”约束他们的虚假代言行为已经越来越无力，用时髦的话说，他们的“违法成本”太低。因此，除非要付出更大的代价，否则“侯药华”们或许只会不屑地认为，丢几分钟的脸算什么，数自己的钱，让“蜗居”的人谴责去吧！<br />\r\n<table align="center">\r\n<tbody>\r\n<tr>\r\n<td><img src="http://i4.ce.cn/ce/xwzx/gnsz/gdxw/200912/30/W020091230406647801095.jpg" border="1" height="363" width="450" /></td></tr></tbody></table>\r\n最新奇<br /><br />　　　　<strong>“防甲流口罩”：产品新奇</strong><br /><br />　　\r\n2009年11月8日，一个据称经过国家相关部门检测，对甲型H1N1流感病毒抑制率达92%的专用口罩横空出世，为正处在甲流第二波疫情的公众带来了胜\r\n利的希望。而所谓的“分子链接抗微生物技术和远红外技术”和“长效抗病毒、杀病菌，水洗也不失效”的特点，更让公众对这一“高科技”产品给予了厚望。<br /><br />　\r\n　然而，事情的发展却颇具喜感，11月11日，国家食品药品监督管理局在新闻发布会上明确表示，“可有效抑制甲型H1N1流感病毒的抗病毒口罩”并未获得\r\n《医疗器械注册证》，已被查封；12月18日，国家食品药品监督管理局网站公布了“防流感杀菌美容口罩”的处理结果，没收违法产品及违法所得3850元，\r\n并处罚款3万元。12月18日，国家食品药品监督管理局公布了“防流感杀菌美容口罩”的处理结果：没收违法产品及违法所得3850元，并处罚款3万元。<br /><br />　\r\n　或许厂家最初真的是怀着悲天悯人的责任感来制造和生产口罩的，并且在强大的“心理暗示”作用下，将仍存在于想象中的“美好寄望”变成了现实宣传中的“神\r\n奇功效”。只是，在如此特殊的时代背景下，“防甲流口罩”完美的契合了人们“病急乱投医”心态，从而引发了始料未及的关注。<br /><br />　　只是，厂家猜中了开头却没猜对结果，恰恰是这样的关注，最终将自己推向了绝路。<br /><br />　　<strong>“金钱镇痛”：观点新奇</strong><br /><br />　\r\n　今年6月，中山大学心理学系副教授周欣悦作为第一作者即将发表在国际著名心理学刊物《心理科学》上的论文《金钱的符号作用：启动金钱概念改变社会痛苦和\r\n生理性疼痛》引起了学术界之外的关注，经过公众的统一认识，这一观点被概括成了“金钱镇痛”，并且毫无悬念地掀起了一场新的口诛笔伐。<br /><br />　\r\n　“金钱镇痛”连同它的研究者周教授被冠以“荒谬”、“拜金”的罪名，受到了国人几乎“一边倒”的声讨。其中“损失金钱会令人们感到生理性疼痛”这一论\r\n点，招来的“口水”最多，并被当做是利用公权揽私财的“理论依据”。许多人不禁担忧，如果所有人都以此为动力，理直气壮地追求更多的“止痛药”，那么整个\r\n社会将变得怎样疯狂？<br /><br />　　学术的东西，我们外行不懂，所以，今后再有涉及“金钱”这类敏感事物的研究，请各位学者务必慎重，千万别引来大家的误解而遭“围攻”，更别“助纣为虐”地成为居心不良的人干坏事的“幌子”。<br /><br />　　不过话说回来，有关部门可以在制定“精神赔偿”标准的时候考虑一下“金钱镇痛”，根据“疼痛等级”确定“药量”总是比漫天要价靠谱！<br /><br />　　<strong>解酒药：想法新奇</strong><br /><br />　　自从今年10月中国官方开始严查酒后驾车，“解酒药”就被贪杯司机当成了保护神，并且迅速占领了各酒店、药房的显眼位置。<br /><br />　\r\n　粗略统计，仅在网络上销售的“解酒药”种类就多达上千种，让人眼花缭乱，不知如何选择。虽然不同品牌的“解酒药”在价格上分出了三六九等，但是所有产品\r\n的宣传口径却出奇地一致，均声称“可速效解酒，迅猛提升酒量”。在官方来势汹汹的高压严打之下，众位酒驾司机对“解酒药”的奇效深信不疑，并把它当成了逃\r\n避检查的“夺宝奇兵”。<br /><br />　　然而很快，就有专家公开反驳，所谓的“解酒药”只能缓解难受程度，再好一点的可以对肝脏起到一定的保护作用，\r\n至于“消化”酒精，则纯属忽悠。因为，酒精进入人体后，由消化道吸收进血液，再依靠肝脏解毒，分解成二氧化碳和水，最后排除体外，而目前并没有任何一种手\r\n段能改变这一过程。<br /><br />　　可见，吃“解酒药”图的只是一种心理安慰，好让醉眼迷离的司机们再看到路边检查的警察时，能有足够的底气假装没喝，可实际结果如何呢？细一想，原来吃药“解酒”这个想法，就是“掩耳盗铃”的二十一世纪版。<br />', 'gwm', 0, 3),
(193, '元旦放假通知', '', '', '', '2009-12-30 12:35:49', '116.228.141.77', '&nbsp;&nbsp; 接各医院通知，2010年1月1日--3日为元旦放假时间，放假期间个PET-CT中心休息时间，不做PET-CT检查，但是放假期间仍然可以通过派康网预约PET-CT，检查时间请安排在2010年1月4日及以后，派康网有人电话值班，预约电话：400-6125-007，也可以通过网络自助预约！我们会及时为您安排！<br />&nbsp;&nbsp;&nbsp; 祝大家身体健康，节日愉快！<br />', 'gwm', 0, 2),
(194, '卫生部发布孕产妇甲流防治指南', '', '', '', '2009-12-31 09:47:31', '116.228.141.77', '<span style="font-size:14px;"><p><strong>本报北京12月30日电</strong>　鉴于孕产妇感染甲流后,较易发展为重症或死亡病例,卫生部专门制定了《孕产期妇女甲型H1N1流感防治指南(试行)》,并于30日印发各地。</p><p>　　指南认为,孕产期妇女感染甲流后更多表现为气促,更易发生肺炎等并发症,可诱发原有基础疾病的加重,导致流产、早产、胎儿宫内窘迫、胎死</p><table align="left" style="font-size:12px;"><tbody><tr><td style="font-size:12px;"></td></tr></tbody></table>宫内等不良妊娠结局。患有慢性呼吸系统疾病、心血管系统疾病、肾病、肝病、血液系统疾病、神经系统及神经肌肉疾病、代谢及内分泌系统疾病、免疫功能抑制以及肥胖的孕产期妇女,患甲流后更易发展为危重病例。<p>　　指南建议,孕产期妇女的家属及看护人员、从事孕产期保健的工作人员等应优先接种甲流疫苗。孕产期妇女在出现流感样症状之后,可尽早给予达菲和乐感清进行抗病毒治疗,同时进行病毒核酸检测。在产后,应立即隔离患甲流的产妇和新生儿,新生儿应即刻转移至距离产妇2米外的辐射台上,体温稳定后立即洗澡。患甲流的产妇直至满足以下全部条件——服用抗病毒药物48小时后,在不使用退烧药的情况下24小时没有发热症状,无咳嗽、咳痰，方可接触新生儿。医院应在产妇出院后加强产后访视和新生儿访视,鼓励产妇继续母乳喂养。</p></span>', 'gwm', 0, 2),
(195, '入学、就业体检中乙肝5项被取消', '', '', '', '2009-12-31 09:48:31', '116.228.141.77', '<span style="font-size:14px;"><p style="font-size:14px;font-weight:lighter;">红榜</p><p style="font-size:14px;font-weight:lighter;">　　从几个月前传出的疾控中心专家建议,到上周的卫生部新闻发言人发声表态,再到12月29日,卫生部明确表态,宣布我国已于近期制定取消入学就业体检中乙肝5项检查有关政策,明确禁止将携带乙肝病毒作为限制入学就业的条件。</p><p style="font-size:14px;font-weight:lighter;">　　2009年7月,国务院公布《中华人民共和国食品安全法实施条例》。与1995年颁布的《中华人民共和国食品卫生法》等相关法律法规相比,新条例不再明令禁止乙肝病毒携带者从事食品卫生行业。9月1日,22岁的乙肝病毒携带者雷闯历经半个月,在浙江省卫生厅厅长杨敬的督办下,领到了健康证明。这被视为新食品安全法颁发后的首例“试水”成功。此后,安徽、江苏、天津等地的“肝友”纷纷效仿,并成功领取了健康证。</p><p style="font-size:14px;font-weight:lighter;">　　点评:今年被视为乙肝患者维权漫漫长路中的一个转折点,破冰之年,长久郁积的乙肝歧视问题终于看到一线曙光。但担忧声随之出现,对于我国人数近1亿的乙肝病毒携带者来说,他们所面临的社会歧视很难在短时间内消除,毕竟歧视不是几天几个月才形成,而且有单位很可能“上有政策,下有对策”,例如员工进入单位后会有“福利”体检,乙肝携带者依然可能被歧视。希望政府能考虑更周全,不单是简单取消,而是作出更合理、更有实操性的法规。</p></span>', 'gwm', 0, 2);
INSERT INTO `wenzhang_news` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `user_name`, `j_image_count`, `click`) VALUES
(196, '重庆一重症甲流患者治疗花费17万元引发关注', '', '', '', '2009-12-31 09:51:16', '116.228.141.77', '<span style="color:#333333;font-family:宋体;font-size:14px;">日前，重庆一例重症甲流患者治疗花费17万元引起了社会关注，而各地也都陆续出现了甲流患者治疗费昂贵的情况。<br /><br />　　为什么看似温和的甲流，在救治时花费却如此不菲？在现在甲流防治常态化的情况下，医疗费会不会给患者造成过重负担呢？<br /><br /><strong>　　重症患者需综合救治，平均花费75180元</strong><br /><br />　　“抢救甲流危重症患者，花17万元一点也不稀奇。”北京地坛医院危重医学中心主任郭利民说，不只是甲流，几乎所有危重症的抢救，都要花不少钱。在保命的时候，要上最好的药物，上最好的设备，上最好的医生，先把病人抢救过来再说。<br /><br />　　记者从地坛医院拿到两份危重症患者的费用清单，一位患者住了30天院，住院费用8.5万元，其中西药费用4.2万元，检查费用1.14万元，材料费用1.13万元。而另一位患者住院两周，总费用8万元，光是抗真菌药一针1450元的优立康只唑就用了24支，花费了3.48万元。还有几名患者的治疗费用超过了20万元。<br /><br />　　治疗费用高，主要是因为患者本身有基础病，如肺栓塞、高血压、心脏病、哮喘等，或因流感引发其他脏器的损伤，导致治疗抢救难度增大，复杂程度加深。郭利民说，重症患者需要上呼吸(机)，保循环，抗凝血，要使用人工心肺支持。一项体外循环膜氧合的耗材就要4万元，一个进口导管大约2万元，血液净化每小时要50元，各项费用少不了。据地坛医院一项抽样统计，重症患者的平均费是75180元。<br /><br /><strong>　　治疗费用可享医保报销医疗救助</strong><br /><br />　　11月份前，北京甲流患者定点收治医院在地坛医院和佑安医院。在这两家医院，免费救治一直延续到10月底。但同期，患者在确诊后并被转入定点医院治疗前，在其他医疗机构就诊费用，仍须按所接受的医疗服务项目付费。<br /><br />　　卫生部卫生应急办公室主任梁万年说，对甲型H1N1流感患者的医疗救治，按照卫生部办公厅等四部门《关于甲型H1N1流感医疗救治费用问题的通知》有关规定实行收费，并把甲型H1N1流感的救治费用纳入医疗保险，包括城市居民医疗保险、城镇职工医疗保险和农村新型合作医疗，救治的费用根据地区经济发展水平的情况来定。<br /><br />　　北京卫生局副局长、新闻发言人邓小虹说，已参加医保的甲型H1N1流感患者，到定点医疗机构进行医学排查和治疗，发生的医疗救治费用通过医保制度按照规定予以报销。11月初，北京所有流感样患者，无论是何种病毒感染，都纳入正常的医疗付费和医保报销范围。<br /><br />　　梁万年说，尚未参加医保的患者或经医保报销后，个人医疗救治费用负担仍较重的贫困患者，可通过城乡医疗救助制度帮助解决。基本医疗保险和新农合经办机构要按规定及时支付医疗救治费用，并做好与当地民政部门医疗救助工作的衔接。<br /><br /><strong>　　减轻患者负担，应变按药报销为按病报销<br /></strong><br />　　“减少医疗费用最好的办法是尽早实施"肺保护"策略，减少重症的发生，早期抗病毒治疗积极防治并发症。”郭利民建议。<br /><br />　　梁万年说，对一些容易变成重症的和已经是重症的人要及时使用达菲，并不一定要等待诊断明确以后再使用达菲，防止重症。<br /><br />　　专家表示，在甲感重症治疗中，为减轻患者负担，应改变医保的报销方式。我国现行的医保制度多是按药品报，而不是按病种来报销，该用的药品不能报，患者费用负担轻不了。<br /><br />　　郭利民介绍说，在临床重症治疗的过程中，要使用抗耐药和抗真菌的药物。如增强免疫力日达仙(胸腺素α1)，抗耐药利奈唑胺(斯沃)等药品，动辄上千元，患者完全自付。而体外循环膜氧合的耗材500元以上的，只报50%。高额的费用，很多重症患者无法承担，容易造成欠费。<br /><br />　　截至11月25日，地坛医院垫付的费用为187万元。这些费用政府对医院进行补贴，基本已经到位。<br /><br />　　对此，专家建议，医保制度的设立，就是为了保大病，救重症。因此，应对医保报销方式进行改革，在规范临床诊疗方案的基础上，可试行按病种付费，让参加医保人员都能看得起病。</span>', 'gwm', 0, 2),
(197, '“心灵感冒”是自杀元凶', '', '', '', '2009-12-31 09:52:42', '116.228.141.77', '<span style="font-size:14px;"><p style="font-size:14px;font-weight:lighter;">抑郁症，常常被人们称为“心灵感冒”。近年来，抑郁症成为自杀的主要原因之一，严重的“心灵感冒”接连吞噬了很多人的生命。</p><p style="font-size:14px;font-weight:lighter;">　　合肥市第四人民医院精神科主任医师周晓琴介绍，随着社会竞争加剧、压力增大，目前，抑郁症患者正呈逐渐增多的趋势。其中，不乏高学历的白领。</p><p style="font-size:14px;font-weight:lighter;">　　周晓琴表示，对于抑郁症患者，应该采取药物结合心理的治疗方法。患者自身要维持药物治疗，同时要增强心理接受能力，排遣不良情绪，家人也应关心支持患者，并鼓励患者接受正规的心理治疗。社会也应给予抑郁症患者更多的理解。</p></span>', 'gwm', 0, 2);

-- --------------------------------------------------------

--
-- Table structure for table `wenzhang_shenfen`
--

CREATE TABLE IF NOT EXISTS `wenzhang_shenfen` (
  `name` varchar(100) NOT NULL COMMENT '省份',
  `pinyin` varchar(200) NOT NULL,
  UNIQUE KEY `name` (`name`),
  KEY `pinyin` (`pinyin`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `wenzhang_shenfen`
--

INSERT INTO `wenzhang_shenfen` (`name`, `pinyin`) VALUES
('检查指南', 'jian cha zhi nan '),
('临床应用', 'lin chuang ying yong '),
('病例介绍', 'bing li jie shao '),
('详细介绍', 'xiang xi jie shao ');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_active`
--

CREATE TABLE IF NOT EXISTS `yiliao_active` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(200) NOT NULL,
  `content` text NOT NULL,
  `add_time` datetime NOT NULL,
  `click` int(11) NOT NULL COMMENT '点击数',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 AUTO_INCREMENT=90 ;

--
-- Dumping data for table `yiliao_active`
--

INSERT INTO `yiliao_active` (`id`, `name`, `content`, `add_time`, `click`) VALUES
(35, '2009年全国PET读片会成功召开', '由中华医学会核医学分会主办、PET及分子显像学组承办的第四届中日韩核医学大会暨2009年全国PET(/CT)读片会及学术研讨会于2009年9月在海滨之城山东省青岛市成功举行。这次大会，是继2009年5月中华医学会核医学分会第八届全国核医学学术交流会之后的又一次成功的学术活动之典范，是中日韩核医学界的交流平台，是对国内PET(/CT)及分子显像技术、学术工作的回顾、肯定、总结，也是对国内PET(/CT)，乃至全体核医学工作者的相互交流、共同进步、展望未来的良机。', '2009-09-27 10:44:31', 70),
(36, '上海PET/CT检查价格是全国最低！', '<p><span style="font-family:宋体;"></span>&nbsp;</p>\r\n<p><span style="font-family:宋体;">上海拥有</span><span>PET/CT</span><span style="font-family:宋体;">中心的医院如下：上海仁济医院、上海</span><span>455</span><span style="font-family:宋体;">医院、上海华山医院、上海肿瘤医院、上海武警总队医院。全身检查价格</span><span>7500</span><span style="font-family:宋体;">元人民币、半身检查价格</span><span>4500</span><span style="font-family:宋体;">元人民币。</span></p>\r\n<p><span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span></span><span style="font-family:宋体;">派康网</span></p>', '2009-09-27 10:44:33', 135),
(30, '美国核医学临床应用漫谈学术讲座', '上海医学会核医学分会于 8月 12日在同济大学附属第十人民医院举行了"美国核医学临床应用漫谈"学术讲座，主讲人为美国UCLA陈卫博士，本次学术活动由同济大学附属第十人民医院影像临床医学中心承办。讲座前，进行了简短的开幕式，由上海核医学会副主任委员吕中伟教授主持。首先由同济大学附属第十人民医院副院长、影像临床医学中心主任程英升教授致欢迎辞，并代表医院向陈卫博士颁发了影像临床医学中心顾问的聘书；然后上海市核医学会主任委员黄钢教授代表学会致辞，欢迎陈卫博士来我市讲学，同时代表学会向陈卫博士赠送了中国以及上海核医学50周年纪念画册；最后马寄晓教授代表老专家对我市年轻一代核医学医务人员的工作提出了希望。', '2009-09-09 22:08:12', 87),
(33, '派康网可以免费预约PET/CT检查了！！', '派康网现在可以预约网站上的PET/CT检查了！！ 方便快捷', '2009-09-09 22:09:37', 102),
(37, '2009世界心脏病日 健康从“心”开始', '2009年9月27日是第九个世界心脏病日。世界心脏病日是世界心脏病联盟于1999年开始发起的重要活动之一，目的是唤起人们对心血管疾病和危险因素，如肥胖、营养失衡、吸烟等的关注。\r\n<p>　　据世界心脏联盟预计，2025年前，在全世界范围内，25岁以上的成年人中，每3人就有1人将罹患心血管疾病。心血管疾病的死亡率远远高于包括癌症、<a class="blue" href="http://jbk.39.net/keshi/crk/4fa82.html" target="_blank"><font color="#000000">艾滋病</font></a>在内的其他疾病，堪称威胁人类健康的“第一杀手”。</p>\r\n<p>　　世界心脏联盟主席Shahryar Sheikh教授说：“预测在未来一些年里，患心血管疾病的人数将会增加50%，但是这种状况不是不可避免的。如果改变不健康的生活方式、降低危险因素水平，那么防治前景会变好。”</p>\r\n<p>　　关心心脏的健康，永不嫌早，永不止歇。我们要对自己的血压、血脂、血糖水平了如指掌，就像了解体重、身高、腰围一样，并将这些指标联系在一起，采取防治措施，减少罹患心血管疾病的风险。世界心脏联盟建议的措施包括规律运动、创建无烟环境和健康饮食。在日常的饮食中，最好每天能有5～7种水果和蔬菜；多吃各种谷物；多吃鱼类、豆类、瘦肉；减少盐的摄入量；选用富含不饱和脂肪酸的橄榄油、葵花油等食用油，这些都有助于预防<a class="blue" href="http://jbk.39.net/keshi/neike/xxgnk/48ef6.html" target="_blank"><font color="#000000">冠心病</font></a>和脑卒中。</p>\r\n<p>　　预防心脏病，</p>', '2009-09-27 10:44:36', 55),
(38, '上海PET-CT检查降价通知', '<font size="4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 接上海市物价局、上海市卫生局、上海市医疗保险局文件通知（沪价费（2008）015号），正电子发射计算机断层—X线计算机体层综合显像（PET—CT）全身检查（含同位素药物）调整为：&nbsp;&nbsp; 7500元/次<br />\r\n局部检查（一个床位，含同位素药物）：4500元/次<br />\r\n&nbsp;并于2008年11月20日开始执行，特此通知！！</font><br />\r\n', '2009-09-27 12:12:04', 132),
(56, 'PETCT可及早确诊癌症 核医学检查有望纳入医保', '<p>2008年7月17日，中华医学会第四届中青年核医学委员学术会议在哈尔滨友谊宫召开。记者从会上获悉，核医学的主要检查手段PETCT今后有望纳入医保，价格也有可能下调，更多的患者将享受到核医学检查。</p>\r\n<p></p>\r\n<p>PETCT将CT与PET融为一体，由CT提供病灶的精确解剖定位，而PET提供病灶详尽的功能与代谢等分子信息，具有灵敏、准确、特异及定位精确等特点，一次显像可获得人体全身各方位的断层图像，可一目了然地了解全身整体状况，达到早期发现病灶和诊断疾病的目的。PET／CT目前是全球最高端的医学影像诊断设备，堪称“现代医学高科技之冠”。以一名肺癌患者为例，经过手术、放化疗等一系列治疗后，如果想知道这名患者体内残留组织中是否还存在活着的癌细胞，做PET／CT就能准确判断出来，而核磁共振、CT、超声等检查都无法判断出来。</p>\r\n<p></p>\r\n<p>目前，哈尔滨市只有一台PET／CT。据中华医学会核医学分会主任委员匡安仁介绍，按照有关规定，每100万人口应该拥有1至1.5台PET／CT，理论上哈尔滨应该拥有10台左右PET／CT才能满足患者的就医需求。</p>\r\n<p></p>\r\n<p>美国核医学会主席Mc·ewan介绍说，目前，美国拥有2000多台PET／CT，分布在公立、私立、社区等各级医院。这次会议后，美国将与中国共同制定培训计划，将美国先进的技术和经验带到中国来，培训中国的核医学医生，推动中国核医学发展。今明两年，我省将有多家医院陆续引进PET／CT。</p>\r\n<p></p>\r\n<p>匡安仁介绍，目前我国共有PET／CT100多台，每台设备的投入大约为三四千万元，做一次PET／CT的价格大约在8000至13000元之间，昂贵的价格让许多患者望而却步。“现在各家医院基本处于亏本状态。”如果每家医院每个月有150至200个患者做PET／CT，基本能保证收支持平，但现在每家医院每个月只有50至70个患者做PET／CT，医院无法保证成本，价格也降不下来。匡安仁说，如果拥有PET／CT的医院每个月能有150个以上的患者做PET／CT，价格定在6000至7000元之间是比较合理的。</p>\r\n<p></p>\r\n<p>中华医学会核医学分会目前正在向国家发改委和社保局反映这一情况，呼吁尽快将PET／CT纳入医保，使更多的患者享受到核医学的好处。</p>', '2009-10-14 14:31:20', 101),
(41, '派康网成功启动在线预约服务', '<p>&nbsp;&nbsp;&nbsp; 在国庆前夕，派康网成功启动在线客服系统，在周一至周五工作时间，在线客服随时在线，访客将可以和在线客服进行无畅通的交流，欢迎新老客户体验前来咨询、预约，体验在线交流的通畅自由。</p>', '2009-09-29 14:41:18', 74),
(42, '湖北省宜昌市核医学会2009年学术交流会召开', '<p><font face="Verdana" size="2">2009年8月14日-16日，湖北省宜昌市核医学会2009年学术交流会在宜昌市姊归县县城茅坪镇召开。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009820104416470.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">参加会议的何作祥、安锐和张永学教授。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009820104442572.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">安锐教授代表湖北省核医学会致辞。</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104517218.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">专题报告</font></p>\r\n<p align="center"><font face="Verdana" size="2">何教授：心血管核医学的新进展</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104537821.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">张永学：核医学质量控制与管理</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104555609.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">会议主持：宜昌市核医学会副主任委员赖建平</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104621497.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">宜昌市核医学会主任委员崔邦平、副主任委员曾国良、赖建平</font></p>\r\n<p align="center"><font size="2"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104659499.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana" size="2">（中华核医学专业网）</font></p>', '2009-09-29 14:48:31', 77),
(43, '同济大学附属第十人民医院举行了“美国核医学临床应用漫谈”学术讲座', '<p><font face="Verdana" size="2">上海医学会核医学分会于2009年8月 12日在同济大学附属第十人民医院举行了"美国核医学临床应用漫谈"学术讲座，主讲人为美国UCLA陈卫博士，本次学术活动由同济大学附属第十人民医院影像临床医学中心承办。<br />\r\n　　讲座前，进行了简短的开幕式，由上海核医学会副主任委员吕中伟教授主持。首先由同济大学附属第十人民医院副院长、影像临床医学中心主任程英升教授致欢迎辞，并代表医院向陈卫博士颁发了影像临床医学中心顾问的聘书；然后上海市核医学会主任委员黄钢教授代表学会致辞，欢迎陈卫博士来我市讲学，同时代表学会向陈卫博士赠送了中国以及上海核医学50周年纪念画册；最后马寄晓教授代表老专家对我市年轻一代核医学医务人员的工作提出了希望。<br />\r\n"美国核医学临床应用漫谈"学术讲座部分由上海核医学会副主任委员王辉教授主持。主要交流了以下四方面的内容：<br />\r\n　　①怎样使经济效益和病人利益更好结合：美国医学体系发展过程的教训 ；<br />\r\n　　②新技术怎样更好地为病人服务：从肿瘤诊断看新技术的合理应用；<br />\r\n　　③Evidence Based and outcome Based Medicine：心导管及心肌灌注显像那一个更重要？<br />\r\n　　④结构与功能：核医学在现代医学中的位置。</font></p>\r\n<p><font face="Verdana" size="2">　　对于各个板块讨论热烈，针对当前中美核医学发展过程中敏感问题的差异，老专家和青年核医学工作者与陈卫教授进行了充分的辩论和交换意见。此次活动对我市核医学的发展及对外交流具有积极的意义。</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009820104836585.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">（中华核医学专业网）</font></p>', '2009-09-29 14:50:03', 93),
(44, '西门子研制出20层configuration CT', '<font face="Verdana" size="2">西门子公司日前研制出一种新型CT辐射剂量低、尺寸新型、空间适中，几乎可以对所有类型的病人进行检查。 <br />\r\n　　西门子公司在在美国明尼阿波利斯诊断成像中心第一次安装了Somatom Definition AS20 层 CT 。副总裁Patricia Zadra表示：“Somatom20层螺旋CT符合我们一贯承诺，即不断为患者和医生提供高质量的图像和服务。除了降低了辐射剂量，该系统的可两侧性也增加了我们的业务量。我们现在非常容易地将我们的CT功能升级，满足不断增加的高质量成像的需求。”<br />\r\n　　Somatom AS通过增加20层成像，七十八厘米的跨度，可以对体重300公斤的病人高速扫描，可以说专为高大病人肥胖研制。除了形态学成像，通过独特的自适应四维螺旋模式，该系统可以提供大脑灌注成像和其他器官成像，覆盖范围达7厘米。 <br />\r\n　　该系统满足医院的工作流程和临床需要，除了它的大口径和高容量，该技术还具有动态方式，如大容量的覆盖范围，200厘米的扫描范围和高达330毫秒每圈的扫面速度。这些功能表示即使遇到最有挑战性的临床患者（如创伤患者）也能进行迅速从头到脚成像。该Definition AS也可在40层、 64层和128层作为补充配置。可以现场升级到其他配置，极少停机。这使得该技术能够满足各种医疗机构的需要，同时最大限度地减少停机时间和收入损失。<br />\r\n（科讯网）</font>', '2009-09-29 14:51:50', 80),
(45, 'GE在苏黎世安装首台Discovery NM/CT 570c', '<p><font face="Verdana" size="2">GE installs first Discovery SPECT/CT<br />\r\nBy AuntMinnie.com staff writers<br />\r\nAugust 11, 2009</font></p>\r\n<p><font face="Verdana" size="2">GE Healthcare of Chalfont St. Giles, U.K., has completed the first installations of its new cadmium zinc telluride-based SPECT/CT nuclear cardiology camera, Discovery NM/CT 570c.</font></p>\r\n<p><font face="Verdana" size="2">The cameras were installed at Rambam Medical Center in Haifa, Israel, and University Hospital Zurich in Switzerland. </font></p>\r\n<p><font face="Verdana" size="2">The system is designed to perform a complete cardiac scan in less than five minutes of acquisition time, including myocardial perfusion imaging, attenuation correction, CT angiography, and calcium scoring.<br />\r\n（中华核医学专业网）</font></p>', '2009-09-29 14:52:16', 84),
(46, '2009年国家自然科学基金(核医学C100703)中标项目', '<p><font face="Verdana" size="2">项目批准号/申请代码<br />\r\n项目名称<br />\r\n项目负责人<br />\r\n依托单位<br />\r\n批准金额（万元）<br />\r\n项目起止年月</font></p>\r\n<p><font face="Verdana" size="2">30970857/C100703<br />\r\n&nbsp;寡核苷酸适配子介导反基因放射治疗前列腺癌的实验研究<br />\r\n&nbsp;张勇<br />\r\n&nbsp;中山大学<br />\r\n&nbsp;30 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30900375/C100703<br />\r\n&nbsp;分子显像无创监测MLC-2v为启动子的双基因重组腺病毒靶向治疗心肌缺血的实验研究 <br />\r\n&nbsp;张淼<br />\r\n&nbsp;上海交通大学<br />\r\n&nbsp;19<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30900377/C100703<br />\r\n&nbsp;新型分子影像探针的设计、合成及其在细胞凋亡研究中的应用<br />\r\n&nbsp;曾文彬<br />\r\n&nbsp;中南大学<br />\r\n&nbsp;20 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970847/ C100703<br />\r\n&nbsp;放射性同位素测量miRNA在肿瘤的表达及SPECT显像研究<br />\r\n&nbsp;杨卫东 <br />\r\n&nbsp;中国人民解放军第四军医大学<br />\r\n&nbsp;32<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970852/ C100703<br />\r\n&nbsp;18F-FDG PET/CT 心肌"缺血记忆"显像的实验研究<br />\r\n&nbsp;杨敏福<br />\r\n&nbsp;中国医学科学院 <br />\r\n&nbsp;8 2010-01至2010-12</font></p>\r\n<p><font face="Verdana" size="2">30970854/ C100703 <br />\r\n&nbsp;肺腺癌血管特异性分子表达谱的研究<br />\r\n&nbsp;王自正<br />\r\n&nbsp;南京医科大学<br />\r\n&nbsp;8 <br />\r\n&nbsp;2010-01至2010-12</font></p>\r\n<p><font face="Verdana" size="2">30930030/ C100703<br />\r\n&nbsp;integrin αvβ3 阳性肿瘤的分子显像与放射靶向治疗<br />\r\n&nbsp;王凡<br />\r\n&nbsp;北京大学<br />\r\n&nbsp;185 <br />\r\n&nbsp;2010-01至2013-12</font></p>\r\n<p><font face="Verdana" size="2">30970846/ C100703<br />\r\n&nbsp;188Re联合肿瘤血管靶向生物制剂NGR-VEGI协同杀伤肿瘤的实验研究<br />\r\n&nbsp;汪静 <br />\r\n&nbsp;中国人民解放军第四军医大学<br />\r\n&nbsp;35<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970859/ C100703 <br />\r\n&nbsp;靶向结核杆菌细胞壁ManLAM的多肽型显像剂，用于鉴别诊断结核病灶与肿瘤病灶的实验研究<br />\r\n&nbsp;唐恭顺 <br />\r\n&nbsp;四川大学<br />\r\n&nbsp;32<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970856/ C100703<br />\r\n&nbsp;恶性肿瘤细胞凋亡新型小分子PET显像剂的研制<br />\r\n&nbsp;唐刚华<br />\r\n&nbsp;中山大学<br />\r\n&nbsp;30 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970851/ C100703<br />\r\n&nbsp;重组肿瘤抑素肽T7-NGR融合蛋白及其放射受体显像剂的研究<br />\r\n&nbsp;宋娜玲<br />\r\n&nbsp;中国医学科学院 <br />\r\n&nbsp;8<br />\r\n&nbsp;2010-01至2010-12</font></p>\r\n<p><font face="Verdana" size="2">30900376/ C100703<br />\r\n&nbsp;核因子κB在甲状腺癌核素治疗耐药机制和治疗中的作用<br />\r\n&nbsp;孟召伟<br />\r\n&nbsp;天津医科大学<br />\r\n&nbsp;20 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30900374/ C100703<br />\r\n&nbsp;靶向人端粒酶催化亚单位（hTERT）基因显像与治疗研究<br />\r\n&nbsp;刘萌<br />\r\n&nbsp;北京大学<br />\r\n&nbsp;21 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970842/ C100703<br />\r\n&nbsp;p53基因介导糖酵解促细胞存活或凋亡的差异性研究<br />\r\n&nbsp;刘建军<br />\r\n&nbsp;上海交通大学<br />\r\n&nbsp;27 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970850/ C100703<br />\r\n&nbsp;甲亢与脑多巴胺系统关系的核医学分子影像学研究<br />\r\n&nbsp;林岩松<br />\r\n&nbsp;中国医学科学院<br />\r\n&nbsp;33 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970843/ C100703<br />\r\n&nbsp;肿瘤干细胞体内可视化研究及核素治疗初探<br />\r\n&nbsp;李少林<br />\r\n&nbsp;重庆医科大学<br />\r\n&nbsp;29 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970853/ C100703 新型报告基因系统 hERL-FES PET/CT显像监测心肌缺血细胞/基因联合治疗的实验研究<br />\r\n&nbsp;兰晓莉<br />\r\n&nbsp;华中科技大学<br />\r\n&nbsp;8 <br />\r\n&nbsp;2010-01至2010-12</font></p>\r\n<p><font face="Verdana" size="2">30900378/ C100703<br />\r\n&nbsp;放射性核素188Re标记新型水溶性卟啉化合物对肿瘤靶向显像和靶向治疗的基础研究 <br />\r\n&nbsp;贾志云<br />\r\n&nbsp;四川大学<br />\r\n&nbsp;18<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30900373/ C100703<br />\r\n&nbsp;整合素受体介导Re-188标记的新型多肽分子探针用于肿瘤显像与治疗实验研究<br />\r\n&nbsp;贾兵 <br />\r\n&nbsp;北京大学<br />\r\n&nbsp;19<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970848/ C100703<br />\r\n&nbsp;多肽VEGF125-136的改造及其核素靶向双效抗肿瘤作用的实验研究<br />\r\n&nbsp;黄定德 <br />\r\n&nbsp;中国人民解放军第三军医大学<br />\r\n&nbsp;33<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970849/ C100703<br />\r\n&nbsp;干细胞调节心肌细胞代谢的分子显像研究<br />\r\n&nbsp;何作祥<br />\r\n&nbsp;中国医学科学院<br />\r\n&nbsp;30 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970855/ C100703<br />\r\n&nbsp;探讨125I-AFPasON增效siRNA沉默靶基因的RNAi方法<br />\r\n&nbsp;程木华<br />\r\n&nbsp;中山大学 <br />\r\n&nbsp;32<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970844/ C100703<br />\r\n&nbsp;氟[18F]标记的DTBZ衍生物的合成及用于囊泡单胺转运体显像的实验研究<br />\r\n&nbsp;陈正平 <br />\r\n&nbsp;江苏省原子医学研究所<br />\r\n&nbsp;33<br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970858/ C100703<br />\r\n&nbsp;SPECT-MRI脱氧葡萄糖双功能显像剂的实验研究<br />\r\n&nbsp;陈跃<br />\r\n&nbsp;泸州医学院<br />\r\n&nbsp;30 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">30970845/ C100703<br />\r\n&nbsp;microRNA-1对人胚胎干细胞心肌分化调控的分子影像研究<br />\r\n&nbsp;曹丰 <br />\r\n&nbsp;中国人民解放军第四军医大学<br />\r\n&nbsp;33 <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font face="Verdana" size="2">以下两项是申请代码为C171009（肿瘤分子靶向治疗）的核医学相关项目</font></p><font face="Verdana">\r\n<p><font size="2">30973481/C171009&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n&nbsp;联合188Re和/或siRNA的适配子靶向治疗胶质瘤的实验研究&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n&nbsp;张兴梅&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n&nbsp;南方医科大学&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n&nbsp;30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n&nbsp;2010-01至2012-12</font></p>\r\n<p><font size="2">30901770/C171009 <br />\r\n&nbsp;125I-PQ3增强TFO对人肝癌细胞生长抑制效应的实验研究<br />\r\n&nbsp;侯敏<br />\r\n&nbsp;同济大学<br />\r\n&nbsp;20<br />\r\n&nbsp;2010-01至2012-12<br />\r\n（中华核医学专业网）</font></p></font>', '2009-09-29 14:53:11', 111),
(47, '中华医学会核医学分会第四届中日韩核医学大会暨2009年全国PET(/CT)读片会及学术研讨会成功召开', '<p><font face="Verdana" size="2">由中华医学会核医学分会主办、PET及分子显像学组承办的第四届中日韩核医学大会暨 2009年全国PET(/CT)读片会及学术研讨会于2009年9月在海滨之城山东省青岛市成功举行。这次大会，是继2009年5月中华医学会核医学分会第八届全国核医学学术交流会之后的又一次成功的学术活动之典范，是中日韩核医学界的交流平台，是对国内PET(/CT)及分子显像技术、学术工作的回顾、肯定、总结，也是对国内PET(/CT)，乃至全体核医学工作者的相互交流、共同进步、展望未来的良机。<br />\r\n　　本次会议邀请了国内外专家就 PET(/CT)及分子显像领域进行了专题报告，内容涉及广泛，不仅包括国内外的最新科研进展，还包括实用性极强的读片技巧等，令与会代表受益匪浅。同时经专家委员会评选出优秀病例、优秀壁报奖项，令与会者有极强互动性的思辨奖和壁报病例PET/CT诊断竞赛优胜奖，以及充满趣味性的由中华医学会核医学分会青年委员学组承办的青年读片竞赛奖项，并予以奖励。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009924105545124.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/200992410562645.jpg" border="0" />\r\n</p><font face="Verdana"></font>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 田嘉禾教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105644132.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;匡安仁教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105711741.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 李亚明教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105731331.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;李方教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105752949.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 赵军教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105812487.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 李立伟教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105834429.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 朱朝晖教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105857625.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hee-Seung_Bom教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105916318.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Keigo_Endo教授</font></font></p>\r\n<p align="center"><font face="Verdana"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924105946518.jpg" border="0" />\r\n</font></p>\r\n<p><font face="Verdana"><font size="2">　　现场国内外专家与代表200余人欢聚一堂，共同研讨PET(/CT)及分子显像领域的进展，交流经验，呈现出一派和谐的景象。</font></font></p>\r\n<p><font face="Verdana"><font size="2">（中华核医学专业网）</font></font></p>', '2009-09-29 14:54:01', 67),
(48, '2009年青岛PET（/CT）读片会和学术研讨会评奖结果', '<p><font face="Verdana" size="2">大会发言</font></p>\r\n<p><font face="Verdana" size="2">1 优秀病例<br />\r\n一等奖：李立伟 　空军总医院<br />\r\n二等奖：尹雅芙 　中国医科大学附属第一医院<br />\r\n　　　　陈　雯 　卫生部北京医院<br />\r\n三等奖：靳晓娜 　北京协和医院<br />\r\n　　　　邵　丹　 广东省人民医院<br />\r\n　　　　陈虞梅　上海交通大学医学院附属仁济医院</font></p>\r\n<p><font face="Verdana" size="2">2 思辨奖<br />\r\n吴湖炳&nbsp;&nbsp; 南方医院<br />\r\n周&nbsp; 硕&nbsp;&nbsp; 福建省立医院<br />\r\n梁英魁&nbsp;&nbsp; 海军总医院<br />\r\n宋秀宇&nbsp;&nbsp; 天津医科大学附属肿瘤医院<br />\r\n杨&nbsp; 鹏&nbsp;&nbsp; 深圳市PET/CT中心<br />\r\n张敬勉&nbsp;&nbsp; 河北医科大学第四医院</font></p>\r\n<p><font face="Verdana" size="2">壁报</font></p>\r\n<p><font face="Verdana" size="2">1 优秀壁报<br />\r\n赵　葵&nbsp;&nbsp; 浙江大学医学院附属第一医院<br />\r\n田　野&nbsp;&nbsp; 四川大学华西医院<br />\r\n钟尉端&nbsp;&nbsp; 卫生部北京医院</font></p><font face="Verdana"></font>\r\n<p><font face="Verdana"><br />\r\n<font size="2">2 壁报病例PET/CT诊断竞赛优胜奖<br />\r\n王　欣&nbsp;&nbsp;&nbsp; 哈尔滨肿瘤医院<br />\r\n李文婵&nbsp;&nbsp;&nbsp; 卫生部北京医院<br />\r\n曲莉莉&nbsp;&nbsp;&nbsp; 齐鲁医院<br />\r\n王建方&nbsp;&nbsp;&nbsp; 河北医科大学第四医院<br />\r\n董孟杰&nbsp;&nbsp;&nbsp; 浙江大学医学院附属第一医院<br />\r\n梁英魁&nbsp;&nbsp;&nbsp; 海军总医院<br />\r\n赵新明&nbsp;&nbsp;&nbsp; 河北医科大学第四医院<br />\r\n赵晋华&nbsp;&nbsp;&nbsp; 上海市第一人民医院<br />\r\n张雯杰&nbsp;&nbsp;&nbsp; 中国医学科学院肿瘤医院<br />\r\n宋建华&nbsp;&nbsp;&nbsp; 上海市第一人民医院<br />\r\n&nbsp;<br />\r\n青年读片竞赛参赛：</font></font></p>\r\n<p><font face="Verdana"><font size="2">一等奖：上海队&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n市一医院 宋建华<br />\r\n肿瘤医院 杨忠毅<br />\r\n瑞金医院 徐昊平<br />\r\n仁济医院 陈虞梅<br />\r\n二等奖：北京队<br />\r\n海军总医院 梁英魁<br />\r\n宣武医院 苏玉盛<br />\r\n北京医院 陈&nbsp; 雯<br />\r\n医科院肿瘤医院 张雯杰<br />\r\n解放军总医院 关志伟<br />\r\n三等奖：东北队<br />\r\n哈尔滨肿瘤医院 王&nbsp; 欣<br />\r\n吉林大学第一医院 赵红光<br />\r\n黑龙江农垦医院 张嘉文<br />\r\n中国医大一附院 李雪娜</font></font></p>\r\n<p><font face="Verdana"><font size="2">优秀奖：<br />\r\n中部西部队&nbsp; <br />\r\n四军医大西京医院 王胜军<br />\r\n华西医院 苏鸣岗<br />\r\n内蒙古医学院 张国建<br />\r\n武汉协和医院 魏&nbsp; 昊</font></font></p>\r\n<p><font face="Verdana"><font size="2">华东华北队<br />\r\n南京军区总医院 吴&nbsp; 江<br />\r\n福建省立医院 周&nbsp; 硕<br />\r\n烟台毓璜顶医院 徐志英<br />\r\n天津医大肿瘤医院 宋秀宇<br />\r\n河北医大四院 张敬勉</font></font></p>\r\n<p><font face="Verdana"><font size="2">广州队<br />\r\n中山大学第一医院 王晓燕<br />\r\n广州医学院附一院 陈仰纯<br />\r\n广东省人民医院 王思云<br />\r\n中山大学肿瘤医院 张&nbsp; 旭<br />\r\n（中华核医学专业网）<br />\r\n</font>&nbsp;</font></p>', '2009-09-29 14:54:47', 87),
(49, '国际原子能机构PET临床应用质量管理培训班在京成功举办', '<p><font face="Verdana" size="2">根据国际原子能机构（IAEA）技术合作项目的安排并与中国国家原子能机构商定，IAEA 正电子发射断层（PET）临床应用质量管理培训班（Quality management of Clinical Practice of PET）于2009年8月31日至9月4日在北京长安大酒店举办。中国医学科学院肿瘤医院为IAEA及中国国家原子能机构确定的承办单位，该院核医学科陈盛祖教授为培训班班主任。<br />\r\n　　培训班学员及教师来自13个国家，30余人，培训班历时5天，授课24节，参观4家医院及工厂。中国医学科学院肿瘤医院院长赵平教授在开班仪式上致欢迎辞，北京医院王院长在参观北京医院时致辞。我国PET-CT专家陈盛祖、田嘉禾、何作祥、李立伟、姚稚明、吴宁、郑容教授参与了授课。授课内容集中在PET/CT在肿瘤中的应用、病例阅读及讨论、质量管理及PET/CT检查的规范化。</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/200992411351630.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/20099241144761.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">　　学员对日程安排、授课内容及老师的演讲给予了充分的肯定和赞扬，收获很大，对北京印象很深。</font></p><font face="Verdana" size="2">\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/200992411422781.jpg" border="0" />\r\n</p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/200992411435467.jpg" border="0" />\r\n<br />\r\n</p>\r\n<p align="left">（中华核医学专业网）</p></font>', '2009-09-29 14:55:33', 75),
(50, '全国PET-CT（PET）配置、使用情况调查报告', '<p><font face="Verdana" size="2">2009年6月，中华医学会核医学分会受国家卫生部规划财务司的委托，对全国（不包括港澳台）的PET-CT（含PET和医用回旋加速器）的配置使用情况进行了一次调查。现将情况汇报如下。</font></p>\r\n<p><font face="Verdana" size="2">一、调查的一般情况<br />\r\n1. 调查的工作安排<br />\r\n　　获知卫生部规财司的委托意向后，中华医学会核医学分会（以下简称学会）立即通知了全体常委和各省市自治区核医学分会（以下简称分会）主任委员，并在主要设备厂家的配合下，整理出各厂家在各地的装机名单，先期通过电子邮件发给各分会进行核实。<br />\r\n2. 数据的收集与核实<br />\r\n　　6月10日收到规划司的正式函件，调查工作自6月12日启动。学会建议填表人原则上由非本单位人员负责。考虑到部分省区不同使用单位在不同城市，可以由各省市自行决定填表人，学会负责差旅费。要求所填调查表需经各省区主委核实、签名后统一集中；调查期间，学会对各省区报来的数据及时核对，凡缺项或有疑问处，均经电话核实。对个别因种种原因没有按时上报调查结果的省区均及时提醒、督促。在全国各相关省区分会、各使用单位的大力配合下，至6月25日晨，本次调查发出的114份调查表全部收回。<br />\r\n3. 调查工作总体情况<br />\r\n　　(1)本次调查中，各地分会和各使用单位均给予了高度支持和配合。除2家单位不愿提供数据，另一单位原PET-CT引进计划改变外，目前学会掌握的其他所有使用单位的数据均较完整地收集到位。<br />\r\n　　(2)从统计结果结合学会掌握的信息判断，个别数据，特别是涉及使用范围、管理模式等方面的数据，个别单位可能没有完全据实报送。因此，这些数据的统计和引用应有所保留。<br />\r\n二、调查结果<br />\r\n1. 全国PET-CT配置情况<br />\r\n　　(1)此次调查，共涉及到115个单位的PET/CT数据调查表。其中，2007年12月底前安装使用的PET/CT共87个单位89台，分布于24个省市自治区；2008年装机单位8台；2009年即将装机20台；1台情况不明。<br />\r\n　　本次调查未包括港澳台地区；未包括使用二手设备的个别单位；国产设备（亿仁公司PET）因没有正式供货信息，学会不掌握其供应、使用单位情况，没有包括在统计之内。<br />\r\n　　2009年卫生部大型设备集中采购共21台PET-CT和10台加速器，部分单位无具体采购信息，部分内容未纳入本次调查统计。<br />\r\n　　(2)按目前安装（或即将安装）PET/CT台数排序：北京23台，广东14台，上海10台；详细配置情况请见附件1。<br />\r\n　　(3)PET-CT厂家配置台数排序：通用电器（GE）：58台（包括64排VCT 5台，16排STE 10台，16排ST 18台，8排ST 6台，4排ST 4台，16排LS 2台，8排LS 3台，4排LS 10台）。西门子：43台(包括64层HD 3台，64层52环 3台，64层39环 5台，40层39环 2台，16层39环 21台，2排 3台，单纯PET 6台)。飞利浦：16台（包括64排TOF 1台，16排TOF 1台，16排8台，2排 1台，C-PET 5台）。<br />\r\n　　(4)加速器配置：GE：35台；西门子：17台；住友：9台；IBA：2台；EBCO：2台。<br />\r\n2. 全国PET-CT使用情况<br />\r\n　　(1)管理运行模式：PET-CT由医院管理占76.6％，医院和投资方合作管理占22.5％，合作方管理占0.9%；隶属核医学科占55.0％，隶属放射科占10.8％，独立PET-CT中心占34.2％。<br />\r\n　　(2)2008年全国PET-CT检查总数：11.59万例；平均单台设备检查：1348.4例。年检查例数1000以上46家（53.9％），年检查量低于400例的单位10家（12%）。<br />\r\n　　(3)2009年PET/CT平均开机：4.31天/周；其中每周开机5天以上的占51.0％，开机4天的占20.4％，开机3天以下的占28.6％。较高的单一月份PET-CT检查量平均为163.3例（4～5月份）；较低的单一月检查量平均为82例（1月份，春节长假）。<br />\r\n　　(4)PET-CT工作内容：肿瘤学检查73.9％，心血管检查1.3％，神经系统检查3.7％，查体18.5％，其他2.6％。其中查体比例最高者：100％。受检者来源分布：门诊患者占41.2％，住院患者37.8%，外单位介绍21.0％。<br />\r\n　　(5)在2007年前装机单位中，近年PET-CT检查工作量上升的单位76个（88.37％），工作量下降单位4个（4.65％），持平单位6个（6.98％）。<br />\r\n　　(6)PET-CT检查收费：全身检查平均收费：8826元，局部检查平均收费：6020元；最高收费：全身13000元，局部11640元；最低收费：全身6370元，局部3500元。除4家医院外，PET-CT的同机CT检查，均未另加收费用。<br />\r\n　　(7)医疗保险复盖：目前国内有6家PET-CT全部费用进入医保，主要分布于深圳、黑龙江和湖南省；6家单位检查显像剂（药费）部分进入医保，主要分布于北京、辽宁和山东。<br />\r\n　　(8)临床医生与患者对PET-CT的认可情况：认可或非常认可者占绝大多数，没有负面反应。目前社会和临床上对PET-CT使用反映最多的问题包括：检查价格贵，不能报销；存在部分假阳性或假阴性结果；部分临床医生对PET-CT的期望值不客观等。<br />\r\n三、调查结果的初步解读<br />\r\n1. 国内PET-CT技术的需求在不断增加。<br />\r\n　　北京医院曾对2006年6~8月国内10家三甲医院工作进行抽样调查，与相比，本次调查显示：月平均检查量从120.72例（110.66~130.78）上升为163.3例（考虑到前次抽查均为大医院且选择工作量较高的月份，这一增长幅度还是很有意义的）；年均检查量超过 1000例的单位比例由不足1/3增加到53.9％；月检查例数超过100例的单位从20.0％增加到59.8％。同时，体检所占工作量比重由32.9％下降到18.5％。<br />\r\n2. 国内PET-CT使用情况的发展极不平衡。2008年全国PET-CT单机最高检查量与最低检查量间相差75倍。即使是同类医疗单位、同种机型、相似工作条件，工作量的差别也达3倍以上<br />\r\n3. 国内PET-CT技术发展的几个特点<br />\r\n　　(1)地区：目前PET-CT工作状态好的地区，除北京、上海、广东、江苏等传统经济发达地区外，黑龙江、辽宁、浙江、湖北、湖南、安徽及新疆的使用情况也相对较好。但同一地区不同单位的使用情况差距较大。同时，需要进一步研究的是，5家年工作量最低的单位中，3家来自相对发达地区（深圳、上海）。<br />\r\n　　(2)单位：大型综合性医院与肿瘤专科医院的工作量差别不明显。总体上看，医院的学术地位与PET-CT使用量之间有联系，越有影响的单位，PET-CT使用情况越好。但也有例外。<br />\r\n　　(3)医保：无论医院大小、性质，凡有医保支持的单位，PET-CT的使用情况均较好。<br />\r\n　　(4)市场行为：由于市场运作多不公开，本次调查未能得到市场运作对PET-CT工作量的情况的真实数据。据了解，至少部分单位有不同程度的市场运作行为，一些单位的工作量增长与市场行为的参预直接相关。然而，即使在有市场行为的PET-CT中心，至少部分患者的PET-CT检查是正当和必要的，而且得益于市场运作中的学术方面的宣传。当然，肯定有部分检查不是PET-CT适应证，如何规范市场行为应该引起高度重视。<br />\r\n　　(5)加速器和PET- CT配置比例：根据国外资料和对加速器功能的分析，PET-CT与加速器配置的合理比例应该在4:1 ~ 6:1左右。而目前国内此比例约为1.82:1。这种失当的配置比例无疑会造成资源的巨大浪费。而同时，由于政策限制和资源共享困难等因素，没有加速器的 PET-CT单位，常因药品供应问题而影响正常使用和技术发展，进而刺激了加速器的购置需求。<br />\r\n4. 使用单位对卫生行政主管部门的建议<br />\r\n　　PET-CT使用单位对管理部门的建议，按提出的频度依次为：尽快解决有条件、有控制的医保复盖；明确适应证、合理定价，限制不正当竞争和滥用；在合理增加配置额度基础上加强宏观配置管理；加强对加速器的配置管理、合理使用与医疗单位间药物配送的政策引导；加强质量控制与规范化使用方面的引导；强化技术准入、培训与规范化方面的管理等。 </font></p>', '2009-09-29 14:56:10', 256),
(51, '北美放射学会年会重申放射剂量对病人安全性', '<font face="Verdana" size="2">放射科医生最近报告说，影像学检查是美国电离辐射照射的主要来源，而且重复检查可导致高辐射剂量累积。 <br />\r\n　　在2009年8月27日举办的北美放射学会年会上重申要着重考虑剂量对病人安全的承诺，研究结果刊登在新英格兰医学上（NEJM）。 <br />\r\n　　美国埃默里大学医学院伊朗泽勒博士和同事以医疗机构的研究为基础撰写了这份报告；预防和人口科学和心血管疾病的司主任，心脏病专家迈克尔劳尔博士在新英格兰医学杂志陈述了同样的问题。 <br />\r\n　　在放射学科领域中，绝大多数专家一致认为，成像过程有一定的风险，但适当的利用低剂量，并对病人的使用剂量加以追踪记录，潜在的好处是远远超过风险的。 <br />\r\n　　放射科医师、医疗物理学家和其他放射专业人士早就认识到放射成像应该在最有有需要的领域使用，认真贯彻电离辐射的使用标准。 <br />\r\n　　除了适当的成像遵循严格的使用标准，放射诊断和医疗物理学家共同努力，改善成像检查的安全性，最大限度地减少使用剂量并提高诊断能力。他们直接参与的技术和协议的发展，以确保医疗成像情况下病人的安全。放射科学家与制造商紧密合作，以降低辐射剂量，而不会失去的图像质量。 <br />\r\n　　为了提高累积剂量和其他辐射风险和寻求机会，以改善患者安全意识，北美放射学会已与美国放射学院创建ACR/RSNA，并于2007年推出的小儿患者安全影像。 <br />\r\n　　累积剂量的风险仍然是一个重大关切，相关程序正在开始追踪个别病人的医疗成像过程及其相关的辐射剂量。美国国立卫生研究院放射学和影像临床中心研究所最近公布的计算机断层扫描（CT）和正电子发射断层扫描（PET）/ CT临床中心将病人通常在医院辐射剂量暴露在电子病历中记录。这是一个重要的步骤，以确保影像学检查期间病人暴露于电离辐射的安全性。 <br />\r\n　　医学影像检查是诊断和治疗病人的宝贵工具，放射专家将继续努力改善这些检查措施的安全性。<br />\r\n（科讯网）</font>', '2009-09-29 14:59:52', 78);
INSERT INTO `yiliao_active` (`id`, `name`, `content`, `add_time`, `click`) VALUES
(52, '我国高端医疗装备研制取得重大突破—16层CT、1.5T超导磁共振在东软问世', '<p><font face="Verdana" size="2">16层CT、1.5T超导磁共振在东软问世，<br />\r\n向全球领先的医疗设备、医疗IT解决方案及健康服务提供商迈进</font></p>\r\n<p><font face="Verdana" size="2">　　8月28日，东软医疗系统有限公司（以下简称“东软医疗”）举行了主题为“创新·挑战·超越”的公司战略及新产品发布会，正式向全球发布其三款旗舰新品NeuViz 16多层螺旋CT、Sparkler 1.5T超导磁共振成像系统、Neulife直线加速器治疗系统，这标志着东软在CT、MRI以及治疗系统等高端医疗设备的研制与生产方面取得了新的重大突破。其中，NeuViz 16多层螺旋CT和Sparkler 1.5T超导磁共振成像系统的成功研制再次填补中国在该领域的空白，打破跨国公司多年来对中国和全球市场的垄断，中国也因此跻身到全球高端医疗设备生产国的行列。<br />\r\n　　东软医疗在发布3款旗舰新品的同时，还首次发布公司新的定位、愿景与使命。2009年伊始，东软集团着手对东软医疗业务进行重组和整合，先后将医疗软件事业部和健康服务业务并入东软医疗公司。如今，东软医疗公司业务定位为三个部分：大型或高附加值医疗设备产品与服务、医疗IT解决方案以及健康服务；东软医疗公司的愿景与使命是致力于成为全球领先的医疗设备，医疗IT解决方案及健康服务提供商，并通过医疗设备与IT技术的创新，服务于人类的健康。</font></p>\r\n<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924135912894.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">　　沈阳市副市长邹大挺，沈阳浑南新区管委会主任黄凯等省市政府和有关部门领导，行业知名专家，国内外客户以及新闻媒体记者约700余人出席了东软医疗战略及新产品发布会，共同见证了东软医疗三款新品的闪亮登场和公司战略愿景的发布。<br />\r\n　　东软集团副总裁、东软医疗系统有限公司总裁江根苗在致辞中表示，从医院临床应用的发展趋势来看，16层CT和1.5T磁共振成像系统将成为今后高端医疗器械领域的主导机型，而我国的这一领域却长期被国际厂商所垄断。作为国内唯一的CT厂商，东软医疗16层CT的研制成功不仅打破了国际垄断、填补了中国在多层螺旋CT市场的空白，而且其首台产品已经出口美国，这标志着东软16层CT产品已经成功进入全球高端医疗市场。<br />\r\n　　据了解，东软医疗 NeuViz 16多层螺旋CT以博采众长的技术特征、至臻的诊断效率、至善的患者关爱和高性价比的维护成本，实现了CT常规从形态学检查到功能性成像的飞跃，大幅缩短了中国CT技术与国际先进CT技术的差距。东软医疗Sparkler 1.5T超导磁共振成像系统的问世也同样打破了我国高场磁共振技术领域被外资企业垄断的局面。Sparkler1.5T超导磁共振基于临床实用性超导磁共振的定位，具有技术成熟、性能稳定和性价比高等特点，并以其高效快速的SENSE技术，强大的临床应用广受好评。有专家表示Sparkler 1.5T超导磁共振成像系统的推出将为医院磁共振的临床应用开展、医院医学影像的发展带来更加广阔的前景。<br />\r\n　　此外，Neulife直线加速器治疗系统是东软医疗面向广大医疗机构对肿瘤治疗的需求而研发的临床实用型数字化医用直线加速器，它的问世也标志着东软医疗正式进入放射治疗领域。随着该款直线加速器的推出，东软第一个面向基层的放疗解决方案应运而生——由CT模拟定位系统、治疗计划系统和加速器治疗系统组成的临床实用型流程方案既满足精确放疗的要求又便于放疗的普及推广。在此基础上，东软医疗还将提供EPID影像验证，动态楔形治疗以及行业放疗信息管理系统和肿瘤科管理系统，东软医疗的放疗解决方案将引领中国放疗行业尤其是基层放疗的技术应用达到新的高度。<br />\r\n　　东软集团董事长兼CEO刘积仁博士在讲话中表示，在国家、省、市各级领导的亲切关怀和大力支持下，12年来，东软医疗以“科技创造健康生活”的理念，不断创新、不断跨越，获得了快速发展。面向未来，随着信息技术、网络技术、医学影像学、医药学和数字化医疗设备之间的不断融合、优势互补，将使临床治疗达到新的水平，一方面现代大型医疗器械越来越向智能化方向发展，另一方面整个医疗模式将由过去单纯的医院内诊治为主的模式逐步发展为院前急救、临床诊治和康复保健结合的社区医疗、家庭护理的多元化的现代医疗保障体系，医疗IT和健康服务将成为医疗行业新的增长点。为了迎接这样一个全新时代的到来，东软已经整合全集团所有医疗行业的业务资源，确定了东软医疗新的业务定位与发展目标。我们希望通过3-5年的持续创新与不断努力，将东软医疗打造成为全球领先的医疗设备、医疗IT解决方案与健康服务的供应商。<br />\r\n　　刘积仁表示，东软在大力发展行业解决方案与服务外包产业的同时，将加大对发展医疗业务的投入，使医疗业务很快成为东软集团核心业务支柱并保持高速成长。与此同时，公司还将通过不断构建与加强市场能力、研发能力、运营能力；持续开发人力资源；深入理解与挖掘客户需求，以创新思维设计和开发具独特优势的解决方案与服务；不断提高运营速度和效率, 持续构建成本优势；不断提升技术核心能力与创新速度；坚持全方位的持续的质量改进，从而打造东软医疗的产品与服务品牌。<br />\r\n　　沈阳市副市长邹大挺在讲话中表示：在PET研制成功之后短短3个月的时间里，东软又推出了“16排CT、超导磁共振、直线加速器”三款高端新品，这是中国企业在高端医疗产品领域取得的重大突破，体现了东软医疗不断创新和开拓进取的精神。在当前全球金融危机的背景下，东软这种逆势而上的发展势头，已成为推进东北老工业基地振兴的重要力量，为中国的医疗健康产业做出了突出贡献，这是沈阳人的骄傲！他希望东软能够继续坚持科技创新和国际化发展的理念，不断研制和推出更多、更先进并且更加适用的高端医疗产品与服务，惠及民生，让百姓受益于中国的高科技产品与服务。<br />\r\n　　中国是一个拥有13.5亿人口的大国，医疗设备需求庞大，是世界上最大的普及型医疗器械市场，而长期以来我国高端医疗设备主要依赖进口。专家认为，东软医疗在CT、MRI、PET高端医疗设备方面获得的突破，将打破我国高端设备长期被国外厂商垄断的市场格局，并推动高端医疗设备更广泛地应用于临床诊断，使得高端医疗设备服务百姓，惠及民生成为现实。<br />\r\n（科讯网）</font></p>', '2009-09-29 15:01:02', 70),
(53, '厦门市第一医院举行双源CT等大型影像设备开机典礼', '<font face="Verdana" size="2">8月29日，双源CT等大型影像设备开机典礼暨福建省影像学新进展研讨会在厦门市第一医院隆重举行。厦门市人大常委会副主任曾国玲出席了典礼。<br />\r\n&nbsp;&nbsp; 　专程来厦祝贺的中华医学会放射学分会主委郭启勇评价说，厦门市第一医院此次启用的双源CT、3T磁共振、双板DSA均是目前国内最先进的医疗设备，可以在更短的时间内提供更精确详细的检查，使病变的显示率和诊断精确度明显提高，为介入治疗开拓了许多新的应用领域。以双源CT为例，它的辐射量只有常规CT 的50%，最大限度地保护了患者的健康和安全；它还可用于早期无创筛查冠心病，其成像成功率是传统CT无可比拟的。而3T磁共振是目前场强最高的磁共振，以前磁共振扫描脑部需20多分钟，3T磁共振则只需5分钟。<br />\r\n&nbsp;&nbsp; 　据悉，厦门市第一医院筹资引进的双源CT、3T磁共振、双板DSA这3个医疗设备均是闽南惟一的。院长杨叔禹表示，该院引进这些设备是为了进一步加快学科建设、提高医疗水平，随着这些设备的启用，该院的综合实力将大大增强，可以更好地满足厦门及周边地区百姓疑难病症检查治疗的需求。<br />\r\n（科讯网）</font>', '2009-09-29 15:01:27', 77),
(54, '内蒙古医学院附属医院引进PET-CT等重要影像设备', '<p align="center"><img src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/2009924141310367.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp; 8月28日上午，具有国际先进水平的PET-CT、3.0TMRL和64排CT在内蒙古医学院附属医院正式开机，这对于提高内蒙古医疗设备水平，更好的服务内蒙古人民提供了可靠的技术支持。<br />\r\n　　PET-CT是目前世界上灵敏度最高、采集速度最快、注射计量最低的分子影像诊断设备，也是临床应用中最佳的分子影像设备。PET-CT的引进也填补了内蒙古缺少高端检查设备方面的空白。GE公司的64排CT、3.0TMRL同样以无创、高效、精确、立体的医学影像技术，为临床提供了更好、更多、更准确的图像，解决了以往一些医学难题，取代了一些有创的检查手段。 <br />\r\n　　据了解，内蒙古医学院附属医院是我国在少数民族自治区建立的第一所医院院校的附属医院，目前是内蒙古一所著名的大型综合性三甲医院。<br />\r\n（科讯网）</font></font></p>', '2009-09-29 15:01:58', 44),
(55, '卫生部称三级医院可与中介合作开展预约挂号', '早在8月5日，卫生部出台文件，就预约挂号向社会公开征求意见，其中“公立医院开展预约诊疗服务，必须按照物价管理部门和卫生行政管理部门规定的标准收取挂号费用和相关费用，不得擅自提高收费标准。公立医院不得与任何社会中介机构合作开展向患者收取费用的预约挂号服务”，引起社会争议。在最终稿中还是保留了这一提法。到底是“医院不得和中介机构合作”，还是“可以合作但不得额外收费”?昨日，记者电话咨询了卫生部医疗服务监管司(以下简称“医管司”)，得到明确答复：医院可以与第三方中介机构合作开展预约挂号，但收费不得高于物价部门规定的标准。', '2009-10-12 10:33:29', 31),
(57, '卫生部、国家发改委发布2008～2010年正电子发射型断层扫描仪配置规划', '<span><font size="+0"><font color="#222222">&nbsp;</font> \r\n<p style="text-indent:32pt;"><span style="font-size:16pt;font-family:仿宋_gb2312;">卫生部、国家发改委日前发布<span>2008</span>～<span>2010</span>年正电子发射型断层扫描仪配置规划，要求各地按照配置规划要求，认真调查辖区内正电子发射型断层扫描仪检查的合理需求，确定本区域的配置规划实施方案。<span></span></span></p>\r\n<p style="text-indent:32pt;"><span style="font-size:16pt;font-family:仿宋_gb2312;">正电子发射型断层扫描仪（<span>PET-CT,</span>含<span>PET</span>）是一种融机体功能代谢影像和解剖结构影像技术为一体的大型医用设备，在肿瘤、心脏和神经等疾病的诊断与分期、疗效评价等方面具有重要的临床价值。该设备应用技术要求高、购置价格贵、检查收费高。多年来，卫生部、国家发改委一直提倡合理配置和有效利用<span>PET-CT</span>，制止医疗机构盲目装备。<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:黑体;">　　年工作量低于千例不得添置<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">　　规划要求，配置<span>PET-CT</span>（包括配套的医用回旋加速器）以省级区域为规划单位，综合考虑人口、患病率、经济社会发展水平和区域功能定位、卫生服务能力及可及性等因素，合理确定各地配置数量。本次规划重点考虑全国性医疗服务中心、区域中心城市配置需求，兼顾配置空白地区的需要。原则上已装备<span>PET-CT</span>但年工作量低于<span>1000</span>例的区域，不得申请新增配置。本周期规划配置<span>PET-CT</span></span><span style="font-size:16pt;"><font face="宋体">&nbsp;</font></span><span style="font-size:16pt;font-family:仿宋_gb2312;">38</span><span style="font-size:16pt;font-family:仿宋_gb2312;">台，至<span>2010</span>年年底全国总体控制在<span>96</span>台以内。按照<span>1</span>台回旋加速器生产的放射性核素至少可满足<span>2</span>～<span>3</span>台<span>PET-CT</span>的工作需要，确定回旋加速器配置数量，促进资源共享。原则上除配置空白地区外，不再新增回旋加速器配置数量。<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:黑体;">　　医疗机构需具备相应资质<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">　　该规划提出医疗机构配置<span>PET-CT</span>要符合以下要求：<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">　　一、三级甲等医院或相当于三级甲等医院规模和水平的医疗机构。综合医院床位数在<span>1000</span>张以上，日门急诊量不少于<span>3500</span>人次，具有实力较强、水平较高的肿瘤科、心脏科、神经科、胸外科和影像科。肿瘤、心血管等专科医院床位在<span>500</span>张以上，日门急诊量不少于<span>800</span>人次，或年手术量不少于<span>5000</span>台。社会举办的医疗机构的床位、门急诊量、手术量等业务指标要求可略作调整。<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">　　二、与<span>PET-CT</span>应用相关学科具备较高水平的教学和科研能力。近期承担有省部级以上科研课题；在国际或国家级学术刊物上发表过有关学科基础研究和临床应用的论文。<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">　　三、设置独立的核医学科，成立时间<span>5</span>年以上，具备较高的核医学诊疗水平，装备并使用<span>SPECT</span>不少于<span>3</span>年，近<span>3</span>年每年脏器显像例数不少于<span>2000</span>人次。<span></span></span></p>\r\n<p style="text-indent:32.25pt;"><span style="font-size:16pt;font-family:仿宋_gb2312;">四、具有较高水平的核医学专业、医学工程和影像专业技术人员。学科负责人具有高级临床专业技术职称，至少具有<span>5</span>年以上核医学专业工作经验。配置回旋加速器的，还须具有较高水平的药学或放射化学专业技术人员。所有专业技术人员均须具备相应的上岗资质。<span></span></span></p>\r\n<p style="text-indent:32.25pt;"><span style="font-size:16pt;font-family:仿宋_gb2312;">五、管理制度健全，具有全面的医疗质量管理方案。<span></span></span></p>\r\n<p style="text-indent:32.25pt;"><span style="font-size:16pt;font-family:仿宋_gb2312;">六、经济运行状况良好，财政拨款或自有资金有保障。非营利性医疗机构不得以合作、贷款等融资形式购置。<span></span></span></p>\r\n<p><span style="font-size:16pt;font-family:仿宋_gb2312;">&nbsp;&nbsp; 七、符合各级卫生、环保等部门有关要求。</span></font></span></p>\r\n<p>　　2008~2010年全国正电子发射型断层扫描仪配置分省规划如下：配制量为5台的有广东省，配制量为4台的有北市，配制量为3台的有上海市、河南省，配制量为2台的有山西、吉林、江苏、浙江、山东、四川，配制量为1台的有天津、黑龙江、安徽、福建、北、海南、重庆、贵州、西藏、青海、宁夏。</p>', '2009-11-10 09:19:41', 54),
(58, '2009湖北省核医学学术年会在十堰市召开 ', '湖北省核医学会<span>2009年学术年会于2009年11月6-8日在车城十堰市召开。来</span>自全省各医疗、教学及科研单位的核医学工作者代表共 60 余人代表参加了本次学术活动。会议由由武汉大学人民医院核医学科陈辉霖主任主持。\r\n<p>　　会议首先由湖北省医学会核医学会主任委员安锐教授致辞，十堰市卫生局杨敬富局长、十堰市太和医院刘菊英副院长及湖北省医学会林勇副秘书长讲话。</p>\r\n<p>　　在<span>7号的学术交流会上，首先由来自武汉协和医院的张永学教授做了“分子影像对当今医学实践的影响”的专题报告，报告指出分子影像在疾病的早期诊断、病情分期、复发监测、治疗反应的早期评估以及预后估计方面的应用将极大的影响临床实践，从而改变传统的治疗思维和治疗方法的选择。接着分四个单元进行论文交流，有18篇论文进行了大会交流。交流的论文内容包括SPECT显像、PET及符合线路、核素治疗、体外分析、骨密度测定等各个方面，各位代表展示了各自的研究成果，并提问和讨论。本次会议还进行了优秀论文评选活动，经过六位专家以现场评分的方式，评选出一、二、三等优秀论文奖。同济医院赵明副教授获得一等奖、武汉协和医院兰晓莉副教授、同济医院朱小华主任、十堰市太和医院陈宇医生获得二等奖，武汉市中心医院陆涤宇主任、十堰市太和医院刘刚主任、襄樊中心医院刘国强主任、湖北省肿瘤医院徐崇飞医生、武汉大学中南医院沈影医生、武汉协和医院戴宇医生获得三等奖。在闭幕式上，学会领导为每位获奖者颁发了证书和奖金。</span></p>', '2009-11-17 13:14:38', 22),
(59, '安徽省立医院PET/CT检查降价通知', '<p><span style="font-family:宋体;">我院为了响应国家卫生部医改指示精神，参照安徽省物价局规定，经医院研究决定调整</span><span>PET-CT</span><span style="font-family:宋体;">检查收费标准，让广大的检查人群可以得到更安全、准确、省时、优质的检查。收费：全身检查收费:</span><span>8200</span><span style="font-family:宋体;">元，局部检查收费:</span><span>6500</span><span style="font-family:宋体;">元，头颅检查收费:</span><span>5000</span><span style="font-family:宋体;">元。同时我们将保持原来服务品质，遵循医院及科室各项服务承诺，真诚及时的为您提供服务。特此通知！</span></p>', '2009-11-24 18:32:38', 36),
(60, '安徽医科大学第一附属医院PET/CT开业了！', '<p style="text-indent:21pt;"><span style="color:black;font-family:仿宋_gb2312;">国内第四台<span>52</span>环<span>64</span>层<span>PET-CT</span>在安徽医科大学第一附属医院<span>PET/CT</span>中心成功落地开张了，<?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><span>11</span>月<span>3</span>日，安医大一附院全球最高端的<span>52</span>环<span>64</span>层<span>PET-CT</span>正式投入使用。该设备的投入使用，标志着安徽省医疗诊断水平迈入国内先进水平。据悉，该设备是当今世界核医学最高水平的标志，它可以发现<span>2mm</span>的肿瘤，对肿瘤的早期诊断、分级、分期、疗效监测和协助指导治疗及肿瘤在全身累及状况方面具有突出功能。传统需要<span>30</span>分钟的<span>PET-CT</span>检查，该设备只需要<span>7</span>分钟即可完成，并且可以得到更好的图像质量，能更早发现早期微小的<span>2mm</span>肿瘤转移灶。另一个突出的优势是独有的肿瘤随访引擎，能对肿瘤进行容积分析，<span>PET</span>、<span>CT</span>融合图像分析，使医生能够比较病人两个扫描时间点的图像，帮助其作出更加精确的诊断和制定后续治疗方案，对肿瘤早期治疗、个性化治疗提供有力保障。</span></p><span style="color:black;font-family:仿宋_gb2312;">\r\n<p style="text-indent:21pt;" align="right"><span style="color:black;font-family:仿宋_gb2312;">派康网编辑<span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /></span></span></p><span></span></span>', '2009-11-24 19:33:31', 43),
(61, '2009湖北省核医学学术年会在十堰市召开 ', '湖北省核医学会<span>2009年学术年会于2009年11月6-8日在车城十堰市召开。来</span>自全省各医疗、教学及科研单位的核医学工作者代表共 60 余人代表参加了本次学术活动。会议由由武汉大学人民医院核医学科陈辉霖主任主持。\r\n<p>　　会议首先由湖北省医学会核医学会主任委员安锐教授致辞，十堰市卫生局杨敬富局长、十堰市太和医院刘菊英副院长及湖北省医学会林勇副秘书长讲话。</p>\r\n<p>　　在<span>7号的学术交流会上，首先由来自武汉协和医院的张永学教授做了“分子影像对当今医学实践的影响”的专题报告，报告指出分子影像在疾病的早期诊断、病情分期、复发监测、治疗反应的早期评估以及预后估计方面的应用将极大的影响临床实践，从而改变传统的治疗思维和治疗方法的选择。接着分四个单元进行论文交流，有18篇论文进行了大会交流。交流的论文内容包括SPECT显像、PET及符合线路、核素治疗、体外分析、骨密度测定等各个方面，各位代表展示了各自的研究成果，并提问和讨论。本次会议还进行了优秀论文评选活动，经过六位专家以现场评分的方式，评选出一、二、三等优秀论文奖。同济医院赵明副教授获得一等奖、武汉协和医院兰晓莉副教授、同济医院朱小华主任、十堰市太和医院陈宇医生获得二等奖，武汉市中心医院陆涤宇主任、十堰市太和医院刘刚主任、襄樊中心医院刘国强主任、湖北省肿瘤医院徐崇飞医生、武汉大学中南医院沈影医生、武汉协和医院戴宇医生获得三等奖。在闭幕式上，学会领导为每位获奖者颁发了证书和奖金。</span></p>', '2009-11-24 21:53:05', 16),
(62, '江苏省医学会第七次核医学年会纪实 ', '<p>由中华医学会江苏省核医学分会主办，国家重点实验室江苏省原子医学研究所承办的"江苏省第七次核医学年会江苏省第六届核医学年会"于2009年11月13-15日在无锡江原山庄隆重召开，会议期间同时进行了第六届核医学分会换届选举，产生了由34名委员组成的新一届委员会，主任委员由江苏省人民医院核医学科李殿富教授担任，副主任委员分别是南京临床核医学中心王自正教授；江苏省原子医学研究所罗世能所长；徐州市中心医院核医学科王跃涛教授；南京军区总院核医学科朱虹主任和苏州大学附属第一医院核医学科张玮副主任，会议同时任命南京核医学中心王峰副主任为新一届委员会秘书。 <br />\r\n<br />\r\n　　本次核医学年会总共收到论文将近150份，参会代表人数达到110位，南京临床核医学中心在所投论文总数和参会代表人数均排第一，大会总结中对此提出赞扬，充分证明了近几年来我中心在科研方面所做的努力以及对临床学术交流的积极态度。</p>\r\n<p align="right">派康网编辑</p>', '2009-11-24 21:57:57', 25),
(63, '《改革药品和医疗服务价格形成机制的意见》发布', '<p><span style="font-size:9pt;font-family:宋体;">国家发展改革委、卫生部、人力资源社会保障部日前联合发布《改革药品和医疗服务价格形成机制的意见》<span style="font-size:9pt;font-family:宋体;">按照贯彻落实科学发展观和构建社会主义和谐社会的要求，从我国医药产业发展现状和医疗服务特点出发，充分发挥价格杠杆调节作用，合理调控药品和医疗服务价格水平，促进卫生事业和医药产业健康发展，满足人民群众不断增长的医疗卫生需求。</span></span></p>\r\n<p align="right"><span style="font-size:9pt;font-family:宋体;"><span style="font-size:9pt;font-family:宋体;">&nbsp;派康网编辑</span></span></p>', '2009-11-24 22:13:12', 15),
(64, '我国首台飞利浦带TOF的PET-CT安装 ', '<span style="font-size:12px;color:#333333;"><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">据悉，唐山工人医院核医学科最新引进了一台</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">philips</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">公司生产的</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">PET/CT</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">（</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">64</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">排），这台机器具有先进的的</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">TOF</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">技术，分辨率可以达到</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">2mm</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">.</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">这是国内引进的第一台由</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">PHILIPS</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">公司生产的</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">PET/CT</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">（</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">64</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">排）。</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;"></span></span></p><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">什么是</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">TOF?</span></span></p><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">TOF</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">即</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">time of fly&nbsp;</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">飞行时间技术。</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;"></span></span></p><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">在飞行质谱的检测系统中，蛋白芯片根据色谱原理，表面经化学</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">(</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">阳离子、阴离子、疏水、亲水和金属离子整合等</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">)</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">或生物化学</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">(</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">抗体、受体、</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">DNA</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">等</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">)</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">处理，芯片特异性地和血清中测定蛋白结合，再通过选择性清洗，获得高分辨率的保留蛋白谱</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">(</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">第一次分离</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">)</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">。当加入能量吸收分子</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">(EAM)</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">后，芯片上保留的蛋白形成晶体。在特异的激光照射后，晶体发生解离作用，带电分子在通过电场时加速，记录仪记录飞行时间的长短，质量越轻，相对所带的电荷越多</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">(</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">质荷比</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">M/Z</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">越小</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">)</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">，飞行时间越短。信号由高速的模拟数字转化器传化并记录，被测定的蛋白质以一系列峰的形式呈现，这些特异的峰可看成此类疾病的指纹。单个蛋白在谱图上的位置取决于飞行时间。</span></span><span style="font-size:12px;color:#0a1414;"><br /><span style="font-size:12px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">飞行质谱这一技术目前已广泛用于多种疾病，如癌症、老年病、感染性疾病、心血管病和神经系统疾病，认为可以提高多种疾病的诊断率，其中应用于癌症的最多。国外研究人员应用</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">SELDI</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">检测了转移性黑色素瘤、肉瘤和肾癌，敏感性达</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">87%</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">。他们认为，该方法根据独特的</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">8</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">～</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">24</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">条蛋白指纹图可以用于多种癌症的诊断，如肝癌、前列腺癌、乳腺癌、膀胱癌、食道癌，其检测限为飞摩尔</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">/</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">升。据报道，美国华盛顿伊丽莎白医院利用该技术检测肺癌，敏感性达</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">98%</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">，特异性</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">97%</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">；美国霍普金斯医学院检测了卵巢癌敏感性</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">82%</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">，特异性</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">98%.</span></span><span style="font-size:12px;color:#0a1414;"><br /></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">美国科学顾问委员会的</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">300</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">多位从事生命科学或医疗一线的研究者普遍认为飞行质谱是一个极有前途的应用技术，将给诊断学带来一场革命或革新，大大改变目前一些疾病如肿瘤、心血管病等诊断落后的情况，前景美好。</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;"></span></span></p><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">TOF</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">应用于</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">PET-CT</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">，将</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;">PET-CT</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;">技术带来极大的进步，主要来说有如下的优势：</span></span><span style="font-size:12px;"><span style="font-size:12px;color:#0a1414;"></span></span></p><p style="font-size:12px;text-indent:21pt;"><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">一、</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">TOF</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">通过</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;">2</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">个光子到达晶体的飞行时间差来缩小重建范围，实现局部重建，从而压制噪声，提高图像的信噪比，由于信噪比提高了，相当于有效计数的百分比提高了，从而可以缩短扫描时间、减少用药剂量。</span></span><span style="font-size:12px;"><span style="font-size:12px;font-family:helvetica;color:black;"></span></span></p><p style="font-size:12px;"><span style="font-size:12px;"><span style="font-size:12px;font-family:宋体;color:black;">二、，信噪比的提高可以提高图像质量，对小病灶和高本地处的病灶应该都可以看出来。三、由于实现了局部重建，所以重建患者的体积没有关系了，可以提高肥胖病人的图像质量。</span></span></p></span>', '2009-11-25 14:57:52', 33),
(65, '核医学检查成为发现肿瘤“萌芽” 新武器', '<span style="font-family:helvetica, arial, sans-serif;font-size:14px;">&nbsp;&nbsp;从日前召开的全国<span>PET</span>（／CT）读片会和学术研讨会上获悉，这一技术可发现小到3毫米的早期肿瘤。&nbsp;<br />　　据解放军总医院核医学科主任、中华医学会核医学分会主任委员田嘉禾介绍，核医学检查技术是功能代谢与细胞分子水平上的影像诊断技术。病人检查前注射或口服被称为“疾病探针”的显像药物，随后，医生用高科技手段追踪探查这些药物在人体内发出的微弱信号，对常规放射影像学检查不能发现或诊断困难的各种恶性肿瘤早期定位、定性、定量和定期诊断，这对高危人群早期筛查恶性肿瘤有很大帮助。<br /><br />　　北京朝阳医院核医学科主任、中华医学会核医学分会副主任委员王铁说，核医学检查技术可以发现2厘米以下、小到3毫米的早期肿瘤，形成扫描图像上明显的“亮点”，使肉眼能看到代谢特别旺盛的癌症细胞，早期发现隐藏的癌症病灶。<br /><br />　　北京协和医院核医学科主任、中华医学会核医学分会常委李方则指出，核医学检查技术的出现，避免了不必要的其他检查或有创性检查、治疗等方面的高额费用，对病人特别是对恶性肿瘤患者或具有恶性肿瘤发病倾向的高危人群来讲，是相对合理的医疗消费。<br /><br />　　医学专家表示，对于工作压力大的中年人或有肿瘤家族史的人，定期进行核医学检查技术检查将有利于早期发现病变。除孕妇外，这一技术适用于绝大部分人群，患有糖尿病或不能自主保持稳定的患者则需先告知医生，在采取相应措施后方可进行检查。<br /></span>', '2009-11-25 15:52:15', 22),
(66, '东软和Positron 合资生产的PET获得美国FDA认证！', '<span style="font-family:helvetica, arial, sans-serif;font-size:14px;">新华网沈阳５月２６日专电（记者徐扬、田晓航）东软集团股份有限公司２６日对外宣布，由其全资子公司东软医疗系统有限公司成功自主研发ＰＥＴ（正电子发射断层扫描装置），并获得了美国ＦＤＡ（美国食品药物管理局）认证，使我国成为全球少数几个能够独立研制和生产ＰＥＴ的国家之一。<br /><br />&nbsp; &nbsp; 据东软集团副总裁、<br />东软医疗系统有限公司总裁刘健介绍，ＰＥＴ作为分子影像学设备，涉及核物理学、软件学、快电子学、机械学、医学、药学、分子生物学、分子影像学等诸多领域，由１３００余种物资、数万个零件（包括阻容件）组成，技术门槛高，全球只有几家跨国公司能够独立研制和生产，并垄断全球市场，我国则全部依靠进口。此次成功研发并生产的东软系列ＰＥＴ包括ＮＳＰ－Ｐ８和ＮＳＰ－Ｐ６Ｃ两个型号的产品，已经达到国际同类产品的先进水平，能够满足肿瘤、神经系统的临床应用，且在心脏疾病诊断方面具有技术优势。<br /><br />&nbsp; &nbsp; 据业内专家介绍，ＰＥＴ（正电子发射断层扫描装置）在全身肿瘤和心脏等疾病的早期诊断与治疗方面有巨大的临床价值。比起传统的检测方法如Ｘ线、ＣＴ、ＭＲＩ等，ＰＥＴ对各种身体病变的早期诊断更胜一筹，不仅能够保证足够的治疗时间，而且能够大大降低相关的治疗费用。<br /></span>', '2009-11-25 16:09:31', 17),
(67, '江苏省医学会第七次核医学年会暨第六届江苏省核医学分会换届选举会议纪实', '<span style="color:#012b31;font-family:verdana, arial, helvetica, sans-serif;font-size:14px;"><p align="left">由中华医学会江苏省核医学分会主办，国家重点实验室江苏省原子医学研究所承办的"江苏省第七次核医学年会江苏省第六届核医学年会"于2009年11月13-15日在无锡江原山庄隆重召开，会议期间同时进行了第六届核医学分会换届选举，产生了由34名委员组成的新一届委员会，主任委员由江苏省人民医院核医学科李殿富教授担任，副主任委员分别是南京临床核医学中心王自正教授；江苏省原子医学研究所罗世能所长；徐州市中心医院核医学科王跃涛教授；南京军区总院核医学科朱虹主任和苏州大学附属第一医院核医学科张玮副主任，会议同时任命南京核医学中心王峰副主任为新一届委员会秘书。&nbsp;<br /><br />　　本次核医学年会总共收到论文将近150份，参会代表人数达到110位，南京临床核医学中心在所投论文总数和参会代表人数均排第一，大会总结中对此提出赞扬，充分证明了近几年来我中心在科研方面所做的努力以及对临床学术交流的积极态度。</p><p align="left">&nbsp;</p><p align="center"><img src="http://www.csnm.com.cn/upload/2009/11/18/20091118073726_746_20091118142422295.jpg" alt="" /></p><p align="center">&nbsp;</p><p align="left">　　在为期2天的会议中，包括来自中华医学会核医学分会候任主委、上海核医学分会主任委员黄钢在内的6位专家做了专题演讲，黄钢教授对"中国核医学的发展和思考"这个题目进行了报告，不仅提出了核医学现在所面临的挑战也为大家指明了应对挑战的途径；中华核医学杂志编辑部副主编丁虹教授针对大家普遍关心的论文发表问题讲述了"如何写一篇好的科研论文"；江苏省原子医学研究所所长罗世能主讲了"放射性药物研究现状及进展"，江苏省人民医院核医学科李殿富主任对"冠心病的规范化处理与心肌显像的临床应用价值"和代表进行了讨论；徐州市中心医院核医学科王跃涛主任对"PET/CT在冠心病的应用现状与展望" 发表了自己看法；最后我中心主任王自正对"肿瘤分子标志在核医学中的应用"进行了演讲，引起参会人员的广大兴趣，并与听众进行了积极的互动交流，得到了大会代表们的一致好评。</p><p align="left">&nbsp;</p><p align="center"><img src="http://www.csnm.com.cn/upload/2009/11/18/20091118073809_342_20091118142439585.jpg" alt="" />　</p><p>　　另外在14日下午的大会发言及讨论中，来自我中心两位硕士研究生高玉婷和侯彦杰分别对"99mTc-DOTANOC标记方法学及生物学研究 "及"32P-磷酸铬-聚L-乳酸缓释粒子的制备与肝内植入的初步研究"进行了发言，这不仅体现了中心对新人培养的力度，也展现了中心良好的科研氛围。<br /></p><p>　　本次会议旨在交流近一年来各级医院、单位以及个人在核医学临床和科研方面取得的进展，加强全省核医学资源整合和信息沟通，并促进各核医学单位间的学术和科研的交流，共同探讨未来几年我省核医学发展的方向。</p><p><br />(撰稿：南京市第一医院核医学科：侯彦杰)</p></span>', '2009-11-26 11:37:05', 28),
(68, '2009年黑龙江省医学会核医学年会暨PET/CT学组与放免学组成立大会', '<span style="color:#494949;font-size:12px;"><p>黑龙江省核医学专业委员会于2009年10月31日在哈医大附属肿瘤医院召开了核医学年会，会议主要内容为成立PET/CT学组和放免学组。共有来自全省各地的71名核医学工作者参加了此次会议，分别来自哈、齐、牡、佳、伊春和鸡西和大庆等地，覆盖面较广。</p><p>　　在上午8：30首先召开了PET/CT学组与放免学组成立会议</p><p>　　参加人员有省医学会杜广洲秘书长，省医学会学术部李大纪主任，省核医学会主任委员赵长久书记，PET/CT学组和放免学组成员共40人。会上由黑龙江省医学会杜广洲秘书长及学术部李大纪主任分别作重要讲话。杜广洲秘书长讲话中称，这两个学组的成立是根据目前黑龙江省核医学中放免和PET/CT的发展需要而经过相关论证后决定设立的。放免和PET/CT分别是核医学学科中开展较早和新兴领域的代表，成立这两个学组对于发扬核医学中的传统项目和扶持新兴项目意义重大。 李大纪主任依据学会相关章程对学组的权利、责任、义务、主要工作方向等方面作重要指示。黑龙江省核医学会主任委员赵长久书记讲话，黑龙江省医学会学术部左方宣布学组成员名单，然后学组组长发言。</p><p>　　学术会议在上午9：30举行，首先由哈尔滨医科大学附属肿瘤医院PET/CT中心主任于丽娟教授宣布学术会议开始，同时介绍参会领导和来宾，哈尔滨医科大学附属肿瘤医院党委书记冯军致辞，然后哈尔滨医科大学附属一院影像教研室级核医学科主任杨志杰教授主持学术讲座，放免学组组长芮东红教授进行了题为《体外免疫分析实验室的质量管理》的专题讲座。讲座回顾了放免的发展史及现状，讲述了目前国家对临床实验室的要求，分析了目前我省核医学科放免室的现状，讲解了如何建立放免室的管理体系，如何做好质量控制和质量保证及如何编写管理体系文件。PET/CT学组组长于丽娟教授做了题为《PET/CT临床应用及发展》的学术讲座，讲座讲解了PET/CT的工作原理、技术优势、临床应用的领域、重点阐述了PET/CT在肿瘤学的上的具体应用，附有许多典型病例的图片，同时介绍了黑龙江省PET/CT的发展情况，在国内所处的地位，以及所取得的成绩。最后由黑龙江省核医学会主任委员、哈尔滨医科大学第四医院党委赵长久书记传达了8月份结束的中华核医学会双委会精神并布署省核医学会的下一年工作重点：做好临床工作的同时，加强核医学相关的科研工作，增大重点核心期刊的投稿数量和质量，发展我省核医学事业。</p><p>　　放免是核医学最基本和最基层的工作，由于各种原因交流较少，与会代表对成立放免学组非常高兴，佳木斯中心医院的杨主任说“我们终于有了我们的组织，对于今后我们的交流搭建了平台，并且代表们就如何开展核医学工作和宣传展开了讨论，充分体现了我省核医学积极要求发展的良好势头。</p><p>　　PET/CT作为核医学的最新技术，近年来发展迅猛，有关PET/CT的临床应用及科研论文非常活跃，是核医学的一支新生力量，代表们纷纷表示通过此次会议了解了PET/CT的相关知识，PET/CT学组的成立为PET/CT的交流和科研搭建了平台，对于促进黑龙江省PET/CT的发展意义重大。</p><p><span>　　</span>参会人员普遍反映此次会议日程安排紧凑，会议内容安排合理，学术气氛浓厚，收获较大。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/2009112095354787.jpg" /></p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/2009112095428755.jpg" /></p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/2009112095436775.jpg" /></p></span>', '2009-11-26 11:38:05', 22);
INSERT INTO `yiliao_active` (`id`, `name`, `content`, `add_time`, `click`) VALUES
(69, '飞利浦中国核医学5周年暨用户会议消息', '<span style="color:#494949;font-size:12px;"><p><font face="宋体">11</font><span style="font-family:宋体;">月<span>14</span>日，飞利浦中国</span><span style="font-family:宋体;">核医学</span><span style="font-family:宋体;">5</span><span style="font-family:宋体;">周年暨用户会议在春城昆明隆重举行，飞利浦中国总裁<span>Desmond</span>、飞利浦全球</span><span style="font-family:宋体;">核医学</span><span style="font-family:宋体;">销售总监<span>Peter Kohl</span>、飞利浦中国影像市场部总监缪宏及飞利浦中国</span><span style="font-family:宋体;">核医学</span><span style="font-family:宋体;">市场部王真经理出席了该会议并致辞，诚挚表达飞利浦和中国</span><span style="font-family:宋体;">核医学</span><span style="font-family:宋体;">界携手并进的愿望。本次会议邀请了国内外诸多</span><span style="font-family:宋体;">核医学</span><span style="font-family:宋体;">专家进行经验交流及技术介绍，包括荷兰肿瘤中心的<span>Dr. Hoeafnagel</span>教授，田嘉禾教授，匡安仁教授，朱家瑞教授，陈盛祖教授，林祥通教授，叶广春教授，吴文凯教授、史蓉芳教授、王铁教授、石洪成教授、蒋宁一教授、张晓明教授等专家领导。</span></p><p><span style="font-family:宋体;">　　会议主要内容包括<span>Dr. Hoeafnagel</span>教授《飞行时间技术在低剂量</span><span style="font-family:宋体;">FDG</span><span style="font-family:宋体;">肿瘤显像中的应用》，上海中山医院核医学科主任石洪成教授《<span>SP</span></span><span style="font-family:宋体;">ECT</span><span style="font-family:宋体;">/CT</span><span style="font-family:宋体;">的临床应用价值》，唐山工人医院张晓明主任《<span>&nbsp;TOF&nbsp;</span></span><span style="font-family:宋体;">PET</span><span style="font-family:宋体;">的质控》，<span>Peter Kohl</span>《新产品新技术介绍》。会上还举行了飞利浦核医学俱乐部授牌仪式。</span></p></span>', '2009-11-26 11:42:22', 19),
(70, '江苏省第七次核医学学术会议暨第六届江苏省核医学分会换届选举会议报道', '<span style="font-family:verdana, arial, 宋体;font-size:12px;"><p><font size="2" face="Verdana"><font size="1">2009年11月20日</font><br />&nbsp;&nbsp;&nbsp;&nbsp; 2009年11月13-15日，由中华医学会江苏省核医学分会主办，国家重点实验室江苏省原子医学研究所承办的“江苏省第七次核医学年会江苏省第六届核医学年会”在江原山庄隆重召开。<br />&nbsp;&nbsp;&nbsp;&nbsp; 本次会议由东道主江苏省原子医学研究所罗世能所长主持。会议期间多位专家做了专题讲座：中华医学会核医学分会候任主委、上海核医学分会主任委员黄钢教授就“中国核医学的发展与挑战”进行演讲，阐述了在核医学的发展方向和此领域中所面临的挑战；中华核医学杂志编辑部副主编丁虹做了“如何写一篇好的科研论文”的专题报告，讲解了撰写发表论文的方法和要点。此外江苏省原子医学研究所罗世能所长、江苏省人民医院核医学科李殿富主任、徐州中心医院核医学科王跃涛主任和南京市第一医院核医学科王自正主任先后做了精彩的报告与演讲。会议气氛活跃，专家学者相互交流，研讨本学科的发展与创新，取得了良好的成效。<br />&nbsp;&nbsp;&nbsp;&nbsp; 通过此次会议，省内学科专家学者之间加强了相互沟通与交流。核医学从业人员也得到了一次难得的学习机会。借此机会公司销售部与新老朋友有了更加深入的了解，也和更多的医院及科室建立了良好的联系。会议于11月15日中午圆满结束！</font></p><p align="center"><img border="0" src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/20091120131650825.jpg" /></p><p align="center"><font size="2">黄钢教授</font></p><p align="center"><img border="0" src="http://www.pet-tracer.com.cn/eWebEditor/UploadFile/20091120131722832.jpg" /></p><p align="center"><font size="2">罗世能所长</font></p><p><font face="Verdana"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp; 会议期间同时进行了第六届核医学分会换届选举。会后了解到选举结果，本次换届选举产生了由34名委员组成的新一届委员会：主任委员由江苏省人民医院核医学科李殿富教授担任；副主任委员分别是南京临床核医学中心王自正教授、江苏省原子医学研究所罗世能所长、徐州市中心医院核医学科王跃涛教授、南京军区总院核医学科朱虹主任和苏州大学附属第一医院核医学科张玮副主任；会议同时任命南京核医学中心王峰副主任为新一届委员会秘书。<br />（文/阎晓冬 图/郭先伟）</font></font></p></span>', '2009-11-26 12:06:46', 29),
(71, '华山医院《PET/CT临床应用医师培训班》暨上海市核医学第76次《PET/CT专题联合读片会》纪要', '<span style="color:#494949;font-size:12px;"><p style="text-align:left;">由复旦大学附属华山医院承办的第八期国家级继续医学教育项目《PET/CT临床应用医师培训班》(No. 20090904017)于2009年11月19日-23日在上海市技贸宾馆成功举行。 11月19日学习班报到当日下午同期举办了上海市核医学第76次《PET/CT专题联合读片会》。<br />　　在本次读片会上，对上海华山、瑞金、市一、肿瘤及武警五家医院及外省市学员带来的病例进行了交流。出席读片会的专家有马寄晓、朱承谟、黄钢等教授，特邀专家台湾林口长庚医院阎紫宸教授，读片会分别由上海核医学分会副主任委员王辉教授和华山医院赵军主任医师主持，时间持续4个多小时，参加人员达120人之多，包括上海、苏州核医学工作者及参加学习班的外省市学员。读片会内容分三部分：首先借鉴2009年青岛PET/CT读片会的成熟经验，分别由赵军（华山医院）、刘建军（仁济医院）、左长京（长海医院）3位全国核医学青年委员作了脑部PET、体部PET及胸腹部CT读片技巧和要领的专题讲座；接着分别由7位上海青年医生对5个病例进行相互读片，阐述各自见解，同时现场持有不同观点的其他医师踊跃发言，现场气氛相当热烈，当病理结果揭晓的时候更是达到高潮，这些病例都是常见病不典型表现或罕见病不典型表现——分别是结节病伴良性畸胎瘤、甲状腺结核伴多发骨结核、腺癌化疗后并发脾梗死、双侧卵巢癌、肠系膜根部硬纤维瘤。虽然部分病例读片结果与最终病理诊断有一定的出入，但却能够让大家开阔眼界，拓展思维及进一步思索。第三部分为参加学习班的外省市学员对相互提供的PET/CT疑难病例进行讨论，哈尔滨医科大学肿瘤医院与广州军区总医院进行南北读片，尤其后者提供的AIDS并发霉菌感染的病例让听众广为惊叹，完全出乎大家的意料。因为时间关系，安徽省立医院、中山大学第一医院及深圳保健办医院携带的3个病例只好放在学习班期间讨论。最后邀请台湾阎紫宸教授对以上病例进行学术点评，阎教授的精辟分析给大家留下了深刻的印象。中华医学会核医学分会候任主任委员及上海核医学分会主任委员黄钢教授在晚宴中致欢迎词，欢迎参加华山医院PET学习班的各位学员，并且希望上海读片会这一品牌学术交流活动在老一辈核医学专家、中青年骨干力量以及各位核医学同行的大力支持下持续做好。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091126114052641.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/2009112611412180.jpg" />&nbsp;<br /><img alt="" src="http://csnm.cma.org.cn/upload/20091126114528809.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/20091126114123231.jpg" />&nbsp;<br /><img alt="" src="http://csnm.cma.org.cn/upload/20091126114133449.jpg" /></p><p style="text-align:left;">　　第八期国家级继续教育项目PET/CT学习班于2009年11月20日上午开班，开班仪式上林祥通教授致开幕词，简要介绍了全国PET/CT人员培训及华山医院承办的前7期培训班情况、人员培训的重要性及培训班教学效果如何评鉴，对阎紫宸教授、何志礼教授及各位授课老师表示感谢，对远道而来的各位学员表示欢迎。本次学习班培训共有39名注册学员，其中北京8名、广东6名、山西5名、上海4名、江苏3名、河南2名、山东2名、黑龙江、湖北、江西、安徽、福建、天津、澳门等省市9名，授课18位教授，授课22学时，病例示教及讨论5个学时。同以往几届学习班相比，本次学习班在坚持以往精品授课内容的基础上，不断创新，以满足学员新的需要，此次学习班的主题有两个：即PET/CT临床应用规范化及质量保证、临床科研工作设计及初期成果展示。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091126114142156.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/20091126114150459.jpg" /></p><p style="text-align:left;"><br />　　11月20日上午林祥通教授做了再论PET/CT医疗质量保证的几个问题的专题演讲，结合国内外相关文献资料发表了个人前瞻性的总结，使大家获益匪浅，坚定了对PET/CT未来美好发展的信心。来自宝岛台湾的著名核医学专家阎紫宸教授，结合长庚医院口腔肿瘤外科的优势，提出PET/CT诊断中要密切结合临床，只有PET/CT表现能解释临床改变，才能得出PET/CT的真正价值，此外阎教授还讲解了PET在神经系统科研的实验研究，她渊博的知识和风趣的互动方式，让各位学员收益匪浅，并且留下了深刻的印象。另一位在Journal of Nuclear Medicine发表封面文章的香港何志礼教授，做了11C-乙酸盐临床科研设计及医疗质量保证的专题演讲，他让大家意识到11C-乙酸盐不仅可以在高分化肝细胞癌可以应用，而且在肾错构瘤、前列腺癌甚至在多发性骨髓瘤中也有重要的价值。在阎紫宸及何志礼教授演讲结束后，为感谢两位多年来为华山国家级继续教育项目所做出的重大贡献，林祥通教授代表华山医院向两位教授颁发荣誉奖牌。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091126114159504.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/2009112611426347.jpg" />&nbsp;<br /><img alt="" src="http://csnm.cma.org.cn/upload/20091126114213196.jpg" /></p><p style="text-align:left;">　　11月20日下午西门子郭永彤经理介绍了PET/CT技术的新进展，尤其是PET的HD技术及各向同性处理，使得PET精确分辨率得到明显的提高，使得核医学机器真正从unclear到newclear再到trueclear。接着华山医院PET中心的加速器及放射药物技术人员，分别就加速器原理、正电子药物制备质量控制进行了简要介绍，让各位学员对于正电子药物有了大致的了解。<br />　　11月21日及22日华山医院临床、放射、超声及PET/CT专家分别做了肺癌、淋巴瘤、胰腺癌、神经系统疾病等PET/CT影像诊断及与相关科室科研合作的内容报告及交流。其中赵军教授对中华医学会核医学分会制定的18F-FDG PET/CT肺占位病变显像技术操作和临床应用指导原则(建议版2008 )进行了详细解读，对报告书写规范化进行了初步探讨，并对PET/CT在肺癌诊断和临床分期中的价值进行了较为客观的评价。管一晖教授讲解了PET在脑肿瘤、癫痫、痴呆、帕金森及强迫症、抑郁等神经性疾病的应用价值，并指出传统的FDG脑显像在病灶定位、药物疗效有着很大的潜力，关于帕金森病提出除了11C-CPT及18F-Dopa外，根据多巴胺生物机制针对其他作用靶点研制出的显像剂对该病诊断也有着很大的帮助，管教授还提到PET/CT除了临床应用外，在药物研发中也有着举足轻重的作用。此外管教授还对肝胆胰、胃肠、泌尿生殖肿瘤对FDG摄取特点进行总结，提出依据不同肿瘤的生物学特性可以采取不同延迟时间、不同显像剂及增强扫描来提高诊断率。左传涛副教授根据华山神经优势及自身在美国学习的经验，提出使用SPM分析方法在脑部PET图像分析和研究中具有重要作用。华逢春博士向学员讲解了2009年NCCN淋巴瘤中重新修订的PET/CT最新内容。华东医院放射科滑炎卿教授详细讲解了胸部及腹部断层解剖知识，让学员们深知影像定位在PET/CT重要地位。接着来自华山临床专家普外科倪泉兴教授、放射治疗专家戴嘉中教授、神经内科王坚副教授、超声医学科王怡教授、中医科董竞成教授、手外科徐文东教授分别就如何应用PET进行科研工作做了精彩的演讲，介绍了相应的临床和初期科研成果，充分肯定了PET在临床和科研中的重要价值。倪泉兴教授也语重心长叮嘱各位学员，PET/CT在胰腺肿瘤中还有一定的假阳性、假阴性，希望将来能找到更好的显像剂以弥补不足，让学员们感到任重而道远。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091126114221673.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/20091126114230663.jpg" /></p><p style="text-align:left;">　　在各位专家授课的同时，学习班还还安排了华山医院多位年青医师和研究生进行典型和疑难病例示教和讨论，大大调动了学员的积极性，也同时增加他们临床实用经验，这种教学模式得到学员们一致好评。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091126114237902.jpg" />&nbsp;<img alt="" src="http://csnm.cma.org.cn/upload/20091126114244412.jpg" />&nbsp;<br /><img alt="" src="http://csnm.cma.org.cn/upload/20091126114251990.jpg" /></p><p style="text-align:left;">　　学习班进行了认真的结业考核和满意度测评。最后在学习班结业仪式上，华山PET中心许震生主任简要介绍了华山中心十年来成功的管理和运营经验，学员们踊跃提问、讨论热烈。来自哈尔滨医科大学肿瘤医院王欣副教授及北京大学肿瘤医院王雪娟博士两位学员代表结合自己参加国内和美国斯坦福大学PET/CT培训的体会，对华山PET中心课程设计、授课效果及生活安排给予高度评价，让她（他）们收获颇多，非常感谢华山医院PET中心组织这样高质量的学习班。大家在欢快的气氛中互相道别踏上了归程。<br />（华山医院PET中心 赵军 供稿）</p></span>', '2009-11-27 10:12:39', 30),
(72, '飞利浦宣布研发PET/MR取得重大突破', '<span style="font-family:verdana, arial, 宋体;font-size:12px;"><p><font size="2" face="Verdana">Philips reports PET/MR R&amp;D milestone<br />By AuntMinnie.com staff writers<br />October 29, 2009</font></p><p><font size="2" face="Verdana">Philips Healthcare parent Royal Philips Electronics has announced a breakthrough in its development of a hybrid PET/MR scanner.</font></p><p><font size="2" face="Verdana">Philips is developing the scanner with funds provided by the European Union as part of the HYPERImage research project. The project began in 2008 and involves eight partners from six European countries; it has a total budget of around 7 million euros ($10.4 million).</font></p><p><font size="2" face="Verdana">The design of the new scanner is based on concurrent acquisition of images using the company‘s time-of-flight PET technology, as well as MRI data. The announced milestone is the development of a functional gamma-ray detector that meets the performance requirements of the latest time-of-flight PET scanners and that is compatible with the strong magnetic fields in a combined PET/MRI scanner.</font></p><p><font size="2" face="Verdana">Details of the group‘s results are being presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference, which is taking place this week in Orlando, FL.</font></p><p><font face="Verdana"><font size="2">The Philips research group anticipates that the hybrid scanner will advance the accuracy of diagnostic imaging in cardiology and oncology, as well as assist in developing new approaches to therapy planning, guidance, and response monitoring.</font></font></p></span>', '2009-11-27 10:27:57', 37),
(73, '', '<span style="font-family:verdana;font-size:small;">云南省核医学著名专家，中共党员，昆明医学院第一附属医院核医学科原主任吴光瑛教授，因病医治无效于2009年11月21日凌晨2时35分在昆明医学院第一附属医院不幸逝世，享年73岁。<br />　　吴光瑛教授1960年7月以优异的成绩从昆明医学院医疗系毕业留校任教。曾先后任助教、讲师、副教授、教授。1970年参与组建昆明医学院第一附属医院核医学科并担任科主任，率先建成了我省第一个具有一定规模的开放型放射性核素诊疗室。同时吴光瑛教授任核医学教研室主任，长期从事核医学临床及教学工作，为昆明医学院第一附属医院核医学科的创立、发展无私奉献一生。<br />　　吴光瑛教授是云南省核医学创始人之一，曾任中华医学会核医学分会第一届委员，《中华核医学杂志》第三、四届编委，云南省核医学分会委员、云南省核医学分会名誉主任委员和《云南医药》编委。曾主编和参编全国及地方性教材多部，为云南核医学事业以及云南省核医学会的建立、发展做出了卓越贡献。在病榻上他仍不忘关心云南核医学发展情况，谆谆教导学生们如何做好该做的一切，他以宽大的胸襟感动了大家。<br />　　吴光瑛教授还是一位医德高尚，众人赞誉的好大夫，关怀病人疾苦，技术高超的好医生。同时又是一位对医学教育事业无限热爱、执着敬业的好教师。<br />　　吴光瑛教授是一位治学严谨的医学教育家。他毕生教书育人，诲人不倦，生命不息，奉献不止，培养了大批优秀的核医学科学人才，为我省核医学事业的建设和发展，人才培养注入了毕生的心血。在他从医从教四十多年来。曾主持和参与多项科学研究工作，先后发表和交流论文多篇，其中被美国科学引文SCI收录论文一篇，参与主持的科研项目有多项获云南省科技进步奖表彰，并参与编写核医学教材。<br />　　他的离去，是云南省核医学事业重大损失，我们深感哀恸。<br />　　在深切缅怀吴光瑛教授的同时，我们要永远学习他的崇高为人风范及对科学的严谨态度，化悲痛为力量，为促进云南省核医学事业的发展做出贡献，以此慰藉长眠的吴光瑛教授。</span>', '2009-12-11 10:51:40', 5),
(74, '飞利浦开展新型医学成像技术PET/MR研究', '<span style="font-family:verdana;font-size:small;">飞利浦医疗保健领导的Union-funded HYPERImage成像项目已经实现了里程碑式进展，该项目创建一个新的医学成像技术，即混合型 PET/MR。这项新技术是基于时间的同时获得飞行正电子发射断层扫描（PET）和磁共振（MR）图像。<br />　　该项目来自6个欧洲国家的8个合作伙伴，拥有总预算约700万欧元。该项目的最终目标是促进在心脏病和肿瘤诊断的正确性，以及在治疗中开辟新的方法，指导新的领域，用于应急监测。<br />　　混合型PET/MR成像仪可以同时提供解剖和功能信息，使用最先进的MR扫描仪（检测软组织对比度和血管生理过程）和PET提供的分子成像。因此，它结合了世界上两种最好的技术，最终可能有助于更准确的查明身体上的相关疾病。<br />　　对于混合型扫描仪，同时提供PET和MR图像采集，两个基本问题需要解决：与MR整合的 PET探测器和一个用于PET衰减核算方法（PET产生高能量的伽玛射线）。&nbsp;<br />　　飞利浦研究与飞利浦医疗保健研究项目负责人高级副总裁 Henk van Houten表示：“HYPERImage团队综合半导体物理、信号处理和医疗扫描仪的设计，与临床知识专家整合在一起，该项目的是建立一个新的成像工具，目的是帮助医生诊断和治疗世界上最流行的致命疾病，如乳腺癌。我很自豪地说，MR/PET兼容性探测器了不到1.5年时间研制成功。它清楚地表明，良好的合作带来非常快的进展。”&nbsp;</span>', '2009-12-11 10:52:39', 10),
(77, '东北地区第五届正电子显像学术研讨会在沈阳召开', '<span style="font-size:12px;color:#494949;"><div style="font-size:12px;">东北地区卫生部规划首台配置PET/CT和医用回旋加速器于2004年在临床开始应用。截止2009年12月，东北地区已有8台PET/CT在临床应用，另有两台正在安装中。2009年12月5日，东北地区第五届正电子显像学术研讨会暨卫生部规划首台配置PET/CT和医用回旋加速器临床应用5周年在中国医科大学附属第一医院核医学科召开。</div><div style="font-size:12px;">　　五年来，东北各省正电子显像都有了长足的发展，为地区医学事业的发展和疾病的诊治做出了积极和重要的贡献，得到了社会和同行的肯定。五年来，通过加强队伍建设和人才培养，从业队伍的服务能力和水平有了较大提高，在今年全国PET/CT读片团体竞赛中，东北代表队获得了总分第三的好成绩。本次学术研讨会分上、下午两个会场，分别邀请专家做了医学影像的融合技术的进展、分子影像与临床决策等专题报告，为与会者开拓了眼界，提出了新的学习、工作和研究方向。与会的其他学科专家也纷纷表示，功能影像将对其临床决策提供很好的依据。</div><p style="font-size:12px;text-align:right;"><br /></p><p style="font-size:12px;text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/2009129132510206.jpg" />　　<img alt="" src="http://csnm.cma.org.cn/upload/2009129132517223.jpg" /></p></span>', '2009-12-11 10:56:23', 7),
(76, '沈阳市医师协会核医学分会成立', '<span style="color:#494949;font-size:12px;"><p>根据中国医师协会章程的有关规定和沈阳市的工作情况，经沈阳市医师协会决定，成立沈阳市医师协会核医学分会，这是沈阳市医师协会成立的第28个专科分会。成立大会于2009年12月5日在中国医科大学附属第一医院第三会议室举行。沈阳市医师协会会长、沈阳市卫生局副局长刘正贵，沈阳市医师协会秘书长董艳红，沈阳市医师协会办公室主任王兴波出席会议。会议由王兴波主任主持。经选举，中国医科大学附属第一医院核医学科主任李亚明教授当选为第一届分会主任委员，沈阳市第五人民医院冯济龙主任、沈阳军区总医院张国序主任、中国医科大学附属盛京医院辛军主任当选为副主任委员，中国医科大学附属第一医院核医学科李雪娜讲师。刘正贵会长在会上做了讲话，明确了医师协会的工作要求和特点，提出了希望。李亚明主委代表第一届委员会讲话，表示要努力工作，完成好协会的职责和任务。</p><p style="text-align:right;"><span>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</span></p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/2009129132814140.jpg" /><br /></p><div style="text-align:center;">沈阳市医师协会会长、沈阳市卫生局副局长刘正贵，沈阳市医师协会秘书长董艳红，沈阳市医师协会办公室主任王兴波出席会议并讲话</div></span>', '2009-12-11 10:55:14', 8),
(79, 'Wagner教授和核医学界同仁告别', '<span style="font-family:helvetica, arial, sans-serif;font-size:14px;">Wagner教授宣布2009年在Toronto SNM年会上的Highlights是他的最后一次总结报告<br />Wagner Highlights Tradition Ends<br />From the Newsline editor: On October 26, Henry N.Wagner, Jr., MD, forwarded the following letter to Heinrich Schelbert, MD, PhD, editor in chief of The Journal of&nbsp;<span>Nuclear</span>&nbsp;<span>Medicine</span>&nbsp;(JNM). It appears in its entirety in Newsline, where excerpts from Wagner’s internationally<br />acclaimed Highlights lectures appeared in various formats for more than 3 decades. Since 2000, we have been honored each year to work with Dr. Wagner in publishing in Newsline the complete Highlights lecture, including the majority of images presented.<br /><br />THANKS TO ALL!<br />On October 20, I met 10 young, bright Japanese nuclear medicine physicians, with their distinguished leader, Jin-ichi Sasanuma, MD, from the Southern Tohoko Hospital in Fukushima, Japan, at the outpatient entrance to Johns Hopkins Hospital and accompanied them on a tour of the<br />in- and outpatient nuclear medicine department. We then presented a program in which senior Johns Hopkins scientists presented their research in radiation oncology and radiopharmaceutical design and development. The next day, with my wife, Anne, I watched the sunrise over the Atlantic Ocean and the brilliant sky at sunset. We decided<br />then that the time had come to say goodbye to my annual Highlights<br />talks at the end of each meeting of the SNM. The 33rd consecutive<br />talk, delivered in Toronto, was my last.<br />I want to thank all who attended the talks over all these years, those who sent me slides and discussed their work with me, Judy Buchanan who did the statistical analysis of the submitted material, and Nancy<br />Knight, PhD, who edited the written version of my talks for subsequent publication in the Newsline section of JNM.<br />Thanks to all of you. Keep up your revolutionary work that is transforming the practice of medicine, including the design and development of new drugs and the increasingly rational approach to surgical treatment. All the best.</span>', '2009-12-14 16:29:43', 10),
(80, '2009年原子高科与北京地区核医学界研讨会在京召开', '<span style="color:#494949;font-size:12px;"><p>2009年<span>12月12日</span>下午由原子高科与北京市核医学分会共同召开原子高科与北京地区核医学界研讨会。<span>160余位北京地区核医学工作者及原子高科股份有限公司高层领导参加了会议。</span><br /><br />　　会议由原子高科副总经理范国民主持，首先由原子高科总裁张锦荣就“全球钼危机，中国怎么办？”为题向与会者报告了目前全球鍀药状况，全球现有<span>54个核反应堆，仅有6个可以生产钼-99同位素，因设备老化退役或生产能力小等原因，只有南非的钼料液可向中国市场供应，而中国目前尚无生产钼的核反应堆运行，建造新的反应堆提供料液需一年半时间，因此，现在处于鍀药供应相对困难时期，原子高科请核医学界理解，并愿与全国核医学界同心协力，共渡难关。</span>其后，陈大明经理汇报了原子高科体内药物研究的最新进展。<br /><br />　　北京医学会付志春主任、中华核医学分会田嘉禾主委、北京核医学分会李方主委代表北京核医学界感谢原子高科多年来对中国核医学界的支持，理解原子高科及其它供药厂家面临的困难，愿与厂家共同配合，通力协作，同心同德，站在长远战略高度上促进中国核医学发展。<br /><br />　　大会在热情、友好的气氛中圆满结束。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091216102412578.jpg" />　<img alt="" src="http://csnm.cma.org.cn/upload/20091216102421958.jpg" /></p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091216102428134.jpg" />　<img alt="" src="http://csnm.cma.org.cn/upload/20091216102436218.jpg" /></p></span>', '2009-12-16 11:48:50', 8),
(81, '2009年北京年核医学学术年会在北京召开', '<span style="color:#494949;font-size:12px;"><p>　200<span>9</span>年12月13日上午由北京医学会第八届核医学专业委员会与首都医科大学核医学系联合在北京召开了2009年核医学年会，有来自北京市各医院的核医学工作者近200人参加了大会。<br /><br />　　会议由北京核医学分会王铁副主任委员和马云川副主任委员主持，北京医学会组织管理部付志春主任和全国核医学分会田嘉禾主任委员分别致辞，对第八届北京核医学分会的工作给予充分肯定和高度评价，希望全体北京分会委员、青年委员及北京核医学工作者共同努力，推动核医学发展的进程。<br /><br />　　北京核医学分会李方主任委员向北京地区核医学工作者汇报了第八届北京核医学分会成立以来为北京核医学发展所做的工作。<br /><br />　　大会上对北京市在长沙核医学学术大会及青岛PET/CT读片会的优秀论文获奖的核医学工作者进行了表彰，感谢他们为北京核医学分会争了光，为中国核医学发展做出了贡献。<br /><br />　　两会获奖者分别在大会上做了优秀论文和优秀病例报告，给北京地区没有参加两会的核医学工作者提供了一个学习的机会，与会者积极参与讨论，会议学术气氛浓厚，大会取得圆满成功。</p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091216103126386.jpg" />　<img alt="" src="http://csnm.cma.org.cn/upload/20091216103133254.jpg" /></p><p style="text-align:center;"><img alt="" src="http://csnm.cma.org.cn/upload/20091216103141287.jpg" />　<img alt="" src="http://csnm.cma.org.cn/upload/20091216103147126.jpg" /></p></span>', '2009-12-16 11:49:22', 10),
(82, '广东省医学会核医学分会第四季度学术活动总结', '<span style="color:#494949;font-size:12px;">　2009年12月14日下午3：00，在南方医院PET中心三楼学术报告厅由法国南特（Nantes）大学YVES THOMAS教授进行学术讲座。法国南特大学投资3亿余欧元建成了目前全球最大功率70MeV的ARRONAX回旋加速器中心，讲座内容主要介绍南特大学南特ARRONAX回旋加速器关于放射性药物的研究进展，包括正电子显像药物及α核素内照射治疗药物等。同时YVES THOMAS教授受南特大学校长委托前来中国招收研究生，并希望在广州寻找合作伙伴。<br /><br />　　参加这次学术活动的有广州和深圳的核医学工作人员50余人，还有中国原子能科学研究院广州原子高科及广州君奇医药科技有限公司的领导和专家参加了会议。YVES THOMAS教授讲座结束后，就大家关心的问题进行了的讨论，气氛热烈，收到良好效果。<span>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></span>', '2009-12-16 11:49:42', 5),
(83, '最先进肿瘤检查设备落户武汉 做检查仅10分钟', '<span style="font-size:15px;font-family:verdana, arial, sunsans-regular, sans-serif;">华中地区最先进的肿瘤检查设备落户广州军区武汉总医院。该院PET-CT中心主任李国雄介绍，用这种设备做一次全身检查仅需10分钟，它可对肿瘤、复杂病变区域进行精确定性及定位，可获得更准确的“一站式”诊断图像。</span>', '2009-12-17 10:29:41', 23),
(84, 'RapdiArc直线加速器在山东省肿瘤医院落户', '<span style="color:#333333;font-family:tahoma, arial, sans-serif;font-size:12px;"><p>2009年11月15日，山东省肿瘤医院隆重举行RapdiArc直线加速器开机典礼。这是我院报省卫生厅批准新引进的、目前国际领先的美国瓦里安公司最新一代装备RapdiArc和IGRT功能的Trilogy直线加速器，经过前期安装调试和试运行，于今天正式交付临床开机使用。<br /><br />　　开机典礼在我院放疗区举行，中华医学会肿瘤放疗分会副主任委员张洪志教授、中华医学会肿瘤放疗分会秘书长夏廷毅教授及分会的部分常委、美国瓦里安公司市场和商务拓展总监Thomas Patrick Duffy博士、山东省肿瘤医院副院长李敏教授、以及来自省内外的部分专家应邀出席。中华医学会放射肿瘤治疗学分会主任委员、山东省肿瘤医院院长于金明教授致欢迎词，瓦里安公司Thomas Patrick Duffy博士致辞，山东省肿瘤医院院长助理李宝生教授主持。</p><p><a target="_blank" href="http://www.sd-cancer.com/pics/2009/11/yu_thomas.jpg"><img alt="于金明教授与Thomas Patrick Duffy博士亲切交谈" src="http://www.sd-cancer.com/pics/2009/11/yu_thomas-200.jpg" height="150" width="200" /></a>　　于金明院长代表山东省肿瘤医院对出席开机典礼的嘉宾表示热烈欢迎，他指出RapdiArc直线加速器的成功运行标志着我院肿瘤疾病的诊疗工作进入一个新的发展阶段，将为提高我省医疗服务水平、增强肿瘤学临床教学和科研能力、解决群众看病难问题做出新贡献。他希望山东省肿瘤医院以此为契机，团结协作，刻苦钻研，充分发挥先进设备的作用，争取创造最大的社会效益，在技术创新的实践中，不断提高医疗技术水平，服务于病人，奉献于社会。<br /><br />　　Thomas Patrick Duffy博士在致辞中表示，瓦里安公司对于与山东省肿瘤医院保持了长达20年的合作伙伴关系深感荣幸，山东省肿瘤医院去年申报的关于肝癌的IGRT研究项目获得了瓦里安医疗系统面向全球的科研经费资助，也是中国第一个获得瓦里安专项支持的项目，同时感谢以于金明教授为首的放射肿瘤学团队为中国放射治疗事业进步所做出的贡献。<br /><br />　　据介绍，这是山东省第一台装备RapdiArc和IGRT功能的直线加速器，与其他的直线加速器相比，RapdiArc直线加速器具有速度快、损伤小等突出优势。<br /><br />　　开机仪式结束后，“Best of Arstro 2009”学术研讨会拉开帷幕，于金明教授做了关于“Best of ASTRO in Lung Cancer”的精彩报告,总结了2009年Arstro会议肺癌优秀研究成果，把国际前沿的研究信息带给了大家。李宝生教授、徐博教授、李建彬教授、王若峥教授等专家以及三位ASTRO大会报告者分别进行了学术讲座，使与会者享受了一次学术盛宴。</p></span>', '2009-12-21 11:39:37', 5),
(85, '山东齐鲁医院院举行PET-CT开机典礼', '<span style="color:#333333;font-family:宋体;font-size:12px;">2009年12月13日上午，山东大学齐鲁医院PET-CT开机典礼暨与上海东泓实业发展有限公司开展技术服务合作签约仪式在济南喜来登酒店隆重举行。中华核医学会副主任委员、候任主任委员李亚明，山东省卫生厅副巡视员王天胜，德州市委常委、政法委书记李传武等来自国内、省内有关单位和兄弟医院的领导、专家200余人济济一堂、共襄盛举。典礼由山东电视台著名主持人李敏主持。<br />　　活动主办方代表――山东大学齐鲁医院院长魏奉才，远东国际租赁有限公司执行董事、常务副总经理方蔚豪，美国GE医疗集团大中华区副总裁宋金松先后致辞。魏奉才在致辞中指出，山东大学齐鲁医院是有着119年悠久历史的百年名院，多年来，医院始终坚持“博施济众”的办院理念，秉承“医道从德、术业求精”的院训，将深邃厚重的历史积淀和与时俱进的办院方针相结合，不断开创适应医学科学发展和社会需求的新局面。医院克服重重困难，建立PET-CT室，目的在于进一步推动山东大学齐鲁医院诊疗技术和科研水平实现全面提升，更好地满足人民日益增长的医疗服务需求，魏奉才在讲话中希望PET-CT室立足高起点，着眼高水平，树立高标杆，努力打造全省乃至全国一流的PET-CT室。<br />　　典礼上，魏奉才和方蔚豪分别代表山东大学齐鲁医院与上海东泓实业发展有限公司，在技术服务合作协议书上签字。9：18分，在震撼全场的鼓乐声中，山东大学齐鲁医院党委书记周日光、院长魏奉才与合作方代表方蔚豪、宋金松共同启动象征PET-CT项目的“水晶球”，现场彩条飞舞、亮光四射，象征着山东大学齐鲁医院PET-CT室光明美好的前景，整个典礼在热烈的掌声中落幕。<br />　　在随后举行的学术报告会上，我国核医学领域著名专家李亚明教授、吴翼伟教授等，就PET-CT应用技术、肿瘤早期诊断和PET-CT管理等作了精彩的学术报告。</span>', '2009-12-21 12:20:35', 13),
(86, '中国核学会2009年学术年会胜利闭幕', '<span style="color:#000000;"><span style="font-size:12px;font-family:verdana, arial, 宋体;"><br />\r\n<img height="265" src="/UploadPic/2009122111427243.jpg" width="400" />\r\n\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 在完成了全部预定目标之后，中国核学会2009年学术年会于11月20日在北京国家会议中心胜利闭幕。在三天的学术交流活动中，来自我国核工业、核基础科学、核应用技术等领域的知名院士、专家、教授及一线青年核科学技术工作者1300余人参加了会议。44位院士百忙之中亲临大会，研讨学术、交流观点和指导青年科技工作者。中国核科学技术所属21个二级学科的科技工作者，共提交了1719篇论文。参会者围绕核科学技术创新和核技术产业可持续发展等话题进行广泛的学术交流和研讨。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111459583.jpg" border="0" />\r\n</p>\r\n<p align="left"><font face="Verdana" size="2">大会主会场盛况</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 近年来，核电及相关产业蓬勃发展，科技创新硕果累累，核技术产业化进程加快，“创新”已经成为核科学技术进步的原动力和主旋律。因此，中国核学会将本届年会的主题确立为：“创新——核科学技术发展的不竭源泉”。 其目的就是为了展示和交流核科学技术各个学科领域的创新成果，推动各个学科交流、交叉与融合，促进核科技人才成长与提高，增强自主创新能力，推进核电、核燃料关联产业、核技术产业、核基础科学、核医学、核农学的全面发展。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111531870.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">大会主席台</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111545349.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">学术年会孙勤主席讲话</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/200912211161803.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">执行主席李冠兴院士致开幕词</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 本届学术年会由中国核工业集团公司承办，中核集团公司党组书记兼总经理孙勤同志担任大会主席；中国核工业建设集团公司、中国电力投资集团公司、国家核电技术公司、中国广东核电集团有限公司、中国人民解放军总装备部、中国工程物理研究院、清华大学等单位（部门）为协办单位。此外，中国核学会21个分支机构及21个省级地方核学会共同参与了筹办。为了开好本届学术年会，中国核学会七届一次常务理事会，于2008年11月4日决定建立学术年会制度，搭建全国性学术交流平台，更好发挥学术交流主渠道作用，以适应核电发展的大好形势，繁荣和发展核科学技术。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111624253.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">参会的学界前辈们</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111639355.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">44名参会院士与学会领导合影</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 在年会开幕式上，国家能源局、国家核安全局、国家原子能机构、国家科技部、中国科协等上级部门领导，及核能行业协会的领导出席开幕式，对学术年会的顺利召开表示祝贺。副理事长穆占英、孙汉虹、杨长利、邱爱慈等分别主持了开幕式和三个时段的邀请报告。中国核学会理事长李冠兴院士在学术年会开幕式上致辞。李院士指出，中国核学会始终秉承王淦昌等老一辈核科学家创会时的立会宗旨，紧密团结全国核科技工作者，充分发挥核科技领域学术交流主渠道、科普工作主力军、国际民间科技交流主要代表的作用，搭建高水平学术交流平台，大力推动核科学技术领域的自主创新和各学科间的交流与融合，围绕核技术发展中的重大问题，展示成果，交流观点，探讨学问，启迪思路，集思广益，博采众长，促进科技进步，促进人才成长。<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp; 孙勤同志在讲话中指出，提高科技创新力，建设创新性国家，是国家发展战略的核心和提高综合国力的关键。中核集团公司作为国家战略核力量的核心和核能发展的中坚，将本着“开放、包容、合作”的理念，加强与业界同行的沟通、交流与合作，围绕实现产能规模化发展，大力推进科技创新能力的全面提升。孙勤同志详细介绍了集团公司的发展思路，并对中国核学会的发展提出了三点殷切希望。孙勤同志希望中国核学会：进一步提高学术交流质量，鼓励自主创新；深入开展科普工作，营造和谐发展氛围；稳步推进学会改革，适应形势发展。</font></p>\r\n<p align="center"><img src="http://pet-tracer.com.cn/eWebEditor/UploadFile/2009122111711475.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana" size="2">11个分会场掠影</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 本届学术年会会期三天，除主会场外，还设立了11个分会场和4个时段的张贴报告区。中国工程物理研究院彭先觉院士、总装备部论证中心吕敏院士、国家核安全局李干杰局长、国家核电技术公司王炳华董事长、中国广东核电集团（有限）公司贺禹总经理、中核集团公司地质局张金带研究员、中国原子能科学研究院徐銤研究员、中国核电工程（有限）公司范仲研究员、中国国际核聚变能源计划执行中心程津培院士、高能物理所张闯研究员、清华大学康克军教授、浙江大学徐步进教授、上海医科大学黄钢教授等13名相关领域专家，应邀在主会场作大会报告。486名科技工作者分别在11个分会场，进行口头报告交流；此外，在张贴报告区，4个时段共张贴1220篇报告，作者与感兴趣的同行在现场进行面对面的交流与讨论。年会期间，还举行了青年科技工作者座谈会。</font></p>\r\n<p align="center"><img src="/eWebEditor/UploadFile/2009122111821357.jpg" border="0" />\r\n</p>\r\n<p align="center"><img style="width:580px;height:387px;" height="387" alt="" src="/eWebEditor/UploadFile/2009122111835731.jpg" width="580" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">张贴报告区掠影</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11月19日，学术年会学术委员会依据中国核学会七届二次常务理事会通过的《中国核学会学术年会优秀学术论文评选表彰办法（试行）》和《中国核学会学术年会青年优秀科技论文评选表彰办法（试行）》，在各学科推荐的基础上，经过严格评审，评选出获奖的103篇论文，其中优秀学术论文一等奖18篇、二等奖24篇、三等奖35篇，青年优秀科技论文奖26篇。</font></p>\r\n<p align="center"><img src="/eWebEditor/UploadFile/2009122111936691.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">年会期间举行的卫星会议</font></p>\r\n<p align="center"><img src="/eWebEditor/UploadFile/2009122111956268.jpg" border="0" />\r\n</p>\r\n<p align="center"><font face="Verdana" size="2">青年座谈会会场</font></p>\r\n<p><font face="Verdana" size="2">&nbsp;&nbsp;&nbsp;&nbsp; 大会于11月20日下午结束全部议程，当天晚上举行了隆重简洁的闭幕仪式及晚宴，闭幕式及晚宴由核学会秘书长潘传红主持。闭幕式上李冠兴院士致辞，热烈祝贺本届年会取得圆满成功，感谢为大会作出贡献的单位和个人，勉励与会核科技工作者再接再厉，并相约两年后下一届学术年会再见。随后，副理事长丁中智代表中国核学会，宣读表彰2009年学术年会“优秀学术论文”和“青年优秀科技论文”的决定，学会领导和院士向获奖论文的作者颁发获奖证书，颁奖仪式结束后，学术年会组委会举办了隆重的招待宴会。</font></p>\r\n<p align="center"><img src="/eWebEditor/UploadFile/20091221111019965.jpg" border="0" />\r\n</p>\r\n<p><font face="Verdana"><font size="2">获一等奖的“优秀学术论文”作者们</font></font></p><font face="Verdana"><font size="2">\r\n<p align="center"><img src="/eWebEditor/UploadFile/20091221111048145.jpg" border="0" />\r\n</p></font></font>\r\n<p align="left"><font face="Verdana"><font size="2">（中国核学会）</font></font></p></span></span>', '2009-12-29 10:13:29', 2);
INSERT INTO `yiliao_active` (`id`, `name`, `content`, `add_time`, `click`) VALUES
(87, '国际性“少钼缺鍀”看中国核医学的发展 ', '<span style="color:#000000;"><span style="font-size:14px;color:#012b31;font-family:verdana, arial, helvetica, sans-serif;">\r\n\r\n这些幻灯片应该可以对近期出现的"少钼缺鍀"，以及传说的放射性药物涨价的问题有一个解释。张锦荣总裁说由于全球钼的产量不足，现在进口的99钼料液已经从270$/Ci涨到600$/Ci，而且供货量总比订货量少，这就造成国内"缺鍀"。张总建议，通过合理安排病人可以解决大部分问题：比如把多数检查和较高剂量的检查（骨骼、心脏）安排在周一、二、三，此时发生器的淋洗液的比活度高，剂量足。<br />\r\n<br />\r\n　　不过，更加紧迫的问题是0004号幻灯。泱泱大中国99钼的用量竟然还赶不上韩国，可见咱们国家核医学是个什么水平要引起大家深思．<br />\r\n\r\n　　有句俗语：水里的鱼永远不知道水是什么，因为它们就生活在水里．\r\n\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11425&amp;nothumb=yes" target="_blank">0002.jpg</a><span>&nbsp;</span><em>(147.22 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0002.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_b333f3c6b64f1db0fe80X16ZWFZA4XZg.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11426&amp;nothumb=yes" target="_blank">0003.jpg</a><span>&nbsp;</span><em>(204.1 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0003.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_b48f3e540f881c73cbab9LAVpr3Q8IcR.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11427&amp;nothumb=yes" target="_blank">0004.jpg</a><span>&nbsp;</span><em>(135.1 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0004.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_164d38061c3d4a155639uuwlsTxuIV0s.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11428&amp;nothumb=yes" target="_blank">0005.jpg</a><span>&nbsp;</span><em>(184.77 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0005.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_befdedcf68aeb5540189O30YHGJ9jwsY.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11429&amp;nothumb=yes" target="_blank">0006.jpg</a><span>&nbsp;</span><em>(191.77 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0006.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_c632b0fdb0a43ae6b9c1q13lUZdjM0oB.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11430&amp;nothumb=yes" target="_blank">0007.jpg</a><span>&nbsp;</span><em>(186.25 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0007.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_0fa2ca4db5a1dd20c772xK1aglTlzF3P.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11431&amp;nothumb=yes" target="_blank">0008.jpg</a><span>&nbsp;</span><em>(182.86 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0008.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_a88de9ad031df0d8a0a2IOXOayoz5cpf.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11432&amp;nothumb=yes" target="_blank">0009.jpg</a><span>&nbsp;</span><em>(179.03 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0009.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_8a2fc1d358f7982a7fb6ouGPWNkbEmKU.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11433&amp;nothumb=yes" target="_blank">0011.jpg</a><span>&nbsp;</span><em>(221.42 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0011.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_d63cee5c03fc32d87551VyUMhp5hN8en.jpg" />\r\n</p>\r\n\r\n<p>&nbsp;</p>\r\n<p><img alt="0012.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_7b0b03383b6189e42b24cl04a1pM3uKu.jpg" />\r\n</p>\r\n\r\n<img alt="" src="http://bbs.csnm.com.cn/images/attachicons/image.gif" border="0" />\r\n<span>&nbsp;</span><a href="http://bbs.csnm.com.cn/attachment.php?aid=11435&amp;nothumb=yes" target="_blank">0013.jpg</a><span>&nbsp;</span><em>(162.36 KB)</em>\r\n\r\n<p>2009-12-13 22:25</p>\r\n<p><img alt="0013.jpg" src="http://bbs.csnm.com.cn/attachments/month_0912/20091213_6b7268f401db9176d12dVJkaIUTsj1MD.jpg" />\r\n</p>　</span></span>', '2009-12-29 10:16:46', 2),
(88, '核医学习题集（第2版）近日已由人卫社出版 ', '<span style="color:#000000;"><span style="font-size:14px;color:#012b31;font-family:verdana, arial, helvetica, sans-serif;">\r\n<p align="left">　由华中科技大学协和医院高再荣教授主编的《核医学与核医学技术精选模拟习题集》（第2版）近日已由人民卫生出版社出版，书号ISBN 978-7-117-12193-4/R.12194。 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />\r\n<br />\r\n　　为了配合全国<span style="font-family:宋体;">卫生专业技术资格考试，我们于2008年编写了《核医学与核医学技术精选模拟习题集》（第1版），该习题集自出版以来，受到了广大读者的欢迎。结合新版考试指导，我们决定对第</span><span>1</span><span style="font-family:宋体;">版习题集进行修订，以满足读者需要。</span><span><span></span></span></p>\r\n<p><br />\r\n　　<span style="font-family:宋体;">第</span><span>2</span><span style="font-family:宋体;">版习题集在基础知识、相关专业知识、专业知识和专业实践能力等四个方面对每一考点均针对性地加强了习题训练，按照熟练掌握（掌握）、熟悉和了解等不同要求，在题量上有所侧重，力争通过对本版习题集的学习，达到全面掌握相关内容的目的。因新的考试指南在部分内容上有所改变，因此本版习题集的题目也进行了相应的删减和增加。如本版习题集中新增了磷屏成像、呼吸系统部分疾病（肺动脉栓塞、慢性阻塞性肺病、肺结核）的临床表现、诊断、治疗、预后和其他影像学表现等内容的题目；删除了肿瘤章节中的放射免疫显像、</span><sup><span>99m</span></sup><span>Tc(V)-DMSA</span><span style="font-family:宋体;">肿瘤显像和生长抑素受体显像等内容的题目。另外，在核医学技术部分，有关首次通过法心室造影的题目也被删除。<br />\r\n</span></p>\r\n<p><span style="font-family:宋体;">　　</span><span style="font-family:宋体;">该模拟习题集既作为参加初中级职称考试的考生尽快掌握考点和适应考试形式的学习资料，也可作为教学和临床工作的工具书。人民卫生出版社购书热线：010-67605754，65264830。</span></p>\r\n<p align="center"><span style="font-family:宋体;"></span></p></span></span>', '2009-12-29 10:20:09', 4),
(89, '中华医学会核医学分会就人力资源和社会保障部颁布《药品目录》问题的说明', '<tr><td class="xhuiz" style="font-size:12px;color:#494949;"><div>人力资源和社会保障部于2009年11月27日颁布了《国家基本医疗保险、工伤保险和生育保险药品目录（2009年版）》，在给各地人力资源和社会保障厅（局）的通知中，第十二条明确提出“本版《药品目录》未列入的放射性同位素药物，将纳入医疗服务项目管理…”。现就有关背景介绍如下：</div><div>&nbsp;</div><div><span>1．&nbsp;</span>人力资源和社会保障部今年在重新修订《药品目录》的工作中，调查了各个国家相应《药品目录》的执行情况，发现大多数国家的《药品目录》中都不包括放射性药物等诊断性药物，而是包含在诊疗项目中。今年8月15日人力资源和社会保障部医保司领导召集在京的部分核医学、放射、超声的专家座谈，就国外的情况做了说明，并建议国内放射性药物等诊断性药物也不列入我国的《药品目录》，而纳入医疗服务项目管理（如<sup>99m</sup>Tc-MDP包含在骨显像项目中）。与会专家对医保司的建议进行了充分的讨论，基本同意了将诊断性药物纳入医疗服务项目管理。因核医学治疗的特殊性，核医学分会提交了核素治疗的相关材料，同样建议纳入医疗服务项目管理。</div><div>&nbsp;</div><div><span>2．&nbsp;</span>在人力资源和社会保障部的通知中，第五条指明“各省应于2010年3月31日前发布本地区医疗保险、工伤保险和生育保险药品目录，各统筹地区要在2010年6月30日前完成计算机信息管理系统药品数据库的更新工作” 。</div><div>&nbsp;</div><div>&nbsp;</div><div>中华核医学会领导对此事非常重视，田主委指示将“通知”尽快送达各省、市的核医学分会的主委，并要求各分会组织相应的医保工作组，于2010年3月31日前做好放射性药物纳入医疗服务项目管理的工作。</div><div>&nbsp;</div><div>附：人力资源和社会保障部“通知”</div><div>&nbsp;</div><div><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>中华医学会核医学分会</div><div><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2009-12-15</span></div><p></p><div align="center"><b><span style="font-size:22pt;color:#3f3f3f;">关于印发国家基本医疗保险、工伤保险</span></b></div><div align="center"><b><span style="font-size:22pt;color:#3f3f3f;">和生育保险<u>药品目录</u>的通知</span></b></div><div align="left" style="text-align:left;"><span style="font-size:14pt;color:#3f3f3f;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="font-size:14pt;color:#3f3f3f;">11/27/2009</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">各省、自治区、直辖市人力资源社会保障（劳动保障）厅（局），新疆生产建设兵团劳动保障局：</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">为贯彻落实《中共中央国务院关于深化医药卫生体制改革的意见》(中发［2009］6号)、《国务院关于印发医药卫生体制改革近期重点实施方案(2009-2011年)的通知》(国发［2009］12号)精神，重点做好与加快医疗保障体系建设、初步建立国家基本药物制度、加强医疗服务监管和探索建立医疗保险谈判机制4方面政策的衔接，我部按照《医药卫生体制五项重点改革2009年工作安排》（国办函［2009］75号）的要求，以及《城镇职工基本医疗保险用药范围管理暂行办法》（劳社部发［1999］15号）和《工伤保险条例》的规定，经过组织专家进行药品遴选，制定了《国家基本医疗保险、工伤保险和生育保险药品目录（2009年版）》（以下简称《药品目录》），现印发各地，请遵照执行。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">一、调整制定2009年版《药品目录》，是贯彻落实党中央、国务院深化医药卫生体制改革文件的重要举措，对于完善医疗、工伤、生育保险制度，提高群众的保障水平，逐步实现人人享有基本医疗保障的目标，具有重要的意义。各省（自治区、直辖市）人力资源社会保障部门要统一思想，提高认识，认真做好《药品目录》的组织实施工作。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">二、2009年版《药品目录》在保持参保人员用药政策相对稳定连续的基础上，根据临床医药科技进步与参保人员用药需求变化，适当扩大了用药范围和提高了用药水平。本版《药品目录》适用于基本医疗保险、工伤保险和生育保险，是基本医疗保险、工伤保险和生育保险基金支付参保人员药品费用和强化医疗保险医疗服务管理的政策依据及标准。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">三、《药品目录》分西药、中成药和中药饮片3部分。其中，西药部分和中成药部分用准入法，规定基金准予支付费用的药品，基本医疗保险支付时区分甲、乙类，工伤保险和生育保险支付时不分甲、乙类；中药饮片部分用排除法，规定基金不予支付费用的药品。参保人员使用目录内西药、中成药和目录外中药饮片所发生的费用，具体给付标准按基本医疗保险、工伤保险和生育保险的有关规定执行。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">四、《国家基本药物目录》内的治疗性药品已全部列入《药品目录》甲类药品。统筹地区对于甲类药品，要按照基本医疗保险的规定全额给付，不得再另行设定个人自付比例。对于乙类药品可根据基金承受能力，先设定一定的个人自付比例，再按基本医疗保险的规定给付。对于国家免费提供的抗艾滋病病毒药物和国家基本公共卫生项目涉及的抗结核病药物、抗疟药物和抗血吸虫病药物，参保人员使用且符合公共卫生支付范围的，基本医疗保险、工伤保险和生育保险基金不予支付；不符合公共卫生支付范围的，基本医疗保险、工伤保险和生育保险基金按规定支付。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">五、各地要分步做好《药品目录》的组织实施工作。甲类药品，各省（自治区、直辖市）不再进行调整，各统筹地区应于今年12月份开始执行使用。乙类药品，各省（自治区、直辖市）可按规定进行调整后，再由所辖统筹地区执行使用。民族药和中药饮片部分，各地按现有政策继续执行。</span><b><span style="font-size:14pt;color:red;">各省（自治区、直辖市）应于2010年3月31日前发布本地基本医疗保险、工伤保险和生育保险药品目录，各统筹地区要在2010年6月30日前完成计算机信息管理系统药品数据库的更新工作。</span></b></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">六、各省（自治区、直辖市）调整乙类药品时，不得要求企业申报，不得以任何名目向企业收取费用。对国家基本药物和仅限工伤保险的品种，不得将其从目录中调出。对《药品目录》规定的药品限定支付范围，可以进行调整但不得取消。对药品名称不得使用或标注商品名。各省（自治区、直辖市）乙类药品调整品种应按规定报我部备案，调整品种总数（含调入、调出和调整限定支付范围的药品品种）不得超过243个。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">七、各统筹地区要严格执行本省（自治区、直辖市）基本医疗保险、工伤保险和生育保险药品目录，并按照有关规定更新定点医疗机构纳入基金支付范围的医院制剂清单，但不得以任何名义调整《药品目录》或另行制订药品目录。要根据辖区内医疗机构和零售药店药品使用情况，做好《药品目录》内药品名称的对应工作，及时更新信息管理系统的药品数据库，有条件的省（自治区、直辖市）可统一更新药品数据库。要按照药品通用名称支付参保人员药品费用，不得按商品名进行限定，不能以药品数据库没有更新为由拒付参保人员费用。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">八、各地要加强《药品目录》使用情况的监测与分析。通过统一药品代码，完善分析指标，逐步建立药品使用情况的监测分析体系。要充分利用药品使用情况基础数据，对参保人员各类药品用量和各项保险费用支出情况进行分析，加强对用量大、费用支出多药品的重点监测，有重点、有针对性地采取监管措施，以加强对医疗过程中药品滥用等不良行为的控制。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">九、各地要加强定点医疗机构和零售药店使用《药品目录》的管理。医师开具西药处方须符合西医疾病诊治原则，开具中成药处方须遵循中医辩证施治原则和理法方药，对于每一最小分类下的同类药品原则上不宜叠加使用。对按西医诊断开具中成药、按中医诊断开具西药等不合理用药、重复用药和药物滥用等，要明确相应的处罚措施并纳入定点协议管理。要采取措施鼓励医师按照先甲类后乙类、先口服制剂后注射制剂、先常释剂型后缓（控）释剂型等原则选择药品，鼓励药师在调配药品时首先选择相同品种剂型中价格低廉的药品。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">十、各地要参照卫生等有关部门制定的处方管理办法、临床技术操作规范、临床诊疗指南和药物临床应用指导原则等，加强对临床用药合理性的监督检查，进一步明确药品限定支付范围，完善药品费用审核办法，严格药品费用支付管理。要将定点医疗机构和定点零售药店执行使用《药品目录》的情况，纳入定点服务协议管理和定点服务考核范围，并进一步完善管理考核指标，加大监督检查力度。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">十一、各地要进一步完善医疗保险用药分类支付管理办法。对于《药品目录》内同一品种剂型规格的药品，可探索设定最高支付限额标准。对乙类药品中主要起辅助治疗作用的药品，可适当加大个人自付比例，拉开与其他乙类药品的支付比例档次。对临床紧急抢救与特殊疾病治疗所必需的目录外药品，要建立定点医疗机构申报制度并明确相应的审核管理办法。对于《药品目录》内可用于自我药疗的药品，原则上规定为，参保人员住院使用时由基本医疗保险统筹基金支付；门诊使用时限个人帐户支付。对于未列入《药品目录》但由目录内西药品种组成的复合药（包括含药大输液），如果其价格不高于其所组成药品价格之和的，可视同乙类药品按规定予以支付，具体管理办法由各地制订。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">十二、做好药品目录管理与医疗服务项目管理和费用结算管理的衔接。</span><b><span style="font-size:14pt;color:red;">本版《药品目录》未列入的放射性同位素类药物，将纳入医疗服务项目范围进行管理，各地在具体办法出台前仍可按原有政策执行</span></b><span style="font-size:14pt;color:#3f3f3f;">。</span><b><span style="font-size:14pt;color:red;">对于《药品目录》内的影像诊断用药，要结合医疗服务项目管理，加强费用的审核支付</span></b><span style="font-size:14pt;color:#3f3f3f;">。对实行按总额、按病种、按定额等结算办法的地区，要从保障参保人员获得必需药品的角度出发，探索完善相应的考核管理措施，以确保在控制费用、强化管理和建立风险共担机制的同时，保障参保人员的基本权益。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">十三、本次发布的《药品目录》中未包括谈判准入的药品。我部将会同有关部门研究制订药品谈判机制的有关规则，建立相应的工作组织体系，确定谈判准入的药品类别，组织社会保险经办机构与药品供应商，对临床疗效确切有重大创新价值但价格昂贵可能对基金产生风险的部分药品品种及其费用支付方式和标准进行谈判。具体办法另行发布。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">十四、各地在《药品目录》调整工作和组织实施过程中，如有重大问题，要及时报告。</span></div><div align="left"><span style="font-size:14pt;color:#3f3f3f;">　　</span></div><div align="right"><span style="font-size:14pt;color:#3f3f3f;">　　人力资源和社会保障部</span></div><div align="right"><span style="font-size:14pt;color:#3f3f3f;">　　二00九年十一月二十七日</span></div></td></tr>', '2009-12-31 13:37:43', 1);

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_guangao`
--

CREATE TABLE IF NOT EXISTS `yiliao_guangao` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(200) NOT NULL,
  `content` text NOT NULL,
  `add_time` datetime NOT NULL,
  `click` int(11) NOT NULL COMMENT '点击数',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 AUTO_INCREMENT=26 ;

--
-- Dumping data for table `yiliao_guangao`
--

INSERT INTO `yiliao_guangao` (`id`, `name`, `content`, `add_time`, `click`) VALUES
(1, '恭喜李先生预约上海PET/CT检查成功！', '', '2009-11-18 21:08:25', 0),
(3, '恭喜朱女士预约无锡PET/CT检查成功！', '', '2009-11-18 21:09:22', 0),
(4, '恭喜蔡先生预约上海PET/CT检查成功！', '', '2009-11-18 21:36:52', 0),
(5, '恭喜王先生预约北京PET/CT检查成功！', '', '2009-11-18 21:37:15', 0),
(6, '恭喜刘先生预约浙江PET/CT检查成功！', '', '2009-11-18 21:37:35', 0),
(7, '恭喜龚先生预约南京PET/CT检查成功！', '', '2009-11-18 21:37:52', 0),
(8, '恭喜杨女士预约杭州PET/CT检查成功！', '', '2009-11-18 21:38:18', 0),
(9, '恭喜陆先生预约福建PET/CT检查成功！', '', '2009-11-18 21:38:52', 0),
(10, '恭喜何先生预约合肥PET/CT检查成功！', '', '2009-11-18 21:39:30', 0),
(11, '恭喜徐女士预约北京PET/CT检查成功！', '', '2009-11-18 21:42:34', 0),
(12, '恭喜郭先生预约河北PET/CT检查成功！', '', '2009-11-18 21:43:07', 0),
(13, '恭喜罗先生预约广州PET/CT检查成功！', '', '2009-11-18 21:44:29', 0),
(14, '恭喜何先生预约广州PET/CT检查成功！', '', '2009-11-18 21:44:50', 0),
(15, '恭喜孙先生预约福建PET/CT检查成功！', '', '2009-11-18 21:45:14', 0),
(16, '恭喜张先生预约四川PET/CT检查成功！', '', '2009-11-18 21:45:50', 0),
(17, '恭喜刘先生预约宁波PET/CT检查成功！', '', '2009-11-18 21:46:02', 0),
(18, '恭喜顾先生预约上海PET/CT检查成功！', '', '2009-11-26 10:19:07', 0),
(19, '恭喜陶先生预约江苏PET/CT检查成功！', '', '2009-11-26 10:19:23', 0),
(20, '恭喜汪先生预约北京PET/CT检查成功！', '', '2009-11-26 10:19:38', 0),
(21, '恭喜孙先生预约华西村PET/CT检查成功！', '', '2009-12-02 19:16:19', 0),
(22, '恭喜戴先生预约上海PET/CT检查成功！', '', '2009-12-11 21:43:02', 0),
(23, '恭喜旺先生预约上海PET/CT检查成功！', '', '2009-12-11 21:43:14', 0),
(24, '恭喜刘先生预约河北PET/CT检查成功！', '', '2009-12-11 21:43:33', 0),
(25, '恭喜吴女士预约北京PET/CT检查成功！', '', '2009-12-11 21:43:50', 0);

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_jigou`
--

CREATE TABLE IF NOT EXISTS `yiliao_jigou` (
  `j_id` int(11) NOT NULL AUTO_INCREMENT,
  `j_name` varchar(200) NOT NULL,
  `j_shenfen` varchar(100) NOT NULL COMMENT '所在省份',
  `j_jiage` varchar(20) NOT NULL COMMENT '检查价格',
  `j_jibie` varchar(30) NOT NULL COMMENT '医院级别',
  `j_time` datetime NOT NULL,
  `j_ip` varchar(20) NOT NULL,
  `j_content` text NOT NULL,
  `j_zhuanjia` text NOT NULL COMMENT '专家介绍',
  `user_name` varchar(200) NOT NULL,
  `j_image_count` int(10) unsigned NOT NULL DEFAULT '0',
  `j_click` int(11) NOT NULL DEFAULT '0' COMMENT '点击排序',
  `j_star` int(11) NOT NULL,
  `home_page` int(11) NOT NULL COMMENT '首页显示的位置',
  `google_map` varchar(200) NOT NULL COMMENT 'google地图的坐标点',
  `j_weizi` varchar(255) NOT NULL COMMENT '医院位置',
  `click` int(11) NOT NULL COMMENT '点击数',
  PRIMARY KEY (`j_id`),
  KEY `j_jiage` (`j_jiage`),
  KEY `j_click` (`j_click`),
  KEY `j_star` (`j_star`),
  KEY `home_page` (`home_page`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=126 ;

--
-- Dumping data for table `yiliao_jigou`
--

INSERT INTO `yiliao_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `j_zhuanjia`, `user_name`, `j_image_count`, `j_click`, `j_star`, `home_page`, `google_map`, `j_weizi`, `click`) VALUES
(35, '上海仁济医院PET-CT中心', '上海', '7500', '三甲', '2009-08-11 10:03:56', '116.228.54.246', '【医院介绍】仁济医院建于1844年,迄今已有164年的历史,成为学科门类齐全，集医疗、教学、科研于一体的综合性三级甲等医院。\r\n\r\n【中心介绍】2003年7月伴随着上海第一台PET-CT,GE''s Discovery LS PET/CT 装置在上海仁济医院顺利装机、投入试运行，上海仁济医院PET-CT中心宣告成立。PET-CT运行、操作、诊疗的质量保证与质量控制的规范和流程，并在随后的实际操作中不断改进、充实，目前已经形成了一个比较稳定、完善的PET-CT中心运行、诊疗和管理体系。\r\n\r\n【设备型号】GE Discovery LS PET/CT\r\n\r\n\r\n\r\n【乘车路线】01、581、593、606、610、614、771、772、789、\r\n814、980、989、大桥二线、隧道九线、轨道交通四号线、六号线均可到达。\r\n\r\n\r\n', '【中心专家】本中心现有从业人员15人，其中：医生6人，工程技术人员3人，护理人员4人，其他管理和医疗辅助人员2人；医技人员中，高级职称者3人，中级职称者3人。本中心聘请我国著名放射学专家、华山医院原院长陈星荣教授，上海医学放射学会秘书长、仁济医院放射科主任许建荣教授等为顾问、会诊专家定期或不定期地在本中心进行疑难病例讨论、会诊。', 'admin', 12, 0, 5, 2, '31.20726,121.524152', '上海市浦东新区东方路1630号仁济医院东部2号楼', 517),
(34, '上海455医院PET-CT高端体检中心', '上海', '7500', '部队三甲', '2009-08-10 20:07:32', '114.81.19.25', '【中心介绍】全国首家以PET-CT高级检查和常规体检一体化管理的高端体检中心。中心总面积1200多平方米，拥有目前最先进的数字化体检管理平台、能够保证体检结果的快速（3个工作日）、准确、可靠，同时实现了Internet网上查询及短信查询功能。\r\n\r\n【设备型号】Discovery ST16 PET－CT\r\n\r\n\r\n\r\n【乘车路线】轨道交通：地铁三号线、四号线虹桥路下 公交：48、72、113、26、76、572、806、138、506路均可 火车：上海火车站西南出口乘113路公交车到番禺路站下 飞机：虹桥机场乘坐806路公交车至番禺路站下', '【中心专家】杨春山：上海455医院PET－CT中心医疗主任，第二军医大学附属长征医院影像专业博士、复旦大学附属中山医院影像专业博士后、副主任医师。从事CT、MRI诊断20余年，擅长胸、腹部肿瘤的早期诊断。以第一作者发表论文30余篇，获军队科技进步二、三、四等奖6项，获上海市博士后及上海市科委PET－CT重点基金各一项。\r\n \r\n    陈宪英：中心核医学专家，研究生导师。从事临床核医学专业30多年，主要研究方向：肿瘤核医学及核心脏病学，获省部级科学进步二等奖2项，军队科技进步三等奖1项，四等奖8项，在核心期刊发表论文50余篇。\r\n\r\n    马庆和：中心影像学专家，中华医学会甘肃分会超声影像学专业委员会常务理事，兰州大学医学院副教授，省级医学杂志常务编委，中石化总公司职称晋升委员会委员。从事临床及影像诊断工作近30年，对各种疾病的CT诊断及超声诊断有丰富的临床经验。曾担任甘肃及广州三级甲等医院影像科主任多年，撰写影像专业论文20余篇，编著《CT临床200问》一部。  ', 'admin', 10, 0, 5, 1, '31.234908,121.452881', '上海市淮海西路33号，靠番禹路', 399),
(39, '上海肿瘤医院PET-CT中心', '上海', '7500', '三甲', '2009-08-12 12:37:41', '114.81.25.17', '【医院介绍】是国家教育部直属的集医疗 教学 科研 预防为一体的三级甲等医院 医院创建于1931年 是我国成立最早的肿瘤专科医院\r\n\r\n【设备型号】 SMS biograph 16 ( Hi-Rez) \r\n\r\n【乘车路线】乘49、50、72、89、41、44、218、104、572路及隧道二线\r\n', '', 'admin', 0, 0, 5, 4, '31.199381,121.428195', '上海市东安路270号门诊大楼地下2楼', 252),
(37, '浙江宁波明州医院PET-CT中心', '浙江', '9000', '', '2009-08-11 10:10:40', '116.228.54.246', '【医院介绍】宁波明州医院凝波明州医院是由奥克斯集团投资建设的一所集医疗、科研、教学、康复、疗养、保健为一体的一所大型现代化综合性医院。\r\n\r\n【中心介绍】于宁波市鄞州区,位于泰安西路168号,毗邻南部商务区，PET-CT中心引进当今国际最先进的PET-CT系统\r\n\r\n【设备型号】GE Disvovery ST16。\r\n\r\n\r\n\r\n\r\n【乘车路线】火车南站和汽车南站：乘公交560、514、353、906、10、106 路至李惠利医院（或交警支队）站下，换乘102或360路至明州医院（终点站）。乘出租车约需20元。\r\n汽车北站：乘公交350 路至灵桥东站下，换乘102 路至明州医院（终点站）。\r\n鄞州汽车站：乘公交102、360 路至明州医院（终点站）。\r\n市客运中心：乘公交369 路至三星奥克斯站下，换乘102 路至明州医院（终点站）。\r\n汽车东站：乘公交516、15、556 路至七塔寺站下，换乘102 路至明州医院（终点站）。\r\n\r\n位置：医院北门内东侧核医学楼二楼\r\n\r\n\r\n', '【中心专家】 李光军主任  毕业于大连医科大学影像与核医学专业，硕士学位。曾工作于辽宁省肿瘤医院放射科、中山大学附属肿瘤医院PET/CT、上海交大附属仁济医院PET/CT，2007年-2008年在上海复旦大学附属肿瘤医院PET/CT主诊。先后在《中国公共卫生杂志》、《中国临床影像杂志》《中国实用内科杂志》《大连医科大学早报》《国外医学临床放射学分册》《中国临床医学影像学杂志》发表论文数篇。\r\n\r\n孙达，男，主任医师，中国医学影像技术研究会常务理事兼核医学分会副主任委员、浙江省核学会理事兼副秘书长、浙江省核医学会副主任委员。从事核医学工作已35年。曾在美国加州大学洛杉矶分校（UCLA）进修3年，重点学习和研究核素脑显像及PET的应用。编写和主编专著《放射性核素脑显像》和《放射性核素骨显像》，另外还参与主编、副主编和编写专著6本。在《J of Nucl Med (美国核医学杂志)》、《中华核医学杂志》、等国内外刊物和学术会议上发表论文60余篇。', 'admin', 22, 0, 5, 4, '29.825306,121.568012', '泰安西路168号', 228),
(38, '上海瑞金医院PET-CT中心', '上海', '7500', '三甲', '2009-08-12 12:32:53', '114.81.25.17', '', '', 'admin', 0, 0, 2, 10, '31.235114,121.464844', '', 206),
(40, '上海武警总队医院PET-CT中心', '上海', '7500', '部队三甲', '2009-08-12 12:38:08', '114.81.25.17', '【医院介绍】1982年8月由上海警备区警备师医院改编为 "武警上海市总队医院"。1990年11月医院新院正式落成使用，医院进入了全面发展时期，已成为集医疗、教学、科研、预防为一体的大型综合性“三级甲等”医院。\r\n\r\n【中心介绍】于2003年初成立了健康体检中心，在体检方式上从单一门诊体检逐渐发展为门诊体检、住院体检、上门体检等多种形式，在服务对象上从单一部队官兵发展为社会各界人士。\r\n\r\n\r\n【设备型号】GE DISCOVERY ST', '', 'admin', 0, 0, 5, 5, '31.285593,121.464844', '上海市长宁区虹许路831号', 160),
(41, '上海华山医院PET-CT中心', '上海', '7500', '三甲', '2009-08-12 12:38:26', '114.81.25.17', '【医院介绍】上海华山医院创建于1907年，1992年首批通过国家三级甲等医院评审，目前已成为国家级高层次的医教研中心之一，是复旦大学附属综合性教学医院和中国红十字会直属医院，是上海地区中国人最早创办的医院，在国内外享有较高声誉。\r\n\r\n【中心介绍】复旦大学附属华山医院PET中心于1996年由核医学科提出申请并做了技术方案论证，经院部批准报市卫生局、1997年3月国家卫生部批准立项。\r\n\r\n\r\n\r\n【设备型号】Siemens EXACT HR+型\r\n\r\n', '【中心专家】2005年4月许震生同志任PET中心主任，管一晖、赵军担任PET中心副主任，管一晖、赵军仍继续担任核医学科副主任。至2006年8月，科室人员13人，固定编制11人。', 'admin', 0, 0, 4, 3, '31.210991,121.430631', '上海市吴中东路518号', 239),
(42, '浙江嘉兴武警医院PET-CT中心', '浙江', '9000', '部队三甲', '2009-08-12 12:39:05', '114.81.25.17', '【医院介绍】浙江武警总队医院位于党的诞生地嘉兴南湖之畔　始建于1940年　1983年由解放军第111医院改编为武警浙江省总队医院　医院占地面积12．7万平方米　建筑面积9．6万平方米　其中医疗用房7．7万平方米。\r\n\r\n\r\n\r\n【设备型号】GE Discovery 16sT\r\n\r\n【乘车路线】交通：公交7路武警医院站下，汽车北站、汽车西站、雀幕桥等地设免费班车往返（上午7：30-11：30，下午12：45-15：45，每30分钟一班） \r\n', '【中心专家】余党凡 主任医师 ', 'admin', 0, 0, 5, 10, '35.86166,104.195397', '浙江嘉兴南湖区南湖路16号', 146),
(43, '浙江湖州98医院PET-CT中心', '浙江', '8990', '部队三甲', '2009-08-12 12:39:32', '114.81.25.17', '【医院介绍】解放军第98医院位于浙江湖州市，建院百年，是集医疗、教学、科研、预防、保健于一体的大型三级甲等综合性园林式医院。现医院斥巨资引进国内为数不多的德国西门子公司最新PET/CT，该设备功能齐全、图像清晰、技术领先。\r\n\r\n【中心介绍】解放军第98医院PET/CT中心，技术实力和服务质量在申苏浙皖等地独树一帜。由浙江大学第二医院原核医学科主任孙达教授担任中心主任，常年坐诊进行肿瘤的全面诊断。\r\n\r\n\r\n\r\n【乘车路线】乘4路、6路、9路、2路、1路至九八医院站下车。\r\n', '【中心专家】孙达教授担任中心主任，现任中国医学影像技术研究会常务理事兼核医学分会副主任委员、浙江省核学会理事兼副秘书长、浙江省核医学会副主任委员。', 'admin', 0, 0, 5, 6, '31.230708,121.472916', '湖州市车站路9号', 169),
(45, '浙江杭州117部队医院PET-CT中心', '浙江', '9000', '部队三甲', '2009-08-12 12:53:47', '114.81.25.17', '【医院介绍】中国人民解放军第117医院位于杭州西湖灵隐风景区，离西湖和灵隐均不足500米，周围被植物园环抱，院内环境优美，四季鸟语花香，素有花园式医院之称。\r\n\r\n【中心介绍】体检中心是医院按四星级酒店标准建造的集体检、住宿、餐饮、娱乐和康复于一体的综合性保健中心，占地面积近2万平方米，专用停车场可停车上百辆，拥有国际上最先进的医疗检查设备，还拥有舒适典雅的各类客房、套房及大小会议室，餐厅、棋牌、健身中心等。中心作为一所三级甲等医院的专业健康体检中心，具备雄厚的专业背景、专业技能、专业设施和军队医院的良好信誉，是一家最具现代化、专业化、规模化和目前华东地区最高档的健康体检中心。', '', 'admin', 4, 0, 4, 11, '30.759539,104.110565', '杭州市西湖风景区灵隐路14号', 132),
(78, '江苏苏州九龙医院PET-CT中心', '江苏', '7500', '', '2009-10-11 09:07:27', '116.228.54.246', '【医院介绍】由香港九龙集团投资兴建，并与上海交通大学医学院合作建设的一所大型中外合资、合作医院，是苏州工业园区政府的公共设施重点配套工程之一。\r\n\r\n\r\n\r\n【设备型号】西门子Biograph 2 PET/CT\r\n\r\n【乘车路线】2路、6路、28路、47路、100路、219路、812路。\r\n\r\n', '【中心专家】刘建军 核医学专家，硕士研究生学历，上海交通大学医学院苏州九龙医院核医学科科主任，副主任医师。上海交通大学医学院临床核医学研究所办公室主任，上海市核医学会中青年委员。', 'llz007', 3, 0, 4, 0, '31.597179,120.288084', '苏州工业园区万盛街118号', 133),
(50, '江苏江阴市华西村医院PET-CT中心', '江苏', '7500', '', '2009-08-12 13:02:39', '114.81.25.17', '【中心介绍】 江阴华西健康体检中心是华东地区第一家设备最先进、功能最齐全的专业健康体检机构。本中心以国际健康体检标准为依据、与解放军第二军医大学上海长海医院共同创建，并按照星级酒店标准建立了集体检、疗养、康复、旅游、住宿、餐饮、娱乐于一体的综合性保健中心。目前，体检中心已拥有当今世界最先进的德国西门子PET/CT，美国GE16层螺旋CT、DR、CR，以及乳腺红外线、钼靶、IU22、HD11彩超、胃镜、肠镜、肺功能、经颅多普勒、骨密度、动脉硬化和人体成分分析等众多国际先进的医疗设备。\r\n\r\n\r\n\r\n【设备型号】西门子公司Biograph 39环大视野LSO晶体PET带16层螺旋CT的PET/CT\r\n\r\n【乘车路线】\r\n', '【中心专家】王凌元 主任医师、教授。第二军医大学长海医院主任医师、教授，专业技术5级，大校军衔。历任二军大外训系参谋，长海医院主任医师、教授。现任长海医院华西诊疗中心主任。', 'admin', 0, 0, 4, 20, '31.861793,120.542093', '江阴市华西村幸福园6号塔', 186),
(51, '苏州无锡九龙医院PET-CT中心', '无锡', '8800', '三甲', '2009-08-12 13:04:12', '114.81.25.17', '', '', 'admin', 0, 0, 0, 0, '', '', 18),
(52, '成都军区总医院PET-CT中心', '四川', '9800', '部队三甲', '2009-08-12 13:05:01', '114.81.25.17', '【中心介绍】中心技术力量雄厚。现有主要工作人员12人，其中高级职称3人，专业水平高，有力的保证了报告的及时性和准确性。2008年7月，中心与西门子（中国）有限公司合作，成立了西南分子影像技术合作中心。\r\n\r\n【中心专家】周克，副主任医师，中心主任。1984年7月毕业于第三军医大学，2005年任成都军区总医院PET中心主任。擅长肿瘤疾病的诊治、放射介入及CT、磁共振、PET等影像学诊断。\r\n\r\n【设备型号】德国西门子Biograph Sensation16型PET/CT\r\n\r\n', '', 'admin', 1, 0, 0, 20, '31.345721,120.656662', '成都市外北天回镇', 86),
(59, '北京第二炮兵总医院PET-CT中心', '北京', '9800', '部队三甲', '2009-08-12 13:25:28', '114.81.25.17', '【医院介绍】第二炮兵总医院是一所集医疗、教学、科研、预防保健为一体的综合性三级甲等医院。PET－CT高端体检中心是本院的重点学科。医院投入巨资，引进当今世界最新型美国GE公司的PET－CT（Discovery STE)，建立了以影像医学和核医学著名专家一体化管理的高端体检中心。\r\n\r\n【中心介绍】PET-CT高端诊断中心位于二炮总医院住院部部南边，北京师范大学京师大厦斜对面，占地 1800 多平方米，配备有世界一流的PET-CT机、医用回旋加速器及相应在的配套设备，中心定编医务人员 10 人，拥有多名具有影像诊断和核医学诊断经验的专业医务人员，并且聘请有国内一流的顶尖知名专家为顾问。设有专门的导诊护士全程陪同检查。中心与国内知名的解放军第四五五医院、华山医院建立良好学术交流平台，技术与世界同步。\r\n\r\n【中心特色】为帮助医务人员和受检者解决临床困惑，正确解读PET－CT片，中心汇集北京著名影像专家、核医学专家和临床各科室专家、定期免费为广大受检者提供医疗咨询服务。PET－CT大会诊时间：每周二、周四下午3－5点.\r\n\r\n\r\n\r\n', '【专家介绍】\r\n    李德鹏  副主任医师 医学影像与核医学专业博士，中心医疗主任，中华医学会核医学分会第七届委员会科普专家，原首都医科大学宣武医院PET中心业务骨干和诊断组组长，师从我国影像学泰斗李坤成教授，研究方向为PET显像与CT、MRI的结构变化，从事PET的临床诊断与应用研究工作十余年，擅长将PET的功能代谢影像与病灶的CT、MRI结构影像有机结合，根据病灶的代谢特征和结构变化特征，做出恰当的、符合临床要求的诊断报告。\r\n    黄志强  中心主任，医学博士，毕业于中南大学湘雅医学院。曾先后在湖南湘雅医院、上海411医院伽玛刀中心、江西省人民医院伽玛刀中心、上海仁济医院PET-CT中心等担任管理工作。从医十余年，具有丰富的肿瘤早期诊治经验和一定的经营管理阅历。参与了早期体部伽玛刀的基础和临床研究，建立了影像与核医学一体化管理的PET-CT会诊中心，创立了全国首家PET-CT和常规体检一体化管理的高端体检中心。\r\n    ', 'admin', 4, 0, 5, 34, '39.930089,116.389924', '北京市西城区新外大街16号', 208),
(61, '广州医学院第一附属医院PET/CT中心', '广东', '9000', '三甲', '2009-08-12 13:26:03', '114.81.25.17', '', '', 'admin', 0, 0, 3, 0, '', '', 87),
(62, '天津肿瘤医院PET-CT中心', '天津', '10000', '三甲', '2009-08-12 13:29:19', '114.81.25.17', '', '', 'admin', 0, 0, 0, 20, '', '', 77),
(63, '天津医科大学总医院PET-CT中心', '天津', '10000', '三甲', '2009-08-12 13:30:41', '114.81.25.17', '', '', 'admin', 0, 0, 0, 0, '', '', 82),
(64, '山东省立医院PET-CT中心', '山东', '', '三甲', '2009-08-12 13:34:12', '114.81.25.17', '', '', 'admin', 0, 0, 0, 0, '', '', 68),
(65, '山东省肿瘤医院PET-CT中心', '山东', '7800', '三甲', '2009-08-12 13:34:51', '114.81.25.17', '山东省肿瘤防治研究院建院于1958年，1971年由以结核病防治为主的医疗机构组建为肿瘤专科医院，是国内建院较早的省级肿瘤专科医院和肿瘤防治研究机构之一。1999年经省政府批准，山东省肿瘤防治研究院同时应用第二名称“山东省肿瘤医院”。\r\n    医院占地20万平方米（约305亩），建筑面积15.8万平方米，固定资产3.1亿元，现有正式职工887人，其中高级专业技术人员223人，占专业技术人员总数的30%，有省拔尖人才和享受国家政府特贴者12人，博士、硕士研究生导师30余人，有60多名专家分别在国内外肿瘤及相关学术团体中担任主任、副主任委员、常务理事、理事等职务，形成了一支以老专家为龙头、中青年业务骨干为主体、老中青三结合的专家群体队伍，活跃在医疗、科研、教学第一线，为医院学科建设和发展奠定了雄厚的基础。\r\n    医院设有病床1000余张，其中正式病床854张，适合患者医疗康复的简易病床300张。设有肿瘤外科、肿瘤内科、放射治疗科、妇瘤科、麻醉和急诊医学等四大专业十九个临床科室，医学影像、核医学、病理学、检验、特检、药剂等20多个医技科室和以肿瘤基础研究中心为主体的包括放射生物、放射物理、医学激光、肿瘤药物、肿瘤流行病以及与各学科相匹配的10余个基础研究室。先后建立了“中国癌症基金会无创伤治疗研究中心”、“山东省乳腺病防治中心”、“山东省乳腺病防治研究技术推广中心”、“山东放射治疗中心”等国内和全省专病和特色专业技术中心。\r\n    在注重专业人才梯队、学科建设和发展的同时，医院积极引进和配备与当今医学科技发展和肿瘤诊疗前沿技术相适应的医疗设备，建设了现代化的中心实验室，配备了先进的仪器设备。\r\n　　目前拥有万元以上医疗设备300余台套，除螺旋CT、ECT、核磁共振、三维立体彩超、系列光导纤维内窥镜、高中低不同能量的直线加速器、钴60治疗机、放射治疗计划系统等诊疗设备外，近几年先后引进了一批代表国际先进和国内一流水平的大型仪器设备，如亚洲第一台BSD2000型微波加温治疗机（微波刀）、高能聚焦刀、多弹头射频治疗仪、骨髓移植及外周血干细胞移植配套设备及多叶光栅、颅脑X刀、体部X刀和国内首台全身Υ刀、超级Υ刀、适形、调强放射治疗系统、CT－PET、电子回旋加速器等，实现了高技术人才和高科技设备的有机结合，形成了以手术、放射治疗、化疗、中医药为主体，生物治疗、冷冻、加温、电化学治疗、微波加温治疗、激光、介入、骨髓及外周血干细胞移植、术中放疗与多弹头射频治疗等十多种先进技术相互配合的综合治疗优势。\r\n　　尤其是肿瘤的放射治疗，除开展常规的放疗技术外，积极跟踪世界先进水平，全身Υ刀、Ｘ刀等立体放疗技术以及在国内率先开展的适形调强放射治疗技术的临床应用，使我院跨入了肿瘤治疗的历史新阶段，大大提高了患者的生存率和生存质量，占据了国内肿瘤治疗的至高点，成为国内设备配套完善、技术先进、治疗项目齐全的学科之一。\r\n    按照“以临床促科研、以科研带临床”的指导思想，我院积极开展临床科学研究，九五以来，先后承担国家、省（部）级科研课题包括“十五”攻关课题和国家自然科学基金项目共60余项，分获省（部）级科技进步奖、医学科技进步奖和全国发明奖50余项，获国家专利20多项。\r\n　　现开展了以CT－PET为主体的生物学靶区临床应用、分子影像学研究和基因增敏治疗等研究，《肿瘤精确放疗临床应用系列研究》和《乳腺癌保乳放疗的系列临床研究》分别于2003年和2004年获山东省科学技术进步一等奖，使我院的肿瘤综合治疗技术达到一个更高的水平。\r\n　　同时，医院注重国内外学术交流与合作，近年来，平均每年选派10余名学科带头人和业务骨干，出国研修、讲学、考察和进行学术交流，先后与美国东弗吉尼亚医学院、斯坦福大学医学院、英国布里斯托尔大学医学院、俄罗斯莫斯科大学以及日本、以色列、韩国等国家医学院校、医疗及科研机构建立了业务协作关系，并成功举办了十余次国际及全国大型肿瘤学术会议，主编、参编并出版肿瘤学专著30余部，其中两部被译为英文版在国外发行，平均每年在国内外公开刊物发表学术论文200余篇，国外权威杂志及国内核心期刊占发表总数的40%以上。\r\n　　每年举办一期肿瘤临床医师学习班，面向省内外培养进修医生近百名，为国外带教放疗医师两名，并面向全国招收临床肿瘤外科、肿瘤内科、肿瘤妇科、放射治疗、影像诊断等专业的硕士研究生，为天津大学等带教博士研究生，为国内外培养了不同层次的肿瘤防治人才。', '', 'admin', 3, 0, 3, 0, '37.03764,118.322754', '济南市槐荫区济兖路440号', 53),
(66, '安徽省立医院PET-CT中心', '安徽', '8200', '三甲', '2009-08-12 13:38:15', '114.81.25.17', '【医院介绍】安徽省立医院的前身为合肥基督医院，1898年建院。医院地处省府合肥市中心，北临繁华的四牌楼商业区，南靠风景秀丽的包河公园，是一所设备先进、专科齐全、技术力量雄厚，集医、教、研、预防、保健、康复、急救为一体的省级大型综合性医院。\r\n\r\n【中心介绍】PET-CT中心位于医院住院部部南边，紧邻美丽的包河公园，占地 1800 多平方米，中心耗资3000余万元配备有世界一流的PET-CT 主机、医用回旋加速器及相应在的配套设备，具有完善的服务设施和优美的就诊环境。中心暂时定编医务人员 10 人，其中有主任医师 1 人，有相关专业的研究生3名，顾问2名（核医学和影像医学专业）。有导诊护士全程陪伴检查。中心秉承“一流的人才、一流的设备、一流的技术、一流的环境、一流的服务”的理念，竭诚为人民服务，必将造福于安徽的人民。\r\n\r\n【设备型号】\r\n\r\n【乘车路线】1路：火车站-胜利广场-元一时代广场-长淮新村-大东门-小东门-黄山大厦-长江饭店-三孝口-安徽报社-稻香楼-桐城路-屯溪路-东陈岗-韩家洼-传染病医院-金安花园-南园新村-宿松路-小余岗-王下份-张小郢-薛河-南门换乘中心\r\n\r\n', '', 'admin', 0, 0, 3, 0, '', '安徽省合肥市庐江路17号', 86),
(67, '广州中山大学附属肿瘤医院PET/CT中心', '广州', '', '三甲', '2009-08-12 13:50:59', '114.81.25.17', '', '', 'admin', 0, 0, 0, 7, '', '', 48),
(71, '江苏无锡解放军101医院PET-CT中心', '江苏', '7500', '部队三甲', '2009-09-07 20:29:53', '116.232.231.236', '【医院介绍】中国人民解放军第101医院（无锡市太湖医院）是一所集预防、医疗、保健、教学、科研、急救为一体的大型综合性三级甲等医院。\r\n\r\n【中心介绍】PET/CT影像中心耗资近四千万元引进世界最先进的美国G E公司最新型Discovery  STE型PET/CT，致力于多种肿瘤、心血管和中枢神经系统的影像诊断和科研工作。\r\n\r\n\r\n\r\n【设备型号】G E公司最新型Discovery  STE型\r\n\r\n【乘车路线】10路、60路、98路、115路火车站出发至101医院， 96路、213路、606路招商城汽车南站至101医院605路、680路周山浜客运总站至101医院， 6路、17路凤翔分公司至101医院，73路公交三场至101医院，610路前洲客运站至101医院。\r\n', '【中心专家】陈绍亮，影像医学与核医学教授，博士生导师。上海核学会核医学主任委员，上海医学会核医学分会顾问，中国物理学会同步辐射学会委员，中国医学装备协会委员，复旦大学核医学研究所所长，上海市影像医学研究所副所长。长期从事影像医学核医学临床诊断、治疗, 科学研究和教学。专长于肿瘤、心血管、脑血流、甲状腺、骨等疾病的核医学诊断和放射性核素治疗。', 'xltxlm', 12, 0, 5, 3, '31.566148,120.303027', '无锡市兴源路、凤宾路交界', 245),
(77, '北京309医院PET-CT中心 ', '北京', '12450', '部队三甲', '2009-10-10 15:15:17', '116.228.141.77', '【医院介绍】解 放 军 第 309 医 院 是一所大型综合性三级甲等性医院，北京市花园式单位。南望皇家园林颐和园，北连百望山森林公园，依山傍水，空气清新，环境优雅，四季宜人，是工作、疗养和医伤治病的好地方。医院占地总面积69万平方米，现有病床1700余张，专业学科37个，医务人员中高级技术职称110余名；门诊部除开设有常规科室外，还有肿瘤放射诊断治疗、疼痛治疗、遗传病、不孕症、男性性功能障碍、肾移植、结核病等10余种专科、专病门诊。医院肝胆外科、泌尿外科、骨科、普外科、心胸外科、神经外科、结核科、呼吸科、心内科等专科在军内外享有一定声誉。 \r\n\r\n【中心介绍】核医学科建立于1975年，有30年从事放射性诊断、治疗的历史，科室现有人员6人，其中高级专业技术职称1人、中级职称3人，叶一秀主任从事核医学诊断20余年,有丰富经验，技术精湛，发表论文50余篇，先后获得中华医学科技进步二等奖1项，军队医疗成果三等奖和军队科技进步三等奖4项。\r\n\r\n\r\n\r\n【交通位置】特4、303、330、346、384、375、697、716、718、运通112，在黑山扈下车 \r\n', '【专家介绍】\r\n叶一秀\r\n副主任医师  1974年毕业于第三军医大学医疗系,从事核医学诊断近三十年,有较扎实理论基础及丰富的临床工作经验和独立解决问题能力,带领全科开展SPECT功能显像并引进先进的电化学发光技术,近几年开展131I-治疗甲亢及放射核素标记单克隆靶向治疗晚期病人,效果明显,得到临床及患者的好评,近年发表论文50多篇,先后8次获得科技成果奖。', 'gwm', 0, 0, 5, 19, '40.055476,116.336975', '北京市海淀区黑山沪甲17号', 122),
(74, '北京海军总医院PET-CT中心', '北京', '12450', '三甲', '2009-10-10 14:46:04', '116.228.141.77', '【中心介绍】海军总医院核医学科作为海军核医学专科中心，由ECT室、PET/CT中心和核素治疗室组成。在全军乃至全国核医学界都具有较高的知名度和影响力。作为博士学位培养点和博士后工作站，技术力量雄厚，现有工作人员12人，其中主任医师（教授）2名，副主任医师1名，主治医师2名，住院医师1名，各类中级医学技术及工程人员6名。\r\n\r\n【设备型号】美国GE公司最新一代超高档多功能全身扫描PET/CT系统, 是先进的16层螺旋CT和最高档PET扫描仪的一体化集合。是目前最先进的扫描速度最快的PET/CT，一次检查可以同时提供功能、代谢、受体、酶、基因和解剖结构的图像。是高端健康体检的最佳手段之一\r\n\r\n', '【专家介绍】\r\n川玲 \r\n毕业于湖南医学院医疗系，获第二军医大学心血管专业硕士学位。现任海军总医院核医学主任、主任医师，中国医学影像研究会理事，核医学分会委员。长期坚持核医学临床一线工作。擅长心脏核医学，在应用核素心肌负荷试验诊断冠心病、心肌梗死定位定性、心肌存活的检出、心脏介入治疗的疗效评价（包括冠脉搭桥、PTCA,Stent）、缺血性和非缺血性心肌病的鉴别诊断、心脏干细胞植入前后心肌血流和代谢的评估、冠脉慢血流与心肌缺血的关系等方面做了大量工作和研究。系列观察了癫痫病定位、脑外伤颅脑损伤范围和程度的评估、CO中毒性脑病的诊断和预后评估、结节病的特征性诊断、嗜铬细胞瘤的定位定性，并形成了我科SPECT的特色检查。应用ECT/CT和PET/CT在肿瘤的良恶性鉴别诊断、疗效观察、治疗后复发和瘢痕的鉴别、恶性病灶放射治疗前生物靶区的确定、肿瘤的转移和寻找原发灶等方面作了大量细致的工作。治疗上百例甲亢、甲癌术后及骨转移瘤骨痛的患者。以第1作者在专业学术刊物及国际国内学术会议发表论文近40余篇；参加科内多项临床科研工作，获军队科技进步二等奖1项，军队医疗成果二等奖3项，军队医疗成果。\r\n朱家瑞\r\n男，毕业于第四军医大学医疗系，曾赴法国肿瘤研究所（IGR）进修和工作。1993年8月到海军总医院核医学科工作。现任核医学科主任医师、博士研究生导师。中国医学影像技术研究会核医学分会主任委员、全军临床核医学专业委员会副主任委员、中华核医学专业网负责人、中华医学会和总后医学会医疗事故技术鉴定专家库成员、全国卫生技术资格考试专家委员会委员、环保总局辐射环境影响评估委员会委员。JNM&JNMT（美国核医学杂志和核医学技术杂志）中文版副主编、《影像诊断与介入治疗》编委。2006年享受国务院颁发的政府特殊津贴。临床和研究工作侧重于核医学在肿瘤、心血管和内分泌学的应用、核医学图像的处理与分析、图像融合在医学影像中的应用等。参加科内多项临床科研工作，获军队科技进步二等奖1项，军队医疗成果二等奖3项，军队医疗成果三等奖3项。在专业学术刊物及国际国内学术会议发表论文50余篇，主编著作1部，参编12部。\r\n赵文锐\r\n男，毕业于第四军医大学医疗系，获北京医科大学核医学专业硕士，现为海军总医院核医学科副主任、副主任医师。从1988年开始从事临床核医学工作以来，始终在临床核医学诊断和治疗第一线工作，在科内临床、科研、教学中发挥着主力军的作用。全面掌握核医学影像（包括SPECT和PET/CT）诊断和核素治疗的理论和临床应用知识。熟悉本专业的相关临床前沿知识。基础理论和专业知识扎实。具有独立解决本专业疑难病症的能力。特别在泌尿和肿瘤临床核医学方面有较多研究。亲自治疗甲亢逾千例、甲状腺癌数百例，积累了丰富的临床经验。带教军内外进修实习生30余人，指导北京、河北、山西、辽宁、内蒙等多家医院开展SPECT工作。参加科内多项临床科研工作，获军队科技进步二等奖1项，军队医疗成果二等奖3项，军队医疗成果三等奖3项。在专业学术刊物及国际国内学术会议发表论文30余篇，参编书籍1部。 ', 'gwm', 0, 0, 5, 5, '', '北京市海淀区阜成路6号海军总医院影像中心3层', 145),
(75, '北京307医院PET-CT中心', '北京', '9725', '部队三甲', '2009-10-10 15:07:14', '116.228.141.77', '【医院介绍】解放军三〇七医院是一所集医疗、科研、教学于一体的三级甲等医院，位于北京市丰台区东大街，承接丰北快速路，东接西三环，北邻京石高速，南靠丰台火车站。医院创建于1957年，前身是国家卫生部同位素医院。 1958年医院移交军队，隶属解放军军事医学科学院。\r\n\r\n\r\n\r\n【设备型号】美国GE公司新型Discovery STE 型PET/CT\r\n\r\n', '【中心专家】丁勇,主任医师，核医学博士，核医学科主任。学科带头人，全军核医学专业委员会常委，秘书。主要从事肿瘤核医学研究，是国内较早从事PET、PET/CT诊断专家之一', 'llz007', 0, 0, 5, 5, '', '北京市丰台区东大街8号', 115),
(79, '江苏苏州大学附属第一人民医院PET-CT中心', '江苏', '7515', '三甲', '2009-10-19 16:01:20', '116.228.141.77', '【医院介绍】苏州大学附属第一医院是集医疗、教学、科研、预防、保健于一体的综合性医院，医院座落在“小桥、流水”的古城区内，环境优雅，占地面积15.8万平方米，建筑面积19.5万平方米。在职职工（含合同制）2112人，实际开放床位1464张。现门急诊量近130余万人次，出院4.36万人次，年择期手术1.77万例。　医院总资产11.47亿元，固定资产9.05亿元，其中百万元以上设备57台。拥有PET-CT?、平板式全数字化心血管造影仪、全数字化医用直线加速器、数字化X线诊断系统（DSA）等多种先进设备。医院现有国家重点学科2个（内科血液病学、骨外科学），血栓与止血实验室成为卫生部重点实验室，医院在异体骨髓移植等多个技术上达到国家或国际先进水平。\r\n\r\n【乘车路线】1、从火车站/汽车北站乘： 游2路、40路、50路（北）、202路、529路到第一人民医院西下2、从汽车南站可乘： 200路（南）、529路、811路到第一人民医院西下3、从汽车西站可乘： 89路到第一人民医院西下4、另外8路、55路、204路、309、501路也可到达第一人民医院', '', 'gwm', 0, 0, 4, 0, '31.718822,119.959717', '江苏省苏州市十梓街188号 ', 82),
(80, '江苏南京鼓楼医院PET-CT中心', '江苏', '7590', '三甲', '2009-10-20 12:52:06', '222.95.255.167', '【医院介绍】鼓楼医院悠久的历史，积淀着深厚的文化底蕴。鼓医人以求索、创新为基调、以优质服务为音符、以病人满意为主旋律，不断创造中国医学史上一个个第一，谱写着一曲曲现代医学神奇乐章！医院先后被中央文明委、江苏省及南京市表彰为“全国创建文明行业工作先进集体”、“文明单位”；被国家卫生部授予“全国卫生系统先进单位”、“全国医院文化工作先进单位”等称号。\r\n\r\n【中心介绍】中心现有医务人员18名，其中副主任医师1人，主治医师2人，副主任技师1人，主管技师6人。是南京大学医学院和南京医科大学核医学课程承担单位，同时还负责担任东南大学、徐州医学院、山东泰山医学院和南京金陵学院学员的带教、实习任务，目前承担江苏省卫生厅课题1项，南京市卫生局重点课题2项，年发表论文近10篇。\r\n\r\n\r\n【设备型号】荷兰PHILIPS公司GEMINI GXL 16 PET/CT\r\n', '【中心专家】郭万华  核医学科行政主任、副主任医师、上海第二医科大学博士，兼任南京大学医学院核医学教研组组长、江苏省医学会核医学分会委员、江苏省核学会理事、南京医学会核医学分会副主任委员。', 'llz007', 3, 0, 4, 0, '32.058365,118.796468', '南京市中山路321号', 120),
(81, '江苏南京军区总医院PET-CT中心', '江苏', '8800', '部队三甲', '2009-10-20 13:05:32', '222.95.255.167', '【医院介绍】中国人民解放军南京军区南京总医院位于六朝古都南京，\r\n坐落于风景秀丽的钟山脚下，是一所历史悠久、医教研协调发\r\n展的大型现代化综合性医院。医院前身为1929年筹建、1930年\r\n建成的国民政府中央医院.\r\n\r\n\r\n', '【中心专家】朱虹，核医学核主任，副主任医师。毕业于苏州大学医学院。从事临床核医学工作近20年，有丰富的临床经验，医学基础理论和核医学理论基础扎实，在心脏疾病、肿瘤、骨骼疾病的核素影像诊断和鉴别诊断方面有较深造诣。', 'llz007', 0, 0, 3, 0, '32.04155,118.805294', '南京市中山东路305号 ', 49),
(82, '江苏徐州市中心医院PET-CT中心', '江苏', '8300', '三甲', '2009-10-22 20:59:39', '222.185.254.2', '【医院介绍】医院始建于1953年，1996年被列为南京铁道医学院（现为东南大学医学院）附属徐州医院，是集医疗、科研、教学、预防保健于一体的三级综合性医院。近年来，医院先后获“徐州市先进集体”、江苏省“十佳医院”、 江苏省“文明单位”、“全国卫生系统先进集体”、“全国卫生文化建设先进单位”等荣誉称号。为江苏省首批创建基本现代化医院试点医院之一。\r\n\r\n\r\n', '【中心专家】王跃涛，毕业于徐州医学院医疗系，主任医师。是创造性地提出了“设备的融合、人才的融合、诊断的融合”的新模式，将核医学、影像科和临床紧密结合在一起，把诊断结果和临床相对照，不断提高诊断的准确性，现已成熟应用于肿瘤的良恶性诊断、鉴别诊断及肿瘤的分期、分级、疗效评价等，成为肿瘤诊治不可或缺的重要手段。', 'llz007', 1, 0, 4, 0, '31.810077,119.974454', '徐州市解放南路199号', 73),
(83, '江苏省人民医院PET-CT中心', '江苏', '8800', '三甲', '2009-10-22 21:10:53', '222.185.254.2', '【医院介绍】江苏省人民医院，亦名南京医科大学第一附属医院、江苏省红十字医院。其前身是1936年成立的江苏省立医政学院附设诊疗所。是江苏省规模最大的综合性医院，担负着全省医疗、教学和科研三项中心任务。医院占地12.3万平方米，现有建筑面积18.8万平方米。\r\n\r\n【中心介绍】科室人员配备齐全，技术力量雄厚， 医术精湛，10名工作人员中博士1名，硕士3名，教授、主任及副主任医师2名，硕士生导师1名。不断优化服务流程，以方便病人为宗旨，长期坚持早上班，中午连班，外地病人以快递形式及时将报告送达。24小时值班，方便病人咨询、预约。\r\n\r\n\r\n\r\n【设备型号】PET/CT为西门子（Siemens）公司生产的biograph 16 HR.回旋加速器为通用电器公司（GE）生产的PET trace。可生产18F、11C、13N等正电子放射性核素，可合成多种正电子放射性药物，满足PET/CT检查的需要。\r\n\r\n【乘车路线】乘18路，32路、39路、56路至金盛百货大市场，11路、42路、43路、65路、66路、72路、73路、75路、91路至龙江小区下车均可到达。\r\n', '【中心专家】黄庆娟，主任医师。硕士研究生导师，PET/CT中心副主任。兼任江苏省中西医结合学会影像专业委员会副主任委员，大型仪器设备评审专家。', 'llz007', 0, 0, 4, 0, '', '南京市广州路300号', 55),
(84, '河南省肿瘤医院PET-CT中心', '河南', '8500', '三甲', '2009-11-05 15:34:39', '116.228.141.77', '【医院介绍】河南省肿瘤医院是一所设备先进、技术精良、环境优美、服务优质，集医疗、科研、预防、教学为一体，采用手术、放疗、化疗、生物治疗、介入治疗等方法进行综合治疗的省级三级甲等肿瘤专科医院。\r\n【中心专家】杨建伟 主任医师\r\n【设备型号】GE Discovery STE 16\r\n【乘车路线】来我院乘车路线 乘101、105、2、23、205、77、57路公共汽车可直达\r\n', '', 'llz007', 0, 0, 4, 0, '', '河南省郑州市东明路127号', 23),
(85, '天津254医院PET-CT中心', '天津', '10000', '三甲', '2009-11-11 10:34:19', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '', 45),
(86, '天津武警医学院附属医院PET-CT', '天津', '9800', '三甲', '2009-11-11 10:34:55', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '天津市河东区成林道211号(成林道与天山路交口处东南角)', 52),
(88, '福建省立医院PET-CT中心', '福建', '8400', '三甲', '2009-11-11 10:45:05', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '', 41),
(90, '福建医科大学附属厦门市第一医院PET-CT中心', '福建', '8400', '三甲', '2009-11-11 10:47:31', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '', 51),
(92, '广东省人民医院PET-CT中心', '广东', '9500', '三甲', '2009-11-11 10:53:01', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '', 69),
(93, '广州军区广州总医院PET-CT中心', '广东', '9500', '三甲', '2009-11-11 10:59:58', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '', 53),
(94, '南方医科大学南方医院PET-CT中心', '广东', '9000', '三甲', '2009-11-11 11:00:50', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '广州市广州大道北1838号', 51),
(95, '深圳龙珠医院PET-CT中心', '广东', '9053', '三甲', '2009-11-11 11:01:47', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '深圳南山区西丽龙苑路16号', 58),
(96, '深圳市边防武警总队医院PET-CT中心', '广东', '9325', '部队三甲', '2009-11-11 11:02:41', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '深圳市金湖路8号', 53),
(97, '广东省武警总队医院PET-CT中心', '广东', '9800', '部队三甲', '2009-11-11 11:03:28', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '广州市天河区燕岭路268号', 21),
(98, '中山大学附属第一医院', '广东', '9600', '三甲', '2009-11-11 11:04:05', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '广州市中山二路58号', 24),
(99, '中山大学肿瘤防治中心PET-CT中心', '广东', '9600', '三甲', '2009-11-11 11:04:48', '116.228.141.77', '', '', 'llz007', 0, 0, 3, 0, '', '广州市东风东路651号', 28),
(100, '四川大学华西医院PET-CT中心', '四川', '9916', '三甲', '2009-11-11 11:18:32', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '成都市外南国学巷37号', 53),
(101, '四川省人民医院PET-CT中心', '四川', '9800', '三甲', '2009-11-11 11:19:14', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '成都市一环路西二段32号', 40),
(102, '第四军医大学西京医院PET-CT中心', '陕西', '12100', '三甲', '2009-11-11 11:24:08', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '西安市长乐西路15号', 58),
(103, '西安市长安医院PET-CT中心', '陕西', '12000', '三甲', '2009-11-11 11:24:45', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '西安市文景路17号', 38),
(104, '第四军医大学唐都医院PET-CT中心', '陕西', '9800', '三甲', '2009-11-11 11:25:36', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '西安市灞桥区新寺路1号', 39),
(105, '西安高新医院PET-CT中心', '陕西', '9800', '三甲', '2009-11-11 11:26:13', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '西安高新技术产业开发区团结南路16号', 52),
(106, '黑龙江大庆油田总医院PET-CT中心', '黑龙江', '9600', '三甲', '2009-11-11 11:47:20', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '黑龙江大庆市中康街9号', 11),
(107, '哈尔滨医科大学附属肿瘤医院PET-CT中心', '黑龙江', '9800', '三甲', '2009-11-11 11:48:11', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '哈尔滨市南岗区哈平路150号', 11),
(108, '黑龙江省农垦总局总医院PET-CT中心', '黑龙江', '9600', '三甲', '2009-11-11 11:49:15', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '哈双路235号', 9),
(109, '第三军医大学附属西南医院PET-CT中心', '重庆', '8250', '三甲', '2009-11-11 11:58:06', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '重庆市沙坪区坝区高滩岩正街30号', 35),
(110, '第三军医大学第三附属医院', '重庆', '8250 ', '三甲', '2009-11-11 11:59:06', '116.228.141.77', '', '', '', 0, 0, 3, 0, '', '重庆大坪长江支路10号', 20),
(111, '广东佛山市第一人民医院PET/CT中心', '广东', '8800', '三甲', '2009-11-20 15:35:48', '114.81.236.44', '', '', 'llz007', 0, 0, 3, 0, '', '', 16),
(112, '安徽医科大学第一附属医院PET-CT中心', '安徽', '8500', '三甲', '2009-11-24 19:50:14', '220.178.118.18', '【医院简介】安徽医科大学第一附属医院前身为上海东南医学院附属东南医院，创办于1926年。1949年响应党和政府号召，随校内迁至安徽怀远县，1952年再迁至合肥市。经过80多年的发展，医院已成为国家卫生部三级甲等医院，全国卫生系统先进集体，卫生部临床药理基地，安徽省文明标兵单位，是安徽省规模最大的、集医疗、教学、科研、预防、康复、急救为一体的综合性教学医院。\r\n医院目前占地面积224.9亩，总建筑面积28万平方米。现有在职职工2100人，开放病床1890张，设临床科室39个，医技科室19个，临床教研室19个。有皮肤性病学、老年医学、内科学（含8个三级学科）、神经病学4个博士学位授予点和1个临床博士后科研流动站，硕士学位点覆盖所有的临床科室。\r\n医院拥有一批高素质的专家队伍，其中博士生导师16人，副高职称以上专家555人，中级职称人员738人，博士和在读博士120余人，硕士270人，享受国务院和省政府特殊津贴114人，担任省级以上医学学术团体负责人60多人，有4人入选全国"百千万人才工程"，2人被卫生部授予“有突出贡献的中青年专家”，省厅以上跨世纪学术技术带头人、骨干教师107人，位居安徽省医疗机构第一。\r\n医院年门诊量143余万人次，年住院病人6.9万人次，年手术近2.5万台次，年教学工作量约1.7万学时，年接收实习生、进修医生1000余人。\r\n医院学科齐全，重点学科数在安徽省医疗机构中最多，有国家级重点学科1个，安徽省临床医学重点学科7个，安徽省临床医学重点发展学科16个，安徽省临床医学重点扶持学科2个，安徽省教育厅认定的重点学科3个，安徽省教育厅重点扶持学科1个，安医大重点学科和重点扶持学科8个。省级重点实验室1个，省部级共建重点实验室1个。\r\n医院坚持科教兴院战略，学科技术水平不断取得新的突破，受国家卫生部委托建立第一个中国人脑库，填补国内空白；银屑病的遗传学研究处于国际领先水平，盐裂皮肤免疫荧光技术诊断表皮下大疱病，国内领先。同种异体肝脏移植、自体干细胞移植、异体干细胞移植、异体肾脏移植、体外循环、心脏不停跳冠脉搭桥、心脑血管介入治疗、胸腔和腹腔微创手术、辅助生殖技术、断指再植和显微外科等专业技术水平处国内先进水平。在中西医结合治疗大面积烧伤、微粒皮移植、显微输卵管复通手术、眼移角膜移植、人工晶体植入术和眼激光治疗、小儿脑瘫治疗等方面积累了丰富的经验,处省内领先地位。\r\n近四年，医院承担包括中国人银屑病易感基因研究、大别山隔离人群遗传资源调查等国家863计划和973计划、国家自然科学基金、安徽省自然科学基金等科研课题200余项，其中2004、2005年、2006年、2007年共获国家自然科学基金34项；获省部级以上奖项30余项，其中2007年获国家科技进步二等奖1项，教育部自然科学一等奖1项，2005、2006连续两年获中华医学科技一等奖，都填补了安徽省医疗行业获国家级奖项的空白。国家发表论文2137篇，出版专著103部，主办5种国内外公开发行杂志：《肝胆外科杂志》、《临床骨科杂志》、《临床眼科杂志》、《临床护理杂志》、《临床肺科杂志》。医院与美国、荷兰、日本、香港等国家和地区的科学研究机构建立了密切的科研合作关系。\r\n\r\n【设备型号】sms Biograph 64', '', '', 1, 0, 3, 0, '31.846005,117.266458', '合肥市绩溪路218号', 48);
INSERT INTO `yiliao_jigou` (`j_id`, `j_name`, `j_shenfen`, `j_jiage`, `j_jibie`, `j_time`, `j_ip`, `j_content`, `j_zhuanjia`, `user_name`, `j_image_count`, `j_click`, `j_star`, `home_page`, `google_map`, `j_weizi`, `click`) VALUES
(113, '解放军第105医院PET-CT中心', '安徽', '8500', '三甲', '2009-11-25 13:12:57', '116.228.141.77', '解放军105医院健康体检中心是全省目前检查质量最权威、设备最齐全、服务最完善、环境最优雅、档次最高、性价比最优的现代化体检中心，也是我省青年参军、学生报考军校的唯一指定体检机构。\r\n \r\n体检中心采用国际最新的理念，采用“医检分离”的模式，实行一站式检齐的流程，推行管家式服务，使用全程数字化的管理系统，安排专业的健康顾问跟踪体检结果，开通全国、全军、省内知名医院、专家绿色转诊通道，是目前安徽最权威、最专业、最高档的体检中心.\r\n \r\n体检中心环境优雅舒适，与病区完全分离的独立二层楼，由国际体检设计师量身打造，分为接待区、更衣区、沐浴区、餐饮区、体检区、贵宾区。\r\n \r\n第105医院体检中心走廊\r\n \r\n接待区，分为接待咨询、休息等待、养生咨询、首检、终检五大功能区。\r\n \r\n更衣区、沐浴区为全省首创，是全省唯一集换鞋、更衣、沐浴、体检于一体的体检中心。\r\n \r\n餐饮区拥有全省唯一全透明、视野最好、面积最大西式观景餐厅，提供的体检早餐为营养搭配、品种丰富的免费中西自助餐。\r\n \r\n第105医院体检中心备餐区\r\n \r\n贵宾区提供独立的客厅、卫生间、沐浴间、一站式VIP上门服务，男女贵宾区可合可分.\r\n \r\n体检中心拥有全省最齐全的专用体检设备，如彩色B超、DR、热CT、动脉硬化仪、肺功能仪、骨密度仪、体成分仪、脑彩超、一滴血检测仪、虹膜检查仪、全自动生化仪、五分类血球仪、尿液仪、血流变仪、幽门螺旋杆菌检测仪、微量元素检测仪、免疫系统测试仪等。\r\n \r\n体检中心可开展全省品种最多的体检专用项目，如PET-CT肿瘤筛查、热CT肿瘤筛查、基因检测肿瘤筛查、血液免疫肿瘤筛查、妇科肿瘤TCT检测、食物不耐受检测、过敏源检测、螺旋CT、MRI检查等，拥有全省最多最全的套餐品种，并可为体检者量身定做相应套餐。\r\n \r\n体检中心医生均为军队医学界权威专家，以雄厚的技术力量、细致的工作态度、严谨的工作精神、规范的工作流程，保证了高品质的体检质量，并有知名资深军队医学专家终检把关。\r\n \r\n体检中心拥有国内最先进的专业体检软件、自动排队叫号系统、全程无纸化的体检处理系统、周到私密的健康管理系统，信息化程度全省最高。\r\n \r\n体检中心遵循全方位一站式检齐理念，检前、检中、检后提供健康知识培训讲座、上门体检、团队专车接送、全过程导检、短信语音健康提醒等全省最全面、最细致、最丰富的体检系列服务', '专家', 'gwm', 0, 0, 4, 0, '', '合肥市长江西路424号', 68),
(114, '山西煤炭中心医院PET/CT中心', '山西', '10000', '三甲', '2009-12-08 15:14:36', '59.49.16.170', '山西煤炭中心医院是一所集医疗、教学、科研为一体的综合医院,成立于1983 年，地处太原市学府街101号，占地面积150亩。2002年底山西梅园工贸集团受山西省煤炭工业局之命，自筹资金3亿元按照创一流医院的目标对医院进行改扩建，使医院医疗区建筑面积达5万平米，固定资产近5亿元，具备开设800张床位的规模。\r\n\r\n【PET/CT中心介绍】医院于2006年从美国引进的全省首台正电子发射计算机断层扫描影像系统（PET-CT、俗称派特CT）和回旋加速器，能够将功能成像与形态成像完美结合，用于肿瘤的早期诊断及定位、定性和分期诊断，还用于心脏疾病的特异性检查以及健康体检。', '', 'llz007', 0, 0, 4, 0, '', '山西省太原市小店区学府街101号', 15),
(115, '石家庄白求恩国际和平医院PET中心', '河北', '7900', '部队三甲', '2009-12-09 17:38:57', '121.28.147.138', '中国人民解放军白求恩国际和平医院，建于1937年11月7日，为纪念援华医疗队队长诺尔曼&#8226;白求恩这位伟大的国际主义战士，1940年1月医院命名为白求恩国际和平医院。目前，医院已发展成为一所集医疗、教学、科研、康复、保健和急救为一体的现代化综合性三级甲等医院。医院占地35万平方米，分为工作区和生活区两个院落，总建筑面积19万平方米。工作区占地30万平方米，建有门诊大楼、住院部大楼、体检中心大楼和综合科技楼等多座现代化建筑，医疗用房9万平方米。近年落成投入使用的外科大楼，使用面积3.3万平方米，可容纳750张床位。医疗设备先进，拥有派特（PET）、双光子全数字化电子直线加速器、核磁共振、螺旋CT、大型X光系列、大型全自动生化分析仪、大型电子显微镜、彩色B超、伽马刀、X刀、电子胃镜、血液透析机、高压氧仓等现代化设备5900多台（件），总价值4亿元。\r\n\r\n【公交路线】火车站乘1、15、25、29、38路公交车,“和平医院”站下车即到。\r\n\r\n', '', 'llz007', 0, 0, 4, 0, '', '中山西路398号', 19),
(116, '河北保定252医院PET/CT中心', '河北', '10240', '部队三甲', '2009-12-10 22:35:09', '114.255.26.194', '    是一所集医疗、教学、科研、预防保健、康复、急救为一体，既具有以肿瘤、结核、肾病、肝病为强大专科特色，又具有内、外、妇、儿、五官、皮肤、放疗等服务功能齐全的二级甲等综合医院，为保定市四强医院之一。医院214.5亩，建筑面积12万平方米，绿化面积1.6万平方米，基本实现了三季有花，四季常青的园林式医院。 医院开放病床538张，在职职工600人，其中高级职称83人，中级职称182人，博士2人，硕士10人，硕士研究生12人，硕士生导师4人，自然学科带头人7人，保定市名医4人。年收治住院病人8000人次，门诊量30万人次，手术4000人次。 \r\n', '', 'llz007', 0, 0, 4, 0, '', '保定市花园街第81号', 12),
(117, '北京军区总医院PET/CT中心', '北京', '9870.17', '部队三甲', '2009-12-11 16:24:17', '115.171.100.252', '    北京军区总医院核医学科具有悠久的历史，是北京军区总医院临床科室的重要组成部分。该科室拥有美国GE公司多功能ECT 1台，2005年8月又引进了GE公司生产的大型功能分子影像设备Discovery ST16 PET-CT系统（16排螺旋CT）。该设备是先进16层螺旋CT和最高档PET扫描仪设备功能的一体化集合。PET-CT在早期发现肿瘤病灶，良、恶性肿瘤的鉴别诊断，寻找原发灶及转移癌，肿瘤疗效评估，鉴别肿瘤复发和坏死以及放疗生物靶区定位方面具有其他影像设备不可替代的优势，被誉为21世纪三大医学发明之一。现已开展肿瘤、心脏和脑等疾病的PET-CT检查和SPECT显像诊断工作, 并率先在北京地区开展利用PET-CT进行放疗生物靶区勾画的研究工作。核医学科全体工作人员信守以病人为本的理念，以人性化的服务，精益求精的技术作风出色的完成了包括数十名军队、地方首长及国外友人的数千人次的诊断和保健工作，为提高医院的医疗水平、保障人民健康做出了贡献。', '目前核医学科拥有一支医术精湛、素质过硬的专业技术队伍，共有医、技、护人员十二人，含博士及硕士5人，已成为拥有四千多万元大型设备、集核素诊断、治疗和科研于一体的综合性科室。', 'llz007', 0, 0, 5, 0, '39.93238,116.424608', '北京东城区南门仓5号', 31),
(118, '北京306医院PET/CT中心', '北京', '9725', '部队三甲', '2009-12-13 13:44:50', '125.46.33.146', '【医院介绍】解放军第306医院是一所技术人才密集、临床学科齐全、仪器设备先进、整体医疗水平较高的现代化综合性三级甲等医院，展开床位1008张，编设44个科室；医院环境优美、病房整洁舒适，是北京市首批“基本医疗保险定点医院”、国家航天发射卫勤保障的定点医院、北京急救中心(120)北区分中心。  医院拥有一批技术雄厚的医学专科中心：全军脊柱外科中心、全军口腔疾病诊治中心、全军糖尿病诊治中心、全军信息与技术支持基地和总装心血管中心、普通外科中心、特种病诊治中心、医学影像中心，形成了以全军专科中心为重点的优势学科群；拥有一大批国内外、军内外有较高知名度和影响力的医学专家。医院配备有3.0T核磁、双源64排螺旋CT、彩超、数字化电子胃肠镜、全自动生化分析仪、陀螺刀、高压氧舱等医疗设备850台件，有效地提高了对各类疾病的诊断治疗水平。\r\n\r\n【乘车路线】  医院乘车路线公交车：315、345、909、695、618、625、407、751、851路在苇子坑站下车。 \r\n地  铁：环线积水潭站下车转315、345路即到。\r\n', '', 'llz007', 0, 0, 5, 0, '', '北京市朝阳区德胜门外安翔北里9号 ', 52),
(119, '河南武警总队医院PET/CT中心', '河南', '8500', '部队三甲', '2009-12-14 13:35:20', '125.46.33.146', '　作为武警部队首批评定的三级甲等医院，武警河南总队医院已拥有固定资产一亿多元，展开床位520张；拥有临床科室32个，其中，眼科、腹腔镜技术、椎间盘技术、体外震波碎石技术在省内乃至国内外居于领先地位，初步形成了特色科室突出，互相促进，综合发展的良好局面，成为省会医疗界冉冉升起的一颗新星。', '', 'llz007', 0, 0, 4, 0, '', '河南郑州市康复中街1号', 11),
(120, '济南军区总医院PET-CT中心', '山东', '8800', '部队三甲', '2009-12-16 10:32:49', '116.228.141.77', '中国人民解放军济南军区总医院成立于1954年，是一所集医疗、教学、科研于一体的现代化大型综合性医院，是鲁、豫战区最高级别的医疗机构，担负济南军区三军官兵的医疗保健及医疗救护工作，属全国七个大军区的总医院之一。 医院占地面积26万平方米，建筑面积19余万平方米，开展临床科室49个，设有国际远程医疗会诊中心，展开床位1200余张，医院现有职工2600多名，其中高级技术职务263人，硕士以上学历238人，博士后12人，博士67人，博士生导师、硕士生导师39人，被军地院校聘为兼职教授、副教授109人，被国家评为有突出贡献的中青年专家1人，享受政府特殊津贴21人，军区专业技术拔尖人才46人。\r\n    医院现有万元以上设备700余台（件），有磁共振、螺旋CT、双向数字减影X光机、数字化X光机、遥控摇篮床X光机、全身X刀、后装铱治疗机、直线加速器、多弹头自动导航RF肝癌治疗系统、高压氧舱群、血液净化设备、动态心电图检查仪、全自动生化分析仪、全自动酶标检测仪、血细胞分离机等，总价值近2亿元。医院为全国首批“三级甲等”医院、“第二军医大学临床医学院”、全国首批“百姓放心示范医院”，被联合国儿童基金会评为“爱婴医院”、被山东省评为“爱民医院”、“山东省百佳医院”，连续3次被总部表彰为“为部队服务先进医院”。\r\n    多年来，医院在院党委的领导下，始终将科技兴院和人才建设作为建院之本，瞄准科技前沿，狠抓科技创新，自1991年以来全院共获国家和军队各种医疗科技成果奖453项，发表论文5300余篇，出版专著18部，发表论文数多年位居全军同类医院第二位，在省内医院中亦名列第二位。并先后获得了首批全国“明明白白看病百姓放心医院”、“山东省优质服务优胜医院”、“消费者满意单位”等多个荣誉称号。并借助军队大型医院的整体优势，以优良的环境、完善的设施、先进的技术及人性化的服务受到越来越多的患者和社会各界人士的高度赞誉。 ', '', 'gwm', 5, 0, 3, 0, '36.695763,116.985222', '济南市天桥区师范路25号', 16),
(121, '山东齐鲁医院PET-CT中心', '山东', '7000', '三甲', '2009-12-16 14:30:08', '113.129.137.45', '山东大学齐鲁医院是山东大学直属医院，也是国家卫生部直管医院。它坐落于泉城济南风景秀丽的趵突泉畔，是集医疗、教学、科研和预防保健于一体的大型综合性三级甲等医院。医院始建于1890年，先后称华美医院、共合医院、齐鲁医院、山东省立第二医院、山东医学院附属医院、山东医科大学附属医院。2000年10月医院正式更名为山东大学齐鲁医院。\r\n　　现开放床位1740张，年门诊量193万余人次，年出院病人5.13万余人次，年手术量2.89万余台次。各种诊断、治疗技术与水平位于国内领先或先进水平。医院每年承担大量的临床教学和毕业生见习实习任务，涉及博士、硕士、七年制、本科等不同层次。由院教师主编的《内科学》、《妇产科学》入选国家“十一五”计划教材，开设了国家精品课程《诊断学》、省级精品课程《妇产科学》、《手术学》，拥有《山东大学齐鲁医院报》、《现代妇产科进展》、《中国现代普通外科进展》、《腹腔镜外科》4种国内外公开发行的报纸和学术刊物。\r\n\r\n　　现有临床、医技科室60个，其中拥有省部级重点学科（实验室）6个，省卫生系统重点学科（实验室）9个，省“十一五”重点建设学科5个。其中高级专业技术人员589人，拥有中国工程院院士1人，百千万人才工程专家1人，国家和省部级突出贡献专家15人次，享受国务院政府特殊津贴的76人，教育部新世纪优秀人才2人，山东省卫生系统杰出学科带头人15人。目前担任中华医学系列杂志副总编、常务编委及编委29人，担任中华医学会副主任委员、常委8人，担任山东省医学会主任委员43人，副主任委员100余人。医院设有国家临床药理基地和博士后流动站，拥有泰山学者5名，和山东大学临床一级学科博士点，博士生导师94人，硕士点33个，硕士生导师212人。卫生部专科医师培训试点基地29个（其中普通专科16个，亚专科13个），卫生部内镜诊疗技术培训基地6个，卫生部临床药师培训试点基地3个，省级住院医师规范化培训基地16个。\r\n\r\n　　一个多世纪以来，经过医院几代人的共同努力，一些科室已经成为具有较高医疗水平和专业特色的科室，如心血管内科、血液病科、妇产科、耳鼻喉科、神经外科、普通外科、消化内科、小儿内科等。同时，也为我国的医疗卫生事业培养了一大批在国内外享有较高知名度的专家教授，如尤家俊、赵常林、孙鸿泉、高学勤、于复新、孙桂毓、朱汉英、张振湘、江森、王天铎、侯宝璋、杨仁中、张茂宏、张运等就是其中具有代表性的知名专家。\r\n\r\n　　医院始终贯彻“科技兴院”的指导方针，科学研究水平不断提高，近三年来纵向科研经费均在2000万元以上，截至2008年，中标国家自然科学基金项目105项，863、973科研项目4项，科技部重点项目4项，卫生部重点临床项目7项，省部、厅局级科研项目600余项。获国家科学技术进步奖二等奖2项，省部级奖励181项，厅局级奖励139项。\r\n\r\n　　为满足人民群众日益增长的医疗卫生服务的需要，医院陆续添置和引进了大批国际国内一流的医技设备。医院现有大型仪器（50万元以上）149台件，拥有世界最先进的西门子双源CT、共聚焦电子内镜，亚洲首台GE3.0T双梯度磁共振，飞利浦双梯度1.5磁共振，PET/CT，瓦里安23EXIGRT直线加速器、西门子IMRT直线加速器，省内首台以色列胶囊内镜，德国神经导航系统，西门子染色体核型分析系统、蛋白质芯片质谱仪等，设备水平已达国内一流。\r\n\r\n　　医院先后同美国、英国、德国、瑞典、日本、加拿大、澳大利亚以及香港、澳门等国家和地区的20多所大学、医院、科研机构建立了学术交流合作关系。2007-2008年派出国进修学习110余人次，国内外学者来院讲学140人次，举办全国性和省级学术会议和继续医学教育学习班71次。', '', 'llz007', 0, 0, 4, 0, '36.831272,117.647095', '济南市历下区文化西路107号', 21),
(122, '福建漳州市175医院PET-CT中心', '福建', '7800', '三甲', '2009-12-24 13:21:34', '114.81.90.90', '', '', 'llz007', 0, 0, 4, 0, '', '漳州市漳华中路269号', 7),
(123, '南京军区福州总医院PET-CT中心', '福建', '8390', '部队三甲', '2009-12-24 13:22:55', '114.81.90.90', '', '', 'llz007', 0, 0, 4, 0, '', '福州市西二环路156号', 7),
(124, '福建医科大学附属协和医院PET-CT中心', '福建', '8400', '三甲', '2009-12-24 13:24:10', '114.81.90.90', '', '', 'llz007', 0, 0, 4, 0, '', '福州市鼓楼区新权路29号', 9);

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_jigou_dianpin`
--

CREATE TABLE IF NOT EXISTS `yiliao_jigou_dianpin` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `j_id` int(11) NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `add_time` datetime NOT NULL,
  `star` int(5) NOT NULL,
  `content` text NOT NULL,
  `ip` varchar(20) NOT NULL,
  `j_name` varchar(200) NOT NULL,
  PRIMARY KEY (`id`),
  KEY `j_id` (`j_id`),
  KEY `user_name` (`user_name`),
  KEY `add_time` (`add_time`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 AUTO_INCREMENT=15 ;

--
-- Dumping data for table `yiliao_jigou_dianpin`
--


-- --------------------------------------------------------

--
-- Table structure for table `yiliao_jigou_image`
--

CREATE TABLE IF NOT EXISTS `yiliao_jigou_image` (
  `i_id` int(11) NOT NULL AUTO_INCREMENT,
  `j_id` int(11) unsigned NOT NULL,
  `i_name` varchar(50) NOT NULL,
  `i_time` datetime NOT NULL,
  `user_name` varchar(200) NOT NULL,
  `j_ip` varchar(20) NOT NULL,
  PRIMARY KEY (`i_id`),
  KEY `j_id` (`j_id`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=116 ;

--
-- Dumping data for table `yiliao_jigou_image`
--

INSERT INTO `yiliao_jigou_image` (`i_id`, `j_id`, `i_name`, `i_time`, `user_name`, `j_ip`) VALUES
(10, 5, '9b1765cbf16dcfdb44646c4c8ebff61b.jpg', '2009-08-07 01:10:36', 'admin', '116.232.231.188'),
(2, 2, 'b6d6f79bf8f642d77b946441c8a900d1.jpg', '2009-08-07 00:47:28', 'admin', '116.232.231.188'),
(7, 5, '0218b5300b300a84b446a67aa2399f48.jpg', '2009-08-07 01:07:46', 'admin', '116.232.231.188'),
(11, 5, 'a3342efecfbc201cc779d6167c041a1f.jpg', '2009-08-07 01:10:40', 'admin', '116.232.231.188'),
(5, 3, '3496bdfa1601d32764d9e2041493885a.jpg', '2009-08-07 00:52:30', 'admin', '116.232.231.188'),
(8, 5, 'e7b7c05023a137befb90b367b8f02b63.jpg', '2009-08-07 01:08:16', 'admin', '116.232.231.188'),
(9, 3, 'f3acc5a117978fc5c6b2e7a44bc7928f.jpg', '2009-08-07 01:08:29', 'admin', '116.232.231.188'),
(32, 37, 'e0ef371bcbdcd5a8f958704861e9408d.jpg', '2009-09-23 16:28:12', 'llz007', '116.228.54.246'),
(56, 37, 'ae0919e64377c2daba0af34ead27a17c.jpg', '2009-09-28 12:27:25', 'gwm', '116.228.141.77'),
(40, 37, 'a1d931b073791503a6e4e8b99628849e.jpg', '2009-09-24 15:41:36', 'gwm', '114.81.197.107'),
(34, 37, 'f52f9d2962150d2623fd7b4b3af6a4dc.jpg', '2009-09-23 16:33:59', 'llz007', '116.228.54.246'),
(54, 37, '2a77491219df7448442da942250d9ad7.jpg', '2009-09-28 12:27:18', 'gwm', '116.228.141.77'),
(55, 37, '53c3df24c9e97b4939f18c218a06bb1c.jpg', '2009-09-28 12:27:21', 'gwm', '116.228.141.77'),
(30, 34, '3c552cf493d5dd251d18ee56a3540a5c.jpg', '2009-09-23 15:59:58', 'llz007', '116.228.54.246'),
(31, 34, '08b23b594d6b69a704e96d3e995389c4.jpg', '2009-09-23 16:02:00', 'llz007', '116.228.54.246'),
(39, 37, '84551cfe84f8143160b91cb43cde6432.jpg', '2009-09-24 15:38:43', 'gwm', '114.81.197.107'),
(36, 35, '59c3be38724b2c361daa7d3e77bb88c5.jpg', '2009-09-24 15:04:29', 'llz007', '114.81.197.107'),
(37, 35, '0d3a949dae5c5c3f6738857cb9b85209.jpg', '2009-09-24 15:25:47', 'gwm', '114.81.197.107'),
(38, 35, 'db10f7b7d8600816fc33ac66c1a399f0.jpg', '2009-09-24 15:31:43', 'gwm', '114.81.197.107'),
(44, 35, '7a15d1724b6f58d6e65181dac77aa606.jpg', '2009-09-27 15:00:36', 'gwm', '116.228.141.77'),
(45, 35, '11a8017c5f8d1d0f49e25285683c1ad7.jpg', '2009-09-27 15:00:42', 'gwm', '116.228.141.77'),
(46, 35, '44ef64d212154b55d22e59f8b509a014.jpg', '2009-09-27 15:00:46', 'gwm', '116.228.141.77'),
(47, 35, 'ccbecf7dfbe7588454cc7048eb765839.jpg', '2009-09-27 15:00:50', 'gwm', '116.228.141.77'),
(48, 35, '81ddf643f58a618ab72b40c0ce6ead2e.jpg', '2009-09-27 15:00:54', 'gwm', '116.228.141.77'),
(49, 35, 'c705634dc062e4d85304d392b569f6e5.jpg', '2009-09-27 15:00:59', 'gwm', '116.228.141.77'),
(50, 35, '0b90dcb4188c7be62137e43f3dbe89f2.jpg', '2009-09-27 15:01:01', 'gwm', '116.228.141.77'),
(51, 35, 'b8af90545cc097d79decf11f90eadd66.jpg', '2009-09-27 15:01:05', 'gwm', '116.228.141.77'),
(52, 35, '11555bca2b2e4171ba03521211a66c1d.jpg', '2009-09-27 15:01:12', 'gwm', '116.228.141.77'),
(53, 59, '5dce5482f1a9131affeed5807be7e47c.jpg', '2009-09-27 15:17:14', 'gwm', '116.228.141.77'),
(57, 37, 'b55986d0f2305ae907dd4dbe9b18f48b.jpg', '2009-09-28 12:27:29', 'gwm', '116.228.141.77'),
(58, 37, 'f2c041566aefe78793bcbc2e20069b97.jpg', '2009-09-28 12:27:32', 'gwm', '116.228.141.77'),
(59, 37, 'e5655d9904fb2cb8e90fbcc4709c1b6e.jpg', '2009-09-28 12:27:39', 'gwm', '116.228.141.77'),
(60, 37, '22f7eb6eeece9fb135dbe864a2ac670c.jpg', '2009-09-28 12:27:43', 'gwm', '116.228.141.77'),
(61, 37, '429a0faaf2dedda5e73b2a2c0333e57c.jpg', '2009-09-28 12:27:46', 'gwm', '116.228.141.77'),
(62, 37, '16a7455c7c37c599c4fd8809bce23afa.jpg', '2009-09-28 12:27:49', 'gwm', '116.228.141.77'),
(63, 37, '955fe778babd0229761326b1bbba167d.jpg', '2009-09-28 12:27:52', 'gwm', '116.228.141.77'),
(64, 37, '032b26c853f3e3e4bfa18d8b3a9acaa2.jpg', '2009-09-28 12:27:54', 'gwm', '116.228.141.77'),
(65, 37, '89a622ba0e77fbd263869dab9c6b7442.jpg', '2009-09-28 12:27:57', 'gwm', '116.228.141.77'),
(66, 37, '297d1fb2d06565c55710638760ff3cf8.jpg', '2009-09-28 12:27:59', 'gwm', '116.228.141.77'),
(67, 37, 'b624b9791f8d287390a2c1a833e3df4c.jpg', '2009-09-28 12:28:02', 'gwm', '116.228.141.77'),
(68, 37, 'dc6b2336a0c78f2269a5cc9f1b9d052e.jpg', '2009-09-28 12:28:08', 'gwm', '116.228.141.77'),
(69, 34, '01664c39a7beedc7aeeb65e852a7bbdf.jpg', '2009-09-29 16:22:18', 'gwm', '116.228.141.77'),
(70, 34, 'a59c3c819183acf2528c7d7b6c250d8d.jpg', '2009-09-29 16:22:25', 'gwm', '116.228.141.77'),
(71, 34, '0a2b615cef2aec4bd92d32b9824696c1.jpg', '2009-09-29 16:22:29', 'gwm', '116.228.141.77'),
(72, 34, '971a6ba2bf50a837bbe9f217d0a19ecc.jpg', '2009-09-29 16:22:32', 'gwm', '116.228.141.77'),
(73, 34, 'd5526c8f4770e61576401b9a2c8db78f.jpg', '2009-09-29 16:22:39', 'gwm', '116.228.141.77'),
(74, 34, '221f85f36f60425d39677a0e40689189.jpg', '2009-09-29 16:22:44', 'gwm', '116.228.141.77'),
(75, 34, '4aebca7aec39d50075a919a7f3157cbb.jpg', '2009-09-29 16:22:47', 'gwm', '116.228.141.77'),
(76, 34, '1505b5167c593372120099f8e5453840.jpg', '2009-09-29 16:22:51', 'gwm', '116.228.141.77'),
(77, 59, '36652c01fe70e8454a0bcef0ab2f3f88.jpg', '2009-10-10 12:40:57', 'gwm', '116.228.141.77'),
(78, 59, 'bb3af5e7f1cd820446b61c328a738d9e.jpg', '2009-10-10 12:41:04', 'gwm', '116.228.141.77'),
(79, 59, '7ec8b27a5ce45292a04b648cdd91762d.jpg', '2009-10-10 12:41:19', 'gwm', '116.228.141.77'),
(80, 52, '3eac9ea31bccc81f8b9cc7aa045f8b0c.jpg', '2009-10-10 15:56:05', 'llz007', '116.228.141.77'),
(81, 78, 'cd42fa0d49a363c4dca5176be579e92c.jpg', '2009-10-11 09:09:05', 'llz007', '116.228.54.246'),
(82, 78, '1be8c365c03b14e22b693c2c04d91389.jpg', '2009-10-11 09:10:14', 'llz007', '116.228.54.246'),
(83, 78, '9db8b7540833f890d2fe36c6de0234bb.jpg', '2009-10-11 09:11:25', 'llz007', '116.228.54.246'),
(84, 80, 'dd7c911f1581f68a0501ad05091558a4.jpg', '2009-10-20 12:53:40', 'llz007', '222.95.255.167'),
(85, 80, '86adee172e50e1e8465dae900da73ccc.jpg', '2009-10-20 12:53:48', 'llz007', '222.95.255.167'),
(86, 80, '6201262004391521f310af358020e75a.jpg', '2009-10-20 12:53:54', 'llz007', '222.95.255.167'),
(87, 82, '8c3153fe32e97b1a70c4ff4206f07b5e.jpg', '2009-10-22 20:59:49', 'llz007', '222.185.254.2'),
(88, 71, 'f0ef00e59f9356e2e62b34520501e1ac.jpg', '2009-10-27 16:02:31', 'gwm', '116.228.141.77'),
(89, 71, '609fdd69d1d46b7ecdd6cd961374006e.jpg', '2009-10-27 16:02:36', 'gwm', '116.228.141.77'),
(90, 71, '0b6a68af9ed2caee8fe4ed8b2c3fec62.jpg', '2009-10-27 16:02:39', 'gwm', '116.228.141.77'),
(91, 71, '456773830ad68453781429ea933a9977.jpg', '2009-10-27 16:02:41', 'gwm', '116.228.141.77'),
(92, 71, '9528ead1c9db2f17667bc82244afb5d5.jpg', '2009-10-27 16:02:44', 'gwm', '116.228.141.77'),
(93, 71, 'c3ef6006c0d0ba7a739a3aaba199b387.jpg', '2009-10-27 16:02:46', 'gwm', '116.228.141.77'),
(94, 71, '5ad7e9d0941c2c09294d05af865056e1.jpg', '2009-10-27 16:02:49', 'gwm', '116.228.141.77'),
(95, 71, '7e4d9facac8bac0c41d5de61e3a0b152.jpg', '2009-10-27 16:02:51', 'gwm', '116.228.141.77'),
(96, 71, '283f69829c4794f66780060062490e40.jpg', '2009-10-27 16:02:55', 'gwm', '116.228.141.77'),
(97, 71, 'ecddda37429494cae204cb50f2b91b2f.jpg', '2009-10-27 16:03:01', 'gwm', '116.228.141.77'),
(98, 71, 'f58f4d4d6548b2a50c6993ff5ed691b6.jpg', '2009-10-27 16:03:04', 'gwm', '116.228.141.77'),
(99, 71, '976f96c5ad3ba1934a4afeda8fd6a1c6.jpg', '2009-10-27 16:03:09', 'gwm', '116.228.141.77'),
(100, 37, 'efb5475b8ca42da50b50cc2e7aba9805.jpg', '2009-11-12 13:02:56', 'gwm', '116.228.141.77'),
(101, 37, 'c9e061dd66f72e88676e9002f99ea5fb.jpg', '2009-11-12 13:03:00', 'gwm', '116.228.141.77'),
(102, 37, '6f6d10ae4fdf36642586c1701505dac0.jpg', '2009-11-12 13:03:03', 'gwm', '116.228.141.77'),
(103, 112, 'fb223e910fee1caca25fdfc44a24d0aa.jpg', '2009-12-08 14:34:09', 'gwm', '116.228.141.77'),
(104, 45, '644b766192eacc1f9c640c860cac7f0c.jpg', '2009-12-08 15:12:07', 'gwm', '116.228.141.77'),
(105, 45, '0d372a96ebfe306a695ccb8b0eac9ac7.jpg', '2009-12-08 15:12:10', 'gwm', '116.228.141.77'),
(106, 45, 'edbb51747523f7eb87e91fdf1e080d9b.jpg', '2009-12-08 15:12:14', 'gwm', '116.228.141.77'),
(107, 45, 'ad5c80e082ea958d5435ca33d95b7972.jpg', '2009-12-08 15:12:18', 'gwm', '116.228.141.77'),
(108, 120, '1616ec8296f6a8e87718e252bedce78a.jpg', '2009-12-21 11:32:05', 'gwm', '116.228.141.77'),
(109, 120, 'ab68e743bd27da3129a110f0662251be.jpg', '2009-12-21 11:32:08', 'gwm', '116.228.141.77'),
(110, 120, '38a184aa0d9ba570870317dac1d3e235.jpg', '2009-12-21 11:32:11', 'gwm', '116.228.141.77'),
(111, 120, 'a20aa8bc8949c35f0869fafef5b102d6.jpg', '2009-12-21 11:32:15', 'gwm', '116.228.141.77'),
(112, 120, '4a73de225975162abc91f4064fbcbf96.jpg', '2009-12-21 11:32:19', 'gwm', '116.228.141.77'),
(113, 65, 'ac8cf833d33656185aa0c4e962b61153.jpg', '2009-12-21 12:02:47', 'gwm', '116.228.141.77'),
(114, 65, 'eab6f5ab727f723103a5d5f9d7bfd7b0.jpg', '2009-12-21 12:02:51', 'gwm', '116.228.141.77'),
(115, 65, '49f30d78f2e5f26e915e7987deb43eb7.jpg', '2009-12-21 12:02:53', 'gwm', '116.228.141.77');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_jigou_timer`
--

CREATE TABLE IF NOT EXISTS `yiliao_jigou_timer` (
  `j_id` int(11) NOT NULL,
  `j_name` varchar(200) NOT NULL,
  `j_date` date NOT NULL,
  `j_hour` varchar(100) NOT NULL,
  UNIQUE KEY `j_date` (`j_date`,`j_hour`,`j_id`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk COMMENT='机构就诊时间表';

--
-- Dumping data for table `yiliao_jigou_timer`
--

INSERT INTO `yiliao_jigou_timer` (`j_id`, `j_name`, `j_date`, `j_hour`) VALUES
(68, '上海第一人民医院PET-CT中心', '2009-08-15', '14'),
(68, '上海第一人民医院PET-CT中心', '2009-08-15', '12'),
(68, '上海第一人民医院PET-CT中心', '2009-08-15', '10'),
(63, '天津市医科大学总医院PET-CT中心', '2009-08-15', '14'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '8'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '9'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '10'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '12'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '13'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '14'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '15'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '16'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-09', '17'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '12'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '13'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '14'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '15'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '16'),
(34, '上海455部队医院PET-CT高端体检中心', '2009-09-10', '17');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_shenfen`
--

CREATE TABLE IF NOT EXISTS `yiliao_shenfen` (
  `name` varchar(100) NOT NULL COMMENT '省份',
  `pinyin` varchar(200) NOT NULL,
  `orderby` int(11) NOT NULL DEFAULT '0' COMMENT '排序',
  `home` varchar(2) NOT NULL DEFAULT 'N' COMMENT '首页显示',
  UNIQUE KEY `name` (`name`),
  KEY `pinyin` (`pinyin`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `yiliao_shenfen`
--

INSERT INTO `yiliao_shenfen` (`name`, `pinyin`, `orderby`, `home`) VALUES
('上海', 'shang hai ', 1, 'Y'),
('广东', 'guang dong ', 5, 'Y'),
('浙江', 'zhe jiang ', 4, 'Y'),
('北京', 'bei jing ', 2, 'Y'),
('黑龙江', 'hei long jiang ', 0, 'N'),
('江苏', 'jiang su ', 3, 'Y'),
('四川', 'si chuan ', 6, 'Y'),
('湖南', 'hu nan ', 0, 'N'),
('天津', 'tian jin ', 11, 'Y'),
('山东', 'shan dong ', 0, 'N'),
('安徽', 'an hui ', 9, 'Y'),
('福建', 'fu jian ', 5, 'Y'),
('陕西', 'shan xi ', 10, 'Y'),
('吉林', 'ji lin ', 0, 'N'),
('辽宁', 'liao ning ', 0, 'N'),
('内蒙', 'nei meng ', 0, 'N'),
('山西', 'shan xi ', 0, 'N'),
('河北', 'he bei ', 0, 'N'),
('河南', 'he nan ', 0, 'N'),
('湖北', 'hu bei ', 0, 'N'),
('江西', 'jiang xi ', 0, 'N'),
('广西', 'guang xi ', 0, 'N'),
('云南', 'yun nan ', 0, 'N'),
('新疆', 'xin jiang ', 0, 'N');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_user`
--

CREATE TABLE IF NOT EXISTS `yiliao_user` (
  `user_id` int(10) unsigned NOT NULL AUTO_INCREMENT,
  `user_name` varchar(200) NOT NULL,
  `user_pass` varchar(40) NOT NULL,
  `user_time` datetime NOT NULL,
  `user_last_ip` varchar(20) NOT NULL,
  `user_last_time` datetime NOT NULL,
  `user_shenfen` varchar(100) NOT NULL,
  `user_jifen` int(11) NOT NULL DEFAULT '0' COMMENT '积分',
  `user_location` varchar(30) NOT NULL COMMENT 'IP地址来源',
  `user_realname` varchar(200) NOT NULL COMMENT '帐户的真实姓名',
  `user_sex` varchar(5) NOT NULL COMMENT '帐户性别',
  `user_tel` varchar(50) NOT NULL COMMENT '电话号码',
  `user_email` varchar(200) NOT NULL COMMENT '邮箱地址',
  `user_address` varchar(200) NOT NULL COMMENT '联系地址',
  PRIMARY KEY (`user_id`),
  UNIQUE KEY `user_name` (`user_name`)
) ENGINE=MyISAM  DEFAULT CHARSET=gbk AUTO_INCREMENT=20 ;

--
-- Dumping data for table `yiliao_user`
--

INSERT INTO `yiliao_user` (`user_id`, `user_name`, `user_pass`, `user_time`, `user_last_ip`, `user_last_time`, `user_shenfen`, `user_jifen`, `user_location`, `user_realname`, `user_sex`, `user_tel`, `user_email`, `user_address`) VALUES
(10, 'liliu', 'e27f985f52823cc55212ff29ccf9f931', '2009-09-21 10:33:22', '121.229.45.173', '2009-09-21 10:33:22', '', 0, '江苏省南京市', '', '', '', '', ''),
(11, '常越萍', '4eab59cd3497141207f3ae6c92054dfc', '2009-09-21 10:41:35', '121.229.45.173', '2009-09-21 10:41:35', '', 0, '江苏省南京市', '', '', '', '', ''),
(6, 'xltxlm', 'c4ca4238a0b923820dcc509a6f75849b', '2009-08-18 22:30:34', '116.232.235.88', '2009-08-18 22:30:34', '', 20, '上海市徐汇区', '夏琳泰', '男', '15921427453', 'xltxlm@qq.com', '上海市乐山路10弄1号304'),
(7, 'lingzhi', '670b14728ad9902aecba32e22fa4f6bd', '2009-08-26 09:08:56', '116.228.54.246', '2009-08-26 09:08:56', '', 10, '上海市', '', '', '', '', ''),
(12, 'gaowuming2008', '73e991c404cc6a6f62a65ba25b015c92', '2009-10-13 11:47:58', '116.228.141.77', '2009-10-13 11:47:58', '', 20, '上海市黄浦区', '', '', '', '', ''),
(9, 'grant', 'e27f985f52823cc55212ff29ccf9f931', '2009-09-08 10:23:39', '221.215.53.210', '2009-09-08 10:23:39', '', 20, '北京市海淀区', '', '', '', '', ''),
(13, 'hirozhen', '082b18cd2caa73614755bdc5efdd9682', '2009-11-14 14:41:36', '125.108.167.1', '2009-11-14 14:41:36', '', 0, '浙江省温州市', '', '', '', '', ''),
(14, 'sheleo', '25d55ad283aa400af464c76d713c07ad', '2009-12-01 14:01:36', '116.232.163.233', '2009-12-01 14:01:36', '', 0, '上海市徐汇区', '', '', '', '', ''),
(15, 'xltxlm_test', 'c4ca4238a0b923820dcc509a6f75849b', '2009-12-07 10:19:45', '116.228.6.98', '2009-12-07 10:19:45', '', 0, '上海市', '', '', '', 'xltxm@qq.com', ''),
(16, 'at15', '323767b19ffe05f5692e72e09f7b3f43', '2009-12-23 21:50:08', '61.173.96.144', '2009-12-23 21:50:08', '', 0, '上海市普陀区', '', '', '', 'at15@163.com', ''),
(17, 'bcwchina', 'd9269c88892dbd03032f7bf377bbdd31', '2009-12-24 09:21:47', '218.90.151.105', '2009-12-24 09:21:47', '', 0, '江苏省无锡市', '', '', '', 'bcwchina@163.com', ''),
(18, 'gaowuing', '73e991c404cc6a6f62a65ba25b015c92', '2009-12-28 22:57:06', '58.35.106.110', '2009-12-28 22:57:06', '', 0, '上海市黄浦区', '', '', '', '81198849@qq.com', ''),
(19, 'jenny_yin', 'cb05cab65afefab8fd3831d92cfc68be', '2009-12-29 09:09:22', '116.228.141.77', '2009-12-29 09:09:22', '', 0, '上海市', '', '', '', 'jenny@petkang.com', '');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_user_jifen`
--

CREATE TABLE IF NOT EXISTS `yiliao_user_jifen` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `user_name` varchar(200) NOT NULL,
  `add_time` datetime NOT NULL,
  `j_id` int(11) NOT NULL COMMENT '机构ID',
  `j_name` varchar(200) NOT NULL COMMENT '机构名称',
  `jifen` int(11) NOT NULL COMMENT '本次获得积分数量',
  `yuding_id` int(11) NOT NULL COMMENT '订单号码',
  PRIMARY KEY (`id`),
  KEY `j_id` (`j_id`),
  KEY `j_name` (`j_name`),
  KEY `add_time` (`add_time`),
  KEY `user_name` (`user_name`),
  KEY `yuding_id` (`yuding_id`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 COMMENT='积分原因记录' AUTO_INCREMENT=6 ;

--
-- Dumping data for table `yiliao_user_jifen`
--

INSERT INTO `yiliao_user_jifen` (`id`, `user_name`, `add_time`, `j_id`, `j_name`, `jifen`, `yuding_id`) VALUES
(1, 'gaowuming2008', '2009-10-13 11:54:30', 34, '上海455医院PET-CT高端体检中心', 80000, 59),
(2, 'llz007', '2009-11-24 23:24:36', 50, '江苏江阴市华西村医院PET-CT中心', 100, 69),
(3, 'gwm', '2009-12-14 09:47:44', 66, '安徽省立医院PET-CT中心', 1, 79),
(4, 'gwm', '2009-12-29 09:55:17', 35, '上海仁济医院PET-CT中心', 100, 92),
(5, 'gwm', '2009-12-31 13:39:32', 35, '上海仁济医院PET-CT中心', 90000, 92);

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_user_shenfen`
--

CREATE TABLE IF NOT EXISTS `yiliao_user_shenfen` (
  `name` varchar(100) NOT NULL COMMENT '省份',
  `pinyin` varchar(200) NOT NULL,
  UNIQUE KEY `name` (`name`),
  KEY `pinyin` (`pinyin`)
) ENGINE=MyISAM DEFAULT CHARSET=gbk;

--
-- Dumping data for table `yiliao_user_shenfen`
--

INSERT INTO `yiliao_user_shenfen` (`name`, `pinyin`) VALUES
('医生帐户', 'yi sheng zhang hu '),
('中心机构帐户', 'zhong xin ji gou zhang hu ');

-- --------------------------------------------------------

--
-- Table structure for table `yiliao_user_yuding`
--

CREATE TABLE IF NOT EXISTS `yiliao_user_yuding` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `j_id` int(11) NOT NULL,
  `j_name` varchar(200) NOT NULL,
  `user_realname` varchar(200) NOT NULL COMMENT '真实姓名',
  `contact_realname` varchar(200) NOT NULL COMMENT '联系人姓名',
  `user_contact` varchar(200) NOT NULL COMMENT '联系方式',
  `post_date` varchar(30) NOT NULL COMMENT '预约日期',
  `post_hour` varchar(20) NOT NULL COMMENT '预约时间段',
  `stat` varchar(50) NOT NULL DEFAULT '未处理' COMMENT '状态',
  `user_name` varchar(200) NOT NULL COMMENT 'cookie',
  `user_sex` varchar(10) NOT NULL COMMENT '性别',
  `user_tel` varchar(100) NOT NULL COMMENT '电话号码',
  `user_binshi` text NOT NULL COMMENT '病史档案',
  `add_time` datetime NOT NULL COMMENT '下单时间',
  `ip` varchar(20) NOT NULL COMMENT 'IP地址',
  `ip_local` varchar(200) NOT NULL COMMENT '具体地址',
  `body_part` varchar(50) NOT NULL COMMENT '检测部位',
  PRIMARY KEY (`id`),
  KEY `user_name` (`user_realname`),
  KEY `j_id` (`j_id`),
  KEY `add_time` (`add_time`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 AUTO_INCREMENT=96 ;

--
-- Dumping data for table `yiliao_user_yuding`
--

INSERT INTO `yiliao_user_yuding` (`id`, `j_id`, `j_name`, `user_realname`, `contact_realname`, `user_contact`, `post_date`, `post_hour`, `stat`, `user_name`, `user_sex`, `user_tel`, `user_binshi`, `add_time`, `ip`, `ip_local`, `body_part`) VALUES
(63, 71, '江苏无锡解放军101医院PET-CT中心', '朱立秀', '', '', '2009-11-20', '9', '成功', '', '女', '15961700773', '结肠癌术后11月 CEA持续升高，待查明病灶', '2009-11-18 20:56:25', '117.84.37.210', '江苏省无锡市', '全身'),
(64, 92, '广东省人民医院PET-CT中心', '张丽贞', '', '', '2009-11-21', '10', '失败', '', '女', '13632267973', '', '2009-11-20 09:01:44', '113.70.0.73', '广东省佛山市', '全身'),
(65, 66, '安徽省立医院PET-CT中心', '7777', '', '', '2009-11-21', '8', '失败', '', '男', '05516534588', '7777', '2009-11-20 10:09:48', '60.168.21.113', '安徽省合肥市', '全身'),
(66, 35, '上海仁济医院PET-CT中心', '陶裕主', '', '', '2009-11-27', '13', '失败', 'llz007', '男', '13566013757', '发现CEA升高6.29', '2009-11-24 23:12:28', '220.178.118.18', '安徽省合肥市', '全身'),
(70, 100, '四川大学华西医院PET-CT中心', 'yxypih', '', '', '2009-11-30', '9', '未处理', '', '男', '57939290', 'ytnmkmdqzoyokxfmememjpabgffyej', '2009-11-29 08:15:54', '124.42.99.34', '北京市', '局部'),
(69, 50, '江苏江阴市华西村医院PET-CT中心', '顾伟', '', '', '2009-11-28', '8', '成功', 'llz007', '男', '13815293183', '全身体检', '2009-11-24 23:15:54', '220.178.118.18', '安徽省合肥市', '全身'),
(62, 80, '江苏南京鼓楼医院PET-CT中心', '韦木金', '', '', '2009-11-17', '10', '失败', '', '男', '013952953251', 'X片 右肺有阴影\r\n增强CT片 右肺上叶肺癌伴多发淋巴结转移，左肺门淋巴结钙化\r\nECT 未见明显异常\r\n纤支镜 刷检 未见癌细胞\r\n待确诊！', '2009-11-16 21:27:23', '114.229.203.232', '江苏省镇江市', '局部'),
(61, 71, '江苏无锡解放军101医院PET-CT中心', '朱立秀', '', '', '2009-10-20', '8', '失败', '', '女', '15961700773', '结肠癌术后9月 化疗6次后CEA逐渐升高到10', '2009-10-18 19:30:12', '121.235.45.224', '江苏省无锡市', '全身'),
(71, 101, '四川省人民医院PET-CT中心', 'yxypih', '', '', '2009-11-30', '9', '未处理', '', '男', '25998988', 'ytnmkmdqzoyokxfmememjpabgffyej', '2009-11-29 08:16:01', '124.42.99.34', '北京市', '局部'),
(72, 102, '第四军医大学西京医院PET-CT中心', 'yxypih', '', '', '2009-11-30', '9', '未处理', '', '男', '15744137', 'ytnmkmdqzoyokxfmememjpabgffyej', '2009-11-29 08:16:08', '124.42.99.34', '北京市', '局部'),
(73, 82, '江苏徐州市中心医院PET-CT中心', '孙秀华', '', '', '2009-12-1', '9', '未处理', '', '女', '15905214197', '左侧乳房肿瘤，全切除一年半', '2009-11-29 11:09:10', '121.14.246.50', '广东省中山市', '全身'),
(74, 80, '江苏南京鼓楼医院PET-CT中心', '胡碧华', '', '', '2009-12-07', '8', '成功', '', '男', '13909600258', '胃癌中晚期', '2009-12-06 13:46:55', '114.103.82.87', '安徽省', '局部'),
(75, 79, '江苏苏州大学附属第一人民医院PET-CT中心', '黄照兰', '', '', '2009-12-08', '10', '失败', '', '女', '13771286008', '', '2009-12-06 18:39:06', '117.84.204.66', '江苏省无锡市', '局部'),
(76, 89, '福建南京军区福州总医院PET-CT中心', '林贤邦', '', '', '2009-12-08', '9', '失败', '', '男', '18965025010', '', '2009-12-07 23:53:52', '117.25.18.73', '福建省福州市', '全身'),
(77, 59, '北京第二炮兵总医院PET-CT中心', '张扬', '', '', '2009-12-12', '8', '失败', '', '男', '13901392369', '体检', '2009-12-11 22:45:41', '211.166.56.136', '北京市', '全身'),
(78, 65, '山东省肿瘤医院PET-CT中心', '陈照新', '', '', '2009-12-12', '14', '失败', '', '男', '13863663360', '2002年肺癌，经放化疗后康复至今。现疑似复发。', '2009-12-12 08:16:43', '117.136.9.44', '山东省青岛市', '全身'),
(79, 66, '安徽省立医院PET-CT中心', '吉秋萍', '', '', '2009-12-14', '10', '成功', 'gwm', '女', '13956391032', '', '2009-12-14 09:45:14', '116.228.141.77', '上海市', '全身'),
(80, 86, '天津武警医学院附属医院PET-CT', '张冬梅', '', '', '2009-12-16', '8', '失败', '', '女', '13352858523', '查体', '2009-12-15 14:44:42', '60.30.96.92', '天津市', '全身'),
(81, 75, '北京307医院PET-CT中心', '王桂芝', '', '', '2010-1-3', '8', '成功', '', '女', '13644321016', '子宫肌瘤 崎胎瘤 肝部实质性病变、', '2009-12-17 12:06:40', '122.137.147.185', '吉林省', '全身'),
(82, 105, '西安高新医院PET-CT中心', '李安捷', '', '', '2009-12-22', '9', '成功', '', '男', '13509132666', 'CT平扫4*5.5*4.6厘米软组织块状影，邻近胸膜肥大，左下支气管开口受压', '2009-12-17 23:50:22', '220.181.109.123', '北京市', '全身'),
(83, 63, '天津医科大学总医院PET-CT中心', '123', '', '', '2009-12-25', '8', '失败', '', '男', '123456789', '', '2009-12-24 11:05:42', '221.196.205.32', '天津市北辰区', '局部'),
(84, 90, '福建医科大学附属厦门市第一医院PET-CT中心', '李丽月', '', '', '2009-12-28', '8', '成功', '', '女', '13905986339', '', '2009-12-26 09:33:21', '120.42.68.43', '福建省厦门市', '全身'),
(85, 37, '浙江宁波明州医院PET-CT中心', '郁先生', '', '', '2009-12-28', '9', '成功', '', '男', '13958329395', '五个月前单位体检前列腺异性抗原达到13左右,后用了消炎药,每月抽血基本上都在10左右.因不想做活检,是否用PET-CT能检查出炎症还是别的原因?', '2009-12-27 18:45:20', '60.178.124.7', '浙江省宁波市', '局部'),
(86, 52, '成都军区总医院PET-CT中心', '彭华金', '', '', '2009-12-28', '11', '成功', '', '男', '15892678267', '2006年6月小肝癌切除，最近甲胎蛋白偏高，普通CT不能明确确定', '2009-12-27 22:28:52', '222.67.75.69', '上海市杨浦区', '全身'),
(87, 41, '上海华山医院PET-CT中心', '张君', '', '', '2009-12-29', '8', '成功', 'gwm', '', '15900971743', '', '2009-12-28 14:57:41', '116.228.141.77', '上海市', '全身'),
(88, 41, '上海华山医院PET-CT中心', '李强国', '', '', '2009-12-30', '10', '成功', 'gwm', '', '13918703683', '', '2009-12-28 15:00:06', '116.228.141.77', '上海市', '全身'),
(89, 59, '北京第二炮兵总医院PET-CT中心', '罗新', '', '', '2009-12-29', '8', '失败', '', '男', '13701063272', '', '2009-12-28 17:49:44', '222.129.49.181', '北京市', '全身'),
(90, 35, '上海仁济医院PET-CT中心', '夏琳泰', '', '', '2009-12-29', '', '未处理', 'xltxlm', '男', '15921427453', '111111111', '2009-12-28 22:12:42', '116.232.119.210', '上海市徐汇区', '全身'),
(67, 39, '上海肿瘤医院PET-CT中心', '陶裕主', '', '', '2009-11-27', '9', '成功', 'llz007', '男', '13566013757', '发现CEA升高6.29', '2009-11-24 23:14:21', '220.178.118.18', '安徽省合肥市', '全身'),
(68, 35, '上海仁济医院PET-CT中心', '吴翠娥', '', '', '2009-11-27', '13', '成功', 'llz007', '女', '15067072183', '', '2009-11-24 23:15:01', '220.178.118.18', '安徽省合肥市', '全身'),
(91, 35, '上海仁济医院PET-CT中心', '夏琳泰', '夏琳泰11', '', '2009-12-29', '', '未处理', 'xltxlm', '男', '15921427453', '222', '2009-12-28 22:17:48', '116.232.119.210', '上海市徐汇区', '全身'),
(92, 35, '上海仁济医院PET-CT中心', '测试', '联系人', '', '2009-12-29', '', '未处理', 'gwm', '男', '11345678', '倒萨发生地方撒旦法', '2009-12-28 22:20:21', '58.35.106.110', '上海市黄浦区', '全身'),
(93, 121, '山东齐鲁医院PET-CT中心', '路克长', '路先生', '', '2009-12-29', '', '成功', 'gwm', '男', '13963457968', '食管癌，肝脏有不明病灶，不能确定是否为转移。', '2009-12-29 09:31:23', '116.228.141.77', '上海市', '全身'),
(94, 34, '上海455医院PET-CT高端体检中心', '曾泳如', '邹伟', '', '2010-1-5', '', '成功', 'gwm', '男', '13870093527', '', '2009-12-30 10:25:13', '116.228.141.77', '上海市', '全身'),
(95, 35, '上海仁济医院PET-CT中心', '万贯家', '万贯家', '', '2009-12-31', '', '失败', '', '男', '13761258645', '', '2009-12-30 23:19:57', '220.234.138.212', '上海市', '全身');
